PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	AULTRICHE, DB; YUAN, CS; BORCHARDT, RT				AULTRICHE, DB; YUAN, CS; BORCHARDT, RT			A SINGLE MUTATION AT LYSINE-426 OF HUMAN PLACENTAL S-ADENOSYLHOMOCYSTEINE HYDROLASE INACTIVATES THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-HOMOCYSTEINE; BACTERIOPHAGE-T7 DNA-POLYMERASE; AMINO-ACID SEQUENCE; RAT-LIVER; DICTYOSTELIUM-DISCOIDEUM; ESCHERICHIA-COLI; CDNA SEQUENCE; L929 CELLS; PURIFICATION; MECHANISM	S-Adenosylhomocysteine (AdoHcy) hydrolase catalyzes the conversion of AdoHcy to adenosine (Ado) and homocysteine (Hey), as well as the reverse reaction, through a mechanism involving an NAD(+)-dependent oxidation of the 3'-hydroxyl group of AdoHcy (3'-oxidative activity), followed by elimination of Hey to form 3'-keto-4',5'-didehydro-5'-deoxy-Ado. The addition of water at the 5'-position (5'-hydrolytic activity) of this tightly bound intermediate, followed by an NADH-dependent reduction, results in the formation of Ado. Based on a computer graphics model of the active site of this enzyme, it was hypothesized that amino acid residues at the carboxyl-terminal end of the protein reside in the active site of the enzyme and could play a role in catalyzing the 5'-hydrolytic reaction (Yeh, J. C., Borchardt, R. T., and Vedani, A. (1991) J. Comput. Aided Mol. Des. 5, 213-234), Using site-directed mutagenesis, we show here that lysine 426 is essential for the catalytic activity of the enzyme and that it appears to play a crucial role in the 5'-hydrolytic activity and/or stability of the quaternary structure of the human placental enzyme, Mutation of Lys-426 to arginine (K426R) produces a stable tetrameric enzyme that lacks overall catalytic activity and that was isolated predominantly as its NADH form containing tightly bound 3'-keto-Ado, suggesting that the K426R mutant has oxidative activity, but lacks 5'-hydrolytic activity, preventing it from completing the entire catalytic cycle, Mutations of Lys-426 to glutamic acid (K426E) and alanine (K426A) produce enzymes that exist primarily as monomers, do not bind NAD(+) or NADH, and lack catalytic activity, The results of the Lys-426 mutations suggest that this lysine residue is crucial for the 5'-hydrolytic activity of the enzyme and/or stabilizing the quaternary structure of the enzyme.	UNIV KANSAS, DEPT BIOCHEM, LAWRENCE, KS 66045 USA	University of Kansas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AULTRICHE DB, 1993, MOL PHARMACOL, V43, P989; BITONTI AJ, 1990, BIOCHEM PHARMACOL, V40, P601, DOI 10.1016/0006-2952(90)90562-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COULTERKARIS DE, 1989, ANN HUM GENET, V53, P169, DOI 10.1111/j.1469-1809.1989.tb01781.x; DELAHABA G, 1959, J BIOL CHEM, V234, P603; DOSKELAND SO, 1982, BIOCHIM BIOPHYS ACTA, V708, P185, DOI 10.1016/0167-4838(82)90219-9; FUJIOKA M, 1981, J BIOL CHEM, V256, P1631; GOMI T, 1985, J BIOL CHEM, V260, P2789; GOMI T, 1989, J BIOL CHEM, V264, P16138; GOMI T, 1990, J BIOL CHEM, V265, P16102; GUITTON MC, 1988, CELL DIFFER DEV, V22, P203, DOI 10.1016/0045-6039(88)90012-7; GURANOWSKI A, 1977, EUR J BIOCHEM, V80, P517, DOI 10.1111/j.1432-1033.1977.tb11907.x; HASOBE M, 1989, MOL PHARMACOL, V36, P490; HASOBE M, 1988, MOL PHARMACOL, V33, P713; HASOBE M, 1989, ANTIMICROB AGENTS CH, V33, P828, DOI 10.1128/AAC.33.6.828; HENDERSON DM, 1992, MOL BIOCHEM PARASIT, V53, P169, DOI 10.1016/0166-6851(92)90019-G; HERSHFIELD MS, 1985, BIOCHEM J, V230, P43, DOI 10.1042/bj2300043; HOHMAN RJ, 1984, ARCH BIOCHEM BIOPHYS, V233, P785, DOI 10.1016/0003-9861(84)90507-1; HOHMAN RJ, 1985, P NATL ACAD SCI USA, V82, P4578, DOI 10.1073/pnas.82.14.4578; KAJANDER EO, 1981, BIOCHEM J, V193, P503, DOI 10.1042/bj1930503; KASIR J, 1988, BIOCHEM BIOPH RES CO, V153, P359, DOI 10.1016/S0006-291X(88)81231-2; KAWALLECK P, 1992, P NATL ACAD SCI USA, V89, P4713, DOI 10.1073/pnas.89.10.4713; Keller B. T., 1988, ANTIVIRAL DRUG DEV M, P123; KIM IK, 1983, ARCH BIOCHEM BIOPHYS, V226, P65, DOI 10.1016/0003-9861(83)90271-0; KNUDSEN RC, 1972, J BACTERIOL, V112, P569, DOI 10.1128/JB.112.1.569-575.1972; LIU S, 1992, ANTIVIR RES, V19, P247, DOI 10.1016/0166-3542(92)90083-H; LOOKER D, 1988, NUCLEIC ACIDS RES, V16, P7198, DOI 10.1093/nar/16.14.7198; MATUSZEWSKA B, 1987, J BIOL CHEM, V262, P265; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PORCELLI M, 1993, BIOCHIM BIOPHYS ACTA, V1164, P179, DOI 10.1016/0167-4838(93)90246-N; POULTON JE, 1976, ARCH BIOCHEM BIOPHYS, V172, P135, DOI 10.1016/0003-9861(76)90058-8; Sambrook J, 1989, MOL CLONING LABORATO; SGANGA MW, 1992, P NATL ACAD SCI USA, V89, P6328, DOI 10.1073/pnas.89.14.6328; SHIMIZU S, 1984, EUR J BIOCHEM, V141, P385, DOI 10.1111/j.1432-1033.1984.tb08203.x; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TABOR S, 1989, J BIOL CHEM, V264, P6447; TAKATA Y, 1983, J BIOL CHEM, V258, P7374; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; UELAND PM, 1982, PHARMACOL REV, V34, P223; UELAND PM, 1980, J BIOL CHEM, V255, P7722; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WOLFE MS, 1991, J MED CHEM, V34, P1521, DOI 10.1021/jm00109a001; WOLOS JA, 1993, CELL IMMUNOL, V149, P402, DOI 10.1006/cimm.1993.1165; WOLOS JA, 1993, J IMMUNOL, V151, P526; YEH JC, 1991, J COMPUT AID MOL DES, V5, P213, DOI 10.1007/BF00124340; YUAN CS, 1993, J BIOL CHEM, V268, P17030; YUAN CS, 1994, BIOCHEMISTRY-US, V33, P12305, DOI 10.1021/bi00206a038; ZIMMERMAN JK, 1974, BIOCHEMISTRY-US, V13, P384, DOI 10.1021/bi00699a025	49	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31472	31478						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989313				2022-12-25	WOS:A1994PX30300025
J	HOHENEGGER, M; NANOFF, C; AHORN, H; FREISSMUTH, M				HOHENEGGER, M; NANOFF, C; AHORN, H; FREISSMUTH, M			STRUCTURAL AND FUNCTIONAL-CHARACTERIZATION OF THE INTERACTION BETWEEN 2',3'-DIALDEHYDE GUANINE-NUCLEOTIDE ANALOGS AND THE STIMULATORY G-PROTEIN ALPHA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; H-RAS P21; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BINDING-SITE; TRIPHOSPHATE CONFORMATION; SARCOPLASMIC-RETICULUM; ACTIVE-SITE; GTP-BINDING; 2 FORMS	We have searched for irreversible ligands which target the guanine nucleotide binding pocket of G protein alpha-subunits by testing the ability of periodate-oxidized 2',3'-dialdehyde guanine nucleotide analogues of GTP (oGTP) and GTP gamma S (oGTP gamma S) to bind to the recombinant cy-subunit of the stimulatory G protein, rG(s alpha-s). oGTP and oGTP gamma S bind to rG(s alpha-s) in a quasi-irreversible manner via formation of a Schiff's base, which can be reduced with borhydrid resulting in covalent incorporation of [alpha-P-32]oGTP and [S-35]oGTP gamma S into rG(s alpha-s). When bound to rG(s alpha), oGTP is hydrolyzed and traps the protein in the inactive conformation, while oGTP gamma S persistently activates rG(s alpha). Thus, oGTP and oGTP gamma S act as irreversible G protein antagonist and agonist, respectively, and represent a pair of nucleotide analogues suitable as functional and structural tools, Cleavage of covalently Iabeled rG(s alpha-s) with cyanogen bromide generates several labeled fragments. Labeled fragments were assigned to the G(1) and G(4) region of the guanine nucleotide binding pocket using sequence-specific antisera. An additional, labeled fragment was identified by amino-terminal sequencing and corresponded to the helix alpha A in the recently determined crystal structure of the transducin alpha-subunit (Noel, J. P., Hamm, H. E., and Sigler, P. B. (1993) Nature 366, 654-663), In the oGDP-liganded conformation, incorporation occurs predominantly into the G(1)-fragment, while [S-35]oGTP gamma S labels the additional fragments to a similar extent indicating tight packing around the guanine nucleotide binding pocket in the active conformation, Furthermore, rG(s alpha-s) contains a single acid cleavable bond (Asp(317)-pro(318)), such that formic acid releases a carboxyl-terminal fragment from [alpha(32)PGTP- and [S-35]oGTP gamma S-liganded rG(s alpha-s). This fragment contains a single lysine residue (Lys(324)) which is only labeled by [S-35]oGTP gamma S. Lys(324) is unique to G(s alpha) and lies within its effector binding region, Hence, during the switch from the inactive to the active state, this region undergoes a major conformational change that moves it closer to the nucleotide binding pocket.	UNIV VIENNA, INST PHARMACOL, A-1090 VIENNA, AUSTRIA; ERNST BOEHRINGER INST ARZNEIMITTELFORSCH, DEPT PROT CHEM, A-1120 VIENNA, AUSTRIA	University of Vienna			Hohenegger, Martin/AAF-6479-2020	Hohenegger, Martin/0000-0001-6537-9574; nanoff, christian/0000-0002-8857-2470; Freissmuth, Michael/0000-0001-9398-1765				BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIDWAI AP, 1989, J BIOL CHEM, V264, P11790; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; EASTERBROOKSMITH SB, 1976, EUR J BIOCHEM, V62, P125, DOI 10.1111/j.1432-1033.1976.tb10105.x; FIELDS TA, 1994, BIOCHEMISTRY-US, V33, P6877, DOI 10.1021/bi00188a017; FREISSMUTH M, 1991, P NATL ACAD SCI USA, V88, P8548, DOI 10.1073/pnas.88.19.8548; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HOHENEGGER M, 1992, EUR J BIOCHEM, V205, P173, DOI 10.1111/j.1432-1033.1992.tb16765.x; ITOH H, 1991, J BIOL CHEM, V266, P16226; JOCKERS R, 1994, IN PRESS J BIOL CHEM; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; LACOUR TFM, 1985, EMBO J, V4, P191; LINDEN J, 1984, MOL PHARMACOL, V26, P414; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOW A, 1993, EUR J BIOCHEM, V215, P473, DOI 10.1111/j.1432-1033.1993.tb18056.x; LOW A, 1992, FEBS LETT, V303, P64, DOI 10.1016/0014-5793(92)80478-Y; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MIGNACO J, 1990, BIOCHIM BIOPHYS ACTA, V1039, P305, DOI 10.1016/0167-4838(90)90263-F; MILLIGAN G, 1989, BIOCHEM J, V262, P643, DOI 10.1042/bj2620643; MIZIORKO HM, 1990, J BIOL CHEM, V265, P3642; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; NANOFF C, 1994, J BIOL CHEM, V269, P31999; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PETER ME, 1988, BIOCHEMISTRY-US, V27, P9132, DOI 10.1021/bi00426a010; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIRMER NK, 1991, EUR J BIOCHEM, V200, P295, DOI 10.1111/j.1432-1033.1991.tb16185.x; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	37	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					32008	32015						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989377				2022-12-25	WOS:A1994PX30300102
J	ROSTAGNO, A; WILLIAMS, MJ; BARON, M; CAMPBELL, ID; GOLD, LI				ROSTAGNO, A; WILLIAMS, MJ; BARON, M; CAMPBELL, ID; GOLD, LI			FURTHER CHARACTERIZATION OF THE NH2-TERMINAL FIBRIN-BINDING SITE ON FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; NUCLEAR-MAGNETIC-RESONANCE; COLD-INSOLUBLE GLOBULIN; PLASMINOGEN-ACTIVATOR; STAPHYLOCOCCUS-AUREUS; CROSS-LINKING; DOMAIN; COLLAGEN; MODULES; TISSUE	The fibronectin (Fn) monomer contains two major sites of fibrin binding affinity present within the NH,terminal and COOH-terminal domains; they consist of five ((1)F1-(5)F1) and three ((10)F1-(12)F1) consecutive type 1 modules, respectively. Recently, we have reported that the fourth and fifth type 1 module pair ((4)F1.(5)F1) of the NH2-terminaI domain of fibronectin demonstrated fibrin binding ability (Williams, M. J., Phan, I., Harvery, T. S., Rostagno, A., Gold, L. I., and Campbell, I. D. (1994) J. Mol. Biol. 235, 1303-1311). In an attempt to further localize fibrin binding activity and to characterize the nature of the interaction between different type 1 modules of Fn and fibrin, we have tested a range of recombinant proteins and subtilisin generated proteolytic fragments of Fn in an enzyme-linked immunosorbent assay (ELISA) and by fibrin affinity chromatography. Of the recombinant proteins, we found that only the (4)F1.(5)F1 exhibited significant fibrin binding activity, while (1)F1, (1)F1.(2)F1, (7)F1, and (10)F1 had little to no affinity for fibrin. On a molar basis, 4-5 times more (4)F1.(5)F1 than a proteolytic fragment, corresponding to (1)F1-(5)F1 (25.9 kDa) was required to cause 50% inhibition (IC50) of intact biotinylated Fn binding to fibrin in a competitive ELISA. This suggests that all five type 1 modules in tandem engender higher fibrin binding activity than the (4)F1.(5)F1 alone. Furthermore, since fibrin binding activity of the intact Fn molecule was inhibited, by 70-80%, by the (4)F1.(5)F1, the 25.9-kDa fragment, and a MoAb mapped to an epitope on the (4)F1.(5)F1, the fibrin-binding site within the (4)F1.(5)F1 contributes greatly to the non-covalent interaction of intact Fn with fibrin. These results provide significant insight into the Fn/fibrin interaction, a major component of the processes of wound repair and fibrin matrix assembly.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	New York University; University of Oxford			Rostagno, Agueda/A-5801-2008	Rostagno, Agueda/0000-0002-6817-2074				BARON M, 1990, NATURE, V345, P642, DOI 10.1038/345642a0; BARON M, 1990, PROTEIN PRODUCTION B, P49; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; CLARK RAF, 1985, PLASMA FIBRONECTIN S, P197; CONSTANTINE KL, 1992, J MOL BIOL, V223, P281, DOI 10.1016/0022-2836(92)90731-X; DOWNING AK, 1992, J MOL BIOL, V225, P821, DOI 10.1016/0022-2836(92)90403-7; ENGVALL E, 1978, J EXP MED, V147, P1584, DOI 10.1084/jem.147.6.1584; GARCIAPARDO A, 1983, J BIOL CHEM, V258, P2670; GARCIAPARDO A, 1985, J BIOL CHEM, V260, P320; GOLD LI, 1979, P NATL ACAD SCI USA, V76, P4803, DOI 10.1073/pnas.76.10.4803; GOLD LI, 1983, BIOCHEMISTRY-US, V22, P4113, DOI 10.1021/bi00286a019; GOLD LI, 1982, J CELL BIOL, V95, P127; HAYASHI M, 1983, J BIOL CHEM, V258, P3332; HEENE D L, 1973, Thrombosis Research, V2, P137, DOI 10.1016/0049-3848(73)90025-X; HOMANDBERG GA, 1986, BIOCHEMISTRY-US, V25, P6917, DOI 10.1021/bi00370a027; HORMANN H, 1980, H-S Z PHYSIOL CHEM, V361, P1449; Hynes RO, 1990, FIBRONECTINS; KAPLAN JE, 1989, J LAB CLIN MED, V113, P168; KESKIOJA J, 1981, BIOCHEM J, V193, P615, DOI 10.1042/bj1930615; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KURKINEN M, 1980, LAB INVEST, V43, P47; LITVINOV I, 1989, BIOKHIMIYA, V53, P1203; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MATSUKA YV, 1994, J BIOL CHEM, V269, P9539; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MOSHER DF, 1975, J BIOL CHEM, V250, P6614; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; Mosher DF, 1989, FIBRONECTIN; PASCALL JC, 1991, J MOL ENDOCRINOL, V6, P63, DOI 10.1677/jme.0.0060063; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; ROSTAGNO AA, 1991, J IMMUNOL, V146, P2687; ROSTAGNO AA, 1989, J IMMUNOL, V143, P3277; RUOSLAHTI E, 1980, BIOCHIM BIOPHYS ACTA, V631, P350, DOI 10.1016/0304-4165(80)90308-6; SEKIGUCHI K, 1983, J BIOL CHEM, V258, P3967; SEKIGUCHI K, 1980, BIOCHEM BIOPH RES CO, V97, P709, DOI 10.1016/0006-291X(80)90322-8; SHEKHONIN BV, 1990, J MOL CELL CARDIOL, V22, P533, DOI 10.1016/0022-2828(90)90955-2; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; STATHAKIS NE, 1978, BLOOD, V51, P1211; THOMPSON LK, 1986, J BIOL CHEM, V261, P5209; WILLIAMS MJ, 1993, BIOCHEMISTRY-US, V32, P7388, DOI 10.1021/bi00080a008; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1303; ZSEBO KM, 1986, J BIOL CHEM, V261, P5858	46	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31938	31945						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989369				2022-12-25	WOS:A1994PX30300093
J	CASCIOLAROSEN, LA; MILLER, DK; ANHALT, GJ; ROSEN, A				CASCIOLAROSEN, LA; MILLER, DK; ANHALT, GJ; ROSEN, A			SPECIFIC CLEAVAGE OF THE 70-KDA PROTEIN-COMPONENT OF THE U1 SMALL NUCLEAR RIBONUCLEOPROTEIN IS A CHARACTERISTIC BIOCHEMICAL FEATURE OF APOPTOTIC CELL-DEATH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE CED-3; ENZYME; MECHANISMS	The U1 small nuclear ribonucleoprotein particle is essential for splicing of precursor mRNA, an activity that depends upon both the RNA and protein components of the U1 particle. One of the U1-specific proteins that is functionally important in this splicing reaction is the 70-kDa protein (U1-70kDa). We report here that U1-70kDa is specifically cleaved in apoptotic cells, resulting in the generation of a 40-kDa fragment. The kinetics of this cleavage coincided with the appearance of cells with apoptotic morphology in the population, and the proportion of 40-kDa fragment observed was markedly increased in apoptotic cells that had become detached from the substratum. Although the inhibitor characteristics of the activity cleaving U1-70kDa suggest that interleukin 1 beta-converting enzyme (ICE) might be responsible, the specific ICE inhibitor N-(N-acetyl-tyrosinylvalinyl-alaninyl)- 3-amino-4-oxobutanoic acid (YVAD-CHO) did not prevent cleavage, and U1-70kDa was not cleaved by purified ICE in vitro. Further study of this novel cleavage and the enzyme responsible will yield information about proteolytic events that might be central in the mechanism and control of apoptosis.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV RHEUMATOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT DERMATOL, BALTIMORE, MD 21205 USA; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, RAHWAY, NJ 07065 USA	Johns Hopkins University; Johns Hopkins University; Merck & Company					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032490, R01AR040018] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-40018, AR-32490] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; HOWARD AD, 1991, J IMMUNOL, V147, P2964; JOHNSON AM, 1986, MANUAL CLIN LABORATO, P14; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WYLLIE AH, 1982, AM J PATHOL, V109, P78; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	19	381	393	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30757	30760						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983001				2022-12-25	WOS:A1994PV51000005
J	KAUFFMANNZEH, A; KLINGER, R; ENDEMANN, G; WATERFIELD, MD; WETZKER, R; HSUAN, JJ				KAUFFMANNZEH, A; KLINGER, R; ENDEMANN, G; WATERFIELD, MD; WETZKER, R; HSUAN, JJ			REGULATION OF HUMAN TYPE-II PHOSPHATIDYLINOSITOL KINASE-ACTIVITY BY EPIDERMAL GROWTH FACTOR-DEPENDENT PHOSPHORYLATION AND RECEPTOR ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; PHOSPHOLIPASE-C-GAMMA; ALTERED AUTOPHOSPHORYLATION SITES; ACTIN-BINDING PROTEIN; EGF-RECEPTOR; A431 CELLS; SIGNALING COMPLEXES; MONOCLONAL-ANTIBODY; PLASMA-MEMBRANES; 3-KINASE	Epidermal growth factor (EGF) stimulates phosphatidylinositol (PtdIns) hydrolysis in many cell types by effecting the specific interaction between the EGF receptor and phospholipase C gamma. Several studies have suggested that PtdIns 4-kinase activity can also be regulated by EGF, but the mechanism of this stimulation was unclear. We report here that EGF treatment of intact A431 cells increased the association of type II PtdIns kinase with the EGF receptor within 1 min at 37 degrees C. Phosphorylation of immunoprecipitated EGF receptor also increased the association of PtdIns 4-kinase. Furthermore dephosphorylation of phosphoserine residues on the stimulated receptor immune complex led to inactivation of the bound PtdIns 4-kinase, while dephosphorylation of phosphotyrosine residues led to activation. Unlike the stimulated activity measured in total cell and plasma membrane lysates, the changes in activity of the immunoprecipitates were apparent at high substrate concentration. Metabolic labeling was used to shaw that a 55-kDa phosphoserine and phosphotyrosine-containing protein comigrated with renatured PtdIns 4-kinase activity on SDS-polyacrylamide gel electrophoresis, while in vitro labeling revealed only serine phosphorylation. These data are discussed with reference to the direct regulation of PtdIns 4-kinase by phosphorylation, PtdIns compartmentalization, and the formation of a multienzyme signal transduction complex.	UCL, SCH MED, LUDWIG INST CANC RES, LONDON WC1E 6BT, ENGLAND; UCL, SCH MED, PROT BIOCHEM GRP, LONDON WC1E 6BT, ENGLAND; UNIV JENA, MAX PLANCK RES GRP GROWTH FACTOR SIGNAL TRANSDUCT, D-07740 JENA, GERMANY; UNIV JENA, INST BIOCHEM 2, D-07740 JENA, GERMANY; SCIOS NOVA INC, MT VIEW, CA 94043 USA; UCL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; Friedrich Schiller University of Jena; Max Planck Society; Friedrich Schiller University of Jena; Scios; University of London; University College London			Hsuan, Justin/C-8825-2009; Wetzker, Reinhard/AAD-8713-2019	Hsuan, Justin/0000-0001-6083-7564; 				APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; COCHET C, 1991, J BIOL CHEM, V266, P637; COCKCROFT S, 1992, BIOCHEM J, V288, P1; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNES CP, 1993, CURR BIOL, V3, P794; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Ehle H, 1985, FEBS Lett, V183, P413; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FRY MJ, 1993, PROTEIN SCI, V2, P1785, DOI 10.1002/pro.5560021102; GIRAUD F, 1988, BIOCHIM BIOPHYS ACTA, V968, P367, DOI 10.1016/0167-4889(88)90029-8; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HALENDA SP, 1984, BIOCHEM BIOPH RES CO, V124, P507, DOI 10.1016/0006-291X(84)91583-3; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HELIN K, 1991, J BIOL CHEM, V266, P8363; HERNANDEZSOTOMAYOR SMT, 1993, BIOCHEM J, V293, P507, DOI 10.1042/bj2930507; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; Hsuan J J, 1989, Prog Growth Factor Res, V1, P23, DOI 10.1016/0955-2235(89)90039-2; HSUAN JJ, 1993, ANTICANCER RES, V13, P2521; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MICHELL RH, 1988, PHILOS T ROY SOC B, V320, P239, DOI 10.1098/rstb.1988.0074; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; MONACO ME, 1992, ENDOCR REV, V13, P707, DOI 10.1210/er.13.4.707; MORRISON P, 1993, J BIOL CHEM, V268, P15536; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NOTHWOOD IC, 1990, J BIOL CHEM, V266, P15266; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PARKER PJ, 1984, J BIOL CHEM, V259, P9906; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAYRASTRE B, 1991, BIOCHIM BIOPHYS ACTA, V1056, P19, DOI 10.1016/S0005-2728(05)80068-4; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIKE L, 1992, ENDOCR REV, V14, P692; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RUIZLARREA F, 1993, BIOCHEM J, V290, P609, DOI 10.1042/bj2900609; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SOLER C, 1994, J BIOL CHEM, V269, P12320; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TAYLOR MV, 1984, NATURE, V312, P462, DOI 10.1038/312462a0; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; THOMPSON DM, 1985, J BIOL CHEM, V260, P8824; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VICENDO P, 1991, BIOCHEM J, V278, P435, DOI 10.1042/bj2780435; VOGEL S, 1986, EUR J BIOCHEM, V154, P253, DOI 10.1111/j.1432-1033.1986.tb09390.x; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WETZKER R, 1991, EUR J BIOCHEM, V200, P179, DOI 10.1111/j.1432-1033.1991.tb21065.x; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WILLIAMS R, 1993, J BIOL CHEM, V268, P18213	78	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31243	31251						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983068				2022-12-25	WOS:A1994PV51000077
J	FRIDMAN, M; TIKOO, A; VARGA, M; MURPHY, A; NUREKAMAL, MSA; MARUTA, H				FRIDMAN, M; TIKOO, A; VARGA, M; MURPHY, A; NUREKAMAL, MSA; MARUTA, H			THE MINIMAL FRAGMENTS OF C-RAF-1 AND NF1 THAT CAN SUPPRESS V-HA-RAS-INDUCED MALIGNANT PHENOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE-PRODUCT; PROTEIN-KINASE; ONCOGENIC RAS-P21; GAP; RAF-1; INTERACTS; SEQUENCE; DOMAIN; PHOSPHORYLATION; NEUROFIBROMIN	v-Ha-Ras, an oncogenic Ras mutant, causes malignant transformation of mammalian cells by recruiting c-Raf-1, a cytosolic Ser/Thr kinase, to the plasma membranes/cytoskeleton, The kinase activity of c-Raf-1 resides in the C-terminal half, which activates mitogen-activated protein (MAP) kinase kinase, while it is the N-terminal half of c-Raf-1 (Raf257, residues 1-257) that binds the Ras-GTP complex and can compete Ras GTPase-activating proteins such as NF1 for binding to Ras. However, it still remains to be clarified whether overexpression of Raf257 or its minimal Ras-binding fragment alone is sufficient to suppress Ras-induced malignancy. In this paper we demonstrate for the first time that the 81-amino acid fragment (Raf81, residues 51-131), the minimal Ras-binding fragment of Raf, indeed can suppress v-Ha-Ras-induced malignant phenotype. A further deletion of the first 6 amino acids causes 65% reduction in the Ras binding of Raf81. The resultant 75 amino acid fragment (Raf75, residues 57-131) consists of a single alpha-helix, five anti-paralleled beta-sheets and five loops. We have found that a further deletion of either the first beta-sheet/loop or the last two beta-sheets/loops completely abolishes Ras binding. In addition we have found that the removal of the C-terminal 35 amino acids from a Ras-binding 91-amino acid fragment of NF1 (NF91, residues 1441-1531) does not abolish its ability to suppress the Ras-induced malignancy.	ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOS JL, 1989, CANCER RES, V49, P4682; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V19, P265, DOI 10.1007/BF01233074; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MARUTA H, 1994, BIOESSAYS, V16, P486; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NUREKAMAL MSA, 1993, J BIOL CHEM, V268, P22331; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; NUREKAMAL MSA, 1992, MOL BIOL CELL, V3, P1437, DOI 10.1091/mbc.3.12.1437; PULVERER BJ, 1991, NATURE, V353, P67; RAPP UR, 1991, ONCOGENE, V6, P495; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	31	38	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30105	30108						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982912				2022-12-25	WOS:A1994PU52500011
J	KATOH, Y; LOUKIANOV, E; KOPRAS, E; ZILBERMAN, A; PERIASAMY, M				KATOH, Y; LOUKIANOV, E; KOPRAS, E; ZILBERMAN, A; PERIASAMY, M			IDENTIFICATION OF FUNCTIONAL PROMOTER ELEMENTS IN THE RABBIT SMOOTH-MUSCLE MYOSIN HEAVY-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY REGULATED EXPRESSION; CARDIAC ACTIN GENE; DNA-BINDING; TRANSCRIPTIONAL CONTROL; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; CDNA CLONING; ALPHA-ACTIN; CELLS; ISOFORMS	Despite the importance of smooth muscle cell proliferation in vascular pathophysiological states, the mechanisms regulating smooth muscle cell growth and differentiation are poorly understood. Previous studies have shown that adult rabbit smooth muscles express two types of myosin heavy chain (MHC) isoforms, SM1 and SM2, which are generated through alternative RNA splicing from a single smooth muscle MHC (SMHC) gene. In the present study, we isolated and characterized the rabbit SMHC gene promoter. DNA sequence analysis of the upstream region of the SMHC gene revealed several putative cis-DNA regulatory elements proximal to the transcription start site. Most notably, cis-acting regulatory elements that closely resemble CC(A/T)(6)GG (CArG box) and myocyte enhancer binding factor 2 (MEF-2)-type sequence motifs were found in the SMHC 5'-flanking region. In addition, six E-box motifs were found in the 5'-flanking region of the SMHC gene between -374 and -2109 base pairs from the transcription start site. A series of transient transfection assays using SMHC promoter deletion constructs indicated that a promoter fragment extending to 2266 base pairs upstream of the transcription start site has the highest reporter activity in cultured rat aortic smooth muscle cells. Gel mobility shift analyses using the MEF-2-like sequence located at -1540 revealed a specific DNA protein complex, whereas the CArG-like element located at -1275 did not show protein binding. The SMHC promoter construct, p509-CAT, which included neither the CArG- nor MEF-2-type motifs, conferred 32% of chloramphenicol acetyltransferase activity in the same cells, whereas the construct p188-CAT, which contained the minimal promoter elements (TATA box), was significantly less active (7%; 2.0-fold over background). This is the first report describing the promoter elements of a gene whose expression is restricted to smooth muscle cells.	UNIV CINCINNATI,COLL MED,DIV CARDIOL,MOLEC CARDIOL LAB,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,CARDIOVASC RES CTR,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati			Loukianov, Evgeny/AAC-9794-2022	Periasamy, Muthu/0000-0001-8834-5975; Kopras, Elizabeth J/0000-0001-5429-2609	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038355] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 38355] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; BABIJ P, 1992, AM J PHYSIOL, V262, pC607, DOI 10.1152/ajpcell.1992.262.3.C607; BABIJ P, 1991, P NATL ACAD SCI USA, V88, P10676, DOI 10.1073/pnas.88.23.10676; BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BORRIONE AC, 1989, EUR J BIOCHEM, V183, P413, DOI 10.1111/j.1432-1033.1989.tb14943.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRENT FR, 1987, CURRENT PROTOCOLS MO, V2; CARROLL SL, 1986, J BIOL CHEM, V261, P8965; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P475; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; FRID MG, 1992, DEV BIOL, V153, P185, DOI 10.1016/0012-1606(92)90104-O; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GULICK J, 1987, EUR J BIOCHEM, V169, P79, DOI 10.1111/j.1432-1033.1987.tb13583.x; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAHODA CAB, 1991, J CELL SCI, V99, P627; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KHOURYCHRISTIAN.AM, 1992, P NATL ACAD SCI USA, V89, P11503; KROPP KE, 1987, J BIOL CHEM, V262, P16536; KUROO M, 1991, J BIOL CHEM, V266, P3768; KUROO M, 1989, J BIOL CHEM, V264, P18272; MAHDAVI V, 1986, UCLA S MOL CELL BIOL, V29, P345; MANIATIS T, 1989, MOL CLONING LABORATO, P8; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; NAGAI R, 1989, J BIOL CHEM, V264, P9734; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; PELED A, 1991, BLOOD, V78, P304; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; ROBBINS J, 1989, GENE, V85, P541, DOI 10.1016/0378-1119(89)90449-6; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPPINO AP, 1990, LAB INVEST, V63, P144; SCHMITTGRAFF A, 1990, DIFFERENTIATION, V43, P115, DOI 10.1111/j.1432-0436.1990.tb00437.x; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; SUKOVICH DA, 1993, NUCLEIC ACIDS RES, V21, P2723, DOI 10.1093/nar/21.11.2723; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZAKUT R, 1982, NATURE, V298, P857, DOI 10.1038/298857a0; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	49	57	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30538	30545						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982972				2022-12-25	WOS:A1994PU52500077
J	QUICK, MW; SIMON, MI; DAVIDSON, N; LESTER, HA; ARAGAY, AM				QUICK, MW; SIMON, MI; DAVIDSON, N; LESTER, HA; ARAGAY, AM			DIFFERENTIAL COUPLING OF G-PROTEIN ALPHA-SUBUNITS TO 7-HELIX RECEPTORS EXPRESSED IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; THYROTROPIN-RELEASING-HORMONE; NUCLEOTIDE REGULATORY PROTEINS; BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; PERTUSSIS TOXIN; ALPHA-2-ADRENERGIC RECEPTOR; ESCHERICHIA-COLI; LAEVIS OOCYTES	Xenopus oocytes were used to examine the coupling of the serotonin 1c (5HT1c) and thyrotropin-releasing hormone (TRH) receptors to both endogenous and heterologously expressed G protein alpha subunits. Expression of either G protein-coupled receptor resulted in agonist-induced, Ca2+-activated Cl- currents that were measured using a two-electrode voltage clamp. 5HT-induced Cl- currents were reduced 80% by incubating the injected oocytes with pertussis toxin (PTX) and inhibited 50-65% by injection of antisense oligonucleotides to the PTX-sensitive Go alpha subunit. TRH-induced Cl- currents were reduced only 20% by PTX treatment but were inhibited 60% by injection of antisense oligonucleotides to the PTX-insensitive Gq alpha subunit. Injection of antisense oligonucleotides to a novel Xenopus phospholipase C-beta inhibited the 5HT1c (and Go)-induced Cl- current with little effect on the TRH (and Gq)-induced current. These results suggest that receptor-activated Go and Gq interact with different effecters, most likely different isoforms of phospholipase C-beta. Go-expression of each receptor with seven different mammalian G protein alpha subunit cRNAs (Goa, Gob, Gq, G11, Gs, Golf, and Gt) was also examined. Co-expression of either receptor with the first four of these G alpha subunits resulted in a maximum 4-6-fold increase in Cl- currents; the increase depended on the amount of G alpha subunit cRNA injected. This increase was blocked by PTX for G alpha oa and G alpha ob co-expression but not for G alpha q or G alpha 11 co-expression. Co-expression of either receptor with Gs, Golf, or Gt had no effect on Ca2+-activated Cl- currents; furthermore, co-expression with Gs or Golf also failed to reveal 5HT- or TRH-induced changes in adenylyl cyclase as assessed by activation of the cystic fibrosis transmembrane conductance regulator Cl- channel. These results indicate that in oocytes, the 5HT1c and TRH receptors do the following: 1) preferentially couple to PTX-sensitive (Go) and PTX-insensitive (Gq) G proteins and that these G proteins act on different effectors, 2) couple within the same cell type to several different heterologously expressed G protein alpha subunits to activate the oocyte's endogenous Cl- current, and 3) fail to couple to G protein alpha subunits that activate cAMP or phosphodiesterase.			QUICK, MW (corresponding author), CALTECH, DIV BIOL 15629, PASADENA, CA 91125 USA.		Aragay, Anna M/K-3813-2014	Aragay, Anna M/0000-0002-8240-4126	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049716] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29836] Funding Source: Medline; NIMH NIH HHS [MH-49716] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BLITZER RD, 1993, J BIOL CHEM, V268, P7532; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CANTIELLO HF, 1989, J BIOL CHEM, V264, P16000; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; CHABRE M, 1988, COLD SPRING HARB SYM, V53, P313, DOI 10.1101/SQB.1988.053.01.038; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COUPRY I, 1992, J BIOL CHEM, V267, P9852; DASCAL N, 1986, MOL BRAIN RES, V1, P201, DOI 10.1016/0169-328X(86)90026-4; DUZIC E, 1992, J BIOL CHEM, V267, P9844; GILLO B, 1987, J PHYSIOL-LONDON, V392, P349, DOI 10.1113/jphysiol.1987.sp016784; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KURACHI Y, 1992, PROG NEUROBIOL, V39, P229, DOI 10.1016/0301-0082(92)90017-9; LIPINSKY D, 1992, FEBS LETT, V307, P237, DOI 10.1016/0014-5793(92)80775-C; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LYNCH CJ, 1986, MOL PHARMACOL, V29, P196; MA HW, 1993, J BIOL CHEM, V268, P19915; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MCINTOSH RP, 1987, P NATL ACAD SCI USA, V84, P9045, DOI 10.1073/pnas.84.24.9045; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; OLATE J, 1989, FEBS LETT, V244, P188, DOI 10.1016/0014-5793(89)81190-1; ORON Y, 1987, MOL ENDOCRINOL, V1, P918, DOI 10.1210/mend-1-12-918; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; QUICK MW, 1992, BIOTECHNIQUES, V13, P357; QUICK MW, 1994, METH NEUROSCI, V19, P261; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; UEDA H, 1989, J BIOL CHEM, V264, P3732; UEZONO Y, 1993, RECEPTOR CHANNEL, V1, P233; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	54	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30164	30172						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982922				2022-12-25	WOS:A1994PU52500022
J	XUE, JC; CHEN, CG; ZHU, JM; KUNAPULI, S; DERIEL, JK; YU, L; LIUCHEN, LY				XUE, JC; CHEN, CG; ZHU, JM; KUNAPULI, S; DERIEL, JK; YU, L; LIUCHEN, LY			DIFFERENTIAL BINDING DOMAINS OF PEPTIDE AND NON PEPTIDE LIGANDS IN THE CLONED RAT KAPPA-OPIOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; NEUROKININ-1 RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; SELECTIVITY; ANTAGONIST; DYNORPHIN; BINALTORPHIMINE; AGONIST; GENES	This study was to identify specific regions in kappa opioid receptors that accounted for binding selectivity of kappa ligands. Six chimeric mu/kappa receptors were constructed from cloned rat kappa and mu opioid receptors and transiently expressed in COS-1 cells. All six chimeric mu/kappa receptors bound [H-3] diprenorphine with high affinities, indicating that these chimeras retain opioid receptor conformation. Binding affinities of three peptide ligands (dynorphin A, alpha-neo-endorphin, and dynorphin B) and three nonpeptide ligands (nor-binaltorphimine, U50,488H, and U69,593) for chimeras were determined and compared to those for mu and kappa opioid receptors. The second extracellular loop and the adjoining C-terminal portion of the fourth transmembrane helix were essential for the high affinity binding of dynorphin A, alpha-neo-endorphin, and dynorphin B to the kappa receptor. The third extracellular loop and the sixth and seventh transmembrane helices played an important role in determining the selectivity of nor-binaltorphimine for the kappa over the mu receptor. U50,488H and U69,593 appeared to require the whole kappa receptor except the second extracellular loop to attain high affinity binding. Thus, the kappa opioid receptor has differential binding domains for peptide and non-peptide ligands.	TEMPLE UNIV,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST MOLC BIOL & CANC RES,PHILADELPHIA,PA 19140; INDIANA UNIV,SCH MED,DEPT MED & MOLEC GENET,INDIANAPOLIS,IN 46202	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004745, R29DA004745] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 04745] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FONG TM, 1992, J BIOL CHEM, V267, P25668; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1993, NATURE, V362, P350; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOUGHTEN RA, 1983, LIFE SCI, V33, P1811, DOI 10.1016/0024-3205(83)90689-6; JAMES IF, 1984, J PHARMACOL EXP THER, V228, P88; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LAI J, 1992, J PHARMACOL EXP THER, V262, P173; LI SX, 1993, BIOCHEM J, V295, P629, DOI 10.1042/bj2950629; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; PASTERNAK GW, 1988, OPIATE RECEPTORS; PORTOGHESE PS, 1988, J MED CHEM, V31, P836, DOI 10.1021/jm00399a026; PORTOGHESE PS, 1987, LIFE SCI, V40, P1287, DOI 10.1016/0024-3205(87)90585-6; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; TURCOTTE A, 1984, INT J PEPT PROT RES, V23, P361; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7	32	129	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30195	30199						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982926				2022-12-25	WOS:A1994PU52500026
J	MACLEANHUNTER, S; MAKELA, TP; GRZESCHICZEK, A; ALITALO, K; MOROY, T				MACLEANHUNTER, S; MAKELA, TP; GRZESCHICZEK, A; ALITALO, K; MOROY, T			EXPRESSION OF A RLF L-MYC MINIGENE INHIBITS DIFFERENTIATION OF EMBRYONIC STEM-CELLS AND EMBROID BODY FORMATION	ONCOGENE			English	Article							C-MYC; DNA-BINDING; N-MYC; PROVIRAL INSERTION; MYELOID-LEUKEMIA; PROTEIN; GENE; GROWTH; ACTIVATION; APOPTOSIS	Rearrangements of the L-myc proto-oncogene with the cellular gene rlf occur in a subset of human small cell lung carcinoma (SCLC) resulting in the expression of a fusion protein. To investigate whether expression of such a rlf/L-myc fusion protein could contribute to the development of SCLC we constructed a chimeric minigene where the rlf first exon and the L-myc second and third exon are under the control of the rlf promoter thereby recapitulating the events of the rearrangement. Attempts to generate transgenic mice with this minigene showed that mouse embryos containing high copy numbers of the rlf/L-myc minigene fail to develop, suggesting that the expression of a rlf/L-myc fusion protein interferes with early differentiation processes. To investigate the nature of this potential embryonic lethality further, we transfected the rlf/L-myc construct stably into embryonic stem (ES) cells. Transfected ES lines that express the rlf/L-myc construct do not show a higher proliferation rate than the parental ES line but fail to properly develop embroid bodies. In addition, outgrowth and differentiation of cells from embroid bodies was severely impaired in ES cells expressing the rlf/L-myc construct when compared to normal ES cells, again suggesting an interference of rlf/L-myc expression with proper differentiation. Expression of a rlf/L-myc fusion may therefore be of critical importance in tumorigenesis by blocking differentiation and thereby allowing continued proliferation of cells and the aquisition of further mutations leading to a fully malignant tumor.	UNIV MARBURG, INST MOLEKULARBIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY; UNIV CAMBRIDGE, SCION HLTH LTD, CAMBRIDGE CB3 0JQ, ENGLAND; UNIV HELSINKI, DEPT PATHOL, MOLEC CANC BIOL LAB, SF-00014 HELSINKI, FINLAND	Philipps University Marburg; University of Cambridge; University of Helsinki			Alitalo, Kari K/J-5013-2014; Moroy, Tarik/D-9923-2011; makela, tomi/B-3734-2009	Alitalo, Kari K/0000-0002-7331-0902; makela, tomi/0000-0002-4869-8044				ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ASKEW DS, 1991, ONCOGENE, V6, P1915; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOLLER K, 1993, COLD SPRING HARBOR C, P39; BRULET P, 1980, P NATL ACAD SCI-BIOL, V77, P4113, DOI 10.1073/pnas.77.7.4113; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DOLCETTI R, 1989, ONCOGENE, V4, P1009; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HARLOW E, 1988, ANTIBODIES LABORATOR; HOGAN B, 1986, MANIPULATION MOUSE E; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KOSKINEN PJ, 1993, SEMIN CANCER BIOL, V4, P3; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; MAKELA TP, 1992, ONCOGENE, V7, P405; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENBAUM H, 1989, EMBO J, V8, P748; Sambrook J, 1989, MOL CLONING LABORATO; SETOGUCHI M, 1989, MOL CELL BIOL, V9, P4515, DOI 10.1128/MCB.9.10.4515; SEWING A, 1993, J CELL SCI, V104, P545; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VASTRIK I, 1994, IN PRESS CRIT REV ON; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	35	10	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3509	3517						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970711				2022-12-25	WOS:A1994PT39200013
J	DELPHIN, C; BAUDIER, J				DELPHIN, C; BAUDIER, J			THE PROTEIN-KINASE-C ACTIVATOR, PHORBOL ESTER, COOPERATES WITH THE WILD-TYPE P53 SPECIES OF RAS-TRANSFORMED EMBRYO FIBROBLASTS GROWTH ARREST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR TUMOR-ANTIGEN; NF-KAPPA-B; MUTANT P53; DNA-BINDING; CELLS; EXPRESSION; CYCLE; SUBSTRATE; PHOSPHORYLATION; PROLIFERATION	Clone 112 cells, a rat embryo fibroblast cell line cotransfected by an activated ras gene and a temperature-sensitive mutant p53 gene (p53val135) grow well at 37 degrees C but cease DNA synthesis and cell division when shifted to 32 degrees C (Michalovitz, D., Halevy, O., and Oren, M. (1990) Cell 62, 671-680). Characterization of the p53 protein in exponentially growing clone 112 cells at 37 degrees C revealed that both wild-type (reactive with the monoclonal antibody PAb 246) and mutant (reactive with PAb 240) p53 conformational forms are co-expressed. These results indicate that in clone 112 cells the growth suppressor activity of the wild-type p53 species is inactivated at 37 degrees C. We show that clone 112 cells grown at 37 degrees C elicits specific growth inhibition response to stimulation by the tumor promoter phorbol ester, phorbol 12-myristate 13-acetate (PMA). At 37 degrees C, PMA induced nuclear accumulation of the p53 protein, a behavior that is also observed in growth-arrested cells at 32 degrees C. Furthermore, when cells are growth arrested at 32 degrees C, PMA prevented the cells from re-entering the cell cycle when they are shifted back to 37 degrees C. All these observations suggest that PMA. can cooperate with the wild-type p53 in cell growth arrest. At 37 and 32 degrees C, PMA stimulation of clone 112 cells resulted in specific enhancement of phosphorylation of the wild-type p53 species but not of the mutant form. We also demonstrate that the growth arrest of clone 112 cells at 37 degrees C is correlated with stimulation of the nuclear wild-type p53-DNA binding activities. The PMA-mediated increase in p53 DNA binding activity coincides with the loss of the PAb 421 epitope on the p53 DNA complex, PAb 421 non-reactivity with p53 has been shown by others to occur in growth-arrested cells and upon phosphorylation of p53 by protein kinase C. We also provide evidence that, in vitro, the protein kinase C mode of phosphorylation stimulates DNA binding activities of purified recombinant wild-type p53 and that in a mutant conformation p53 is not a substrate for protein kinase C. We propose that wild-type p53 and protein kinase C, the cellular receptor of phorbol ester, could participate in the negative feedback controls associated with the phosphoinositide-derived signals common to a number of mitogenic stimulations.	CEN,CEA,INSERM,U309,DEPT BIOL MOLEC & STRUCT,F-38041 GRENOBLE,FRANCE	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)			Baudier, Jacques/O-2183-2016	jacques, baudier/0000-0001-8427-4444				BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BORNER C, 1992, J BIOL CHEM, V267, P12892; CACACE AM, 1993, ONCOGENE, V8, P2095; DELOULME JC, 1990, J CELL BIOL, V111, P1559, DOI 10.1083/jcb.111.4.1559; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; DOTTO GP, 1985, NATURE, V318, P472; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1988, ONCOGENE, V3, P313; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; HERGET T, 1993, P NATL ACAD SCI USA, V90, P2945, DOI 10.1073/pnas.90.7.2945; HSIAO WWL, 1989, MOL CELL BIOL, V267, P2641; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HUPP TR, 1994, IN PRESS COLD SPRING; KHOCHBIN S, 1989, CYTOMETRY, V10, P484, DOI 10.1002/cyto.990100418; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SKOUV J, 1994, CELL GROWTH DIFFER, V5, P329; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	43	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29579	29587						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961944				2022-12-25	WOS:A1994PU28400043
J	HANNAERTMERAH, Z; COQUIL, JF; COMBETTES, L; CLARET, M; MAUGER, JP; CHAMPEIL, P				HANNAERTMERAH, Z; COQUIL, JF; COMBETTES, L; CLARET, M; MAUGER, JP; CHAMPEIL, P			RAPID KINETICS OF MYOINOSITOL TRISPHOSPHATE BINDING AND DISSOCIATION IN CEREBELLAR MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE RECEPTOR; SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; FUNCTIONAL-CHARACTERIZATION; PERIPHERAL-TISSUES; POSSIBLE MECHANISM; INSP3 RECEPTOR; CA-2+ RELEASE; CA2+ RELEASE; SITES	Using sheep cerebellum microsomes adsorbed on a filter, we measured the kinetics of [H-3]inositol 1,4,5-trisphosphate (InsP(3)) binding and dissociation on the subsecond time scale during rapid perfusion of the filter with [(3H)]InsP(3)-containing or InsP(3)-free media. At 20 degrees C and pH 7.1, in a cytosol-Like medium containing MgCl2, the half-time for InsP(3) dissociation was as short as 125 ms. The receptor behaved as a simple target for binding of its ligand, with the rate constant for InsP(3) binding increasing Linearly with InsP(3) concentration. Various modulators of InsP(3) binding (KCl, NaCl, pH, Mg2+, and Ca2+) mere found to affect the receptor's apparent affinity for InsP(3) mainly by altering the rate constant for [H-3]InsP(3), dissociation. ATP (but not InsP(3)) also accelerated [H-3]InsP(3) dissociation. In contrast to these modulators, luminal Ca2+ was found to have no effect on the amount of microsome-bound [(3H)]LnsP(3).	CTR ETUD SACLAY,CEA,DEPT BIOL CELLULAIRE & MOLEC,BIOPHYS PROT & MEMBRANES SECT,F-91191 GIF SUR YVETTE,FRANCE; UNIV PARIS 11,INSERM,U274,UNITE RECH,F-91405 ORSAY,FRANCE; ECOLE CENT PARIS,BIOL LAB,F-92295 CHATENAY MALABRY,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	HANNAERTMERAH, Z (corresponding author), CTR ETUD SACLAY,CNRS,URA 1290,F-91191 GIF SUR YVETTE,FRANCE.		Combettes, Laurent/L-1842-2013	Combettes, Laurent/0000-0002-1376-4574				BAUKAL AJ, 1985, BIOCHEM BIOPH RES CO, V133, P532, DOI 10.1016/0006-291X(85)90939-8; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; CALLAMARAS N, 1994, CELL CALCIUM, V15, P66, DOI 10.1016/0143-4160(94)90105-8; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; COMBETTES L, 1994, J BIOL CHEM, V269, P17561; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; DUPONT Y, 1987, METHOD ENZYMOL, V148, P675; DUPONT Y, 1984, ANAL BIOCHEM, V142, P505; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; GUILLEMETTE G, 1987, J BIOL CHEM, V262, P1010; HILLY M, 1993, J BIOL CHEM, V268, P16488; HINGORANI SR, 1991, ANAL BIOCHEM, V194, P204, DOI 10.1016/0003-2697(91)90169-T; HIROMI K, 1979, KINETICS FAST ENZYME, P255; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; KAMATA H, 1992, J BIOCHEM-TOKYO, V111, P546, DOI 10.1093/oxfordjournals.jbchem.a123793; KHODAKHAH K, 1993, P NATL ACAD SCI USA, V90, P4976, DOI 10.1073/pnas.90.11.4976; KUNO M, 1994, BIOCHEM BIOPH RES CO, V199, P1128, DOI 10.1006/bbrc.1994.1348; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAYRLEITNER M, 1991, CELL CALCIUM, V12, P505, DOI 10.1016/0143-4160(91)90032-A; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MOHR FC, 1993, BIOCHIM BIOPHYS ACTA, V1147, P105, DOI 10.1016/0005-2736(93)90320-Y; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; OLDERSHAW KA, 1993, BIOCHEM J, V292, P631, DOI 10.1042/bj2920631; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARYS JB, 1993, J BIOL CHEM, V268, P25206; RIBEIRODOVALLE RM, 1994, CELL CALCIUM, V15, P79, DOI 10.1016/0143-4160(94)90106-6; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROUXEL FP, 1992, J BIOL CHEM, V267, P20017; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; VANDELDEN C, 1993, J BIOL CHEM, V268, P12443; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; WHITE AM, 1991, BIOCHEM J, V278, P759, DOI 10.1042/bj2780759; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAMAGUCHI M, 1989, METHOD ENZYMOL, V157, P233	49	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29642	29649						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961953				2022-12-25	WOS:A1994PU28400053
J	NADEAU, OW; CARLSON, GM				NADEAU, OW; CARLSON, GM			ZERO LENGTH CONFORMATION-DEPENDENT CROSS-LINKING OF PHOSPHORYLASE-KINASE SUBUNITS BY TRANSGLUTAMINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT-SKELETAL-MUSCLE; CALMODULIN BINDING DOMAINS; BETA-SUBUNITS; MOLECULAR-BASIS; PROTEIN-KINASE; ALPHA-SUBUNITS; GAMMA-SUBUNIT; CDNA CLONING; B KINASE; IDENTIFICATION	Transglutaminase, a zero length cross-linker that catalyzes the formation of isopeptide bonds between proximal Gln and Lys side chains, was used as a structural and conformational probe of the hexadecameric phosphorylase kinase molecule (alpha beta gamma delta)(4). Brief cross-linking of nonactivated kinase caused formation of alpha-beta dimers, with no cross-linking involving the gamma- and delta-subunits. When the kinase was first activated by autophosphorylation, significant amounts of (alpha-alpha dimers were also observed in addition to the alpha-beta, demonstrating the occurrence of a conformational change in the alpha-subunits concomitant with activation. Both dimers resulted from intramolecular cross-linking. Because the COOH-terminal regions of the alpha-subunits are at the lobe tips of this bilobal kinase (Wilkinson D. A, Marion, T. N., Tillman, D. Ri., Norcum, M. T., Hainfeld, J. F., Seyer, J. Ri., and Carlson, G. M. (1994) J. Mel. Biol. 235, 974-982), the formation of zero length cross-linked alpha-alpha dimers indicates that the polypeptide backbones of these subunits must stretch from the lobe tips to a more central location where they abut each other. Excess putrescine, as the amine substrate in place of endogenous Lys, was incorporated by transglutaminase predominately into the alpha-subunits of the kinase, with only slight modification of the beta- and gamma-subunits. Exogenous calmodulin (delta'), an activator of the kinase with a binding site on the alpha-subunits (James, P., Cohen, P., and Carafoli, E. (1991) J. Biol. Chem. 266, 7087-7091), was a potent inhibitor of crosslinking. It also inhibited incorporation of putrescine into the alpha-subunits but stimulated incorporation into the beta- and gamma-subunits. Heparin, another activator of the kinase, had the same effects as exogenous calmodulin on cross-linking and putrescine incorporation, suggesting a commonality in the mechanism through which these two effecters activate the holoenzyme, including promoting a conformational change that increases the surface accessibility of target Gln residues on the catalytic gamma subunit.	UNIV TENNESSEE, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center					NIDDK NIH HHS [DK32953] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032953] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOLLEN M, 1987, ARCH BIOCHEM BIOPHYS, V254, P437, DOI 10.1016/0003-9861(87)90122-6; CARLSON GM, 1982, FED PROC, V41, P869; CHAN KFJ, 1982, J BIOL CHEM, V257, P5956; CHENG A, 1988, J BIOL CHEM, V263, P5534; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; COHEN P, 1983, METHOD ENZYMOL, V99, P243; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; COUSSONS PJ, 1992, BIOCHEM J, V282, P929, DOI 10.1042/bj2820929; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; FITZGERALD TJ, 1984, J BIOL CHEM, V259, P3266; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GRAND RJA, 1981, EUR J BIOCHEM, V113, P359, DOI 10.1111/j.1432-1033.1981.tb05074.x; HARMANN B, 1991, J BIOL CHEM, V266, P15631; HEILMEYER LMG, 1991, BIOCHIM BIOPHYS ACTA, V1094, P168, DOI 10.1016/0167-4889(91)90005-I; HEILMEYER LMG, 1993, MOL CELL BIOCHEM, V128, P19, DOI 10.1007/BF01076754; HESSOVA Z, 1985, EUR J BIOCHEM, V146, P107, DOI 10.1111/j.1432-1033.1985.tb08626.x; HINRICHSEN A, 1989, BIOL CHEM H-S, V370, P125, DOI 10.1515/bchm3.1989.370.1.125; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JAMES P, 1991, J BIOL CHEM, V266, P7087; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KILIMANN MW, 1988, P NATL ACAD SCI USA, V85, P9381, DOI 10.1073/pnas.85.24.9381; KING MM, 1983, J BIOL CHEM, V258, P9925; KING MM, 1981, J BIOL CHEM, V256, P1058; KREBS EG, 1964, BIOCHEMISTRY-US, V3, P1022, DOI 10.1021/bi00896a003; KREBS EG, 1956, BIOCHIM BIOPHYS ACTA, V20, P150, DOI 10.1016/0006-3002(56)90273-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LORAND L, 1968, BIOCHEMISTRY-US, V7, P1214, DOI 10.1021/bi00843a043; LORAND L, 1972, ANAL BIOCHEM, V50, P623, DOI 10.1016/0003-2697(72)90074-7; NADEAU OW, 1993, FASEB J, V7, pA1162; NEWSHOLME P, 1992, J BIOL CHEM, V267, P810; NORCUM MT, 1994, J MOL BIOL, V241, P94, DOI 10.1006/jmbi.1994.1476; Pickett-Gies CA., 1986, ENZYMES, V17, P395; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SANCHEZBLANCO VE, 1993, THESIS U TENNESSEE M; SHARMA RK, 1980, J BIOL CHEM, V255, P1102; SHENOLIKAR S, 1979, EUR J BIOCHEM, V100, P329, DOI 10.1111/j.1432-1033.1979.tb04175.x; SKUSTER JR, 1980, J BIOL CHEM, V255, P2203; TREMPE MR, 1987, J BIOL CHEM, V262, P4333; TREMPE MR, 1986, J BIOL CHEM, V261, P2882; WILKINSON DA, 1994, J MOL BIOL, V235, P974, DOI 10.1006/jmbi.1994.1051; WILKINSON DA, 1993, THESIS U TENNESSEE M; ZANDER NF, 1988, P NATL ACAD SCI USA, V85, P2929, DOI 10.1073/pnas.85.9.2929	47	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29670	29676						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961956				2022-12-25	WOS:A1994PU28400057
J	STOCKEL, J; MEINL, E; HAHNEL, C; MALOTKA, J; SEITZ, R; DREXLER, K; WEKERLE, H; DORNMAIR, K				STOCKEL, J; MEINL, E; HAHNEL, C; MALOTKA, J; SEITZ, R; DREXLER, K; WEKERLE, H; DORNMAIR, K			REFOLDING OF HUMAN CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES ISOLATED FROM ESCHERICHIA-COLI - ASSEMBLY OF PEPTIDE-FREE HETERODIMERS AND INCREASED REFOLDING-YIELD IN THE PRESENCE OF ANTIGENIC PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; SEPARATE ALPHA-CHAINS; MHC MOLECULE; IMMUNOGENIC PEPTIDES; DENATURED RHODANESE; MULTIPLE-SCLEROSIS; SURFACE EXPRESSION; PH-DEPENDENCE; BETA-CHAINS; HEAVY-CHAIN	The alpha- and beta-chains of the heterodimeric major histocompatibility complex molecules HLA-DRB5*0101 and DRB1*0101 were expressed separately in Escherichia coli. The cytoplasmic and membrane-spanning domains of both chains were replaced by oligohistidine tags to allow purification by metal chelate chromatography. The recombinant proteins were refolded to peptide-free, water-soluble heterodimers by removal of major amounts of detergents and concomitant reoxidiation of disulfide bonds. Correct conformation was documented by three criteria: (a) affinity binding experiments using the antibody L243, which is known to recognize a conformational epitope formed only by correctly associated heterodimers; (b) specific binding of peptides to the refolded molecules; (c) recognition of peptides bound to refolded HLA-DR molecules by T-cells as reflected by Ca2+ influx into T cells and production of interferon-gamma. The refolding reaction did not absolutely depend on the presence of peptides. The yield of peptide-free heterodimers was 3.0%. However, the yield of refolded heterodimer was increased to 10% if refolding was performed in the presence of antigenic peptides.	MAX PLANCK INST PSYCHIAT,NEUROIMMUNOL ABT,D-82152 MARTINSRIED,GERMANY	Max Planck Society				Meinl, Edgar/0000-0002-2570-6785				AGRAWAL B, 1994, J IMMUNOL, V152, P965; ALTMAN JD, 1993, P NATL ACAD SCI USA, V90, P10330, DOI 10.1073/pnas.90.21.10330; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BUELOW R, 1993, EUR J IMMUNOL, V23, P69, DOI 10.1002/eji.1830230112; CARLSON JD, 1992, BIO-TECHNOL, V10, P86, DOI 10.1038/nbt0192-86; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; DORNMAIR K, 1990, P NATL ACAD SCI USA, V87, P4134, DOI 10.1073/pnas.87.11.4134; DORNMAIR K, 1991, P NATL ACAD SCI USA, V88, P1335, DOI 10.1073/pnas.88.4.1335; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P3121, DOI 10.1002/eji.1830221214; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GIEGERICH G, 1992, EUR J IMMUNOL, V22, P753, DOI 10.1002/eji.1830220319; GOOCHEE CF, 1991, BIO-TECHNOL, V9, P1347, DOI 10.1038/nbt1291-1347; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; HUTH JR, 1993, J BIOL CHEM, V268, P16472; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; JENSEN PE, 1991, J EXP MED, V174, P1111, DOI 10.1084/jem.174.5.1111; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASALLE JM, 1992, J EXP MED, V176, P177, DOI 10.1084/jem.176.1.177; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MEINL E, 1993, J CLIN INVEST, V92, P2633, DOI 10.1172/JCI116879; MOURITSEN S, 1992, J IMMUNOL, V148, P1438; MUELLER DL, 1990, J IMMUNOL, V144, P3701; NAG B, 1992, J IMMUNOL, V148, P369; PARKER KC, 1992, J BIOL CHEM, V267, P5451; REAY PA, 1992, EMBO J, V11, P2829, DOI 10.1002/j.1460-2075.1992.tb05350.x; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; ROTNES JS, 1994, EUR J IMMUNOL, V24, P851, DOI 10.1002/eji.1830240412; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SCHEIRLE A, 1992, J IMMUNOL, V149, P1994; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; SETTE A, 1992, J IMMUNOL, V148, P844; SPRINGER TA, 1977, J BIOL CHEM, V252, P6201; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TAMPE R, 1991, P NATL ACAD SCI USA, V88, P10667, DOI 10.1073/pnas.88.23.10667; TANDON S, 1987, J BIOL CHEM, V262, P4486; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VALLI A, 1993, J CLIN INVEST, V91, P616, DOI 10.1172/JCI116242; WEBER F, 1993, P NATL ACAD SCI USA, V90, P11049, DOI 10.1073/pnas.90.23.11049; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; WILKINSON D, 1988, J EXP MED, V167, P1442, DOI 10.1084/jem.167.4.1442; WITT SN, 1992, J AM CHEM SOC, V114, P3506, DOI 10.1021/ja00035a052; ZARDENETA G, 1992, J BIOL CHEM, V267, P5811; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; 1992, IMMUNOGENETICS, V36, P135	63	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29571	29578						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961943				2022-12-25	WOS:A1994PU28400042
J	WELLS, NJ; ADDISON, CM; FRY, AM; GANAPATHI, R; HICKSON, ID				WELLS, NJ; ADDISON, CM; FRY, AM; GANAPATHI, R; HICKSON, ID			SERINE-1524 IS A MAJOR SITE OF PHOSPHORYLATION ON HUMAN TOPOISOMERASE II-ALPHA PROTEIN IN-VIVO AND IS A SUBSTRATE FOR CASEIN KINASE-II IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-DEPENDENT PHOSPHORYLATION; DNA TOPOISOMERASE; SACCHAROMYCES-CEREVISIAE; PHORBOL ESTER; CELL-LINE; YEAST; CHROMOSOMES; MITOSIS; ENZYME; SEGREGATION	Topoisomerase II protein is essential for cell proliferation and is known to exist as a phosphoprotein in cells from both lower and higher eukaryotic species. In this paper, we have investigated the phosphorylation of the alpha isozyme of human topoisomerase II. The topoisomerase II alpha protein was phosphorylated predominantly on serine residues in the human tumor cell lines HeLa and NSCLC-3. Two-dimensional tryptic phosphopeptide mapping studies revealed several sites of phosphorylation in vivo, including a major site that was common to topoisomerase II alpha protein from both HeLa and NSCLC-3 cells. To identify sites of phosphorylation, the regulatory C-terminal domain of human topoisomerase II alpha protein was overexpressed in Escherichia coli as a hexahistidine-tagged fusion protein and purified by nickel chelate chromatography. Tryptic phosphopeptide mapping revealed that casein kinase II phosphorylated the C-terminal domain primarily on 2 serine residues in vitro, which were shown to be sites of modification in vivo. Site-directed mutagenesis studies identified these casein kinase II-specific phosphorylation sites as serine 1524 and serine 1376.	UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND LABS, OXFORD OX3 9DU, ENGLAND; CLEVELAND CLIN FDN, RES INST, CLEVELAND, OH 44195 USA	Cancer Research UK; University of Oxford; Cleveland Clinic Foundation			Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X	NATIONAL CANCER INSTITUTE [R01CA035531] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA35531] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEVORE RF, 1992, CANCER RES, V52, P2156; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; FRY AM, 1992, BRIT J CANCER, V65, P24; GANAPATHI R, 1993, BIOCHEM BIOPH RES CO, V192, P1274, DOI 10.1006/bbrc.1993.1554; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; Hsieh T, 1990, CURR OPIN CELL BIOL, V2, P461, DOI 10.1016/0955-0674(90)90128-2; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NEGRI C, 1992, EXP CELL RES, V200, P452, DOI 10.1016/0014-4827(92)90195-E; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; ROSE D, 1993, MOL CELL BIOL, V13, P3445, DOI 10.1128/MCB.13.6.3445; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SMITH PJ, 1989, CANCER RES, V49, P1118; TAN KB, 1992, CANCER RES, V52, P231; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT P, 1994, IN PRESS BIOCH J; WOODGETT JR, 1992, NEURONAL CELL LINES, P133	44	90	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29746	29751						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961967				2022-12-25	WOS:A1994PU28400068
J	KUROSE, T; PASHMFOROUSH, M; YOSHIMASA, Y; CARROLL, R; SCHWARTZ, GP; BURKE, GT; KATSOYANNIS, PG; STEINER, DF				KUROSE, T; PASHMFOROUSH, M; YOSHIMASA, Y; CARROLL, R; SCHWARTZ, GP; BURKE, GT; KATSOYANNIS, PG; STEINER, DF			CROSS-LINKING OF A B25 AZIDOPHENYLALANINE INSULIN DERIVATIVE TO THE CARBOXYL-TERMINAL REGION OF THE ALPHA-SUBUNIT OF THE INSULIN-RECEPTOR - IDENTIFICATION OF A NEW INSULIN-BINDING DOMAIN IN THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; LIGAND-BINDING; ABNORMAL INSULIN; MONOCLONAL-ANTIBODIES; STRUCTURAL BASIS; 2 ISOFORMS; DETERMINANTS; SITE; CHAIN; GENE	To identify a site within the insulin receptor ectodomain which forms a binding pocket for B25 Phe and is responsible for initiating conformational changes required for high affinity binding of insulin we have used a novel photoreactive insulin, despentapeptide-(B26-B30) [B25 p-azidophenylalanine-alpha-carboxamide] insulin (APC insulin). This derivative has a highly photoreactive azido group incorporated into the aromatic ring of the B25 phenylalanine amide. APC insulin bound to human insulin receptors overexpressed on a transfected Chinese hamster ovary cell line (P3-A) with an apparent potency of 9-fold relative to that of native insulin and stimulated lipogenesis in rat adipocytes with an average potency equal to porcine insulin. Addition of biotin to the B1 Phe amino group to form despentapeptide-(B26-B30) [B1 (6-biotinylamidocaproyl)phenylalanine B25 p-azidophenylalanine-alpha-carboxamide] insulin derivative (Bio APC insulin) did not adversely affect receptor-binding affinity and provided a convenient ligand for purification of cross-linked complexes. The efficiency of receptor cross-linking with these reagents was high (70%). To identify the site(s) of cross-linking, the insulin receptor in P3-Acells was first metabolically labeled with various individual H-3-labeled amino acids and then pho to affinity labeled with I-125-Bio-APC insulin, isolated, and digested with Lys-C endoproteinase. The resulting crosslinked peptide fragments were separated by streptavidin-affinity chromatography and sequenced. The smallest identified fragment comprised residues 704-718 of the COOH terminus of the alpha-subunit of the insulin receptor. This B25 Phe cross-linked region of the alpha-subunit lies just upstream of the Exon 11-encoded 12-amino acid COOH-terminal region. Aromatic residues in this predicted alpha-helical region may form a binding pocket for B25 Phe to initiate conformational changes required for stabilizing the high affinity binding state.	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	Howard Hughes Medical Institute; University of Chicago; University of Chicago; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013914, R01DK013914, R01DK012925, P60DK020595] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 20595, DK 13914, DK 12925] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; Bayley H, 1977, Methods Enzymol, V46, P69; BI RC, 1984, BIOPOLYMERS, V23, P391, DOI DOI 10.1002/BIP.360230302; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FABRY M, 1992, J BIOL CHEM, V267, P8950; FAHRENHOLZ F, 1980, INT J PEPT PROT RES, V15, P323; GARBAYJAUREGUIBERRY C, 1984, P NATL ACAD SCI-BIOL, V81, P7718, DOI 10.1073/pnas.81.24.7718; GEIGER R, 1971, Hoppe-Seyler's Zeitschrift fuer Physiologische Chemie, V352, P1487, DOI 10.1515/bchm2.1971.352.2.1487; GIVEN BD, 1980, NEW ENGL J MED, V302, P129, DOI 10.1056/NEJM198001173020301; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HANGAUER DG, 1984, BIOCHEMISTRY-US, V23, P5730, DOI 10.1021/bi00319a011; HEDO JA, 1981, BIOCHEMISTRY-US, V20, P3385, DOI 10.1021/bi00515a013; HOFMANN K, 1984, BIOCHEMISTRY-US, V23, P2547, DOI 10.1021/bi00307a002; HUA QX, 1992, P NATL ACAD SCI USA, V89, P2379, DOI 10.1073/pnas.89.6.2379; JOSHI S, 1990, J PROTEIN CHEM, V9, P235, DOI 10.1007/BF01025314; KATSOYAN.PG, 1967, BIOCHEMISTRY-US, V6, P2656, DOI 10.1021/bi00861a003; KELLERER M, 1993, DIABETOLOGIA, V36, P628, DOI 10.1007/BF00404072; KUBIAK T, 1986, INT J PEPT PROT RES, V27, P514; KWOK SCM, 1983, DIABETES, V32, P872, DOI 10.2337/diabetes.32.9.872; MARKUSSEN J, 1985, INT J PEPT PROT RES, V26, P70; MASAKI T, 1978, AGR BIOL CHEM TOKYO, V42, P1443, DOI 10.1080/00021369.1978.10863183; MCCLAIN DA, 1991, MOL ENDOCRINOL, V5, P734, DOI 10.1210/mend-5-5-734; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOSTHAF L, 1993, P NATL ACAD SCI USA, V90, P2633, DOI 10.1073/pnas.90.7.2633; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; NAKAGAWA SH, 1986, J BIOL CHEM, V261, P7332; NORGREN S, 1993, DIABETES, V42, P675, DOI 10.2337/diabetes.42.5.675; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; RUBENSTEIN AH, 1969, DIABETES, V18, P598, DOI 10.2337/diab.18.9.598; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; SINGH J, 1985, FEBS LETT, V191, P1, DOI 10.1016/0014-5793(85)80982-0; TAGER H, 1979, NATURE, V281, P122, DOI 10.1038/281122a0; TAGER HS, 1990, MOL BIOL ISLETS LANG, P263; ULLRICH A, 1985, NATURE, V313, P7566; VOGT B, 1991, BIOCHEM BIOPH RES CO, V177, P1013, DOI 10.1016/0006-291X(91)90639-O; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; YAMAGUCHI Y, 1993, ENDOCRINOLOGY, V132, P1132, DOI 10.1210/en.132.3.1132; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	53	94	114	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29190	29197						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961885				2022-12-25	WOS:A1994PU16800098
J	YUAN, HS; WANG, SS; YANG, WZ; FINKEL, SE; JOHNSON, RC				YUAN, HS; WANG, SS; YANG, WZ; FINKEL, SE; JOHNSON, RC			THE STRUCTURE OF FIS MUTANT PRO(61)ALA ILLUSTRATES THAT THE KINK WITHIN THE LONG ALPHA-HELIX IS NOT DUE TO THE PRESENCE OF THE PROLINE RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN FIS; DNA INVERSION; AMINO-ACIDS; CONFORMATION; REFINEMENT	The influence of proline on bending of the alpha-helix was investigated by replacement of the proline residue located in the middle of the long alpha-helix of the Fis protein with alanine, serine, or leucine. Each of the three substitutions folded into a stable protein with the same or higher melting points than the wild-type, but only Pro(61)Ala was functionally active in stimulating Hin-mediated DNA inversion. Pro(61)Ala formed crystals that were isomorphous with the wild-type protein allowing the structure to be determined at 1.9-Angstrom resolution by x-ray diffraction methods. The structure of the Pro(61)Ala mutant is almost identical to the wild-type protein, consistent with its near wild-type activity. One of the alpha-helices, the B-helix, is kinked in the wild-type Fis protein by 20 degrees which was previously assumed to be caused solely by the presence of proline 61 in the center of the helix. However, the B-helix is still kinked by 16 degrees when proline 61 is replaced by alanine. Local peptide backbone movement around residue 57 adjusts the geometry of the helix to accommodate the new main chain hydrogen bond between the -CO group in Glu(57) and the -NH group in Ala(61). Thus, the kink of the alpha-helix in Pro(61)Ala does not require the presence of proline.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	YUAN, HS (corresponding author), ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN.		Yuan, Hanna S./AAA-4005-2021	Yuan, Hanna S./0000-0001-9671-6967	NIGMS NIH HHS [GM38509] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038509, R01GM038509] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BLUNDELL T, 1983, NATURE, V306, P281, DOI 10.1038/306281a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DEMPSEY CE, 1991, FEBS LETT, V281, P240, DOI 10.1016/0014-5793(91)80402-O; ELWELL M, 1975, BIOCHIM BIOPHYS ACTA, V386, P309, DOI 10.1016/0005-2795(75)90273-1; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; KOCH C, 1986, J BIOL CHEM, V261, P5673; KOCH C, 1991, NUCLEIC ACIDS RES, V19, P5915, DOI 10.1093/nar/19.21.5915; KOSTREWA D, 1992, J MOL BIOL, V226, P209, DOI 10.1016/0022-2836(92)90134-6; KOSTREWA D, 1991, NATURE, V349, P178, DOI 10.1038/349178a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LYU PC, 1991, P NATL ACAD SCI USA, V88, P5317, DOI 10.1073/pnas.88.12.5317; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MERUTKA G, 1990, BIOCHEMISTRY-US, V29, P7511, DOI 10.1021/bi00484a021; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSUNA R, 1991, EMBO J, V10, P1593, DOI 10.1002/j.1460-2075.1991.tb07680.x; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PAN CQ, 1994, P NATL ACAD SCI USA, V91, P1721, DOI 10.1073/pnas.91.5.1721; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SANKARARAMAKRISHNAN R, 1993, PROTEINS, V15, P26, DOI 10.1002/prot.340150105; SAUER UH, 1992, J BIOL CHEM, V267, P2393; YUAN HS, 1991, P NATL ACAD SCI USA, V88, P9558, DOI 10.1073/pnas.88.21.9558	26	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28947	28954						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961857				2022-12-25	WOS:A1994PU16800067
J	KOMIYA, T; HACHIYA, N; SAKAGUCHI, M; OMURA, T; MIHARA, K				KOMIYA, T; HACHIYA, N; SAKAGUCHI, M; OMURA, T; MIHARA, K			RECOGNITION OF MITOCHONDRIA-TARGETING SIGNALS BY A CYTOSOLIC IMPORT STIMULATION FACTOR, MSF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; RAT-LIVER; PROTEIN TRANSLOCATION; BINDING-SPECIFICITY; EXTENSION PEPTIDES; ENZYME PRECURSORS; MEMBRANE; AMPHIPHILICITY; POLYPEPTIDES; PRESEQUENCES	MSF, a mitochondrial import stimulation factor purified from rat liver cytosol, is an ATP-dependent precursor protein conformational modulator. As a step toward understanding the specificity of substrate recognition by MSF, various synthetic peptides were examined for their ability to induce MSF ATPase activity. The peptides corresponding to various mitochondria-targeting signal sequences elicited significant ATPase activity. MSF bound the synthetic mitochondrial signal peptides, and ATP hydrolysis caused dissociation of the peptides from MSF. Basic amino acid residues in the signal peptides seemed to be essential for recognition. Thus, MSF is a member of the polypeptide chain-binding protein family with unique recognition specificity and is distinct from the hsp70 family of proteins.	KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN	Kyushu University								AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALAM R, 1994, J BIOCHEM-TOKYO, V116, P416, DOI 10.1093/oxfordjournals.jbchem.a124541; ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DEKROON AIPM, 1991, BIOCHIM BIOPHYS ACTA, V1068, P111, DOI 10.1016/0005-2736(91)90199-I; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FURUYA S, 1987, J BIOCHEM, V102, P821, DOI 10.1093/oxfordjournals.jbchem.a122121; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1991, Current Opinion in Cell Biology, V3, P580, DOI 10.1016/0955-0674(91)90026-U; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HACHIYA N, 1994, IN PRESS EMBO J, V13; HARANO T, 1988, J BIOCHEM-TOKYO, V103, P149, DOI 10.1093/oxfordjournals.jbchem.a122221; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; ITO A, 1985, J BIOCHEM-TOKYO, V98, P1571, DOI 10.1093/oxfordjournals.jbchem.a135426; IWAHASHI J, 1994, J BIOCHEM-TOKYO, V116, P156, DOI 10.1093/oxfordjournals.jbchem.a124488; KUMAMOTO T, 1989, J BIOCHEM-TOKYO, V105, P72, DOI 10.1093/oxfordjournals.jbchem.a122622; KUMAMOTO T, 1987, J BIOCHEM-TOKYO, V102, P833, DOI 10.1093/oxfordjournals.jbchem.a122122; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; LITHGOW T, 1993, FEBS LETT, V329, P1, DOI 10.1016/0014-5793(93)80179-X; MIHARA K, 1990, J BIOCHEM-TOKYO, V108, P1022, DOI 10.1093/oxfordjournals.jbchem.a123301; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI K, 1993, J BIOCHEM-TOKYO, V113, P61, DOI 10.1093/oxfordjournals.jbchem.a124004; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; PARK N G, 1989, Peptide Research, V2, P178; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; SUBRAMANI S, 1992, J MEMBRANE BIOL, V125, P99; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WELCH WJ, 1985, MOL CELL BIOL, V5, P1571, DOI 10.1128/MCB.5.7.1571; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x	47	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30893	30897						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983021				2022-12-25	WOS:A1994PV51000027
J	NAKAMURA, J; FURUKOHRI, T				NAKAMURA, J; FURUKOHRI, T			2 TYPES OF PROTON-MODULATED CALCIUM-BINDING IN THE SARCOPLASMIC-RETICULUM CA2+-ATPASE .1. A MODEL OF 2 DIFFERENT CONFORMATIONS OF CHEMICALLY EQUIVALENT ATPASE MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ADENOSINE-TRIPHOSPHATASE; HIGH-AFFINITY; CA-2+-ATPASE; PUMP; MECHANISM; CA-2+; SITES; TEMPERATURE; MEMBRANE	Two pools of calcium binding sites of the sarcoplasmic reticulum Ca2+-ATPase have been found at 0 degrees C: Half of the calcium sites are in a slow (t(1/2) greater than or equal to 2 s)/rapid (t(1/2) < 2 s) binding state dependent on pH, and the other half are in a slow binding state independent of pH (Nakamura, J. (1989) J. Biol. Chem. 264, 17029-17031). Herein, to clarify the molecular basis of the two calcium sites, the relation between calcium binding to the enzyme and phosphorylation of the enzyme was examined at pH 7.40, where the calcium sites are split into rapid and slow binding states. The enzyme was slowly or rapidly phosphorylated with ATP, accompanied by slow or rapid calcium binding with a stoichiometry of about 1:2. Analysis of the amino acid sequence of lysyl endopeptidase peptides of the ATPase preparation confirmed the homogeneity of the preparation, which was of fast twitch muscle type. These results suggest that each of the two pools of calcium sites belongs to one of the two different conformations of chemically equivalent ATPase molecules, which are in pH-dependent equilibrium between E(1) (high affinity state for calcium) and E(2) (low affinity state for calcium) and predominantly in E(2) independent of pH, respectively, before calcium binding.	KOCHI UNIV, FAC SCI, INST BIOL, KOCHI 780, JAPAN	Kochi University	NAKAMURA, J (corresponding author), TOHOKU UNIV, FAC SCI, INST BIOL, AOBA KU, AOBA YAMA, SENDAI, MIYAGI 980, JAPAN.							BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; De Meis L., 1982, MEMBRANE TRANSPORT C, P141; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; FORGE V, 1993, J BIOL CHEM, V268, P10961; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; HASSELBACH W, 1964, PROG BIOPHYS MOL BIO, V14, P167, DOI 10.1016/S0079-6107(64)80006-7; HEEGAARD CW, 1990, J BIOL CHEM, V265, P12020; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; IKEMOTO N, 1981, J BIOL CHEM, V256, P809; IKEMOTO N, 1984, J BIOL CHEM, V259, P1790; IKEMOTO N, 1981, J BIOL CHEM, V256, P8593; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MCINTOSH DB, 1988, J BIOL CHEM, V263, P12220; MOUNTIN MJ, 1991, J BIOL CHEM, V266, P5580; NAKAMURA J, 1987, J BIOL CHEM, V262, P14492; NAKAMURA J, 1986, BIOCHIM BIOPHYS ACTA, V870, P495, DOI 10.1016/0167-4838(86)90258-X; NAKAMURA J, 1983, BIOCHIM BIOPHYS ACTA, V723, P182, DOI 10.1016/0005-2728(83)90118-4; NAKAMURA J, 1994, J BIOL CHEM, V269, P30822; NAKAMURA J, 1989, J BIOL CHEM, V264, P17029; NAKAMURA J, 1977, BIOCHIM BIOPHYS ACTA, V18, P108; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P8626, DOI 10.1021/bi00423a018; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SUZUKI T, 1985, J BIOL CHEM, V260, P3145; TADA M, 1978, PHYSIOL REV, V58, P1; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VERJOVSKIALMEIDA S, 1981, J BIOL CHEM, V256, P2940; YAMASAKI K, 1991, J BIOCHEM, V110, P915, DOI 10.1093/oxfordjournals.jbchem.a123689	36	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30818	30821						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983012				2022-12-25	WOS:A1994PV51000016
J	SHRAGALEVINE, Z; BENMENAHEM, D; NAOR, Z				SHRAGALEVINE, Z; BENMENAHEM, D; NAOR, Z			ACTIVATION OF PROTEIN-KINASE-C BETA-GENE EXPRESSION BY GONADOTROPIN-RELEASING-HORMONE IN ALPHA-T3-1 CELL-LINE - ROLE OF CA2+ AND AUTOREGULATION BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY GONADOTROPHS; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL EXPRESSION; PHORBOL ESTERS; MESSENGER-RNAS; CALCIUM; GROWTH; RECEPTOR; CLONING; REDISTRIBUTION	The gonadotroph-derived alpha T3-1 cell line was used to investigate the effect of gonadotropin-releasing hormone (GnRH) upon conventional protein kinase C subtypes (cPKCs) gene expression. Addition of the stable analog [D-Trp(6)]GnRH (GnRH-A, 0.1 nM) resulted in a rapid increase (30 min) of the steady state levels of PKC beta, but not PKC alpha, mRNA levels, while PKC gamma is not expressed in the cells. The rapid stimulatory effect of GnRH-A was blocked by pretreatment with actinomycin D or with the GnRH antagonist (D-pGlu(1), pClPhe(2), D-Trp(3,6))GnRH and was not mimicked by thyrotropin-releasing hormone. Addition of the PKC activator 12-O-tetradecanoylphorbol-13-acetate (TPA) resulted also in a rapid (30 min) and selective increase in PKC beta, but not PKC alpha, mRNA levels. In contrast, the calcium ionophore, ionomycin, increased rapidly (30 min) both PKC alpha and PKC beta mRNA levels, and its stimulatory effect on PKC beta was not additive with that of TPA. The rapid stimulatory effect of GnRH-A was blocked by the PKC inhibitor bisindolylmaleimide (GF 109203X) or by down-regulation of endogenous PKC. Similarly, the rapid effect of GnRH-A was abolished by the intracellular Ca2+ chelator 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) or by removal of extracellular Ca2+. Stimulation of PKC beta mRNA levels by ionomycin was only reduced by GF 109203X and was not affected by down-regulation of PKC. In contrast the effect of TPA on PKC beta mRNA levels was reduced by BAPTA and abolished by removal of Ca2+. We conclude that Ca2+ and PKC act sequentially during GnRH-A-induced PKC beta gene expression and that PKC beta gene expression induced by GnRH-A is autoregulated by PKC.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University								ANDERSON WB, 1985, ADV CYCLIC NUCL PROT, V19, P287; BENMENAHEM D, 1994, BIOCHEMISTRY-US, V33, P3698, DOI 10.1021/bi00178a029; BENMENAHEM D, 1992, BIOCHEMISTRY-US, V31, P12893, DOI 10.1021/bi00166a026; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHANG JP, 1986, J BIOL CHEM, V261, P9105; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GARCIANAVARRO S, 1991, ENDOCRINOLOGY, V129, P2780, DOI 10.1210/endo-129-5-2780; HIROTA K, 1985, J BIOL CHEM, V260, P3243; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KIM MK, 1993, J BIOL CHEM, V268, P23366; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LIU F, 1993, J BIOL CHEM, V268, P6714; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; NAOR Z, 1990, ENDOCR REV, V11, P326, DOI 10.1210/edrv-11-2-326; NAOR Z, 1989, P NATL ACAD SCI USA, V86, P4501, DOI 10.1073/pnas.86.12.4501; NAOR Z, 1986, J BIOL CHEM, V261, P2506; NAOR Z, 1985, P NATL ACAD SCI USA, V82, P8203, DOI 10.1073/pnas.82.23.8203; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; NAOR Z, 1990, ENDOCRINOLOGY, V126, P1521, DOI 10.1210/endo-126-3-1521; NAOR Z, 1988, MOL ENDOCRINOL, V2, P512, DOI 10.1210/mend-2-6-512; NETIV E, 1991, FEBS LETT, V295, P107, DOI 10.1016/0014-5793(91)81396-P; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1992, J BIOL CHEM, V267, P20804; OBEID LM, 1990, J BIOL CHEM, V265, P2370; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; REINHART J, 1992, J BIOL CHEM, V267, P21281; SHEARMAN MS, 1987, BIOCHEM BIOPH RES CO, V147, P911, DOI 10.1016/S0006-291X(87)80157-2; STOJILKOVIC SS, 1991, J BIOL CHEM, V266, P10377; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; WADA H, 1989, BIOCHEM BIOPH RES CO, V165, P533, DOI 10.1016/0006-291X(89)91102-9; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; WONDISFORD FE, 1993, J BIOL CHEM, V268, P2749; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9863	47	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31028	31033						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983040				2022-12-25	WOS:A1994PV51000047
J	BOZIC, CR; GERARD, NP; VONUEXKULLGULDENBAND, C; KOLAKOWSKI, LF; CONKLYN, MJ; BRESLOW, R; SHOWELL, HJ; GERARD, C				BOZIC, CR; GERARD, NP; VONUEXKULLGULDENBAND, C; KOLAKOWSKI, LF; CONKLYN, MJ; BRESLOW, R; SHOWELL, HJ; GERARD, C			THE MURINE INTERLEUKIN-8 TYPE-B RECEPTOR HOMOLOG AND ITS LIGANDS - EXPRESSION AND BIOLOGICAL CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MACROPHAGE INFLAMMATORY PROTEIN-2; INTERCRINE CYTOKINE FAMILY; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; C5A ANAPHYLATOXIN; HUMAN EOSINOPHILS; GROWTH-FACTOR; GENE; IDENTIFICATION; INHIBITION	KC, the product of an immediate early gene induced in mouse fibroblasts by platelet derived growth factor, was synthesized as a recombinant protein in Escherichia coli and binds with 0.8 nM affinity to mouse neutrophils. Human neutrophils also bind recombinant KC at a site competitive with human interleukin (IL8) and Gro-alpha/ MGSA, consistent with binding at the IL8 type B receptor (IL8RB). The cDNA corresponding to human IL8RB hybridizes strongly with two restriction fragments in murine genomic DNA, representing candidate receptor genes for KC, Molecular cloning of both mouse genomic DNA and neutrophil exudate cell cDNA libraries yielded a receptor with similar to 68% sequence identity to both the human IL8 type A and B receptors. Transient expression of the murine receptor cDNA in COS cells conferred binding ability to KC and a related gene product, macrophage inflammatory protein-2 (MIP-2) with high affinity (similar to 5 nM). Human IL8 was a poor agonist for this expressed receptor (K-d = similar to 400 nM). The potent activity of human IL8 on mouse polymorphonuclear neutrophils is not consistent with binding on the cloned receptor and suggests that murine homologues of IL8 and an IL8 type A receptor remain to be identified. Our data indicate that KC is the murine homologue of human Gro-alpha, and the KC receptor is an ILS type B receptor homologue capable of binding both KC and macrophage inflammatory protein-2 with high affinity.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, INA SUE PERLMUTTER LAB, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA; PFIZER INC, PFIZER CENT RES, DEPT IMMUNOL, GROTON, CT 06340 USA; PFIZER INC, PFIZER CENT RES, DEPT INFECT DIS, GROTON, CT 06340 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pfizer; Pfizer					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036162, R01HL036162] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36162, HL71910] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CERRETTI DP, 1993, GENOMICS, V18, P410, DOI 10.1006/geno.1993.1486; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; CUNHA FQ, 1991, BRIT J PHARMACOL, V104, P765, DOI 10.1111/j.1476-5381.1991.tb12502.x; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; FRANKE AE, 1988, METHOD ENZYMOL, V162, P653; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; GROB PM, 1990, J BIOL CHEM, V265, P8311; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARVATH L, 1987, J IMMUNOL, V139, P3055; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SHIRATORI Y, 1993, BIOCHEM BIOPH RES CO, V197, P319, DOI 10.1006/bbrc.1993.2478; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WATANABE K, 1989, J BIOL CHEM, V264, P19559; WATANABE K, 1992, EXP MOL PATHOL, V56, P60, DOI 10.1016/0014-4800(92)90023-5; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	38	224	229	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29355	29358						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961909				2022-12-25	WOS:A1994PU28400006
J	WILKS, A; TORPEY, J; DEMONTELLANO, PRO				WILKS, A; TORPEY, J; DEMONTELLANO, PRO			HEME OXYGENASE (HO-1) - EVIDENCE FOR ELECTROPHILIC OXYGEN ADDITION TO THE PORPHYRIN RING IN THE FORMATION OF ALPHA-MESO-HYDROXYHEME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; CARBON-MONOXIDE; ALKYLHYDRAZINES; EXPRESSION; MESSENGER	Previous studies have established that reaction of the rat heme-heme oxygenase complex with H2O2 proceeds normally to give verdoheme, whereas reaction of the complex with meta-chloroperbenzoic acid yields a ferryl (Fe-IV = O) species and a protein radical but no verdoheme. The heme-heme oxygenase complex is shown here to react regiospecifically with ethyl hydroperoxide to give alpha-meso-ethoxyheme. Formation of this product exactly parallels the formation of alpha-meso-hydroxyheme in the normal reaction supported by cytochrome P450 reductase/NADPH or H2O2. These results rule out a nucleophilic mechanism for the alpha-meso-hydroxylation catalyzed by heme oxygenase and indicate that it involves electrophilic (or possibly radical) addition of the distal oxygen of iron-bound peroxide (Fe-III-OOH) to the porphyrin ring.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIDDK NIH HHS [5 P30DK26743, DK30297] Funding Source: Medline; NIGMS NIH HHS [GM32488] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297, P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATOR MA, 1987, J BIOL CHEM, V262, P14954; BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; CHOE YS, 1991, J BIOL CHEM, V266, P8523; FUHRHOP JH, 1975, PORPHYRINS METALLOPO, P800; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V182, P981, DOI 10.1016/0006-291X(92)91828-E; Maines M.D., 1992, HEME OXYGENASE CLIN; MAINES MD, 1986, J BIOL CHEM, V261, P411; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; SUN J, 1994, IN PRESS BIOCHEMISTR; SUN Y, 1990, ARCH BIOCHEM BIOPHYS, V282, P340, DOI 10.1016/0003-9861(90)90126-J; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WILKS A, 1993, J BIOL CHEM, V268, P22357; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	16	101	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29553	29556						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961940				2022-12-25	WOS:A1994PU28400039
J	MIGEON, JC; THOMAS, SL; NATHANSON, NM				MIGEON, JC; THOMAS, SL; NATHANSON, NM			REGULATION OF CAMP-MEDIATED GENE-TRANSCRIPTION BY WILD-TYPE AND MUTATED G-PROTEIN ALPHA-SUBUNITS - INHIBITION OF ADENYLYL-CYCLASE ACTIVITY BY MUSCARINIC RECEPTOR-ACTIVATED AND CONSTITUTIVELY ACTIVATED G(0)ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEIN; CELL-SPECIFIC EXPRESSION; HUMAN PITUITARY-TUMORS; SIGNAL-TRANSDUCTION; BOVINE BRAIN; BETA-GAMMA; MEMBRANE ASSOCIATION; LIPID MODIFICATIONS; CHICK HEART; MYRISTOYLATION	We have used a luciferase reporter gene under the transcriptional control of a cAMP response element (CRE) to monitor the effects of G-protein alpha subunits on cAMP-regulated gene expression and to examine muscarinic acetylcholine receptor (mAChR) functional coupling to G-proteins. Expression in JEG-3 cells of a mutationally activated G(i) alpha-2 in which glutamine 205 is replaced with leucine (Q205L) decreased forskolin-stimulated expression from the CRE-luciferase gene by up to 75%. Similarly, mutation of glycine 43 (corresponding to glycine 12 in p21(ras)) to valine decreased forskolin-stimulated expression from the CRE-luciferase gene by a maximum of 50%, indicating that this mutation activates the G-protein and is potentially oncogenic. Transfection of the activated Q205L G(o) alpha subunit decreased forskolin stimulation of CRE-luciferase expression. Transfected wild type G(o) alpha was also able to couple the m4 mAChR receptor to inhibition of AC. The amino-terminal myristoylation site was removed from wild type G(i) alpha-2 and Q205L G(i) alpha-2 by changing glycine 2 to alanine (G2A). G(i) alpha-2 with the G2A and Q205L mutations was unable to decrease forskolin stimulation of CRE-mediated luciferase activity. Furthermore, G2A G(i) alpha-2 was unable to couple the m4 mAChR to inhibition of AC. Thus, myristoylation is required both for the function of constitutively active Q205L G(i) alpha-2 and for receptor-mediated activation of wild type G(i) alpha-2.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM07108, GM07750] Funding Source: Medline; NINDS NIH HHS [NS07332] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUDIGIER Y, 1990, J CELL BIOL, V111, P1427, DOI 10.1083/jcb.111.4.1427; BEALS CR, 1987, P NATL ACAD SCI USA, V84, P7886, DOI 10.1073/pnas.84.22.7886; BEALS CR, 1989, THESIS U WASHINGTON; BLUMER KJ, 1991, ANNU REV PHYSIOL, V53, P37; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; CHARPENTIER N, 1993, J BIOL CHEM, V268, P8980; CLEMENTI E, 1990, ONCOGENE, V5, P1059; DAY RN, 1989, J BIOL CHEM, V264, P431; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P9695, DOI 10.1073/pnas.89.20.9695; GIBBS JB, 1985, TRENDS BIOCHEM SCI, V10, P350, DOI 10.1016/0968-0004(85)90110-0; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KABIR AM, 1993, CELL SIGNAL, V5, P443, DOI 10.1016/0898-6568(93)90084-Y; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KROLL SD, 1992, J BIOL CHEM, V267, P23183; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LUETJE CW, 1987, BIOCHEMISTRY-US, V26, P4876, DOI 10.1021/bi00389a040; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MIGEON JC, 1994, J BIOL CHEM, V269, P9767; MILLIGAN G, 1988, BIOCHEM J, V254, P391, DOI 10.1042/bj2540391; MILLIGAN G, 1985, J BIOL CHEM, V260, P2057; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PARKER EM, 1991, J BIOL CHEM, V266, P519; PEI L, 1991, MOL ENDOCRINOL, V5, P521, DOI 10.1210/mend-5-4-521; RICHARDSON RM, 1991, MOL PHARMACOL, V40, P908; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, BIOCHEM BIOPH RES CO, V164, P46, DOI 10.1016/0006-291X(89)91680-X; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TIETJE KM, 1990, J BIOL CHEM, V265, P2828; TOTA MR, 1990, MOL PHARMACOL, V37, P950; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WOON CW, 1989, BIOCHEMISTRY-US, V28, P4547, DOI 10.1021/bi00437a006	54	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29146	29152						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961880				2022-12-25	WOS:A1994PU16800092
J	NEWTON, CL; MIGNERY, GA; SUDHOF, TC				NEWTON, CL; MIGNERY, GA; SUDHOF, TC			COEXPRESSION IN VERTEBRATE TISSUES AND CELL-LINES OF MULTIPLE INOSITOL 1,4,5-TRISPHOSPHATE (INSP(3)) RECEPTORS WITH DISTINCT AFFINITIES FOR INSP(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; ESCHERICHIA-COLI; TRISPHOSPHATE; BINDING; PURIFICATION; MECHANISM; FORMS	Inositol 1,4,5-trisphosphate (InsP(3)) is a ubiquitous second messenger in eukaryotic cells that triggers Ca2+ release from intracellular stores. Three types of InsP(3) receptors have been identified in mammals. The three receptor types are encoded by homologous genes and are structurally similar, suggesting two alternative hypotheses about the biological significance of multiple InsP(3) receptors: (a) the different InsP(3) receptors could have similar functions as InsP(3)-gated Ca2+ channels, and the presence of multiple genes could then serve as a mechanism to allow tissue-specific differential expression of receptors; or (b) the different receptors are coexpressed in cells but have distinct biological roles in these cells. To test these hypotheses, we have investigated the similarities and differences between the expression, alternative splicing, and ligand binding of different receptors. Our results demonstrate co-expression of different InsP(3) receptors in almost all tissues and cell lines tested. Although all receptor types exhibit a similar specificity for inositol phosphates, the different receptors have different affinities for InsP(3), with a relative order of affinities of type II > type I > type III. These findings suggest that the presence of multiple InsP(3)-sensitive Ca2+ pools with differential responsiveness to InsP(3) may be a general property of all cells mediated by the presence of multiple types of InsP(3) receptors.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DEPT MOLEC GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIMH NIH HHS [R01-MH47510] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047510] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; KIJIMA Y, 1992, BIOCHEM BIOPH RES CO, V189, P728, DOI 10.1016/0006-291X(92)92262-V; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIGNERY GA, 1993, METH NEUROSCI, V18, P247; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PIETRI F, 1990, CELL SIGNAL, V2, P253, DOI 10.1016/0898-6568(90)90053-D; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPPATTAPONE S, 1988, J BIOL CHEM, V263, P1530	20	253	257	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28613	28619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961809				2022-12-25	WOS:A1994PU16800018
J	BUJALOWSKI, W; KLONOWSKA, MM; JEZEWSKA, MJ				BUJALOWSKI, W; KLONOWSKA, MM; JEZEWSKA, MJ			OLIGOMERIC STRUCTURE OF ESCHERICHIA-COLI PRIMARY REPLICATIVE HELICASE DNAB PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; SINGLE-STRANDED-DNA; TRANSFER RNA-PHE; PHYSICAL-PROPERTIES; BINDING-PROTEIN; ATP HYDROLYSIS; ANTICODON LOOP; GENE PRODUCT; MECHANISM; ASSOCIATION	The oligomeric structure of the Escherichia coli primary replicative helicase DnaB protein in relation to the functions of the enzyme and the energetics of its stability has been characterized. Sedimentation equilibrium, sedimentation velocity, and ligand binding studies show that, in solutions containing magnesium ions, the DnaB helicase exists as a stable hexamer over a wide protein concentration range (similar to 10(-7) to 10(-5) M (hexamer)). The sedimentation coefficient of the hexamer (s(20,w)(0) = 10.3 +/- 0.3 S) provides an apparent frictional ratio of 1.09 +/- 0.03, which suggests that the hexamer has a nonspherical shape and, when modeled as a prolate ellipsoid of revolution, has an axial ratio of a/b = 2.6 +/- 0.6. Magnesium ions play a crucial structural role in stabilizing the hexameric structure of the DnaB helicase. In the absence of Mg2+, the DnaB protein forms a trimer that, at low protein concentrations, dissociates into monomers, Analysis of the sedimentation data indicates that the dimerization of the trimers into the active DnaB hexamer is accompanied by an uptake of similar to 4 magnesium cations. The sedimentation coefficient of the DnaB monomer (s(20,w)(0) = 2.8 +/- 0.3 S) provides an apparent frictional ratio of 1.22 +/- 0.05, which indicates that the monomer has an elongated structure with an axial ratio of a/b = 5.2 +/- 0.8 when modeled as a prolate ellipsoid of revolution. Analysis of the ratio of the sedimentation coefficients (the sedimentation ratio) of the DnaB hexamer and monomer, which depends solely on the shape of the protomer and the mode of aggregation, strongly suggests that elongated DnaB protomers aggregate with cyclic symmetry in which the protomer-protomer contacts are limited to only two neighboring subunits.			BUJALOWSKI, W (corresponding author), UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,301 UNIV BLVD,GALVESTON,TX 77555, USA.				NIGMS NIH HHS [R01 GM-46679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1991, J BIOL CHEM, V266, P22096; ANDREWS PR, 1980, BIOPHYS CHEM, V11, P49, DOI 10.1016/0301-4622(80)85007-1; ANDREWS PR, 1976, BIOPHYS CHEM, V4, P93, DOI 10.1016/0301-4622(76)80010-5; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, J BIOL CHEM, V256, P5247; ARAI K, 1981, J BIOL CHEM, V256, P5267; ARAI K, 1981, J BIOL CHEM, V256, P5273; ARAI K, 1981, J BIOL CHEM, V256, P5253; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P6372, DOI 10.1021/bi00369a005; BUJALOWSKI W, 1994, BIOCHEMISTRY-US, V33, P4682, DOI 10.1021/bi00181a028; BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31359; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P6365, DOI 10.1021/bi00369a004; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; BUJALOWSKI W, 1991, J MOL BIOL, V217, P63, DOI 10.1016/0022-2836(91)90611-9; BUJALOWSKI W, 1991, J BIOL CHEM, V266, P1616; BUJALOWSKI W, 1988, BIOPHYS CHEM, V30, P151, DOI 10.1016/0301-4622(88)85012-9; BULL HB, 1968, ARCH BIOCHEM BIOPHYS, V128, P488, DOI 10.1016/0003-9861(68)90055-6; Cantor C.R., 1980, BIOPHYSICAL CHEM 2; Cox D. J, 1978, METHOD ENZYMOL, V48F, P212; DELAUDER WB, 1971, BIOCHIM BIOPHYS ACTA, V243, P153, DOI 10.1016/0005-2795(71)90071-7; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; Hill T. L., 1985, COOPERATIVITY THEORY; Kornberg A., 1992, DNA REPLICATION; KUNTZ ID, 1971, J AM CHEM SOC, V93, P514, DOI 10.1021/ja00731a036; Lakowicz JR, 1983, PRINCIPLES FLUORESCE, P489; LANKA E, 1978, P NATL ACAD SCI USA, V75, P799, DOI 10.1073/pnas.75.2.799; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Lee J C, 1979, Methods Enzymol, V61, P26; LIN TH, 1991, J BIOL CHEM, V266, P1635; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MCMACKEN R, 1977, J BIOL CHEM, V253, P3313; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; NAKAYAMA N, 1984, J BIOL CHEM, V259, P97; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; SCHEKMAN R, 1975, J BIOL CHEM, V250, P5859; SCHEKMAN R, 1974, SCIENCE, V186, P987, DOI 10.1126/science.186.4168.987; SEIFRIED SE, 1991, J MOL BIOL, V221, P1139; Tanford C., 1961, PHYS CHEM MACROMOLEC; UEDA K, 1978, J BIOL CHEM, V253, P261; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WICKNER S, 1973, P NATL ACAD SCI USA, V71, P783; WICKNER SH, 1978, COLD SPRING HARB SYM, V43, P303; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100; YOUNG MC, 1994, J MOL BIOL, V285, P1436	57	144	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31350	31358						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989299				2022-12-25	WOS:A1994PX30300008
J	FAN, YH; MCCLOSKEY, MA				FAN, YH; MCCLOSKEY, MA			DUAL PATHWAYS FOR GTP-DEPENDENT REGULATION OF CHEMOATTRACTANT-ACTIVATED K(+) CONDUCTANCE IN MURINE J774 MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; CELL-LINE J774.1; INTRACELLULAR CALCIUM; MOUSE MACROPHAGES; EXTRACELLULAR ATP; MAST-CELLS; EXPRESSION CLONING; RECEPTORS; CHANNELS; BINDING	Whole-cell patch clamp recording and digital imaging microscopy were used to investigate the electrical and calcium signaling responses of murine J774 monocytes to chemoattractants and other calcium-mobilizing agonists, A latent outwardly rectifying K+ conductance, Gk(OR), was elicited within seconds by each of the following agonists: C5a, ATP,ADP, interleukin-8, and the adenosine analog 5'-(N-ethylcarboxamido)-adenosine. In terms of its pharmacologic profile and current-voltage (I-V) relation, Gk(OR) was very similar to a P-2 purinoceptor-activated K+ conductance previously described in rat mast cells and to a K+ conductance elicited in J774 cells by the GTP analog guanosine 5'-O-(3-thiotriphosphate), Agonist-induced elevation of calcium, primarily due to intracellular release, and the induction of Gk(OR) both required a GTP-binding protein of the G(i) family, as both events were blocked by pertussis toxin; intracellular dialysis with guanosine 5'-O-(2-thiodiphosphate) also prevented the induction of Gk(OR), further implicating mediation by a G; protein, Induction of Gk(OR) did not depend upon influx of Ca2+, as it occurred equally well when the concentration of external Ca2+ was 100 nM Or 2 mM. We attempted to uncouple agonist-induced calcium release from induction of Gk(OR) by dialyzing the cell, cytoplasm with Ca2+-EGTA or Ca2+-1,2-bis-(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (EAPTA) buffers before agonist application, When the concentration of free Ca2+ ([Ca2+](i)) was set to approximate to 15 nM with 1.1 or 11 mM EGTA, a ''slow'' Ca2+ buffer, 10 nM C5a induced a large Gk(OR) (11 nS at 1.1 mM EGTA versus 13.4 nS at 11 mM EGTA), Surprisingly, when [Ca2+](i) was buffered at 15 nM with 10 mM BAPTA, a ''rapid'' Ca2+ buffer, C5a elicited a much smaller although significant K+ conductance (approximate to 3 nS), Systematic increase in cytosolic [Ca2+](i) upon dialysis with a series of 10 mM BAPTA-Ca2+ buffers (15-2400 nar [Ca2+](i)) revealed activation of a very large K+ conductance (maximum 17.4 nS), even in the presumed absence of receptor stimulation, This conductance had a similar I-V relationship to Gk(OR), and activation occurred within the range of[Ca2+](i) observed in intact cells following stimulation with C5a or ADP (EC(50)approximate to 475 nM [Ca2+](i)). Activation of Gk thus may proceed in part via the release of intracellular calcium from a source in close proximity to the channel or other calcium-binding regulatory protein, A separate mechanism for activation of Gk appears to exist, however, because for each ICa2+](i) tested, application of C5a elevated Gk approximately 2-fold over the level achieved with calcium alone, Hence, it appears that multiple G protein-linked receptors in the murine J774 monocyte cell line activate a large outwardly rectifying K+ conductance like that present in rat mast cells, In the case of C5a, two activation pathways appear to diverge at the level of a pertussis toxin-sensitive G protein, One pathway may involve rapid signaling via local elevation of calcium near the immediate effector, similar to the initiation of transmitter release at the presynaptic plasma membrane.	IOWA STATE UNIV SCI & TECHNOL, DEPT ZOOL & GENET, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, SIGNAL TRANSDUCT TRAINING GRP, AMES, IA 50011 USA	Iowa State University; Iowa State University					NIGMS NIH HHS [GM48144-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048144] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER EM, 1991, J NEUROSCI, V11, P1496; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BARANKIEWICZ J, 1990, BIOL ACTIONS EXTRACE, P380; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; CHEN YC, 1992, TOXICOL APPL PHARM, V117, P249, DOI 10.1016/0041-008X(92)90244-M; CONRAD GW, 1986, J CELL BIOL, V103, P439, DOI 10.1083/jcb.103.2.439; CUSACK NJ, 1990, ANN NY ACAD SCI, V603, P172; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DIVIRGILIO F, 1988, J IMMUNOL, V140, P915; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; GALLIN EK, 1989, AM J PHYSIOL, V257, pC77, DOI 10.1152/ajpcell.1989.257.1.C77; GALLIN EK, 1977, J CELL BIOL, V75, P277, DOI 10.1083/jcb.75.1.277; GALLIN EK, 1985, J PHYSIOL-LONDON, V369, P475, DOI 10.1113/jphysiol.1985.sp015911; GALLIN EK, 1991, PHYSIOL REV, V71, P775, DOI 10.1152/physrev.1991.71.3.775; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GROB PM, 1990, J BIOL CHEM, V265, P8311; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARA N, 1990, FEBS LETT, V267, P281, DOI 10.1016/0014-5793(90)80945-F; HIDE M, 1991, MOL PHARMACOL, V40, P473; ICHINOSE M, 1992, BIOCHEM BIOPH RES CO, V182, P372, DOI 10.1016/S0006-291X(05)80155-X; ICHINOSE M, 1992, BIOCHIM BIOPHYS ACTA, V1111, P165, DOI 10.1016/0005-2736(92)90307-8; KAKUTA Y, 1988, J ALLERGY CLIN IMMUN, V81, P460, DOI 10.1016/0091-6749(88)90918-9; KAO JPY, 1988, BIOPHYS J, V53, P635, DOI 10.1016/S0006-3495(88)83142-4; KRUSKAL BA, 1987, J CELL BIOL, V105, P2685, DOI 10.1083/jcb.105.6.2685; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MARTY A, 1985, J PHYSIOL-LONDON, V367, P117, DOI 10.1113/jphysiol.1985.sp015817; MCCLOSKEY MA, 1994, J BIOL CHEM, V269, P14813; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MCKINNEY LC, 1988, J MEMBRANE BIOL, V103, P41, DOI 10.1007/BF01871931; MCKINNEY LC, 1992, J MEMBRANE BIOL, V130, P265; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PENNER R, 1988, FEBS LETT, V226, P307, DOI 10.1016/0014-5793(88)81445-5; QIAN YX, 1993, P NATL ACAD SCI USA, V90, P7844, DOI 10.1073/pnas.90.16.7844; RALPH P, 1975, J IMMUNOL, V114, P898; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SMITH PD, 1984, ANAL BIOCHEM, V143, P188, DOI 10.1016/0003-2697(84)90575-X; SULLIVAN R, 1987, J BIOL CHEM, V262, P1274; SUNG SSJ, 1985, J BIOL CHEM, V260, P3442	45	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31533	31543						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989321				2022-12-25	WOS:A1994PX30300034
J	JAIN, S; DOLWICK, KM; SCHMIDT, JV; BRADFIELD, CA				JAIN, S; DOLWICK, KM; SCHMIDT, JV; BRADFIELD, CA			POTENT TRANSACTIVATION DOMAINS OF THE AH RECEPTOR AND THE AH RECEPTOR NUCLEAR TRANSLOCATOR MAP TO THEIR CARBOXYL TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINDED GENE ENCODES; LOOP-HELIX PROTEINS; MAMMALIAN-CELLS; DNA-BINDING; DIOXIN RECEPTOR; TRANSCRIPTION ACTIVATION; GLUTAMINE-RICH; EXPRESSION; CLONING; LIGAND	The Ah receptor (AHR) is a ligand-activated transcription factor that is structurally related to its dimerization partner, the Ah receptor nuclear translocator (ARNT), and two Drosophila proteins, SIM and PER. Ah four proteins contain a region of homology now referred to as a PAS homology domain. In addition, the AHR, ARNT, and SIM harbor a basic region helix-loop-helix motif in their N termini, whereas PER does not. Previous mapping studies of the AHR have demonstrated that the PAS domain contains sequences required for ligand recognition, dimerization, and interaction with the 90-kDa heat shock protein. They also have confirmed that the basic region helix-loop-helix domain plays a role in both dimerization and sequence-specific DNA binding. To identify domains involved in transactivation of target genes, we generated chimeras of AHR/ARNT deletion mutants with the DNA binding region of the yeast Gal4 protein, transiently expressed these in COS-l cells, and monitored their capacity to activate the chloramphenicol acetyltransferase reporter gene under the control of a minimal promoter driven by enhancer elements recognized by Gal4. Extensive analysis of these fusions revealed that the AHR and ARNT harbor potent transactivation domains within their C termini. Importantly, the amino-terminal halves of both the AHR and ARNT were found to be devoid of transactivation activity.	NORTHWESTERN UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,CHICAGO,IL 60611	Northwestern University				jain, sanjay/0000-0003-2804-127X	NATIONAL CANCER INSTITUTE [T32CA009560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005703, T32ES007124, R37ES005703, R01ES005703] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09560] Funding Source: Medline; NIEHS NIH HHS [ES05703, T32 ES07124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALVARES K, 1992, P NATL ACAD SCI USA, V89, P4908, DOI 10.1073/pnas.89.11.4908; AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V2; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DELIDOW BC, 1993, PCR PROTOCOLS CURREN, V15, P1; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HALL JC, 1987, BIOESSAYS, V7, P108, DOI 10.1002/bies.950070304; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAMBROOK J, 1989, MOL CLONING LABORATO, V1, P53; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; STONE G, 1993, EMBO J, V12, P1375, DOI 10.1002/j.1460-2075.1993.tb05782.x; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811	52	139	141	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31518	31524						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989319				2022-12-25	WOS:A1994PX30300032
J	RUTLEDGE, EA; GREEN, FA; ENNS, CA				RUTLEDGE, EA; GREEN, FA; ENNS, CA			GENERATION OF THE SOLUBLE TRANSFERRIN RECEPTOR REQUIRES CYCLING THROUGH AN ENDOSOMAL COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIC HL60 CELLS; ERYTHROLEUKEMIA-CELLS; MEMBRANE-PROTEINS; GROWTH-FACTOR; TGF-ALPHA; RELEASE; REDISTRIBUTION; CLEAVAGE; SURFACE; SERUM	The transmembrane protein, transferrin receptor (TER), is found in a soluble form in human serum and in the medium of cell lines grown in tissue culture, The soluble form is generated by proteolytic cleavage between Arg-100 and Leu-101. We used two mutant human TfRs expressed in Chinese hamster ovary (CHO) cells lacking endogenous transferrin receptor to characterize the protease that cleaves the TfR and determine its location in the cell, The T104D mutant TER lacks the O-linked carbohydrate at position 104, and is more susceptible to proteolytic cleavage at Arg-100 than the wildtype human TfR in these cells. We find that the protease is not a component of the serum in the growth medium, and it is not secreted by the cells, Cleavage does not occur during biosynthesis of the TfR, and occurs after the TfR has reached the cell surface, Expression of the T104D TfR in a temperature-sensitive acidification defective CHO cell line, G.7.1, shows that cleavage of the TfR is not dependent on acidification of endosomes, The C20A23 TfR is an endocytosis deficient mutant lacking an internalization signal, This mutant TfR, which is mainly localized to the cell surface, is cleaved less efficiently than the wild-type TfR, indicating that the protease is localized to an intracellular compartment.	OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043111] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK08910] Funding Source: Medline; NIGMS NIH HHS [GM-43111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN JH, 1993, BLOOD, V81, P2442; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAYNES RD, 1991, BRIT J HAEMATOL, V78, P450, DOI 10.1111/j.1365-2141.1991.tb04463.x; BAYNES RD, 1993, P SOC EXP BIOL MED, V204, P65; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHITAMBAR CR, 1990, J LAB CLIN MED, V116, P345; CHITAMBAR CR, 1989, BLOOD, V74, P602; COLBAUGH PA, 1988, SOMAT CELL MOLEC GEN, V14, P499, DOI 10.1007/BF01534715; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FISHMAN JB, 1987, CELL, V48, P157, DOI 10.1016/0092-8674(87)90366-7; FLOWERS CH, 1989, J LAB CLIN MED, V114, P368; HUEBERS HA, 1990, BLOOD, V75, P102; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; JOHNSTONE RM, 1992, BIOCHEM CELL BIOL, V70, P179, DOI 10.1139/o92-028; KOHGO T, 1988, JPN J MED, V27, P54; KOHGO Y, 1986, BRIT J HAEMATOL, V64, P277, DOI 10.1111/j.1365-2141.1986.tb04120.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARNELL MH, 1984, J CELL BIOL, V99, P1907, DOI 10.1083/jcb.99.6.1907; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; RUBIN LA, 1985, J IMMUNOL, V135, P3172; RUTLEDGE EA, 1994, BLOOD, V83, P580; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; TANNER LI, 1987, J BIOL CHEM, V262, P8975; TIMCHAK LM, 1986, J BIOL CHEM, V261, P14154; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; WEISSMAN AM, 1986, J CELL BIOL, V102, P951, DOI 10.1083/jcb.102.3.951; WILEY HS, 1985, J BIOL CHEM, V260, P5290; WILLIAMS AM, 1991, J BIOL CHEM, V266, P17648; WOODS JW, 1986, J CELL BIOL, V103, P277, DOI 10.1083/jcb.103.1.277; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	43	33	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31864	31868						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989360				2022-12-25	WOS:A1994PX30300082
J	HANSON, E; MATHEWS, CK				HANSON, E; MATHEWS, CK			ALLOSTERIC EFFECTORS ARE REQUIRED FOR SUBUNIT ASSOCIATION IN T4 PHAGE RIBONUCLEOTIDE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; ESCHERICHIA-COLI; DIPHOSPHATE REDUCTASE; CARBOXYL TERMINUS; CATALYTIC ACTIVITY; BACTERIOPHAGE-T4; COMPLEX; ENZYME; INHIBITION; PEPTIDES	Bacteriophage T4 encodes its own aerobic ribonucleotide reductase (RNR), which reduces ribonucleoside diphosphates to the corresponding deoxyribonucleoside diphosphates. T4 RNR is composed of homodimeric large (R1) and small (R2) subunits. Intricate regulation of enzymatic activity is accomplished by the binding of nucleotide effecters to R1. Berglund (Berglund, O. (1972) J. Biol. Chem. 247, 7270-7275) described similarities between T4 RNR and the corresponding enzyme from aerobic Escherichia coli. An important difference, however, is that T4 RNR forms a tight R1.R2 complex, while the E. coli R1 and R2 more readily dissociate. In this study we purified the phage R2 subunit from an overexpression vector constructed by Tseng et al. (Tseng, M., Hilfinger, J., He, P., and Greenberg, R. (1992) J. Bacteriol. 174, 5740-5744) and used this as an immunogen to generate polyclonal antiserum. Using co-immunoprecipitation techniques, we probed in vitro for interactions between the phage-induced R1 and R2 subunits. Our studies indicate that tight binding of the phage RNR subunits is completely dependent upon the known allosteric effecters of the enzyme. Once the R1.R2 holoenzyme has been formed it appears to be remarkably stable when in the presence of dATP. However, if dATP is removed, the R1.R2 complex readily dissociates.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331	Oregon State University								ALLEN JR, 1980, J BIOL CHEM, V255, P7583; ALLEN JR, 1983, J BIOL CHEM, V258, P5746; AVERETT DR, 1983, J BIOL CHEM, V258, P9831; BACCHETTI S, 1986, J VIROL, V57, P1177, DOI 10.1128/JVI.57.3.1177-1181.1986; BERGLUND O, 1975, J BIOL CHEM, V250, P7450; BERGLUND O, 1972, J BIOL CHEM, V247, P7276; BERGLUND O, 1972, J BIOL CHEM, V247, P7270; BERGLUND O, 1972, EUR J BIOCHEM, V28, P492, DOI 10.1111/j.1432-1033.1972.tb01936.x; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CHIU CS, 1980, J BIOL CHEM, V255, P2747; CHIU CS, 1982, J BIOL CHEM, V257, P5087; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; COOK KS, 1983, J BIOL CHEM, V258, P6064; COSENTINO G, 1991, BIOCHEM CELL BIOL, V69, P79, DOI 10.1139/o91-011; ERIKSSON S, 1983, J BIOL CHEM, V258, P5674; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FILATOV D, 1992, J BIOL CHEM, V267, P15816; FRAME MC, 1985, J GEN VIROL, V66, P1581, DOI 10.1099/0022-1317-66-7-1581; INGEMARSON R, 1987, VIROLOGY, V156, P417, DOI 10.1016/0042-6822(87)90422-3; JI JP, 1991, J BIOL CHEM, V266, P16289; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; LANKINEN H, 1982, J VIROL, V41, P893, DOI 10.1128/JVI.41.3.893-900.1982; LARSSON A, 1966, J BIOL CHEM, V241, P2540; LARSSON A, 1966, J BIOL CHEM, V241, P2533; LIN ANI, 1987, BIOCHEMISTRY-US, V26, P6905, DOI 10.1021/bi00396a006; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MATHEWS CK, 1988, TRENDS BIOCHEM SCI, V13, P394, DOI 10.1016/0968-0004(88)90182-X; MATHEWS CK, 1987, EUR J BIOCHEM, V166, P279, DOI 10.1111/j.1432-1033.1987.tb13512.x; Moen L K, 1988, J Mol Recognit, V1, P48, DOI 10.1002/jmr.300010109; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; SJOBERG BM, 1987, J BIOL CHEM, V262, P9736; SJOBERG BM, 1986, EMBO J, V5, P2031, DOI 10.1002/j.1460-2075.1986.tb04460.x; THELANDER L, 1974, J BIOL CHEM, V249, P4858; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER L, 1973, J BIOL CHEM, V248, P4591; TSENG MJ, 1992, J BACTERIOL, V174, P5740, DOI 10.1128/JB.174.17.5740-5744.1992; UHLIN U, 1994, FEBS LETT, V336, P148; YANG FD, 1990, FEBS LETT, V272, P61, DOI 10.1016/0014-5793(90)80449-S	41	10	10	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30999	31005						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983036				2022-12-25	WOS:A1994PV51000043
J	ZHANG, YX; BECK, CA; POLETTI, A; EDWARDS, DP; WEIGEL, NL				ZHANG, YX; BECK, CA; POLETTI, A; EDWARDS, DP; WEIGEL, NL			IDENTIFICATION OF PHOSPHORYLATION SITES UNIQUE TO THE B-FORM OF HUMAN PROGESTERONE-RECEPTOR - IN-VITRO PHOSPHORYLATION BY CASEIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-DEPENDENT PHOSPHORYLATION; CELL-CYCLE PROGRESSION; GROWTH-FACTOR; SIGNALING PATHWAYS; PROTEIN-KINASES; A-RECEPTORS; DNA-BINDING; EXPRESSION; ESTROGEN; PURIFICATION	The human progesterone receptor (PR), a member of the steroid/thyroid receptor superfamily of ligand-activated transcription factors, is expressed in most tissues as two forms that exhibit differential transcriptional activation potentials, full-length PR-B and NH2-terminally truncated PR-A. In human breast cancer cells (T47D) both forms of PR are constitutively phosphorylated but phosphorylation is increased in response to hormone treatment, suggesting that this modification has a role in regulating the activation state of the receptor. To more directly define the functional role of phosphorylation in the action of A and B receptors requires knowledge of the phosphorylated amino acid residues and the protein kinase(s) involved. Toward this end toe have developed a strategy that combines isolation of PR phosphotryptic peptides by reverse phase high performance liquid chromatography, secondary analytical protease digestion, manual Edman degradation, and release of P-32 that resulted in identification of two major phosphorylation sites, Ser(81) and Ser(162). Both sites are located in the amino-terminal region unique to PR-B, and one of these sites (Ser(81)) is encompassed in a casein kinase II (CKII) consensus sequence. Although human PR contains 11 potential CKII consensus sequences, CKII in vitro phosphorylated purified PR-B only at Ser(81) suggesting that this may be an authentic site for CKII in vivo.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; UNIV COLORADO, HLTH SCI CTR, DEPT PATHOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, PROGRAM MOLEC BIOL, DENVER, CO 80262 USA	Baylor College of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Poletti, Angelo/A-9016-2011	Poletti, Angelo/0000-0002-8883-0468; Zhang, Yixian/0000-0002-6429-3127	NCI NIH HHS [P30 CA46934, CA46938, CA57539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057539, P30CA046934, R01CA046938, R55CA057539] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; CONNEELY OM, 1987, MOL ENDOCRINOL, V1, P517, DOI 10.1210/mend-1-8-517; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1989, ENDOCRINOLOGY, V125, P3051, DOI 10.1210/endo-125-6-3051; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLINEUR C, 1989, ONCOGENE, V4, P1247; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; JURUTKA PW, 1993, J BIOL CHEM, V268, P6791; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MOUDGIL VK, 1990, BIOCHIM BIOPHYS ACTA, V1055, P243, DOI 10.1016/0167-4889(90)90040-K; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; POLETTI A, 1993, BIOCHEMISTRY-US, V32, P9563, DOI 10.1021/bi00088a007; POLETTI A, 1993, MOL ENDOCRINOL, V7, P241, DOI 10.1210/me.7.2.241; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1990, J BIOL CHEM, V265, P1419; RAO KVS, 1987, BIOCHEM BIOPH RES CO, V146, P1357, DOI 10.1016/0006-291X(87)90799-6; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SHERIDAN PL, 1989, J BIOL CHEM, V264, P7054; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; TAKIMOTO GS, 1991, 73RD P ANN M END SOC, P309; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577	40	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31034	31040						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983041				2022-12-25	WOS:A1994PV51000048
J	EDER, M; ERNST, TJ; GANSER, A; JUBINSKY, PT; INHORN, R; HOELZER, D; GRIFFIN, JD				EDER, M; ERNST, TJ; GANSER, A; JUBINSKY, PT; INHORN, R; HOELZER, D; GRIFFIN, JD			A LOW-AFFINITY CHIMERIC HUMAN ALPHA/BETA-GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR INDUCES LIGAND-DEPENDENT PROLIFERATION IN A MURINE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTOR; HUMAN GROWTH-HORMONE; COMMON BETA-SUBUNIT; HUMAN MYELOID CELLS; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR DOMAIN; HEMATOPOIETIC-CELLS; CYTOPLASMIC DOMAINS; MOLECULAR CONTROL	The high affinity receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) is composed of at least two subunits, an 85-kDa low affinity GM-CSF-binding protein (alpha-GMR) and a 120-kDa beta-subunit (beta-GMR) necessary for high affinity binding and signal transduction. Previous studies have shown that deletion of the intracellular do main of alpha-GMR inactivates the receptor's ability to support proliferation, but has no effect on GM-CSF binding. Using anti-alpha-GMR and anti-beta-GMR-specific antibodies, we show that alpha-GMR and beta-GMR coprecipitate only after GM-CSF binding, suggesting that binding of GM-CSF induces stabilization or assembly of an activated receptor complex involving recruitment of beta-GMR chains. To understand the contribution of each subunit of this receptor to the generation of an activated receptor complex, we attempted to construct minimal receptors with some or all of the functions of the wild-type heterodimer. We found that a hybrid human alpha/beta-GMR molecule in which the extracellular and transmembrane segments are composed of alpha-GMR sequences and the intracellular segment is composed of beta-GMR bound GM-CSF with low affinity, but activated tyrosine kinase activity, induced receptor internalization, and supported short- and long-term proliferation of transfected Ba/F3 cells. At least 1 ng/ml human GM-CSF was required for growth stimulation, and maximal proliferation occurred at a concentration of 10 ng/ml. This was 10-100-fold more than needed to stimulate growth of Ba/F3 cells expressing both full-length human alpha-GMR and beta-GMR and 1000-fold less than needed to stimulate growth of Ba/F3 cells expressing only human alpha-GMR. These results indicate that the cytoplasmic domain of alpha-GMR is not required to initiate a unique signaling event for proliferation in Ba/F3 cells, but can be functionally replaced by the cytoplasmic domain of beta-GMR.	UNIV FRANKFURT, DEPT HEMATOL, D-60590 FRANKFURT, GERMANY; DANA FARBER CANC INST, DIV HEMATOL MALIGNANCY, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DIV PEDIAT ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Goethe University Frankfurt; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School					NCI NIH HHS [CA34183, CA 36167] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034183, R01CA036167, R37CA036167] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BUDEL LM, 1993, J BIOL CHEM, V268, P10154; CANNISTRA SA, 1990, J BIOL CHEM, V265, P12656; CROZIER KE, 1991, P NATL ACAD SCI USA, V88, P7744; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DANDREA R, 1994, BLOOD, V83, P2820; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; KANAKURA Y, 1991, BLOOD, V77, P1033; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; METCALF D, 1990, P NATL ACAD SCI USA, V87, P4670, DOI 10.1073/pnas.87.12.4670; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; MIYAJIMA A, 1993, BLOOD, V82, P1960; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; OKUDA K, 1991, BLOOD, V78, P1928; OKUDA K, 1992, BLOOD, V79, P2880; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RONCO LV, 1994, J BIOL CHEM, V269, P277; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WEISS M, 1993, BLOOD, V82, P3298	36	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30173	30180						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982923				2022-12-25	WOS:A1994PU52500023
J	KWON, H; GREEN, MR				KWON, H; GREEN, MR			THE RNA-POLYMERASE-I TRANSCRIPTION FACTOR, UPSTREAM BINDING-FACTOR, INTERACTS DIRECTLY WITH THE TATA BOX-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-IIB; COMPLEX; INVITRO; COMPONENTS; INITIATION; MECHANISM; DOMAINS; REGION; GENE	The accurate transcription of human rRNA genes by RNA polymerase I requires two transcription factors, upstream binding factor (UBF) and promoter selectivity factor (SL1). Human SL1 (hSL1) is a multisubunit complex, one of whose components is TATA box-binding protein (TBP). hSL1 binds to the core region of the rRNA promoter, but does so inefficiently in the absence of human UBF (hUBF). hUBF interacts with the upstream control element of the rRNA promoter and facilitates binding of hSL1. The molecular basis by which hUBF increases binding of hSL1 remains to be elucidated. In this report, we use an immobilized protein binding assay to identify and purify a 95-kDa TBP-binding polypeptide. Microsequence analysis reveals that the 95-kDa TBP-binding protein is hUBF. We show that hUBF is stably associated with TBP and is present in large TBP-containing complexes. Our results indicate that the cooperative binding of hUBF and hSL1 on the rRNA promoter is mediated by direct interaction between hUBF and TBP. We also provide evidence that hUBF associates with TFIID, a TBP-containing RNA polymerase II transcription factor.	UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,WORCESTER,MA 01605	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONOWAY JW, 1991, J BIOL CHEM, V266, P7804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HALTINER MM, 1986, MOL CELL BIOL, V6, P227, DOI 10.1128/MCB.6.1.227; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KUHN A, 1992, P NATL ACAD SCI USA, V89, P7340, DOI 10.1073/pnas.89.16.7340; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; OMAHONY DJ, 1992, NUCLEIC ACIDS RES, V20, P1301; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3310; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949	28	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30140	30146						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982918				2022-12-25	WOS:A1994PU52500018
J	LI, CCH; DAI, RM; CHEN, E; LONGO, DL				LI, CCH; DAI, RM; CHEN, E; LONGO, DL			PHOSPHORYLATION OF NF-KAPPA-B1-P50 IS INVOLVED IN NF-KAPPA-B ACTIVATION AND STABLE DNA-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; TRANSCRIPTIONAL ACTIVATION; REL; DORSAL; CELLS; PRECURSOR; SUBUNITS; INVITRO; COMPLEX	We have previously shown that NF-kappa B/Rel family members are physically associated phosphoproteins, and p105 and p50 are hyperphosphorylated after NF-kappa B activation. In this report, we further studied the phosphorylation involved in NF-kappa B activation in Jurkat T cells responding to phorbol 12-myristate 13-acetate and phytohemagglutinin. Immediately following stimulation, p50 is hyperphosphorylated, and a phosphorylated form of p50 (pp50) is translocated from the cytoplasm to the nucleus. The kinetics of this nuclear translocation paralleled that of the appearance of an active kappa B DNA-binding complex. An at least 30-fold higher level of kappa B DNA binding was detected in pp50 than p50. The enhanced binding could be attributed to a much greater stability detected in the complex consisting of kappa B DNA and pp50, but not p50. These results suggest that phosphorylation of p50, and perhaps other family members as well, may be involved in the activation of NF-kappa B/Rel family transcription factors.	NCI,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	LI, CCH (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702, USA.		Longo, Dan L./F-6022-2011					BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAUERLE PA, 1988, SCIENCE, V242, P540; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GRILLI M, 1993, INT REV CYTOL, V143, P1; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	24	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30089	30092						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982908				2022-12-25	WOS:A1994PU52500007
J	TSCHESCHE, H; KOPP, C; HORL, WH; HEMPELMANN, U				TSCHESCHE, H; KOPP, C; HORL, WH; HEMPELMANN, U			INHIBITION OF DEGRANULATION OF POLYMORPHONUCLEAR LEUKOCYTES BY ANGIOGENIN AND ITS TRYPTIC FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOLYTIC ACTIVITY; PROTEINS; MUTAGENESIS; CLEAVAGE; SEQUENCE; SERUM; CELLS	A degranulation inhibiting protein was purified to apparent homogeneity from plasma ultrafiltrates of patients with uremia using gel-permeation chromatography, ion-exchange chromatography, affinity chromatography on blue Sepharose, and ion-exchange chromatography on a Mono S HR 5/5 fast protein liquid chromatography column. The identity of the isolated degranulation inhibiting protein with angogenin was demonstrated by amino acid sequence determination, immunoblotting, and identical inhibitory activity effects on leukocyte degranulation. At concentrations in the nanomolar range, the protein inhibited spontaneous degranulation of polymorphonuclear leukocytes (PMNL) to 40%. The protein discharge of cells, which were preincubated with nanomolar concentrations of angiogenin and then stimulated with the chemotactic peptide formyl-norleucyl-leucyl-phenylalanyl-norleucyl-tyrosyl-leucine (FNLPNTL), was inhibited by 70%. Cellular functions such as chemotaxis, phagocytosis, and the oxidative respiratory burst were not obviously affected by angiogenin. A polyclonal antibody to human recombinant angiogenin abolished the inhibitory effect of the isolated protein upon PMNL. The same but reduced effect was induced by the disulfide C-39-C-92 containing tryptic angiogenin fragment L-H-G-G-S-P-W P-P-C-92-Q-Y-R G-L-T-S-P-C-39-K, indicating a new, so far unknown biologically active site of angiogenin which is different from the sites responsible for angiogenic or ribonucleolytic activity. Two synthetic peptides containing residues 83-95, one with S-92 instead of C-92, revealed the same inhibitory effect on the protein degranulation of PMNL as the entire tryptic fragment.	UNIV BIELEFELD, FAK CHEM, LEHRSTUHL BIOCHEM, DEPT BIOCHEM, D-33501 BIELEFELD, GERMANY; ALLGEMEINES KRANKENHAUS STADT WIEN, NEPHROL & DIALYSE ABT, A-1090 VIENNA, AUSTRIA	University of Bielefeld								BERGMANN U, 1989, J CLIN CHEM CLIN BIO, V27, P351; BERGMEYER HU, 1983, METHOD ENZYMAT AN, P232; BLASER J, 1993, EUR J CLIN CHEM CLIN, V31, P513; BLASER J, 1991, EUR J BIOCHEM, V202, P1223, DOI 10.1111/j.1432-1033.1991.tb16494.x; BOHME HJ, 1972, J CHROMATOGR, V69, P209, DOI 10.1016/S0021-9673(00)83103-9; BOND MD, 1990, BIOCHEMISTRY-US, V29, P3341, DOI 10.1021/bi00465a028; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADE V, 1974, J IMMUNOL, V112, P1845; BRIGGS WA, 1983, KIDNEY INT S, V24, P93; CLAIR DKS, 1987, P NATL ACAD SCI USA, V84, P8330; DAMERVAL C, 1987, ELECTROPHORESIS, V8, P158, DOI 10.1002/elps.1150080308; DUPONT D, 1988, APPLIED BIOSYSTEMS A, V420; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; HALLAHAN TW, 1991, P NATL ACAD SCI USA, V88, P2222, DOI 10.1073/pnas.88.6.2222; HALLAHAN TW, 1992, BIOCHEMISTRY-US, V31, P8022, DOI 10.1021/bi00149a036; HARPER JW, 1989, BIOCHEMISTRY-US, V28, P1875, DOI 10.1021/bi00430a067; HARPER JW, 1988, P NATL ACAD SCI USA, V85, P7139, DOI 10.1073/pnas.85.19.7139; HEATH WF, 1989, P NATL ACAD SCI USA, V86, P2718, DOI 10.1073/pnas.86.8.2718; HORL WH, 1990, P NATL ACAD SCI USA, V87, P6353, DOI 10.1073/pnas.87.16.6353; HUNKAPILLER MW, 1985, APPLIED BIOSSYSTEMS, V14; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSELL MA, 1981, CLIN SCI, V61, P43, DOI 10.1042/cs0610043; METCALF JA, 1986, LABORATORY MANUAL NE, P109; METCOFF J, 1978, AM J CLIN NUTR, V31, P1627, DOI 10.1093/ajcn/31.9.1627; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NELSON RD, 1975, J IMMUNOL, V115, P1650; RITCHEY EE, 1981, KIDNEY INT, V19, P349, DOI 10.1038/ki.1981.26; RYBAK SM, 1989, BIOCHEM BIOPH RES CO, V162, P535, DOI 10.1016/0006-291X(89)92030-5; SAXENA SK, 1992, J BIOL CHEM, V267, P21982; SCHETTLER A, 1991, EUR J BIOCHEM, V197, P197, DOI 10.1111/j.1432-1033.1991.tb15899.x; SCOTT MG, 1988, BIOCHEM BIOPH RES CO, V155, P1353, DOI 10.1016/S0006-291X(88)81290-7; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; SHAPIRO R, 1987, BIOCHEMISTRY-US, V26, P5141, DOI 10.1021/bi00390a037; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P8783, DOI 10.1073/pnas.84.24.8783; TOLKOFFRUBIN NE, 1990, NEW ENGL J MED, V322, P770, DOI 10.1056/NEJM199003153221109; TSCHESCHE H, 1989, 8TH BIL SEM INT BUR, P31; WEBER K, 1969, J BIOL CHEM, V244, P4406; 1990, NOVASYN GEM INSTRUCT	39	76	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30274	30280						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982938				2022-12-25	WOS:A1994PU52500038
J	KRIEF, P; AUGERYBOURGET, Y; PLAISANCE, S; MERCK, MF; ASSIER, E; TANCHOU, V; BILLARD, M; BOUCHEIX, C; JASMIN, C; AZZARONE, B				KRIEF, P; AUGERYBOURGET, Y; PLAISANCE, S; MERCK, MF; ASSIER, E; TANCHOU, V; BILLARD, M; BOUCHEIX, C; JASMIN, C; AZZARONE, B			A NEW CYTOKINE (IK) DOWN-REGULATING HLA CLASS-II - MONOCLONAL-ANTIBODIES, CLONING AND CHROMOSOME LOCALIZATION	ONCOGENE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CELL-LINES; EXPRESSION; DNA; ANTIGENS; GAMMA; GENE; INTERFERON; MOLECULES; SEQUENCE	The role of HLA class II Antigens in the control of the immune response is determined not only by the genetic polymorphism of these molecules, but also by their density on the cell surface. It is therefore essential to identify the signals that modulate HLA Class II gene activity in normal and neoplastic cells. We have purified a cytokine (IK factor, 19 kDa) secreted by the leukemic cell line K562 and several cancer cells, which inhibits HLA Class II antigen induction by IFN-gamma. We produced specific mAbs which antagonize the biological effect of IK in colon carcinoma Cole 205 cells induced to express HLA-DR molecules by IFN-gamma. Moreover, in Cole 205, HLA-DR can also be induced by the protein synthesis inhibitor Cycloheximide (0.1 mu g ml(-1)) and addition of IK factor almost completely abolishes HLA class II expression. We have also performed the cloning and the sequencing of a specific cDNA. This probe recognizes a 2.1 Kb mRNA in different eel types. The nucleotide sequence exhibits no homologies with known cytokines. IK gene localization shows that it maps on chromosome 2p15-p14. The transient transfection of the cDNA in COS cells induces the secretion of a biologically active 19 kDa protein which is recognized in Western blot by 1C5B11 blocking mAb. This paper reports the characterization of a new cytokine downregulating HLA class II Antigens, whose analysis will help to better understand HLA class II gene regulation and the mechanism of escape from immunorecognition in cancer cells,	INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; INST COCHIN GENET MOLEC,INSERM,U332,F-75014 PARIS 14,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	KRIEF, P (corresponding author), HOP PAUL BROUSSE,INSERM,U268,114 AVE PAUL VAILLANT COUTURIER,F-94800 VILLEJUIF,FRANCE.		Krief, Patricia/M-6073-2014; Plaisance, Stephane/ABI-6307-2020; Azzarone, Bruno/AAH-9251-2019; Plaisance, Stephane/B-3488-2009	Krief, Patricia/0000-0001-5106-466X; Plaisance, Stephane/0000-0002-1651-241X; Azzarone, Bruno/0000-0002-5962-3849; Plaisance, Stephane/0000-0002-1651-241X; Assier, Eric/0000-0001-8366-1645; Boucheix, Claude/0000-0003-4184-7008				BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOSS JM, 1986, P NATL ACAD SCI USA, V83, P9139, DOI 10.1073/pnas.83.23.9139; BOUCHEIX C, 1986, METHOD ENZYMOL, V121, P580; CHENG JH, 1993, BIOCHEM J, V294, P589, DOI 10.1042/bj2940589; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DOHERTY PC, 1985, ADV CANCER RES, V42, P1; DOUKAS J, 1990, J IMMUNOL, V145, P1088; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FESTENSTEIN H, 1986, NATURE, V322, P502, DOI 10.1038/322502a0; GUERRASIO A, 1981, BLOOD CELLS, V7, P165; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; JANEWAY CA, 1984, IMMUNOL TODAY, V5, P99, DOI 10.1016/0167-5699(84)90043-4; KOELER G, 1975, NATURE, V256, P495; KRIEF P, 1989, INT J CANCER, V43, P658, DOI 10.1002/ijc.2910430420; KRIEF P, 1987, EUR J IMMUNOL, V17, P1021, DOI 10.1002/eji.1830170719; KRIEF P, 1988, VIRAL HEPATITIS LIVE, P217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLER RI, 1985, J IMMUNOL, V135, P2914; LEVESQUE JP, 1991, BIOTECHNIQUES, V11, P313; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MATIS LA, 1983, P NATL ACAD SCI-BIOL, V80, P6019, DOI 10.1073/pnas.80.19.6019; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MERCK MFR, 1991, HUMAN GENET, V86, P350; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; POVEY S, 1989, CYTOGENET CELL GENET, V51, P91, DOI 10.1159/000132782; RADKA SF, 1986, HUM IMMUNOL, V16, P390, DOI 10.1016/0198-8859(86)90065-0; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TABILIO A, 1983, CANCER RES, V43, P4569; UCER U, 1985, INT J CANCER, V36, P103, DOI 10.1002/ijc.2910360116; VIRELIZIER JL, 1984, EUR J IMMUNOL, V14, P106, DOI 10.1002/eji.1830140120; YUNIS JJ, 1978, CYTOGENET CELL GENET, V22, P679, DOI 10.1159/000131052	34	37	39	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3449	3456						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970704				2022-12-25	WOS:A1994PT39200006
J	LAROCCA, SA; CROUCH, DH; GILLESPIE, DAF				LAROCCA, SA; CROUCH, DH; GILLESPIE, DAF			C-MYC INHIBITS MYOGENIC DIFFERENTIATION AND MYOD EXPRESSION BY A MECHANISM WHICH CAN BE DISSOCIATED FROM CELL-TRANSFORMATION	ONCOGENE			English	Article							TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; TERMINAL DIFFERENTIATION; MUSCLE-CELLS; PROTEIN; GENE; MAX; PROLIFERATION; ONCOGENE; JUN	The c-Myc oncoprotein is a basic-helix-loop-helix-leucine zipper (b-HLH-LZ) transcription factor involved in regulating cell proliferation and differentiation. We have used retrovirus-mediated gene transfer to investigate the effect of ectopic c-Myc expression on the spontaneous differentiation of primary quail myoblasts in vitro. Unlike normal myoblasts, c-Myc-expressing myoblasts are unable to form myotubes or express muscle-specific genes, such as myosin, and show severely reduced expression of the myogenic regulatory factors myoD, myogenin, and myf5. The c-Myc leucine zipper (LZ) motif is essential for the differentiation block since myoblasts expressing a mutant with a partial deletion of this region, c-Myc Delta 7, differentiate and express myoD family regulators and muscle-specific genes normally. Remarkably, c-Myc Delta 7, like wild-type c-Myc, retains the capacity to transform the growth phenotype of myoblasts, and associates with the b-HLH-LZ Myc partner protein Max in transformed cells. We conclude that the block to myogenic differentiation induced by c-Myc can be dissociated from cell transformation per se, and that this attribute correlates more closely with down-regulation of myoD family gene expression. These findings are discussed in the light of current models of Myc function.	BEATSON INST CANC RES,WOLFSON LAB MOLEC PATHOL,CANC RES CAMPAIGN BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND	Beatson Institute			la rocca, severina anna/D-8028-2011; Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CATLING AD, 1993, ONCOGENE, V8, P1875; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; CROUCH DH, 1990, ONCOGENE, V5, P683; CROUCH DH, 1993, ONCOGENE, V8, P1849; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ENRIETTO PJ, 1989, VIROLOGY, V168, P256, DOI 10.1016/0042-6822(89)90265-1; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GROSSI M, 1991, ONCOGENE, V6, P1767; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PATCHINSKY T, 1986, J VIROL, V59, P341; Penn L J, 1990, Semin Cancer Biol, V1, P69; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RAMSAY GM, 1990, P NATL ACAD SCI USA, V87, P2102, DOI 10.1073/pnas.87.6.2102; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SOLLENBERGER KG, 1994, ONCOGENE, V9, P661; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; SU HY, 1991, ONCOGENE, V6, P1759; TATO F, 1983, DIFFERENTIATION, V24, P131, DOI 10.1111/j.1432-0436.1983.tb01312.x; VOGEL Z, 1972, P NATL ACAD SCI USA, V69, P3180, DOI 10.1073/pnas.69.11.3180; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	50	62	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3499	3508						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970710				2022-12-25	WOS:A1994PT39200012
J	RAPP, UR; TROPPMAIR, J; BECK, T; BIRRER, MJ				RAPP, UR; TROPPMAIR, J; BECK, T; BIRRER, MJ			TRANSFORMATION BY RAF AND OTHER ONCOGENES RENDERS CELLS DIFFERENTIALLY SENSITIVE TO GROWTH-INHIBITION BY A DOMINANT-NEGATIVE C-JUN MUTANT	ONCOGENE			English	Article							MAP KINASE-KINASE; PROTEIN-KINASE; V-RAF; SIGNAL TRANSDUCTION; EMBRYO CELLS; MYC PROTEIN; TRANSCRIPTION; EXPRESSION; ACTIVATION; PHOSPHORYLATION	In NIH3T3 cells expressing active Raf-1 protein serine/threonine kinase (PSK) c-jun expression is constitutive while c-fos expression is attenuated. This alteration prompted us to determine whether oncogene transformation would render cells differentially sensitive to growth inhibition by a dominant negative mutant of c-jun, TAM 67. Growth inhibition was observed in three types of assays: (1) transfection of TAM 67 into cells stably transformed by a variety of oncogenes, (2) cotransfection of TAM 67 with oncogene expression plasmids into NIH3T3 cells and (3) titration of oncogene-expressing retroviruses on cells stably expressing TAM 67. The results clearly demonstrate that Raf-1 dependent oncogenes, which include receptor protein tyrosine kinases (PTKs)-, intracellular PTKs- and Ras-derived genes share the Raf phenotype of constitutive c-jun expression, attenuated c-fos induction, and high sensitivity to growth suppression by TAM 67. Additionally, the intracellular PSK oncogene, mos and the nuclear oncogenes c-myc, c-fos, and SV40 T antigen were TAM 67-sensitive for transformation This universal pattern of altered growth regulation in oncogene transformed fibroblast cell lines highlights the potential usefulness of c-jun based inhibitors for control of tumor cell growth.	NCI, DIV CANC PREVENT & CONTROL, BIOMARKERS & PREVENT RES BRANCH, ROCKVILLE, MD 20850 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA; UNIV WURZBURG, INST STRAHLEN & ZELLFORSCH, WURZBURG, GERMANY; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC, BCDP, FREDERICK, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Wurzburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Troppmair, Jakob/0000-0002-0611-3837				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BROWN PH, 1993, ONCOGENE, V8, P877; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEAN M, 1987, ONCOGENE RES, V1, P279; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GRUGEL S, UNPUB; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOLCH W, 1993, ONCOGENE, V8, P361; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MIYASHITA T, UNPUB; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PROPST F, 1993, MOL BASIS HUMAN CANC, P173; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rapp U R, 1987, Haematol Blood Transfus, V31, P450; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RAPP UR, IN PRESS CELLULAR VI; RAPP UR, 1988, LUNG CANCER, V4, P162; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WANG HG, 1994, ONCOGENE, V9, P2751; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	52	60	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3493	3498						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970709				2022-12-25	WOS:A1994PT39200011
J	CHIT, NW; KOLODNER, RD				CHIT, NW; KOLODNER, RD			THE EFFECT OF DNA MISMATCHES ON THE ATPASE ACTIVITY OF MSH1, A PROTEIN IN YEAST MITOCHONDRIA THAT RECOGNIZES DNA MISMATCHES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; COLI UVRABC ENDONUCLEASE; BINDING; MUTATIONS; HOMOLOGS; CANCER; GENES	MSH1 is a DNA-binding protein in yeast mitochondria that recognizes nucleotide mismatches in DNA and plays a role in mitochondrial mutation avoidance (Chi, W., and Kolodner, R. D. (1994) J. Biol. Chem. 269, 29984-29992). MSH1 exhibits an ATPase activity that hydrolyses similar to 1 ATP molecule/min in the absence of DNA, In this study, we show that DNA alters the pH dependence of the MSH1 ATPase and stimulates ATP hydrolysis at neutral pH. Using heteroduplex DNA containing mismatches with various affinity, we show an inverse correlation between the extent of ATPase stimulation by DNA and the binding affinity of MSH1 for the DNA effector. We also show that the presence of ATP increases the mismatch specificity of MSH1-DNA binding. Taken together, the observed interaction between the ATPase and the mismatch-binding activities suggests that MSH1 binds to ATP and mismatches with positive cooperativity. This interaction may provide a system for elucidating the role of ATP in mismatch recognition and repair.	DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School					NHGRI NIH HHS [HG00305] Funding Source: Medline; NIGMS NIH HHS [GM50006] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1992, J BIOL CHEM, V267, P12142; BROWN TL, 1978, CHEM CENTRAL SCI; Cantor C.R., 1980, BIOPHYS CHEM; CHI W, 1994, J BIOL CHEM, V269, P29984; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GORBALENYA AE, 1990, J MOL BIOL, V213, P583, DOI 10.1016/S0022-2836(05)80243-8; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HENDERSON P J F, 1992, P277; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; LIPTON KF, 1979, METHOD ENZYMOL, V63, P183; LIPTON KF, 1992, ENZYME ASSAYS PRACTI, P1; MADIRAJU MVVS, 1992, J BACTERIOL, V174, P7705, DOI 10.1128/JB.174.23.7705-7710.1992; Maniatis T., 1982, MOL CLONING; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; SELWYN MJ, 1965, BIOCHIM BIOPHYS ACTA, V105, P193, DOI 10.1016/S0926-6593(65)80190-4; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; THIAGALINGAM S, 1993, J BIOL CHEM, V268, P18382; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Watson J. D., 1987, MOL BIOL GENE; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6	31	6	6	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29993	29997						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961999				2022-12-25	WOS:A1994PU28400103
J	JAYAWICKREME, CK; QUILLAN, JM; GRAMINSKI, GF; LERNER, MR				JAYAWICKREME, CK; QUILLAN, JM; GRAMINSKI, GF; LERNER, MR			DISCOVERY AND STRUCTURE-FUNCTION ANALYSIS OF ALPHA-MELANOCYTE-STIMULATING HORMONE ANTAGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FEMALE RAT; MELANOTROPINS; RECEPTORS; MELANOPHORES; CELLS; PROTEIN; DESIGN; MSH; NEUROPEPTIDES; SUPERPOTENT	Structure-function relationships of alpha-melanocyte-stimulating hormone (alpha-MSH, alpha-melanotropin) were investigated and novel alpha-MSH receptor antagonists were identified. Based on the alpha-MSH-[5-13] peptide sequence, a multi-use peptide library consisting of 31,360 structurally different candidates was generated, and approximately 40% of the peptides were individually screened for their ability to block receptor function. This led to the identification of antagonists with a range of potencies and revealed structural requirements necessary for receptor inactivation. The most potent antagonist Met-Pro D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2 has an IC50 value of 11 +/- 7 nM. Analysis revealed that D-Trp(5) and Phe(6) were crucial to its antagonistic properties which could be potentiated by D-Phe(3). This study demonstrates that residues in positions 5-6, 7-9, and 10 of the alpha-MSH sequence constitute crucial determinants for potent antagonist activity.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT INTERNAL MED,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT PHARMACOL,NEW HAVEN,CT 06536	Yale University; Yale University					NIGMS NIH HHS [R01 GM42490-05] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042490] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALOBEIDI F, 1989, J AM CHEM SOC, V111, P3413, DOI 10.1021/ja00191a044; ALOBEIDI F, 1990, INT J PEPT PROT RES, V35, P228; BARNAWELL EB, 1982, ADV COMP PHYSIOL BIO, V8, P53; BERGASA NV, 1993, ANN NY ACAD SCI, V680, P454, DOI 10.1111/j.1749-6632.1993.tb19706.x; CANNON JG, 1986, J IMMUNOL, V137, P2232; CATANIA A, 1993, ENDOCR REV, V14, P564, DOI 10.1210/er.14.5.564; CERIANI G, 1994, NEUROENDOCRINOLOGY, V59, P138, DOI 10.1159/000126650; CODY WL, 1985, J MED CHEM, V28, P583, DOI 10.1021/jm50001a008; DANIOLOS A, 1990, PIGM CELL RES, V3, P38, DOI 10.1111/j.1600-0749.1990.tb00260.x; DEWIED D, 1993, ANN NY ACAD SCI, V680, P20, DOI 10.1111/j.1749-6632.1993.tb19672.x; DEWIED D, 1982, PHYSIOL REV, V62, P976, DOI 10.1152/physrev.1982.62.3.976; EBERLE AN, 1993, ANN NY ACAD SCI, V680, P320, DOI 10.1111/j.1749-6632.1993.tb19693.x; EBERLE AN, 1988, MELANOTROPINS CHEM P; EHYMAYED HM, 1992, PHYSIOL RES, V41, P57; ELLERKMANN E, 1992, ENDOCRINOLOGY, V130, P133, DOI 10.1210/en.130.1.133; FIELDS C G, 1991, Peptide Research, V4, P95; Fields G. B., 1992, SYNTHETIC PEPTIDES U, P77; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GISPEN WH, 1993, ANN NY ACAD SCI, V680, P401, DOI 10.1111/j.1749-6632.1993.tb19698.x; GRAMINSKI GF, 1993, J BIOL CHEM, V268, P5957; HADLEY ME, 1988, MELANOTROPIC PEPTIDE, P1; HARRIS JI, 1957, NATURE, V179, P1346, DOI 10.1038/1791346a0; HILL JB, 1993, ENDOCRINOLOGY, V133, P2991, DOI 10.1210/en.133.6.2991; HORI T, 1992, PHYSIOL RES, V41, P77; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HRUBY VJ, 1993, ANN NY ACAD SCI, V680, P51, DOI 10.1111/j.1749-6632.1993.tb19674.x; JAYAWICKREME CK, 1994, P NATL ACAD SCI USA, V91, P1614, DOI 10.1073/pnas.91.5.1614; KARNE S, 1993, J BIOL CHEM, V268, P19126; KHORRAM O, 1984, P NATL ACAD SCI-BIOL, V81, P8004, DOI 10.1073/pnas.81.24.8004; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEE TH, 1956, J BIOL CHEM, V221, P943; LERNER AB, 1961, NATURE, V189, P176, DOI 10.1038/189176a0; LIU MA, 1988, SCIENCE, V239, P395, DOI 10.1126/science.3257303; MCCLINTOCK TS, 1993, ANAL BIOCHEM, V209, P298, DOI 10.1006/abio.1993.1123; MEDZIHRADSZKY K, 1979, PEPTIDES 1978, P593; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MURPHY JR, 1986, P NATL ACAD SCI USA, V83, P8258, DOI 10.1073/pnas.83.21.8258; MURPHY MT, 1983, SCIENCE, V221, P192, DOI 10.1126/science.6602381; OTSUKA H, 1964, B CHEM SOC JPN, V37, P1465, DOI 10.1246/bcsj.37.1465; POTENZA MN, 1992, PIGM CELL RES, V5, P372, DOI 10.1111/j.1600-0749.1992.tb00565.x; POTENZA MN, 1992, ANAL BIOCHEM, V206, P315, DOI 10.1016/0003-2697(92)90372-E; POTENZA MN, 1991, PIGM CELL RES, V4, P186, DOI 10.1111/j.1600-0749.1991.tb00437.x; SAWYER TK, 1980, P NATL ACAD SCI-BIOL, V77, P5754, DOI 10.1073/pnas.77.10.5754; SAWYER TK, 1990, PEPTIDES, V11, P351, DOI 10.1016/0196-9781(90)90092-J; STRAND FL, 1993, ANN NY ACAD SCI, V680, P29, DOI 10.1111/j.1749-6632.1993.tb19673.x; SUGG EE, 1988, BIOCHEMISTRY-US, V27, P8181, DOI 10.1021/bi00421a029; TATRO JB, 1990, BRAIN RES, V536, P124, DOI 10.1016/0006-8993(90)90016-5; THODY AJ, 1983, PHYSIOL BEHAV, V31, P67, DOI 10.1016/0031-9384(83)90097-5; WOLTERINK G, 1990, BRAIN RES, V507, P115, DOI 10.1016/0006-8993(90)90529-K; YEHUDA S, 1991, PEPTIDES, V12, P465, DOI 10.1016/0196-9781(91)90085-4	50	51	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29846	29854						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961978				2022-12-25	WOS:A1994PU28400082
J	KIRK, J; KIRK, K				KIRK, J; KIRK, K			INHIBITION OF VOLUME-ACTIVATED I- AND TAURINE EFFLUX FROM HELA-CELLS BY P-GLYCOPROTEIN BLOCKERS CORRELATES WITH CALMODULIN INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES TUMOR-CELLS; MULTIDRUG-RESISTANCE; CALCIUM-ANTAGONISTS; TRANSPORT PATHWAYS; CHLORIDE CHANNELS; HUMAN-LYMPHOCYTES; PHOSPHODIESTERASE; TAMOXIFEN; BINDING; BRAIN	P-glycoprotein, an active transporter that pumps a diverse range of hydrophobic compounds out of cells, has recently been proposed to function as, or regulate, a volume-activated, anion-selective channel (Valverde, M. A, Diaz, M., Sepulveda, F. V., Gill, D. R., Hyde, S. C., and Higgins, C. F. (1992) Nature 355, 830-833). In this study a number of compounds known to inhibit P-glycoprotein-mediated drug pumping were tested for their effect on the osmotically activated release from HeLa cells of I-, a known substrate of volume-activated anion channels, and taurine, a sulfonic amino acid that serves as an important organic osmolyte in many cell-types. Tamoxifen, 4-iodotamoxifen, and pyrrolidino-4-iodotamoxifen (idoxifene) were potent blockers of osmotically activated I- and taurine efflux. Other known P-glycoprotein inhibitors (verapamil, cyclosporin A, pimozide, trifluoperazine, ICI 164, and ICI 182) were less effective. For all compounds tested the effect on taurine release was the same as that on I- release, consistent with the hypothesis that swelling-activated taurine release is via anion-selective channels. There was no positive correlation between the effect of the inhibitors on osmotically activated solute release and their effect on P-glycoprotein-mediated drug transport. In contrast, there was a strong positive correlation between the IC50 values for the effect of the inhibitors on volume-activated solute release and those for their effect on calmodulin. These data raise doubts as to whether the effect of P-glycoprotein inhibitors on volume-activated channels is a consequence of their interaction with P-glycoprotein and indicate a possible role for calmodulin, or a cell component having at least some physical similarities, in controlling channel activity.			KIRK, J (corresponding author), UNIV OXFORD, PHYSIOL LAB, PARKS RD, OXFORD OX1 3PT, ENGLAND.		Kirk, Kiaran/C-8299-2009	Kirk, Kiaran/0000-0002-5613-2622				ASANO M, 1984, CALCIUM CELL FUNCTIO, V5, P123; BANDERALI U, 1992, AM J PHYSIOL, V263, pC1200, DOI 10.1152/ajpcell.1992.263.6.C1200; BARRERA G, 1986, BIOCHEM PHARMACOL, V35, P2984, DOI 10.1016/0006-2952(86)90500-9; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BRANDES LJ, 1986, CANCER CHEMOTH PHARM, V18, P21, DOI 10.1007/BF00253057; CAHALAN MD, 1994, BIOPHYS J, V66, pA3; DIAZ M, 1993, PFLUG ARCH EUR J PHY, V422, P347, DOI 10.1007/BF00374290; EHRING GR, 1994, BIOPHYS J, V66, pA142; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GARCIAROMEU F, 1991, J PHYSIOL-LONDON, V440, P547, DOI 10.1113/jphysiol.1991.sp018724; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOLDENRING JR, 1985, J NEUROCHEM, V44, P1229, DOI 10.1111/j.1471-4159.1985.tb08748.x; GRINSTEIN S, 1982, J GEN PHYSIOL, V79, P849, DOI 10.1085/jgp.79.5.849; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HAIT WN, 1986, SCIENCE, V233, P987, DOI 10.1126/science.3016900; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; HIDAKA H, 1979, MOL PHARMACOL, V15, P49; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P7844; HOFFMANN EK, 1984, J MEMBRANE BIOL, V78, P211, DOI 10.1007/BF01925969; HOFFMANN EK, 1986, J MEMBRANE BIOL, V91, P227, DOI 10.1007/BF01868816; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HU XF, 1991, EUR J CANCER, V27, P773, DOI 10.1016/0277-5379(91)90187-I; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; JACKSON PS, 1993, AM J PHYSIOL, V265, pC1489, DOI 10.1152/ajpcell.1993.265.6.C1489; JARMAN M, 1986, ANTI-CANCER DRUG DES, V1, P259; KIRK J, 1994, BIOCHEM PHARMACOL, V48, P277, DOI 10.1016/0006-2952(94)90098-1; KIRK K, 1993, FEBS LETT, V336, P153, DOI 10.1016/0014-5793(93)81630-I; KIRK K, 1992, J BIOL CHEM, V267, P23475; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; LAM HYP, 1984, BIOCHEM BIOPH RES CO, V118, P27, DOI 10.1016/0006-291X(84)91062-3; LAMBERT IH, 1993, J MEMBRANE BIOL, V131, P67, DOI 10.1007/BF02258535; LAW RO, 1994, BBA-MOL CELL RES, V1221, P21, DOI 10.1016/0167-4889(94)90211-9; LEE GL, 1985, LIFE SCI, V36, P347, DOI 10.1016/0024-3205(85)90120-1; LEGRUE SJ, 1986, SCIENCE, V234, P68, DOI 10.1126/science.3749892; LEVIN RM, 1976, MOL PHARMACOL, V12, P581; LINCKE CR, 1990, CANCER RES, V50, P1779; MACNEIL S, 1989, J INVEST DERMATOL, V93, P291, DOI 10.1111/1523-1747.ep12277595; MATSUDA Y, 1990, BIOCHEM PHARMACOL, V39, P841; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; MCEWAN GTA, 1992, FEBS LETT, V304, P233, DOI 10.1016/0014-5793(92)80626-R; MINTENIG GM, 1993, RECEPTOR CHANNEL, V1, P305; NORMAN JA, 1987, MOL PHARMACOL, V31, P535; OHISHI K, 1985, GEN PHARMACOL, V16, P335, DOI 10.1016/0306-3623(85)90192-2; PAPADOPOULOS V, 1989, MOL CELL ENDOCRINOL, V63, P23, DOI 10.1016/0303-7207(89)90078-6; RASOLA A, 1994, J BIOL CHEM, V269, P1432; ROBSON KJH, 1993, PHILOS T R SOC B, V340, P39, DOI 10.1098/rstb.1993.0047; ROWLANDS MG, 1990, BIOCHEM PHARMACOL, V40, P283, DOI 10.1016/0006-2952(90)90689-I; ROY G, 1992, J MEMBRANE BIOL, V130, P83; SARKADI B, 1985, AM J PHYSIOL, V248, pC480, DOI 10.1152/ajpcell.1985.248.5.C480; SCHAEFFER P, 1991, EUR J PHARM-MOLEC PH, V206, P325, DOI 10.1016/0922-4106(91)90117-Z; SILVER PJ, 1989, CARDIOVASC DRUG THER, V3, P675, DOI 10.1007/BF01857619; STOUT MA, 1992, J CELL PHYSIOL, V153, P169, DOI 10.1002/jcp.1041530121; STRANGE K, 1993, AM J PHYSIOL, V265, pC244, DOI 10.1152/ajpcell.1993.265.1.C244; TREZISE AEO, 1992, EMBO J, V11, P4291, DOI 10.1002/j.1460-2075.1992.tb05528.x; TSURUO T, 1982, CANCER RES, V42, P4730; VALVERDE MA, 1993, PFLUG ARCH EUR J PHY, V425, P552, DOI 10.1007/BF00374885; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WAKELING AE, 1987, J ENDOCRINOL, V112, pR7, DOI 10.1677/joe.0.112R007; WAKELING AE, 1988, J STEROID BIOCHEM, V30, P141, DOI 10.1016/0022-4731(88)90086-6; WANG XY, 1994, CLIN EXP PHARMACOL P, V21, P101, DOI 10.1111/j.1440-1681.1994.tb02475.x; ZHANG JJ, 1994, IN PRESS J CLIN INVE	62	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29389	29394						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961917				2022-12-25	WOS:A1994PU28400015
J	MILLE, B; WATTON, J; BARROWCLIFFE, TW; MANI, JC; LANE, DA				MILLE, B; WATTON, J; BARROWCLIFFE, TW; MANI, JC; LANE, DA			ROLE OF N-TERMINAL AND C-TERMINAL AMINO-ACIDS IN ANTITHROMBIN BINDING TO PENTASACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-BOND LOOP; HEREDITARY ABNORMAL ANTITHROMBIN; SURFACE-PLASMON RESONANCE; REDUCED HEPARIN AFFINITY; MOLECULAR WEIGHT HEPARIN; ANTI-THROMBIN-III; CRYSTAL-STRUCTURE; CONFORMATIONAL CHANGE; TARGET PROTEINASES; SUBSTRATE REACTION	We have used a monoclonal antibody-based binding procedure to determine the dissociation constants of the interactions between the essential antithrombin-binding pentasaccharide and a series of 13 distinct N- and C-terminal antithrombin substitution mutation variants with defective binding interaction with heparin. The reduction in binding affinity of the pentasaccharide with the N-terminal variants (with substitution mutations Pro-41 --> Leu, Arg-47 --> Cys and His, Leu-99 --> Val and Phe, Gln-118 --> Pro, Arg-129 --> Gln) compared to normal antithrombin, K-d 200 nM, ranged from 15-984-fold and was generally less than 150-fold. Reduced binding affinity is assumed to arise mostly by perturbation, direct or indirect, of the initial contact of pentasaccharide with basic residues of antithrombin. Surprisingly, the binding interaction of the pentasaccharide with the C-terminal variants (with substitution mutations in or near strand 1C/4B, Phe-402 --> Leu, Cys, and Ser, Ala-404 --> Thr, Pro-407 --> Thr, Pro-429 --> Leu) was more uniformly and yet substantially (135-482-fold) decreased, despite the spatial separation between the site of mutation and the proposed primary contact site of the pentasaccharide. These results demonstrate that strand 1C/4B region integrity is required for optimum interaction with the pentasaccharide, suggesting its involvement in transmission of the induced conformation change required for high affinity binding.	CHARING CROSS & WESTMINSTER MED SCH,DEPT HAEMATOL,LONDON W6 8RP,ENGLAND; NATL INST BIOL STAND & CONTROLS,DIV HAEMATOL,S MIMMS EN6 3QG,HERTS,ENGLAND; FAC PHARM MONTPELLIER,CNRS,UMR 9921,F-34060 MONTPELLIER 1,FRANCE	Imperial College London; National Institute for Biological Standards & Control; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier				Lane, David/0000-0003-4283-3695	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABILDGAARD U, 1968, SCAND J CLIN LAB INV, V21, P89, DOI 10.3109/00365516809076981; AUSTIN RC, 1991, BLOOD, V77, P2185; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1992, J BIOL CHEM, V267, P19047; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BJORK I, 1989, HEPARIN CHEM BIOL PR; BORG JY, 1990, FEBS LETT, V266, P163, DOI 10.1016/0014-5793(90)81530-2; BORG JY, 1988, J CLIN INVEST, V81, P1292, DOI 10.1172/JCI113447; BRENNAN SO, 1988, FEBS LETT, V237, P118, DOI 10.1016/0014-5793(88)80183-2; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CASO R, 1990, THROMB RES, V58, P185, DOI 10.1016/0049-3848(90)90175-C; CASO R, 1991, BRIT J HAEMATOL, V77, P87, DOI 10.1111/j.1365-2141.1991.tb07953.x; CHANG JY, 1986, J BIOL CHEM, V261, P1174; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DAWES J, 1994, BIOCHEMISTRY-US, V33, P4375, DOI 10.1021/bi00180a035; DESTEFANO V, 1994, BLOOD COAGUL FIBRIN, V5, P7; DUBS MC, 1991, IMMUNOL LETT, V31, P59; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; IRELAND H, 1991, BRIT J HAEMATOL, V79, P70, DOI 10.1111/j.1365-2141.1991.tb08009.x; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; JORDAN RE, 1980, J BIOL CHEM, V255, P81; JORDAN RE, 1980, J BIOL CHEM, V255, P73; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LANE DA, 1992, J CLIN INVEST, V90, P2422, DOI 10.1172/JCI116133; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MALMQVIST M, 1993, CURR OPIN IMMUNOL, V5, P282, DOI 10.1016/0952-7915(93)90019-O; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; OKAJIMA K, 1993, BLOOD, V81, P1300; OLDS RJ, 1990, NUCLEIC ACIDS RES, V18, P1926, DOI 10.1093/nar/18.7.1926; OLDS RJ, 1992, FEBS LETT, V300, P241, DOI 10.1016/0014-5793(92)80854-A; OLDS RJ, 1992, BLOOD, V79, P1206, DOI 10.1182/blood.V79.5.1206.bloodjournal7951206; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1992, J BIOL CHEM, V267, P12528; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SCREUDER HA, 1994, NATURE STRUCTURAL BI, V1, P48; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; WATTON J, 1993, BIOCHEMISTRY-US, V32, P7286, DOI 10.1021/bi00079a027; Watton J, 1990, Blood Coagul Fibrinolysis, V1, P619	43	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29435	29443						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961924				2022-12-25	WOS:A1994PU28400022
J	JOSEPH, G; GORZALCZANY, Y; KOSHKIN, V; PICK, E				JOSEPH, G; GORZALCZANY, Y; KOSHKIN, V; PICK, E			INHIBITION OF NADPH OXIDASE ACTIVATION BY SYNTHETIC PEPTIDES MAPPING WITHIN THE CARBOXYL-TERMINAL DOMAIN OF SMALL GTP-BINDING PROTEINS - LACK OF AMINO-ACID-SEQUENCE SPECIFICITY AND IMPORTANCE OF POLYBASIC MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; SODIUM DODECYL-SULFATE; DEPENDENT SUPEROXIDE PRODUCTION; MEMBRANE-ASSOCIATED COMPONENT; PLASMA-MEMBRANE; RAS PROTEINS; MACROPHAGES; SIGNAL; CYTOCHROME-B559; TRANSLOCATION	The small GTP-binding protein (G protein) Rac1 is an obligatory participant in the assembly of the superoxide (O-2(radical anion))-generating NADPH oxidase complex of macrophages. We investigated the effect of synthetic peptides, mapping within the near carboxyl-terminal domains of Rac1 and of related G proteins, on the activity of NADPH oxidase in a cell-free system consisting of solubilized guinea pig macrophage membrane, a cytosolic fraction enriched in p47(phox) and p67(phox) (or total cytosol), highly purified Rac1-GDP dissociation inhibitor for Rho (Rho GDI) complex, and the activating amphiphile, lithium dodecyl sulfate. Peptides Rac1-(178-188) and Rac1-(178-191), but not Rac2-(178-188), inhibited NADPH oxidase activity in a Rac1-dependent system when added prior to or simultaneously with the initiation of activation. However, undecapeptides corresponding to the near carboxyl-terminal domains of RhoA and RhoC and, most notably, a peptide containing the same amino acids as Rac1-(178-188), but in reversed orientation, were also inhibitory. Surprisingly, O-2(radical anion) production in a Rac2-dependent cell-free system was inhibited by Rac1-(178-188) but not by Rac2-(178-188). Finally, basic polyamino acids containing lysine, histidine, or arginine, also inhibited NADPH oxidase activation. We conclude that inhibition of NADPH oxidase activation by synthetic peptides mapping within the carboxyl-terminal domain of certain small G proteins is not amino acid sequence-specific but related to the presence of a polybasic motif. It has been proposed that such a motif serves as a plasma membrane targeting signal for a number of small G proteins (Hancock, J.F., Paterson, H., and Marshall, C.J. (1990) Cell 63, 133-139).	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IMMUNOPHARMACOL LAB,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine			Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233				ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1994, FASEB J, V8, pA1451; ISOMURA M, 1991, ONCOGENE, V6, P119; KLINGER E, 1991, BIOCHEM J, V285, P632; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; KRECK ML, 1994, J BIOL CHEM, V269, P4161; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; MACLEAN CM, 1993, BIOCHEM J, V294, P325, DOI 10.1042/bj2940325; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PICK E, 1993, EUR J BIOCHEM, V217, P441, DOI 10.1111/j.1432-1033.1993.tb18264.x; PICK E, 1987, J BIOL CHEM, V262, P16476; PICK E, 1989, J IMMUNOL, V143, P4180; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROTROSEN D, 1992, INFLAMMATION BASIC P, P589; SAWAI T, 1993, BIOCHEM BIOPH RES CO, V195, P264, DOI 10.1006/bbrc.1993.2039; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SHAAG D, 1989, J BIOCHEM BIOPH METH, V19, P121, DOI 10.1016/0165-022X(89)90056-0	33	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29024	29031						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961867				2022-12-25	WOS:A1994PU16800077
J	KOBAYASHI, T; URABE, K; ORLOW, SJ; HIGASHI, K; IMOKAWA, G; KWON, BS; POTTERF, B; HEARING, VJ				KOBAYASHI, T; URABE, K; ORLOW, SJ; HIGASHI, K; IMOKAWA, G; KWON, BS; POTTERF, B; HEARING, VJ			THE PMEL-17 SILVER LOCUS PROTEIN - CHARACTERIZATION AND INVESTIGATION OF ITS MELANOGENIC FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TYROSINASE; MELANIN BIOSYNTHESIS; DOPACHROME; IDENTIFICATION; PIGMENTATION; MELANOCYTES; GENE; TAUTOMERASE; EXPRESSION; CULTURE	The silver mutation in mice causes progressive graying of hair due to the loss of functional follicular melanocytes. Recently the silver locus gene (called Pmel 17) has been cloned; its encoded product shares homology with a chick melanosomal matrix protein and a bovine retinal pigment epithelial protein. Although the sequence of the silver gene and the correlation of its expression with pigment production have been reported, its function in melanogenesis is still unknown. In an effort to characterize that function, we have synthesized the predicted carboxyl-terminal peptide of the mouse Pmel 17 protein and generated a rabbit polyclonal antibody (alpha PEP13) to it; that antibody recognized the silver protein specifically. The immunoaffinity-purified silver protein lacked all of the known melanogenic catalytic activities which other tyrosinase-related proteins (TRP) have, nor did it appear to modulate any of those TRP activities. Metabolic labeling experiments demonstrated that the silver protein disappears in vivo within a few hours, indicating that it is rapidly degraded, or quickly processed to lose its carboxyl terminus. Crossreactivity experiments showed that a recently reported anti-melanosomal matrix protein antibody (alpha MX) also recognizes the silver protein, although at a different epitope from that of alpha PEP13. Using Western immunoblotting, we analyzed subcellular fractions isolated from B16 F10 melanoma cells and found that the silver protein was rich in the melanosome fraction but was absent from coated vesicles which deliver TRPs to melanosomes. These results suggest that the silver locus product is a melanosomal matrix protein which may contribute to melanogenesis as a structural protein, although the possibility remains that it also has a novel catalytic function in melanogenesis.	NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA; KAO INST FUNDAMENTAL RES, HAGA, TOCHIGI 32134, JAPAN; NYU, SCH MED, RONALD O PERELMAN DEPT DERMATOL, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT CELL BIOL, NEW YORK, NY 10016 USA; INDIANA UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); New York University; New York University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute				Orlow, Seth/0000-0003-2548-7380; Kobayashi, Takeshi/0000-0002-4372-5285	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041880, R55AR041880] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41880] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADEMA GJ, 1994, J BIOL CHEM, V269, P20126; AROCA P, 1993, J BIOL CHEM, V268, P25650; AROCA P, 1992, BIOCHEM J, V284, P109, DOI 10.1042/bj2840109; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; BENNETT DC, 1993, INT REV CYTOL, V146, P191, DOI 10.1016/S0074-7696(08)60383-6; BENNETT DC, 1985, J CELL SCI, V77, P167; BENNETT DC, 1989, DEVELOPMENT, V105, P379; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CHAKRABORTY AK, 1994, PIGM CELL RES, V7, pS22; CHASE HB, 1950, J MORPHOL, V87, P381, DOI 10.1002/jmor.1050870209; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HOU L, 1994, PIGM CELL RES, V7, pS15; HOUGHTON AN, 1994, J EXP MED, V180, P1, DOI 10.1084/jem.180.1.1; IMOKAWA G, 1982, CANCER RES, V42, P1994; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; JOHNSON R, 1992, NAT GENET, V1, P226, DOI 10.1038/ng0692-226; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KIM RY, 1992, EXP EYE RES, V55, P657, DOI 10.1016/0014-4835(92)90170-W; KOBAYASHI T, 1994, PIGM CELL RES, V7, P227, DOI 10.1111/j.1600-0749.1994.tb00054.x; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; KORNER AM, 1980, J INVEST DERMATOL, V75, P192, DOI 10.1111/1523-1747.ep12522650; KWON BS, 1993, J INVEST DERMATOL, V100, pS134, DOI 10.1111/1523-1747.ep12465022; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; KWON BS, 1987, MOL BIOL MED, V4, P339; Kwon Byoung S., 1993, Pigment Cell Research, V6, P274; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOCHII M, 1991, PIGM CELL RES, V4, P41, DOI 10.1111/j.1600-0749.1991.tb00312.x; OLD LJ, 1962, ANN NY ACAD SCI, V101, P80, DOI 10.1111/j.1749-6632.1962.tb26446.x; ORLOW SJ, 1993, J INVEST DERMATOL, V101, P141, DOI 10.1111/1523-1747.ep12363626; ORLOW SJ, 1993, J INVEST DERMATOL, V100, P55, DOI 10.1111/1523-1747.ep12354138; PALUMBO A, 1987, BIOCHIM BIOPHYS ACTA, V925, P203, DOI 10.1016/0304-4165(87)90110-3; QUEVEDO WC, 1981, PIGMENT CELL 1981 PH, P177; SEIJI M, 1963, ANN NY ACAD SCI, V100, P497, DOI 10.1111/j.1749-6632.1963.tb42911.x; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SPANAKIS E, 1992, DEVELOPMENT, V114, P675; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; URABE K, 1994, BBA-MOL CELL RES, V1221, P272, DOI 10.1016/0167-4889(94)90250-X; ZHOU BK, 1994, P NATL ACAD SCI USA, V91, P7076, DOI 10.1073/pnas.91.15.7076	42	132	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29198	29205						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961886				2022-12-25	WOS:A1994PU16800099
J	TOHGO, A; TAKASAWA, S; NOGUCHI, N; KOGUMA, T; NATA, K; SUGIMOTO, T; FURUYA, Y; YONEKURA, H; OKAMOTO, H				TOHGO, A; TAKASAWA, S; NOGUCHI, N; KOGUMA, T; NATA, K; SUGIMOTO, T; FURUYA, Y; YONEKURA, H; OKAMOTO, H			ESSENTIAL CYSTEINE RESIDUES FOR CYCLIC ADP-RIBOSE SYNTHESIS AND HYDROLYSIS BY CD38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ANTIGEN CD38; BETA-CELLS; CYCLASE; SURFACE; ENZYME; GLYCOHYDROLASE; EXPRESSION; NAD+; ACID	We have recently demonstrated that cyclic ADP-ribose (cADPR) serves as a second messenger for glucose-induced insulin secretion (Takasawa, S., Nata, K., Yonekura, H., and Okamoto, H. (1993) Science 259, 370-373) and that human leukocyte antigen CD38 has both ADP-ribosyl cyclase and cADPR hydrolase activities (Takasawa, S., Tohgo, A., Noguchi, N., Koguma, T., Nata, K., Sugimoto, T., Yonekura, Il., and Okamoto, H. (1993) J. Biol. Chem. 268, 26052-26054). Although the amino acid sequence of Aplysia ADP-ribosyl cyclase exhibits a high degree of amino acid sequence identity with that of CD38, the Aplysia enzyme shows only ADP-ribosyl cyclase but not cADPR hydrolase. In the present study, me introduced site-directed mutations to CD38 and found that C119K- and/or C201E-CD38 exhibited only ADP-ribosyl cyclase activity. Furthermore, Aplysia ADP-ribosyl cyclase into which we introduced the mutations K95C and E176C, which correspond to residues 119 and 201 of human CD38, exhibited not only ADP-ribosyl cyclase activity but also cADPR hydrolase. These results indicate that cysteine residues 119 and 201 in CD38 have crucial roles in the synthesis and hydrolysis of cADPR.	TOHOKU UNIV, SCH MED, DEPT BIOCHEM, AOBA KU, SENDAI, MIYAGI 98077, JAPAN	Tohoku University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; HARADA N, 1993, J IMMUNOL, V151, P3111; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KNAPP W, 1989, TISSUE ANTIGENS, V33, P123; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; OKAMOTO H, 1993, DIABETES, V42, pA76; OKAMOTO H, 1992, 1ST C INT UN BIOCH M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TAKASAWA S, 1993, SCIENCE, V262, P585, DOI 10.1126/science.262.5133.585-a; TAKASAWA S, 1993, SEIKAGAKU, V65, P1089; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	23	98	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28555	28557						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961800				2022-12-25	WOS:A1994PU16800009
J	LEVI, S; CORSI, B; ROVIDA, E; COZZI, A; SANTAMBROGIO, P; ALBERTINI, A; AROSIO, P				LEVI, S; CORSI, B; ROVIDA, E; COZZI, A; SANTAMBROGIO, P; ALBERTINI, A; AROSIO, P			CONSTRUCTION OF A FERROXIDASE CENTER IN HUMAN FERRITIN L-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEED PISUM-SATIVUM; H-CHAIN; HUMAN-LIVER; 3-FOLD CHANNELS; IRON-UPTAKE; MECHANISM; SITE; APOFERRITIN; MUTANTS; CORES	Ferritins are 24-mer proteins which store and detoxify intracellular iron. Mammalian ferritins are made of two subunit types, the H- and L-chains, with different functional specificity. The H-chain has a metal-binding site (the ferroxidase center) which confers ferroxidase activity to the protein and accelerates iron incorporation. In the L-chain the center is substituted by a salt bridge. We performed several site directed mutageneses in the L-chain with the aim to construct the center and confer ferroxidase activity to the protein. Most variants were insoluble and did not refold into homopolymers, probably due to electrostatic repulsion introduced by the substitutions. However, they formed hybrids when they were renatured together with the L- or H-chains. The heteropolymers made of 90% L-chain and 10% of an L-variant with all the ligand residues of the H-chain center had 25-30% of the ferroxidase activity of the H-chain homopolymer. This corresponds to the activity of an H/L heteropolymer with 7% H-chain. It is concluded that: (i) it is possible to construct a ferroxidase center in the L-chain with an activity equivalent to that of the H-chain, (ii) the residues of the center interfere with the folding/assembly of the L-, but not of the H-chain, (iii) heteropolymers can be made even between ferritin subunits with large differences of refolding rates.	CNR, IST TECNOL BIOMED AVANZATE, I-20131 MILAN, ITALY; UNIV BRESCIA, DEPT BIOMED TECHNOL, BRESCIA, ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Brescia	LEVI, S (corresponding author), SAN RAFFAELE SCI INST, DEPT BIOL & TECHNOL RES, VIA OLGETTINA 58, I-20132 MILAN, ITALY.		arosio, paolo/E-6817-2010; Cozzi, Anna/AAN-3821-2020; levi, sonia/A-3161-2015; Santambrogio, Paolo/AAN-3837-2020	levi, sonia/0000-0002-5092-0847; Santambrogio, Paolo/0000-0002-5481-2130; arosio, paolo/0000-0002-5343-8992; albertini, alberto/0000-0002-7989-649X				ANDREWS SC, 1992, J INORG BIOCHEM, V47, P161, DOI 10.1016/0162-0134(92)84062-R; BAUMINGER ER, 1991, P ROY SOC B-BIOL SCI, V244, P211, DOI 10.1098/rspb.1991.0073; BAUMINGER ER, 1991, BIOCHIM BIOPHYS ACTA, V1118, P48, DOI 10.1016/0167-4838(91)90440-B; BAUMINGER ER, 1993, BIOCHEM J, V296, P709, DOI 10.1042/bj2960709; DESIDERI A, 1991, FEBS LETT, V287, P10, DOI 10.1016/0014-5793(91)80004-M; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; HARRISON PM, 1991, ADV INORG CHEM, V36, P449; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; LEVI S, 1987, GENE, V51, P269, DOI 10.1016/0378-1119(87)90315-5; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; LEVI S, 1989, BIOCHEM J, V264, P381, DOI 10.1042/bj2640381; LOBREAUX S, 1992, BIOCHEM J, V288, P931, DOI 10.1042/bj2880931; LUZZAGO A, 1986, BIOCHIM BIOPHYS ACTA, V872, P61, DOI 10.1016/0167-4838(86)90147-0; SANTAMBROGIO P, 1992, J BIOL CHEM, V267, P14077; SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744; SUN SJ, 1993, BIOCHEMISTRY-US, V32, P9362, DOI 10.1021/bi00087a015; TREFFRY A, 1989, FEBS LETT, V247, P268, DOI 10.1016/0014-5793(89)81350-X; TREFFRY A, 1993, BIOCHEM J, V296, P721, DOI 10.1042/bj2960721; TREFFRY A, 1992, FEBS LETT, V302, P108, DOI 10.1016/0014-5793(92)80417-F; WADE VJ, 1991, J MOL BIOL, V221, P1443, DOI 10.1016/0022-2836(91)80137-J; WADE VJ, 1993, BIOCHIM BIOPHYS ACTA, V1161, P91, DOI 10.1016/0167-4838(93)90201-2	25	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30334	30339						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982945				2022-12-25	WOS:A1994PU52500047
J	MCPHERSON, PS; TAKEI, K; SCHMID, SL; DECAMILLI, P				MCPHERSON, PS; TAKEI, K; SCHMID, SL; DECAMILLI, P			P145, A MAJOR GRB2-BINDING PROTEIN IN BRAIN, IS CO-LOCALIZED WITH DYNAMIN IN NERVE-TERMINALS WHERE IT UNDERGOES ACTIVITY-DEPENDENT DEPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE PHOSPHOPROTEINS; SYNAPSIN-I; SH3 DOMAINS; DROSOPHILA; MEMBRANE; ASSOCIATION; RECEPTOR; RELEASE; GTPASE; PHOSPHORYLATION	Three major rat brain proteins were recently found to bind the SH3 domains of Grb2: synapsin I, dynamin, and a novel 145-kDa protein (p145) (McPherson, P. S., Czernik, A. J., Chilcote, T. J., Onofri, F., Benfenati, F., Greengard, P., Schlessinger, J., and De Camilli, P. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 6486-6490). We have now used antibodies raised against p145 which had been purified by Grb2 affinity chromatography and SDS-polyacrylamide gel electrophoresis to characterize this protein. p145 is neuron-specific and co-distributes with dynamin in subcellular fractions of rat brain. Both proteins are partially recovered in soluble and particulate fractions. By immunofluorescence, p145 is closely co-localized with dynamin, which we show here to be highly concentrated in nerve terminals. In contrast to synapsin I, which is highly enriched in a purified synaptic vesicle fraction, both p145 and dynamin are de-enriched in this fraction. However, both proteins are found on membranes which are immunoisolated with antibodies directed against the synaptic vesicle membrane protein synaptophysin, suggesting that dynamin and p145 are localized in part on organelles which rep resent intermediate stages in the reformation of synaptic vesicles during recycling. Finally, we have determined that p145, like dynamin, is a phosphoprotein which undergoes dephosphorylation in response to nerve terminal depolarization. These findings suggest that p145 participates with dynamin in synaptic vesicle endocytosis and recycling.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	MCPHERSON, PS (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.			Takei, Kohji/0000-0002-6555-9425; Schmid, Sandra/0000-0002-1690-7024	NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042455] Funding Source: NIH RePORTER; NCI NIH HHS [CA 46128] Funding Source: Medline; NIGMS NIH HHS [GM 42455] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BENFENATI F, 1992, NEURON, V8, P337; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DAMKE E, 1994, IN PRESS J CELL BIOL; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; GOSLIN K, 1990, CULTURING NERVE CELL, P251; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANDELL JW, 1992, J NEUROSCI, V12, P1736; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCMAHON HT, 1992, J BIOL CHEM, V267, P21338; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MCPHERSON PS, 1994, SEMIN NEUROSCI, V6, P137; MIKI H, 1994, J BIOL CHEM, V269, P5489; Mundigl O., 1993, Molecular Biology of the Cell, V4, p430A; NAKATA T, 1993, J CELL SCI, V15, P1; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SHARP AH, 1993, J NEUROSCI, V13, P3051; SIHRA TS, 1989, P NATL ACAD SCI USA, V86, P8108, DOI 10.1073/pnas.86.20.8108; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TAKEI K, 1992, J NEUROSCI, V12, P489; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249	54	149	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30132	30139						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982917				2022-12-25	WOS:A1994PU52500017
J	ISHIKAWA, R; HAYASHI, K; SHIRAO, T; XUE, YH; TAKAGI, T; SASAKI, Y; KOHAMA, K				ISHIKAWA, R; HAYASHI, K; SHIRAO, T; XUE, YH; TAKAGI, T; SASAKI, Y; KOHAMA, K			DREBRIN, A DEVELOPMENT-ASSOCIATED BRAIN PROTEIN FROM RAT EMBRYO, CAUSES THE DISSOCIATION OF TROPOMYOSIN FROM ACTIN-FILAMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; CULTURED-CELLS; ALPHA-ACTININ; F-ACTIN; IMMUNOCYTOCHEMICAL LOCALIZATION; NONMUSCLE CALDESMON; RAPID PURIFICATION; MULTIPLE ISOFORMS; NERVOUS-SYSTEM; BINDING	Drebrin is a development-associated neuroprotein whose cDNA into fibroblasts causes the formation of dendrite-like structures (Shirao, T., Kojima, N., and Obata, K. (1992) Neuroreport 3, 109-112). To explore molecular functions of drebrin during brain development, we purified drebrin from brains of rat embryos. Drebrin bound to actin filaments at a stoichiometry of 1:5 with a dissociation constant (K-d) of 1.2 x 10(-7) M. It strongly inhibited the actin binding activity of tropomyosin. Excess amounts of tropomyosin also inhibited the drebrin binding to actin filaments, suggesting that drebrin and tropomyosin competitively bind to actin filaments. Further, drebrin inhibited not only the actin binding activity of alpha-actinin but also the actin cross-linking activity of alpha-actinin. Gene transfection experiments revealed that tropomyosin was dissociated from actin filaments in drebrin-overexpressing fibroblasts. Thus we hypothesize that drebrin may destabilize actin filaments by dissociating tropomyosin and alpha-actinin from actin filaments, resulting in the formation of axon and dendrites during neuronal development.	GUNMA UNIV,SCH MED,DEPT NEUROBIOL & BEHAV,MAEBASHI,GUMMA 371,JAPAN; TOHOKU UNIV,FAC SCI,INST BIOL,SENDAI,MIYAGI 980,JAPAN	Gunma University; Tohoku University	ISHIKAWA, R (corresponding author), GUNMA UNIV,SCH MED,DEPT PHARMACOL,MAEBASHI,GUMMA 371,JAPAN.		Shirao, Tomoaki/I-9257-2016	Shirao, Tomoaki/0000-0003-4323-028X; Hayashi, Kensuke/0000-0002-2417-7922				ASADA H, 1994, J NEUROSCI RES, V38, P149, DOI 10.1002/jnr.490380205; BERNSTEIN BW, 1982, CELL MOTIL CYTOSKEL, V2, P1, DOI 10.1002/cm.970020102; BONDER EM, 1983, J CELL BIOL, V96, P1097, DOI 10.1083/jcb.96.4.1097; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BURGESS DR, 1987, J CELL BIOL, V104, P29, DOI 10.1083/jcb.104.1.29; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; FATTOUM A, 1983, BIOCHEMISTRY-US, V22, P1187, DOI 10.1021/bi00274a031; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HINSSEN H, 1981, EUR J CELL BIOL, V23, P234; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; ISHIKAWA R, 1992, FEBS LETT, V299, P54, DOI 10.1016/0014-5793(92)80099-3; ISHIKAWA R, 1992, J MUSCLE RES CELL M, V13, P321, DOI 10.1007/BF01766460; ISHIKAWA R, 1991, J BIOL CHEM, V266, P21784; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KOJIMA N, 1993, MOL BRAIN RES, V19, P101, DOI 10.1016/0169-328X(93)90154-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1976, J CELL BIOL, V68, P202, DOI 10.1083/jcb.68.2.202; LEGRAND C, 1986, DEV BRAIN RES, V30, P231, DOI 10.1016/0165-3806(86)90113-6; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MAEKAWA S, 1988, EXP CELL RES, V178, P127, DOI 10.1016/0014-4827(88)90384-9; MATSUMURA F, 1985, J BIOL CHEM, V260, P3851; MATSUMURA F, 1983, J BIOL CHEM, V258, P6636; MATSUMURA F, 1981, J MOL BIOL, V157, P163; SHIRAO T, 1986, DEV BRAIN RES, V29, P233, DOI 10.1016/0165-3806(86)90099-4; SHIRAO T, 1985, J NEUROCHEM, V44, P1210, DOI 10.1111/j.1471-4159.1985.tb08745.x; SHIRAO T, 1987, BRAIN RES, V413, P374, DOI 10.1016/0006-8993(87)91032-8; SHIRAO T, 1992, NEUROREPORT, V3, P109, DOI 10.1097/00001756-199201000-00029; SHIRAO T, 1989, P JPN ACAD B-PHYS, V65, P169, DOI 10.2183/pjab.65.169; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG YL, 1987, J CELL BIOL, V105, P2811, DOI 10.1083/jcb.105.6.2811; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; XIE HX, 1983, CELL STRUCT FUNCT, V8, P315, DOI 10.1247/csf.8.315; YAMAMOTO M, 1986, J NEUROSCI, V6, P3576; YAMASHIROMATSUMURA S, 1986, J CELL BIOL, V103, P631, DOI 10.1083/jcb.103.2.631; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062	41	144	151	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29928	29933						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961990				2022-12-25	WOS:A1994PU28400094
J	VINITSKY, A; CARDOZO, C; SEPPLORENZINO, L; MICHAUD, C; ORLOWSKI, M				VINITSKY, A; CARDOZO, C; SEPPLORENZINO, L; MICHAUD, C; ORLOWSKI, M			INHIBITION OF THE PROTEOLYTIC ACTIVITY OF THE MULTICATALYTIC PROTEINASE COMPLEX (PROTEASOME) BY SUBSTRATE-RELATED PEPTIDYL ALDEHYDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NEUTRAL ENDOPEPTIDASE; PROLYL ENDOPEPTIDASE; PITUITARY; UBIQUITIN; DEGRADATION; SPECIFICITY; COMPONENTS; SUBUNITS; SYSTEM; CHAIN	Evidence indicates that a component of the multicatalytic proteinase complex (MPC) that preferentially cleaves bonds after branched chain amino acids (BrAAP) is a major factor responsible for the protein-degrading activity of the MPC. me report here the synthesis of substrate-related peptidyl aldehydes that inhibit the activity of this component toward both synthetic peptide substrates and proteins. The most potent of the inhibitors, Cbz-Gly-Pro-Phe-leucinal (Cbz-GPFL-CHO) inhibits competitively with a K-i of 1.5 mu M. The peptidyl aldehydes also inhibit the small neutral amino acid preferring and the peptidylglutamyl-peptide hydrolyzing activities of the MPC. The chymotrypsin-like activity is only weakly inhibited, and the trypsin-like activity is moderately activated. The importance of a Pro residue in the P-3 position and a leucinal residue in the P-3 position for inhibition of the BrAAP component is indicated by the finding that replacement of these residues by a glycine or phenylalaninal, respectively, markedly increases the K-i. Cbz-GPFL-CHO inhibited the BrAAP activity with the same K-i both before and after activation of this component by exposure of the MPC to 3,4-dichloroisocoumarin, suggesting that the peptidyl aldehyde is an effective inhibitor of both the overt and latent proteolytic activities of the MPC. Incubation of a human breast cancer cell line (MCF-7) in culture with the inhibitors of the BrAAP component led to an accumulation of ubiquitin-protein conjugates, indicating inhibition of the ubiquitin-dependent proteolytic pathway.	CUNY MT SINAI SCH MED, DEPT PHARMACOL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT MED, NEW YORK, NY 10029 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM CELL BIOL & GENET, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, NEW YORK, NY 10021 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Cardozo, Christopher/R-6021-2019	Cardozo, Christopher/0000-0003-4013-2537	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025377] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO8 HL08254] Funding Source: Medline; NIDDK NIH HHS [DK 25377] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMENOFF J, 1983, BIOCHEMISTRY-US, V22, P590, DOI 10.1021/bi00272a011; ANDERSON GW, 1964, J AM CHEM SOC, V86, P1839, DOI 10.1021/ja01063a037; BAKKER AV, 1990, BIOCHEM J, V271, P559, DOI 10.1042/bj2710559; Bratton AC, 1939, J BIOL CHEM, V128, P537; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; CARDOZO C, 1994, BIOCHEMISTRY-US, V33, P6483, DOI 10.1021/bi00187a014; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FRIEDMAN H, 1994, P NATL ACAD SCI USA, V91, P2031, DOI 10.1073/pnas.91.6.2031; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBARG JA, 1958, CANCER, V11, P283, DOI 10.1002/1097-0142(195803/04)11:2<283::AID-CNCR2820110209>3.0.CO;2-8; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; ORLOWSKI M, 1993, J LAB CLIN MED, V121, P187; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; ORLOWSKI M, 1981, BIOCHEM BIOPH RES CO, V101, P814; PEREIRA ME, 1992, J BIOL CHEM, V267, P7949; PFITZNER KE, 1965, J AM CHEM SOC, V87, P5661, DOI 10.1021/ja00952a026; Pfleiderer G, 1970, METHOD ENZYMOL, V19, P514; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REINGOLD DF, 1979, J NEUROCHEM, V32, P907, DOI 10.1111/j.1471-4159.1979.tb04574.x; RIVETT AJ, 1993, BIOCHEM J, V291, P1; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; WALTER R, 1971, SCIENCE, V173, P828, DOI 10.1126/science.173.3999.827; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; WILK S, 1983, J NEUROCHEM, V41, P69, DOI 10.1111/j.1471-4159.1983.tb11815.x	38	112	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29860	29866						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961980				2022-12-25	WOS:A1994PU28400084
J	WATTS, JD; AFFOLTER, M; KREBS, DL; WANGE, RL; SAMELSON, LE; AEBERSOLD, R				WATTS, JD; AFFOLTER, M; KREBS, DL; WANGE, RL; SAMELSON, LE; AEBERSOLD, R			IDENTIFICATION BY ELECTROSPRAY-IONIZATION MASS-SPECTROMETRY OF THE SITES OF TYROSINE PHOSPHORYLATION-INDUCED IN ACTIVATED JURKAT T-CELLS ON THE PROTEIN-TYROSINE KINASE ZAP-70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR-ZETA; AFFINITY-CHROMATOGRAPHY; THYMOCYTE DEVELOPMENT; SIGNAL TRANSDUCTION; IL-2 RECEPTOR; TCR ZETA; P56LCK; P56(LCK); CHAIN; ASSOCIATION	We have developed a rapid and sensitive two capillary-column chromatography and mass spectrometry-based method for the determination of protein phosphorylation sites following recovery of individual phosphopeptides from two-dimensional phosphopeptide maps. With a standard phosphopeptide, we demonstrate detection sensitivity of at least 250 fmol for this system. me applied this technique to the analysis of in vitro sites of tyrosine phosphorylation induced on the T cell-specific protein tyrosine kinase ZAP-70 in the absence and presence of p56(lck). me show that ZAP-70 has a primary autophosphorylation site at Tyr-292, with a secondary site at Tyr-126. We also show additional phosphorylation at Tyr-69, Tyr-178, Tyr-492, and Tyr-493 upon the addition of the protein tyrosine kinase, p56(lck). By comparative two-dimensional phosphopeptide mapping, we show that ZAP-70 isolated from Jurkat T cells also autophosphorylates at Tyr-292 and Tyr-126. Similar analysis of P-32-labeled Jurkat cells stimulated with anti-T cell receptor antibodies reveals Tyr-492 and Tyr-493 as the principal sites of T cell antigen receptor-induced tyrosine phosphorylation, with additional phosphorylation at the Tyr-292, but not the Tyr-126 autophosphorylation site. The high degree of sensitivity achieved with this technology should greatly facilitate the direct biochemical determination of inducible protein phosphorylation events, an experimental strategy that until now has been both time consuming and difficult.	UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA; NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA	University of British Columbia; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Wange, Ronald/0000-0001-9593-3572; Affolter, Michael/0000-0003-1568-4516; Krebs, Danielle/0000-0002-6522-7308				ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BIFFEN M, 1994, EMBO J, V13, P1920, DOI 10.1002/j.1460-2075.1994.tb06461.x; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COVEY T, 1991, ADV LIF SCI, P249; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRY MJ, 1993, PROTEIN SCI, V2, P1785, DOI 10.1002/pro.5560021102; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HUDDLESTON MJ, 1993, J AM SOC MASS SPECTR, V4, P710, DOI 10.1016/1044-0305(93)80049-5; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; ISAKOV N, 1994, J LEUKOCYTE BIOL, V55, P265, DOI 10.1002/jlb.55.2.265; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MOLINA TJ, 1993, J IMMUNOL, V151, P699; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; NUWAYSIR LM, 1993, J AM SOC MASS SPECTR, V4, P662, DOI 10.1016/1044-0305(93)85031-R; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; VANOERS NSC, 1993, MOL CELL BIOL, V13, P5771, DOI 10.1128/MCB.13.9.5771; VANOERS NSC, 1992, ADV EXP MED BIOL, V323, P89; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WATTS JD, 1993, J BIOL CHEM, V268, P23275; WATTS JD, 1992, J BIOL CHEM, V267, P901; WATTS JD, 1993, J IMMUNOL, V151, P6862; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	53	215	223	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29520	29529						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961936				2022-12-25	WOS:A1994PU28400035
J	FUKUDA, M; ARUGA, J; NIINOBE, M; AIMOTO, S; MIKOSHIBA, K				FUKUDA, M; ARUGA, J; NIINOBE, M; AIMOTO, S; MIKOSHIBA, K			INOSITOL-1,3,4,5-TETRAKISPHOSPHATE BINDING TO C2B DOMAIN OF IP4BP SYNAPTOTAGMIN-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; INOSITOL 1,3,4,5-TETRAKISPHOSPHATE; NEUROTRANSMITTER RELEASE; PHOSPHOLIPID-BINDING; SYNAPTIC VESICLES; RECEPTOR; CALCIUM; DROSOPHILA; EXPRESSION; EXOCYTOSIS	IP4BP/Synaptotagmin II is an inositol-1,3,4,5-tetrakisphosphate (IP4) or inositol polyphosphate-binding protein, which is accumulated at nerve terminals. Here we report a novel function of the C2B domain, which was originally thought to be responsible for Ca2+-dependent binding to phospholipid membranes. A study of deletion mutants showed that about 30 amino acids of the central region of the C2B domain of mouse IP4BP/synaptotagmin II (315 IHLMQNGKRLKKKKTTVKKK-TLNPYFNESFSF 346) are essential for inositol polyphosphate binding. This binding domain includes a sequence corresponding to the squid Pep20 peptide, which is also known to be essential for neurotransmitter release (Bommert, K., Charlton, M. P., DeBello, W. M., Chin, G. J. Betz, H., and Augustine, G. J. (1993) Nature 363, 165-165), suggesting that inositol polyphosphate has some effect on neurotransmitter release. Rabphilin 3A, another neuronal protein containing C2 domains, cannot bind IP4, indicating that the IP4 binding property is specific to the C2B domain of synaptotagimin. Phospholipid and IP4 binding experiments clearly indicated that the C2A and C2B domains have different functions. The C2A domain binds phospholipid in a Ca2+-dependent manner, but the C2B domain binds inositol polyphosphate and phospholipid irrespective of the presence of Ca2+. Our data suggest that the C2B domain of synaptotagimin is the inositol polyphosphate sensor at the synaptic vesicle and may be involved in synaptic function.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC NEUROBIOL LAB,TSUKUBA,IBARAKI 305,JAPAN; UNIV TOKYO,INST MED SCI,INST MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	RIKEN; University of Tokyo; Osaka University			Mikoshiba, Katsuhiko/N-7943-2015; Fukuda, MItsunori/I-1511-2015; Aruga, Jun/H-5837-2011	Fukuda, MItsunori/0000-0002-8620-5853; Aruga, Jun/0000-0001-7936-1375				BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BOUSTEAD CM, 1993, CELLULAR CALCIUM, P247; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVLETOV B, 1993, J BIOL CHEM, V268, P6816; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; DONIE F, 1991, BIOCHEM J, V275, P453, DOI 10.1042/bj2750453; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; ELY JA, 1990, BIOCHEM J, V268, P333, DOI 10.1042/bj2680333; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P8625; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MATHEW WD, 1981, J CELL BIOL, V91, P257; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PARKER I, 1987, PROC R SOC SER B-BIO, V232, P59, DOI 10.1098/rspb.1987.0061; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SMITH RB, 1986, GENE AMST, V67, P31; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; YOO SH, 1991, BIOCHEM J, V278, P381, DOI 10.1042/bj2780381	39	236	240	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29206	29211						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961887				2022-12-25	WOS:A1994PU16800100
J	HAGAN, DL; KIENZLE, B; JAMIL, H; HARIHARAN, N				HAGAN, DL; KIENZLE, B; JAMIL, H; HARIHARAN, N			TRANSCRIPTIONAL REGULATION OF HUMAN AND HAMSTER MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN GENES - CELL-TYPE-SPECIFIC EXPRESSION AND RESPONSE TO METABOLIC REGULATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CHOLESTEROL 7-ALPHA-HYDROXYLASE; PROMOTER; INSULIN; ABETALIPOPROTEINEMIA; SEQUENCE; ELEMENT; INVIVO; HNF-4; C/EBP	In order to characterize the molecular mechanisms that dictate microsomal triglyceride transfer protein (MTP) gene transcription in human and hamster, two species with similar plasma lipoprotein profiles, the MTP gene promoters were cloned, sequenced, and functionally characterized by transient transfection analysis. The results presented in this report indicate that the 5' ends of human and hamster MTP genes share similar structural features. The promoter sequences are well conserved and consist of similar functional elements. Transient transfection analysis of MTP promoter-driven luciferase gene expression showed that the promoter is active in liver and intestinal cells but not in epithelial cells, consistent with endogenous MTP gene expression. The -123 to -85 bp region of the human promoter is critical for the expression and contains the consensus recognition sequences for liver cell-specific factors HNF-1 and HNF-4 and activator protein AP-1. The pro meter contains a modified sterol response element and a negative insulin response element. The human promoter activity is positively regulated by cholesterol and negatively regulated by insulin. From the functional analysis of MTP promoters, it is concluded that the elements that regulate the cell type-specific expression in human and hamster are well conserved and that insulin and cholesterol can regulate the activity of the MTP promoter in opposite directions.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT METAB DIS, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CASTANO JG, 1991, ADV ENZYME REGUL, V31, P185, DOI 10.1016/0065-2571(91)90013-C; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Frayn Keith N., 1993, Current Opinion in Lipidology, V4, P197, DOI 10.1097/00041433-199306000-00004; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; KRITIS AA, 1993, NUCLEIC ACIDS RES, V21, P5882, DOI 10.1093/nar/21.25.5882; LIN MCM, 1994, IN PRESS J BIOL CHEM; MENDEL DB, 1991, J BIOL CHEM, V266, P677; METZGER S, 1993, J BIOL CHEM, V268, P16831; MOLOWA DT, 1992, BIOCHEMISTRY-US, V31, P2539, DOI 10.1021/bi00124a014; MYANT NB, 1977, J LIPID RES, V18, P135; NIETO A, 1990, BIOCHEM J, V267, P317, DOI 10.1042/bj2670317; Sambrook J, 1989, MOL CLONING LABORATO; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHARP D, 1994, BIOCHEMISTRY-US, V33, P9057, DOI 10.1021/bi00197a005; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SPRONSEN AV, 1993, EUR J BIOCHEM, V271, P1117; SRIVASTAVA RAK, 1991, BIOCHIM BIOPHYS ACTA, V1086, P29, DOI 10.1016/0005-2760(91)90151-7; SUNDSETH SS, 1990, J BIOL CHEM, V265, P15090; WETTERAU JR, 1992, SCIENCE, V258, P999; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	30	114	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28737	28744						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961826				2022-12-25	WOS:A1994PU16800036
J	LEE, E; MANOIL, C				LEE, E; MANOIL, C			MUTATIONS ELIMINATING THE PROTEIN EXPORT FUNCTION OF A MEMBRANE-SPANNING SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE FUSIONS; POSITIVELY CHARGED RESIDUES; AMINO-ACID SEQUENCES; ESCHERICHIA-COLI; SIGNAL SEQUENCE; GENE FUSIONS; CYTOPLASMIC MEMBRANE; TOPOLOGY ANALYSIS; DETERMINANTS; INSERTION	Individual membrane protein spanning sequences can promote protein export. To help define the sequence features necessary for this action, we identified mutations disrupting export mediated by the first spanning sequence (TM1) of the Escherichia coli serine chemoreceptor. Mutant spanning sequences were generated and characterized using beta-galactosidase and alkaline phosphatase gene fusions. The protein export function of TM1 was remarkably tolerant of single charged residues, and the introduction of pairs of charged amino acids was necessary to eliminate export. The results are accommodated by a model in which export requires a stretch of uncharged residues whose summed hydrophobicity exceeds a particular threshold value. This threshold approximates the minimum hydrophobicity required for cleavable signal sequence function. In addition, the threshold was near the minimum hydrophobicity observed for wild-type spanning sequences in a collection of topologically characterized membrane proteins.	UNIV WASHINGTON,DEPT GENET,SK-50,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM46493] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046493] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; ALLARD JD, 1992, J BIOL CHEM, V267, P17809; BECKWITH J, 1983, METHOD ENZYMOL, V97, P3; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOYD A, 1983, NATURE, V301, P623, DOI 10.1038/301623a0; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BUHR A, 1993, J BIOL CHEM, V268, P11599; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; CHOU MM, 1990, J BIOL CHEM, V265, P2873; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; DOUD SK, 1993, BIOCHEMISTRY-US, V32, P1251, DOI 10.1021/bi00056a008; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GRODZICKER T, 1968, J MOL BIOL, V38, P305, DOI 10.1016/0022-2836(68)90388-4; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10155, DOI 10.1021/bi00106a012; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KEHRY MR, 1983, P NATL ACAD SCI-BIOL, V80, P3599, DOI 10.1073/pnas.80.12.3599; KRIKOS A, 1985, P NATL ACAD SCI USA, V82, P1326, DOI 10.1073/pnas.82.5.1326; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1989, J BACTERIOL, V171, P4609, DOI 10.1128/jb.171.9.4609-4616.1989; LOCKER JK, 1992, J BIOL CHEM, V267, P21911; Maniatis T., 1982, MOL CLONING; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MICHAELIS S, 1986, J BACTERIOL, V167, P160, DOI 10.1128/jb.167.1.160-167.1986; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MODEL P, 1990, CELL, V61, P739, DOI 10.1016/0092-8674(90)90180-M; MOWBRAY SL, 1985, J BIOL CHEM, V260, P1711; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; SELIGMAN L, 1994, J BIOL CHEM, V269, P19888; SHORTLE D, 1985, GENETICS, V110, P539; SHUMAN HA, 1987, ANNU REV GENET, V21, P155, DOI 10.1146/annurev.ge.21.120187.001103; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SJOSTROM M, 1987, EMBO J, V6, P823, DOI 10.1002/j.1460-2075.1987.tb04825.x; STADER J, 1986, J BIOL CHEM, V261, P5075; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; VONHEIJNE G, 1990, PROTEIN ENG, V4, P109, DOI 10.1093/protein/4.2.109; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; ZHU HY, 1989, J BIOL CHEM, V264, P11833	54	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28822	28828						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961839				2022-12-25	WOS:A1994PU16800049
J	CARUCCIO, N; ROSS, J				CARUCCIO, N; ROSS, J			PURIFICATION OF A HUMAN POLYRIBOSOME-ASSOCIATED 3' TO 5' EXORIBONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE MESSENGER-RNA; DOUBLE-STRANDED-RNA; CELL-FREE-EXTRACTS; ENDONUCLEOLYTIC CLEAVAGE; EXONUCLEASE ACTIVITY; UNTRANSLATED REGION; GENE-EXPRESSION; SUBSTRATE-SPECIFICITY; CYTOPLASMIC EXTRACTS; POLY(A) DEFICIENT	In cells and cell-free extracts, the early steps in histone mRNA decay occur at the 3' terminus and appear to be catalyzed by a polysome-associated 3' to 5' exoribonuclease. We describe the purification of a polysomal 3' to 5' exoribonuclease that is magnesium-dependent, active at pH 7-8 in salt concentrations below 200 mM, and resistant to the inhibitor of the RNase A family of RNases. The purified enzyme is inactive with 3'-phosphorylated RNA substrates and with DNA but can degrade duplex RNA in the absence of added ATP. The enzyme migrates at similar to 37 kDa by native state gel filtration and at 33 kDa in a SDS-polyacrylamide gel. It degrades poly(A) but not a complex of poly(A) with poly(A) binding protein, and it accelerates histone mRNA decay in high salt-washed (enzyme-depleted) polysomes. Similarities between the purified exoribonuclease and the activity that degrades histone mRNA in vitro suggest that the enzyme might be a mammalian messenger ribonuclease.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [P01CA023076, P30CA007175, R01CA063676] Funding Source: NIH RePORTER; NCI NIH HHS [CA07175, CA63676, CA23076] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; ASTROM J, 1992, J BIOL CHEM, V267, P18154; BAUMBACH LL, 1987, BIOCHEMISTRY-US, V26, P6178, DOI 10.1021/bi00393a034; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BINDER R, 1989, J BIOL CHEM, V264, P16910; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; BROWN PH, 1989, J BIOL CHEM, V264, P13383; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; COUTTS M, 1993, BIOCHIM BIOPHYS ACTA, V1173, P57, DOI 10.1016/0167-4781(93)90242-6; COUTTS M, 1993, BIOCHIM BIOPHYS ACTA, V1173, P49, DOI 10.1016/0167-4781(93)90241-5; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P104, DOI 10.1016/0968-0004(91)90042-T; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; DEUTSCHER MP, 1985, CELL, V40, P731, DOI 10.1016/0092-8674(85)90330-7; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; DEWILLE JW, 1989, J CELL PHYSIOL, V138, P358, DOI 10.1002/jcp.1041380219; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; ECKNER R, 1992, NUCLEIC ACIDS RES, V20, P1023, DOI 10.1093/nar/20.5.1023; EICHLER DC, 1985, BIOCHEMISTRY-US, V24, P686, DOI 10.1021/bi00324a022; ENGLAND TE, 1978, NATURE, V275, P560, DOI 10.1038/275560a0; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HALL SH, 1977, J BIOL CHEM, V252, P4092; HARGROVE JL, 1991, BIOESSAYS, V13, P667, DOI 10.1002/bies.950131209; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARUS HM, 1967, P NATL ACAD SCI USA, V57, P1386, DOI 10.1073/pnas.57.5.1386; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEVINE BJ, 1987, P NATL ACAD SCI USA, V84, P6189, DOI 10.1073/pnas.84.17.6189; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; MARZLUFF WF, 1988, TRENDS BIOCHEM SCI, V13, P49, DOI 10.1016/0968-0004(88)90027-8; MCLAREN RS, 1993, J BIOL CHEM, V268, P14637; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)90806-H; MEADOR J, 1990, EUR J BIOCHEM, V187, P549, DOI 10.1111/j.1432-1033.1990.tb15336.x; MEINSMA D, 1992, NUCLEIC ACIDS RES, V20, P5003, DOI 10.1093/nar/20.19.5003; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NIELSEN FC, 1992, J BIOL CHEM, V267, P19404; OHTSUKI K, 1977, J BIOL CHEM, V252, P483; PANDEY NB, 1991, NUCLEIC ACIDS RES, V19, P5653, DOI 10.1093/nar/19.20.5653; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PELTZ SW, 1987, MOL CELL BIOL, V7, P4345, DOI 10.1128/MCB.7.12.4345; PELTZ SW, 1987, J BIOL CHEM, V262, P9382; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; RANDERATH K, 1968, THIN LAYER CHROMATOG, P229; RECH J, 1976, NUCLEIC ACIDS RES, V3, P2055, DOI 10.1093/nar/3.8.2055; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1986, MOL CELL BIOL, V6, P4362, DOI 10.1128/MCB.6.12.4362; ROSS J, 1987, J BIOL CHEM, V262, P9374; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHUMPERLI D, 1986, CELL, V45, P471, DOI 10.1016/0092-8674(86)90277-1; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; STEVENS A, 1987, NUCLEIC ACIDS RES, V15, P695, DOI 10.1093/nar/15.2.695; STOECKLE MY, 1989, MOL CELL BIOL, V9, P4738, DOI 10.1128/MCB.9.11.4738; STOECKLE MY, 1992, NUCLEIC ACIDS RES, V20, P1123, DOI 10.1093/nar/20.5.1123; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; VREKEN P, 1992, MOL CELL BIOL, V12, P2986, DOI 10.1128/MCB.12.7.2986; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	71	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31814	31821						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989354				2022-12-25	WOS:A1994PX30300075
J	KASPER, S; RENNIE, PS; BRUCHOVSKY, N; SHEPPARD, PC; CHENG, H; LIN, L; SHIU, RPC; SNOEK, R; MATUSIK, RJ				KASPER, S; RENNIE, PS; BRUCHOVSKY, N; SHEPPARD, PC; CHENG, H; LIN, L; SHIU, RPC; SNOEK, R; MATUSIK, RJ			COOPERATIVE BINDING OF ANDROGEN RECEPTORS TO 2 DNA-SEQUENCES IS REQUIRED FOR ANDROGEN INDUCTION OF THE PROBASIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; TRANSCRIPTIONAL SYNERGISM; NONRECEPTOR FACTORS; RESPONSE ELEMENT; ACTIVATION; ENHANCER; EXPRESSION	The functional and structural interactions of two androgen receptor-binding sites in the 5'-flanking DNA of the rat probasin gene were determined, Deletion mapping and DNase I footprinting analysis had previously identified two androgen receptor-binding sites (ARBS) necessary for androgen induction of the probasin gene: ARBS-1, which resembled a glucocorticoid-responsive element, and ARBS-2, which had a unique sequence, In this study, maximal androgen induction in transient transfection studies only occurred when both sites were present, Neither binding site functioned independently, and deletion of the DNA sequence between the sites resulted in a 60% loss of androgen inducibility, Moreover, point mutations in either ARBS-1 or ARBS-2 led to >90% loss in activity. Scatchard analysis indicated that ARBS I and ARBS-2 bound a synthetic androgen receptor, AR2, with K-d values of 20.0 and 6.7 nm, respectively, Consistent with the higher affinity, ARBS-2 bound AR2 at half the threshold concentration (200 ng) of that required in reciprocal DNase I footprinting experiments with ARBS-1, By comparison, protection occurred at a much lower threshold concentration of AR2 (60 ng) and to the same extent over each site when both sites were present, suggesting a cooperative interaction between the two sites, The cooperative effect was further substantiated when a point mutation in ARBS-1 blocked AR2 binding not only to ARBS-1, but also to ARBS-2, Similarly, a point mutation in ARBS-2 also prevented receptor binding to both sites, Androgen-specific: regulation of probasin gene transcription therefore required an androgen-responsive region (positions -286 and +28) containing two androgen receptor-binding sites, where the binding of the androgen receptor to both sites occurred in a cooperative, mutually dependent manner,	BRITISH COLUMBIA CANC AGCY,DEPT CANC ENDOCRINOL,VANCOUVER V5Z 4E6,BC,CANADA	British Columbia Cancer Agency	KASPER, S (corresponding author), UNIV MANITOBA,DEPT PHYSIOL,730 WILLIAM AVE,WINNIPEG R3E 3J7,MB,CANADA.			Matusik, Robert/0000-0003-2057-9892				ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DODD JG, 1983, J BIOL CHEM, V258, P731; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; NACHTIGAL MW, 1989, NUCLEIC ACIDS RES, V17, P4327, DOI 10.1093/nar/17.11.4327; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615	19	118	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31763	31769						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989349				2022-12-25	WOS:A1994PX30300068
J	MELLENTINMICHELOTTI, J; JOHN, S; PENNIE, WD; WILLIAMS, T; HAGER, GL				MELLENTINMICHELOTTI, J; JOHN, S; PENNIE, WD; WILLIAMS, T; HAGER, GL			THE 5' ENHANCER OF THE MOUSE MAMMARY-TUMOR VIRUS LONG TERMINAL REPEAT CONTAINS A FUNCTIONAL AP-2 ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; MULTIPLE REGULATORY ELEMENTS; NEGATIVE REGULATION; TRANSGENIC MICE; GENE-EXPRESSION; PROMOTER; BINDING; INVITRO; REGION; DNA	The mouse mammary tumor virus (MMTV) retrovirus causes mammary adenocarcinomas in mice by proviral insertion near members of the wnt family of proto-oncogenes, leading to their deregulation and cellular transformation. The 5' end of the MMTV long terminal repeat (LTR) has been implicated in tissue-specific activation of these gems. In this study, we characterize an enhancer element (Ban2; -1075 to -978) at the 5' end of the MMTV LTR, We show that this enhancer is 8-fold more active in a murine mammary carcinoma cell fine (34i) than in a fibroblast cell line (NIH3T3), and is inactive in the liver carcinoma cell line HepG2. Mutagenesis of the enhancer reveals four cis-acting elements that are required for maximal activity, DNA-binding proteins that interact with each of the four elements have been identified, One of these factors, designated mp5, is either identical to, or closely related to, the transcription factor AP-2, The mp5/AP-2 DNA binding activity co-migrates with recombinant AP-2 and is supershifted by anti-AP-2 antibodies, We also show that the lack of enhancer activity in HepG2 cells results from the absence of AP-2 protein in these cells. Co-transfection of an AP-2 expression vector restores the activity of this enhancer in HepG2 cells, and requires an intact mp5-binding site.	NCI,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BALL JK, 1988, J VIROL, V62, P2985, DOI 10.1128/JVI.62.8.2985-2993.1988; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; GARCIA M, 1986, EMBO J, V5, P127, DOI 10.1002/j.1460-2075.1986.tb04186.x; GHOSH D, 1992, NUCLEIC ACIDS RES, V20, P2091, DOI 10.1093/nar/20.suppl.2091; GOUILLEUX F, 1991, NUCLEIC ACIDS RES, V19, P1563, DOI 10.1093/nar/19.7.1563; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; LUBON H, 1987, NUCLEIC ACIDS RES, V15, P2103, DOI 10.1093/nar/15.5.2103; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MICHALIDES R, 1986, VIROLOGY, V154, P76, DOI 10.1016/0042-6822(86)90431-9; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOK E, 1992, J VIROL, V66, P7529, DOI 10.1128/JVI.66.12.7529-7532.1992; MOSER M, 1993, NUCLEIC ACIDS RES, V21, P4844, DOI 10.1093/nar/21.20.4844; MUCHARDT C, 1992, NEW BIOL, V4, P541; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARKS WP, 1976, CELL, V8, P87, DOI 10.1016/0092-8674(76)90189-6; ROSS SR, 1990, MOL CELL BIOL, V10, P5822, DOI 10.1128/MCB.10.11.5822; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; SONNENBERG A, 1986, CANCER RES, V46, P5913; STEWART TA, 1988, MOL CELL BIOL, V8, P473, DOI 10.1128/MCB.8.1.473; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YANAGAWA S, 1991, J VIROL, V65, P526, DOI 10.1128/JVI.65.1.526-531.1991	35	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31983	31990						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989375				2022-12-25	WOS:A1994PX30300099
J	HALLORAN, SM; VULLIET, PR				HALLORAN, SM; VULLIET, PR			MICROTUBULE-ASSOCIATED PROTEIN KINASE-2 PHOSPHORYLATES AND ACTIVATES TYROSINE-HYDROXYLASE FOLLOWING DEPOLARIZATION OF BOVINE ADRENAL CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; DEPENDENT MULTIPROTEIN KINASE; SIGNAL-REGULATED KINASES; SERINE-THREONINE KINASE; MYELIN BASIC-PROTEIN; MAP-KINASE; CATECHOLAMINE BIOSYNTHESIS; RAT PHEOCHROMOCYTOMA; ENZYME ACTIVATION; INDUCED INCREASE	Depolarization of cultured bovine adrenal chromaffin cells with KCl increased the activity of a proline-directed protein kinase that phosphorylates tyrosine hydroxylase. Characterization of the KCl-activated protein kinase activity revealed that it shared similar biochemical and chromatographic properties with the microtubule-associated protein-2 kinase/extracellularly regulated kinase (MAP/ERK) family of protein kinases. This protein kinase activity was found to elute hom Mono Q, Superose, and phenyl-Sepharose columns under conditions described for MAP/ERK kinases, and active fractions were found to react with specific antibodies directed against ERKs. The KCl-activated protein kinase was found to phosphorylate the serine 31 site of endogenous bovine adrenal tyrosine hydroxylase. This phosphorylation resulted in an approximately 2-fold activation of tyrosine hydroxylase.			HALLORAN, SM (corresponding author), UNIV CALIF DAVIS, SCH VET MED, DEPT MOLEC BIOSCI, DAVIS, CA 95616 USA.							ACHESON A, 1987, J NEUROCHEM, V48, P1416, DOI 10.1111/j.1471-4159.1987.tb05680.x; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P7713, DOI 10.1073/pnas.81.24.7713; ALMAS B, 1992, EUR J BIOCHEM, V209, P249, DOI 10.1111/j.1432-1033.1992.tb17283.x; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAHILL AL, 1991, J NEUROCHEM, V57, P1832, DOI 10.1111/j.1471-4159.1991.tb06392.x; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; DAHMER MK, 1991, J NEUROCHEM, V57, P1347, DOI 10.1111/j.1471-4159.1991.tb08300.x; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; GEORGE RJ, 1989, J NEUROCHEM, V52, P274, DOI 10.1111/j.1471-4159.1989.tb10928.x; GEORGENASCIMENTO C, 1988, BIOCHEMISTRY-US, V27, P797, DOI 10.1021/bi00402a046; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HAAVIK J, 1988, BIOCHIM BIOPHYS ACTA, V953, P142, DOI 10.1016/0167-4838(88)90019-2; HAAVIK J, 1989, FEBS LETT, V251, P36, DOI 10.1016/0014-5793(89)81424-3; HALL FL, 1991, J BIOL CHEM, V266, P17430; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HAYCOCK JW, 1988, P NATL ACAD SCI USA, V85, P1677, DOI 10.1073/pnas.85.5.1677; HAYCOCK JW, 1993, NEUROCHEM RES, V18, P15, DOI 10.1007/BF00966919; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HAYCOCK JW, 1982, J BIOL CHEM, V257, P2641; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HAYCOCK JW, 1991, J NEUROCHEM, V56, P2139, DOI 10.1111/j.1471-4159.1991.tb03477.x; HORELLOU P, 1988, J NEUROCHEM, V51, P652, DOI 10.1111/j.1471-4159.1988.tb01088.x; JOH TH, 1978, P NATL ACAD SCI USA, V75, P4744, DOI 10.1073/pnas.75.10.4744; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCTIGUE M, 1985, J BIOL CHEM, V260, P9047; MELIGENI JA, 1982, J BIOL CHEM, V257, P2632; MITCHELL JP, 1990, J BIOL CHEM, V265, P22358; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NIGGLI V, 1984, J NEUROCHEM, V43, P646, DOI 10.1111/j.1471-4159.1984.tb12784.x; PAVLOVICSURJANCEV B, 1992, J NEUROCHEM, V59, P2134; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POCOTTE SL, 1986, J NEUROCHEM, V46, P610, DOI 10.1111/j.1471-4159.1986.tb13011.x; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; RIBEIRO P, 1992, P NATL ACAD SCI USA, V89, P9593, DOI 10.1073/pnas.89.20.9593; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROSKOSKI R, 1987, J NEUROCHEM, V48, P236, DOI 10.1111/j.1471-4159.1987.tb13153.x; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; TACHIKAWA E, 1986, MOL PHARMACOL, V30, P476; VULLIET PR, 1984, J BIOL CHEM, V259, P3680; VULLIET PR, 1980, P NATL ACAD SCI-BIOL, V77, P92, DOI 10.1073/pnas.77.1.92; VULLIET PR, 1985, FEBS LETT, V182, P335, DOI 10.1016/0014-5793(85)80328-8; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WAYMIRE JC, 1988, J BIOL CHEM, V263, P12439; WILSON SP, 1987, J NEUROSCI METH, V19, P163, DOI 10.1016/0165-0270(87)90031-8; YAMAUCHI T, 1979, J BIOL CHEM, V254, P6408; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404; YANAGIHARA N, 1987, BIOCHEM BIOPH RES CO, V146, P530, DOI 10.1016/0006-291X(87)90561-4	58	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30960	30965						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983031				2022-12-25	WOS:A1994PV51000037
J	HJORTH, SA; SCHAMBYE, HT; GREENLEE, WJ; SCHWARTZ, TW				HJORTH, SA; SCHAMBYE, HT; GREENLEE, WJ; SCHWARTZ, TW			IDENTIFICATION OF PEPTIDE BINDING RESIDUES IN THE EXTRACELLULAR DOMAINS OF THE AT(1) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II RECEPTOR; BETA-ADRENERGIC-RECEPTOR; LUTROPIN CHORIOGONADOTROPIN RECEPTOR; PROTEIN-COUPLED RECEPTOR; NEUROKININ-1 RECEPTOR; OVERLAP EXTENSION; LIGAND-BINDING; HIGH-AFFINITY; ACTIVATION; EXPRESSION	To locate essential determinants for angiotensin II binding, we have performed a systematic mutational analysis of the exterior domain of the AT(1) receptor. Receptor mutants, deficient in peptide binding, were analyzed using radiolabeled nonpeptide ligand as an important tool. Two independent strategies for mutagenesis were employed: conservative segment exchange and point mutagenesis of evolutionarily conserved residues. Results from the conservative segment exchange in which 6-17 residues were replaced with chemically similar, yet different, amino acid sequences of the same length suggested that important peptide ligand binding epitopes are located in the N-terminal extension of the AT(1) receptor, in particular adjacent to the top of transmembrane segment I (TM-I), and in the third extracellular loop, close to the top of TM-VII. The substitution of residues from either of these regions resulted in a 5,000-20,000-fold decrease in affinity for the peptide agonist angiotensin II (AII) and the peptide antagonist [Sar(1),Leu(8)]AII without affecting the binding of nonpeptide antagonists. Alanine substitution of evolutionarily conserved residues demonstrated that peptide binding was dependent on several residues in the N-terminal extension, near the top of TM-I, a tyrosine residue located in extracellular loop 1, close to TM-II, and 2 aspartate residues positioned in extracellular loop 3 on the same face of an alpha-helical extension of TM-VII. In all cases the binding of nonpeptide antagonist was unaffected by these substitutions. It is concluded that important epitopes involved in angiotensin II binding are located around the top of transmembrane segments I, II, and VII which conceivably are in close spatial proximity in the folded receptor structure.	MERCK SHARP & DOHME LTD,RES LABS,EXPLORATORY CHEM,RAHWAY,NJ 07065	Merck & Company	HJORTH, SA (corresponding author), UNIV COPENHAGEN,RIGSHOSP 6321,DEPT CLIN BIOCHEM,MOLEC ENDOCRINOL LAB,BLEGDAMSVEJ 9,DK-2100 COPENHAGEN,DENMARK.			Schwartz, Thue W./0000-0002-0261-6904; Hjorth, Siv Annegrethe/0000-0002-6470-650X				BALDWIN JM, 1992, EMBO J, V12, P1693; BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BERGSMA DJ, 1993, MOL PHARMACOL, V44, P277; BURBACH JPH, 1992, EUR J PHARM-MOLEC PH, V227, P1, DOI 10.1016/0922-4106(92)90136-J; BURNS HD, 1994, J NUCL MED, V35, pP246; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; HUMPHREY PPA, 1993, TRENDS PHARMACOL SCI, V14, P233, DOI 10.1016/0165-6147(93)90016-D; JI H, 1994, J BIOL CHEM, V269, P16533; JI I, 1991, J BIOL CHEM, V266, P13076; JI IH, 1993, J BIOL CHEM, V268, P22971; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE JA, 1994, P NATL ACAD SCI USA, V91, P7046; MANTLO NB, 1991, J MED CHEM, V34, P2922; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; PALLA E, 1993, J BIOL CHEM, V268, P13486; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REISINE T, 1993, TRENDS NEUROSCI, V16, P34; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; TAKASUKA T, 1994, J BIOL CHEM, V269, P7509; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WALKER P, 1994, J BIOL CHEM, V269, P2863; WESS J, 1992, J BIOL CHEM, V267, P19313; XIE YB, 1990, J BIOL CHEM, V265, P21411; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	45	175	180	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30953	30959						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983030				2022-12-25	WOS:A1994PV51000036
J	JEYARAJAH, S; PRONIEWICZ, LM; BRONDER, H; KINCAID, JR				JEYARAJAH, S; PRONIEWICZ, LM; BRONDER, H; KINCAID, JR			LOW-FREQUENCY VIBRATIONAL-MODES OF OXYGENATED MYOGLOBIN, HEMOGLOBINS, AND MODIFIED DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; ISOTOPE SENSITIVE BANDS; HEME-PROTEINS; SPIN STATE; IRON; HISTIDINE; COMPLEXES; DIOXYGEN; OXYHEMOGLOBIN; ASSIGNMENT	The low frequency resonance Raman spectra of the dioxygen adducts of myoglobin, hemoglobin, its isolated subunits, mesoheme-substituted hemoglobin, and several deuteriated heme derivatives are reported. The observed oxygen isotopic shifts are used to assign the iron-oxygen stretching (similar to 570 cm(-1)) and the heretofore unobserved delta(Fe-O-O) bending (similar to 420 cm(-1)) modes. Although the delta(Fe-O-O) is not enhanced in the case of oxymyoglobin, it is observed for all the hemoglobin derivatives, its exact frequency being relatively invariable among the derivatives. The lack of sensitivity to H2O/D2O buffer exchange is consistent with our previous interpretation of H2O/D2O-induced shifts of nu(O-O) in the resonance Raman spectra of dioxygen adducts of cobalt-substituted heme proteins; namely, that those shifts are associated with alterations in vibrational coupling of nu(O-O) with internal modes of proximal histidyl imidazole rather than to steric or electronic effects of H/D exchange at the active site. No evidence is obtained for enhancement of the nu(Fe-N) stretching frequency of the linkage between the heme iron and the imidazole group of the proximal histidine.	MARQUETTE UNIV,DEPT CHEM,MILWAUKEE,WI 53233; JAGIELLONIAN UNIV,REG LAB PHYS CHEM ANAL & STRUCT RES,PL-30060 KRAKOW,POLAND	Marquette University; Jagiellonian University					NIDDK NIH HHS [DK13153] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGADE PV, 1984, J AM CHEM SOC, V106, P6593, DOI 10.1021/ja00334a024; BAJDOR K, 1984, J AM CHEM SOC, V106, P7273, DOI 10.1021/ja00335a085; BENKO B, 1983, P NATL ACAD SCI USA, V81, P5106; BRUHA A, 1988, J AM CHEM SOC, V110, P6006, DOI 10.1021/ja00226a014; BRUNNER H, 1974, NATURWISSENSCHAFTEN, V121, P61; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; CHOI S, 1983, J AM CHEM SOC, V105, P3692, DOI 10.1021/ja00349a057; CHOI SH, 1983, J AM CHEM SOC, V105, P3683, DOI 10.1021/ja00349a056; HU SH, 1991, J AM CHEM SOC, V113, P7189, DOI 10.1021/ja00019a015; HU SZ, 1993, INORG CHEM, V32, P1081, DOI 10.1021/ic00059a010; JEYARAJAH S, 1990, BIOCHEMISTRY-US, V29, P5087, DOI 10.1021/bi00473a013; KITAGAWA T, 1979, FEBS LETT, V104, P376, DOI 10.1016/0014-5793(79)80856-X; KITAGAWA T, 1982, NATURE, V298, P869, DOI 10.1038/298869a0; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; LI XY, 1989, J AM CHEM SOC, V111, P7012, DOI 10.1021/ja00200a018; ONDRIAS MR, 1982, BIOCHEMISTRY-US, V21, P3428, DOI 10.1021/bi00257a028; PRONIEWICZ LM, 1991, J AM CHEM SOC, V113, P3294, DOI 10.1021/ja00009a012; PRONIEWICZ LM, 1990, J AM CHEM SOC, V112, P675, DOI 10.1021/ja00158a028; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; RIGGS A, 1981, METHOD ENZYMOL, V131, P350; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SPIRO TG, 1974, J AM CHEM SOC, V96, P338, DOI 10.1021/ja00809a004; SPIRO TG, 1983, PHYSICAL BIOINORGANI, V2, P89; TSUBAKI M, 1982, BIOCHEMISTRY-US, V21, P1132, DOI 10.1021/bi00535a004; UCHIDA K, 1988, J BIOCHEM-TOKYO, V103, P979, DOI 10.1093/oxfordjournals.jbchem.a122397; WALTERS MA, 1982, BIOCHEMISTRY-US, V21, P6989, DOI 10.1021/bi00269a057; WELLS AV, 1991, J AM CHEM SOC, V113, P9655, DOI 10.1021/ja00025a034; YAMAMOTO T, 1973, J BIOL CHEM, V248, P5211; YU NT, 1984, P NATL ACAD SCI-BIOL, V81, P5106, DOI 10.1073/pnas.81.16.5106; YU NT, 1988, BIOL APPLICATIONS RA, V3, P96	30	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31047	31050						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983043				2022-12-25	WOS:A1994PV51000050
J	RIBEIRO, A; BROWN, A; LEE, KAW				RIBEIRO, A; BROWN, A; LEE, KAW			AN IN-VIVO ASSAY FOR MEMBERS OF THE CAMP RESPONSE ELEMENT-BINDING PROTEIN FAMILY OF TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; LEUCINE ZIPPER PROTEINS; DNA-BINDING; GENE-TRANSCRIPTION; DIMERIZATION SPECIFICITY; FACTOR CREB; KINASE-A; PROMOTER; DOMAIN; FOS	The CREB/ATF family of dimeric basic/leucine zipper (bZIP) transcription factors have been implicated in signal transduction by several agents including intracellular cAMP. The ubiquity of the cAMP-signaling pathway in mammalian cells has made it difficult to assay individual family members in their native form and dissect their roles in signal transduction. In Light of observations that ATF1 exhibits several cell-specific characteristics and is allosterically regulated, the above problem has represented a particular Limitation for studying ATF1. To address this we have exploited the modular nature of the bZIP domain to design fusion proteins that closely resemble native ATF1 but have altered DNA binding and dimerization specificity. The activity of these novel proteins can be monitored following their introduction into a cAMP-responsive cell type. Thus we describe an assay for members of the CREB family that should be generally applicable in a range of cell types and to other bZIP protein families.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND				Ribeiro, Agnès/Q-9702-2017	Ribeiro, Agnès/0000-0003-2063-6084				Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; JONES C, 1991, MOL CELL BIOL, V11, P4297, DOI 10.1128/MCB.11.9.4297; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LIU F, 1993, J BIOL CHEM, V268, P6714; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; MASSON N, 1992, MOL CELL BIOL, V12, P1096, DOI 10.1128/MCB.12.3.1096; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P4166, DOI 10.1093/nar/21.18.4166; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P1163, DOI 10.1093/nar/21.5.1163; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; TAYLOR N, 1991, J VIROL, V65, P4033, DOI 10.1128/JVI.65.8.4033-4041.1991; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WAEBER G, 1992, ENDOCRINOLOGY, V131, P2010, DOI 10.1210/en.131.4.2010; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z	34	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31124	31128						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983053				2022-12-25	WOS:A1994PV51000060
J	BUXBAUM, LU; RAPER, J; OPPERDOES, FR; ENGLUND, PT				BUXBAUM, LU; RAPER, J; OPPERDOES, FR; ENGLUND, PT			MYRISTATE EXCHANGE - A 2ND GLYCOSYL PHOSPHATIDYLINOSITOL MYRISTOYLATION REACTION IN AFRICAN TRYPANOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; HEPATIC MONOACYLGLYCEROL ACYLTRANSFERASE; MEMBRANE ANCHOR; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPASE-C; BRUCEI; BIOSYNTHESIS; ACYL; SPECIFICITY; BILAYER	The variant surface glycoprotein of African trypanosomes has a glycosyl phosphatidylinositol (GPI) anchor that is unusual in that its fatty acids are exclusively myristate. We showed previously that the myristate is added to a free GPI in a fatty acid remodeling reaction involving deacylation and reacylation, forming glycolipid A, the anchor precursor. We now demonstrate that trypanosomes have a second pathway for GPI anchor myristoylation distinct from the fatty acid remodeling pathway, which we call ''myristate exchange.'' This reaction involves exchange of myristate into both the sn-1 and sn-2 positions of glycolipid A, which already contain myristate. Myristoyl-CoA, the probable myristate donor in the exchange reaction, has an apparent K-m of about 6 nM. We have now identified a lyso-GPI, named theta', which has myristate as its sole fatty acid; the kinetics of formation and utilization of theta' are consistent with it being an intermediate in exchange. Myristate exchange and fatty acid remodeling appear to occur in different sub cellular compartments, and the two reactions have different sensitivities to inhibitors. The myristate exchange reaction may be a proofreading system to ensure that the fatty acids on variant surface glycoproteins are exclusively myristate.	INT INST CELLULAR & MOLEC PATHOL,TROP DIS RES UNIT,B-1200 BRUSSELS,BELGIUM		BUXBAUM, LU (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.		Opperdoes, Fred/N-9922-2019	Opperdoes, Fred/0000-0003-1984-3764; Raper, Jayne/0000-0002-8723-9748	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021334] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21334] Funding Source: Medline; NIGMS NIH HHS [5T32GM07329] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHE R, 1987, ARCH BIOCHEM BIOPHYS, V257, P131, DOI 10.1016/0003-9861(87)90551-0; BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BHAT BG, 1993, ARCH BIOCHEM BIOPHYS, V300, P663, DOI 10.1006/abbi.1993.1092; COLEMAN RA, 1984, J BIOL CHEM, V259, P8934; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; DOERING T L, 1990, Methods (Orlando), V1, P288, DOI 10.1016/S1046-2023(05)80330-5; DOERING TL, 1994, BIOCHEM J, V299, P741, DOI 10.1042/bj2990741; DOERING TL, 1993, J BIOL CHEM, V268, P9215; EIBL H, 1970, BIOCHEMISTRY-US, V9, P423, DOI 10.1021/bi00804a033; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; GBENLE GO, 1986, ACTA TROP, V43, P295; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1992, J BIOL CHEM, V267, P754; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MENSAWILMOT K, 1992, MOL BIOCHEM PARASIT, V56, P311, DOI 10.1016/0166-6851(92)90180-R; OPPERDOES FR, 1981, MOL BIOCHEM PARASIT, V4, P311, DOI 10.1016/0166-6851(81)90063-3; OPPERDOES FR, 1982, MOL BIOCHEM PARASIT, V5, P309, DOI 10.1016/0166-6851(82)90038-X; PLUCKTHUN A, 1982, BIOCHEMISTRY-US, V21, P1743; PRADOFIGUEROA M, 1994, MOL BIOCHEM PARASIT, V63, P255, DOI 10.1016/0166-6851(94)90061-2; SANSBURY K, 1989, J LIPID RES, V30, P1251; SLOTBOOM AJ, 1963, RECL TRAV CHIM PAY B, V82, P469; STEIGER RF, 1980, EUR J BIOCHEM, V105, P163, DOI 10.1111/j.1432-1033.1980.tb04486.x; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987	33	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30212	30220						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982929				2022-12-25	WOS:A1994PU52500029
J	ELGORT, A; SHIELDS, D				ELGORT, A; SHIELDS, D			PROSOMATOSTATIN PROCESSING IN PITUITARY GH(3) CELLS - IDENTIFICATION AND SECRETION OF THE INTACT PROPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASES; TARGETING SIGNAL; AMINO TERMINUS; PREPROSOMATOSTATIN; SOMATOSTATIN; EXPRESSION; CLEAVAGE; SEQUENCE; YEAST; ENDOPROTEASES	Preprosomatostatin (preproSRIF) is a peptide hormone precursor that undergoes tissue-specific processing at either a single set of paired basic residues to yield SRIF-14 or, alternatively, at a monobasic site to produce SRIF-28, an NH2 terminally extended form of SRIF-14. Mammalian preproSRIFs are a family of precursors that are remarkably conserved from rat to humans. In five species, the signal peptide and propeptides are similar to 96% identical; this high degree of sequence identity may be indicative of functional conservation. Since the propeptide is approximately five times larger than SRIF-14, we hypothesized that it would be secreted as a separate polypeptide following proSRIF proteolytic processing. To test this idea, we raised polyclonal antibodies to the entire propeptide to follow its biosynthesis and secretion. Here we demonstrate that in transfected rat anterior pituitary GH(3) cells both SRIF-14 and the intact 9.5-kDa propeptide were processed coordinately from proSRIF with identical kinetics. Treatment of the cells with chloroquine, a weak base which inhibits processing to mature SRIF-14, also inhibited the appearance of the 9.5-kDa propeptide. Approximately 40% of the propeptide was targeted to the regulated secretory pathway as determined by its quantitative secretion in response to secretagogues. We also examined the secretion of the SRIF propeptide independently of SRIF-14 by expressing a truncated ''propeptide'' in which SRIF-14 was deleted. Significantly, the SRIF propeptide was itself efficiently transported through the secretory pathway and secreted into the culture medium, This suggests that the propeptide possesses all the topogenic information necessary for intracellular transport. The coordinate secretion of the intact propeptide with mature SRIF-14 suggests that it might function as a novel bioactive peptide.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	ELGORT, A (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV & MOLEC BIOL,BRONX,NY 10461, USA.				NCI NIH HHS [P30CA13330] Funding Source: Medline; NIDDK NIH HHS [DK21860] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021860, R37DK021860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARON DC, 1986, ENDOCRINOLOGY, V118, P218, DOI 10.1210/endo-118-1-218; ARON DC, 1984, BIOCHEM BIOPH RES CO, V124, P450, DOI 10.1016/0006-291X(84)91574-2; BENOIT R, 1982, BIOCHEM BIOPH RES CO, V107, P944, DOI 10.1016/0006-291X(82)90614-3; BENOIT R, 1987, SCIENCE, V238, P1126, DOI 10.1126/science.2891188; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; DANOFF A, 1991, J BIOL CHEM, V266, P10004; DANOFF A, 1993, EUR J BIOCHEM, V218, P1063, DOI 10.1111/j.1432-1033.1993.tb18466.x; DANOFF A, 1993, MECHANISMS INTRACELL, P131; GALANOPOULOU AS, 1993, J BIOL CHEM, V268, P6041; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; PATEL YC, 1985, SOMATOSTATIN, P71; SEETHALER G, 1991, J CELL BIOL, V114, P1125, DOI 10.1083/jcb.114.6.1125; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SHEN LP, 1982, P NATL ACAD SCI-BIOL, V79, P4575, DOI 10.1073/pnas.79.15.4575; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STOLLER TJ, 1989, J BIOL CHEM, V264, P6922; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TAGER HS, 1974, ANNU REV BIOCHEM, V43, P509, DOI 10.1146/annurev.bi.43.070174.002453; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; WARREN TG, 1984, CELL, V39, P547, DOI 10.1016/0092-8674(84)90461-6; XU HX, 1994, J BIOL CHEM, V269, P22875; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; ZHOU A, 1993, J BIOL CHEM, V268, P1763	32	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30668	30675						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982986				2022-12-25	WOS:A1994PU52500095
J	SCHULZE, A; ZERFASS, K; SPITKOVSKY, D; HENGLEIN, B; JANSENDURR, P				SCHULZE, A; ZERFASS, K; SPITKOVSKY, D; HENGLEIN, B; JANSENDURR, P			ACTIVATION OF THE E2F TRANSCRIPTION FACTOR BY CYCLIN D1 IS BLOCKED BY P16(INK4), THE PRODUCT OF THE PUTATIVE TUMOR-SUPPRESSOR GENE MTS1	ONCOGENE			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; FIBROBLASTS; G(1); SITE; IDENTIFICATION; OVEREXPRESSION; PROGRESSION; INHIBITION	The oncoprotein cyclin D1 binds to and activates cyclin-dependent kinase 4 (cdk4), whose activity is inhibited by p16(INK4), the product of the putative tumor suppressor gene MTS1. Cyclin D1 controls the timing of S phase onset in mammalian cells. We show that cyclin D1 acts as a positive regulator of the transcription factor E2F. In particular, cyclin D1 overexpression leads to the activation of the dihydrofolate reductase (DHFR) gene promoter. Activation depends on the E2F binding site in the DHFR promoter, known to mediate its activation at the G1/S transition in vivo. Cyclin D1 can also activate the adenovirus E2 promoter via E2F. Both promoters are repressed by p16(INK4) and this repression can be released by overexpression of cdk4. The data reported here support a direct role for cyclin D1 and its associated kinase in cell cycle regulation of E2F activity and S phase-specific gene expression. In addition, we show that both E2F sites bind complexes containing the retinoblastoma protein (pRB) and that in RB-deficient cell lines overexpression of cyclin D1 fails to activate E2F-dependent transcription, indicating that pRB may be involved in promoter activation.	DEUTSCH KREBSFORSCHUNGSZENTRUM, FORSCHUNGSSCHWERPUNKT ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY; CNRS, CTR GENET MOLEC, F-91190 GIF SUR YVETTE, FRANCE	Helmholtz Association; German Cancer Research Center (DKFZ); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Jansen-Dürr, Pidder/ABG-2466-2020; Schulze, Almut/AAX-8257-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Schulze, Almut/0000-0002-8199-6422				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; BOEUF H, 1990, ONCOGENE, V5, P691; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARPER JW, 1993, CELL, V75, P805; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LOVEC H, 1994, ONCOGENE, V9, P323; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1992, ONCOGENE, V7, P1681; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WIMMEL A, 1994, ONCOGENE, V9, P995; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	36	60	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3475	3482						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970707				2022-12-25	WOS:A1994PT39200009
J	BU, GJ; MAKSYMOVITCH, EA; GEUZE, H; SCHWARTZ, AL				BU, GJ; MAKSYMOVITCH, EA; GEUZE, H; SCHWARTZ, AL			SUBCELLULAR-LOCALIZATION AND ENDOCYTIC FUNCTION OF LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN IN HUMAN GLIOBLASTOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; LONG-TERM POTENTIATION; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; LDL-RECEPTOR; MEDIATED ENDOCYTOSIS; HEYMANN NEPHRITIS; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; 39-KDA PROTEIN	The low density lipoprotein receptor-related protein (LRP) is a multifunctional cell surface receptor that binds and endocytoses several structurally and functionally distinct ligands. Several of the ligands for LRP participate in both normal physiology and pathophysiology of the central nervous system. To begin to gain insights into the role of LRP in the central nervous system, we have analyzed the expression, subcellular distribution, and endocytic function of LRP in human glioblastoma U87 cells. These cells express an abundance of LRP at both the mRNA and protein levels. A 39-kDa protein, which copurifies with LRP and regulates its ligand binding activity, is also highly expressed in U87 cells. The subcellular localization of LRP and the 39-kDa protein was analyzed using scanning laser confocal and electron microscopy combined with immunolabeled U87 cells. At the plasma membrane, LRP was largely confined to clathrin-coated pits. Within cells, LRP and the 39-kDa protein partially colocalized within rough endoplasmic reticulum and the Golgi complex, suggesting a potential intracellular interaction between the two proteins. Little 39-kDa protein was found in endosomes in which LRP occurred abundantly. In examining the functional role of LRP in U87 cells, we found that LRP at the cell surface and along the cellular processes was functional in the binding and endocytosis of its ligands, and its activity therein was regulated by the 39-kDa protein. Using truncated recombinant 39-kDa protein constructs, we also demonstrated that distinct regions of the 39-kDa protein were responsible for inhibiting the binding of different LRP ligands on U87 cells. Our results thus strongly suggest several potential roles for LRP in brain protein and lipoprotein metabolism, as web as control of extracellular protease activity.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; UNIV UTRECHT,SCH MED,DEPT CELL BIOL,3584 CX UTRECHT,NETHERLANDS	Washington University (WUSTL); Utrecht University	BU, GJ (corresponding author), WASHINGTON UNIV,ST LOUIS CHILDRENS HOSP,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [HL52040, HL07275] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; ANDRES DA, 1990, J BIOL CHEM, V265, P5952; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1994, J BIOL CHEM, V269, P18521; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1993, J BIOL CHEM, V268, P13002; Bu Guojun, 1994, P259; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MURPHY PR, 1992, MOL ENDOCRINOL, V6, P877, DOI 10.1210/me.6.6.877; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PITAS RE, 1987, J BIOL CHEM, V262, P14352; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SWANSON LW, 1988, P NATL ACAD SCI USA, V85, P9821, DOI 10.1073/pnas.85.24.9821; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WOLF BB, 1992, AM J PATHOL, V141, P37; YOMAMOTO T, 1984, CELL, V39, P27	56	129	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29874	29882						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961982				2022-12-25	WOS:A1994PU28400086
J	DASCHER, C; MATTESON, J; BALCH, WE				DASCHER, C; MATTESON, J; BALCH, WE			SYNTAXIN-5 REGULATES ENDOPLASMIC-RETICULUM TO GOLGI TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SEMI-INTACT CELLS; VESICULAR TRANSPORT; PROTEIN-TRANSPORT; BETA-COP; COMPLEX; IDENTIFICATION; COMPARTMENT; FUSION; FAMILY; YEAST	Syntaxins are a family of vesicular transport receptors that are involved in membrane traffic through both the constitutive and regulated secretory pathways. Syntaxins 1A/B, 2, 3, and 4 are principally associated with the plasma membrane. Two of the syntaxins, 1A and 1B, have been suggested to be the docking receptors for synaptic vesicles with the presynaptic membrane. The most distant member of the family, syntaxin 5, has been found in the Golgi region and has significant homology (35% identity) with Sed5p, an essential protein in yeast which is required for vesicular transport from the endoplasmic reticulum (ER) to the Golgi stack. Here we present evidence that syntaxin 5 performs an analogous function in ER to Golgi transport in mammalian cells. Transient expression of an hemagglutinin-tagged full-length clone of syntaxin 5 and a truncated mutant lacking the transmembrane domain inhibited the transport of vesicular stomatitis virus glycoprotein to the Golgi stack. Under these conditions, vesicular stomatitis virus glycoprotein accumulated in pre-Golgi intermediates, which were strongly enriched in syntaxin 5. Our resuits suggest that syntaxin 5 is the functional mammalian homologue of Sed5p and provides evidence for its role in regulating the potential targeting and/or fusion of carrier vesicles following export from the ER.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NCRR NIH HHS [RR08176, RRO7273] Funding Source: Medline; NIGMS NIH HHS [GM 42336] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; INOUE A, 1992, J BIOL CHEM, V267, P10613; JONES E, 1976, GENETICS, V85, P23; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MORITA T, 1992, BIOMED RES-TOKYO, V13, P357, DOI 10.2220/biomedres.13.357; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; Saraste J, 1992, Semin Cell Biol, V3, P343, DOI 10.1016/1043-4682(92)90020-V; SARASTE J, 1991, J CELL SCI, V100, P415; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39	39	129	130	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29363	29366						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961911				2022-12-25	WOS:A1994PU28400008
J	GANSS, R; SCHUTZ, G; BEERMANN, F				GANSS, R; SCHUTZ, G; BEERMANN, F			THE MOUSE TYROSINASE GENE - PROMOTER MODULATION BY POSITIVE AND NEGATIVE REGULATORY ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOCYTE-STIMULATING HORMONE; YEAST ARTIFICIAL CHROMOSOME; TRANSGENIC MICE; AMINOTRANSFERASE GENE; ALBINO MUTATION; BROWN LOCUS; CYCLIC-AMP; EXPRESSION; TRANSCRIPTION; ENHANCER	Tyrosinase, the key enzyme in melanin synthesis, is expressed specifically in pigment-producing cells. Studies with transgenic mice and gene transfer experiments have demonstrated that the 270-base pair 5'-flanking sequence of the mouse tyrosinase gene leads to weak but cell type-specific and developmentally regulated expression. To elucidate the underlying transcriptional control, we focused on the identification of cis-acting elements within this 270-base pair minimal promoter. We also addressed the potential role of promoter elements in the control of cAMP regulation of the tyrosinase gene. Deletion and linker scanning mutagenesis revealed that promoter activity is modulated by two positive elements and one negative element. One of the positive elements includes the M-box, a sequence motif shared with the promoter of two other melanocyte-specific genes, trp-1 and trp-2. Cotransfection experiments provide evidence that a basic helix-loop-helix-zipper protein, encoded at the microphthalmia gene locus, transactivates the tyrosinase promoter, probably by binding to the M-box. Activating cis elements are bound by nuclear factors in vitro and confer increased expression to a reporter gene both in melanoma cells and in fibroblasts. We therefore suggest that the positive promoter elements modulate tyrosinase expression rather than determine cell specificity in vivo, whereas the negative element acts cell type specifically.	GERMAN CANC RES CTR,DIV MOLEC BIOL CELL 1,D-69120 HEIDELBERG,GERMANY; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	Helmholtz Association; German Cancer Research Center (DKFZ); Swiss Institute Experimental Cancer Research				Ganss, Ruth/0000-0002-5551-045X				Ausubel FM, 1992, CURRENT PROTOCOLS MO; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BEERMANN F, 1990, EMBO J, V9, P2819, DOI 10.1002/j.1460-2075.1990.tb07470.x; BEERMANN F, 1992, P NATL ACAD SCI USA, V89, P2809, DOI 10.1073/pnas.89.7.2809; BEERMANN F, 1991, NUCLEIC ACIDS RES, V19, P9587; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; BURCHILL SA, 1993, J ENDOCRINOL, V137, P189, DOI 10.1677/joe.0.1370189; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FULLER BB, 1993, ANN NY ACAD SCI, V680, P302, DOI 10.1111/j.1749-6632.1993.tb19692.x; FULLER BB, 1987, J BIOL CHEM, V262, P4024; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GRUNDSTROM T, 1985, NUCLEIC ACIDS RES, V13, P3305, DOI 10.1093/nar/13.9.3305; HEARING VJ, 1989, PIGM CELL RES, V2, P75, DOI 10.1111/j.1600-0749.1989.tb00166.x; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HOGANSON GE, 1989, SOMAT CELL MOLEC GEN, V15, P255, DOI 10.1007/BF01534876; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JACKSON IJ, 1993, NATURE, V362, P587, DOI 10.1038/362587a0; JACKSON IJ, 1993, CURR BIOL, V3, P518, DOI 10.1016/0960-9822(93)90045-P; JACKSON IJ, 1990, P NATL ACAD SCI USA, V87, P7010, DOI 10.1073/pnas.87.18.7010; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KLUPPEL M, 1991, P NATL ACAD SCI USA, V88, P3777, DOI 10.1073/pnas.88.9.3777; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; Le Douarin N.M., 1982, NEURAL CREST; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MINTZ B, 1991, P NATL ACAD SCI USA, V88, P9643, DOI 10.1073/pnas.88.21.9643; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; Overbeek Paul A., 1991, Transgenic Research, V1, P31, DOI 10.1007/BF02512994; PROTA G, 1980, J INVEST DERMATOL, V75, P122, DOI 10.1111/1523-1747.ep12521344; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; RUPPERT S, 1988, EMBO J, V7, P2715, DOI 10.1002/j.1460-2075.1988.tb03125.x; SCHEDL A, 1992, NUCLEIC ACIDS RES, V20, P3073, DOI 10.1093/nar/20.12.3073; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIBAHARA S, 1990, EUR J BIOCHEM, V189, P455, DOI 10.1111/j.1432-1033.1990.tb15510.x; SHIBAHARA S, 1991, J BIOL CHEM, V266, P15895; SHIBAHARA S, 1993, J INVEST DERMATOL S2, V100, P146; SHIBATA K, 1992, J BIOL CHEM, V267, P20584; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; STEEL KP, 1992, DEVELOPMENT, V115, P1111; STEINER C, 1987, NUCLEIC ACIDS RES, V15, P4163, DOI 10.1093/nar/15.10.4163; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TANAKA S, 1990, DEVELOPMENT, V108, P223; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; WOLFE HG, 1964, GENET RES, V5, P432, DOI 10.1017/S001667230003487X; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YAMAMOTO H, 1992, PIGM CELL RES, V5, P284, DOI 10.1111/j.1600-0749.1992.tb00551.x; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293	64	92	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29808	29816						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961973				2022-12-25	WOS:A1994PU28400077
J	MAK, DOD; FOSKETT, JK				MAK, DOD; FOSKETT, JK			SINGLE-CHANNEL INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR CURRENTS REVEALED BY PATCH-CLAMP OF ISOLATED XENOPUS OOCYTE NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RYANODINE RECEPTOR; SMOOTH-MUSCLE; ION CHANNELS; FUNCTIONAL-CHARACTERIZATION; TRISPHOSPHATE RECEPTOR; SARCOPLASMIC-RETICULUM; CARDIAC MYOCYTES; CALCIUM-RELEASE; IP(3) RECEPTOR; LIVER NUCLEI	Patch clamp of the outer nuclear membrane of isolated Xenopus oocyte nucleus was used to measure the single-channel properties of the inositol 1,4,5-trisphosphate (IP3) receptor (IP(3)R). The observed channel was activated by IP3, inhibited by heparin, and Ca2+-selective, with ion permeabilities P-Ca:P-K:P-Cl = 8:1:0.05. In symmetric KCI buffer, the channel was ohmic (113 picosiemens in 140 mM KCl) at low channel currents but rectified at higher positive currents. The nuclear IP(3)R exhibited three conductance substates: a main substate occurring similar to 90% of channel open time, a double substate with twice the main substate conductance and a third substate with half the main substate conductance, which was observed rarely. Channel open probability fluctuated over time and among nuclei. Mean open channel durations of the main and double substates were similar to 5 and 1 ms, respectively. Many channels exhibited periods of closure lasting seconds, and most inactivated permanently within 5 min of IP3 stimulation. These results provide the first characterization of the single-channel properties of the IP(3)R in its native membrane environment and demonstrate that patch clamp electrophysiology of intact nuclei can be used to directly record currents through the IP(3)R.	HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO M5G 1X8,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Foskett, Kevin/R-2549-2019	Foskett, J. Kevin/0000-0002-8854-0268				BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERTL A, 1992, SCIENCE, V258, P873, DOI 10.1126/science.1439795; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1994, MOL BIOL CELL, V5, P97, DOI 10.1091/mbc.5.1.97; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BUSTAMANTE JO, 1994, J MEMBRANE BIOL, V138, P105; BUSTAMANTE JO, 1993, BIOPHYS J, V64, P1735, DOI 10.1016/S0006-3495(93)81545-5; BUSTAMANTE JO, 1992, PFLUG ARCH EUR J PHY, V421, P473, DOI 10.1007/BF00370259; BUSTAMANTE JO, 1994, J MEMBRANE BIOL, V138, P77; CALLAMARAS N, 1994, CELL CALCIUM, V15, P66, DOI 10.1016/0143-4160(94)90105-8; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; GOLDBERG MW, 1993, J CELL SCI, V106, P261; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; Hille B., 1992, IONIC CHANNELS EXCIT; IINO M, 1994, MOL CELL ENDOCRINOL, V98, P141, DOI 10.1016/0303-7207(94)90132-5; INNOCENTI B, 1993, J MEMBRANE BIOL, V131, P137, DOI 10.1007/BF02791322; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MATTER N, 1993, J BIOL CHEM, V268, P732; MATZKE AJM, 1990, FEBS LETT, V271, P161, DOI 10.1016/0014-5793(90)80397-2; MAYRLEITNER M, 1991, CELL CALCIUM, V12, P505, DOI 10.1016/0143-4160(91)90032-A; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; MAZZANTI M, 1991, J MEMBRANE BIOL, V121, P189, DOI 10.1007/BF01870532; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TABARES L, 1991, J MEMBRANE BIOL, V123, P49, DOI 10.1007/BF01993962; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; WATRAS J, 1991, J NEUROSCI, V11, P3239; WILLIAMS AJ, 1992, J MUSCLE RES CELL M, V13, P7, DOI 10.1007/BF01738423	52	124	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29375	29378						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961913				2022-12-25	WOS:A1994PU28400011
J	MENDEZ, J; BLANCO, L; LAZARO, JM; SALAS, M				MENDEZ, J; BLANCO, L; LAZARO, JM; SALAS, M			PRIMER-TERMINUS STABILIZATION AT THE PHI-29 DNA-POLYMERASE ACTIVE-SITE - MUTATIONAL ANALYSIS OF CONSERVED MOTIF TX(2)GR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; FUNCTIONAL-RELATIONSHIPS; DIRECTED MUTAGENESIS; PHOSPHONOACETIC ACID; NUCLEOTIDE-SEQUENCE; SECONDARY-STRUCTURE; LARGEST SUBUNITS; KLENOW FRAGMENT	The functional significance of the conserved motif TX(2)GR, included in one of the six main regions of amino acid sequence similarity identified in the C-terminal portion of both Escherichia coli DNA polymerase I-like and eukaryotic-type DNA polymerases (Blanco, L., Bernad, A., Blasco, M.A., and Salas, M. (1991) Gene (Amst.) 100, 27-38) has been studied by site-directed mutagenesis in the phi 29 DNA polymerase. A revised multiple alignment of this region, including 61 DNA polymerases belonging to these two superfamilies, is presented. In addition, based on amino acid sequence comparisons and by extrapolation to the crystal structure of T7 RNA polymerase, a similar motif (DX(2)GR) is predicted to be structurally and functionally equivalent in RNA polymerases, the other class of DNA-dependent polymerases. The severe defect in polymerization displayed by two of the phi 29 DNA polymerase mutants used in this study (T434N and R438I) is interpreted as the consequence of a decreased capacity to stabilize the binding of primer-template DNA structures in a polymerization-competent conformation. These mutants were also severely affected in the formation of terminal protein (TP)-dAMP initiation complex, a reaction in which phi 29 DNA polymerase is able to use the TP as primer.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Salas, Margarita/J-9873-2014; Mendez, Juan/K-8001-2014; Blanco, Luis/I-1848-2015	Salas, Margarita/0000-0001-5939-3441; Mendez, Juan/0000-0002-3235-2559; 	NIGMS NIH HHS [5R01 GM27242-15] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BLANCO L, 1994, IN PRESS METHODS ENZ; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1993, J BIOL CHEM, V268, P16763; BLASCO MA, 1993, J BIOL CHEM, V268, P24106; BLASCO MA, 1992, CHROMOSOMA, V102, pS32, DOI 10.1007/BF02451783; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V19, P4045; CHAN BSS, 1991, CURR GENET, V20, P225; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; CULLMANN G, 1993, GENE, V134, P191, DOI 10.1016/0378-1119(93)90093-I; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DELARUE M, 1990, PROTEIN ENG, V3, P4611; DONG Q, 1993, J BIOL CHEM, V268, P24163; DONG Q, 1993, J BIOL CHEM, V268, P23175; DORSKY DI, 1990, J VIROL, V64, P1394, DOI 10.1128/JVI.64.3.1394-1397.1990; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBBS JS, 1988, P NATL ACAD SCI USA, V85, P6672, DOI 10.1073/pnas.85.18.6672; GRABHERR R, 1992, VIROLOGY, V188, P721, DOI 10.1016/0042-6822(92)90527-V; HERMANNS J, 1992, CURR GENET, V22, P491, DOI 10.1007/BF00326415; IGLOI GL, 1990, MOL GEN GENET, V221, P379, DOI 10.1007/BF00259403; INCIARTE MR, 1976, VIROLOGY, V74, P314, DOI 10.1016/0042-6822(76)90338-X; JOUNG I, 1991, VIROLOGY, V184, P235, DOI 10.1016/0042-6822(91)90840-8; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KNOPF CW, 1987, J GEN VIROL, V68, P1429, DOI 10.1099/0022-1317-68-5-1429; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LAZARO JM, 1994, IN PRESS METHODS ENZ; LEAVITT MC, 1989, P NATL ACAD SCI USA, V86, P4465, DOI 10.1073/pnas.86.12.4465; LI WB, 1989, NUCLEIC ACIDS RES, V17, P9621, DOI 10.1093/nar/17.23.9621; LOPEZ P, 1989, J BIOL CHEM, V264, P4255; MARCY AI, 1990, J VIROL, V64, P5883, DOI 10.1128/JVI.64.12.5883-5890.1990; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MATSUMOTO K, 1989, GENE, V84, P247; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; MOFFATT BA, 1984, J MOL BIOL, V173, P265, DOI 10.1016/0022-2836(84)90194-3; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; RODRIGUEZ JM, 1993, GENE, V136, P103, DOI 10.1016/0378-1119(93)90453-A; ROHE M, 1991, CURR GENET, V20, P527, DOI 10.1007/BF00334782; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; YANEZ RJ, 1993, NUCLEIC ACIDS RES, V21, P2423, DOI 10.1093/nar/21.10.2423; ZABALLOS A, 1989, GENE, V83, P187, DOI 10.1016/0378-1119(89)90104-2	65	45	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					30030	30038						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7962004				2022-12-25	WOS:A1994PU28400108
J	MIURA, Y; MIURA, O; IHLE, JN; AOKI, N				MIURA, Y; MIURA, O; IHLE, JN; AOKI, N			ACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY BY THE ERYTHROPOIETIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; CYTOPLASMIC REGION; GROWTH-FACTOR; SHC PROTEINS; BETA-CHAIN; MAP KINASE; CELL-LINE	The erythropoietin receptor (EpoR) belongs to the cytokine receptor family, members of which lack a tyrosine kinase domain. Recent studies, however, have shown that a cytoplasmic tyrosine kinase, JAK2, interacts with the cytoplasmic domain of the EpoR and becomes activated upon binding of Epo to the receptor. Epo has also been shown to stimulate activation of Pas and Raf-l. The present studies were undertaken to examine the possible involvement of Epo-induced tyrosine phosphorylation in activation of the Ras/mitogen-activated protein kinase (MAP kinase) pathway and to determine its significance on the growth signaling from the EpoR. In an interleukin (IL)-3-dependent cell Line expressing the transfected wild-type EpoR, Epo, or IL-3 induced tyrosine phosphorylation of She and its association with Grb2. These cytokines also induced tyrosine phosphorylation and activation of MAP kinase isoforms ERK1 and ERK2. A mutant EpoR with a carboxyl-terminal deletion of 108 amino acids (H mutant), which is mitogenically functional but lacks tyrosine phosphorylation sites in the carboxyl-terminal region, showed markedly diminished abilities to induce tyrosine phosphorylation of She and to phosphorylate and activate MAP kinases. A mutant receptor (PM4 mutant) inactivated by a point mutation, Trp(282) to Arg, which abrogates the interaction with JAK2, failed to induce any effect on Shc or MAP kinases. In cells expressing a mutant EpoR that is constitutively activated by a point mutation, Arg(129) to Cys, in the extracellular portion of the receptor, neither tyrosine phosphorylation of She nor activation of MAP kinases by phosphorylation was detectable without stimulation with Epo or IL-3. These results suggest that the carboxyl-terminal region of EpoR may play a crucial role in activation of MAP kinases through the Ras signaling pathway which may be activated by tyrosine phosphorylation of She and its association with Grb2. The activation of MAP kinases, however, failed to correlate with the mitogenic activity of mutant EpoRs and thus may not be required for growth signaling from the EpoR.	TOKYO MED & DENT UNIV, DEPT INTERNAL MED 1, BUNKYO KU, TOKYO 113, JAPAN; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	Tokyo Medical & Dental University (TMDU); St Jude Children's Research Hospital				Miura, Osamu/0000-0002-0981-3054				BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; Ihle J N, 1993, Semin Immunol, V5, P375, DOI 10.1006/smim.1993.1043; IHLE JN, 1990, INT J CELL CLONING, V8, P130, DOI 10.1002/stem.5530080712; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KOMATSU N, 1992, BLOOD, V80, P53; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KRANTZ SB, 1991, BLOOD, V77, P419; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA O, 1993, BLOOD, V81, P1739; MIURA O, 1994, IN PRESS BLOOD; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; OKUDA K, 1992, BLOOD, V79, P2880; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE FW, 1991, J BIOL CHEM, V266, P609; RAINES MA, 1992, BLOOD, V79, P3350; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TORTI M, 1992, J BIOL CHEM, V267, P8293; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	56	189	193	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29962	29969						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961995				2022-12-25	WOS:A1994PU28400099
J	WU, WI; CARMAN, GM				WU, WI; CARMAN, GM			REGULATION OF PHOSPHATIDATE PHOSPHATASE-ACTIVITY FROM THE YEAST SACCHAROMYCES-CEREVISIAE BY NUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDYLINOSITOL 4-KINASE; PROTEIN-KINASE; 104-KDA FORMS; 55-KDA FORMS; INOSITOL; 45-KDA; ENZYME; MUTANT	Regulation of Saccharomyces cerevisiae membrane-associated phosphatidate phosphatase (3-sn-phosphatidate phosphohydrolase, EC 3.1.3.4) activity by nucleotides was examined using pure enzyme and Triton X-100/phosphatidate-mixed micelles. Adenosine, guanosine, cytidine, and uridine nucleotides inhibited phosphatidate phosphatase activity in a dose-dependent manner. ATP and CTP were the most potent inhibitors of the enzyme. A kinetic analysis was performed to determine the mechanism of enzyme inhibition by nucleotides. The mechanism of inhibition by ATP and CTP with respect to phosphatidate (the substrate) was complex. The dependence of phosphatidate phosphatase activity on phosphatidate was cooperative, and nucleotides affected both V-max and K-m. ATP did not inhibit phosphatidate phosphatase activity by binding to the enzyme or to phosphatidate. Phosphatidate phosphatase dependence on Mg2+ ions (the cofactor) followed saturation kinetics, and the mechanism of nucleotide inhibition with respect to Mg2+ ions was competitive. Thus, the mechanism of enzyme inhibition by nucleotides was the chelation of Mg2+ ions. The inhibitor constant for ATP was lower than its cellular concentration in glucose-grown cells. However, the inhibitor constant for ATP was higher than its cellular concentration in glucose-starved cells. Changes in the cellular concentration of ATP affected the proportional synthesis of triacylglycerols and phospholipids. These results were consistent with the regulation of phosphatidate phosphatase activity by ATP through a Mg2+ ion chelation mechanism.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick					NIGMS NIH HHS [GM-28140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B, 1994, MOL BIOL CELL, P508; BERGLUND L, 1989, BIOCHIM BIOPHYS ACTA, V1002, P382, DOI 10.1016/0005-2760(89)90353-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINDLEY DN, 1984, PROG LIPID RES, V23, P115, DOI 10.1016/0163-7827(84)90001-8; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CULBERTSON MR, 1975, GENETICS, V80, P23; EXTON JH, 1990, J BIOL CHEM, V265, P1; GREENBERG ML, 1982, MOL GEN GENET, V186, P157, DOI 10.1007/BF00331845; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; Kates M., 1986, TECHNIQUES LIPIDOLOG; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; LEWIS CT, 1989, BIOCHEMISTRY-US, V28, P9248, DOI 10.1021/bi00450a003; LIN YP, 1989, J BIOL CHEM, V264, P8641; LIN YP, 1990, J BIOL CHEM, V265, P166; MOORE TS, 1982, ANNU REV PLANT PHYS, V33, P235, DOI 10.1146/annurev.pp.33.060182.001315; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; NICKELS JT, 1993, J BIOL CHEM, V268, P24083; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; Segel I.H., 1975, ENZYME KINETICS; SMITH SW, 1957, J BIOL CHEM, V228, P915; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; STORER AC, 1976, BIOCHEM J, V159, P1; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; TAYLOR FR, 1979, BIOCHIM BIOPHYS ACTA, V575, P204, DOI 10.1016/0005-2760(79)90022-5; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WU WI, 1993, J BIOL CHEM, V268, P13830	37	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29495	29501						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961932				2022-12-25	WOS:A1994PU28400031
J	BRICKEY, DA; BANN, JG; FONG, YL; PERRINO, L; BRENNAN, RG; SODERLING, TR				BRICKEY, DA; BANN, JG; FONG, YL; PERRINO, L; BRENNAN, RG; SODERLING, TR			MUTATIONAL ANALYSIS OF THE AUTOINHIBITORY DOMAIN OF CALMODULIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; LIGHT-CHAIN KINASES; CA-2+ CALMODULIN; REGULATORY DOMAIN; CATALYTIC SUBUNIT; INTRASTERIC REGULATION; INHIBITORY PEPTIDES; SYNTHETIC PEPTIDE; ALPHA-SUBUNIT; AUTOPHOSPHORYLATION	Calmodulin (CaM)-kinase II is inactive in the absence of Ca2+/CaM due to interaction of its autoinhibitory domain with its catalytic domain. Previous studies using synthetic autoinhibitory domain peptides (residues 281-302) identified several residues as important for inhibitory potency and suggested that His(282) may interact with the ATP-binding motif of the catalytic domain. To further examine the autoinhibitory domain, site specific mutants were expressed using the baculovirus/Sf9 cell system. The purified mutants had many biochemical properties identical to wild-type kinase, but mutants H282Q, H282R, R283E, and T286D had 10-20% constitutive Ca2+-independent activities, indicating that these residues are involved in the autoinhibitory interaction. The Ca2+-independent activities of the H282Q, H282R, and R283E mutants exhibited 10-fold lower K-m values for ATP than the wild-type kinase. Wild-type and mutant kinases, except T286A and T286D, generated Ca2+ independence upon autophosphorylation in the presence of Ca2+/CaM, and those mutants having constitutive Ca2+ independence also exhibited enhanced Ca2+/CaM-independent autophosphorylation. This Ca2+-independent autophosphorylation resulted in a decrease in total kinase activity, but there was little increase in Ca2+ independent activity, consistent with autophosphorylation of predominantly Thr(306) rather than Thr(286). These results are consistent with an inhibitory interaction of His(282) and possibly Arg(283) With the ATP-binding motif of the catalytic domain, and they indicate that constitutively active CaM-kinase II cannot autophosphorylate on Thr(286) in the absence of bound Ca2+/CaM. Based on these and other biochemical characterizations, we propose a molecular model for the interaction of a bisubstrate autoinhibitory domain with the catalytic domain of CaM-kinase II.	OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97201	Oregon Health & Science University	BRICKEY, DA (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201, USA.			Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41292] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FONG YL, 1989, J BIOL CHEM, V264, P16759; FONG YL, 1990, J BIOL CHEM, V265, P11091; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HAGIWARA T, 1991, J BIOL CHEM, V266, P16401; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; IKEBE M, 1990, BIOCHEM BIOPH RES CO, V168, P714, DOI 10.1016/0006-291X(90)92380-I; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KENNELLY PJ, 1992, BIOCHEMISTRY-US, V31, P5394, DOI 10.1021/bi00138a022; KING MM, 1988, J BIOL CHEM, V263, P4754; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KWIATKOWSKI AP, 1990, BIOCHEMISTRY-US, V29, P153, DOI 10.1021/bi00453a019; KWIATKOWSKI AP, 1988, J BIOL CHEM, V263, P6484; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MUKHERJI S, 1994, J BIOL CHEM, V269, P20733; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PONGOR S, 1987, METHOD ENZYMOL, V154, P450; ROSKOSKI R, 1985, METHOD ENZYMOL, V99, P3; SHIELDS SM, 1984, J NEUROCHEM, V43, P1599, DOI 10.1111/j.1471-4159.1984.tb06084.x; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SMITH MK, 1992, J BIOL CHEM, V267, P1761; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555, P1; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; WAXHAM MN, 1990, P NATL ACAD SCI USA, V87, P1273, DOI 10.1073/pnas.87.4.1273; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	52	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29047	29054						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961870				2022-12-25	WOS:A1994PU16800080
J	BURCHAM, PC; MARNETT, LJ				BURCHAM, PC; MARNETT, LJ			SITE-SPECIFIC MUTAGENESIS BY A PROPANODEOXYGUANOSINE ADDUCT CARRIED ON AN M13 GENOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM HISD3052; FRAMESHIFT MUTAGENESIS; DELETION MUTAGENESIS; GUANINE NUCLEOSIDES; MUTATION FREQUENCY; PALINDROMIC DNA; HOT-SPOT; MALONDIALDEHYDE; SPECTRUM; VECTOR	The spectrum of mutations induced upon in vivo replication of an M13 genome containing a site-specifically located propanodeoxyguanosine (PdG) adduct was determined. PdG was used as a model for the major deoxyguanosine adduct produced on reaction of DNA with the endogenous genotoxin malondialdehyde. PdG was introduced at position 6256 of M13MB102 by ligating the oligodeoxynucleotide 5'-GGT(PdG)TCCG-3' into an 8-base gap in the (-)-strand of duplex M13MB102. Replication of the adducted strand was maximized by incorporation of uracil into the unadducted (+)-strand. Following replication of dG-containing and PdG-containing M13MB102 genomes in Escherichia coli JM105, frameshift mutations were detected as phenotypic changes in the lacZ(a) marker gene. Base pair substitutions were detected by differential hybridization using P-32-labeled 13-mers bearing different bases opposite position 6256. Neither frameshift nor base pair substitution mutations were detected following replication of PdG-adducted genomes in non-SOS-induced JM105. However, PdG --> T transversions and PdG --> A transitions were detected following transformation of PdG-adducted M13MB102 into SOS-induced JM105. Both types of mutations were detected at comparable frequencies, and the total mutation frequency was approximately 2%. The results indicate that PdG is an efficient premutagenic lesion in E. coli strains in which the SOS response is induced.	VANDERBILT UNIV, SCH MED,CTR MOLEC TOXICOL,DEPT BIOCHEM, AB HANCOCK JR MEM LAB CANC RES, NASHVILLE, TN 37232 USA	Vanderbilt University					NCI NIH HHS [CA47479] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; BASU AK, 1988, CHEM RES TOXICOL, V1, P53, DOI 10.1021/tx00001a010; BASU AK, 1983, CARCINOGENESIS, V4, P331, DOI 10.1093/carcin/4.3.331; BENAMIRA M, 1993, CHEM RES TOXICOL, V6, P317, DOI 10.1021/tx00033a011; BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; BENAMIRA M, 1994, IN PRESS CARCINOGENE; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; CHANDHARY AK, 1994, BIOL MASS SPECTROM, V23, P457, DOI 10.1002/bms.1200230802; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; CMARIK JL, 1992, J BIOL CHEM, V267, P6672; COOPER DN, 1990, HUM GENET, V85, P55; ECHOLS H, 1990, MUTAT RES, V236, P301, DOI 10.1016/0921-8777(90)90013-U; GLICKMAN BW, 1984, P NATL ACAD SCI-BIOL, V81, P512, DOI 10.1073/pnas.81.2.512; GROLLMAN AP, 1990, PROG CLIN BIOL RES, V340, P61; KOUCHAKDJIAN M, 1990, BIOCHEMISTRY-US, V29, P4456, DOI 10.1021/bi00470a028; KOUCHAKDJIAN M, 1989, BIOCHEMISTRY-US, V28, P5647, DOI 10.1021/bi00439a047; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LATHAM GJ, 1993, J BIOL CHEM, V268, P23427; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Maniatis T, 1989, MOL CLONING; MARINELLI ER, 1990, CHEM RES TOXICOL, V3, P49, DOI 10.1021/tx00013a009; Marnett L J, 1994, IARC Sci Publ, P151; MARNETT LJ, 1986, J AM CHEM SOC, V108, P1348, DOI 10.1021/ja00266a065; MARNETT LJ, 1993, CHEM RES TOXICOL, V6, P771, DOI 10.1021/tx00036a005; MORIYA M, 1994, IN PRESS P NATL ACAD; PAULY GT, 1988, CHEM RES TOXICOL, V1, P391, DOI 10.1021/tx00006a011; PLUM GE, 1992, BIOCHEMISTRY-US, V31, P12096, DOI 10.1021/bi00163a019; POOT M, 1990, MUTAT RES, V238, P203, DOI 10.1016/0165-1110(90)90012-Z; REID TM, 1990, BIOCHEMISTRY-US, V29, P6153, DOI 10.1021/bi00478a007; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; RIPLEY LS, 1982, P NATL ACAD SCI-BIOL, V79, P4128, DOI 10.1073/pnas.79.13.4128; SETO H, 1983, B CHEM SOC JPN, V56, P1799, DOI 10.1246/bcsj.56.1799; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; SINGER B, 1991, CARCINOGENESIS, V12, P949; SINGH US, 1993, CHEM RES TOXICOL, V6, P825, DOI 10.1021/tx00036a012; Spalding J. W., 1988, NATL TOXICOL PROGRAM, V331, P5; STONE K, 1990, CHEM RES TOXICOL, V3, P467, DOI 10.1021/tx00017a013; STONE K, 1990, CHEM RES TOXICOL, V3, P33, DOI 10.1021/tx00013a006; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; YAU TM, 1979, MECH AGEING DEV, V11, P137, DOI 10.1016/0047-6374(79)90031-9	45	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28844	28850						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961843				2022-12-25	WOS:A1994PU16800053
J	CHEN, GC; LIU, WQ; DUCHATEAU, P; ALLAART, J; HAMILTON, RL; MENDEL, CM; LAU, K; HARDMAN, DA; FROST, PH; MALLOY, MJ; KANE, JP				CHEN, GC; LIU, WQ; DUCHATEAU, P; ALLAART, J; HAMILTON, RL; MENDEL, CM; LAU, K; HARDMAN, DA; FROST, PH; MALLOY, MJ; KANE, JP			CONFORMATIONAL DIFFERENCES IN HUMAN APOLIPOPROTEIN B-100 AMONG SUBSPECIES OF LOW-DENSITY LIPOPROTEINS (LDL) - ASSOCIATION OF ALTERED PROTEOLYTIC ACCESSIBILITY WITH DECREASED RECEPTOR-BINDING OF LDL SUBSPECIES FROM HYPERTRIGLYCERIDEMIC SUBJECTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LOW-DENSITY; GRADIENT GEL-ELECTROPHORESIS; HUMAN-SKIN FIBROBLASTS; MONOCLONAL-ANTIBODIES; ENHANCED SUSCEPTIBILITY; STRUCTURAL DOMAINS; INVITRO OXIDATION; B EPITOPES; SUBFRACTIONS; SEQUENCE	We asked at what point in the metabolic cascade of very low density lipoproteins (VLDL) to low density lipoproteins (LDL) the accessibility of proteolytic cleavage sites in B-100 changes, and we evaluated the effect of hypertriglyceridemia on the proteolytic accessibility, secondary structure, and receptor-binding affinity of B-100 in LDL subspecies of varying density. Limited proteolysis with Staphtylococcus aureus V8 protease and cathepsin D identified the density (about 1.033 g/ml) between two LDL subspecies, designated LDL-1 and -2, as the transition point during VLDL metabolism of both normolipidemic (N-) and hypertriglyceridemic (HTG-) subjects at which accessibility to protease attack changed in three peptide regions of B-100. Hypertriglyceridemia greatly altered proteolytic accessibility of B-100 in the denser LDL subspecies. Specifically, B-100 in HTG LDL exposed more cleavage sites than in N-LDL, including two novel sites, similar to 120 and similar to 130 kDa from the NH2 terminus in the small and dense subspecies (designated LDL-4, -4.5 or -5, d = 1.048-1.062 g/ml). Analysis of circular dichroic spectra indicated no difference in helical content between B-100 in N- and HTG-LDL but showed a greater content of beta-structure in HTG-LDL. Binding affinity for the LDL receptor of human fibroblasts decreased markedly with increasing density among HTG-LDL subspecies (by similar to 50% for LDL-4.5 or -5). We conclude that the changes in proteolytic accessibility observed between LDL-1 and -2 and in LDL-4, -4.5, or -5 indicate significant differences in local conformation of B-100 at specific peptide regions. The association of exposure of more cleavage sites, especially novel sites in the NH2-terminal regions, with greatly decreased receptor-binding affinity in LDL-4.5 or -5 suggests that altered local conformation in B-100 apart from the putative receptor-binding domain might affect interaction with the receptor.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; SCIOS NOVA INC,MT VIEW,CA 94043	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Scios	CHEN, GC (corresponding author), UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HL 14237] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014237] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAD Y, 1992, CIRCULATION, V86, P551; ARAD Y, 1992, CIRCULATION, V86, P2194; BERMAN M, 1978, J LIPID RES, V19, P38; BRADLEY WA, 1984, J BIOL CHEM, V259, P4728; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHAIT A, 1993, AM J MED, V94, P350, DOI 10.1016/0002-9343(93)90144-E; CHAPMAN MJ, 1988, J LIPID RES, V29, P442; CHEN GC, 1989, J BIOL CHEM, V264, P14369; CHEN GC, 1989, BIOCHEMISTRY-US, V28, P2477, DOI 10.1021/bi00432a019; CHEN GC, 1991, J BIOL CHEM, V266, P12581; CHIANG TC, 1978, ANAL BIOCHEM, V91, P13; CHIAT A, 1984, BIOCHIM BIOPHYS ACTA, V795, P314; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; DECKELBAUM RJ, 1984, ARTERIOSCLEROSIS, V4, P225, DOI 10.1161/01.ATV.4.3.225; DECKELBAUM RJ, 1982, J BIOL CHEM, V257, P6509; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; DEGRAAF J, 1993, ARTERIOSCLER THROMB, V13, P712, DOI 10.1161/01.ATV.13.5.712; DEJAGER S, 1993, J LIPID RES, V34, P295; EISENBERG S, 1984, J CLIN INVEST, V74, P470, DOI 10.1172/JCI111444; FISHER WR, 1983, METABOLISM, V32, P283, DOI 10.1016/0026-0495(83)90194-4; GALEANO NF, 1994, J BIOL CHEM, V269, P511; GAMBERT P, 1990, J LIPID RES, V31, P1199; GOTTO AM, 1986, METHOD ENZYMOL, V128, P1; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HIRAMATSU K, 1985, DIABETES, V34, P8, DOI 10.2337/diabetes.34.1.8; JAAKKOLA O, 1989, BIOCHIM BIOPHYS ACTA, V1005, P118, DOI 10.1016/0005-2760(89)90176-8; KANE JP, 1980, P NATL ACAD SCI-BIOL, V77, P2465, DOI 10.1073/pnas.77.5.2465; KINOSHITA M, 1990, J LIPID RES, V31, P701; KLEINMAN Y, 1985, J CLIN INVEST, V75, P1796, DOI 10.1172/JCI111892; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KRAUSS RM, 1982, J LIPID RES, V23, P97; KRUL ES, 1988, J LIPID RES, V29, P937; KUNITAKE ST, 1990, J BIOL CHEM, V265, P20739; LAW SW, 1986, P NATL ACAD SCI USA, V83, P8142, DOI 10.1073/pnas.83.21.8142; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCKEONE BJ, 1993, J CLIN INVEST, V91, P1926, DOI 10.1172/JCI116411; MCNAMARA JR, 1987, ARTERIOSCLEROSIS, V7, P483, DOI 10.1161/01.ATV.7.5.483; MCNAMARA JR, 1993, CIRCULATION, V88, P133; MCNAMARA JR, 1993, CIRCULATION, V88, P703; MENDEL CM, 1994, ANAL BIOCHEM, V216, P328, DOI 10.1006/abio.1994.1049; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NIGON F, 1991, J LIPID RES, V32, P1741; SALMON S, 1984, BIOCHEM BIOPH RES CO, V125, P704, DOI 10.1016/0006-291X(84)90596-5; SCOTT J, 1989, MOL BIOL MED, V6, P65; SHEN MMS, 1981, J LIPID RES, V22, P236; SIGURDSSON G, 1975, J CLIN INVEST, V56, P1481, DOI 10.1172/JCI108229; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SWINKELS DW, 1989, ARTERIOSCLEROSIS, V9, P604, DOI 10.1161/01.ATV.9.5.604; SWINKELS DW, 1990, BIOCHIM BIOPHYS ACTA, V1047, P212, DOI 10.1016/0005-2760(90)90519-4; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; TENG B, 1985, J BIOL CHEM, V260, P5067; TIKKANEN MJ, 1983, J LIPID RES, V24, P1494; TIKKANEN MJ, 1984, ARTERIOSCLEROSIS, V4, P138, DOI 10.1161/01.ATV.4.2.138; TSAO BP, 1982, J BIOL CHEM, V257, P5222; VAKAKIS N, 1983, BIOCHIM BIOPHYS ACTA, V751, P280, DOI 10.1016/0005-2760(83)90285-0; WALSH MT, 1991, CIRCULATION, V84, P456; WALSH MT, 1991, CIRCULATION, V84, P1816; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG CY, 1993, J LIPID RES, V34, P1311	59	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29121	29128						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961878				2022-12-25	WOS:A1994PU16800089
J	HOWARD, PW; MAURER, RA				HOWARD, PW; MAURER, RA			THYROTROPIN-RELEASING-HORMONE STIMULATES TRANSIENT PHOSPHORYLATION OF THE TISSUE-SPECIFIC TRANSCRIPTION FACTOR, PIT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PROLACTIN GENE-TRANSCRIPTION; MESSENGER-RNA SEQUENCES; CELL-SPECIFIC ELEMENTS; RAT PITUITARY-CELLS; GROWTH-HORMONE; CYCLIC-AMP; CATALYTIC SUBUNIT; NUCLEAR-PROTEIN; MAMMALIAN-CELLS	The hypothalamic hormone, thyrotropin releasing hormone (TRH), stimulates prolactin (PRL) secretion and gene transcription in the GH(3) pituitary cell line. Several studies have provided indirect evidence that phosphorylation of the pituitary-specific transcription factor Pit-1 may mediate TRH effects on PRL transcription. In the present study we have investigated the ability of TRH to alter the phosphorylation of Pit-1. In vivo P-32 labeling experiments demonstrated that TRH stimulated a transient phosphorylation of Pit-1, reaching a maximum in 5 min and returning to basal levels within 30 min. Phosphopeptide mapping experiments demonstrated that TRH induced the transient phosphorylation of specific sites in Pit-1. TRH-stimulated phosphorylation of Pit-1 was blocked by treatments that deplete the cellular content of protein kinase C. Metabolic labeling and Western blot analysis demonstrate that TRH does not alter the total cellular content or nuclear concentration of Pit-1. TRH-mediated stimulation of a PRL promoter-luciferase fusion gene occurred under conditions that blocked the transient phosphorylation of Pit-1. These studies suggest that phosphorylation of Pit-1 may not be necessary for TRH mediated enhancement of PRL gene transcription.	OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA; UNIV IOWA, MOLEC BIOL PHD PROGRAM, IOWA CITY, IA 52242 USA	Oregon Health & Science University; University of Iowa					NIDDK NIH HHS [DK40339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040339] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ALBERT PR, 1984, J BIOL CHEM, V259, P5350; BANDYOPADHYAY SK, 1989, J BIOL CHEM, V264, P14216; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DAY RN, 1989, J BIOL CHEM, V264, P431; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; FEARON CW, 1985, J BIOL CHEM, V260, P8366; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; GERSHENGORN MC, 1984, J BIOL CHEM, V259, P675; GICK GG, 1985, J BIOL CHEM, V260, P7614; HARVEY C, 1991, MOL ENDOCRINOL, V5, P836, DOI 10.1210/mend-5-6-836; HOGGARD N, 1991, MOL ENDOCRINOL, V5, P1748, DOI 10.1210/mend-5-11-1748; HOWARD P, 1991, J BIOL CHEM, V266, P10189; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KIM KE, 1988, MOL ENDOCRINOL, V2, P1374, DOI 10.1210/mend-2-12-1374; KIM MK, 1993, J BIOL CHEM, V268, P23366; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAVERRIERE JN, 1988, ENDOCRINOLOGY, V122, P333, DOI 10.1210/endo-122-1-333; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MAURER RA, 1982, ENDOCRINOLOGY, V110, P1957, DOI 10.1210/endo-110-6-1957; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MURDOCH GH, 1982, SCIENCE, V218, P1315, DOI 10.1126/science.6293056; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; MURDOCH GH, 1983, J BIOL CHEM, V258, P5329; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHUPNIK MA, 1992, MOL ENDOCRINOL, V6, P43, DOI 10.1210/me.6.1.43; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3130, DOI 10.1073/pnas.88.8.3130; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; THAW CN, 1984, AM J PHYSIOL, V247, pC150, DOI 10.1152/ajpcell.1984.247.3.C150; VERRIJZER CP, 1992, MOL CELL BIOL, V12, P542, DOI 10.1128/MCB.12.2.542; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WHITE BA, 1981, J BIOL CHEM, V256, P5942; YAN GZ, 1991, MOL ENDOCRINOL, V5, P535, DOI 10.1210/mend-5-4-535; YAN GZ, 1991, MOL ENDOCRINOL, V5, P1488, DOI 10.1210/mend-5-10-1488	54	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28662	28669						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961816				2022-12-25	WOS:A1994PU16800025
J	PLATT, KA; CLAFFEY, KP; WILKISON, WO; SPIEGELMAN, BM; ROSS, SR				PLATT, KA; CLAFFEY, KP; WILKISON, WO; SPIEGELMAN, BM; ROSS, SR			INDEPENDENT REGULATION OF ADIPOSE TISSUE-SPECIFICITY AND OBESITY RESPONSE OF THE ADIPSIN PROMOTER IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASE HOMOLOG; MESSENGER-RNA; GENE; EXPRESSION; PROTEINS; CLONING	Transcription of the adipocyte specific adipsin gene is dramatically reduced in the adipose tissue of a number of genetically and chemically-induced obese rodents. To map the region of the adipsin gene that confers this response to obesity transgenic mice were made containing -114, -250, -400, -700, and -938 base pairs (bp) to +35 bp of the promoter linked to the bacterial chloramphenicol acetyltransferase gene. Transgenic mice containing as few as 114 bp of the adipsin promoter had high levels of chloramphenicol acetyltransferase activity in adipose tissue. However, only those mice with 938 bp of the adipsin upstream regulatory region showed suppression of expression in adipose tissue in mice that were induced to become obese with monosodium glutamate. Using gel retardation assays, we showed that a 56-bp fragment of DNA mapping between -687 and -743 bp upstream from the start of adipsin expression was bound by protein factors in nuclear extracts prepared from adipose tissue. There was much greater retardation of this fragment with nuclear extracts prepared from adipose tissue of lean versus obese mice. These results indicate that a tissue-specific transcription factor(s) that regulates adipsin expression is less active in the adipose tissue of obese animals.	UNIV ILLINOIS, SCH MED, DEPT BIOCHEM MC 536, CHICAGO, IL 60612 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 01225 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 01225 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 42539] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042539] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWELL N, 1987, BIOL ADIPOCYTE, P255; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CELANDER D, 1987, J VIROL, V61, P269, DOI 10.1128/JVI.61.2.269-275.1987; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FLIER JS, 1989, RECENT PROG HORM RES, V45, P567; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; LUBON H, 1987, NUCLEIC ACIDS RES, V15, P2103, DOI 10.1093/nar/15.5.2103; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PLATT KA, 1989, P NATL ACAD SCI USA, V86, P7490, DOI 10.1073/pnas.86.19.7490; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SPIEGELMAN BM, 1989, J BIOL CHEM, V264, P1811; WILKISON WO, 1990, J BIOL CHEM, V265, P477	20	12	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28558	28562						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961801				2022-12-25	WOS:A1994PU16800010
J	VALERA, A; SOLANES, G; FERNANDEZALVAREZ, J; PUJOL, A; FERRER, J; ASINS, G; GOMIS, R; BOSCH, F				VALERA, A; SOLANES, G; FERNANDEZALVAREZ, J; PUJOL, A; FERRER, J; ASINS, G; GOMIS, R; BOSCH, F			EXPRESSION OF GLUT-2 ANTISENSE RNA IN BETA-CELLS OF TRANSGENIC MICE LEADS TO DIABETES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STIMULATED INSULIN-SECRETION; GLUCOSE TRANSPORTER; ISLET CELLS; LIVER; HYPERGLYCEMIA; GLUCOKINASE; GENE; RATS	An insulin response to glucose is required to correct hyperglycemia, Two proteins, the glucose transporter GLUT-2 and the glucose-phosphorylating enzyme glucokinase, have been implicated in the control of glucose metabolism in beta cells. To study the role of glucose transporter GLUT-2 in the regulation of insulin secretion and in the development of diabetes mellitus, we have obtained transgenic mice expressing high levels of GLUT-2 antisense RNA in beta cells. Western blot analysis showed an 80% reduction in GLUT-2 protein in the beta cells of these animals. Islets from transgenic mice showed impaired glucose-stimulated insulin secretion. In addition, much higher levels of blood glucose were detected in transgenic mice than in controls when glucose tolerance tests were performed. These results suggest that the reduction of GLUT-2 in the pancreas could be a crucial step in the development of diabetes mellitus.	UNIV AUTONOMA BARCELONA,SCH VET MED,DEPT BIOCHEM & MOLEC BIOL,E-08193 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN BARCELONA,DEPT ENDOCRINOL,E-08036 BARCELONA,SPAIN	Autonomous University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona			Ferrer, Jorge/A-3176-2012; Pujol, Anna/J-7939-2017	Ferrer, Jorge/0000-0002-5959-5729; Pujol, Anna/0000-0002-3484-598X; BOSCH, FATIMA/0000-0002-7705-5515				[Anonymous], 2012, BIOMETRY PRINCIPLES; CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANDOYDRON F, 1991, NUCLEIC ACIDS RES, V19, P4925, DOI 10.1093/nar/19.18.4925; HOGAN B, 1986, MANIPULATING MOUSE E; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LIANG Y, 1990, J BIOL CHEM, V265, P16863; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MUECKLER M, 1994, J BIOL CHEM, V269, P17765; NEWGARD CB, 1990, BIOCHEM SOC T, V18, P851, DOI 10.1042/bst0180851; OGAWA A, 1992, J CLIN INVEST, V90, P497, DOI 10.1172/JCI115886; OHNEDA M, 1993, DIABETES, V42, P1065, DOI 10.2337/diabetes.42.7.1065; ORCI L, 1990, P NATL ACAD SCI USA, V87, P9953, DOI 10.1073/pnas.87.24.9953; SUZUE K, 1989, NUCLEIC ACIDS RES, V17, P10099, DOI 10.1093/nar/17.23.10099; TAYLOR R, 1988, BIOCHEM J, V250, P625, DOI 10.1042/bj2500625; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; WINSTON SE, 1991, CURRENT PROTOCOLS IM	24	82	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28543	28546						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961797				2022-12-25	WOS:A1994PU16800006
J	LEE, AC; ZIZI, M; COLOMBINI, M				LEE, AC; ZIZI, M; COLOMBINI, M			BETA-NADH DECREASES THE PERMEABILITY OF THE MITOCHONDRIAL OUTER-MEMBRANE TO ADP BY A FACTOR OF 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIANTHUS-TUBEROSUS MITOCHONDRIA; PEPTIDE-SENSITIVE CHANNEL; INTACT PLANT-MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; P-31 NMR; NAD(P)H DEHYDROGENASES; POTATO MITOCHONDRIA; SYNTHETIC POLYANION; ADENYLATE KINASE; EXOGENOUS NADH	Mitochondria with intact outer membrane (99% intact based on cytochrome c impermeability) were isolated and used to measure the permeability of their outer membrane to ADP. beta-NADH reduced the permeability in a concentration dependent manner (K-D = 87 +/- 5 mu M) by a factor of 6. alpha-NADH and beta-NAD(+) cannot mimic the action of beta-NADH. The mitochondrial outer membranes become rate-limiting in the presence of beta-NADH at low physiologically relevant, ADP concentrations (<30 mu M). beta-NADH has been shown to increase the voltage dependence of VDAC (a major pathway for metabolite transport across the outer membrane) in a reconstituted system and this may be the way it acts on the isolated mitochondria. Inhibition of beta-NADH dehydrogenases does not inhibit the action of beta-NADH indicating that it is not acting by delivering reducing equivalents. The ability of beta-NADH, produced by glycolysis, to inhibit mitochondrial function by reducing the permeability of the outer membrane may be one pathway responsible for the Crabtree effect.			LEE, AC (corresponding author), UNIV MARYLAND, DEPT ZOOL, CELL BIOL LABS, COLLEGE PK, MD 20742 USA.		Colombini, Marco/A-1540-2014					ARRON GP, 1980, PLANT PHYSIOL, V65, P591, DOI 10.1104/pp.65.4.591; BALABAN RS, 1989, MOL CELL BIOCHEM, V89, P191; BARMAN TE, 1969, ENZYME HDB, V1, P57; BELTRANDELRIO H, 1991, ARCH BIOCHEM BIOPHYS, V286, P183, DOI 10.1016/0003-9861(91)90026-F; BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BERG OG, 1990, BIOPOLYMERS, V30, P1027, DOI 10.1002/bip.360301104; BRIN M, 1956, CANCER RES, V16, P364; BRINDLE KM, 1989, BIOCHEMISTRY-US, V28, P4887, DOI 10.1021/bi00437a054; BROWN GC, 1992, BIOCHEM J, V284, P1; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; CHICH JF, 1991, EUR J BIOCHEM, V196, P29, DOI 10.1111/j.1432-1033.1991.tb15781.x; COE EL, 1964, BIOCHIM BIOPHYS ACTA, V93, P209, DOI 10.1016/0304-4165(64)90287-9; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1980, J MEMBRANE BIOL, V53, P79, DOI 10.1007/BF01870576; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P279, DOI 10.1016/0005-2736(87)90456-1; COWLEY RC, 1980, J EXP BOT, V31, P199, DOI 10.1093/jxb/31.1.199; Crabtree HG, 1929, BIOCHEM J, V23, P536, DOI 10.1042/bj0230536; DAY DA, 1979, J EXP BOT, V30, P539, DOI 10.1093/jxb/30.3.539; DIHANICH M, 1987, EMBO J, V6, P723, DOI 10.1002/j.1460-2075.1987.tb04813.x; DOUCE R, 1973, BIOCHIM BIOPHYS ACTA, V292, P105, DOI 10.1016/0005-2728(73)90255-7; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; DOUCE R, 1986, BIOCHIM BIOPHYS ACTA, V850, P64, DOI 10.1016/0005-2728(86)90009-5; FEVRE F, 1993, J BIOENERG BIOMEMBR, V25, P55, DOI 10.1007/BF00768068; FROM AHL, 1990, BIOCHEMISTRY-US, V29, P3731, DOI 10.1021/bi00467a020; GEISBUHLER T, 1984, CIRC RES, V54, P536, DOI 10.1161/01.RES.54.5.536; GELLERICH FN, 1993, BIOCHIM BIOPHYS ACTA, V1142, P217, DOI 10.1016/0005-2728(93)90150-E; GELLERICH FN, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P349; GULLANS SR, 1984, J MEMBRANE BIOL, V78, P257, DOI 10.1007/BF01925973; GUO XJ, 1986, YEAST, V2, pS138; GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x; HAMPP R, 1984, PLANT PHYSIOL, V75, P1017, DOI 10.1104/pp.75.4.1017; HEBER UW, 1965, BIOCHIM BIOPHYS ACTA, V109, P390, DOI 10.1016/0926-6585(65)90166-4; Hille B, 1992, IONIC CHANNELS EXCIT, P291; HOLDEN MJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P396, DOI 10.1016/0005-2728(93)90126-Z; HOLDEN MJ, 1988, FEBS LETT, V241, P105, DOI 10.1016/0014-5793(88)81040-8; IBSEN KH, 1958, BIOCHIM BIOPHYS ACTA, V30, P384, DOI 10.1016/0006-3002(58)90064-7; ISBEN KH, 1971, ARCH BIOCHEM BIOPHYS, V143, P187, DOI 10.1016/0003-9861(71)90199-8; JOBSIS FF, 1967, J GEN PHYSIOL, V50, P1009, DOI 10.1085/jgp.50.4.1009; KATZ LA, 1989, AM J PHYSIOL, V256, pH265, DOI 10.1152/ajpheart.1989.256.1.H265; KATZ LA, 1987, FEBS LETT, V221, P270, DOI 10.1016/0014-5793(87)80939-0; KOOBS DH, 1972, SCIENCE, V178, P127, DOI 10.1126/science.178.4057.127; KRAMER R, 1982, BIOCHEMISTRY-US, V21, P1082; KRAMER R, 1980, BIOCHIM BIOPHYS ACTA, V592, P615, DOI 10.1016/0005-2728(80)90104-8; KROMER S, 1991, BIOCHIM BIOPHYS ACTA, V1057, P42, DOI 10.1016/S0005-2728(05)80082-9; LARDY HA, 1952, J BIOL CHEM, V195, P215; LIU MY, 1992, BIOCHIM BIOPHYS ACTA, V1098, P255, DOI 10.1016/S0005-2728(05)80344-5; MOLLER IM, 1981, PHYSIOL PLANTARUM, V53, P413, DOI 10.1111/j.1399-3054.1981.tb02724.x; MOLLER IM, 1981, BIOCHEM J, V194, P487, DOI 10.1042/bj1940487; MOLLER IM, 1986, ANNU REV PLANT PHYS, V37, P309, DOI 10.1146/annurev.arplant.37.1.309; MORIKOFERZWEZ S, 1989, BIOCHEM J, V259, P117; NEUBURGER M, 1985, PLANT PHYSIOL, V78, P405, DOI 10.1104/pp.78.2.405; NEUBURGER M, 1983, BIOCHEM J, V216, P443, DOI 10.1042/bj2160443; PALMER JM, 1982, TRENDS BIOCHEM SCI, V7, P258, DOI 10.1016/0968-0004(82)90039-1; PFAFF E, 1968, EUR J BIOCHEM, V5, P222, DOI 10.1111/j.1432-1033.1968.tb00361.x; PFAFF E, 1969, EUR J BIOCHEM, V10, P484, DOI 10.1111/j.1432-1033.1969.tb00715.x; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; RIMMER T, 1993, INVEST OPHTH VIS SCI, V34, P3246; ROTH K, 1991, MAGNET RESON MED, V22, P505, DOI 10.1002/mrm.1910220258; SAKS VA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P134, DOI 10.1016/0005-2728(93)90166-D; SAPICO V, 1972, BIOCHIM BIOPHYS ACTA, V258, P436, DOI 10.1016/0005-2744(72)90235-5; SCHWITZGUEBEL JP, 1984, PLANT PHYSIOL, V75, P670, DOI 10.1104/pp.75.3.670; SIES H, METABOLIC COMPARTMEN; SOBOLL S, 1978, EUR J BIOCHEM, V87, P377, DOI 10.1111/j.1432-1033.1978.tb12387.x; SU S, 1967, BIOCHIM BIOPHYS ACTA, V132, P370, DOI 10.1016/0005-2744(67)90156-8; TAGER JM, 1983, FEBS LETT, V151, P1, DOI 10.1016/0014-5793(83)80330-5; THIEFFRY M, 1992, BIOPHYS J, V63, P333, DOI 10.1016/S0006-3495(92)81626-0; TOBIN A, 1980, PLANT PHYSIOL, V66, P225, DOI 10.1104/pp.66.2.225; TYLER D, 1992, MITOCHONDRION HLTH D; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; VINK R, 1988, J BIOL CHEM, V263, P757; WAN B, 1993, AM J PHYSIOL, V265, pH453, DOI 10.1152/ajpheart.1993.265.2.H453; WERKHEISER WC, 1957, BIOCHEM J, V66, P79, DOI 10.1042/bj0660079; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; WOJTCZAK L, 1969, BIOCHIM BIOPHYS ACTA, V193, P64, DOI 10.1016/0005-2736(69)90059-5; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; ZIZI M, 1994, J BIOL CHEM, V269, P1614	80	117	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30974	30980						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983033				2022-12-25	WOS:A1994PV51000039
J	LO, ACY; HAASS, C; WAGNER, SL; TEPLOW, DB; SISODIA, SS				LO, ACY; HAASS, C; WAGNER, SL; TEPLOW, DB; SISODIA, SS			METABOLISM OF THE SWEDISH AMYLOID PRECURSOR PROTEIN VARIANT IN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; BETA-PROTEIN; PLASMA-MEMBRANES; EPITHELIAL-CELLS; CLEAVAGE SITE; PEPTIDE; IDENTIFICATION; SECRETION; SURFACE; PHOSPHORYLATION	The 4-kDa beta-amyloid peptide (A beta), a major constituent of parenchymal amyloid deposits in Alzheimer's disease, is derived from larger amyloid precursor proteins (APP). We have examined the metabolism of APP in Madin-Darby canine kidney cells stably transfected with cDNA encoding either wild-type human APP-695 or human APP-695 that harbors the Swedish double mutation associated with familial early-onset Alzheimer's disease. Although similar to 90% of total soluble APP secreted from wild-type cells is secreted basolaterally following cleavage at the alpha-secretase site, soluble derivatives cleaved near or at the amino terminus of A beta (presumably the ''beta-secretase'' site) are preferentially secreted into the apical compartment of SWE cells. Concomitantly, levels of a specific A beta-containing carboxyl-terminal fragment are elevated in SWE cell lysates. Using domain-specific biotinylation and release assays, we failed to detect a beta-secretase-generated soluble derivative (APP(s beta)) released from the surface of SWE cells. However, APP(s beta) can be detected in SWE cell lysates, consistent with ''beta-secretase'' cleavage occurring in an intracellular compartment. Finally, we demonstrate that A beta is secreted into the basolateral compartment of SWE cells and that the majority of these A beta-related species contains an aminoterminal aspartate residue (+1).	JOHNS HOPKINS UNIV, SCH MED, NEUROPATHOL LAB, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, CTR NEUROL DIS, BOSTON, MA 02115 USA; IND ASSOCIATES INC, SALK INST BIOTECHNOL, LA JOLLA, CA 92037 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Salk Institute			Lo, Amy C. Y./C-1195-2009	Lo, Amy C. Y./0000-0003-4239-6851	NIA NIH HHS [AG 05146] Funding Source: Medline; NINDS NIH HHS [NS 20471] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS020471, P50NS020471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FELSENSTEIN KM, 1994, NAT GENET, V6, P251, DOI 10.1038/ng0394-251; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; HILBICH C, 1993, J BIOL CHEM, V268, P26571; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.physiol.51.1.755; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; MARTIN LJ, 1991, P NATL ACAD SCI USA, V88, P1461, DOI 10.1073/pnas.88.4.1461; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MORIN PJ, 1993, J NEUROCHEM, V61, P464; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRICE DL, 1994, ANNU REV MED, V45, P435; PROBST A, 1991, ACTA NEUROPATHOL, V83, P21, DOI 10.1007/BF00294426; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELKOE DJ, 1987, SCIENCE, V235, P873, DOI 10.1126/science.3544219; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIEMERS KA, 1993, SCIENCE, V260, P554, DOI 10.1126/science.260.5107.554; SISODIA S S, 1990, New Biologist, V2, P66; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SUZUKI T, 1992, NEUROSCIENCE, V48, P755, DOI 10.1016/0306-4522(92)90264-3; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1989, NATURE, V341, P546; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WEISZ OA, 1992, J BIOL CHEM, V267, P22282	53	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30966	30973						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983032				2022-12-25	WOS:A1994PV51000038
J	OKAMURA, S; YAMASHITA, S				OKAMURA, S; YAMASHITA, S			PURIFICATION AND CHARACTERIZATION OF PHOSPHATIDYLCHOLINE PHOSPHOLIPASE-D FROM PIG LUNG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MOLECULAR-SPECIES ANALYSIS; EPIDERMAL GROWTH-FACTOR; RAT-BRAIN; D ACTIVATION; LYSOPHOSPHATIDIC ACID; HUMAN-NEUTROPHILS; KINETIC-ANALYSIS; ALPHA-THROMBIN; PHOSPHATIDATE PHOSPHOHYDROLASE	Phospholipase D, which mediates phosphatidylcholine hydrolysis in response to agonist stimulation, is an important component of signal transduction. We now report the purification of this enzyme to homogeneity from pig lung microsomes. The enzyme was solubilized with heptylthioglucoside and purified 2,200-fold by successive chromatography on sulfate-Cellulofine, ether-Toyopearl, chelate-Toyopearl, Q-Sepharose, heparin-Toyopearl, and hydroxyapatite. The final enzyme preparation gave a single protein band of M(r) = 190,000 on SDS-polyacrylamide gel electrophoresis. The enzyme hydrolyzed phosphatidylcholine but not lysophosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol. Optimum pH was 6.6. Half-maximal activity was obtained at 0.8 mM dipalmitoylglycerophosphocholine. The products were identified as phosphatidic acid and choline, but in the presence of ethanol, phosphatidylethanol was produced at the expense of phosphatidic acid. Ethanolamine and serine were not utilized as the phosphatidyl acceptor. Although not obligatory Ca2+ and Mg2+ were stimulatory at high concentrations. The enzyme was markedly stimulated by unsaturated fatty acids in the presence of Mg2+ but not in its absence or by saturated fatty acids. N-Ethylmaleimide and detergents were inhibitory. Sucrose monolaurate had an aberrant effect on enzyme activity.	GUNMA UNIV,SCH MED,DEPT BIOCHEM,MAEBASHI,GUMMA 371,JAPAN	Gunma University								ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BALSINDE J, 1989, EUR J BIOCHEM, V186, P717, DOI 10.1111/j.1432-1033.1989.tb15265.x; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; CHALIFOUR R, 1982, J NEUROCHEM, V39, P299, DOI 10.1111/j.1471-4159.1982.tb03946.x; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; GENY B, 1993, EUR J BIOCHEM, V215, P389, DOI 10.1111/j.1432-1033.1993.tb18045.x; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; GROVE RI, 1982, BIOCHIM BIOPHYS ACTA, V711, P272, DOI 10.1016/0005-2760(82)90036-4; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; GUSTAVSSON L, 1987, BIOCHEM BIOPH RES CO, V142, P958, DOI 10.1016/0006-291X(87)91507-5; GUY GR, 1983, CANCER RES, V43, P5564; HARRIS WE, 1992, BIOCHEM J, V281, P675, DOI 10.1042/bj2810675; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HOLBROOK PG, 1992, J BIOL CHEM, V267, P16834; HORWITZ J, 1993, BIOCHEM J, V295, P793, DOI 10.1042/bj2950793; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUANG R, 1991, J BIOL CHEM, V266, P1652; KANAHO Y, 1992, J IMMUNOL, V149, P622; KANFER JN, 1972, J LIPID RES, V13, P468; KANOH H, 1992, J BIOL CHEM, V267, P25309; KANOH H, 1991, LIPIDS, V26, P426, DOI 10.1007/BF02536068; KHAN WA, 1994, J BIOL CHEM, V269, P9729; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1991, J BIOL CHEM, V266, P3215; MIZUNUMA M, 1993, BIOCHIM BIOPHYS ACTA, V1168, P213; MOTOZAKI T, 1989, J BIOL CHEM, V264, P14729; MURRAY JJ, 1990, BIOCHEM J, V270, P63, DOI 10.1042/bj2700063; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKASHIMA S, 1991, BIOCHEM J, V275, P355, DOI 10.1042/bj2750355; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON SC, 1991, J BIOL CHEM, V266, P17236; OSADA S, 1992, FEBS LETT, V297, P271, DOI 10.1016/0014-5793(92)80554-T; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; QIAN Z, 1990, J BIOL CHEM, V265, P3607; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SHIMAMOTO T, 1985, J BIOCHEM-TOKYO, V97, P1807, DOI 10.1093/oxfordjournals.jbchem.a135240; SIDDIQUI RA, 1992, EUR J BIOCHEM, V210, P601, DOI 10.1111/j.1432-1033.1992.tb17460.x; SMITH SW, 1957, J BIOL CHEM, V228, P915; TAKI T, 1979, J BIOL CHEM, V254, P9761; THOMPSON W, 1964, BIOCHEM J, V91, P233, DOI 10.1042/bj0910233; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; WANG P, 1991, J BIOL CHEM, V266, P14877; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	66	140	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31207	31213						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983063				2022-12-25	WOS:A1994PV51000072
J	SHENG, SJ; PEMBERTON, PA; SAGER, R				SHENG, SJ; PEMBERTON, PA; SAGER, R			PRODUCTION, PURIFICATION, AND CHARACTERIZATION OF RECOMBINANT MASPIN PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; ESCHERICHIA-COLI; BINDING; ALPHA-1-ANTITRYPSIN; PAI-1	Maspin, a novel mammary serine protease inhibitor, was shown to have tumor suppressing activity (Zou, Z., Anisowicz, A., Hendrix, M. J. C., Thor, A., Neveu, M., Sheng, S., Rafidi, K., Seftor, E., and Sager, R. (1994) Science 263, 526-529). In this paper, we report the production of recombinant glutathione S-transferase-maspin fusion protein, expressed in the bacterium Escherichia coli, and recombinant maspin, expressed in the insect Spodoptera frugiperda cells. The fusion protein was purified by glutathione affinity chromatography. Maspin expressed in insect cells was purified by a combination of Bio-Rad AG1-2X anion exchange chromatography and heparin affinity chromatography. The recombinant maspin from insect cells was cleaved at the putative reactive center, as confirmed by protein sequencing. Both recombinant proteins demonstrated strong inhibitory effects on the invasion by two breast tumor cell lines across reconstituted basement membranes and such inhibitory effect was abolished in the presence of the polyclonal antibody made against the reactive center region of maspin. The trypsin-cleaved recombinant maspin did not inhibit invasion, indicating that the inhibitory activity requires the intact putative reactive center. This paper provides evidence that recombinant maspin protein itself inhibits invasion, and supports the role of maspin as a tumor suppressor.	LXR BIOTECHNOL INC,RICHMOND,CA 94804; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC GENET,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; GANESH S, 1994, CANCER RES, V54, P4065; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI, P34; HARLOW E, 1988, ANTIBODIES LAB MANUA, P585; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JANICKE F, 1993, BREAST CANCER RES TR, V24, P195, DOI 10.1007/BF01833260; JAY GD, 1990, ANAL BIOCHEM, V185, P324, DOI 10.1016/0003-2697(90)90302-P; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; Sambrook J, 1989, MOL CLONING LABORATO; SISK WP, 1990, GENE, V96, P305, DOI 10.1016/0378-1119(90)90269-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOLLEFSEN DM, 1986, J BIOL CHEM, V261, P8854; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	20	150	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30988	30993						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983035				2022-12-25	WOS:A1994PV51000041
J	RIETHMACHER, D; LANGHOLZ, O; GODECKE, S; SACHS, M; BIRCHMEIER, C				RIETHMACHER, D; LANGHOLZ, O; GODECKE, S; SACHS, M; BIRCHMEIER, C			BIOCHEMICAL AND FUNCTIONAL-CHARACTERIZATION OF THE MURINE ROS PROTOONCOGENE	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; MOUSE MYELOID CELLS; I CSF-1 RECEPTOR; SEVENLESS PROTEIN; HEMATOPOIETIC-CELLS; EGF RECEPTOR; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; SIGNAL TRANSDUCTION	The ros gene was originally found because it can, when mutated, induce malignant transformation. The proto-oncogene encodes an orphan receptor tyrosine kinase. We report here the isolation and characterization of the mouse c-ros cDNA and, in addition, the biochemical characterization of the receptor. Both, the endogenous c-ros protein from embryonal tissues and the recombinant protein are glycosylated molecules with an apparent molecular weight of 260 000. Pulse-chase analysis in Sf9 cells demonstrates that the c-ros protein is synthesized as a single chain, uncleaved molecule. Since the specific ligand of c-ros is not known, a hybrid receptor (trk/c-ros) which transmits c-ros-specific signals in response to nerve growth factor (NGF) was used to study the biological activities. In NIH3T3 cells, this trk/c-ros hybrid induces growth, a fusiform cell shape, and loss of contact inhibition of growth. However, the active hybrid receptor cannot replace IL-3 as survival factor in 32D myeloid cells. Compared to other receptors, the active c-ros tyrosine kinase domain displays thus overlapping, but not identical signalling specificities.	MAX PLANCK GESELL,MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY; MAX DELBRUCK CENTRUM MOLEK MED,D-13122 BERLIN,GERMANY	Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Riethmacher, Dieter/A-6242-2010; Riethmacher, Dieter/AAP-2227-2021; Riethmacher, Dieter/AAB-8690-2022	Riethmacher, Dieter/0000-0002-4206-5529; 				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASLER K, 1988, CELL, V54, P299; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BIRCHMEIER C, 1993, BIOESSAYS, V15, P185, DOI 10.1002/bies.950150307; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BIRCHMEIER C, 1987, P NATL ACAD SCI USA, V84, P9270, DOI 10.1073/pnas.84.24.9270; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; CHEN JM, 1991, ONCOGENE, V6, P257; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HARLOW E, 1988, ANTIBODIES LABORATOR; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HSIEH P, 1984, J BIOL CHEM, V259, P2375; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KATO JY, 1990, BLOOD, V75, P1780; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; KATZAV S, 1989, ONCOGENE, V4, P1129; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1994, MOL CELL BIOL, V13, P663; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SHARMA S, 1989, ONCOGENE RES, V5, P91; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; SUMMERS M, 1987, TEX AGR EP STN B, V1555; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILKS AF, 1993, ADV CANCER RES, V60, P43; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; ZONG CS, 1993, J VIROL, V67, P6453, DOI 10.1128/JVI.67.11.6453-6462.1993	62	20	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3617	3626						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970722				2022-12-25	WOS:A1994PT39200025
J	ERMOLIEFF, J; BOUDIER, C; LAINE, A; MEYER, B; BIETH, JG				ERMOLIEFF, J; BOUDIER, C; LAINE, A; MEYER, B; BIETH, JG			HEPARIN PROTECTS CATHEPSIN-G AGAINST INHIBITION BY PROTEIN PROTEINASE-INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; HUMAN-SERUM ALPHA-1-ANTICHYMOTRYPSIN; MOLECULAR-WEIGHT HEPARIN; ALPHA-1-PROTEINASE INHIBITOR; NEUTROPHIL ELASTASE; EGLIN-C; GRANULOCYTIC ELASTASE; PANCREATIC ELASTASE; CRYSTAL-STRUCTURE; CHYMOTRYPSIN-LIKE	Cathepsin G, a cationic serine proteinase present in neutrophils and monocytes, is able to cleave biologically important proteins and may thus participate in tissue destruction during inflammation. Its activity is physiologically controlled by the fast-acting serpins, alpha(1),-antichymotrypsin (k(a) = 5 x 10(7) M(-1) s(-1)) and alpha(1)-proteinase inhibitor (k(a) = 2.7 x 10(5) M(-1) s(-1)). We have shown that cathepsin G forms a tightly bound 1:1 complex with a 5-kDa heparin fragment (K-d = 1.9 x 10(-8) M). The partial enzymatic activity retained by this complex is inhibited extremely slowly by the above 68- and 53-kDa serpins. The activity of the complex is also virtually resistant to inhibition by eglin c, an 8-kDa non-serpin inhibitor. A detailed kinetic investigation showed that the inhibition of heparin-bound cathepsin G by the three proteins proceeded via a two step mechanism. GRAPHICS MECHANISM 1 The three inhibitors have widely different K-i* values (0.18-13 mu M) (K-i* = k(-1)/k(1)). Their isomerization constants k, are, however, all in the same range and their extremely low values (0.7-3 ms(-1)) account for the very low rate of cathepsin G inhibition. The second order inhibition rate constants k(2)/K-i* were 4300, 700, and 52 M(-1) s(-1) for alpha(1)-antichymotrypsin, alpha(1)-antitrypsin, and eglin c, respectively, indicating that, if heparin is present in vivo, the two former physiological inhibitors will be unable to prevent cathepsin G-mediated proteolysis. Neutrophil elastase binds the 5-kDa heparin fragment with an affinity identical to that of cathepsin G.alpha(1)-Proteinase inhibitor reacts, however, much faster with heparin elastase (k(a) = 1.8 x 10(6) M(-1) s(-1)) than with heparincathepsin G (k(2)/K-i* = 700 M(-1) s(-1)).	INSERM,U377,BIOL & PHYSIOPATHOL CELLULES MUCIPARES LAB,F-59045 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	ERMOLIEFF, J (corresponding author), UNIV LOUIS PASTEUR STRASBOURG 1,INSERM,U392,ENZYMOL LAB,F-67400 ILLKIRCH GRAFFENS,FRANCE.		Boudier, Christian/N-3841-2018	Boudier, Christian/0000-0002-5534-6389				ABDULLAH M, 1983, ARCH BIOCHEM BIOPHYS, V225, P306, DOI 10.1016/0003-9861(83)90034-6; ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ALBERTY RA, 1958, J PHYS CHEM-US, V62, P154, DOI 10.1021/j150560a005; BAICI A, 1984, BIOCHEM J, V218, P829, DOI 10.1042/bj2180829; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BEATTY K, 1980, J BIOL CHEM, V255, P3931; Bieth JG, 1986, REGULATION MATRIX AC, P217; BOTTS J, 1953, T FARADAY SOC, V49, P696, DOI 10.1039/tf9534900696; BRAUN NJ, 1987, BIOL CHEM H-S, V368, P299, DOI 10.1515/bchm3.1987.368.1.299; BRUCH M, 1986, BIOCHEM J, V238, P269, DOI 10.1042/bj2380269; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CAMPBELL EJ, 1988, J CELL BIOL, V106, P667, DOI 10.1083/jcb.106.3.667; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHA S, 1976, BIOCHEM PHARMACOL, V25, P1561; CHARNEY J, 1947, J BIOL CHEM, V171, P501; DANISHEFSKY I, 1979, BIOCHEM BIOPH RES CO, V91, P862, DOI 10.1016/0006-291X(79)91959-4; DUSWALD KH, 1985, SURGERY, V98, P892; EGBRING R, 1977, BLOOD, V49, P219; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; EVANGELISTA V, 1993, BLOOD, V81, P2947; FABER JP, 1993, J HEPATOL, V18, P313, DOI 10.1016/S0168-8278(05)80275-2; FALLER B, 1992, BIOCHEMISTRY-US, V31, P8285, DOI 10.1021/bi00150a023; FALLER B, 1991, BIOCHEM J, V280, P27, DOI 10.1042/bj2800027; FALLER B, 1993, BIOCHEMISTRY-US, V32, P9230, DOI 10.1021/bi00086a031; FALLER B, 1990, BIOCHEM J, V270, P639, DOI 10.1042/bj2700639; FERRERLOPEZ P, 1990, AM J PHYSIOL, V258, pC1100, DOI 10.1152/ajpcell.1990.258.6.C1100; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; HACHULLA E, 1988, CLIN CHEM, V34, P911; HIRSH J, 1992, BLOOD, V79, P1; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JANOFF A, 1983, AM REV RESPIR DIS, V127, P531; JANUSZ MJ, 1991, J IMMUNOL, V146, P3922; LAINE A, 1981, BIOCHIM BIOPHYS ACTA, V668, P429, DOI 10.1016/0005-2795(81)90177-X; LAINE A, 1985, EUR J BIOCHEM, V151, P327, DOI 10.1111/j.1432-1033.1985.tb09104.x; LAINE A, 1982, BIOCHEM BIOPH RES CO, V105, P186, DOI 10.1016/S0006-291X(82)80029-6; LAINE A, 1984, EUR J BIOCHEM, V140, P105, DOI 10.1111/j.1432-1033.1984.tb08072.x; LAMBIN P, 1984, ADV EXP MED BIOL, V167, P263; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MAROSSY K, 1981, BIOCHIM BIOPHYS ACTA, V659, P351, DOI 10.1016/0005-2744(81)90061-9; MARTODAM RR, 1979, PREP BIOCHEM, V9, P15, DOI 10.1080/00327487908061669; MILLER KW, 1989, J BACTERIOL, V171, P2166, DOI 10.1128/jb.171.4.2166-2172.1989; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; POWERS JC, 1984, J BIOL CHEM, V259, P4288; PRATT CW, 1990, J BIOL CHEM, V265, P6092; REDINI F, 1988, BIOCHEM J, V252, P515, DOI 10.1042/bj2520515; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHONBAUM G, 1961, J BIOL CHEM, V236, P2930; SCHRADER J, 1985, KIDNEY INT, V28, P823, DOI 10.1038/ki.1985.204; SEEMULLER U, 1977, H-S Z PHYSIOL CHEM, V358, P1105, DOI 10.1515/bchm2.1977.358.2.1105; SELAK MA, 1988, BIOCHEM J, V251, P293, DOI 10.1042/bj2510293; SIDDIQUI AA, 1980, BIOCHEM BIOPH RES CO, V95, P1737, DOI 10.1016/S0006-291X(80)80099-4; STENMAN UH, 1991, CANCER RES, V51, P222; SZEDLACSEK SE, 1988, BIOCHEM J, V254, P311, DOI 10.1042/bj2540311; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRAVIS J, 1978, BIOCHEMISTRY-US, V17, P5651, DOI 10.1021/bi00619a011; TSUDA M, 1986, CANCER RES, V46, P6136; Williams J W, 1979, Methods Enzymol, V63, P437; WINTROUB BU, 1984, BIOCHEMISTRY-US, V23, P227, DOI 10.1021/bi00297a009	62	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29502	29508						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961933				2022-12-25	WOS:A1994PU28400032
J	ESTEBAN, LM; FUJIMURA, T; GARCIACUELLAR, MP; ESTEBAN, R				ESTEBAN, LM; FUJIMURA, T; GARCIACUELLAR, MP; ESTEBAN, R			ASSOCIATION OF YEAST VIRAL 23 S RNA WITH ITS PUTATIVE RNA-DEPENDENT RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; SACCHAROMYCES-CEREVISIAE; POSITIVE-STRAND; 20-S RNA; 20S RNA; VIRUS; GENES; IDENTIFICATION; ANTIGEN; BINDING	T double-stranded RNA (dsRNA) and its single-stranded RNA (ssRNA) counterpart, 23 S RNA, are present in some strains of the yeast Saccharomyces cerecisiae. 23 S RNA is identical with the T (+)-strand, and both are cytoplasmically inherited. The T (+)-strand encodes a protein of 104 kilodaltons (kDa) (p104) that has sequences diagnostic of RNA-dependent RNA polymerases from (+)-strand and double-stranded RNA viruses. Here we show that p104 is expressed only in yeast strains carrying T dsRNA (and 23 S RNA) and that the ability to produce p104 is co-transmitted from one strain to another by cytoplasmic mixing (cytoduction) along with T dsRNA. Neither T nor 23 S RNA is encapsidated into viral particles; however, the latter was found to be noncovalently associated with p104. This finding was based on the evidence that: (i) both 23 S RNA and p104 co-sedimented in sucrose gradients and that (ii) 23 S RNA was immunoprecipitated by a p104-specific polyclonal antiserum. Consistent with this association, p104 shows single-stranded RNA-binding activity in Northwestern blots. We have localized the RNA-binding domain of p104 within its C terminus 234 amino acids.	UNIV SALAMANCA,CSIC,INST MICROBIOL BIOQUIM,DEPT GENET & MICROBIOL,E-37071 SALAMANCA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca			Fujimura, Tsutomu/K-5807-2014; Esteban, Rosa/K-4356-2014	Fujimura, Tsutomu/0000-0002-9457-6769; Esteban, Rosa/0000-0001-6804-7209				ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BEALL JA, 1986, J IMMUNOL METHODS, V86, P217, DOI 10.1016/0022-1759(86)90456-4; BRUENN JA, 1991, NUCLEIC ACIDS RES, V19, P217, DOI 10.1093/nar/19.2.217; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; ESTEBAN LM, 1992, J BIOL CHEM, V267, P10874; ESTEBAN R, 1993, PROG NUCLEIC ACID RE, V46, P155, DOI 10.1016/S0079-6603(08)61021-1; ESTEBAN R, 1986, MOL CELL BIOL, V6, P1552, DOI 10.1128/MCB.6.5.1552; FRIED HM, 1978, P NATL ACAD SCI USA, V75, P4224, DOI 10.1073/pnas.75.9.4224; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; ICHO T, 1989, J BIOL CHEM, V264, P6716; KADOWAKI K, 1971, J BACTERIOL, V105, P831, DOI 10.1128/JB.105.3.831-836.1971; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; Koonin EV, 1992, SEMIN VIROL, V3, P327; KROGSTAD PA, 1990, J VIROL, V64, P2796, DOI 10.1128/JVI.64.6.2796-2801.1990; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LAZINSKI DW, 1993, J VIROL, V67, P2672, DOI 10.1128/JVI.67.5.2672-2680.1993; LEE CZ, 1993, J VIROL, V67, P2221, DOI 10.1128/JVI.67.4.2221-2227.1993; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; MATSUMOTO Y, 1991, J BIOL CHEM, V266, P12779; Matthews REF., 2002, PLANT VIROLOGY; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; ROSE M, 1981, P NATL ACAD SCI-BIOL, V78, P2460, DOI 10.1073/pnas.78.4.2460; Sambrook J, 1989, MOL CLONING LABORATO; SOMMER SS, 1982, CELL, V31, P429, DOI 10.1016/0092-8674(82)90136-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOHE A, 1980, J BACTERIOL, V141, P413, DOI 10.1128/JB.141.1.413-416.1980; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; WICKNER RB, 1978, GENETICS, V88, P419; WICKNER RB, 1994, IN PRESS MYCOTA, V3; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905	39	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29771	29777						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961969				2022-12-25	WOS:A1994PU28400072
J	LANGE, Y; STECK, TL				LANGE, Y; STECK, TL			CHOLESTEROL HOMEOSTASIS - MODULATION BY AMPHIPHILES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMA-MEMBRANE CHOLESTEROL; LEYDIG TUMOR-CELLS; ACYL-COENZYME-A; HUMAN-FIBROBLASTS; REDUCTASE-ACTIVITY; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; INTRACELLULAR CHOLESTEROL; MULTIDRUG-RESISTANCE; PROGESTERONE; SUBSTRATE	Diverse amphiphiles act on cellular cholesterol metabolism as if signaling regulatory sites. One class (oxysterols) mimics the homeostatic effects of excess cell cholesterol, inhibiting cholesterol biosynthesis and stimulating plasma membrane cholesterol esterification. A second class of amphiphiles has effects precisely opposite to the oxysterols, i.e. they immediately inhibit plasma membrane cholesterol esterification and progressively induce 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and cholesterol biosynthesis. This second class of agents includes steroids, hydrophobic amines, phenothiazines, ionophores, colchicine, cytochalasins, and lysophosphatides, most of which interact with P-glycoproteins. These data support a general hypothesis describing cellular cholesterol homeostasis. (a) Proteins regulating sterol metabolism are embedded in intracellular membranes where their activities are governed by the local level of cholesterol. (b) Excess plasma membrane and lysosomal cholesterol circulates through those intracellular membranes and sets the homeostatic activities therein. (c) The two classes of agents mentioned above affect cholesterol homeostasis by increasing or decreasing, respectively, the ambient level of cholesterol at the sites of regulation.	RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT BIOCHEM,CHICAGO,IL 60612; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	Rush University; University of Chicago	LANGE, Y (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PATHOL,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.		Lange, Yvonne/A-7794-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028448, R55HL028448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047282] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28448] Funding Source: Medline; NIGMS NIH HHS [GM47282] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL JJ, 1976, J BIOL CHEM, V251, P1745; BROWN MS, 1973, P NATL ACAD SCI USA, V70, P2162, DOI 10.1073/pnas.70.7.2162; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CARLSON JC, 1983, ENDOCRINOLOGY, V113, P190, DOI 10.1210/endo-113-1-190; COK SJ, 1993, THESIS U CHICAGO; DAHL NK, 1993, J BIOL CHEM, V268, P16979; DASHTI N, 1992, J BIOL CHEM, V267, P7160; DEBRY PW, 1994, CLIN RES, V42, pA85; DREVON CA, 1980, J BIOL CHEM, V255, P9128; FIELDING CJ, 1985, BIOCH LIPIDS MEMBRAN, P404; FORD JM, 1990, PHARMACOL REV, V42, P155; FREEMAN DA, 1989, ENDOCRINOLOGY, V124, P2527, DOI 10.1210/endo-124-5-2527; FURUCHI T, 1993, J BIOL CHEM, V268, P27345; GADDUM JH, 1957, PHARMACOL REV, V9, P211; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HARMALA AS, 1994, BBA-LIPID LIPID MET, V1211, P317, DOI 10.1016/0005-2760(94)90156-2; IIDA S, 1989, ENDOCRINOLOGY, V124, P2619, DOI 10.1210/endo-124-5-2619; KODAVANTI UP, 1990, PHARMACOL REV, V42, P327; LANGE Y, 1992, J LIPID RES, V33, P315; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LANGE Y, 1991, J LIPID RES, V32, P329; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LISCUM L, 1992, J LIPID RES, V33, P1239; LISCUM L, 1989, J BIOL CHEM, V264, P11796; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; METHERALL JE, 1991, J BIOL CHEM, V266, P12734; MILLER SC, 1984, J LIPID RES, V25, P991; MOHANDAS N, 1978, J SUPRAMOL STR CELL, V9, P453, DOI 10.1002/jss.400090315; MURPHY BD, 1989, OXFORD REV REPROD B, V11, P179; NAGY L, 1990, ENDOCRINOLOGY, V126, P2267, DOI 10.1210/endo-126-5-2267; NAGY L, 1990, BIOCHEM J, V271, P809, DOI 10.1042/bj2710809; OKWU AK, 1994, J LIPID RES, V35, P644; OMKUMAR RV, 1994, J BIOL CHEM, V269, P6810; PANINI SR, 1987, J BIOL CHEM, V262, P14435; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; SAEKI T, 1992, BIOCHIM BIOPHYS ACTA, V1107, P105, DOI 10.1016/0005-2736(92)90334-I; STRAKA MS, 1990, J BIOL CHEM, V265, P7145; TABAS I, 1988, J BIOL CHEM, V263, P1266; TSURUO T, 1991, MOL CELLULAR BIOL MU, P349; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; XU XX, 1991, J BIOL CHEM, V266, P17040	44	114	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29371	29374						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961912				2022-12-25	WOS:A1994PU28400010
J	LIU, NG; FINE, RE; SIMONS, E; JOHNSON, RJ				LIU, NG; FINE, RE; SIMONS, E; JOHNSON, RJ			DECREASING CALRETICULIN EXPRESSION LOWERS THE CA2+ RESPONSE TO BRADYKININ AND INCREASES SENSITIVITY TO IONOMYCIN IN NG-108-15 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; MUSCLE SARCOPLASMIC-RETICULUM; GLIOMA HYBRID-CELLS; INOSITOL PHOSPHATES; BOVINE BRAIN; CA-2+ STORE; SEQUENCE; IDENTIFICATION; ACTIVATION; INVITRO	It has been suggested that the multifunctional protein, calreticulin, is a major calcium sequestering protein in the inositol 1,4,5-trisphosphate receptor-containing endoplasmic reticulum subcompartment. In neuroblastoma X glioma NG-108-15 cells, bradykinin can effectively stimulate the release of inositol 1,4,5-trisphosphate and cause a cytosolic calcium transient. To explore the function of calreticulin as an intracellular calcium sequestering protein, we investigated calcium dynamics in NG-108-15 cells after treatment with an antisense oligonucleotide against calreticulin, CrtAS1. Cells treated with either CrtAS1 or the corresponding sense oligonucleotide CrtPS1 were examined for their calreticulin content by Western blotting, the amplitude of their calcium transient in response to bradykinin, and their sensitivity toward the calcium ionophore, ionomycin. Treatment with CrtAS1 decreased the amount of calreticulin in comparison to CrtPS1-treated and untreated control cells. At the same time, CrtAS1-treated cells had a significantly reduced calcium response to bradykinin and were more sensitive to ionomycin-induced cell death. These data show that the level of calreticulin expression is directly related to the calcium storage capacity of the inositol 1,4,5-trisphosphate-sensitive calcium pool and indicate a direct relationship between the level of calreticulin and the protection against cytotoxic calcium overload.	BOSTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,BOSTON,MA 02118; EDITH NOURSE ROGERS MEM VET ADM HOSP,BEDFORD,MA 01730	Boston University	LIU, NG (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOCHEM,K-122,80 E CONCORD ST,BOSTON,MA 02118, USA.				NATIONAL INSTITUTE ON AGING [R37AG005894] Funding Source: NIH RePORTER; NIA NIH HHS [AG-00115, R37 AG-05894] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKSH S, 1991, J BIOL CHEM, V266, P21458; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BORENFREUND E, 1985, TOXICOL LETT, V24, P119, DOI 10.1016/0378-4274(85)90046-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DA, 1988, J PHYSIOL-LONDON, V397, P167, DOI 10.1113/jphysiol.1988.sp016994; BROWN DA, 1988, J PHYSIOL-LONDON, V397, P149, DOI 10.1113/jphysiol.1988.sp016993; BURNS K, 1992, J BIOL CHEM, V267, P19039; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; Burns Kimberly, 1994, Trends in Cell Biology, V4, P152, DOI 10.1016/0962-8924(94)90190-2; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; DAVIES TA, 1991, J NUTR BIOCHEM, V2, P102, DOI 10.1016/0955-2863(91)90038-7; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; Engvall E, 1980, Methods Enzymol, V70, P419; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FRANDSEN A, 1992, P NATL ACAD SCI USA, V89, P2590, DOI 10.1073/pnas.89.7.2590; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JACKSON TR, 1987, EMBO J, V6, P49, DOI 10.1002/j.1460-2075.1987.tb04717.x; JOHNSON RJ, 1992, MOL BRAIN RES, V12, P69, DOI 10.1016/0169-328X(92)90069-N; KRAUSE KH, 1990, BIOCHEM J, V270, P545, DOI 10.1042/bj2700545; LENGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; LIU N, 1993, BIOCHIM BIOPHYS ACTA, V1202, P70, DOI 10.1016/0167-4838(93)90064-X; LO TM, 1993, AM J PHYSIOL, V264, pC641, DOI 10.1152/ajpcell.1993.264.3.C641; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1991, J BIOL CHEM, V266, P7155; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; REISER G, 1990, EXP CELL RES, V186, P47, DOI 10.1016/0014-4827(90)90208-R; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; WILKBLASZCZAK MA, 1994, NEURON, V12, P109, DOI 10.1016/0896-6273(94)90156-2	32	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28635	28639						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961812				2022-12-25	WOS:A1994PU16800021
J	POLLESELLO, P; OVASKA, M; KAIVOLA, J; TILGMANN, C; LUNDSTROM, K; KALKKINEN, N; ULMANEN, I; NISSINEN, E; TASKINEN, J				POLLESELLO, P; OVASKA, M; KAIVOLA, J; TILGMANN, C; LUNDSTROM, K; KALKKINEN, N; ULMANEN, I; NISSINEN, E; TASKINEN, J			BINDING OF A NEW CA2+ SENSITIZER, LEVOSIMENDAN, TO RECOMBINANT HUMAN CARDIAC TROPONIN-C - A MOLECULAR MODELING, FLUORESCENCE PROBE, AND PROTON NUCLEAR-MAGNETIC-RESONANCE STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOL-O-METHYLTRANSFERASE; SKELETAL-MUSCLE; CONFORMATIONAL TRANSITION; ESCHERICHIA-COLI; CALCIUM-BINDING; TERMINAL DOMAIN; DISULFIDE BOND; RAT-LIVER; PROTEINS; PURIFICATION	The binding of a new calcium sensitizer, levosimendan, to human cardiac troponin C (cTnC) is described. Fluorescence studies done on dansylated recombinant human cTnC and a site-directed mutant showed that levosimendan modulated the calcium-induced conformational change in cTnC, and revealed the role of Asp-88 in the binding of the drug to the NH2-terminal domain of cTnC. Furthermore, NMR studies performed on the NH2-terminal fragment of cTnC showed a spatial proximity between levosimendan and Met(81), Met(85), and Phe(77) in the drug-protein complex. These data were used to build an optimized model of the drug protein complex, in which levosimendan binds cTnC at the hydrophobic pocket of the NH2 terminal domain. The role of the binding of levosimendan to cTnC in the pharmacological action of this drug in vivo is discussed.	UNIV HELSINKI,INST BIOTECHNOL,SF-00014 HELSINKI,FINLAND	University of Helsinki	POLLESELLO, P (corresponding author), ORION CORP,ORION FARMOS,ORION RES,CHEM RES DEPT,POB 65,SF-02101 ESPOO,FINLAND.		Kalkkinen, Nisse EJ/B-3923-2010	Tilgmann, Carola/0000-0001-6241-2359; pollesello, piero/0000-0001-6994-768X				BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BLANCHARD EM, 1984, CIRC RES, V55, P382, DOI 10.1161/01.RES.55.3.382; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P10236, DOI 10.1021/bi00106a023; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DRABIKOWSKI W, 1985, EUR J BIOCHEM, V151, P17, DOI 10.1111/j.1432-1033.1985.tb09063.x; EVANS JS, 1980, BIOCHIM BIOPHYS ACTA, V623, P10, DOI 10.1016/0005-2795(80)90003-3; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; Geguchadze R N, 1990, Biomed Sci, V1, P37; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUSEV NB, 1991, J BIOL CHEM, V266, P16622; HAIKALA H, 1992, Journal of Molecular and Cellular Cardiology, V24, pS260; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HERZIG JW, 1992, Z KARDIOL, V81, P49; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOLROYDE MJ, 1979, BIOCHIM BIOPHYS ACTA, V586, P63, DOI 10.1016/0304-4165(79)90405-7; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; KALKKINEN N, 1988, J PROTEIN CHEM, V7, P242; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEE JA, 1990, BRIT MED J, V300, P551, DOI 10.1136/bmj.300.6724.551; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; LUNDSTROM K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P149, DOI 10.1016/0167-4781(92)90479-J; LUNDSTROM K, 1991, SITE-DIRECTED MUTAGENESIS AND PROTEIN ENGINEERING, P119; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9754; OVASKA M, 1991, PROTEINS, V11, P79, DOI 10.1002/prot.340110202; OVASKA M, 1992, Journal of Molecular and Cellular Cardiology, V24, pS260; PARMACEK MS, 1991, CIRCULATION, V84, P991, DOI 10.1161/01.CIR.84.3.991; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; STEVENSON WG, 1989, AM HEART J, V118, P1182, DOI 10.1016/0002-8703(89)90007-0; THOMSEN J, 1988, J PROTEIN CHEM, V7, P295; TILGMANN C, 1990, FEBS LETT, V264, P95, DOI 10.1016/0014-5793(90)80774-D; VANEERD JP, 1973, BIOCHEMISTRY-US, V12, P4972, DOI 10.1021/bi00748a024; WANG Y, 1988, BIOTECHNIQUES, V6, P843; WETZEL B, 1988, TRENDS PHARMACOL SCI, V9, P166, DOI 10.1016/0165-6147(88)90031-4; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	46	224	227	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28584	28590						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961805				2022-12-25	WOS:A1994PU16800014
J	RIETVELD, AG; CHUPIN, VV; KOORENGEVEL, MC; WIENK, HLJ; DOWHAN, W; DEKRUIJFF, B				RIETVELD, AG; CHUPIN, VV; KOORENGEVEL, MC; WIENK, HLJ; DOWHAN, W; DEKRUIJFF, B			REGULATION OF LIPID POLYMORPHISM IS ESSENTIAL FOR THE VIABILITY OF PHOSPHATIDYLETHANOLAMINE-DEFICIENT ESCHERICHIA-COLI-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CHAIN ORDER; MEMBRANE-LIPIDS; BIOLOGICAL RELEVANCE; FATTY-ACIDS; PHOSPHOLIPIDS; SPECTROSCOPY; PROTEINS; DYNAMICS; H-2-NMR; PHASE	Escherichia coli strain AD93 is unable to synthesize the nonbilayer lipid phosphatidylethanolamine and requires high concentrations of specific divalent cations for growth. Previous studies suggested that in this strain, cardiolipin in combination with divalent cations functionally replaces phosphatidylethanolamine, reflecting polymorphic regulation of membrane lipid composition. However, it is also possible that divalent cations are required for regulation of lipid packing or membrane surface potential. H-2 MMR was employed to measure the effect of different divalent cations on lipid packing in aqueous dispersions of lipid extracts isolated from AD93 and the wild type parental strain W3899, which were grown with [11,11-H-2(2)]oleic acid. The results indicate that a range of acyl chain order is compatible with growth and that Ba2+, which cannot support growth of AD93, can increase chain packing to the wild type level. By means of microelectrophoresis, it was shown that the growth-promoting cations and Ba2+ have a strong and comparable ability to screen the surface charge of large unilamellar vesicles prepared from AD93 lipid extracts. Therefore, it is unlikely that the growth-promoting capacity of divalent cations is primarily due to their effect on lipid packing or their potency to decrease the surface potential. Furthermore, the addition of small amounts of Ba2+ to a AD93 lipid dispersion with excess Mg2+ diminished H-II phase formation. This observation can explain the growth arrest in AD93 cultures upon the addition of Ba2+ and further supports the conclusion that the cation requirement of this strain arises mainly from polymorphic regulation of lipid composition.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	University of Texas System	RIETVELD, AG (corresponding author), UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,DEPT MEMBRANE BIOCHEM,PADUALAAN 8,3584 CH UTRECHT,NETHERLANDS.		Wienk, Hans/P-8929-2015; chupin, vladimir/J-8986-2015	Wienk, Hans/0000-0001-9577-0064; 	NIGMS NIH HHS [GM 20487] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKUTSU H, 1981, BIOCHEMISTRY-US, V20, P7366, DOI 10.1021/bi00529a007; AVEYARD R, 1973, INTRO PRINCIPLES SUR, P31; AXELROD D, 1983, J MEMBRANE BIOL, V75, P1, DOI 10.1007/BF01870794; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHUPIN V, 1987, BIOPHYS J, V51, P395, DOI 10.1016/S0006-3495(87)83361-1; CRONAN JE, 1978, ANNU REV BIOCHEM, V47, P163, DOI 10.1146/annurev.bi.47.070178.001115; CRONAN JE, 1972, BIOCHIM BIOPHYS ACTA, V265, P25, DOI 10.1016/0304-4157(72)90018-4; CRONAN JE, 1975, BACTERIOL REV, V39, P232, DOI 10.1128/MMBR.39.3.232-256.1975; DAVIS JH, 1983, BIOCHIM BIOPHYS ACTA, V737, P117, DOI 10.1016/0304-4157(83)90015-1; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; DEKRUIJFF B, 1987, NATURE, V329, P587, DOI 10.1038/329587a0; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; DEWOLF FA, 1992, BIOCHEMISTRY-US, V31, P9252, DOI 10.1021/bi00153a019; EPAND RM, 1991, CHEM PHYS LIPIDS, V57, P75, DOI 10.1016/0009-3084(91)90051-C; FINE JB, 1982, J LIPID RES, V23, P660; GALLY HU, 1979, BIOCHEMISTRY-US, V18, P5605, DOI 10.1021/bi00592a013; GARWIN JL, 1980, J BACTERIOL, V141, P1457, DOI 10.1128/JB.141.3.1457-1459.1980; HAEST CWM, 1969, CHEM PHYS LIPIDS, V3, P413, DOI 10.1016/0009-3084(69)90048-6; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; KILLIAN JA, 1992, BIOCHIM BIOPHYS ACTA, V1105, P253, DOI 10.1016/0005-2736(92)90202-W; KILLIAN JA, 1994, BBA-BIOMEMBRANES, V1189, P225; KRAAYENHOF R, 1993, BIOCHEMISTRY-US, V32, P10057, DOI 10.1021/bi00089a022; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; LINDBLOM G, 1993, J BIOL CHEM, V268, P16198; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P71; MOHAN R, 1976, ANAL BIOCHEM, V70, P506, DOI 10.1016/0003-2697(76)90477-2; MONCK MA, 1992, BIOCHEMISTRY-US, V31, P10037, DOI 10.1021/bi00156a025; RAETZ CRH, 1978, MICROBIOL REV, V42, P614, DOI 10.1128/MMBR.42.3.614-659.1978; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SMAAL EB, 1985, J LIPID RES, V26, P634	33	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28670	28675						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961817				2022-12-25	WOS:A1994PU16800026
J	SAVOURET, JF; RAUCH, M; REDEUILH, G; SAR, S; CHAUCHEREAU, A; WOODRUFF, K; PARKER, MG; MILGROM, E				SAVOURET, JF; RAUCH, M; REDEUILH, G; SAR, S; CHAUCHEREAU, A; WOODRUFF, K; PARKER, MG; MILGROM, E			INTERPLAY BETWEEN ESTROGENS, PROGESTINS, RETINOIC ACID AND AP-1 ON A SINGLE REGULATORY SITE IN THE PROGESTERONE-RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; TRANSCRIPTION FACTOR AP-1; RAT PROLACTIN GENE; DNA-BINDING DOMAIN; RESPONSIVE ELEMENT; GLUCOCORTICOID RECEPTOR; C-JUN; ACTIVATING DOMAINS; HORMONE RECEPTORS; STEROID BINDING	Transcriptional regulation of the progesterone receptor gene involves induction by estrogens and down-regulation by progestins, retinoic acid, and AP-1 proteins. We have previously identified an intragenic (+698/+723) estrogen-responsive element present in the progesterone receptor gene, which binds the estradiol receptor and mediates estrogen and 4-OH tamoxifen induction. Progesterone receptor gene expression was equally stimulated by estradiol and 4-OH tamoxifen in the presence of a NH2 terminally deleted estrogen receptor mutant lacking activation function 1, suggesting that activation function 2 was the predominant activation domain. This was confirmed by the lack of activity of an estrogen receptor mutant deleted of activation function 2. Repression by progestins, retinoic acid, and AP-1 was mediated by the same estrogen responsive element although retinoic and progesterone receptors as well as AP-1 proteins did not bind to this element. Repression by these proteins appears to involve different transactivating regions of the estrogen receptor. Repression by retinoic receptors involved only activation function 2 whereas repression by progesterone receptor and AP-1 necessitated both functional domains. Since these proteins act without directly contacting the DNA, it seems likely that repression may be achieved by protein-protein interactions among different domains of the estrogen receptor and/or the transcriptional machinery.	HOP BICETRE, INSERM, U135, F-94275 LE KREMLIN BICETRE, FRANCE; HOP BICETRE, INSERM, U33, F-94275 LE KREMLIN BICETRE, FRANCE; IMPERIAL CANC RES FUND, MOLEC ENDOCRINOL LAB, LONDON WC2A 3PX, ENGLAND	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Cancer Research UK			Chauchereau, Anne/N-8880-2016; CHAUCHEREAU, Anne/B-1074-2009	Chauchereau, Anne/0000-0001-9447-3797; 				ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BLANKENSTEIN MA, 1983, EUR J CANCER CLIN ON, V19, P365, DOI 10.1016/0277-5379(83)90134-7; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRENNER RM, 1975, ANNU REV PHYSIOL, V37, P273, DOI 10.1146/annurev.ph.37.030175.001421; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CLARKE CL, 1990, MOL CELL ENDOCRINOL, V70, pC29, DOI 10.1016/0303-7207(90)90210-Y; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; GARCIA E, 1988, J CLIN ENDOCR METAB, V67, P80, DOI 10.1210/jcem-67-1-80; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; HAI MTV, 1977, ANN NY ACAD SCI, V286, P199, DOI 10.1111/j.1749-6632.1977.tb29417.x; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HORWITZ KB, 1978, CANCER RES, V38, P2434; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; HORWITZ KB, 1978, ENDOCRINOLOGY, V103, P1742, DOI 10.1210/endo-103-5-1742; ING NH, 1992, J BIOL CHEM, V267, P17617; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KASSIS JA, 1986, ENDOCRINOLOGY, V118, P603, DOI 10.1210/endo-118-2-603; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KORTE JM, 1988, MOL CELL ENDOCRINOL, V58, P93, DOI 10.1016/0303-7207(88)90057-3; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LESSEY BA, 1988, J CLIN ENDOCR METAB, V67, P334, DOI 10.1210/jcem-67-2-334; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LOGEAT F, 1985, BIOCHEMISTRY-US, V24, P1029, DOI 10.1021/bi00325a034; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARTIN PM, 1988, P NATL ACAD SCI USA, V85, P2533, DOI 10.1073/pnas.85.8.2533; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MESTER J, 1977, EUR J BIOCHEM, V72, P405, DOI 10.1111/j.1432-1033.1977.tb11265.x; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MILGROM E, 1973, J BIOL CHEM, V248, P6366; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; REDEUILH G, 1987, J BIOL CHEM, V262, P6969; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROOS W, 1986, P NATL ACAD SCI USA, V83, P991, DOI 10.1073/pnas.83.4.991; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SABBAH M, 1991, P NATL ACAD SCI USA, V88, P390, DOI 10.1073/pnas.88.2.390; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SERFLING E, 1989, TRENDS GENET, V5, P131, DOI 10.1016/0168-9525(89)90049-8; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; SUMIDA C, 1988, ENDOCRINOLOGY, V122, P3, DOI 10.1210/endo-122-1-3; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YLIKOMI T, 1984, J STEROID BIOCHEM, V20, P445, DOI 10.1016/0022-4731(84)90251-6; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	73	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28955	28962						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961858				2022-12-25	WOS:A1994PU16800068
J	TOKUMITSU, H; BRICKEY, DA; GLOD, J; HIDAKA, H; SIKELA, J; SODERLING, TR				TOKUMITSU, H; BRICKEY, DA; GLOD, J; HIDAKA, H; SIKELA, J; SODERLING, TR			ACTIVATION MECHANISMS FOR CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE-IV - IDENTIFICATION OF A BRAIN CAM-KINASE-IV KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE METHOD; AUTOINHIBITORY DOMAIN; CALMODULIN; GR; AUTOPHOSPHORYLATION; EXPRESSION; BINDING; GENE; LOCALIZATION; PURIFICATION	This manuscript examines the mechanisms by which Ca2+/calmodulin-dependent protein kinase IV (CaM-kinase IV) is activated through the binding of Ca2+/CaM and by phosphorylation. Studies with the synthetic autoinhibitory domain peptides of CaM-kinase II indicate that CaM-kinase IV has a similarly located autoinhibitory domain, and this was confirmed since site-directed mutagenesis of this region (HMDT(308) to DEDD and FN317 to DD) generated fully active Ca2+/CaM-independent kinases. Total activities of purified, baculovirus-expressed wild type and mutant kinases were increased 2-fold by intramolecular autophosphorylation, but this reaction was extremely slow (1-2 h) and probably not physiological. However, CaM-kinase IV can be activated by brain CaM-kinase IV kinase resulting in large increases in both total (5-7-fold) and Ca2+/CaM-independent (>20-fold) CaM-kinase IV activities. This activation reaction required Mg2+/ATP and Ca2+/CaM, was intermolecularly catalyzed, and was reversed by protein phosphatase 2A. Activation of CaM-kinase IV resulted in a 10-fold decrease in K-m for syntide-2 with little effect on K-m for ATP or V-max. CaM-kinase IV kinase was highly purified from rat brain extract and was shown to be a 68-kDa monomer. The results of this study demonstrate that CaM-kinase IV does have an autoinhibitory domain within residues His(305)-Lys(321) that suppresses kinase activity in the absence of Ca2+/CaM. CaM-kinase IV is not significantly activated by autophosphorylation, but it can be activated 10 fold by a CaM-kinase IV kinase. This kinase cascade activation mechanism may be important for the physiological function of CaM-kinase IV such as transcriptional regulation through phosphorylation of cAMP responsive element binding protein (Enslen, H., Sun, P., Brickey, D., Soderling, S. H., Klamo, E., and Soderling, T. R. (1994) J. Biol. Chem. 269, 15520-15527).	OREGON HLTH SCI UNIV,VOLLUM INST L474,PORTLAND,OR 97201; NAGOYA UNIV,SCH MED,DEPT PHARMACOL,NAGOYA,AICHI 466,JAPAN; COLORADO MED CTR,DEPT PHARMACOL,DENVER,CO 80262	Oregon Health & Science University; Nagoya University			Glod, John/U-9925-2019; Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794	NIGMS NIH HHS [GM 41292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; ENSLEN H, 1994, IN PRESS J BIOL CHEM, V269; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JSC, 1994, J BIOL CHEM, V269, P2158; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MIYANO O, 1992, J BIOL CHEM, V267, P1198; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; ROSKOSKI R, 1985, METHOD ENZYMOL, V99, P3; SIKELA JM, 1989, GENOMICS, V4, P21, DOI 10.1016/0888-7543(89)90309-1; SMITH MK, 1992, J BIOL CHEM, V267, P1761; SODERLING TR, 1990, J BIOL CHEM, V265, P1823	33	145	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28640	28647						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961813				2022-12-25	WOS:A1994PU16800022
J	WISNIEWSKI, JR; GHIDELLI, S; STEUERNAGEL, A				WISNIEWSKI, JR; GHIDELLI, S; STEUERNAGEL, A			REGION OF INSECT HIGH-MOBILITY GROUP (HMG)-1 PROTEIN HOMOLOGOUS TO HELIX-2 OF THE RAT HMG1-B BOX IS IN CLOSE CONTACT WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; DROSOPHILA-MELANOGASTER; ALPHA-ENHANCER; BINDING MOTIF; FACTOR-I; SEQUENCE; DOMAIN; SEGMENTS; GENE; SRY	The dipteran insects Chironomus and Drosophila have high mobility group (HMG) 1 proteins that are similar to mammalian HMG1 but contain one instead of two HMG1 boxes. The interaction of the Chironomus HMG1 proteins cHMG1a and cHMG1b with double-stranded and four-way junction DNA was analyzed by investigating the accessibility of defined sequences of the HMG1 box to specific antibodies within the DNA-protein complex in vitro. Antibody epitopes located in the three helices and in the turn between helices 1 and 2 of the HMG1 box were identified on a membrane onto which 90 decapeptides with overlapping sequences spanning the entire sequence of cHMG1a had been bound. Monospecific antibodies directed against selected epitopes were purified from a polyclonal antiserum by affinity chromatography. Helices 1 and 3 as well as the turn between helices 1 and 2 were found 60 be accessible to antibodies in the complex. In contrast, antibodies recognizing an epitope on putative helix 2 of cHMG1a and cHMG1b were unable to produce supershifts on gels of the DNA-protein complexes with both DNAs. These data suggest that helix 2 of the HMG1 box of proteins cHMG1a and cHMG1b is essentially responsible for contacts with DNA.			WISNIEWSKI, JR (corresponding author), UNIV GOTTINGEN,ZOOL INST ENTWICKLUNGSBIOL 3,DEPT ZOOL 3,HUMBOLDTALLE 34A,D-37073 GOTTINGEN,GERMANY.							BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BUSTIN M, 1985, BIOCHEM BIOPH RES CO, V133, P633, DOI 10.1016/0006-291X(85)90952-0; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; NER SS, 1993, NUCLEIC ACIDS RES, V21, P4369, DOI 10.1093/nar/21.18.4369; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; SCHMIDT ER, 1981, FEBS LETT, V129, P21, DOI 10.1016/0014-5793(81)80745-4; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WAGNER CR, 1992, MOL CELL BIOL, V12, P1915, DOI 10.1128/MCB.12.5.1915; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WISNIEWSKI JR, 1992, J BIOL CHEM, V267, P17170; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713	22	17	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29261	29264						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961895				2022-12-25	WOS:A1994PU16800108
J	SAKAI, M; MIYAZAKI, A; HAKAMATA, H; SASAKI, T; YUI, S; YAMAZAKI, M; SHICHIRI, M; HORIUCHI, S				SAKAI, M; MIYAZAKI, A; HAKAMATA, H; SASAKI, T; YUI, S; YAMAZAKI, M; SHICHIRI, M; HORIUCHI, S			LYSOPHOSPHATIDYLCHOLINE PLAYS AN ESSENTIAL ROLE IN THE MITOGENIC EFFECT OF OXIDIZED LOW-DENSITY-LIPOPROTEIN ON MURINE MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PROTEIN-KINASE-C; DEPENDENT ARTERIAL RELAXATION; RAT PERITONEAL-MACROPHAGES; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; ATHEROSCLEROTIC LESIONS; POTENTIAL ROLE; CULTURED HUMAN; CROSS-LINKING	We previously demonstrated that the growth of starch-induced murine macrophages was stimulated by modified low density lipoproteins, such as oxidized low density lipoprotein (Ox-LDL) and acetylated low density lipoprotein (acetyl-LDL), and that the mitogenic effect of Ox-LDL was much greater than that of acetyl-LDL (Yul, S., Sasaki, T., Miyazaki, A., Horiuchi, S., and Yamazaki, M. (1993) Arterioscler. Thromb. 13, 331-337). The present study was undertaken to elucidate the factor(s) that are involved in this growth-stimulating effect of Ox-LDL. The growth-stimulating effect of acetyl-LDL on murine resident macrophages was negligibly weak compared with that of Ox-LDL. However, the treatment of acetyl-LDL with phospholipase A, led to an increase in lysophosphatidylcholine (lyse-PC) (75% of total phospholipids) and a concomitant increase in the mitogenic activity of acetyI-LDL. In contrast, cell-free incubation of Ox-LDL with high density lipoprotein resulted in a decrease in lyse-PC content and a concomitant loss of growth-stimulating activity. These results suggest that lyse-PC may play an essential role in the mitogenic activity of Ox-LDL.	KUMAMOTO UNIV, SCH MED, DEPT BIOCHEM, KUMAMOTO 860, JAPAN; KUMAMOTO UNIV, SCH MED, DEPT METAB MED, KUMAMOTO 860, JAPAN; TEIKYO UNIV, FAC PHARMACEUT SCI, KANAGAWA 19901, JAPAN	Kumamoto University; Kumamoto University; Teikyo University								ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; AVIRAM M, 1989, THROMB RES, V53, P561, DOI 10.1016/0049-3848(89)90145-X; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHEN BDM, 1988, BLOOD, V71, P997; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; HAMILTON JA, 1983, J CELL PHYSIOL, V115, P67, DOI 10.1002/jcp.1041150111; HAMILTON JA, 1981, J CELL PHYSIOL, V106, P445, DOI 10.1002/jcp.1041060314; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KUGIYAMA K, 1993, CIRC RES, V73, P335, DOI 10.1161/01.RES.73.2.335; KUGIYAMA K, 1992, CIRC RES, V71, P1422, DOI 10.1161/01.RES.71.6.1422; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; MATSUDA Y, 1993, CIRC RES, V72, P1103, DOI 10.1161/01.RES.72.5.1103; MIYAZAKI A, 1994, J BIOL CHEM, V269, P5264; MIYAZAKI A, 1991, BIOCHIM BIOPHYS ACTA, V1082, P143; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; MURAKAMI M, 1987, J BIOCHEM-TOKYO, V101, P729, DOI 10.1093/jb/101.3.729; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHTA T, 1989, FEBS LETT, V257, P435, DOI 10.1016/0014-5793(89)81590-X; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAKAI M, 1992, FEBS LETT, V314, P199, DOI 10.1016/0014-5793(92)80974-L; SHINOHARA M, 1992, J BIOL CHEM, V267, P1603; SPAGNOLI LG, 1991, ATHEROSCLEROSIS, V88, P87, DOI 10.1016/0021-9150(91)90260-A; STANLEY ER, 1978, NATURE, V274, P168, DOI 10.1038/274168a0; STANLEY ER, 1976, J EXP MED, V143, P631, DOI 10.1084/jem.143.3.631; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STIKORAHM A, 1992, ARTERIOSCLER THROMB, V12, P1099, DOI 10.1161/01.ATV.12.9.1099; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YUI S, 1986, J IMMUNOL, V136, P1334; YUI S, 1989, J LEUKOCYTE BIOL, V45, P189, DOI 10.1002/jlb.45.3.189; YUI S, 1994, J IMMUNOL, V152, P1943; YUI S, 1987, J LEUKOCYTE BIOL, V41, P392, DOI 10.1002/jlb.41.5.392; YUI S, 1990, J IMMUNOL, V144, P1466; YUI S, 1986, J LEUKOCYTE BIOL, V39, P713, DOI 10.1002/jlb.39.6.713; YUI S, 1990, J IMMUNOL, V144, P1461; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331	47	205	213	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31430	31435						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989310				2022-12-25	WOS:A1994PX30300019
J	CHENG, T; WANG, YS; DAI, W				CHENG, T; WANG, YS; DAI, W			TRANSCRIPTION FACTOR EGR-1 IS INVOLVED IN PHORBOL 12-MYRISTATE 13-ACETATE-INDUCED MEGAKARYOCYTIC DIFFERENTIATION OF K562 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROLEUKEMIA-CELLS; LEUKEMIA-CELLS; MEGAKARYOBLASTIC DIFFERENTIATION; ERYTHROID-DIFFERENTIATION; GENE-EXPRESSION; PROTEIN; BINDING; LINE; INHIBITOR; PROMOTER	Transcription factors play important roles in regulating cell growth and differentiation. egr-1, a transcription factor of the zinc finger family, is rapidly activated in many types of cells after mitogen treatment. In this report, we demonstrate that egr-1 mRNA expression, detected by Northern blotting, is activated within 30 min of treatment of the erythroleukemia cell line K562 with phorbol 12-myristate 13-acetate (PMA), and the increased egr-1 mRNA level is associated with an elevated egr-1 antigen expression detected by Western blotting and with its DNA binding activity shown by the gel mobility shift assay In addition, PMA-mediated activation of egr-1 mRNA expression involves no new protein synthesis and is followed by sequential down-regulation of the mRNA level of GATA-1 and glycophorin A. On the other hand, CD41a surface antigen expression is dramatically up-regulated. Furthermore, enforced expression of egr-1, through transfection of K562 cells with the egr-1 expression plasmid construct, results in expression of the egr-1 transcript that accompanies a significant accumulation on the cell surface of CD41a but not CD14 nor glycophorin A. These observations suggest that egr-1 is involved in regulating PMA-induced megakaryocytic differentiation of K562 cell line.	HIPPLE CANC RES CTR,DAYTON,OH 45439						NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032483] Funding Source: NIH RePORTER; NIAID NIH HHS [R29 AI32483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALITALO R, 1988, BLOOD, V71, P899; ALITALO R, 1990, BLOOD, V75, P1974; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; AUSEBEL FM, 1988, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUSIN E, 1991, NUCLEIC ACIDS RES, V19, P3881, DOI 10.1093/nar/19.14.3881; DAI W, 1990, BIOCHEM BIOPH RES CO, V168, P1, DOI 10.1016/0006-291X(90)91666-G; DAI W, 1993, BLOOD, V81, P1214; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GREEN AR, 1992, ONCOGENE, V7, P652; HASSAN HT, 1991, CHEMOTHERAPY, V37, P441, DOI 10.1159/000238892; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KHABANDA S, 1991, J CLIN INVEST, V33, P571; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MOLLINEDO F, 1991, EUR J BIOCHEM, V200, P483, DOI 10.1111/j.1432-1033.1991.tb16208.x; MOROI M, 1993, BIOCHIM BIOPHYS ACTA, V6, P139; NEUBERG M, 1989, NATURE, V341, P243, DOI 10.1038/341243a0; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NICHOLAS RH, 1991, CELL GROWTH DIFFER, V2, P129; OGURA M, 1988, BLOOD, V72, P49; OGURA M, 1988, BLOOD, V72, P3168; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; ROUSSELOT P, 1994, ONCOGENE, V9, P545; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; ROWLEY PT, 1992, INT J CELL CLONING, V10, P232, DOI 10.1002/stem.5530100406; Sambrook J, 1989, MOL CLONING LABORATO; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SIEBERT PD, 1985, J BIOL CHEM, V260, P640; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSIFTSOGLOU AS, 1991, EXP HEMATOL, V19, P928	34	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30848	30853						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983016				2022-12-25	WOS:A1994PV51000021
J	GHOSH, S; BELL, RM				GHOSH, S; BELL, RM			IDENTIFICATION OF DISCRETE SEGMENTS OF HUMAN RAF-1 KINASE CRITICAL FOR HIGH-AFFINITY BINDING TO HA-RAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL-TRANSDUCTION PATHWAY; PROTEIN-KINASE; MAP KINASE; CELLS; PEPTIDOMIMETICS; PRO-LEU-GLY-NH2; ACTIVATION; DOWNSTREAM; P21(RAS); GROWTH	A critical event in a signal transduction pathway downstream of receptor tyrosine kinases is the physical association of GTP-liganded Ras with the serine/threonine kinase, Raf-1. The binding of Raf-1 to Ras results in translocation of the kinase to the plasma membrane and facilitates its activation by an unknown mechanism. A deletion mutagenesis approach was employed to elucidate critical sequences in Raf-1 necessary for binding to Ras and to resolve seemingly contradictory data in the literature. While an N-terminal fragment consisting of residues 2-130 of Raf-1 was able to bind Ras, residues 131-147 were found to be critically important for conferring high affinity binding to Ras. Surprisingly, a second domain between residues 52-64 was an essential element for Raf-Ras interaction, although it did not appear to form an independent binding site for Ras. These findings may prove useful for the design of peptides or peptidomimetic drugs for the modulation of Raf-Ras interaction in neoplastic disorders.			BELL, RM (corresponding author), DUKE UNIV,CTR COMPREHENS CANC,DEPT MOLEC CANC BIOL,DURHAM,NC 27710, USA.		GHOSH, SUJOY/I-3729-2017	GHOSH, SUJOY/0000-0002-7601-165X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038737] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 20259] Funding Source: Medline; NIGMS NIH HHS [GM 38737] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CHUNG E, 1994, MOL CELL BIOL, V14, P5318; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; GENIN MJ, 1993, J MED CHEM, V36, P3481, DOI 10.1021/jm00074a032; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MINATO T, 1994, J BIOL CHEM, V269, P20845; REDDY MR, 1994, J MED CHEM, V37, P1145, DOI 10.1021/jm00034a012; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SMITH AB, 1994, J MED CHEM, V37, P215, DOI 10.1021/jm00028a001; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUBASINGHE NL, 1993, J MED CHEM, V36, P2356, DOI 10.1021/jm00068a013; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WU TP, 1993, PROTEIN ENG, V6, P471, DOI 10.1093/protein/6.5.471; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	30	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30785	30788						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983008				2022-12-25	WOS:A1994PV51000012
J	NAKATA, PA; ANDERSON, JM; OKITA, TW				NAKATA, PA; ANDERSON, JM; OKITA, TW			STRUCTURE AND EXPRESSION OF THE POTATO ADP-GLUCOSE PYROPHOSPHORYLASE SMALL-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL GLYCOGEN-SYNTHESIS; ADPGLUCOSE PYROPHOSPHORYLASE; GENE-EXPRESSION; STARCH BIOSYNTHESIS; BETA-GLUCURONIDASE; WHEAT ENDOSPERM; MESSENGER-RNAS; CDNA CLONES; SEQUENCES; PLANTS	ADP-glucose pyrophosphorylase (AGP) catalyzes a key regulatory step in starch synthesis. To elucidate the molecular basis for the expression of the potato (Solanum tuberosum L.) AGP during tuber development, the structure of the small subunit AGP (sAGP) gene and its patterns of expression were examined. DNA sequence analysis revealed that the sAGP gene is over 5.5 kilobases long and has a complex structure including eight introns. Unlike the situation in other plants where tissue-specific sAGP are found, our Southern and Northern blot analysis indicated that the same sAGP gene is expressed both in tubers (non-photosynthetic tissue) and leaves (photosynthetic tissue). These data were supported by comparing sequences of isolated sAGP leaf cDNAs to the tuber cDNA sequence, by primer extension analysis of leaf and tuber poly(A)(+) RNAs, and by the spatial expression patterns of a gusA (beta-glucuronidase) reporter gene driven by the potato sAGP promoter in transgenic potato plants. Although the sAGP gene appeared to be transcriptionally controlled in both developing tubers and in leaves, the relative level of leaf antigen was significantly lower than its level of transcript, indicating that sAGP expression in leaves is primarily regulated post-transcriptionally. The observed tissue type-dependent regulation of sAGP expression appears to control the extent of starch biosynthesis by regulating the levels of this enzyme and, thus, alleviate the need for tissue-specific forms of the sAGP in potato.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	Washington State University; Washington State University				Okita, Tom/0000-0002-2246-0599; Nakata, Paul/0000-0002-6331-9700				AINSWORTH C, 1993, PLANT MOL BIOL, V23, P23, DOI 10.1007/BF00021416; An G., 1989, PLANT MOL BIOL MANUA, P1, DOI [DOI 10.1007/978-94-009-0951-9, 10.1007/978-94-017-5294-7_3]; Anderson J. M., 1990, The molecular and cellular biology of the potato., P159; ANDERSON JM, 1991, GENE, V97, P199, DOI 10.1016/0378-1119(91)90052-D; BRIARTY LG, 1979, ANN BOT-LONDON, V44, P641, DOI 10.1093/oxfordjournals.aob.a085779; BROWN JWS, 1981, THEOR APPL GENET, V59, P349, DOI 10.1007/BF00276448; CALLIS J, 1987, GENE DEV, V1, P1183, DOI 10.1101/gad.1.10.1183; COPELAND L, 1981, PLANT PHYSIOL, V68, P996, DOI 10.1104/pp.68.5.996; ENTWISTLE G, 1990, BIOCHEM J, V271, P467, DOI 10.1042/bj2710467; FREHNER M, 1990, PLANT PHYSIOL, V94, P538, DOI 10.1104/pp.94.2.538; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; HELDT HW, 1977, PLANT PHYSIOL, V59, P1146, DOI 10.1104/pp.59.6.1146; HENIKOFF S, 1984, GENE, V11, P4891; HYLTON C, 1992, PLANT PHYSIOL, V99, P1626, DOI 10.1104/pp.99.4.1626; ISHIGURO S, 1992, PLANT MOL BIOL, V18, P97, DOI 10.1007/BF00018460; JEFFERSON R, 1990, PLANT MOL BIOL, V14, P995, DOI 10.1007/BF00019396; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KEELING PL, 1988, PLANT PHYSIOL, V87, P311, DOI 10.1104/pp.87.2.311; KLECZKOWSKI LA, 1993, PLANT PHYSIOL, V101, P179, DOI 10.1104/pp.101.1.179; KLOSGEN RB, 1986, MOL GEN GENET, V203, P237, DOI 10.1007/BF00333960; KOSUGI S, 1990, PLANT SCI, V70, P133, DOI 10.1016/0168-9452(90)90042-M; KRISHNAN HB, 1986, PLANT PHYSIOL, V81, P642, DOI 10.1104/pp.81.2.642; LIN TP, 1988, PLANT PHYSIOL, V88, P1175, DOI 10.1104/pp.88.4.1175; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MAAS C, 1991, PLANT MOL BIOL, V16, P199, DOI 10.1007/BF00020552; MORELL MK, 1987, PLANT PHYSIOL, V85, P182, DOI 10.1104/pp.85.1.182; MULLERROBER B, 1994, PLANT CELL ENVIRON, V17, P601, DOI 10.1111/j.1365-3040.1994.tb00152.x; MULLERROBER BT, 1990, MOL GEN GENET, V224, P136, DOI 10.1007/BF00259460; Nakata P. A., 1994, The molecular and cellular biology of the potato., P31; NAKATA PA, 1991, PLANT MOL BIOL, V17, P1089, DOI 10.1007/BF00037149; NEUHAUS HE, 1990, PLANTA, V182, P445, DOI [10.1007/BF02411398, 10.1007/BF00197565]; OHTA S, 1991, MOL GEN GENET, V225, P369, DOI 10.1007/BF00261676; OKITA TW, 1990, PLANT PHYSIOL, V93, P785, DOI 10.1104/pp.93.2.785; OKITA TW, 1993, STADLER GEN, P161; OLIVE MR, 1989, PLANT MOL BIOL, V12, P525, DOI 10.1007/BF00036967; OPARKA KJ, 1992, ENV PLANT B, P91; PEREZ CM, 1975, PLANT PHYSIOL, V56, P579, DOI 10.1104/pp.56.5.579; PLAXTON WC, 1987, PLANT PHYSIOL, V83, P105, DOI 10.1104/pp.83.1.105; PREISS J, 1989, ADV MICROB PHYSIOL, V30, P183; PREISS J, 1984, ANNU REV MICROBIOL, V38, P419, DOI 10.1146/annurev.mi.38.100184.002223; PREISS J, 1991, BIOCHEM SOC T, V19, P539, DOI 10.1042/bst0190539; PREISS J, 1991, PURE APPL CHEM, V63, P535, DOI 10.1351/pac199163040535; Preiss J., 1988, BIOCH PLANTS, V14., P181; PRIOUL JL, 1994, PLANT PHYSIOL, V104, P179, DOI 10.1104/pp.104.1.179; REEVES CD, 1986, PLANT PHYSIOL, V82, P34, DOI 10.1104/pp.82.1.34; Rogers SO, 1988, PLANT MOL BIOL MAN A, VA6, P1, DOI DOI 10.1007/978-94-017-5294-7_; Sambrook J, 1989, MOL CLONING LABORATO; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; TYSON RH, 1988, PLANTA, V175, P33, DOI 10.1007/BF00402879; VILLAND P, 1992, PLANT MOL BIOL, V19, P381, DOI 10.1007/BF00023385; VILLAND P, 1993, PLANT MOL BIOL, V23, P1279, DOI 10.1007/BF00042361; VILLAND P, 1994, Z NATURFORSCH C, V49, P215; WENZLER H, 1989, PLANT SCI, V63, P79, DOI 10.1016/0168-9452(89)90103-9; WERR W, 1985, EMBO J, V4, P1373, DOI 10.1002/j.1460-2075.1985.tb03789.x	55	29	32	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30798	30807						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983010				2022-12-25	WOS:A1994PV51000014
J	NORDSTEDT, C; NASLUND, J; TJERNBERG, LO; KARLSTROM, AR; THYBERG, J; TERENIUS, L				NORDSTEDT, C; NASLUND, J; TJERNBERG, LO; KARLSTROM, AR; THYBERG, J; TERENIUS, L			THE ALZHEIMER A-BETA-PEPTIDE DEVELOPS PROTEASE RESISTANCE IN ASSOCIATION WITH ITS POLYMERIZATION INTO FIBRILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMYLOID PROTEIN; DISEASE; PRECURSOR; INVITRO; CDNA; DEPOSITS; PATHWAY; CELLS	An intriguing property of the polypeptide constituents of amyloid is that they apparently can escape the proteolytic mechanisms that normally catalyze turnover and prevent abnormal tissue accumulation of polypeptides. Here, we demonstrate that the AP peptide, the principal component of cerebrovascular amyloid deposits in Alzheimer's disease, becomes resistant to an array of proteases as a result of structural changes associated with its polymerization into amyloid fibrils. It is further demonstrated that fibril formation per se does not lead to protease resistance but probably structural changes associated with polymerization. The results suggest that higher order structural changes, regulated by the primary structure, enable amyloidogenic polypeptides to escape proteolytic degradation and accumulate in tissues.	KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT GERIATR MED,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,INST MED NOBEL,DEPT CELL & MOLEC BIOL,S-17177 STOCKHOLM,SWEDEN; PHARMACIA,DEPT BIOCHEM,S-11287 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet; Pfizer; Pharmacia Corporation	NORDSTEDT, C (corresponding author), KAROLINSKA HOSP,DEPT CLIN NEUROSCI,DRUG ADDICT RES SECT,S-17176 STOCKHOLM,SWEDEN.				NHLBI NIH HHS [HL49571-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beynon R.J., 1989, PROTEOLYTIC ENZYMES; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1994, J BIOL CHEM, V269, P12152; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P7323; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MORI H, 1992, J BIOL CHEM, V267, P17082; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROHER AE, 1993, J BIOL CHEM, V268, P3071; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; STONE MJ, 1990, BLOOD, V75, P531; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0	30	93	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30773	30776						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983005				2022-12-25	WOS:A1994PV51000009
J	ROHLFS, RJ; HILLE, R				ROHLFS, RJ; HILLE, R			THE REACTION OF TRIMETHYLAMINE DEHYDROGENASE WITH DIETHYLMETHYLAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ELECTRON-TRANSFER; COVALENTLY BOUND COENZYME; STEADY-STATE KINETICS; AMINO-ACID OXIDASE; DIMETHYLAMINE DEHYDROGENASE; METHYLOTROPHIC BACTERIA; PROSTHETIC GROUPS; IDENTIFICATION; SUBSTRATE; CATALYSIS	The reductive half-reaction of trimethylamine dehydrogenase has been studied using the substrate diethylmethylamine over the pH range 6-10. It is found that the reaction occurs with three distinct and, under most conditions, fully resolved kinetic phases. The hyperbolic substrate concentration dependence of the observed rate constant for the fast kinetic phase is consistent with a two-step scheme in which free enzyme and substrate are in rapid equilibrium with an enzyme-substrate Michaelis complex, which then reacts to produce reduced flavin. The pH dependence of the limiting rate constant for the fast phase of the reaction (k(lim)) exhibits a pK(a) value of 7.9, whereas k(lim)/K-d exhibits a pK(a) value of 8.7. The rate constant for the intermediate kinetic phase, which reflects intramolecular electron transfer, is controlled by an ionizable group exhibiting a pK(a) value of 7.3. The equilibrium distribution of reducing equivalents between the flavin and iron-sulfur center of the enzyme at the end of the intermediate phase is controlled by a different ionizable group exhibiting a pK(a) value of approximately 6. An overall reductive half-reaction kinetic mechanism is proposed involving formation and decay of a covalent substrate-flavin intermediate, with intrinsically rapid intramolecular electron transfer limited by the rate of decay of the covalent adduct. Under conditions of excess substrate, product release is followed by binding of a second substrate molecule, which results in full development of the spectral properties diagnostic of the spin-interacting state.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	Ohio State University								BARBER MJ, 1992, J BIOL CHEM, V267, P6611; BELLAMY HD, 1989, J BIOL CHEM, V264, P11887; Bevington PR, 1969, DATA REDUCTION ERROR; BRAY RC, 1985, BIOCHEM SOC T, V13, P560, DOI 10.1042/bst0130560; BRAY RC, 1961, BIOCHEM J, V81, P180; DENU JM, 1994, BIOCHEMISTRY-US, V33, P4001, DOI 10.1021/bi00179a029; DSILVA C, 1987, BIOCHEMISTRY-US, V26, P1717, DOI 10.1021/bi00380a034; DUDLEY KH, 1965, HELV CHIM ACTA, V47, P1354; GHISLA S, 1980, J BIOL CHEM, V255, P5688; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; Ghisla S., 1982, FLAVINS FLAVOPROTEIN, P133; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; LIM LW, 1986, J BIOL CHEM, V261, P5140; MASSEY V, 1967, J BIOL CHEM, V242, P1259; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; MASSEY V, 1964, FED PROC, V23, P18; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MATHEWS FS, 1987, FLAVINS FLAVOPROTEIN, P663; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; NAGY J, 1979, J BIOL CHEM, V254, P2684; PORTER DJT, 1977, J BIOL CHEM, V252, P4464; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; SILVERMAN RB, 1982, FLAVINS FLAVOPROTEIN, P213; SINGER TP, 1980, FLAVINS FLAVOPROTEIN, P277; STEENKAMP DJ, 1982, BIOCHEM J, V207, P233, DOI 10.1042/bj2070233; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEENKAMP DJ, 1978, MECHANISMS OXIDIZING, P127; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; WEAST RC, 1968, HDB CHEM PHYSICS, pD89	35	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30869	30879						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983019				2022-12-25	WOS:A1994PV51000024
J	TUMA, PL; COLLINS, CA				TUMA, PL; COLLINS, CA			ACTIVATION OF DYNAMIN GTPASE IS A RESULT OF POSITIVE COOPERATIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; MOUSE MX1 PROTEIN; SEA-URCHIN EGGS; CYTOPLASMIC DYNEIN; MECHANOCHEMICAL ENZYME; BINDING PROTEINS; YEAST REQUIRES; ATPASE; GENE; DOMAINS	Dynamin is a GTP-binding protein thought to be involved in the early stages of endocytosis. Presently, it is not known how dynamin GTP binding and hydrolysis are related to its role in this process. We previously characterized the ability of acidic phospholipid vesicles and microtubules to strongly stimulate the GTPase activity of purified brain dynamin. In a further analysis of dynamin enzymatic properties, we have found that the increase of dynamin GTP hydrolysis in the presence of activating agent depends on enzyme concentration. At low enzyme concentration, Little or no activation is observed. Plots of dynamin GTPase activity with increasing enzyme concentration in the presence of either activating agent are strongly sigmoidal, indicating that positive cooperativity is responsible for the increased activity observed. A Hill coefficient of 2.3 was determined, implying that at least two dynamin molecules associate for maximal GTPase activity. No cooperative effects in GTP binding were observed. Linear transformation of reaction velocity versus enzyme concentration data indicate an apparent II, for dynamin-dynamin interactions of 37 nM, which is significantly lower than the physiological concentration of dynamin in brain. These results suggest that cooperative interactions between dynamin molecules are responsible for the apparent activation of GTPase observed and are likely involved in dynamin function in vivo.	NORTHWESTERN UNIV, SCH MED, DEPT CELL & MOLEC BIOL, CHICAGO, IL 60611 USA	Northwestern University								ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; ARNHEITER H, 1990, New Biologist, V2, P851; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Collins C A, 1991, Trends Cell Biol, V1, P57, DOI 10.1016/0962-8924(91)90090-V; COLLINS CA, 1986, P NATL ACAD SCI USA, V83, P4799, DOI 10.1073/pnas.83.13.4799; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUAN KL, 1993, CURR GENET, V24, P141, DOI 10.1007/BF00324678; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MIKI H, 1994, J BIOL CHEM, V269, P5489; NAKATA T, 1993, J CELL SCI, V105, P1; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; NEELY MD, 1990, J BIOL CHEM, V265, P8691; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Segel I.H., 1975, ENZYME KINETICS; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; STACHNIAK M C, 1990, Journal of Cell Biology, V111, p291A; Tuma P. L., 1993, Molecular Biology of the Cell, V4, p323A; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VALLEE RB, 1986, METHOD ENZYMOL, V134, P116; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P12444; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	43	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30842	30847						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983015				2022-12-25	WOS:A1994PV51000020
J	CHUNG, SW; CAI, YL; NYEIN, R; BRIZZOLARA, E; DERIEL, K; WONG, PMC				CHUNG, SW; CAI, YL; NYEIN, R; BRIZZOLARA, E; DERIEL, K; WONG, PMC			ENDOGENOUS GROWTH-FACTOR PATTERNS MODULATE HEMATOPOIETIC LINEAGE DEVELOPMENT	ONCOGENE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; ABL TYROSINE KINASE; ABELSON VIRUS; C-ABL; AUTOCRINE GROWTH; STEM-CELLS; V-ABL; MYELOPROLIFERATIVE DISEASE	Hemopoietic growth factors play an important role during stem cell differentiation, and multipotent hemopoietic cells expressing abl oncogenes can cause stem cell diseases in mice. To further elucidate the mechanism of disease development, we examined the initial changes of normal and abl-transduced progenitor cells early in culture, including the endogenous production of growth factors. From 2-3 days methycellulose cultures, we isolated colonies of early cells and subjected them to RT-PCR analysis. They were found to produce endogenous IL-1 alpha and IL-4. Treatment of these early cells with the antisense oligonucleotides directed against the mRNA of the growth factors did not prevent colony formation. However, the percentage of pure macrophage colonies in cultures containing the antisense IL-1 alpha was increased from 26-60%. This effect was not observed when the antisense oligomers were added 2 days after initiation of culture. We also transduced the progenitor cells with retrovirus vectors carrying either a neo(r) gene (N2) or a v-abl oncogene (A-MuLV or NSabl). After their culture in methylcellulose, we examined the types of colonies developed, growth factor expression by the early cells and their proliferation rate. While the ratio of erythroid to non-erythroid hemopoietic colonies in uninfected culture and N2-infected culture was 0.8, the ratio in A-MuLV-infected culture was 6.0, and in NSabl-infected culture, 3.1. RT-PCR analysis on colonies of abl-transduced cells from 2-3 day cultures indicated a reduction of IL-4 and IL-1 alpha in these cells, and they entered cell division sooner. Our data suggest that hematopoietic lineage development may be a function of the pattern of endogenous as well as exogenous growth factors, and alteration of this pattern either through antisense treatment or v-abl transduction affects the hemopoietic differentiation program.	TEMPLE UNIV, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, DEPT IMMUNOL & MICROBIOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	CHUNG, SW (corresponding author), SUNY HLTH SCI CTR, MORSE INST MOLEC GENET, DEPT MICROBIOL & IMMUNOL, BROOKLYN, NY 11203 USA.				NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041298] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA12227] Funding Source: Medline; NHLBI NIH HHS [HL46547] Funding Source: Medline; NIDDK NIH HHS [DK41298] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CHUNG SW, 1988, BLOOD, V71, P973; CHUNG SW, 1986, BLOOD, V68, P1074; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; CHUNG SW, 1987, RECENT ADV LEUKEMIA, V61, P181; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; HAN XD, 1991, P NATL ACAD SCI USA, V88, P10129, DOI 10.1073/pnas.88.22.10129; Hariharan I K, 1988, Oncogene Res, V3, P387; HERMINE O, 1991, BLOOD, V78, P2253; HUMPHRIES RK, 1988, EXP HEMATOL, V16, P774; JEAN JYW, 1993, CURR BIOL, V3, P35; JOHNSON GR, 1985, EXP HEMATOL, V13, P200; JURGENSEN CH, 1986, J IMMUNOL, V136, P4542; KATAYAMA N, 1993, BLOOD, V81, P610; KELLER G, 1989, GENE DEV, V3, P827, DOI 10.1101/gad.3.6.827; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KISHI K, 1989, J CELL PHYSIOL, V139, P463, DOI 10.1002/jcp.1041390303; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; MURAGUCHI A, 1986, J IMMUNOL, V137, P179; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PECH N, 1993, BLOOD, V82, P1502; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; RAMBALDI A, 1987, BLOOD, V69, P1409; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SIRARD C, 1994, BLOOD, V83, P1575; SMITH KA, 1980, J EXP MED, V151, P1551, DOI 10.1084/jem.151.6.1551; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; WANECK GL, 1981, CELL, V26, P79, DOI 10.1016/0092-8674(81)90035-0; WANECK GL, 1986, CELL, V44, P337, DOI 10.1016/0092-8674(86)90768-3; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WONG PMC, 1987, EXP HEMATOL, V15, P280; WONG PMC, 1988, EXP HEMATOL, V16, P5; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; WONG PMC, 1982, P NATL ACAD SCI-BIOL, V79, P2952, DOI 10.1073/pnas.79.9.2952; WONG PMC, 1987, GENE DEV, V1, P358, DOI 10.1101/gad.1.4.358; ZUBIAGA AM, 1991, J IMMUNOL, V146, P3849	49	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3527	3533						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970713				2022-12-25	WOS:A1994PT39200015
J	KATAHIRA, J; SIOMI, H; ISHIZAKI, T; UMEMOTO, T; TANAKA, Y; SHIDA, H				KATAHIRA, J; SIOMI, H; ISHIZAKI, T; UMEMOTO, T; TANAKA, Y; SHIDA, H			A CELLULAR PROTEIN WHICH IS COPRECIPITATED WITH HTLV-I REX PROTEIN IN THE PRESENCE OF THE TARGET MESSENGER-RNA	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; RNA RESPONSE ELEMENTS; DOMINANT-NEGATIVE MUTANTS; LEUKEMIA-VIRUS; HIV-1 REV; GENE-EXPRESSION; MESSENGER-RNA; TYPE-1 REV; REGULATORY PROTEINS	We examined the cellular protein(s) which can associate with Rex protein of human T cell leukemia virus type I (HTLV-I), using Rex-maltose binding protein (MBP) fusion protein. Immunoprecipitation of RexMBP with anti-MBP antibody revealed that a 24 kD protein (p24) associated with RexMBP only in the presence of Rex-responsive mRNA. The fact that p24 was present in both the nucleus and the cytoplasm is consistent with a role of Rex in the nucleo-cytoplasmic transport of viral mRNAs. P24 did not interact with nonfunctional Rex mutant proteins even if they had RNA binding activity in vitro. These results suggest the possible involvement of p24 in the Rex function through a complex formation with Rex on Rex-responsive mRNA.	KYOTO UNIV,INST VIRUS RES,KYOTO 60601,JAPAN; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; KITASATO UNIV,SCH HYG SCI,DEPT IMMUNOL,SAGAMIHARA,KANAGAWA 228,JAPAN; UNIV OSAKA PREFECTURE,COLL AGR,VET PUBL HLTH LAB,SAKAI,OSAKA 591,JAPAN	Kyoto University; University of Pennsylvania; Kitasato University; Osaka Metropolitan University			Siomi, Haruhiko/A-7020-2015	Siomi, Haruhiko/0000-0001-8690-3822				AHMED YF, 1990, GENE DEV, V4, P1014, DOI 10.1101/gad.4.6.1014; ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; BALLAUN C, 1991, J VIROL, V65, P4408, DOI 10.1128/JVI.65.8.4408-4413.1991; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; BOGERD HP, 1991, P NATL ACAD SCI USA, V88, P5704, DOI 10.1073/pnas.88.13.5704; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; ETCHISON D, 1987, J VIROL, V61, P2702, DOI 10.1128/JVI.61.9.2702-2710.1987; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRASSMANN R, 1991, J VIROL, V65, P3721, DOI 10.1128/JVI.65.7.3721-3727.1991; HADZOPOULOUCLAD.M, 1989, J VIROL, V63, P1959; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOLLAND MJ, 1990, PCR PROTOCOLS GUIDE, P169; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; RIMSKY L, 1989, NATURE, V341, P453, DOI 10.1038/341453a0; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; SAKAI H, 1990, J VIROL, V64, P5833, DOI 10.1128/JVI.64.12.5833-5839.1990; SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI JG, 1985, J VIROL, V55, P831, DOI 10.1128/JVI.55.3.831-835.1985; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; TRONO D, 1990, EMBO J, V9, P4155, DOI 10.1002/j.1460-2075.1990.tb07638.x; UNGE T, 1991, P NATL ACAD SCI USA, V88, P7145, DOI 10.1073/pnas.88.16.7145; WEICHSELBRAUN I, 1992, J VIROL, V66, P4540, DOI 10.1128/JVI.66.7.4540-4545.1992; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; WINSLOW BJ, 1993, J VIROL, V67, P2349, DOI 10.1128/JVI.67.4.2349-2354.1993; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	59	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3535	3544						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970714				2022-12-25	WOS:A1994PT39200016
J	TREADWAY, JL; HARGROVE, DM; NARDONE, NA; MCPHERSON, RK; RUSSO, JF; MILICI, AJ; STUKENBROK, HA; GIBBS, EM; STEVENSON, RW; PESSIN, JE				TREADWAY, JL; HARGROVE, DM; NARDONE, NA; MCPHERSON, RK; RUSSO, JF; MILICI, AJ; STUKENBROK, HA; GIBBS, EM; STEVENSON, RW; PESSIN, JE			ENHANCED PERIPHERAL GLUCOSE-UTILIZATION IN TRANSGENIC MICE EXPRESSING THE HUMAN GLUT4 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; TRANSPORTER GENE; DIABETIC RATS; PRETRANSLATIONAL SUPPRESSION; DIFFERENTIAL REGULATION; DECREASED EXPRESSION; ADIPOSE-TISSUE; INSULIN; ADIPOCYTES; MELLITUS	Human GLUT4 protein expression in muscle and adipose tissues of transgenic mice decreases plasma insulin and glucose levels and improves glucose tolerance compared with nontransgenic controls (Liu, M.-L., Gibbs, E. M., McCoid, S. C., Milici, A. J., Stukenbrok, H. A., McPherson, R. K., Treadway, J. L., and Pessin, J. E. (1993) Proc. Natl. Acad. Sci. U.S. A. 90, 11346-11350). We examined the basis of improved glycemic control in hGLUT4 transgenic mice by determining glucose homeostasis and metabolic profiles in vivo. Glucose turnover experiments indicated a 1.4-fold greater systemic glucose clearance in hGLUT4 mice relative to controls (p < 0.05), whereas hepatic glucose production was similar despite 26% lower (p < 0.05) glucose levels. Glucose infusion rate during an euglycemic-hyperinsulinemic clamp was e-fold greater (p < 0.05) in hGLUT4 mice versus controls, and skeletal muscle and heart glycogen content were increased 3-5-fold (p < 0.05). The increased peripheral glucose clearance in hGLUT4 mice was associated with increased (25-32%) basal and insulin-stimulated glucose transport rate in soleus muscle (p < 0.01), and increased muscle plasma membrane-associated GLUT4 protein. Fed hGLUT4 mice displayed 20-30% lower plasma glucose and insulin levels (p < 0.05) and 43% elevated glucagon levels (p < 0.001) compared with controls. Triglycerides, free fatty acids, and P-hydroxybutyrate were elevated 43-63% (p < 0.05) in hGLUT4 mice due to hypoinsulinemia-induced lipolysis. Free fatty acids and P-hydroxybutyrate levels in hGLUT4 mice increased further upon fasting, and skeletal muscle glycogen levels decreased markedly compared with controls. The data demonstrate that high level expression of hGLUT4 increases systemic glucose clearance and muscle glucose utilization in vivo and also results in marked compensatory Lipolysis and muscle glycogenolysis during a fast.	PFIZER INC,DIV CENT RES,DEPT IMMUNOL & INFECT DIS,GROTON,CT 06340; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Pfizer; University of Iowa	TREADWAY, JL (corresponding author), PFIZER INC,DIV CENT RES,DEPT METAB DIS,EASTERN POINT RD,GROTON,CT 06340, USA.				NIDDK NIH HHS [DK42452, DK44612, DK25925] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042452, R01DK044612] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRETT EJ, 1994, METABOLISM, V43, P285, DOI 10.1016/0026-0495(94)90094-9; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BRANT AM, 1992, CELL SIGNAL, V4, P641, DOI 10.1016/0898-6568(92)90045-A; BUSE JB, 1992, DIABETES, V41, P1436, DOI 10.2337/diabetes.41.11.1436; DEEMS RO, 1994, BIOCHEM BIOPH RES CO, V199, P662, DOI 10.1006/bbrc.1994.1279; DOHM GL, 1991, AM J PHYSIOL, V260, pE459, DOI 10.1152/ajpendo.1991.260.3.E459; EZAKI O, 1993, P NATL ACAD SCI USA, V90, P3348, DOI 10.1073/pnas.90.8.3348; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; HASSID WZ, 1957, METHOD ENZYMOL, V3, P34, DOI 10.1016/S0076-6879(57)03345-5; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KAHN BB, 1991, J CLIN INVEST, V87, P561, DOI 10.1172/JCI115031; KAHN BB, 1991, J CLIN INVEST, V87, P2197, DOI 10.1172/JCI115254; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MILICI AJ, 1991, J ELECTRON MICR TECH, V19, P305, DOI 10.1002/jemt.1060190306; OLSON AL, 1993, J BIOL CHEM, V268, P9839; REN JM, 1993, J BIOL CHEM, V268, P16113; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; ZORZANO A, 1985, BIOCHEM J, V232, P585, DOI 10.1042/bj2320585	24	93	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29956	29961						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961994				2022-12-25	WOS:A1994PU28400098
J	DAVLETOV, BA; SUDHOF, TC				DAVLETOV, BA; SUDHOF, TC			CA2+-DEPENDENT CONFORMATIONAL CHANGE IN SYNAPTOTAGMIN-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE-C; P65; CALCIUM; BINDING; DOMAIN	Synaptotagmin I is a Ca2+/phospholipid binding protein of synaptic vesicles with a proposed function as a Ca2+ sensor in synaptic vesicle exocytosis. Using controlled partial proteolysis as an assay, we now show that synaptotagmin I undergoes a conformational change as a function of Ca2+ binding. As observed for phospholipid binding, Ba2+ and SR(2+) but not Mg2+, substitute for Ca2+ in effecting this conformational change. The first C-2 domain from synaptotagmin I that represents the Ca2+-dependent phospholipid binding domain of synaptotagmin also undergoes a Ca2+-dependent change in controlled partial proteolysis. In contrast, no effect of Ca2+ was observed with mutant C-2 domains containing point mutations that abolish Ca2+ binding. The Ca2+ concentration dependence of the effect of Ca2+ on proteolysis mirrors the Ca2+ dependence of phospholipid binding. The conformational shift in synaptotagmin I caused by Ca2+/phospholipid binding could be the basis for its Ca2+-regulated function in triggering neurotransmitter release.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275				BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OHNISHI M, 1987, BIOCHEMISTRY-US, V26, P7458, DOI 10.1021/bi00397a039; ORR JW, 1994, J BIOL CHEM, V269, P8383; PERIN MS, 1994, J BIOL CHEM, V269, P8576; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; WISE BC, 1982, J BIOL CHEM, V257, P8481; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	23	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28547	28550						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961798				2022-12-25	WOS:A1994PU16800007
J	INOUE, I; RECHSTEINER, M				INOUE, I; RECHSTEINER, M			ON THE RELATIONSHIP BETWEEN THE METABOLIC AND THERMODYNAMIC STABILITIES OF T4 LYSOZYMES - MEASUREMENTS IN EUKARYOTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELA-CELLS; INTRACELLULAR-DISTRIBUTION; SERUM WITHDRAWAL; PEST HYPOTHESIS; HEAT-SHOCK; DEGRADATION; PROTEINS; UBIQUITIN; PEPTIDE; MICROINJECTION	We have measured the metabolic stabilities of wildtype and 17 temperature-sensitive mutants of T4 lysozyme in HeLa cells, in Xenopus egg extract, and in reticulocyte lysate. [S-35]Methionine-labeled T4 lysozymes were expressed in Escherichia coli, purified, injected into HeLa cells, and their degradation rates were determined. Wild-type T4 lysozyme has a half-life of 4 h; the half-lives of 16 lysozyme variants ranged from 2 to 10 h. Surprisingly, the most temperature-sensitive enzyme in the set, R96H, was significantly more stable (half-life = 10 h). Different T4 lysozyme variants yield conflicting answers to the proposed relationship between thermal and metabolic stabilities. For mutations at Thr(157) there is no correlation between melting temperature and half life. By contrast, T4 lysozymes mutated at various positions show a definite correlation between the two parameters. Treatment of injected HeLa cells with the lysosomotropic agents chloroquine or ammonium chloride did not alter the stability of T4 lysozyme. However, the enzyme's half-life increased 10-fold in HeLa cells depleted of ATP. Although T4 lysozyme is degraded rapidly within HeLa cells, the molecule is stable in reticulocyte lysate and Xenopus egg extract. Presumably, there is a specific proteolytic event(s) in HeLa cells which is not manifest in the in vitro extracts.			INOUE, I (corresponding author), UNIV UTAH, SCH MED, DEPT BIOCHEM, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027159] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-27159] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKER JM, 1983, P NATL ACAD SCI-BIOL, V80, P2166, DOI 10.1073/pnas.80.8.2166; BACKER JM, 1986, P NATL ACAD SCI USA, V83, P5830, DOI 10.1073/pnas.83.16.5830; BALLARD FJ, 1976, BIOCHEM J, V154, P717, DOI 10.1042/bj1540717; BIGELOW S, 1981, CELL, V25, P83, DOI 10.1016/0092-8674(81)90233-6; BRAKCH N, 1989, J BIOL CHEM, V264, P15912; CARLSON N, 1987, J CELL BIOL, V104, P537, DOI 10.1083/jcb.104.3.537; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIN DT, 1982, P NATL ACAD SCI-BIOL, V79, P5857, DOI 10.1073/pnas.79.19.5857; DIAZNIDO J, 1991, J CELL SCI, V98, P409; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FRANCIS GL, 1980, BIOCHEM J, V186, P581, DOI 10.1042/bj1860581; HALBAN PA, 1994, BIOCHEM J, V299, P1; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOPGOOD MF, 1988, BIOCHEM J, V256, P81, DOI 10.1042/bj2560081; INOUE I, 1994, J BIOL CHEM, V269, P29241; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; MCGARRY T, 1983, J CELL BIOL, V96, P338, DOI 10.1083/jcb.96.2.338; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; PAKULA AA, 1989, PROTEINS, V5, P202, DOI 10.1002/prot.340050303; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RECHSTEINER M, 1974, J CELL PHYSIOL, V84, P409, DOI 10.1002/jcp.1040840309; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROGERS SW, 1988, J BIOL CHEM, V263, P19833; ROGERS SW, 1988, J BIOL CHEM, V263, P19850; ROGERS SW, 1988, J BIOL CHEM, V263, P19843; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; ZAVORTINK M, 1979, J CELL PHYSIOL, V100, P175, DOI 10.1002/jcp.1041000118	38	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29247	29251						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961893				2022-12-25	WOS:A1994PU16800106
J	NISHIHARA, S; NARIMATSU, H; IWASAKI, H; YAZAWA, S; AKAMATSU, S; ANDO, T; SENO, T; NARIMATSU, I				NISHIHARA, S; NARIMATSU, H; IWASAKI, H; YAZAWA, S; AKAMATSU, S; ANDO, T; SENO, T; NARIMATSU, I			MOLECULAR-GENETIC ANALYSIS OF THE HUMAN LEWIS HISTO-BLOOD GROUP SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; FUCT-III GENE; FUCOSYL-TRANSFERASE; NEGATIVE INDIVIDUALS; GOLGI RETENTION; GASTROINTESTINAL CANCER; DETERMINES EXPRESSION; CARBOHYDRATE LIGANDS; COLORECTAL-CARCINOMA; ADHESION MOLECULES	The expression of Lewis histo-blood group antigen is determined by the Lewis type alpha(1,3/1,4) fucosyltransferase encoded in Fuc-TIII gene (Le gene) on chromosome 19. Weak hemagglutination reactions are often observed in the Lewis blood typing to cause false-negative reactions. The level of CA19-9 tumor marker, defined as sialylated Le(a) (sLe(a)), is influenced by the Lewis blood phenotype. The sLe(a) antigen is also considered to play a role in hematogenous metastasis of tumor cells. The accurate genotyping of Fuc-TIII gene would be, therefore, necessary for solving above questions. In addition to the two missense mutations previously reported by us, i.e. the T59G and the G508G further sequence analyses revealed a new single base substitution, the T1067A, changing the Ile(356) to Lys in the catalytic region. Polymerase chain reaction-restriction fragment length polymorphism methods were developed for the detection of these three missense mutations and applied in 15 Lewis negative (le/le) and 65 Lewis positive individuals (Le/Le or Le/le). These methods were found to be useful for genetic diagnosis for the Lewis histo-blood typing. Ah le alleles had the T59G mutation, whereas none of the Le alleles did. The le alleles were divided in two types, le1, having the G508A mutation, and le2, having the T1067A mutation. The T1067A mutation reduced the enzyme activity less than 10%, whereas the G508A mutation in the catalytic domain made the enzyme completely inactive. The frequency of occurrence of Le, le1, and le2 in the Japanese population by random sampling study was found to be 66, 30, and 4%, respectively.	SOKA UNIV,INST LIFE SCI,CELL BIOL GRP,HACHIOJI,TOKYO 192,JAPAN; GUNMA UNIV,SCH MED,DEPT LEGAL MED,MAEBASHI,GUMMA 371,JAPAN; OTSUKA PHARMACEUT CO LTD,DIV DIAGNOST,TOKUSHIMA 77101,JAPAN; BML INC,DIV BASIC RES,KAWAGOE,SAITAMA,JAPAN; OSAKA RED CROSS BLOOD CTR,OSAKA,JAPAN; SAISEIKAI CENT HOSP,DEPT MED,MIYOSHI,SAITAMA,JAPAN	Soka University; Gunma University; Otsuka Pharmaceutical; BML, Inc.; Osaka Red Cross Hospital; Tokyo Saiseikai Central Hospital				Nishihara, Shoko/0000-0002-1668-2603				AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; ARENDS JW, 1984, INT J CANCER, V34, P193, DOI 10.1002/ijc.2910340209; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BURKE J, 1992, J BIOL CHEM, V267, P24433; ELMGREN A, 1993, BIOCHEM BIOPH RES CO, V196, P515, DOI 10.1006/bbrc.1993.2280; FRANCOIS A, 1986, VOX SANG, V50, P227, DOI 10.1111/j.1423-0410.1986.tb04887.x; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOD AH, 1992, VOX SANG, V62, P180, DOI 10.1111/j.1423-0410.1992.tb01195.x; HAKOMORI SI, 1992, HISTOCHEM J, V24, P771, DOI 10.1007/BF01046348; HAMMAR L, 1981, VOX SANG, V40, P27, DOI 10.1111/j.1423-0410.1981.tb00665.x; HERLYN M, 1982, J CLIN IMMUNOL, V2, P135, DOI 10.1007/BF00916897; HONKE K, 1993, HUM GENET, V92, P451, DOI 10.1007/BF00216449; KODA Y, 1993, BLOOD, V82, P2915; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MAKNI S, 1987, EXP CLIN IMMUNOGENET, V4, P136; MANDEL U, 1991, VOX SANG, V61, P205, DOI 10.1111/j.1423-0410.1991.tb00947.x; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MOURO I, 1993, NAT GENET, V5, P62, DOI 10.1038/ng0993-62; NAKAMORI S, 1993, CANCER RES, V53, P3632; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V196, P624, DOI 10.1006/bbrc.1993.2295; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; SALMON C, 1984, LEWIS SYSTEM HUMAN B, P162; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SIDMANN FK, 1981, TECHNICAL MANUAL AM; STIGENDAL L, 1984, J CLIN PATHOL, V37, P778, DOI 10.1136/jcp.37.7.778; TAKADA A, 1993, CANCER RES, V53, P354; Watkins W M, 1980, Adv Hum Genet, V10, P1; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WICKER G, 1991, J BIOL CHEM, V266, P21386; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; YAGO K, 1993, CANCER RES, V53, P5559; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1993, VOX SANG, V64, P175, DOI 10.1111/j.1423-0410.1993.tb05158.x; YAZAWA S, 1990, ANAL BIOCHEM, V187, P374, DOI 10.1016/0003-2697(90)90472-L; YAZAWA S, 1992, CLIN CHEM, V38, P2392; YAZAWA S, 1988, JPN J CANCER RES, V79, P538, DOI 10.1111/j.1349-7006.1988.tb01624.x	43	119	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29271	29278						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961897				2022-12-25	WOS:A1994PU16800110
J	WARRIAR, N; YU, CY; PAGE, N; GOVINDAN, MV				WARRIAR, N; YU, CY; PAGE, N; GOVINDAN, MV			SUBSTITUTION OF CYS-560 BY PHE, TRP, TYR, AND SER IN THE FIRST ZINC-FINGER OF HUMAN ANDROGEN RECEPTOR AFFECTS HORMONAL SENSITIVITY AND TRANSCRIPTIONAL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLUCOCORTICOID RECEPTOR; GENITAL SKIN FIBROBLASTS; HUMAN ESTROGEN-RECEPTOR; N-TERMINAL DOMAIN; FUNCTIONAL DOMAINS; BINDING DOMAINS; STEROID-BINDING; DNA-BINDING; GENE; INSENSITIVITY	We have established and characterized four human androgen receptor (AR) mutants, AR C560F, C560W, C560Y, C560S). To assess the functional significance of these substitutions, we compared the transcriptional activation, hormone binding affinity, receptor-DNA interaction, and the subcellular distribution of the hormone-receptor complexes. Binding studies showed that all mutants bound methyltrienolone (R1881) with wild type affinity (K-d = 0.5 nM). Transactivation efficiency, as compared to wild type AR, increased 150% with C560F and decreased to 70% with C560W and C560Y and to 40% with mutant C560S. Subcellular receptor distribution showed that 85% of C560F bound with hormone was extracted from the nuclear fraction and 15% in the cytosol. Gel mobility shift assays showed that C560F expressed in CV-1 cells bound to an androgen responsive element (ARE) with equal efficiency as the wild type human AR. The mutants C560W and C560Y demonstrated a lower ability to bind to ARE, whereas C560S showed a significantly lower ability to interact with ARE. We propose that the change in polarity introduced into the loop structure by C560S leads to a shorter period of contact between the mutant receptor and DNA resulting in decreased transcriptional activation levels.	CHU LAVAL,RES CTR,MRC,MOLEC ENDOCRINOL GRP,QUEBEC CITY G1V 4G2,PQ,CANADA; UNIV LAVAL,QUEBEC CITY G1V 4G2,PQ,CANADA	Laval University; Laval University								BROWN TR, 1990, MOL ENDOCRINOL, V4, P1759, DOI 10.1210/mend-4-12-1759; BROWN TR, 1988, P NATL ACAD SCI USA, V85, P8151, DOI 10.1073/pnas.85.21.8151; BROWN TR, 1982, J CLIN ENDOCR METAB, V55, P61, DOI 10.1210/jcem-55-1-61; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FABER PW, 1989, MOL CELL ENDOCRINOL, V61, P257, DOI 10.1016/0303-7207(89)90137-8; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GOVINDAN MV, 1990, MOL ENDOCRINOL, V4, P417, DOI 10.1210/mend-4-3-417; GOVINDAN MV, 1982, P NATL ACAD SCI-BIOL, V79, P5157, DOI 10.1073/pnas.79.17.5157; GOVINDAN MV, 1991, J STEROID BIOCHEM, V39, P91, DOI 10.1016/0960-0760(91)90017-Y; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GUICHONMANTEL A, 1989, NATURE, V336, P695; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KAZEMIESFARJANI P, 1993, MOL ENDOCRINOL, V7, P37, DOI 10.1210/me.7.1.37; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; Maniatis T., 1982, MOL CLONING; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; RISSTALPERS C, 1991, MOL ENDOCRINOL, V5, P1562, DOI 10.1210/mend-5-10-1562; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SMITH DF, 1990, J BIOL CHEM, V265, P3996; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; TRAPMAN J, 1988, BIOCHEM BIOPH RES CO, V153, P241, DOI 10.1016/S0006-291X(88)81214-2; TRIFIRO M, 1991, MOL CELL ENDOCRINOL, V75, P37, DOI 10.1016/0303-7207(91)90243-L; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WARRIAR N, 1994, PROSTATE, V24, P176, DOI 10.1002/pros.2990240403; WARRIAR N, 1993, J STEROID BIOCHEM, V46, P699, DOI 10.1016/0960-0760(93)90311-J; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WILSON JD, 1974, NEW ENGL J MED, V290, P1097, DOI 10.1056/NEJM197405162902001; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	42	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29016	29023						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961866				2022-12-25	WOS:A1994PU16800076
J	KALAFATIS, M; RAND, MD; MANN, KG				KALAFATIS, M; RAND, MD; MANN, KG			THE MECHANISM OF INACTIVATION OF HUMAN FACTOR-V AND HUMAN FACTOR VA BY ACTIVATED PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; HUMAN FACTOR-VIII; THROMBIN-CATALYZED ACTIVATION; POOR ANTICOAGULANT RESPONSE; ANTI-HEMOPHILIC FACTOR; BOVINE FACTOR-V; FACTOR-XA; BLOOD-COAGULATION; COFACTOR ACTIVITY; ENZYME COMPLEXES	The cleavage of human factor V and human factor Va by human activated protein C (APC) was analyzed in the absence and presence of phospholipid vesicles containing 75% phosphatidylcholine (PC) and 25% phosphatidylserine (PS). Membrane-bound human factor V (250 nM) is cleaved by APC (2.5 nM) to give M(r) = 200,000, 70,000, 45,000, and 30,000 fragments and an M(r) = 22/20,000 doublet. These fragments are released after four sequential cleavages of the membrane bound procofactor at Arg(308), Arg(506), Arg(679) and Lys994. No cofactor activity is observed following thrombin treatment of the membrane-bound APC-cleaved procofactor. In the absence of a membrane surface, no cleavage of factor V by APC is observed, and following thrombin activation factor Va retains full cofactor activity, Membrane-bound human factor Va (600 nM) loses more than 90% of its initial cofactor activity after 10 min of incubation with APC (10.9 nM), and virtually no cofactor activity is observed after 1 h of incubation. Under similar conditions but in the absence of PCPS vesicles, factor Va is cleaved but retains approximately 80% of its initial cofactor activity after 2 h of incubation with APC, In the presence of PCPS vesicles, the APC related loss of activity is correlated with cleavage of the heavy chain and appearance of fragments of M(r) = 45,000, 30,000, and of 28/26,000, and 22/20,000 doublets, These products correspond to three cleavages of the heavy chain (at Arg(306), Arg(506) and Arg(679)). Cleavage at Arg(506) of factor Va precedes and appears to be required for cleavage at Arg(306) and Arg(679). In the absence of membrane, proteolysis at Arg(506) produces an M(r) = 75,000 fragment which corresponds to the NH2-terminal portion of the human factor Va heavy chain (residues 1-506), and a carboxyI-terminal doublet of M(r) = 28/26,000 (residues 507-709) which is cleaved by APC at Arg(679) to generate an M(r) = 22/20,000 doublet and an M(r) = 6,000 peptide. No cleavage of the light chain of the human cofactor is observed in the presence or absence of PCPS vesicles following 2 h of incubation with APC, Our data demonstrate that inactivation of human factor V and human factor Va only occurs in the presence of a membrane surface after cleavage at Arg(306). However, while this cleavage site is exposed an membrane bound human factor V, cleavage at Arg(506) on the heavy chain of factor Va appears necessary for complete exposure of the cleavage site at Arg(306).	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405	University of Vermont					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034575, T32HL007594] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL34575, T32 HL07594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOVILL EG, 1992, BLOOD, V79, P1456, DOI 10.1182/blood.V79.6.1456.bloodjournal7961456; BRANDT JT, 1986, ARCH PATHOL LAB MED, V110, P224; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; EATAM D, 1986, BIOCHEMISTRY-US, V25, P505; ESMON CT, 1979, J BIOL CHEM, V254, P964; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; FULCHER CA, 1984, BLOOD, V63, P486; Gomori G, 1942, J LAB CLIN MED, V27, P955; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; GRIFFIN JH, 1993, BLOOD, V82, P1989; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KALAFATIS M, 1993, BLOOD, V81, P704; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KANE WH, 1981, J BIOL CHEM, V256, P1002; KAPUR A, 1993, AM J HEMATOL, V42, P384, DOI 10.1002/ajh.2830420410; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KISIEL W, 1981, METHOD ENZYMOL, V80, P275; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LU DS, 1994, BLOOD, V84, P687; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MARLAR RA, 1982, BLOOD, V59, P1067; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NESHEIM ME, 1986, J CLIN INVEST, V77, P405, DOI 10.1172/JCI112318; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NESHEIM ME, 1980, METHOD ENZYMOL, V80, P243; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; SALEM HH, 1983, J BIOL CHEM, V258, P8531; SALEM HH, 1983, P NATL ACAD SCI-BIOL, V80, P1584, DOI 10.1073/pnas.80.6.1584; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SUN X, 1994, BLOOD, V83, P3120; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TAILLAN B, 1989, AM J MED, V87, P360; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7	66	359	368	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31869	31880						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989361				2022-12-25	WOS:A1994PX30300083
J	PESTELL, RG; HOLLENBERG, AN; ALBANESE, C; JAMESON, JL				PESTELL, RG; HOLLENBERG, AN; ALBANESE, C; JAMESON, JL			C-JUN REPRESSES TRANSCRIPTION OF THE HUMAN CHORIONIC-GONADOTROPIN ALPHA-GENES AND BETA-GENES THROUGH DISTINCT TYPES OF CRES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; DNA-BINDING ACTIVITY; CYCLIC-AMP; RESPONSE ELEMENT; SUBUNIT GENE; FOS JUN; V-JUN; FUNCTIONAL ANTAGONISM; HETERODIMER FORMATION; NEGATIVE REGULATOR	Chorionic gonadotropin (CG) is a heterodimeric placental hormone encoded by separate alpha and beta subunit genes that is essential for the maintenance of pregnancy. The production of CG is stimulated by DNA synthesis inhibitors and by cAMP. The present study demonstrates that the proto-oncogene c-jun represses transcription of the human CG alpha and CG beta promoters. c-Jun repressed the CG alpha promoter through a canonical cAMP response element (CRE) that is known to bind c-Jun and other members of the B-Zip transcription factor family. In the CG beta promoter, two adjacent sites, CRE1 (-299 to -289) and CRE2 (-240 to -219), conveyed cAMP responsiveness via sequences that are distinct from the canonical element, TGACGTCA. Mutations within CG beta CRE1 or CRE2 reduced or abolished, respectively, c-jun-mediated repression. Although the CG beta CREs do not contain consensus sequences previously described to bind c-Jun, CRE2 bound c-Jun and c-Fos in electrophoretic mobility shift assays. Supershift assays, using anti-JUN antibody, demonstrated that Jun formed part of the native complex that binds the CRE2 in JEG-3 cells. A series of c-Jun mutants were used to analyze the transcription factor domains required for repression of the CG subunit promoters. The DNA binding and leucine zipper domains of c-Jun as web as the amino terminus, were required for repression of both subunit promoters. Thus, both the CG alpha and CG beta genes are repressed by c-Jun through promoter regions that convey cAMP-induced transcription, although these DNA sequences are unrelated.	NORTHWESTERN UNIV,SCH MED,DIV ENDOCRINOL METAB & MOLEC MED,CHICAGO,IL 60611	Northwestern University				Jameson, James/0000-0001-9538-4059	NICHD NIH HHS [HD 23519] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023519] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBANESE C, 1991, MOL ENDOCRINOL, V5, P693, DOI 10.1210/mend-5-5-693; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARBISER JL, 1994, ENDOCRINOLOGY, V134, P582, DOI 10.1210/en.134.2.582; ASPILLAGA MO, 1983, BRIT J OBSTET GYNAEC, V90, P596, DOI 10.1111/j.1471-0528.1983.tb09274.x; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; AZIZKHAN JC, 1979, CANCER RES, V39, P1952; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAUNSTEIN GD, 1976, AM J OBSTET GYNECOL, V126, P678, DOI 10.1016/0002-9378(76)90518-4; CHANG JY, 1978, J CLIN ENDOCR METAB, V47, P46; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; COX GS, 1982, ARCH BIOCHEM BIOPHYS, V216, P234, DOI 10.1016/0003-9861(82)90208-9; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; DRUST DS, 1991, MOL ENDOCRINOL, V5, P1541, DOI 10.1210/mend-5-10-1541; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; GHOSH NK, 1977, BIOCHEM J, V166, P265, DOI 10.1042/bj1660265; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Hussa R O, 1980, Endocr Rev, V1, P268; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; JAMESON JL, 1988, MOL CELL BIOL, V8, P5100, DOI 10.1128/MCB.8.12.5100; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KATO Y, 1991, ENDOCRINOLOGY, V128, P401, DOI 10.1210/endo-128-1-401; KAY TWH, 1992, MOL ENDOCRINOL, V6, P1767, DOI 10.1210/me.6.11.1767; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MILSTED A, 1987, DNA-J MOLEC CELL BIO, V6, P213, DOI 10.1089/dna.1987.6.213; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RINGLER GE, 1989, ENDOCRINOLOGY, V124, P1625, DOI 10.1210/endo-124-4-1625; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STEGER DJ, 1993, MOL ENDOCRINOL, V7, P1579, DOI 10.1210/me.7.12.1579; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WOOD WM, 1989, J BIOL CHEM, V264, P14840; WRANA JL, 1992, COLD SPRING HARB SYM, V57, P81, DOI 10.1101/SQB.1992.057.01.011; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YANGYEN HF, 1991, NEW BIOL, V3, P1206	73	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31090	31096						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983049				2022-12-25	WOS:A1994PV51000056
J	TAYLOR, EW; FEAR, AL; BOHM, A; KIM, SH; KOTHS, K				TAYLOR, EW; FEAR, AL; BOHM, A; KIM, SH; KOTHS, K			STRUCTURE-FUNCTION STUDIES ON RECOMBINANT HUMAN MACROPHAGE-COLONY-STIMULATING FACTOR (M-CSF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING SITE; FACTOR-I; 3-DIMENSIONAL STRUCTURE; HUMAN INTERLEUKIN-6; CRYSTAL-STRUCTURE; GROWTH-FACTORS; EXPRESSION; ACTIVATION; FMS; LOCATION	Human macrophage colony-stimulating factor (M-CSF) is a homodimeric cytokine that is a member of a structurally related family of hormones defined by an unusual up-up-down-down alpha-helical bundle. To identify regions on the surface of M-CSF that might interact with the M-CSF receptor, single and double amino acid substitutions were introduced into a truncated form of human M-CSF by site directed mutagenesis, and the homodimeric M-CSF analogs were purified and characterized. Certain substitutions in the region before and in helix A and in helix C decreased specific bioactivity and correlated with an approximately equivalent reduction in M-CSF receptor affinity. The most dramatic change was observed in an analog in which residues His-9 and His-15 were replaced with alanines, resulting in a 9,100-fold decrease in specific bioactivity. X-ray crystallographic analysis of this M-CSF alpha H9A,H15A analog at a resolution of 2.5 Angstrom revealed no significant changes in structure other than the expected new side chains at residues 9 and 15. Analogs containing only one of these two histidine substitutions exhibited a decrease in specific bioactivity of 6- and 1200-fold for the H9A and H15A mutations, respectively. It appears that selected amino acids in the NH2-terminal region of M-CSF and possibly portions of the surface formed by helices A and C are significantly involved in interactions with the M-CSF receptor.	CHIRON CORP, DEPT BIOL THERAPEUT RES, EMERYVILLE, CA 94608 USA; UNIV CALIF BERKELEY, BIOPHYS GRAD GRP, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV STRUCT BIOL, BERKELEY, CA 94720 USA	Novartis; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley								ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; BERNDT WG, 1994, BIOCHEMISTRY-US, V33, P6571, DOI 10.1021/bi00187a026; BLOOM RD, 1993, KIDNEY INT, V43, P1000, DOI 10.1038/ki.1993.141; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DENESYUK AI, 1994, BIOCHEM BIOPH RES CO, V201, P1396, DOI 10.1006/bbrc.1994.1858; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; HALENBECK R, 1989, BIO-TECHNOL, V7, P710, DOI 10.1038/nbt0789-710; HERCUS TR, 1994, BLOOD, V83, P3500; Higuchi R., 1989, PCR TECHNOLOGY, P61; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; INABA T, 1992, J BIOL CHEM, V267, P5693; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KAUSHANSKY K, 1993, BLOOD, V82, P3229; KAWASAKI ES, 1990, COLONY STIMULATING F, P155; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LI XM, 1993, J BIOL CHEM, V268, P22377; LOPEZ AF, 1992, P NATL ACAD SCI USA, V89, P11842, DOI 10.1073/pnas.89.24.11842; MCKAY DB, 1992, SCIENCE, V257, P412, DOI 10.1126/science.257.5068.412; MUNN DH, 1992, SEMIN ONCOL, V19, P395; NAKOINZ I, 1990, J IMMUNOL, V145, P860; NEMUNAITIS J, 1993, BLOOD, V82, P1422; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; SCHNOLL M, 1993, MOL CARCINOG, V7, P207; SHADLE PJ, 1989, EXP HEMATOL, V17, P154; SHADLE PJ, 1989, J CELL BIOCHEM, V40, P91, DOI 10.1002/jcb.240400110; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STOUDEMIRE JB, 1991, BLOOD, V77, P750; TAKAHASHI M, 1989, BIOCHEM BIOPH RES CO, V161, P892, DOI 10.1016/0006-291X(89)92683-1; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WLODAVER A, 1992, FEBS LETT, V309, P59, DOI 10.1016/0014-5793(92)80739-4; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348; ZURAWSKI SM, 1993, EMBO J, V12, P5113, DOI 10.1002/j.1460-2075.1993.tb06206.x	48	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31171	31177						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983059				2022-12-25	WOS:A1994PV51000067
J	KORCHAK, HM; KANE, LH; ROSSI, MW; CORKEY, BE				KORCHAK, HM; KANE, LH; ROSSI, MW; CORKEY, BE			LONG-CHAIN ACYL-COENZYME-A AND SIGNALING IN NEUTROPHILS - AN INHIBITOR OF ACYL-COENZYME-A SYNTHETASE, TRIACSIN-C, INHIBITS SUPEROXIDE ANION GENERATION AND DEGRANULATION BY HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONOYL-COA SYNTHETASE; PROTEIN-KINASE-C; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CALCIUM-MOBILIZING LIGANDS; FATTY-ACID COMPOSITION; PHOSPHOLIPID-METABOLISM; COVALENT MODIFICATION; LEUCYL-PHENYLALANINE; TRANSPORT VESICLES; GOLGI CISTERNAE	Ligand-initiated activation of neutrophils triggers O-2(-) generation, degranulation, phospholipid remodeling, and release of fatty acids such as arachidonate, oleate, and palmitate. Long chain acyl-CoA synthetase converts free fatty acids to acyl-CoA esters; a role for acyl-CoA esters as positive modulators of neutrophil functions is proposed. Physiologically relevant concentrations (1-10 mu M) of acyl-CoA esters such as palmitoyl-CoA, enhanced O-2(-) generation triggered by fMet Leu-Phe or guanosine 5'-O-(thiotriphosphate) (GTP gamma S) but did not act as a trigger per se. Triacsin C, an inhibitor of acyl-CoA synthetase, inhibited fMet-Leu-Phe-elicited O-2(-) generation and degranulation in a concentration-dependent manner. Triacsin C inhibited O-2(-) generation elicited by fMet-Leu-Phe and GTP gamma S in electroporated neutrophils, indicating that acyl-CoA acted downstream from the receptor. Palmitoyl CoA reversed the Triacsin C-induced inhibition of O-2(-) generation. fMet-Leu-Phe elicited a prompt increase in total long chain acyl CoA esters. Arachidonoyl-CoA and oleoyl-CoA were elevated 5 s after addition of fMet-Leu-Phe, while palmitoyl-CoA was not elevated until 60 s. Triacsin C inhibited fMet-Leu-Phe initiated increases in arachidonoyl-CoA, oleoyl-CoA, and palmitoyl-CoA. These results suggest a role for acyl CoA esters in regulating activation of O-2(-) generation and degranulation at the G protein or subsequent step(s).	UNIV PENN, SCH MED, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA; BOSTON UNIV, SCH MED, DEPT MED, BOSTON, MA 02118 USA	University of Pennsylvania; Boston University			Corkey, Barbara/E-7712-2015	Corkey, Barbara/0000-0002-5467-1630	NIAID NIH HHS [AI 24840] Funding Source: Medline; NIDDK NIH HHS [DK35914, DK 46200] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035914, R01DK035914, P30DK046200, R56DK035914] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; BADWEY JA, 1981, J BIOL CHEM, V256, P2640; BAKKEN AM, 1991, BIOCHEM J, V274, P145, DOI 10.1042/bj2740145; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; BERTHIAUME L, 1994, J BIOL CHEM, V269, P6498; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRONFMAN M, 1988, BIOCHEM BIOPH RES CO, V152, P987, DOI 10.1016/S0006-291X(88)80381-4; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; COCKCROFT S, 1984, BIOCHEM J, V222, P557, DOI 10.1042/bj2220557; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1990, FEMS MICROBIOL IMMUN, V64, P3; CORKEY BE, 1988, METHOD ENZYMOL, V166, P55; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; DONATELLO S, 1988, AM J PHYSIOL, V254, pE181, DOI 10.1152/ajpendo.1988.254.2.E181; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; HAINES KA, 1987, BIOCHEM J, V241, P55, DOI 10.1042/bj2410055; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANSEL BC, 1984, J BIOL CHEM, V259, P1423; HARTMAN EJ, 1989, PROSTAGLANDINS, V37, P655, DOI 10.1016/0090-6980(89)90103-2; HUANG WH, 1989, J BIOL CHEM, V264, P2605; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAKAR SS, 1987, J BIOL CHEM, V262, P42; KLER RS, 1991, J BIOL CHEM, V266, P22932; KORCHAK HM, 1984, J BIOL CHEM, V259, P4076; KORCHAK HM, 1988, J BIOL CHEM, V263, P11090; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; KORCHAK HM, 1984, J BIOL CHEM, V259, P4070; KORCHAK HM, 1984, FED PROC, V43, P2749; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LAPOSATA M, 1985, J BIOL CHEM, V260, P1016; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MAJUMDAR S, 1993, BIOCHIM BIOPHYS ACTA, V1176, P276, DOI 10.1016/0167-4889(93)90056-U; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MCPHAIL LC, 1993, EUR J HAEMATOL, V51, P294; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MUSZBEK L, 1993, J BIOL CHEM, V268, P18243; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; POWELL GL, 1985, FED PROC, V44, P81; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SAMUELSSON B, 1991, Z RHEUMATOL, V50, P3; SCHAFER L, 1991, J INVEST DERMATOL, V96, P16, DOI 10.1111/1523-1747.ep12514674; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P951, DOI 10.1016/0006-291X(82)90615-5; SMOLEN JE, 1980, INFLAMMATION, V4, P145, DOI 10.1007/BF00914161; SOLING HD, 1987, J BIOL CHEM, V262, P16786; STEINBECK MJ, 1991, J LEUKOCYTE BIOL, V49, P360, DOI 10.1002/jlb.49.4.360; STUTCHFIELD J, 1988, BIOCHEM J, V250, P375, DOI 10.1042/bj2500375; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; WALSH CE, 1983, BIOCHIM BIOPHYS ACTA, V750, P32, DOI 10.1016/0005-2760(83)90201-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; WOLDEGIORGIS G, 1985, ANAL BIOCHEM, V150, P8, DOI 10.1016/0003-2697(85)90434-8; WOLDEGIORGIS G, 1982, J BIOL CHEM, V257, P4783; WYNKOOP EM, 1986, BIOCHEM J, V236, P829, DOI 10.1042/bj2360829; YANO K, 1983, BIOCHIM BIOPHYS ACTA, V752, P137, DOI 10.1016/0005-2760(83)90241-2	61	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30281	30287						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982939				2022-12-25	WOS:A1994PU52500039
J	LARM, JA; VAILLANT, F; LINNANE, AW; LAWEN, A				LARM, JA; VAILLANT, F; LINNANE, AW; LAWEN, A			UP-REGULATION OF THE PLASMA-MEMBRANE OXIDOREDUCTASE AS A PREREQUISITE FOR THE VIABILITY OF HUMAN NAMALWA RHO(0) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MITOCHONDRIAL-DNA DELETIONS; CHICK-EMBRYO CELLS; RESPIRATION-DEFICIENT; ELECTRON-TRANSPORT; ETHIDIUM-BROMIDE; AGING PROCESS; NADH OXIDASE; RAT-LIVER; FERRICYANIDE; GROWTH	We have studied aspects of the regulatory interrelationship between the plasma membrane oxidoreductase (PMOR) system and the mitochondrial respiratory capacity of human Namalwa cells. Although the role of mitochondria in the maintenance of cellular redox and energetic states is well established, the PMOR system in comparison is a poorly characterized enzyme system whose functions, particularly in relation to cellular metabolism, have not been clearly elucidated. Therefore we compared the PMOR and mitochondrial respiratory activities of human Namalwa cells during the induction by ethidium bromide treatment of rho(0) cells, which lack a functional mitochondrial respiratory system. The plasma membrane NADH-ferricyanide reductase activity of the PMOR system was found to increase in a stepwise manner concomitant with a decline in cellular mitchondrial respiratory activity. Addition of p-chloromercuriphenylsulfonic acid to the culture medium, at a concentration totally inhibiting the plasma membrane NADH-ferricyanide reductase in vitro, leads to cell death of rho(0) but not of rho(+) cells. Thus, the up-regulation of a functional PMOR system is a necessary phenomenon in maintaining the viability of mammalian rho(0) cells.	MONASH UNIV,DEPT BIOCHEM & MOLEC BIOL,CLAYTON,VIC 3168,AUSTRALIA; MONASH UNIV,CTR MOLEC BIOL & MED,CLAYTON,VIC 3168,AUSTRALIA	Monash University; Monash University			Linnane, Anthony W/A-6546-2011; Lawen, Alfons/A-6598-2008	Lawen, Alfons/0000-0001-6553-9945				ALEDORT LM, 1968, BLOOD, V31, P471, DOI 10.1182/blood.V31.4.471.471; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BAUMER A, 1994, AM J HUM GENET, V54, P618; BRIGHTMAN AO, 1992, BIOCHIM BIOPHYS ACTA, V1105, P109, DOI 10.1016/0005-2736(92)90168-L; CLARK MG, 1981, BIOCHEM J, V200, P565, DOI 10.1042/bj2000565; CRANE FL, 1982, J BIOENERG BIOMEMBR, V14, P191, DOI 10.1007/BF00745020; CRANE FL, 1991, J BIOENERG BIOMEMBR, V23, P773, DOI 10.1007/BF00786001; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; DESJARDINS P, 1986, SOMAT CELL MOLEC GEN, V12, P133, DOI 10.1007/BF01560660; ELLEM KAO, 1983, BIOCHEM BIOPH RES CO, V112, P183, DOI 10.1016/0006-291X(83)91814-4; GOLDENBERG H, 1979, J BIOL CHEM, V254, P2491; GREGOIRE M, 1984, EUR J BIOCHEM, V142, P49, DOI 10.1111/j.1432-1033.1984.tb08249.x; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LAWEN A, 1994, IN PRESS MOL ASP MED; LEIBOWITZ RD, 1971, J CELL BIOL, V51, P116, DOI 10.1083/jcb.51.1.116; LINNANE AW, 1992, MUTAT RES, V275, P195, DOI 10.1016/0921-8734(92)90023-I; LINNANE AW, 1990, BIOCHEM INT, V22, P1067; LINNANE AW, 1992, MOL BIOL MYOCARDIUM, P119; MARTINUS RD, 1993, BIOCHEM MOL BIOL INT, V31, P997; MARZUKI S, 1991, PROG NEUROPATH, V7, P181; MORAIS R, 1980, BIOCHEM BIOPH RES CO, V94, P71, DOI 10.1016/S0006-291X(80)80189-6; MORRE DJ, 1991, J BIOENERG BIOMEMBR, V23, P469, DOI 10.1007/BF00771015; MULLERHOCKER J, 1992, BRAIN PATHOL, V2, P149, DOI 10.1111/j.1750-3639.1992.tb00683.x; MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167; OLDFORS A, 1992, J NEUROL SCI, V110, P169, DOI 10.1016/0022-510X(92)90025-G; Shoubridge Eric A., 1993, P109; SUN IL, 1992, P NATL ACAD SCI USA, V89, P11126, DOI 10.1073/pnas.89.23.11126; SUN IL, 1984, J BIOENERG BIOMEMBR, V16, P583, DOI 10.1007/BF00743247; SUN IL, 1985, EXP CELL RES, V156, P528, DOI 10.1016/0014-4827(85)90559-2; VAILLANT F, 1991, BIOCHEM INT, V23, P571; VAILLANT F, 1994, THESIS MONASH U CLAY; VANSTEVENINCK J, 1965, J GEN PHYSIOL, V48, P617, DOI 10.1085/jgp.48.4.617; WARING MJ, 1965, J MOL BIOL, V13, P269, DOI 10.1016/S0022-2836(65)80096-1; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7	36	130	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30097	30100						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982910				2022-12-25	WOS:A1994PU52500009
J	CHI, NW; KOLODNER, RD				CHI, NW; KOLODNER, RD			PURIFICATION AND CHARACTERIZATION OF MSH1, A YEAST MITOCHONDRIAL PROTEIN THAT BINDS TO DNA MISMATCHES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTS-ENCODED PROTEIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; PYRIMIDINE DIMERS; GENE CONVERSION; RIBOSOMAL-RNA; REPAIR; RECOMBINATION; SEQUENCES	MSH1 is a homologue of the Escherichia coli MutS gene that is proposed to play an important role in the repair and maintenance of mitochondrial DNA in Saccharomyces cerevisiae (Reenan, R. A., and Kolodner, R. D. (1992) Genetics 132, 975-985). In this study, we demonstrate that msh1/MSH1 strains accumulate point mutations in mitochondria seven times faster than the wild-type. We also show that the MSH1 protein is targeted to the mitochondria where its mitochondrial-targeting sequence is removed. Purified MSH1 hydrolyzes ATP and recognizes DNA substrates containing nucleotide mismatches and unpaired nucleotides. The hierarchy of binding affinity of MSH1 among various mismatches is similar to that of MutS, suggesting that both proteins share a highly conserved scheme for recognizing mismatches. The specific binding of MSH1 to mismatches is more resistant to NaCl inhibition and has a slower dissociation rate as compared to the nonspecific binding to complementary DNA sequences. Our data support the idea that MSH1 plays a role in eliminating biosynthetic errors and homeologous recombination in mitochondrial genome by recognizing premutagenic DNA mismatches.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00305] Funding Source: Medline; NIGMS NIH HHS [GM50006] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1994, GENETICS, V137, P19; AU KG, 1992, J BIOL CHEM, V267, P12142; BACKER J, 1985, CURR GENET, V10, P7, DOI 10.1007/BF00418487; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; CHI NW, 1994, J BIOL CHEM, V269, P29984; CLARKWALKER GD, 1991, CURR GENET, V20, P195, DOI 10.1007/BF00326232; CUI Z, 1989, CURR GENET, V16, P273, DOI 10.1007/BF00422114; DIECKMANN CL, 1987, EMBO J, V6, P4197, DOI 10.1002/j.1460-2075.1987.tb02767.x; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; FALZON M, 1993, J BIOL CHEM, V268, P10546; FEINSTEIN SI, 1986, GENETICS, V113, P13; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHEL RA, 1986, J MOL BIOL, V188, P147, DOI 10.1016/0022-2836(86)90300-1; FLECK O, 1992, NUCLEIC ACIDS RES, V20, P2271, DOI 10.1093/nar/20.9.2271; FOURY F, 1982, EUR J BIOCHEM, V124, P253; FOURY F, 1987, EMBO J, V6, P1441, DOI 10.1002/j.1460-2075.1987.tb02385.x; FOURY F, 1979, P NATL ACAD SCI USA, V76, P6529, DOI 10.1073/pnas.76.12.6529; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FUJII H, 1989, J BIOL CHEM, V264, P10057; GAILLARD C, 1980, NATURE, V283, P218, DOI 10.1038/283218a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRIMES GW, 1974, J CELL BIOL, V61, P565, DOI 10.1083/jcb.61.3.565; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HASTINGS PJ, 1984, COLD SPRING HARB SYM, V49, P49, DOI 10.1101/SQB.1984.049.01.008; HAYES W, 1970, GENETICS BACTERIA TH; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; JOHNSTON LH, 1979, MOL GEN GENET, V170, P327, DOI 10.1007/BF00267066; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JONES M, 1987, GENETICS, V115, P605; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KURIHARA T, 1993, MOL BIOL CELL, V4, P919, DOI 10.1091/mbc.4.9.919; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEWIN AS, 1980, P NATL ACAD SCI-BIOL, V77, P3998, DOI 10.1073/pnas.77.7.3998; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIRET JJ, 1993, J BIOL CHEM, V268, P3507; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; MORISHIMA N, 1993, CURR GENET, V23, P537, DOI 10.1007/BF00312648; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NETTER P, 1989, GENE, V83, P25, DOI 10.1016/0378-1119(89)90400-9; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; PAOLETTI C, 1972, BIOCHEM BIOPH RES CO, V48, P950, DOI 10.1016/0006-291X(72)90701-2; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PASUPATHY K, 1992, MUTAT RES, V273, P281, DOI 10.1016/0921-8777(92)90090-P; PERCIVAL KJ, 1989, J BIOL CHEM, V264, P2593; PRAKASH L, 1975, J MOL BIOL, V98, P781, DOI 10.1016/S0022-2836(75)80010-6; RADMAN M, 1986, ANNU REV GENET, V20, P523, DOI 10.1146/annurev.ge.20.120186.002515; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; Sherman F., 1983, METHODS YEAST GENETI; SKELLY PJ, 1990, MOL CELL BIOL, V10, P1530, DOI 10.1128/MCB.10.4.1530; SOR F, 1983, NUCLEIC ACIDS RES, V11, P339, DOI 10.1093/nar/11.2.339; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; WAGNER R, 1984, COLD SPRING HARB SYM, V49, P611, DOI 10.1101/SQB.1984.049.01.069; WATERS R, 1974, BIOCHIM BIOPHYS ACTA, V366, P241, DOI 10.1016/0005-2787(74)90282-2; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; YASUI A, 1992, MUTAT RES, V273, P231, DOI 10.1016/0921-8777(92)90084-G; ZAMAROCZY M, 1985, GENE, V37, P1; ZIMMERMAN S, 1961, J BIOL CHEM, V236, P1480	69	147	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29984	29992						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961998				2022-12-25	WOS:A1994PU28400102
J	KINSELLA, BT; OMAHONY, DJ; FITZGERALD, GA				KINSELLA, BT; OMAHONY, DJ; FITZGERALD, GA			PHOSPHORYLATION AND REGULATED EXPRESSION OF THE HUMAN THROMBOXANE A(2) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLONING; PROSTAGLANDIN; DNA; ACTIVATION; SYNTHASE; KINASES; BINDING; CDNA	Recombinant forms of the human thromboxane A(2) (TXA(2)) receptor composed of the carboxyl-terminal amino acid residues 220-343 were phosphorylated in vitro by both cAMP-dependent protein kinase A (PKA) and protein kinase C (PKC), and these phosphorylations were competed for by synthetic peptides corresponding to the proposed carboxyl-terminal cytoplasmic tail and/or the third extracellular loop of the receptor, respectively. Exogenous addition of PKA or PKC to membrane preparations of human embryonic kidney 293 cells, transfected with the TXA(2) receptor, typically reduced TXA(2) receptor binding by 10 and 30%, respectively. In vivo inhibition of PKC or PKA in the transfected human embryonic kidney 293 cells increased TXA(2) receptor binding to 121.4% (+/- 5.3%) and 110.4% (+/- 4.6%), respectively, relative to control cells. In vivo activation of PKC in the platelet-like human erythroleukemia (HEL) cells by the phorbol ester phorbol 12-myristate 13-acetate (PMA) resulted in an initial reduction followed by a time-dependent increase in TXA(2) receptor ligand binding. Stimulation of HEL cells with the TXA(2) receptor agonist [15-(alpha,2 beta(5Z)-3 alpha(E,3S)-4 alpha)]-7-[3(3-hydroxy-4-(p-iodophenoxy)-1-butenyl) -7-oxabicyclo[-2.2,1-]hept-2-yl]-5-heptenoic acid or basic fibroblast growth factor, alone or together, resulted in a marked decrease in TXA(2) receptor binding. Northern blot studies in HEL cells demonstrated that PMA stimulation induced the expression of the TXA(2) receptor gene with mRNA levels peaking following PMA stimulation for 4-8 h. This induction is consistent with the presence of a phorbol ester response element in promoter I of the TXA(2) receptor gene. Dexamethasone did not induce the expression of the receptor gene, despite the presence of a glucocorticoid response element in promoter II of the TXA(2) receptor gene. In summary, our results indicate that the cellular responses to TXA(2) are mediated both by phosphorylation of the TXA(2) receptor by different protein kinases and by regulated expression of the TXA(2) receptor gene.			KINSELLA, BT (corresponding author), NATL UNIV IRELAND UNIV COLL DUBLIN,MATER HOSP,CTR CARDIOVASC SCI,DEPT MED & EXPTL THERAPEUT,DUBLIN 7,IRELAND.		FitzGerald, Garret A/A-4222-2010	Kinsella, B. Therese/0000-0003-3072-941X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEKSIC NM, 1993, BLOOD, V82, P69; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARITA H, 1989, PROG LIPID RES, V28, P273, DOI 10.1016/0163-7827(89)90002-7; BORG C, 1994, J BIOL CHEM, V269, P6109; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DORN GW, 1990, CIRCULATION, V81, P212, DOI 10.1161/01.CIR.81.1.212; FITZGERALD DJ, 1990, LANCET, V335, P751, DOI 10.1016/0140-6736(90)90869-7; FUNK CD, 1993, MOL PHARMACOL, V44, P934; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATMI M, 1991, BRIT J PHARMACOL, V104, P554, DOI 10.1111/j.1476-5381.1991.tb12467.x; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JONES DA, 1993, J BIOL CHEM, V268, P9049; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; KERINS DM, 1992, HDB EXPT PHARM, V101, P299; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONCADA S, 1985, PHARMACOL BASIS THER, P660; MORINELLI TA, 1991, TRENDS CARDIOVAS MED, V1, P157, DOI 10.1016/1050-1738(91)90021-6; MURRAY R, 1989, P NATL ACAD SCI USA, V86, P124, DOI 10.1073/pnas.86.1.124; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OATES JA, 1988, NEW ENGL J MED, V319, P761, DOI 10.1056/NEJM198809223191206; PALEZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387; PATRONO C, 1992, TRENDS CARDIOVAS MED, V2, P15, DOI 10.1016/1050-1738(92)90039-U; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; RIGGS P, 1990, CURRENT PROTOCOLS MO; Sambrook J, 1989, MOL CLONING LABORATO; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; USHIKUBI F, 1993, J EXP MED, V178, P1825, DOI 10.1084/jem.178.5.1825; ZIE W, 1991, P NATL ACAD SCI USA, V88, P2692	38	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29914	29919						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961988				2022-12-25	WOS:A1994PU28400092
J	MCCORMACK, FX; KUROKI, Y; STEWART, JJ; MASON, RJ; VOELKER, DR				MCCORMACK, FX; KUROKI, Y; STEWART, JJ; MASON, RJ; VOELKER, DR			SURFACTANT PROTEIN-A AMINO-ACIDS GLU(195) AND ARG(197) ARE ESSENTIAL FOR RECEPTOR-BINDING, PHOSPHOLIPID AGGREGATION, REGULATION OF SECRETION, AND THE FACILITATED UPTAKE OF PHOSPHOLIPID BY TYPE-II CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A SP-A; PULMONARY SURFACTANT; HIGH-AFFINITY; RAT; APOPROTEIN; PHOSPHATIDYLCHOLINE; COMPONENTS; DOMAINS; LIPIDS; GENE	Pulmonary surfactant protein A (SP-A) is a mammalian lectin that regulates the uptake and secretion of surfactant by alveolar type II cells and is an important component of surfactant complexes. The domains of SP-A which mediate these functions have not been fully mapped. The binding of SP-A to its high affinity receptor on alveolar type II cells is thought to be dependent on a carbohydrate recognition domain (CRD), while the interaction with lipids has been attributed to the hydrophobic neck region of the molecule. To explore the role of the CRD in the interactions of SP-A with type II cells and lipids, we introduced mutations into the cDNA to encode for the substitutions G1u195 --> Gln and Arg(197) --> Asp (Sp-A(hyp,Gln195,Asp197)) and expressed the mutant protein in insect (Sf9) cells using recombinant baculoviruses. Similar mutations introduced into mannose-binding protein A have been shown to switch the carbohydrate binding specificity from mannose > galactose to the converse. Wild type SP-A produced in Sf9 cells does not contain hydroxyproline (SP.A(hyp)), but like rat SP-A it binds to carbohydrate affinity columns, lipids, and the SP-A receptor and is a potent inhibitor of the secretion of surfactant from type II cells (IC50 = 0.5-1.0 mu g/ml). The Sp-A(hyp,Gln195Asp197) also bound to affinity matrices of galactose Sepharose and mannose-Sepharose but the indicated mutations rendered the binding at least 100 times more susceptible than Sp-A(hyp) to competition by free galactose. The Sp-A(hyp,Gln195,Asp197) did not compete with rat SP-A for occupancy of its high affinity receptor on type II cells and the mutant protein was 25-50-fold less potent as an inhibitor of the secretion of surfactant from type II cells (IC50 = 26.0 mu g/ml). Unlike SP-A(hyp), the inhibition of secretion of surfactant by SPA(hyp,Gln195,Sp197) was reversed by 0.25 M alpha-methylmannoside or galactose. In addition, the Sp-A(hyp,Gln195,Asp197) bound avidly to phospholipid but did not aggregate vesicles or augment the uptake of phospholipid into type II cells. We conclude that the binding of SP-A to its receptor and the inhibition of surfactant secretion are critically dependent on the carbohydrate binding specificity of the CRD. Furthermore, phospholipid aggregation and augmentation of phospholipid uptake into type II cells are mediated by the COOH-terminal region of SP-A by a mechanism that is distinct from phospholipid binding.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,LORD & TAYLOR LAB LUNG BIOCHEM,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DIV PULM SCI & CRIT CARE MED,DENVER,CO 80226	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464	NHLBI NIH HHS [HL-02423, HL-45286] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045286] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KAWADA H, 1989, AM REV RESPIR DIS, V140, P460, DOI 10.1164/ajrccm/140.2.460; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; RICE WR, 1988, BIOCHIM BIOPHYS ACTA, V958, P205, DOI 10.1016/0005-2760(88)90178-6; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; ROSS GF, 1986, J BIOL CHEM, V261, P14283; ROSS GF, 1988, AM REV RESPIR DIS, V137, pA278; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SUMMERS MD, 1988, MANUAL BACULOVIRUS V; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410	33	81	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29801	29807						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961972				2022-12-25	WOS:A1994PU28400076
J	PURANAM, KL; BLACKSHEAR, PJ				PURANAM, KL; BLACKSHEAR, PJ			CLONING AND CHARACTERIZATION OF RECQL, A POTENTIAL HUMAN HOMOLOG OF THE ESCHERICHIA-COLI DNA HELICASE RECQ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION REPAIR; SERUM RESPONSE ELEMENT; H-RAS P21; HELA-CELLS; SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURE; PROTEIN; GENE; RECOMBINATION; YEAST	A potential human DNA helicase, RECQL, was partially purified from HeLa cells, and a cDNA encoding this protein was subsequently cloned from a HeLa library. The RECQL cDNA contains a protein coding region of 1977 base pairs, and encodes a 659-amino-acid polypeptide with a predicted M(r) 72,000. This predicted protein sequence contains several domains that have extensive sequence identity with similar domains of the RecQ protein hom Escherichia coli that has been shown to be an ATP-dependent DNA helicase. Overall amino acid sequence identity between the two proteins is 32%; overall sequence similarity is 57%. The similarities between the two sequences are particularly high in the seven consecutive domains characteristic of DNA and RNA helicases. Expression of the RECQL cDNA in reticulocyte lysates and in transiently transfected cells confirms the M(r) 72,000 of the protein; this protein reacted with antibodies raised against synthetic peptides comprising both the predicted amino- and carboxyl-terminal sequences. These antibodies demonstrated that RECQL is located predominantly in the nucleus of human fibroblasts. Based on its sequence similarity 60 the E. coli RecQ protein, it is possible that the putative human helicase RECQL may play a role in the repair of DNA that is damaged by ultraviolet light or other mutagens.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR,DEPT MED,DIV ENDOCRINOL, DIABET & METAB SECT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR,DEPT BIOCHEM,DIV ENDOCRINOL, DIABET & METAB SECT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, SARAH W STEDMAN CTR NUTR STUDIES, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HARLOW E, 1988, ANTIBODIES LABORATOR; HODGMAN TC, 1988, NATURE, V333, P578, DOI 10.1038/333578a0; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P173, DOI 10.1016/0168-9525(93)90164-D; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; IRINO N, 1986, MOL GEN GENET, V205, P298, DOI 10.1007/BF00430442; JURNAK F, 1988, TRENDS BIOCHEM SCI, V13, P195, DOI 10.1016/0968-0004(88)90080-1; KISHIMOTO A, 1991, METHOD ENZYMOL, V200, P447; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SEKI M, 1994, J BIOCHEM-TOKYO, V115, P523, DOI 10.1093/oxfordjournals.jbchem.a124369; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SEO YS, 1991, J BIOL CHEM, V266, P13161; SEO YS, 1993, J BIOL CHEM, V268, P10282; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; THOMMES P, 1990, FEBS LETT, V268, P325, DOI 10.1016/0014-5793(90)81279-W; TUTEJA N, 1990, NUCLEIC ACIDS RES, V18, P6785, DOI 10.1093/nar/18.23.6785; TUTEJA N, 1993, NUCLEIC ACIDS RES, V21, P2323, DOI 10.1093/nar/21.10.2323; TUTEJA N, 1991, NUCLEIC ACIDS RES, V19, P3613, DOI 10.1093/nar/19.13.3613; TUTEJA N, 1992, NUCLEIC ACIDS RES, V20, P5329, DOI 10.1093/nar/20.20.5329; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; XIE WQ, 1991, BIOTECHNIQUES, V11, P324	53	189	199	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29838	29845						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961977				2022-12-25	WOS:A1994PU28400081
J	SANDOR, A; JOHNSON, JH; SRERE, PA				SANDOR, A; JOHNSON, JH; SRERE, PA			COOPERATION BETWEEN ENZYME AND TRANSPORTER IN THE INNER MITOCHONDRIAL-MEMBRANE OF YEAST - REQUIREMENT FOR MITOCHONDRIAL, CITRATE SYNTHASE FOR CITRATE AND MALATE TRANSPORT IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; TRICARBOXYLATE CARRIER; DEHYDROGENASE; PURIFICATION; AMINOTRANSFERASE; RECONSTITUTION; COMPLEX; CYCLE	We have characterized 1,2,3-benzenetricarboxylic acid-sensitive, mersalyl-insensitive citrate uptake by mitochondria from two strains of Saccharomyces cerevisiae by describing the time course, K-m and V-max values, pH dependence, and response to inhibitors. In unloaded mitochondria from PSY142 CS1(-) cells, a mutant that lacks mitochondrial citrate synthase, both citrate uptake and efflux were reduced 7- and 8-fold, respectively, compared with the parental strain. No malate uptake was detectable in mitochondria from CS1(-) cells, while in the parental strain, uptake was 5.4 nmol/min/mg of protein. In contrast, mutations in peroxisomal citrate synthase (CS2(-)) or in other tricarboxylic acid cycle enzymes did not result in changes in mitochondrial citrate transport, suggesting a specific functional role for mitochon- drial citrate synthase in citrate transport. More important, liposomes containing protein extracts from CS1(-) mitochondria showed the same citrate and malate transport rates as liposomes made from protein extracts of parental strain mitochondria. Thus, an apparently normal amount of both the citrate transporter and the dicarboxylate carrier is present in CS1(-) mitochondria, but both function abnormally in undisrupted mitochondria. We suggest that cooperation between the citrate trans porter and mitochondrial citrate synthase is necessary for normal function of the transporter.	DEPT VET AFFAIRS MED CTR,RES SERV,DALLAS,TX 75216; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM & INTERNAL MED,DALLAS,TX 75216	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK11313] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK011313] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEECKMANS S, 1981, EUR J BIOCHEM, V117, P527; BISSACIA F, 1989, BIOCHIM BIOPHYS ACTA, V977, P171; BISSON LF, 1983, P NATL ACAD SCI-BIOL, V80, P1730, DOI 10.1073/pnas.80.6.1730; BRENT LG, 1987, J BIOL CHEM, V262, P319; BRIQUET M, 1977, BIOCHIM BIOPHYS ACTA, V459, P290, DOI 10.1016/0005-2728(77)90029-9; Chappell JB, 1967, BIOCH MITOCHONDRIA, P75; CLAEYS D, 1989, J BIOL CHEM, V264, P14627; COHEN NS, 1987, J BIOL CHEM, V262, P203; CONNOVER TE, 1987, TRENDS BIOCHEM SCI, V12, P88; DAUM G, 1982, J BIOL CHEM, V257, P3028; FAHIEN LA, 1985, J BIOL CHEM, V260, P6069; GLERUM DM, 1990, EUR J BIOCHEM, V194, P681, DOI 10.1111/j.1432-1033.1990.tb15668.x; Grigorenko E V, 1990, J Mol Recognit, V3, P215, DOI 10.1002/jmr.300030508; HALPER LA, 1977, ARCH BIOCHEM BIOPHYS, V184, P529, DOI 10.1016/0003-9861(77)90462-3; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KAPLAN RS, 1986, METHOD ENZYMOL, V125, P671; KAPLAN RS, 1990, J BIOL CHEM, V265, P13379; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KISPAL G, 1989, J BIOL CHEM, V264, P11204; LANCARBENBA J, 1994, BBA-BIOMEMBRANES, V1190, P213, DOI 10.1016/0005-2736(94)90076-0; MCGIVAN JD, 1971, EUR J BIOCHEM, V20, P392, DOI 10.1111/j.1432-1033.1971.tb01405.x; ODSOUZA SF, 1982, J BIOL CHEM, V258, P4706; PALMIERI F, 1978, BIOENERGETICS MITOCH, P5; PANDE SV, 1988, MICROCOMPARTMENTATIO, P93; PERSSON LO, 1992, BIOCHEM BIOPH RES CO, V6, P70; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; SUMEGI B, 1980, BIOCHIM BIOPHYS ACTA, V616, P158, DOI 10.1016/0005-2744(80)90134-5; SUMEGI B, 1990, BIOCHEMISTRY-US, V29, P9106, DOI 10.1021/bi00491a002; SUMEGI B, 1984, J BIOL CHEM, V259, P5040; TYISKA RL, 1986, NATO SERIES A, V127, P177	30	14	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29609	29612						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961948				2022-12-25	WOS:A1994PU28400048
J	WILLIAMS, TA; CORVOL, P; SOUBRIER, F				WILLIAMS, TA; CORVOL, P; SOUBRIER, F			IDENTIFICATION OF 2 ACTIVE-SITE RESIDUES IN HUMAN ANGIOTENSIN I-CONVERTING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 HOMOLOGOUS DOMAINS; DIPEPTIDYL CARBOXYPEPTIDASE; CATALYTIC PROPERTIES; MOLECULAR-CLONING; ZINC ENZYMES; THERMOLYSIN; INHIBITORS; BINDING	Angiotensin I-converting enzyme (ACE) contains two zinc dependent catalytic domains (N and C domains) each bearing the motif HEXXH where the two histidines form two of the three amino acid zinc Ligands. Sequence alignment of each ACE domain with other zinc metalloproteases, indicates a glutamate residue which putatively constitutes the third zinc ligand and an aspartate residue which may form an indirect zinc interaction. We investigated the functional roles of the glutamate and aspartate residues in the ACE C domain (Glu(987), and Asp(991)) using a cDNA encoding an inactive N domain. We mutated Glu(987) to aspartate (E987D) or valine (E987V) and Asp(991) to glutamate (D991E) or alanine (D991A). Catalytically active mutants (E987D, D991E and D991A) exhibited similar K-m values for hippuryl-His-Leu compared to non-mutated C domain. E987D displayed a 300-fold decrease in k(cat) and a 25-fold reduction in sensitivity to the ACE inhibitor trandolaprilat, whose binding is zinc-dependent. E987V was catalytically inactive and did not bind [H-3]trandolaprilat. D991E and D991A exhibited a 3.8- and 22-fold decrease in k(cat), respectively, and the K-i' values for trandolaprilat were increased 8- and 29-fold. These results provide strong evidence that Glu(987) constitutes the third zinc Ligand in the ACE C domain and suggest a role for Asp(991) in positioning the C domain active site zinc ion.			WILLIAMS, TA (corresponding author), COLL FRANCE,INSERM,U36,3 RUE ULM,F-75005 PARIS,FRANCE.		Williams, Tracy/K-5604-2013	Williams, Tracy Ann/0000-0002-2388-6444				ALHENCGELAS F, 1983, J LAB CLIN MED, V101, P83; BROWN NL, 1988, EUR J PHARMACOL, V148, P79, DOI 10.1016/0014-2999(88)90456-6; BULL HG, 1985, J BIOL CHEM, V260, P2952; COLMAN PM, 1972, J MOL BIOL, V70, P701, DOI 10.1016/0022-2836(72)90569-4; Cornell Michael J., 1993, Biochemical Society Transactions, V21, p243S; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; ELDORRY HA, 1982, J BIOL CHEM, V257, P4128; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; KESTER WR, 1977, BIOCHEMISTRY-US, V16, P2506, DOI 10.1021/bi00630a030; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; LEMOUAL H, 1991, J BIOL CHEM, V266, P15670; Safer R. L., 1981, BIOCH REGULATION BLO, P123; Sambrook J, 1989, MOL CLONING LABORATO; SEN I, 1993, J BIOL CHEM, V268, P25748; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; Waeber BNJ, 1990, HYPERTENSION PATHOPH, P2209; WEI L, 1992, J BIOL CHEM, V267, P13398; WEI L, 1991, J BIOL CHEM, V266, P9002; WEI L, 1991, J BIOL CHEM, V266, P5540; WILLIAMS TA, 1992, BIOCHEM J, V288, P875, DOI 10.1042/bj2880875; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6	28	65	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29430	29434						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961923				2022-12-25	WOS:A1994PU28400021
J	DOEGE, KJ; GARRISON, K; COULTER, SN; YAMADA, Y				DOEGE, KJ; GARRISON, K; COULTER, SN; YAMADA, Y			THE STRUCTURE OF THE RAT AGGRECAN GENE AND PRELIMINARY CHARACTERIZATION OF ITS PROMOTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCAN CORE PROTEIN; CHONDROITIN SULFATE PROTEOGLYCAN; BOVINE CARTILAGE PROTEOGLYCAN; LINK PROTEIN; SEQUENCE-ANALYSIS; ADHESION RECEPTORS; MESSENGER-RNA; CHICK-EMBRYO; PARTIAL CDNA; CLONING	Aggrecan is a major structural component of cartilage extracellular matrix and a specific gene product of differentiated chondrocytes, cDNA clones have been used to isolate rat aggrecan genomic clones from phage and cosmid libraries, producing over 80 kilobases (kb) of overlapping DNA containing the complete rat aggrecan gene, including 12 kb of 5'- and 8 kb of 3'-flanking DNA. DNA sequencing shows 18 exons, most of which encode structural or functional modules; exceptions are do mains G1-B and G2-B, which are split into two exons and the G3 lectin domain, which is encoded by three exons. There is one expressed epidermal growth factor-like exon and in addition a non-expressed ''pseudo-exon'' encoding a heavily mutated epidermal growth factor-like domain. Intron sizes have been determined by restriction mapping and inter exon polymerase chain reaction; a 30-kb intron separates exons 1 and 2. Exon 1 has been mapped by primer extension and S1 nuclease protection; it encodes 381 base pairs (bp) of 5'-untranslated sequence. There is a minor promoter which initiates transcription an additional 68 bp 5' of the major promoter start site. DNA sequence is reported for a 529-bp fragment encompassing exon 1, including 120 bp of 5'-flanking DNA comprising the promoter. This promoter is lacking the TATAA or CCAAT elements but has several putative binding sites for transcription factors. A 922-bp DNA fragment with 640-bp 5'-flanking DNA and 282-bp exon 1 sequence showed higher promoter activity in transfected chondrocytes than in fibroblasts, is completely inactive in the reverse orientation, and is strongly enhanceable in the forward direction by the SV40 enhancer.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA; NIDR, DEV BIOL LAB, BETHESDA, MD 20892 USA	Oregon Health & Science University; Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	DOEGE, KJ (corresponding author), OREGON HLTH SCI UNIV, SHRINERS HOSP CRIPPLED CHILDREN, RES UNIT, 3101 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA.							ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; BOYD CD, 1993, MATRIX, V13, P457, DOI 10.1016/S0934-8832(11)80112-5; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHANDRASEKARAN L, 1992, BIOCHEM J, V288, P903, DOI 10.1042/bj2880903; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS T, 1991, J BIOL CHEM, V266, P2466; DEAK F, 1991, NUCLEIC ACIDS RES, V19, P4983, DOI 10.1093/nar/19.18.4983; DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE K, 1990, BIOCHEM SOC T, V18, P200, DOI 10.1042/bst0180200; DOEGE K, 1986, J BIOL CHEM, V261, P8108; DOEGE K, 1990, COLLAGEN GENES STRUC, P137; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FINKELSTEIN JE, 1991, AM J HUM GENET, V48, P97; FULOP C, 1993, J BIOL CHEM, V268, P17377; GRAY A, 1983, NATURE, V303, P236; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KIMURA JH, 1987, METHOD ENZYMOL, V144, P372; KOHNO K, 1985, J BIOL CHEM, V260, P4441; KORENBERG JR, 1993, GENOMICS, V16, P546, DOI 10.1006/geno.1993.1228; KOSHER RA, 1989, DEV BIOL, V131, P558, DOI 10.1016/S0012-1606(89)80026-0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG JO, 1985, J BIOL CHEM, V260, P2523; LI H, 1993, J BIOL CHEM, V268, P23504; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; OXFORD JT, 1994, EXP CELL RES, V213, P28, DOI 10.1006/excr.1994.1169; PENOTTI FE, 1990, J MOL BIOL, V213, P37, DOI 10.1016/S0022-2836(05)80120-2; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RHODES C, 1988, J BIOL CHEM, V263, P6063; RHODES C, 1991, NUCLEIC ACIDS RES, V19, P1933, DOI 10.1093/nar/19.8.1933; SAI S, 1986, P NATL ACAD SCI USA, V83, P5081, DOI 10.1073/pnas.83.14.5081; Sambrook J, 1989, MOL CLONING LABORATO; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STIRPE NS, 1989, DEVELOPMENT, V107, P23; TANAKA T, 1988, J BIOL CHEM, V263, P15831; WALCZ E, 1994, GENOMICS, V22, P364, DOI 10.1006/geno.1994.1396; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; WONG M, 1992, J BIOL CHEM, V267, P5592; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	56	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29232	29240						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961891				2022-12-25	WOS:A1994PU16800104
J	LAWRENCE, R; CHANG, LJ; SIEBENLIST, U; BRESSLER, P; SONENSHEIN, GE				LAWRENCE, R; CHANG, LJ; SIEBENLIST, U; BRESSLER, P; SONENSHEIN, GE			VASCULAR SMOOTH-MUSCLE CELLS EXPRESS A CONSTITUTIVE NF-KAPPA-B-LIKE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SUBUNIT; C-MYC PROMOTER; TRANSCRIPTION FACTOR; P65 SUBUNIT; GENE; REL; ACTIVATION; ALPHA; SITE; TRANSACTIVATION	The NF-kappa B/Rel family of transcription factors is commonly expressed in non-hematopoietic cells in an inactive form within the cytoplasm, complexed with an inhibitor I kappa B protein. Thus, it was surprising that NF-kappa B element-driven heterologous promoter-reporter gene constructs were active upon transient transfection into vascular smooth muscle cells (VSMCs). Here, we report that VSMCs express a constitutive nuclear NF-kappa B-like activity. In electrophoretic mobility shift assays, nuclear extracts demonstrated binding to a wild type NF-kappa B element but not to those mutated at nucleotides critical for Rel-protein DNA interaction. Binding was abrogated by the presence of I kappa B-alpha. Furthermore, addition of an antibody to the p50 subunit of classical NF-kappa B (but not p65, c-Rel, or RelB) resulted in supershifted complexes. Transactivation of element-driven constructs was negatively affected by co-transfection of a vector expressing a dominant negative p50 subunit, which can dimerize with other Rel subunits but not bind DNA. The long terminal repeat of the human immunodeficiency virus-1, which is driven in part by two NF-kappa B elements, displayed strong activity within VSMCs. This activity was abrogated upon co-transfection of the vector expressing the dominant negative p50 mutant. Taken together, these experiments indicate that VSMCs constitutively express a functional NF-kappa B-like trans-acting factor, which may play a significant role in the regulation of proliferation and viral infection of these cells.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV ALBERTA,GLAXO HERITAGE RES INST,DEPT MED MICROBIOL & INFECT DIS,EDMONTON T6G 2H7,AB,CANADA; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	Boston University; GlaxoSmithKline; University of Alberta; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)					NATIONAL CANCER INSTITUTE [R01CA036355] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NCI NIH HHS [CA36355] Funding Source: Medline; NHLBI NIH HHS [HL13262] Funding Source: Medline; NIA NIH HHS [AG00115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHANG LJ, 1993, J VIROL, V67, P743, DOI 10.1128/JVI.67.2.743-752.1993; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KESSLER DJ, 1992, ONCOGENE, V7, P2447; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KORNER M, 1991, BIOCHEM BIOPH RES CO, V181, P80, DOI 10.1016/S0006-291X(05)81384-1; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUBEN S, 1991, SCIENCE, V251, P490; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; STEPP MA, 1986, J BIOL CHEM, V261, P6542; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x	37	72	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28913	28918						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961853				2022-12-25	WOS:A1994PU16800063
J	WHITE, AL; LANFORD, RE				WHITE, AL; LANFORD, RE			CELL-SURFACE ASSEMBLY OF LIPOPROTEIN(A) IN PRIMARY CULTURES OF BABOON HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; EXPRESSING HUMAN APOLIPOPROTEIN(A); APO(A) MESSENGER-RNA; RECOMBINANT APOLIPOPROTEIN(A); PLASMA-LIPOPROTEIN; BINDING-SITES; HEPG2 CELLS; PLASMINOGEN; ISOFORMS; KRINGLE	Lipoprotein(a) (Lp(a)) consists of a low density lipoprotein particle in which apolipoprotein(a) (apo(a)), is disulfide linked to apoB. Lp(a) is produced by the liver, and high plasma levels represent an independent risk factor for cardiovascular diseases. However, pathways of production and metabolism of Lp(a) are poorly understood. We used primary cultures of baboon hepatocytes to analyze the steps involved in Lp(a) biogenesis. The results demonstrated that Lp(a) assembly was extracellular, since it was inhibited when anti apo(a) antiserum was present in the culture medium. In addition, free apo(a) produced by hepatocytes could associate extracellularly with apoB in either very low density or low density Lipoproteins. Lp(a) assembly required lysine-binding pockets in apo(a) kringles, as it was inhibited by the lysine analog, 6-amino hexanoic acid. A portion of apo(a) was also bound to the cell surface via its kringle domains and could be released into the medium by 6-amino hexanoic acid or proline. In add-back experiments, apo(a), but not Lp(a), bound to the cell surface. Addition of low density lipoprotein or very low density Lipoprotein to hepatocyte cultures released apo(a) from the cell surface into the lipoprotein fraction of culture medium. We conclude that assembly of Lp(a) can occur at the cell surface. This represents one potential mechanism of Lp(a) production in vivo.	SW FDN BIOMED RES,DEPT VIROL & IMMUNOL,SAN ANTONIO,TX	Texas Biomedical Research Institute					NHLBI NIH HHS [HL50426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050426] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG VW, 1990, J LIPID RES, V31, P429; AZROLAN N, 1991, J BIOL CHEM, V266, P13866; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BIHARIVARGA M, 1988, ARTERIOSCLEROSIS, V8, P851, DOI 10.1161/01.ATV.8.6.851; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; CHIESA G, 1992, J BIOL CHEM, V267, P24369; COHN JS, 1991, ATHEROSCLEROSIS, V90, P59, DOI 10.1016/0021-9150(91)90244-W; DUVIC CR, 1985, J LIPID RES, V26, P540; FLESS GM, 1989, J LIPID RES, V30, P651; FLESS GM, 1985, J LIPID RES, V26, P1224; FLESS GM, 1986, J BIOL CHEM, V261, P8712; Gaubatz J W, 1986, Methods Enzymol, V129, P167; GAUBATZ JW, 1990, J LIPID RES, V31, P603; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; GAVISH D, 1989, J CLIN INVEST, V84, P2021, DOI 10.1172/JCI114395; GUEVARA J, 1993, BIOPHYS J, V64, P686, DOI 10.1016/S0006-3495(93)81428-0; GUEVARA J, 1993, ARTERIOSCLER THROMB, V13, P758, DOI 10.1161/01.ATV.13.5.758; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HARKES L, 1988, FEBS LETT, V227, P27, DOI 10.1016/0014-5793(88)81406-6; HEINECKE JW, 1993, J LIPID RES, V34, P2051; HIXSON JE, 1989, J BIOL CHEM, V264, P6013; JI ZS, 1994, J BIOL CHEM, V269, P2764; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; KREMPLER F, 1980, J CLIN INVEST, V65, P1483, DOI 10.1172/JCI109813; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LANFORD RE, 1989, IN VITRO CELL DEV B, V25, P174; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LEBLOND L, 1993, J BIOL CHEM, V268, P1670; LILLYSTAUDERMAN M, 1993, J LIPID RES, V34, P190; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MARCOVINA SM, 1993, BIOCHEM BIOPH RES CO, V191, P1192, DOI 10.1006/bbrc.1993.1343; MARKUS G, 1978, J BIOL CHEM, V253, P727; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1985, J BIOL CHEM, V260, P4303; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MORRISETT JD, 1990, LIPOPROTEIN A, P53; PFAFFINGER D, 1991, J LIPID RES, V32, P679; PHILLIPS ML, 1993, BIOCHEMISTRY-US, V32, P3722, DOI 10.1021/bi00065a026; RADER DJ, 1993, J CLIN INVEST, V91, P443, DOI 10.1172/JCI116221; RAINWATER DL, 1989, BIOCHIM BIOPHYS ACTA, V1003, P30, DOI 10.1016/0005-2760(89)90094-5; RAINWATER DL, 1989, J LIPID RES, V30, P549; ROUY D, 1992, BIOCHEMISTRY-US, V31, P6333, DOI 10.1021/bi00142a024; SALONEN EM, 1989, EMBO J, V8, P4035, DOI 10.1002/j.1460-2075.1989.tb08586.x; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1993, J CLIN INVEST, V91, P283, DOI 10.1172/JCI116182; SCOTT J, 1992, NATURE, V360, P631, DOI 10.1038/360631a0; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; WHITE AL, 1994, J BIOL CHEM, V269, P9060; WHITE AL, 1993, J LIPID RES, V34, P509; WHITE AL, 1994, CHEM PHYS LIPIDS, V67-8, P123, DOI 10.1016/0009-3084(94)90131-7; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; YE SQ, 1992, J BIOL CHEM, V267, P21961	63	106	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28716	28723						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961823				2022-12-25	WOS:A1994PU16800033
J	GALE, M; CARTER, V; PARSONS, M				GALE, M; CARTER, V; PARSONS, M			TRANSLATIONAL CONTROL MEDIATES THE DEVELOPMENTAL REGULATION OF THE TRYPANOSOMA-BRUCEI NRK PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; GENE-EXPRESSION; SIGNALING PROTEINS; LIFE-CYCLE; DOMAIN; IDENTIFICATION; NIMA; DIFFERENTIATION; PHOSPHORYLATION; CULTIVATION	The expression and function of eukaryotic protein kinases is highly regulated, primarily through transcriptional and post-translational processes, In this report we demonstrate an unusual mechanism for controlling protein kinase function, translational control. The Trypanosoma brucei Nrk loci encode predicted protein kinases. Here we show that Nrk has protein serine-threonine kinase activity and examine the expression and activity of Nrk during parasite development, While Nrk transcripts were previously found to be constitutively expressed throughout the life cycle, we now find that expression of Nrk protein is highly stage-regulated. Immunoblot analysis revealed that Nrk expression dramatically increased as the parasites differentiated from proliferative slender bloodforms to the non-proliferative stumpy bloodforms, Procyclic form organisms ex pressed moderate levels of Nrk, Analysis of Nrk activity demonstrated that it too was highest in stumpy blood-forms, Metabolic labeling and pulse chase analysis demonstrated that Nrk accumulation was highest in stumpy bloodforms and indicated that Nrk abundance is primarily controlled at the level of biosynthesis rather than turnover, AU Nrk mRNA was contained in the poly(A)(+) fraction, and the 5' ends of the transcript were the same in each developmental stage. Thus, Nrk is under translational control, The strict developmental regulation of the Nrk enzymes within the trypanosome life cycle suggests that the Nrk protein kinase may play a role in parasite differentiation.	UNIV WASHINGTON, DEPT PATHOBIOL, SEATTLE, WA 98195 USA; SEATTLE BIOMED RES INST, SEATTLE, WA 98109 USA	University of Washington; University of Washington Seattle; Center for Infectious Disease Research				Gale, Michael/0000-0002-6332-7436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031077, R56AI031077] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 31077] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOAGYEKWARTENG T, 1991, BIOCHEM J, V275, P7, DOI 10.1042/bj2750007; ALEXANDER K, 1993, MOL BIOCHEM PARASIT, V60, P255; BHAT GJ, 1992, MOL BIOCHEM PARASIT, V52, P231, DOI 10.1016/0166-6851(92)90055-O; BHAUMIK M, 1991, PARASITOLOGY, V103, P197, DOI 10.1017/S0031182000059485; BRUN R, 1979, ACTA TROP, V36, P289, DOI DOI 10.5169/SEALS-312533; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GALE M, 1993, MOL BIOCHEM PARASIT, V59, P111, DOI 10.1016/0166-6851(93)90012-M; GALE M, 1994, J CELL SCI, V107, P1825; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GEHRKE L, 1987, TRNASLATIONAL REGULA, P367; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLOW E, 1988, ANTIBODIES LABORATOR; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HIDE G, 1989, MOL BIOCHEM PARASIT, V36, P51, DOI 10.1016/0166-6851(89)90199-0; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; KEITH K, 1990, MOL BIOCHEM PARASIT, V43, P107, DOI 10.1016/0166-6851(90)90135-9; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LU KP, 1993, J BIOL CHEM, V268, P8769; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MICHELOTTI EF, 1987, J BIOL CHEM, V262, P927; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MORRIS DR, 1993, BIOCHEMISTRY-US, V32, P2931, DOI 10.1021/bi00063a001; MOTTRAM JC, 1994, PARASITOL TODAY, V10, P253, DOI 10.1016/0169-4758(94)90136-8; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PALATNIK CM, 1984, CELL, V36, P1017, DOI 10.1016/0092-8674(84)90051-5; PARSONS M, 1993, P NATL ACAD SCI USA, V90, P2656, DOI 10.1073/pnas.90.7.2656; PARSONS M, 1991, MOL BIOCHEM PARASIT, V45, P241, DOI 10.1016/0166-6851(91)90091-J; PARSONS M, 1994, MOL BIOCHEM PARASIT, V63, P69, DOI 10.1016/0166-6851(94)90009-4; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRO SZ, 1984, ACTA TROP, V41, P313; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUART K, 1984, PARASITOLOGY, V70, P747; THOMASHOW LS, 1983, CELL, V38, P309; TORRI AF, 1993, MOL BIOCHEM PARASIT, V57, P305, DOI 10.1016/0166-6851(93)90206-D; VANDERPLOEG LHT, 1986, CELL, V47, P479, DOI 10.1016/0092-8674(86)90608-2; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; WHEELERALM E, 1992, J PROTOZOOL, V39, P413, DOI 10.1111/j.1550-7408.1992.tb01473.x; 1986, WHO TECH REP SER, V739, P1	49	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31659	31665						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989338				2022-12-25	WOS:A1994PX30300053
J	GREINER, EF; GUPPY, M; BRAND, K				GREINER, EF; GUPPY, M; BRAND, K			GLUCOSE IS ESSENTIAL FOR PROLIFERATION AND THE GLYCOLYTIC ENZYME-INDUCTION THAT PROVOKES A TRANSITION TO GLYCOLYTIC ENERGY-PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE RESPONSE ELEMENT; TRICARBOXYLIC-ACID CYCLE; PYRUVATE-KINASE GENE; RAT THYMOCYTES; GLUTAMINE-METABOLISM; AEROBIC GLYCOLYSIS; MAXIMUM ACTIVITIES; MESSENGER-RNA; CANCER-CELLS; LYMPHOCYTES	A transition from aerobic to anaerobic metabolism occurs as mitogen-activated thymocytes undergo proliferation. Glucose utilization and lactate formation increases 18- and 38-fold, respectively, during proliferation, The absolute amount of (CO2)-C-14 production by pyruvate dehydrogenase remains constant, while (CO2)-C-14 production by the tricarboxylic acid cycle is reduced during transition from a resting to a proliferating state. Addition of 2,4-dinitrophenol, an agent uncoupling oxidative phosphorylation, and phenacinemethosulfate, an electron acceptor, provide evidence that the reduction of glucose oxidation in proliferating thymocytes is caused neither by limitation of the tricarboxylic acid cycle itself nor by an insufficient supply of ADP. Our data suggest that enhanced cytosolic regeneration of NAD(+) by induction of the glycolytic enzymes during proliferation effectively competes with NADH transport and its subsequent oxidation in the mitochondria. Mitogen-stimulated rat thymocytes cultured in a conventional medium containing glucose induce their glycolytic enzymes 8-10-fold in the S phase of the cell cycle and divide within a culture period of 72 h. Replacement of glucose by glutamine, glutamine and ribose, or glutamine and uridine prevents glycolytic enzyme induction and thymocyte proliferation. The effect of glucose on glycolytic enzyme induction cannot be mimicked by 3-O-methylglucose or 2-deoxyglucose. In conclusion, glucose is required for proliferation and the glycolytic enzyme induction that mediates the transition from oxidative to glycolytic energy production during the G(1)/S transition of rat thymocytes.	UNIV ERLANGEN NURNBERG,FAK MED,INST BIOCHEM,D-91054 ERLANGEN,GERMANY; UNIV WESTERN AUSTRALIA,DEPT BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA	University of Erlangen Nuremberg; University of Western Australia								ARDAWI MSM, 1982, BIOCHEM J, V208, P743, DOI 10.1042/bj2080743; ARDAWI MSM, 1983, BIOCHEM J, V212, P835, DOI 10.1042/bj2120835; ARGILES JM, 1990, MED HYPOTHESES, V32, P151, DOI 10.1016/0306-9877(90)90039-H; ARORA KK, 1988, J BIOL CHEM, V263, P17422; BAGETTO LG, 1992, BIOCHIMIE, V74, P959; BAUMANN M, 1988, TUMOR BIOL, V9, P281, DOI 10.1159/000217573; Bergmeyer H. V., 1974, METHOD ENZYMAT AN, V2, P1196; BERGMEYER HU, 1983, METHOD ENZYMAT AN, V2, P222; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; BRAND K, 1987, J BIOL CHEM, V262, P15232; BRAND K, 1988, EUR J BIOCHEM, V172, P695, DOI 10.1111/j.1432-1033.1988.tb13944.x; BRAND K, 1985, BIOCHEM J, V228, P353, DOI 10.1042/bj2280353; BRAND K, 1984, BIOCHEM J, V221, P471, DOI 10.1042/bj2210471; BRAND K, 1986, IMMUNOBIOLOGY, V173, P23, DOI 10.1016/S0171-2985(86)80086-9; BRUN T, 1993, J BIOL CHEM, V268, P18905; Crabtree HG, 1929, BIOCHEM J, V23, P536, DOI 10.1042/bj0230536; CRANE RK, 1955, METHOD ENZYMOL, V1, P277, DOI 10.1016/0076-6879(55)01037-9; CREPIN KM, 1989, EUR J BIOCHEM, V183, P433, DOI 10.1111/j.1432-1033.1989.tb14946.x; CULVENOR JG, 1976, BIOCHIM BIOPHYS ACTA, V437, P354, DOI 10.1016/0304-4165(76)90005-2; CURI R, 1988, BIOCHEM J, V250, P383, DOI 10.1042/bj2500383; DUNAWAY GA, 1985, J BIOL CHEM, V260, P4180; EIGENBRODT E, 1980, TRENDS PHARMACOL SCI, V1, P240, DOI 10.1016/0165-6147(80)90009-7; EIGENBRODT E, 1985, REGULATION CARBOHYDR, V2, P141; FUJII H, 1983, METHOD ENZYMAT AN, V3, P496; GAWEHN K, 1974, METHOD ENZYMAT AN, P1492; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GOSALVEZ M, 1974, EUR J BIOCHEM, V46, P133, DOI 10.1111/j.1432-1033.1974.tb03605.x; GROSS G, 1988, BIOCHIM BIOPHYS ACTA, V962, P220, DOI 10.1016/0005-2760(88)90163-4; GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; KATZ J, 1966, J BIOL CHEM, V241, P727; Lamprecht W., 1988, METHOD ENZYMAT AN, VVI, P570; LANOUE KF, 1977, HORMONES CANCER, P131; LIU ZR, 1993, J BIOL CHEM, V268, P12787; MARJANOVIC S, 1990, BIOCHIM BIOPHYS ACTA, V1097, P1; NETZKER R, 1992, J BIOL CHEM, V267, P6421; NETZKER R, IN PRESS BIOCH BIOPH; NOGUCHI T, 1984, J BIOL CHEM, V259, P2651; RACKER E, 1976, J CELL PHYSIOL, V89, P697, DOI 10.1002/jcp.1040890429; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; SALISBURY JG, 1979, J BIOCHEM BIOPH METH, V1, P341, DOI 10.1016/0165-022X(79)90025-3; SCHOBITZ B, 1990, J BIOL CHEM, V265, P15387; SEMENKOVICH CF, 1993, J BIOL CHEM, V268, P6961; SENER A, 1988, J BIOL CHEM, V263, P1904; SHIH HM, 1992, J BIOL CHEM, V267, P13222; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TOLLEFSBOL TO, 1985, J CELL PHYSIOL, V122, P98, DOI 10.1002/jcp.1041220115; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; WANG T, 1976, NATURE, V261, P702, DOI 10.1038/261702a0; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1924, BIOCHEM Z, V152, P309; WEBER G, 1977, NEW ENGL J MED, V296, P486, DOI 10.1056/NEJM197703032960905; WEINHOUSE S, 1976, Z KREBSFORSCH KLIN O, V87, P115; WICE BM, 1982, J BIOL CHEM, V257, P2578; WICE BM, 1981, J BIOL CHEM, V256, P7812	56	238	245	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31484	31490						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989314				2022-12-25	WOS:A1994PX30300027
J	VUDAC, N; SCHOONJANS, K; LAINE, B; FRUCHART, JC; AUWERX, J; STAELS, B				VUDAC, N; SCHOONJANS, K; LAINE, B; FRUCHART, JC; AUWERX, J; STAELS, B			NEGATIVE REGULATION OF THE HUMAN APOLIPOPROTEIN-A-I PROMOTER BY FIBRATES CAN BE ATTENUATED BY THE INTERACTION OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR WITH ITS RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIC-ACID-DERIVATIVES; TISSUE-SPECIFIC EXPRESSION; ACYL-COA OXIDASE; RAT-LIVER; GENE-EXPRESSION; MESSENGER-RNA; RETINOIC ACID; FATTY-ACIDS; TRANSCRIPTIONAL REGULATION; CHOLESTEROL-BIOSYNTHESIS	Fibrates have been reported to modulate plasma high density lipoprotein cholesterol and apolipoprotein (apo)A-I concentrations. Therefore, the molecular mechanisms underlying the regulation of human apoA-I gene expression by fibrates was investigated. Fenofibrate reduced the expression of a reporter gene driven by the DNA sequences between -192 and +91 (BC-P-chloramphenicol acetyltransferase; CAT) relative to the apoA-I gene transcription start site approximately 3-fold. The sequences involved in the down-regulation of apoA-I gene transcription by fenofibrate were localized between -41 and +91 (P-CAT) relative to the transcription start site. The reduction of the expression of BC-P-CAT was dose-dependent and maximal at 500 mu M (20 +/- 7%). Different peroxisome proliferators showed different levels of repression varying from 39 +/- 4% for fenofibrate, 43 +/- 5% for tetradecylthioacetic acid, 48 +/- 4% for bezafibrate, 54 +/- 2% for 5,8,11,14-eicotetraynoic acid, 76 +/- 2% for ciprofibrate, whereas Wy 14643 only marginally inhibited the expression of BC-P-CAT. By contrast, inclusion of sequences between -256 and -192 (ABC-P-CAT) attenuated the repression by fenofibrate. Furthermore, the apoA-I A site (-214 to -192; A(wt)-P-CAT) could counteract the repression of P-CAT by fenofibrate in the presence of cotransfected mPPAR alpha (peroxisome proliferator-activated receptor). In addition, the acyl-CoA oxidase-peroxisome proliferator response element (PPRE) could substitute the wild-type A-site in blocking the fenofibrate-induced reduction of the apoA-I promoter by mPPAR alpha. The protective effect of PPAR on fenofibrate induced inhibition of apoA-I expression was abolished after mutation of the direct repeat in the A site (A(m)-P-CAT). Consistent with these functional data only the wild-type, but not the mutated A site bound PPAR/retinoic X receptor heterodimers in gel shift assays. These data suggest that certain peroxisome proliferators can reduce the expression of the apoA-I promoter in a PPAR-independent fashion, through modulation of factors interacting with sequences localized between -41 and +91 of the apoA-I gene transcription initiation site. This inhibitory effect can be overcome when PPAR interacts with a functional PPRE, such as the apoA-I A site or the acyl-CoA oxidase-PPRE.	INST PASTEUR,DEPT ATHEROSCLEROSE,INSERM,U325,BIOL REGULAT EUCARYOTES,F-59019 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Staels, Bart/N-9497-2016; Auwerx, Johan/ABE-9307-2021	Staels, Bart/0000-0002-3784-1503; Schoonjans, Kristina/0000-0003-1247-4265; Auwerx, Johan/0000-0002-5065-5393				AUWERX J, 1992, HORM RES, V38, P269, DOI 10.1159/000182557; BALFOUR JA, 1990, DRUGS, V40, P260, DOI 10.2165/00003495-199040020-00007; BERNDT J, 1978, ATHEROSCLEROSIS, V30, P147, DOI 10.1016/0021-9150(78)90057-6; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; BOVARDHOUPPERMANS S, 1994, BIOCHEM BIOPH RES CO, V198, P764, DOI 10.1006/bbrc.1994.1110; BROWN WV, 1987, AM J MED, V83, P85, DOI 10.1016/0002-9343(87)90876-X; CHAMBAZ J, 1991, J BIOL CHEM, V266, P11676; CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CHATTERJEE B, 1987, EUR J BIOCHEM, V166, P273, DOI 10.1111/j.1432-1033.1987.tb13511.x; COHEN BI, 1974, BIOCHIM BIOPHYS ACTA, V369, P79; COSENTINI R, 1989, ATHEROSCLEROSIS, V79, P253, DOI 10.1016/0021-9150(89)90131-7; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; GOLDBERG AP, 1979, NEW ENGL J MED, V301, P1073, DOI 10.1056/NEJM197911153012001; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRETEN H, 1977, ATHEROSCLEROSIS, V26, P563, DOI 10.1016/0021-9150(77)90123-X; GRUNDY SM, 1987, AM J MED, V83, P9, DOI 10.1016/0002-9343(87)90866-7; HELLER F, 1983, EUR J CLIN PHARMACOL, V25, P57, DOI 10.1007/BF00544015; HIGUCHI K, 1988, J BIOL CHEM, V263, P18530; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LARSEN ML, 1993, CURR OPIN LIPIDOL, V4, P34, DOI 10.1097/00041433-199302000-00007; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSSIERCACAN S, 1989, ATHEROSCLEROSIS, V78, P167, DOI 10.1016/0021-9150(89)90221-9; MANNAERTS GP, 1993, BIOCHIMIE, V75, P147, DOI 10.1016/0300-9084(93)90072-Z; MANNINEN V, 1983, AM J CARDIOL, V52, pB35, DOI 10.1016/0002-9149(83)90656-2; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MILLER GJ, 1975, LANCET, V1, P16; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NIKKILA EA, 1977, METABOLISM, V26, P179, DOI 10.1016/0026-0495(77)90053-1; NIKKILA EA, 1976, P ROY SOC MED, V69, P58; OSADA J, 1991, BIOCHEM BIOPH RES CO, V180, P162, DOI 10.1016/S0006-291X(05)81270-7; PETIT D, 1988, ATHEROSCLEROSIS, V74, P215, DOI 10.1016/0021-9150(88)90240-7; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1982, ANN NY ACAD SCI, V386, P81, DOI 10.1111/j.1749-6632.1982.tb21409.x; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; ROMNEY JS, 1992, MOL ENDOCRINOL, V6, P943, DOI 10.1210/me.6.6.943; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SCHOONJANS K, 1993, EUR J BIOCHEM, V216, P615, DOI 10.1111/j.1432-1033.1993.tb18181.x; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SIRTORI CR, 1988, PHARMACOL THERAPEUT, V37, P167, DOI 10.1016/0163-7258(88)90024-1; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; STAELS B, 1990, ENDOCRINOLOGY, V126, P2153; STAELS B, 1992, BIOCHIM BIOPHYS ACTA, V1123, P227, DOI 10.1016/0005-2760(92)90115-C; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; STAELS B, 1992, J LIPID RES, V33, P727; STAELS B, 1992, DEVELOPMENT, V115, P1035; STUCCHI AF, 1991, ARTERIOSCLER THROMB, V11, P1719, DOI 10.1161/01.ATV.11.6.1719; SVOBODA DJ, 1966, J CELL BIOL, V30, P442, DOI 10.1083/jcb.30.2.442; TAM SP, 1991, ATHEROSCLEROSIS, V91, P51, DOI 10.1016/0021-9150(91)90186-7; TODD PA, 1988, DRUGS, V36, P31; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VESSBY B, 1980, ATHEROSCLEROSIS, V37, P257, DOI 10.1016/0021-9150(80)90011-8; WALSH A, 1989, J BIOL CHEM, V264, P6488; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	67	208	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31012	31018						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983038				2022-12-25	WOS:A1994PV51000045
J	MARSHALLHEYMAN, H; ENGEL, G; LJUNGDAHL, S; SHOSHAN, MC; SVENSSON, C; WASYLYK, B; LINDER, S				MARSHALLHEYMAN, H; ENGEL, G; LJUNGDAHL, S; SHOSHAN, MC; SVENSSON, C; WASYLYK, B; LINDER, S			TUMORIGENIC AND METASTATIC PROPERTIES OF 2 RAS-ONCOGENE TRANSFECTED RAT FIBROSARCOMA CELL-LINES DEFECTIVE IN C-JUN	ONCOGENE			English	Article							EMBRYO FIBROBLASTS; TRANSCRIPTIONAL ACTIVATION; MOUSE FIBROBLASTS; MAMMALIAN-CELLS; PHORBOL ESTERS; GENE PROMOTER; GROWTH ARREST; FOS PROTEINS; TRANSFORMATION; AP-1	We here report the spontaneous loss of both homologues of the c-jun gene in two cell lines, isolated after transfection of rat embryo fibroblasts with single ras-oncogenes. These cells lines (designated A14 and B25) grow rapidly in vitro, have transformed morphologies and are invasive through reconstituted basal membranes. Both c-jun defective cell lines were found to be tumorigenic and metastatic in athymic mice. Loss of c-jun was paralleled by a dramatic decrease in interstitial collagenase expression, whereas stromelysin mRNA expression in c-jun(-) A14 and B25 cells was similar to that observed in c-jun(+) transformed cell lines. Transient transfection experiments using reporter plasmids showed that stromelysin promoter activity in A14 cells was severely impaired by a point mutation in the -71 to -65 AP-1 motif, and was inhibited by a Jun dominant negative mutant. Gel mobility shift studies demonstrated the presence of a factor in A14 nuclear extracts capable of binding the stromelysin TRE. This factor bound JunB, JunD and Fos antibodies. Our findings suggest that c-Jun is not required for the tumorigenic and metastatic potential of vas-transformed fibrosarcoma cells, and that AP-1 protein(s) lacking c-Jun are capable of activating the stromelysin gene promoter.	KAROLINSKA HOSP & INST, RADIUM HEMMET, DEPT GEN ONCOL, DIV EXPTL ONCOL, S-17176 STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MICROBIAL GENET, S-17176 STOCKHOLM, SWEDEN; FAC MED STRASBOURG, INST CHIM BIOL,CNRS,U184 BIOL MOLEC,INSERM, GENET MOLEC EUCARYOTES LAB, F-67085 STRASBOURG, FRANCE	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALBINI A, 1987, CANCER RES, V47, P3239; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; DELALUNA S, 1992, METHOD ENZYMOL, V216, P376; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; EDMONDS M, 1969, J BIOL CHEM, V244, P1314; ENGEL G, 1993, INT J ONCOL, V3, P457; GINSBERG D, 1991, ONCOGENE, V6, P669; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LINDER S, 1992, ONCOGENE, V7, P439; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL H, 1993, ONCOGENE, V8, P1303; MARSHALL H, 1991, EXP CELL RES, V194, P35, DOI 10.1016/0014-4827(91)90126-F; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	53	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3655	3663						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970724				2022-12-25	WOS:A1994PT39200029
J	RUVEN, HJT; SEELEN, CMJ; LOHMAN, PHM; VANKRANEN, H; VANZEELAND, AA; MULLENDERS, LHF				RUVEN, HJT; SEELEN, CMJ; LOHMAN, PHM; VANKRANEN, H; VANZEELAND, AA; MULLENDERS, LHF			STRAND-SPECIFIC REMOVAL OF CYCLOBUTANE PYRIMIDINE DIMERS FROM THE P53 GENE IN THE EPIDERMIS OF UVB-IRRADIATED HAIRLESS MICE	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMAS; GROUP-C FIBROBLASTS; DNA-REPAIR; ULTRAVIOLET RADIATION; TRANSCRIBED STRAND; ACTIVE GENES; DHFR GENE; MUTATIONS; MOUSE; SKIN	Removal of UVB-induced cyclobutane pyrimidine dimers (CPD) from each of the two strands of the transcriptionally active p53 tumor suppressor gene and the hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene was determined in the epidermis of the hairless mouse using the CPD-specific enzyme T4 endonuclease V. Mice were exposed to a single dose of UVB (2 kJ/m(2)) and kept in darkness for up to 24 h. About 80% of the CPD were removed from the transcribed strand of the p53 and HPRT genes within 24 h. Most rapid removal was observed during the first 4 h. Tn contrast, very little removal of CPD from the nontranscribed strand of the p53 and the HPRT genes was observed in 24 h. The same low level of repair was observed in the inactive cmos proto-oncogene. The efficient repair of the transcribed strand compared to the nontranscribed strand of transcriptionally active genes in the epidermis of the hairless mouse resembles the repair of CPD in cultured rodent cells. Moreover, the selective removal of CPD from the transcribed strand of the p53 gene correlates well with the known strand bias of u.v.-induced mutations at dipyrimidine sites in the p53 gene of u.v.- induced mouse skin tumors.	LEIDEN UNIV,MGC,DEPT RADIAT GENET & CHEM MUTAGENESIS,2333 AL LEIDEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,3720 BA BILTHOVEN,NETHERLANDS; INTERUNIV RES INST RADIOPATHOL & RADIAT,JA COHEN INST,LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Netherlands National Institute for Public Health & the Environment								BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P3782; BRUNET S, 1989, MUTAT RES, V219, P217, DOI 10.1016/0921-8734(89)90003-9; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; EPSTEIN JH, 1970, PHOTOCHEM PHOTOBIOL, V12, P57, DOI 10.1111/j.1751-1097.1970.tb06038.x; EVANS MK, 1993, CANCER RES, V53, P5377; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GATTONI S, 1982, MOL CELL BIOL, V2, P42, DOI 10.1128/MCB.2.1.42; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KANJILAL S, 1993, CANCER RES, V53, P2961; KONECKI DS, 1982, NUCLEIC ACIDS RES, V81, P2147; KRESS S, 1992, CANCER RES, V52, P6400; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; NEKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; PROPST F, 1984, NUCLEIC ACIDS RES, V12, P8381, DOI 10.1093/nar/12.22.8381; RADY P, 1992, CANCER RES, V52, P3804; RUVEN HJT, 1993, CANCER RES, V53, P1642; RUVEN HJT, 1994, MUTAT RES-DNA REPAIR, V315, P189, DOI 10.1016/0921-8777(94)90018-3; TORMANEN VT, 1992, ONCOGENE, V7, P1729; VANWEELDEN H, 1988, BRIT J DERMATOL, V119, P11; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; YUSPA SH, 1981, J INVEST DERMATOL, V76, P144, DOI 10.1111/1523-1747.ep12525490; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	32	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3427	3432						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970701				2022-12-25	WOS:A1994PT39200003
J	LAYTON, MJ; OWCZAREK, CM; METCALF, D; CLARK, RL; SMITH, DK; TREUTLEIN, HR; NICOLA, NA				LAYTON, MJ; OWCZAREK, CM; METCALF, D; CLARK, RL; SMITH, DK; TREUTLEIN, HR; NICOLA, NA			CONVERSION OF THE BIOLOGICAL SPECIFICITY OF MURINE TO HUMAN LEUKEMIA INHIBITORY FACTOR BY REPLACING 6 AMINO-ACID-RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; IL-6 SIGNAL TRANSDUCER; HUMAN GROWTH-HORMONE; HUMAN INTERLEUKIN-4; CRYSTAL-STRUCTURE; ONCOSTATIN-M; RECEPTOR; BINDING; CELLS; MUTAGENESIS	Mouse and human leukemia inhibitory factor (mLIF and hLIF) have similar to 80% amino acid identity, but mLIF cannot bind to the hLIF receptor (hLIF-R), while hLIF binds to the cw-chain of the mLIF receptor (mLIF-R) with a much higher affinity than does mLIF. We have previously shown that the same regions confer both these properties of hLIF and map to an area within the predicted third alpha-helix and two of the loops of hLIF (Owczarek, C. M., Layton, M. J., Metcalf, D., Lock, P., Willson, T. A., Gough, N. M., and Nicola, N. A. (1993) EMBO J. 12, 3487-3495). The present studies, using interspecies chimeras of mLIF and hLIF have defined 6 residues (Asp(57), Ser(107), His(112), Ser(113), Val(155), and Lys(158)) that contribute most of the binding energy involved in the interaction of hLIF and the hLIF-R alpha-chain, and form a surface at one end of the predicted four alpha-helical bundle of the hLIF molecule. Mouse LIF is unable to bind to the hLIF-R alpha-chain or activate the cellular hLIF-R, but when these 6 residues were substituted onto an mLIF framework, they were able to reconstitute both the binding and biological activities specific to hLIF.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; BIOMOLEC RES INST,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research; Royal Melbourne Hospital			Treutlein, Herbert Rudolf/AAC-7648-2021; Layton, Meredith/E-9171-2014; Nicola, Nicos/D-2989-2011	Treutlein, Herbert Rudolf/0000-0001-5553-5553; Nicola, Nicos/0000-0003-1054-7889; Smith, David/0000-0003-3608-0586	NCI NIH HHS [CA22556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; BRANDHUBER BJ, 1987, J BIOL CHEM, V262, P12306; BRUNDER AT, 1992, XPLOR SYSTEM CRYSTAL; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1994, J BIOL CHEM, V91, P1119; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAUSHANSKY K, 1993, BLOOD, V82, P3229; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; METCALF D, 1988, LEUKEMIA, V2, P216; Metcalf D, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046921; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; NICOLA NA, 1993, BIOCHEM BIOPH RES CO, V190, P20, DOI 10.1006/bbrc.1993.1004; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; SMITH DK, 1986, THESIS U CANBERRA	29	36	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29891	29896						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961984				2022-12-25	WOS:A1994PU28400088
J	OGASAWARA, Y; MCCORMACK, FX; MASON, RJ; VOELKER, DR				OGASAWARA, Y; MCCORMACK, FX; MASON, RJ; VOELKER, DR			CHIMERAS OF SURFACTANT PROTEIN-A AND PROTEIN-D IDENTIFY THE CARBOHYDRATE-RECOGNITION DOMAINS AS ESSENTIAL FOR PHOSPHOLIPID INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A SP-A; II CELLS; STRUCTURAL SIMILARITY; SPECIFICALLY BINDS; LUNG; SECRETION; PHOSPHATIDYLINOSITOL; CONGLUTININ; SEQUENCE; CDNA	Pulmonary surfactant proteins A (SP-A) and D (SP-D) possess similar structure as members of the mammalian C-type lectin superfamily. Both proteins are composed of four characteristic domains which are: 1) an NH2-terminal domain involved in interchain disulfide formation (denoted Al domain for SP-A or D1 for SP-D); 2) a collagenous domain (denoted A2 or D2); 3) a neck domain (denoted A3 or D3); and 4) a carbohydrate recognition domain (denoted A4 or D4). SP-A specifically binds to dipalmitoylphosphatidylcholine, the major lipid component of surfactant, and can regulate the secretion and recycling of this lipid by alveolar type II cells. SP-D binds to phosphatidylinositol (PI) and glucosylceramide (GlcCer), and its role in alveolar lipid metabolism remains to be clarified. To understand the relationship between the structure and the function of both proteins with respect to their interaction with lipids, we expressed recombinant wild type rat SP-D (rSP-D) and chimeric molecules of SP-A and SP-D (A1A2A3D4, A1A2D3D4, and D1D2A3A4) using a baculovirus expression system, and performed lipid binding and aggregation assays. The rSP-D effectively competed with I-125-labeIed native rat SP-D in a solid phase binding assay to PI and GIcCer in a manner nearly identical to native SP-D. The rSP-D also bound to PI liposomes with approximately half the affinity of native rat SP-D. Chimera A1A2D3D4 competed with iodinated SP-D in the solid phase binding assay to both PI and GlcCer. This chimera did not bind to dipalmitoylphosphatidyIcholine (DPPC) liposomes or induce their aggregation. Chimera A1A2A3D4 did not bind solid phase PI or GlcCer but was equivalent to rSP-D in binding to PI liposomes. This chimera exhibited weak binding to DPPC but failed to aggregate DPPC liposomes. Chimera D1D2A3A4 failed to bind PI and GlcCer and bound weakly to DPPC liposomes but was quite effective at inducing aggregation of DPPC Iiposomes. These findings demonstrate that the D3 plus D4 domains of SP-D play a role in lipid binding and that the D4 domain is essential for PI binding. Furthermore, the A3 domain of SP-A cannot account for all the lipid binding activity of this protein. In addition, the results implicate the A4 domain of SP-A as an important structural domain in lipid aggregation phenomena.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,LORD & TAYLOR LAB LUNG BIOCHEM,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV PULM SCI & CRIT CARE MED,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029891, R37HL029891, R01HL045286] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02423, HL45286, HL29891] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; HAAGSMAN HP, 1991, BIOCHEM J, V275, P273, DOI 10.1042/bj2750273; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; KUROKI Y, 1991, BIOCHEM J, V279, P115, DOI 10.1042/bj2790115; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V187, P963, DOI 10.1016/0006-291X(92)91291-W; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM BL, 1993, IMMUNOLOGY, V78, P159; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; OGASAWARA Y, 1991, BIOCHIM BIOPHYS ACTA, V1083, P252, DOI 10.1016/0005-2760(91)90079-W; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1990, J BIOL CHEM, V265, P5755; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; PROCKOP DJ, 1976, BIOCH COLLAGEN, P161; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; ROSS GF, 1986, J BIOL CHEM, V261, P14283; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888	34	74	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29785	29792						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961971				2022-12-25	WOS:A1994PU28400074
J	SUDBECK, BD; PARKS, WC; WELGUS, HG; PENTLAND, AP				SUDBECK, BD; PARKS, WC; WELGUS, HG; PENTLAND, AP			COLLAGEN-STIMULATED INDUCTION OF KERATINOCYTE COLLAGENASE IS MEDIATED VIA TYROSINE KINASE AND PROTEIN-KINASE-C ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN FIBROBLAST COLLAGENASE; STROMELYSIN GENE-EXPRESSION; PHORBOL-MYRISTATE ACETATE; HUMAN-SKIN FIBROBLASTS; TRANS-RETINOIC ACID; TISSUE INHIBITOR; TRANSCRIPTIONAL ACTIVATION; EXTRACELLULAR-MATRIX; IV COLLAGENASE	We have previously shown that during mound healing migrating keratinocytes, which are in contact with the dermal matrix, express interstitial collagenase, whereas basal epidermal cells, which reside on an intact basement membrane, do not. Duplicating this in vivo pattern, collagenase production was induced in primary human keratinocytes grown on native type I collagen, but only background levels of enzyme were detected in cells cultured on denatured type I collagen or on Matrigel(TM). Using genistein, herbimycin A, and sodium orthovanadate, we show that tyrosine kinase activity was required for collagen-mediated induction of keratinocyte collagenase. Similarly, collagenase steady-state mRNA levels and the activity of a transfected human collagenase-promoter CAT construct were inhibited by genistein and enhanced by orthovanadate. Staurosporine and H-7 also blocked collagenase production, indicating that protein kinase C activity was also required for collagen-mediated induction of keratinocyte collagenase. Ah inhibitory effects were dose-dependent, and no compound significantly affected total protein synthesis. Furthermore, both tyrosine kinase and protein kinase C inhibitors blocked phorbol ester-mediated induction of collagenase, but only protein kinase C antagonists abrogated phorbol ester-mediated induction of c-fos mRNA These data suggest that similar signal transduction pathways are used by various agonists to mediate the stimulation of interstitial collagenase production.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, MED CTR, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	SUDBECK, BD (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MED DERMATOL, ST LOUIS, MO 63110 USA.		Parks, William C./AAH-6786-2021		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001849, R01AR035805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038111] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-01849, AR-35805] Funding Source: Medline; NIDDK NIH HHS [DK-38111] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Angel P, 1992, Matrix Suppl, V1, P156; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BAUER EA, 1975, BIOCHEM BIOPH RES CO, V64, P232, DOI 10.1016/0006-291X(75)90243-0; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLARK SD, 1985, ARCH BIOCHEM BIOPHYS, V241, P36, DOI 10.1016/0003-9861(85)90358-3; COLIGE AC, 1992, BIOCHEM J, V285, P215, DOI 10.1042/bj2850215; COOPER TW, 1983, COLLAGEN REL RES, V3, P205; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEAN NM, 1989, BIOCHEM BIOPH RES CO, V165, P795, DOI 10.1016/S0006-291X(89)80036-1; DELANY AM, 1992, J CELL BIOCHEM, V50, P400, DOI 10.1002/jcb.240500409; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DLUGOSZ AA, 1991, CANCER RES, V51, P4677; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GIPSON IK, 1993, EXP CELL RES, V207, P86, DOI 10.1006/excr.1993.1166; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOSHOWAKI H, 1988, PROSTAGLANDINS, V36, P107, DOI 10.1016/0090-6980(88)90106-2; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; HINEK A, 1991, CONNECT TISSUE RES, V26, P155, DOI 10.3109/03008209109152434; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jeffrey J. J., 1986, REGULATION MATRIX AC, P53; JUHASZ I, 1993, AM J PATHOL, V143, P1458; KUTUZOVA GD, 1989, BIOCHIMIE, V71, P579, DOI 10.1016/0300-9084(89)90190-9; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MAUVIEL A, 1992, J BIOL CHEM, V267, P5644; MAUVIEL A, 1994, J CELL BIOCHEM, V54, P465, DOI 10.1002/jcb.240540413; MIGNATTI P, 1988, MOL CELLULAR BIOL WO, P497; MURPHY G, 1985, J BIOL CHEM, V260, P3079; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PARKS WC, 1988, J BIOL CHEM, V263, P4416; PELLEGRINI G, 1992, J CLIN INVEST, V89, P1783, DOI 10.1172/JCI115782; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; PENTLAND AP, 1991, AM J PHYSIOL, V261, pR543, DOI 10.1152/ajpregu.1991.261.3.R543; PENTLAND AP, 1993, J INVEST DERMATOL; PETERSEN MJ, 1990, J INVEST DERMATOL, V94, P341, DOI 10.1111/1523-1747.ep12874471; PIERCE RA, 1992, J BIOL CHEM, V267, P11593; RICHARDS CD, 1991, MATRIX, V11, P161, DOI 10.1016/S0934-8832(11)80154-X; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHAPIRO SD, 1993, BIOCHEMISTRY-US, V32, P4286, DOI 10.1021/bi00067a018; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TRELSTAD RL, 1976, ANAL BIOCHEM, V71, P114, DOI 10.1016/0003-2697(76)90016-6; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; Welgus H G, 1992, Matrix Suppl, V1, P363; WELGUS HG, 1986, J CLIN INVEST, V77, P1675, DOI 10.1172/JCI112485; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOODLEY DT, 1993, DERMATOL CLIN, V11, P641, DOI 10.1016/S0733-8635(18)30217-1; WOODLEY DT, 1986, J INVEST DERMATOL, V86, P418, DOI 10.1111/1523-1747.ep12285689; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZAFARULLAH M, 1992, FEBS LETT, V306, P169, DOI 10.1016/0014-5793(92)80992-P	71	91	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					30022	30029						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7962003				2022-12-25	WOS:A1994PU28400107
J	WILCOX, BD; DUMIN, JA; JEFFREY, JJ				WILCOX, BD; DUMIN, JA; JEFFREY, JJ			SEROTONIN REGULATION OF INTERLEUKIN-1 MESSENGER-RNA IN RAT UTERINE SMOOTH-MUSCLE CELLS - RELATIONSHIP TO THE PRODUCTION OF INTERSTITIAL COLLAGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-HT2 BINDING CHARACTERISTICS; GENE-EXPRESSION; PURIFICATION; STIMULATION; CULTURES; RECEPTOR; ANALOGS; CLONING; ENZYME	Previous studies have shown that the production of interstitial collagenase by rat myometrial smooth muscle cells is dependent on serotonin. These cells fail to produce collagenase early in culture, however, and produce the enzyme only 8-12 days after confluence. During the early quiescent period, collagenase production can be induced by low concentrations of bacterial endotoxin. Under these conditions, interleukin (IL)-1 alpha and IL-1 beta mRNAs increase coincident with collagenase and collagenase mRNA. Serotonin removal decreases IL-1 alpha and IL-1 beta mRNAs, an effect that is rapidly reversed upon readdition of serotonin. Conversely, seretonin-dependent increases in IL-1 mRNAs are blocked by progesterone. Experiments with 5-HT2 receptor agonists and antagonists indicate that induction is mediated by the 5-HT2 receptor subtype. In serotonin-treated cells late in culture, IL-1 mRNAs increase coincident with the production of collagenase. Similarly, exogenous IL-1 fully substitutes for lipopolysaccharide in stimulating myometrial cells to produce collagenase early in culture. Cells treated with IL-1 receptor antagonist fail to make IL-1 mRNAs or collagenase but produce collagenase and IL-1 mRNAs following antagonist removal. These results indicate that serotonin-dependent IL-1 production by the myometrial cell is required for collagenase production and that IL-1 participates in its own production via an autocrine mechanism.	ALBANY MED COLL,DEPT BIOCHEM & MOLEC BIOL,ALBANY,NY 12208; ALBANY MED COLL,DEPT PHARMACOL & TOXICOL,ALBANY,NY 12208	Albany Medical College; Albany Medical College	WILCOX, BD (corresponding author), ALBANY MED COLL,DEPT MED,DIV HEMATOL,A-52,47 NEW SCOTLAND AVE,ALBANY,NY 12208, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005291, R37HD005291] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 05291] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLAIR HC, 1986, J CELL PHYSIOL, V129, P111, DOI 10.1002/jcp.1041290116; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; FINI ME, 1994, J BIOL CHEM, V269, P11291; GLENNON RA, 1986, J MED CHEM, V29, P2375, DOI 10.1021/jm00161a038; GLENNON RA, 1986, J MED CHEM, V29, P194, DOI 10.1021/jm00152a005; HALME J, 1980, ARCH BIOCHEM BIOPHYS, V199, P51, DOI 10.1016/0003-9861(80)90255-6; HARKNESS MLR, 1956, J PHYSIOL-LONDON, V132, P492, DOI 10.1113/jphysiol.1956.sp005542; HARKNESS RD, 1956, J PHYSIOL-LONDON, V132, P502, DOI 10.1113/jphysiol.1956.sp005543; JEFFREY JJ, 1990, J CELL PHYSIOL, V143, P396, DOI 10.1002/jcp.1041430226; JEFFREY JJ, 1991, J CELL PHYSIOL, V146, P399, DOI 10.1002/jcp.1041460310; JEFFREY JJ, 1970, BIOCHEMISTRY-US, V9, P269; KRANE SM, 1990, ANN NY ACAD SCI, V580, P340, DOI 10.1111/j.1749-6632.1990.tb17943.x; LEYSEN JE, 1982, MOL PHARMACOL, V21, P301; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; LOPPNOW H, 1992, EXP CELL RES, V198, P283, DOI 10.1016/0014-4827(92)90381-H; NAGAI Y, 1966, BIOCHEMISTRY-US, V5, P3123, DOI 10.1021/bi00874a007; PEROUTKA SJ, 1979, MOL PHARMACOL, V16, P687; POSTLETHWAITE AE, 1983, J EXP MED, V157, P801, DOI 10.1084/jem.157.2.801; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROSWIT WT, 1988, ARCH BIOCHEM BIOPHYS, V262, P67, DOI 10.1016/0003-9861(88)90169-5; RYDELEKFITZGERALD L, 1993, MOL CELL ENDOCRINOL, V91, P67, DOI 10.1016/0303-7207(93)90256-J; SCHATZ F, 1983, ENDOCRINOLOGY, V113, P1274, DOI 10.1210/endo-113-4-1274; STEPHENSON ML, 1987, BIOCHEM BIOPH RES CO, V144, P583, DOI 10.1016/S0006-291X(87)80006-2; WARNER SJC, 1987, J EXP MED, V165, P1316, DOI 10.1084/jem.165.5.1316; WARNER SJC, 1987, J IMMUNOL, V139, P1911; WILCOX BD, 1994, MOL CELL ENDOCRINOL, V101, P67, DOI 10.1016/0303-7207(94)90220-8; WILCOX BD, 1992, J BIOL CHEM, V267, P20752; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	28	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29658	29664						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961954				2022-12-25	WOS:A1994PU28400055
J	ZANOTTI, G; MARCELLO, M; MALPELI, G; FOLLI, C; SARTORI, G; BERNI, R				ZANOTTI, G; MARCELLO, M; MALPELI, G; FOLLI, C; SARTORI, G; BERNI, R			CRYSTALLOGRAPHIC STUDIES ON COMPLEXES BETWEEN RETINOIDS AND PLASMA RETINOL-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; REFINEMENT; RESOLUTION; LIGAND; TRANSTHYRETIN	The three-dimensional structures of complexes between bovine plasma retinol-binding protein (RBP) and three retinol analogs with different end groups (fenretinide, all-trans retinoic acid, and axerophthene) have been determined to 1.8-1.9-Angstrom resolution. Their models are very similar to that of the bovine retinol.RBP complex: the root mean square deviations between equivalent alpha-carbons in the two proteins range from 0.17 to 0.24 Angstrom. The retinoid molecules fit in the beta-barrel cavity assuming the same conformation of the vitamin, and the substitutions have no consequences on the overall protein structure. While confirming that an intact hydroxyl end group is not an absolute requirement for a correct retinoid binding to RBP, this study has shown the occurrence of conformational changes, although limited, in the rather flexible loop region at the entrance of the beta-barrel upon fenretinide and retinoic acid binding. These changes are suitable for accommodating the end groups of the above retinoids. Instead, no such changes have been revealed in RBP complexed with axerophthene, a retinol analog bearing a hydrogen atom in place of the hydroxyl end group, The protein conformational changes in the above loop region, the steric hindrance of bulky end groups of bound retinoids, and the lack of the retinol hydroxyl group appear to be responsible for the possible reduced affinity of retinoids for RBP relative to retinol and, at the same time, for the abolished or reduced affinity of retinoid.RBP complexes for transthyretin relative to retinol-RBP.	CNR,BIOPOLYMER RES CTR,I-35131 PADUA,ITALY; UNIV PARMA,INST BIOCHEM SCI,I-43100 PARMA,ITALY; UNIV PARMA,DEPT ORGAN & IND CHEM,I-43100 PARMA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Parma; University of Parma	ZANOTTI, G (corresponding author), UNIV PADUA,DEPT ORGAN CHEM,VIA MARZOLO 1,I-35131 PADUA,ITALY.			Zanotti, Giuseppe/0000-0002-0945-6501; Berni, Rodolfo/0000-0002-1839-0479; Malpeli, Giorgio/0000-0002-2996-2903				BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O; BERNI R, 1993, FASEB J, V7, P1179, DOI 10.1096/fasebj.7.12.8375617; BERNI R, 1989, COMP BIOCHEM PHYS B, V94, P79, DOI 10.1016/0305-0491(89)90014-X; BERNI R, 1993, RETINOIDS PROGR RES, P91; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COSTA A, 1994, CANCER RES, V54, pS2032; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LI E, 1991, J BIOL CHEM, V266, P3622; LOMBARDO A, 1994, J BIOL CHEM, V269, P7297; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; NEWTON DL, 1978, CANCER RES, V38, P1734; NOY N, 1992, BIOCHEMISTRY-US, V31, P11118, DOI 10.1021/bi00160a023; Ong David E., 1994, P283; PETKOVICH M, 1987, NATURE, V330, P440; SOPRANO DR, 1994, RETINOIDS, P267; STAM CH, 1972, ACTA CRYSTALL B-STRU, VB 28, P2936, DOI 10.1107/S0567740872007253; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; ZANOTTI G, 1993, J MOL BIOL, V230, P613, DOI 10.1006/jmbi.1993.1173; ZANOTTI G, 1993, J BIOL CHEM, V268, P24873; ZANOTTI G, 1993, J BIOL CHEM, V268, P10728	28	51	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29613	29620						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961949				2022-12-25	WOS:A1994PU28400049
J	INOUE, I; RECHSTEINER, M				INOUE, I; RECHSTEINER, M			ON THE RELATIONSHIP BETWEEN THE METABOLIC AND THERMODYNAMIC STABILITIES OF T4 LYSOZYMES - MEASUREMENTS IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 LYSOZYME; PROTEIN-STRUCTURE; ALPHA-HELIX; RAPID DEGRADATION; PHAGE-T4 LYSOZYME; HEAT-SHOCK; CELLS; MUTANT; SUBSTITUTIONS; PROTEOLYSIS	Escherichia coli cells were transformed with plasmids encoding 12 site-specific variants of T4 lysozyme, and pulse-chase protocols were used to measure the metabolic stability of each protein. The resulting half-lives ranged from 1 h to more than 50 h. Although the metabolic half-lives of T4 lysozymes correlated roughly with their thermal stabilities, three mutant enzymes were clear exceptions. A reasonably temperature-resistant variant, G156D, exhibited a half-life of 1 h. By contrast, two temperature-sensitive variants, T157I and I3G, were as metabolically stable as wild-type T4 lysozyme. Degradation of two short lived variants, L91P and G156P, required ATP both in vivo and in vitro. Degradation of variant and wild-type enzymes was unimpaired in cells lacking the Lon protease, Clp A or Clp P. However, degradation of L91P and G156D was inhibited in Clp B-cells. Decreased proteolysis of L91P was accompanied by its accumulation in inclusion bodies, indicating that Clp B prevents accumulation of aggregated protein either by preventing aggregation of misfolded polypeptides or solubilizing aggregates.			INOUE, I (corresponding author), UNIV UTAH, SCH MED, DEPT BIOCHEM, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027159] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-27159] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1988, SCIENCE, V239, P631, DOI 10.1126/science.3277275; ALBER T, 1985, PROTEIN STRUCTURE FO, P307; BISHAI WR, 1987, J BACTERIOL, V169, P5140, DOI 10.1128/jb.169.11.5140-5151.1987; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; CREIGHTON TE, 1979, J MOL BIOL, V129, P235, DOI 10.1016/0022-2836(79)90279-1; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DIXON MM, 1992, J MOL BIOL, V227, P917, DOI 10.1016/0022-2836(92)90231-8; DRUBIN D, 1988, J CELL BIOL, V106, P1583, DOI 10.1083/jcb.106.5.1583; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HEINZ DW, 1992, P NATL ACAD SCI USA, V89, P3751, DOI 10.1073/pnas.89.9.3751; HEINZ DW, 1994, PROTEIN ENG, V7, P301, DOI 10.1093/protein/7.3.301; HEINZ DW, 1993, NATURE, V361, P561, DOI 10.1038/361561a0; HERMAN C, 1993, P NATL ACAD SCI USA, V90, P10861, DOI 10.1073/pnas.90.22.10861; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; INOUE I, 1994, J BIOL CHEM, V269, P29247; KLEMM JD, 1991, BIOCHEMISTRY-US, V30, P589, DOI 10.1021/bi00216a038; KULESH DA, 1989, MOL CELL BIOL, V9, P1553, DOI 10.1128/MCB.9.4.1553; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NOBLE JA, 1993, P NATL ACAD SCI USA, V90, P10866, DOI 10.1073/pnas.90.22.10866; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; PAKULA AA, 1989, PROTEINS, V5, P202, DOI 10.1002/prot.340050303; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; RECHSTEINER M, 1987, TRENDS BIOCHEM SCI, V12, P390; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; ROGERS SW, 1988, J BIOL CHEM, V263, P19833; ROGERS SW, 1988, J BIOL CHEM, V263, P19850; ROGERS SW, 1988, J BIOL CHEM, V263, P19843; SAUER UH, 1992, J BIOL CHEM, V267, P2393; SHAEFFER JR, 1988, J BIOL CHEM, V263, P13663; SHERMAN MY, 1992, EMBO J, V11, P71; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; TIDOR B, 1991, BIOCHEMISTRY-US, V30, P3217, DOI 10.1021/bi00227a009; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WEAVER LH, 1989, BIOCHEMISTRY-US, V28, P3793, DOI 10.1021/bi00435a025; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X	50	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29241	29246						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961892				2022-12-25	WOS:A1994PU16800105
J	KAWAMINAMI, S; OZAKI, K; SUMITOMO, N; HAYASHI, Y; ITO, S; SHIMADA, I; ARATA, Y				KAWAMINAMI, S; OZAKI, K; SUMITOMO, N; HAYASHI, Y; ITO, S; SHIMADA, I; ARATA, Y			A STABLE ISOTOPE-AIDED NMR-STUDY OF THE ACTIVE-SITE OF AN ENDOGLUCANASE FROM A STRAIN OF BACILLUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-THERMOCELLUM; NUCLEOTIDE-SEQUENCE; 3-DIMENSIONAL STRUCTURE; CHEMICAL MODIFICATION; TRICHODERMA-REESEI; PLASMID DNA; SP KSM-330; CELLULASE; GENE; RESIDUES	Heteronuclear single-quantum coherence two-dimensional NMR spectroscopy has been used to investigate the active site of endoglucanase K (46 kDa) from Bacillus sp. KSM-330, in which Trp are important for expression of the activity. Endoglucanase K, which was specifically labeled with [indole-2-C-13]Trp, was prepared from recombinant Bacillus subtilis that carried the gene for this enzyme on an expression vector, pHSP-KC331. Twelve cross-peaks originating from the C-2 position of Trp residues of endoglucanase K were separately observed in H-1-C-13 heteronuclear single-quantum coherence spectrum, and six of the cross-peaks have been assigned site specifically by using site-directed mutagenesis. The chemical shifts of the cross-peaks originating from Trp-174 and Trp-243 were affected by the addition of cellotriose that was used as a competitive inhibitor of the enzyme. On the basis of the NMR data obtained after chemical modification of the enzyme by N-bromosuccinimide, it appears that Trp-174 was oxidized first with retention of 56% of the original activity and Trp-243 was then oxidized with complete loss of activity. Substitution of Trp-174 or Trp-243 by Tyr residue caused a decrease in the specific activity of the enzyme to 49 or 8% of that of the wild-type enzyme, respectively. K-m values of these mutant enzymes for p-nitrophenyl beta-D-cellotrioside increased to 5 and 8 times those of the wild-type enzyme, respectively, while k(cat) values of both of the mutant enzymes decreased to one-fifth of those of the wild-type enzymes. These results suggest that Trp-174 and Trp-243 play an important role in binding of the substrate and/or in the catalytic activity.	UNIV TOKYO, FAC PHARMACEUT SCI, TOKYO 113, JAPAN	University of Tokyo	KAWAMINAMI, S (corresponding author), KAO CORP, BIOL SCI LABS, 2606 AKABANE, HAGA, TOCHIGI 32134, JAPAN.							BAGNARATARDIF C, 1992, GENE, V119, P17, DOI 10.1016/0378-1119(92)90062-T; BAIRD SD, 1990, BIOCHEM BIOPH RES CO, V169, P1035, DOI 10.1016/0006-291X(90)91998-8; BEGUIN P, 1985, J BACTERIOL, V162, P102; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; BELAICH A, 1992, J BACTERIOL, V174, P4677, DOI 10.1128/JB.174.14.4677-4682.1992; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUENO A, 1990, NUCLEIC ACIDS RES, V18, P4248, DOI 10.1093/nar/18.14.4248; CHANG S, 1979, MOL GEN GENET, V168, P111, DOI 10.1007/BF00267940; CLARKE AJ, 1987, BIOCHIM BIOPHYS ACTA, V912, P424, DOI 10.1016/0167-4838(87)90048-3; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9; HURST PL, 1977, BIOCHEM J, V167, P549, DOI 10.1042/bj1670549; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NAKAMURA K, 1986, J BIOTECHNOL, V4, P247, DOI 10.1016/0168-1656(86)90035-0; NAVAS J, 1992, BIOCHEM BIOPH RES CO, V189, P807, DOI 10.1016/0006-291X(92)92274-2; NORWOOD TJ, 1989, FEBS LETT, V255, P369, DOI 10.1016/0014-5793(89)81124-X; OZAKI K, 1991, J GEN MICROBIOL, V137, P41, DOI 10.1099/00221287-137-1-41; OZAKI K, 1991, J GEN MICROBIOL, V137, P2299, DOI 10.1099/00221287-137-10-2299; OZAKI K, 1994, BBA-PROTEIN STRUCT M, V1207, P159, DOI 10.1016/0167-4838(94)00060-3; PETTERSS.G, 1968, ARCH BIOCHEM BIOPHYS, V126, P776, DOI 10.1016/0003-9861(68)90471-2; PY B, 1991, PROTEIN ENG, V4, P325, DOI 10.1093/protein/4.3.325; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; Spande T.F., 1967, DETERMINATION TRYPTO, P498; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUMITOMO N, 1992, BIOSCI BIOTECH BIOCH, V56, P872, DOI 10.1271/bbb.56.872; TOMME P, 1989, FEBS LETT, V243, P239, DOI 10.1016/0014-5793(89)80136-X; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG QP, 1993, J BIOL CHEM, V268, P14096	32	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28752	28756						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961828				2022-12-25	WOS:A1994PU16800038
J	KOBAYASHI, H; STEWART, E; POON, RYC; HUNT, T				KOBAYASHI, H; STEWART, E; POON, RYC; HUNT, T			CYCLIN-A AND CYCLIN-B DISSOCIATE FROM P34(CDC2) WITH HALF-TIMES OF 4 AND 15 H, RESPECTIVELY, REGARDLESS OF THE PHASE OF THE CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC2 PROTEIN-KINASE; MESSENGER-RNA; PROMOTING FACTOR; DNA-REPLICATION; MITOTIC ARREST; A-TYPE; NUCLEAR; ACTIVATION; DEGRADATION; EXTRACTS	The exchange rate of cyclin A and cyclin B between endogenous p34(cdc2) and bacterially expressed GST-cdc2 was measured in concentrated Xenopus egg extracts. The half-lives of the cyclin A.p34(cdc2) and the cyclin B.p34(cdc2) complexes are estimated as 4 and 15 h, respectively. There is no significant difference in these affinities when they are measured in mitosis, interphase, or during transition between these two states. The tight association between cyclin and p34(cdc2) in the cell cycle may be significant for mechanisms of cyclin destruction.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND					Poon, Randy/0000-0001-5571-6231				ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; HARLOW E, 1988, ANTIBODIES LABORATOR; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOHKA MJ, 1989, J CELL SCI, V92, P131; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LOREA T, 1992, FEBS LETT, V306, P90; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MARIDOR G, 1993, J CELL SCI, V106, P535; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P573; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; VANDERVELDEN HMW, 1993, MOL CELL BIOL, V13, P1480, DOI 10.1128/MCB.13.3.1480; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	48	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29153	29160						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961881				2022-12-25	WOS:A1994PU16800093
J	KRUSCHWITZ, HL; MCDONALD, D; COSSINS, EA; SCHIRCH, V				KRUSCHWITZ, HL; MCDONALD, D; COSSINS, EA; SCHIRCH, V			5-FORMYLTETRAHYDROPTEROYLPOLYGLUTAMATES ARE THE MAJOR FOLATE DERIVATIVES IN NEUROSPORA-CRASSA CONIDIOSPORES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC SERINE HYDROXYMETHYLTRANSFERASE; MOUSE LEUKEMIA-CELLS; ESCHERICHIA-COLI; 5,10-METHENYLTETRAHYDROFOLATE SYNTHETASE; DIHYDROFOLATE-REDUCTASE; REACTION SPECIFICITY; LACTOBACILLUS-CASEI; RABBIT LIVER; FOLIC-ACID; PURIFICATION	5-Formyltetrahydropteroylpolyglutamate (5-CHO-H(4)PteGlu(n)) is the only reduced folate derivative that is stable to oxidation and alkaline pH. However, no metabolic role has been assigned to this folate derivative, and evidence for its existence in cells has been questioned. Recently, serine hydroxymethyltransferase was shown to catalyze the formation of 5 CHO-H(4)PteGlu(n) from 5,10-methenyl-H(4)PteGlu(n) (Stover, P., and Schirch, V. (1990) J. Biol. Chem. 265, 14227-14233). We have proposed that 5-CHO-H(4)PteGlu(n) may serve as a storage form of reduced folates and one-carbon groups in cells that are in a dormant stage. This hypothesis was tested by determining the levels of H(4)PteGlu(n) derivatives in the mycelia and conidiospores of Neurospora crassa and a mutant strain that lacks cytosolic serine hydroxymethyltransferase. N. crassa serine hydroxymethyltransferase was purified to homogeneity and characterized with respect to kinetic constants, quaternary structure, stability, and reaction specificity. Anew assay for determining the concentration of the polyglutamate forms of H(4)PteGlu(n) derivatives was also developed. Using this assay, it was shown that 85% of the tetrahydropteroylpolyglutamates in conidiospores was 5-CHO-H(4)PteGlu(n). After adding the spores to growth media, the 5-CHO-H(4)PteGlu(n) was reduced to less than 10% of the folate pool in 20 min. Mycelia had no detectable 5-CHO-H(4)PteGlu(n). Only 10-20% of the folate pool in conidiospores from the mutant strain lacking cytosolic serine hydroxymethyltransferase was in the form of 5 CHO-H(4)PteGlu(n).	VIRGINIA COMMONWEALTH UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, RICHMOND, VA 23298 USA; UNIV ALBERTA, DEPT BOT, EDMONTON T6G 2E9, AB, CANADA	Virginia Commonwealth University; University of Alberta					NIGMS NIH HHS [GM 28143] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGELACCIO S, 1992, BIOCHEMISTRY-US, V31, P155, DOI 10.1021/bi00116a023; ARTIGUES A, 1990, J BIOL CHEM, V265, P4853; ARTIGUES A, 1993, J BIOL CHEM, V268, P13784; BIRDSALL B, 1981, BIOCHEMISTRY-US, V20, P7186, DOI 10.1021/bi00528a021; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAN PY, 1984, Z PFLANZENPHYSIOL, V114, P455, DOI 10.1016/S0044-328X(84)80065-3; CHEN MS, 1973, J BIOL CHEM, V248, P3631; COSSINS EA, 1976, BIOCHEM J, V160, P305, DOI 10.1042/bj1600305; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FRIEDKIN M, 1975, J BIOL CHEM, V250, P5614; FUJII K, 1982, J BIOL CHEM, V257, P2144; GONZALEZ JC, 1992, BIOCHEMISTRY-US, V31, P6045, DOI 10.1021/bi00141a013; GRIMSHAW CE, 1984, J BIOL CHEM, V259, P2728; GUIGNARD R, 1983, EXP MYCOL, V7, P133, DOI 10.1016/0147-5975(83)90056-7; HOPKINS S, 1984, J BIOL CHEM, V259, P5618; KRUSCHWITZ H, 1993, ADV EXP MED BIOL, V338, P719; KVALNESKRICK K, 1987, BIOCHEMISTRY-US, V26, P7391, DOI 10.1021/bi00397a029; MacKenzie R E, 1984, FOLATES PTERINS CHEM, V1, P255; MCCLUNG CR, 1992, MOL CELL BIOL, V12, P1412, DOI 10.1128/MCB.12.4.1412; MORAN RG, 1976, J BIOL CHEM, V251, P3569; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ROSENBLATT DS, 1979, J CLIN INVEST, V63, P1019, DOI 10.1172/JCI109370; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIRCH L, 1968, J BIOL CHEM, V243, P5651; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; SCHIRCH L, 1978, ARCH BIOCHEM BIOPHYS, V189, P283, DOI 10.1016/0003-9861(78)90214-X; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; SHIN YS, 1975, CAN J BIOCHEM CELL B, V53, P338, DOI 10.1139/o75-047; STOVER P, 1992, ANAL BIOCHEM, V202, P82, DOI 10.1016/0003-2697(92)90210-X; STOVER P, 1992, BIOCHEMISTRY-US, V31, P2148, DOI 10.1021/bi00122a036; STOVER P, 1992, BIOCHEMISTRY-US, V31, P2155, DOI 10.1021/bi00122a037; STOVER P, 1990, J BIOL CHEM, V265, P14227; STOVER P, 1991, J BIOL CHEM, V266, P1543; STOVER P, 1992, J BIOL CHEM, V267, P17679; STOVER P, 1993, ADV EXP MED BIOL, V338, P723; STRONG WB, 1989, BIOCHEMISTRY-US, V28, P9430, DOI 10.1021/bi00450a028; TEMPLE C, 1984, CHEM BIOCH FOLATES, V1, P80; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5342, DOI 10.1021/bi00643a027; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; WITTWER AJ, 1981, J BIOL CHEM, V256, P4102	42	48	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28757	28763						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961829				2022-12-25	WOS:A1994PU16800039
J	XING, LP; QUINN, PG				XING, LP; QUINN, PG			3 DISTINCT REGIONS WITHIN THE CONSTITUTIVE ACTIVATION DOMAIN OF CAMP REGULATORY ELEMENT-BINDING PROTEIN (CREB) ARE REQUIRED FOR TRANSCRIPTION ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; RESPONSE ELEMENT; MAMMALIAN-CELLS; EXPRESSION; PHOSPHORYLATION; MULTIPLE; PROMOTER; FAMILY; BASAL; SITES	The transcription factor cAMP regulatory element-binding protein (CREB) mediates both constitutive and cAMP-induced gene expression through distinct, independently acting domains. The constitutive activation domain (CAD) (amino acids (aa) 165-252) encompasses and overlaps exon 9 of the CREB gene (E9, aa 180-243). In the present study, deletion of either the CAD or exon 9 from CREB-GAL4 (CRG) reduced constitutive activity to less than 2-fold, without affecting kinase inducible activity. However, fusion of the CAD to the GAL4 DNA binding domain (CAD-G4) stimulated transcription, whereas fusion of exon 9 sequences did not. Deletion of the amino-terminal flanking region of exon 9 (aa 165-180), but not COOH-terminal flanking sequences (aa 243-252), decreased constitutive activation in either the CAD-G4 or CRG background. Deletion of the previously characterized glutamine-rich region (Q3, aa 218-252) or of a region containing a hydrophobic cluster of amino acids (HC, aa 180-218) also reduced constitutive activation by either CAD-G4 or CRG. No single mutation of hydrophobic residues within HC impaired activity of the CAD, but double and triple mutations did, suggesting that multiple weak interactions are involved in function of the HC region. Thus, exon 9 of the CREB gene is necessary but not sufficient for constitutive activation. The CAD requires three distinct regions for function, suggesting that CREB may interact with multiple targets in the RNA polymerase II complex.	PENN STATE UNIV,COLL MED,CELL & MOLEC BIOL PROGRAM,HERSHEY,PA 17033; PENN STATE UNIV,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043871] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43871] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; FABER S, 1993, J BIOL CHEM, V268, P24976; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KIM KS, 1993, J BIOL CHEM, V268, P15689; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; PERRIN S, 1990, NUCLEIC ACIDS RES, V18, P7433, DOI 10.1093/nar/18.24.7433; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; QUINN PG, 1993, J BIOL CHEM, V268, P16999; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WAEBER G, 1990, T ASSOC AM PHYSICIAN, V103, P28; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	43	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28732	28736						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961825				2022-12-25	WOS:A1994PU16800035
J	DOSEMECI, A; GOLLOP, N; JAFFE, H				DOSEMECI, A; GOLLOP, N; JAFFE, H			IDENTIFICATION OF A MAJOR AUTOPHOSPHORYLATION SITE ON POSTSYNAPTIC DENSITY-ASSOCIATED CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LONG-TERM POTENTIATION; II MUTANT MICE; CA-2+ CALMODULIN; CA-2+-INDEPENDENT ACTIVITY; SEQUENCE-ANALYSIS; INHIBITION; PHOSPHORYLATION; EXPRESSION; FOREBRAIN; FRACTION	One of the most abundant proteins in postsynaptic densities is identical or very similar to the ar subunit of the Ca2+/calmodulin-dependent protein kinase II. Autophosphorylation of this protein in isolated postsynaptic densities was studied under various conditions, following inhibition of endogenous phosphatase activity with microcystin-LR. Phosphorylation accompanied by a shift in the enzyme's electrophoretic mobility was observed upon incubation with Ca2+ and calmodulin at 37 degrees C. Brief incubation with Ca2+ and calmodulin at 0 degrees C resulted in a low level of phosphorylation and no change in mobility, Following this limited Ca2+-dependent phosphorylation, however, a high level of phosphorylation could be achieved in the absence of Ca2+, upon incubation at 37 degrees C. Comparison of reverse-phase HPLC phosphopeptide elution profiles obtained following phosphorylation at 37 degrees C, in the presence and absence of Ca2+, as described above, showed differences, suggesting that certain distinct sites may be phosphorylated under each condition, A major phosphopeptide peak, however, with the amino acid sequence Met-Leu-Thr(P)-Ile Asn-Pro Ser-Lys was identified under both conditions, This sequence is identical to the predicted sequence containing Thr-253 of the Ca2+/calmodulin-dependent protein kinase II, The results suggest that phosphorylation at Thr-253 requires an initial Ca2+-dependent phosphorylation, which may be at a different site, but does not depend on the continued presence of Ca2+ to proceed. The observed mode of regulation of autophosphorylation at Thr-253 appears to be unique to the postsynaptic density-associated enzyme.	NINCDS,NEUROCHEM LAB,PROTEIN & PEPTIDE SEQUENCING FACIL,BETHESDA,MD 20892; NHLBI,BIOCHEM GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	DOSEMECI, A (corresponding author), NINCDS,NEUROBIOL LAB,BLDG 36,RM 2A21,BETHESDA,MD 20892, USA.							BLOMBERG F, 1977, J CELL BIOL, V74, P204, DOI 10.1083/jcb.74.1.204; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; DADD CA, 1993, BIOTECHNIQUES, V14, P266; DOSEMECI A, 1993, J NEUROCHEM, V61, P550; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; LOU LL, 1989, J NEUROSCI, V9, P2020; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Meyer Helmut E., 1993, Protein Sequences and Data Analysis, V5, P197; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MILLER SG, 1985, J BIOL CHEM, V260, P9039; OCHIISHI T, 1993, BRAIN RES, V610, P97, DOI 10.1016/0006-8993(93)91222-E; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RICH DP, 1989, J NEUROCHEM, V53, P807, DOI 10.1111/j.1471-4159.1989.tb11777.x; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENSEL WH, 1991, TECHNIQUES PROTEIN C, V2, P181	32	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31330	31333						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989295				2022-12-25	WOS:A1994PX30300003
J	HASAN, AAK; CINES, DB; ZHANG, J; SCHMAIER, AH				HASAN, AAK; CINES, DB; ZHANG, J; SCHMAIER, AH			THE CARBOXYL-TERMINUS OF BRADYKININ AND AMINO-TERMINUS OF THE LIGHT-CHAIN OF KININOGENS COMPRISE AN ENDOTHELIAL-CELL BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; EXPRESSION; ANTIBODIES; VEIN; RECEPTOR; RELEASE; SURFACE; IDENTIFICATION; KALLIKREIN; PLATELETS	Bradykinin (BK), a potent vasoactive nonapeptide formed by proteolytic cleavage of kininogen, mediates its activity by binding to specific cell surface receptors, Delivery of BK to these receptors is limited by cell-bound and plasma kininases that degrade BR to inactive fragments, Binding of its parent compound, kininogen, to specific endothelial cell receptors may provide an environment in which the degradation of BH by kininases is restricted, The determinants that mediate kininogen binding to endothelial cells have not been fully elucidated, The present studies suggest that part of BK and the amino-terminal amino acids of kininogens' common light chain constitute part of this recognition sequence, Human umbilical vein endothelial cells (HUVEC) in culture at 37 degrees C express 2-3-fold more binding sites for biotinylated high molecular weight kininogen (biotin-HK) containing BK than for biotin-HK from which BH: has been liberated by plasma kallikrein, Binding of BK-free biotin-HK was not restored by preincubating HUVEC with BR, arguing against the possibility that BK released from biotin-HB: stimulated expression of additional HH receptors, The extent of biotin-HH binding to HUVEC at 37 degrees C directly correlated with the amount of BK retained within the protein, Four Lines of evidence suggest that part of BK and the amino terminus of the light chain of kininogens are part of the sequence recognized by the endothelial cell kininogen receptor, First, monoclonal antibodies to the carboxyl terminus of BK (MBK3) and the common light chains of the kininogens (HKL6, HKL8) inhibited biotin-HK binding to HUVEC, Second, a synthetic, dimeric bradykinin receptor antagonist blocked biotin-HK (IC50 = 9 mu M) binding to HUVEC as did two synthetic tissue kallikrein inhibitors modeled after the carboxyl-terminal sequence of BK. Third, synthetic peptides containing the carboxyl-terminal portion of BH and the amino terminus of kininogens' common light chain, MKRPPGFSPFRSSRIG and GFSPFRSSRIG, blocked binding of biotin-HK (IC50 = 2-3 mM), whereas an overlapping peptide, SPFRSSRIGEIKEETT, at 5 mM and a scrambled peptide, FSGPKRSPIMGRPSFR, did not. Fourth, biotinylated GMKRPPGFSPFRSSRIG specifically bound to HUVEC, and its binding was blocked by HK. Since the presence of the nonapeptide BE in HK contributes to maximal binding of HK to HUVEC, there is a novel type of BK receptor in which part of the nonapeptide is recognized within the context of its parent molecule, Optimal binding of HK to HUVEC under physiologic conditions requires contact between the kininogen receptor and three regions on HK: domain 3 and the light chain of HK and BK. The presentation of HH in its putative receptor may be important to protect the nonapeptide from kininases thereby modulating its bioavailability at sites of inflammation.	UNIV MICHIGAN, DEPT INTERNAL MED, DIV HEMATOL & ONCOL, ANN ARBOR, MI 48109 USA; UNIV PENN, DEPT PATHOL, PHILADELPHIA, PA 19104 USA	University of Michigan System; University of Michigan; University of Pennsylvania			Schmaier, Alvin/AAM-1063-2020	Schmaier, Alvin/0000-0002-3884-6234	NHLBI NIH HHS [HL49566, HL45486, HL35553] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049566, P50HL045486, R01HL035553] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLA SA, 1993, J BIOL CHEM, V268, P17277; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERONIS JC, 1994, J MED CHEM, V37, P348, DOI 10.1021/jm00029a006; CINES DB, 1984, J CLIN INVEST, V73, P611, DOI 10.1172/JCI111251; GRAF K, 1992, J CARDIOVASC PHARM, V20, pS16, DOI 10.1097/00005344-199200209-00005; GREEN NM, 1965, BIOCHEM J, V94, pC23, DOI 10.1042/bj0940023C; HAASEMANN M, 1991, J IMMUNOL, V147, P3882; HASAN AAK, 1993, THROMB HAEMOSTASIS, V69, P782; HOLLAND JA, 1990, J CELL PHYSIOL, V143, P21, DOI 10.1002/jcp.1041430104; HONG SL, 1980, THROMB RES, V18, P787, DOI 10.1016/0049-3848(80)90201-7; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JIANG YP, 1992, J BIOL CHEM, V267, P3712; JOHNSON DA, 1987, THROMB RES, V48, P187, DOI 10.1016/0049-3848(87)90415-4; JONG YJI, 1993, P NATL ACAD SCI USA, V90, P10994, DOI 10.1073/pnas.90.23.10994; KAUFMANN J, 1993, J BIOL CHEM, V268, P9079; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MELONI FJ, 1992, BLOOD, V79, P1233; NAKASHIMA M, 1993, J CLIN INVEST, V92, P2867, DOI 10.1172/JCI116907; NISHIKAWA K, 1992, BLOOD, V80, P1980; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; REDDIGARI SR, 1993, BLOOD, V81, P1306; SCHMAIER AH, 1989, METHOD ENZYMOL, V169, P276; SCHMAIER AH, 1984, THROMB RES, V33, P51, DOI 10.1016/0049-3848(84)90154-3; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; SMITH D, 1985, BLOOD, V66, P835; TAYEH MA, 1994, J BIOL CHEM, V269, P16318; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; VANIWAARDEN F, 1988, BLOOD, V71, P1268; YANG HYT, 1971, J PHARMACOL EXP THER, V177, P291; ZINI JM, 1993, BLOOD, V81, P2936	33	51	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31822	31830						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989355				2022-12-25	WOS:A1994PX30300076
J	HUANG, WD; SANTI, DV				HUANG, WD; SANTI, DV			ISOLATION OF A COVALENT STEADY-STATE INTERMEDIATE IN GLUTAMATE-60 MUTANTS OF THYMIDYLATE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LACTOBACILLUS-CASEI; BINDING; ENZYME; 10-PROPARGYL-5,8-DIDEAZAFOLATE	Glutamate 60 of thymidylate synthase coordinates a hydrogen bond network important in proton transfer reactions to and from the substrate dUMP. The E60A and E60L mutants of Lactobacillus casei thymidylate synthase catalyzed tritium exchange from [5-H-3]dUMP for solvent protons faster than dTMP formation, indicating accumulation of a steady-state intermediate and a change in partitioning of the intermediate. A covalent complex consisting of E60A or E60L thymidylate synthase, dUMP, and the cofactor CH(2)H(4)folate was isolated on SDS-polyacrylamide gel electrophoresis and shown to be chemically and kinetically competent to form dTMP. These results provide proof of the formation of a covalent steady-state intermediate in the reaction pathway of thymidylate synthase and demonstrate that the rate-determining step in the mutants occurs during conversion of the covalent intermediate to dTMP.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R01CA014394, R37CA014394] Funding Source: NIH RePORTER; NCI NIH HHS [CA-14394] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARRERAS CW, 1992, BIOCHEMISTRY-US, V31, P6038, DOI 10.1021/bi00141a012; CHRISTIAN RB, 1992, J MOL BIOL, V227, P711, DOI 10.1016/0022-2836(92)90219-A; CLIMIE S, 1990, J BIOL CHEM, V265, P18776; FERSHT A, 1985, ENZYME STRUCTURE MEC, P193; FINERMOORE J, 1993, J MOL BIOL, V232, P1101, DOI 10.1006/jmbi.1993.1463; FINERMOORE JS, 1990, BIOCHEMISTRY-US, V29, P6977, DOI 10.1021/bi00482a005; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HUANG WD, 1994, ANAL BIOCHEM, V218, P454, DOI 10.1006/abio.1994.1206; KEALEY JT, 1992, PROTEIN EXPRES PURIF, V3, P380, DOI 10.1016/S1046-5928(05)80039-7; MALASHKEVICH VN, 1993, BIOCHEMISTRY-US, V32, P13451, DOI 10.1021/bi00212a010; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; MOORE MA, 1986, BIOCHEMISTRY-US, V25, P3311, DOI 10.1021/bi00359a034; PERRY KM, 1990, PROTEINS, V8, P315, DOI 10.1002/prot.340080406; PERRYMAN SM, 1986, MOL BIOL EVOL, V3, P313; POGOLOTTI AL, 1986, J MED CHEM, V29, P478, DOI 10.1021/jm00154a009; POGOLOTTI AL, 1979, BIOCHEMISTRY-US, V18, P2794, DOI 10.1021/bi00580a016; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8606, DOI 10.1021/bi00400a017; SANTI DV, 1984, FOLATES PTERINS, V1, P345; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; WALSH C, 1979, ENZYMATIC REACTION M, P71; WELLS JA, 1986, PHILOS T R SOC A, V317, P415, DOI 10.1098/rsta.1986.0051; ZAPF JW, 1993, BIOCHEMISTRY-US, V32, P9274, DOI 10.1021/bi00087a003	23	28	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31327	31329						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989294				2022-12-25	WOS:A1994PX30300002
J	TAOKA, S; PADMAKUMAR, R; LAI, MT; LIU, HW; BANERJEE, R				TAOKA, S; PADMAKUMAR, R; LAI, MT; LIU, HW; BANERJEE, R			INHIBITION OF THE HUMAN METHYLMALONYL-COA MUTASE BY VARIOUS COA-ESTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-CATALYZED REACTION; COENZYME-A; HYPOGLYCIN-A; DEHYDROGENASE; INACTIVATION; (METHYLENECYCLOPROPYL)ACETYL-COA; SYNTHETASE; METABOLITE; BINDING; LIVER	Human methyhnalonyl-CoA mutase is inhibited by ethylmalonyl-CoA, cyclopropylcarbonyl-CoA carboxylate, and methylenecyclopropylacetyl-CoA, which are substrate, intermediate, and product analogs, respectively. The mode of inhibition by each analog is reversible and mixed with respect to the substrate, methylmalonyl-CoA. This implies that the inhibitors are able to bind to both free enzyme and to the enzyme-substrate complex, although with affinities that are 4.5- to 10-fold different for the two species. The K-i1, for the cyclopropylcarbonyl-CoA carboxylate (0.26 +/- 0.07 mM), is 4-fold greater than the K-m(app) measured for the substrate, methylmalonyl-CoA. Additionally, ethylmalonyl-CoA functions as an alternate substrate and is metabolized to methylsuccinyl-CoA. The human mutase is a homodimer that binds 1 mol of cobalamin per subunit. So, the observed mixed inhibition kinetics by substrate analogs is curious. Our finding that methylenecyclopropylacetyl-CoA, the causative agent of Jamaican ''vomiting sickness,'' inhibits methylmalonyl-CoA mutase, while interesting, is probably not physiologically important because of the relatively high inhibition constants (K-i1 = 0.41 +/- 0.12 mM and K-i2 = 2 +/- 0.34 mM) observed with this compound.	UNIV NEBRASKA, DEPT BIOCHEM, LINCOLN, NE 68583 USA; UNIV MINNESOTA, DEPT CHEM, MINNEAPOLIS, MN 55455 USA	University of Nebraska System; University of Nebraska Lincoln; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040541, K04GM000559] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40541, GM00559] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS E, 1993, BIOCHEM MED METAB B, V50, P135, DOI 10.1006/bmmb.1993.1055; CANNATA JJB, 1965, J BIOL CHEM, V240, P3249; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FENTON WA, 1982, ARCH BIOCHEM BIOPHYS, V214, P815, DOI 10.1016/0003-9861(82)90088-1; JANSEN R, 1989, GENOMICS, V4, P198, DOI 10.1016/0888-7543(89)90300-5; KOLHOUSE JF, 1977, P NATL ACAD SCI USA, V74, P921, DOI 10.1073/pnas.74.3.921; LAI MT, 1990, J AM CHEM SOC, V112, P4034, DOI 10.1021/ja00166a048; LAI MT, 1991, J AM CHEM SOC, V113, P7388, DOI 10.1021/ja00019a040; LEDLEY FD, 1991, BIOCHEM BIOPH RES CO, V177, P1076, DOI 10.1016/0006-291X(91)90648-Q; LENN ND, 1989, J AM CHEM SOC, V111, P3065, DOI 10.1021/ja00190a051; MELLMAN IS, 1977, P NATL ACAD SCI USA, V74, P916, DOI 10.1073/pnas.74.3.916; PADMAKUMAR R, 1993, ANAL BIOCHEM, V214, P318, DOI 10.1006/abio.1993.1494; PATEL SS, 1987, J BIOL CHEM, V262, P7132; RETEY J, 1978, EUR J BIOCHEM, V83, P437, DOI 10.1111/j.1432-1033.1978.tb12110.x; ROSENBERG LE, 1983, METABOLIC BASIS INHE, P474; TAI MT, 1991, J AM CHEM SOC, V114, P3160; VONHOLT C, 1966, BIOCHIM BIOPHYS ACTA, V125, P1, DOI 10.1016/0005-2760(66)90138-X; WENZ A, 1981, J BIOL CHEM, V256, P9809; YA SH, 1984, COMP BIOCHEM PHYS B, V78, P41, DOI 10.1016/0305-0491(84)90142-1; ZHAO YM, 1994, CAN J CHEM, V72, P164, DOI 10.1139/v94-025	20	46	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31630	31634						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989334				2022-12-25	WOS:A1994PX30300048
J	BRYANT, WP; BERGERT, ER; MORRIS, JC				BRYANT, WP; BERGERT, ER; MORRIS, JC			DELINEATION OF AMINO-ACID-RESIDUES WITHIN HTSHR-256-275 THAT PARTICIPATE IN HORMONE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROTROPIN RECEPTOR; SOLID-PHASE SYNTHESIS; HUMAN TSH RECEPTOR; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PEPTIDES; EXPRESSION; CDNA; INHIBITION	The amino acid sequence 256-275 of the human thyrotropin (TSH) receptor extracellular domain has previously been shown to participate in a high affinity TSH binding site by a synthetic peptide approach as well as by site-directed mutagenesis. To further investigate this binding site, we synthesized a series of peptides with alanine substitutions for each residue in the native sequence. Peptides were also synthesized containing truncations or deletions of the native sequence. Each peptide was tested for its ability to inhibit I-125-bTSH binding to porcine thyroid membrane preparations, and the concentration at which 50% inhibition of binding occurred was determined (EC(50)). Alanine substitution at residues Tyr(258), Cys(262), Cys(263), Phe(265) Lys(266) Asn(267) Lys(269), Lys(270), and Arg(272) all resulted in statistically significant decreases in activity when compared to the native sequence (p < 0.05). Alanine substitution of the remaining residues did not alter their activity. Comparison of this sequence with the corresponding sequences of the remaining glycoprotein hormone receptors (human lutropin and human follitropin receptors) reveals that these residues lie within one of the most highly conserved regions of the extracellular domain. We conclude that 9 specific amino acids within the sequence 256-275 of hTSHr (-Y-CC-FKN-KK-R-) participate in the interaction of the hTSHr-extracellular domain with TSH. This may represent a site in which the nonconserved residues are involved in the binding of the beta-subunit and the conserved residues are involved in the binding of the common alpha-subunit or a region of the beta-subunit that is common to all glycoprotein hormones.	MAYO CLIN & MAYO FDN,ENDOCRINE RES UNIT,ROCHESTER,MN 55905	Mayo Clinic								AKAMIZU T, 1993, ENDOCR J, V40, P363, DOI 10.1507/endocrj.40.363; AKAMIZU T, 1994, THYROID, V4, P43, DOI 10.1089/thy.1994.4.43; BURMAN KD, 1985, ENDOCR REV, V6, P183, DOI 10.1210/edrv-6-2-183; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; MINEGISH T, 1991, BIOCHEM BIOPH RES CO, V175, P1125, DOI 10.1016/0006-291X(91)91682-3; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; MORRIS JC, 1993, J BIOL CHEM, V268, P10900; MORRIS JC, 1990, J BIOL CHEM, V265, P1881; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P456, DOI 10.1210/endo-123-1-456; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NAGAYAMA Y, 1992, ENDOCRINOLOGY, V131, P548, DOI 10.1210/en.131.2.548; NAGAYAMA Y, 1994, THYROID TODAY, V17, P1; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; TAKAHASHI H, 1978, J CLIN ENDOCR METAB, V47, P870, DOI 10.1210/jcem-47-4-870	17	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30935	30938						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983027				2022-12-25	WOS:A1994PV51000033
J	TSUBAKI, M; MOGI, T; HORI, H; HIROTA, S; OGURA, T; KITAGAWA, T; ANRAKU, Y				TSUBAKI, M; MOGI, T; HORI, H; HIROTA, S; OGURA, T; KITAGAWA, T; ANRAKU, Y			MOLECULAR-STRUCTURE OF REDOX METAL CENTERS OF THE CYTOCHROME-BO COMPLEX FROM ESCHERICHIA-COLI - SPECTROSCOPIC CHARACTERIZATIONS OF THE SUBUNIT-I HISTIDINE MUTANT OXIDASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COPPER BINUCLEAR CENTER; O UBIQUINOL OXIDASE; CYOE GENE-PRODUCT; C-OXIDASE; HEME-O; TERMINAL OXIDASE; ELECTRON-TRANSFER; QUINOL OXIDASE; RAMAN-SPECTRA	A site-directed mutagenesis study on the conserved subunit I histidines of the cytochrome bo complex in Escherichia coli identified ligands of the low spin heme B and Cu-B centers; however, the assignment of the proximal Ligand of the high spin heme O was ambiguous (Minagawa, J., Mogi, T., Gennis, R. B., and Auraku, Y. (1992) J. Biol. Chem. 267, 2096-2104). We have extended this work and characterized the metal centers in the purified histidine mutant oxidases by optical, EPR, and resonance Raman spectroscopies and by biochemical analysis. We found that the H284A and H333A oxidases contain two heme B molecules, which exhibit the g(z) = 2.99 low spin and cyanide-sensitive g(perpendicular to)=6 high-spin EPR signals, whereas the H419A oxidase contains only low spin heme B, which shows the g, component in a considerably higher magnetic field at g = 2.92. The Cu-B center was partially retained in the H284A oxidase but was almost completely lost in the H333A and H419A oxidases. Thus, we concluded that His(419) is the proximal ligand of the high spin heme O and that His(284) is located at the distal side of the high spin heme O. His(284) plays an indispensable role in maintaining the structure of the Fe-o-Cu-B binuclear site suitable for the exogenous ligand bindings in the reduced state, since its substitution eliminated the CO binding activity. In addition, we found that His(106) and His(421) are in fact the axial ligands of the low spin heme B, although the H421A mutation perturbed the binuclear metal center seriously. Based upon experimental results with isotopic substitutions on iron in the oxidases, we assigned the Raman band at 208 cm(-1) to the iron-histidine stretching mode (nu(Fe2+-N(His)) of the wild-type ferrous cytochrome o, which was upshifted slightly by a loss of the Cu-B center in the H333A oxidase. A molecular structure of the metal centers and a possible mechanism of the electron transfer-coupled proton pumping in the cytochrome bo complex are proposed on the basis of our present findings.	UNIV TOKYO,GRAD SCH SCI,DEPT PLANT SCI,BUNKYO KU,TOKYO 113,JAPAN; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN; GRAD UNIV ADV STUDIES,OKAZAKI NATL RES INST,INST MOLEC SCI,OKAZAKI,AICHI 444,JAPAN	University of Tokyo; Osaka University; Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Okazaki Institute for Integrative Bioscience (OIIB)	TSUBAKI, M (corresponding author), HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN.		Hirota, Shun/AAD-2651-2021	Hirota, Shun/0000-0003-3227-8376				ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BROWN S, 1994, BBA-BIOENERGETICS, V1183, P521, DOI 10.1016/0005-2728(94)90080-9; CALHOUN MW, 1993, BIOCHEMISTRY-US, V32, P10905, DOI 10.1021/bi00091a046; CALHOUN MW, 1993, BIOCHEMISTRY-US, V32, P13254, DOI 10.1021/bi00211a038; CALHOUN MW, 1993, BIOCHEMISTRY-US, V32, P11524, DOI 10.1021/bi00094a008; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CLORE GM, 1980, BIOCHEM J, V185, P155, DOI 10.1042/bj1850155; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; GENNIS RB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P21, DOI 10.1016/S0005-2728(05)80260-9; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P3120, DOI 10.1021/bi00176a047; HARTZELL CR, 1974, BIOCHIM BIOPHYS ACTA, V368, P318, DOI 10.1016/0005-2728(74)90178-9; HATA A, 1985, BIOCHIM BIOPHYS ACTA, V810, P62, DOI 10.1016/0005-2728(85)90206-3; HILL J, 1992, BIOCHEMISTRY-US, V31, P11435, DOI 10.1021/bi00161a023; INGLEDEW WJ, 1991, BIOCHEM SOC T, V19, P613, DOI 10.1042/bst0190613; KITA K, 1982, J BIOL CHEM, V257, P7933; KITAGAWA T, 1979, FEBS LETT, V104, P376, DOI 10.1016/0014-5793(79)80856-X; LAURAEUS M, 1992, BIOCHEMISTRY-US, V31, P10054, DOI 10.1021/bi00156a027; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; MINAGAWA J, 1990, J BIOL CHEM, V265, P11198; MINAGAWA J, 1992, THESIS U TOKYO; MINGHETTI KC, 1992, BIOCHEMISTRY-US, V31, P6917, DOI 10.1021/bi00145a008; MOGI T, 1994, J BIOCHEM-TOKYO, V116, P741; NAKAMURA H, 1990, J BIOL CHEM, V265, P11193; NAKAMURA H, 1990, THESIS U TOKYO; OERTLING WA, 1994, BIOCHEMISTRY-US, V33, P3128, DOI 10.1021/bi00176a048; OGURA T, 1983, J AM CHEM SOC, V105, P7781, DOI 10.1021/ja00364a072; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; SAIKI K, 1993, J BIOL CHEM, V268, P26041; SAIKI K, 1993, J BIOL CHEM, V268, P26927; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; SALERNO JC, 1990, J BIOL CHEM, V265, P4364; SALERNO JC, 1991, EUR J BIOCHEM, V198, P789, DOI 10.1111/j.1432-1033.1991.tb16082.x; SALMEEN I, 1978, BIOCHEMISTRY-US, V17, P800, DOI 10.1021/bi00598a008; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4786, DOI 10.1073/pnas.89.11.4786; SONE N, 1986, BIOCHIM BIOPHYS ACTA, V850, P139, DOI 10.1016/0005-2728(86)90018-6; SONE N, 1994, BIOCHEMISTRY-US, V33, P849, DOI 10.1021/bi00170a001; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P164, DOI 10.1021/bi00052a022; UNO T, 1994, J BIOL CHEM, V269, P11912; UNO T, 1985, J BIOL CHEM, V260, P6755; WELTER R, 1994, BIOPHYS J, V66, pA367; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859; WU W, 1992, J AM CHEM SOC, V114, P1182, DOI 10.1021/ja00030a009; YUMOTO I, 1993, J BIOCHEM-TOKYO, V114, P88, DOI 10.1093/oxfordjournals.jbchem.a124145	51	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30861	30868						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983018				2022-12-25	WOS:A1994PV51000023
J	ADAMSKA, I; KLOPPSTECH, K				ADAMSKA, I; KLOPPSTECH, K			LOW-TEMPERATURE INCREASES THE ABUNDANCE OF EARLY LIGHT-INDUCIBLE TRANSCRIPT UNDER LIGHT STRESS CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PISUM-SATIVUM-L; CHLOROPLAST PROTEIN; PHOTOSYSTEM-II; HIGHER-PLANTS; POLYACRYLAMIDE GELS; MESSENGER-RNA; PEA; PHOTOINHIBITION; NUCLEAR; GENE	Green pea plants respond to light stress by expression of a nuclear ELIP (early light inducible protein) gene. Here we report that the accumulation of ELIP transcript in pea plants during light stress is enhanced by low temperature treatment. The enhanced level of ELIP transcript during combined light and cold stress was found to be due to an increased stability of ELIP messenger RNA under these conditions. This transcript is translatable in vitro. In vivo, however, the amount of accumulated protein in the thylakoids declines with the decrease in the temperature because the translational activity is strongly reduced already at 10 degrees C. Plants exposed to light stress at temperatures that do not allow accumulation of ELIP transcript respond by induction of ELIP mRNA and protein during recovery at low light intensity and ambient temperature. The amount of protein that accumulates as a result of this ''memory effect'' is, however, much lower than that which accumulates as a result of direct light stress. The memory of a perceived light stress persists in plants stored at low temperature for at least 3 h, and the stress response can be released after an increase in temperature. Prolonged cold treatment, however, has a negative effect on the translatability of the ELIP transcript that accumulates during recovery.	UNIV HANNOVER, INST BOT, D-30419 HANNOVER, GERMANY	Leibniz University Hannover								ADAMSKA I, 1993, J BIOL CHEM, V268, P5438; ADAMSKA I, 1992, J BIOL CHEM, V267, P24732; ADAMSKA I, 1992, P NATL ACAD SCI USA, V89, P2610, DOI 10.1073/pnas.89.7.2610; ARO EM, 1990, BIOCHIM BIOPHYS ACTA, V1019, P269, DOI 10.1016/0005-2728(90)90204-H; BARTELS D, 1992, EMBO J, V11, P2771, DOI 10.1002/j.1460-2075.1992.tb05344.x; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CARLBERG I, 1992, BIOCHIM BIOPHYS ACTA, V1099, P111, DOI 10.1016/0304-4173(92)90015-7; CHAUVIN LP, 1993, PLANT MOL BIOL, V23, P255, DOI 10.1007/BF00029002; CHOW WS, 1989, PHOTOSYNTH RES, V21, P17, DOI 10.1007/BF00047171; DEMMIG B, 1987, PLANTA, V171, P171, DOI 10.1007/BF00391092; FLUHR R, 1986, SCIENCE, V232, P1106, DOI 10.1126/science.232.4754.1106; GALLAGHER TF, 1982, EMBO J, V1, P1493, DOI 10.1002/j.1460-2075.1982.tb01345.x; GONG H, 1989, J PLANT PHYSIOL, V135, P9, DOI 10.1016/S0176-1617(89)80216-0; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; GRIMM B, 1989, PLANT MOL BIOL, V13, P583, DOI 10.1007/BF00027318; GRIMM B, 1987, EUR J BIOCHEM, V167, P493, DOI 10.1111/j.1432-1033.1987.tb13364.x; HAHN M, 1989, PLANT PHYSIOL, V91, P930, DOI 10.1104/pp.91.3.930; HUNTER NPA, 1993, PHOTOSYNTH RES, V37, P19; KOLANUS W, 1987, MOL GEN GENET, V209, P234, DOI 10.1007/BF00329648; KRAUSE GH, 1988, PHYSIOL PLANTARUM, V74, P566, DOI 10.1111/j.1399-3054.1988.tb02020.x; KRUSE E, 1992, EUR J BIOCHEM, V208, P195, DOI 10.1111/j.1432-1033.1992.tb17174.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERS A, 1991, J BIOL CHEM, V266, P13698; LEVY H, 1992, J BIOL CHEM, V267, P18831; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MEYER G, 1984, EUR J BIOCHEM, V138, P201, DOI 10.1111/j.1432-1033.1984.tb07900.x; OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229, DOI 10.1111/j.1751-1097.1989.tb04101.x; OQUIST G, 1987, PHOTOINHIBITION, P67; OTTO B, 1988, PLANT PHYSIOL, V88, P21, DOI 10.1104/pp.88.1.21; PEMBERTON RE, 1975, ANAL BIOCHEM, V66, P18, DOI 10.1016/0003-2697(75)90720-4; POTTER E, 1993, EUR J BIOCHEM, V214, P779, DOI 10.1111/j.1432-1033.1993.tb17980.x; RICHTER M, 1990, PHOTOSYNTH RES, V24, P237, DOI 10.1007/BF00032311; ROBERTS BE, 1973, P NATL ACAD SCI USA, V70, P2330, DOI 10.1073/pnas.70.8.2330; SCHONER S, 1990, CURRENT RES PHOTOSYN, V2, P483; SCHUSTER G, 1988, EMBO J, V7, P1; SHORT TW, 1992, PHOTOCHEM PHOTOBIOL, V55, P773; TAYLOR WC, 1989, ANNU REV PLANT PHYS, V40, P211, DOI 10.1146/annurev.pp.40.060189.001235; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	38	39	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30221	30226						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982930				2022-12-25	WOS:A1994PU52500030
J	KAWATE, N; MENON, KMJ				KAWATE, N; MENON, KMJ			PALMITOYLATION OF LUTEINIZING-HORMONE HUMAN CHORIOGONADOTROPIN RECEPTORS IN TRANSFECTED CELLS - ABOLITION OF PALMITOYLATION BY MUTATION OF CYS-621 AND CYS-622 RESIDUES IN THE CYTOPLASMIC TAIL INCREASES LIGAND-INDUCED INTERNALIZATION OF THE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; RAT LUTEAL CELLS; GONADOTROPIN RECEPTOR; DOWN-REGULATION; BINDING; ACID; PROTEINS; DOMAINS; OVARY; VIRUS	We have examined whether the two cysteine residues (621 and 622) of the carboxyl-terminal cytoplasmic domain of the rat luteinizing hormone (LH/hCG) receptor are potential sites for palmitoylation. The full-length LH/hCG receptor cDNA was cloned into an expression vector (hCGR-pCMV4). A human embryonic kidney cell line expressing large T antigen (293T cells) was transiently transfected with hCGR-pCMV4 by the calcium phosphate precipitation technique. The functional expression of the receptor was confirmed by S-35-labeled cysteine incorporation into the receptor as well as by I-125-human chorionic gonadotropin (hCG) binding. The transfected cells were then labeled with [H-3]palmitic acid, and the labeled receptors purified on hCG-Affi-Gel matrix and subjected to SDS polyacrylamide gel electrophoresis and autoradiography. The hCGR-pCMV4 trans fected cells incorporated [H-3]palmitic acid into a 92-kDa band corresponding to the mature form of the LH/hCG receptor; this band was absent in cells transfected with vector alone. Site directed mutagenesis of either cysteine 621 or 622 to serine residue was partially inhibitory, whereas mutation of both cysteine residues (621 and 622) completely abolished palmitoylation. Scatchard analyses revealed that the mutant and wild type receptors have similar affinities for I-125-hCG. The biological function of palmitoylation was then examined in the transfected cells. The results showed that although the intracellular trafficking of the receptor and the ability to stimulate cyclic AMP production were unaffected, the rate of ligand-induced internalization of the receptor was higher in palmitoylation-deficient mutants compared to the wild type receptors. The first order rate constants of internalization of the mutant receptors were over 2-fold higher than the wild type. Intracellular degradation of the receptor-bound ligand was also higher in the mutants. These studies suggest that the native LH/hCG receptor is palmitoylated at cysteine residues 621 and 622, creating a membrane-anchoring site at the putative cytoplasmic domain. This palmitic acid-mediated anchoring decreases the ligand-induced receptor internalization thereby prolonging the retention of the ligand-bound receptor on the cell surface.	UNIV MICHIGAN, DEPT OBSTET & GYNECOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NICHD NIH HHS [HD 06656, I-P 30 HD 18258] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD006656] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD018258, R37HD006656] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; AZHAR S, 1981, J BIOL CHEM, V256, P6548; AZHAR S, 1976, J BIOL CHEM, V251, P7398; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; FOLCH J, 1951, J BIOL CHEM, V191, P807; Gilman A G, 1974, Methods Enzymol, V38, P49; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KUSUDA S, 1988, J BIOL CHEM, V263, P3046; LEVERS E, 1990, J BIOL CHEM, V265, P16644; LU DL, 1993, ENDOCRINOLOGY, V132, P235, DOI 10.1210/en.132.1.235; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MENON KMJ, 1974, FERTIL STERIL, V25, P732; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RAJAN VP, 1985, BIOL REPROD, V33, P60, DOI 10.1095/biolreprod33.1.60; ROCHE PC, 1989, J BIOL CHEM, V264, P4636; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SOJAR HT, 1989, J BIOL CHEM, V264, P2552; STAUFENBIEL M, 1986, P NATL ACAD SCI USA, V83, P318, DOI 10.1073/pnas.83.2.318; ZHANG QY, 1989, P NATL ACAD SCI USA, V86, P8294, DOI 10.1073/pnas.86.21.8294	28	103	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30651	30658						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982985				2022-12-25	WOS:A1994PU52500093
J	NOMIZU, M; OTAKA, A; UTANI, A; ROLLER, PP; YAMADA, Y				NOMIZU, M; OTAKA, A; UTANI, A; ROLLER, PP; YAMADA, Y			ASSEMBLY OF SYNTHETIC LAMININ PEPTIDES INTO A TRIPLE-STRANDED COILED-COIL STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANES; CIRCULAR-DICHROISM; B2 CHAIN; LONG ARM; PROTEINS; GLYCOPROTEIN; MECHANISM; DOMAIN; TRIMERIZATION; HETERODIMER	Laminin, a large multidomain glycoprotein specific to basement membranes, is a heterotrimer with alpha, beta, and gamma chains held together in an cu-helical coiled-coil structure. Synthetic peptides comprising two 51-mers (B1 and B2) from the beta 1 and gamma 1 subunits and a 55-mer (M) from alpha 2 were used to study the molecular mechanisms in laminin chain assembly. Using the synthetic peptides in various mixing experiments, the heterotrimer (B1-B2-M) was preferentially produced. The thermal stability of the heterotrimer increased dramatically (by approximately 20 degrees C) over that of the B1-B2 heterodimer as measured by circular dichroism (CD) spectroscopy. The B1-B1 homodimer (T-m = 60 degrees C) showed higher thermal stability when compared to B1-B2 and B2-B2 dimers. However, the B1+B2 mixture produced principally the B1-B2 heterodimer. These results suggested that the preferential formations of heterodimer was regulated by kinetic interactions between each chain. The B2 and M peptides have many hydrophobic isoleucine residues which were replaced by leucines. These substitutions were predicted to favor an alpha-helical conformation and a higher propensity for zipper formation. B2L and ML, in which all isoleucine residues were replaced by leucine, showed significantly increased alpha-helicities. While B2L was able to form heterodimers and heterotrimers similar to B2, ML was not able to participate in heterotrimer formation as efficiently as the M peptide, The thermal stability of B1-B2L was comparable to that of B1-B2, but B2L and/or ML containing trimers showed lower thermal stability than B1-B2-M. These results suggest that the isoleucine residues in the alpha 2 and gamma 1 chains are critical for stabilizing the heteromeric triple-stranded coiled coil structure.	NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, MED CHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	NOMIZU, M (corresponding author), NIDR, DEV BIOL LAB, BLDG 30, RM 427, BETHESDA, MD 20892 USA.							ALBERICIO F, 1990, J ORG CHEM, V55, P3730, DOI 10.1021/jo00299a011; BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BERNIER S, 1994, IN PRESS MATRIX BIOL; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGEL J, 1991, BIOCHEM SOC T, V19, P839, DOI 10.1042/bst0190839; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; Engel J., 1993, MOL CELLULAR ASPECTS, P147, DOI [10.1016/B978-0-12-593165-6.50014-0, DOI 10.1016/B978-0-12-593165-6.50014-0]; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUNTER I, 1992, J BIOL CHEM, V267, P6006; HUNTER I, 1990, EUR J BIOCHEM, V188, P205, DOI 10.1111/j.1432-1033.1990.tb15391.x; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; MORITA A, 1985, BIOCHEM J, V229, P259, DOI 10.1042/bj2290259; NOMIZU M, 1991, INT J PEPT PROT RES, V37, P145; NOMIZU M, 1992, INT J PEPT PROT RES, V40, P72; NOMIZU M, 1991, J CHEM SOC CHEM COMM, P1434, DOI 10.1039/c39910001434; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PAULSSON M, 1985, EMBO J, V4, P309, DOI 10.1002/j.1460-2075.1985.tb03630.x; PAULSSON M, 1993, MOL CELLULAR ASPECTS, P177; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; STEWART JM, 1976, J MACROMOL SCI CHEM, VA 10, P259, DOI 10.1080/00222337608068099; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; UTANI A, 1994, J BIOL CHEM, V269, P19167; YAJIMA H, 1988, TETRAHEDRON, V44, P805, DOI 10.1016/S0040-4020(01)86118-4; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHU BY, 1992, INT J PEPT PROT RES, V40, P171	48	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30386	30392						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982952				2022-12-25	WOS:A1994PU52500055
J	OHH, M; TAKEI, F				OHH, M; TAKEI, F			INTERFERON-GAMMA-MYRISTATE AND PHORBOL-MYRISTATE ACETATE-RESPONSIVE ELEMENTS INVOLVED IN INTERCELLULAR-ADHESION MOLECULE-1 MESSENGER-RNA STABILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; ICAM-1 CD54; LFA-1; CLONING; INDUCTION; GENE; ANTIBODIES; EXPRESSION; ADHERENCE	Treatment of cells with interferon (IFN)-gamma or phorbol myristate acetate (PMA) induces up-regulation of the level of intercellular adhesion molecule-1 (ICAM-1; CD54) mRNA by stabilization of an otherwise labile mRNA. Here, we have generated various deletion mutants of ICAM-1 and stably transfected them into the murine fibroblast Ltk(-) cells that express no endogenous ICAM-1 or -2 (CD102) in an effort to define the regions within ICAM-1 mRNA responsive to IFN-gamma or PMA. Induction of ICAM-1 mRNA in the transfected L cells by the treatment with IFN-gamma revealed that the truncation of the region of ICAM-1 mRNA encoding the cytoplasmic domain made it non-responsive to IFN-gamma whereas all other regions were dispensable. In contrast, PMA-induced accumulation of ICAM-1 mRNA required the 3'-untranslated region (UTR). To further elucidate the role of these regions in mRNA destabilization and responsiveness to IFN-gamma and PMA, ICAM-2 mRNA that is stable and not responsive to IFN-gamma or PMA was used as a reporter gene. The putative IFN-gamma-responsive region of ICAM-1 mRNA encoding its cytoplasmic domain rendered it unstable and responsive to IFN-gamma but not PMA. Conversely, the 3'-UTR of ICAM-1 fused with ICAM-2 mRNA also made it unstable and responsive to PMA but not IFN-gamma. Half life analysis showed that the induction of these chimeric mRNAs by IFN-gamma and PMA was due, at least in part, to the prolongation of their turnover rate. These results taken together demonstrate that two distinct regions of ICAM-1 mRNA regulate its stability, one encoding the cytoplasmic domain and responsive to IFN-gamma and the other in the 3'-UTR and responsive to PMA.	BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER V5Z 1L3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V5Z 1L3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PATHOL,VANCOUVER V5Z 1L3,BC,CANADA	British Columbia Cancer Agency; University of British Columbia; University of British Columbia				Takei, Fumio/0000-0002-3620-5046				BARTON RW, 1989, J IMMUNOL, V143, P1278; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSIMI AB, 1990, J IMMUNOL, V144, P4604; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1986, J IMMUNOL, V137, P245; HORLEY KJ, 1989, EMBO J, V8, P2889, DOI 10.1002/j.1460-2075.1989.tb08437.x; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; JACKSON RJ, 1993, CELL, V74, P93; KAY R, 1991, Methods in Molecular and Cellular Biology, V2, P254; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; OHH M, 1994, IN PRESS BLOOD; POBER JS, 1986, J IMMUNOL, V137, P1893; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J, 1989, MOL CLONING LABORATO; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WAWRYK SO, 1989, IMMUNOL REV, V108, P135, DOI 10.1111/j.1600-065X.1989.tb00016.x; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WELDER CA, 1993, J IMMUNOL, V150, P2203; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	28	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30117	30120						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982915				2022-12-25	WOS:A1994PU52500014
J	PILLAI, R; STAUB, SF; COLICELLI, J				PILLAI, R; STAUB, SF; COLICELLI, J			MUTATIONAL MAPPING OF KINETIC AND PHARMACOLOGICAL PROPERTIES OF A HUMAN CARDIAC CAMP-PHOSPHODIESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE PHOSPHODIESTERASE; CLONING; PHOSPHORYLATION; PURIFICATION; EXPRESSION; ACTIVATION; INSULIN; DOMAIN	We have created a series of deletion mutants of a human cardiac cAMP phosphodiesterase in order to define sequences necessary for function and to identify residues required for inhibition by cGMP and by the drugs milrinone and trequinsin. These truncated constructs were expressed in yeast cells, and their biochemical properties were analyzed. The mutations define an amino acid sequence that is essential for function. Among the active constructs, there was considerable variability in the level of expression and in the stability of the proteins, with the full-length and near full-length constructs being the least stable. There were, however, no significant changes in K-m values among the active enzymes. Cation studies confirmed that Mn2+ is a more efficient cofactor than Mg2+ or Co2+. Interestingly, Mn2+ acts as a more efficient cofactor for cGMP inhibition as well. Although IC50 values for the drugs trequinsin and milrinone were not significantly altered by deletions, there was a decrease in cGMP IC50 values for the smaller constructs, indicating a role for amino acid residues out side the catalytic region in cGMP inhibition. We also demonstrate in vivo inhibition of this enzyme in yeast cells grown in the presence of pharmacological inhibitors, allowing for the selection of drug-resistant mutants. Finally, we have constructed and analyzed chimeric genes in which portions of this phosphodiesterase are replaced with homologous sequences from a closely related phosphodiesterase isozyme that is expressed in brain. Our results demonstrate that sequence variations between related isozymes account for more than just pharmacological distinctions and may reflect significant structural differences.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, STRUCT BIOL & MOLEC MED LAB, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031911] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31911] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BELTMAN J, 1993, MOL CELL BIOCHEM, V128, P239, DOI 10.1007/BF01076775; BENTLEY J K, 1992, Current Opinion in Cell Biology, V4, P233; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRANCIS SH, 1994, FASEB J, V8, pA371; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; GRANT PG, 1984, BIOCHEMISTRY-US, V23, P1801, DOI 10.1021/bi00303a034; HARRISON SA, 1986, MOL PHARMACOL, V29, P506; HARRISON SA, 1985, FED PROC, V44, P728; HENKELTIGGES J, 1990, MOL PHARMACOL, V37, P7; JIN SLC, 1992, J BIOL CHEM, V267, P18929; KITAJIMA Y, 1990, J BIOL CHEM, V265, P17493; LONDESBOROUGH J, 1980, J BIOL CHEM, V255, P9262; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MARTINS TJ, 1983, FED PROC, V42, P1846; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; MORI H, 1993, J BIOL CHEM, V268, P5574; NIKAWA JI, 1987, MOL CELL BIOL, V7, P3629, DOI 10.1128/MCB.7.10.3629; PILLAI R, 1993, P NATL ACAD SCI USA, V90, P11970, DOI 10.1073/pnas.90.24.11970; PYNE NJ, 1987, BIOCHEM J, V242, P33, DOI 10.1042/bj2420033; RUPPERT D, 1982, LIFE SCI, V31, P2037, DOI 10.1016/0024-3205(82)90095-9; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; TORPHY TJ, 1992, J BIOL CHEM, V267, P1798	32	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30676	30681						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982987				2022-12-25	WOS:A1994PU52500096
J	WOLF, BB; GIBSON, CA; KAPUR, V; HUSSAINI, IM; MUSSER, JM; GONIAS, SL				WOLF, BB; GIBSON, CA; KAPUR, V; HUSSAINI, IM; MUSSER, JM; GONIAS, SL			PROTEOLYTICALLY ACTIVE STREPTOCOCCAL PYROGENIC EXOTOXIN-B CLEAVES MONOCYTIC CELL UROKINASE RECEPTOR AND RELEASES AN ACTIVE FRAGMENT OF THE RECEPTOR FROM THE CELL-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; SINGLE-CHAIN UROKINASE; PLASMINOGEN-ACTIVATOR; IDENTIFICATION; GLYCOSYLATION; PURIFICATION; PROTEOLYSIS; EXPRESSION; INHIBITOR; INVASION	Urokinase plasminogen activator (u-PA) receptor (u-PAR) is a glycosyl-phosphatidylinositol anchored membrane protein that promotes pericellular proteolysis and cellular migration. This investigation demonstrates that u-PAR is a substrate for the proteolytically active form of streptococcal pyrogenic exotoxin B (SPE B), a potent virulence factor secreted by Streptococcus pyogenes. Treatment of U937 monocyte like cells with SPE B decreased specific I-125-labeled single-chain u-PA binding by up to 85%. Cysteine proteinase inhibitors neutralized SPE B without affecting the activity of phosphatidylinositol-specific phospholipase C. Due to decreased u-PA binding, SPE B-treated U937 cells expressed decreased activity against a u-PA-specific fluorogenic substrate and plasminogen. SPE B released single-chain u-PA that was noncovalently bound to U937 cells or cross-linked to cellular receptors with bis(sulfosuccinimidyl) suberate. The mass of the released u-PA-receptor complex was 100 kDa, Western blot analysis confirmed that the u-PA receptor that was cleaved by SPE B is u-PAR. After deglycosylation, the mass of SPE B-released u-PAR was 35 kDa, slightly smaller than the phosphatidylinositol-specific phospholipase C-derived form of this receptor. SPE B-released u-PAR retained the ability to bind u-PA, as determined by u-PA affinity chromatography. We conclude that SPE B may inhibit u-PA binding to monocytic cells by at least two mechanisms: (i) by decreasing the level of functional cell surface u-PAR and (ii) by releasing a soluble form of u-PAR that competes with the cellular receptor for ligand.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908; BAYLOR COLL MED,DEPT PATHOL,MOLEC PATHOBIOL SECT,HOUSTON,TX 77030	University of Virginia; University of Virginia; Baylor College of Medicine			Kapur, Vivek/F-7610-2013	Kapur, Vivek/0000-0002-9648-0138	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45786] Funding Source: Medline; NIGMS NIH HHS [GM 07267] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALOUF JE, 1991, SOURCEBOOK BACTERIAL, P367; BEHRENDT N, 1993, METHOD ENZYMOL, V223, P207; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BISNO AL, 1990, PRINCIPLES PRACTICE, V3, P1518; BJORCK L, 1989, NATURE, V337, P385, DOI 10.1038/337385a0; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHAPMAN HA, 1990, AM J PHYSIOL, V259, P6432; CHAUSSEE MS, 1993, INFECT IMMUN, V61, P3719, DOI 10.1128/IAI.61.9.3719-3723.1993; CRADDOCK PR, 1976, BLOOD, V47, P931; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DUNN DL, 1982, SURGERY, V92, P513; ELLIS V, 1992, FIBRINOLYSIS, V6, P27; ELLIS V, 1992, ANN NY ACAD SCI, V667, P13, DOI 10.1111/j.1749-6632.1992.tb51591.x; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; GARDNER F H, 1972, Series Haematologica, V5, P78; GERLACH D, 1982, REEDBOOKS SURVEY, P137; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HOLM SE, 1992, J INFECT DIS, V166, P31, DOI 10.1093/infdis/166.1.31; HOYERHANSEN G, 1992, J BIOL CHEM, V267, P18224; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; KAPUR V, 1993, P NATL ACAD SCI USA, V90, P7676, DOI 10.1073/pnas.90.16.7676; KIRCHHEIMER JC, 1989, J IMMUNOL, V143, P2634; KORTT AA, 1973, BIOCHEMISTRY-US, V12, P320, DOI 10.1021/bi00726a023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIU TY, 1969, J BIOL CHEM, V244, P5745; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MILES LA, 1987, THROMB HAEMOSTASIS, V58, P936; MINTA JO, 1985, AM J PATHOL, V119, P11; MOLLER LB, 1993, J BIOL CHEM, V268, P11152; MOLLER LB, 1993, BLOOD COAGUL FIBRIN, V4, P293; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NURSAT AR, 1991, J CLIN INVEST, V87, P1091; NYKJAER A, 1994, J IMMUNOL, V152, P505; NYKJAER A, 1992, FEBS LETT, V300, P13, DOI 10.1016/0014-5793(92)80154-9; NYKJAER A, 1990, BIOCHIM BIOPHYS ACTA, V1052, P399, DOI 10.1016/0167-4889(90)90149-8; PAUL WE, 1990, FUNDAMENTAL IMMUNOLO; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PLESNER T, 1994, BLOOD, V83, P808; PLOUG M, 1992, EUR J BIOCHEM, V208, P397, DOI 10.1111/j.1432-1033.1992.tb17200.x; PLOUG M, 1993, J BIOL CHEM, V268, P17539; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOUG M, 1992, BLOOD, V79, P1447; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROSENBERRY TL, 1991, CELL BIOL INT REP, V15, P1133, DOI 10.1016/0309-1651(91)90060-V; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TODD RF, 1990, BLOOD CELLS, V16, P167; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; WOLF BB, 1993, J BIOL CHEM, V268, P16327; YOMTOVIAN R, 1992, TRANSFUSION BETHESDA, V33, P852	55	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30682	30687						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982988				2022-12-25	WOS:A1994PU52500097
J	SOULIER, J; MADANI, A; CACHEUX, V; ROSENZWAJG, M; SIGAUX, F; STERN, MH				SOULIER, J; MADANI, A; CACHEUX, V; ROSENZWAJG, M; SIGAUX, F; STERN, MH			THE MTCP-1 C6.1B GENE ENCODES FOR A CYTOPLASMIC 8-KD PROTEIN OVEREXPRESSED IN T-CELL LEUKEMIA BEARING A T(X,14)-TRANSLOCATION	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ATAXIA-TELANGIECTASIA; CHROMOSOME; ABNORMALITIES	The t(X;14)(q28;q11.2) translocation is associated with mature T-cell proliferations. Recently this translocation has been shown to implicate the MTCP-1/c6.1B gene on chromosome Xq28, leading to aberrant or overexpressed MTCP-1 transcripts. The potential coding role of this gene was made uncertain by the lack of a long open reading frame in its major transcripts. However, a short 204 bases open reading frame is potentially coding for a 68 amino-acid protein. Here, we show that this open reading frame sequence and the deduced product are well conserved in mouse. A 8 kD protein (p8), which corresponds to the predicted molecular weight was revealed in transient transfectants and in cell lines by Western blotting, using a rabbit antiserum. This product was absent in lymphoblastoid cell lines with deletions of the MTCP-1/c6.1B locus. A dramatic overexpression of p8 was found in leukemic cells from a patient with a t(X;14). This small protein was localized in the cytoplasm by immunofluorescence. In conclusion, MTCP-1 encodes for a cytoplasmic 8 kD product. Its potential role in leukemogenesis is supported by its overexpression in leukemia with t(X;14), but its function remains unknown.	HOP ST LOUIS,HEMATOL MOLEC LAB,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			Rosenzwajg, Michelle/AAF-6276-2019; Stern, Marc-Henri/A-2728-2011	Rosenzwajg, Michelle/0000-0001-5312-6203; Stern, Marc-Henri/0000-0002-8100-2272				BEATTY DW, 1986, S AFR MED J, V69, P115; CANKI N, 1983, ZDRAV VESTN, V52, P567; DALLAPICCOLA B, 1984, INT J CANCER, V34, P171, DOI 10.1002/ijc.2910340206; FISCH P, 1993, ONCOGENE, V8, P3271; GOYNS MH, 1993, LEUKEMIA, V7, P848; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KENWRICK S, 1992, HUM MOL GENET, V1, P179, DOI 10.1093/hmg/1.3.179; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Sambrook J, 1989, MOL CLONING LABORATO; SMITH DB, 1992, CURRENT PROTOCOLS MO; STERN MH, 1989, BLOOD, V73, P1285; STERN MH, 1993, ONCOGENE, V8, P2475; STERN MH, 1993, CAUSES CONSEQUENCES, P165; TAYLOR AMR, 1981, INT J CANCER, V27, P311, DOI 10.1002/ijc.2910270309; TAYLOR AMR, 1992, LEUKEMIA, V6, P961; THICK J, 1994, LEUKEMIA, V8, P564; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WITZIG TE, 1986, AM J HEMATOL, V21, P139, DOI 10.1002/ajh.2830210204	18	38	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3565	3570						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970717				2022-12-25	WOS:A1994PT39200019
J	FISHER, MT; YUAN, XS				FISHER, MT; YUAN, XS			THE RATES OF COMMITMENT RENATURATION OF RHODANESE AND GLUTAMINE-SYNTHETASE IN THE PRESENCE OF THE GROE CHAPERONINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BETA-LACTAMASE; PROTEIN; INVITRO; RECONSTITUTION; AGGREGATION; CARBOXYLASE; ATP	Current models of chaperonin-assisted folding suggest that proteins undergo multiple rounds of binding and release before they are released in a form that is committed to folding to the native state. Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme. Rhodanese and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable ''folding arrested'' complexes with groEL. At various times during the groE-dependent renaturations, groEL was rapidly removed from the renaturation mixture by immunoprecipitation and centrifugation (30 s). The conformers that are committed to the native state remained in the supernatant and were assayed after 1 h. At 25 degrees C, the rate profiles indicate the release and commitment to folding of GS to its native state occurs far earlier (t(1/2) < 1 min) than for rhodanese (t(1/2) = 5 min). In light of previous results, it appears that GS monomers can attain a groE-independent assembly competent conformation after a brief interaction with the chaperonin. In contrast, the renaturation rate for rhodanese with the groE chaperonins mirrored the committed renaturation rates following groEL depletion. This suggests that rhodanese must interact with groEL throughout most of its folding reaction before it acquires a folding competent (groE independent) state. If current models of chaperonin mechanism are correct, rhodanese undergoes more rebinding and release cycles than does GS. Structurally, the degree of cycling and hence the rate of commitment to folding to the active form are probably dictated by the hydrophobic nature, number, and lifetimes of the folding intermediates that interact with the chaperonins.			FISHER, MT (corresponding author), UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160, USA.				NIGMS NIH HHS [GM49309] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049309] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; FISHER MT, 1992, J BIOL CHEM, V267, P1872; FISHER MT, 1993, J BIOL CHEM, V268, P13777; FISHER MT, 1994, J BIOL CHEM, V269, P13629; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; GRIMM R, 1993, J BIOL CHEM, V268, P5220; HORWICH A, 1994, NATURE, V371, P614; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; PHADTARE S, 1994, BBA-PROTEIN STRUCT M, V1208, P189, DOI 10.1016/0167-4838(94)90178-3; ROY H, 1992, PROTEIN SCI, V1, P925, DOI 10.1002/pro.5560010711; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029	28	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29598	29601						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961947				2022-12-25	WOS:A1994PU28400046
J	GUPTA, MP; GUPTA, M; ZAK, R				GUPTA, MP; GUPTA, M; ZAK, R			AN E-BOX M-CAT HYBRID MOTIF AND COGNATE BINDING PROTEIN(S) REGULATE THE BASAL MUSCLE-SPECIFIC AND CAMP-INDUCIBLE EXPRESSION OF THE RAT CARDIAC ALPHA-MYOSIN HEAVY-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; TRANSCRIPTION FACTOR; THYROID-HORMONE; HEART MYOCYTES; FACTOR MEF-2; BETA-GENE; ENHANCER; PROMOTER; CELLS; DISTINCT	Expression of the cardiac myosin heavy chain (MHC) genes is regulated developmentally and by numerous epigenetic factors. Here we report the identification of a cis-regulatory element and cognate nuclear binding protein(s) responsible for cAMP-induced expression of the rat cardiac (alpha-MHC gene. By Northern blot analysis, we found that, in primary cultures of fetal rat heart myocytes, the elevation of intracellular levels of cAMP results in up-regulation of alpha-MHC and down-regulation of beta-MHC mRNA expression. This effect of cAMP was dependent upon the basal level of expression of both MHC transcripts and was sensitive to cycloheximide. In transient expression analysis employing a series of alpha-MHC/CAT constructs, we identified a 31-base pair fragment located in the immediate upstream region (-71 to -40), which confers both muscle-specific and cAMP-inducible expression of the gene. Within this 31-base pair fragment there are two regions, an AT-rich portion and a hybrid motif which contains overlapping sequences of E-box and M-CAT binding sites (GGCACGTGGAATG). By substitution mutation analysis, both elements were found important for the basal muscle-specific expression; however, the cAMP-inducible expression of the gene is conferred only by the E-box/M-CAT hybrid motif (EM element). Using mobility gel shift competition assay, immunoblotting, and UV-cross-linking analyses, we found that a protein binding to the EM element is indistinguishable from the transcription enhancer factor-1 (TEF-1) in terms of sequence recognition, molecular mass, and immunoreactivity. Methylation interference and point mutation analyses indicate that, besides MCAT sequences, center CG dinucleotides of the E-box motif CACGTG are essential for protein binding to the EM element and for its functional activity. Furthermore, our data also show that, in addition to TEE-1, another HF-1a-related factor may be recognized by the alpha-MHC gene EM element. These results are first to demonstrate transcriptional activation of a sarcomeric gene by cAMP and support the role of TEE-1 and HF-1a-like factors in the regulation of alpha-MHC gene expression in cardiac myocytes.	UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL & ORGANISMAL BIOL, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago	GUPTA, MP (corresponding author), UNIV CHICAGO, DEPT MED, CARDIOL SECT, CHICAGO, IL 60637 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020592, R01HL045646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20592, HL-45646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADOLPH EA, 1993, J BIOL CHEM, V268, P5349; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BUTTRICK PM, 1993, CIRC RES, V72, P1211, DOI 10.1161/01.RES.72.6.1211; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORSI PS, 1988, NATURE, V334, P314; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.bi.56.070187.003403; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; GUPTA MP, 1991, BIOCHEM BIOPH RES CO, V174, P1196, DOI 10.1016/0006-291X(91)91548-Q; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KARIN M, 1989, TRENDS GENET, V5, P65, DOI 10.1016/0168-9525(89)90027-9; KARIYA K, 1993, J BIOL CHEM, V268, P26658; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LOMPRE AM, 1981, DEV BIOL, V84, P286, DOI 10.1016/0012-1606(81)90396-1; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; Maxam A M, 1980, Methods Enzymol, V65, P499; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P2602; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOSS JB, 1994, J BIOL CHEM, V269, P12731; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OLSEN DB, 1990, P NATL ACAD SCI USA, V87, P1451, DOI 10.1073/pnas.87.4.1451; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAEZ LJ, 1987, NUCLEIC ACIDS RES, V15, P5443, DOI 10.1093/nar/15.13.5443; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SMITH WR, 1989, CELLULAR MOL BIOL MU, P359; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WINTER B, 1993, J BIOL CHEM, V268, P9869; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YUTZEY KE, 1992, NUCLEIC ACIDS RES, V20, P5105, DOI 10.1093/nar/20.19.5105	48	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29677	29687						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961957				2022-12-25	WOS:A1994PU28400058
J	KIM, YS; BYUN, HS				KIM, YS; BYUN, HS			PURIFICATION AND PROPERTIES OF A NOVEL TYPE OF MALONATE DECARBOXYLASE FROM ACINETOBACTER-CALCOACETICUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME INTERMEDIATE; ACETYL ENZYME; MECHANISM; BACTERIA; ION	A novel type of malonate decarboxylase which is induced and located in periplasm of Acinetobacter calcoaceticus grown on malonate as sole carbon and energy source was purified to homogeneity. The purified 185-kDa decarboxylase was found to be an oligomer composed of three different polypeptides in a ratio of 2:1:1, designated cu (65 kDa), beta (32 kDa), and gamma (25 kDa). Optimum pH was 6.8, while pI was 6.39. The enzyme was highly specific for malonate with K-m 1.4 mM. This enzyme contained a biotin prosthetic group on (alpha subunit which does not seem to be directly related to malonate decarboxylation. The purified enzyme showed almost no activity; activity was restored, however, by treatment with acetic anhydride or malonyl-CoA, which formed an acetyl-enzyme. The C-14-acylated enzyme was isolated by a gel filtration from the reaction mixtures containing [2-C-14]malonyl-CoA and the enzyme or [2-C-14]malonate, malonyl-CoA, and the enzyme. When treated by thiol-specific reagents, such as N-ethylmaleimide, 5,5'-dinitro-bis (2-nitrobenzoic acid), and 2-nitro-5-thiocyanobenzoic acid, the purified enzyme showed no increase in activity after the acetic anhydride treatment. The thiol-specific reagents failed to inhibit, however, the catalytically active acetyl-enzyme, suggesting that the site of acylation is the thiol group. Further evidence was provided when sodium borohydride inactivated the acetylenzyme. These results suggest that malonate decarboxylation by this enzyme may proceed by a catalytic cycle in which the acetyl group on the active enzyme is displaced by malonate, which binds covalently to a thiol group on the enzyme and is subsequently decarboxylated.			KIM, YS (corresponding author), YONSEI UNIV,COLL SCI,BIOPROD RES CTR,DEPT BIOCHEM,SEOUL 120749,SOUTH KOREA.							ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; ANKE H, 1975, BIOCHEM BIOPH RES CO, V67, P767, DOI 10.1016/0006-291X(75)90879-7; ARKOWITZ RA, 1991, BIOCHEMISTRY-US, V30, P4090, DOI 10.1021/bi00230a039; BARTOS D, 1993, ANAL BIOCHEM, V213, P241, DOI 10.1006/abio.1993.1416; BUCKEL W, 1976, EUR J BIOCHEM, V64, P255, DOI 10.1111/j.1432-1033.1976.tb10295.x; BUCKEL W, 1973, EUR J BIOCHEM, V37, P205; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; DIMROTH P, 1976, EUR J BIOCHEM, V64, P269, DOI 10.1111/j.1432-1033.1976.tb10297.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GREENSPAN MD, 1969, J BIOL CHEM, V244, P6477; HILBI H, 1992, EUR J BIOCHEM, V207, P117, DOI 10.1111/j.1432-1033.1992.tb17028.x; HILPERT W, 1984, EMBO J, V3, P1665, DOI 10.1002/j.1460-2075.1984.tb02030.x; HILPERT W, 1983, EUR J BIOCHEM, V132, P579, DOI 10.1111/j.1432-1033.1983.tb07403.x; KIM YS, 1988, BIOCHIM BIOPHYS ACTA, V956, P103, DOI 10.1016/0167-4838(88)90255-5; KIM YS, 1978, ARCH BIOCHEM BIOPHYS, V190, P243; KIM YS, 1985, KOREAN J MICROBIOL, V23, P230; KIM YS, 1993, J BIOL CHEM, V269, P8014; KOEPPEN AH, 1974, BIOCHEMISTRY-US, V13, P3589, DOI 10.1021/bi00714a029; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER R, 1993, J BIOL CHEM, V268, P24726; Matsudaira P. T., 1989, PRACTICAL GUIDE PROT, P53; MIZIORKO HM, 1977, J BIOL CHEM, V252, P1414; PRESCOTT DJ, 1972, ADV ENZYMOL RAMB, V36, P269; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STREETER JG, 1989, J GEN MICROBIOL, V135, P3477; TAKAMURA Y, 1981, BIOCHEM INT, V3, P483	26	19	19	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29636	29641						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961952				2022-12-25	WOS:A1994PU28400052
J	KITAJIMA, S; CHIBAZAKURA, T; YONAHA, M; YASUKOCHI, Y				KITAJIMA, S; CHIBAZAKURA, T; YONAHA, M; YASUKOCHI, Y			REGULATION OF THE HUMAN GENERAL TRANSCRIPTION INITIATION-FACTOR TFIIF BY PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; ACCURATE INITIATION; INVITRO TRANSCRIPTION; FUNCTIONAL-PROPERTIES; SMALL SUBUNIT; CALF THYMUS; PURIFICATION; BINDING; PROTEINS; COMPLEX	The transcription initiation factor, TFIIF, is essential not only for the initiation of transcription but also for efficient elongation of mRNA synthesis by mammalian RNA polymerase II and is extensively phosphorylated in vivo. The possible regulation of TFIIF activity by protein phosphorylation was investigated by comparing the biochemical properties of alkaline phosphatase-treated HeLa TFIIF with those of native or bacterially expressed factor. Alkaline phosphatase treatment decreased the size of the large subunit (RAP74) of TFIIF to that of the recombinant protein but did not change the size of the small subunit (RAP30). Both the transcription initiation and elongation stimulating activities of the alkaline phosphatase-treated TFIIF decreased to 15-20% of the native form under conditions in which the amount of TFIIF was rate-limiting for transcription. Furthermore, phosphatase-treated TFIIF assembled the DBPolF complex and bound to RNA polymerase Bless efficiently than the native protein. When hybrid TFIIFs were reconstituted using native or recombinant subunits, a native form of RAP74 stimulated both transcription and DBPolF complex formation activity regardless of whether native or recombinant RAP30 was used. We propose that TFIIF activity is regulated by protein phosphorylation, particularly of the RAP74 subunit. The functional role of RAP74 in assembling the preinitiation complex and modulating TFIIF activity is discussed.			KITAJIMA, S (corresponding author), TOKYO MED & DENT UNIV,MED RES INST,DEPT MOLEC GENET,BUNKYO KU,1-5-45 YUSHIMA,TOKYO 113,JAPAN.							ASO T, 1992, NATURE, V355, P464; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CHANG CH, 1993, J BIOL CHEM, V268, P20482; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KARLIN S, 1993, P NATL ACAD SCI USA, V90, P5593, DOI 10.1073/pnas.90.12.5593; KAWAGUCHI T, 1990, P NATL ACAD SCI USA, V87, P6619, DOI 10.1073/pnas.87.17.6619; KITAJIMA S, 1990, NUCLEIC ACIDS RES, V18, P4843, DOI 10.1093/nar/18.16.4843; KITAJIMA S, 1989, P NATL ACAD SCI USA, V86, P6106, DOI 10.1073/pnas.86.16.6106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRICE DH, 1987, J BIOL CHEM, V262, P3244; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STONE N, 1991, PHARM TECHNOL, V15, P36; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; SZENTIRMAY MN, 1991, P NATL ACAD SCI USA, V88, P10691, DOI 10.1073/pnas.88.23.10691; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; YONAHA M, 1993, NUCLEIC ACIDS RES, V21, P273, DOI 10.1093/nar/21.2.273; ZHU H, 1994, J BIOL CHEM, V269, P3489	58	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29970	29977						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961996				2022-12-25	WOS:A1994PU28400100
J	TAKENAKA, M; PRESTON, AS; KWON, HM; HANDLER, JS				TAKENAKA, M; PRESTON, AS; KWON, HM; HANDLER, JS			THE TONICITY-SENSITIVE ELEMENT THAT MEDIATES INCREASED TRANSCRIPTION OF THE BETAINE TRANSPORTER GENE IN RESPONSE TO HYPERTONIC STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INOSITOL COTRANSPORTER; OSMOTIC REGULATION; ESCHERICHIA-COLI; ALDOSE REDUCTASE; CELL LINES; MDCK CELLS; PROTEIN; CLONING; MYOINOSITOL; PHYSIOLOGY	BGT1, the Na+- and Cl--coupled betaine transporter, is responsible for the accumulation of high concentrations of the non-perturbing osmolyte betaine in hypertonic Madin-Darby canine kidney (MDCK) cells and presumably in the hypertonic renal medulla. In MDCK cells, the increase in activity of the betaine transporter is preceded by an increase in transcription of BGT1 and in the abundance of BGT1 mRNA. To investigate the molecular mechanism of transcriptional regulation by tonicity, we have characterized the 5'-flanking region of the gene. Transient transfection assays in MDCK cells cultured in isotonic or hypertonic medium using luciferase reporter constructs containing various fragments of the 5'-flanking region revealed that the region spanning base pairs -69 to -50 5' to the transcription initiation site (-69/-50) has hypertonicity-responsive enhancer activity. A double-stranded -69/-50 concatemer cloned 5' to an SV40 basal promoter and luciferase reporter gene in hypertonic cells exhibited more than 11-fold the activity in isotonic cells. Expression assays and electrophoretic mobility shift assays of mutants of -69/-50 identified a smaller region that is required for hypertonicity to induce increased expression and a slowly migrating band on mobility shift assays.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV NEPHROL,BALTIMORE,MD 21205	Johns Hopkins University			Lee-Kwon, Whaseon/D-6021-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044484] Funding Source: NIH RePORTER; NIDDK NIH HHS [1PO1 DK-44484] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMOSHLIH, 1973, J GEN VIROL, V18, P189; BARRON A, 1986, J BACTERIOL, V167, P433, DOI 10.1128/jb.167.2.433-438.1986; BLOMBERG A, 1992, ADV MICROB PHYSIOL, V33, P145, DOI 10.1016/S0065-2911(08)60217-9; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; DUNLAP VJ, 1985, J BACTERIOL, V163, P296, DOI 10.1128/JB.163.1.296-304.1985; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; KWON HM, 1992, J BIOL CHEM, V267, P6297; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; NAKANISHI T, 1989, P NATL ACAD SCI USA, V86, P6002, DOI 10.1073/pnas.86.15.6002; NAKANISHI T, 1988, AM J PHYSIOL, V255, pC181, DOI 10.1152/ajpcell.1988.255.2.C181; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; SUTHERLAND L, 1986, J BACTERIOL, V168, P805, DOI 10.1128/jb.168.2.805-814.1986; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197; YAMAUCHI A, 1993, AM J PHYSIOL, V264, pF20, DOI 10.1152/ajprenal.1993.264.1.F20; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	27	181	182	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29379	29381						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961914				2022-12-25	WOS:A1994PU28400012
J	KIM, JY; DEVREOTES, PN				KIM, JY; DEVREOTES, PN			RANDOM CHIMERAGENESIS OF G-PROTEIN-COUPLED RECEPTORS - MAPPING THE AFFINITY OF THE CAMP CHEMOATTRACTANT RECEPTORS IN DICTYOSTELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROTROPIN RECEPTOR; FORMYL PEPTIDE RECEPTOR; LIGAND-BINDING; ADENYLYL-CYCLASE; EXTRACELLULAR DOMAIN; DIFFERENT ROLES; DISCOIDEUM; IDENTIFICATION; CELLS; MUTAGENESIS	G-protein coupled receptors mediate a wide variety of responses to extracellular stimuli in eucaryotic cells. Binding of the ligand to these receptors is thought to involve contacts within a pocket formed by the seven transmembrane domains inferred from the sequences of these genes. A family of four surface cAMP receptors that mediate responses to secreted cAMP coordinates the developmental program of Dictyostelium. A large difference in affinity for cAMP exists between cAR1 (25 and 230 nM) and cAR2 (>5 mu m). To understand the basis for this affinity difference, we generated an extensive series of cAR1/cAR2 and cAR2/cAR1 chimeras using a technique designated ''random chimeragenesis.'' When a linearized plasmid was transformed into Escherichia coli, tandemly positioned cAR1 and cAR2 genes crossed over at homologous regions. The cAMP binding properties and EC(50) values for agonist-induced phosphorylation of each of the chimeras were characterized in order to map the domains that determine the affinity. These studies implicated a domain in the second extracellular loop in which only 5 residues differ between the two receptors as the major determinant of affinity. A secondary domain including residues 110-147 (11 residue differences) was identified as a minor determinant of affinity.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034933] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34933] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CATERINA MJ, 1994, J BIOL CHEM, V269, P1523; CHEN MY, 1994, J BIOL CHEM, V269, P20925; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DEVREOTES PN, 1994, NEURON, V12, P1; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FIDLAY JBC, 1981, NATURE, V293, P314; GAO JL, 1993, J BIOL CHEM, V268, P25395; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HERELD D, 1994, J BIOL CHEM, V269, P7036; JOHNSON RL, 1992, COLD SPRING HARB SYM, V57, P169, DOI 10.1101/SQB.1992.057.01.022; JOHNSON RL, 1991, BIOCHEMISTRY-US, V30, P6982, DOI 10.1021/bi00242a025; JOHNSON RL, 1992, J BIOL CHEM, V267, P4600; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KLEIN P, 1987, J BIOL CHEM, V262, P358; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MILNE JL, 1993, MOL BIOL CELL, V4, P283, DOI 10.1091/mbc.4.3.283; NAGAYAMA Y, 1992, ENDOCRINOLOGY, V131, P548, DOI 10.1210/en.131.2.548; NAGAYAMA Y, 1991, J BIOL CHEM, V266, P14926; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PITT GS, 1993, GENE DEV, V7, P2172, DOI 10.1101/gad.7.11.2172; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SAXE CL, 1993, GENE DEV, V7, P262, DOI 10.1101/gad.7.2.262; SCHAAP P, 1984, P NATL ACAD SCI-BIOL, V81, P2122, DOI 10.1073/pnas.81.7.2122; STRADER CD, 1988, J BIOL CHEM, V263, P10267; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; VANHAASTERT PJM, 1985, BIOCHIM BIOPHYS ACTA, V845, P254, DOI 10.1016/0167-4889(85)90184-3; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538; WANG CD, 1991, MOL PHARMACOL, V40, P168; WANG JK, 1980, BIOCHEMISTRY-US, V19, P5111, DOI 10.1021/bi00563a027; WILLIAMS JG, 1989, DEVELOPMENT, V107, P91; XIE YB, 1990, J BIOL CHEM, V265, P21411; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	40	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28724	28731						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961824				2022-12-25	WOS:A1994PU16800034
J	LI, JY; HOLLFELDER, K; HUANG, KS; LOW, MG				LI, JY; HOLLFELDER, K; HUANG, KS; LOW, MG			STRUCTURAL FEATURES OF GPI-SPECIFIC PHOSPHOLIPASE-D REVEALED BY PROTEOLYTIC FRAGMENTATION AND CA2+ BINDING-STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEINS; ALKALINE-PHOSPHATASE; ANCHORED PROTEINS; LIGAND-BINDING; PHOSPHATIDYLINOSITOL; MEMBRANE; ADHESION; CALCIUM; PURIFICATION; GLYCOPROTEIN	Glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) is abundant in plasma and is potentially capable of degrading the anchor utilized by many cell surface proteins. The goal of this work was to study structural features of the GPI-PLD that might be involved in regulation of its activity. Trypsin cleaved the 100-110 kDa GPI-PLD polypeptide into three major fragments (two of similar to 40 kDa and a carboxyl-terminal fragment of 30 kDa) which were relatively resistant to further proteolysis. Pretreatment of the GPI-PLD with chelators resulted in complete degradation. During the cleavage process the GPI-PLD enzymatic activity increased similar to 3-4-fold but no other major change in its properties (e.g. inhibition by chelators and lipids, thermal stability, oligomerization, etc.) was observed. Intact or trypsinized GPI-PLD bound Ca-45(2+) (similar to 5.5 ions/molecule GPI-PLD); K-d similar to 16.1 mu M as determined by equilibrium dialysis) which could not be blocked by the addition of other divalent metal ions. However, inhibition of enzymatic activity by divalent cation chelators appeared to involve removal of bound Zn2+ rather than Ca2+. A metal analysis of GPI-PLD revealed similar to 5 and 10 atom/molecule of calcium and zinc, respectively. The data suggest that the predicted integrin E-F hand-like sites in GPI-PLD are functional but not directly involved in enzymatic activity.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT PHYSIOL & CELLULAR BIOPHYS, NEW YORK, NY 10032 USA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT MOLEC SCI, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT INFLAMAT AUTOIMMUNE DIS, NUTLEY, NJ 07110 USA	Columbia University; Roche Holding; Roche Holding					NIGMS NIH HHS [GM-35873, GM-40083] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040083, R01GM035873, R55GM040083] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMQVIST P, 1988, J BIOL CHEM, V263, P12709; BAIROCH A, 1990, FEBS LETT, V269, P454, DOI 10.1016/0014-5793(90)81214-9; BERGMAN AS, 1994, BIOCHEM J, V298, P661, DOI 10.1042/bj2980661; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; FUNG WJC, 1991, J CELL BIOL, V115, P471; GULINO D, 1992, J BIOL CHEM, V267, P1001; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; HOENER MC, 1990, EUR J BIOCHEM, V190, P593, DOI 10.1111/j.1432-1033.1990.tb15614.x; HOENER MC, 1993, FEBS LETT, V327, P203, DOI 10.1016/0014-5793(93)80170-Y; HOENER MC, 1992, EUR J BIOCHEM, V206, P747, DOI 10.1111/j.1432-1033.1992.tb16981.x; HUANG KS, 1991, METHOD ENZYMOL, V197, P567; HUANG KS, 1990, J BIOL CHEM, V265, P17738; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; Low M.G., 1992, LIPID MODIFICATION P, P117; LOW MG, 1993, J BIOL CHEM, V268, P8480; LOW MG, 1991, BIOCHEM J, V279, P483, DOI 10.1042/bj2790483; LOW MG, 1988, P NATL ACAD SCI USA, V85, P980, DOI 10.1073/pnas.85.4.980; MALIK AS, 1986, BIOCHEM J, V240, P519, DOI 10.1042/bj2400519; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; METZ CN, 1994, EMBO J, V13, P1741, DOI 10.1002/j.1460-2075.1994.tb06438.x; METZ CN, 1992, AM J PATHOL, V140, P1275; METZ CN, 1991, J BIOL CHEM, V266, P17733; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; SCALLON BJ, 1992, BIO-TECHNOL, V10, P550, DOI 10.1038/nbt0592-550; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; SESKO AM, 1991, FASEB J, V5, pA839; SMITH JW, 1991, J BIOL CHEM, V266, P11429; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; WONG YW, 1992, CLIN CHEM, V38, P2517; XIE MS, 1993, AM J PHYSIOL, V265, pC1156; XIE MS, 1994, BIOCHEM J, V297, P547, DOI 10.1042/bj2970547	40	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28963	28971						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961859				2022-12-25	WOS:A1994PU16800069
J	PAUL, AV; CAO, XM; HARRIS, KS; LAMA, J; WIMMER, E				PAUL, AV; CAO, XM; HARRIS, KS; LAMA, J; WIMMER, E			STUDIES WITH POLIOVIRUS POLYMERASE 3D(POL) - STIMULATION OF POLY(U) SYNTHESIS IN-VITRO BY PURIFIED POLIOVIRUS PROTEIN 3AB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-LINKED PROTEIN; ADENOVIRUS DNA-POLYMERASE; DEPENDENT RNA-POLYMERASE; VIRAL-RNA; BINDING-PROTEIN; ESCHERICHIA-COLI; HOST FACTOR; REPLICATION; VPG; IDENTIFICATION	The synthesis in vitro of poly(U) on a poly(A) template with oligo(dT)(15) primer by poliovirus RNA polymerase 3D(pol) (280 ng/ml) is strongly stimulated (50-100 fold) by the addition of purified poliovirus polypeptide 3AB. The synthesis of product continues linearly with time for up to 90 min. The reaction with 3D(pol) alone can be reactivated and similarly enhanced by the addition of 3AB at 30 min of incubation. Optimal stimulation is achieved under conditions where the concentration of 3D(pol) and of template is low, when the molar ratio of 3AB to 3D(pol) is about 100:1 and that of 3AB to poly(A) is about 25:1. In the presence of 3AB, the yield of product made by 3D(pol) is much increased but its size is unchanged. From a number of basic proteins and peptides tested, a few were found which also exhibited limited enhancement of polymerase activity. The stimulatory effect of 3AB is probably related to its ability to bind both the template-primer, poly(A).oligo(dT)(15), and 3D(pol) (Molla, A., Harris, K. S., Paul, A. V., Shin, S. H., Mugavero, J., and Wimmer, E. J. (1994) J. Biol. Chem. 269, 27015-27020). RNA synthesis on purified poliovirus RNA with oligo(dT)(15) primer is enhanced by 3AB about 5-10 fold, and this reaction is highly sensitive to detergent.			PAUL, AV (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, SCH MED, DEPT MOLEC GENET & MICROBIOL, STONY BROOK, NY 11790 USA.				NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015122, R01AI032100, R01AI015122] Funding Source: NIH RePORTER; NCI NIH HHS [CA28146] Funding Source: Medline; NIAID NIH HHS [AI32100, AI15122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS BM, 1968, COLD SPRING HARB SYM, V33, P289, DOI 10.1101/SQB.1968.033.01.033; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDREWS NC, 1986, P NATL ACAD SCI USA, V83, P221, DOI 10.1073/pnas.83.2.221; BERNSTEIN HD, 1988, J VIROL, V62, P2922, DOI 10.1128/JVI.62.8.2922-2928.1988; BIENZ K, 1990, J VIROL, V64, P1156, DOI 10.1128/JVI.64.3.1156-1163.1990; BLUMENTHAL T, 1973, BIOCHEM BIOPH RES CO, V55, P680, DOI 10.1016/0006-291X(73)91198-4; BRYANT FR, 1985, J BIOL CHEM, V260, P1196; CALIGUIRI LA, 1974, VIROLOGY, V58, P526, DOI 10.1016/0042-6822(74)90086-5; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHO MW, 1993, J VIROL, V67, P3010, DOI 10.1128/JVI.67.6.3010-3018.1993; CLEAT PH, 1989, EMBO J, V8, P1841, DOI 10.1002/j.1460-2075.1989.tb03579.x; CUI T, 1993, J BIOL CHEM, V268, P26093; DATTA U, 1994, J VIROL, V68, P4468, DOI 10.1128/JVI.68.7.4468-4477.1994; FIELD J, 1984, J BIOL CHEM, V259, P9487; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P961, DOI 10.1073/pnas.74.3.961; FLANEGAN JB, 1979, J VIROL, V29, P352, DOI 10.1128/JVI.29.1.352-360.1979; GIACHETTI C, 1991, J VIROL, V65, P2647, DOI 10.1128/JVI.65.5.2647-2654.1991; HARRIS KS, 1992, J VIROL, V66, P7481, DOI 10.1128/JVI.66.12.7481-7489.1992; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JACOBSON SJ, 1993, J VIROL, V67, P2961, DOI 10.1128/JVI.67.6.2961-2971.1993; JOHNSON KL, 1991, J VIROL, V65, P4341, DOI 10.1128/JVI.65.8.4341-4349.1991; KORNBERG A, 1992, DNA REPLICATION, P323; KUHN RJ, 1988, J VIROL, V62, P4207, DOI 10.1128/JVI.62.11.4207-4215.1988; KUHN RJ, 1987, MOL BIOL POSITIVE ST, P15; LAMA J, 1994, J BIOL CHEM, V269, P66; LEE YF, 1977, P NATL ACAD SCI USA, V74, P59, DOI 10.1073/pnas.74.1.59; LICHY JH, 1981, P NATL ACAD SCI-BIOL, V78, P2678, DOI 10.1073/pnas.78.5.2678; LINDENBAUM JO, 1986, J BIOL CHEM, V261, P218; MEYER J, 1978, VIROLOGY, V85, P445, DOI 10.1016/0042-6822(78)90451-8; MIRZAYAN C, 1994, VIROLOGY, V199, P176, DOI 10.1006/viro.1994.1110; MOLLA A, 1994, J BIOL CHEM, V269, P27015; MOLLA A, 1993, VIROLOGY, V196, P739, DOI 10.1006/viro.1993.1531; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; OBERSTE MS, 1988, NUCLEIC ACIDS RES, V16, P10338; PILIPENKO EV, 1992, NUCLEIC ACIDS RES, V20, P1739, DOI 10.1093/nar/20.7.1739; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; REKOSH DMK, 1977, CELL, V11, P283, DOI 10.1016/0092-8674(77)90045-9; REUER Q, 1990, J VIROL, V64, P2967, DOI 10.1128/JVI.64.6.2967-2975.1990; RODRIGUEZ PL, 1993, J BIOL CHEM, V268, P8105; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; SCHMIDT G, 1968, METHODS ENZYMOLOGY B, V12, P230; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; STILLMAN BW, 1983, CELL, V35, P7, DOI 10.1016/0092-8674(83)90201-5; STILLMAN BW, 1985, GENETIC ENG PRINCIPL, V7, P1; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TOBIN GJ, 1989, CELL, V59, P511, DOI 10.1016/0092-8674(89)90034-2; TOYODA H, 1987, J VIROL, V61, P2816, DOI 10.1128/JVI.61.9.2816-2822.1987; VANDYKE TA, 1980, J VIROL, V35, P732, DOI 10.1128/JVI.35.3.732-740.1980; WIMMER E, 1982, CELL, V28, P199, DOI 10.1016/0092-8674(82)90335-X; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; WIMMER E, 1969, NATURE, V221, P1122, DOI 10.1038/2211122a0; WITHERELL GW, 1993, BIOCHEMISTRY-US, V32, P8268, DOI 10.1021/bi00083a030; YOGO Y, 1972, P NATL ACAD SCI USA, V69, P1877, DOI 10.1073/pnas.69.7.1877	55	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29173	29181						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961883				2022-12-25	WOS:A1994PU16800096
J	SEKIGUCHI, J; SHUMAN, S				SEKIGUCHI, J; SHUMAN, S			VACCINIA TOPOISOMERASE BINDS CIRCUMFERENTIALLY TO DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECO RI ENDONUCLEASE; SITE-SPECIFIC INTERACTION; ESCHERICHIA-COLI; DUPLEX DNA; CLEAVAGE; RECOGNITION; SEQUENCE; RNA	Vaccinia DNA topoisomerase, a member of the eukraryotic type I enzyme family, binds duplex DNA and forms a covalent adduct at sites containing a conserved sequence element 5'-CCCTT down arrow in the scissile strand. The protein-DNA interface entails essential contacts with four phosphate moieties within the CCCTT motif, including the scissile phosphate, and three phosphates within the GGGAA sequence on the noncleaved strand, Critical protein-phosphate contacts are arrayed across the minor groove of the DNA helix, Base-specific contacts with the pentamer element are within the major groove and are situated on the opposite face of the helix. Thus, vaccinia topoisomerase binds circumferentially to its target site in duplex DNA, This binding mode suggests that the eukaryotic enzyme adopts a toroidal shape in the DNA-bound state, Conformational isomerization of the bound protein provides a plausible mechanism for DNA relaxation.	SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center				Sekiguchi, JoAnn/0000-0002-7178-4258	NIGMS NIH HHS [GM46330] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330, R37GM046330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GOTT JM, 1991, BIOCHEMISTRY-US, V30, P6290, DOI 10.1021/bi00239a030; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LIU LF, 1990, DNA TOPOLOGY ITS BIO, P371; LU AL, 1981, J BIOL CHEM, V256, P3200; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; STIVERS JT, 1994, IN PRESS BIOCHEMISTR	21	54	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31731	31734						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989346				2022-12-25	WOS:A1994PX30300064
J	TSUJIMURA, K; OGAWARA, M; TAKEUCHI, Y; IMAJOHOHMI, S; HA, MH; INAGAKI, M				TSUJIMURA, K; OGAWARA, M; TAKEUCHI, Y; IMAJOHOHMI, S; HA, MH; INAGAKI, M			VISUALIZATION AND FUNCTION OF VIMENTIN PHOSPHORYLATION BY CDC2 KINASE DURING MITOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENT PROTEINS; FIBRILLARY ACIDIC PROTEIN; MYELIN BASIC-PROTEIN; HELICAL HEAD DOMAIN; CELL-CYCLE; IMMUNOFLUORESCENCE MICROSCOPY; MITOTIC CELLS; AMNION CELLS; M-PHASE; INVITRO	To investigate the role of intermediate filament (IF) protein phosphorylation by cdc2 kinase during mitosis, we developed a monoclonal antibody 4A4 recognizing Ser(55)-phosphorylated vimentin. Western blotting indicated that this antibody reacted with vimentin phosphorylated by cdc2 kinase but not with non phosphorylated vimentin or with vimentin phosphorylated by other kinases such as cAMP-dependent protein kinase, protein kinase C, or Ca2+-calmodulin dependent protein kinase II. Immunofluorescence and immunoelectron microscopy showed that vimentin Ser(55) residues distributed in the entire cytoplasmic vimentin filament system are phosphorylated when the cells enter mitosis and dephosphorylated in cytokinesis. All cell lines examined showed a similar appearance of immunoreactivity with antibody 4A4. Fractionation of mitotic cell extracts on Mono-Q Sepharose revealed a single peak of vimentin Ser(55) kinase activity, and the anti-p34(cdc2) antibody reacted with the 34 kDa band in the kinase containing fractions. Vimentin Ser(55) kinase activities were nil in the interphase cell extract. Immunofluorescent evidence using antibody 4A4 and biochemical analysis using vimentin Ser(55) peptide showed that the degree of disassembly of vimentin filament of various cell types at early mitotic phase correlated well with the amount of mitotically activated cdc2 kinase.	TOKYO METROPOLITAN GERIATR HOSP & INST GERENTOL, DEPT NEUROPHYSIOL, ITABASHI KU, TOKYO 173, JAPAN; UNIV TOKYO, INST MED SCI, MINATO KU, TOKYO 108, JAPAN	University of Tokyo			Inagaki, Masaki/B-9920-2016					ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; AUBIN JE, 1980, EXP CELL RES, V129, P149, DOI 10.1016/0014-4827(80)90340-7; BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; Beavo J A, 1974, Methods Enzymol, V38, P299; BLOSE SH, 1982, EXP CELL RES, V142, P57, DOI 10.1016/0014-4827(82)90408-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; Engvall E, 1980, Methods Enzymol, V70, P419; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; EVANS RM, 1988, FEBS LETT, V234, P73, DOI 10.1016/0014-5793(88)81306-1; EVANS RM, 1988, EUR J CELL BIOL, V46, P152; EVANS RM, 1982, CELL, V29, P43, DOI 10.1016/0092-8674(82)90088-5; FEY SJ, 1983, FEBS LETT, V157, P165, DOI 10.1016/0014-5793(83)81138-7; FRANKE WW, 1982, CELL, V30, P103, DOI 10.1016/0092-8674(82)90016-2; FRANKE WW, 1983, J CELL BIOL, V97, P1255, DOI 10.1083/jcb.97.4.1255; Galfre G, 1981, Methods Enzymol, V73, P3; GARD DL, 1980, CELL, V19, P263, DOI 10.1016/0092-8674(80)90408-0; GEISLER N, 1989, EUR J BIOCHEM, V183, P441, DOI 10.1111/j.1432-1033.1989.tb14947.x; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GONDA Y, 1990, BIOCHEM BIOPH RES CO, V167, P1316, DOI 10.1016/0006-291X(90)90667-C; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HISANAGA S, 1990, CELL REGUL, V1, P237, DOI 10.1091/mbc.1.2.237; HORWITZ B, 1981, EXP CELL RES, V134, P281, DOI 10.1016/0014-4827(81)90427-4; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; INAGAKI M, 1987, ARCH BIOCHEM BIOPHYS, V254, P136, DOI 10.1016/0003-9861(87)90089-0; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; JONES JCR, 1985, J CELL BIOL, V100, P93, DOI 10.1083/jcb.100.1.93; KEMP BE, 1979, J BIOL CHEM, V254, P2638; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; KITAMURA S, 1989, J BIOL CHEM, V264, P5674; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; KUSUBATA M, 1993, BIOCHEM BIOPH RES CO, V190, P927, DOI 10.1006/bbrc.1993.1138; LANE EB, 1982, EMBO J, V1, P1365, DOI 10.1002/j.1460-2075.1982.tb01324.x; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNOR CM, 1981, CELL, V23, P135, DOI 10.1016/0092-8674(81)90278-6; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; OSBORN M, 1977, P NATL ACAD SCI USA, V74, P2490, DOI 10.1073/pnas.74.6.2490; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; PINES J, 1990, New Biologist, V2, P389; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; REEVES SA, 1989, P NATL ACAD SCI USA, V86, P5178, DOI 10.1073/pnas.86.13.5178; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; TOKUI T, 1990, BIOCHEM BIOPH RES CO, V169, P896, DOI 10.1016/0006-291X(90)91977-Z; TOLLE HG, 1987, EUR J CELL BIOL, V43, P35; TSUJIMURA K, 1994, J BIOCHEM, V116, P426, DOI 10.1093/oxfordjournals.jbchem.a124542; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WESTWOOD JT, 1985, J BIOL CHEM, V260, P308; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x; YANG HY, 1985, J CELL BIOL, V100, P620, DOI 10.1083/jcb.100.2.620; YANO T, 1991, EUR J BIOCHEM, V197, P281, DOI 10.1111/j.1432-1033.1991.tb15909.x; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6; ZIEVE GW, 1980, J CELL BIOL, V87, P160, DOI 10.1083/jcb.87.1.160	66	127	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31097	31106						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983050				2022-12-25	WOS:A1994PV51000057
J	KOJIMA, N; KUROSAWA, N; NISHI, T; HANAI, N; TSUJI, S				KOJIMA, N; KUROSAWA, N; NISHI, T; HANAI, N; TSUJI, S			INDUCTION OF CHOLINERGIC DIFFERENTIATION WITH NEURITE SPROUTING BY DE-NOVO BIOSYNTHESIS AND EXPRESSION OF GD3 AND B-SERIES GANGLIOSIDES IN NEURO2A CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; GM1 GANGLIOSIDE; BLASTOMA CELLS; NEURITOGENESIS; OUTGROWTH; RAT; PHEOCHROMOCYTOMA; INVITRO; BRAIN	The expression of a single glycosyltransferase, GD3 synthase, caused cholinergic differentiation with neu rite sprouting. The cells that expressed GD3 were established from Neuro2a cells by transfection of a mammalian expression vector into which were carried a cDNA encoding GD3 synthase and the blasticidin-S-deaminase gene with a SV40 promoter, followed by selection with blasticidin-S-hydrochloride. The blasticidin-S-hydrochloride-resistant colonies derived from the cells transfected with the cDNA encoding GD3 synthase and the clonal cells (N2a-GD3) were spontaneously sprouting neurites but not those derived from cells transfected with only the vector without the cDNA encoding GD3 synthase (N2a-bsr). GD3 expression by N2a-GD3 was confirmed by immunostaining of the cells using the anti-GD3 monoclonal antibody, KM643. N2a-GD3 expressed not only GD3 but also GQ1b, one of the b-series ganglio sides, whereas N2a-bsr did not express these ganglio sides. Cell proliferation of N2a-GD3 was greatly reduced, as compared with that of N2a-bsr, and, after several passages, it completely stopped. In addition, N2a-GD3 expressed acetylcholine esterase, indicating that the differentiation of Neuro2a cells was induced by expression of GD3 synthase and subsequent modification of the biosynthesis and expression of gangliosides. These results strongly suggest that the de novo synthesis and expression of GD3 and/or b-series gangliosides induce neurite outgrowth and differentiation of Neuro2a cells. Exogenous GM1 stimulated the neuritogenesis of N2a-bsr but not differentiated N2a-GD3, indicating that the mechanism of neurite sprouting in this system may be overlapped en route with that of exogenous GM1.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,DEPT MOLEC GLYCOBIOL,WAKO,SAITAMA 35101,JAPAN; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LAB,MACHIDA,TOKYO 194,JAPAN	RIKEN; Kyowa Kirin Ltd				Kurosawa, Nobuyuki/0000-0002-1548-4541				BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BYRNE MC, 1983, J NEUROCHEM, V41, P1214, DOI 10.1111/j.1471-4159.1983.tb00814.x; CUELLO AC, 1986, BRAIN RES, V376, P373, DOI 10.1016/0006-8993(86)90202-7; DOHERTY P, 1985, J NEUROCHEM, V44, P1259, DOI 10.1111/j.1471-4159.1985.tb08752.x; FACCI L, 1984, J NEUROCHEM, V42, P299, DOI 10.1111/j.1471-4159.1984.tb02678.x; FERRARI G, 1983, DEV BRAIN RES, V8, P215, DOI 10.1016/0165-3806(83)90006-8; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HIRABAYASHI Y, 1989, NEUROSCI LETT, V106, P193, DOI 10.1016/0304-3940(89)90225-5; KATOHSEMBA R, 1984, J NEUROSCI RES, V12, P299, DOI 10.1002/jnr.490120217; KOJIMA N, 1994, BIOCHEMISTRY-US, V33, P5772, DOI 10.1021/bi00185a014; LEBEL JM, 1994, P NATL ACAD SCI USA, V91, P2644, DOI 10.1073/pnas.91.7.2644; LEDEEN RW, 1984, J NEUROSCI RES, V12, P147, DOI 10.1002/jnr.490120204; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; LEON A, 1984, J NEUROSCI RES, V12, P277, DOI 10.1002/jnr.490120215; LEON A, 1982, DEV NEUROSCI-BASEL, V5, P108, DOI 10.1159/000112666; LESKAWA KC, 1985, J NEUROSCI RES, V13, P539, DOI 10.1002/jnr.490130409; MATTA SG, 1986, DEV BRAIN RES, V27, P243, DOI 10.1016/0165-3806(86)90250-6; Nagai Y, 1988, NEW TRENDS GANGLIOSI, P329; OHTA S, 1993, CANCER IMMUNOL IMMUN, V36, P260, DOI 10.1007/BF01740908; OHTA S, 1993, ANTICANCER RES, V13, P331; ROESNER H, 1987, NATO ASI SERIES H, V7, P373; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SKAPER SD, 1985, INT J DEV NEUROSCI, V3, P187, DOI 10.1016/0736-5748(85)90009-7; SKAPER SD, 1985, DEV BRAIN RES, V23, P19, DOI 10.1016/0165-3806(85)90003-3; Spoerri P E, 1983, Int J Dev Neurosci, V1, P383, DOI 10.1016/0736-5748(83)90020-5; Svennerholm L, 1980, Adv Exp Med Biol, V125, P533; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; TAGO H, 1986, J HISTOCHEM CYTOCHEM, V34, P1431, DOI 10.1177/34.11.2430009; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSUJI S, 1983, J BIOCHEM-TOKYO, V94, P303, DOI 10.1093/oxfordjournals.jbchem.a134344; TSUJI S, 1988, J NEUROCHEM, V50, P414, DOI 10.1111/j.1471-4159.1988.tb02928.x; VANITI G, 1988, BRAIN RES, V448, P252; VARKI A, 1991, CELL, V65, P56; VARON S, 1988, NEW TRENDS GANGLIOSI, P607; WIEGANDT H, 1967, J NEUROCHEM, V14, P671, DOI 10.1111/j.1471-4159.1967.tb09571.x; YAMASHITA T, 1991, Glycobiology, V1, P149, DOI 10.1093/glycob/1.2.149	38	93	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30451	30456						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982960				2022-12-25	WOS:A1994PU52500064
J	PAN, GH; GREENBLATT, J				PAN, GH; GREENBLATT, J			INITIATION OF TRANSCRIPTION BY RNA-POLYMERASE-II IS LIMITED BY MELTING OF THE PROMOTER DNA IN THE REGION IMMEDIATELY UPSTREAM OF THE INITIATION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MINIMAL SET; IDENTIFICATION; SUFFICIENT; PROTEINS; COMPLEX; RAP30; BIND	To further elucidate the mechanism of transcriptional initiation, we used synthetic oligonucleotides to prepare templates containing heteroduplex regions of varying size and location along the DNA of the adenovirus major late promoter. Unlike closed, linear DNA, or DNA with a downstream mismatch, DNA with a mismatch upstream of the initiation site only required the general factors TATA box-binding protein and transcription factor (TF) IIB to direct specific and accurate initiation in vitro by calf thymus RNA polymerase II. In the presence of TFIIF, initiation was possible on closed, linear DNA, but an upstream mismatch region still stimulated transcriptional initiation by more than 100-fold, leading to production of similar to 0.5 transcript/template in the absence of TFIIE, TFIIH, or ATP. The presence of a DNA mismatch was most effective in the -9 to -1 region; furthermore, stimulation by a mismatch did not require that the initiation site be included in the heteroduplex region. Efficient initiation at the immunoglobulin heavy chain promoter in the presence of TATA box-binding protein and TFIIB was also achieved when a mismatch region was introduced from -9 to +3. Our results suggest that initiation by RNA polymerase II in the absence of transcriptional activation is limited by melting of the promoter DNA upstream of the initiation site.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ON,CANADA; UNIV TORONTO,DEPT MED & MOLEC GENET,TORONTO M5G 1L6,ON,CANADA	University of Toronto; University of Toronto								BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; Coulombe Benoit, 1992, Gene Expression, V2, P99; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HA I, 1991, NATURE, V352, P688; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; TANTIN D, 1994, J BIOL CHEM, V269, P17397; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	23	100	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30101	30104						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982911				2022-12-25	WOS:A1994PU52500010
J	CHOW, LML; DAVIDSON, D; FOURNEL, M; GOSSELIN, P; LEMIEUX, S; LYU, MS; KOZAK, CA; MATIS, LA; VEILLETTE, A				CHOW, LML; DAVIDSON, D; FOURNEL, M; GOSSELIN, P; LEMIEUX, S; LYU, MS; KOZAK, CA; MATIS, LA; VEILLETTE, A			2 DISTINCT PROTEIN ISOFORMS ARE ENCODED BY NTK, A CSK-RELATED TYROSINE PROTEIN-KINASE GENE	ONCOGENE			English	Article							SRC FAMILY KINASES; RECEPTOR; P56LCK; AUTOPHOSPHORYLATION; PHOSPHORYLATES; ASSOCIATION; ACTIVATION; EXPRESSION; P50(CSK); P56(LCK)	Recently, we and others have cloned cDNAs encoding a second member of the Csk family of inhibitory tyrosine protein kinases, which we have termed Ntk. Intriguingly, the mouse ntk cDNA sequences published by two independent groups differed by the presence or absence of a 136 nucleotide-insert near their 5' ends. In this report, we demonstrate that this 136 nucleotide-sequence likely corresponds to a complete exon in the ntk gene (termed exon 2), and that the two types of cDNAs/transcripts are produced by alternative splicing. Using ribonuclease protection assays, it was also established that brain and lymphoid organs, as well as most hemopoietic cells, predominantly expressed ntk transcripts lacking exon 2. In contrast, selected hemopoietic cell lines, such as the immature myeloid cell lines 32D cl3(G) and WEHI-3B, exclusively possessed exon 2-bearing RNAs. Interestingly, exon 2 introduced a novel in-frame upstream AUG in the ntk transcript, which is in the appropriate context for translation initiation. Evidence was obtained that this AUG is utilized in vivo, and that it extends the amino-terminal sequence of Ntk by 40 amino acids. Indeed, while exon 2-deficient ntk RNAs were translated into a 52 kilodalton (kDa) polypeptide (p52(ntk)), those bearing exon 2 produced a 56 kDa protein (p56(ntk)). Furthermore, p56(ntk), but not p52(ntk), was recognized by an antiserum directed against the novel amino-terminal sequence encoded by exon 2. Additional biochemical characterizations showed that p52(ntk) and p56(ntk) were localized to the cytoplasm, and that they partially accumulated in the detergent-insoluble cellular fraction. This last finding suggested that the Ntk proteins can associate with the cytoskeleton. Finally, through linkage analysis of two multilocus crosses, the ntk gene was mapped to Chromosome 10 in the mouse. Taken together, these data showed that ntk, a csk-related tyrosine protein kinase gene, encodes two protein isoforms expressed in distinct cell types. Moreover, they raised the possibility that Ntk may be involved in the regulation of Src-Like enzymes in detergent-insoluble cellular compartments.	MCGILL UNIV,CTR CANC,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL H3G 1Y6,PQ,CANADA; UNIV QUEBEC,INST ARMAND FRAPPIER,CTR RECH IMMUNOL,LAVAL H7V 1B7,PQ,CANADA; NIAID,BETHESDA,MD 20892; ALEXION PHARMACEUT INC,NEW HAVEN,CT 06511; MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,PQ,CANADA; MONTREAL GEN HOSP,DEPT ONCOL,MONTREAL H3G 1A4,PQ,CANADA	McGill University; McGill University; McGill University; McGill University; University of Quebec; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); McGill University; McGill University				Chow, Lionel/0000-0001-8447-063X				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BRAUNINGER A, 1993, ONCOGENE, V8, P1365; CARTIER M, 1987, MOL CELL BIOL, V7, P1623, DOI 10.1128/MCB.7.5.1623; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOW LML, 1992, MOL CELL BIOL, V12, P1226, DOI 10.1128/MCB.12.3.1226; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Coligan JKA, 1991, CURRENT PROTOCOLS IM; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Gosselin Pierre, 1993, Molecular Immunology, V30, P1185, DOI 10.1016/0161-5890(93)90137-Z; Green EL, 1981, GENETICS PROBABILITY, P77; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAKE LE, 1994, IN PRESS GENOMICS; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEMIEUX S, 1991, CELL IMMUNOL, V134, P191, DOI 10.1016/0008-8749(91)90342-9; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARTANEN J, 1991, ONCOGENE, V6, P2013; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SAKANO S, 1994, ONCOGENE, V9, P1155; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	41	35	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3437	3448						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970703				2022-12-25	WOS:A1994PT39200005
J	FILMUS, J; ROBLES, AI; SHI, W; WONG, MJ; COLOMBO, LL; CONTI, CJ				FILMUS, J; ROBLES, AI; SHI, W; WONG, MJ; COLOMBO, LL; CONTI, CJ			INDUCTION OF CYCLIN D1 OVEREXPRESSION BY ACTIVATED RAS	ONCOGENE			English	Article							INTESTINAL EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; DEPENDENT KINASES; NUCLEAR-PROTEIN; EXPRESSION; FIBROBLASTS; ONCOGENE; G(1); G1; PROGRESSION	Activated ras genes are known to alter control of cell proliferation. This is consistent with the fact that ras proteins are a key component of the biochemical pathway triggered by ligand-bound cell surface receptors that are tyrosine kinases. Although an important part of the ras signaling pathway has been recently uncovered, the molecular target(s) that mediates the effects of ras on cell cycle control remains unknown. Cyclins and cyclin-dependent kinases are key molecules in the control of cell cycle. Cyclin D1, in particular, is a critical target for proliferative signals in G(1) and it has been shown that ectopic overexpression of this cyclin can significantly alter cell cycle regulation. Here we report that activated ras induces significant overexpression of cyclin D1 in epithelial cells derived from normal rat intestine and mouse mammary gland. A definitive causal role for activated ras in this overexpression is demonstrated by using intestinal cells transfected with an inducible ras expression vector. Treatment of the ras-transformed intestinal clones with anti-sense cyclin D1 oligonucleotides reduces their rate of cell proliferation indicating that the increment in cyclin D1 expression induced by activated ras is instrumental in the higher rate of cell proliferation conferred by the ras oncogene to the IEC cells. Based on these results we propose that, at least in certain cell types, cyclin D1 can be one of the mediators of the transforming action of activated ras.	UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON, CANADA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, DIV RES, HOUSTON, TX USA	University of Toronto; University of Texas System; UTMD Anderson Cancer Center	FILMUS, J (corresponding author), SUNNYBROOK HLTH SCI CTR, DIV CANC RES, S-218, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ON, CANADA.			Robles, Ana/0000-0001-5019-4374				ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; ARNOLD A, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63; ATCHISON ML, 1989, MOL CELL BIOL, V9, P2067, DOI 10.1128/MCB.9.5.2067; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FILMUS J, 1992, ONCOGENE, V7, P521; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QUARONI A, 1981, J NATL CANCER I, V67, P1353; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHAO JM, 1993, EXP CELL RES, V204, P82, DOI 10.1006/excr.1993.1011	42	280	282	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3627	3633						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970723				2022-12-25	WOS:A1994PT39200026
J	SHEIKH, MS; LI, XS; CHEN, JC; SHAO, ZM; ORDONEZ, JV; FONTANA, JA				SHEIKH, MS; LI, XS; CHEN, JC; SHAO, ZM; ORDONEZ, JV; FONTANA, JA			MECHANISMS OF REGULATION OF WAF1 CIP1 GENE-EXPRESSION IN HUMAN BREAST-CARCINOMA - ROLE OF P53-DEPENDENT AND INDEPENDENT SIGNAL-TRANSDUCTION PATHWAYS	ONCOGENE			English	Article							DNA-DAMAGING AGENTS; P53 PROTEIN EXPRESSION; WILD-TYPE P53; TRANSCRIPTIONAL ACTIVITY; CANCER CELLS; GROWTH; BINDING; SUPPRESSION; MUTATIONS; CYCLE	WAF1/Cip1 was recently identified as the wild-type p53 target that appears to mediate the tumor suppressing effects of p53. We investigated the mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma (HBC) cells. Our results demonstrate that the HBC cells harboring wild-type p53 express 26-33-fold higher WAF1/Cip1 mRNA levels than the cells harboring mutant p53. The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression. Serum starvation-induced growth arrest although not altering the endogenous p53 levels or its ability to transactivate the reporter gene, induced WAF1/Cip1 gene expression in cells carrying wild-type as well as mutant p53. These results further implicated the involvement of p53-independent signal transduction pathways in WAF1/Cip1 gene regulation. Our data also suggest that WAF1/Cip1 gene expression is tightly associated with cell cycle progression in cells containing either wild-type or mutant p53. WAF1/Cip1 expression was transiently induced in response to serum treatment and declined as the cells passed through the S-phase of the cell cycle. We thus provide evidence that the mechanisms of WAF1/Cip1 gene regulation involve p53-dependent and independent signaling pathways in HBC.	UNIV MARYLAND,SCH MED,DEPT MED,DIV ONCOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR CANC,BALTIMORE,MD 21201; VET ADM MED CTR,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Fontana, Joseph/0000-0003-3829-3358	NATIONAL CANCER INSTITUTE [R01CA063335] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63335] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JY, 1993, ONCOGENE, V8, P2159; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MCGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253; MICHIELI P, 1994, CANCER RES, V54, P3391; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SHEIKH MS, 1993, ANTICANCER RES, V13, P1387; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1993, J CELL PHYSIOL, V155, P556, DOI 10.1002/jcp.1041550314; TISHLER RB, 1993, CANCER RES, V53, P2212; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1993, J CELL SCI, V105, P607; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V7, P1126; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG W, 1993, CANCER RES, V53, P4772; ZHANG W, 1993, ONCOGENE, V8, P2555	38	246	248	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3407	3415						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970699				2022-12-25	WOS:A1994PT39200001
J	GRINIUS, LL; GOLDBERG, EB				GRINIUS, LL; GOLDBERG, EB			BACTERIAL MULTIDRUG-RESISTANCE IS DUE TO A SINGLE MEMBRANE-PROTEIN WHICH FUNCTIONS AS A DRUG PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; DISINFECTANT RESISTANCE; P-GLYCOPROTEIN; ANTIMICROBIAL RESISTANCE; NUCLEOTIDE-SEQUENCE; LAC PERMEASE; GENE; RECONSTITUTION; PURIFICATION	Multidrug transport system in proteoliposomes was reconstituted using the highly purified membrane transport protein responsible for bacterial multidrug resistance. This protein (named Smr, for staphylococcal multidrug resistance) consists of 107 amino acid residues and displays four putative transmembrane domains. The Smr protein was tagged with a FLAG epitope, and the modified protein was expressed, purified, characterized, and reconstituted into proteoliposomes. With this in vitro experimental system, it has been demonstrated that a highly purified multidrug resistance protein functions as a drug pump, which transports methyltriphenylphosphonium actively against a 10(3)-fold concentration gradient. Delta<(mu)over tilde>(H+) was shown 60 be a driving force, and an electrogenic drug/proton antiport was suggested as the molecular mechanism of the drug transport. Of the 2 Glu residues in putative extramembrane loops of the Smr polypeptide chain, Glu-24 was shown to be involved in determining the specificity of drug resistance. Replacement of both of these Glu residues with Asp produced active Smr. In contrast, Smr was unable to protect cells from multiple drugs when a Glu-13 --> Asp-13 replacement was made. We suggest that Glu-13, a unique acidic residue located in the hydrophobic domain of Smr, is directly involved in the drug/proton antiport.	TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,BOSTON,MA 02111	Tufts University								AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; AUSUBEL FM, 1990, CURRENNT PROTOCOLS M; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; COHEN SP, 1993, J BACTERIOL, V175, P1484, DOI 10.1128/JB.175.5.1484-1492.1993; COLE ST, 1987, EUR J BIOCHEM, V167, P481, DOI 10.1111/j.1432-1033.1987.tb13362.x; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GREENER T, 1993, EMBO J, V12, P889, DOI 10.1002/j.1460-2075.1993.tb05729.x; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; GRINIUS LL, 1987, ENERGY TRANSDUCTION; GROS P, 1992, BIOCHEMISTRY-US, V31, P1992, DOI 10.1021/bi00122a014; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; LITTLEJOHN TG, 1991, GENE, V101, P59, DOI 10.1016/0378-1119(91)90224-Y; LITTLEJOHN TG, 1992, FEMS MICROBIOL LETT, V95, P259; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; LYON BR, 1987, MICROBIOL REV, V51, P88, DOI 10.1128/MMBR.51.1.88-134.1987; MIDGLEY M, 1987, MICROBIOL SCI, V4, P125; MORIMYO M, 1992, NUCLEIC ACIDS RES, V20, P3159, DOI 10.1093/nar/20.12.3159; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PAULSEN IT, 1993, ANTIMICROB AGENTS CH, V37, P761, DOI 10.1128/AAC.37.4.761; PERRIN S, 1990, NUCLEIC ACIDS RES, V18, P7433, DOI 10.1093/nar/18.24.7433; PUREWAL AS, 1991, FEMS MICROBIOL LETT, V68, P73; ROUCH DA, 1990, MOL MICROBIOL, V4, P2051, DOI 10.1111/j.1365-2958.1990.tb00565.x; Sambrook J, 1989, MOL CLONING LABORATO; SASATSU M, 1989, NUCLEIC ACIDS RES, V17, P10103, DOI 10.1093/nar/17.23.10103; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TENNENT JM, 1989, J GEN MICROBIOL, V135, P1; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429	36	118	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29998	30004						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7962000				2022-12-25	WOS:A1994PU28400104
J	UMEZU, K; KOLODNER, RD				UMEZU, K; KOLODNER, RD			PROTEIN INTERACTIONS IN GENETIC-RECOMBINATION IN ESCHERICHIA-COLI - INTERACTIONS INVOLVING RECO AND RECR OVERCOME THE INHIBITION OF RECA BY SINGLE-STRANDED DNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS RECOMBINATION; GENE-32 PROTEIN; UVSX-PROTEIN; SSB PROTEIN; BACTERIOPHAGE-T4; MUTANT; PURIFICATION; EXCHANGE; CLONING; CHROMATOGRAPHY	RecA promotes homologous pairing of single-stranded DNA (ssDNA) with double-stranded DNA (dsDNA). This reaction occurs inefficiently if the ssDNA substrate is preincubated with Escherichia coli ssDNA-binding protein (SSB). However, RecO and RecR can act together as accessory factors for RecA to overcome this inhibition by SSB (Umezu, It., Chi, N.-W, and Kolodner, R. D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3875-3879). To elucidate the mechanism that underlies this process, we examined protein-protein interactions between Reck RecF, RecO, RecR, and SSB, and characterized the structure and activity of the ssDNA complexes formed with different combinations of these proteins. We obtained the following results. (i) RecO physically interacts with both RecR and SSB. The interaction between RecO and SSB is stronger than the RecO-RecR interaction. (ii) RecO and RecR do not remove SSB from SSB.ssDNA complexes, but instead bind to these complexes. The resulting RecO.RecR.SSB.ssDNA complexes were more active in Reck-mediated joint molecule formation than were SSB.ssDNA complexes. (iii) RecA can nucleate on the RecO.RecR.SSB.ssDNA complexes more efficiently than on SSB.ssDNA complexes. (iv) When RecA presynaptic filaments were formed in the presence of SSB, RecO, and RecR, the protein-DNA complexes obtained contained 70% of the amount of RecA required to saturate ssDNA These complexes, however, can mediate joint molecule formation and strand exchange as efficiently as presynaptic filaments which are fully saturated with Reck Based on these results, we propose dual roles for RecO and RecR in joint molecule formation. First, RecO and RecR bind to SSB.ssDNA complexes and modify their structure to allow RecA to nucleate on them efficiently. Second, RecO and RecR are retained in RecA presynaptic filaments and play a role in the subsequent homologous pairing process promoted by RecA.	DANA FARBER CANC INST,DIV CELL & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026017, R01GM026017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; BLANAR MA, 1984, P NATL ACAD SCI-BIOL, V81, P4622, DOI 10.1073/pnas.81.15.4622; CHASE JW, 1984, J BIOL CHEM, V259, P805; CHOW SA, 1988, J BIOL CHEM, V263, P200; CLARK AJ, 1991, BIOCHIMIE, V73, P523, DOI 10.1016/0300-9084(91)90124-J; COX MM, 1982, J BIOL CHEM, V257, P8523; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1984, COLD SPRING HARB SYM, V49, P363, DOI 10.1101/SQB.1984.049.01.043; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; GRIFFIN TJ, 1990, J BACTERIOL, V172, P6921; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HASHIMOTO K, 1991, J BIOL CHEM, V266, P4883; HINTON DM, 1986, J BIOL CHEM, V261, P5663; HORII T, 1980, P NATL ACAD SCI-BIOL, V77, P313, DOI 10.1073/pnas.77.1.313; JIANG H, 1993, J BIOL CHEM, V268, P7904; KODADEK T, 1989, J BIOL CHEM, V264, P16451; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LLOYD RG, 1987, MOL GEN GENET, V209, P135, DOI 10.1007/BF00329848; LUISIDELUCA C, 1994, J MOL BIOL, V236, P124, DOI 10.1006/jmbi.1994.1123; MADIRAJU MVVS, 1988, P NATL ACAD SCI USA, V85, P6592, DOI 10.1073/pnas.85.18.6592; MAHAJAN SK, 1988, GENETIC RECOMBINATIO, P87; MAHDI AA, 1989, NUCLEIC ACIDS RES, V17, P6781, DOI 10.1093/nar/17.17.6781; MAHDI AA, 1989, MOL GEN GENET, V216, P503, DOI 10.1007/BF00334397; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MOREAU PL, 1988, J BACTERIOL, V170, P2493, DOI 10.1128/jb.170.6.2493-2500.1988; MORRISON PT, 1989, J BACTERIOL, V171, P3641, DOI 10.1128/jb.171.7.3641-3649.1989; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; RADDING CM, 1988, GENETIC RECOMBINATIO, P87; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P4274, DOI 10.1073/pnas.78.7.4274; SANCAR A, 1980, P NATL ACAD SCI-BIOL, V77, P2611, DOI 10.1073/pnas.77.5.2611; SAWITZKE JA, 1992, GENETICS, V130, P7; SMITH GR, 1988, MICROBIOL REV, V52, P1; THRESHER RJ, 1988, J MOL BIOL, V201, P101, DOI 10.1016/0022-2836(88)90442-1; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; VOLKERT MR, 1984, J BACTERIOL, V157, P498, DOI 10.1128/JB.157.2.498-506.1984; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	45	219	221	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					30005	30013						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7962001				2022-12-25	WOS:A1994PU28400105
J	SCHRAVEN, B; SCHOENHAUT, D; BRUYNS, E; KORETZKY, G; ECKERSKORN, C; WALLICH, R; KIRCHGESSNER, H; SAKORAFAS, P; LABKOVSKY, B; RATNOFSKY, S; MEUER, S				SCHRAVEN, B; SCHOENHAUT, D; BRUYNS, E; KORETZKY, G; ECKERSKORN, C; WALLICH, R; KIRCHGESSNER, H; SAKORAFAS, P; LABKOVSKY, B; RATNOFSKY, S; MEUER, S			LPAP, A NOVEL 32-KDA PHOSPHOPROTEIN THAT INTERACTS WITH CD45 IN HUMAN-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; PROTEIN-TYROSINE-PHOSPHATASE; LEUKOCYTE-COMMON ANTIGEN; MEDIATED SIGNAL TRANSDUCTION; KINASE-ACTIVITY; PHOSPHOTYROSINE PHOSPHATASE; ALTERNATIVE PATHWAY; ACTIVATION; FAMILY; PHOSPHORYLATION	CD45, a leukocyte-specific protein tyrosine phosphatase involved in signal transduction, has previously been shown to associate with a 32-kDa phosphoprotein in human T-lymphocytes and T-lymphoma cell lines. The 32-kDa protein was purified and its coding cDNA cloned. Since expression of the protein was found to be restricted to B- and T-lymphocytes it was termed LPAP (lymphocyte phosphatase-associated phosphoprotein). LPAP exists in two differentially phosphorylated forms in resting human T-lymphocytes c, both of which undergo alterations during T-lymphocyte activation. Analysis of LPAP protein and mRNA expression in CD45-deficient mutant T-cell lines suggests that LPAP protein is subjected to degradation in the absence of its binding partner, CD45. Stable expression of LPAP protein seems to require particular portions of CD45 distinct from the phosphatase domains. In pervanadate-treated human T-lymphocytes LPAP undergoes phosphorylation on tyrosine residues in vivo. Since tyrosine phosphorylation of LPAP is undetectable in T-lymphocytes expressing enzymatically active CD45, these data suggest that LPAP likely represents a novel substrate for CD45.	BASF BIORES CORP,WORCESTER,MA 01605; UNIV IOWA,COLL MED,IOWA CITY,IA 52242; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	BASF; University of Iowa; Max Planck Society	SCHRAVEN, B (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,DEPT APPL IMMUNOL,FSP4,NEUENHEIMER FELD 280,D-69120 HEIDELBERG,GERMANY.		Koretzky, Gary/AAU-5381-2021					APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2929; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P1967; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DEUSCH K, 1986, EUR J IMMUNOL, V16, P1433, DOI 10.1002/eji.1830161119; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HUANG S, 1990, NUCLEIC ACIDS RES, V18, P7; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOEBIUS U, 1990, EUR J IMMUNOL, V20, P889, DOI 10.1002/eji.1830200426; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OOSTERGARD HL, 1989, P NATL ACAD SCI USA, V86, P8959; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; PEYRON JF, 1991, INT IMMUNOL, V3, P1357, DOI 10.1093/intimm/3.12.1357; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; ROSEL F, 1994, J VIROL, V68, P2142; ROSS SE, 1994, BIOCHEM BIOPH RES CO, V198, P88, DOI 10.1006/bbrc.1994.1013; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; Sambrook J, 1989, MOL CLONING LABORATO; SCHEIDTMANN KH, 1990, PROTEIN STRUCTURE PR, P93; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1989, EUR J IMMUNOL, V19, P397, DOI 10.1002/eji.1830190226; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TAKEDA A, 1994, J BIOL CHEM, V269, P2357; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; THOMAS ML, 1988, IMMUNOL TODAY, V9, P320, DOI 10.1016/0167-5699(88)91326-6; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415	58	73	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29102	29111						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961877				2022-12-25	WOS:A1994PU16800087
J	BABA, T; AZUMA, S; KASHIWABARA, S; TOYODA, Y				BABA, T; AZUMA, S; KASHIWABARA, S; TOYODA, Y			SPERM FROM MICE CARRYING A TARGETED MUTATION OF THE ACROSIN GENE CAN PENETRATE THE OOCYTE ZONA-PELLUCIDA AND EFFECT FERTILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSIN-LIKE ACTIVITY; CDNA SEQUENCE; BOAR SPERMATOZOA; BINDING-PROTEIN; PROACROSIN; PURIFICATION; ACTIVATION; EXPRESSION; SPERMATOGENESIS; IDENTIFICATION	The physiological function of mammalian sperm acrosin has long been believed to be involved in the limited proteolysis of the oocyte zona pellucida, thus enabling the sperm to penetrate this extracellular matrix and to gain access to the oocyte plasma membrane. Here we show that male mice homozygous for a targeted mutation in the mouse acrosin gene are still fertile in spite of the complete absence of acrosin protease activity in the sperm. In vitro fertilization assays verified that sperm from the homozygous mutant mice penetrate the zona pellucida and effect fertilization. Therefore, acrosin is not essential for both sperm penetration of the zona pellucida and fertilization.	UNIV TOKYO,INST MED SCI,DEPT REPROD & DEV BIOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo	BABA, T (corresponding author), UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN.							ARBOLEDA CE, 1987, J EXP ZOOL, V244, P277, DOI 10.1002/jez.1402440212; AZUMA S, 1991, Japanese Journal of Animal Reproduction, V37, P37; BABA T, 1989, J BIOL CHEM, V264, P11920; BABA T, 1989, FEBS LETT, V244, P296, DOI 10.1016/0014-5793(89)80549-6; BABA T, 1989, BIOCHEM BIOPH RES CO, V160, P1026, DOI 10.1016/S0006-291X(89)80105-6; BABA T, 1994, J BIOL CHEM, V269, P10133; BROWN CR, 1983, J REPROD FERTIL, V69, P289, DOI 10.1530/jrf.0.0690289; HEDRICK JL, 1989, BIOCATALYSIS AGR BIO, P215; JONES R, 1987, EXP CELL RES, V171, P503, DOI 10.1016/0014-4827(87)90182-0; KASHIWABARA S, 1990, J BIOCHEM-TOKYO, V108, P785, DOI 10.1093/oxfordjournals.jbchem.a123281; KLEMLING H, 1991, DNA SEQUENCE, V2, P57; KLEMM U, 1991, HUM GENET, V87, P635; KLEMM U, 1990, DIFFERENTIATION, V42, P160, DOI 10.1111/j.1432-0436.1990.tb00757.x; KOYAMA Y, 1984, J REPROD IMMUNOL, V6, P141, DOI 10.1016/0165-0378(84)90019-6; KREMLING H, 1991, GENOMICS, V11, P828, DOI 10.1016/0888-7543(91)90005-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; POLAKOSKI KL, 1977, J BIOL CHEM, V252, P1888; SALING PM, 1981, P NATL ACAD SCI-BIOL, V78, P6231, DOI 10.1073/pnas.78.10.6231; SAWADA H, 1984, J BIOL CHEM, V259, P2900; SAWAI S, 1991, NEW BIOL, V3, P861; SIEGEL MS, 1985, BIOL REPROD, V32, P713, DOI 10.1095/biolreprod32.3.713; SIEGEL MS, 1987, BIOL REPROD, V36, P1063, DOI 10.1095/biolreprod36.4.1063; TOPFERPETERSEN E, 1987, FEBS LETT, V226, P18; URCH UA, 1991, DEVELOPMENT, V111, P1165; WATANABE K, 1991, J BIOCHEM-TOKYO, V109, P828, DOI 10.1093/oxfordjournals.jbchem.a123466; WOLF DP, 1977, J EXP ZOOL, V199, P149, DOI 10.1002/jez.1401990117; Yanagimachi R., 1994, P189; YI LSH, 1992, ANDROLOGIA, V24, P41; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]; Zaneveld L.J.D., 1975, PROTEINASE BIOL CONT, P236	31	304	311	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31845	31849						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989357				2022-12-25	WOS:A1994PX30300079
J	CHAN, H; AGGARWAL, BB				CHAN, H; AGGARWAL, BB			ROLE OF TUMOR-NECROSIS-FACTOR RECEPTORS IN THE ACTIVATION OF NUCLEAR FACTOR KAPPA-B IN HUMAN HISTIOCYTIC LYMPHOMA U-937 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HIGH-AFFINITY RECEPTORS; CYTO-TOXIC RESPONSE; FACTOR-ALPHA; MOLECULAR-CLONING; INTRACELLULAR ROLE; DOWN-REGULATION; EXPRESSION; TRANSCRIPTION; MACROPHAGES	Tumor necrosis factor (TNF) has been shown to mediate numerous cellular responses through its interaction with two distinct types of receptor. However, the relationship between TNF receptor and the biological response is not well understood. Modulation of the number of cell surface receptors by various agents has shown a lack of direct correlation with biological responses to the cytokine. In this report, we used several approaches to investigate the relationship between TNF receptor number and an early response in human histiocytic lymphoma U-937 cells. When we examined the activation of the nuclear transcription factor kappa B (NF-kappa B), an event mediated by TNF within 10-15 min, we discovered a correlation between TNF receptor occupancy up to a certain threshold and the extent of activation of the transcription factor, In addition, by kinetically down-regulating TNF receptor expression with phorbol esters, cycloheximide, or trypsin, we determined that receptors were necessary for transduction of the TNF signal. However, 10-25% of total receptors were sufficient for optimum induction of the NF-kappa B signal. When examined in different cell lines, the activation of an early biological response was found to be related not only to the TNF receptor number but also to the type of TNF receptor. These results, overall, suggest that although TNF receptors are essential for induction of NF-kappa B, a small percentage is sufficient to fully transduce this signal.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,CYTOKINE RES LAB,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					AGGARWAL BB, 1987, J BIOL CHEM, V262, P10000; AGGARWAL BB, 1986, J BIOL CHEM, V261, P3652; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1987, J BIOL CHEM, V262, P16450; BAGLIONI C, 1985, J BIOL CHEM, V260, P3395; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CHATURVEDI MM, 1994, LYMPHOKINE CYTOK RES, V13, P309; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; DING AH, 1989, J BIOL CHEM, V264, P3924; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; FIDLER IJ, 1985, J IMMUNOL, V135, P4289; HASS PE, 1985, J BIOL CHEM, V260, P2214; HIGUCHI M, 1993, J BIOL CHEM, V268, P5624; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON SE, 1988, J BIOL CHEM, V263, P5686; KAGAN BL, 1992, SCIENCE, V255, P1427, DOI 10.1126/science.1371890; KILLION JJ, 1989, J NATL CANCER I, V81, P1387, DOI 10.1093/jnci/81.18.1387; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LIN YZJ, 1992, P NATL ACAD SCI USA, V89, P9691, DOI 10.1073/pnas.89.20.9691; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MILLER DS, 1988, SCIENCE, V240, P506, DOI 10.1126/science.2451860; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; PANG XP, 1989, ENDOCRINOLOGY, V125, P599; RUGGIERO V, 1987, J IMMUNOL, V138, P2711; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH MR, 1990, J IMMUNOL, V144, P1777; SMITH MR, 1990, J IMMUNOL, V144, P162; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; TSUJIMOTO M, 1987, J BIOCHEM-TOKYO, V102, P1571, DOI 10.1093/oxfordjournals.jbchem.a122206	40	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31424	31429						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989309				2022-12-25	WOS:A1994PX30300018
J	JARVIS, WD; FORNARI, FA; BROWNING, JL; GEWIRTZ, DA; KOLESNICK, RN; GRANT, S				JARVIS, WD; FORNARI, FA; BROWNING, JL; GEWIRTZ, DA; KOLESNICK, RN; GRANT, S			ATTENUATION OF CERAMIDE-INDUCED APOPTOSIS BY DIGLYCERIDE IN HUMAN MYELOID-LEUKEMIA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HL-60 CELLS; INTERNUCLEOSOMAL FRAGMENTATION; PHORBOL ESTER; DNA; DEATH; DIFFERENTIATION; INHIBITION; CLEAVAGE; LINE	Prior studies demonstrated that increased intracellular availability of ceramide induces apoptotic DNA degradation and cell death in the human leukemia cell lines HL-60 and U937 (Jarvis, W.D., Kolesnick, R.N., Fornari, F.A., Traylor, R.S., Gewirtz, D.A., and Grant, S. (1994) Proc. Natl. Acad, Sci. U.S.A. 91, 73-77), The present findings show that diglyceride opposes ceramide-related apoptosis in HL-60 and U937 cells, Acute (6-12-h) exposure to sphingomyelinase (100 milliunits/ml) or synthetic ceramide (10 mu M) promoted apoptotic degradation of genomic DNA as indicated by (a) the appearance of both similar to 50-kilobase pair (kbp) DNA fragments and similar to 0.2-1.2-kbp DNA fragment ladders on agarose gels, (b) formation and release of small double-stranded DNA fragments, and (c) loss of integrity of bulk DNA, DNA damage was associated with reduced clonogenicity and expression of apoptotic morphology, In contrast, exposure to phospholipase C (0.001-100 milliunits/ml) or synthetic diglyceride (10 mu M) failed to promote apoptosis and abolished the lethal actions of ceramide as defined by each of the indices outlined above, Ceramide-related apoptosis was also reduced by acute (6-h) exposure to tumor promoters such as phorbol dibutyrate and mezerein and the non-tumor-promoting agent bryostatin I; conversely, chronic (24-h) pretreatment with these agents failed to modify ceramide-mediated cytotoxicity, but abolished the protective actions of diglyceride, These findings demonstrate that diglyceride and pharmacological protein kinase C activators reduce or abolish ceramide-mediated apoptosis in human leukemia cells and support the concept of a cytoprotective function for protein kinase C in the regulation of leukemic cell survival, In addition, the capacity of diglyceride to prevent very early genomic lesions (e.g. generation of 50-kbp DNA fragments) suggests that acute activation of protein kinase C arrests apoptosis at an initial stage,	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED CHEM, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, RICHMOND, VA 23298 USA; CORNELL UNIV, COLL MED, SLOAN KETTERING INST, PROGRAM MOLEC PHARMACOL, NEW YORK, NY 10021 USA	Virginia Commonwealth University; Virginia Commonwealth University; Cornell University; Memorial Sloan Kettering Cancer Center	JARVIS, WD (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA,MED HEM,ONC,DEPT MED, BOX 230 MCV STN, RICHMOND, VA 23298 USA.				NCI NIH HHS [CA-63753, CA-16059, CA-57400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063753, R01CA057400, P30CA016059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BROWN DG, 1993, J BIOL CHEM, V268, P3037; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DELBINO G, 1994, LEUKEMIA, V8, P281; DIVE C, 1993, P AM ASSOC CANC RES, V34, P516; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; EASTMAN A, 1992, CANCER INVEST, V10, P229, DOI 10.3109/07357909209032765; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GRANT S, 1994, ONCOL RES, V6, P87; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1993, ADV LIPID RES, V25, P43; ISAKOV N, 1993, J IMMUNOL, V150, P1195; JARVIS WD, 1994, BIOCHEM PHARMACOL, V47, P839; JARVIS WD, 1994, CANCER RES, V54, P1707; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KHARBANDA S, 1991, BIOCHEMISTRY-US, V30, P7947, DOI 10.1021/bi00246a011; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KRAUSE JR, 1987, AM J CLIN PATHOL, V87, P419; KUCERA GL, 1992, CANCER RES, V52, P3886; LOTEM J, 1991, BLOOD, V78, P953; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MAY WS, 1993, BLOOD S, V82, P1738; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MIYASHITA T, 1993, BLOOD, V81, P151; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; PETTIT GR, 1970, NATURE, V227, P962, DOI 10.1038/227962a0; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SOLARY E, 1993, BLOOD, V81, P1359; STONE RM, 1988, BLOOD, V72, P739; STRUM JC, 1994, J BIOL CHEM, V269, P15493; SUGAMA S, 1991, BRAIN DEV-JPN, V13, P104, DOI 10.1016/S0387-7604(12)80116-1; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; WYLLIE AH, 1986, CELL DEATH BIOL PATH, P9	44	165	170	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31685	31692						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989341				2022-12-25	WOS:A1994PX30300057
J	KIM, YG; LI, L; CHANDRASEGARAN, S				KIM, YG; LI, L; CHANDRASEGARAN, S			INSERTION AND DELETION MUTANTS OF FOKI RESTRICTION-ENDONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODIFICATION SYSTEM; DNA-BINDING; CLEAVAGE; RECOGNITION; SEQUENCE; ENZYMES; DOMAINS; SITES	FokI restriction endonuclease recognizes the nonpalindromic pentadeoxyribonucleotide, 5'-GGATG-3':5'CATCC-3' in duplex DNA and cleaves 9 and 13 nucleotides away from the recognition site, We have reported the presence of two distinct and separable protein domains within this enzyme: one for the sequence-specific recognition of DNA (the DNA binding domain) and the other for the endonucleases activity (the cleavage domain), Our studies have suggested that the two domains are connected by a linker region, which appears to be amenable for repositioning of the DNA-sequence recognition domain with respect to the catalytic domain, Here, we report the construction of several insertion (4-, 8-, 12-, 18-, 19-, or 23-amino acid residues) and deletion (4- or 7-amino acid residues) mutants of the linker region of FokI endonuclease. The mutant enzymes were purified, and their cleavage properties were characterized, The mutants have the same DNA sequence specificity as the wild-type enzyme, However, compared with the wild-type enzyme, the insertion mutants cleave predominantly one nucleotide further away from the recognition site on both strands of the DNA substrate, The four-codon deletion mutant shows relaxed specificity at the cut site while the seven-codon deletion appears to inactivate the enzyme, The DNA binding and cleavage domains of FokI appear to be Linked by a relatively malleable linker, No simple linear relationship exists between the linker length and the distance of the cut site from the recognition site, Furthermore, the four-codon insertion mutants cleave DNA substrates containing hemi-methylated FokI sites; they do not cleave fully methylated substrates, These results are best explained as a consequence of protein-protein interactions between the domains.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT ENVIRONM HLTH SCI,BALTIMORE,MD 21205	Johns Hopkins University					NIGMS NIH HHS [GM 42140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KACZOROWSKI T, 1989, GENE, V80, P209, DOI 10.1016/0378-1119(89)90285-0; KIM YG, 1994, P NATL ACAD SCI USA, V91, P883, DOI 10.1073/pnas.91.3.883; KITA K, 1989, J BIOL CHEM, V264, P5751; KITA K, 1989, NUCLEIC ACIDS RES, V17, P8741, DOI 10.1093/nar/17.21.8741; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1993, GENE, V133, P79, DOI 10.1016/0378-1119(93)90227-T; LI L, 1992, P NATL ACAD SCI USA, V89, P4275, DOI 10.1073/pnas.89.10.4275; LI L, 1993, P NATL ACAD SCI USA, V90, P2764, DOI 10.1073/pnas.90.7.2764; LOONEY MC, 1989, GENE, V80, P193, DOI 10.1016/0378-1119(89)90284-9; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; PODHAJSKA AJ, 1985, GENE, V40, P175, DOI 10.1016/0378-1119(85)90040-X; PRICE C, 1989, J MOL BIOL, V205, P115, DOI 10.1016/0022-2836(89)90369-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKOWRON P, 1993, GENE, V125, P1, DOI 10.1016/0378-1119(93)90738-O; SUGIMURA H, 1992, J COMPUT ASSIST TOMO, V16, P73, DOI 10.1097/00004728-199201000-00013; SZYBALSKI W, 1991, GENE, V100, P13, DOI 10.1016/0378-1119(91)90345-C; SZYBALSKI W, 1985, GENE, V40, P169, DOI 10.1016/0378-1119(85)90039-3; WAUGH DS, 1993, P NATL ACAD SCI USA, V90, P9596, DOI 10.1073/pnas.90.20.9596; WAUGH DS, 1994, J BIOL CHEM, V269, P12298	20	31	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31978	31982						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989374				2022-12-25	WOS:A1994PX30300098
J	BENJAMIN, CW; JONES, DA				BENJAMIN, CW; JONES, DA			PLATELET-DERIVED GROWTH-FACTOR STIMULATES GROWTH-FACTOR RECEPTOR-BINDING PROTEIN-2 ASSOCIATION WITH SHC IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE-C-GAMMA; TYROSINE KINASES; SIGNAL TRANSDUCTION; BETA-SUBUNIT; PHOSPHATIDYLINOSITOL-3 KINASE; PHOSPHORYLATION SITES; MITOGENIC SIGNAL; GRB2; RAS	Platelet-derived growth factor (PDGF) stimulates smooth muscle cell proliferation and migration in vascular disorders such as atherosclerosis and restenosis. Growth factor receptor binding protein-2 (GRB2) and Shc have been shown to link growth factor receptor activation with guanine nucleotide exchange on p21-ras. We have examined this pathway in cultures of rat A10 vascular smooth muscle cells. Our data demonstrate that PDGF stimulates tyrosine phosphorylation on Shc in a concentration- and time-dependent manner that parallels PDGF beta-receptor activation. Immunoprecipitates of Shc from cells exposed to PDGF revealed Shc.GRB2 complexes. She immune complexes also contained PDGF beta-receptors. Complex formation was maximal with 30 ng/ml PDGF and peaked within 10 min of exposure. Although PDGF beta-receptors contain a putative GRB2 binding site, activated receptors failed to bind GRB2 directly. Evaluation of Shc from membrane and cytosolic fractions of A10 cells showed little redistribution of Shc following PDGF exposure. Cytosolic Shc bound only GRB2, whereas, membrane-associated Shc complexed with GRB2, the PDGF beta-receptor, Src, and additional tyrosine phosphorylated proteins. We conclude that Shc serves as a primary docking protein for GRB2 in smooth muscle cells and is critical for proliferation in response to PDGF.	UPJOHN CO,CARDIOVASC PHARMACOL,KALAMAZOO,MI 49001	Pfizer								BOBIK A, 1993, PHARMACOL REV, V45, P1; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	40	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30911	30916						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983024				2022-12-25	WOS:A1994PV51000030
J	LEECK, CL; FORNEY, JD				LEECK, CL; FORNEY, JD			THE UPSTREAM REGION IS REQUIRED BUT NOT SUFFICIENT TO CONTROL MUTUALLY EXCLUSIVE EXPRESSION OF PARAMECIUM SURFACE-ANTIGEN GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAURELIA; PRIMAURELIA; DNA; PROTEINS; SEQUENCE	Paramecium tetraurelia stock 51 can express at least 11 different surface antigens, yet only one type is found on the surface of a cell at any given time. The mechanism that controls this mutually exclusive expression is unknown. A previous study has shown that the 51A surface antigen gene is regulated at the level of transcription (Gilley, D., Rudman, B. M., Preer, J. R., Jr., and Polisky, B. (1990) Mol. Cell. Biol. 10, 1538-1544). We show here that the 51B surface antigen gene is also transcriptionally regulated, and when the 51A and 51B genes are cotransformed into an A(-), B- mutant, the 51A antigen is dominant at 27 degrees C just as in wild type cells. We have utilized this cotransformation system to experimentally determine that 273 base pairs of DNA upstream of the 51A gene is sufficient to allow the dominant expression of A, but 150 base pairs is not adequate. A hybrid gene that contains the upstream region of 51B attached to the 51A transcribed region was cotransformed with the 51B gene into the A(-), B- mutant. Despite containing the same upstream sequences, only the hybrid 51B/A was transcribed at 27 degrees C. These results suggest the upstream region is required but not sufficient for mutually exclusive transcriptional control.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus			Forney, James/D-8314-2018	Forney, James/0000-0002-6144-732X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043357] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43357] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAPDEVILLE Y, 1979, IMMUNOGENETICS, V9, P77, DOI 10.1007/BF01570395; CAPDEVILLE Y, 1979, J CELL PHYSIOL, V99, P383, DOI 10.1002/jcp.1040990313; CAPDEVILLE Y, 1971, MOL GEN GENET, V112, P306, DOI 10.1007/BF00334432; CARON F, 1989, ANNU REV MICROBIOL, V43, P23, DOI 10.1146/annurev.micro.43.1.23; DELBRUCK M, 1949, C N R S PARIS, V7, P33; EPSTEIN LM, 1984, MOL CELL BIOL, V4, P1583, DOI 10.1128/MCB.4.8.1583; FINGER I, 1974, PARAMECIUM, P147; FORNEY JD, 1983, MOL CELL BIOL, V3, P466, DOI 10.1128/MCB.3.3.466; GILLEY D, 1990, MOL CELL BIOL, V10, P1538, DOI 10.1128/MCB.10.4.1538; GODISKA R, 1987, MOL GEN GENET, V208, P529, DOI 10.1007/BF00328151; GODISKA R, 1987, P NATL ACAD SCI USA, V84, P7590, DOI 10.1073/pnas.84.21.7590; KIM CS, 1992, DEV GENET, V13, P97; MARGOLIN P, 1956, GENETICS, V41, P685; MARTIN LD, 1994, DEV GENET, V15, P443, DOI 10.1002/dvg.1020150507; NIELSEN E, 1991, J MOL BIOL, V222, P835, DOI 10.1016/0022-2836(91)90573-O; PRAT A, 1986, J MOL BIOL, V189, P47, DOI 10.1016/0022-2836(86)90380-3; Preer J.R. Jr, 1986, P301; PREER JR, 1981, P NATL ACAD SCI-BIOL, V78, P6776, DOI 10.1073/pnas.78.11.6776; PREER JR, 1968, RES PROTOZOOL, P219; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; RUDMAN B, 1991, GENETICS, V129, P47; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT HJ, 1987, MOL GEN GENET, V208, P450, DOI 10.1007/BF00328138; SCOTT J, 1993, GENETICS, V133, P189; SCOTT JM, 1994, MOL CELL BIOL, V14, P2479, DOI 10.1128/MCB.14.4.2479; SMITH DL, 1992, J PROTOZOOL, V39, P628, DOI 10.1111/j.1550-7408.1992.tb04862.x; Sommerville J., 1970, Adv. microb. Physiol., V4, P131; SONNEBORN TM, 1950, J EXP ZOOL, V113, P87, DOI 10.1002/jez.1401130106	28	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31283	31288						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983073				2022-12-25	WOS:A1994PV51000082
J	ONO, M; RAAB, G; LAU, K; ABRAHAM, JA; KLAGSBRUN, M				ONO, M; RAAB, G; LAU, K; ABRAHAM, JA; KLAGSBRUN, M			PURIFICATION AND CHARACTERIZATION OF TRANSMEMBRANE FORMS OF HEPARIN-BINDING EGF-LIKE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; CELL-SURFACE; FACTOR-ALPHA; VERO CELLS; PRECURSOR; EXPRESSION; STIMULATION; MIGRATION; AFFINITY; CLEAVAGE	Heparin-binding epidermal growth factor-like growth factor (HB-EGF), whose cDNA has a predicted 208-codon open reading frame, is synthesized as a membrane spanning precursor that is processed to release mature mitogenic proteins of similar to 73-87 amino acids in length. Previous work has focused on the structural and biological properties of secreted HB-EGF. In this study, human recombinant transmembrane HB-EGF, produced by expression of HB-EGF(1-208) cDNA in a baculovirus system, has been isolated, purified, and characterized structurally and biologically. Two isoforms of transmembrane HB-EGF (HB-EGF(TM)) were purified from membrane fractions of infected insect cells by a combination of heparin affinity chromatography and reversed-phase high performance liquid chromatography. The isoform designated as HB-EGF(TM-I), a 21.5-kDa protein, yielded no N-terminal sequence, suggesting that it is N-terminally blocked. However, KB-EGF(TM-II), a 24-kDa protein, was N-terminally sequenced and found to be initiated at Asp(63) in the 208-amino acid residue primary translation product. This N terminus is the same as that determined for a 18-kDa isoform of secreted HB-EGF purified from the conditioned medium of insect cells expressing HB-EGF(1-149) cDNA and is also identical to the N terminus of the longest form of secreted HB-EGF initially purified from human macrophage-like U-937 cell conditioned medium. HB-EGF(TM-II) cross-reacted on a Western blot with an antibody directed against the 16 C-terminal amino acids of the cytoplasmic tail of HB-EGF, indicating that it contains a putative transmembrane domain. HB-EGF(TM-II) was bioactive and stimulated the proliferation of BALB/c 3T3 cells and smooth muscle cells and the motility of smooth muscle cells, albeit with similar to 10-25% of the specific activity of secreted HB-EGF isoforms. We concluded that transmembrane HB-EGF is bioactive when isolated, consistent with the possibility of its functioning as a juxtacrine growth factor when still tethered to the cell.	CHILDRENS HOSP, DEPT SURG, BOSTON, MA 02115 USA; SCIOS NOVA INC, MT VIEW, CA 94043 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Scios; Harvard University; Harvard Medical School					NCI NIH HHS [CA 37392] Funding Source: Medline; NIGMS NIH HHS [GM 46166, GM 47397] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037392, R37CA037392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397, R44GM046166, R43GM046166] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; Bailey M J, 1991, Methods Mol Biol, V7, P147, DOI 10.1385/0-89603-178-0:147; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; CHUNG DW, 1977, BIOCHIM BIOPHYS ACTA, V483, P248, DOI 10.1016/0005-2744(77)90053-5; DAS SK, 1994, DEVELOPMENT, V120, P1071; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MORRIS RE, 1985, INFECT IMMUN, V50, P721, DOI 10.1128/IAI.50.3.721-727.1985; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZETTER BR, 1980, NATURE, V285, P41, DOI 10.1038/285041a0	33	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31315	31321						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983076				2022-12-25	WOS:A1994PV51000087
J	BEYER, D; SKRIPKIN, E; WADZACK, J; NIERHAUS, KH				BEYER, D; SKRIPKIN, E; WADZACK, J; NIERHAUS, KH			HOW THE RIBOSOME MOVES AMONG THE MESSENGER-RNA DURING PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-BINDING; ALLOSTERIC 3-SITE MODEL; MESSENGER-RNA; ELONGATION CYCLE; TRANSLOCATION; SITE; TRANSLATION; SUPPRESSION; PARAMETERS	The movement of a ribosome along the mRNA was assessed by the following experimental strategy. mRNAs were synthesized which contained a short coding sequence with at least four codons and a P-32 label at one end and an oligo(C) sequence at the other end. When these mRNAs were fixed on the ribosome with tRNAs specific for the defined codons, the oligo(C) stretches were partially outside of the ribosome, whereas the labeled ends were inside the ribosome and thus protected. The overhanging oligo(C) regions were trimmed with the cytidyl-specific RNase CL3 identifying the nucleotides of the mRNAs, which emerged from the ribosome. An mRNA enters the ribosome at nucleotide 18 +/- 1, when counting starts at the first nucleotide of the P-site codon, and leaves the ribosome at nucleotide -21 +/- 2. The ribosome does not move at either side upon A-site occupation but does so at both sides simultaneously upon translocation. The results further indicate that most of the mRNA stretches downstream and upstream of the coding region are not required for the translocation reaction. It is therefore likely that the tRNAs are pulling the mRNA through the ribosome via codon-anticodon interactions in the course of translocation.	MAX PLANCK INST MOLEC GENET, D-14195 BERLIN, GERMANY	Max Planck Society								BALAKIN AG, 1992, NUCLEIC ACIDS RES, V20, P563, DOI 10.1093/nar/20.3.563; Belitsina N V, 1979, Methods Enzymol, V60, P761; BOSSI L, 1984, P NATL ACAD SCI-BIOL, V81, P6105, DOI 10.1073/pnas.81.19.6105; CERI H, 1973, BIOCHIM BIOPHYS ACTA, V312, P337, DOI 10.1016/0005-2787(73)90378-X; CHUANG DM, 1971, P NATL ACAD SCI USA, V68, P1474, DOI 10.1073/pnas.68.7.1474; De Groot N, 1971, Eur J Biochem, V23, P523; DONALD LR, 1973, NATURE, V242, P230; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; GROSS M, 1993, EUR J BIOCHEM, V218, P463, DOI 10.1111/j.1432-1033.1993.tb18397.x; GUPTA SL, 1971, BIOCHEMISTRY-US, V10, P4410, DOI 10.1021/bi00800a010; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HAUSNER TP, 1988, J BIOL CHEM, V263, P13103; HINDLEY J, 1969, NATURE, V224, P964, DOI 10.1038/224964a0; HOLSCHUH K, 1981, NATURE, V293, P675, DOI 10.1038/293675a0; KANG C, 1985, J MOL BIOL, V181, P241, DOI 10.1016/0022-2836(85)90088-9; KUECHLER E, 1970, NATURE, V225, P920, DOI 10.1038/225920a0; LEVY CC, 1980, J BIOL CHEM, V255, P2153; LUHRMANN R, 1979, NATURE, V280, P423, DOI 10.1038/280423a0; MAIZELS N, 1974, NATURE, V249, P647, DOI 10.1038/249647b0; OMAHONY DJ, 1989, J BACTERIOL, V171, P3824, DOI 10.1128/jb.171.7.3824-3830.1989; PHILIPPE C, 1993, P NATL ACAD SCI USA, V90, P4394, DOI 10.1073/pnas.90.10.4394; REMME J, 1989, EUR J BIOCHEM, V183, P281, DOI 10.1111/j.1432-1033.1989.tb14925.x; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; RINKEAPPEL J, 1993, NUCLEIC ACIDS RES, V21, P2853, DOI 10.1093/nar/21.12.2853; ROTH JR, 1981, CELL, V24, P601, DOI 10.1016/0092-8674(81)90086-6; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4703; SCHREIER MH, 1971, P NATL ACAD SCI USA, V68, P805, DOI 10.1073/pnas.68.4.805; SPIRIN AS, 1987, J MOL BIOL, V194, P119, DOI 10.1016/0022-2836(87)90720-0; STEEGE DA, 1977, J MOL BIOL, V114, P559, DOI 10.1016/0022-2836(77)90178-4; STEITZ JA, 1969, NATURE, V224, P957, DOI 10.1038/224957a0; THACH SS, 1971, P NATL ACAD SCI USA, V68, P1791, DOI 10.1073/pnas.68.8.1791; WURMBACH P, 1979, P NATL ACAD SCI USA, V76, P2143, DOI 10.1073/pnas.76.5.2143	32	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30713	30717						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982992				2022-12-25	WOS:A1994PU52500102
J	EICHLER, J; KREIMER, DI; VARON, L; SILMAN, I; WEINER, L				EICHLER, J; KREIMER, DI; VARON, L; SILMAN, I; WEINER, L			A MOLTEN GLOBULE OF TORPEDO ACETYLCHOLINESTERASE UNDERGOES THIOL-DISULFIDE EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; PROTEIN; STATE; CALIFORNICA	Torpedo acetylcholinesterase is a disulfide-linked homodimer containing three intramolecular disulfide bonds, as well as a single free thiol on Cys-231. We report that in a ''molten globule'' state, produced by 1.5 M guanidine hydrochloride, this enzyme undergoes rapid intramolecular thiol-disulfide exchange, in the absence of reducing agents, resulting in the production of novel species. Most strikingly, this results in appearance of enzyme monomers. Chemical modification of the free thiol group prevents these changes. Unfolded acetylcholinesterase, namely in 5 M guanidine hydrochloride, also undergoes intramolecular thiol-disulfide exchange, including production of enzyme monomers, but at a much lower rate. Our data show that the molten globule state, in contrast to the native and unfolded states, is both compact and flexible, thus being especially amenable to thiol-disulfide exchange.	WEIZMANN INST SCI, DEPT ORGAN CHEM, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science			Lev, Weiner/GZK-4484-2022; EICHLER, JERRY/F-2351-2012	EICHLER, JERRY/0000-0001-9409-8026				ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P1707, DOI 10.1021/bi00058a003; Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; CHANG JY, 1993, FEBS LETT, V336, P53, DOI 10.1016/0014-5793(93)81607-2; CREIGHTON TE, 1994, BIOCHEMISTRY-US, V33, P1534, DOI 10.1021/bi00172a033; Creighton Thomas E., 1992, P301; DOLGINOVA EA, 1992, BIOCHEMISTRY-US, V31, P12248, DOI 10.1021/bi00163a039; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; FLYNN GC, 1993, P NATL ACAD SCI USA, V90, P10826, DOI 10.1073/pnas.90.22.10826; FREEDMAN RB, 1991, CONFORMATIONS FORCES, P204; FUTERMAN AH, 1985, BIOCHEM BIOPH RES CO, V129, P312, DOI 10.1016/0006-291X(85)91439-1; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIBNEY G, 1988, J BIOL CHEM, V263, P1140; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KREIMER DI, IN PRESS P NATL ACAD; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MCKENZIE HA, 1972, BIOCHEMISTRY-US, V11, P4539, DOI 10.1021/bi00774a017; MEHLERT A, 1993, BIOCHEM J, V296, P473, DOI 10.1042/bj2960473; Ptitsyn Oleg B., 1992, P243; SIKORAV JL, 1988, EMBO J, V7, P2983, DOI 10.1002/j.1460-2075.1988.tb03161.x; STEINBERG N, 1990, BIOCHEM INT, V21, P1043; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TORCHINSKY YM, 1981, SULFUR PROTEINS, P225; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINER L, 1994, BIOCHEM BIOPH RES CO, V198, P915, DOI 10.1006/bbrc.1994.1130; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x	28	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30093	30096						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982909				2022-12-25	WOS:A1994PU52500008
J	CERESA, BP; LIMBIRD, LE				CERESA, BP; LIMBIRD, LE			MUTATION OF AN ASPARTATE RESIDUE HIGHLY CONSERVED AMONG G-PROTEIN-COUPLED RECEPTORS RESULTS IN NONRECIPROCAL DISRUPTION OF ALPHA(2)-ADRENERGIC RECEPTOR G-PROTEIN INTERACTIONS - A NEGATIVE CHARGE AT AMINO-ACID RESIDUE-79 FORECASTS ALPHA(2A)-ADRENERGIC RECEPTOR SENSITIVITY TO ALLOSTERIC MODULATION BY MONOVALENT CATIONS AND FULLY EFFECTIVE RECEPTOR G-PROTEIN COUPLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; ALPHA-2-ADRENERGIC RECEPTORS; AGONIST BINDING; ALPHA-2A-ADRENERGIC RECEPTOR; ADRENERGIC RECEPTORS; ANTAGONIST BINDING; ADENYLATE-CYCLASE; HUMAN-PLATELETS; SODIUM	We have mutated the aspartate residue in the putative second transmembrane spanning domain of the alpha(2A)-adrenergic receptor (alpha(2A)AR) to the non-negatively charged asparagine (D79N) and glutamine (D79Q) and the negatively charged glutamate (D79E) residue in an effort to better characterize the role of this residue, highly conserved among G-protein-coupled receptors, in Na+ regulation of ligand binding and in receptor G-protein coupling. Allosteric modulation of receptor-ligand interactions by Na+ is retained by the D79E (alpha(2A)AR but lost upon mutation to the uncharged D79N and D79Q residues. Loss of allosteric effects of Na+ is paralleled by a complete loss of retrograde information transfer from G-proteins to (alpha(2A)AR in AtT20 cells, measured via the sensitivity of radiolabeled agonist binding to Gpp(NH)p. In contrast to the complete elimination of retrograde signaling via the D79N and D79Q (alpha(2A)AR, anterograde information transfer from receptor to G-protein is modified in a more subtle quantitative way, since agonist-stimulated GTPase activity via D79N and D79Q and alpha(2A)AR, although apparently attenuated compared to wild type and D79E alpha(2A)AR, is no less than the GTPase activity elicited by endogenous somatostatin receptors in AtT20 cells. These data indicate that a negative charge at amino acid residue 79 forecasts sensitivity to allosteric regulation by monovalent cations and its mutation to non-negatively charged residues elicits a nonparallel modulation of receptor --> G-protein versus G-protein --> receptor communication between alpha(2A)AR and pertussis toxin-sensitive GTP-binding proteins.			CERESA, BP (corresponding author), VANDERBILT UNIV,MED CTR,DEPT PHARMACOL,NASHVILLE,TN 37215, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025182] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25182] Funding Source: Medline; NIGMS NIH HHS [GM07629] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BEHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133; BLUME AJ, 1978, P NATL ACAD SCI USA, V76, P5636; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COSTA T, 1990, MOL PHARMACOL, V37, P383; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GERHARDT MA, 1990, MOL PHARMACOL, V38, P214; GOODMAN RR, 1982, MOL PHARMACOL, V21, P329; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HO BY, 1992, FEBS LETT, V312, P259, DOI 10.1016/0014-5793(92)80948-G; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; JAGADEESH G, 1990, J PHARMACOL EXP THER, V252, P1184; JAKOBS KH, 1979, MOL CELL ENDOCRINOL, V16, P147, DOI 10.1016/0303-7207(79)90023-6; JI L, 1991, J BIOL CHEM, V266, P14953; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KONG HY, 1993, J BIOL CHEM, V268, P23055; KONG HY, 1993, MOL PHARMACOL, V44, P380; KOSTERLITZ HW, 1988, J RECEPTOR RES, V8, P363, DOI 10.3109/10799898809048998; KUO CC, 1993, NATURE, V365, P258, DOI 10.1038/365258a0; LEE NH, 1992, J PHARMACOL EXP THER, V262, P312; LIMBIRD LE, 1982, MOL PHARMACOL, V21, P609; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LUINI A, 1986, J NEUROSCI, V6, P3128; MAHAN LC, 1987, SOMATOSTATIN BASIC C, P137; MICHEL T, 1980, NATURE, V288, P709, DOI 10.1038/288709a0; MINUTH M, 1986, N-S ARCH PHARMACOL, V333, P124, DOI 10.1007/BF00506514; MOTULSKY HJ, 1983, J BIOL CHEM, V258, P3913; NEUBIG RR, 1985, MOL PHARMACOL, V28, P475; NEVE KA, 1991, MOL PHARMACOL, V39, P733; NEVE KA, 1990, J PHARMACOL EXP THER, V252, P1198; NUNNARI JM, 1987, J BIOL CHEM, V262, P12387; PENNEFATHER PS, 1988, BRAIN RES, V444, P346, DOI 10.1016/0006-8993(88)90944-4; PERT CB, 1974, MOL PHARMACOL, V10, P868; QUINTANA J, 1993, MOL ENDOCRINOL, V7, P767, DOI 10.1210/me.7.6.767; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMBROOK J, 1989, MOL CLONING LAB MANU, pF1; STRADER CD, 1988, J BIOL CHEM, V263, P10267; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; TATSUMI H, 1990, J NEUROSCI, V10, P1675; TSAI BS, 1978, MOL PHARMACOL, V14, P540; WANG CD, 1993, MOL PHARMACOL, V43, P931; WANG CD, 1991, MOL PHARMACOL, V40, P168; WILSON AL, 1991, MOL PHARMACOL, V39, P481; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P368	50	108	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29557	29564						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961941				2022-12-25	WOS:A1994PU28400040
J	HAUSLADEN, A; FRIDOVICH, I				HAUSLADEN, A; FRIDOVICH, I			SUPEROXIDE AND PEROXYNITRITE INACTIVATE ACONITASES, BUT NITRIC-OXIDE DOES NOT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROXY-ACID DEHYDRATASE; FE-S CLUSTER; ESCHERICHIA-COLI; PURIFICATION; ENZYME; IRON; BIOSYNTHESIS; SENSITIVITY; OXIDATION; NITRATE	The Escherichia coli and recombinant human cytosolic aconitases are inactivated by O-2(radical anion), with a rate constant of similar to 3 x 10(7) M(-1) s(-1); the corresponding value for the porcine mitochondrial aconitase is similar to 0.8 x 10(7) M(-1) s(-1). Nitric oxide, which is reported to inactivate aconitase, did not do so at a perceptible rate, while incubation with peroxynitrite led to a rapid loss of aconitase activity. We propose that the reported inactivation of aconitase by nitric oxide in vivo is actually mediated through peroxynitrite, the product of the reaction between O-2(radical anion) and NO..	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN OR, 1978, BIOCHEM BIOPH RES CO, V85, P1219, DOI 10.1016/0006-291X(78)90672-1; BROWN OR, 1993, FUNDAM APPL TOXICOL, V3, P209; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; FLINT D H, 1990, P285; FLINT DH, 1993, J BIOL CHEM, V268, P25547; FLINT DH, 1993, J BIOL CHEM, V268, P22369; GAMBLE JL, 1951, COMPANIONSHIP WATER, P15; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KUO CF, 1987, J BIOL CHEM, V262, P4724; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; LOWRY OH, 1949, J BIOL CHEM, V180, P399; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; PIRRUNG MC, 1989, J ORG CHEM, V54, P1543, DOI 10.1021/jo00268a014; PRODROMOU C, 1991, J GEN MICROBIOL, V137, P2505, DOI 10.1099/00221287-137-11-2505; RACKER E, 1950, BIOCHIM BIOPHYS ACTA, V4, P211, DOI 10.1016/0006-3002(50)90026-6; RADI R, 1991, J BIOL CHEM, V266, P4244; REED JW, 1974, J AM CHEM SOC, V96, P1248, DOI 10.1021/ja00811a062; SMYKRANDALL E, 1993, FREE RADICAL BIO MED, V14, P609, DOI 10.1016/0891-5849(93)90142-H; STADLER J, 1991, AM J PHYSIOL, V260, pC910, DOI 10.1152/ajpcell.1991.260.5.C910; TAKABATAKE T, 1992, CHEM PHARM BULL, V40, P1644; WAUD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695, DOI 10.1016/0003-9861(75)90214-3; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x	32	500	507	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29405	29408						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961919				2022-12-25	WOS:A1994PU28400017
J	KOBAYASHI, K; MORITA, S; MIZUGUCHI, T; SAWADA, H; YAMADA, K; NAGATSU, I; FUJITA, K; NAGATSU, T				KOBAYASHI, K; MORITA, S; MIZUGUCHI, T; SAWADA, H; YAMADA, K; NAGATSU, I; FUJITA, K; NAGATSU, T			FUNCTIONAL AND HIGH-LEVEL EXPRESSION OF HUMAN DOPAMINE-BETA-HYDROXYLASE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND FORMS; UNCLEAVED SIGNAL PEPTIDE; MESSENGER-RNA; ELECTROCHEMICAL DETECTION; ORTHOSTATIC HYPOTENSION; LIQUID-CHROMATOGRAPHY; TYROSINE-HYDROXYLASE; NERVOUS-SYSTEM; ADRENAL-GLANDS; CELLS	Dopamine beta-hydroxylase (DBH; EC 1.14.17.1) catalyzes the production of the neurotransmitter and hormone norepinephrine in the third step of the catecholamine biosynthesis pathway. Transgenic mice were generated with multiple copies of a human DBH minigene construct containing the full-length cDNA connected downstream of the 4-kilobase upstream promoter region to achieve overexpression of DBH. Human DBH mRNA and immunoreactivity were detected tissue-specifically in the brain and adrenal gland of these transgenic mice. The transgene products were correctly processed to a glycosylated mature polypeptide with a molecular mass of 72 kDa and existed in the secretory vesicles as both soluble and membrane-bound forms. We detected a marked increase in DBH activity in various catecholamine-containing tissues of the mice that occurred as a consequence of expression of the catalytically active human DBH enzyme. However, in these transgenics the steady-state levels of norepinephrine and epinephrine were normally maintained without the acceleration of the catecholamine turnover rate, suggesting that there are some regulatory mechanisms to preserve a constant rate of norepinephrine synthesis in spite of the increased amount of DBH protein. These transgenic mice with the minigene construct provide one approach to study the mechanisms underlying biogenesis of the DBH polypeptide and regulation of norepinephrine synthesis.	FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN; FUJITA HLTH UNIV,SCH MED,DEPT ANAT,TOYOAKE,AICHI 47011,JAPAN; CHUBU NATL HOSP,DEPT CLIN RES,OBU,AICHI 474,JAPAN	Fujita Health University; Fujita Health University								AUNIS D, 1976, CLIN CHIM ACTA, V70, P455, DOI 10.1016/0009-8981(76)90359-4; BENEDICT CR, 1979, BRIT J PHARMACOL, V66, P521, DOI 10.1111/j.1476-5381.1979.tb13689.x; BENEDICT CR, 1978, BRIT J PHARMACOL, V64, P305, DOI 10.1111/j.1476-5381.1978.tb17305.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG JT, 1992, NEUROSCI LETT, V136, P36, DOI 10.1016/0304-3940(92)90641-J; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FILLENZ M, 1993, J NEUROCHEM, V61, P132, DOI 10.1111/j.1471-4159.1993.tb03547.x; FRIEDMAN S, 1965, J BIOL CHEM, V240, P4763; GAVINE FS, 1984, J NEUROCHEM, V43, P1243, DOI 10.1111/j.1471-4159.1984.tb05379.x; GIBSON KR, 1993, J BIOL CHEM, V268, P9490; HAEUPTLE MT, 1989, J CELL BIOL, V108, P1227, DOI 10.1083/jcb.108.4.1227; HOGAN B, 1986, MANIPULATING MOUSE E; HORNYKIEWICZ O, 1982, NATURE, V299, P484, DOI 10.1038/299484a0; INTVELD AJM, 1987, LANCET, V1, P183; ISHII A, 1991, NEUROSCI LETT, V125, P25, DOI 10.1016/0304-3940(91)90121-9; KOBAYASHI K, 1992, P NATL ACAD SCI USA, V89, P1631, DOI 10.1073/pnas.89.5.1631; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; KOPIN IJ, 1983, J CLIN ENDOCR METAB, V57, P632, DOI 10.1210/jcem-57-3-632; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LENGYEL J, 1975, METHOD CELL BIOL, P195; LEWIS EJ, 1990, J BIOL CHEM, V265, P1021; LEWIS EJ, 1992, J BIOL CHEM, V267, P494; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; MCHUGH EM, 1985, J BIOL CHEM, V260, P4409; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MORITA S, 1993, MOL BRAIN RES, V17, P239, DOI 10.1016/0169-328X(93)90007-C; NAGATSU I, 1990, NEUROSCI LETT, V120, P141, DOI 10.1016/0304-3940(90)90023-3; NAGATSU I, 1979, HISTOCHEMISTRY, V64, P131, DOI 10.1007/BF00490094; NAGATSU T, 1972, CLIN CHIM ACTA, V39, P417, DOI 10.1016/0009-8981(72)90061-7; NAGATSU T, 1967, BIOCHIM BIOPHYS ACTA, V139, P319, DOI 10.1016/0005-2744(67)90035-6; NAGATSU T, 1986, NEUROTRANSMITTER ENZ, P79; NAKANO T, 1992, BIOCHEM BIOPH RES CO, V189, P590, DOI 10.1016/0006-291X(92)91598-K; NOHTA H, 1984, ANAL CHIM ACTA, V165, P171, DOI 10.1016/S0003-2670(00)85197-1; OKA K, 1984, J CHROMATOGR, V308, P43, DOI 10.1016/0378-4347(84)80194-2; OYARCE AM, 1991, ARCH BIOCHEM BIOPHYS, V290, P503, DOI 10.1016/0003-9861(91)90573-2; OYARCE AM, 1989, J MOL NEUROSCI, V1, P171, DOI 10.1007/BF02918903; ROBERTSON D, 1986, NEW ENGL J MED, V314, P1494, DOI 10.1056/NEJM198606053142307; ROBERTSON JG, 1990, J BIOL CHEM, V265, P1029; ROSSANT J, 1990, NEURON, V2, P323; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SAXENA A, 1983, J BIOL CHEM, V258, P4147; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; SUZUKI H, 1985, J CHROMATOGR, V341, P176, DOI 10.1016/S0378-4347(00)84024-4; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDENFRIE.S, 1966, PHARMACOL REV, V18, P43; VANOOYEN A, 1979, SCIENCE, V206, P337, DOI 10.1126/science.482942; VAYER P, 1990, NEUROSCI RES COMMUN, V6, P77; WONG DL, 1990, NEUROPSYCHOPHARMACOL, V3, P115; ZIEGLER MG, 1977, NEW ENGL J MED, V296, P293, DOI 10.1056/NEJM197702102960601	51	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29725	29731						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961964				2022-12-25	WOS:A1994PU28400065
J	FERRARI, S; RONFANI, L; CALOGERO, S; BIANCHI, ME				FERRARI, S; RONFANI, L; CALOGERO, S; BIANCHI, ME			THE MOUSE GENE CODING FOR HIGH-MOBILITY GROUP-1 PROTEIN (HMG1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; DNA; LOCALIZATION; EXPRESSION; BINDING; AMPHOTERIN; CELLS; CDNAS; BOX	We have isolated an active gene encoding the mouse HMG1 protein among a multitude of cross-hybridizing sequences, which most likely are retrotransposed pseudogenes. The hmg1 gene contains five exons, of which the first is not translated, and the last contains a long 3'-untranslated sequence and three alternative polyadenylation sites. We found no evidence for a sequence encoding a membrane localization signal in the hmg1 gene, despite the presence of HMG1 protein on the surface of several cell types. The hmg1 promoter coincides with a CpG island, contains no TATA sequence, and drives the expression of reporter genes placed under its control. The hmg1 gene may be a member of a family of closely related genes but appears to be the major or the only active gene coding for HMG1 protein.	IST SCI SAN RAFFAELE,DIBIT,I-20132 MILAN,ITALY; UNIV MILAN,DIPARTIMENTO GENET & BIOL MICRORGANISMI,I-20133 MILAN,ITALY	Vita-Salute San Raffaele University; University of Milan			Ronfani, Lorenza/AAN-7807-2020; Bianchi, Marco Emilio/K-3417-2018	Bianchi, Marco Emilio/0000-0002-5329-6445; Ronfani, Lorenza/0000-0002-4602-3502	Telethon [A.007] Funding Source: Medline	Telethon(Fondazione Telethon)		BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BIANCHI ME, 1992, NUCLEIC ACIDS MOL BI, V6, P112; BIANCHI ME, 1994, IN PRESS MOL MICROBI, V13; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GRASSER KD, 1991, NUCLEIC ACIDS RES, V19, P2573, DOI 10.1093/nar/19.10.2573; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; KOLODRUBETZ D, 1989, J BIOL CHEM, V265, P3234; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LEE KLD, 1987, NUCLEIC ACIDS RES, V15, P5051, DOI 10.1093/nar/15.13.5051; LOCKER J, 1993, GENE TRANSCRIPTION P, P320; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; NER SS, 1993, NUCLEIC ACIDS RES, V21, P4369, DOI 10.1093/nar/21.18.4369; NER SS, 1994, EMBO J, V13, P1817, DOI 10.1002/j.1460-2075.1994.tb06450.x; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; ROTH SY, 1987, NUCLEIC ACIDS RES, V19, P8112; SHEFLIN LG, 1989, BIOCHEMISTRY-US, V28, P5658, DOI 10.1021/bi00439a048; SHIRAKAWA H, 1992, J BIOL CHEM, V267, P6641; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; TSUDA K, 1988, BIOCHEMISTRY-US, V27, P6159, DOI 10.1021/bi00416a050; VANDEWETERING M, 1992, J BIOL CHEM, V267, P8530; WAGNER CR, 1992, MOL CELL BIOL, V12, P1915, DOI 10.1128/MCB.12.5.1915; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; YOTOV WV, 1992, NUCLEIC ACIDS RES, V20, P3516, DOI 10.1093/nar/20.13.3516	28	62	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28803	28808						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961836				2022-12-25	WOS:A1994PU16800046
J	JIN, HM; ROBINSON, DF; LIANG, YX; FAHL, WE				JIN, HM; ROBINSON, DF; LIANG, YX; FAHL, WE			SIS/PDGF-B PROMOTER ISOLATION AND CHARACTERIZATION OF REGULATORY ELEMENTS NECESSARY FOR BASAL EXPRESSION OF THE SIS/PDGF-B GENE IN U2-OS OSTEOSARCOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-II; SIMIAN SARCOMA-VIRUS; MAMMALIAN-CELLS; SIS; IDENTIFICATION; TRANSFORMATION; SEQUENCE; ONCOGENE; LINES	Platelet-derived growth factor BB, encoded by the SIS/PDGF-B gene, is a potent mitogen for cells of mesenchymal origin, and the SIS/PDGF-B gene is expressed in a large percentage of human mesenchymal tumor cells establishing a growth-promoting, autocrine growth circuit. A 4-kb fragment, containing the SIS/PDGF-B promoter, was isolated from a human genomic library, and a series of 5'-nested deletions and linker-scanning mutants were used to identify positive regulatory elements that are necessary for the constitutive expression of this gene in human U2-OS osteosarcoma cells. A 250-bp fragment, lying immediately 5' to the SIS/PDGF-B mRNA initiation site (+1), retained full pro meter activity and positive regulatory elements at -228 to -219, -97 to -88 (SIS distal element) and -58 to -39 (SIS proximal element, SPE) were identified. insertion of the 20-bp SPE into a heterologous, minimal promoter resulted in >5-fold transcriptional activation which was ablated by mutations to the SPE. High resolution mutagenesis within the 20-bp SPE, indicated the necessity of a CACCC motif for activity Gel shift analysis of SPE-binding proteins in U2-OS nuclear extracts identified Sp1 and two additional binding factors that could be competed away from SPE binding by adding excess consensus Sp1 or CACCC oligonucleotides. The individual and aggregate roles of the SPE and two weaker positive regulatory elements in regulating SIS/PDGF-B transcription in these tumor cells is considered.	UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [R37CA042024, T32CA009681, P30CA007175] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09681-01A1, R37 CA-42024, P30 CA-07175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HENRIKSEN R, 1993, CANCER RES, V53, P4550; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; PERES R, 1987, CANCER RES, V47, P3425; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RAO CD, 1986, COLD SPRING HARB SYM, V51, P959, DOI 10.1101/SQB.1986.051.01.109; RATNER L, 1989, NUCLEIC ACIDS RES, V17, P4101, DOI 10.1093/nar/17.11.4101; ROSS R, 1978, CELL, V14, P203, DOI 10.1016/0092-8674(78)90107-1; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; VANDENOUWELAND MW, 1986, NUCLEIC ACIDS RES, V14, P765, DOI 10.1093/nar/14.2.765; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0	27	23	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28648	28654						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961814				2022-12-25	WOS:A1994PU16800023
J	TACHIBANA, H; KIDO, I; MURAKAMI, H				TACHIBANA, H; KIDO, I; MURAKAMI, H			HETEROGENEOUS EXPRESSION OF HUMAN-ANTIBODY LAMBDA-CHAINS BY CONCANAVALIN A-RESISTANT HYBRIDOMAS LEAD TO CHANGED ANTIGEN-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN LIGHT CHAIN; VARIABLE GENE SEGMENT; V REGION VARIANTS; CARBOHYDRATE CHAINS; CHO CELLS; MUTANT; RECOMBINATION; SPECIFICITY; GENERATION	Human HB4C5 hybridoma cells produce a lung cancer-specific human monoclonal antibody that possesses a lambda light chain on which a N-linked carbohydrate chain is attached at the first complementary determining region. Up to six light chains of various sizes are secreted by the original and concanavalin A (ConA)-resistant HB4C5 clones. Two of these six light chains are derived directly from the HB4C5 original and are 30 and 32 kDa in size. The structural difference between these two light chains has been shown to be a N-linked carbohydrate located at a single site. The other four variants, which are derived from ConA-resistant variants, have light chain sizes ranging from about 26 to 29 kDa. No changes in the secretory forms were observed when glycosylation was inhibited by the addition of tunicamycin, indicating that the heterogeneous light chain forms produced by these ConA-resistant variants resulted from the size differences of core polypeptides and not from N-glycosylation. Sequence analysis from one of the variant light chains revealed that its VA gene segment differs markedly from identified human VA gene segments (at most, 60% homology with known human VA subgroups) and, furthermore, the variant light chain shares 80% homology with the rabbit VA gene. In addition, the antigen binding ability of these variant antibodies changed significantly in both specificity and affinity. These results suggest that heterogeneous light chains expression by ConA-resistant variants may provide a new way for developing an antigen specific human monoclonal antibody repertoire.			TACHIBANA, H (corresponding author), KYUSHU UNIV, GRAD SCH GENET RESOURCES TECHNOL, HIGASHI KU, 6-10-1 HAKOZAKI, FUKUOKA 812, JAPAN.							BAGSHAWE KD, 1987, BRIT J CANCER, V56, P531, DOI 10.1038/bjc.1987.237; BRUGGEMANN M, 1982, EMBO J, V1, P629, DOI 10.1002/j.1460-2075.1982.tb01219.x; CIFONE MA, 1979, J CELL PHYSIOL, V100, P39, DOI 10.1002/jcp.1041000105; CLARKE SH, 1985, J EXP MED, V161, P687, DOI 10.1084/jem.161.4.687; COMBRIATO G, 1991, EUR J IMMUNOL, V21, P1513, DOI 10.1002/eji.1830210627; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V5, pD229; DILDROP R, 1982, EMBO J, V1, P635, DOI 10.1002/j.1460-2075.1982.tb01220.x; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; Hashizume S, 1991, Hum Antibodies Hybridomas, V2, P142; Hashizume S, 1991, Hum Antibodies Hybridomas, V2, P51; HAYZER DJ, 1987, J IMMUNOL, V138, P2316; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; IRIE RF, 1986, P NATL ACAD SCI USA, V83, P8694, DOI 10.1073/pnas.83.22.8694; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; Kato M, 1991, Hum Antibodies Hybridomas, V2, P94; Kato Masatoshi, 1993, Human Antibodies and Hybridomas, V4, P9; KIM S, 1981, CELL, V27, P573, DOI 10.1016/0092-8674(81)90399-8; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; LARRICK JW, 1989, BIO-TECHNOL, V7, P934, DOI 10.1038/nbt0989-934; MAIZELS N, 1989, TRENDS GENET, V5, P4, DOI 10.1016/0168-9525(89)90004-8; Maxam A M, 1980, Methods Enzymol, V65, P499; MORRISON SL, 1989, ADV IMMUNOL, V44, P65; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MURAKAMI H, 1985, IN VITRO CELL DEV B, V21, P593; MURAKAMI H, 1982, P NATL ACAD SCI USA, V79, P575; NOVICK KE, 1992, INT IMMUNOL, V4, P1103, DOI 10.1093/intimm/4.10.1103; PARFETT CLJ, 1981, EXP CELL RES, V136, P1, DOI 10.1016/0014-4827(81)90032-X; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; RIPKA J, 1986, MOL CELL BIOL, V6, P1268, DOI 10.1128/MCB.6.4.1268; ROSENWALD AG, 1990, J LIPID RES, V31, P523; SEIDMAN JG, 1980, NATURE, V286, P779, DOI 10.1038/286779a0; SHOKAT KM, 1990, ANNU REV IMMUNOL, V8, P335; SOX HC, 1970, P NATL ACAD SCI USA, V66, P975, DOI 10.1073/pnas.66.3.975; STANLEY P, 1981, MOL CELL BIOL, V1, P687, DOI 10.1128/MCB.1.8.687; STANLEY P, 1983, SOMAT CELL GENET, V9, P593, DOI 10.1007/BF01574260; TACHIBANA H, 1993, BIOCHIM BIOPHYS ACTA, V1182, P257, DOI 10.1016/0925-4439(93)90067-B; TACHIBANA H, 1992, BIOCHEM BIOPH RES CO, V189, P625, DOI 10.1016/0006-291X(92)92246-T; TANIGUCHI T, 1985, BIOCHEMISTRY-US, V24, P5551, DOI 10.1021/bi00341a040; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANO T, 1988, J SURG ONCOL, V39, P108, DOI 10.1002/jso.2930390208; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	46	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29061	29066						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961872				2022-12-25	WOS:A1994PU16800082
J	LEBBAR, S; KARIBIAN, D; DEPRUN, C; CAROFF, M				LEBBAR, S; KARIBIAN, D; DEPRUN, C; CAROFF, M			DISTRIBUTION OF LIPID-A SPECIES BETWEEN LONG AND SHORT-CHAIN LIPOPOLYSACCHARIDES ISOLATED FROM SALMONELLA, YERSINIA, AND ESCHERICHIA AS SEEN BY CF-252 PLASMA DESORPTION MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GEL-ELECTROPHORESIS; BORDETELLA-PERTUSSIS; FORM LIPOPOLYSACCHARIDE; ENDOTOXIN PREPARATIONS; FATTY-ACID; HETEROGENEITY; TYPHIMURIUM	Smooth type endotoxins of Salmonella, Yersinia, and Escherichia were fractionated into long and short chain lipopolysaccharides by silica gel chromatography. Lipid A was prepared from the fractions and analyzed by plasma desorption mass spectrometry. Both Yersinia and Salmonella endotoxins had a large proportion of aminoarabinose-containing lipopolysaccharide molecular species that were found to be concentrated in the long chain fraction, In the Escherichia endotoxin, hypoacylated lipopolysaccharides (lacking the tetradecanoate and one of the four hydroxytetradecanoates) were found mostly in the short chain fraction, Possible implications of these results for the lipopolysaccharide biosynthetic pathway and for studies on the influence of sugar chain length on the biological effects of endotoxins are discussed,	UNIV PARIS 11,INST BIOCHIM,CNRS,URA 1116,EQUIPE ENDOTOXINES,F-91405 ORSAY,FRANCE; INST PHYS NUCL LYON,CNRS,IN2P3,EQUIPE INTERACT ION SURFACE & MAT,F-91406 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3)			Caroff, Martine/N-4293-2019	CAROFF, Martine/0000-0002-7329-5247				BHAT R, 1990, J BACTERIOL, V172, P6631, DOI 10.1128/jb.172.12.6631-6636.1990; BORDET C, 1977, EUR J BIOCHEM, V79, P443, DOI 10.1111/j.1432-1033.1977.tb11826.x; CAROFF M, 1991, J BIOL CHEM, V266, P18543; CAROFF M, 1993, J BIOL CHEM, V268, P12321; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CAROFF M, 1990, J BACTERIOL, V172, P1121, DOI 10.1128/jb.172.2.1121-1128.1990; CAROFF MGL, 1990, APPL ENVIRON MICROB, V56, P1957, DOI 10.1128/AEM.56.6.1957-1959.1990; GALANOS C, 1988, J CHROMATOGR, V440, P397, DOI 10.1016/S0021-9673(00)94543-6; GOLDMAN RC, 1980, EUR J BIOCHEM, V107, P145, DOI 10.1111/j.1432-1033.1980.tb04635.x; Holst O, 1992, BACTERIAL ENDOTOXIC, VI, P135; JANN B, 1975, EUR J BIOCHEM, V60, P239, DOI 10.1111/j.1432-1033.1975.tb20996.x; JIAO BH, 1989, EUR J BIOCHEM, V180, P515, DOI 10.1111/j.1432-1033.1989.tb14676.x; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KARIBIAN D, 1991, INT J MASS SPECTROM, V111, P273, DOI 10.1016/0168-1176(91)85060-Y; KARIBIAN D, 1995, 3RD P C INT END SOC; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDUR A, 1978, EUR J BIOCHEM, V84, P579, DOI 10.1111/j.1432-1033.1978.tb12201.x; LEHMANN V, 1977, EUR J BIOCHEM, V81, P443, DOI 10.1111/j.1432-1033.1977.tb11969.x; MORRISON DC, 1975, EUR J BIOCHEM, V107, P137; NOWOTNY A, 1983, HDB ENDOTOXINS, V1, P308; PALVA ET, 1980, EUR J BIOCHEM, V107, P137, DOI 10.1111/j.1432-1033.1980.tb04634.x; PETERSON AA, 1985, J BACTERIOL, V162, P738, DOI 10.1128/JB.162.2.738-745.1985; RADZIEJEWSKALEBRECHT J, 1994, EUR J BIOCHEM, V221, P343, DOI 10.1111/j.1432-1033.1994.tb18746.x; Raetz Christian R. H., 1992, P67; RIETSCHEL ET, 1984, HDB ENDOTOXINS, V1, P187; ROTTEM S, 1978, EUR J BIOCHEM, V85, P445, DOI 10.1111/j.1432-1033.1978.tb12258.x; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; VUKAJLOVICH SW, 1983, J IMMUNOL, V130, P2804; WOLLENWEBER HW, 1983, EUR J BIOCHEM, V130, P167	30	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31881	31884						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989362				2022-12-25	WOS:A1994PX30300084
J	FERNANDESALNEMRI, T; LITWACK, G; ALNEMRI, ES				FERNANDESALNEMRI, T; LITWACK, G; ALNEMRI, ES			CPP32, A NOVEL HUMAN APOPTOTIC PROTEIN WITH HOMOLOGY TO CAENORHABDITIS-ELEGANS CELL-DEATH PROTEIN CED-3 AND MAMMALIAN INTERLEUKIN-1-BETA-CONVERTING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CONVERTING ENZYME; INSECT CELLS; GENE CED-3; SURVIVAL; ENCODES	We have cloned a novel apoptotic gene from human Jurkat T-lymphocytes. The new gene encodes a 32-kDa putative cysteine protease (CPP32) with significant homology to Caenorhabditis elegans cell death protein Ced-3, mammalian interleukin-1 beta-converting enzyme (ICE), and the product of the mouse nedd2 gene. The CPP32 transcript is highly expressed and most abundant in cell lines of lymphocytic origin. Overexpression of CPP32 or ICE in Sf9 insect cells resulted in apoptosis. In addition, coexpression of recombinant p20 and p11 derived from the parental full-length CPP32 sequence resulted in apoptosis in Sf9 cells. Our data suggest that similar to ICE, CPP32 is made of two subunits, p20 and pll, which form the active CPP32 complex. Time apoptotic activity of CPP32 and its high expression in lymphocytes suggest that CPP32 is an important mediator of apoptosis in the immune system.	THOMAS JEFFERSON UNIV,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035035] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35035-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ALNEMRI ES, 1991, J BIOL CHEM, V266, P3925; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Ellis H.M., 1991, ANN REV CELL BIOL, V7, P663, DOI DOI 10.1146/ANNUREV.CB.07.110191.003311; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	18	1144	1221	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30761	30764						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983002				2022-12-25	WOS:A1994PV51000006
J	HOLZMAN, LB; MERRITT, SE; FAN, G				HOLZMAN, LB; MERRITT, SE; FAN, G			IDENTIFICATION, MOLECULAR-CLONING, AND CHARACTERIZATION OF DUAL LEUCINE-ZIPPER BEARING KINASE - NOVEL SERINE/THREONINE PROTEIN-KINASE THAT DEFINES A 2ND SUBFAMILY OF MIXED LINEAGE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; TYROSINE KINASE; CONSERVED FEATURES; ENDOTHELIAL-CELLS; ESCHERICHIA-COLI; FAMILY; GENE; RECEPTOR; DOMAINS; ENCODES	Molecular cloning using a degenerate oligonucleotide-based polymerase chain reaction was undertaken to test the possibility that novel, developmentally regulated protein kinases are expressed in the embryonic mouse kidney. Several receptor tyrosine kinase and serine/threonine kinase cDNA clones were identified. One of these, designated DLK represented a novel gene product whose 3.6-kilobase transcript was expressed in a tissue-specific and developmentally regulated fashion. Several clones encoding the entire open reading frame were isolated and sequenced. The identified open reading frame encodes an 888-amino acid polypeptide that defines a new subfamily within the mixed lineage protein kinase family. Sequence analysis revealed: 1) a kinase catalytic domain most characteristic of serine/threonine kinases but hybrid between members of the family of microtubule-associated protein kinase kinase kinases and the fibroblast growth factor receptor family; 2) two putative alpha-helical leucine zipper motifs separated by a 25-amino acid charged intermediate segment but lacking an NH2-terminal basic domain; and 3) COOH-terminal and NH2-terminal proline-rich domains suggestive of src homology 3 (SH3) domain binding regions. Rabbit polyclonal immune sera generated against a carboxyl-terminal bacterial fusion protein recognized a protein with an apparent molecular mass of 130 kDa in COS 7 cells that were transiently transfected with a full-length DLK cDNA expression vector Moreover, COS 7 cells transiently transfected with an epitope-tagged DLK expression vector expressed protein with an apparent molecular mass of 130 kDa that became autophosphorylated on serine and threonine in an in vitro kinase assay.			HOLZMAN, LB (corresponding author), UNIV MICHIGAN, SCH MED,DEPT INTERNAL MED,DIV NEPHROL,RM 1560, MED SCI RES BLDG 2, ANN ARBOR, MI 48109 USA.			Holzman, Lawrence/0000-0002-8961-234X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001924] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01924] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BUECHLER JA, 1988, BIOCHEMISTRY-US, V27, P7356, DOI 10.1021/bi00419a027; CHALEFF DT, 1985, MOL CELL BIOL, V5, P1878, DOI 10.1128/MCB.5.8.1878; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; DUMONT DJ, 1993, ONCOGENE, V8, P1293; EZOE K, 1994, ONCOGENE, V9, P935; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPUR AG, 1992, ONCOGENE, V7, P1347; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; HU JC, 1992, NUCLEIC ACIDS MOL BI, P39; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; ING YL, 1994, ONCOGENE, V9, P1745; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; OELRICHS RB, 1993, ONCOGENE, V8, P11; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sambrook J, 1989, MOL CLONING LABORATO; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SAXEN L, 1986, ANAT EMBRYOL, V175, P1, DOI 10.1007/BF00315450; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUKHATME VP, 1993, SEMIN NEPHROL, V13, P422; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YANG XJ, 1993, J NEUROSCI, V13, P3006; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	44	108	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30808	30817						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983011				2022-12-25	WOS:A1994PV51000015
J	KNOTTS, S; RINDT, H; NEUMANN, J; ROBBINS, J				KNOTTS, S; RINDT, H; NEUMANN, J; ROBBINS, J			IN-VIVO REGULATION OF THE MOUSE BETA-MYOSIN HEAVY-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC EXPRESSION; VENTRICULAR ALPHA-MYOSIN; CIS-ACTING ELEMENT; NUCLEAR PROTEINS; SKELETAL-MUSCLE; SIMIAN VIRUS-40; BINDING-FACTOR; SV40 ENHANCER; PROMOTER; TRANSCRIPTION	The interactions of trans-acting factors with their respective cis-acting elements in the 5' upstream region of the beta myosin heavy chain gene (MyHC) regulate its tissue- and developmental stage-specific expression. The role of three conserved elements, an MCAT or TEF-1 binding site, a C-rich region, and a beta e3 region, in muscle-specific gene expression was analyzed in vivo. Each cis-acting site was ablated in the context of the beta MyHC promoter, fused to the chloramphenicol acetyltransferase reporter gene, and used to generate transgenic mice. In contrast to results obtained in vitro, the data demonstrate that mutating any one of these cis-acting elements does not affect the level or tissue specificity of transgene expression. Sequences upstream of -600 can functionally substitute for any one of these regulatory cassettes and are important both for high levels of expression as well as for controlled muscle specificity. Mutation of any two of the cis-acting elements also does not affect transgene expression. However, simultaneous mutation of the three sites significantly reduces expression, indicating that these conserved sequences do play an important role and that combinatorial interactions underlie the beta MyHC's regulation.	CHILDRENS HOSP RES FDN,DEPT PEDIAT,DIV MOLEC CARDIOVASC BIOL,CINCINNATI,OH 45229; UNIV CINCINNATI,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of Cincinnati					NHLBI NIH HHS [HL41496, HL22619, HL46826] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, P01HL046826, P01HL041496] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAMAYO R, 1993, EMBO J, V12, P2039, DOI 10.1002/j.1460-2075.1993.tb05853.x; BOHELER KR, 1992, J BIOL CHEM, V267, P12979; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CRIBBS LL, 1989, J BIOL CHEM, V264, P10672; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; GULICK J, 1991, J BIOL CHEM, V266, P9180; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hogan B, 1986, MANIPULATING MOUSE E, P89; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KURABAYASHI M, 1988, J CLIN INVEST, V82, P524, DOI 10.1172/JCI113627; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LITTEN RZ, 1982, CIRC RES, V50, P856, DOI 10.1161/01.RES.50.6.856; LOMPRE AM, 1979, NATURE, V282, P105, DOI 10.1038/282105a0; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; NG WA, 1991, CIRC RES, V69, P1742; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; RINDT H, 1993, J BIOL CHEM, V268, P5332; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUBINSTEIN NA, 1978, DEV BIOL, V62, P473, DOI 10.1016/0012-1606(78)90229-4; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHWARTZ K, 1981, J MOL CELL CARDIOL, V13, P1071, DOI 10.1016/0022-2828(81)90297-2; SHIMIZU N, 1992, NUCLEIC ACIDS RES, V20, P1793, DOI 10.1093/nar/20.7.1793; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SINHA AM, 1984, J BIOL CHEM, V259, P6674; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; VIVARELLI E, 1988, J CELL BIOL, V107, P2191, DOI 10.1083/jcb.107.6.2191; Walter C A, 1989, Biotechniques, V7, P1065; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YU YT, 1989, MOL CELL BIOL, V9, P1839, DOI 10.1128/MCB.9.5.1839	49	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31275	31282						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983072				2022-12-25	WOS:A1994PV51000081
J	OKADOME, T; YAMASHITA, H; FRANZEN, P; MOREN, A; HELDIN, CH; MIYAZONO, K				OKADOME, T; YAMASHITA, H; FRANZEN, P; MOREN, A; HELDIN, CH; MIYAZONO, K			DISTINCT ROLES OF THE INTRACELLULAR DOMAINS OF TRANSFORMING GROWTH-FACTOR-BETA TYPE-I AND TYPE-II RECEPTORS IN SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CLONING; EXPRESSION; COMPLEX; KINASE; CELLS	Transforming growth factor-beta (TGF-beta) transduces signals through binding to type I (T beta R-I) and type II (T beta R-II) serine/threonine kinase receptors. T beta R-I requires T beta R-II for ligand binding, whereas T beta R-II requires T beta R-I for signaling. We generated two different chimeric TGF-beta receptors, i.e. T beta R-1.2 containing the extracellular domain of T beta R-I and the intracellular domain of T beta R-II, and T beta R-2.1 containing the extracellular domain of T beta R-II and the intracellular domain of T beta R-I. T beta R-2.1 bound I-125-TGF-beta 1 alone, whereas T beta R-1.2 bound the ligand only in the presence of T beta R-II or T beta R-2.1. When transfected into a mutant mink lung epithelial cell line that lacks functional T beta R-II, T beta R-II cDNA, but not T beta R2.1 cDNA, restored the responsiveness to TGF-beta 1 with regard to transcriptional activation of plasminogen activator inhibitor-1 gene promoter and 12-O-tetradecanoylphorbol-13-acetate-responsive elements. In a mutant mink lung epithelial cell line lacking T beta R-I, T beta R-I cDNA stimulated promoter activity, but the T beta R-1.2 cDNA did not. T beta R-2.1, formed an oligomer with T beta R-II when transfected into COS cells, but the complex did not transduce the signal after ligand stimulation. On the other hand, co-transfection of T beta R-1.2 and T beta R-2.1 cDNAs restored the responsiveness to TGF-beta 1. These results indicate that an interaction between the intracellular regions of T beta R-I and T beta R-II, triggered by ligand binding to the extracellular domains of these receptors, leads to efficient signal transduction by TGF-beta.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research								BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	22	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30753	30756						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983000				2022-12-25	WOS:A1994PV51000004
J	SEKINE, M; HASHIMOTO, Y; SUZUKI, M; INAGAKI, F; TAKIO, K; SUZUKI, A				SEKINE, M; HASHIMOTO, Y; SUZUKI, M; INAGAKI, F; TAKIO, K; SUZUKI, A			PURIFICATION AND CHARACTERIZATION OF UDP-GLCNAC-IV(3)-BETA-GAL-GB(4)CER BETA-1,6-GLCNAC TRANSFERASE FROM MOUSE KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANE; WISKOTT-ALDRICH SYNDROME; EXTENDED GLOBOGLYCOLIPIDS; EMBRYONIC ANTIGEN-1; SSEA-1 DETERMINANT; EXPRESSION; BIOSYNTHESIS; PROTEINS; LYMPHOCYTES; GLCNAC	The Gsl-5 gene mapped on mouse chromosome 19 controls the expression of IV6 beta Gal beta 1-4(Fuc alpha 1-3)GlcNAc, IV3 beta Gal-Gb(4)Cer in mouse kidney through regulation of the activity of UDP-GlcNAc:IV3 beta Gal-Gb(4)Cer beta-1,6-GlcNAc transferase (GNT), which transfers GlcNAc to the C-6 position of GalNAc of IV3 beta Gal-Gb(4)Cer (GL-X). Here me report that GNT has been purified to apparent homogeneity from mouse kidney by means of preparation of a microsomal fraction, solubilization with Triton X-100, and sequential column chromatographies on CM-Sepharose, UDP-hexanolamine-Sepharose, and Gg(4)Ose-Aminocellulo-fine. GNT purified 11,000 fold from the microsomal fraction exhibited a specific activity of 26.15 mu mol/min/mg protein and an apparent molecular mass of 50 kDa on SDS-polyacrylamide gel electrophoresis. The K-m Values for UDP-GlcNAc and GL-X were 0.36 and 0.11 mM, respectively. Among glycolipids tested as substrates, GL-X was the best and Gg(4)Cer the next best, but Lc(3)Cer, Gb(4)Cer, and G(M1) did not act as a substrate. GNT was also able to transfer GlcNAc to Gal beta 1-3GalNAc beta 1-benzyl and Gal beta 1-3GalNAc alpha 1-p-nitrophenyl at C-6 of GalNAc through beta linkage but not to GlcNAc beta 1-3GalNAc alpha 1-p-nitrophenyl. The purified GNT was digested with lysyl endopeptidase, and four peptides generated were sequenced. The sequence of four peptides spanning 35 amino acid residues in total exhibited 80% homology with that of the reported human core 2 GlcNAc transferase.	TOKYO METROPOLITAN INST MED SCI,DEPT MEMBRANE BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; INST PHYS & CHEM RES,DIV BIOMOLEC CHARACTERIZAT,WAKO,SAITAMA 35101,JAPAN	Tokyo Metropolitan Institute of Medical Science; RIKEN								[Anonymous], 1978, J Lipid Res, V19, P114; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; HAKOMORI S, 1983, JNCI-J NATL CANCER I, V71, P231; HASHIMOTO Y, 1993, J BIOL CHEM, V268, P25857; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HOSHI M, 1975, BIOCHIM BIOPHYS ACTA, V388, P152; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; PILLER F, 1984, J BIOL CHEM, V259, P3385; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; ROPP PA, 1991, J BIOL CHEM, V266, P23863; SANGADALA S, 1991, MOL CELL BIOCHEM, V101, P125; SEKINE M, 1989, J BIOCHEM-TOKYO, V105, P680, DOI 10.1093/oxfordjournals.jbchem.a122726; SEKINE M, 1987, J BIOCHEM-TOKYO, V101, P563, DOI 10.1093/jb/101.3.563; SEKINE M, 1987, J BIOCHEM-TOKYO, V101, P553, DOI 10.1093/jb/101.3.553; SEKINE M, 1988, J BIOCHEM-TOKYO, V103, P722, DOI 10.1093/oxfordjournals.jbchem.a122335; SEKINE M, 1909, J BIOCHEM-TOKYO, V108, P103; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WIEGANDT H, 1968, ANGEW CHEM INT EDIT, V7, P87, DOI 10.1002/anie.196800871; WILLIAMS DE, 1964, ANN NY ACAD SCI, V121, P373, DOI 10.1111/j.1749-6632.1964.tb14210.x; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	29	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31143	31148						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983056				2022-12-25	WOS:A1994PV51000063
J	SHEN, B; HUTCHINSON, CR				SHEN, B; HUTCHINSON, CR			TRIPLE HYDROXYLATION OF TETRACENOMYCIN-A2 TO TETRACENOMYCIN-C IN STREPTOMYCES-GLAUCESCENS - OVEREXPRESSION OF THE TCMG GENE IN STREPTOMYCES-LIVIDANS AND CHARACTERIZATION OF THE TETRACENOMYCIN-A2 OXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; METABOLIC PRODUCTS; OXYTETRACYCLINE BIOSYNTHESIS; HETEROLOGOUS EXPRESSION; POLYKETIDE SYNTHASE; ESCHERICHIA-COLI; PLASMID VECTORS; PURIFICATION; PROTEIN; MICROORGANISMS	Nucleotide sequence analysis of the tcmG gene has suggested that the TcmG protein is responsible for the triple-hydroxylation of tetracenomycin (Tcm) A2 to Tcm C in Streptomyces glaucescens (Decker, H., Motamedi, H., and Hutchinson, C. R. (1993) J. Bacteriol. 175, 3876-3886). The heterologous expression of the tcmG gene in Streptomyces lividans and the purification and characterization of TcmG protein, which we have named Tcm A2 oxygenase, are described here. NH2-terminal amino acid analysis of the purified enzyme led to the revision of the translational start site of tcmG to a TTG, 33 base pairs downstream of the GTG site assigned initially on the basis of nucleotide sequence analysis. Tcm A2 oxygenase is a monomeric protein in solution and contains 1 mol of non-covalently bound FAD; the apoenzyme can be partially reconstituted in vitro by addition of FAD. Tcm A2 oxygenase exhibits an optimal pH of 9.0-9.5 and prefers NADPH over NADH as an electron donor. The apparent K'(m) of the enzyme for Tcm A2, NADH, and NADPH are 1.81 +/- 0.38, 260 +/- 19, and 82.1 +/- 17 mu M, respectively, and the apparent V'(max) for the reaction is 14.7 +/- 1.1 nmol Tcm C/min.mg. Purification and characterization of Tcm A2 oxygenase provide direct evidence to support the notion that the angular hydroxy groups of naphthacenequinones like Tcm C are introduced from O-18(2) via a mono- or dioxygenase process.	UNIV WISCONSIN, SCH PHARM, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [R01CA035381] Funding Source: NIH RePORTER; NCI NIH HHS [CA35381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON MG, 1989, J ANTIBIOT, V42, P640, DOI 10.7164/antibiotics.42.640; BALBAS P, 1990, METHOD ENZYMOL, V185, P14; BERNAN V, 1985, GENE, V37, P101, DOI 10.1016/0378-1119(85)90262-8; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1982, MOL GEN GENET, V187, P265, DOI 10.1007/BF00331128; BINNIE C, 1989, J BACTERIOL, V171, P887, DOI 10.1128/jb.171.2.887-895.1989; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; COLOMBO AL, 1992, J BACTERIOL, V174, P1641, DOI 10.1128/jb.174.5.1641-1646.1992; DE JESUS AE, 1982, J CHEM SOC CHEM COMM, P902, DOI 10.1039/c39820000902; DECKER H, 1993, J BACTERIOL, V175, P3876, DOI 10.1128/JB.175.12.3876-3886.1993; DECKER H, 1993, J BACTERIOL, V175, P3887, DOI 10.1128/JB.175.12.3887-3892.1993; DOWD P, 1992, J AM CHEM SOC, V114, P7613, DOI 10.1021/ja00046a001; DRAUTZ H, 1985, J ANTIBIOT, V38, P1291, DOI 10.7164/antibiotics.38.1291; EGERT E, 1992, J ANTIBIOT, V45, P1190, DOI 10.7164/antibiotics.45.1190; FIEDLER HP, 1986, J ANTIBIOT, V39, P856, DOI 10.7164/antibiotics.39.856; GRAMAJO HC, 1991, J BACTERIOL, V173, P6475, DOI 10.1128/jb.173.20.6475-6483.1991; GUILFOILE PG, 1992, J BACTERIOL, V174, P3651, DOI 10.1128/JB.174.11.3651-3658.1992; HAIGLER BE, 1990, J BACTERIOL, V172, P457, DOI 10.1128/JB.172.1.457-464.1990; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P60, DOI 10.1002/elps.1150090112; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; HUANG SL, 1993, J BIOL CHEM, V268, P18987; Husain M, 1978, Methods Enzymol, V53, P429; KLINE BC, 1992, J BACTERIOL, V174, P3004, DOI 10.1128/JB.174.9.3004-3010.1992; KULIOPULOS A, 1992, BIOCHEMISTRY-US, V31, P7722, DOI 10.1021/bi00148a037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SY, 1990, BIOTECHNIQUES, V9, P676; LIGHT DR, 1980, ANAL BIOCHEM, V109, P87, DOI 10.1016/0003-2697(80)90014-7; MOTAMEDI H, 1987, P NATL ACAD SCI USA, V84, P4445, DOI 10.1073/pnas.84.13.4445; MOTAMEDI H, 1986, J BACTERIOL, V167, P575, DOI 10.1128/jb.167.2.575-580.1986; Muller F., 1991, CHEM BIOCH FLAVOENZY; OIKAWA H, 1988, J CHEM SOC CHEM COMM, P600, DOI 10.1039/c39880000600; OMURA S, 1981, J BIOCHEM-TOKYO, V90, P291; PORTER TD, 1987, ARCH BIOCHEM BIOPHYS, V254, P353, DOI 10.1016/0003-9861(87)90111-1; ROHR J, 1992, NAT PROD REP, V9, P103, DOI 10.1039/np9920900103; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITTJOHN T, 1992, APPL MICROBIOL BIOT, V36, P493; SHEN B, 1992, J BACTERIOL, V174, P3818, DOI 10.1128/JB.174.11.3818-3821.1992; SHEN B, 1993, SCIENCE, V262, P1535, DOI 10.1126/science.8248801; SHEN B, 1991, BIOCHEMISTRY-US, V30, P8936, DOI 10.1021/bi00101a004; SHEN B, 1993, J NAT PROD, V56, P1288, DOI 10.1021/np50098a013; SHEN B, 1993, BIOCHEMISTRY-US, V32, P11149, DOI 10.1021/bi00092a026; SHEN B, 1993, BIOCHEMISTRY-US, V32, P6656, DOI 10.1021/bi00077a019; SIEBERS J, 1979, THESIS U GOTTINGEN G; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; STROHL WR, 1992, NUCLEIC ACIDS RES, V20, P961, DOI 10.1093/nar/20.5.961; SUBRAMANIAN V, 1981, J BIOL CHEM, V256, P2723; SUMMERS RG, 1993, J BACTERIOL, V175, P7571, DOI 10.1128/JB.175.23.7571-7580.1993; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; TAI JTN, 1993, J BACTERIOL, V175, P6996, DOI 10.1128/jb.175.21.6996-7005.1993; THOMAS R, 1985, J CHEM SOC CHEM COMM, P802, DOI 10.1039/c39850000802; UDVARNOKI G, 1992, J ORG CHEM, V57, P1274, DOI 10.1021/jo00030a041; VANBERKEL WJH, 1988, EUR J BIOCHEM, V178, P197; VANMIDDLESWORTH F, 1986, J CHEM SOC CHEM COMM, P1156, DOI 10.1039/c39860001156; VARA J, 1989, J BACTERIOL, V171, P5872, DOI 10.1128/jb.171.11.5872-5881.1989; WEBER W, 1979, ARCH MICROBIOL, V121, P111, DOI 10.1007/BF00689973; XUAN LJ, 1992, J ANTIBIOT, V45, P1974, DOI 10.7164/antibiotics.45.1974; YE Y, 1984, KANGSHENGSU, V9, P28; YUE S, 1986, J BACTERIOL, V167, P581, DOI 10.1128/jb.167.2.581-586.1986	59	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30726	30733						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982994				2022-12-25	WOS:A1994PU52500104
J	HENNIGAN, RF; HAWKER, KL; OZANNE, BW				HENNIGAN, RF; HAWKER, KL; OZANNE, BW			FOS-TRANSFORMATION ACTIVATES GENES ASSOCIATED WITH INVASION	ONCOGENE			English	Article							C-FOS; BINDING-PROTEIN; CELL-LINE; CATHEPSIN-L; DIFFERENTIAL EXPRESSION; SIGNAL-TRANSDUCTION; METASTATIC CELLS; EARLY RESPONSE; GROWTH-FACTORS; FIBROBLASTS	Fos oncoproteins transform cells by functioning as transcription factors. Over-expression of c-fos results in minimal morphological transformation while the two viral isolates, FBJ and FBR v-fos, result in full morphological transformation. Fos-transformed cells are serum dependent for proliferation but not for morphological transformation. To identify Fos target genes which might be involved in morphological transformation me screened a cDNA library constructed from RNA isolated from serum starved FBR-transformed cells with cDNA probes prepared from both FBR-transformed cells and untransformed parental fibroblasts, 208F. We identified 10 genes which are differentially expressed between FBR and 208F cells. One is a novel gene. Nine are upregulated in c-fos- and FBJ-transformed cells and also in mutant c-Ha-Ras-transformed 208Fs. All nine of the upregulated genes have been associated previously with invasion or metastasis. We demonstrate that the FBR-transformed cells are invasive in an in vitro assay and that their ability to invade is enhanced by platelet derived growth factor. We conclude that the fos oncogenes target genes involved in morphological transformation, and invasion.	BEATSON INST CANC RES, CRC, BEATSON LABS, GLASGOW G61 1BD, LANARK, SCOTLAND; UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA	Beatson Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								Angel P, 1992, Matrix Suppl, V1, P156; ANGEL P, 1987, J CELL BIOCHEM, V42, P193; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BECKNER ME, 1993, J NATL CANCER I, V1990, P1836; BURCK KB, 1988, ONCOGENES INTRO CONC; CHAUHAN SS, 1991, CANCER RES, V51, P1478; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1989, ONCOGENE HDB; DAVIES BR, 1993, ONCOGENE, V8, P999; DELARCOJ, 1978, P NATL ACAD SCI USA, V70, P369; DENHARDT DT, 1987, ONCOGENE, V2, P55; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; EPNER DE, 1993, CANCER RES, V53, P1995; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FINKEL MP, 1975, FRONT RAD THER ONCOL, V10, P205; FRIGERI LG, 1992, J IMMUNOL, V148, P861; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HIRAI SI, 1990, ONCOGENE, V5, P39; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JIA SH, 1988, J BIOL CHEM, V263, P6009; KANE SE, 1988, MOL CELL BIOL, V8, P3316, DOI 10.1128/MCB.8.8.3316; KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3; Kerr L D, 1992, Matrix Suppl, V1, P176; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KOLCH W, 1993, ONCOGENE, V8, P361; KONDOH N, 1992, CANCER RES, V52, P791; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LITZJACKSON S, 1992, BLOOD, V79, P2404; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOTAN R, 1983, CANCER RES, V43, P2088; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MECHAM RP, 1991, ANNU REV CELL BIOL, V7, P71, DOI 10.1146/annurev.cb.07.110191.000443; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; MERCOLA D, 1987, BIOCHEM BIOPH RES CO, V147, P288, DOI 10.1016/S0006-291X(87)80119-5; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; MILLER AD, 1984, CELL, V36, P51; MINAFRA S, 1992, J CELL SCI, V102, P323; OCHIENG J, 1992, BIOCHEM BIOPH RES CO, V186, P1674, DOI 10.1016/S0006-291X(05)81601-8; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PARK AJ, 1991, J BIOL CHEM, V266, P1584; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PRICE CHG, 1972, BRIT J CANCER, V26, P15, DOI 10.1038/bjc.1972.5; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RAZ A, 1984, EMBO J, V3, P2979, DOI 10.1002/j.1460-2075.1984.tb02244.x; RAZ A, 1986, CANCER RES, V46, P3667; RAZ A, 1981, CANCER RES, V41, P3642; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Sambrook J, 1989, MOL CLONING LABORATO; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SENIOR RM, 1984, J CELL BIOL, V99, P870, DOI 10.1083/jcb.99.3.870; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3212; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TANIGUCHI S, 1989, CANCER RES, V49, P6738; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TROEN BR, 1991, CELL GROWTH DIFFER, V2, P23; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VERMA IM, 1992, PROG CLIN BIOL RES, V376, P41; WICK M, 1992, ONCOGENE, V7, P859; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	71	129	131	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3591	3600						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970719				2022-12-25	WOS:A1994PT39200022
J	HUANG, F; HSU, S; YAN, ZF; WINAWER, S; FRIEDMAN, E				HUANG, F; HSU, S; YAN, ZF; WINAWER, S; FRIEDMAN, E			THE CAPACITY FOR GROWTH-STIMULATION BY TGF-BETA-1 SEEN ONLY IN ADVANCED COLON CANCERS CANNOT BE ASCRIBED TO MUTATIONS IN APC, DCC, P53 OR RAS	ONCOGENE			English	Note							HEXAMETHYLENE BISACETAMIDE; COLORECTAL TUMORIGENESIS; CARCINOMA CELLS; GENE-MUTATIONS; DIFFERENTIATION; IDENTIFICATION; FACTOR-BETA-1; EXPRESSION; ONCOGENES; CHROMOSOME-5Q21	Human colon cancer development is associated with the accumulation of mutations and deletions in the suppressor genes DCC, APC and p53 and mutations in the dominant oncogene K-ras, with loss of wild type alleles. In earlier studies we had observed that about half of the resected human colon cancers placed into primary culture were growth stimulated by TGF beta 1. This group included the more advanced cancers which were either poorly differentiated primary-site cancers or metastases. In contract, the more differentiated colon cancers were inhibited or unaffected by TGF beta 1, indicating that a switch fn response to TGF beta 1 occurs during colon cancer progression. Different sublines of the HT29 colon carcinoma cell line model the resected cancers, responding to TGF beta 1 by proliferation, inhibition or no growth modulation. The current study shows that while the poorly differentiated, TGF beta 1-stimulated sublines are most tumorigenic, all the sublines have the same spectrum of mutations: truncating mutations in both APC (adenomatous polyposis coli) alleles, no activated vas genes, mutated and thus overexpressed p53, and very low expression of DCC compared to normal colon cells. Genes other than the four already implicated in colon carcinoma evolution are responsible for the mitogenic response to TGF beta 1 found in the more advanced cancers.	MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [IT32CAO9628] Funding Source: Medline; PHS HHS [R0145783, R0150645] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009628] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHROY P, 1990, CANCER RES, V50, P261; SCHROY PC, 1988, CANCER RES, V48, P5487; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YAN ZF, 1993, CELL GROWTH DIFFER, V4, P785; YAN ZF, 1994, J BIOL CHEM, V269, P13231; YAN ZF, 1992, ONCOGENE, V7, P801	26	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3701	3706						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970729				2022-12-25	WOS:A1994PT39200035
J	BANDYOPADHYAY, S; GRONOSTAJSKI, RM				BANDYOPADHYAY, S; GRONOSTAJSKI, RM			IDENTIFICATION OF A CONSERVED OXIDATION-SENSITIVE CYSTEINE RESIDUE IN THE NFI FAMILY OF DNA-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; PHOTOCHEMICAL CROSS-LINKING; HUMAN-IMMUNODEFICIENCY-VIRUS; FACTOR-KAPPA-B; REDOX REGULATION; TRANSCRIPTION FACTOR; AFFINITY-CHROMATOGRAPHY; RECOGNITION SITE; ACTIVITY INVITRO; ACID COMPLEXES	The nuclear factor I (NFI) family of site-specific DNA-binding proteins plays a role in both transcription and adenovirus DNA replication. The DNA binding domain of NFI family members contains 4 cysteine residues (Cys-2, Cys-3, Cys-4, and Cys-5) that are conserved in all NFI proteins. Mutation of the Cys-2, Cys-4, and Cys-5 residues in the human NFI-C protein to several other amino acids abolished DNA binding, while 8 of 10 mutations of the Cys-3 residue had little or no effect on binding. Wild-type NFI-C was inactivated by N-ethylmaleimide in vitro, while the active Cys-3 mutant proteins were resistant to N-ethylmaleimide. Treatment of wild-type NFI in vitro with the oxidizing agent diamide also inactivated DNA binding, and subsequent reduction with dithiothreitol restored binding activity. The active Cys-3 mutant NFI proteins were resistant to diamide-inactivation, indicating that the Cys-3 residue is required for modulation of DNA-binding by oxidation state. These studies indicate that oxidative-inactivation can play an important role in the modifying NFI-DNA-protein interactions. The presence of this nonessential Cys-3 residue in all known NFI proteins raises the possibility that it may function in a manner similar to redox-sensitive cysteine residues found in other site-specific DNA-binding proteins.	CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University	BANDYOPADHYAY, S (corresponding author), CLEVELAND CLIN FDN,DEPT CANC BIOL NN1,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.			Gronostajski, Richard/0000-0003-4264-208X				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; CLEGHON V, 1992, J BIOL CHEM, V267, P17872; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HAY RT, 1985, EMBO J, V4, P421, DOI 10.1002/j.1460-2075.1985.tb03645.x; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKENSMITH JW, 1991, METHOD ENZYMOL, V208, P211; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; KRUSE U, 1991, NUCLEIC ACIDS RES, V19, P6641, DOI 10.1093/nar/19.23.6641; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MERRILL BM, 1984, J BIOL CHEM, V259, P850; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NOVAK A, 1992, J BIOL CHEM, V267, P12986; NOVAK AN, 1994, J BIOL CHEM, V268, P26032; OKUNO H, 1993, ONCOGENE, V8, P695; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARADISO PR, 1982, J BIOL CHEM, V257, P1462; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; REIDHAAROLSON JF, 1991, METHOD ENZYMOL, V208, P564; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAMOO Y, 1988, PROTEINS, V4, P1, DOI 10.1002/prot.340040103; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P2038; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WILLIAMS KR, 1991, METHOD ENZYMOL, V208, P516; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23	61	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29949	29955						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961993				2022-12-25	WOS:A1994PU28400097
J	CATLING, AD; REUTER, CWM; COX, ME; PARSONS, SJ; WEBER, MJ				CATLING, AD; REUTER, CWM; COX, ME; PARSONS, SJ; WEBER, MJ			PARTIAL-PURIFICATION OF A MITOGEN-ACTIVATED PROTEIN-KINASE KINASE ACTIVATOR FROM BOVINE BRAIN - IDENTIFICATION AS B-RAF OR A B-RAF-ASSOCIATED ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAY; SERINE THREONINE KINASE; MAP KINASE; PC12 CELLS; PHOSPHORYLATION SITES; ONCOGENIC P21(RAS); IN-VITRO; TYROSINE; CASCADE	A classical biochemical approach was taken to identify mitogen-activated protein kinase kinase (MEK) activators in bovine brain. Fractionation revealed the presence of one major MEK-stimulating activity that was distinct from c-Raf-1 and MEK kinase. Similar results were obtained using bovine adrenal chromaffin cells, and in both cases, immunoblotting and immunoprecipitation experiments demonstrated co-purification of MEK activator with B-Raf. Partially purified MEK activator stimulated phosphorylation of MEK1 on residues tentatively identified as serine 218 and serine 222. Little or no MEK activator was associated with c-Raf-1 in bovine brain or chromaffin cells, although this protein was expressed, suggesting that B-Raf might be the major MEK activator in cells of neural origin.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047332] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44199] Funding Source: Medline; NIGMS NIH HHS [GM47332] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GOMEZ N, 1992, FEBS LETT, V314, P461, DOI 10.1016/0014-5793(92)81527-S; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; JELINEK T, 1993, BIOTECHNIQUES, V15, P628; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MEYER HE, 1991, METHOD ENZYMOL, V201, P206; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; OSBORNE WRA, 1990, HUM GENE THER, V1, P31, DOI 10.1089/hum.1990.1.1-31; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RAPP UR, 1991, ONCOGENE, V6, P495; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SEGER R, 1992, J BIOL CHEM, V267, P25628; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STORM SM, 1990, ONCOGENE, V5, P345; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	77	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					30014	30021						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7962002				2022-12-25	WOS:A1994PU28400106
J	HAWES, BE; TOUHARA, K; KUROSE, H; LEFKOWITZ, RJ; INGLESE, J				HAWES, BE; TOUHARA, K; KUROSE, H; LEFKOWITZ, RJ; INGLESE, J			DETERMINATION OF THE G-BETA-GAMMA-BINDING DOMAIN OF PHOSDUCIN - A REGULATABLE MODULATOR OF G-BETA-GAMMA SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; ROD OUTER SEGMENTS; G-PROTEIN; ALPHA-2-ADRENERGIC RECEPTOR; RHODOPSIN KINASE; PINEAL-GLAND; PH DOMAIN; SUBUNITS; EXPRESSION; RETINA	Although a role for the beta gamma-subunits of heterotrimeric G proteins (G(beta gamma)) in signal transduction by several cellular systems has been established, the structural features of cellular proteins interacting with G(beta gamma) have yet to be fully elucidated. The G(beta gamma)-binding region of beta-adrenergic receptor kinase (beta ARK), a cytosolic enzyme recruited to the membrane receptor substrate by G(beta gamma), has been localized to the carboxyl terminus of the enzyme. Here, we demonstrate that the amino terminus of phosducin, a 33-kDa G beta gamma-binding retinal phosphoprotein, contains sequences homologous with the G(beta gamma)-binding domain of PARK. Accordingly, a glutathione S-transferase-fusion protein containing only the amino-terminal 105 amino acids of phosducin displayed G(beta gamma) binding ability. This domain of phosducin contains a protein kinase A (PKA) phosphorylation site, and upon phosphorylation, the binding of full-length phosducin to G(beta gamma) is reduced. In addition, transient expression of phosducin in COS-7 cells significantly inhibits G beta gamma-mediated phosphoinositide hydrolysis. This inhibitory effect is completely reversed by pretreatment of cells with dibutyryl cAMP an activator of PKA. Thus, the binding of G(beta gamma) to phosducin can be regulated by PKA-phosphorylation in an intact cell model system.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE T, 1990, GENE, V91, P209, DOI 10.1016/0378-1119(90)90090-E; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CIMONO M, 1987, J NEUROCHEM, V48, P1069; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA SC, 1988, P NATL ACAD SCI USA, V86, P6878; CRAFT CM, 1991, GENOMICS, V10, P400, DOI 10.1016/0888-7543(91)90325-9; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; EASON MG, 1992, J BIOL CHEM, V267, P15795; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JAFFE LA, 1993, J CELL BIOL, V121, P775, DOI 10.1083/jcb.121.4.775; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KUO CH, 1993, BIOCHEM BIOPH RES CO, V191, P1097, DOI 10.1006/bbrc.1993.1329; KUO CH, 1989, MOL BRAIN RES, V6, P1, DOI 10.1016/0169-328X(89)90022-3; KUROSE H, 1993, MOL PHARMACOL, V43, P444; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1992, J BIOL CHEM, V267, P25104; LEE RH, 1981, BIOCHEMISTRY-US, V20, P7532, DOI 10.1021/bi00529a031; LOLLEY RN, 1977, BIOCHEM BIOPH RES CO, V78, P572, DOI 10.1016/0006-291X(77)90217-0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCGINNIS JF, 1985, CURR EYE RES, V4, P1127, DOI 10.3109/02713688509003359; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PEITSCH MC, 1993, TRENDS BIOCHEM SCI, V18, P292, DOI 10.1016/0968-0004(93)90038-O; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REIG JA, 1990, J BIOL CHEM, V265, P5816; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; YAMADA M, 1994, BIOCHEM BIOPH RES CO, V200, P1484, DOI 10.1006/bbrc.1994.1618	48	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29825	29830						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961975				2022-12-25	WOS:A1994PU28400079
J	HUNT, TW; CARROLL, RC; PERALTA, EG				HUNT, TW; CARROLL, RC; PERALTA, EG			HETEROTRIMERIC G-PROTEINS CONTAINING G(ALPHA-I3) REGULATE MULTIPLE EFFECTOR ENZYMES IN THE SAME CELL - ACTIVATION OF PHOSPHOLIPASE-C AND PHOSPHOLIPASE-A(2) AND INHIBITION OF ADENYLYL-CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CATALYZED ADP-RIBOSYLATION; CYCLIC-AMP ACCUMULATION; M2 MUSCARINIC RECEPTOR; GTP-BINDING PROTEIN; ALPHA-SUBUNITS; CHOLERA-TOXIN; MAP KINASE; STIMULATION; HYDROLYSIS	Previous studies have shown that a single type of transmembrane receptor is able to regulate multiple effecters through the activation of heterotrimeric G proteins. For example, the m2 muscarinic acetylcholine receptor (mAChR) expressed in Chinese hamster ovary (CHO) cells inhibits adenylyl cyclase, stimulates phospholipase C-dependent intracellular Ca2+ release, and activates phospholipase A(2) through pertussis toxin-sensitive G proteins. However, it is unclear whether multiple effector enzymes can be regulated by one type of heterotrimeric G protein within a single cell. To investigate this question, we constructed a derivative of G(alpha i3) (termed G(alpha i3)C>S) in which the carboxyl-terminal cysteine residue, the site for pertussis toxin modification, was changed to a serine. Following pertussis toxin treatment of transfected CHO cells expressing the m2 mAChR, we found that the G(alpha i3)C>S protein underwent guanine nucleotide exchange in response to the muscarinic agonist carbachol, while the m2 mAChR failed to activate the endogenous G(alpha i2) and G(alpha i3) proteins. Moreover, coupling of heterotrimeric G proteins containing G(alpha i3)C>S to the m2 mAChR resulted in pertussis toxin-resistant inhibition of adenylyl cyclase, stimulation of phospholipase C-induced intracellular Ca2+ release, and phospholipase A(2)-mediated arachidonic acid release. Therefore, these studies provide conclusive evidence that heterotrimeric G proteins containing just G(alpha i3) can regulate multiple effector enzymes within the same cell type.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University								ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; ASHKENAZI A, 1994, CRC HDB RECEPTORS CH, V1, P1; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CODINA J, 1988, J BIOL CHEM, V263, P6746; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FELDER CC, 1991, P NATL ACAD SCI USA, V88, P6477, DOI 10.1073/pnas.88.15.6477; FELDER CC, 1989, J BIOL CHEM, V264, P20356; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P2039; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; IIRI T, 1989, J BIOL CHEM, V264, P21394; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE SB, 1993, J BIOL CHEM, V268, P25952; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARCHALL PJ, 1980, P NATL ACAD SCI USA, V77, P3292; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; RIBEIRONETO FAP, 1989, P NATL ACAD SCI USA, V86, P2577, DOI 10.1073/pnas.86.8.2577; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRYER L, 1991, J BIOL CHEM, V266, P10711; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; WEST RE, 1985, J BIOL CHEM, V260, P4428; WINITZ S, 1994, J BIOL CHEM, V269, P1889; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297	48	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29565	29570						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961942				2022-12-25	WOS:A1994PU28400041
J	LOMONTE, B; MORENO, E; TARKOWSKI, A; HANSON, LA; MACCARANA, M				LOMONTE, B; MORENO, E; TARKOWSKI, A; HANSON, LA; MACCARANA, M			NEUTRALIZING INTERACTION BETWEEN HEPARINS AND MYOTOXIN-II, A LYSINE-49 PHOSPHOLIPASE A(2) FROM BOTHROPS-ASPER SNAKE-VENOM - IDENTIFICATION OF A HEPARIN-BINDING AND CYTOLYTIC TOXIN REGION BY THE USE OF SYNTHETIC PEPTIDES AND MOLECULAR MODELING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODIES; DIMETHYL-SULFOXIDE; PLATELET FACTOR-4; TERCIOPELO VENOM; RESOLUTION; GLYCOSAMINOGLYCANS; OLIGOSACCHARIDES; ANTICOAGULANT; PURIFICATION	Heparin binds to phospholipase A(2) myotoxins from Bothrops asper snake venom, inhibiting their toxic activities. This interaction was investigated using purified myotoxin II, a Lys-49 phospholipase A(2) of this venom, and a series of heparin variants, fragments, and other glycosaminoglycans. The binding was correlated to toxin neutralization, using endothelial cells as a target. Myotoxin II binds radiolabeled heparin in solution unselectively, and forms macromolecular complexes with an optimum at a heparin:toxin molar ratio of 1:5. Both O-sulfates and N-sulfates play a role in heparin binding, in the order of importance 2-O-sulfates > 6-Osulfates > N-sulfates. The shortest heparin oligosaccharides interacting with myotoxin II are hexasaccharides, The binding of a neutralizing monoclonal antibody (MAb-3) to myotoxin II was not inhibited by heparin, indicating that the two molecules interact with different sites on the toxin. A synthetic peptide (residues 115-129 in the numbering system of Renetseder et al. (Renetseder, R., Brunie, S., Dijkstra, B. W., Drenth, J., and Sigler, P. B. (1985) J. Biol. Chem. 260, 11627-11634) of myotoxin II displays both heparin-binding and cytolytic activities. It is concluded that heparin neutralizes myotoxin II by binding to a strongly cationic site in the region of residues 115-129, a possible contribution of lysines 36 and 38 suggested by molecular modeling studies. As this cationic region appears to be responsible for the cytolytic activity of the toxin, the present report constitutes the first identification of a cytotoxic region an a phospholipase A(2) myotoxin.	GOTHENBURG UNIV,DEPT BIOCHEM MED,GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT RHEUMATOL,GOTHENBURG,SWEDEN; UNIV COSTA RICA,FAC MICROBIOL,INST CLODOMIRO PICADO,SAN JOSE,COSTA RICA; CTR MOLEC IMMUNOL,HAVANA,CUBA; UPPSALA UNIV,UPPSALA BIOMED CTR,DEPT MED & PHYSIOL CHEM,UPPSALA,SWEDEN	University of Gothenburg; University of Gothenburg; Universidad Costa Rica; Uppsala University	LOMONTE, B (corresponding author), GOTHENBURG UNIV,DEPT CLIN IMMUNOL,GULDHEDSGATAN 10,GOTHENBURG,SWEDEN.		maccarana, marco/AAB-4764-2021; Lomonte, Bruno/B-8862-2019; Moreno, Ernesto/D-2128-2012	Lomonte, Bruno/0000-0003-2419-6469; Moreno, Ernesto/0000-0002-2309-4826; Maccarana, Marco/0000-0003-3549-8921				BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Bolanos R, 1980, Bol Oficina Sanit Panam, V88, P189; BULTRON E, 1993, BIOCHIM BIOPHYS ACTA, V1179, P253, DOI 10.1016/0167-4889(93)90080-9; BUSSOLINO F, 1991, J IMMUNOL, V147, P2122; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; CHWETZOFF S, 1989, FEBS LETT, V248, P1, DOI 10.1016/0014-5793(89)80419-3; DANISHEFSKY I., 1965, BIOCHIM BIOPHYS ACTA, V101, P37, DOI 10.1016/0926-6534(65)90028-X; DIAZ C, 1991, BIOCHIM BIOPHYS ACTA, V1070, P455, DOI 10.1016/0005-2736(91)90086-N; DICCIANNI MB, 1991, BIOCHEMISTRY-US, V30, P9090, DOI 10.1021/bi00101a026; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; DUA R, 1994, EUR J BIOCHEM, V221, P481, DOI 10.1111/j.1432-1033.1994.tb18761.x; FRANCIS B, 1991, ARCH BIOCHEM BIOPHYS, V284, P352, DOI 10.1016/0003-9861(91)90307-5; GUTIERREZ JM, 1986, TOXICON, V24, P885, DOI 10.1016/0041-0101(86)90089-9; HOLLAND DR, 1990, J BIOL CHEM, V265, P17649; HOMSIBRANDEBURGO MI, 1988, TOXICON, V26, P615, DOI 10.1016/0041-0101(88)90244-9; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; IBEL K, 1986, BIOCHIM BIOPHYS ACTA, V870, P58, DOI 10.1016/0167-4838(86)90008-7; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; KAISER II, 1990, ARCH BIOCHEM BIOPHYS, V278, P319, DOI 10.1016/0003-9861(90)90266-2; KIHARA H, 1992, BIOCHEM INT, V28, P895; KINI RM, 1989, INT J PEPT PROT RES, V34, P277; KINI RM, 1986, TOXICON, V24, P895; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRIZAJ I, 1991, EUR J BIOCHEM, V202, P1165, DOI 10.1111/j.1432-1033.1991.tb16485.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LIU SY, 1990, J BIOCHEM, V107, P400, DOI 10.1093/oxfordjournals.jbchem.a123057; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LOMONTE B, 1989, TOXICON, V27, P725, DOI 10.1016/0041-0101(89)90039-1; LOMONTE B, 1994, BIOCHEM PHARMACOL, V47, P1509, DOI 10.1016/0006-2952(94)90525-8; LOMONTE B, 1992, TOXICON, V30, P239, DOI 10.1016/0041-0101(92)90866-4; LOMONTE B, 1988, TOXICON, V26, P675, DOI 10.1016/0041-0101(88)90249-8; LOMONTE B, 1994, TOXICON, V32, P1359, DOI 10.1016/0041-0101(94)90408-1; LYCKE E, 1991, J GEN VIROL, V72, P1131, DOI 10.1099/0022-1317-72-5-1131; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MARAGANORE JM, 1984, J BIOL CHEM, V259, P3839; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; PEJLER G, 1988, J BIOL CHEM, V263, P5197; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; Rosenberg P., 1990, HDB TOXINOLOGY, P67; Rosenberg P., 1986, NATURAL TOXINS ANIMA, P129; RUFINI S, 1992, BIOCHEMISTRY-US, V31, P12424, DOI 10.1021/bi00164a018; SCOTT DL, 1992, J BIOL CHEM, V267, P22645; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; VALERIO RM, 1993, INT J PEPT PROT RES, V42, P1; WESTERLUND B, 1992, FEBS LETT, V301, P159, DOI 10.1016/0014-5793(92)81238-H; YOSHIZUMI K, 1990, TOXICON, V28, P43, DOI 10.1016/0041-0101(90)90005-R	54	198	199	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29867	29873						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961981				2022-12-25	WOS:A1994PU28400085
J	BHATTACHARYA, A; BHATTACHARYYA, B; ROY, S				BHATTACHARYA, A; BHATTACHARYYA, B; ROY, S			MAGNESIUM-INDUCED STRUCTURAL-CHANGES IN TUBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; GUANINE-NUCLEOTIDE-BINDING; PURE TUBULIN; POLYMERIZATION; INVITRO; FLUORESCENCE; BRAIN; ION; REQUIREMENTS; GLYCEROL	Exogenously added Mg2+, in the intracelluar concentration range, has significant effect on the conformation of tubulin as monitored by tryptophan fluorescence. This magnesium-induced conformational change is reflected in the change of the slope and intercept of the Lehrer plot. The off-rate of colchicine from colchicine-tubulin complex is also decreased severalfold upon the addition of exogenous magnesium. The conformational change is magnesium-specific, and magnesium can only be replaced by manganese. GTP, CaCl2, and NaCl have no effect. Magnesium, however has no effect on tryptophan accessibilities of tubulin-S. Implications of these results are discussed in terms of C-terminal tail-body interaction.	BOSE INST,DEPT BIOPHYS,CALCUTTA 700054,W BENGAL,INDIA; BOSE INST,DEPT BIOCHEM,CALCUTTA 700054,W BENGAL,INDIA	Department of Science & Technology (India); Bose Institute; Department of Science & Technology (India); Bose Institute								BHATTACHARYYA B, 1985, J BIOL CHEM, V260, P208; BHATTACHARYYA T, 1991, EUR J BIOCHEM, V200, P739, DOI 10.1111/j.1432-1033.1991.tb16239.x; BUTTLAIRE DH, 1980, J BIOL CHEM, V255, P2164; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P433; CORREIA JJ, 1988, J BIOL CHEM, V263, P10681; CORREIA JJ, 1987, J BIOL CHEM, V262, P17278; CROOM HB, 1985, BIOCHEMISTRY-US, V24, P768, DOI 10.1021/bi00324a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FRIGON RP, 1975, BIOCHEMISTRY-US, V14, P4567, DOI 10.1021/bi00692a002; HAMEL E, 1983, BIOCHEMISTRY-US, V22, P3664, DOI 10.1021/bi00284a020; HAMEL E, 1984, BIOCHIM BIOPHYS ACTA, V797, P117, DOI 10.1016/0304-4165(84)90390-8; HAMEL E, 1981, ARCH BIOCHEM BIOPHYS, V209, P29, DOI 10.1016/0003-9861(81)90253-8; HAMEL E, 1983, BIOCHEMISTRY-US, V22, P1271, DOI 10.1021/bi00274a044; HERZOG W, 1977, P NATL ACAD SCI USA, V74, P1860, DOI 10.1073/pnas.74.5.1860; HIMES RH, 1977, J BIOL CHEM, V252, P6222; HOROWITZ P, 1984, J BIOL CHEM, V259, P4647; HOWARD WD, 1986, BIOCHEMISTRY-US, V25, P8292, DOI 10.1021/bi00373a025; HUANG AB, 1985, BIOCHIM BIOPHYS ACTA, V832, P22, DOI 10.1016/0167-4838(85)90170-0; LEE JC, 1977, BIOCHEMISTRY-US, V16, P1754, DOI 10.1021/bi00627a037; LEE YC, 1974, J NEUROBIOL, V5, P317, DOI 10.1002/neu.480050404; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; MACDONALD TL, 1987, SCIENCE, V236, P183, DOI 10.1126/science.3105058; MEJILLANO MR, 1991, J BIOL CHEM, V266, P657; MUKHOPADHYAY K, 1990, BIOCHEMISTRY-US, V29, P6845, DOI 10.1021/bi00481a013; OBRIEN ET, 1989, BIOCHEMISTRY-US, V28, P1413, DOI 10.1021/bi00429a070; OLMSTED JB, 1975, BIOCHEMISTRY-US, V14, P2996, DOI 10.1021/bi00684a032; ORTIZ M, 1993, ARCH BIOCHEM BIOPHYS, V303, P159, DOI 10.1006/abbi.1993.1267; OSEI AA, 1990, FEBS LETT, V276, P85, DOI 10.1016/0014-5793(90)80513-I; PANDA D, 1992, BIOCHEMISTRY-US, V31, P9709, DOI 10.1021/bi00155a026; PEYROT V, 1990, ARCH BIOCHEM BIOPHYS, V279, P328, DOI 10.1016/0003-9861(90)90499-O; ROYCHOWDHURY S, 1986, BIOCHEMISTRY-US, V25, P7847, DOI 10.1021/bi00372a010; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024	32	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28655	28661						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961815				2022-12-25	WOS:A1994PU16800024
J	CLARK, EA; SHATTIL, SJ; GINSBERG, MH; BOLEN, J; BRUGGE, JS				CLARK, EA; SHATTIL, SJ; GINSBERG, MH; BOLEN, J; BRUGGE, JS			REGULATION OF THE PROTEIN-TYROSINE KINASE PP72(SYK) BY PLATELET AGONISTS AND THE INTEGRIN ALPHA(IIB)BETA(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODIES; RABBIT PLATELETS; IIIA RECEPTOR; ZETA-CHAIN; ACTIVATION; PHOSPHORYLATION; ASSOCIATION; THROMBIN; AGGREGATION	Agonist stimulation of platelets induces multiple waves of tyrosine phosphorylation, several of which are dependent on the integrin alpha(IIb)beta(3). At least two classes of protein tyrosine kinases are activated during various stages of platelet activation, 1) Src family tyrosine kinases are activated during an early phase of platelet activation by an integrin-independent mechanism and 2) pp125(FAK) is activated during a late stage of platelet activation, and it is dependent on platelet aggregation mediated by fibrinogen binding to alpha(IIb)beta(3). In this report, we examined the mechanism of agonist-induced phosphorylation and activation of the tyrosine kinase pp72(syk), which is known to couple with immune response receptors in B cells and mast cells. pp72(syk) was found to be regulated by both agonist and integrin receptors in a pattern distinct from that of pp60(src) and pp125(FAK). Specifically, thrombin induced the tyrosine phosphorylation and activation of pp72(syk) independent of platelet aggregation. However, full activation of pp72(syk) required integrin engagement since treatment with antibodies that block fibrinogen binding to alpha(IIb)beta(3) reduced pp72(syk) phosphorylation by 40%. Furthermore, fibrinogen binding to alpha(IIb)beta(3) stimulated directly with an anti-beta(3) antibody activated pp72(syk) 3-fold and stimulated its tyrosine phosphorylation. Thus, pp72(syk) is the only platelet tyrosine kinase identified to date that can be directly activated through integrin ligation. In addition, we found that the activation of pp72(syk) is dependent upon the state of actin polymerization and that pp72(syk) redistributes to actin-rich cytoskeletal complexes in an aggregation-dependent manner. These results suggest a role for pp72(syk) in both early, integrin-independent tyrosine phosphorylation events as well as those dependent upon subsequent integrin engagement.	ARIAD PHARMACEUT INC, CAMBRIDGE, MA 02139 USA; UNIV PENN, SCH MED, GRAD GRP CELL BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, PRINCETON, NJ 08543 USA	Takeda Pharmaceutical Company Ltd; Takeda Oncology; University of Pennsylvania; University of Pennsylvania; Scripps Research Institute; Bristol-Myers Squibb					NCI NIH HHS [CA47572] Funding Source: Medline; NHLBI NIH HHS [HL48728, HL40387] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047572] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, P01HL040387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CLARK EA, 1993, TRENDS CARDIOVAS MED, V3, P218, DOI 10.1016/1050-1738(93)90043-6; CLARK EA, 1994, J BIOL CHEM, V269, P21940; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COLLER BS, 1989, CIRCULATION, V80, P1766, DOI 10.1161/01.CIR.80.6.1766; DHAR A, 1990, MOL PHARMACOL, V37, P519; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRANK SJ, 1992, J BIOL CHEM, V267, P13656; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KIENER PA, 1993, J BIOL CHEM, V268, P24442; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; OHTA S, 1992, BIOCHEM BIOPH RES CO, V185, P1128, DOI 10.1016/0006-291X(92)91743-A; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WONG S, 1992, ONCOGENE, V7, P2407; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195	34	225	227	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28859	28864						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961845				2022-12-25	WOS:A1994PU16800055
J	LIU, K; BERGSON, C; LEVENSON, R; SCHMAUSS, C				LIU, K; BERGSON, C; LEVENSON, R; SCHMAUSS, C			ON THE ORIGIN OF MESSENGER-RNA ENCODING THE TRUNCATED DOPAMINE D-3-TYPE RECEPTOR D-3NF AND DETECTION OF D-3NF-LIKE IMMUNOREACTIVITY IN HUMAN BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CAENORHABDITIS-ELEGANS; RAT; IDENTIFICATION; EXONS; LOCALIZATION; INTRONS; SITES	A truncated dopamine D-3-receptor-like mRNA, named D-3nf, predicts a protein that differs from the D-3-receptor only in the carboxyl terminus. However, such a protein has lost the predicted membrane topology typically found for G protein-coupled receptors. Results presented here show that D-3nf mRNA arises from the D-3-encoded primary transcript via alternative splicing. This splicing, however, appears to involve cleavage of an unusual 3' splice site. Therefore, we tested the possibility that D-3nf mRNA results from a splicing error. If this were the case, D-3nf mRNA would be expected to be present in the cytoplasm only at very low amounts, and it would not be expected to be translated into protein. However, the relative abundance of cytoplasmic D-3/D-3nf mRNA in human cortical tissues was found to be similar. Furthermore, we raised polyclonal antisera against the predicted carboxyl-terminal peptide sequence of D-3nf that reacts specifically with a protein expressed in stably D-3nf mRNA-expressing COS 7 cells. The use of this antiserum also revealed the presence of a similar to 68 kDa D-3nf like immunoreactive protein in human brain, suggesting that the atypically processed D-3nf mRNA is translated.	CUNY MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Yale University				Levenson, Robert/0000-0002-0936-8421	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049023] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 49023] Funding Source: Medline; NIMH NIH HHS [MH 45212] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AROIAN RV, 1993, MOL CELL BIOL, V13, P626, DOI 10.1128/MCB.13.1.626; BOUTHENET ML, 1991, BRAIN RES, V564, P203, DOI 10.1016/0006-8993(91)91456-B; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; COCQUERELLE C, 1992, EMBO J, V11, P1095, DOI 10.1002/j.1460-2075.1992.tb05148.x; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; FISHBURN CS, 1993, J BIOL CHEM, V268, P5872; GIROS B, 1991, BIOCHEM BIOPH RES CO, V176, P1584, DOI 10.1016/0006-291X(91)90469-N; GIROS B, 1990, CR ACAD SCI III-VIE, V311, P501; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; NAGAI Y, 1993, BIOCHEM BIOPH RES CO, V194, P386; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; NIMCHINSKY EA, 1994, DOPAMINE D 3 RECEPTO; POTENZA MN, 1994, J NEUROSCI, V14, P1463, DOI 10.1523/JNEUROSCI.14-03-01463.1994; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMAUSS C, 1993, P NATL ACAD SCI USA, V90, P8942, DOI 10.1073/pnas.90.19.8942; SCHOTTE A, 1992, EUR J PHARMACOL, V218, P373, DOI 10.1016/0014-2999(92)90196-B; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHYJAN AW, 1992, METHOD MOL BIOL, V13, P93; SNYDER LA, 1991, BIOCHEM BIOPH RES CO, V180, P1031, DOI 10.1016/S0006-291X(05)81169-6; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J	30	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29220	29226						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961889				2022-12-25	WOS:A1994PU16800102
J	LOMBARDO, CR; WEED, SA; KENNEDY, SP; FORGET, BG; MORROW, JS				LOMBARDO, CR; WEED, SA; KENNEDY, SP; FORGET, BG; MORROW, JS			BETA-II-SPECTRIN (FODRIN) AND BETA-I-SIGMA-2-SPECTRIN (MUSCLE) CONTAIN NH2-TERMINAL AND COOH-TERMINAL MEMBRANE ASSOCIATION DOMAINS (MAD1 AND MAD2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-MEMBRANE; BINDING-SITE; CYTOSKELETAL REGULATION; SIGNALING PROTEINS; CELL-ADHESION; HUMAN-BRAIN; ANKYRIN; CDNA; TRANSMEMBRANE; ORGANIZATION	Central to spectrin's function is its association with the plasma membrane. The linking proteins ankyrin and protein 4.1 partly mediate this association, and their interactions with spectrin are well understood. Both beta I (erythrocyte) and beta II (fodrin, beta(G)) spectrin also associate with unknown protein receptors in crude membrane preparations by ankyrin and protein 4.1 independent mechanisms. As a first step to understanding this interaction, kinetic and equilibrium assays have been used to monitor which regions of beta I and beta II spectrin inhibit the binding of purified (125)-labeled bovine brain spectrin to demyelinated and NaOH-stripped bovine brain membranes. A series of 19 recombinant proteins spanning the entire sequence of beta II spectrin, including an alternatively spliced NH2-terminal isoform (beta II Sigma 2 spectrin), were prepared as glutathione S-transferase fusion proteins. Also prepared were peptides representing the alternatively spliced COOH-terminal domain found in beta I Sigma 2 spectrin (''muscle spectrin''). Two distinct sequence motifs inhibited the binding of native brain spectrin. Membrane association domain 1 (MAD1) was repre sented in all fusion peptides that included spectrin repeat 1. These peptides slowed the kinetics of brain spectrin binding and inhibited up to 46% of the maximal binding under the conditions of these assays (apparent K-i less than or equal to 0.2 mu m). Peptides representative of repeats 2-17 of beta II spectrin were devoid of inhibitory activity. The second membrane association domain (MAD2) was identified in penultimate COOH-terminal sequences (domain III) of both beta II and beta I Sigma 2 spectrin. These sequences were absent in beta I Sigma 1 (erythrocyte) spectrin. MAD2 competitively inhibited over 80% of brain spectrin binding in these assays, with an apparent K-i, less than or equal to 0.1 mu M. Direct binding studies confirmed that both MAD1 and MAD2 peptides associated with membranes with affinities comparable to their inhibition constants. Sequence comparisons suggest that MAD1 is created by the insertion of two non-homologous sequence motifs into repeat 1, extending it from 106 to 122 amino acids. Similarly, MAD2 encompasses a putative site of beta gamma-heterotrimeric G-protein binding called the pleckstrin homology domain, and MAD2 may in fact be the pleckstrin homology domain although this has not been rigorously proven. Collectively these studies identify two novel functional motifs in spectrin that mediate ankyrin independent association with membranes. We hypothesize that these motifs and their still to be discovered ligands play a primary role in the nascent assembly and stabilization of an ordered and polarized spectrin skeleton.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT MED, NEW HAVEN, CT 06510 USA	Yale University; Yale University; Yale University				Weed, Scott/0000-0001-7033-9999				AMIN KM, 1993, GENOMICS, V18, P118, DOI 10.1006/geno.1993.1434; BECKER PS, 1990, EUR J BIOCHEM, V193, P827, DOI 10.1111/j.1432-1033.1990.tb19406.x; BENNETT V, 1986, METHOD ENZYMOL, V134, P55; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; CHANG JG, 1993, GENOMICS, V17, P287, DOI 10.1006/geno.1993.1323; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HARRIS AS, 1985, BIOCHIM BIOPHYS ACTA, V830, P147, DOI 10.1016/0167-4838(85)90022-6; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HOWE CL, 1985, J CELL BIOL, V101, P1379, DOI 10.1083/jcb.101.4.1379; HU RJ, 1992, J BIOL CHEM, V267, P18715; HU RJ, 1991, J BIOL CHEM, V266, P18200; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KENNEDY SP, 1994, J BIOL CHEM, V269, P11400; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; Lombardo C. R., 1993, Molecular Biology of the Cell, V4, p57A; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; MALCHIODIALBEDI F, 1993, J CELL SCI, V106, P67; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; REID ME, 1990, BLOOD, V75, P2229; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J, 1989, MOL CLONING LABORATO; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; Stabach P. R., 1993, Molecular Biology of the Cell, V4, p58A; STEINER JP, 1988, J BIOL CHEM, V263, P14417; STEINER JP, 1989, J BIOL CHEM, V264, P2783; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097	42	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29212	29219						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961888				2022-12-25	WOS:A1994PU16800101
J	LUTZ, MS; JASKIEWICZ, E; DARLING, DS; FURUKAWA, K; YOUNG, WW				LUTZ, MS; JASKIEWICZ, E; DARLING, DS; FURUKAWA, K; YOUNG, WW			CLONED BETA-1,4N-ACETYLGALACTOSAMINYLTRANSFERASE SYNTHESIZES G(A2) AS WELL AS GANGLIOSIDES G(M2) AND G(D2) - G(M3) SYNTHESIS HAS PRIORITY OVER G(A2) SYNTHESIS FOR UTILIZATION OF LACTOSYLCERAMIDE SUBSTRATE IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; BREFELDIN-A; RAT-LIVER; N-ACETYLGALACTOSAMINYLTRANSFERASE; GOLGI VESICLES; MOUSE-LIVER; SIALIC-ACID; BIOSYNTHESIS; EXPRESSION; GM2	Earlier studies reached conflicting conclusions as to the ability of the beta 1,4 N-acetylgalactosaminyltransferase (GalNAc-T) that synthesizes gangliosides G(M2), and G(D2) to also produce gangliotriosylceramide (G(A2)). We constructed an experimental system in which to address this question. Wild type Chinese hamster ovary (CHO) cells contain ganglioside G(M3) as the most complex glycosphingolipid (GSL), whereas the CHO glycosylation mutant Lec2, which is deficient in sialylation, accumulates lactosylceramide with little G(M3) being produced. We transfected both cell types with a plasmid containing a cloned GalNAc-T. Whereas transfected CHO cells produced G(M2), as the major complex GSL, the major product in transfected Lec2 cells was G(A2). Both types of transfected cells but not the untransfected cells expressed the transfected gene and contained high levels of enzyme activity for synthesizing both G(M2) and G(D2) in vitro. In summary, these results indicate that this enzyme can in fact synthesize G(A2) as well as G(M2) and G(D2). In addition, these findings suggest that in CHO cells the synthesis of G(M3) in vivo has priority over G(A2) synthesis for utilization of the substrate lactosylceramide, resulting in little G(A2) being produced even though GalNAc-T is present and active. Thus, competition for substrate between glycosylation pathways may have profound effects on the GSL pattern of cells.	UNIV LOUISVILLE,HLTH SCI CTR,DEPT BIOL & BIOPHYS SCI,LOUISVILLE,KY 40292; UNIV LOUISVILLE,HLTH SCI CTR,DEPT BIOCHEM,LOUISVILLE,KY 40292; NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN	University of Louisville; University of Louisville; Nagasaki University			Darling, Douglas S/D-4573-2009	Darling, Douglas/0000-0002-9039-1169	NIDDK NIH HHS [DK44332] Funding Source: Medline; NIGMS NIH HHS [GM42698] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044332] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASU M, 1987, METHOD ENZYMOL, V138, P575; BRILES EB, 1977, J BIOL CHEM, V252, P1107; CURATOLO W, 1987, BIOCHIM BIOPHYS ACTA, V906, P137, DOI 10.1016/0304-4157(87)90009-8; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HANDA S, 1969, LIPIDS, V4, P589, DOI 10.1007/BF02531046; HASHIMOTO Y, 1993, J BIOL CHEM, V268, P25857; IBER H, 1990, EUR J CELL BIOL, V52, P236; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KONO M, 1991, J BIOCHEM-TOKYO, V109, P132, DOI 10.1093/oxfordjournals.jbchem.a123333; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MANDON EC, 1992, J BIOL CHEM, V267, P11144; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NATOLI EJ, 1986, CANCER RES, V46, P4116; NICHOLS GE, 1986, BIOCHIM BIOPHYS ACTA, V887, P1, DOI 10.1016/0167-4889(86)90115-1; POHLENTZ G, 1988, BIOL CHEM H-S, V369, P55, DOI 10.1515/bchm3.1988.369.1.55; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; POTVIN B, 1990, J BIOL CHEM, V265, P1615; SAITO T, 1971, J LIPID RES, V12, P257; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANDHOFF K, 1993, ADV LIPID RES, V26, P119; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P348; SJOBERG ER, 1993, J BIOL CHEM, V268, P10185; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH PL, 1994, J BIOL CHEM, V269, P15162; STEIGERWALD JC, 1975, J BIOL CHEM, V250, P6727; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; YOGEESWARAN G, 1974, BIOCHEM BIOPH RES CO, V56, P1010, DOI 10.1016/S0006-291X(74)80289-5; YOUNG WW, 1992, J BIOL CHEM, V267, P12011; YOUNG WW, 1993, ADV LIPID RES, V26, P161; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YOUNG WW, 1979, J EXP MED, V150, P1008, DOI 10.1084/jem.150.4.1008	35	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29227	29231						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961890				2022-12-25	WOS:A1994PU16800103
J	MORASH, SC; MCMASTER, CR; HJELMSTAD, RH; BELL, RM				MORASH, SC; MCMASTER, CR; HJELMSTAD, RH; BELL, RM			STUDIES EMPLOYING SACCHAROMYCES-CEREVISIAE CPT1 AND EPT1 NULL MUTANTS IMPLICATE THE CPT1 GENE IN COORDINATE REGULATION OF PHOSPHOLIPID BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLSERINE DECARBOXYLASE; PHOSPHATIDATE PHOSPHATASE; TRANSFER PROTEIN; INOSITOL; YEAST; SYNTHASE; ETHANOLAMINEPHOSPHOTRANSFERASE; METHYLATION; CHOLINE; PATHWAY	The Saccharomyces cerevisiae CPT1 and EPT1 genes are structural genes encoding sn-1,2-diacylglycerol choline phosphotransferase and sn-1,2-diacylglycerol choline/ethanolamine phosphotransferase, respectively. Incorporation of P-32(i) into phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine in wild type and ept1 strains was decreased in the presence of exogenous inositol. In contrast, inositol did not affect P-32(i) incorporation into phospholipid in cpt1 or cpt1ept1 strains. In membranes isolated from wild type and ept1 strains grown in the presence of inositol or inositol/choline, the CPT1-derived cholinephosphotransferase activities were reduced 40-50 and 65%, respectively. Inositol-dependent reductions in CPT1 derived cholinephosphotransferase activity correlated with transcript levels in both wild type and ept- backgrounds. The ethanolaminephosphotransferase activity of the EPT1 gene product in wild type cells was reduced 40% by exogenous inositol alone and 50% by inositol/choline. In the cpt1 strain, however, the ethanolaminephosphotransferase activity was unaffected by exogenous inositol or inositol/choline. The inositol-dependent reduction of ethanolaminephosphotransferase activity observed in wild type cells correlated with reduced levels of EPT1 transcripts; in the cpt1 strain, EPT1 transcript levels were not affected by inositol. These results indicate that 1) a functional CPT1 gene or gene product is required for inositol-dependent regulation of phospholipid synthesis; 2) the enzyme activities of both the CPT1 and EPT1 gene products are repressed by inositol and inositol/choline, and require an intact CPT1 gene; 3) inositol mediates its regulatory effects on phospholipid synthesis via a transcriptional mechanism.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University	MORASH, SC (corresponding author), DUKE UNIV, MED CTR, DEPT MOLEC CANC BIOL, DURHAM, NC 27710 USA.			McMaster, Christopher/0000-0003-0822-5776	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020015] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20015] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; AMES BN, 1960, J BIOL CHEM, V235, P769; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1984, GENETICS, V108, P533; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARSON MA, 1984, J BIOL CHEM, V259, P6267; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CULBERTSON MR, 1976, J BACTERIOL, V126, P243, DOI 10.1128/JB.126.1.243-250.1976; ESKO JD, 1983, ENZYMES, V16, P207; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; HOSAKA K, 1990, J BACTERIOL, V172, P2005, DOI 10.1128/jb.172.4.2005-2012.1990; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; LAMPING E, 1991, J BACTERIOL, V173, P6432, DOI 10.1128/jb.173.20.6432-6437.1991; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; Maniatis T, 1989, MOL CLONING; MAVIS RD, 1972, J BIOL CHEM, V247, P2835; MCALISTER L, 1980, J BACTERIOL, V143, P603, DOI 10.1128/JB.143.2.603-612.1980; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, IN PRESS J BIOL CHEM, V269; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; YAMASHITA S, 1982, EUR J BIOCHEM, V128, P589	36	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28769	28776						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961831				2022-12-25	WOS:A1994PU16800041
J	SATOWATANABE, M; MOGI, T; MIYOSHI, H; IWAMURA, H; MATSUSHITA, K; ADACHI, O; ANRAKU, Y				SATOWATANABE, M; MOGI, T; MIYOSHI, H; IWAMURA, H; MATSUSHITA, K; ADACHI, O; ANRAKU, Y			STRUCTURE-FUNCTION STUDIES ON THE UBIQUINOL OXIDATION SITE OF THE CYTOCHROME BO COMPLEX FROM ESCHERICHIA-COLI USING P-BENZOQUINONES AND SUBSTITUTED PHENOLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC RESPIRATORY-CHAIN; ELECTRON-TRANSPORT INHIBITION; COPPER BINUCLEAR CENTER; TERMINAL OXIDASE; HEME-COPPER; CYOE GENE; DIRECTED MUTAGENESIS; HERBICIDE BINDING; PHOTOSYSTEM-II; C OXIDASES	To characterize the structural features of the quinol oxidation site (the Q(L) site) of the cytochrome bo complex, a heme-copper respiratory oxidase in Escherichia coli, we carried out structure-inhibitory potency analyses using 7 p-benzoquinones and 33 substituted phenols. Their effects on its ubiquinol-1 oxidase activity were compared with those on the cytochrome bd complex in E. coli and on cytochromes o and a(1) in Acetobacter aceti. They showed similar structural properties of the Q(L) site, although cytochrome o was more sensitive to 4-cyanophenols, suggesting a specific interaction of the hydrogen bond-accepting cyano group with the binding pocket. Replacing one of the methyl groups of 2,6-dimethyl-p-benzoquinone, which is the most potent competitive inhibitor, with an ethyl group markedly decreased the inhibitory activity, indicating that the Q(L) site specifically recognizes one C=O group with two methyl groups as the ortho-substituents. In substituted phenols, ortho-chlorine substituents were the most effective in recognition, and the electron-withdrawing ability of the para-substituent determined an inhibitory potency, probably by stabilizing an anionic form. Based on these observations, we postulate that the Q(L) site of the cytochrome bo complex asymmetrically recognizes exogenous ligands and that this property accounts for the sequential electron transfer from ubiquinols to the low-spin heme.	UNIV TOKYO,GRAD SCH SCI,DEPT PLANT SCI,BUNKYO KU,TOKYO 113,JAPAN; KYOTO UNIV,DEPT AGR CHEM,SAKYO KU,KYOTO 606,JAPAN; YAMAGUCHI UNIV,FAC AGR,DEPT BIOL CHEM,YAMAGUCHI 753,JAPAN	University of Tokyo; Kyoto University; Yamaguchi University								ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; AZZI A, 1990, ARCH BIOCHEM BIOPHYS, V280, P242, DOI 10.1016/0003-9861(90)90326-T; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001; CALHOUN MW, 1993, BIOCHEMISTRY-US, V32, P13254, DOI 10.1021/bi00211a038; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; DASSA J, 1991, MOL GEN GENET, V229, P341, DOI 10.1007/BF00267454; DAUZONNE D, 1981, SYNTHESIS-STUTTGART, P739; DUEWEKE TJ, 1990, J BIOL CHEM, V265, P4273; FALK JE, 1964, PORPHYRINS METALLOPO, P181; FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x; FUKAYA M, 1993, J BACTERIOL, V175, P4307, DOI 10.1128/JB.175.14.4307-4314.1993; GREEN GN, 1988, J BIOL CHEM, V263, P13138; HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035; Hansch C, 1979, SUBSTITUENT CONSTANT; HATA A, 1985, BIOCHIM BIOPHYS ACTA, V810, P62, DOI 10.1016/0005-2728(85)90206-3; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HILL J, 1992, BIOCHEMISTRY-US, V31, P11435, DOI 10.1021/bi00161a023; KITA K, 1984, J BIOL CHEM, V259, P3368; KITA K, 1984, J BIOL CHEM, V259, P3375; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; LIOTTA D, 1982, J ORG CHEM, V48, P2932; MATSUSHITA K, 1992, J BIOL CHEM, V267, P24748; MATSUSHITA K, 1984, BIOCHEMISTRY-US, V23, P4703, DOI 10.1021/bi00315a028; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; MINAGAWA J, 1990, J BIOL CHEM, V265, P11198; MINGHETTI KC, 1992, BIOCHEMISTRY-US, V31, P6917, DOI 10.1021/bi00145a008; MIYOSHI H, 1993, BIOCHIM BIOPHYS ACTA, V1143, P23, DOI 10.1016/0005-2728(93)90211-W; MORTON RA, 1965, BIOCH QUINONES, P23; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; SAIKI K, 1993, J BIOL CHEM, V268, P26927; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; SAITOH I, 1992, EUR J BIOCHEM, V209, P73, DOI 10.1111/j.1432-1033.1992.tb17262.x; SALERNO JC, 1990, J BIOL CHEM, V265, P4364; SARASTE M, 1991, BIOCHEM SOC T, V19, P608, DOI 10.1042/bst0190608; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28908; SINNING I, 1992, TRENDS BIOCHEM SCI, V17, P150, DOI 10.1016/0968-0004(92)90324-3; TAN AK, 1993, J BIOL CHEM, V268, P19328; TOKUTAKE N, 1991, BIOCHIM BIOPHYS ACTA, V1057, P377, DOI 10.1016/S0005-2728(05)80151-3; TREBST A, 1987, Z NATURFORSCH C, V42, P742; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TSUBAKI M, 1993, FEBS LETT, V335, P13, DOI 10.1016/0014-5793(93)80430-3; UNO T, 1994, J BIOL CHEM, V269, P11912; UNO T, 1985, J BIOL CHEM, V260, P6755; WELTER R, 1994, BIOPHYS J, V66, P367	46	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28899	28907						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961851				2022-12-25	WOS:A1994PU16800061
J	SOREGHAN, B; KOSMOSKI, J; GLABE, C				SOREGHAN, B; KOSMOSKI, J; GLABE, C			SURFACTANT PROPERTIES OF ALZHEIMERS A-BETA PEPTIDES AND THE MECHANISM OF AMYLOID AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LYSOSOMOTROPIC DETERGENTS; SECONDARY STRUCTURE; DISEASE; PROTEIN; INVITRO; PATHOGENESIS; DEPOSITION; TOXICITY; FIBRILS; ANALOGS	The major proteinaceous component of amyloid deposits associated with Alzheimer's disease is a self-assembling 40-42-residue peptide, known as A beta, which is generated by the proteolytic processing of the amyloid precursor protein (Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., Multhaup, G., Beyreuther, K., and Muller-Hill, B. (1987) Nature 325, 733-736; Haass, C., Hung, A. Y., Schlossmacher, M. G., Oltersdorf, T., Teplow, D. B., and Selkoe, D. J. (1993) Ann. N. Y.: Acad. Sci. 695, 109-116; Estus, S., Golde, T. E., and Younkin S. G. (1992) Ann. N. Y. Acad. Sci. 674, 138-148) and is implicated as one of the causal factors in the pathology of the disease. A beta is now shown to display properties commonly associated with surfactants or detergents, which form micelles in solution. Increasing concentrations of A beta lower the surface tension of water up to a critical concentration, above which little further decrease in surface tension is observed. At concentrations above this critical concentration, increasing amounts of non-covalent aggregates of A beta are observed. A beta aggregation is also correlated with the formation of a hydrophobic environment that excludes water. The extent of this hydrophobic environment, as reflected by the partitioning of hydrophobic fluorescent probes, is much higher for the longer A beta 1-42 isoform, which may be more intimately associated with Alzheimer's disease pathology than A beta 1-40. Although the solution structure of A beta is not yet known, these results suggest that the structure of A beta has the same type of axial amphipathic organization as detergent molecules and that the same principles that govern micelle formation may also apply to A beta aggregation and amyloid fibril self-assembly.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL INSTITUTE ON AGING [P01AG000538] Funding Source: NIH RePORTER; NIA NIH HHS [AG00538] Funding Source: Medline; NINDS NIH HHS [NS31230] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BENNES R, 1991, J CARDIOVASC PHAR S7, V17, P44; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BURDICK D, 1992, J BIOL CHEM, V267, P546; CHATTOPADHYAY A, 1984, ANAL BIOCHEM, V139, P408, DOI 10.1016/0003-2697(84)90026-5; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; FIRESTONE RA, 1979, J MED CHEM, V22, P1130, DOI 10.1021/jm00195a026; FORSTER S, 1987, BIOCHIM BIOPHYS ACTA, V924, P452, DOI 10.1016/0304-4165(87)90160-7; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MAY PC, 1992, NEUROBIOL AGING, V13, P605, DOI 10.1016/0197-4580(92)90064-5; MAYER RJ, 1992, LANCET, V340, P156, DOI 10.1016/0140-6736(92)93224-B; MILLER DK, 1983, J CELL BIOL, V97, P1841, DOI 10.1083/jcb.97.6.1841; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MIYAKAWA T, 1986, VIRCHOWS ARCH B, V52, P99, DOI 10.1007/BF02889954; NIXON RA, 1992, ANN NY ACAD SCI, V674, P65; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; RADLICK LW, 1992, BIOCHIM BIOPHYS ACTA, V1120, P193, DOI 10.1016/0167-4838(92)90269-J; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SPENCER RGS, 1991, BIOCHEMISTRY-US, V30, P10382, DOI 10.1021/bi00107a004; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANFORD C, 1980, HYDROPHOBIC EFFECT; WISNIEWSKI HM, 1988, CIBA F SYMP, V135, P224; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	38	242	254	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28551	28554						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961799				2022-12-25	WOS:A1994PU16800008
J	FUJISE, A; MIZUNO, K; UEDA, Y; OSADA, S; HIRAI, S; TAKAYANAGI, A; SHIMIZU, N; OWADA, MK; NAKAJIMA, H; OHNO, S				FUJISE, A; MIZUNO, K; UEDA, Y; OSADA, S; HIRAI, S; TAKAYANAGI, A; SHIMIZU, N; OWADA, MK; NAKAJIMA, H; OHNO, S			SPECIFICITY OF THE HIGH-AFFINITY INTERACTION OF PROTEIN-KINASE-C WITH A PHYSIOLOGICAL SUBSTRATE, MYRISTOYLATED ALANINE-RICH PROTEIN-KINASE-C SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMINENT CELLULAR SUBSTRATE; PHOSPHORYLATION SITE DOMAIN; MOLECULAR-CLONING; PHORBOL ESTER; MAJOR SUBSTRATE; RAT-BRAIN; CALMODULIN BINDING; GLYCOGEN-SYNTHASE; CARDIAC TROPONIN; SKELETAL-MUSCLE	Although myristoylated alanine-rich C kinase substrate (MARCKS), has been employed as an indicator for the activation of protein kinase C (PRC) in intact cells, little is known about its specificity for PKC family members. To address this question, we partially purified human MARCKS from baculovirus-infected cells and compared the kinetic parameters for phosphorylation by PKC isozymes, conventional PKC alpha (cPKC alpha), novel PKC delta (nPKC delta), nPKC epsilon, and atypical PKC zeta (aPKC zeta), all of which are distributed in a wide variety of cells. cPKC alpha, nPKC delta, and nPKC epsilon efficiently phosphorylated intact MARCKS protein in vitro. The affinity of MARCKS for cPKC alpha, nPKC delta, and nPKC epsilon was extremely high and decreased in the order alpha > delta > epsilon with K-m values of 10.7, 20.7, and 29.8 nM, respectively. The rate of phosphorylation also decreased in the same order. In contrast, aPKC zeta did not phosphorylate MARCKS efficiently, and we were unable to estimate the kinetic parameters. These results suggest that cPKC alpha, nPKC delta, and nPKC epsilon but not aPKC zeta are enzymes that phosphorylate MARCKS in response to PHC activators in intact cells. The structural requirements of MARCKS for efficient phosphorylation by these PKC members were then examined using a peptide that surrounds the phosphorylation site of MARCKS (peptide MARCKS). Interestingly, intact MARCKS showed a 90-150 times lower rate of phosphorylation by PKCs compared with peptide MARCKS, whereas the former showed a 40-180 times higher affinity for these PI(C members. This implies that intact MARCKS protein retains a very high affinity for PRC with the sacrifice of its phospho-accepting activity. The structural requirements of PI(C were then examined using a calpain-cleaved active fragment of nPKC delta. MARCKS was phosphorylated by the active catalytic fragment as efficiently as by intact nPKC delta, indicating that the kinase domain is sufficient far the high affinity interaction with intact MARCKS. However, gel overlay assay revealed that both intact nPKC delta and its regulatory domain bind to MARCKS, suggesting that both the kinase and regulatory domains of nPKC delta are involved in the high affinity interaction with intact MARCKS protein.	YOKOHAMA CITY UNIV, SCH MED, DEPT BIOL MOLEC, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN; YOKOHAMA CITY UNIV, SCH MED, DEPT DERMATOL, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN; KEIO UNIV, SCH MED, DEPT MOLEC BIOL, SHINJUKU KU, TOKYO 160, JAPAN; KYOTO PHARMACEUT UNIV, INST MOLEC & CELLULAR BIOL PHARMACEUT SCI, YAMASHINA KU, KYOTO 607, JAPAN	Yokohama City University; Yokohama City University; Keio University; Kyoto Pharmaceutical University			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; AHMAD Z, 1984, J BIOL CHEM, V259, P8743; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; AKIYAMA T, 1986, J BIOL CHEM, V261, P5648; AMESS B, 1992, FEBS LETT, V297, P285; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLUMENTHAL DK, 1978, J BIOL CHEM, V253, P334; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; BURNETTE B, 1993, J BIOL CHEM, V268, P8698; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FORSBERG PO, 1990, J BIOL CHEM, V265, P2941; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GOODE N, 1992, J BIOL CHEM, V267, P16878; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HOUSE C, 1987, J BIOL CHEM, V262, P772; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; HYATT SL, 1994, CELL GROWTH DIFFER, V5, P495; IDO M, 1987, FEBS LETT, V219, P215, DOI 10.1016/0014-5793(87)81219-X; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KENNELLY PJ, 1987, J BIOL CHEM, V262, P11958; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOLAND TA, 1989, J BIOL CHEM, V264, P20778; O'Reilly DR, 1992, BACULOVIRUS EXPRESSI, P139; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHNO S, 1988, BIOCHEMISTRY-US, V27, P2083, DOI 10.1021/bi00406a040; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; PATEL J, 1987, J BIOL CHEM, V262, P16686; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SAKAI K, 1992, GENOMICS, V14, P175, DOI 10.1016/S0888-7543(05)80301-5; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SHEU FS, 1990, BIOCHEM BIOPH RES CO, V171, P1236, DOI 10.1016/0006-291X(90)90818-8; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WADA H, 1989, BIOCHEM BIOPH RES CO, V165, P533, DOI 10.1016/0006-291X(89)91102-9; WOLF M, 1986, J BIOL CHEM, V261, P3327	72	93	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31642	31648						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989336				2022-12-25	WOS:A1994PX30300050
J	IKEZU, T; OKAMOTO, T; MURAYAMA, Y; OKAMOTO, T; HOMMA, Y; OGATA, E; NISHIMOTO, I				IKEZU, T; OKAMOTO, T; MURAYAMA, Y; OKAMOTO, T; HOMMA, Y; OGATA, E; NISHIMOTO, I			BIDIRECTIONAL REGULATION OF C-FOS PROMOTER BY AN ONCOGENIC GIP2 MUTANT OF G-ALPHA(12) - A NOVEL IMPLICATION OF RETINOBLASTOMA GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-II; CYCLIC-AMP ACCUMULATION; PROTEIN-KINASE-C; SUSCEPTIBILITY GENE; TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENT; ALPHA-SUBUNITS; CELL-CYCLE; 3T3 CELLS; EXPRESSION	G alpha(i2) is a tissue-specific proto-oncogene product, whose activated mutant gip2 induces transformation through less defined downstream pathways, We found that c-fos promoter is a target of gip2 in multiple kinds of cells, Serum response element was shown to be the positive enhancer element that mediates gip2-induced c-fos expression. We further demonstrated that gip2 stimulates the negative silencer activity of the retinoblastoma (Rb) control element (RCE) and inhibits the c-fos promoter activity through RCE located in the c-fos promoter region. The effect of gip2 on RCE was shown to be mediated by the Rb gene product (pRb). Furthermore, gip2 augmented underphosphorylated active form of pRb by promoting pRb expression and by affecting the phosphorylation state of pRb. gip2 therefore propagates both positive and negative signals to the c-fos promoter through two different elements, and pRb mediates the negative signal of gip2. We conclude that gip2 has bifunctional roles in transformation which pRb critically regulates. Given that Rat-1 cells, which gip2 can transform, lack the sensitivity to the gip2/pRb-mediated negative pathway, this study provides a novel insight into oncogenesis by gip2 and its tissue specificity.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CARDIOVASC RES CTR,CVRC,DEPT MED,BOSTON,MA 02129; UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,BUNKYO KU,TOKYO 112,JAPAN; CANC RES INST,TOSHIMA KU,TOKYO 170,JAPAN	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Tokyo				Ikezu, Tsuneya/0000-0002-3979-8596				ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HATA A, 1993, J BIOL CHEM, V268, P9122; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERMOUET S, 1993, CELL SIGNAL, V5, P215, DOI 10.1016/0898-6568(93)90072-T; HOLTZMAN EJ, 1991, J BIOL CHEM, V266, P1763; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; HOWE PH, 1989, BIOCHEM J, V261, P879, DOI 10.1042/bj2610879; KATAOKA R, 1993, J BIOL CHEM, V268, P19851; KNUDSON AG, 1991, MUTAT RES, V247, P185, DOI 10.1016/0027-5107(91)90013-E; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; NUKADA T, 1986, FEBS LETT, V197, P305, DOI 10.1016/0014-5793(86)80347-7; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PARK K, 1994, J BIOL CHEM, V269, P6083; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	39	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31955	31961						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989371				2022-12-25	WOS:A1994PX30300095
J	ARNOLD, CE; WITTRUP, KD				ARNOLD, CE; WITTRUP, KD			THE STRESS-RESPONSE TO LOSS OF SIGNAL RECOGNITION PARTICLE FUNCTION IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; 54 KDA SUBUNIT; PROTEIN TRANSLOCATION; POLYPEPTIDE TRANSLOCATION; NASCENT PREPROLACTIN; SECRETORY PROTEINS; YEAST; SEQUENCE; GENE; MECHANISM	It has been shown previously that growth and endoplasmic reticulum (ER) translocation defects occur in response to depletion of the 54-kDa subunit of signal recognition particle (SRP54) in Saccharomyces cerevisiae (Hann, B. B., and Waiter, P. (1991) Cell 67, 131-144). We report here that cells depleted of SRP54p undergo a general stress response, the onset of which is observed almost two-cell doublings after SRP54 protein levels fall below the limits of detection. The stress response to SRP54p depletion occurs in two distinct phases, unlike the response to other stressors such as heat shock. In the initial phase, the cytoplasmic Hsp70 levels are drastically increased coincident with an abrupt slowing of growth and accumulation of untranslocated species of the ER-resident chaperone BiP. During this first response, levels of the yeast DnaJ homolog Ydj1p are also increased. In the second phase, which is detected 5 h later, levels of the cytoplasmic heat shock proteins Hsp82 and Hsp104 are increased. BiP is also induced during this second phase, while the ER levels of the resident foldase protein disulfide isomerase are significantly reduced. Since only those cytoplasmic stress proteins which have been shown to participate in membrane translocation are induced in the first phase, these findings indicate the presence of a stress response specific to accumulation of secretory protein precursors in the cytoplasm.	UNIV ILLINOIS,DEPT CHEM ENGN,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign								ALTHOFF S, 1994, IN PRESS MOL CELL BI; AMAYA Y, 1991, FEBS LETT, V283, P325, DOI 10.1016/0014-5793(91)80619-E; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; CYR DM, 1992, J BIOL CHEM, V267, P20927; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FARRELLY FW, 1984, J BIOL CHEM, V259, P5745; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; KIRK N, 1991, YEAST, V7, P539, DOI 10.1002/yea.320070602; KOBAYASHI N, 1990, P NATL ACAD SCI USA, V87, P6550, DOI 10.1073/pnas.87.17.6550; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LARRIBA G, 1993, YEAST, V9, P441, DOI 10.1002/yea.320090502; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SIKORSKI RS, 1989, GENETICS, V122, P19; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WERNERWASHBURNE M, 1989, J BACTERIOL, V171, P2680, DOI 10.1128/jb.171.5.2680-2688.1989; WIECH H, 1993, J BIOL CHEM, V268, P7414; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0	41	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30412	30418						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982955				2022-12-25	WOS:A1994PU52500059
J	BASU, T; WARNE, PH; DOWNWARD, J				BASU, T; WARNE, PH; DOWNWARD, J			ROLE OF SHC IN THE ACTIVATION OF RAS IN RESPONSE TO EPIDERMAL GROWTH-FACTOR AND NERVE GROWTH-FACTOR	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; GRB2 ADAPTER PROTEIN; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCTION; SEVENLESS GENE; PC12 CELLS; PHOSPHORYLATION; DOMAINS; P21RAS	Treatment of the rat pheochromocytoma cell line PC12 with nerve growth factor (NGF) or epidermal growth factor (EGF) is known to result in activation of Ras. In response to EGF treatment, complexes form between Sos, Grb2 and tyrosine phosphorylated She and/or EGF receptor. In response to NGF treatment, complexes form between Sos, Grb2 and tyrosine phosphorylated Shc. While She is also found bound to the activated NGF receptor, Trk, no complexes were detectable that contained both Trk and Grb2 or Sos. In streptolysin O permeabilised cells, a tyrosine phosphopeptide, EGFR-Y1068P, which binds to the SH2 domain of Grb2, totally blocks growth factor induced formation of complexes between Grb2 and She or EGF receptor, and also blocks activation of nucleotide exchange on Ras. At low concentrations, another tyrosine phosphopeptide, TRK-Y490P, which binds to the SH2 domain of She, blocks growth factor induced formation of complexes between Shc and the EGF receptor or Trk, but fails to block activation of nucleotide exchange on Ras. Higher concentrations of TRK-Y490P inhibit tyrosine phosphorylation of She and the formation of She complexes with Grb2: this results in strong inhibition of Ras activation by NGF and partial inhibition of Ras activation by EGF. These data demonstrate that the formation of a trimeric complex between tyrosine phosphorylated Shc, Grb2 and Sos is the key event in the activation of Ras in response to NGF. The binding of Sos to tyrosine phosphorylated receptor, via Grb2 may also contribute to Ras activation by EGF but not NGF, while stable complex formation between She and receptors is not necessary for Ras activation by either growth factor.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK				Downward, Julian/0000-0002-2331-4729				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU BX, 1993, ONCOGENE, V8, P3081; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MUROYA K, 1992, ONCOGENE, V7, P277; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OUWENS DM, 1993, J CELL BIOCH S A, V17, P237; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	80	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3483	3491						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970708				2022-12-25	WOS:A1994PT39200010
J	MORRISON, BW; LEDER, P				MORRISON, BW; LEDER, P			NEU AND RAS INITIATE MURINE MAMMARY-TUMORS THAT SHARE GENETIC-MARKERS GENERALLY ABSENT IN C-MYC AND INT-2-INITIATED TUMORS	ONCOGENE			English	Article							TRANSGENIC MICE; BREAST-CANCER; RETINOIC ACID; HA-RAS; MOUSE; ONCOGENE; SEQUENCE; PROTEIN; CELLS; TUMORIGENESIS	We have previously shown that each of four activated oncogenes (c-myc, nea, ras, and int-2) can serve as transgenic initiators of morphologically distinct adenocarcinomas of the murine mammary gland. Since abnormalities of these oncogenes are found frequently in human breast cancers, such differences are of particular interest. Thus, the distinctiveness of each murine tumor type might reflect a relationship between a specific oncogene and a susceptible target cell or might reflect distinctive changes brought about by the idiosyncratic action of each oncogene. We have identified six genes (two of them novel) expressed in tumors initiated by nea, but usually absent from tumors initiated by c-myc. The expression of these genes (kappa-casein, transferrin, cellular retinol binding protein I (CRBPI), WDNM1, and the two novel ones) cannot be induced in c-myc-initiated tumors by the introduction of an activated nea oncogene nor can their expression be inhibited in nea-initiated tumors by the introduction of c-myc. Therefore, these genes appear to represent markers of a cell type preferentially transformed by neu. Further analysis reveals that the six markers are also expressed by ras-initiated mammary tumors, but not by int-2 initiated tumors suggesting that neu/ras-initiated tumors share a common cellular lineage and/or a common signal transduction pathway. Interestingly, one of the novel marker genes (Mat-8) appears to encode a cell-surface chloride channel and the other, a secreted protein with homologies to glycosyl hydrolases, both of which might be useful for the diagnosis and treatment of specific mammary tumors.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute					NCI NIH HHS [K11 CA01578] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDRES AC, 1994, ONCOGENE, V9, P1461; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARDIFF RD, 1993, CANCER SURV, V16, P97; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; CHEN LH, 1987, J BIOL CHEM, V262, P17247; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEAR TN, 1988, CANCER RES, V48, P5203; DEAR TN, 1991, BIOCHEM BIOPH RES CO, V176, P247, DOI 10.1016/0006-291X(91)90916-U; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAKALA BE, 1993, J BIOL CHEM, V28, P25803; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MORRISON BW, 1992, J BIOL CHEM, V267, P11957; MORRISON BW, 1994, HEMATOL ONCOL CLIN N, V8, P15, DOI 10.1016/S0889-8588(18)30185-0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; NYIRKOS P, 1990, BIOCHEM J, V268, P265; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PENTECOST BT, 1987, J BIOL CHEM, V262, P10134; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; REJMAN JJ, 1988, BIOCHEM BIOPH RES CO, V150, P329, DOI 10.1016/0006-291X(88)90524-4; ROSEN PP, 1991, BREAST DISEASES, P245; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGATTO O, 1993, ONCOGENE, V8, P2105; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; THOMAS P, 1981, P NATL ACAD SCI USA, V77, P5201; THOMPSON MD, 1985, DNA-J MOLEC CELL BIO, V4, P263, DOI 10.1089/dna.1985.4.263; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	50	206	223	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3417	3426						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970700				2022-12-25	WOS:A1994PT39200002
J	PRASAD, DDK; OUCHIDA, M; LEE, L; RAO, VN; REDDY, ESP				PRASAD, DDK; OUCHIDA, M; LEE, L; RAO, VN; REDDY, ESP			TLS FUS FUSION DOMAIN OF TLS FUS-ERG CHIMERIC PROTEIN RESULTING FROM THE T(1621) CHROMOSOMAL TRANSLOCATION IN HUMAN MYELOID-LEUKEMIA FUNCTIONS AS A TRANSCRIPTIONAL ACTIVATION DOMAIN	ONCOGENE			English	Article							ETS-RELATED GENE; SERUM RESPONSE FACTOR; RNA-BINDING PROTEIN; DNA-BINDING; FLI-1 GENE; FAMILY; ELK-1; C-ETS-1; MEMBER; ERYTHROLEUKEMIA	EWS and TLS/FUS genes, which code for RNA binding proteins are involved in a wide variety of human solid tumors. The TLS/FUS gene is involved both in human myxoid liposarcomas which carry a characteristic chromosomal translocation, t(12;16)(q13;p11) and in human myeloid leukemias with recurrent chromosomal translocation, t(16;21)(p11:q22). The TLS/FUS gene is fused to a transcriptional repressor, CHOP (in human myxoid liposarcomas) or transcriptional activator, erg (in human myeloid leukemias). To understand better the functional role of TLS/FUS-erg in human myeloid leukemias, we have cloned the TLS/FUS and TLS/FUS-erg cDNAs and studied the functional properties of their gene products. TLS/FUS protein binds to RNA in vitro and shows preferential binding to poly G. Both the amino- and the carboxy- terminal regions of TLS/FUS containing the conserved RNA binding motifs are needed for poly G specific RNA binding activity. The TLS/FUS fusion domain (TFD) appears to regulate the DNA binding activity of TLS/FUS-erg chimeric protein which shows weaker transcriptional activation properties compared to normal erg proteins. Mutational analysis of the TLS/FUS-erg chimeric protein reveals TFD to function as a transcriptional activation domain thus replacing the amino terminal transcriptional activation domain of the erg protein. Therefore alterations in both DNA binding and transcriptional activation properties of aberrant erg proteins may be responsible for the genesis of t(16;21) chromosomal translocation-bearing human myeloid leukemias.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC,FREDERICK,MD 21702	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [CA 58642, CA 57157, CA 51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058642, R01CA057157, P01CA051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; HAYNES SR, 1992, NEW BIOL, V4, P421; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LADANYI M, 1994, CANCER RES, V54, P2837; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MITELMAN F, 1991, CATALOG CHROMOSOME A; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; PRASAD DDK, 1992, CANCER RES, V52, P5833; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1990, CANCER RES, V50, P5013; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; [No title captured]	51	138	140	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3717	3729						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970732				2022-12-25	WOS:A1994PT39200038
J	BOOKSTEIN, C; MUSCH, MW; DEPAOLI, A; XIE, Y; VILLEREAL, M; RAO, MC; CHANG, EB				BOOKSTEIN, C; MUSCH, MW; DEPAOLI, A; XIE, Y; VILLEREAL, M; RAO, MC; CHANG, EB			A UNIQUE SODIUM-HYDROGEN EXCHANGE ISOFORM (NHE-4) OF THE INNER MEDULLA OF THE RAT-KIDNEY IS INDUCED BY HYPEROSMOLARITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-H+ EXCHANGER; OSMOTIC ACTIVATION; MOLECULAR-CLONING; NA/H EXCHANGER; EXPRESSION; PROTEINS; ANTIPORTER	Membrane sodium-hydrogen exchangers (NHEs), found in virtually all cell types, appear to have diverse and essential roles in regulating cellular pH and mediating vectorial transport by epithelial cells. However, the functional and physiological role of the recently cloned isoform NHE-4 remains unknown. Unlike other Na-H exchanger isoforms, NHE-4 transfected into NHE-deficient mutant fibroblasts demonstrated no amiloride-inhibitable sodium uptake, under basal or acid-loaded isoosmotic conditions. By immunoblot analysis, only the NHE-4 transfectants synthesized a 100-kDa protein, which cross-reacted to polyclonal antibody made to an NHE-4 fusion protein. However, when cells were subjected to acute hyperosmolar cell shrinkage conditions, amiloride-sensitive NHE activity was readily detected at 420 mosm, exhibiting maximal activity at 490 mosm. By in situ hybridization, NHE-4 expression in the rat kid ney was found to be Limited to the inner renal medullary collecting tubules, the region of highest tissue osmolarity fluctuations in the body. We conclude that NHE-4 is an unusual isoform of sodium-hydrogen exchangers that may play a specialized supplementary role in cell volume regulation.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NIDDK NIH HHS [DK 38510, DK 42086-04] Funding Source: Medline; NIGMS NIH HHS [GM 28359] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038510, P30DK042086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028359] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; CLARK JD, 1991, AM J PHYSIOL, V261, pC945, DOI 10.1152/ajpcell.1991.261.6.C945; DAVIS BA, 1992, AM J PHYSIOL, V262, pC533, DOI 10.1152/ajpcell.1992.262.2.C533; DAVIS BA, 1992, AM J PHYSIOL, V263, pC246, DOI 10.1152/ajpcell.1992.263.1.C246; ESCOBALES N, 1990, AM J PHYSIOL, V259, pC640, DOI 10.1152/ajpcell.1990.259.4.C640; FRANCHI A, 1986, J BIOL CHEM, V261, P4614; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; KLEINZELLER A, 1986, CURRENT TOPICS MEMBR, V26; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; TAKAICHI K, 1993, AM J PHYSIOL, V264, pC944, DOI 10.1152/ajpcell.1993.264.4.C944; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; WANG Z, 1993, J BIOL CHEM, V268, P11925	20	96	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29704	29709						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961960				2022-12-25	WOS:A1994PU28400061
J	CASTRO, L; RODRIGUEZ, M; RADI, R				CASTRO, L; RODRIGUEZ, M; RADI, R			ACONITASE IS READILY INACTIVATED BY PEROXYNITRITE, BUT NOT BY ITS PRECURSOR, NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROSYL COMPLEX-FORMATION; ELECTRON-PARAMAGNETIC-RES; IRON REGULATORY FACTOR; ESCHERICHIA-COLI; SUPEROXIDE SENSITIVITY; RESONANCE SPECTROSCOPY; ACTIVATED MACROPHAGES; CYTOSOLIC ACONITASE; RADICAL PRODUCTION; RAT HEPATOCYTES	Mitochondrial and cytosolic aconitases have been indicated as major targets of (NO)-N-.- and O-2(radical anion)-mediated toxicity in cells due to the oxidant-mediated disruption of the [4Fe-4S] prosthetic group. However, under circumstances in which both (NO)-N-. and O-2(radical anion) are generated, their almost diffusion-controlled combination reaction (k = 6.7 x 10(9) M(-1) s(-1)), leading to the formation of peroxynitrite anion (ONOO-), can out-compete the direct reactions of (NO)-N-. and O-2(radical anion) with aconitase and even the enzymatic dismutation of O-2(radical anion) by superoxide dismutase. In this work, we report that ONOO- reacts with isolated pig heart mitochondrial aconitase at 1.4 x 10(5) M(-1) s(-1), resulting in a significant loss of enzymatic activity. Aconitase activity was totally recovered after postincubation with thiols and ferrous iron, indicating that ONOO- reactions with the enzyme involve the perturbation of the labile Fe alpha to yield the inactive [3Fe-4S] cluster, which is also evident by spectral changes. On the other hand, anaerobic exposure of isolated aconitase to high concentrations of (NO)-N-. (>100 mu M) led to a moderate inhibition of the enzyme, which could be fully overcome by (NO)-N-. displacement under an argon-saturated atmosphere, in agreement with the formation of a reversible inhibitory complex between (NO)-N-. and the active site of aconitase. Superoxide inactivated mitochondrial drial aconitase at (3.5 +/- 2) x 10(6) M(-1) s(-1), a reaction rate 3 orders of magnitude slower than its reaction rate with (NO)-N-.. O-2(radical anion) could represent the main mechanism of inactivation of the enzyme in systems in which it is formed without significant concomitant production of (NO)-N-.. Our results imply that the mechanisms by which (NO)-N-. and O-2(radical anion) inactivate aconitase in cell systems may not be simple due to their direct reactions with the iron-sulfur cluster, but may rely on the formation of ONOO-.	UNIV REPUBLICA,FAC MED,DEPT BIOCHEM,11800 MONTEVIDEO,URUGUAY	Universidad de la Republica, Uruguay								BARLETT D, 1994, IN PRESS FREE RADICA; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEINERT H, 1993, FASEB J, V7, P1442, DOI 10.1096/fasebj.7.15.8262329; Bray R. C., 1975, ENZYMES, P300; BRUSCHI M, 1976, BIOCHIM BIOPHYS ACTA, V449, P275, DOI 10.1016/0005-2728(76)90139-0; CAZEVIEILLE C, 1993, FREE RADICAL BIO MED, V14, P389, DOI 10.1016/0891-5849(93)90088-C; COTTON FA, 1986, ADV INORG CHEM RAD, P515; CROW JP, 1994, FREE RADICAL BIO MED, V16, P331, DOI 10.1016/0891-5849(94)90034-5; CURRAN RD, 1991, FASEB J, V5, P2085, DOI 10.1096/fasebj.5.7.1707021; DENICOLA A, 1993, ARCH BIOCHEM BIOPHYS, V304, P279, DOI 10.1006/abbi.1993.1350; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; FIELD L, 1978, J CHEM SOC CHEM COMM, V6, P249; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FLORIS R, 1993, EUR J BIOCHEM, V215, P767, DOI 10.1111/j.1432-1033.1993.tb18091.x; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; Fridovich I, 1985, HDB METHODS OXYGEN R, P121; GARDNER PR, 1993, ARCH BIOCHEM BIOPHYS, V301, P98, DOI 10.1006/abbi.1993.1120; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GAWRON O, 1974, BIOCHEM J, V139, P709, DOI 10.1042/bj1390709; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HEISS LN, 1994, P NATL ACAD SCI USA, V91, P267, DOI 10.1073/pnas.91.1.267; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V310, P352; JIN X, 1994, IN PRESS P NATL ACAD; KENNEDY MC, 1987, P NATL ACAD SCI USA, V84, P8854, DOI 10.1073/pnas.84.24.8854; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KENT TA, 1985, J BIOL CHEM, V260, P6871; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; KING PA, 1992, J AM CHEM SOC, V114, P5430, DOI 10.1021/ja00039a068; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KUO CF, 1987, J BIOL CHEM, V262, P4724; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MATHEIS G, 1992, AM J PHYSIOL, V262, pH616, DOI 10.1152/ajpheart.1992.262.2.H616; MORENO JJ, 1992, CHEM RES TOXICOL, V5, P425, DOI 10.1021/tx00027a017; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OURY TD, 1993, J BIOL CHEM, V268, P15394; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; ROSE IA, 1967, J BIOL CHEM, V242, P1870; RUBBO H, 1991, BIOCHIM BIOPHYS ACTA, V1074, P386, DOI 10.1016/0304-4165(91)90089-Y; STADLER J, 1991, ARCH SURG-CHICAGO, V126, P186; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; STADLER J, 1991, AM J PHYSIOL, V260, P910; STAMLER JS, 1992, ANAL CHEM, V64, P779, DOI 10.1021/ac00031a014; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643; WANG JF, 1991, BIOCHEM J, V279, P311, DOI 10.1042/bj2790311; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; WERT MM, 1990, BIOCHEMISTRY-US, V29, P10526; WINTERBOURN CC, 1987, FREE RADICAL BIO MED, V3, P33, DOI 10.1016/0891-5849(87)90037-2; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265	66	500	512	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29409	29415						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961920				2022-12-25	WOS:A1994PU28400018
J	LEE, GF; BURROWS, GG; LEBERT, MR; DUTTON, DP; HAZELBAUER, GL				LEE, GF; BURROWS, GG; LEBERT, MR; DUTTON, DP; HAZELBAUER, GL			DEDUCING THE ORGANIZATION OF A TRANSMEMBRANE DOMAIN BY DISULFIDE CROSS-LINKING - THE BACTERIAL CHEMORECEPTOR TRG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ASPARTATE RECEPTOR; SENSORY RECEPTOR; ACETYLCHOLINE-RECEPTOR; COVALENT MODIFICATION; PROTEIN-STRUCTURE; TRANSDUCER; CHEMOTAXIS; MUTANTS; SITES	The transmembrane domain of chemoreceptor Trg from Escherichia coli contains four segments, two from each subunit of the homodimer. me used site specific mutagenesis to introduce cysteines into those segments and oxidative cross-linking of cysteine pairs to identify residues that are near each other in space. Propensity for cross-linking was determined for pairs of homologously placed cysteines in the two subunits of the dimer at all 54 possible positions. Also, combinations of cysteines were identified that readily oxidized to join heterologous segments within or between monomers. These patterns of cross-licking were used to develop a model for the three-dimensional structure of the transmembrane domain in which the four transmembrane segments are helices associated in a bundle, with stronger interactions near the periplasm and weaker interactions near the cytoplasm. The striking similarity of this model to a model for the transmembrane domain of chemoreceptor Tar, derived using the same experimental strategy, strengthens the notion that a combination of comprehensive cysteine substitutions and analysis of patterns of disulfide cross-licking is sufficient to deduce a detailed three-dimensional structure for a transmembrane domain.	WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164	Washington State University					NIGMS NIH HHS [T32 GM08336, GM29963] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029963, T32GM008336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1973, J GEN MICROBIOL, V74, P77, DOI 10.1099/00221287-74-1-77; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BUBIS J, 1990, J BIOL CHEM, V265, P12995; BURROWS GG, 1989, J BIOL CHEM, V264, P17309; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; CHELSKY D, 1980, BIOCHEMISTRY-US, V19, P4633, DOI 10.1021/bi00561a015; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FIRST EA, 1984, J BIOL CHEM, V265, P13702; Hazelbauer GL, 1992, CURR OPIN STRUC BIOL, V2, P505; KARLIN A, 1983, J BIOL CHEM, V258, P6678; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MORGAN DG, 1993, J BACTERIOL, V175, P133, DOI 10.1128/JB.175.1.133-140.1993; NOWLIN DM, 1988, PROTEINS, V3, P102, DOI 10.1002/prot.340030205; NOWLIN DM, 1987, J BIOL CHEM, V262, P6039; ORDAL GW, 1974, J BACTERIOL, V117, P509, DOI 10.1128/JB.117.2.509-516.1974; OWEN P, 1979, BIOCHEMISTRY-US, V18, P1422, DOI 10.1021/bi00575a005; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PAKULA AA, 1991, METHODS COMPANION ME, V3, P175; PARK C, 1986, J BACTERIOL, V167, P101, DOI 10.1128/jb.167.1.101-109.1986; PARK CY, 1990, J BACTERIOL, V172, P7179, DOI 10.1128/jb.172.12.7179-7187.1990; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STODDARD BL, 1992, BIOCHEMISTRY-US, V31, P11978, DOI 10.1021/bi00163a004	30	100	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29920	29927						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961989				2022-12-25	WOS:A1994PU28400093
J	MONTERO, M; GARCIASANCHO, J; ALVAREZ, J				MONTERO, M; GARCIASANCHO, J; ALVAREZ, J			ACTIVATION BY CHEMOTACTIC PEPTIDE OF A RECEPTOR-OPERATED CA2+ ENTRY PATHWAY IN DIFFERENTIATED HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; DIVALENT-CATION ENTRY; HUMAN LEUKEMIA-CELLS; SEA-URCHIN EGGS; PLASMA-MEMBRANE; HL-60 CELLS; HUMAN-NEUTROPHILS; CA-2+ INFLUX; INOSITOL PHOSPHATES; HUMAN PLATELETS	N-Formyl-methionyl-leucyl-phenylalanine (fMLP) is able to accelerate Ca2+ entry into differentiated HL60 cells by a rather indirect mechanism consisting of the opening of a plasma membrane pathway activated by the emptying of the intracellular Ca2+ stores caused by the agonist. This Ca2+ pathway can also be fully activated by Ca2+ pathway store depletion with thapsigargin. We show here that, in addition to this store-operated Ca2+ entry pathway (SOCP), fMLP is able to activate another receptor-operated Ca2+ pathway in thapsigargin-treated HL60 cells differentiated for 24 h with dimethyl sulfoxide. Activation by fMLP was produced even in cells with fully empty Ca2+ stores. It started 30 s after fMLP addition, was maximal after 2 min and then disappeared within 5 min. This pathway was similar to SOCP in that it allowed passage of Mn2+ and Ba2+ and was antagonized by Ni2+ and by cytochrome P-450 inhibitors. fMLP is also able to inhibit SOCP by a mexhanism involving protein phosphorylation. Both the fMLP-induced activation of Ca2+ entry and the inhibition of SOCP were prevented by pretreatment with pertussis toxin. However, the first appeared earlier than the last along differentiation of HL60 cells. This suggests that the inhibition of SOCP requires not only the development of fMLP receptors but also an additional component placed distally to the G protein in the transduction mechanism.	UNIV VALLADOLID,FAC MED,DEPT BIOQUIM & BIOL MOLEC & FISIOL,E-47005 VALLADOLID,SPAIN	Universidad de Valladolid			Montero, Mayte/K-8212-2014; Alvarez, Javier/K-8210-2014; Garcia-Sancho, Javier/K-2975-2014	Montero, Mayte/0000-0001-7702-6653; Alvarez, Javier/0000-0003-0636-5521; Garcia-Sancho, Javier/0000-0003-4573-7930				ALONSO MT, 1990, BIOCHEM J, V272, P435, DOI 10.1042/bj2720435; ALONSOTORRE SR, 1993, BIOCHEM J, V289, P761, DOI 10.1042/bj2890761; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ALVAREZ J, 1989, EUR J BIOCHEM, V183, P709, DOI 10.1111/j.1432-1033.1989.tb21102.x; ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DEMAUREX N, 1992, J CLIN INVEST, V90, P830, DOI 10.1172/JCI115958; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P4574; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FRUMAN DA, 1991, AGENTS ACTIONS, V34, P16, DOI 10.1007/BF01993225; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; IRVINE RF, 1987, BIOCHEM BIOPH RES CO, V146, P284, DOI 10.1016/0006-291X(87)90723-6; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; KORCHAK HM, 1978, P NATL ACAD SCI USA, V75, P3818, DOI 10.1073/pnas.75.8.3818; KRAUTWURST D, 1992, BIOCHEM J, V288, P1025, DOI 10.1042/bj2881025; KWAN CY, 1990, J BIOL CHEM, V265, P678; LEW PD, 1986, J BIOL CHEM, V261, P3121; MCLEISH KR, 1989, BIOCHEM J, V260, P427, DOI 10.1042/bj2600427; MERTZ LM, 1990, J BIOL CHEM, V265, P15010; MISSIAEN L, 1990, J PHYSIOL-LONDON, V427, P171, DOI 10.1113/jphysiol.1990.sp018166; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1993, PFLUG ARCH EUR J PHY, V424, P465, DOI 10.1007/BF00374909; MONTERO M, 1993, J BIOL CHEM, V268, P26911; MONTERO M, 1993, J BIOL CHEM, V268, P13055; MONTERO M, 1990, BIOCHEM J, V271, P535, DOI 10.1042/bj2710535; MONTERO M, 1994, J BIOL CHEM, V269, P3963; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; NACCACHE PH, 1984, J CELL PHYSIOL, V119, P241, DOI 10.1002/jcp.1041190215; PITTET D, 1990, J BIOL CHEM, V265, P14256; PITTET D, 1989, J BIOL CHEM, V264, P7251; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SULLIVAN R, 1987, J BIOL CHEM, V262, P1274; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; VILLALOBOS C, 1992, FASEB J, V6, P2742, DOI 10.1096/fasebj.6.9.1319362	45	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29451	29456						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961926				2022-12-25	WOS:A1994PU28400024
J	TSAKIRIDIS, T; VRANIC, M; KLIP, A				TSAKIRIDIS, T; VRANIC, M; KLIP, A			DISASSEMBLY OF THE ACTIN NETWORK INHIBITS INSULIN-DEPENDENT STIMULATION OF GLUCOSE-TRANSPORT AND PREVENTS RECRUITMENT OF GLUCOSE TRANSPORTERS TO THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L6 MUSCLE-CELLS; RAT SKELETAL-MUSCLE; B BINDING-SITES; GROWTH FACTOR-I; 3T3-L1 ADIPOCYTES; CYTOCHALASIN-B; SUBCELLULAR-DISTRIBUTION; EPITHELIAL-CELLS; SODIUM-CHANNEL; GLUT4	In muscle and fat tissues, insulin stimulates glucose transport through the translocation of glucose transporter proteins from an intracellular storage pool to the plasma membrane. The mechanism of this translocation is unknown. me have examined the possible role of the actin microfilament network in the stimulation of glucose transport by insulin and on the distribution of glucose transporters, in differentiated L6 rat skeletal muscle cells. Insulin (10(-7) M for 30 min) caused a major reorganization of the actin network of differentiated L6 myotubes. Cytochalasin D, a widely used inhibitor of actin filament formation, caused a dose- and time-dependent disassembly of the actin network, which was associated with an 80% inhibition of the insulin stimulation of glucose transport, without affecting the basal rate of glucose uptake. L6 myotubes express three glucose transporter isoforms, named GLUT1, GLUT3, and GLUT4. Disassembly of the actin network by cytochalasin D did not affect the number of basal glucose transporters in the plasma membrane but reduced the content of all three glucose transporters in intracellular membranes and prevented their appearance at the plasma membrane in response to insulin. The inhibitory effect of cytochalasin D treatment on the insulin stimulation of glucose transport occurred downstream of tyrosine phosphorylation of the insulin receptor substrate-l and of binding of phosphatidylinositol S-kinase to the insulin receptor substrate-1. Using immunoprecipitation of intact membranes, we detected specific association of the actin-binding protein spectrin with GLUT4 glucose transporter-containing vesicles. We conclude that an intact actin network is required for the correct intracellular localization of glucose transporters, as well as for their incorporation into the plasma membrane in response to insulin. A direct interaction may exist between the actin network and the glucose transporter vesicles which may be mediated through a spectrin containing skeleton attached to glucose transporter-containing vesicles.	HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ADAMS RJ, 1986, NATURE, V322, P754, DOI 10.1038/322754a0; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BILAN PJ, 1992, BIOCHEM BIOPH RES CO, V186, P1129, DOI 10.1016/0006-291X(92)90864-H; BLACK JD, 1988, J CELL BIOL, V106, P97, DOI 10.1083/jcb.106.1.97; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; CASTELLINO F, 1992, P NATL ACAD SCI USA, V89, P3775, DOI 10.1073/pnas.89.9.3775; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; CORMONT M, 1992, EUR J BIOCHEM, V207, P185, DOI 10.1111/j.1432-1033.1992.tb17036.x; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; GOSHIMA K, 1984, J CELL BIOL, V98, P801, DOI 10.1083/jcb.98.3.801; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; GUMA A, 1992, BIOCHEM J, V281, P407, DOI 10.1042/bj2810407; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; INOUE G, 1993, J BIOL CHEM, V268, P5272; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JARETT L, 1979, J CLIN INVEST, V63, P571, DOI 10.1172/JCI109338; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KLIP A, 1982, BIOCHIM BIOPHYS ACTA, V687, P265, DOI 10.1016/0005-2736(82)90555-7; KLIP A, 1993, CELL SIGNAL, V5, P519, DOI 10.1016/0898-6568(93)90047-P; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; OHMORI H, 1992, J CELL BIOL, V116, P933, DOI 10.1083/jcb.116.4.933; OKAA T, 1994, J BIOL CHEM, V269, P3568; RAMPAL AL, 1980, BIOCHEMISTRY-US, V19, P679, DOI 10.1021/bi00545a011; REIZMAN H, 1993, TRENDS CELL BIOL, V3, P273; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; SARGEANT RJ, 1993, BIOCHEM J, V290, P913, DOI 10.1042/bj2900913; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; YANG J, 1993, J BIOL CHEM, V268, P4600	46	183	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29934	29942						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961991				2022-12-25	WOS:A1994PU28400095
J	WITTSCHIEBEN, J; SHUMAN, S				WITTSCHIEBEN, J; SHUMAN, S			MUTATIONAL ANALYSIS OF VACCINIA DNA TOPOISOMERASE DEFINES AMINO-ACID-RESIDUES ESSENTIAL FOR COVALENT CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; I GENE; PHENOTYPIC SELECTION; DIRECTED MUTAGENESIS; SCANNING MUTAGENESIS; ESCHERICHIA-COLI; MUTANT ALLELES; DUPLEX DNA; CLONING; CLEAVAGE	The eukaryotic family of type I DNA topoisomerases includes the nuclear type I enzymes and the enzymes encoded by vaccinia and other poxviruses. The small size of the vaccinia topoisomerase (314 amino acids as compared to 765-972 amino acids for the cellular enzymes) makes it likely that this protein constitutes the minimal functional unit of a eukaryotic type I enzyme and provides an opportunity for a comprehensive structure-function analysis through mutagenesis. Two protein subregions were targeted for mutagenesis in the present study. The role of the Ser-Lys-X-X-Tyr sequence present at the active site of all family members was examined by replacing each conserved residue with alanine. Alanine substitution at the active site Tyr abrogated topoisomerase activity. In contrast, mutations at Ser-270 and Lys-271 had no effect on enzyme activity. The region of the vaccinia topoisomerase from amino acids 126-142 (MFFIRFGKMKYLKENET) is highly conserved and contains a residue, Gly-132, shown previously to be essential. Twenty-nine different mutations were generated in this region, with at least one substitution at each position. Point mutations were identified at three positions, Arg-130, Tyr-136, and Leu-137, which either abrogated or severely reduced DNA relaxation. The effects on activity could be attributed to a defect in formation of the covalent intermediate. Alterations of 13 other amino acids, including conserved residues, had little or no effect on topoisomerase activity.			WITTSCHIEBEN, J (corresponding author), SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM46330] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT WF, 1991, J BIOL CHEM, V266, P5191; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; ENG WK, 1989, J BIOL CHEM, V264, P13373; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GUPTA M, 1994, J BIOL CHEM, V269, P573; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HSIEH TS, 1992, NUCLEIC ACIDS RES, V20, P6177, DOI 10.1093/nar/20.23.6177; KIEBER JJ, 1992, PLANT PHYSIOL, V99, P1493, DOI 10.1104/pp.99.4.1493; KLEMPERER N, 1993, J BIOL CHEM, V268, P15887; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEVIN NA, 1993, GENETICS, V133, P799; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; THRASH C, 1985, P NATL ACAD SCI USA, V82, P4374, DOI 10.1073/pnas.82.13.4374; UEMURA T, 1987, NUCLEIC ACIDS RES, V15, P9727, DOI 10.1093/nar/15.23.9727; UPTON C, 1990, VIROLOGY, V176, P439, DOI 10.1016/0042-6822(90)90013-H	27	35	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29978	29983						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961997				2022-12-25	WOS:A1994PU28400101
J	ALLEN, BG; ANDREA, JE; WALSH, MP				ALLEN, BG; ANDREA, JE; WALSH, MP			IDENTIFICATION AND CHARACTERIZATION OF PROTEIN-KINASE C-ZETA-IMMUNOREACTIVE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; SMOOTH-MUSCLE; DOWN-REGULATION; PKC-ZETA; SUBSTRATE-SPECIFICITY; PHORBOL ESTERS; ACTIVATION; ISOFORMS; CELLS; PURIFICATION	Two immunoreactive proteins (75 and 80 kDa) were detected in rat brain and rabbit aorta using a polyclonal peptide-directed antibody to the C terminus of the zeta isoenzyme of protein kinase C (PKC). The 75-kDa protein resembled authentic PKC zeta; it was recovered in cytosolic fractions prepared in the presence or absence of Ca2+. The 80-kDa protein, however, bound to the particulate fraction in a Ca2+-dependent and reversible manner, but phosphorylated a synthetic peptide derived from the autoinhibitory domain of PKC epsilon in a Ca2+-independent but phospholipid- and diacylglycerol-dependent manner. Purification of the 80-kDa protein from rat brain, which separated two PKC zeta immunoreactive proteins of 81.3 and 79.4 kDa, was achieved by EGTA extraction of the particulate fraction followed by chromatography on DEAE-Sephacel, phenyl-Sepharose, and hydroxylapatite. The 81.3-kDa protein copurified with PKC alpha, and the 79.4-kDa protein copurified with PKC beta and PKC gamma. PKC alpha, -beta, and -gamma isoenzymes separated by hydroxylapatite chromatography all cross-reacted with anti-PKC zeta. Using recombinant PKC isoenzymes, however, anti-PKC zeta was shown to recognize rPKC alpha, rPKC beta(I), and rPKC beta(II), but not rPKC gamma. The regulatory properties of these isoenzymes differed from each other and depended on the particular substrate. PKC alpha was found to separate into two peaks on hydroxylapatite chromatography. The first peak exhibited regulatory properties characteristic of PKC alpha, whereas the second peak (PKC alpha') exhibited constitutive activity. PKC alpha' appears to be derived from PKC alpha by irreversible oxidative modification.	UNIV CALGARY,MRC,SIGNAL TRANSDUCT GRP,CALGARY T2N 4N1,AB,CANADA; UNIV CALGARY,FAC MED,DEPT BIOCHEM MED,CALGARY T2N 4N1,AB,CANADA	University of Calgary; University of Calgary			Allen, Bruce G/B-4693-2008	Allen, Bruce G/0000-0001-9000-9495				AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ANDREA JE, 1992, HYPERTENSION, V20, P585, DOI 10.1161/01.HYP.20.5.585; Bell R M, 1986, Methods Enzymol, V124, P353; BORNER C, 1992, J BIOL CHEM, V267, P12892; CHEN CC, 1993, FEBS LETT, V332, P169, DOI 10.1016/0014-5793(93)80506-P; COLBURN JC, 1988, J BIOL CHEM, V263, P19166; COLLINS EM, 1992, AM J PHYSIOL, V262, pH754, DOI 10.1152/ajpheart.1992.262.3.H754; DEVRIES G, 1989, BIOCHEM CELL BIOL, V67, P260, DOI 10.1139/o89-039; FRASER ED, 1991, FEBS LETT, V294, P285, DOI 10.1016/0014-5793(91)81450-M; FUJIHARA M, 1994, J IMMUNOL, V152, P1898; GOPALAKRISHNA R, 1987, FEBS LETT, V225, P233, DOI 10.1016/0014-5793(87)81164-X; GOPALAKRISHNA R, 1991, ARCH BIOCHEM BIOPHYS, V285, P382, DOI 10.1016/0003-9861(91)90377-U; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GSCHWENDT M, 1992, FEBS LETT, V307, P151, DOI 10.1016/0014-5793(92)80756-7; HA KS, 1993, J BIOL CHEM, V268, P10534; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUANG KP, 1986, J BIOL CHEM, V261, P2134; JOHNSON MS, 1993, FEBS LETT, V333, P67, DOI 10.1016/0014-5793(93)80376-6; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PALUMBO EJ, 1992, BIOCHEM BIOPH RES CO, V187, P1439, DOI 10.1016/0006-291X(92)90463-U; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SIMBOLICAMPBELL M, 1993, FOCUS, V15, P12; STANDAERT ML, 1993, ENDOCRINOLOGY, V132, P689, DOI 10.1210/en.132.2.689; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WOLF M, 1984, BIOCHEM BIOPH RES CO, V122, P1268, DOI 10.1016/0006-291X(84)91229-4; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C	44	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29288	29298						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961899				2022-12-25	WOS:A1994PU16800112
J	BAUMGARTNER, JW; WELLS, CA; CHEN, CM; WATERS, MJ				BAUMGARTNER, JW; WELLS, CA; CHEN, CM; WATERS, MJ			THE ROLE OF THE WSXWS EQUIVALENT MOTIF IN GROWTH-HORMONE RECEPTOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-6 SIGNAL TRANSDUCER; ERYTHROPOIETIN RECEPTOR; PROLACTIN RECEPTOR; MOLECULAR-CLONING; LIGAND-BINDING; EXTRACELLULAR DOMAIN; EXPRESSION; GP130; GENE; IDENTIFICATION	Members of the cytokine receptor family have a consensus WSXWS sequence (WS motif) in the extracellular domain. With the interleukin-2, erythropoietin, and prolactin receptors, alteration of the WS sequence disrupts ligand binding and receptor signaling. The structural basis for these effects is unclear. To examine the role of the WS equivalent sequence (Y(222)GEFS(226)) in the function of the growth hormone receptor, each residue was mutated to alanine or to the WS consensus sequence. Although we used stable cell lines expressing all of these mutants, we show only three mutants, Y222A, G223A and S226A, which display lower ligand affinity. Using conformation-specific monoclonal antibodies, we show that Y222A and S226A receptors have structural perturbations, which result in decreased signal transduction. This was shown by a decreased ability of growth hormone to stimulate protein synthesis and to transactivate the c-fos promoter with these mutants. The crystal structure of the ligand-occupied extracellular domain of growth hormone receptor indicates that Tyr(222) and Ser(226) have important interactions within the second p-barrel domain, providing a structural basis for our results. The WS segment is not involved in sequence-specific accessory protein interaction, as mutation of residues Gly(223), Glu(224), and Phe(225) does not alter receptor function.	UNIV QUEENSLAND,CTR MOLEC BIOL & BIOTECHNOL,BRISBANE,QLD 4072,AUSTRALIA	University of Queensland	BAUMGARTNER, JW (corresponding author), UNIV QUEENSLAND,DEPT PHYSIOL PHARMACOL,BRISBANE,QLD 4072,AUSTRALIA.		Wells, Christine A/A-5071-2010; waters, michael j/C-9582-2014	Wells, Christine A/0000-0003-3133-3628; 				ARGETSINGER LS, 1993, CELL, V74, P1; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6634; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DURIEZ B, 1993, MOL ENDOCRINOL, V7, P806, DOI 10.1210/me.7.6.806; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; FUH G, 1993, J BIOL CHEM, V268, P5376; FUKANAGA R, 1990, CELL, V61, P341; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1989, EMBO J, V8, P667; GOBIUS KS, 1992, J MOL ENDOCRINOL, V9, P213, DOI 10.1677/jme.0.0090213; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; HUGHES JP, 1985, ANNU REV PHYSIOL, V47, P469, DOI 10.1146/annurev.ph.47.030185.002345; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; QUELLE DE, 1992, MOL CELL BIOL, V12, P4553, DOI 10.1128/MCB.12.10.4553; ROWLINSON SW, 1994, IN PRESS BIOCHEMISTR; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; WATERS MJ, 1988, PROG ENDOCRINOL, V1, P601; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	41	80	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29094	29101						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961876				2022-12-25	WOS:A1994PU16800086
J	DALGAARD, JZ; GARRETT, RA; BELFORT, M				DALGAARD, JZ; GARRETT, RA; BELFORT, M			PURIFICATION AND CHARACTERIZATION OF 2 FORMS OF I-DMOI, A THERMOPHILIC SITE-SPECIFIC ENDONUCLEASE ENCODED BY AN ARCHAEAL INTRON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENE; ARCHAEBACTERIUM-DESULFUROCOCCUS-MOBILIS; ESCHERICHIA-COLI; RECOGNITION SITE; DNA TARGET; TD INTRON; SEQUENCES; PHAGE-T4; POLYMERASE; MECHANISM	The archaeal intron in the 23 S rRNA gene of the hyperthermophile Desulfurococcus mobilis has previously been shown to encode a site-specific DNA endonuclease that contains the LAGLIDADG motif. The enzyme, I-DmoI, has been shown to be active in two forms when expressed in vitro, from RNAs representing either the linear (I-DmoIl) or circular (I-DmoIc) intron. In this study we have overexpressed I-DmoIl and I-DmoIc and purified the enzymes from Escherichia coli. The optimal conditions for the enzymatic activity in vitro were determined, and the enzyme was used to delimit the recognition boundary on its DNA substrate (14-20 nucleotides), an intronless 23 S rRNA gene. Despite belonging to the archaeal kingdom, and being the product of a hyperthermophile, I-DmoI shares many properties with LAGLIDADG intron and intein endonucleases in other kingdoms. These results support the view that these phylogenetically diverse enzymes, which function to mobilize the DNA sequences that encode them, share a common ancestry.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,GENET MOLEC PROGRAM,ALBANY,NY 12201; NEW YORK STATE DEPT HLTH,SCH PUBL HLTH,ALBANY,NY 12201; UNIV COPENHAGEN,INST MOLEC BIOL,DK-1307 COPENHAGEN,DENMARK	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; University of Copenhagen			Garrett, Roger A/M-2450-2014	Garrett, Roger A/0000-0001-8452-9099; Dalgaard, Jacob/0000-0001-9545-7254; Belfort, Marlene/0000-0002-1592-5618	NIGMS NIH HHS [GM39422, GM44844] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039422, R01GM044844, R37GM039422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLPEDERSEN D, 1990, NUCLEIC ACIDS RES, V18, P3763, DOI 10.1093/nar/18.13.3763; BELLPEDERSEN D, 1991, P NATL ACAD SCI USA, V88, P7719, DOI 10.1073/pnas.88.17.7719; BROSIUS J, 1980, P NATL ACAD SCI-BIOL, V77, P201, DOI 10.1073/pnas.77.1.201; BRYK M, 1993, EMBO J, V12, P2141, DOI 10.1002/j.1460-2075.1993.tb05862.x; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHU FK, 1991, NUCLEIC ACIDS RES, V19, P6863, DOI 10.1093/nar/19.24.6863; COLLEAUX L, 1988, P NATL ACAD SCI USA, V85, P6022, DOI 10.1073/pnas.85.16.6022; DALGAARD JZ, 1992, GENE, V121, P103, DOI 10.1016/0378-1119(92)90167-N; DALGAARD JZ, 1993, P NATL ACAD SCI USA, V90, P5414, DOI 10.1073/pnas.90.12.5414; DOOLITTLE RF, 1993, P NATL ACAD SCI USA, V90, P5379, DOI 10.1073/pnas.90.12.5379; EDDY SR, 1991, GENE DEV, V5, P1032, DOI 10.1101/gad.5.6.1032; GARRETT RA, 1994, SYST APPL MICROBIOL, V16, P680; GIMBLE FS, 1994, J BIOL CHEM, V268, P21844; HENSGENS LAM, 1983, CELL, V32, P379, DOI 10.1016/0092-8674(83)90457-9; KJEMS J, 1988, CELL, V54, P693, DOI 10.1016/S0092-8674(88)80014-X; KJEMS J, 1985, NATURE, V318, P675, DOI 10.1038/318675a0; KJEMS J, 1992, SYST APPL MICROBIOL, V15, P203, DOI 10.1016/S0723-2020(11)80093-7; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LIU SL, 1993, P NATL ACAD SCI USA, V90, P6874, DOI 10.1073/pnas.90.14.6874; LOWRY R, 1992, PROMEGA NOTES, V38, P8; MARSHALL P, 1994, EUR J BIOCHEM, V220, P855, DOI 10.1111/j.1432-1033.1994.tb18688.x; MARSHALL P, 1992, NUCLEIC ACIDS RES, V20, P6401, DOI 10.1093/nar/20.23.6401; MONTEILHET C, 1990, NUCLEIC ACIDS RES, V18, P1407, DOI 10.1093/nar/18.6.1407; MUELLER JE, 1993, NUCLEASES, P111; MUSCARELLA DE, 1990, MOL CELL BIOL, V10, P3386, DOI 10.1128/MCB.10.7.3386; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; SARGUEIL B, 1990, NUCLEIC ACIDS RES, V18, P5659, DOI 10.1093/nar/18.19.5659; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VESTER B, 1987, BIOCHIMIE, V69, P891, DOI 10.1016/0300-9084(87)90217-3; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WERNETTE C, 1992, MOL CELL BIOL, V12, P716, DOI 10.1128/MCB.12.2.716; WERNETTE CM, 1990, J BIOL CHEM, V265, P18976; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZILLIG W, 1982, ZBL BAKT MIK HYG I C, V3, P304, DOI 10.1016/S0721-9571(82)80044-6	36	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28885	28892						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961849				2022-12-25	WOS:A1994PU16800059
J	MAYER, AN; BARANY, F				MAYER, AN; BARANY, F			INTERACTION OF TAQI ENDONUCLEASE WITH THE PHOSPHATE BACKBONE - EFFECTS OF STEREOSPECIFIC PHOSPHATE MODIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORV RESTRICTION ENDONUCLEASE; DNA-SEQUENCES; CRYSTAL-STRUCTURE; ACID INTERACTIONS; NUCLEIC-ACIDS; BASE ANALOG; RECOGNITION; SPECIFICITY; PROTEINS; CLEAVAGE	The restriction endonuclease TaqI exhibits extreme specificity for its cognate sequence, TCGA, but a direct hydrogen bond readout model fails to account for this property. The present study examines the role of phosphate contacts in the enzyme-substrate and transition state complexes. An S-methyl group was introduced into each of the pTpCpGpApNpN internucleotide linkages using a hybrid chemical enzymatic synthesis, in which sulfur substitutions of nonbridging phosphate oxygens directed the placement of methyl groups. The resulting 12 diastereomerically pure phosphate-modified substrates were tested for binding and cleavage by TaqI. The largest binding effects were induced by pro-S-p methylations at the pTpCpGA phosphates, which destabilized the enzyme-substrate complex by 1.0-1.6 kcal/mol. Cleavage of the modified strand was inhibited completely by modifications at the TpCpGpA phosphates and inhibited significantly at the TCGApNp phosphates. Cleavage of both strands was completely inhibited by modification of the TCGpA linkage. Effects on the cleavage of the unmodified strand were used to implicate phosphate modifications that caused global perturbations in the structure of the transition state complex. These results lend support for a model for the specificity of TaqI, in which sequence-specific phosphate contacts are formed in the transition state, thus amplifying the apparent contribution of base contacts to transition state stabilization.	CORNELL UNIV,COLL MED,HEARST MICROBIOL RES CTR,DEPT MICROBIOL,NEW YORK,NY 10021	Cornell University					NIGMS NIH HHS [GM-41337-05] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKEN CR, 1991, METHOD ENZYMOL, V208, P433; BARANY F, 1988, GENE, V65, P149, DOI 10.1016/0378-1119(88)90452-0; BARANY F, 1988, GENE, V65, P167, DOI 10.1016/0378-1119(88)90453-2; BARANY F, 1987, GENE, V56, P13, DOI 10.1016/0378-1119(87)90154-5; BARANY F, 1992, GENE, V112, P13, DOI 10.1016/0378-1119(92)90297-3; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; CONNOLLY BA, 1984, BIOCHEMISTRY-US, V23, P3443, DOI 10.1021/bi00310a010; Fersht A., 1985, ENZYME STRUCTURE MEC; FIDANZA JA, 1992, J AM CHEM SOC, V114, P5509, DOI 10.1021/ja00040a004; GHOSH SS, 1990, NUCLEIC ACIDS RES, V18, P5063, DOI 10.1093/nar/18.17.5063; KEZDY FJ, 1962, BIOCHEMISTRY-US, V1, P1097, DOI 10.1021/bi00912a021; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KOZIOLKIEWICZ M, 1992, BIOCHEMISTRY-US, V31, P9460, DOI 10.1021/bi00154a019; LESSER DR, 1992, J BIOL CHEM, V267, P24810; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LOHMAN TM, 1980, BIOCHEMISTRY-US, V19, P3522, DOI 10.1021/bi00556a017; NERDAL W, 1989, BIOCHEMISTRY-US, V28, P10008, DOI 10.1021/bi00452a020; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9902, DOI 10.1021/bi00494a021; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; Segel IH, 1976, BIOCH CALCULATIONS; SMITH HO, 1973, J MOL BIOL, V81, P419, DOI 10.1016/0022-2836(73)90152-6; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; TAYLOR JD, 1989, BIOCHEMISTRY-US, V28, P6198, DOI 10.1021/bi00441a011; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; THIELKING V, 1992, BIOCHEMISTRY-US, V31, P3727, DOI 10.1021/bi00130a001; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; VU H, 1991, TETRAHEDRON LETT, V32, P3005, DOI 10.1016/0040-4039(91)80672-S; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; ZEBALA JA, 1992, J BIOL CHEM, V267, P8106; ZEBALA JA, 1992, J BIOL CHEM, V267, P8097	37	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29067	29076						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961873				2022-12-25	WOS:A1994PU16800083
J	SHEN, WH; CHOE, SY; EISENBERG, D; COLLIER, RJ				SHEN, WH; CHOE, SY; EISENBERG, D; COLLIER, RJ			PARTICIPATION OF LYSINE-516 AND PHENYLALANINE-530 OF DIPHTHERIA-TOXIN IN RECEPTOR RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE METHOD; BINDING DOMAIN; A-DOMAIN; FRAGMENT; CLONING; CELLS; DNA; MUTAGENESIS; EXPRESSION; MUTATIONS	To identify amino acid residues within diphtheria toxin that participate in receptor recognition, we made alanine replacements for each of 12 solvent-accessible residues within a loop (residues 516-530) of the toxin's R domain, which prominently extends from the main surface of the domain. Amino acid replacements were generated in an enzymatically attenuated form of the toxin (in compliance with regulations for cloning in Escherichia coli), and the mutant toxins were purified and assayed for toxicity on Vero cells. The largest effects were seen with K516A and F530A, which caused similar to 22- and similar to 10-fold increases, respectively, in the toxin concentration required for half-maximal inhibition of protein synthesis (IC50). Smaller effects were seen at certain other sites and no effect at still others. K516A caused similar to 500-fold reduction in ability to compete with radiolabeled wildtype toxin for receptors, and F530A gave similar to 100-fold reduction. The small differences in IC50 with the mutants, compared with differences in receptor binding, are attributable to nonlinearity in the cytotoxicity assay with the enzymatically attenuated toxin. K516A and F530A also inhibited the receptor-blocking activity of the isolated R domain. Neither mutation caused a change in the circular dichroism spectrum of the R domain. These results indicate important roles for Lys-516 and Phe-530 in receptor recognition. In addition, on the basis of cytotoxicity data, four other residues (Tyr-514, Val-523, Asn-524, and Lys-526) are proposed play roles in receptor binding. These findings support the notion that the toxin's receptor binds to the solvent exposed face of the R domain opposite the catalytic domain.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, SHIPLEY INST MED, BOSTON, MA 02115 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT ENERGY, STRUCT BIOL & MOLEC MED LAB, LOS ANGELES, CA 90024 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				Collier, R John/0000-0002-2427-4239	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022021, R37AI022021, R01AI022848] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22848, AI-22021] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912; BENNETT MJ, 1994, PROTEIN SCI, V3, P1444, DOI 10.1002/pro.5560030911; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CARROLL SF, 1986, BIOCHEMISTRY-US, V25, P2425, DOI 10.1021/bi00357a019; CARROLL SF, 1988, METHOD ENZYMOL, V165, P218; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; ESBENSEN QY, 1993, BIOCHEM J, V294, P663, DOI 10.1042/bj2940663; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FREER J, 1993, BACTERIAL PROTEIN TO; FU H, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P379; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GREENFIELD L, 1987, SCIENCE, V238, P536, DOI 10.1126/science.3498987; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HU VW, 1987, BIOCHIM BIOPHYS ACTA, V902, P24, DOI 10.1016/0005-2736(87)90132-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEKADA E, 1985, J BIOL CHEM, V260, P2148; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NEVILLE DM, 1992, P NATL ACAD SCI USA, V89, P2585, DOI 10.1073/pnas.89.7.2585; NICHOLLS PJ, 1993, J BIOL CHEM, V268, P5302; OKEEFE DO, 1989, P NATL ACAD SCI USA, V86, P343, DOI 10.1073/pnas.86.1.343; ROLF JM, 1990, J BIOL CHEM, V265, P7331; Sambrook J, 1989, MOL CLONING LABORATO; SAMUEL JE, 1990, INFECT IMMUN, V58, P611, DOI 10.1128/IAI.58.3.611-618.1990; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; STENMARK H, 1992, J BIOL CHEM, V267, P8957; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	35	22	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29077	29084						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961874				2022-12-25	WOS:A1994PU16800084
J	STOECKLIN, G; HAHN, S; MORONI, C				STOECKLIN, G; HAHN, S; MORONI, C			FUNCTIONAL HIERARCHY OF AUUUA MOTIFS IN MEDIATING RAPID INTERLEUKIN-3 MESSENGER-RNA DECAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; MAST-CELLS; GM-CSF; MURINE INTERLEUKIN-3; EUKARYOTIC CELLS; RICH SEQUENCES; C-FOS; TRANSFORMATION; DEGRADATION	In mast cells, expression of interleukin 3 (IL-3) is induced following IgE-receptor activation via calcium-dependent mRNA stabilization. We performed a mutational analysis of the 8 AUUUA motifs located in the 3'-untranslated region of IL-3 mRNA, and analyzed the effect on mRNA stability in PB-3c mast cells. Similar to endogenous IL-3 mRNA, exogenous IL-3 transcripts had a short half-life and were stabilized following stimulation of calcium influx by ionomycin. Specific mutation of 3 AUUUA motifs had almost the same stabilizing effect as deletion of the entire AU-rich region. Mutating even a single critical motif led to a weak, but significant mRNA stabilization. Ionomycin treatment did not further enhance the expression of mutationally stabilized transcripts. Our data fit a model, where within a cluster of 6 AUUUA motifs, 3 adjacent motifs are required for binding of a factor which mediates rapid IL-3 mRNA decay, Activity of such a factor might be under control of a calcium-dependent pathway.	UNIV BASEL,DEPT MED MICROBIOL,CH-4003 BASEL,SWITZERLAND	University of Basel				Stoecklin, Georg/0000-0001-9284-9834				ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; ALGATE PA, 1993, ONCOGENE, V8, P1221; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BONNIEU A, 1990, ONCOGENE, V5, P1585; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CARTER BZ, 1991, LAB INVEST, V65, P610; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HAHN S, 1991, ONCOGENE, V6, P2327; HAHN S, 1994, LYMPHOKINE CYTOK RES, V13, P245; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HATFIELD SM, 1992, J PHARMACOL EXP THER, V260, P680; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kelso A, 1989, GROWTH FACTORS, V1, P165, DOI 10.3109/08977198909029126; KINDLER V, 1986, P NATL ACAD SCI USA, V83, P1001, DOI 10.1073/pnas.83.4.1001; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777	42	101	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28591	28597						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961806				2022-12-25	WOS:A1994PU16800015
J	DIAZMECO, MT; LOZANO, J; MUNICIO, MM; BERRA, E; FRUTOS, S; SANZ, L; MOSCAT, J				DIAZMECO, MT; LOZANO, J; MUNICIO, MM; BERRA, E; FRUTOS, S; SANZ, L; MOSCAT, J			EVIDENCE FOR THE IN-VITRO AND IN-VIVO INTERACTION OF RAS WITH PROTEIN-KINASE-C-ZETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGENIC SIGNAL-TRANSDUCTION; MAP KINASE; IN-VITRO; ACTIVATION; RAF-1; PATHWAY; GROWTH; RECEPTORS; CELLS	The zeta isoform of protein kinase C (zeta PKC) has been shown to be involved in the maturation of Xenopus oocytes and mitogenic signaling in fibroblasts. zeta PKC also regulates the important transcription factor nuclear factor kappa B, most probably by phosphorylation of the inhibitory molecule I kappa B. The mechanisms that control zeta PKC activity are still poorly characterized. This kinase is not activated by diacylglycerol but is potently stimulated in vitro by the products of phosphatidylinositol 3-kinase (PI 3-kinase), which suggests that zeta PKC is at least one of the critical targets of PI 3-kinase-triggered signals, and strengthens its role in cell proliferation. PI 3-kinase has been shown, like Raf, to be a direct effector of Pas. zeta PKC is a required step for Pas mitogenic signaling. Therefore, it is possible that zeta PKC directly interacts with Pas during mitogenic activation. Tire demonstrate here that Pas interacts in vitro with the regulatory domain of zeta PKC as well as that the association of zeta PKC with Pas in vivo is triggered by platelet-derived growth factor. It is also shown here that the expression of a dominant negative mutant of Pas (Asn-l7) severely impairs the activation of zeta PKC in mouse fibroblasts.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Moscat, Jorge/A-7011-2009; Berra, Edurne/F-9692-2011; Lozano, José/C-2760-2014	Berra, Edurne/0000-0002-3820-5744; Lozano, José/0000-0002-8187-2833; Diaz-Meco, Maria/0000-0003-0147-0998				BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOTANI K, 1994, EMBO J, P2313; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OKADA T, 1994, J BIOL CHEM, V269, P3568; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	34	214	217	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31706	31710						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989344				2022-12-25	WOS:A1994PX30300060
J	FINLEY, EM; KORNFELD, S				FINLEY, EM; KORNFELD, S			SUBCELLULAR-LOCALIZATION AND TARGETING OF CATHEPSIN-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANES; ACID PROTEINASE; ASPARTIC PROTEINASES; IMMUNOHISTOCHEMICAL LOCALIZATION; GASTRIC-MUCOSA; PROCATHEPSIN-E; BETA-GLUCURONIDASE; MOLECULAR-CLONING; SECRETORY PROTEIN; BLOOD-CELLS	The subcellular distribution and targeting of the nonlysosomal aspartic proteinase cathepsin E have been studied using mouse L cells and monkey Cos 1 cells that were transfected with cDNA encoding cathepsin E. The cathepsin E was retained in L cells for at least 20 h without significant degradation and its single N-linked oligosaccharide remained sensitive to endo-beta-N-acetyl-glucosaminidase H. When cathepsin E was overexpressed by transient transfection in Cos 1 cells, it was very slowly secreted into the media. The intracellular form of the enzyme contained a high mannose oligosaccharide which was processed to a complex type species upon secretion. In double label immunofluorescence studies, cathepsin E co-localized with cathepsin D myc-KDEL, an endoplasmic reticulum (ER) marker. Subcellular fractionation on a Percoll density gradient showed that the cathepsin E co-migrated with membranous vesicles that were distinct from dense lysosomes. Only a trace amount of the enzyme was recovered in the soluble fraction. These findings indicate that in L cells and Cos 1 cells, the intracellular location of cathepsin E is the endoplasmic reticulum. To identify the protein sequences required for ER retention, we made chimeric proteins between cathepsin E and pepsinogen, an aspartic proteinase that is rapidly secreted by Cos 1 cells. We found that amino acids 1-48 of cathepsin E are important for its retention in the ER. Within this region, Cys(7), which is involved in covalent dimer formation, plays a significant role in the retention.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [R37CA008759, R01CA008759] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER; NCI NIH HHS [CA08759] Funding Source: Medline; NHLBI NIH HHS [HL07088-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; ATHAUDA SBP, 1991, BIOCHEM BIOPH RES CO, V175, P152, DOI 10.1016/S0006-291X(05)81213-6; ATHAUDA SBP, 1990, BIOCHEM BIOPH RES CO, V168, P878, DOI 10.1016/0006-291X(90)92403-M; AZUMA T, 1992, J BIOL CHEM, V267, P1609; AZUMA T, 1989, J BIOL CHEM, V264, P16748; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; BOSI F, 1993, AM J RESP CELL MOL, V8, P626, DOI 10.1165/ajrcmb/8.6.626; BOWERS WE, 1977, BIOCHIM BIOPHYS ACTA, V497, P272, DOI 10.1016/0304-4165(77)90160-X; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FINZI G, 1993, HISTOCHEMISTRY, V99, P201, DOI 10.1007/BF00269138; HARA K, 1993, J INVEST DERMATOL, V100, P394, DOI 10.1111/1523-1747.ep12472009; HAUGEJORDEN SM, 1991, J BIOL CHEM, V266, P6015; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG JS, 1979, J BIOL CHEM, V254, P1405; ICHIMARU E, 1990, J BIOCHEM-TOKYO, V108, P1009, DOI 10.1093/oxfordjournals.jbchem.a123299; KAGEYAMA T, 1980, J BIOCHEM, V87, P725, DOI 10.1093/oxfordjournals.jbchem.a132801; KAGEYAMA T, 1992, J BIOL CHEM, V267, P16450; LI H, 1990, J BIOL CHEM, V265, P14732; MACINTYRE SS, 1992, J CELL BIOL, V118, P253, DOI 10.1083/jcb.118.2.253; MACINTYRE SS, 1992, MOL BIOL CELL S, V3, P120; MANGLA JC, 1974, BIOCHEM MED METAB B, V10, P83, DOI 10.1016/0006-2944(74)90011-8; MEDDA S, 1987, J BIOL CHEM, V262, P7248; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUTO N, 1988, J BIOCHEM-TOKYO, V103, P629, DOI 10.1093/oxfordjournals.jbchem.a122318; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; SAKAI H, 1989, BIOCHIM BIOPHYS ACTA, V991, P367, DOI 10.1016/0304-4165(89)90130-X; SAKU T, 1991, J BIOCHEM-TOKYO, V110, P956, DOI 10.1093/oxfordjournals.jbchem.a123696; SAMLOFF IM, 1987, GASTROENTEROLOGY, V93, P77, DOI 10.1016/0016-5085(87)90317-9; SCHMID SL, 1994, NATURE, V369, P103, DOI 10.1038/369103a0; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SOLCIA E, 1993, EUR J HISTOCHEM, V37, P19; TAKEDAEZAKI M, 1993, ARCH BIOCHEM BIOPHYS, V304, P352, DOI 10.1006/abbi.1993.1361; TSUKUBA T, 1993, J BIOL CHEM, V268, P7276; YAGO N, 1975, J BIOL CHEM, V250, P4749; YAMAMOTO K, 1978, EUR J BIOCHEM, V92, P499, DOI 10.1111/j.1432-1033.1978.tb12772.x; YAMAMOTO K, 1985, J BIOCHEM-TOKYO, V97, P821, DOI 10.1093/oxfordjournals.jbchem.a135122; YAMAMOTO K, 1984, BIOCHIM BIOPHYS ACTA, V790, P208, DOI 10.1016/0167-4838(84)90024-4; YONEZAWA S, 1988, ARCH BIOCHEM BIOPHYS, V267, P176, DOI 10.1016/0003-9861(88)90021-5; YONEZAWA S, 1991, BIOCHIM BIOPHYS ACTA, V1073, P155; YONEZAWA S, 1990, BIOCHEM BIOPH RES CO, V166, P1032, DOI 10.1016/0006-291X(90)90914-9	44	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31259	31266						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983070				2022-12-25	WOS:A1994PV51000079
J	PURI, KD; SUROLIA, A				PURI, KD; SUROLIA, A			AMINO-ACID-SEQUENCE OF THE WINGED BEAN (PSOPHOCARPUS-TETRAGONOLOBUS) BASIC LECTIN - ADENINE BINDING AND IDENTIFICATION OF THE ACTIVE-SITE TRYPTOPHAN RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHRINA-CORALLODENDRON LECTIN; CONCANAVALIN-A; 3-DIMENSIONAL STRUCTURE; CARBOHYDRATE BINDING; PHASEOLUS-VULGARIS; CRYSTAL-STRUCTURE; PEA LECTIN; X-RAY; SPECIFICITY; PROTEINS	The complete amino acid sequence of winged bean basic agglutinin (WBA I) was obtained by a combination of manual and gas-phase sequencing methods. Peptide fragments for sequence analyses were obtained by enzymatic cleavages using trypsin and Staphylococcus aureus V8 endoproteinase and by chemical cleavages using iodosobenzoic acid, hydroxylamine, and formic acid. COOH-terminal sequence analysis of WBA I and other peptides was performed using carboxypeptidase Y. The primary structure of WBA I was homologous to those of other legume lectins and more so to Erythrina corallodendron. Interestingly, the sequence shows remarkable identities in the regions involved in the association of the two monomers of E. corallodendron lectin. Other conserved regions are the double metal-binding site and residues contributing to the formation of the hydrophobic cavity and the carbohydrate-binding site. Chemical modification studies both in the presence and absence of N-acetylgalactosamine together with sequence analyses of tryptophan-containing tryptic peptides demonstrate that tryptophan 133 is involved in the binding of carbohydrate ligands by the lectin. The location of tryptophan 133 at the active center of WBA I for the first time subserves to explain a role for one of the most conserved residues in legume lectins.	INDIAN INST SCI, MOLEC BIOPHYS UNIT, BANGALORE 560012, KARNATAKA, INDIA	Indian Institute of Science (IISC) - Bangalore			SUROLIA, AVADESHA/C-5442-2009					ACHARYA S, 1990, J BIOL CHEM, V265, P11586; ARANGO R, 1990, FEBS LETT, V264, P109, DOI 10.1016/0014-5793(90)80777-G; ARANGO R, 1993, FEBS LETT, V330, P133, DOI 10.1016/0014-5793(93)80258-V; BANERJEE R, 1994, P NATL ACAD SCI USA, V91, P227, DOI 10.1073/pnas.91.1.227; Bornstein P, 1977, Methods Enzymol, V47, P132; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; CHANG JY, 1983, METHOD ENZYMOL, V91, P455; CHANG JY, 1978, FEBS LETT, V93, P205, DOI 10.1016/0014-5793(78)81105-3; CHANG JY, 1988, ANAL BIOCHEM, V170, P542, DOI 10.1016/0003-2697(88)90670-7; CHIPMAN DM, 1967, J BIOL CHEM, V242, P4388; CHRAMBAC.A, 1967, ANAL BIOCHEM, V20, P150, DOI 10.1016/0003-2697(67)90272-2; COOPER JDH, 1984, J CHROMATOGR, V285, P490, DOI 10.1016/S0021-9673(01)87790-6; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; FONTANA A, 1983, METHOD ENZYMOL, V91, P311; GEGG CV, 1992, BIOCHEMISTRY-US, V31, P6938, DOI 10.1021/bi00145a011; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; HIGUCHI M, 1985, BIOCHIM BIOPHYS ACTA, V829, P51, DOI 10.1016/0167-4838(85)90067-6; HOFFMAN LM, 1985, EMBO J, V4, P883, DOI 10.1002/j.1460-2075.1985.tb03714.x; JONES BN, 1986, METHODS PROTEIN MICR, P344; KHAN MI, 1986, J BIOL CHEM, V261, P3013; KONAMI Y, 1991, BIOL CHEM H-S, V372, P95, DOI 10.1515/bchm3.1991.372.1.95; KORTT AA, 1985, ARCH BIOCHEM BIOPHYS, V236, P544, DOI 10.1016/0003-9861(85)90657-5; KORTT AA, 1984, EUR J BIOCHEM, V138, P519, DOI 10.1111/j.1432-1033.1984.tb07946.x; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P43; Landon, 1977, Methods Enzymol, V47, P145; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALIARIK MJ, 1988, J BIOL CHEM, V263, P11274; Marshall R D, 1974, Biochem Soc Symp, P17; MATSUDA T, 1989, MOL IMMUNOL, V26, P189, DOI 10.1016/0161-5890(89)90101-6; MISAKI A, 1977, J BIOL CHEM, V252, P6995; REEKE GN, 1975, J BIOL CHEM, V250, P1525; REEKE GN, 1986, SCIENCE, V234, P1108, DOI 10.1126/science.3775378; RICHARDSON M, 1979, FEBS LETT, V104, P322, DOI 10.1016/0014-5793(79)80843-1; RINI JM, 1993, J BIOL CHEM, V268, P10126; SANKARANARAYANAN R, 1993, J MOL BIOL, V229, P558, DOI 10.1006/jmbi.1993.1056; SCHWARZ FP, 1991, J BIOL CHEM, V266, P24344; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; SHARON N, 1989, LECTINS, P69; SOJAR HT, 1987, ARCH BIOCHEM BIOPHYS, V259, P52, DOI 10.1016/0003-9861(87)90469-3; Spande T.F., 1967, DETERMINATION TRYPTO, P498; STRONG DD, 1979, BIOCHEMISTRY-US, V18, P5399, DOI 10.1021/bi00591a022; TAGUE BW, 1990, PLANT CELL, V2, P533, DOI 10.1105/tpc.2.6.533; VODKIN LO, 1983, CELL, V34, P1023, DOI 10.1016/0092-8674(83)90560-3; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMAUCHI D, 1990, FEBS LETT, V260, P127, DOI 10.1016/0014-5793(90)80083-U; YOUNG NM, 1991, EUR J BIOCHEM, V196, P631, DOI 10.1111/j.1432-1033.1991.tb15859.x; ZALUSEC EJ, 1990, LECTINS BIOL BIOCH C, V7, P151	56	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30917	30926						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983025				2022-12-25	WOS:A1994PV51000031
J	SAMANIEGO, F; CHIN, J; IWAI, K; ROUAULT, TA; KLAUSNER, RD				SAMANIEGO, F; CHIN, J; IWAI, K; ROUAULT, TA; KLAUSNER, RD			MOLECULAR CHARACTERIZATION OF A 2ND IRON-RESPONSIVE ELEMENT-BINDING PROTEIN, IRON REGULATORY PROTEIN-2 - STRUCTURE, FUNCTION, AND POSTTRANSLATIONAL REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR; SULFUR CLUSTER; AFFINITY PURIFICATION; UNTRANSLATED REGION; ACONITASE ACTIVITY; REPRESSOR PROTEIN; IDENTIFICATION; EXPRESSION; CLONING	Several genes critical to the uptake, sequestration, and utilization of iron are regulated at the post-transcriptional level. The mRNAs encoded by these genes contain highly conserved stem-loop structures called iron-responsive elements (IREs). IREs function as the nucleic acid-binding sites for a cytosolic RNA-binding protein called the IRE-binding protein or IRE-BP. Binding of the IRE-BP to IREs is reversibly regulated by the iron status of the cell. The IRE-BP is highly conserved among human, rat, mouse, and rabbit, and it is identical to the cytosolic form of aconitase. In this study, we demonstrate that a distinct human gene encoding a protein which is 57% identical to the initially described IRE-BP, now referred to as iron regulatory protein 1 or IRP1, is also capable of binding to IREs with the same in vitro affinity and specificity as the originally identified protein. This second gene product, which we call IRP2, is expressed in many tissues, but its mRNA abundance and tissue distribution are different from IRP1. In most cell lines tested, levels of IRP2 are inversely regulated by iron levels due to iron-dependent regulation of the half-life of the protein. In addition to changes in total amounts of IRP2, we demonstrate that the IRE binding activity of IRP2 can also vary up to 4-fold in the absence of any change in IRP2 protein levels. The possible reasons for the existence of a second IRP are discussed.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			IWAI, KAZUHIRO/GSN-7385-2022	Iwai, Kazuhiro/0000-0001-5620-5951				AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BASILION JP, 1994, ARCH BIOCHEM BIOPHYS, V311, P517, DOI 10.1006/abbi.1994.1270; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHAN RYY, 1994, EUR J BIOCHEM, V220, P683, DOI 10.1111/j.1432-1033.1994.tb18669.x; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; GOESSLING LS, 1994, J BIOL CHEM, V269, P4343; GRAY NK, 1993, EUR J BIOCHEM, V218, P657, DOI 10.1111/j.1432-1033.1993.tb18420.x; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LEIBOLD EA, 1990, NUCLEIC ACIDS RES, V18, P1819, DOI 10.1093/nar/18.7.1819; LEIBOLD EA, 1988, P NATL ACD SCI US, V85, P3171; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1992, EUR J BIOCHEM, V208, P597, DOI 10.1111/j.1432-1033.1992.tb17224.x; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; PATINO MM, 1992, J BIOL CHEM, V267, P19011; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TANG CK, 1992, J BIOL CHEM, V267, P24466; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; YU Y, 1992, J BIOL CHEM, V267, P19005; ZHENG L, 1992, J BIOL CHEM, V267, P7895	44	200	204	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30904	30910						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983023				2022-12-25	WOS:A1994PV51000029
J	BROMME, D; BONNEAU, PR; LACHANCE, P; STORER, AC				BROMME, D; BONNEAU, PR; LACHANCE, P; STORER, AC			ENGINEERING THE S-2 SUBSITE SPECIFICITY OF HUMAN CATHEPSIN-S TO A CATHEPSIN-L-LIKE AND CATHEPSIN-B-LIKE SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CYSTEINE PROTEINASES; PAPAIN; MODEL	The primary specificity of papain-like proteinases is largely determined by S-2-P-2 site interactions. According to the three dimensional structure of a papain-inhibitor complex, the S-2 subsite is defined by residues 67, 68, 133, 157, 160, and 205, with residues 133, 157, and 205 integrated into the wall and bottom of the side chain binding cavity. The S-2 binding site specificity of this enzyme has been altered to mimic that of cathepsin B or L by the application of site-directed mutagenesis at these latter three positions in the cathepsin S sequence. The replacement of Gly-133 in cathepsin S by an alanine residue that is normally found at this position in both cathepsin B and L results in a pattern of specificity toward hydrophobic residues in P-2 that is very similar to that of cathepsin B and L. The replacement of other cathepsin S S-2 subsite residues with their cathepsin L equivalents (mutants Val-157 --> Leu, Phe-205 --> Ala) does not significantly change the specificity of cathepsin S. Cathepsin B is distinguished hom both cathepsin L and S by its ability to efficiently hydrolyze substrates containing a basic P-2 residue. A single mutation in position 205 of cathepsin S (Phe-205 --> Glu) results in a change of specificity toward that of cathepsin B, i.e. the second order rate constant for the hydrolysis of the cathepsin B-specific substrate benzyloxycarbonyl-Arg-Arg-4-methyl-7-coumarylamide is increased 77-fold for this mutant compared with the wild-type enzyme. A cathepsin S double mutant Gly-133 --> Ala/Phe-205 --> Glu is characterized by somewhat improved kinetic parameters compared with the Phe-205 --> Glu single mutant. The hydrolysis rate of the benzyloxycarbonyl-Arg-Arg-4-methyl-7-coumarylamid substrate by this double mutant is 130-fold higher than that of the wildtype enzyme. As with cathepsin B, the activities of the Phe-205 --> Glu single and the Gly-133 --> Ala/Phe-205 --> Glu double mutants of cathepsin S toward the dibasic substrate is modulated by an additional ionizable group with a pK(alpha) of 5.7.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,PHARMACEUT BIOTECHNOL SECTOR,MONTREAL H4P 2R2,PQ,CANADA	National Research Council Canada								BARICOS WH, 1991, ARCH BIOCHEM BIOPHYS, V288, P468, DOI 10.1016/0003-9861(91)90222-5; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BROMME D, 1994, BIOL CHEM H-S, V375, P343, DOI 10.1515/bchm3.1994.375.5.343; BROMME D, 1994, METHOD ENZYMOL, V244, P671; BROMME D, 1993, J BIOL CHEM, V268, P4832; BROMME D, 1989, BIOCHEM J, V264, P475; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; Fersht A, 1985, ENZYME STRUCTURE MEC, P105; GOURSALIN BJ, 1993, J MED CHEM, V36, P720, DOI 10.1021/jm00058a008; HASNAIN S, 1993, J BIOL CHEM, V268, P235; KHOURI HE, 1991, BIOCHEMISTRY-US, V30, P8929, DOI 10.1021/bi00101a003; KHOURI HE, 1991, BIOCHEM J, V275, P751, DOI 10.1042/bj2750751; Kirschke H., 1987, CHEM LYSOSOMAL PROTE, P193; KRANTZ A, 1991, BIOCHEMISTRY-US, V30, P4678, DOI 10.1021/bi00233a007; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; POLGAR L, 1982, BIOCHEM J, V207, P1; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHAW E, 1981, METHOD ENZYMOL, V80, P80; TRABANDT A, 1991, ARTHRITIS RHEUM, V34, P1444; [No title captured]	23	76	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30238	30242						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982933				2022-12-25	WOS:A1994PU52500033
J	MCCAFFREY, PG; GOLDFELD, AE; RAO, A				MCCAFFREY, PG; GOLDFELD, AE; RAO, A			THE ROLE OF NFATP IN CYCLOSPORINE A-SENSITIVE TUMOR-NECROSIS-FACTOR-ALPHA GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; NUCLEAR FACTOR; INTERLEUKIN-4 GENE; PROMOTER; CALCINEURIN; MACROPHAGE; IDENTIFICATION; EXPRESSION; CONTAINS; SIGNALS	The tumor necrosis factor-alpha (TNF alpha) gene is an immediate early gene in activated T cells, in that it is rapidly induced without a requirement for protein synthesis. Maximal induction of TNP alpha mRNA can be induced by treatment of T cells with calcium ionophores alone, via a calcineurin dependent process that is blocked by cyclosporin A. We have previously identified a promoter element, kappa 3, that is required for calcium-stimulated, cyclosporin A-sensitive induction of the TNF alpha gene in activated T cells. Here, we demonstrate that the kappa 3 binding factor contains NFATp, a cyclosporin-sensitive DNA-binding protein required for interleukin-a gene transcription. NFATp binds to two sites within the kappa 3 element, and occupancy of both sites is required for TNF alpha gene induction. Thus, although the kappa 3 element has little sequence similarity to other NFATp-binding sites, it appears to function as a cyclosporin-sensitive promoter element in T cells by virtue of its ability to bind NFATp. The involvement of NFATp in transcriptional activation of both the interleukin-2 and TNF alpha genes suggests that this factor plays an important role in the coordinate induction of multiple cytokine genes, starting at the earliest stages of T cell activation.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Goldfeld, Anne/AAF-1818-2019		NATIONAL CANCER INSTITUTE [R29CA058735, R01CA042471, R37CA042471] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42471, CA-58735] Funding Source: Medline; NIGMS NIH HHS [GM-46227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BROWN DA, 1991, EUR J IMMUNOL, V21, P1879, DOI 10.1002/eji.1830210815; BRUHN KW, 1993, P NATL ACAD SCI USA, V90, P9707, DOI 10.1073/pnas.90.20.9707; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; HARDY KJ, 1987, J IMMUNOL, V138, P2353; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	38	128	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30445	30450						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982959				2022-12-25	WOS:A1994PU52500063
J	YARFITZ, SL; DEER, JLR; FROELICK, G; COLLEY, NJ; HURLEY, JB				YARFITZ, SL; DEER, JLR; FROELICK, G; COLLEY, NJ; HURLEY, JB			IN-SITU ASSAY OF LIGHT-STIMULATED G-PROTEIN ACTIVITY IN DROSOPHILA PHOTORECEPTOR G-PROTEIN BETA-MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE; RHODOPSIN; GENE; MEMBRANES; CELLS; TRANSDUCTION; HYDROLYSIS; HOMOLOGY; SYSTEM; BRAIN	An in situ S-35-labeled guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) binding procedure was developed to assay light-stimulated G protein activity in Drosophila compound eyes. We found that Drosophila with mutations in G beta e, an abundant photoreceptor-specific G protein beta subunit essential for photoexcitation, are defective in light-stimulated [S-35]GTP gamma S binding. We confirmed that G beta e interacts with a GTP-binding protein by demonstrating that immunoprecipitation of G beta e is sensitive to GTP gamma S. These results suggest that G beta e functions as the beta subunit of a heterotrimeric G protein that couples photoactivation of rhodopsin to down-stream components in the Drosophila phototransduction cascade.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of California System; University of California San Diego					NEI NIH HHS [EY08768, R01 EY008768] Funding Source: Medline; PHS HHS [E406641] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY008768, R01EY008768] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAER KM, 1988, J BIOL CHEM, V263, P17; BLUMENFELD A, 1985, P NATL ACAD SCI USA, V82, P7116, DOI 10.1073/pnas.82.20.7116; CHEN DM, 1992, VISUAL NEUROSCI, V9, P461, DOI 10.1017/S0952523800011263; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DOLPH PJ, 1994, NATURE, V370, P59, DOI 10.1038/370059a0; FEIN A, 1981, SCIENCE, V212, P555, DOI 10.1126/science.6782676; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; HARRIS WA, 1977, NATURE, V266, P648, DOI 10.1038/266648a0; HEIDBUCHEL H, 1992, CIRC RES, V71, P808, DOI 10.1161/01.RES.71.4.808; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; HUBER A, 1990, J BIOL CHEM, V265, P17906; HURLEY JB, 1977, NATURE, V270, P540, DOI 10.1038/270540a0; HWANG PM, 1990, P NATL ACAD SCI USA, V87, P7395, DOI 10.1073/pnas.87.19.7395; HWANG PM, 1990, SCIENCE, V249, P802, DOI 10.1126/science.1975122; JOHNSON EC, 1986, J GEN PHYSIOL, V88, P651, DOI 10.1085/jgp.88.5.651; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; MCGRATH CM, 1991, BIOTECHNIQUES, V11, P352; MINKE B, 1992, SENSORY TRANSDUCTION, P202; OTOUSA JE, 1989, J NEUROGENET, V6, P41, DOI 10.3109/01677068909107099; PAYNE R, 1986, PHOTOBIOCH PHOTOBIOP, V13, P373; REID PD, 1992, TISSUE PRINTING TOOL; SZUTS EZ, 1986, BIOCHEM J, V240, P929, DOI 10.1042/bj2400929; WOLFGANG WJ, 1990, J NEUROSCI, V10, P1014; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; YARFITZ S, 1991, NEURON, V7, P429, DOI 10.1016/0896-6273(91)90295-B	29	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30340	30344						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982946				2022-12-25	WOS:A1994PU52500048
J	MALONE, RW; HICKMAN, MA; LEHMANNBRUINSMA, K; SIH, TR; WALZEM, R; CARLSON, DM; POWELL, JS				MALONE, RW; HICKMAN, MA; LEHMANNBRUINSMA, K; SIH, TR; WALZEM, R; CARLSON, DM; POWELL, JS			DEXAMETHASONE ENHANCEMENT OF GENE-EXPRESSION AFTER DIRECT HEPATIC DNA INJECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOMEGALO-VIRUS; MUSCLE INVIVO; HEPATOCYTES; PROMOTER; LIVER; CELLS; MECHANISM	The critical physiological functions of the liver make hepatocytes important targets for therapeutic gene delivery. This study reports significant gene expression following direct injection of plasmid DNA into the livers of rats and cats. Transfection was characterized using luciferase and Lac Z expression from plasmids with the cytomegalovirus immediate early promoter/enhancer (CMV IE) or the Rous sarcoma virus long terminal repeat (RSV LTR). Dexamethasone treatment enhanced and prolonged transfected gene expression, possibly by activating gene expression. Southern analysis of total DNA extracted from liver at various times following injection detected persistent unintegrated plasmid DNA which maintained a prokaryotic methylation pattern. This study demonstrates the feasibility of direct DNA injection in the experimental analysis of hepatic gene expression in vivo.	UNIV CALIF DAVIS,DEPT MOLEC & CELLULAR BIOL,DAVIS,CA 95616; UNIV CALIF DAVIS,DEPT MED HEMATOL & ONCOL,DAVIS,CA 95616; UNIV CALIF DAVIS,DEPT VET MED MOLEC BIOSCI,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	MALONE, RW (corresponding author), UNIV CALIF DAVIS,DEPT MED PATHOL,DAVIS,CA 95616, USA.		Malone, Robert/AAI-5317-2021	Malone, Robert/0000-0003-0340-7490				ACSADI G, 1991, NEW BIOL, V3, P71; AKRIGG A, 1985, VIRUS RES, V2, P107, DOI 10.1016/0168-1702(85)90242-4; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONAHUE RE, 1992, J EXP MED, V176, P1125, DOI 10.1084/jem.176.4.1125; DUBENSKY TW, 1984, P NATL ACAD SCI-BIOL, V81, P7529, DOI 10.1073/pnas.81.23.7529; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HATZOGLOU M, 1990, J BIOL CHEM, V265, P17285; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JIAO SS, 1992, HUM GENE THER, V3, P21, DOI 10.1089/hum.1992.3.1-21; KALEKO M, 1991, HUM GENE THER, V2, P27, DOI 10.1089/hum.1991.2.1-27; KAY MA, 1992, P NATL ACAD SCI USA, V89, P89, DOI 10.1073/pnas.89.1.89; LEIBIGER I, 1990, BIOMED BIOCHIM ACTA, V49, P1193; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; MIYANOHARA A, 1992, NEW BIOL, V4, P238; NELSON MR, 1993, AIDS, V7, P375, DOI 10.1097/00002030-199303000-00011; NICOLAU C, 1989, CRIT REV THER DRUG, V6, P239; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; PONDER KP, 1991, HUM GENE THER, V2, P41, DOI 10.1089/hum.1991.2.1-41; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; SEEGER C, 1984, P NATL ACAD SCI-BIOL, V81, P5849, DOI 10.1073/pnas.81.18.5849; TANAKA J, 1984, VIROLOGY, V136, P448, DOI 10.1016/0042-6822(84)90182-X; WEST PG, 1988, J CLIN MICROBIOL, V26, P2510, DOI 10.1128/JCM.26.12.2510-2514.1988; WILL H, 1982, NATURE, V299, P740, DOI 10.1038/299740a0; WILSON JM, 1992, J BIOL CHEM, V267, P11483; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFF JA, 1991, BIOTECHNIQUES, V11, P474; WU CH, 1989, J BIOL CHEM, V264, P16985	29	79	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29903	29907						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961986				2022-12-25	WOS:A1994PU28400090
J	TORTORICI, G; ZHANG, BX; XU, X; MUALLEM, S				TORTORICI, G; ZHANG, BX; XU, X; MUALLEM, S			COMPARTMENTALIZATION OF CA2+ SIGNALING AND CA2+ POOLS IN PANCREATIC ACINI - IMPLICATIONS FOR THE QUANTAL BEHAVIOR OF CA2+ RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EVOKED CALCIUM RELEASE; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR STORES; CYTOSOLIC CALCIUM; G-PROTEINS; CHOLECYSTOKININ ANALOG; AGONIST STIMULATION; CA-2+ RELEASE; CELLS; OSCILLATIONS	Streptolysin O-permeabilized pancreatic acini were used to study compartmentalization of Ca2+ signaling and Ca2+ pools. In these cells, the inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ channels could be activated by a number of agonists (carbachol, cholecystokinin, or bombesin) or by activation of the entire cellular phospholipase C pool with GTP gamma S. Surprisingly, each of the antagonists interacting with acinar cells inactivated the channels after stimulation with GTP gamma S. In addition, when permeabilized cells were stimulated with more than one agonist, any antagonist to the specific agonists employed inactivated the channels. The aberrant behavior of the antagonists in permeable cells was not related to a loss of specificity since (a) when added before GTP gamma S, the antagonists had no effect on Ca2+ release and (b) when cells were stimulated with a single agonist, the antagonists prevented only the effect of their specific agonist. The differential behavior of the antagonists in intact and permeable cells suggests a compartmentalization of Ca2+ signaling into separate, agonist-specific units that is modified by cell permeabilization. Further evidence for compartmentalization of signaling was obtained by showing that the partial agonist (the CCK octapeptide analogue JMV-180) can access and release only 50% of the cholecystokinin or IP3-mobilizabIe Ca2+ pool in intact and permeable cells. Kinetic measurements revealed a multiphasic time course of agonist-evoked Ca2+ release in permeable cells. At high agonist concentrations, all phases were fast and merged into an apparent single event of Ca2+ release. The phases were separated by three independent protocols: reduction in agonist concentrations, addition of heparin, or addition of guanosine-5'-O-(thio)diphosphate. Since all protocols that caused phase separation reduce IP3-mediated Ca2+ release, these findings demonstrate heterogeneity in the affinity for IP3 of channels present in compartmentalized Ca2+ pools of the same cells. Compartmentalization of signaling and the heterogeneity in the affinity for IP3 resulted in a quantal agonist-evoked Ca2+ release. The overall findings are discussed in the context of an integrated model of compartmentalization of signaling complexes, Ca2+ pools, and IP3-activated Ca2+ channels.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938, R01DK046591] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38938, DK46591] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; GAISANO HY, 1994, AM J PHYSIOL, V267, pC220, DOI 10.1152/ajpcell.1994.267.1.C220; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HARDEN KT, 1992, ADV SEC MESS PHOSPH, P11; INAGAKI N, 1991, P NATL ACAD SCI USA, V88, P4215, DOI 10.1073/pnas.88.10.4215; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MATOZAKI T, 1989, AM J PHYSIOL, V257, pG594, DOI 10.1152/ajpgi.1989.257.4.G594; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MINTA A, 1989, J BIOL CHEM, V264, P8171; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MIYAZAKI S, 1988, DEV GROWTH DIFFER, V30, P603; MUALLEM S, 1988, BIOCHEM J, V255, P301; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MUALLEM S, 1992, ADV SEC MESS PHOSPH, P351; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PANDOL SJ, 1985, J BIOL CHEM, V260, P81; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SALUJA AK, 1989, BIOCHEM BIOPH RES CO, V164, P8, DOI 10.1016/0006-291X(89)91675-6; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1993, J BIOL CHEM, V268, P23219; WILLIAMS JA, 1993, PHYSIOL REV, V73, P701, DOI 10.1152/physrev.1993.73.4.701; WILLIAMS JA, 1993, EXOCRINE PANCREAS, P167; XU X, 1994, J BIOL CHEM, V269, P12645; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZHANG BX, 1994, J BIOL CHEM, V269, P17132; ZHANG BX, 1992, J BIOL CHEM, V267, P15419; ZHAO H, 1990, J BIOL CHEM, V265, P14822	42	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29621	29628						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961950				2022-12-25	WOS:A1994PU28400050
J	WEINBERG, RB; COOK, VR; JONES, JB; KUSSIE, P; TALL, AR				WEINBERG, RB; COOK, VR; JONES, JB; KUSSIE, P; TALL, AR			INTERFACIAL PROPERTIES OF RECOMBINANT HUMAN CHOLESTEROL ESTER TRANSFER PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRANSFER PROTEIN; HIGH-DENSITY-LIPOPROTEINS; APOLIPOPROTEIN-A-IV; AIR-WATER-INTERFACE; PARTICLE-SIZE REDISTRIBUTION; HUMAN-PLASMA; SURFACE-ACTIVITIES; NEUTRAL LIPIDS; BINDING; SOLUBILIZATION	We investigated the interfacial behavior of recombinant human cholesterol ester transfer protein (rCETP) using monolayer and surface balance techniques. rCETP bound to egg phosphatidylcholine monolayers spread at the air/water interface with a maximum surface pressure of 23 millinewtons (mN)/m at subphase concentrations between 3 and 5 x 10(-5) g/dl; the estimated dissociation constant was 7.5 x 10(-6) g/dl or 1 nM?. The binding of rCETP to the lipid interface decreased linearly with increasing initial surface pressure; rCETP was excluded at pressures greater than 31 mN/m. rCETP catalyzed the desorption of [C-14]cholesterol oleate from mixed lipid monolayers in a concentration dependent fashion. Similar studies with apolipoproteins A-I and A-IV established that cholesterol ester desorption was not caused by changes in surface pressure or cholesterol ester solubility. The desorption rate was proportional to subphase rCETP concentration, but at all concentrations surface radioactivity remained constant until surface pressure reached a plateau. The calculated binding stochiometry was one molecule of cholesterol ester desorbed for every 1000 molecules of rCETP in the subphase. We conclude that rCETP is surface active, binds to phospholipid monolayers with an affinity equivalent to that of the plasma apolipoproteins, and effects the desorption of cholesterol ester molecules from phospholipid monolayers by a carrier mechanism. Moreover, the relatively low equilibrium surface pressure of rCETP suggests that when bound to lipid the entire rCETP molecule may not penetrate the interface.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10033	Columbia University	WEINBERG, RB (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT INTERNAL MED,GASTROENTEROL SECT,MED CTR BLVD,WINSTON SALEM,NC 27157, USA.		Tall, Alan/AAT-8528-2021		NHLBI NIH HHS [R01 HL030897-23, HL22682, HL30897, R01 HL030897] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022682, R23HL030897, R01HL030897, R01HL022682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTER PJ, 1988, BIOCHEM J, V254, P179, DOI 10.1042/bj2540179; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; ELLSWORTH JL, 1987, BIOCHIM BIOPHYS ACTA, V918, P260, DOI 10.1016/0005-2760(87)90229-3; FRANCESCHINI G, 1991, ATHEROSCLEROSIS, V88, P99, DOI 10.1016/0021-9150(91)90073-C; HAMILTON JA, 1983, J BIOL CHEM, V258, P2821; HARMONY JAK, 1982, BIOCHIM BIOPHYS ACTA, V690, P215, DOI 10.1016/0005-2736(82)90325-X; HESLER CB, 1989, J BIOL CHEM, V264, P11317; HESLER CB, 1987, J BIOL CHEM, V262, P2275; IBDAH JA, 1989, BIOCHEMISTRY-US, V28, P1126, DOI 10.1021/bi00429a029; IBDAH JA, 1988, BIOCHEMISTRY-US, V27, P7155, DOI 10.1021/bi00418a073; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; KREBS KE, 1983, BIOCHIM BIOPHYS ACTA, V751, P470, DOI 10.1016/0005-2760(83)90308-9; LAGROST L, 1991, BIOCHIM BIOPHYS ACTA, V1082, P204, DOI 10.1016/0005-2760(91)90195-N; LAGROST L, 1992, BIOCHIM BIOPHYS ACTA, V1126, P143, DOI 10.1016/0005-2760(92)90284-3; LAGROST L, 1990, J LIPID RES, V31, P1569; LI QT, 1992, J LIPID RES, V33, P503; MARCEL YL, 1990, J CLIN INVEST, V85, P10, DOI 10.1172/JCI114397; MILLER KW, 1983, J BIOL CHEM, V258, P3772; MILNER TG, 1991, BIOCHIM BIOPHYS ACTA, V1082, P71, DOI 10.1016/0005-2760(91)90301-W; MORTON RE, 1990, J LIPID RES, V31, P1559; MORTON RE, 1988, J BIOL CHEM, V263, P12235; OHNISHI T, 1993, BIOCHEMISTRY-US, V32, P5029, DOI 10.1021/bi00070a009; OHNISHI T, 1994, BIOCHEMISTRY-US, V33, P6093, DOI 10.1021/bi00186a008; PHILLIPS MC, 1986, METHOD ENZYMOL, V128, P387; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; RYE KA, 1992, J LIPID RES, V33, P215; SHEN BW, 1980, BIOCHEMISTRY-US, V19, P3643, DOI 10.1021/bi00557a001; SMABY JM, 1987, J LIPID RES, V28, P1078; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPARKS DL, 1989, J LIPID RES, V30, P1491; SPOONER PJR, 1986, BIOCHIM BIOPHYS ACTA, V860, P345, DOI 10.1016/0005-2736(86)90531-6; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; TALL AR, 1993, J LIPID RES, V34, P1255; WEINBERG RB, 1986, BIOCHEM BIOPH RES CO, V135, P756, DOI 10.1016/0006-291X(86)90993-9; WEINBERG RB, 1992, J BIOL CHEM, V267, P8977; WEINBERG RB, 1993, CIRCULATION, V88, P461	38	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29588	29591						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961945				2022-12-25	WOS:A1994PU28400044
J	CARRUTHERS, CJL; UNSON, CG; KIM, HN; SAKMAR, TP				CARRUTHERS, CJL; UNSON, CG; KIM, HN; SAKMAR, TP			SYNTHESIS AND EXPRESSION OF A GENE FOR THE RAT GLUCAGON RECEPTOR - REPLACEMENT OF AN ASPARTIC-ACID IN THE EXTRACELLULAR DOMAIN PREVENTS GLUCAGON BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE RHODOPSIN; I-125-LABELED GLUCAGON; MONOCLONAL-ANTIBODIES; ADENYLATE-CYCLASE; PLASMA-MEMBRANES; HORMONE; CELL; CLONING; HEPATOCYTES; SECRETIN	In order to facilitate structure-function studies of the glucagon receptor by site directed mutagenesis, we have designed and synthesized a gene for the rat glucagon receptor. The gene codes for the native 485-amino-acid protein but contains 91 unique restriction sites. To characterize gene expression, a highly specific, high affinity antipeptide antibody was prepared against the receptor. The synthetic gene was expressed in transiently transfected monkey kidney (COS-1) cells. COS cells expressing the synthetic receptor gene bound glucagon with affinity and specificity similar to that of hepatocytes containing native receptor. The transfected COS cells also showed increased intracellular cAMP levels in response to glucagon. The functional role of an aspartic acid residue in the NH2-terminal tail of the receptor was tested by site-directed mutagenesis. This site in the related growth hormone releasing factor receptor was shown to be responsible for the little mouse (lit) genetic defect that results in mice of small size with hypoplastic pituitary glands. Mutant glucagon receptors with amino acid replacements of Asp(64) were expressed at normal levels in COS cells but failed to bind glucagon. These results indicate that amino acid Asp(64) may play a key role in glucagon binding to receptor.	ROCKEFELLER UNIV,NEW YORK,NY 10021; HOWARD HUGHES MED INST,MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK024039] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK24039] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Barany G, 1979, PEPTIDES           A, V2, P1; BATAILLE D, 1974, ENDOCRINOLOGY, V95, P713, DOI 10.1210/endo-95-3-713; BHARUCHA DB, 1990, J BIOL CHEM, V265, P3070; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CARRUTHERS CJL, 1995, IN PRESS METHODS NEU, V25; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HOSSEIN NM, 1984, FEBS LETT, V178, P83; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; IWANIJ V, 1990, J BIOL CHEM, V265, P21302; IWANIJ V, 1985, P NATL ACAD SCI USA, V82, P325, DOI 10.1073/pnas.82.2.325; IYENGAR R, 1984, J BIOL CHEM, V259, P5222; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KHORANA HG, 1979, SCIENCE, V203, P614, DOI 10.1126/science.366749; KHORANA HG, 1978, BIOORG CHEM, V7, P351, DOI 10.1016/0045-2068(78)90029-9; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; RODBELL M, 1971, J BIOL CHEM, V246, P1861; SAKMAR TP, 1988, NUCLEIC ACIDS RES, V16, P6361, DOI 10.1093/nar/16.14.6361; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SHREEDHARAN SP, 1993, BIOCHEM BIOPH RES CO, V193, P546; SONNE O, 1978, J BIOL CHEM, V253, P3203; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; UNGER RH, 1976, DIABETES, V25, P136, DOI 10.2337/diab.25.2.136; UNSON CG, 1987, P NATL ACAD SCI USA, V84, P4083, DOI 10.1073/pnas.84.12.4083; UNSON CG, 1994, BIOCHEMISTRY-US, V33, P6884, DOI 10.1021/bi00188a018; UNSON CG, 1994, J BIOL CHEM, V269, P12548; UNSON CG, 1994, P NATL ACAD SCI USA, V91, P454, DOI 10.1073/pnas.91.2.454	40	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29321	29328						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961903				2022-12-25	WOS:A1994PU16800116
J	FAIRCHILD, CD; GLAZER, AN				FAIRCHILD, CD; GLAZER, AN			NONENZYMATIC BILIN ADDITION TO THE GAMMA-SUBUNIT OF AN APOPHYCOERYTHRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM FREMYELLA-DIPLOSIPHON; MARINE UNICELLULAR CYANOBACTERIA; CRYSTAL-STRUCTURE ANALYSIS; BILIVERDIN-IX-ALPHA; ATTACHMENT SITES; CRYPTOPHYCEAN ALGAE; INVITRO ATTACHMENT; B-PHYCOERYTHRIN; C-PHYCOCYANIN; ESCHERICHIA-COLI	C-Phycoerythrin is a light-harvesting protein whose alpha and beta subunits carry thioether-linked phycoerythrobilin (PEB) at cysteine residues alpha-82, alpha-139, beta-48,59 (doubly-linked), beta-80, and beta-165. The two subunits of Calothrix sp. PCC 7601 C-phycoerythrin, overexpressed together as apopolypeptides in Escherichia coli, formed inclusion bodies. Purified apo-alpha was soluble in the absence of urea, whereas the apo-beta subunit was only soluble at high urea concentrations. Products of nonenzymatic addition of PEB and phycocyanobilin (PCB) to apo-alpha were characterized by isolation of bilin peptides and spectroscopy. Reaction of PEB with the apo-alpha subunit led primarily to 15,16-dihydrobiliverdin (Cys-82) or urobilin (Cys-139) adducts, and small amounts of the natural PEB adducts at both Cys-82 and Cys-139. PCB reacted primarily with Cys-82 to form phycocyanobilin and mesobiliverdin adducts. Both PEB and PCB also formed relatively small amounts of adducts with Cys-59, which is not a bilin attachment residue in natural phycoerythrin. Sodium azide was found to promote the addition of PEB to simple thiols but not to apo-alpha phycoerythrin.	UNIV CALIF BERKELEY, MCB STANLEY DONNER ASU, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NIGMS NIH HHS [GM28994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; ARCIERO DM, 1988, J BIOL CHEM, V263, P18358; ARCIERO DM, 1988, J BIOL CHEM, V263, P18350; BEALE SI, 1991, J BIOL CHEM, V266, P22328; BEALE SI, 1991, J BIOL CHEM, V266, P22333; BEALE SI, 1991, J BIOL CHEM, V266, P22341; BERKELMAN TR, 1986, ANAL BIOCHEM, V156, P194, DOI 10.1016/0003-2697(86)90173-9; BRYANT DA, 1985, FEMS MICROBIOL LETT, V29, P343, DOI 10.1111/j.1574-6968.1985.tb00888.x; CHAPMAN DJ, 1967, J AM CHEM SOC, V89, P5976, DOI 10.1021/ja00999a058; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; COLE WJ, 1967, EUR J BIOCHEM, V3, P202, DOI 10.1111/j.1432-1033.1967.tb19516.x; CORNEJO J, 1992, J BIOL CHEM, V267, P14790; DEMARSAC NT, 1990, FEMS SYMP, V53, P143; DEMARSAC NT, 1983, B I PASTEUR, V81, P201; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; FAIRCHILD CD, 1994, J BIOL CHEM, V269, P8686; FAIRCHILD CD, 1992, P NATL ACAD SCI USA, V89, P7017, DOI 10.1073/pnas.89.15.7017; FAIRCHILD CD, 1993, THESIS U CALIFORNIA; FICNER R, 1992, J MOL BIOL, V228, P935, DOI 10.1016/0022-2836(92)90876-L; Glazer A.N., 1987, CYANOBACTERIA, P69; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GLAZER AN, 1975, J BIOL CHEM, V250, P5487; GROSSMAN AR, 1993, MICROBIOL REV, V57, P725, DOI 10.1128/MMBR.57.3.725-749.1993; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KLOTZ AV, 1987, J BIOL CHEM, V262, P17350; KLOTZ AV, 1985, J BIOL CHEM, V260, P4856; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGARIAS JC, 1988, J BIOL CHEM, V263, P12977; LI LM, 1992, J BIOL CHEM, V267, P19204; MAZEL D, 1986, NUCLEIC ACIDS RES, V14, P8279, DOI 10.1093/nar/14.21.8279; NAGY JO, 1985, J BIOL CHEM, V260, P4864; OCARRA P, 1964, BIOCHEMISTRY-US, V3, P1343, DOI 10.1021/bi00897a026; ONG LJ, 1991, J BIOL CHEM, V266, P9515; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; RUSSEL M, 1984, J BACTERIOL, V159, P1034, DOI 10.1128/JB.159.3.1034-1039.1984; SCHEER H, 1977, Z NATURFORSCH C, V32, P513; SCHOENLEBER RW, 1984, J BIOL CHEM, V259, P5481; SCHOENLEBER RW, 1984, J BIOL CHEM, V259, P5485; SIDLER W, 1986, BIOL CHEM H-S, V367, P627, DOI 10.1515/bchm3.1986.367.2.627; STUMPE H, 1993, TETRAHEDRON LETT, V34, P4165, DOI 10.1016/S0040-4039(00)60518-X; SWANSON RV, 1991, J BIOL CHEM, V266, P9528; SWANSON RV, 1992, J BIOL CHEM, V267, P16146; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WEDEMAYER GJ, 1991, J BIOL CHEM, V266, P4731; WEDEMAYER GJ, 1992, J BIOL CHEM, V267, P7315; WEMMER DE, 1993, J BIOL CHEM, V268, P1658; WILBANKS SM, 1993, J BIOL CHEM, V268, P1226; ZHOU JH, 1992, J BIOL CHEM, V267, P16138; ZICKENDRAHTWENDELSTADT B, 1980, PHOTOCHEM PHOTOBIOL, V31, P367, DOI 10.1111/j.1751-1097.1980.tb02555.x; ZILINSKAS BA, 1984, ADV PHOTOSYNTHESIS R, V2, P687	51	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28988	28996						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961862				2022-12-25	WOS:A1994PU16800072
J	ISHIKAWA, T; WRIGHT, CD; ISHIZUKA, H				ISHIKAWA, T; WRIGHT, CD; ISHIZUKA, H			GS-X PUMP IS FUNCTIONALLY OVEREXPRESSED IN CIS-DIAMMINEDICHLOROPLATINUM(II)-RESISTANT HUMAN LEUKEMIA HL-60 CELLS AND DOWN-REGULATED BY CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-CONJUGATE; OVARIAN-CARCINOMA CELLS; ATP-DEPENDENT TRANSPORT; RAT-HEART SARCOLEMMA; DIMETHYL-SULFOXIDE; CARDIAC TRANSPORT; ACTIVE-TRANSPORT; GENE-EXPRESSION; DRUG-RESISTANT; RETINOIC ACID	The ATP-dependent glutathione S-conjugate export pump, named GS-X pump, has been shown to eliminate a potentially cytotoxic glutathione-platinum (GS Pt) complex from tumor cells, thereby modulating glutathione (GSH)-associated resistance to cis-diamminedichloroplatinum(II) (cisplatin) (Ishikawa, T., and Ali-Osman, F. (1993) J. Biol. Chem. 268, 20116-20125). The present study provides evidence that the GS-X pump is functionally overexpressed in cisplatin-resistant human promyelocytic leukemia HL-60 (HL-60/R-CP) cells, in which the cellular GSH level was substantially enhanced. Indeed, the rate of ATP-dependent transport of the GS.Pt complex, measured with plasma membrane vesicles, was about 4-fold greater in HL-60/R-CP cells than in HL-60 cells. Three membrane proteins with apparent molecular masses of 200, 110, and 70 kDa were overexpressed in HL-60/R-CP cells, whereas P-glycoprotein (MDR1) was not immunologically detected in the membrane prepa rations from resistant and sensitive cells. Unlike in HL-60 cells, increased numbers of intracellular vesicles were observed in the cytoplasm of HL-60/R-CP cells. Fluorescence microscopy with syn-(ClCH2,CH3)-1,5-diazabicyclo-[3.3.0]-octa-3,6-dione-2,8-dione (monochlorobimane) revealed that the fluorescent glutathione S-conjugate accumulated in intracellular vesicles of the cisplatin-resistant cells in an energy-dependent manner. The GS-X pump is suggested to contribute to vesicle-mediated excretion of GSH-drug conjugates from cells. In addition, both HL-60 and HL-60/R-CP cells underwent cell differentiation in response to 12-O-tetradecanoylphorbol-13-acetate, retinoic acid, and dimethyl sulfoxide, resulting in proliferation arrest as well as a remarkable decrease in the c-myc mRNA levels. After cell differentiation, a significant decrease was observed in the activity of ATP-dependent transport of the GS.Pt complex in membrane vesicles prepared from both HL-60/R-CP and HL-60 cells. These results suggest that the expression of the GS-X pump in both cisplatin-resistant and -sensitive cells is related to cell proliferation.			ISHIKAWA, T (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,MOLEC THERAPEUT SECT,POB 169,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [R01CA060486] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA60486] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON ME, 1990, FASEB J, V4, P3251, DOI 10.1096/fasebj.4.14.2227215; ARRICK BA, 1984, CANCER RES, V44, P4224; BALLATORI N, 1983, AM J PHYSIOL, V244, pG435, DOI 10.1152/ajpgi.1983.244.4.G435; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BRITTINGER G, 1968, J CELL BIOL, V37, P394, DOI 10.1083/jcb.37.2.394; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; DALLAFAVERA R, 1982, NATURE, V299, P61; DIETEL M, 1993, CANCER RES, V53, P2683; EASTMAN A, 1983, BIOCHEMISTRY-US, V22, P3927, DOI 10.1021/bi00285a031; EDELSON PJ, 1978, J EXP MED, V147, P77, DOI 10.1084/jem.147.1.77; ELFERINK RO, 1993, HEPATOLOGY, V17, P343; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOLISCH G, 1970, EUR J BIOCHEM, V16, P110, DOI 10.1111/j.1432-1033.1970.tb01060.x; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12168; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; GRILL E, 1989, P NATL ACAD SCI USA, V86, P6838, DOI 10.1073/pnas.86.18.6838; GYURASICS A, 1991, BIOCHEM PHARMACOL, V41, P937, DOI 10.1016/0006-2952(91)90199-F; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAMAGUCHI K, 1993, CANCER RES, V53, P5225; HAMILTON TC, 1985, BIOCHEM PHARMACOL, V34, P2583, DOI 10.1016/0006-2952(85)90551-9; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; ISHIKAWA T, 1990, TRENDS BIOCHEM SCI, V15, P219, DOI 10.1016/0968-0004(90)90032-7; ISHIKAWA T, 1989, FEBS LETT, V246, P177, DOI 10.1016/0014-5793(89)80278-9; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; ISHIKAWA T, 1989, FEBS LETT, V259, P95, DOI 10.1016/0014-5793(89)81503-0; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; ISHIKAWA T, 1984, J BIOL CHEM, V259, P3838; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; ISHIKAWA T, 1993, STRUCTURE FUNCTION G, P211; ISHIKAWA T, 1994, DRUG TRANSPORT ANTIM; ISONISHI S, 1991, CANCER RES, V51, P5903; ISONISHI S, 1990, J BIOL CHEM, V265, P3623; KASHANISABET M, 1990, EUR J CANCER, V26, P383, DOI 10.1016/0277-5379(90)90238-O; KASHANISABET M, 1990, J BIOL CHEM, V265, P11285; KAWAI K, 1990, J BIOL CHEM, V265, P13137; KIMURA S, 1979, ARCH BIOCHEM BIOPHYS, V198, P580, DOI 10.1016/0003-9861(79)90534-4; KONDO T, 1993, J BIOL CHEM, V268, P20366; KOSOWER EM, 1980, J AM CHEM SOC, V102, P4983, DOI 10.1021/ja00535a028; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM BK, 1992, P NATL ACAD SCI USA, V89, P11598, DOI 10.1073/pnas.89.23.11598; LOTAN R, 1991, CANCER BIOL, V2, P197; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MORROW CS, 1989, GENE, V75, P3, DOI 10.1016/0378-1119(89)90377-6; MULLER M, 1994, IN PRESS P NATL ACAD, V91; MURASUGI A, 1981, BIOCHEM BIOPH RES CO, V103, P1021, DOI 10.1016/0006-291X(81)90911-6; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NICHOLSON DW, 1992, J BIOL CHEM, V267, P17849; OESTERREICH S, 1991, BIOCHEM BIOPH RES CO, V180, P243, DOI 10.1016/S0006-291X(05)81283-5; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; PERRIN DD, 1971, BIOCHIM BIOPHYS ACTA, V230, P96, DOI 10.1016/0304-4165(71)90057-2; RAZZELL WE, 1959, J BIOL CHEM, V234, P2105; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; ROSENBERG B, 1985, CANCER, V55, P2303, DOI 10.1002/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; SHRIEVE DC, 1988, J BIOL CHEM, V263, P14107; SINGHAL RK, 1987, FASEB J, V1, P220, DOI 10.1096/fasebj.1.3.2887478; SODERSTROM M, 1992, BIOCHEM BIOPH RES CO, V189, P1043, DOI 10.1016/0006-291X(92)92309-L; SOMFAIRELLE S, 1984, CANCER TREAT REP, V11, P443; SZASZ G, 1969, CLIN CHEM, V15, P124; TALALAY P, 1946, J BIOL CHEM, V166, P757; TATE SS, 1974, J BIOL CHEM, V249, P7593; TEETER LD, 1986, MOL CELL BIOL, V6, P4268, DOI 10.1128/MCB.6.12.4268; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P429; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; XIA CL, 1993, BIOCHEM J, V292, P845, DOI 10.1042/bj2920845; YEN A, 1985, EXP CELL RES, V156, P198, DOI 10.1016/0014-4827(85)90274-5; ZWELLING LA, 1981, CANCER RES, V41, P640	78	183	186	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29085	29093						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961875				2022-12-25	WOS:A1994PU16800085
J	LORIAUX, MM; BRENNAN, RG; GOODMAN, RH				LORIAUX, MM; BRENNAN, RG; GOODMAN, RH			MODULATORY FUNCTION OF CREB-CENTER-DOT-CREM-ALPHA HETERODIMERS DEPENDS UPON CREM-ALPHA PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; RESPONSIVE ELEMENT; SOMATOSTATIN GENE; CATALYTIC SUBUNIT; KINASE-A; TRANSCRIPTION; ANTAGONIST; EXPRESSION; ACTIVATOR; MULTIPLE	The cAMP-responsive element (CRE) modulator protein CREM alpha has been proposed to be a negative regulator of the CRE-binding protein (CREB). Precisely how CREM alpha inhibits CREB function is unclear, however. CREM alpha and CREB have highly related structures, and both proteins bind to consensus CRE sequences with similar affinities. Furthermore, both proteins can be phosphorylated by cAMP-dependent protein kinase A (PKA). Two models have been proposed to explain how CREM alpha could prevent the activation of genes by PKA-phosphorylated CREB: inhibitory CREM alpha homodimers could prevent occupancy of the CRE by CREB, or CREM alpha could block gene activation by forming nonfunctional CREB.CREM alpha heterodimers. To determine whether CREB.CREM alpha heterodimers are indeed nonfunctional, we engineered the leucine zipper regions of the two proteins to direct the pattern of dimerization. We then tested the biological activities of the phosphorylated and nonphosphorylated complexes in in vivo transcription assays. Our results indicate that CREM alpha can contribute to PKA-mediated gene activation when selectively heterodimerized with CREB. Furthermore, this transcriptional activity depends upon the ability of the complexes to be phosphorylated by PKA.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University				Brennan, Richard/0000-0001-7647-485X	NIDDK NIH HHS [DK45423] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045423] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; MASSON N, 1992, MOL CELL BIOL, V12, P1096, DOI 10.1128/MCB.12.3.1096; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483	23	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28839	28843						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961842				2022-12-25	WOS:A1994PU16800052
J	MOEBIUS, FF; HANNER, M; KNAUS, HG; WEBER, F; STRIESSNIG, J; GLOSSMANN, H				MOEBIUS, FF; HANNER, M; KNAUS, HG; WEBER, F; STRIESSNIG, J; GLOSSMANN, H			PURIFICATION AND AMINO-TERMINAL SEQUENCING OF THE HIGH-AFFINITY PHENYLALKYLAMINE CA2+ ANTAGONIST BINDING-PROTEIN FROM GUINEA-PIG LIVER ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGMA-RECEPTORS; RAT-BRAIN; CEREBRAL-ISCHEMIA; SITES; CYTOCHROME-P-450; IDENTIFICATION; (S)-EMOPAMIL; POLYPEPTIDE; IFENPRODIL; OPIPRAMOL	A high affinity phenylalkylamine Ca2+ antagonist binding polypeptide (Moebius, F. F., Burrows, G. G., Striessnig, J., and Glossmann, H. (1993) Mol. Pharmacol. 43, 139-148) was purified to homogeneity from the endoplasmic reticulum of guinea pig liver with the aid of [H-3]emopamil, an antiischemic agent, and [H-3]azidopamil, a photoaffinity label. The purified protein retained its high affinity for the antiischemic drugs emopamil (K-d = 4 nM), opipramol (IC50 = 15 nM), trifluoperazine (IC50 = 2 nM), and for Zn2+ (IC50 = 2 mu l). Ferguson plots revealed a molecular mass of 27.2 kDa. Partial amino acid sequence information was obtained by Edman degradation and revealed no homology to known protein sequences. Antibodies raised against a synthetic peptide corresponding to the first 25 NH2-terminal amino acid residues specifically immunoprecipitated the [H-3]azidopamil photoaffinity-labeled polypeptide and recognized the protein in Western blots. Crosslinking with a variety of homo- and heterobifunctional agents lead to the formation of dimers. Since in the purified preparation no other subunit could be identified with different protein stains, our results indicate that the [H-3]emopamil binding site is formed by the homodimer of a novel membrane protein.	UNIV INNSBRUCK, INST BIOCHEM PHARMAKOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck			Striessnig, Joerg/S-9334-2017; Glossmann, Hartmut/AAL-9790-2020	Striessnig, Joerg/0000-0002-9406-7120; glossmann, hartmut h./0000-0002-7392-3266				ANTKIEWICZMICHALUK L, 1988, J BIOL CHEM, V263, P17317; BLOCK F, 1993, ACTA NEUROL SCAND, V88, P35; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATELAIN P, 1987, EUR J PHARMACOL, V144, P83, DOI 10.1016/0014-2999(87)90012-4; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; ELGER B, 1994, EUR J PHARMACOL, V254, P65, DOI 10.1016/0014-2999(94)90371-9; Ferrari R, 1991, Drugs, V42 Suppl 1, P14; FERRIS CD, 1991, J NEUROCHEM, V57, P729, DOI 10.1111/j.1471-4159.1991.tb08213.x; FERRIS CD, 1991, MOL PHARMACOL, V39, P199; FISHER M, 1993, DRUGS, V46, P961, DOI 10.2165/00003495-199346060-00003; FRANK RN, 1975, ARCH BIOCHEM BIOPHYS, V171, P1, DOI 10.1016/0003-9861(75)90001-6; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; HASHIMOTO K, 1993, EUR J PHARMACOL, V236, P159, DOI 10.1016/0014-2999(93)90241-9; KLEIN M, 1991, LIFE SCI, V48, P543, DOI 10.1016/0024-3205(91)90469-R; KNIGHT A R, 1991, Molecular Neuropharmacology, V1, P71; LANDON EJ, 1986, BIOCHEM PHARMACOL, V35, P697, DOI 10.1016/0006-2952(86)90369-2; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LIMON I, 1992, J BIOL CHEM, V267, P24645; MATSUMOTO M, 1993, STROKE, V24, P1228, DOI 10.1161/01.STR.24.8.1228; MOEBIUS FF, 1993, MOL PHARMACOL, V44, P966; MOEBIUS FF, 1993, MOL PHARMACOL, V43, P139; MORIKAWA E, 1991, STROKE, V22, P355, DOI 10.1161/01.STR.22.3.355; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; RAO TS, 1990, NEUROPHARMACOLOGY, V29, P1199, DOI 10.1016/0028-3908(90)90045-S; ROSS SB, 1991, PHARMACOL TOXICOL, V68, P293, DOI 10.1111/j.1600-0773.1991.tb01242.x; SAMOVILOVA NN, 1992, EUR J PHARM-MOLEC PH, V225, P69, DOI 10.1016/0922-4106(92)90041-S; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; STRIESSNIG J, 1993, CELL PHYSIOL BIOCHEM, V3, P295, DOI 10.1159/000154695; WALKER JM, 1990, PHARMACOL REV, V42, P355; ZECH C, 1991, EUR J PHARM-MOLEC PH, V208, P119, DOI 10.1016/0922-4106(91)90062-M; ZIVIN JA, 1989, BRAIN RES, V482, P189, DOI 10.1016/0006-8993(89)90560-X	31	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29314	29320						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961902				2022-12-25	WOS:A1994PU16800115
J	NIBU, Y; TAKAHASHI, S; TANIMOTO, K; MURAKAMI, K; FUKAMIZU, A				NIBU, Y; TAKAHASHI, S; TANIMOTO, K; MURAKAMI, K; FUKAMIZU, A			IDENTIFICATION OF CELL TYPE-DEPENDENT ENHANCER CORE ELEMENT LOCATED IN THE 3'-DOWNSTREAM REGION OF THE HUMAN ANGIOTENSINOGEN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE RESPONSE ELEMENT; DNA-BINDING PROTEINS; TRANSGENIC MICE; TRANSCRIPTION FACTORS; INDUCED HYPERTROPHY; MOLECULAR-BIOLOGY; CARDIAC MYOCYTES; BLOOD-PRESSURE; NUCLEAR FACTOR; HUMAN RENIN	We previously demonstrated that the 3.8-kilobase DNA fragment containing exons 4 and 5 of the human angiotensinogen (hAG) gene enhances the expression of chloramphenicol acetyltransferase gene, under control of the hAG promoter, in human hepatoma HepG2 cells. In the present study, to define regulatory elements of the hAG gene, we have functionally dissected this downstream region and localized a cell type-dependent enhancer to the 832-base pair sequence containing the exon 5 and 3'-flanking region. Further deletion analyses revealed that the 24-base pair core DNA fragment present in the 3'-flanking region was responsible for this enhancement, Electrophoretic mobility shift assay demonstrated that the 3'-enhancer core element interacts specifically with two nuclear factors from the HepG2 cells, one of which is an uncharacterized factor (human angiotensinogen enhancer factor-1: hAEF-1), the other is an AP-3-related factor. Mutation analyses indicated that the disruption of hAEF-1 binding alone completely impaired the enhancer activity of the core element. These results suggested that the downstream enhancer core element interacting with hAEF-1 plays an important role in activating the angiotensinogen promoter in a cell type dependent manner.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba			fukamizu, akiyoshi/J-5350-2012; Tanimoto, Keiji/B-2600-2014	fukamizu, akiyoshi/0000-0002-8786-6020; Tanimoto, Keiji/0000-0003-1971-6546; Nibu, Yutaka/0000-0002-4696-7503				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRASIER AR, 1989, MOL ENDOCRINOL, V3, P1022, DOI 10.1210/mend-3-6-1022; BRASIER AR, 1990, MOL ENDOCRINOL, V4, P1921, DOI 10.1210/mend-4-12-1921; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CHUI R, 1987, NATURE, V329, P648; CLOUSTON WM, 1989, EMBO J, V8, P3337, DOI 10.1002/j.1460-2075.1989.tb08495.x; CONGIU M, 1992, J MOL ENDOCRINOL, V9, P19, DOI 10.1677/jme.0.0090019; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; FUKAMIZU A, 1990, J CARDIOVASC PHARM, V16, pS11, DOI 10.1097/00005344-199016004-00004; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; FUKAMIZU A, 1991, BIOMED BIOCHIM ACTA, V50, P659; GANTEN D, 1992, P NATL ACAD SCI USA, V89, P7806, DOI 10.1073/pnas.89.16.7806; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LYNCH KR, 1991, HYPERTENSION, V17, P263, DOI 10.1161/01.HYP.17.3.263; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLER MM, 1988, EUR J BIOCHEM, V176, P485, DOI 10.1111/j.1432-1033.1988.tb14306.x; REID IA, 1978, ANNU REV PHYSIOL, V40, P377, DOI 10.1146/annurev.ph.40.030178.002113; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; RON D, 1990, MOL CELL BIOL, V10, P4389, DOI 10.1128/MCB.10.8.4389; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TAKAHASHI S, 1991, BIOCHEM BIOPH RES CO, V180, P1103, DOI 10.1016/S0006-291X(05)81180-5; TAMURA K, 1993, J BIOL CHEM, V268, P15024; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P3617, DOI 10.1093/nar/20.14.3617; TAMURA K, 1994, J CLIN INVEST, V93, P1370, DOI 10.1172/JCI117113; TANIMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V302, P409, DOI 10.1006/abbi.1993.1232; VERRI A, 1990, NUCLEIC ACIDS RES, V18, P5775, DOI 10.1093/nar/18.19.5775; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59	45	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28598	28605						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961807				2022-12-25	WOS:A1994PU16800016
J	BEGOVAC, PC; SHI, YX; MANSFIELD, D; SHUR, BD				BEGOVAC, PC; SHI, YX; MANSFIELD, D; SHUR, BD			EVIDENCE THAT CELL-SURFACE BETA-1,4-GALACTOSYLTRANSFERASE SPONTANEOUSLY GALACTOSYLATES AN UNDERLYING LAMININ SUBSTRATE DURING FIBROBLAST MIGRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE OUTGROWTH; GALACTOSYLTRANSFERASE; ADHESION	beta 1,4-Galactosyltransferase is unusual among the glycosyltransferases in that a subpopulation exists on the cell surface in addition to its traditional biosynthetic location within the Golgi complex, On the cell surface, galactosyltransferase is expressed in spatially restricted, cell type-specific domains, where it functions as a receptor for extracellular oligosaccharide ligands during selected cellular interactions, For example, galactosyltransferase is found on the leading and trailing edges of migrating cells, where it facilitates lamellipodia formation and cell spreading by binding to specific N-linked oligosaccharides within laminin. Although the ability of galactosyltransferase to serve as a laminin receptor is well documented, it is unclear whether it functions solely in a lectin-like capacity to bind laminin glycoside ligands or uses its intrinsic catalytic activity to release itself from and modify its oligosaccharide substrate. In this study, we determined whether cell surface galactosyltransferase spontaneously galactosylates laminin matrices during cell migration using endogenous galactose donors, Cells were prelabeled with [H-3]galactose, washed, and transferred in small clusters onto laminin matrices, The prelabeled cells migrated out from the cell cluster, during which time they deposited covalently bound [H-3]galactose residues onto the laminin matrix. The degree of galactosylation was both laminin- and time-dependent and required actively migrating intact cells. The radioactivity released from the H-3-galactosylated laminin by acid hydrolysis comigrated with authentic galactose standards on paper chromatography. In parallel assays, there was no radioactivity deposited on laminin matrices when cells were prelabeled with [H-3]fucose or [H-3]leucine, Furthermore, [H-3]galactosylation was dependent upon galactosyltransferase-mediated cell migration, since prelabeled cells did not deposit [H-3]galactose when migrating on fibronectin, upon which migration is integrin-dependent and galactosyltransferase-independent. These results raise the possibility that galactosyltransferase functions catalytically during cell migration, either to dissociate from its oligosaccharide Ligand and/or to modify the extracellular matrix.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007120] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 07120] Funding Source: Medline; NINDS NIH HHS [NS 08597] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APPEDDU PA, 1994, J CELL SCI, V107, P2535; BEGOVAC PC, 1991, J CELL BIOL, V113, P637, DOI 10.1083/jcb.113.3.637; BEGOVAC PC, 1990, J CELL BIOL, V110, P461, DOI 10.1083/jcb.110.2.461; BRANDLEY BK, 1990, DEV BIOL, V140, P161, DOI 10.1016/0012-1606(90)90063-O; Carraway K L, 1972, Methods Enzymol, V25, P616, DOI 10.1016/S0076-6879(72)25060-1; CHEN WT, 1981, J CELL BIOL, V90, P187, DOI 10.1083/jcb.90.1.187; DENNIS J, 1982, NATURE, V300, P274, DOI 10.1038/300274a0; ECKSTEIN DJ, 1989, J CELL BIOL, V108, P2507, DOI 10.1083/jcb.108.6.2507; EVANS SC, 1993, J CELL BIOL, V120, P1045, DOI 10.1083/jcb.120.4.1045; HATHAWAY HJ, 1992, J CELL BIOL, V117, P369, DOI 10.1083/jcb.117.2.369; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; Lukashev M. E., 1993, Molecular Biology of the Cell, V4, p406A; MONARD D, 1987, BIOCHEM PHARMACOL, V36, P1389, DOI 10.1016/0006-2952(87)90103-1; RUNYAN RB, 1988, J CELL BIOL, V107, P1863, DOI 10.1083/jcb.107.5.1863; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; Shur BD, 1993, CURR OPIN CELL BIOL, V5, P854, DOI 10.1016/0955-0674(93)90035-O; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; THOMAS WA, 1990, DEVELOPMENT, V110, P1101; TURLEY EA, 1979, CELL, V17, P109, DOI 10.1016/0092-8674(79)90299-X; YOUAKIM A, 1985, CANCER RES, V45, P5505; YOUAKIM A, 1994, P NATL ACAD SCI USA, V91, P10913, DOI 10.1073/pnas.91.23.10913	22	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31793	31799						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989353				2022-12-25	WOS:A1994PX30300072
J	GIROUX, E; WILLIAMS, MK; KANTROWITZ, ER				GIROUX, E; WILLIAMS, MK; KANTROWITZ, ER			SHARED ACTIVE-SITES OF FRUCTOSE-1,6-BISPHOSPHATASE - ARGININE-243 MEDIATES SUBSTRATE-BINDING AND FRUCTOSE 2,6-BISPHOSPHATE INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER FRUCTOSE-1,6-BISPHOSPHATASE; ESCHERICHIA-COLI; PHENOTYPIC SELECTION; CRYSTAL-STRUCTURE; EXPRESSION; BISPHOSPHATASE; 6-PHOSPHATE; SEQUENCE; CDNA; MUTAGENESIS	The active site of pig kidney fructose-1,6-bisphosphatase (EC 3.1.3.11) is shared between subunits, Arg-243 of one chain interacting with fructose-1,6-bisphosphate or fructose-2,6-bisphosphate in the active site of an adjacent chain. In this study, Arg-243 was replaced by alanine using techniques of site-specific mutagenesis and the cloned pig kidney enzyme expressed in Escherichia coli. Compared with wild-type enzyme, kinetic parameters of the altered enzyme characterizing catalytic efficiency, magnesium binding, and inhibition by AMP differed but by less than an order of magnitude; affinity for substrate fructose 1,6-bisphosphate was 10-fold poorer and affinity for inhibitor fructose 2,6-bisphosphate was 1000-fold poorer. Molecular dynamics simulations were undertaken to determine possible alterations in active sites of the enzyme due to replacement of Arg-243 by Ala and suggested that in the mutant enzyme loss of one cationic group leads to reorganization of the active site especially involving lysine residues 269 and 274. The differences in properties of the mutant enzyme indicate the key importance of Arg-243 in the function of fructose-1,6-bisphosphatase and confirm on a functional basis the shared active site in this important metabolic enzyme.	BOSTON COLL,MERKERT CHEM CTR,DEPT CHEM,CHESTNUT HILL,MA 02167	Boston College					NCRR NIH HHS [1 P41 RR06009] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BURTON VA, 1993, BIOCHEM BIOPH RES CO, V192, P511, DOI 10.1006/bbrc.1993.1445; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; CHEN LR, 1993, ARCH BIOCHEM BIOPHYS, V307, P350, DOI 10.1006/abbi.1993.1599; CHEN M, 1994, J BIOL CHEM, V269, P5554; ELMAGHRABI MR, 1992, J BIOL CHEM, V267, P6526; ELMAGHRABI MR, 1988, P NATL ACAD SCI USA, V85, P8430, DOI 10.1073/pnas.85.22.8430; ELMAGHRABI MR, 1993, J BIOL CHEM, V268, P9466; ELMAGHRABI MR, 1991, BIOCHEM BIOPH RES CO, V176, P137, DOI 10.1016/0006-291X(91)90900-R; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; KE H, 1989, J MOL BIOL, V212, P513; KE HM, 1990, J MOL BIOL, V214, P950; KE HM, 1991, P NATL ACAD SCI USA, V88, P2989, DOI 10.1073/pnas.88.8.2989; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KE HM, 1991, BIOCHEMISTRY-US, V30, P4412, DOI 10.1021/bi00232a007; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIANG JY, 1993, P NATL ACAD SCI USA, V90, P2132, DOI 10.1073/pnas.90.6.2132; MARCUS F, 1976, BIOCHEMISTRY-US, V15, P3505, DOI 10.1021/bi00661a017; MARCUS F, 1975, BIOCHEMISTRY-US, V14, P3916, DOI 10.1021/bi00688a029; MARCUS F, 1982, P NATL ACAD SCI-BIOL, V79, P7161, DOI 10.1073/pnas.79.23.7161; MARCUS F, 1981, REGULATION CARBOHYDR, P269; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PILKIS SJ, 1991, ANNU REV NUTR, V11, P465, DOI 10.1146/annurev.nu.11.070191.002341; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1981, J BIOL CHEM, V256, P3171; REYES A, 1987, J BIOL CHEM, V262, P8451; RIOU JP, 1977, P NATL ACAD SCI USA, V74, P4615, DOI 10.1073/pnas.74.10.4615; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNGADHARAN MG, 1969, BIOCHEMISTRY-US, V8, P1411, DOI 10.1021/bi00832a016; SARNGADHARAN MG, 1970, J BIOL CHEM, V245, P1926; SCHREMMER SD, 1984, COMPUT BIOMED RES, V17, P289, DOI 10.1016/S0010-4809(84)80020-8; SEDIVY JM, 1984, J BACTERIOL, V158, P1048, DOI 10.1128/JB.158.3.1048-1053.1984; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TAKETA K, 1965, J BIOL CHEM, V240, P651; Ulm E H, 1975, Methods Enzymol, V42, P369; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILLIAMS MK, 1992, P NATL ACAD SCI USA, V89, P3080, DOI 10.1073/pnas.89.7.3080; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P1844, DOI 10.1021/bi00058a019	43	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31404	31409						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989306				2022-12-25	WOS:A1994PX30300015
J	INOCENCIO, NM; MOEHRING, JM; MOEHRING, TJ				INOCENCIO, NM; MOEHRING, JM; MOEHRING, TJ			FURIN ACTIVATES PSEUDOMONAS EXOTOXIN-A BY SPECIFIC CLEAVAGE IN-VIVO AND IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN PROTECTIVE ANTIGEN; DIPHTHERIA-TOXIN; PROCESSING ENDOPROTEASES; KEX2-LIKE ENDOPROTEASE; CELLS RESISTANT; MOUSE FURIN; EXPRESSION; AERUGINOSA; DEFICIENT; PROTEASE	We have demonstrated that the native proenzymatic form of Pseudomonas exotoxin A can be cleaved at its specific activation site by furin in intact Chinese hamster ovary cells or in vitro by furin in isolated membrane fractions from these cells. We have compared the activity of furin in cell membrane fractions with that of purified, recombinant human furin. We have verified that RPE.40, a Pseudomonas toxin-resistant mutant cell strain, is mutant in the fur gene, and we have demonstrated that these cells are deficient in cleavage of the toxin. We have also determined that this cleavage of Pseudomonas toxin by furin takes place at the authentic activation site to release the 37 kDa active fragment.	UNIV VERMONT,MARKEY CTR MOLEC GENET,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405; UNIV VERMONT,VERMONT CANC CTR,BURLINGTON,VT 05405	University of Vermont; University of Vermont					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009180] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 09180] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRENNAN SO, 1994, FEBS LETT, V338, P147, DOI 10.1016/0014-5793(94)80353-6; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHIRON MF, 1994, J BIOL CHEM, V269, P18167; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; FARAHBAKHSH ZT, 1989, BIOCHEMISTRY-US, V28, P580, DOI 10.1021/bi00428a025; FRYLING C, 1992, INFECT IMMUN, V60, P497, DOI 10.1128/IAI.60.2.497-502.1992; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; IGLEWSKI BH, 1977, INFECT IMMUN, V15, P138, DOI 10.1128/IAI.15.1.138-144.1977; INOCENCIO NM, 1992, J VIROL, V67, P593; JINNO Y, 1989, J BIOL CHEM, V264, P15953; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LEPPLA SH, 1978, BIOCHEM BIOPH RES CO, V81, P532, DOI 10.1016/0006-291X(78)91567-X; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; LORY S, 1980, INFECT IMMUN, V28, P494; MASON AB, 1991, HYBRIDOMA, V10, P611, DOI 10.1089/hyb.1991.10.611; MOEHRING JM, 1983, INFECT IMMUN, V41, P998, DOI 10.1128/IAI.41.3.998-1009.1983; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; MOEHRING TJ, 1977, CELL, V11, P447, DOI 10.1016/0092-8674(77)90063-0; MOEHRING TJ, 1979, SOMAT CELL GENET, V5, P469, DOI 10.1007/BF01538881; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OGATA M, 1990, J BIOL CHEM, V265, P20678; OGATA M, 1992, J BIOL CHEM, V267, P25396; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; WATSON DG, 1991, J VIROL, V65, P2332, DOI 10.1128/JVI.65.5.2332-2339.1991	31	69	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31831	31835						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989356				2022-12-25	WOS:A1994PX30300077
J	JANSSEN, GMC; VANDAMME, HTF; KRIEK, J; AMONS, R; MOLLER, W				JANSSEN, GMC; VANDAMME, HTF; KRIEK, J; AMONS, R; MOLLER, W			THE SUBUNIT STRUCTURE OF ELONGATION-FACTOR-1 FROM ARTEMIA - WHY 2 ALPHA-CHAINS IN THIS COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; EUKARYOTIC PROTEIN-SYNTHESIS; FACTOR-I; MESSENGER-RNA; FACTOR-TU; RABBIT RETICULOCYTES; FACTOR EF-1-ALPHA; EF-TU; BINDING; CELLS	Elongation factor 1 (EF-1) regulates the specific interaction of aminoacyl-tRNA with the ribosome during the elongation phase of protein biosynthesis. Although individual functions of its separate chains have been well defined, to date there is hardly information about the structure and function of the whole complex. We describe here the complete subunit structure of elongation factor 1, and discuss its change during development of Artemia. Elongation factor 1 consists of a pentameric complex, composed of four different subunits alpha, beta, gamma, and delta in a molar ratio of 2:1:1:1, Although one molecule of EF-1 alpha dissociates easily from the complex EF-1 alpha,beta gamma delta under the influence of aminoacyl-tRNA and GTP, the second molecule of EF-1 alpha was found to remain firmly attached. Thus, in eukaryotic protein synthesis, movement of transfer RNAs to the ribosome seems under the influence of two distinct molecules of EF-1 alpha, a result possibly related to the presumed consumption of two molecules of GTP by EF-Tu during the elongation step of prokaryotic protein synthesis.	LEIDEN UNIV,DEPT MED BIOCHEM,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC								AMONS R, 1994, BBA-GENE STRUCT EXPR, V1218, P346, DOI 10.1016/0167-4781(94)90187-2; BEC G, 1989, J BIOL CHEM, V264, P21131; BELLE R, 1989, FEBS LETT, V255, P101, DOI 10.1016/0014-5793(89)81069-5; BERES L, 1973, BIOCHEMISTRY-US, V12, P3998, DOI 10.1021/bi00744a033; BLUMENTHAL T, 1972, P NATL ACAD SCI USA, V69, P1313, DOI 10.1073/pnas.69.5.1313; BUBUNENKO MG, 1992, BIOCHIMIE, V74, P419, DOI 10.1016/0300-9084(92)90081-O; CARVALHO JF, 1984, ARCH BIOCHEM BIOPHYS, V234, P591, DOI 10.1016/0003-9861(84)90309-6; CAVALLIUS J, 1986, EXP GERONTOL, V21, P149, DOI 10.1016/0531-5565(86)90068-9; CHI KF, 1992, GASTROENTEROLOGY, V103, P98, DOI 10.1016/0016-5085(92)91101-9; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHN EJ, 1948, PROTEINS AMINO ACIDS, P370; EHRENBERG M, 1990, J MOL BIOL, V211, P739, DOI 10.1016/0022-2836(90)90074-V; EJIRI S, 1983, J BIOCHEM-TOKYO, V94, P319, DOI 10.1093/oxfordjournals.jbchem.a134348; FISCHER I, 1980, BIOCHEMISTRY-US, V19, P1417, DOI 10.1021/bi00548a024; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; GROSFELD H, 1976, EUR J BIOCHEM, V70, P589, DOI 10.1111/j.1432-1033.1976.tb11050.x; HASSELL JA, 1976, BIOCHEMISTRY-US, V15, P1375, DOI 10.1021/bi00652a004; HATTORI S, 1983, J BIOCHEM-TOKYO, V94, P79, DOI 10.1093/oxfordjournals.jbchem.a134357; HATTORI S, 1988, J BIOCHEM-TOKYO, V88, P725; HAYASHI Y, 1989, J BIOCHEM-TOKYO, V106, P560, DOI 10.1093/oxfordjournals.jbchem.a122895; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HOVEMANN B, 1988, NUCLEIC ACIDS RES, V16, P3175, DOI 10.1093/nar/16.8.3175; HULTIN T, 1968, DEV BIOL, V17, P143, DOI 10.1016/0012-1606(68)90058-4; JANSSEN GMC, 1988, J BIOL CHEM, V263, P1773; JANSSEN GMC, 1988, J BIOL CHEM, V263, P11063; JANSSEN GMC, 1991, J BIOL CHEM, V266, P14885; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; JANSSEN GMC, 1990, RIBOSOMES PROTEIN SY, P51; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KEMPER WM, 1976, ARCH BIOCHEM BIOPHYS, V174, P603, DOI 10.1016/0003-9861(76)90389-1; KNECHT R, 1986, ADV METHODS PROTEIN, P56; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGON S, 1973, NATURE-NEW BIOL, V241, P150, DOI 10.1038/newbio241150a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAESSEN GDF, 1986, FEBS LETT, V208, P77, DOI 10.1016/0014-5793(86)81536-8; MAESSEN GDF, 1987, FEBS LETT, V223, P181, DOI 10.1016/0014-5793(87)80532-X; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; Moller W., 1987, P451; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; NAGATA S, 1976, ARCH BIOCHEM BIOPHYS, V172, P168, DOI 10.1016/0003-9861(76)90063-1; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NIELSEN PJ, 1980, J CELL PHYSIOL, V104, P269, DOI 10.1002/jcp.1041040302; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PORATH J, 1959, NATURE, V183, P1657, DOI 10.1038/1831657a0; Reichlin M, 1980, Methods Enzymol, V70, P159; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; RYAZANOV AG, 1991, FEBS LETT, V285, P170, DOI 10.1016/0014-5793(91)80798-8; SACCHI GA, 1984, EUR J BIOCHEM, V139, P1, DOI 10.1111/j.1432-1033.1984.tb07967.x; SANDERS J, 1992, NUCLEIC ACIDS RES, V20, P5907, DOI 10.1093/nar/20.22.5907; SANDERS J, 1993, BIOCHIM BIOPHYS ACTA, V1174, P87, DOI 10.1016/0167-4781(93)90097-W; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SLOBIN LI, 1976, EUR J BIOCHEM, V69, P351, DOI 10.1111/j.1432-1033.1976.tb10919.x; SLOBIN LI, 1980, EUR J BIOCHEM, V110, P555, DOI 10.1111/j.1432-1033.1980.tb04898.x; SLOBIN LI, 1975, NATURE, V258, P452, DOI 10.1038/258452a0; SPIRIN AS, 1978, FEBS LETT, V88, P15, DOI 10.1016/0014-5793(78)80596-1; TAL M, 1985, J BIOL CHEM, V260, P9976; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; THOMPSON RC, 1981, J BIOL CHEM, V256, P81; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIUMI T, 1992, J BIOL CHEM, V267, P19179; VANDAMME H, 1991, EUR J BIOCHEM, V197, P505, DOI 10.1111/j.1432-1033.1991.tb15938.x; VANDAMME HTF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P241, DOI 10.1016/0167-4781(90)90174-Z; VANDAMME HTF, 1992, EUR J BIOCHEM, V207, P1025; VANHEMERT FJ, 1984, EMBO J, V3, P1109, DOI 10.1002/j.1460-2075.1984.tb01937.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	70	62	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31410	31417						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989307				2022-12-25	WOS:A1994PX30300016
J	LIU, Q; FENG, Y; FORGAC, M				LIU, Q; FENG, Y; FORGAC, M			ACTIVITY AND IN-VITRO REASSEMBLY OF THE COATED VESICLE (H+)-ATPASE REQUIRES THE 50-KDA SUBUNIT OF THE CLATHRIN ASSEMBLY COMPLEX AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON PUMP; PROTEIN COMPLEX; ADENOSINE-TRIPHOSPHATASE; H+-ATPASE; PURIFICATION; POLYPEPTIDE; INHIBITION; MECHANISM; BINDING	We have previously shown that the 50-kDa subunit of the clathrin assembly complex AP-2 (AP50) stoichiometrically binds to and is immunoprecipitated with the vacuolar (H+)-ATPase (V-ATPase) from clathrin-coated vesicles (Myers, M., and Forgac, M. (1993) J. Biol. Chem. 268, 9184-9186), We now report that treatment of stripped coated vesicles with cystine results in a purified V-ATPase complex lacking the AP50 polypeptide, Removal of AP50 can be reversed upon treatment of the vesicles with dithiothreitol., Removal of AP50 reduces the ATPase activity of the purified V-ATPase by 90% relative to the enzyme containing AP50. This inhibition is not reversed upon treatment of the AP50-depleted enzyme with dithiothreitol in the absence of AP50. The reconstituted V-ATPase depleted of AP50 is devoid of ATP-dependent proton transport activity. We observe further that the peripheral V-1 subunits are unable to reassemble onto the integral V-0 domain in the absence of AP50. The addition of purified AP-2 containing the AP50 polypeptide restores the ability of the V-1 subunits to assemble with the V-0 sector to give a V-ATPase complex that is functional in ATP-dependent proton transport, These results indicate that the AP50 polypeptide is necessary for both activity and in vitro reassembly of the V-ATPase complex.	TUFTS UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02111 USA	Tufts University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34478, R01 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; AHLE S, 1989, J BIOL CHEM, V264, P20089; ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; ARAI K, 1993, J BIOL CHEM, V268, P5649; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; FENG Y, 1992, J BIOL CHEM, V267, P5817; FILLINGAME RH, 1992, J BIOENERG BIOMEMBR, V24, P485, DOI 10.1007/BF00762366; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GLUCK S, 1987, J BIOL CHEM, V262, P15780; KANE PM, 1989, J BIOL CHEM, V264, P19236; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI SP, 1988, J BIOL CHEM, V263, P16731; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MYERS M, 1993, J BIOL CHEM, V268, P9184; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PARRY RV, 1989, J BIOL CHEM, V264, P20015; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; [No title captured]	35	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31592	31597						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989329				2022-12-25	WOS:A1994PX30300042
J	MA, L; KANTROWITZ, ER				MA, L; KANTROWITZ, ER			MUTATIONS AT HISTIDINE-412 ALTER ZINC-BINDING AND ELIMINATE TRANSFERASE-ACTIVITY IN ESCHERICHIA-COLI ALKALINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; AMINO-ACID-SEQUENCE; DNA-POLYMERASE-I; PHENOTYPIC SELECTION; CRYSTAL-STRUCTURE; 2.8-A RESOLUTION; MECHANISM; GENE	His-412 in wild-type Escherichia coli alkaline phosphatase is a direct ligand to one of the two zinc atoms critical for the function of the enzyme, To investigate the function of this residue, site-specific mutagenesis was used to substitute His-412 with asparagine and alanine, generating mutant enzymes H412N and H412A, respectively. Both mutant enzymes show a 5-fold decrease in k(cat) and 30-fold increase in K-m when compared to the corresponding kinetic parameters for the wild-type enzyme. In contrast to the wild-type enzyme, Tris and ethanolamine inhibit both the mutant enzymes by inhibiting the hydrolysis reaction and not participating in the transferase reaction; furthermore, both mutants have lower zinc and phosphate content than the wild-type enzyme. The addition of Zn2+ to the H412N and H412A enzymes restores catalytic activity to within a-fold of; the value for the wild-type enzyme, but more importantly the presence of Zn2+ completely restores substrate affinity. The similarity in the kinetic parameters for the H412N and H412A enzymes in the absence and presence of zinc suggests that the asparagine side chain does not play a significant role in coordinating zinc. Furthermore, both the asparagine and alanine substitutions reduce the affinity of the resulting enzymes for zinc. The pH profiles for the two mutant enzymes are different than the pH profile observed for the wild-type enzyme, suggesting that the amino acid substitutions may have altered the pK(a) of the zinc coordinated water molecule that is critical in the second step of the mechanism. These data suggest that His-412 does not directly participate in the catalytic mechanism but is mainly involved in zinc binding, and therefore is also indirectly involved in substrate binding and product release.	BOSTON COLL,MERKERT CHEM CTR,DEPT CHEM,CHESTNUT HILL,MA 02167	Boston College					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RA, 1976, BIOCHEMISTRY-US, V15, P3710, DOI 10.1021/bi00662a011; ANDERSON RA, 1975, P NATL ACAD SCI USA, V72, P2989, DOI 10.1073/pnas.72.8.2989; ANDERSON SF, 1992, BIOCHEMISTRY-US, V31, P8221, DOI 10.1021/bi00150a015; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BLOCH W, 1973, J BIOL CHEM, V248, P5794; BLOCH W, 1978, J BIOL CHEM, V253, P6211; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHAW RA, 1981, P NATL ACAD SCI-BIOL, V78, P3473, DOI 10.1073/pnas.78.6.3473; CHAIDAROGLOU A, 1988, BIOCHEMISTRY-US, V27, P8338, DOI 10.1021/bi00422a008; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DAYAN J, 1964, BIOCHIM BIOPHYS ACTA, V81, P620, DOI 10.1016/0926-6569(64)90154-3; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; HULETT FM, 1991, J BIOL CHEM, V266, P1077; HULL WE, 1976, BIOCHEMISTRY-US, V15, P1547, DOI 10.1021/bi00652a028; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; KANEKO Y, 1987, GENE, V58, P137; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MULLER B, 1993, BIOCHEMISTRY-US, V32, P7966; PLOCKE DJ, 1962, BIOCHEMISTRY-US, V1, P373, DOI 10.1021/bi00909a001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ JH, 1961, P NATL ACAD SCI USA, V47, P1996, DOI 10.1073/pnas.47.12.1996; SEGEL IH, 1975, ENZYME KINETICS, P120; SIMPSON RT, 1968, BIOCHEMISTRY-US, V7, P4343, DOI 10.1021/bi00852a029; SOWADSKI J M, 1983, Journal of Molecular Biology, V170, P575, DOI 10.1016/S0022-2836(83)80162-4; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P319, DOI 10.1073/pnas.85.2.319; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182; WILSON IB, 1964, J BIOL CHEM, V239, P4182; XU X, 1991, BIOCHEMISTRY-US, V30, P7789, DOI 10.1021/bi00245a018	37	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31614	31619						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989332				2022-12-25	WOS:A1994PX30300045
J	STEVENS, VL; ZHANG, H				STEVENS, VL; ZHANG, H			COENZYME-A DEPENDENCE OF GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS IN A MAMMALIAN CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; VARIANT SURFACE GLYCOPROTEIN; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; RAT-LIVER MICROSOMES; GLYCOSYL-PHOSPHATIDYLINOSITOL; TRYPANOSOMA-BRUCEI; THY-1 GLYCOPROTEIN; ARACHIDONIC-ACID; N-GLYCOSYLATION; LYMPHOMA-CELLS	The biosynthesis of glycosylphosphatidylinositol (GPI) in mammals and yeast involves a step not observed in trypanosomes. This reaction, which is the inositol acylation of glucosamine phosphatidylinositol (GlcN-PI), occurs as the third step in the biosynthetic pathway, In this study, conditions were developed to stimulate this reaction in vitro. The synthesis of the GlcN-PI(acyl) from either UDP-[6-H-3]GlcNAc or [6- 3H] GlcNAc-PI by murine, lymphoma cell microsomes was greatly enhanced by the addition of either CoA or palmitoyl-CoA. Stimulation of this reaction was optimal with 1 mu M of either compound and required that the precursor, GlcN-PI, be synthesized in the presence of GTP, a specific effector of the formation of this glycolipid. That GlcN-PI(acyl) was generated from GlcN-PI was established by pulse-chase analysis, Because no acyl chain specificity for acyl-CoA stimulation of GlcN-PI(acyl) synthesis was found and attempts to demonstrate direct transfer of [H-3]palmiltate from [H-3]palmitoyl-CoA to the third intermediate in GPI biosynthesis were unsuccessful, the possibility that free CoA was the activator of this reaction was considered, CoA-stimulated GlcN-PI acylation occurred in the absence of ATP, an essential cofactor for acyl-CoA synthesis, indicating that free CoA is the endogenous effector of the third step in mammalian GPI biosynthesis. This finding is consistent with this inositol acylation being catalyzed by a CoA dependent transacylase, Mannose-containing GPI intermediates were synthesized in vitro when GDP-mannose was added in the presence of GTP and CoA, Therefore, when effecters of the initial reactions in GPI biosynthesis are included, later steps in this pathway can be studied in mammalian cell-free systems.	EMORY UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,ATLANTA,GA 30335	Emory University								BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHAPMAN A, 1980, J BIOL CHEM, V255, P4441; COLARD O, 1984, BIOCHIM BIOPHYS ACTA, V793, P42, DOI 10.1016/0005-2760(84)90051-1; CONZELMANN A, 1988, MOL CELL BIOL, V8, P674, DOI 10.1128/MCB.8.2.674; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; DARNELL JC, 1991, BIOCHIM BIOPHYS ACTA, V1084, P292, DOI 10.1016/0005-2760(91)90071-O; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FATEMI SH, 1988, J BIOL CHEM, V263, P1288; FERGUSON MAJ, 1992, BIOCHEM J, V284, P297, DOI 10.1042/bj2840297; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; INOUE N, 1993, J BIOL CHEM, V268, P6882; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; KINOSHITA T, 1994, BRAZ J MED BIOL RES, V27, P127; KRAMER RM, 1984, J BIOL CHEM, V259, P2403; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, COVALENT MODIFICATIO, P297; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MENON AK, 1994, BRAZ J MED BIOL RES, V27, P167; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PUOTI A, 1993, J BIOL CHEM, V268, P7215; REDDY PV, 1986, BIOCHIM BIOPHYS ACTA, V879, P369, DOI 10.1016/0005-2760(86)90228-6; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENS VL, 1993, J BIOL CHEM, V268, P9718; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TROTTER J, 1982, J BIOL CHEM, V257, P1816; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9	42	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31397	31403						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989305				2022-12-25	WOS:A1994PX30300014
J	DAMER, CK; CREUTZ, CE				DAMER, CK; CREUTZ, CE			SYNERGISTIC MEMBRANE INTERACTIONS OF THE 2 C2 DOMAINS OF SYNAPTOTAGMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LATROTOXIN RECEPTOR; NEUROTRANSMITTER RELEASE; SYNAPTIC VESICLES; PHOSPHOLIPID-BINDING; CHROMAFFIN GRANULES; PROTEIN; P65; EXOCYTOSIS; DROSOPHILA; FUSION	Synaptotagmin, an integral membrane protein localized to secretory vesicles, has been implicated in the docking and fusion steps in calcium-regulated exocytosis. The large cytoplasmic domain contains two C2 motifs, each similar to the Ca2+ and phospholipid binding domain of protein kinase C. To study the membrane binding and aggregating properties of these C2 domains, three recombinant fragments of rat synaptotagmin I were expressed in Escherichia coli and purified. A recombinant protein containing both C2 domains (p65 1-5) was found to bind to and aggregate bovine chromaffin granules in a calcium-dependent manner, with half-maximal binding and aggregation occurring at similar to pCa(2+) = 4.2. However, recombinant proteins containing either the first (p65 1-3) or second (p65 3-5) C2 domain alone were not able to bind to the granules, indicating that both C2 domains are required for binding to chromaffin granules. p65 1-5 also bound to and aggregated liposomes made from chromaffin granule lipid extracts, as web as granules treated extensively with trypsin, suggesting that p65 1-5 binding to granules is mediated by the lipids in the granule membrane and not the granule membrane proteins. Although p65 1-3 and p65 3-5 did not bind to granules or lipids extracted from granules, both did bind to phosphatidylserine (PS)/phosphatidylcholine (PC) vesicles (10%-40%PS). Half-maximal binding of p65 1-3 to vesicles occurred at similar to pCa(2+) = 5.2, while p65 3-5 appeared to bind independently of calcium over the range of pCa(2+) = 5.5-2.8. p65 1-5 exhibited binding to PS/PC vesicles with characteristics of both the smaller proteins, displaying some binding in EGTA and increased binding in calcium. Larger amounts of p65 1-5 bound to PS/PC vesicles than of either of the smaller fragments. These results suggest that the two C2 domains of synaptotagmin act synergistically to promote binding to biological membranes and to affect calcium sensitivity and membrane binding capacity.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia	DAMER, CK (corresponding author), UNIV VIRGINIA,PROGRAM NEUROSCI,CHARLOTTESVILLE,VA 22908, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031618] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07055] Funding Source: Medline; NINDS NIH HHS [NS31618] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CREUTZ CE, 1981, J CELL BIOL, V91, P247, DOI 10.1083/jcb.91.1.247; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CREUTZ CE, 1983, J BIOL CHEM, V258, P4664; CREUTZ CE, 1992, J CELL SCI, V103, P1; DABROW M, 1980, BIOCHEM BIOPH RES CO, V96, P1164, DOI 10.1016/0006-291X(80)90074-1; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FLOOR E, 1989, J NEUROCHEM, V52, P1433, DOI 10.1111/j.1471-4159.1989.tb09190.x; FOURNIER S, 1989, J NEUROCHEM, V53, P1043, DOI 10.1111/j.1471-4159.1989.tb07393.x; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LOWE AW, 1988, J CELL BIOL, V106, P51, DOI 10.1083/jcb.106.1.51; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PAZOLES CJ, 1978, J BIOL CHEM, V253, P3962; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; Winkler H, 1982, SECRETORY GRANULE, P1; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	41	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31115	31123						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983052				2022-12-25	WOS:A1994PV51000059
J	MOL, PC; PARK, HM; MULLINS, JT; CABIB, E				MOL, PC; PARK, HM; MULLINS, JT; CABIB, E			A GTP-BINDING PROTEIN REGULATES THE ACTIVITY OF (1-]3)-BETA-GLUCAN SYNTHASE, AN ENZYME DIRECTLY INVOLVED IN YEAST-CELL WALL MORPHOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-(1->3)GLUCAN SYNTHETASE; SACCHAROMYCES-CEREVISIAE; 1,3-BETA-GLUCAN SYNTHASE; PRODUCT ENTRAPMENT; NEUROSPORA-CRASSA; MUTANTS; RAS; BIOSYNTHESIS; PURIFICATION; GROWTH	Synthesis of (1-->3)-beta-D-glucan, the major structural component of the yeast cell wall, is synchronized with the budding cycle. Membrane-bound, GTP-stimulated (1-->3)-beta-glucan synthase was dissociated by stepwise treatment with salt and detergents into two soluble fractions, A and B, both required for activity. Fraction A was purified about 800-fold by chromatography on Mono and and Sephacryl S-300 columns. During purification, GTP binding to protein correlated with synthase complementing activity. A 20-kDa GTP-binding protein was identified by photolabeling in the purified preparation. This preparation no longer required GTP for activity, but incubation with another fraction from the Mono Q column (A1) led to hydrolysis of bound GTP to GDP with a concomitant return of the GTP requirement. Thus, fraction A1 appears to contain a GTPase-activating protein. These results show that the GTP-binding protein not only regulates glucan synthase activity but can be regulated in turn, constituting a potential link between cell cycle controls and wall morphogenesis.	NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Heemoon, Park/F-5783-2013	Heemoon, Park/0000-0001-6780-9283				AWALD P, 1993, EXP MYCOL, V17, P130, DOI 10.1006/emyc.1993.1012; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CABIB E, 1988, MICROBIOL SCI, V5, P370; DIAZ M, 1993, EMBO J, V12, P5245, DOI 10.1002/j.1460-2075.1993.tb06220.x; FREDRIKSON K, 1991, PHYSIOL PLANTARUM, V81, P289, DOI [10.1111/j.1399-3054.1991.tb08734.x, 10.1034/j.1399-3054.1991.810301.x]; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KANG MS, 1986, P NATL ACAD SCI USA, V83, P5808, DOI 10.1073/pnas.83.16.5808; KANG MS, 1984, J BIOL CHEM, V259, P4966; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNERS DJ, 1973, BIOCHEM J, V135, P19, DOI 10.1042/bj1350019; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; NOTARIO V, 1982, J BIOL CHEM, V257, P1902; QUIGLEY DR, 1988, EXP MYCOL, V12, P141, DOI 10.1016/0147-5975(88)90003-5; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; RIBAS JC, 1991, J BACTERIOL, V173, P3456, DOI 10.1128/jb.173.11.3456-3462.1991; ROTHMANDENES LB, 1970, P NATL ACAD SCI USA, V66, P967, DOI 10.1073/pnas.66.3.967; SHEMATEK EM, 1980, J BIOL CHEM, V255, P895; SHEMATEK EM, 1980, J BIOL CHEM, V255, P888; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; WU AY, 1991, PLANT PHYSIOL, V97, P684, DOI 10.1104/pp.97.2.684; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	25	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31267	31274						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983071				2022-12-25	WOS:A1994PV51000080
J	PESECKIS, SM; RESH, MD				PESECKIS, SM; RESH, MD			PATTY ACYL TRANSFER BY HUMAN N-MYRISTYL TRANSFERASE IS DEPENDENT UPON CONSERVED CYSTEINE AND HISTIDINE-RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; MYRISTOYLTRANSFERASE; COA; GENE; MYRISTOYLATION; EXPRESSION; MECHANISM; SITE	N-Myristyl transferase (Nmt) catalyzes attachment of myristate onto the N terminus of suitable proteins. In order to identify amino acids important for catalytic functions, human Nmt and mutants representing all six conserved cysteine and histidine residues (Cys-169, Cys-214, His-131, His-171, His-218, and His-293) were expressed in Escherichia coli and analyzed for their ability to bind and transfer myristic acid. N-Terminal histidine-tagged fusion proteins displayed varying abilities to form an association with radiolabeled myristic acid indicative of an acyl-enzyme intermediate. When co-expressed with an acceptor substrate protein, pp60(v-src), the mutants showed differential incorporation of radiolabeled myristic acid into v-Src protein. In vitro experiments monitoring transfer of myristyl CoA to a peptide homologous to the N terminus of pp60(v-src) gave results similar to those obtained in vivo. Our studies showed that mutation at Cys-169, His-171, and especially His-293 interfered with formation of an acyl-enzyme intermediate, while human Nmts containing mutations at Cys-169, His-218, or His-293 showed greatly attenuated abilities to form acylated product. We propose a model for the Nmt reaction mechanism in which Cys-169 sen es as the fatty acid attachment site for a covalent myristyl enzyme intermediate, while His-171 acts as a general acid/base and His-293 as a specific acid/base during acyl-enzyme intermediate formation. His-218 could then act as an acid or base needed to catalyze transfer of the acyl group from the acyl enzyme intermediate to a polypeptide substrate. This working model will be useful for the design of regulators of Nmt function.	MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center				Resh, Marilyn/0000-0001-6118-9466	NCI NIH HHS [CA-52405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052405] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; BERENT S L, 1985, Biotechniques, V3, P208; BHATNAGAR RS, 1994, J BIOL CHEM, V269, P11045; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; LODGE JK, 1994, J BIOL CHEM, V269, P2996; LU TB, 1994, J BIOL CHEM, V269, P5346; MCILHINNEY RAJ, 1994, EUR J BIOCHEM, V222, P137, DOI 10.1111/j.1432-1033.1994.tb18851.x; PERRIN S, 1990, NUCLEIC ACIDS RES, V18, P7433, DOI 10.1093/nar/18.24.7433; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978	26	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30888	30892						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983020				2022-12-25	WOS:A1994PV51000026
J	KING, P; GOODBOURN, S				KING, P; GOODBOURN, S			THE INTERFERON-BETA PROMOTER RESPONDS TO PRIMING THROUGH MULTIPLE INDEPENDENT REGULATORY ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATE VIRUS INDUCIBILITY; IFN-BETA; GENE-REGULATION; TRANSCRIPTION FACTOR; PROTEIN-SYNTHESIS; INDUCTION; IRF-1; EXPRESSION; CELLS; SEQUENCES	The induction of beta-interferon is markedly enhanced in some cell types by a pretreatment with type I interferon itself (priming). We show that induction in response to double-stranded RNA is completely dependent upon priming in HeLa cells. However, unprimed cells can be partially induced by Sendai virus, This indicates that Sendai virus can provide a signal that is different from, or additional to, that provided by double stranded RNA. The requirement for priming cannot be localized to a specific sequence element in the beta-interferon promoter, suggesting that priming may induce an essential component for signal transduction in response to double-stranded RNA.	IMPERIAL CANC RES FUND, GENE EXPRESS LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK				Goodbourn, Stephen/0000-0002-4530-1179	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABREU SL, 1979, J BIOL CHEM, V254, P4114; BARMAK SL, 1973, ARCH GES VIRUSFORSCH, V43, P272, DOI 10.1007/BF01250422; CHARNAY P, 1984, CELL, V38, P251, DOI 10.1016/0092-8674(84)90547-6; Demaeyer E., 1988, INTERFERONS OTHER RE; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DRON M, 1990, MOL CELL BIOL, V10, P854, DOI 10.1128/MCB.10.2.854; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1981, VIROLOGY, V112, P62, DOI 10.1016/0042-6822(81)90612-7; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; Goodbourn S, 1990, Semin Cancer Biol, V1, P89; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; KING P, 1992, NUCLEIC ACIDS RES, V20, P1039, DOI 10.1093/nar/20.5.1039; KINGSBURY DW, 1991, PARAMYXOVIRUSES; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MANIATIS T, 1988, HARVEY LECT, V82, P71; Marcus P I, 1983, Interferon, V5, P115; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MARCUS PI, 1984, INTERFERON, V3, P113; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; NIR U, 1985, J BIOL CHEM, V260, P4242; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; REICH N, 1988, J VIROL, V62, P114, DOI 10.1128/JVI.62.1.114-119.1988; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RINGOLD GM, 1984, P NATL ACAD SCI-BIOL, V81, P3964, DOI 10.1073/pnas.81.13.3964; Sambrook J, 1989, MOL CLONING LABORATO; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; Stewart W, 1979, INTERFERON SYSTEM; STEWART WE, 1971, J VIROL, V7, P792, DOI 10.1128/JVI.7.6.792-801.1971; TAIRA H, 1987, J VIROL, V61, P625, DOI 10.1128/JVI.61.2.625-628.1987; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WHITESIDE ST, 1992, NUCLEIC ACIDS RES, V20, P1531, DOI 10.1093/nar/20.7.1531; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	50	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30609	30615						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982980				2022-12-25	WOS:A1994PU52500087
J	PANDEY, A; LAZAR, DF; SALTIEL, AR; DIXIT, VM				PANDEY, A; LAZAR, DF; SALTIEL, AR; DIXIT, VM			ACTIVATION OF THE ECK RECEPTOR PROTEIN-TYROSINE KINASE STIMULATES PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY; GROWTH-FACTOR; EXPRESSION; BINDING; SYSTEM; DOMAINS; GENE	The Eph/Eck subfamily of receptor protein tyrosine kinases is currently the largest subfamily of receptor protein tyrosine kinases with a dozen members (Van der Geer, P., Hunter, T., and Lindberg, R. A. (1994) Annu. Rev. Cell Biol. 10, 251-337). Using the cytoplasmic domain of Eck as bait in a yeast two-hybrid screen of mouse embryonic and T cell cDNA libraries, it was discovered that the p85 subunit of phosphatidylinositol 3-kinase bound Eck. Further, using glutathione S-transferase fusion proteins, it was found that the C-terminal src homology 2 domain of the p85 subunit specifically interacted with Eck. Additionally, Eck coimmunoprecipitated with p85 in ligand activated cells confirming their interaction in vivo. In keeping with the above observations, activation of Eck by its ligand, B61, increased phosphatidylinositol 3-kinase activity. This is the first description of a signal transduction pathway initiated by any member of the Eph/Eck family.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA	University of Michigan System; University of Michigan; Pfizer			dixit, vishva m/A-4496-2012; Pandey, Akhilesh/B-4127-2009; Saltiel, Alan/L-3632-2019	dixit, vishva m/0000-0001-6983-0326; Pandey, Akhilesh/0000-0001-9943-6127; Saltiel, Alan/0000-0002-9726-9828	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39255] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RON D, 1992, BIOTECHNIQUES, V13, P866; SHAO HN, 1994, J BIOL CHEM, V269, P26606; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WENNSTROM S, 1994, ONCOGENE, V9, P651; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	28	138	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30154	30157						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982920				2022-12-25	WOS:A1994PU52500020
J	AGOFF, SN; WU, B				AGOFF, SN; WU, B			CBF MEDIATES ADENOVIRUS ELA TRANSACTIVATION BY INTERACTION AT THE C-TERMINAL PROMOTER TARGETING DOMAIN OF CONSERVED REGION-3	ONCOGENE			English	Note							E2F TRANSCRIPTION FACTOR; HUMAN HSP70 PROMOTER; E1A GENE-PRODUCTS; PROTEIN; TRANSACTIVATION; TRANSFORMATION; COMPLEXES; MUTANTS; FAMILY; BINDS	Genetic and biochemical evidence suggest that conserved region 3 (CR3) of the adenovirus Ela polypeptide can provide two distinct and separable functions: an N-terminal transcriptional activation region and a C-terminal promoter targeting region. It is thought that the promoter targeting region of Ela CR3 interacts with promoter-specific transcription factors, thereby bringing the activation region of Ela CR3 in proximity of the promoter. Here we report that CBP, a CCAAT-box-binding factor that regulates hsp70 gene expression and mediates Ela trans-activation in vivo, interacts with the promoter targeting region of Ela CR3 in vitro. Point mutations in Ela CR3 that are defective in stimulating transcription from the hsp70 promoter are also defective in stimulating transcription directed by a synthetic activator, GAL-CBF, composed of the DNA-binding domain of yeast GAL4 fused to CBF. These mutations fall into two classes with respect to their abilities to interact with CBF in vitro. Mutations in the transcriptional activation region of Ela CR3 do not affect binding to CBF, but mutation of the promoter targeting region of Ela CR3 prevents association with CBF in vitro.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	Northwestern University								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; CHATTERJEE P, 1988, EMBO J, V5, P835; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GLENN GM, 1987, MOL CELL BIOL, V7, P1004, DOI 10.1128/MCB.7.3.1004; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LILLIE JW, 1987, CELL, V61, P1217; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MONTELL C, 1982, NATURE, V295, P380, DOI 10.1038/295380a0; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; WINBERG G, 1984, EMBO J, V3, P1907, DOI 10.1002/j.1460-2075.1984.tb02066.x; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	28	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3707	3711						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970730				2022-12-25	WOS:A1994PT39200036
J	DAHIYA, R; BUTTERS, CA; TOBACMAN, LS				DAHIYA, R; BUTTERS, CA; TOBACMAN, LS			EQUILIBRIUM LINKAGE ANALYSIS OF CARDIAC THIN FILAMENT ASSEMBLY - IMPLICATIONS FOR THE REGULATION OF MUSCLE-CONTRACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-T FRAGMENTS; SKELETAL-MUSCLE; F-ACTIN; COOPERATIVE INTERACTIONS; TROPOMYOSIN-TROPONIN; BINDING; ISOFORMS; COMPLEX; CA-2+; SENSITIVITY	A major focus in studies of muscle contraction has been the effect of Ca2+ on the interactions among the thin filament's five constituent polypeptides: actin, tropomyosin, troponin C (TnC), troponin T (TnT), and troponin I (TnI). We have investigated these interactions by analyzing thin filament assembly as a linear lattice binding problem with linkage relationships in the associations of tropomyosin, actin, and troponin. Binding of TnT, the binary TnT.TnI complex, or the ternary troponin complex (+/- Ca2+) to tropomyosin was measured spectrofluorimetrically after labeling cardiac tropomyosin with N-(1-pyrene)iodoacetamide. The affinity constants ranged between 0.2 and 0.6 mu M(-1) in the presence of 300 mM KCl. Also, the affinities of tropomyosin, tropomyosin.troponin, tropomyosin TnT, and tropomyosin.TnT TnI for an isolated site on F-actin were determined. The actin association constants were 0.0006 mu M(-1) for tropomyosin, 1 mu M(-1) for tropomyosin.TnT, 2 mu M(-1) for tropomyosin TnT.TnI, 0.5 mu M(-1) for tropomyosin troponin, and 0.5 mu M(-1) for tropomyosin troponin Ca2+. Linked equilibrium analysis permitted calculation of the affinities for actin tropomyosin of TnT (400 mu M(-1)), TnT.TnI (1600 mu M(-1)), troponin (500 mu M(-1)), and troponin Ca2+ (300 mu M(-1)). Therefore, both troponin and tropomyosin troponin retain high actin-affinity even when Ca2+ is present or when TnI is removed, and even in the absence of cooperative contributions. The results are discussed in consideration of increasing evidence for a Ca2+-regulated azimuthal movement of tropomyosin on F-actin (Lehman, W., Craig, R., and Vibert, P. (1994) Nature 368, 65-67). It is proposed that tropomyosin movement may be due to switching between TnI-mediated and TnT-mediated binding of troponin tropomyosin to distinct sites on F-actin.	UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa; University of Iowa					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038834, R29HL038834] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38834] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CHALOVICH JM, 1993, PHARMACOL THERAPEUT, V55, P95; HASELGROVE JC, 1972, COLD SPRING HARB SYM, V37, P225; HEELEY DH, 1988, BIOCHEMISTRY-US, V27, P8227, DOI 10.1021/bi00421a036; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HILL LE, 1992, J BIOL CHEM, V267, P16106; HILL TL, 1985, COOPERATIVITY THEORY, P347; HITCHCOCK SE, 1975, EUR J BIOCHEM, V52, P255, DOI 10.1111/j.1432-1033.1975.tb03993.x; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; INGRAHAM RH, 1984, J BIOL CHEM, V259, P9544; INGRAHAM RH, 1985, BIOCHEMISTRY-US, V24, P5221, DOI 10.1021/bi00340a040; ISHII Y, 1991, J BIOL CHEM, V266, P6894; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; MCAULIFFE JJ, 1990, CIRC RES, V66, P1204, DOI 10.1161/01.RES.66.5.1204; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MEHEGAN JP, 1991, J BIOL CHEM, V266, P966; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; NASSAR R, 1991, CIRC RES, V69, P1470, DOI 10.1161/01.RES.69.6.1470; NOLAND TA, 1992, BIOCHEM J, V288, P123, DOI 10.1042/bj2880123; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; PAN BS, 1992, J BIOL CHEM, V267, P23052; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; POOLE KJV, 1994, BIOPHYS J, V66, pA347; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; REISER PJ, 1992, J PHYSIOL-LONDON, V449, P573, DOI 10.1113/jphysiol.1992.sp019102; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SZCZESNA D, 1989, BIOL CHEM H-S, V370, P399, DOI 10.1515/bchm3.1989.370.1.399; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; TSUCHIYA T, 1982, BIOPOLYMERS, V21, P979, DOI 10.1002/bip.360210510; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	41	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29457	29461						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961927				2022-12-25	WOS:A1994PU28400025
J	SANCHEZ, JC; GIMENEZ, R; SCHNEIDER, A; FESSNER, WD; BALDOMA, L; AGUILAR, J; BADIA, J				SANCHEZ, JC; GIMENEZ, R; SCHNEIDER, A; FESSNER, WD; BALDOMA, L; AGUILAR, J; BADIA, J			ACTIVATION OF A CRYPTIC GENE ENCODING A KINASE FOR L-XYLULOSE OPENS A NEW PATHWAY FOR THE UTILIZATION OF L-LYXOSE BY ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC SYNTHESES; METABOLIC PATHWAYS; ORGANIC-SYNTHESIS; DEHYDROGENASE; DISSIMILATION; 1-PHOSPHATES; EMPLOYS; MUTANTS; REGULON; ENZYMES	A silent gene encoding a kinase that specifically phosphorylates L-xylulose was activated and rendered constitutive in mutant cells of Escherichia coli. L-Xylulose kinase was purified to homogeneity and found to be a dimer of two subunits of 55 kDa, highly specific for L-xylulose with a k(m) of 0.8 mM, a V-max of 33 mu mol/min/mg, and an optimum pH of 8.4. Physical (thin layer chramatography) and spectroscopic (nuclear magnetic resonance and optical rotation) characterization of the product of L-xylulose kinase indicated that the enzyme phosphorylated the sugar at position 5. The gene encoding L-xylulose kinase was mapped in the 80.2 min region of the chromosome by conjugation and transduction. Cloning and comparison of the restriction map with the Kohara map (Kohara, Y., Akiyame, K., and Isono, K. (1987) Cell 50, 495-501) located the gene between positions 3963 and 3965 kilobases. The molecular and functional features of L-xylulose kinase together with the location of the corresponding gene indicate that this enzyme did not derive from mutation of any other known kinase. The new kinase opens a route for the utilization of L-lyxose through the action of rhamnose permease, rhamnose isomerase, and the phosphorylation of the L-xylulose formed to L-xylulose 5-phosphate, which is then introduced into the pentose phosphate pathway for subsequent metabolism.	UNIV BARCELONA,SCH PHARM,DEPT BIOCHEM,E-08028 BARCELONA,SPAIN; UNIV FREIBURG,DEPT ORGAN CHEM,D-79104 FREIBURG,GERMANY; UNIV FREIBURG,DEPT BIOCHEM,D-79104 FREIBURG,GERMANY	University of Barcelona; University of Freiburg; University of Freiburg			Baldomà, Laura/G-7301-2015; Badia, Josefa/G-7292-2015; Giménez, Rosa/V-4777-2017	Baldomà, Laura/0000-0002-7678-269X; Badia, Josefa/0000-0003-0768-5033; Giménez, Rosa/0000-0002-4158-7157				BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BADIA J, 1989, FEMS MICROBIOL LETT, V65, P253, DOI 10.1016/0378-1097(89)90226-7; BADIA J, 1991, J BACTERIOL, V173, P5144, DOI 10.1128/jb.173.16.5144-5150.1991; BALDOMA L, 1987, J BIOL CHEM, V262, P13991; BORONAT A, 1979, J BACTERIOL, V140, P320, DOI 10.1128/JB.140.2.320-326.1979; BRAMMAR WJ, 1967, J GEN MICROBIOL, V47, P87, DOI 10.1099/00221287-47-1-87; BROWN PR, 1972, J GEN MICROBIOL, V70, P287, DOI 10.1099/00221287-70-2-287; BRUIJN FJ, 1984, GENE, V27, P131; CHEN YM, 1987, MOL GEN GENET, V210, P331, DOI 10.1007/BF00325702; CHIU TH, 1964, BIOCHIM BIOPHYS ACTA, V92, P489, DOI 10.1016/0926-6569(64)90009-4; CHIU TH, 1969, BIOCHEMISTRY-US, V8, P98, DOI 10.1021/bi00829a015; CLARK D, 1980, J BACTERIOL, V141, P177, DOI 10.1128/JB.141.1.177-183.1980; DAVIS RW, 1980, MANUAL GENETIC ENG A, P206; DISCHE Z, 1951, J BIOL CHEM, V192, P583; DITTMER JC, 1964, J LIPID RES, V5, P126; FESSNER WD, 1992, TETRAHEDRON LETT, V33, P5231, DOI 10.1016/S0040-4039(00)79140-4; FESSNER WD, 1993, TETRAHEDRON-ASYMMETR, V4, P1183, DOI 10.1016/S0957-4166(00)80227-X; HALL BG, 1983, MOL BIOL EVOL, V1, P109; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; Ingraham JL., 1987, Escherichia coli and Salmonella typhimurium: cellular and molecular biology; JOSEPHSON BL, 1969, J BACTERIOL, V100, P1289, DOI 10.1128/JB.100.3.1289-1295.1969; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER SA, 1964, SCIENCE, V146, P1313, DOI 10.1126/science.146.3649.1313; LIN ECC, 1976, ANNU REV MICROBIOL, V30, P535, DOI 10.1146/annurev.mi.30.100176.002535; LINEWEAVER H, 1934, J AM CHEM SOC, V56, P548; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MOCALI A, 1985, CARBOHYD RES, V143, P288, DOI 10.1016/S0008-6215(00)90722-5; POWER J, 1967, GENETICS, V55, P557; Sambrook J, 1989, MOL CLONING LABORATO; Shi Q., 1990, GEL ELECTROPHORESIS; STOKER NG, 1984, TRANSCRIPTION TRANSL, P154; TAKAGI Y, 1964, BIOCHIM BIOPHYS ACTA, V92, P10, DOI 10.1016/0926-6569(64)90263-9; WALKER DG, 1968, BIOCHEM J, V108, P169, DOI 10.1042/bj1080169; WANNER BL, 1986, J MOL BIOL, V191, P39, DOI 10.1016/0022-2836(86)90421-3; ZHU Y, 1986, J MOL EVOL, V23, P259, DOI 10.1007/BF02115582	38	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29665	29669						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961955				2022-12-25	WOS:A1994PU28400056
J	BOEHMER, PE; CRAIGIE, MC; STOW, ND; LEHMAN, IR				BOEHMER, PE; CRAIGIE, MC; STOW, ND; LEHMAN, IR			ASSOCIATION OF ORIGIN-BINDING PROTEIN AND SINGLE-STRAND DNA-BINDING PROTEIN, ICP8, DURING HERPES-SIMPLEX VIRUS TYPE-1 DNA-REPLICATION IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION VECTORS; POLYMERASE-ALPHA; IDENTIFICATION; INITIATION; SEQUENCE; SUBUNIT; DOMAIN; ORIS; UL9	The herpes simplex virus type 1 (HSV-1) origin binding protein (UL9 protein) interacts specifically with the HSV-1 encoded single strand DNA binding protein ICP8 (Boehmer, P. E. and Lehman, I. R. (1994) Proc. Natl. Acad. Sci. U.S.A. 90, 8444-8448). A UL9 mutant protein (UL9DM27) that lacks the C-terminal 27 amino acids shows normal origin-specific DNA binding and retains its DNA dependent ATPase and helicase activities, but has a greatly reduced affinity for ICP8. The extreme C-terminal portion of the UL9 protein is therefore required for ICP8 binding. The helicase activity of the UL9DM27 protein is approximately 8-fold greater than that of the wild type UL9 protein and is not stimulated by ICP8. The UL9DM27 protein has a reduced ability to replicate origin-containing plasmids in vivo. Consequently, the interaction between the UL9 protein and ICP8 is likely to be important for origin-dependent DNA replication in vivo, presumably to promote efficient unwinding of the DNA at an HSV-1 origin of DNA replication.	STANFORD UNIV, BECKMAN CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA; INST VIROL, MRC, VIROL UNIT, GLASGOW G11 5JR, LANARK, SCOTLAND	Stanford University; University of Glasgow				Boehmer, Paul/0000-0003-4479-0529	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026538] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 26538] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARBUCKLE MI, 1993, J GEN VIROL, V74, P1349, DOI 10.1099/0022-1317-74-7-1349; BISHOP DHL, 1992, SEMINARS VIROLOGY, V3, P253; BOEHMER PE, 1992, J BIOL CHEM, V267, P4981; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; CRUTE JJ, 1990, UCLA SYM BI, V127, P327; DEB S, 1991, J VIROL, V65, P2829, DOI 10.1128/JVI.65.6.2829-2838.1991; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ERDILE LF, 1991, COLD SH Q B, V56, P303; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; KAMAKAKA RT, 1994, IN PRESS MOL CELL BI, V14; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; OLIVO PD, 1989, J VIROL, V63, P196, DOI 10.1128/JVI.63.1.196-204.1989; Sambrook J, 1989, MOL CLONING LABORATO; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STOW ND, 1992, J GEN VIROL, V73, P313, DOI 10.1099/0022-1317-73-2-313; STOW ND, 1993, VIROLOGY, V196, P413, DOI 10.1006/viro.1993.1496; WEIR HM, 1990, J GEN VIROL, V71, P1379, DOI 10.1099/0022-1317-71-6-1379; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	25	60	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29329	29334						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961904				2022-12-25	WOS:A1994PU16800117
J	LIN, MCM; ARBEENY, C; BERGQUIST, K; KIENZLE, B; GORDON, DA; WETTERAU, JR				LIN, MCM; ARBEENY, C; BERGQUIST, K; KIENZLE, B; GORDON, DA; WETTERAU, JR			CLONING AND REGULATION OF HAMSTER MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN - THE REGULATION IS INDEPENDENT FROM THAT OF OTHER HEPATIC AND INTESTINAL PROTEINS WHICH PARTICIPATE IN THE TRANSPORT OF FATTY-ACIDS AND TRIGLYCERIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-B SECRETION; CHOLESTERYL ESTER; DISULFIDE ISOMERASE; CELLS; RECEPTOR; ABETALIPOPROTEINEMIA; STIMULATION; DEGRADATION; MECHANISM	Microsomal triglyceride transfer protein (MTP) is a heterodimer consisting of protein disulfide isomerase and a unique large subunit. Recent studies showing that an absence of MTP is a cause of abetalipoproteinemia indicate that MTP is required for the assembly of very low density lipoproteins in the liver and chylomicrons in the intestine. In this study, complementary DNA encoding the large subunit of hamster MTP was cloned. The cDNA sequence was used to design a 50-base pair oligonucleotide probe for a solution hybridization assay to quantitate MTP large subunit mRNA levels in a study of MTP regulation in male Syrian Golden hamsters. In animals fed a low fat diet, MTP exhibited a proximal to distal gradient of expression in the intestine. MTP activity and large subunit mRNA levels in the liver were about 25 and 10% that found in the proximal intestine, respectively. To investigate the effect of diet on MTP, hamsters were maintained for 31 days on one of four diets: 1) control low fat, 2) high fat, 3) low fat, high sucrose, or 4) diet 1 followed by a 48-h fast. The high fat diet increased MTP large subunit mRNA levels in the liver and throughout the small and large intestine. A 55 and 126% increase was observed in the liver and intestine (duodenum and jejunum), respectively. A 40% increase of intestinal MTP protein mass was also observed. The high sucrose diet caused a significant 55% increase in hepatic MTP mRNA levels but did not significantly affect the intestinal mRNA levels. MTP mRNA levels were unchanged in response to fasting. A short term dietary study showed that intestinal MTP mRNA was up-regulated within 24 h after initiating a high fat diet. An acute hepatic response was not observed. The regulation of MTP mRNA levels by high fat diets was compared to that of the liver fatty acid binding protein (L-FABP) and apolipoprotein B (apoB). ApoB mRNA levels were not significantly affected by a high fat diet. Although L-FABP mRNA levels were increased in the Liver and intestine, the onset of the changes did not parallel that of MTP. These results suggest that L-FABP, apoB, and MTP, three proteins which play important roles in the transport of fatty acids and triglyceride in the liver and intestine, are not coordinately regulated by diet in hamsters.	BRISTOL MYERS SQUIBB CO, DEPT METAB DIS, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								ARBEENY CM, 1992, J LIPID RES, V33, P843; ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; BAIN LE, 1987, INTRO PROBABILITY MA, P145; BARON H, 1976, DIABETES, V25, P509, DOI 10.2337/diabetes.25.6.509; Bass Nathan M., 1993, P421; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BOREN J, 1991, PROG LIPID RES, V30, P205, DOI 10.1016/0163-7827(91)90017-Y; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; DASHTI N, 1991, PROG LIPID RES, V30, P219, DOI 10.1016/0163-7827(91)90018-Z; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIBBONS GF, 1990, BIOCHEM J, V268, P1; IHM J, 1982, J BIOL CHEM, V257, P4818; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; MILLER LC, 1984, J MED TECHNOL, V1, P33; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; OCKNER RK, 1992, PROG CLIN BIOL RES, V375, P189; POTTEN CS, 1979, BIOCHIM BIOPHYS ACTA, V560, P281, DOI 10.1016/0304-419X(79)90022-2; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SMITH TJ, 1990, GENE, V87, P309, DOI 10.1016/0378-1119(90)90319-M; SNIDERMAN AD, 1993, ARTERIOSCLER THROMB, V13, P629, DOI 10.1161/01.ATV.13.5.629; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; TEXTER EC, 1968, PHYSL GASTROINTESTIN, P199; VANCE JE, 1990, ANNU REV NUTR, V10, P337, DOI 10.1146/annurev.nu.10.070190.002005; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WETTERAU JR, 1986, BIOCHIM BIOPHYS ACTA, V875, P610, DOI 10.1016/0005-2760(86)90084-6; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WILLIAMS DL, 1986, METHOD ENZYMOL, V128, P671	38	105	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29138	29145						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961879				2022-12-25	WOS:A1994PU16800091
J	SATOWATANABE, M; MOGI, T; OGURA, T; KITAGAWA, T; MIYOSHI, H; IWAMURA, H; ANRAKU, Y				SATOWATANABE, M; MOGI, T; OGURA, T; KITAGAWA, T; MIYOSHI, H; IWAMURA, H; ANRAKU, Y			IDENTIFICATION OF A NOVEL QUINONE-BINDING SITE IN THE CYTOCHROME BO COMPLEX FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC RESPIRATORY-CHAIN; TERMINAL OXIDASES; MUTANTS	The cytochrome bo complex is a heme BO-type heme-copper quinol oxidase in the aerobic respiratory chain of Escherichia coli and functions as an electron transfer-linked proton pump. To study the protein-mediated electron transfer from substrates to metal centers, we carried out quantitative and qualitative analyses of a bound quinone in the purified oxidase and found that it has a novel high affinity ubiquinone-binding site distinct from the quinol oxidation site. Enzymatic and spectroscopic studies suggest that the quinone-binding site is located close to both the quinol oxidation site in subunit II and low-spin heme B in subunit I. The quinone-binding site of a bound ubiquinone-free oxidase was reconstituted with the potent quinol oxidation site inhibitor 2,6-dichloro-4-nitrophenol, which decreased the V-max value of the ubiquinol-1 oxidase activity to one-fourth of the control activity. These results indicate that the quinone-binding site is essential for the catalytic functions of the cytochrome bo complex and mediates electron transfer from the quinol oxidation site to the low-spin heme.	UNIV TOKYO,GRAD SCH SCI,DEPT PLANT SCI,BUNKYO KU,TOKYO 113,JAPAN; GRAD UNIV ADV STUDIES,OKAZAKI NATL RES INST,INST MOLEC SCI,OKAZAKI,AICHI 444,JAPAN; KYOTO UNIV,DEPT AGR CHEM,KYOTO 606,JAPAN	University of Tokyo; Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Okazaki Institute for Integrative Bioscience (OIIB); Kyoto University								ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; KITA K, 1984, J BIOL CHEM, V259, P3368; MATSUSHITA K, 1984, BIOCHEMISTRY-US, V23, P4703, DOI 10.1021/bi00315a028; MCPHERSON PH, 1990, BIOCHIM BIOPHYS ACTA, V1016, P289, DOI 10.1016/0005-2728(90)90071-B; MOGI T, 1994, J BIOCHEM-TOKYO, V116, P471, DOI 10.1093/oxfordjournals.jbchem.a124548; MUSSER SM, 1993, FEBS LETT, V327, P131, DOI 10.1016/0014-5793(93)80156-O; SARASTE M, 1991, BIOCHEM SOC T, V19, P608, DOI 10.1042/bst0190608; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28899; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; WELTER R, 1994, BIOPHYS J, V66, P367; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815	13	92	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28908	28912						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961852				2022-12-25	WOS:A1994PU16800062
J	WALLUKAT, G; MORWINSKI, R; KUHN, H				WALLUKAT, G; MORWINSKI, R; KUHN, H			MODULATION OF THE BETA-ADRENERGIC RESPONSE OF CARDIOMYOCYTES BY SPECIFIC LIPOXYGENASE PRODUCTS INVOLVES THEIR INCORPORATION INTO PHOSPHATIDYLINOSITOL AND ACTIVATION OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; 15-HYDROXYEICOSATETRAENOIC ACID; MAMMALIAN LIPOXYGENASES; ARACHIDONIC-ACID; EPITHELIAL-CELLS; 15-HYDROXY-5,8,11,13-EICOSATETRAENOIC ACID; RETICULOCYTE LIPOXYGENASE; ATHEROSCLEROTIC LESIONS; SOYBEAN LIPOXYGENASE-1; RABBIT RETICULOCYTES	Arachidonic acid and its 15-lipoxygenase metabolite (15S)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid ((15S)-HETE) modulates the beta-adrenergic response of cultured rat neonatal cardiomyocytes as indicated by an increase in the beating rate following stimulation of the cells with suboptimal isoproterenol concentrations. The effect of 15-HETE was enantioselective for the S-isomer and could be detected at concentrations as low as 10(-12) M. (11S)-HETE and (5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-eicosatetraenoic acid did also exhibit this effect, whereas other mono-, di-, and trihydroxyeicosanoids as well as the 15-lipoxygenase products of 11,14-eicosadienoic acid, of two eicosatrienoic acid isomers and of 5,8,11,14,17-eicosapentaenoic acid were ineffective. Immunohistochemical studies indicated the expression of a 15-lipoxygenase in cardiomyocytes and in resident heart mast cells. Induction of the beta-adrenergic supersensitivity is paralleled by a selective incorporation of (15S)-HETE into the cellular phosphatidylinositol pool. In contrast, (12S)-HETE, which did not induce beta-adrenergic supersensitivity, was incorporated preferentially into phosphatidylcholine and phosphatidylethanolamine. Calphostin C, an inhibitor of protein kinase C, blocked both the induction of supersensitivity by (15S)-HETE and its incorporation into phosphatidylinositol. These data suggest that in cardiomyocytes 15-lipoxygenase metabolites specifically induces a signal transduction cascade leading to a supersensitivity of the cells toward beta-adrenergic agonists, which involves the phosphatidylinositol cycle and a protein kinase C.	HUMBOLDT UNIV BERLIN,UNIV CLIN CHARITE,INST BIOCHEM,D-10115 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	WALLUKAT, G (corresponding author), MAX DELBRUCK CTR MOLEC MED,DEPT CARDIOVASC RES,ROBERT ROSSLE STR 10,D-13125 BERLIN,GERMANY.							ALPERT SE, 1993, AM J RESP CELL MOL, V8, P273, DOI 10.1165/ajrcmb/8.3.273; BAER AN, 1990, J LIPID RES, V31, P125; BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; BURRALL BA, 1988, J INVEST DERMATOL, V91, P294, DOI 10.1111/1523-1747.ep12475450; CHAVIS C, 1992, EICOSANOIDS, V5, P203; FORDHUTCHINSON AW, 1991, EICOSANOIDS, V4, P65; GIBIAN MJ, 1987, ANAL BIOCHEM, V163, P343, DOI 10.1016/0003-2697(87)90234-X; HALLE W, 1970, AM J CARDIOL, V25, P292, DOI 10.1016/S0002-9149(70)80006-6; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; IACAZIO G, 1990, J ORG CHEM, V55, P1690, DOI 10.1021/jo00292a056; JOHNSON HG, 1985, AM REV RESPIR DIS, V131, P917; KUHN H, 1990, J BIOL CHEM, V265, P18351; Kuhn H, 1988, Adv Exp Med Biol, V229, P39; KUHN H, 1990, J BIOL CHEM, V265, P1454; LAI CKW, 1990, AM REV RESPIR DIS, V141, P1423; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; LEVI BD, 1993, J CLIN INVEST, V92, P1572; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LOVELADY GK, 1988, PROSTAGLANDINS, V36, P507, DOI 10.1016/0090-6980(88)90046-9; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; MEIJER L, 1986, J BIOL CHEM, V261, P7040; MORWINSKI R, 1994, IN PRESS AGENTS ACTI; PEERS KE, 1983, CHEM PHYS LIPIDS, V32, P49, DOI 10.1016/0009-3084(83)90069-5; PIACETINI GL, 1991, AM REV RESPIR DIS, V134, P96; RAPOPORT SM, 1990, BLOOD CELL BIOCH, V1, P151; REPKE H, 1987, AGENTS ACTIONS, V20, P216, DOI 10.1007/BF02074673; SALZMANNREINHARDT U, 1985, EUR J BIOCHEM, V153, P189, DOI 10.1111/j.1432-1033.1985.tb09285.x; SCHADE UF, 1987, BIOCHEM BIOPH RES CO, V147, P695, DOI 10.1016/0006-291X(87)90986-7; SCHEWE T, 1991, TRENDS BIOCHEM SCI, V16, P369, DOI 10.1016/0968-0004(91)90153-M; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SETTY BNY, 1986, J CLIN INVEST, V77, P202, DOI 10.1172/JCI112277; SIGAL E, 1988, J BIOL CHEM, V263, P5328; SOBERMAN RJ, 1985, J BIOL CHEM, V260, P4508; VANDERHOEK JY, 1980, J BIOL CHEM, V255, P64; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; WALLUKAT G, 1991, MOL CELL BIOCHEM, V102, P35; WIESNER R, 1993, CRC HDB CHROMATOGRAP, P89; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959	41	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29055	29060						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961871				2022-12-25	WOS:A1994PU16800081
J	WELTER, R; GU, LQ; YU, L; YU, CA; RUMBLEY, J; GENNIS, RB				WELTER, R; GU, LQ; YU, L; YU, CA; RUMBLEY, J; GENNIS, RB			IDENTIFICATION OF THE UBIQUINOL-BINDING SITE IN THE CYTOCHROME BO(3)-UBIQUINOL OXIDASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC RESPIRATORY-CHAIN; OXIDOREDUCTASE COMPLEX-I; TERMINAL OXIDASE; NEUROSPORA-CRASSA; BINUCLEAR CENTER; C REDUCTASE; BO; DERIVATIVES; PURIFICATION	The cytochrome bo(3)-ubiquinol oxidase, one of two ubiquinol oxidases in Escherichia coli, is a member of the heme copper oxidase superfamily. The enzyme contains four protein subunits (I-IV) with apparent molecular masses of 58, 33, 22, and 17 kDa, respectively. Cytochrome bo(3) catalyzes the 2-electron oxidation of ubiquinol and the reduction of molecular oxygen to water. Although the primary structures of all four subunits have been determined, the ubiquinol-binding site has not been investigated. The photoreactive radiolabeled azidoubiquinone derivative 3-[H-3]azido-2-methyl-5-methoxy-6-geranyl-1,4-benzoquinone (azido-Q), which has been widely used in locating the ubiquinone-binding sites of other enzymes, was used to identify the subunit(s) involved in the binding of quinol to cytochrome bo(3). When reduced by dithioerythritol, the azido-Q derivative functioned as a substrate with partial effectiveness, suggesting that azido-Q interacts with a legitimate quinol-binding site. When cytochrome bo(3) was incubated with an 8-fold molar excess of azido-Q, illumination by UV light for 10 min resulted in a 50% loss of activity. The uptake of radiolabeled azido-Q by the oxidase complex upon illumination correlated with the photoinactivation. In the presence of the competitive inhibitor 2-heptyl-4-hydroxyquinoline or ubiquinol, the rate of azido-Q uptake and the loss of enzyme activity upon illumination decreased. Analysis of the distribution of radioactivity among the subunits after separation by SDS-polyacrylamide gel electrophoresis showed that subunit II was heavily labeled by azido-Q, but that the other subunits were not. This suggests that the ubiquinol-binding site of the cytochrome bo(3) complex is located at least partially on subunit II.	UNIV ILLINOIS, SCH CHEM SCI, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	WELTER, R (corresponding author), OKLAHOMA STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, STILLWATER, OK 74078 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; BROWN S, 1993, FEBS LETT, V316, P216, DOI 10.1016/0014-5793(93)81296-C; CARTER K, 1985, J BIOL CHEM, V260, P986; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; HEINRICH H, 1992, BIOCHEMISTRY-US, V31, P11413, DOI 10.1021/bi00161a020; HEINRICH H, 1992, BIOCHEMISTRY-US, V31, P11420, DOI 10.1021/bi00161a021; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; KELLY M, 1993, J BIOL CHEM, V268, P16781; KITA K, 1982, J BIOL CHEM, V257, P7933; KITA K, 1984, J BIOL CHEM, V259, P3368; MATSUSHITA K, 1986, BIOCHEMISTRY-US, V25, P2321, DOI 10.1021/bi00357a004; MINGHETTI KC, 1988, BIOCHEM BIOPH RES CO, V155, P243; MINGHETTI KC, 1992, BIOCHEMISTRY-US, V31, P6917, DOI 10.1021/bi00145a008; MUSSER SM, 1993, FEBS LETT, V327, P131, DOI 10.1016/0014-5793(93)80156-O; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; RICE CW, 1978, J BACTERIOL, V134, P115, DOI 10.1128/JB.134.1.115-124.1978; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; WEBER K, 1969, J BIOL CHEM, V244, P4406; YANG FD, 1986, J BIOL CHEM, V261, P4987; YU CA, 1985, BIOCHEMISTRY-US, V24, P3897, DOI 10.1021/bi00336a013; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YU L, 1985, J BIOL CHEM, V260, P963; YU L, 1982, J BIOL CHEM, V257, P215	25	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28834	28838						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961841				2022-12-25	WOS:A1994PU16800051
J	HEINZEL, T; LURZ, R; DOBRINSKI, B; VELLEMAN, M; SCHUSTER, H				HEINZEL, T; LURZ, R; DOBRINSKI, B; VELLEMAN, M; SCHUSTER, H			C1 REPRESSOR-MEDIATED DNA LOOPING IS INVOLVED IN C1 AUTOREGULATION OF BACTERIOPHAGE-P1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; ESCHERICHIA-COLI; DEOR REPRESSOR; WILD-TYPE; PROTEIN; EXPRESSION; GENE; BOF; PHAGE-P1; COI	C1 repressor is required to repress the lytic functions of a P1 prophage in vivo, Transcription of the cl gene is autoregulated via the C1-controlled operator Op99a,b which overlaps the promoter of the el gene. It is negatively affected by Lxc: corepressor and the DNA region upstream of c1, which contains the additional operators Op99c, d, and e. We have explored these effects by constructing a set of lacZ reporter plasmids with Op99a,b and varying parts of the upstream DNA region, Transcription levels were measured in vivo with a two-plasmid system containing the lacZ reporter and a c1(+) lxc(+) or c1(+) lxc - plasmid, Compared to the C1+Lxc-repressed lacZ reporter with all operators present, the basal level of beta-galactosidase activity increases successively when (i) upstream operators were deleted or inactivated, (ii) Lxc corepressor was removed, and (iii) C1 and Lxc were absent. By that means a 2 x 2 x 15-fold stepwise increase in enzyme activity was found, Using electron microscopy to visualize the interaction of C1 repressor with the operators in vitro, looped DNA molecules were observed. Although all operators can participate in C1-mediated DNA looping, loops between Op99a,b and Op99d occurred predominantly. Lxc is not required but increases drastically the frequency of loop formation. The results indicate that C1-mediated DNA looping may be a second element besides Lxc for fine-tuning the autoregulation of c1 transcription,	MAX PLANCK INST MOLEC GENET, D-14195 BERLIN, GERMANY	Max Planck Society			Heinzel, Thorsten/B-1013-2015					BAGDASARIAN M, 1981, CURR TOP MICROBIOL, V96, P47; BAUMSTARK BR, 1987, VIROLOGY, V156, P404, DOI 10.1016/0042-6822(87)90420-X; BAUMSTARK BR, 1990, VIROLOGY, V179, P217, DOI 10.1016/0042-6822(90)90291-X; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; DREISEIKELMANN B, 1988, J BIOL CHEM, V263, P1391; EISMANN ER, 1990, J MOL BIOL, V213, P763, DOI 10.1016/S0022-2836(05)80262-1; ELIASON JL, 1987, J MOL BIOL, V198, P281, DOI 10.1016/0022-2836(87)90313-5; ENGLESBE.E, 1969, P NATL ACAD SCI USA, V62, P1100, DOI 10.1073/pnas.62.4.1100; HEINRICH J, 1989, NUCLEIC ACIDS RES, V17, P7681; HEINZEL T, 1990, J BIOL CHEM, V265, P17928; HEINZEL T, 1992, J BIOL CHEM, V267, P4183; HEINZEL T, 1990, THESIS FREIE U BERLI; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MORTENSEN L, 1989, EMBO J, V8, P325, DOI 10.1002/j.1460-2075.1989.tb03380.x; OLSEN DB, 1990, P NATL ACAD SCI USA, V87, P1451, DOI 10.1073/pnas.87.4.1451; PEREZMARTIN J, 1989, J BIOL CHEM, V264, P21334; SCHAEFER TS, 1990, J BACTERIOL, V172, P3269, DOI 10.1128/jb.172.6.3269-3277.1990; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHNEIDER K, 1987, METHOD ENZYMOL, V153, P452; SPIESS E, 1988, METHOD MICROBIOL, V20, P293, DOI 10.1016/S0580-9517(08)70057-6; STEFFEN D, 1977, MOL GEN GENET, V157, P341, DOI 10.1007/BF00268672; STEITZ TA, 1974, P NATL ACAD SCI USA, V71, P593, DOI 10.1073/pnas.71.3.593; TOUATISCHWARTZ D, 1979, MOL GEN GENET, V174, P189, DOI 10.1007/BF00268355; VALENTINHANSEN P, 1986, EMBO J, V5, P2015, DOI 10.1002/j.1460-2075.1986.tb04458.x; VELLEMAN M, 1990, J BIOL CHEM, V265, P18511; VELLEMAN M, 1992, J BIOL CHEM, V267, P12174; VELLEMAN M, 1987, P NATL ACAD SCI USA, V84, P5570, DOI 10.1073/pnas.84.16.5570; YARMOLINSKY MB, 1993, GENETIC MAPS, V1; YARMOLINSKY MB, 1988, BACTERIOPHAGES, V1, P291	31	2	2	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31885	31890						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989363				2022-12-25	WOS:A1994PX30300085
J	AMIN, N; PETERKOFSKY, A				AMIN, N; PETERKOFSKY, A			IMPORTANCE OF THE REGION AROUND LYSINE-196 FOR CATALYTIC ACTIVITY OF ADENYLYL-CYCLASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; BACILLUS-ANTHRACIS; ATP BINDING; EXPRESSION; CLONING; GENE; PURIFICATION; STIMULATION; COMPLEX	Escherichia coli adenylyl cyclase contains no sequence that corresponds to the previously defined ATP/GTP binding consensus (A,G)XXXXGK(S,T). Using a search for lysine residues located adjacent to glycine residues, three regions that were possible candidates for part of the ATP binding site were identified. These were the residues located at positions 59, 90, and 196. A plasmid vector capable of overexpressing the cya gene under the control of the lambda P-L promoter was mutated at these three loci to convert those lysine residues to methionine. Assays for catalytic activity of the mutated hyper-expressed proteins revealed that only the mutation at position 196 led to loss of activity. Photoaffinity labeling experiments using 8-azido-ATP provided evidence that the loss of activity was associated with a loss of the capability of the enzyme to bind ATP. A further series of replacement mutations in the hyperexpression vector was created at position 196. Assays of the adenylyl cyclase activity of the mutated proteins showed that replacement of lysine 196 by arginine led to minimal change in the activity. Replacements by histidine, glutamine, or glutamic acid resulted in approximately 10-20-fold reductions in the activity; replacements by methionine, isoleucine, or aspartic acid resulted in total loss of activity. When the mutated forms of the cya gene were expressed under the control of the cya promoter, the activity of the wild-type protein was higher than that of all the mutants, including the arginine replacement mutant. All of the mutants that retained activity also retained the capability of adenylyl cyclase to be stimulated by either inorganic orthophosphate or GTP. A helical wheel analysis of the region of adenylyl cyclase around lysine 196 revealed a structure compatible with an amphipathic helix with one face enriched with basic amino acid residues. Assays for adenylyl cyclase activity of a series of replacement mutations of residues on the hydrophilic face of the helix (R188I, R192I, G195I) as well as on the hydrophobic face (R197I) indicated that the R188I, G195I, and K196I replacement mutants were inactive, and R192I was approximately 30% as active as the wild-type, while the R197I mutant was equivalent to the mild-type control. A model is suggested for a unique binding motif in E. coli adenylyl cyclase in which there is a repetition of 3 basic residues on one face of a helix where there is an interaction with the three phosphate groups of ATP.	NHLBI,BIOCHEM GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								AIBA H, 1984, NUCLEIC ACIDS RES, V12, P9427, DOI 10.1093/nar/12.24.9427; AMIN N, 1992, BIOCHEM BIOPH RES CO, V182, P1218, DOI 10.1016/0006-291X(92)91861-J; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; Bernard H U, 1979, Methods Enzymol, V68, P482; CRASNIER M, 1909, J GEN MICROBIOL, V136, P1825; DANCHIN A, 1988, SEC MESS PHOSPHOPROT, V12, P7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOROCICZ IR, 1993, J BACTERIOL, V175, P7142, DOI 10.1128/JB.175.22.7142-7149.1993; FRASER ADE, 1978, CAN J MICROBIOL, V24, P1423, DOI 10.1139/m78-228; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; HARWOOD JP, 1975, J BIOL CHEM, V250, P4656; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOLLAND MM, 1988, J BIOL CHEM, V263, P14661; LIBERMAN E, 1985, J BIOL CHEM, V260, P4075; MOCK M, 1991, J BACTERIOL, V173, P6265, DOI 10.1128/jb.173.19.6265-6269.1991; MOCK M, 1988, GENE, V64, P277, DOI 10.1016/0378-1119(88)90342-3; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; PETERKOFSKY A, 1993, PROTEIN SCI, V2, P498; PETERKOFSKY A, 1977, TRENDS BIOCHEM SCI, V2, P12, DOI 10.1016/0968-0004(77)90317-6; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; REDDY P, 1985, P NATL ACAD SCI USA, V82, P8300, DOI 10.1073/pnas.82.24.8300; ROY A, 1983, EMBO J, V2, P791, DOI 10.1002/j.1460-2075.1983.tb01502.x; SAWADOGO M, 1991, NUCLEIC ACIDS RES, V19, P674, DOI 10.1093/nar/19.3.674; SHAH S, 1991, J BACTERIOL, V173, P3238, DOI 10.1128/JB.173.10.3238-3242.1991; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; XIA ZG, 1990, J BIOL CHEM, V265, P6517; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4514, DOI 10.1073/pnas.84.13.4514	27	2	2	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31074	31079						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983047				2022-12-25	WOS:A1994PV51000054
J	KANDROR, KV; YU, LC; PILCH, PF				KANDROR, KV; YU, LC; PILCH, PF			THE MAJOR PROTEIN OF GLUT4-CONTAINING VESICLES, GP160, HAS AMINOPEPTIDASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID SEQUENCE; GLUCOSE-TRANSPORTER; MEMBRANE-PROTEINS; RAT ADIPOCYTES; INSULIN; IDENTIFICATION; SECRETION; COMPONENT; GRANULES; KIDNEY	A glycoprotein of M(r) 160,000 (gp160) represents the major protein component of GLUT4-containing vesicles other than GLUT4 itself. These vesicles are the tissue specific secretory-like microsomal structures that are responsible for insulin-dependent translocation of GLUT4 to the cell surface in fat and muscle cells. Our previous studies demonstrated that the expression of gp160 is also limited to fat and muscle tissues, where it is localized exclusively in GLUT4-containing vesicles, and thus, it represents a marker protein for insulin-activated glucose transport. We demonstrate here that gp160 has structural homology to aminopeptidase N and possesses aminopeptidase activity in vitro. Since aminopeptidase activity has also been found in a variety of secretory type vesicles from other tissues, it may be essential for the organization and functioning of secretory machinery in different cell types.			KANDROR, KV (corresponding author), BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA.			Kandror, Konstantin/0000-0002-8601-9313; Pilch, Paul/0000-0003-1997-0499	NIA NIH HHS [AG00115] Funding Source: Medline; NIDDK NIH HHS [DK-30425, DK44269] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030425, P01DK044269] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAUDOIN AR, 1992, INT REV CYTOL, V132, P177, DOI 10.1016/S0074-7696(08)62456-0; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BRAND SH, 1991, J BIOL CHEM, V266, P18949; BRAUN JEA, 1994, J BIOL CHEM, V269, P5328; BROWN D, 1993, J CELL SCI, P49; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CORMONT M, 1993, J BIOL CHEM, V268, P19491; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; GROS C, 1985, BIOCHEMISTRY-US, V24, P2179, DOI 10.1021/bi00330a011; HARRIS HW, 1994, J BIOL CHEM, V269, P11993; HIROI Y, 1993, BIOCHEM MOL BIOL INT, V30, P705; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1987, J BIOL CHEM, V262, P11817; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; Little G H, 1976, Methods Enzymol, V45, P495; LIVETT BG, 1984, CELL BIOL SECRETORY, P310; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; MATSAS R, 1985, BIOCHEM J, V231, P445, DOI 10.1042/bj2310445; NOREN O, 1989, FEBS LETT, V259, P107, DOI 10.1016/0014-5793(89)81506-6; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X; PHAN HH, 1992, PEPTIDES, V13, P53, DOI 10.1016/0196-9781(92)90139-T; PHILLIPS JH, 1973, BIOCHEM J, V136, P579, DOI 10.1042/bj1360579; RAMIREZ M, 1990, CELL MOL BIOL, V36, P175; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Sudhof TC, 1989, CURR OPIN CELL BIOL, V1, P655, DOI 10.1016/0955-0674(89)90030-6; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WATT VM, 1989, J BIOL CHEM, V264, P5480; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	46	117	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30777	30780						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983006				2022-12-25	WOS:A1994PV51000010
J	MAWALDEWAN, M; HENLEY, J; VANDEVOORDE, A; TROJANOWSKI, JQ; LEE, VMY				MAWALDEWAN, M; HENLEY, J; VANDEVOORDE, A; TROJANOWSKI, JQ; LEE, VMY			THE PHOSPHORYLATION STATE OF TAU IN THE DEVELOPING RAT-BRAIN IS REGULATED BY PHOSPHOPROTEIN PHOSPHATASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; RABBIT SKELETAL-MUSCLE; GLYCOGEN-SYNTHASE KINASE-3; ALZHEIMER-LIKE STATE; PROTEIN-TAU; ABNORMAL PHOSPHORYLATION; NEUROFIBRILLARY TANGLES; CELLULAR-REGULATION; ANTIGENIC DETERMINANTS; MAMMALIAN-TISSUES	The paired helical filaments (PHFs) in Alzheimer's disease neurofibrillary tangles are composed of PHF-tau which is thought to be hyperphosphorylated because several residues in postmortem samples of PHF-tau and human fetal tau are phosphorylated while the corresponding sites are not phosphorylated in autopsy-derived normal adult human brain tau. To determine how the phosphorylation of these sites is regulated, we isolated tau from rat brains at different embryonic and postnatal ages in the presence of okadaic acid to obtain tau in its most native in situ phosphorylation state. Fetal tau was highly phosphorylated from embryonic day 18 (E18) until postnatal day 11 (P11). Thereafter, the levels of fetal tau diminished as did its phosphorylation state concomitant with the appearance of the five adult tau isoforms. Several phosphorylation-dependent antibodies (i.e. AT270, AT8, AT180, T3P, and PHF1) that recognize PHF-tau also recognized these tau isoforms, albeit at reduced levels in the mature rat brain. This suggests that Thr(172), Ser(193) Thr(222), Ser(387), and Ser(395) are normal sites of phosphorylation in rat brain tau. The inclusion of OK in the microtubule assembly buffers did not alter the ability of tau to bind microtubules at any age. However, phosphatases were activated and kinases were down-regulated in the rat brain after P12 since adult tau proteins were partially dephosphorylated at and beyond this time in the absence of OK. Protein phosphatase 2A (PP2A) and 2B (PP2B) activities in the adult rat brain extracts dephosphorylated tau efficiently, but protein phosphatases in extracts of the P6 rat brain did not have a similar effect. This suggests that the sensitivity of tau to OK after P12 may be regulated by the de novo induction of adult brain phosphatases. Finally, PP2A and/or PP2B in adult rat brain extracts dephosphorylated tau in a site-specific manner. Thus, PP2A and PP2B (or closely related phosphatases) may regulate the phosphorylation state of adult tau isoforms in vivo, and the generation of PHF-tau in the AD brain may result from the abnormal inactivation of similar phosphatases.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,DIV ANAT PATHOL,PHILADELPHIA,PA 19104; INNOGENET SA,B-9052 GHENT,BELGIUM	University of Pennsylvania; Innogenetics NV								BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BRAMBLETT GT, 1992, LAB INVEST, V66, P212; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRION JP, 1985, ADV APPLIED NEUROLOG, P164; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DREWES G, 1993, FEBS LETT, V336, P425, DOI 10.1016/0014-5793(93)80850-T; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HARRIS KA, 1993, ANN NEUROL, V33, P77, DOI 10.1002/ana.410330113; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HONKANEN RE, 1993, FEBS LETT, V330, P283, DOI 10.1016/0014-5793(93)80889-3; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; KSIEZAKREDING H, 1992, BRAIN RES, V597, P209, DOI 10.1016/0006-8993(92)91476-U; LANG E, 1992, BIOCHEM BIOPH RES CO, V187, P783, DOI 10.1016/0006-291X(92)91264-Q; LEDESMA MD, 1992, FEBS LETT, V308, P218, DOI 10.1016/0014-5793(92)81278-T; Lee V M, 1992, Curr Opin Neurobiol, V2, P653, DOI 10.1016/0959-4388(92)90034-I; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MATSUO ES, 1994, IN PRESS NEURON; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MERCKEN M, 1992, ACTA NEUROPATHOL, V84, P265, DOI 10.1007/BF00227819; NUKINA N, 1986, J BIOCHEM-TOKYO, V99, P1541, DOI 10.1093/oxfordjournals.jbchem.a135625; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEWART AA, 1983, EUR J BIOCHEM, V132, P289, DOI 10.1111/j.1432-1033.1983.tb07361.x; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TROJANOWSKI JQ, 1993, BRAIN PATHOL, V3, P45, DOI 10.1111/j.1750-3639.1993.tb00725.x; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; TROJANOWSKI JQ, 1993, BRAIN RES, V618, P333, DOI 10.1016/0006-8993(93)91286-2; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	56	132	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30981	30987						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983034				2022-12-25	WOS:A1994PV51000040
J	SUWANICHKUL, A; ALLANDER, SV; MORRIS, SL; POWELL, DR				SUWANICHKUL, A; ALLANDER, SV; MORRIS, SL; POWELL, DR			GLUCOCORTICOIDS AND INSULIN REGULATE EXPRESSION OF THE HUMAN GENE FOR INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-1 THROUGH PROXIMAL PROMOTER ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; TYROSINE AMINOTRANSFERASE GENE; RAT HEPATOMA-CELLS; CHLORAMPHENICOL ACETYLTRANSFERASE; MULTIHORMONAL REGULATION; TRANSCRIPTION FACTORS; STEROID-RECEPTORS; MAMMALIAN-CELLS; LIVER; INDUCTION	Glucocorticoids stimulate, while insulin inhibits, the hepatic transcription of insulin-like growth factor-binding protein-1 (IGFBP-1). In the present studies, human HEP G2 hepatoma cells were transiently transfected with human (h)IGFBP-1 promoter constructs. Activity of a construct containing the first 1205 base pairs (bp) of the hIGFBP-1 promoter was stimulated 6-9.5-fold by dexamethasone, and this increase was inhibited similar to 76% by insulin. Deletion and site-directed mutations of the hIGFBP-1 promoter (a) identified two glucocorticoid response elements, located within the first 200 bp of the promoter, which are essential for dexamethasone-stimulated promoter activity and which specifically bind human glucocorticoid receptor; (b) showed that a recently characterized insulin-responsive element, located similar to 110 bp 5' to the transcription start site (Suwanichkul, A., Morris, S. L., and Powell, D. R. (1993) J. Biol. Chem. 268, 17063-17068), confers the entire inhibitory effect of insulin not only on basal but also on glucocorticoid-stimulated promoter activity; and (c) showed that this insulin-responsive element is essential for maximal glucocorticoid-stimulated activity. These studies suggest that the interaction of proteins that bind to a cluster of cis elements located in the first 200 bp of the hIGFBP-1 promoter are of major importance in modulating the opposing effects of glucocorticoids and insulin on he patic hIGFBP-1 expression.	BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; KAROLINSKA INST,DEPT CLIN GENET,S-17146 STOCKHOLM,SWEDEN	Baylor College of Medicine; Karolinska Institutet					NIDDK NIH HHS [R01 DK-38773] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038773] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CONOVER CA, 1992, J CLIN ENDOCR METAB, V74, P1355, DOI 10.1210/jc.74.6.1355; CONOVER CA, 1993, ACTA ENDOCRINOL-COP, V128, P140, DOI 10.1530/acta.0.1280140; CONOVER CA, 1990, J CLIN ENDOCR METAB, V70, P1062, DOI 10.1210/jcem-70-4-1062; CONOVER CA, 1990, DIABETES, V39, P1251, DOI 10.2337/diabetes.39.10.1251; CUBBAGE ML, 1989, MOL ENDOCRINOL, V3, P846, DOI 10.1210/mend-3-5-846; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANGE T, 1989, NUCLEIC ACIDS RES, V17, P8695, DOI 10.1093/nar/17.21.8695; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; LEE PDK, 1993, METABOLISM, V42, P409, DOI 10.1016/0026-0495(93)90095-6; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; LEWITT MS, 1991, ENDOCRINOLOGY, V129, P2254, DOI 10.1210/endo-129-4-2254; LEWITT MS, 1989, J CLIN ENDOCR METAB, V69, P246, DOI 10.1210/jcem-69-2-246; LUO JM, 1990, ENDOCRINOLOGY, V127, P1456, DOI 10.1210/endo-127-3-1456; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; Maxam A M, 1980, Methods Enzymol, V65, P499; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OOI GT, 1990, MOL ENDOCRINOL, V4, P321, DOI 10.1210/mend-4-2-321; ORLOWSKI CC, 1991, MOL ENDOCRINOL, V5, P1180, DOI 10.1210/mend-5-8-1180; ORLOWSKI CC, 1990, MOL ENDOCRINOL, V4, P1592, DOI 10.1210/mend-4-10-1592; POWELL DR, 1991, J BIOL CHEM, V266, P18868; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; SUWANICHKUL A, 1990, J BIOL CHEM, V265, P21185; SUWANICHKUL A, 1993, J BIOL CHEM, V268, P9730; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; TSAI SY, 1990, J BIOL CHEM, V265, P17055; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UNTERMAN TG, 1991, ENDOCRINOLOGY, V128, P2693, DOI 10.1210/endo-128-6-2693; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; WINTER LA, 1990, GENE, V91, P233, DOI 10.1016/0378-1119(90)90093-7; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	47	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30835	30841						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983014				2022-12-25	WOS:A1994PV51000019
J	MARKLUND, U; OSTERMAN, O; MELANDER, H; BERGH, A; GULLBERG, M				MARKLUND, U; OSTERMAN, O; MELANDER, H; BERGH, A; GULLBERG, M			THE PHENOTYPE OF A CDC2 KINASE TARGET SITE-DEFICIENT MUTANT OF ONCOPROTEIN-18 REVEALS A ROLE OF THIS PROTEIN IN CELL-CYCLE CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING PHOSPHOPROTEIN P19; LEUKEMIA-ASSOCIATED GENE; PHOSPHORYLATION SITES; MASS-SPECTROMETRY; IDENTIFICATION; EXPRESSION; ACTIVATION; LYMPHOCYTES; STATHMIN; PURIFICATION	Oncoprotein 18 (Op18) is a cytosolic protein that is expressed in all proliferating cells. This phosphoprotein is up-regulated in a variety of human neoplasm, and phosphorylation of its two Cdc2 kinase target sites, Ser-25 and Ser-38, fluctuates dramatically during the cell cycle. We have investigated the potential role of the Cdc2 kinase-mediated phosphorylation of these two sites by expressing a ''Cdc2 kinase target site-deficient'' mutant of Op18 (Op18-S25,38A), and analyzed the phenotype on the level of cell cycle regulation. The result shows that induced expression of Op18-S25,38A results in rapid accumulation of cells in the G(2) phase of the cell cycle. The block in G(2) seems transient, since prolonged incubation was found to result in a large fraction of the transfected cells entering S phase in the absence of mitosis, i.e. endoreduplication. In addition, a fraction (30%) of the transfected cells was blocked in mitosis. Whereas the morphology of the G(2) arrested cells appeared normal, expression of Op18-S25,38A caused a serious defect during mitotic chromosome segregation. Analyses of the mechanism behind the phenotype of Op18-S25,38A suggest an essential role for Op18 during cell division and that the mutant interferes with the function of the endogenous gene product.	UMEA UNIV,DEPT CELL & MOLEC BIOL,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT PATHOL,S-90187 UMEA,SWEDEN	Umea University; Umea University				Gullberg, Martin/0000-0002-3984-4572				BERETTA L, 1993, J BIOL CHEM, V268, P20076; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; COOPER HL, 1991, J IMMUNOL, V146, P3689; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DOYE V, 1989, J BIOL CHEM, V264, P12134; DOYE V, 1990, J BIOL CHEM, V265, P11650; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; FRIEDRICH B, 1995, IN PRESS PROSTATE; GERDES J, 1984, J IMMUNOL, V133, P1710; GHOSH PK, 1993, ONCOGENE, V8, P2869; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Hunt T, 1991, Semin Cell Biol, V2, P213; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LANDBERG G, 1992, CYTOMETRY, V13, P230, DOI 10.1002/cyto.990130304; LUO XN, 1994, J BIOL CHEM, V269, P10312; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; MELHEM RF, 1991, J BIOL CHEM, V266, P17747; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; ROOS G, 1993, LEUKEMIA, V7, P1538; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG YK, 1993, J BIOL CHEM, V268, P14269; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; ZHU XX, 1989, J BIOL CHEM, V264, P14556	40	104	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30626	30635						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982983				2022-12-25	WOS:A1994PU52500090
J	MUROI, M; MUROI, Y; SUZUKI, T				MUROI, M; MUROI, Y; SUZUKI, T			THE BINDING OF IMMOBILIZED IGG2A TO FC-GAMMA-2A RECEPTOR ACTIVATES NF-KAPPA-B VIA REACTIVE OXYGEN INTERMEDIATES AND TUMOR NECROSIS FACTOR-ALPHA(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RII; PROTEIN KINASE-A; CELL-LINE U937; CROSS-LINKING; TRANSCRIPTION FACTOR; HUMAN-MONOCYTES; TYROSINE PHOSPHORYLATION; MEDIATED PHAGOCYTOSIS; T-CELLS; PROSTAGLANDIN SYNTHESIS	The macrophage-like cell line, J774, was found to respond to immobilized mouse monoclonal IgG2a proteins, but not to soluble forms of IgG2a or IgG2b or to immobilized F(ab')(2) of IgG2a, by the increase in the nuclear proteins of two different types of NF-kappa B proteins which differed in their electrophoretic mobilities. Fc gamma 2a receptor-mediated activation of NF-kappa B was blocked by the presence of pyrrolidinedithiocarbamate, neutralizing anti-tumor necrosis factor (TNF)-alpha antibodies, various protein kinase inhibitors (H-89, genistein, or heparin) or intracellular calcium chelator (1,2-bis(O aminophenoxy)ethane-N,N,N',N'-tetraaeetic acid tetra-(acetoxymethyl) ester, BAPTA/AM) during stimulation. J774 cells were also found to respond to immobilized IgG2a, but not IgG2b, by the increased production of superoxide, H2O2, and TNF-alpha. Fc gamma 2aR-induced production of H2O2 was inhibited by pretreatment of the cells with pyrrolidinedithiocarbamate, H-89, genistein, heparin, or BAPTA/AM, but not with anti-TNF-alpha antibody. Fc gamma 2aR-induced production of TNF-alpha was, on the other hand, not inhibited by pretreatment of the cells with BAPTA/AM. Although J774 cells responded to exogenously added rTNF-alpha, but not to H2O2, by activation of NF-kappa B, the recombinant TNF alpha mediated NF-kappa B activation was enhanced by simultaneous presence of H2O2. These results thus suggest that macro phages respond to the stimulation of Fc gamma 2aR by the production of both reactive oxygen intermediates and TNF-alpha and that endogenous TNF-alpha activates NF-kappa B via the pathway involving reactive oxygen intermediates.	UNIV KANSAS, MED CTR, DEPT MICROBIOL MOLEC GENET & IMMUNOL, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center					NATIONAL CANCER INSTITUTE [P01CA054474, R01CA035977] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA35977, P01 CA54474] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BENSASSON SZ, 1990, P NATL ACAD SCI USA, V87, P1421, DOI 10.1073/pnas.87.4.1421; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROZNA JP, 1988, J IMMUNOL, V141, P1642; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURNOW SJ, 1992, SCAND J IMMUNOL, V36, P221, DOI 10.1111/j.1365-3083.1992.tb03094.x; DEBETS JMH, 1988, J IMMUNOL, V141, P1197; DEBETS JMH, 1990, J IMMUNOL, V144, P1304; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FUJIHARA M, 1993, J BIOL CHEM, V268, P14898; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIRATA Y, 1987, BIOCHEMISTRY-US, V26, P8189, DOI 10.1021/bi00399a025; HOGAN MM, 1988, J IMMUNOL, V141, P4196; KHALILI K, 1984, J MOL BIOL, V175, P453, DOI 10.1016/0022-2836(84)90179-7; KINDT GC, 1993, AM J PHYSIOL, V265, pL178, DOI 10.1152/ajplung.1993.265.2.L178; KRUTMANN J, 1990, J IMMUNOL, V145, P1337; MACINTYRE EA, 1989, J IMMUNOL, V142, P2377; MACINTYRE EA, 1988, J IMMUNOL, V141, P4333; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MUROI M, 1993, CELL SIGNAL, V5, P289, DOI 10.1016/0898-6568(93)90019-I; MUROI M, 1993, J BIOL CHEM, V268, P19534; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NITTA T, 1982, J IMMUNOL, V128, P2527; NITTA T, 1982, J IMMUNOL, V129, P2708; PFEFFERKORN LC, 1989, J BIOL CHEM, V264, P14112; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; POLAT GL, 1993, IMMUNOLOGY, V80, P287; RALPH P, 1975, J IMMUNOL, V114, P898; RANKIN BM, 1993, J IMMUNOL, V150, P605; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; REMVIG L, 1990, SCAND J IMMUNOL, V32, P255, DOI 10.1111/j.1365-3083.1990.tb02918.x; RHODES J, 1985, PROSTAGLANDINS LEUKO, P531; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; ROBERTS PJ, 1991, J IMMUNOL, V147, P3104; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4279, DOI 10.1073/pnas.77.7.4279; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SMOLEN JE, 1980, J CLIN INVEST, V65, P1077, DOI 10.1172/JCI109760; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI T, 1991, FASEB J, V5, P187, DOI 10.1096/fasebj.5.2.1706281; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VANDENDOBBELSTEEN MEA, 1993, KIDNEY INT, V43, P544, DOI 10.1038/ki.1993.81; VANDEWINKEL JGJ, 1990, SCAND J IMMUNOL, V31, P315; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WILLIS HE, 1988, J IMMUNOL, V140, P234; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042	59	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30561	30568						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982975				2022-12-25	WOS:A1994PU52500080
J	OLIVER, JM; BURG, DL; WILSON, BS; MCLAUGHLIN, JL; GEAHLEN, RL				OLIVER, JM; BURG, DL; WILSON, BS; MCLAUGHLIN, JL; GEAHLEN, RL			INHIBITION OF MAST-CELL FC-EPSILON-R1-MEDIATED SIGNALING AND EFFECTOR FUNCTION BY THE SYK-SELECTIVE INHIBITOR, PICEATANNOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; BASOPHILIC LEUKEMIA-CELLS; INDUCED HISTAMINE-RELEASE; HIGH-AFFINITY; PHOSPHOLIPASE C-GAMMA-1; ANTIGEN RECEPTOR; PHOSPHORYLATION; IGE; ACTIVATION; TRANSDUCTION	In RBL-2H3 rat tumor mast cells, antigens that crosslink the high affinity cell surface IgE receptor, Fc epsilon R1, activate at least two receptor-associated protein-tyrosine kinases, Lyn and Syk, and cause the tyrosine phosphorylation of the receptor beta and gamma subunits, PLC gamma 1, Vav, and other proteins. Cross-linking antigens also induce increased phosphatidylinositol turnover, Ca2+ mobilization, secretion, actin polymerization, spreading, and membrane ruffling. We have used the protein-tyrosine kinase inhibitor, piceatannol (3,4,3',5'-tetrahydroxy-trans-stilbene), to explore the coupling of specific kinases to cellular responses. Piceatannol preferentially inhibits the activity of Syk as compared with Lyn when added to in vitro assays with isolated enzymes. Treatment of RBL-2H3 cells with piceatannol strongly inhibits the antigen-stimulated activation of Syk measured in anti-Syk and anti-phosphotyrosine immune complex kinase assays at concentrations that have no effect on receptor subunit phosphorylation and maintain or increase the activity of Lyn in anti-phosphotyrosine immune complex kinase assays. In cells metabolically labeled with [P-32]orthophosphate, piceatannol inhibits the antigen-stimulated tyrosine phosphorylation of Syk and most other proteins. However, receptor,subunit phosphorylation is unchanged. Selective inhibition of Syk in this manner blocks receptor-mediated downstream cellular responses (inositol 1,4,5-trisphosphate production, secretion, ruffling, and spreading) while having only minor effects when these responses are induced with drugs that bypass the receptor complex. These results reveal receptor-mediated Lyn activation as a relatively piceatannol-insensitive event that may contribute to receptor subunit phosphorylation and Syk activation but does not per se elicit cellular responses. Receptor-mediated Syk activation on the other hand is highly sensitive to piceatannol, is essential to Fc epsilon R1-mediated cellular responses, and, based on the increased phosphorylation of Lyn in piceatannol-treated cells, may be involved in terminating Lyn activity.	UNIV NEW MEXICO,SCH MED,CTR CANC,ALBUQUERQUE,NM 87131; PURDUE UNIV,SCH PHARM,DEPT MED CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907	University of New Mexico; Purdue University System; Purdue University; Purdue University West Lafayette Campus	OLIVER, JM (corresponding author), UNIV NEW MEXICO,SCH MED,DEPT PATHOL,CELL PATHOL LAB,SURGE BLDG,ALBUQUERQUE,NM 87131, USA.			Geahlen, Robert/0000-0001-8400-2924	NCI NIH HHS [CA30909, CA37372] Funding Source: Medline; NIGMS NIH HHS [GM49814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037372, R01CA030909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJAJ R, 1987, REV LATINOAM QUIM, V18, P79; BECKER EL, 1972, J EXP MED, V135, P376, DOI 10.1084/jem.135.2.376; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CUSHMAN M, 1991, J MED CHEM, V34, P798, DOI 10.1021/jm00106a047; DEANIN GG, 1991, CELL REGUL, V2, P627, DOI 10.1091/mbc.2.8.627; DEANIN GG, 1991, BIOCHEM BIOPH RES CO, V179, P551, DOI 10.1016/0006-291X(91)91406-3; EISEMAN E, 1992, NATURE, V355, P78; GEAHLEN RL, 1989, BIOCHEM BIOPH RES CO, V165, P241, DOI 10.1016/0006-291X(89)91060-7; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; INAMORI Y, 1991, CHEM PHARM BULL, V39, P805; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIU FT, 1980, J IMMUNOL, V124, P2728; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; OETKEN C, 1994, ONCOGENE, V9, P1625; OLIVER JM, 1988, PROG ALLERGY, V42, P195; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TSURUGA T, 1991, CHEM PHARM BULL, V39, P3276, DOI 10.1248/cpb.39.3276; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YU KT, 1991, J BIOL CHEM, V266, P22564; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	32	313	324	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29697	29703						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961959				2022-12-25	WOS:A1994PU28400060
J	RANDAZZO, PA; TERUI, T; STURCH, S; KAHN, RA				RANDAZZO, PA; TERUI, T; STURCH, S; KAHN, RA			THE AMINO-TERMINUS OF ADP-RIBOSYLATION FACTOR (ARF)-1 IS ESSENTIAL FOR INTERACTION WITH G(S) AND ARF GTPASE-ACTIVATING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLERA-TOXIN; REGULATORY COMPONENT; ADENYLATE-CYCLASE; BINDING PROTEINS; PHOSPHOLIPASE-D; BOVINE BRAIN; COFACTOR; PURIFICATION; NUCLEOTIDES; EXPRESSION	The role of the amino terminus in the actions of ADP-ribosylation factor 1 (ARF1) was examined by comparing wild type ARF1, a 13-residue NB-terminal deletion mutant ([Delta 13]ARF1), and a 17-residue NE(2)-terminal deletion mutant ([Delta 17]ARF1). The amino-terminal 13 residues of ARF1 are required for cofactor activity in the ADP-ribosylation by cholera toxin when G(s) is the substrate. This is in marked contrast to the finding that cofactor activity is the same for wild type and [Delta 13]ARF1 when agmatine is substrate (Pong J.-X., Haun, R. S., Tsai, S.-C., Moss, J., and Vaughan, M. (1994) J. Biol. Chem. 269, 9743-9745). These data support the conclusion that ARF1 interacts with both cholera toxin and G(s) and that the amino terminus of ARF1 is required specifically for binding G(s). Surprisingly, this result also clearly revealed that the two principal assays for ARF activity, cofactor activity for cholera toxin using either G(s) or agmatine as substrates, used for over 10 years in different laboratories, can yield quite different results. While both NH2-terminal deletion mutants failed to support the ADP-ribosylation of G(s) by cholera toxin, [Delta 13]ARF1, but not [Delta 17]ARF1, inhibited the activity of the wild type protein. The GTPase activity of [Delta 13]ARF1 was activated to a small extent by ARF GTPase-activating protein (GAP), whereas that of [Delta 17]ARF1 was unaffected. me conclude that residues 14-17 are involved in the interaction of ARF with both cholera toxin and ARF GAP. The co-purifying nucleotides, nucleotide exchange kinetics, and dependence of exchange on phospholipids for the mutant proteins were all different from the wild type ARF1 proteins. The importance of monitoring the nucleotide binding to ARF proteins under the conditions used in the ARF assay and expressing ARF activities as specific activities, normalized to GTP binding sites, particularly when comparisons between different proteins or preparations are made, is discussed.	NCI, BIOL CHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HONG JX, 1994, J BIOL CHEM, V269, P9743; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1993, GTPASES BIOL, V1, P529; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; ROSENWALD AG, 1994, CHALL MOD MED, V6, P143; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; WEISS O, 1989, J BIOL CHEM, V264, P21066	22	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29490	29494						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961931				2022-12-25	WOS:A1994PU28400030
J	SEOL, JH; YOO, SJ; KIM, KI; KANG, MS; HA, DB; CHUNG, CH				SEOL, JH; YOO, SJ; KIM, KI; KANG, MS; HA, DB; CHUNG, CH			THE 65-KDA PROTEIN-DERIVED FROM THE INTERNAL TRANSLATIONAL INITIATION SITE OF THE CLPA GENE INHIBITS THE ATP-DEPENDENT PROTEASE TI IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; REGULATORY SUBUNIT; ACTIVATED ATPASE; SENSITIVE METHOD; ION GENE; COMPONENT; PROTEOLYSIS; SEQUENCE; DEGRADATION; MUTAGENESIS	The clpA gene that encodes the ATPase subunit of the ATP-dependent protease Ti (Clp) in Escherichia coli contains a putative internal translational initiation site. Here we show that mutagenesis of its 5'-end AUG codon resulted in an exclusive synthesis of the 65-kDa protein (ClpA65), while mutation at the internal 169th AUG codon (Met) to ACG (Thr) produced only the 84-kDa protein (ClpA84T). On the other hand, the cells carrying the wild-type clpA gene produced both the 84- and 65-kDa proteins (ClpA84/65). While the purified ClpA84T and ClpA84/65 hydrolyzed ATP nearly as well as the 84-kDa ClpA alone (ClpA84), ClpA65 cleaved ATP at a rate less than 5% of that by ClpA84. Unlike ClpA84 and ClpA84T, ClpA65 could not support the casein-degrading activity of ClpP. Furthermore, ClpA65 inhibited the proteolysis by the mixture of ClpP with ClpA84 or ClpA84T but not that with ClpA84/65, which could support the proteolytic activity of ClpP only about 40% as well as ClpA84. Nevertheless, ClpA65 showed little or no effect on the basal or protein-activated ATPase activity of ClpA84, ClpA84T, or ClpA84/65 alone or in the presence of ClpP. These results suggest that ClpA65 may interfere the interaction of ClpA84 or ClpA84T with ClpP and, hence, impair their assembly into an active form of the ATP-dependent protease Ti.	SEOUL NATL UNIV,COLL NAT SCI,DEPT MOLEC BIOL,SEOUL 151742,SOUTH KOREA; SEOUL NATL UNIV,COLL NAT SCI,SRC CELL DIFFERENTIAT,SEOUL 151742,SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)			KIM, KEUN IL/D-2959-2011					Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHUNG CH, 1993, SCIENCE, V262, P372, DOI 10.1126/science.8211156; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; KROH HE, 1990, J BACTERIOL, V172, P6026, DOI 10.1128/jb.172.10.6026-6034.1990; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAURIZI MR, 1991, BIOCHEM SOC T, V19, P719, DOI 10.1042/bst0190719; NATH I, 1990, NUCLEIC ACIDS RES, V18, P4935, DOI 10.1093/nar/18.16.4935; PARK SK, 1993, J BIOL CHEM, V268, P20170; PHILLIPS TA, 1984, J BACTERIOL, V159, P283, DOI 10.1128/JB.159.1.283-287.1984; Sambrook J, 1989, MOL CLONING LABORATO; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; WOO KM, 1992, J BIOL CHEM, V267, P20429	31	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29468	29473						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961929				2022-12-25	WOS:A1994PU28400027
J	KOFOD, LV; KAUPPINEN, S; CHRISTGAU, S; ANDERSEN, LN; HELDTHANSEN, HP; DORREICH, K; DALBOGE, H				KOFOD, LV; KAUPPINEN, S; CHRISTGAU, S; ANDERSEN, LN; HELDTHANSEN, HP; DORREICH, K; DALBOGE, H			CLONING AND CHARACTERIZATION OF 2 STRUCTURALLY AND FUNCTIONALLY DIVERGENT RHAMNOGALACTURONASES FROM ASPERGILLUS-ACULEATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRY RAMIFIED REGIONS; ANION-EXCHANGE CHROMATOGRAPHY; PULSED AMPEROMETRIC DETECTION; PRIMARY-CELL WALLS; LYASE GENE PELA; CDNA LIBRARIES; MESSENGER-RNA; PURIFICATION; PECTINS; POLYGALACTURONASE	Two rhamnogalacturonases from the filamentous fungus Aspergillus aculeatus have been cloned and characterized. A cDNA library from A. aculeatus was constructed, and a novel rhamnogalacturonase B was isolated by expression cloning in yeast. For this purpose a new plate screening assay was developed, specific for the detection of rhamnogalacturonase activity. The rhamnogalacturonase A, known from previous reports, was shown not to be expressed in yeast in an active form. Therefore, rhamnogalacturonase A was purified, peptide sequences were obtained, and full-length cDNAs encoding the enzyme were isolated using a polymerase chain reaction-generated product as a probe. Comparison of the deduced primary structures indicates that the two rhamnogalacturonases are structurally different. This is further supported by the finding that polyclonal antibodies raised against native rhamnogalacturonase A do not cross-react with rhamnogalacturonase B. The cloned genes were transformed into Aspergillus oryzae for high level expression. The recombinant enzymes were purified and characterized, revealing significant differences in glycosylation pattern and substrate specificity as well as in pH and temperature optima and stability, Data from the hydrolysis of apple rhamnogalacturonan with the recombinant rhamnogalacturonases suggest that the two enzymes exert their action at different sites in the backbone.			KOFOD, LV (corresponding author), SYMBION, BIOIND GRP, NOVO NORDISK AS, GENEEXPRESS, FRUEBJERGVEJ 31, DK-2100 COPENHAGEN O, DENMARK.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BIELY P, 1985, ANAL BIOCHEM, V144, P142, DOI 10.1016/0003-2697(85)90095-8; BROWN SM, 1990, PLANT CELL, V2, P263, DOI 10.1105/tpc.2.3.263; BUSSINK HJD, 1992, EUR J BIOCHEM, V208, P83, DOI 10.1111/j.1432-1033.1992.tb17161.x; CALL HP, 1983, J FOOD BIOCHEM, V7, P43, DOI 10.1111/j.1745-4514.1983.tb00082.x; CAPRARI C, 1993, MYCOL RES, V97, P497, DOI 10.1016/S0953-7562(09)80138-X; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTENSEN T, 1988, BIO-TECHNOL, V6, P1419, DOI 10.1038/nbt1288-1419; CHRISTGAU S, 1994, BIOCHEM MOL BIOL INT, V33, P917; CHRISTGAU S, 1994, IN PRESS CURR GENET; COLQUHOUN IJ, 1990, CARBOHYD RES, V206, P131, DOI 10.1016/0008-6215(90)84012-J; DALBOGE H, 1994, MOL GEN GENET, V243, P253, DOI 10.1007/BF00301060; DEAN RA, 1989, PLANT CELL, V1, P275, DOI 10.1105/tpc.1.3.275; DEKKER RFH, 1979, POLYSACCHARIDES FOOD, P93; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEISOW MJ, 1992, TRENDS BIOTECHNOL, V10, P333, DOI 10.1016/0167-7799(92)90262-T; GRIERSON D, 1986, NUCLEIC ACIDS RES, V14, P8595, DOI 10.1093/nar/14.21.8595; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARMSEN JAM, 1990, CURR GENET, V18, P161, DOI 10.1007/BF00312604; HOTCHKISS AT, 1990, ANAL BIOCHEM, V184, P200, DOI 10.1016/0003-2697(90)90669-Z; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; KOIZUMI K, 1989, J CHROMATOGR, V464, P365; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU JM, 1985, CARBOHYD RES, V137, P111, DOI 10.1016/0008-6215(85)85153-3; MARKOVIC O, 1992, J CHROMATOGR, V603, P243, DOI 10.1016/0021-9673(92)85367-3; MATSUDAIRA PT, 1989, PRACTICAL GUIDE PROT, P3; MCDOUGALL GJ, 1991, CARBOHYD RES, V219, P123, DOI 10.1016/0008-6215(91)89047-J; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MUTTER M, 1994, PLANT PHYSIOL, V106, P241, DOI 10.1104/pp.106.1.241; NIOGRET MF, 1991, PLANT MOL BIOL, V17, P1155, DOI 10.1007/BF00028732; Nirpjit S, 1996, J GEN MICROBIOL, V18, P1435; O'Neill M., 1990, METHODS PLANT BIOCH, V2, P415, DOI DOI 10.1016/B978-0-12-461012-5.50018-5; PILNIK W, 1979, POLYSACCHARIDES FOOD, P109; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROMBOUTS FM, 1988, CARBOHYD POLYM, V9, P25, DOI 10.1016/0144-8617(88)90075-6; SAKAMOTO T, 1993, BIOSCI BIOTECH BIOCH, V57, P1832, DOI 10.1271/bbb.57.1832; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLS HA, 1994, CARBOHYD RES, V256, P97, DOI 10.1016/0008-6215(94)84230-2; SCHOLS HA, 1994, CARBOHYD RES, V256, P83, DOI 10.1016/0008-6215(94)84229-9; SCHOLS HA, 1990, CARBOHYD RES, V206, P105, DOI 10.1016/0008-6215(90)84010-R; SCHOLS HA, 1990, CARBOHYD RES, V206, P117, DOI 10.1016/0008-6215(90)84011-I; SEARLEVANLEEUWEN MJF, 1992, APPL MICROBIOL BIOT, V38, P347, DOI 10.1007/BF00170084; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIESSERE V, 1992, J GEN MICROBIOL, V138, P1801, DOI 10.1099/00221287-138-9-1801; SIGGAARDANDERSEN M, 1991, P NATL ACAD SCI USA, V88, P4114, DOI 10.1073/pnas.88.10.4114; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; THIBAULT JF, 1993, CARBOHYD RES, V238, P271, DOI 10.1016/0008-6215(93)87019-O; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; VANDEVIS JW, 1991, CARBOHYD POLYM, V16, P167, DOI 10.1016/0144-8617(91)90101-H; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VORAGEN AGJ, 1992, PLANT POLYM CARBOHYD, P3; WEBER M, 1986, J CHROMATOGR, V355, P456, DOI 10.1016/S0021-9673(01)97354-6; YOUNG NM, 1978, CARBOHYD RES, V66, P299; ZEMEK J, 1981, ABHANDLUNGEN AKAD WI, P47	60	79	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29182	29189						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961884				2022-12-25	WOS:A1994PU16800097
J	VANHOOKE, JL; FREY, PA				VANHOOKE, JL; FREY, PA			CHARACTERIZATION AND ACTIVATION OF NATURALLY-OCCURRING ABORTIVE COMPLEXES OF UDP-GALACTOSE 4-EPIMERASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; SUBSTRATE; REDUCTION	UDP-galactose 4-epimerase catalyzes the interconversion of UDP-galactose and UDP-glucose, The enzyme from Escherichia coli is a dimeric protein with an overall molecular weight of 79,000 that contains NAD(+) very tightly but noncovalently bound in the enzymatic active site, NAD(+) is the coenzyme for epimerization and is transiently reduced to NADH in the course of catalysis, Ah samples of highly purified UDP-galactose 4-epimerase contain significant amounts of NADH, and that purified after overexpression in E, coli cells contains a substantial amount of NADH, To the degree that NADH replaces enzyme bound NAD(+) in the coenzyme binding site, the epimerase activity is decreased The extinction coefficient at 345 nm for NADH in its binding site is estimated to be 3.3 mm(-1) cm(-1). P-31 NMR spectroscopic and enzymatic analyses reveal that UDP-glucose, UDP galactose, UDP, and UMP are gradually released from the purified enzyme upon addition of UMP or P-1-5'-uridine-P-2-methyl diphosphate (MeUDP). It is concluded that NADH associated with the purified enzyme is a component of inactive, abortive complexes (E.NADH.uridine nucleotide) that contain tightly bound uridine nucleotides in place of the epimerization intermediate UDP-4-keto-alpha-D-hexoglucopyranose, These complexes are produced in vivo in the course of bacterial growth, The enzymatic activity of purified epimerase is increased by reaction with 1,2-naphthoquinone-4-sulfonate, which oxidizes the NADH to NAD(+). Compositionally defined abortive complexes (E.NADH.uridine nucleotide) containing UMP, UDP, or UDP-hexoses (Glc/Gal) have been prepared in vitro and subjected to activation by 1,2-naphthoquinone-4-sulfonate, Ah are activated at rates comparable to that for the purified enzyme, although those containing UMP and UDP-hexose are more readily activated than those containing UDP. The activity of the reactivated enzyme approaches that of the most highly active epimerase that has been reported from E, coli.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	VANHOOKE, JL (corresponding author), UNIV WISCONSIN, GRAD SCH, INST ENZYME RES, MADISON, WI 53705 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02301] Funding Source: Medline; NIGMS NIH HHS [GM 30480] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAIR WL, 1973, J BIOL CHEM, V248, P4635; BAUER AJ, 1992, PROTEINS, V12, P372, DOI 10.1002/prot.340120409; BAUER AJ, 1991, PROTEINS, V9, P135, DOI 10.1002/prot.340090207; BERTLAND A, 1966, ARCH BIOCHEM BIOPHYS, V116, P280, DOI 10.1016/0003-9861(66)90034-8; BHADURI A, 1965, BIOCHEM BIOPH RES CO, V21, P631, DOI 10.1016/0006-291X(65)90533-4; BOCK RM, 1956, ARCH BIOCHEM BIOPHYS, V62, P253, DOI 10.1016/0003-9861(56)90123-0; CAPUTTO R, 1949, J BIOL CHEM, V179, P497; CREVELING CR, 1965, BIOCHEM BIOPH RES CO, V21, P624, DOI 10.1016/0006-291X(65)90532-2; CREVELING CR, 1964, FED PROC, V23, P420; DARROW RA, 1968, BIOCHEMISTRY-US, V7, P1645, DOI 10.1021/bi00845a005; DAVIS JE, 1974, BIOCHIM BIOPHYS ACTA, V334, P442, DOI 10.1016/0005-2744(74)90189-2; KALCKAR HM, 1970, P NATL ACAD SCI USA, V65, P1113, DOI 10.1073/pnas.65.4.1113; KALCKAR HM, 1969, ROLE NUCLEOTIDES FUN, P247; KANG UG, 1975, J BIOL CHEM, V250, P7099; KETLEY JN, 1973, BIOCHEMISTRY-US, V12, P315, DOI 10.1021/bi00726a022; KETLEY JN, 1972, BIOCHIM BIOPHYS ACTA, V284, P549, DOI 10.1016/0005-2744(72)90152-0; KOLB DA, 1975, BIOCHEMISTRY-US, V14, P4476, DOI 10.1021/bi00691a021; KONOPKA JM, 1989, BIOCHEMISTRY-US, V28, P2645, DOI 10.1021/bi00432a043; MAITRA US, 1971, P NATL ACAD SCI USA, V68, P2660, DOI 10.1073/pnas.68.11.2660; MAXWELL ES, 1960, J BIOL CHEM, V235, P308; NELSESTU.GL, 1971, J BIOL CHEM, V246, P7533; RIZZO V, 1987, PYRIDINE NUCLEOTID A, V2, P99; SWANSON BA, 1993, BIOCHEMISTRY-US, V32, P13231, DOI 10.1021/bi00211a035; WEE TG, 1973, J BIOL CHEM, V248, P33; WILSON DB, 1964, J BIOL CHEM, V239, P2469; WONG SS, 1978, BIOCHEMISTRY-US, V17, P516, DOI 10.1021/bi00596a022; WONG SS, 1977, BIOCHEMISTRY-US, V16, P298, DOI 10.1021/bi00621a022; WONG SS, 1978, BIOCHEMISTRY-US, V17, P3551, DOI 10.1021/bi00610a020; WONG SS, 1976, J AM CHEM SOC, V98, P7886, DOI 10.1021/ja00440a104; [No title captured]	30	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31496	31504						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989316				2022-12-25	WOS:A1994PX30300029
J	LALLY, ET; GOLUB, EE; KIEBA, IR				LALLY, ET; GOLUB, EE; KIEBA, IR			IDENTIFICATION AND IMMUNOLOGICAL CHARACTERIZATION OF THE DOMAIN OF ACTINOBACILLUS-ACTINOMYCETEMCOMITANS LEUKOTOXIN THAT DETERMINES ITS SPECIFICITY FOR HUMAN TARGET-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HEMOLYSIN; TERMINAL SECRETION SIGNAL; HUMAN PERIODONTAL-DISEASE; GRAM-NEGATIVE BACTERIA; ALPHA-HEMOLYSIN; NUCLEOTIDE-SEQUENCE; ERWINIA-CHRYSANTHEMI; HEMOPHILUS PLEUROPNEUMONIAE; PSEUDOMONAS-AERUGINOSA; MONOCLONAL-ANTIBODIES	Although extensive amino acid homology exists among the various Repeats in ToXin (RTX) family of bacterial cytolysins, the cellular and species specificities remain unique for individual toxins (i.e. Actinobacillus actinomycetemcomitans leukotoxin (LtxA) kills human monomyelocytes while a related toxin, Pasteurella hemeolytica leukotoxin (LktA) kills bovine lymphoid cells). To determine the Ltx domain responsible for species specificity, ltxA/lktA chimeric toxin genes were expressed in tandem with the ltxC gene under control of the P-lambda promoter. The ability of lysates to kill either HL-60 (human) or BL-3 (bovine) cells was assessed by trypan blue exclusion. The critical area required for the chimeric toxins to recognize human target cells is a 253-amino acid fragment (residue 688-941) that contains the GGXGXDX(L\I/V\W\Y\F)X repeats. A panel of 12 neutralizing anti-LtxA monoclonal antibodies also recognized specificities within the 253-amino acid fragment. Epitope mapping of the monoclonal antibody panel showed that all antibodies bound to one of three sites on the LtxA molecule. One monoclonal recognized epitope A which was composed of LtxA residues 698-709 (KLDYYYTNKGFK), six antibodies recognized epitope B, a peptide composed of residues 746-757 (LIYGYDGD-DRLY), whereas the remaining five monoclonals recognized epitope C, which is composed of residues 926-937 (DRARLKRQFELQ).			LALLY, ET (corresponding author), UNIV PENN,SCH DENT MED,LEON LEVY RES CTR ORAL BIOL,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE007118, P50DE008239] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08239, DE09517, DE07118] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAEHNI P, 1977, ARCH ORAL BIOL, V22, P685, DOI 10.1016/0003-9969(77)90098-X; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BERKA T, 1988, J BACTERIOL, V170, P21, DOI 10.1128/jb.170.1.21-26.1988; BLOCK PJ, 1973, AM J MED SCI, V266, P387, DOI 10.1097/00000441-197311000-00006; BOEHM DF, 1990, INFECT IMMUN, V58, P1959, DOI 10.1128/IAI.58.6.1959-1964.1990; Caruthers M H, 1983, Gene Amplif Anal, V3, P1; CAVALIERI SJ, 1984, MICROBIOL REV, V48, P326, DOI 10.1128/MMBR.48.4.326-343.1984; CHANG YF, 1989, DNA-J MOLEC CELL BIO, V8, P635, DOI 10.1089/dna.1.1989.8.635; CRUZ WT, 1990, MOL MICROBIOL, V4, P1933, DOI 10.1111/j.1365-2958.1990.tb02042.x; DELEPELAIRE P, 1990, J BIOL CHEM, V265, P17118; DIRIENZO JM, 1985, INFECT IMMUN, V47, P31, DOI 10.1128/IAI.47.1.31-36.1985; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FORESTIER C, 1991, INFECT IMMUN, V59, P4212, DOI 10.1128/IAI.59.11.4212-4220.1991; FORESTIER C, 1990, INFECT IMMUN, V58, P828, DOI 10.1128/IAI.58.3.828-832.1990; GUZZO J, 1991, MOL MICROBIOL, V5, P447, DOI 10.1111/j.1365-2958.1991.tb02128.x; HARDIE KR, 1991, MOL MICROBIOL, V5, P1669, DOI 10.1111/j.1365-2958.1991.tb01914.x; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KORONAKIS V, 1988, MOL GEN GENET, V312, P551; KRAIG E, 1990, INFECT IMMUN, V58, P920, DOI 10.1128/IAI.58.4.920-929.1990; LALLY ET, 1991, MICROB PATHOGENESIS, V11, P111, DOI 10.1016/0882-4010(91)90004-T; LALLY ET, 1989, J BIOL CHEM, V264, P15451; LALLY ET, 1989, BIOCHEM BIOPH RES CO, V159, P256, DOI 10.1016/0006-291X(89)92431-5; LETOFFE S, 1990, EMBO J, V9, P1375, DOI 10.1002/j.1460-2075.1990.tb08252.x; LIAN CJ, 1989, INFECT IMMUN, V57, P3377, DOI 10.1128/IAI.57.11.3377-3382.1989; LO RYC, 1985, INFECT IMMUN, V50, P667, DOI 10.1128/IAI.50.3.667-671.1985; LO RYC, 1987, INFECT IMMUN, V55, P1987, DOI 10.1128/IAI.55.9.1987-1996.1987; LO RYC, 1990, CAN J VET RES, V54, pS33; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; LUDWIG A, 1987, MOL GEN GENET, V206, P238, DOI 10.1007/BF00333579; LUDWIG A, 1991, MOL GEN GENET, V226, P198, DOI 10.1007/BF00273604; MCARTHUR WP, 1981, J PERIODONTAL RES, V16, P159, DOI 10.1111/j.1600-0765.1981.tb00962.x; MCWHINNEY DR, 1992, J BACTERIOL, V174, P291, DOI 10.1128/jb.174.1.291-297.1992; MOBLEY HLT, 1991, INFECT IMMUN, V59, P2036, DOI 10.1128/IAI.59.6.2036-2042.1991; PAGE MI, 1966, NEW ENGL J MED, V275, P181, DOI 10.1056/NEJM196607282750403; PELLETT S, 1990, INFECT IMMUN, V58, P822, DOI 10.1128/IAI.58.3.822-827.1990; ROSENBERG M, 1983, METHOD ENZYMOL, V101, P123; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; ROWE GE, 1994, INFECT IMMUN, V62, P579, DOI 10.1128/IAI.62.2.579-588.1994; SHATZMAN AR, 1994, CURRENT PROTOCOLS MO; SHEWEN PE, 1982, INFECT IMMUN, V35, P91, DOI 10.1128/IAI.35.1.91-94.1982; STANLEY P, 1991, MOL MICROBIOL, V5, P2391, DOI 10.1111/j.1365-2958.1991.tb02085.x; STRATHDEE CA, 1989, J BACTERIOL, V171, P916, DOI 10.1128/jb.171.2.916-928.1989; STRATHDEE CA, 1989, J BACTERIOL, V171, P5955, DOI 10.1128/jb.171.11.5955-5962.1989; Taichman N S, 1987, Oral Microbiol Immunol, V2, P97, DOI 10.1111/j.1399-302X.1987.tb00270.x; TAICHMAN NS, 1980, INFECT IMMUN, V28, P258, DOI 10.1128/IAI.28.1.258-268.1980; TAICHMAN NS, 1984, J PERIODONTAL RES, V19, P133, DOI 10.1111/j.1600-0765.1984.tb00802.x; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; ZAMBON JJ, 1985, J CLIN PERIODONTOL, V12, P1, DOI 10.1111/j.1600-051X.1985.tb01348.x; ZAMBON JJ, 1983, INFECT IMMUN, V41, P19, DOI 10.1128/IAI.41.1.19-27.1983; ZAMBON JJ, 1983, INFECT IMMUN, V40, P205, DOI 10.1128/IAI.40.1.205-212.1983	51	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31289	31295						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983074				2022-12-25	WOS:A1994PV51000083
J	NELSON, EJ; HINKLE, PM				NELSON, EJ; HINKLE, PM			THYROTROPIN-RELEASING-HORMONE ACTIVATES CA2+ EFFLUX - EVIDENCE SUGGESTING THAT A PLASMA-MEMBRANE CA2+ PUMP IS AN EFFECTOR FOR A G-PROTEIN-COUPLED CA2+-MOBILIZING RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; PITUITARY-TUMOR CELLS; GH3 CELLS; ENDOPLASMIC-RETICULUM; SELF-ASSOCIATION; BINDING PROTEIN; CA-2+; CALMODULIN; CHANNELS; INHIBITION	These studies characterize the mechanisms involved in terminating the initial Ca2+ transient stimulated by thyrotropin-releasing hormone (TRH). When TRH was added to GH3 pituitary cells that had been treated with thapsigargin to block any agonist-stimulated increase in [Ca2+](i) TRH caused a decrease in [Ca2+](i). The Ca2+ clearing response was seen in pituitary GH3 cells and in nonexcitable HEK 293 cells transfected with TRH receptor cDNA, was evident at basal or elevated [Ca2+](i) and was mediated by the TRH receptor. The Ca2+ clearing response to TRH was not prevented by thapsigargin, Ca2+ ionophores, nimodipine, or replacement of extracellular Na+ but was inhibited by La3+. La3+ also increased the duration of the TRH-evoked [Ca2+](i) transient. TRH-stimulated Ca2+ extrusion was directly demonstrated using extracellular fluo-3 free acid. TRH produced a 5-20-fold increase in Ca2+ efflux that was independent of extracellular Na+ and inhibited by vanadate. TRH stimulation of Ca2+ efflux was not reproduced by phorbol esters or inhibited by down-regulation of protein kinase C or staurosporine. The results suggest that agonist-activated Ca2+ efflux may be a universal component of an agonist-activated Ca2+ response and further suggest that a plasma membrane Ca2+ pump may be an effector for G-protein-coupled receptors linked to Ca2+ mobilization.	UNIV ROCHESTER, SCH MED & DENT, DEPT PHARMACOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, CTR CANC, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008427] Funding Source: NIH RePORTER; NCI NIH HHS [CA 11098] Funding Source: Medline; NIDDK NIH HHS [DK 19974] Funding Source: Medline; NIGMS NIH HHS [GM 08427] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERT PR, 1984, J BIOL CHEM, V259, P5350; BALLA T, 1991, BIOCHEM J, V273, P399, DOI 10.1042/bj2730399; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CARAFOLI E, 1992, CURR TOP CELL REGUL, V32, P209; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; DAVIS FB, 1991, FASEB J, V5, P2992, DOI 10.1096/fasebj.5.14.1836436; DELFERT DM, 1986, BIOCHEM J, V236, P37, DOI 10.1042/bj2360037; DRUMMOND AH, 1986, J EXP BIOL, V124, P337; DRUMMOND AH, 1985, NATURE, V315, P752, DOI 10.1038/315752a0; DUDDY SK, 1989, J BIOL CHEM, V264, P20863; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; GERSHENGORN MC, 1985, ENDOCRINOLOGY, V116, P591, DOI 10.1210/endo-116-2-591; GERSHENGORN MC, 1989, ENDOCRINOLOGY, V44, P1; GOLLASCH M, 1993, P NATL ACAD SCI USA, V90, P6265, DOI 10.1073/pnas.90.13.6265; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HALPERN J, 1981, P NATL ACAD SCI-BIOL, V78, P587, DOI 10.1073/pnas.78.1.587; HANEL AM, 1990, BIOCHEMISTRY-US, V29, P5210, DOI 10.1021/bi00473a030; HAYMES AA, 1992, AM J PHYSIOL, V262, pC1211, DOI 10.1152/ajpcell.1992.262.5.C1211; HINKLE PM, 1992, J BIOL CHEM, V267, P25553; HINKLE PM, 1989, ANN NY ACAD SCI, V553, P176; HOLL RW, 1989, MOL CELL ENDOCRINOL, V64, P105, DOI 10.1016/0303-7207(89)90070-1; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; ITOH K, 1988, BIOCHEM BIOPH RES CO, V153, P1315, DOI 10.1016/S0006-291X(88)81372-X; JOUNEAUX C, 1993, J BIOL CHEM, V268, P2368; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; LAW GJ, 1990, BIOCHEM J, V267, P359, DOI 10.1042/bj2670359; LEVY J, 1986, ENDOCRINOLOGY, V119, P2405, DOI 10.1210/endo-119-6-2405; LI PZ, 1992, MOL ENDOCRINOL, V6, P1393, DOI 10.1210/me.6.9.1393; LOTERSZTAJN S, 1992, J BIOL CHEM, V267, P2375; MARCHETTI C, 1988, AM J PHYSIOL, V254, pC206, DOI 10.1152/ajpcell.1988.254.1.C206; MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163-7258(91)90014-D; NELSON EJ, 1994, BIOCHEM J, V302, P147, DOI 10.1042/bj3020147; NELSON EJ, 1992, ENDOCRINOLOGY, V130, P3246, DOI 10.1210/en.130.6.3246; NELSON EJ, 1994, ENDOCRINOLOGY, V135, P1084, DOI 10.1210/en.135.3.1084; PAULSSEN RH, 1992, EUR J BIOCHEM, V204, P413, DOI 10.1111/j.1432-1033.1992.tb16651.x; PRPIC V, 1984, J BIOL CHEM, V259, P1382; SHUTTLEWORTH TJ, 1991, J BIOL CHEM, V266, P1410; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; VORHERR T, 1991, J BIOL CHEM, V266, P22; WUYTACK F, 1992, J BIOENERG BIOMEMBR, V24, P285; ZHANG BX, 1992, J BIOL CHEM, V267, P15419	46	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30854	30860						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983017				2022-12-25	WOS:A1994PV51000022
J	YAMAUCHI, K; PESSIN, JE				YAMAUCHI, K; PESSIN, JE			INSULIN-RECEPTOR SUBSTRATE-1 (IRS1) AND SHC COMPETE FOR A LIMITED POOL OF GRB2 IN MEDIATING INSULIN DOWNSTREAM SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE KINASES; TRANSDUCTION PATHWAY; PROTEIN-KINASES; MAP KINASE; IN-VITRO; RAS; PHOSPHORYLATION; DOMAIN; ASSOCIATION	Expression of the insulin receptor substrate-1 (IRS1) or Shc cDNA resulted in both increased protein and insulin-stimulated tyrosine phosphorylation of IRS1 and She proteins, respectively. Although expression of She had no significant effect on insulin-stimulated mitogen-activated protein (MAP) kinase gel shift or c-fos transcriptional activation, expression of IRS1 inhibited these responses. The effect of IRS1 expression on the formation of multisubunit signaling complexes was determined by a series of indirect co-immunoprecipitations. Grb2 immunoprecipitation from IRS1-transfected and insulin-treated cells demonstrated an increased coimmunoprecipitation of Syp and the p85 regulatory subunit of the phosphatidylinositol S-kinase. Similarly, cell extracts immunoprecipitated with a p85 antibody displayed an increased co-immunoprecipitation of Syp and Grb2. However, expression of IRS1 increased the extent of Grb2 associated with IRS1 with a concomitant reduction in the amount of Grb2 associated with She. Furthermore, increased expression of Shc reduced the amount of Grb2 bound to IRS1 with a concomitant increase in Grb2 associated with She. Together, these data demonstrate that IRS1 and She compete for a limited cellular pool of Grb2, and insulin activation of MAP kinase and c-fos transcription predominantly occur through the Shc-Grb2 signaling pathway.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R37DK033823, R01DK033823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33823, DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MIKI H, 1994, J BIOL CHEM, V269, P5489; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SATOH T, 1992, J BIOL CHEM, V267, P24149; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TOBE K, 1993, J BIOL CHEM, V268, P11167; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	56	100	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31107	31114						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983051				2022-12-25	WOS:A1994PV51000058
J	KOZELL, LB; MACHIDA, CA; NEVE, RL; NEVE, KA				KOZELL, LB; MACHIDA, CA; NEVE, RL; NEVE, KA			CHIMERIC D1/D2 DOPAMINE-RECEPTORS - DISTINCT DETERMINANTS OF SELECTIVE EFFICACY, POTENCY, AND SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTORS; D2 RECEPTOR; BINDING; AGONIST; ANTAGONIST; AFFINITY; LIGAND; SPECIFICITY; BENZAZEPINE	D1/D2 chimeras were constructed that had D1 dopamine receptor sequence at the amino terminal end and D2 dopamine receptor sequence at the carboxyl terminal end. The chimeras with the first four, five and six transmembrane domains of the D1 receptor (CH2, CH3, CH4, respectively) bound the D1 receptor antagonist [H-3]SCH 23390 with high affinity. Reciprocal chimeras constructed with D2 receptor sequence at the amino terminal end displayed no detectable specific binding of [H-3]SCH 23390, [I-125]epidepride, or [H-3]spiperone. CH2, CH3, and CH4 had lower affinity than either D1f or D2 dopamine receptors for the nonselective antagonists and agonists and D2-selective antagonists tested. The chimeric receptors had affinities for three D1-selective ligands and the D2-selective agonist, quinpirole, that were intermediate between D1 and D2 receptor affinities for the drugs. The substantial loss or gain of affinity for three ligands upon replacement of D1 transmembrane VII with D2 sequence (CH4) suggests an important role for this region in the selectivity of these drugs. Stimulation of adenylyl cyclase activity by D1 agonists occurred in cells expressing CH3 and CH4, both of which included the D1 third cytoplasmic loop, but not in cells expressing CH1 or CH2, both with the D2 third cytoplasmic loop. However, only CH3 was able to mediate stimulation of adenylyl cyclase by quinpirole, implying that D2 receptor transmembrane domain VI was an important determinant of the selective efficacy of quinpirole. On the other hand, transmembrane domain VII was particularly important for the selective potency of quinpirole. Inhibition of beta-adrenergic receptor-stimulated adenylyl cyclase activity by dopamine was seen in cells expressing D2 receptors and CH1, but not CH2, CH3, or CH4. Thus, the third cytoplasmic loop of D1 dopamine receptors was crucial for the coupling of the receptors to G(s), but inhibition of adenylyl cyclase via G(i) required structural features, such as the second cytoplasmic loop of the D2 receptor, in addition to the 3rd cytoplasmic loop.	VET AFFAIRS MED CTR,RES SERV 151LL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PHARMACOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PSYCHIAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201; OREGON REG PRIMATE RES CTR,DIV NEUROSCI,BEAVERTON,OR 97006; HARVARD UNIV,SCH MED,DEPT GENET,BELMONT,MA 02178; MCLEAN HOSP,BELMONT,MA 02178	US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon National Primate Research Center; Harvard University; Harvard University; McLean Hospital				Kozell, Laura/0000-0003-3059-2046	NIMH NIH HHS [MH45372] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045372] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BILLARD W, 1984, LIFE SCI, V35, P1885, DOI 10.1016/0024-3205(84)90540-X; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CATTERALL WA, 1988, SCIENCE, V243, P236; CHIO CL, 1994, J BIOL CHEM, V269, P11813; CHIO CL, 1994, MOL PHARMACOL, V45, P51; COX BA, 1992, J NEUROCHEM, V59, P627, DOI 10.1111/j.1471-4159.1992.tb09416.x; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HOGBERG T, 1990, HELV CHIM ACTA, V73, P417, DOI 10.1002/hlca.19900730221; HYTTEL J, 1983, EUR J PHARMACOL, V91, P153, DOI 10.1016/0014-2999(83)90381-3; IORIO LC, 1983, J PHARMACOL EXP THER, V226, P462; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; MACHIDA CA, 1992, MOL PHARMACOL, V41, P652; MACKENZIE RG, 1993, FEBS LETT, V323, P59, DOI 10.1016/0014-5793(93)81448-9; MARULLO S, 1990, EMBO J, V9, P1471, DOI 10.1002/j.1460-2075.1990.tb08264.x; MCALLISTER G, 1993, FEBS LETT, V324, P81, DOI 10.1016/0014-5793(93)81537-A; NEVE KA, 1991, MOL PHARMACOL, V39, P733; NEVE KA, 1990, J PHARMACOL EXP THER, V252, P1108; NEVE KA, 1989, MOL PHARMACOL, V36, P446; NEVE KA, 1992, J BIOL CHEM, V267, P25748; OBOYLE KM, 1989, NEUROPHARMACOLOGY, V28, P401, DOI 10.1016/0028-3908(89)90036-1; ODOWD BF, 1993, J NEUROCHEM, V60, P804, DOI 10.1111/j.1471-4159.1993.tb03224.x; PITTEL Z, 1994, MOL PHARMACOL, V45, P61; SCHULZ DW, 1985, J NEUROCHEM, V45, P1601, DOI 10.1111/j.1471-4159.1985.tb07233.x; SETLER PE, 1978, EUR J PHARMACOL, V50, P419, DOI 10.1016/0014-2999(78)90148-6; STRADER CD, 1987, J BIOL CHEM, V262, P16439; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; TANG L, 1994, J PHARMACOL EXP THER, V268, P495; VALLAR L, 1989, TRENDS PHARMACOL SCI, V10, P74, DOI 10.1016/0165-6147(89)90082-5; ZHOU W, 1994, MOL PHARMACOL, V45, P165	31	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30299	30306						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982941				2022-12-25	WOS:A1994PU52500042
J	LEE, MS; ENOCH, T; PIWNICAWORMS, H				LEE, MS; ENOCH, T; PIWNICAWORMS, H			MIK1(+) ENCODES A TYROSINE KINASE THAT PHOSPHORYLATES P34(CDC2) ON TYROSINE-15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC2 PROTEIN-KINASE; CELL-CYCLE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; P34CDC2 KINASE; SCHIZOSACCHAROMYCES-POMBE; ACTIVATES P34CDC2; MITOTIC INDUCER; DEPHOSPHORYLATION; PHOSPHATASE	mik1(+) and wee1(+) function to regulate the tyrosine phosphorylation of p34(cdc2) in, Schizosaccharomyces pombe (Lundgren, K., Walworth, N., Booher, R., Dembski, M., Kirschner, M., and Beach, D. (1991) Cell 64, 1111-1122). wee1(+) encodes a tyrosine kinase that directly phosphorylates p34(cdc2) on tyrosine 15, resulting in the inactivation of the cyclin B/p34(cdc2) complex. We have overproduced the miK1(+) gene product in insect cells and in S. pombe in order to characterize it biochemically. Immunoprecipitates of Mik1 from both sources catalyzed the phosphorylation of p34(cdc2) on tyrosine 15 whereas immunoprecipitates of a kinase-deficient mutant of Mik1 were negative in this assay. Mik1 overproduced in insect cells was partially purified by column chromatography, and column fractions were assayed for their ability to phosphorylate p34(cdc2) on tyrosine 15. Two major peaks of Mik1 protein were detected by gel filtration chromatography. One peak eluted in the void volume, and a second peak eluted with an apparent molecular mass expected for monomeric Mik1 (similar to 68 kDa). The tyrosine 15 kinase activity co-eluted with the 68 kDa form of Mik1. These results indicate that mik1(+) encodes a tyrosine kinase that directly phosphorylates p34(cdc2) on tyrosine 15.	TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Tufts University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Piwnica-Worms, Helen/C-5214-2012					AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; HONDA R, 1992, BIOCHEM BIOPH RES CO, V186, P1333, DOI 10.1016/S0006-291X(05)81552-9; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MILLAR JBA, 1992, EMBO J, V11, P4933, DOI 10.1002/j.1460-2075.1992.tb05600.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PIWNICAWORMS H, 1990, CURRENT PROTOCOLS MO; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; YAMAWAKIKATAOKA Y, 1989, P NATL ACAD SCI USA, V86, P5693, DOI 10.1073/pnas.86.15.5693	46	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30530	30537						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982971				2022-12-25	WOS:A1994PU52500076
J	FOX, PL; SA, G; DOBROWOLSKI, SF; STACEY, DW				FOX, PL; SA, G; DOBROWOLSKI, SF; STACEY, DW			THE REGULATION OF ENDOTHELIAL-CELL MOTILITY BY P21 RAS	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; METASTATIC PHENOTYPE; NIH/3T3 CELLS; ONCOGENE; PROTEIN; MICROINJECTION; PROLIFERATION; TRANSFORMATION; NIH-3T3-CELLS	Directed endothelial cell (EC) movement is required for the development and repair of blood vessels and plays a critical role in angiogenic processes obligatory for large tumor formation. We now report that vas proteins have a critical role in regulation of movement of normal mammalian cells. Bovine aortic EC microinjected with oncogenic Ha-ras enter further into an artificial wound than uninjected cells. Treatment with oncogenic Ha-ras also converts the cell paths from nearly linear in control cells to apparent 'random-walk' trajectories in treated cells, suggesting that oncogenic vas alters the normal control processes regulating cell motility. Botulinum toxin C blocks uas-stimulated motility indicating that a member of the p21 rho family is a downstream participant in the motile pathway. In related experiments we have observed that microinjection of the neutralizing, Pas-specific, Y13-259 monoclonal antibody completely blocks both basal and basic fibroblast growth factor-stimulated movement of aortic EC. Y13-259 blocks the initiation of EC movement, as well as the continued progress of cells already in motion, suggesting that uas activity is continuously required throughout the motile process. Together these data indicate that ras is an integral component of the signaling pathway regulating cell movement.	CLEVELAND CLIN,RES INST,DEPT BIOL MOLEC,CLEVELAND,OH 44195	Cleveland Clinic Foundation	FOX, PL (corresponding author), CLEVELAND CLIN,RES INST,DEPT CELL BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NCI NIH HHS [CA53496] Funding Source: Medline; NHLBI NIH HHS [HL41178, HL40352] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053496] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040352, R01HL041178] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BJORNSSON TD, 1991, P NATL ACAD SCI USA, V88, P8651, DOI 10.1073/pnas.88.19.8651; CHAMBERS AF, 1988, ANTICANCER RES, V8, P861; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KLEINSOYER C, 1992, BIOL CELL, V75, P155, DOI 10.1016/0248-4900(92)90136-O; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUNG HF, 1986, EXP CELL RES, V162, P363, DOI 10.1016/0014-4827(86)90341-1; LINDNER V, 1990, J CLIN INVEST, V85, P2004, DOI 10.1172/JCI114665; MERWIN JR, 1991, AM J PATHOL, V138, P37; MOHLER JL, 1993, CANCER METAST REV, V12, P53, DOI 10.1007/BF00689790; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MURUGESAN G, 1994, CIRC RES, V74, P1149, DOI 10.1161/01.RES.74.6.1149; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; MYRDAL SE, 1985, EXP CELL RES, V159, P441, DOI 10.1016/S0014-4827(85)80017-3; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NICHOLSON GL, 1992, ONCOGENE, V7, P1127; OCHIENG J, 1991, INVAS METAST, V11, P38; PARTIN AW, 1988, CANCER RES, V48, P6050; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; REIF F, 1965, FUNDAMENTALS STATIST; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSEN EM, 1990, CANCER INVEST, V8, P647, DOI 10.3109/07357909009018936; SA G, 1994, J BIOL CHEM, V269, P3219; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STRACKE ML, 1987, BIOCHEM BIOPH RES CO, V146, P339, DOI 10.1016/0006-291X(87)90730-3; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VARANI J, 1986, INVAS METAST, V6, P335	42	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3519	3526						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970712				2022-12-25	WOS:A1994PT39200014
J	IWASAKI, T; WAKAGI, T; ISOGAI, Y; TANAKA, K; IIZUKA, T; OSHIMA, T				IWASAKI, T; WAKAGI, T; ISOGAI, Y; TANAKA, K; IIZUKA, T; OSHIMA, T			FUNCTIONAL AND EVOLUTIONARY IMPLICATIONS OF A [3FE-4S] CLUSTER OF THE DICLUSTER-TYPE FERREDOXIN FROM THE THERMOACIDOPHILIC ARCHAEON, SULFOLOBUS SP STRAIN-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; AZOTOBACTER-VINELANDII FERREDOXIN; IRON-SULFUR CLUSTERS; THERMUS-THERMOPHILUS; SPECTROSCOPIC CHARACTERIZATION; 7FE FERREDOXIN; HALOBACTERIUM-HALOBIUM; PYROCOCCUS-FURIOSUS; 2-OXOACID-FERREDOXIN OXIDOREDUCTASES; DESULFOVIBRIO-AFRICANUS	The dicluster-type ferredoxin is a key electron carrier in the cytoplasm of the aerobic and thermoacidophilic archaeon, Sulfolobus sp. strain 7, and contains 1 aspartate and 7 cysteine residues as possible ligands to two FeS clusters. The optical, electron paramagnetic resonance (EPR), and cyclic voltammetric studies suggest the presence of one each of [3Fe-4S](1+,0) (-280 mV) and [4Fe-4S](2+,1+) (-530 mV) clusters in the purified Sulfolobus ferredoxin, and the lower potential [4Fe-4S] center was scarcely reducible by excess dithionite even at pH 9. While the Sulfolobus ferredoxin has been known to function as an electron acceptor of 2-oxoacid:ferredoxin oxidoreductase (Kerscher, L., Nowitzki, S., and Oesterhelt, D. (1982) fur. J. Biochem. 128, 223-230), it is not known whether one or both of two clusters is reduced during the steady-state turnover of the enzyme. Here we show by combinations of the optical and EPR spectroscopies that only the higher potential [3Fe-4S] cluster is reduced at the physiological pH during the steady-state turnover of the purified 2-oxoacid:ferredoxin oxidoreductase at 50 degrees C. The functional significance and evolutionary implications of the [3Fe-4S] center in dicluster-type ferredoxins are discussed.	INST PHYS & CHEM RES,BIOPHYS CHEM LAB,WAKO,SAITAMA 35101,JAPAN	RIKEN	IWASAKI, T (corresponding author), TOKYO INST TECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 226,JAPAN.		Wakagi, Takayoshi/AAJ-4145-2021	Iwasaki, Toshio/0000-0001-9562-4649; Isogai, Yasuhiro/0000-0001-6905-4208				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ADMAN ET, 1976, J BIOL CHEM, V251, P3801; AONO S, 1992, J BIOCHEM-TOKYO, V112, P792, DOI 10.1093/oxfordjournals.jbchem.a123977; ARMSTRONG FA, 1988, FEBS LETT, V234, P107, DOI 10.1016/0014-5793(88)81313-9; ARMSTRONG FA, 1992, ADV INORG CHEM, V38, P117, DOI 10.1016/S0898-8838(08)60063-X; ARMSTRONG FA, 1989, BIOCHEM J, V264, P265, DOI 10.1042/bj2640265; BEINERT H, 1983, P NATL ACAD SCI-BIOL, V80, P393, DOI 10.1073/pnas.80.2.393; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; BRUSCHI M, 1988, FEMS MICROBIOL LETT, V54, P155, DOI 10.1111/j.1574-6968.1988.tb02741.x; BUSSE SC, 1992, BIOCHEMISTRY-US, V31, P11952, DOI 10.1021/bi00162a038; CAMMACK R, 1980, FEBS LETT, V118, P271, DOI 10.1016/0014-5793(80)80236-5; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; DANSON MJ, 1989, CAN J MICROBIOL, V35, P58, DOI 10.1139/m89-009; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; FUJII T, 1991, J BIOCHEM, V110, P472, DOI 10.1093/oxfordjournals.jbchem.a123605; FUKUYAMA K, 1989, J MOL BIOL, V210, P383, DOI 10.1016/0022-2836(89)90338-0; GEORGE SJ, 1989, BIOCHEM J, V264, P275, DOI 10.1042/bj2640275; HAGEN WR, 1985, BIOCHIM BIOPHYS ACTA, V828, P369, DOI 10.1016/0167-4838(85)90318-8; HASE T, 1978, J BIOCHEM-TOKYO, V83, P1657, DOI 10.1093/oxfordjournals.jbchem.a132078; HATCHIKIAN EC, 1989, J BACTERIOL, V171, P2384, DOI 10.1128/jb.171.5.2384-2390.1989; HILLE R, 1983, J BIOL CHEM, V258, P3008; JOHNSON MK, 1987, BIOCHIM BIOPHYS ACTA, V911, P81, DOI 10.1016/0167-4838(87)90273-1; JOHNSON MK, 1983, J AM CHEM SOC, V105, P6671, DOI 10.1021/ja00360a022; JOHNSON MK, 1985, J BIOL CHEM, V260, P7368; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; KERSCHER L, 1982, EUR J BIOCHEM, V128, P223; KERSCHER L, 1981, EUR J BIOCHEM, V116, P595, DOI 10.1111/j.1432-1033.1981.tb05377.x; KERSCHER L, 1982, TRENDS BIOCHEM SCI, V7, P371, DOI 10.1016/0968-0004(82)90118-9; KERSCHER L, 1976, EUR J BIOCHEM, V71, P101, DOI 10.1111/j.1432-1033.1976.tb11094.x; KERSCHER L, 1977, FEBS LETT, V83, P197, DOI 10.1016/0014-5793(77)81004-1; KERSCHER L, 1981, EUR J BIOCHEM, V116, P587, DOI 10.1111/j.1432-1033.1981.tb05376.x; Koike M, 1976, Adv Biophys, P187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALKIN R, 1973, IRON SULPHUR PROTEIN, V2, P1; MINAMI Y, 1985, J BIOCHEM-TOKYO, V97, P745, DOI 10.1093/oxfordjournals.jbchem.a135114; MOLL R, 1988, FEBS LETT, V232, P359, DOI 10.1016/0014-5793(88)80769-5; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; OHNISHI T, 1980, J BIOL CHEM, V255, P345; ONATE YA, 1989, J BIOL CHEM, V264, P18386; ORMEJOHNSON WH, 1973, IRON SULFUR PROTEINS, V2, P195; PARK JB, 1991, J BIOL CHEM, V266, P19351; PFEIFER F, 1993, MOL GEN GENET, V239, P66, DOI 10.1007/BF00281602; PLAGA W, 1992, EUR J BIOCHEM, V205, P391, DOI 10.1111/j.1432-1033.1992.tb16792.x; SATO S, 1981, BIOCHIM BIOPHYS ACTA, V668, P277, DOI 10.1016/0005-2795(81)90035-0; SHEN BH, 1993, J BIOL CHEM, V268, P25928; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT CD, 1993, J BIOL CHEM, V268, P25920; TROWER MK, 1990, BIOCHIM BIOPHYS ACTA, V1037, P281, DOI 10.1016/0167-4838(90)90026-C; TROWER MK, 1990, BIOCHIM BIOPHYS ACTA, V1037, P290, DOI 10.1016/0167-4838(90)90027-D; WAKAGI T, 1986, SYST APPL MICROBIOL, V7, P342; WAKAO H, 1987, J BIOCHEM, V102, P255, DOI 10.1093/oxfordjournals.jbchem.a122049; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	54	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29444	29450						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961925				2022-12-25	WOS:A1994PU28400023
J	SHAEFFER, JR				SHAEFFER, JR			HETEROGENEITY IN THE STRUCTURE OF THE UBIQUITIN CONJUGATES OF HUMAN ALPHA-GLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEOLYSIS; MULTIUBIQUITIN CHAIN; PROTEIN LIGASE; RECOGNITION; MECHANISM; CLEAVAGE; SYSTEM	Only monoubiquitinated (and to a much lesser extent diubiquitinated) I-125-alpha globin is observed as a conjugated intermediate in the ATP- and ubiquitin (Ub)-dependent proteolysis of I-122-alpha globin catalyzed by an unfractionated reticulocyte lysate (Shaeffer, J. R. (1994) J. Biol. Chem. 269, 22205-22210). A monoubiquitinated with a dilute acid reagent to selectively cleave the I-125-alpha globin moiety between residues 94 (Asp) and 95 (Pro). Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the resulting polypeptides showed that the Ub(1)-alpha conjugate consisted of a mixture of molecules in which 57% had Ub attached to the amino-terminal two-thirds and 43% had Ub attached to the carboxyl-terminal one-third of the I-125-alpha globin monomer. This amino- to carboxyl-terminal region ubiquitination ratio was essentially unchanged when a Ub(1)-alpha conjugate intermediate, pulse-labeled for 15 min in the presence of ubiquitin aldehyde to inhibit disassembly, was analyzed after (a) a 2-h chase incubation with excess nonradioactive alpha globin or (b) isolation and incubation separately as a proteolysis substrate. Similar analysis of the diubiquitinated I-125-alpha globin (Ub(2)-alpha) conjugate molecules showed that, after pulse labeling, 58% were diubiquitinated within the amino-terminal two-thirds and 42% were monoubiquitinated within both amino- and carboxyl-terminal regions of the I-125-alpha globin moiety (a small amount of molecules diubiquitinated within the carboxyl-terminal region may also be present) and that the relative amounts of these molecular types changed little, if any, during the chase incubation. This invariance in the amino- to carboxyl-terminal region ubiquitination ratio during degradation of the Ub(1)-alpha and Ub(2)-alpha conjugates suggests that I-125-alpha globin molecules ubiquitinated within either the amino- or carboxyl-terminal regions were both intermediates in the proteolysis of the unconjugated substrate. This heterogeneous pattern of Ub conjugation may also occur during the proteolysis of other long-lived intracellular proteins.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	SHAEFFER, JR (corresponding author), HARVARD UNIV, SCH MED, CTR BLOOD RES, 800 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NHLBI NIH HHS [HL29379] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029379] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANERJEE A, 1993, J BIOL CHEM, V268, P5668; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V5, pD56; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; FRASER KJ, 1972, BIOCHEMISTRY-US, V11, P4974, DOI 10.1021/bi00776a016; Gros E., 1967, METHOD ENZYMOL, V11, P238; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; PICKART CM, 1988, J BIOL CHEM, V263, P15076; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; Roholt O A, 1972, Methods Enzymol, V25, P438, DOI 10.1016/S0076-6879(72)25039-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAEFFER JR, 1988, J BIOL CHEM, V263, P13663; SHAEFFER JR, 1994, J BIOL CHEM, V269, P22205; SOKOLIK CW, 1992, J BIOL CHEM, V267, P1067; SOKOLIK CW, 1991, J BIOL CHEM, V266, P9100; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K	25	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29530	29536						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961937				2022-12-25	WOS:A1994PU28400036
J	BIGUET, C; WAKASUGI, N; MISHAL, Z; HOLMGREN, A; CHOUAIB, S; TURSZ, T; WAKASUGI, H				BIGUET, C; WAKASUGI, N; MISHAL, Z; HOLMGREN, A; CHOUAIB, S; TURSZ, T; WAKASUGI, H			THIOREDOXIN INCREASES THE PROLIFERATION OF HUMAN B-CELL LINES THROUGH A PROTEIN-KINASE C-DEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-DERIVED FACTOR; PHOSPHATIDYLCHOLINE BREAKDOWN; PHOSPHOLIPASE-C; REDUCTION; PHOSPHOINOSITIDE; DIACYLGLYCEROL; INVOLVEMENT; FIBROBLASTS; DISULFIDES; ACTIVATION	Thioredoxin (Trx) catalyzes thiol-disulfide oxidoreductions. We and others recently showed that human Trx could function as an autocrine growth factor for human lymphoid cells immortalized by the human T-lymphotropic virus type I or the Epstein-Barr virus. Here we report that reduced Trx from Escherichia coli generated by NADPH and thioredoxin reductase increases the proliferation of an Epstein-barr virus((+))-B cell line 1G8, which constitutively produces low amounts of human Trx. This proliferative effect involved the activation of protein kinase C through its translocation to the membrane. Staurosporin and calphostin C, two inhibitors of protein kinase C, but not of H8, a protein kinase A inhibitor, were able to block Trx-dependent proliferation. The addition of Trx to 1G8 cells resulted in the formation of inositol 1,4,5-triphosphate and sn-1,2-diacylglycerol by a phosphoinositide-specific phospholipase C, as well as increased free calcium concentration. Diacylglycerol showed a biphasic increase; the first phase, corresponding to an early peak (30 s) of inositol 1,4,5-triphosphate and a second larger, prolonged phase. The second phase was inhibited by propranolol, a specific inhibitor of phosphohydrolase, indicating that it is most likely derived from phosphatidylcholine hydrolysis by the sequential action of phospholipase D and phosphatidic acid phosphohydrolase. Our data suggest that enhanced phosphoinositide-specific phospholipase C activity induced by the dithiol form of Trx in 1G8 cells is associated to protein kinase C activation, and thus plays a role in the permanent growth of Epstein-Barr virus-infected B cells.	KAROLINSKA INST, MED NOBEL INST BIOCHEM, S-17177 STOCKHOLM, SWEDEN; INST GUSTAVE ROUSSY, BIOL TUMEURS HUMAINES LAB, CNRS, URA 1156, F-94805 VILLEJUIF, FRANCE; BANYU PHARMACEUT CO LTD, TSUKUBA RES INST, TSUKUBA, IBARAKI 30033, JAPAN; CNRS, CYTOMETRIE LAB, F-94805 VILLEJUIF, FRANCE; NATL CANC CTR, RES INST, DIV GENET, CHUO KU, TOKYO 104, JAPAN	Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Merck & Company; Novartis; Centre National de la Recherche Scientifique (CNRS); National Cancer Center - Japan			Chouaib, Salem/F-7939-2016					AYO SH, 1991, AM J PHYSIOL, V261, pF571, DOI 10.1152/ajprenal.1991.261.4.F571; BISHOP WR, 1992, ADV ENZYME REGUL, V32, P177; CARLSSON M, 1989, EUR J IMMUNOL, V19, P913, DOI 10.1002/eji.1830190519; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DITRAPANI G, 1991, HUM REPROD, V6, P450, DOI 10.1093/oxfordjournals.humrep.a137357; EXTON JH, 1992, CIBA F SYMP, V164, P36; EXTON JH, 1991, MOL CELL BIOCHEM, V104, P81; EXTON JH, 1990, J BIOL CHEM, V265, P1; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FU T, 1992, BIOCHEM J, V283, P347, DOI 10.1042/bj2830347; GO M, 1987, BIOCHEM BIOPH RES CO, V144, P598; GRIPPO JF, 1983, J BIOL CHEM, V258, P3658; GROSS JL, 1990, BIOCHEM PHARMACOL, V40, P343, DOI 10.1016/0006-2952(90)90697-J; HAN JK, 1992, J CELL BIOL, V116, P147, DOI 10.1083/jcb.116.1.147; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HSIEH HJ, 1992, J CELL PHYSIOL, V150, P552, DOI 10.1002/jcp.1041500316; LAZARUS AH, 1990, J IMMUNOL, V144, P4147; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; MITSUI A, 1992, BIOCHEM BIOPH RES CO, V186, P1220, DOI 10.1016/S0006-291X(05)81536-0; OBLONG JE, 1994, J BIOL CHEM, V269, P11714; PAI JK, 1991, CELL REGUL, V2, P897, DOI 10.1091/mbc.2.11.897; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; ROZELL B, 1988, EUR J CELL BIOL, V46, P470; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; SCHALLREUTER KU, 1986, BIOCHEM BIOPH RES CO, V136, P630, DOI 10.1016/0006-291X(86)90487-0; SHIMAMOTO Y, 1993, AM J PHYSIOL, V264, pH1300, DOI 10.1152/ajpheart.1993.264.4.H1300; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; SUZUKI Y, 1992, J IMMUNOL, V149, P207; TAGAYA Y, 1988, J IMMUNOL, V140, P2614; TONISSEN KF, 1991, GENE, V102, P221, DOI 10.1016/0378-1119(91)90081-L; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; YODOI J, 1991, ADV CANCER RES, V57, P381; YOUNES A, 1992, J BIOL CHEM, V267, P842	38	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28865	28870						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961846				2022-12-25	WOS:A1994PU16800056
J	HYNDMAN, DJ; MILGROM, YM; BRAMHALL, EA; CROSS, RL				HYNDMAN, DJ; MILGROM, YM; BRAMHALL, EA; CROSS, RL			NUCLEOTIDE-BINDING SITES ON ESCHERICHIA-COLI F1-ATPASE - SPECIFICITY OF NONCATALYTIC SITES AND INHIBITION AT CATALYTIC SITES BY MGADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; BEEF-HEART F1-ATPASE; TIGHTLY BOUND ADP; ADENINE-NUCLEOTIDE; ATP HYDROLYSIS; EPSILON-SUBUNIT; BETA-SUBUNIT; F1 ATPASE; CHLOROPLAST ATPASE; COUPLING FACTOR-F1	Nucleotide-depleted EcF(1) binds a maximum of two GTP, ATP, or ADP at noncatalytic sites, whereas all three sites can only be filled by a combination of nucleoside di- and triphosphates. MgPPi prevents binding of GTP and significantly slows ATP binding, suggesting that noncatalytic sites also bind PPi. No binding of GDP at noncatalytic sites could be detected. The slow rate of GTP dissociation from noncatalytic sites (t(1/2) = 175 min) is increased 2-8-fold by EDTA, MgPPi, MgADP, or EDTA/ATP, but 23-fold by conditions for ATP hydrolysis. ATP hydrolysis by EcF(1), depleted of both its inhibitory epsilon-subunit and endogenous nucleotides, shows a burst of activity. However, it shows a lag if preincubated with MgADP but not when preincubated with Mg2+ alone. For epsilon-depleted EcF(1) containing endogenous inhibitory ADP, preincubation with an ATP-regenerating system results in a burst of activity, whereas the control shows a lag. This same enzyme form shows significant inhibition with increasing concentrations of Mg2+ during ATP hydrolysis but lesser levels of inhibition when other NTP substrates are used. With the five-subunit enzyme, increasing amounts of azide cause an increase in the level of inhibition with a corresponding increase in amount of bound nucleotide resistant to rapid chase. Azide-trappable nucleotide is bound at catalytic sites as shown by covalent incorporation of 2-azido-ADP. The results suggest that ligand specificity may not be a reliable means of distinguishing between catalytic and noncatalytic sites and that MgADP inhibition should be taken into account in the kinetic analysis of EcF(1) mutants.			HYNDMAN, DJ (corresponding author), SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA.				NIGMS NIH HHS [GM 23152] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023152, R01GM023152] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; BEHARRY S, 1992, BIOCHEMISTRY-US, V31, P11472, DOI 10.1021/bi00161a027; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CHERNYAK BV, 1992, ARCH BIOCHEM BIOPHYS, V295, P247, DOI 10.1016/0003-9861(92)90514-W; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DOWNIE JA, 1980, J BACTERIOL, V143, P8, DOI 10.1128/JB.143.1.8-17.1980; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1980, J BIOL CHEM, V255, P113; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GUERRERO KJ, 1990, FEBS LETT, V270, P187, DOI 10.1016/0014-5793(90)81264-O; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V504, P364, DOI 10.1016/0005-2728(78)90060-9; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V463, P245, DOI 10.1016/0304-4173(78)90002-2; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KANAZAWA H, 1980, J BIOCHEM-TOKYO, V88, P695, DOI 10.1093/oxfordjournals.jbchem.a133022; KIRONDE FAS, 1986, J BIOL CHEM, V261, P2544; KIRONDE FAS, 1987, J BIOL CHEM, V262, P3488; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; MELESE T, 1985, J BIOL CHEM, V260, P5398; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; MINKOV IB, 1979, BIOCHEM BIOPH RES CO, V89, P1300, DOI 10.1016/0006-291X(79)92150-8; MUNEYUKI E, 1991, BIOCHIM BIOPHYS ACTA, V1058, P304, DOI 10.1016/S0005-2728(05)80251-8; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; PAGAN J, 1990, FEBS LETT, V273, P147, DOI 10.1016/0014-5793(90)81071-U; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SENDA M, 1983, ARCH BIOCHEM BIOPHYS, V220, P398, DOI 10.1016/0003-9861(83)90429-0; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SENIOR AE, 1980, J BIOL CHEM, V255, P7211; SENIOR AE, 1979, BIOCHEM J, V180, P103, DOI 10.1042/bj1800103; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; VASILYEVA EA, 1980, BIOCHEM J, V188, P807, DOI 10.1042/bj1880807; WEBER J, 1994, J BIOL CHEM, V269, P11261; WISE JG, 1981, J BIOL CHEM, V256, P383; WISE JG, 1987, FEBS LETT, V223, P395, DOI 10.1016/0014-5793(87)80326-5; WOOD JM, 1987, J BIOL CHEM, V262, P2180; XUE ZX, 1987, FEBS LETT, V223, P391, DOI 10.1016/0014-5793(87)80325-3; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027; [No title captured]	56	80	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28871	28877						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961847				2022-12-25	WOS:A1994PU16800057
J	PARK, IK; DEPAOLIROACH, AA				PARK, IK; DEPAOLIROACH, AA			DOMAINS OF PHOSPHATASE INHIBITOR-2 INVOLVED IN THE CONTROL OF THE ATP-MG-DEPENDENT PROTEIN PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CASEIN KINASE-II; GLYCOGEN-SYNTHASE KINASE-3; PHOSPHOPROTEIN PHOSPHATASE; CELLULAR-REGULATION; PHOSPHORYLASE-PHOSPHATASE; SUBUNIT STRUCTURE; AMINO-ACID; ACTIVATION; MECHANISM	Inhibitor-2 (I-2) inhibits the free catalytic subunit of type 1 phosphatase (CS1) and controls the cyclic inactivation/activation of CS1 in the ATP-Mg-dependent protein phosphatase complex. We report here the effect of mutations on these two properties of I-2. Substitution of Thr-72 with Ala, Asp, or Glu generated complexes with CS1 that could not be activated. Mutation of Ser-86 did not affect activation by glycogen synthase kinase-3 (GSK-3) alone but impaired synergistic activation by casein kinase II and GSK-3. Mutations in the region between Thr-72 and Ser-86 did not alter the inhibitory potency of I-2 but prevented complete inactivation of CS1. A mutant without the 35 NH2-terminal residues exhibited an IC50 for CS1 200-fold higher than that of wild-type I-2. However, it formed an inactive phosphatase complex with CS1, which was activated by GSK-3. A mutant with the 59 COOH-terminal residues deleted retained full inhibitory activity and formed an inactive complex that could not be activated by GSK-3. We conclude that the NH2-terminal region of I-2 is involved in inhibition, that the sequence between Thr-72 and Ser-86 is necessary for the conversion of CS1 from an active to an inactive conformation, and that the COOH terminus is required for activation by GSK-3. Thus, different functional domains of I-2 may interact with distinct regions of CS1.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36569] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P288, DOI 10.1016/0167-4838(84)90034-7; AITKEN A, 1982, FEBS LETT, V147, P54, DOI 10.1016/0014-5793(82)81010-7; AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BALLOU LM, 1983, BIOCHEMISTRY-US, V22, P3393, DOI 10.1021/bi00283a014; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DePaoli-Roach A A, 1985, FEBS Lett, V183, P423; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DEPAOLIROACH AA, 1989, ADV PROTEIN PHOSPHAT, V5, P479; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FIOL CJ, 1992, J CELL BIOCH A S, V16, P97; FOULKES JG, 1980, EUR J BIOCHEM, V105, P195, DOI 10.1111/j.1432-1033.1980.tb04489.x; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOLMES CFB, 1987, BIOCHIM BIOPHYS ACTA, V929, P208, DOI 10.1016/0167-4889(87)90178-9; HOLMES CFB, 1986, BIOCHIM BIOPHYS ACTA, V870, P408, DOI 10.1016/0167-4838(86)90248-7; HOLMES CFB, 1986, EUR J BIOCHEM, V155, P173, DOI 10.1111/j.1432-1033.1986.tb09473.x; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; JURGENSEN S, 1984, J BIOL CHEM, V259, P5864; JURGENSEN S, 1986, FED PROC, V45, P1878; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1988, BIOCHEM BIOPH RES CO, V150, P197, DOI 10.1016/0006-291X(88)90505-0; LI HC, 1985, J BIOL CHEM, V260, P6416; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PARK IK, 1994, J BIOL CHEM, V269, P944; PICKING WD, 1991, BIOCHEMISTRY-US, V30, P10280, DOI 10.1021/bi00106a028; RESINK TJ, 1983, EUR J BIOCHEM, V133, P455, DOI 10.1111/j.1432-1033.1983.tb07485.x; ROACH P, 1985, J BIOL CHEM, V260, P6314; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANG PM, 1991, J BIOL CHEM, V266, P15782; TUNG HYL, 1984, EUR J BIOCHEM, V145, P57, DOI 10.1111/j.1432-1033.1984.tb08521.x; VANDENHEEDE JR, 1985, J BIOL CHEM, V260, P512; VANDENHEEDE JR, 1981, J BIOL CHEM, V256, P5894; VANDENHEEDE JR, 1989, ADV PROT PHOSPHATASE, V5, P19; VANDENHEEDE JR, 1985, ADV PROT PHOSPHATASE, V1, P87; VILLAMORUZZI E, 1984, J BIOL CHEM, V259, P5857; WANG QM, 1994, BIOCHEMISTRY-US, V33, P143, DOI 10.1021/bi00167a018; YANG SD, 1981, J BIOL CHEM, V256, P231; YANG SD, 1980, J BIOL CHEM, V255, P1759; YANG SD, 1981, FEBS LETT, V26, P57	58	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28919	28928						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961854				2022-12-25	WOS:A1994PU16800064
J	SHIRK, RA; ELISEN, MGLM; MEIJERS, JCM; CHURCH, FC				SHIRK, RA; ELISEN, MGLM; MEIJERS, JCM; CHURCH, FC			ROLE OF THE H-HELIX IN HEPARIN-BINDING TO PROTEIN-C INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-3; COFACTOR-II; ANTITHROMBIN-III; DERMATAN SULFATE; THROMBIN; PLASMA; INACTIVATION; PURIFICATION; SITE; QUANTITATION	Protein C inhibitor (PCI) is a plasma serine proteinase inhibitor (serpin) that is a major physiological regulator of activated protein C. inhibition of its target proteinase is accelerated by heparin in a reaction that involves the binding of both inhibitor and proteinase to heparin to form a ternary complex. This study was undertaken to understand the role of the H helix region (residues 264-278) of PCI in heparin binding and used (i) a recombinant truncated PCI fusion protein of the first 294 residues, (ii) H helix synthetic peptides containing single Arg/Lys --> Glu substitutions, and (iii) site-directed Ala mutagenesis of 4 basic residues (Arg-269, Lys-270, Lys-276, and Lys-277) in the H helix region of full-length recombinant PCI (rPCI) expressed in Baculovirus. The PCI fusion protein interfered in heparin-accelerated PCI-proteinase inhibition reactions, and it bound to heparin Sepharose. Compared to the wild-type PCI fusion protein, deletion of the H helix from the fusion protein resulted in a reduction of both heparin-Sepharose binding and the ability to compete for heparin during PCI-proteinase inhibition reactions. Competition assays with H helix synthetic peptides revealed that the R269E altered peptide was the least effective at blocking heparin-catalyzed PCI-proteinase inhibition reactions. Compared with full-length active wild-type rPCI, R269A: K270A and K276A:K277A rPCI both had reduced heparin-Sepharose binding, but only R269A:K270A rPCI showed a loss of heparin-accelerated proteinase inhibition for both activated protein C and thrombin. We conclude that a major heparin-binding site of PCI is the H helix, unlike its heparin binding serpin homologues an tithrombin and heparin cofactor II, which bind heparin primarily through the D helix.	UNIV N CAROLINA,SCH MED,DEPT PATHOL,DIV HEMATOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599; UNIV UTRECHT HOSP,DEPT HEMATOL,3508 GA UTRECHT,NETHERLANDS	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Utrecht University; Utrecht University Medical Center			Meijers, J.C.M./S-5981-2019	Meijers, J.C.M./0000-0002-4198-6780	NHLBI NIH HHS [HL-06350] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLINDER MA, 1989, J BIOL CHEM, V264, P5128; BLINDER MA, 1990, J BIOL CHEM, V265, P286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; ESPANA F, 1991, THROMB RES, V64, P309, DOI 10.1016/0049-3848(91)90002-E; ESPANA F, 1993, THROMB HAEMOSTASIS, V70, P989; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; GRIFFITH MJ, 1983, P NATL ACAD SCI-BIOL, V80, P5460, DOI 10.1073/pnas.80.18.5460; HEEB MJ, 1987, J BIOL CHEM, V262, P15813; HERMANS JM, 1994, BIOCHEMISTRY-US, V33, P5440, DOI 10.1021/bi00184a012; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANE DA, 1992, BLOOD COAGUL FIBRIN, V3, P315, DOI 10.1097/00001721-199206000-00012; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P4231, DOI 10.1021/bi00412a005; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; OLSON ST, 1988, J BIOL CHEM, V263, P1698; PETERSON CB, 1987, J BIOL CHEM, V262, P7559; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1989, THROMB RES, V53, P595, DOI 10.1016/0049-3848(89)90149-7; PRATT CW, 1993, BLOOD COAGUL FIBRIN, V4, P479, DOI 10.1097/00001721-199306000-00013; PRATT CW, 1992, J BIOL CHEM, V267, P8789; PRATT CW, 1991, SEMIN HEMATOL, V28, P3; RAGG H, 1990, J BIOL CHEM, V265, P5211; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUMP DC, 1986, J BIOL CHEM, V261, P2759; SUZUKI K, 1989, THROMB HAEMOSTASIS, V61, P337; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1984, J BIOCHEM, V95, P187, DOI 10.1093/oxfordjournals.jbchem.a134583; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; WHINNA HC, 1991, J BIOL CHEM, V266, P8129	33	56	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28690	28695						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961820				2022-12-25	WOS:A1994PU16800029
J	SOARES, H; PENQUE, D; MOUTA, C; RODRIGUESPOUSADA, C				SOARES, H; PENQUE, D; MOUTA, C; RODRIGUESPOUSADA, C			A TETRAHYMENA ORTHOLOGUE OF THE MOUSE CHAPERONIN SUBUNIT CCT-GAMMA AND ITS COEXPRESSION WITH TUBULIN DURING CILIA RECOVERY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-COMPLEX POLYPEPTIDE-1; MICROTUBULE-ASSOCIATED PROTEINS; AMINO-ACID-SEQUENCE; BETA-TUBULIN; MOLECULAR-CLONING; ALPHA-TUBULIN; MESSENGER-RNA; CYTOPLASMIC CHAPERONIN; GENE-EXPRESSION; CODON USAGE	A Tetrahymena pyriformis gene orthologue to the mouse CCT gamma gene has been cloned and sequenced. The coding region of this gene, named TpCCT gamma, is interrupted by six introns and codes for a protein of 559 amino acid residues. This protein shares a 57.6% identity with the mouse CCT gamma protein whereas in average a 30% identity was found with CCT alpha proteins from mammalian to yeast. The expression of this gene was investigated by Northern blot hybridization in Tetrahymena exponentially growing cells and cells during cilia recovery. The TpCCT gamma gene is expressed producing a unique transcript of 2.1 kilobases. A relevant aspect of our findings is the coordinated response of TpCCT gamma and tubulin genes to cilia regeneration. TpCCT gamma and tubulin transcripts reached higher levels between 45-120 min of reciliation compared to those found in exponentially growing cells. These high levels could be the result of the increase in apparent transcription rates detected at 60 min of reciliation. We also observed that TpCCT gamma transcripts are not increased after exposure of Tetrahymena cells to a heat-shock (28 --> 34 degrees C). Our results seem to indicate an important role of this gene in the differentiation process of ciliogenesis.	INST GULBENKIAN CIENCIAS, GENET MOLEC LAB, P-2781 OEIRAS, PORTUGAL	Instituto Gulbenkian de Ciencia			Penque, Deborah/F-4830-2013; Soares, Helena/G-3065-2010	Penque, Deborah/0000-0002-4527-7148; Soares, Helena/0000-0001-6180-7041; Rodrigues-Pousada, Claudina/0000-0002-5075-3639				AIZAWA H, 1990, J BIOL CHEM, V265, P13849; BARAHONA I, 1985, FEBS LETT, V188, P227, DOI 10.1016/0014-5793(85)80377-X; BARAHONA I, 1988, J MOL BIOL, V202, P365, DOI 10.1016/0022-2836(88)90271-9; BRUNK CF, 1990, NUCLEIC ACIDS RES, V18, P323, DOI 10.1093/nar/18.2.323; COIAS R, 1988, EUR J BIOCHEM, V175, P467, DOI 10.1111/j.1432-1033.1988.tb14218.x; CSANK C, 1992, J BIOL CHEM, V267, P4592; CSANK C, 1990, NUCLEIC ACIDS RES, V18, P5133, DOI 10.1093/nar/18.17.5133; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DUPUIS P, 1992, EMBO J, V11, P3713, DOI 10.1002/j.1460-2075.1992.tb05456.x; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAERTIG J, 1993, CELL MOTIL CYTOSKEL, V25, P243, DOI 10.1002/cm.970250305; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GUTTMAN SD, 1979, CELL, V17, P307, DOI 10.1016/0092-8674(79)90156-9; HOROWITZ S, 1985, P NATL ACAD SCI USA, V82, P2452, DOI 10.1073/pnas.82.8.2452; HOROWITZ S, 1987, NUCLEIC ACIDS RES, V15, P141, DOI 10.1093/nar/15.1.141; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; JOLI EC, 1994, BIOCHIM BIOPHYS ACTA, V1217, P224; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KIRCHHOFF C, 1990, NUCLEIC ACIDS RES, V18, P4247, DOI 10.1093/nar/18.14.4247; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; KUCHINO Y, 1985, P NATL ACAD SCI USA, V82, P4758, DOI 10.1073/pnas.82.14.4758; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LOVE HD, 1988, MOL CELL BIOL, V8, P427, DOI 10.1128/MCB.8.1.427; MAERCKER C, 1994, GENE, V141, P147, DOI 10.1016/0378-1119(94)90147-3; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; MIKLOS D, 1994, P NATL ACAD SCI USA, V91, P2743, DOI 10.1073/pnas.91.7.2743; MORI M, 1992, GENE, V122, P381, DOI 10.1016/0378-1119(92)90231-D; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEVES AM, 1991, MOL GEN GENET, V230, P186, DOI 10.1007/BF00290667; NEVES AM, 1991, J DNA SEQUENCING MAP, V2, P173; RODRIGUESPOUSAD.C, 1979, EUR J BIOCHEM, V56, P117; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHULMAN IG, 1991, MOL CELL BIOL, V11, P166, DOI 10.1128/MCB.11.1.166; SHARP PM, 1989, NUCLEIC ACIDS RES, V17, P5029, DOI 10.1093/nar/17.13.5029; SOARES H, 1991, EUR J BIOCHEM, V197, P291, DOI 10.1111/j.1432-1033.1991.tb15910.x; SOARES H, 1993, J BIOL CHEM, V268, P16623; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STARGELL LA, 1994, MOL CELL BIOL, V14, P723, DOI 10.1128/MCB.14.1.723; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TONDRAVI MM, 1990, MOL CELL BIOL, V10, P6091, DOI 10.1128/MCB.10.11.6091; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; URSIC D, 1988, GENE, V68, P267, DOI 10.1016/0378-1119(88)90029-7; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; URSIC D, 1992, NATURE, V356, P392; VOHRA GB, 1992, J MOL EVOL, V34, P383, DOI 10.1007/BF00162995; WICHE G, 1991, INT REV CYTOL, V124, P217; WILLISON KR, 1986, CELL, V44, P727, DOI 10.1016/0092-8674(86)90839-1; WITT I, 1993, EMBO J, V12, P1201, DOI 10.1002/j.1460-2075.1993.tb05761.x; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZEFF RA, 1987, FOCUS, V9, P1	56	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29299	29307						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961900				2022-12-25	WOS:A1994PU16800113
J	BERGWERFF, AA; VANDAM, GJ; ROTMANS, JP; DEELDER, AM; KAMERLING, JP; VLIEGENTHART, JFG				BERGWERFF, AA; VANDAM, GJ; ROTMANS, JP; DEELDER, AM; KAMERLING, JP; VLIEGENTHART, JFG			THE IMMUNOLOGICALLY REACTIVE PART OF IMMUNOPURIFIED CIRCULATING ANODIC ANTIGEN FROM SCHISTOSOMA-MANSONI IS A THREONINE-LINKED POLYSACCHARIDE CONSISTING OF -]6)-(BETA-D-GLCPA-(1-]3))-BETA-D-GALPNAC-(1-] REPEATING UNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHODIC ANTIGEN; SYNTHESIZES GLYCOPROTEINS; CARBOHYDRATE CHAINS; ANTIBODY-RESPONSE; LEWIS-X; OLIGOSACCHARIDES; GUT; PARASITE; PURIFICATION; SPECTRA	The gut-associated excretory antigen CAA (circulating anodic antigen) from adult Schistosoma mansoni worms was isolated by immunoaffinity chromatography. Amino acid analysis following alkaline borohydride treatment indicated that CAA is a glycoprotein, O-glycosylated at Thr. The primary structure of the released O-glycan moiety was investigated by one- and two-dimensional, homo- and heteronuclear H-1 and C-13 NMR spectroscopy. It was found that the major carbohydrate chains have a novel polysaccharide structure, consisting of a branched disaccharide repeating unit containing 2-acetamido-2-deoxy-beta-D-galactopyranose (beta-D-Galp-NAc) and beta-D-glucopyranuronic acid (beta-D-GlcpA). [GRAPHICS] The major antigenic character of CAA arises from this novel polysaccharide, which was shown to be an absolutely specific diagnostic marker in schistosomiasis. The cross-reactivity of CAA with anti-CCA (circulating cathodic antigen) monoclonal antibodies is caused by the presence of a small amount of O-linked CCA-poly-Lewis x carbohydrate chains on the CAA protein chain.	UNIV UTRECHT, BIJVOET CTR,DEPT BIOORGAN CHEM, 3508 TB UTRECHT, NETHERLANDS; LEIDEN UNIV, FAC MED,DEPT PARASITOL, 2300 RC LEIDEN, NETHERLANDS	Utrecht University; Leiden University; Leiden University - Excl LUMC			Bergwerff, Aldert/B-9727-2008	Bergwerff, Aldert/0000-0001-5325-7385				ANDERSON R M, 1991; ARNON R, 1990, ISRAEL J MED SCI, V26, P404; BHAVANANDAN VP, 1993, GLYCONJUGATES COMPOS, P167; CARLIER Y, 1978, ANN INST PASTEUR IMM, VC129, P811; CARLIER Y, 1980, J IMMUNOL, V124, P2442; CHAPPELL CL, 1988, AM J TROP MED HYG, V39, P66, DOI 10.4269/ajtmh.1988.39.66; COLSON P, 1976, CARBOHYD RES, V47, P1, DOI 10.1016/S0008-6215(00)83543-0; DEBAAIJ JA, 1986, SCI TOOLS, V33, P17; DEELDER AM, 1989, AM J TROP MED HYG, V40, P268, DOI 10.4269/ajtmh.1989.40.268; DEELDER AM, 1980, EXP PARASITOL, V50, P16, DOI 10.1016/0014-4894(80)90004-1; DEELDER AM, 1976, EXP PARASITOL, V40, P189, DOI 10.1016/0014-4894(76)90081-3; DEELDER AM, 1989, T ROY SOC TROP MED H, V83, P364, DOI 10.1016/0035-9203(89)90506-3; DEJONGE N, 1990, T ROY SOC TROP MED H, V84, P815, DOI 10.1016/0035-9203(90)90094-U; DEJONGE N, 1991, T ROY SOC TROP MED H, V85, P756, DOI 10.1016/0035-9203(91)90446-6; DUNNE DW, 1990, PARASITOL TODAY, V6, P45, DOI 10.1016/0169-4758(90)90068-F; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; GUARD HE, 1992, CARBOHYD RES, V235, P41, DOI 10.1016/0008-6215(92)80077-E; HARD K, 1991, FEBS LETT, V287, P108, DOI 10.1016/0014-5793(91)80027-Z; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; Kamerling J. P., 1989, CLIN BIOCH PRINCIPLE, P175; LEVERY SB, 1992, J BIOL CHEM, V267, P5542; LIGHTOWLERS MW, 1988, PARASITOLOGY, V96, pS123, DOI 10.1017/S0031182000086017; MATSUMOTO Y, 1988, NATURE, V333, P76, DOI 10.1038/333076a0; MAZZA G, 1990, PARASITE IMMUNOL, V12, P529, DOI 10.1111/j.1365-3024.1990.tb00986.x; MILLER RL, 1992, BRIT MED J, V304, P555, DOI 10.1136/bmj.304.6826.555; NASH TE, 1977, J IMMUNOL, V119, P1627; NASH TE, 1978, AM J TROP MED HYG, V27, P944, DOI 10.4269/ajtmh.1978.27.944; NASH TE, 1985, AM J TROP MED HYG, V34, P236, DOI 10.4269/ajtmh.1985.34.236; NASH TE, 1974, AM J TROP MED HYG, V23, P1085, DOI 10.4269/ajtmh.1974.23.1085; NASH TE, 1978, AM J TROP MED HYG, V27, P938, DOI 10.4269/ajtmh.1978.27.939; NYAME K, 1987, J BIOL CHEM, V262, P7990; NYAME K, 1988, MOL BIOCHEM PARASIT, V28, P265, DOI 10.1016/0166-6851(88)90011-4; NYAME K, 1989, J BIOL CHEM, V264, P3235; NYAME K, 1988, J PARASITOL, V74, P562, DOI 10.2307/3282171; OKOTKOTBER BM, 1978, ANN TROP MED PARASIT, V72, P256; RUPPEL A, 1985, CLIN EXP IMMUNOL, V62, P499; SHER A, 1989, PARASITOLOGY, V98, pS61, DOI 10.1017/S0031182000072255; SISSON TH, 1990, J IMMUNOL METHODS, V127, P215, DOI 10.1016/0022-1759(90)90071-3; SRIVATSAN J, 1992, GLYCOBIOLOGY, V2, P445, DOI 10.1093/glycob/2.5.445; SRIVATSAN J, 1992, J BIOL CHEM, V267, P20196; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; TSANG VCW, 1991, J IMMUNOL METHODS, V138, P291, DOI 10.1016/0022-1759(91)90178-I; VANDAM GJ, 1993, EUR J IMMUNOL, V23, P2807, DOI 10.1002/eji.1830231113; VANDAM GJ, 1994, EUR J BIOCHEM, V225, P467, DOI 10.1111/j.1432-1033.1994.00467.x; VANLIESHOUT L, 1992, AM J TROP MED HYG, V47, P463, DOI 10.4269/ajtmh.1992.47.463; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1	46	75	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31510	31517						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989318				2022-12-25	WOS:A1994PX30300031
J	BOKOCH, GM; BOHL, BP; CHUANG, TH				BOKOCH, GM; BOHL, BP; CHUANG, TH			GUANINE-NUCLEOTIDE EXCHANGE REGULATES MEMBRANE TRANSLOCATION OF RAC/RHO GTP-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; NEUTROPHIL NADPH OXIDASE; RHO GDI; ACTIVATION; P21; PURIFICATION; RAC-2	GTP-binding proteins of the Rho family are maintained as cytosolic complexes with RhoGDI in resting cells, but are released and translocate to the membrane during the course of cell activation, Membrane association of Rac/Rho/CDC42 was specifically induced by GTP analogs and required a heat- and trypsin-labile membrane component. Translocation was associated with the release of Rho family proteins from RhoGDI, but such release did not occur in the absence of membranes, nor was release in the absence of guanosine 5'-O-(thio-triphosphate) (GTP gamma S) sufficient for membrane association, Membrane binding was correlated with exchange of GTP gamma S for GDP on Rac, and only GTP gamma S-bound Rac became membrane localized. We propose that translocation of Rac and other members of the Rho family is controlled by membrane-associated guanine nucleotide exchange factors, providing a mechanism to regulate the release and activation of individual members of the Rho family during cell stimulation.			BOKOCH, GM (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL & CELL BIOL IMM14, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Chuang, Tsung-Hsien/F-9679-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48008] Funding Source: Medline; NIGMS NIH HHS [GM44428] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; CHUANG TH, 1993, J BIOL CHEM, V268, P775; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CURNUTTE JT, 1989, J CLIN INVEST, V83, P1236, DOI 10.1172/JCI114006; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P331; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1994, IN PRESS J BIOL CHEM; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; ISOMURA M, 1991, ONCOGENE, V6, P119; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LANG P, 1993, BIOCHEM BIOPH RES CO, V196, P1522, DOI 10.1006/bbrc.1993.2424; LETO TL, 1991, J BIOL CHEM, V266, P19812; MIURA Y, 1993, J BIOL CHEM, V268, P510; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; QUINN MT, 1993, J BIOL CHEM, V268, P20983; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHI YQ, 1992, J BIOL CHEM, V267, P9547; SOLDATI T, 1994, SCIENCE, V369, P76; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; UEDA T, 1990, J BIOL CHEM, V265, P9373; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0	34	222	223	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31674	31679						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989340				2022-12-25	WOS:A1994PX30300055
J	KENNEDY, ME; LIMBIRD, LE				KENNEDY, ME; LIMBIRD, LE			PALMITOYLATION OF THE ALPHA(2A)-ADRENERGIC RECEPTOR - ANALYSIS OF THE SEQUENCE REQUIREMENTS FOR AND THE DYNAMIC PROPERTIES OF ALPHA(2A)-ADRENERGIC RECEPTOR PALMITOYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; BETA-ADRENERGIC-RECEPTOR; ALPHA-2A-ADRENERGIC RECEPTOR; ALPHA-2-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; PLASMA-MEMBRANE; KINASE; CELLS; PROTEINS; DOMAIN	Previous studies have demonstrated that the alpha(2A)-adrenergic receptor (alpha(2A)AR) incorporates [H-3]palmitate and that replacement of Cys(442) by Ala or Ser eliminates detectable acylation without perturbing coupling to pertussis toxin-sensitive GTP-binding proteins (Kennedy, M. E., and Limbird, L. E. (1993) J. Biol. Chem. 268, 8003-8011) or, as shown here, without perturbing agonist-dependent receptor phosphorylation, in contrast to the consequences of eliminating beta(2)-adrenergic receptor acylation, As a first step in revealing the functional role for this post-translational modification at the alpha(2A)AR, we explored sequences in the alpha(2A)AR which confer alpha(2A)AR acylation and whether or not [H-3]palmitoylation of the alpha(2A)AR is dynamic, Deletion of the 7 terminal amino acids distal to Cys(442) Of the alpha(2A)AR did not eliminate detectable [H-3]palmitoylation of the alpha(2A)AR, whereas truncation to Leu(441) did, indicating both that Cys(442) is the likely site for acylation and that sequences distal to Cys(442) are not required for acylation at Cys(442), Since mutation of sequences proximal to Cys(442) altered overall receptor structure, based on markedly reduced detectable adrenergic receptor binding, proximal motifs required for palmitoylation of the alpha(2A)AR could not be explored fur ther. When the turnover of [S-35]Met/Cys-labeled alpha(2A)AR was compared with the turnover of the [H-3]palmitate-labeled alpha(2A)AR, it was of interest that agonist treatment accelerated the half-life of decay of the [H-3]palmitate-labeled alpha(2A)AR without detectable receptor down-regulation, providing evidence that the acylation of the alpha(2A)AR may be a dynamic process.	VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043671, R37HL043671, R01HL025182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007628] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25182, HL43671] Funding Source: Medline; NIGMS NIH HHS [GM07628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAMP LA, 1993, J BIOL CHEM, V268, P22566; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HAMAGUCHI M, 1989, ONCOGENE RES, V4, P29; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PARSONS JT, 1989, CURR TOP MICROBIOL I, V147, P80; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PLEUS RC, 1993, EUR J PHARM-MOLEC PH, V244, P181, DOI 10.1016/0922-4106(93)90024-4; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; SCHMIDT MFG, 1989, BIOCHEM SOC T, V17, P859, DOI 10.1042/bst0170859; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; VANKOPPEN CJ, 1991, J NEUROCHEM, V57, P1873, DOI 10.1111/j.1471-4159.1991.tb06397.x; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	37	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31915	31922						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989367				2022-12-25	WOS:A1994PX30300089
J	LENZ, HJ; MANNO, DJ; DANENBERG, KD; DANENBERG, PV				LENZ, HJ; MANNO, DJ; DANENBERG, KD; DANENBERG, PV			INCORPORATION OF 5-FLUOROURACIL INTO U2 AND U6 SNRNA INHIBITS MESSENGER-RNA PRECURSOR SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT KB CELLS; SMALL NUCLEAR RIBONUCLEOPROTEIN; DIHYDROFOLATE-REDUCTASE RNA; MESSENGER-RNA; RIBOSOMAL-RNA; YEAST; INVITRO; SEQUENCES; RECONSTITUTION; SUBSTITUTION	The splicing activities of 5-fluorouracil (FUra)-substituted U2 and U6 small nuclear RNAs (snRNAs) were examined in an in vitro splicing system. Yeast splicing extracts were specifically depleted of endogenous U2 and U6 snRNAs by antisense oligonucleotide-directed RNase II hydrolysis, Splicing activity was recovered when the extracts were reconstituted with synthetic U2 and U6 snRNAs. However, U2 snRNA with all uracils substituted with FUra (FU2) did not restore any splicing activity. Nondenaturing gel electrophoresis showed that FU2 failed to promote the assembly of spliceosome complexes. The ability of U2 snRNA to restore splicing in U2-depleted extracts increased as FUra content decreased but was still only 60% of control activity at 25% substitution of uracils with FUra, Addition of FU2 to nondepleted extracts caused strong inhibition of splicing accompanied by increased degradation of the pre-mRNA, suggesting that FU2 forms an inactive complex with a protein splicing factor that normally binds to the pre-mRNA. FU6 restored full splicing activity to U6-depleted extracts, but at a B-fold higher concentration than U6 snRNA, These results demonstrate that the incorporation of FUra can impair the functions of catalytic RNA molecules.	UNIV SO CALIF, SCH MED, DEPT BIOCHEM & MOLEC BIOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, CTR COMPREHENS CANC, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; ARMSTRONG RD, 1986, J BIOL CHEM, V261, P21; ARMSTRONG RD, 1986, J BIOL CHEM, V261, P7366; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; DANENBERG PV, 1992, NUCLEIC ACIDS RES, V20, P573, DOI 10.1093/nar/20.3.573; DANENBERG PV, 1990, CANCER RES, V50, P1757; DOLNICK BJ, 1983, J BIOL CHEM, V258, P3299; DOLNICK BJ, 1985, J BIOL CHEM, V260, P3006; DOONG SL, 1988, J BIOL CHEM, V263, P4467; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, 1992, NUCLEIC ACIDS RES, V20, P3659, DOI 10.1093/nar/20.14.3659; GHOSHAL K, 1994, CANCER RES, V54, P632; GLAZER RI, 1979, MOL PHARMACOL, V16, P270; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57; HERRICK D, 1984, MOL PHARMACOL, V26, P135; HOLLAND JF, 1982, CANCER MED, P801; IGEL AH, 1988, NATURE, V334, P450, DOI 10.1038/334450a0; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KUFE DW, 1983, BIOCHEM PHARMACOL, V32, P1337, DOI 10.1016/0006-2952(83)90443-4; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MCPHEETERS DS, 1989, GENE DEV, V3, P2124, DOI 10.1101/gad.3.12b.2124; PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8; RUBY SW, 1991, TRENDS GENET, V7, P79; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SHUSTER EO, 1990, NATURE, V345, P270, DOI 10.1038/345270a0; SHUSTER EO, 1988, CELL, V55, P41, DOI 10.1016/0092-8674(88)90007-4; SIERAKOWSKA H, 1989, J BIOL CHEM, V264, P19185; SPIEGELMAN S, 1980, CANCER, V45, P1129, DOI 10.1002/1097-0142(19800315)45:5+<1129::AID-CNCR2820451317>3.0.CO;2-I; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; TAKIMOTO CH, 1987, BIOCHEM PHARMACOL, V36, P3243, DOI 10.1016/0006-2952(87)90640-X; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WERSIG C, 1992, MOL CELL BIOL, V12, P1460, DOI 10.1128/MCB.12.4.1460; WILKINSON DS, 1973, J BIOL CHEM, V248, P63; WILL CL, 1986, MOL PHARMACOL, V29, P643; WILL CL, 1987, J BIOL CHEM, V262, P5433; WILL CL, 1989, J BIOL CHEM, V264, P21413; WU XP, 1993, MOL PHARMACOL, V44, P22; ZAVANELLI MI, 1991, GENE DEV, V5, P2521, DOI 10.1101/gad.5.12b.2521	42	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31962	31968						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989372				2022-12-25	WOS:A1994PX30300096
J	CHENG, XD; LEE, JC				CHENG, XD; LEE, JC			ABSOLUTE REQUIREMENT OF CYCLIC-NUCLEOTIDE IN THE ACTIVATION OF THE G141Q MUTANT CAMP RECEPTOR PROTEIN FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							3',5'-MONOPHOSPHATE RECEPTOR; HINGE REORIENTATION; CRYSTAL-STRUCTURE; AMINO-ACID; AMP; BINDING; ANALOGS; RESOLUTION; COMPLEX; CAP	cAMP receptor protein (CRP), when interacting with cAMP, controls the expression of a network of catabolite-sensitive genes in Escherichia coli. To understand the molecular events that lead to the activation of CRP, a combined approach of site-directed mutagenesis and thermodynamic analysis was employed to study a member of a specific class of CRP mutant, CRP*, which activates the in vivo expression of CRP-dependent operons in cya(-) strains in the absence of exogenous cAMP. Results from in vitro studies show that the CRP* mutant G141Q absolutely requires cAMP for interacting with specific DNA. A quantitative comparison of the thermodynamic parameters governing ligand binding and DNA-protein complex formation in the presence of different cycle nucleotides leads to the conclusion that this CRP* mutant is activated only in the presence of cyclic nucleotides. The specificity toward cyclic nucleotides exhibited by wild-type CRP is lost in this mutant. Furthermore, the binding affinity of the ligand for the first binding site of the mutant is essentially the same as that of wild-type CRP regardless of the identity of the cyclic nucleotide. Hence, the observed in vivo activation of CRP-dependent operons by G141Q in the absence of exogenous cAMP is most likely the consequence of the replacement of cAMP by other cyclic nucleotides to activate the mutant. It is also possible that trace levels of cAMP present in the cya(-) strain could account for the in vivo activation of the mutant. Furthermore, these results indicate that this CRP* mutant does not assume the activated conformation in the absence of cyclic nucleotides, in contrast to the cur rent model derived from results of in vivo studies.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston			Lee, James C/A-7849-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045579] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-21489] Funding Source: Medline; NIGMS NIH HHS [GM-45579] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1985, EMBO J, V4, P3329, DOI 10.1002/j.1460-2075.1985.tb04084.x; ANDERSON WB, 1972, J BIOL CHEM, V247, P2717; BERNLOHR RW, 1974, J BIOL CHEM, V249, P4329; BLACK RA, 1980, P NATL ACAD SCI-BIOL, V77, P3879, DOI 10.1073/pnas.77.7.3879; BLAZY B, 1986, J BIOL CHEM, V261, P1645; CHENG XD, 1993, BIOCHEMISTRY-US, V32, P8130, DOI 10.1021/bi00083a011; COOK WR, 1980, J BACTERIOL, V141, P1450, DOI 10.1128/JB.141.3.1450-1453.1980; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DONOSOPARDO JL, 1987, EUR J BIOCHEM, V168, P687, DOI 10.1111/j.1432-1033.1987.tb13470.x; EBRIGHT RH, 1985, J MOL BIOL, V182, P91, DOI 10.1016/0022-2836(85)90030-0; GARGES S, 1985, CELL, V41, P745, DOI 10.1016/S0092-8674(85)80055-6; Goldberg N D, 1973, Adv Cyclic Nucleotide Res, V3, P155; HARMAN JG, 1988, J BIOL CHEM, V263, P8072; HARMAN JG, 1986, J BIOL CHEM, V261, P6332; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; KIM J, 1992, P NATL ACAD SCI USA, V89, P9700, DOI 10.1073/pnas.89.20.9700; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; MACCHIA V, 1981, J BACTERIOL, V147, P931, DOI 10.1128/JB.147.3.931-934.1981; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; Peterkofsky A, 1976, Adv Cyclic Nucleotide Res, V7, P1; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; SCHOLUBBERS HG, 1984, EUR J BIOCHEM, V138, P101, DOI 10.1111/j.1432-1033.1984.tb07887.x; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHIBUYA M, 1975, BIOCHEM BIOPH RES CO, V62, P129, DOI 10.1016/S0006-291X(75)80414-1; SHIBUYA M, 1976, BIOCHEM BIOPH RES CO, V68, P430, DOI 10.1016/0006-291X(76)91163-3; TAKAHASHI M, 1980, BIOCHEMISTRY-US, V19, P5124, DOI 10.1021/bi00563a029; TAKEBE Y, 1978, J BIOCHEM-TOKYO, V83, P1615, DOI 10.1093/oxfordjournals.jbchem.a132073; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WEBER IT, 1987, J BIOL CHEM, V262, P5630	30	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30781	30784						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983007				2022-12-25	WOS:A1994PV51000011
J	FIALKOW, L; CHAN, CK; ROTIN, D; GRINSTEIN, S; DOWNEY, GP				FIALKOW, L; CHAN, CK; ROTIN, D; GRINSTEIN, S; DOWNEY, GP			ACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE SIGNALING PATHWAY IN NEUTROPHILS - ROLE OF OXIDANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; INDUCED TYROSINE PHOSPHORYLATION; EPIDERMAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; MAP KINASE; GENE-PRODUCT; PHOSPHATASE; TRANSDUCTION; VANADATE; MEMBRANE	In addition to their role in bacterial killing, reactive oxygen intermediates (ROI) produced by the NADPH oxidase may participate in the regulation of intracellular pathways. We have recently demonstrated that ROI produced by the oxidase regulate tyrosine phosphorylation in neutrophils, possibly by alterations in the cellular redox state. The purpose of the present study was to characterize the identities of certain of the redox-sensitive tyrosine phosphorylated substrates and the significance of the increased phosphorylation. As a prominent 42-44-kDa phosphorylated band was noted in oxidant-treated cells, we investigated the possible phosphorylation and activation of mitogen-activated protein (MAP) kinase under these conditions. Immunoprecipitation of MAP kinase followed by immunoblotting with anti-phosphotyrosine antibodies indicated that a 42-44-kDa polypeptide was tyrosine-phosphorylated in response to treatment of cells, either with the oxidizing agent diamide or with H2O2 in cells where catalase was inhibited. Using an in vitro renaturation assay with myelin basic protein as the substrate, oxidant-induced stimulation of kinase activity of a 42-44-kDa band was observed in both whole cell extracts and in MAP kinase immunoprecipitates. The mechanism of redox-sensitive activation of MAP kinase was examined. First, exposure of cells to oxidants caused a significant increase in the activity of MEK (the putative activator of MAP kinase), as determined by an in vitro kinase assay using recombinant catalytically inactive glutathione S-transferase-MAP kinase as the substrate. Additionally, oxidant treatment of cells resulted in inhibition of the activity of CD45, a protein tyrosine phosphatase known to dephosphorylate and inactivate MAP kinase. We conclude that oxidant treatment of neutrophils can activate MAP kinase by stimulating its tyrosine and (presumably) threonine phosphorylation via MEK activation, a response that may be potentiated by inhibition of MAP kinase dephosphorylation by phosphatases such as CD45.	UNIV TORONTO,DEPT MED,DIV CLIN SCI,TORONTO M5S 1A8,ON,CANADA; TORONTO HOSP,DIV RESP,TORONTO M5G 1X8,ON,CANADA; HOSP SICK CHILDREN,RES INST,DEPT CELL BIOL,TORONTO M5G 1X8,ON,CANADA; HOSP SICK CHILDREN,RES INST,DEPT RESP RES,TORONTO M5G 1X8,ON,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Downey, Gregory P/0000-0003-3253-5862				AKIMARU K, 1992, ARCH BIOCHEM BIOPHYS, V298, P703, DOI 10.1016/0003-9861(92)90469-D; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANH NG, 1992, CURR OPIN CELL BIOL, V4, P992; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERKOW RL, 1990, BLOOD, V75, P2445; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CROSS AR, 1989, NEUTROPHIL CELLULAR, P97; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GRINSTEIN S, 1991, AM J PHYSIOL, V260, pC1019, DOI 10.1152/ajpcell.1991.260.5.C1019; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; Halliwell B., 1985, FREE RADICALS BIOL M, DOI 10.1016/0748-5514(85)90140-0; HASLETT C, 1985, AM J PATHOL, V119, P101; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGOLIASH E, 1960, BIOCHEM J, V74, P339, DOI 10.1042/bj0740339; MCCOLL SR, 1991, BLOOD, V78, P1842; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MONTEIRO HP, 1991, FEBS LETT, V295, P146, DOI 10.1016/0014-5793(91)81405-W; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATRIANO JA, 1993, J CLIN INVEST, V92, P1564, DOI 10.1172/JCI116737; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TORRES M, 1993, J IMMUNOL, V150, P1563; WARD Y, 1994, SCIENCE, V367, P651; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	55	206	209	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31234	31242						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983067				2022-12-25	WOS:A1994PV51000076
J	CARVER, LA; JACKIW, V; BRADFIELD, CA				CARVER, LA; JACKIW, V; BRADFIELD, CA			THE 90-KDA HEAT-SHOCK PROTEIN IS ESSENTIAL FOR AH RECEPTOR SIGNALING IN A YEAST EXPRESSION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HIGH-EFFICIENCY TRANSFORMATION; DNA-BINDING ACTIVITY; DIOXIN RECEPTOR; INDUCIBLE EXPRESSION; LIGAND; ENHANCER; ELEMENTS; CLONING; DOMAIN; HSP90	In an effort to provide a more powerful system to study the Ah receptor (AHR) signaling pathway, we expressed the AHR, its dimerization partner ARNT, and a beta-galactosidase (lacZ) reporter gene, driven by two dioxin-responsive enhancers, in the yeast Saccharomyces cerevisiae. In this system, the agonists beta-naphthoflavone and alpha-naphthoflavone induced transcription of the lacZ gene, with EC(50) values of 7.9 x 10(-8) and 3.0 x 10(-7) M, respectively, while the nonagonist dexamethasone was without effect. As a first application of this system, we examined the relationship between the 90-kDa heat shock protein (hsp90) and AHR function. To accomplish this in a manner that was independent of the ARNT protein, we constructed a chimeric receptor in which the DNA binding and primary dimerization domains of the AHR were swapped with analogous domains from the LexA protein. Coexpression of this AHR-LexA chimera and a lacZ reporter gene driven by eight LexA operator sites in a yeast strain with regulatable levels of hsp90, yielded pharmacology that closely mirrored that of the AHR/ARNT/dioxin-responsive enhancer system described above, but only when hsp90 levels were held near their wild type levels. When hsp90 levels were reduced to approximately 5% of normal, AHR signaling in response to agonist was completely blocked despite normal cell growth. These results provide the first genetic evidence for the role of hsp90 in AHR signaling and provide the basis for a powerful new system in which to study this pathway.	NORTHWESTERN UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES005703, R01ES005703, T32ES007124, R29ES005703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32-ES07124, ES05703] Funding Source: Medline; NIGMS NIH HHS [T32-GM08061] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRUNELLI JP, 1993, YEAST, V9, P1299, DOI 10.1002/yea.320091203; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JAIN S, 1994, IN PRESS J BIOL CHEM, V269; Knutson J. C., 1981, TOXICITY HALOGENATED, P187; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEBERT DW, 1969, ARCH BIOCHEM BIOPHYS, V134, P76, DOI 10.1016/0003-9861(69)90253-7; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PICARD D, 1990, GENE, V86, P257, DOI 10.1016/0378-1119(90)90287-2; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND AP, 1974, J BIOL CHEM, V249, P5599; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHEN ES, 1992, J BIOL CHEM, V267, P6815; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	36	123	127	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30109	30112						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982913				2022-12-25	WOS:A1994PU52500012
J	GADBUT, AP; TOUPIN, DK; KILBOURNE, EJ; GALPER, JB				GADBUT, AP; TOUPIN, DK; KILBOURNE, EJ; GALPER, JB			LOW-DENSITY LIPOPROTEINS INDUCE PARASYMPATHETIC RESPONSIVENESS IN EMBRYONIC CHICK VENTRICULAR MYOCYTES IN PARALLEL WITH A COORDINATE INCREASE IN EXPRESSION OF GENES-CODING FOR THE M(2), MUSCARINIC RECEPTOR, G-ALPHA(I2),, AND THE ACETYLCHOLINE-SENSITIVE K+ CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; GTP-BINDING PROTEINS; ATRIAL CELLS; REGULATORY PROTEINS; ADENYLATE-CYCLASE; MESSENGER-RNA; MEVINOLIN; HEART; ACTIVATION; RESPONSES	Growth of chick atrial cells in medium supplemented with lipoprotein-depleted serum has been shown to result in an increase in total cell cholesterol, and an increase in the negative chronotropic response to muscarinic stimulation in parallel with an increase in levels of muscarinic receptors and the G-protein alpha-subunits alpha i and alpha o (Haigh, L. S., Leatherman, G. F., O'Hara, D. S., Smith, T. W., and Galper, J. B. (1988) J. Biol. Chem. 263, 15608-15618). In this study we determined whether growth of chick ventricular cells in medium supplemented with lipoprotein depleted serum could alter levels of muscarinic receptors and G-protein alpha-subunits and induce a negative chronotropic response to muscarinic stimulation. We further determined whether levels of mRNA coding for muscarinic receptors, G-proteins, and the acetylcholine sensitive K+ channel were coordinately regulated. Growth of embryonic chick ventricular cells from hearts 14 days in ovo in medium supplemented with lipoprotein depleted serum resulted in a 21 +/- 5% (n = 3, +/- S.E.) increase in muscarinic receptor number as demonstrated by [H-3]quinuclidinyl benzilate binding and a 4.7 +/- 1.0 (+/- S.E., n = 4)-fold increase in G alpha(i2) as demonstrated by Western blot analysis. These changes in receptor and G-protein were associated with a coordinate increase in levels of mRNA coding for the M(2) muscarinic receptor, G alpha(i2) and the acetylcholine sensitive K+ channel as determined by RNase protection. These increases were reversed by addition of 30 mu M mevinolin, an inhibitor of HMG-CoA reductase activity. Carbamylcholine (0.1 an) had no effect on beat rate in ventricular cells grown in medium supplemented with fetal calf serum. Cells grown in medium supplemented with lipoprotein depleted serum demonstrated a 40 +/- 8% (+/- S.E., n = 10, p < 0.0001) decrease in beat rate in response to 0.1 mM carbamylcholine which was reversed by the addition of 30 mu M mevinolin. These data suggest that, during growth in medium supplemented with lipoprotein depleted serum, a component of the cholesterol biosynthetic pathway plays a role in the coordinate induction of mRNAs coding for receptors, G-proteins, and an effector (ion channel) that results in the induction of a parasympathetic response in the ventricular cell characteristic of the atrial phenotype.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL08464, HL36014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008464, R01HL036014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BARNETT JV, 1989, J BIOL CHEM, V264, P10779; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DEHAAN RL, 1967, DEV BIOL, V16, P216, DOI 10.1016/0012-1606(67)90025-5; GADBUT AP, 1994, J BIOL CHEM, V269, P25823; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HADCOCK JR, 1990, J BIOL CHEM, V265, P14782; HADDOCK JR, 1991, J BIOL CHEM, V266, P11915; HAIGH LS, 1988, J BIOL CHEM, V263, P15608; Hutter OF, 1961, NERVOUS INHIBITION, P114; INOUE D, 1984, CIRC RES, V53, P158; JONES DT, 1987, J BIOL CHEM, V262, P14241; JOSEPHSON I, 1982, J GEN PHYSIOL, V79, P69, DOI 10.1085/jgp.79.1.69; KILBOURNE EJ, 1994, IN PRESS GENE AMST; KOUMI SI, 1994, AM J PHYSIOL, V266, pH1812, DOI 10.1152/ajpheart.1994.266.5.H1812; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY MN, 1971, CIRC RES, V29, P437, DOI 10.1161/01.RES.29.5.437; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUETJE CW, 1988, J BIOL CHEM, V263, P13357; MARTIN JM, 1987, J PHARMACOL EXP THER, V240, P683; MCMORN SO, 1993, AM J PHYSIOL, V265, pH1393, DOI 10.1152/ajpheart.1993.265.4.H1393; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PAPPANO AJ, 1984, FED PROC, V43, P2607; PARSONS WJ, 1987, J BIOL CHEM, V262, P841; PERSSON RF, 1956, ACTA PHYSL SCAND, V38, P173; RANSNAS L, 1986, J MOL CELL CARDIOL, V18, P807, DOI 10.1016/S0022-2828(86)80955-5; Sambrook J, 1989, MOL CLONING LABORATO; SAROTA S, 1986, J PHARMACOL EXP THER, V236, P602; SIEGEL RE, 1984, DEV BIOL, V101, P346, DOI 10.1016/0012-1606(84)90148-9; SPERELAK.N, 1969, AM J PHYSIOL, V217, P625, DOI 10.1152/ajplegacy.1969.217.2.625; Sperelakis N, 1965, Am J Physiol, V209, P693; TAN W, 1993, AM J PHYSIOL, V265, pH191, DOI 10.1152/ajpheart.1993.265.1.H191; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	37	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30707	30712						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982991				2022-12-25	WOS:A1994PU52500101
J	CERENIUS, L; LIANG, ZC; DUVIC, B; KEYSER, P; HELLMAN, U; PALVA, ET; IWANAGA, S; SODERHALL, K				CERENIUS, L; LIANG, ZC; DUVIC, B; KEYSER, P; HELLMAN, U; PALVA, ET; IWANAGA, S; SODERHALL, K			STRUCTURE AND BIOLOGICAL-ACTIVITY OF A 1,3-BETA-D-GLUCAN-BINDING PROTEIN IN CRUSTACEAN BLOOD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRAYFISH PACIFASTACUS-LENIUSCULUS; PROPHENOLOXIDASE ACTIVATING SYSTEM; CARBOHYDRATE-RECOGNITION DOMAINS; FRESH-WATER CRAYFISH; CELL-ADHESION FACTOR; LPS BINDING-PROTEIN; LIPOPOLYSACCHARIDE LPS; APHANOMYCES-ASTACI; DE-GRANULATION; PURIFICATION	The prophenoloxidase activating system, an enzyme cascade present in arthropod blood, has been shown to be involved in defense and recognition reactions. This system is converted to its active form by fungal 1,3-beta-D-glucans through binding to a plasma protein, a 1,3-beta-D-glucan-binding protein. Here the molecular cloning and carbohydrate composition of the 1,3-beta-D-glucan-binding protein from the freshwater crayfish Pacifastacus leniusculus are reported. It is also demonstrated that this protein can act as an opsonin, stimulating phagocytic uptake of yeast particles by isolated blood cells. The deduced amino acid sequence of 1,339 residues shows no significant similarity to proteins with similar functions in other animals such as the mannan-binding and lipopolysaccharide-binding proteins present in mammals. However, a short sequence motif with similarity to the active site of microbial 1,3-1,4-beta-D-glucan 4-glucanohydrolases was found to occur twice in the 1,3-beta-D-glucan-binding protein.	UPPSALA UNIV, DEPT PHYSIOL BOT, S-75236 UPPSALA, SWEDEN; LUDWIG INST CANC RES, S-75124 UPPSALA, SWEDEN; SWEDISH UNIV AGR SCI, UPPSALA GENET CTR, DEPT MOLEC GENET, S-75007 UPPSALA, SWEDEN; KYUSHU UNIV 33, FAC SCI, DEPT BIOL, FUKUOKA 812, JAPAN	Uppsala University; Ludwig Institute for Cancer Research; Swedish University of Agricultural Sciences; Kyushu University			Liang, Zicai/A-2646-2013; Duvic, Bernard/ABG-5094-2020	Duvic, Bernard/0000-0002-7618-7719				BARRACCO MA, 1991, CELL TISSUE RES, V266, P491, DOI 10.1007/BF00318590; BARTNICK.S, 1968, ANNU REV MICROBIOL, V22, P87, DOI 10.1146/annurev.mi.22.100168.000511; BORRISS R, 1988, J BASIC MICROB, V28, P3; CERENIUS L, 1984, PHYSIOL PLANTARUM, V60, P247, DOI 10.1111/j.1399-3054.1984.tb04572.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DUVIC B, 1993, J CRUSTACEAN BIOL, V13, P403, DOI 10.2307/1548783; DUVIC B, 1992, EUR J BIOCHEM, V207, P223, DOI 10.1111/j.1432-1033.1992.tb17041.x; DUVIC B, 1990, J BIOL CHEM, V265, P9327; Hed J, 1986, Methods Enzymol, V132, P198; IWANAGA S, 1993, THROMB HAEMOSTASIS, V70, P48; JOHANSSON MW, 1989, INSECT BIOCHEM, V19, P573, DOI 10.1016/0020-1790(89)90022-X; JOHANSSON MW, 1988, J CELL BIOL, V106, P1795, DOI 10.1083/jcb.106.5.1795; JUNCOSA M, 1994, J BIOL CHEM, V269, P14530; KOBAYASHI M, 1990, CELL TISSUE RES, V260, P13, DOI 10.1007/BF00297485; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LIANG ZC, 1992, J INSECT PHYSIOL, V38, P987, DOI 10.1016/0022-1910(92)90008-2; LLOBERAS J, 1991, EUR J BIOCHEM, V197, P337, DOI 10.1111/j.1432-1033.1991.tb15916.x; OCHIAI M, 1988, J BIOL CHEM, V263, P12056; PERSSON M, 1987, J FISH DIS, V10, P471, DOI 10.1111/j.1365-2761.1987.tb01098.x; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; Sambrook J, 1989, MOL CLONING LABORATO; SCHIMMING S, 1992, EUR J BIOCHEM, V204, P13, DOI 10.1111/j.1432-1033.1992.tb16600.x; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SEKI N, 1994, J BIOL CHEM, V269, P1370; SMITH VJ, 1983, CELL TISSUE RES, V233, P295; SODERHALL K, 1990, RES IMMUNOL, V141, P896, DOI 10.1016/0923-2494(90)90190-A; SODERHALL K, 1979, CAN J MICROBIOL, V25, P406, DOI 10.1139/m79-062; SODERHALL K, 1988, INSECT BIOCHEM, V18, P323, DOI 10.1016/0020-1790(88)90045-5; Soderhall Kenneth, 1992, Annual Review of Fish Diseases, V2, P3, DOI 10.1016/0959-8030(92)90053-Z; TAKEMOTO H, 1985, ANAL BIOCHEM, V145, P245, DOI 10.1016/0003-2697(85)90357-4; TAKEYA H, 1990, J BIOL CHEM, V265, P16068; TEATHER RM, 1990, J BACTERIOL, V172, P3837, DOI 10.1128/jb.172.7.3837-3841.1990; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YAMAMOTO A, 1989, J BIOCHEM-TOKYO, V106, P552, DOI 10.1093/oxfordjournals.jbchem.a122892	37	133	136	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29462	29467						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961928				2022-12-25	WOS:A1994PU28400026
J	EISENSTEIN, E; YU, HD; SCHWARZ, FP				EISENSTEIN, E; YU, HD; SCHWARZ, FP			COOPERATIVE BINDING OF THE FEEDBACK MODIFIERS ISOLEUCINE AND VALINE TO BIOSYNTHETIC THREONINE DEAMINASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; HEATS	Control of the regulatory enzyme threonine deaminase from Escherichia coli is achieved by isoleucine inhibition and valine activation. The mechanism by which these heterotropic effecters regulate the enzyme was investigated by measuring the binding of isoleucine and valine by spectroscopic, kinetic, calorimetric and equilibrium dialysis techniques. The addition of isoleucine or valine to threonine deaminase resulted in large changes in the intrinsic fluorescence of the two tryptophans per polypeptide chain. Slightly cooperative binding isotherms for isoleucine were obtained in potassium phosphate, pH 7.5, yielding an average dissociation constant of 4.91 mu M, which was confirmed by equilibrium dialysis measurements. Valine binding was much more cooperative, and yielded an average dissociation constant of 122 mu M. Titration calorimetry experiments indicated that cooperative heterotropic ligand binding was exothermic, and yielded a stoichiometry of four isoleucine bound per tetrameric enzyme, with an average enthalpy of -10.70 kcal/mol. Valine also bound to four sites per tetramer, with an average enthalpy of -7.45 kcal/ mel. The effect of ligands on the fluorescence and circular dichroism spectra of the essential pyridoxal phosphate cofactor indicates that isoleucine and valine bind to effector sites that are distinct from the active sites in threonine deaminase. Shifts in the kinetic properties of threonine deaminase promoted by isoleucine and valine binding are to a first approximation consistent with analyses of effector binding isotherms in terms of a simple two-state model, and suggest that isoleucine regulates threonine deaminase by preferentially binding to the low activity T state, whereas valine binds preferentially to the high activity R state. Finally, analyses of heterotropic effector binding isotherms suggest that active site ligands may have significant affinity for the regulatory sites, which gives rise to underestimates for the allosteric equilibrium constants determined from substrate analog binding isotherms.	NATL INST STAND & TECHNOL,ROCKVILLE,MD 20850; UNIV MARYLAND,DEPT CHEM & BIOCHEM,BALTIMORE,MD 21228	National Institute of Standards & Technology (NIST) - USA; University System of Maryland; University of Maryland Baltimore	EISENSTEIN, E (corresponding author), UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,9600 GUDELSKY DR,ROCKVILLE,MD 20850, USA.							Adair GS, 1925, J BIOL CHEM, V63, P529; BURNS RO, 1968, J BIOL CHEM, V243, P178; CALHOUN DH, 1973, J BIOL CHEM, V248, P3511; CHANGEUX JEAN-PIERRE, 1964, BROOKHAVEN SYMP BIOL, V17, P232; CHANGEUX JP, 1963, COLD SPRING HARB SYM, V28, P497, DOI 10.1101/SQB.1963.028.01.066; CHANGEUX JP, 1961, COLD SPRING HARB SYM, V26, P313, DOI 10.1101/SQB.1961.026.01.037; Dahlquist F W, 1978, Methods Enzymol, V48, P270; DAVIS L, 1965, ANAL BIOCHEM, V12, P36, DOI 10.1016/0003-2697(65)90139-9; DECEDUE CJ, 1975, J BIOL CHEM, V250, P1563; EISENSTEIN E, 1991, J BIOL CHEM, V266, P5801; EISENSTEIN E, 1994, J BIOL CHEM, V269, P29416; FISHER KE, 1993, J BACTERIOL, V175, P6605, DOI 10.1128/jb.175.20.6605-6613.1993; GILL SJ, 1988, BIOCH THERMODYNAMICS, P145; HATFIELD GW, 1970, J BIOL CHEM, V245, P1742; HATFIELD GW, 1971, BIOCHEM BIOPH RES CO, V44, P464, DOI 10.1016/0006-291X(71)90624-3; HENSLEY P, 1981, J MOL BIOL, V152, P131, DOI 10.1016/0022-2836(81)90098-X; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HOFLER JG, 1978, J BIOL CHEM, V253, P1245; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KALLEN RG, 1985, TRANSAMINASES, P37; KLOTZ IM, 1989, PROTEIN FUNCTION PRA, P25; KOERNER K, 1975, BIOCHIM BIOPHYS ACTA, V397, P220, DOI 10.1016/0005-2744(75)90195-3; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MYER YP, 1962, BIOCHIM BIOPHYS ACTA, V55, P361; PARODYMORREALE A, 1987, J BIOL CHEM, V262, P10994; PERUTZ MF, 1990, MECHANISMS COOPERATI; TAILLON BE, 1988, GENE, V63, P245, DOI 10.1016/0378-1119(88)90528-8; UMBARGER HE, 1992, PROTEIN SCI, V1, P1392, DOI 10.1002/pro.5560011019; UMBARGER HE, 1956, SCIENCE, V123, P848, DOI 10.1126/science.123.3202.848; UMBARGER HE, 1957, J BACTERIOL, V73, P105, DOI 10.1128/JB.73.1.105-112.1957; UMBARGER HE, 1957, J BIOL CHEM, V233, P415; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	33	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29423	29429						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961922				2022-12-25	WOS:A1994PU28400020
J	VANVEEN, HW; ABEE, T; KORTSTEE, GJJ; PEREIRA, H; KONINGS, WN; ZEHNDER, AJB				VANVEEN, HW; ABEE, T; KORTSTEE, GJJ; PEREIRA, H; KONINGS, WN; ZEHNDER, AJB			GENERATION OF A PROTON MOTIVE FORCE BY THE EXCRETION OF METAL-PHOSPHATE IN THE POLYPHOSPHATE-ACCUMULATING ACINETOBACTER-JOHNSONII STRAIN 210A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-VESICLES; LACTATE EFFLUX; STREPTOCOCCUS-CREMORIS; ESCHERICHIA-COLI; TRANSPORT; MECHANISM; GRADIENT; ACINETOBACTER-JOHNSONII-210A; BACTERIA; FAECALIS	The strictly aerobic, polyphosphate-accumulating Acinetobacter johnsonii strain 210A degrades its polyphosphate when oxidative phosphorylation is impaired. The endproducts of this degradation, divalent metal ions and inorganic phosphate, are excreted as a neutral metal-phosphate (MeHPO(4)) chelate via the electrogenic MeHPO(4)/H+ symport system of the organism. The coupled excretion of MeHPO(4) and H+ in A. johnsonii 210A can generate a proton motive force. In membrane vesicles and deenergized cells, a membrane potential of about -70 mV and transmembrane pH gradient of about -8 mV were formed in response to an imposed outwardly directed MeHPO, concentration gradient of 120 mV (initial value). The MeHPO(4) efflux-induced proton motive force could drive energy-requiring processes, such as the accumulation of L-proline and L-lysine and the synthesis of ATP via the membrane-bound F0F1 H+-ATPase. In vivo P-31 NMR studies of polyphosphate degradation in anaerobic cell suspensions revealed the presence of a considerable outwardly directed phosphate gradient across the cytoplasmic membrane corresponding to a MgHPO4 concentration gradient of at least 100 mV. This MgHPO4 concentration gradient was maintained for several hours. Thus, energy recycling by MeHPO(4)/H+ efflux will contribute significantly to the overall production of metabolic energy from the degradation of polyphosphate in A. johnsonii 210A.	AGR UNIV WAGENINGEN,DEPT MICROBIOL,6703 CT WAGENINGEN,NETHERLANDS; AGR UNIV WAGENINGEN,DEPT FOOD SCI,6703 HD WAGENINGEN,NETHERLANDS; UNIV NOVA LISBOA,CTR TECNOL QUIM & BIOL,P-2780 OEIRAS,PORTUGAL; UNIV GRONINGEN,DEPT MICROBIOL,9751 NN HAREN,NETHERLANDS	Wageningen University & Research; Wageningen University & Research; Universidade Nova de Lisboa; University of Groningen			Konings, Wilhelmus N./C-7063-2013; Van Veen, Hendrik W./A-4162-2008	Van Veen, Hendrik W./0000-0002-9658-8077; Lourenco Pereira Matias, Helena Cristina/0000-0002-2239-1394				BAKKER EP, 1981, J BACTERIOL, V147, P820, DOI 10.1128/JB.147.3.820-826.1981; BONTING CFC, 1993, ARCH MICROBIOL, V159, P428, DOI 10.1007/BF00288589; BONTING CFC, 1991, J BACTERIOL, V173, P6484, DOI 10.1128/jb.173.20.6484-6488.1991; BONTING CFC, 1992, FEMS MICROBIOL ECOL, V102, P57, DOI 10.1111/j.1574-6968.1992.tb05795.x; BONTING CFC, 1992, ARCH MICROBIOL, V158, P139, DOI 10.1007/BF00245217; BONTING CFC, 1993, ANTON LEEUW INT J G, V64, P75, DOI 10.1007/BF00870924; BRZOSKA P, 1994, J BACTERIOL, V176, P15, DOI 10.1128/JB.176.1.15-20.1994; DEINEMA MH, 1985, WATER SCI TECHNOL, V17, P119, DOI 10.2166/wst.1985.0226; DRIESSEN AJM, 1985, P NATL ACAD SCI USA, V82, P7555, DOI 10.1073/pnas.82.22.7555; DRIESSEN AJM, 1990, BACTERIA, V12, P449; Fuhs GW, 1975, MICROB ECOL, V2, P119, DOI 10.1007/BF02010434; GURR E, 1965, RATIONAL USE DYES BI, P25; Kaback H R, 1974, Methods Enzymol, V31, P698; KABACK HR, 1971, J BIOL CHEM, V246, P5523; KELLY DP, 1988, NITROGEN SULPHUR CYC, P64; LOLKEMA JS, 1982, BIOCHIM BIOPHYS ACTA, V681, P85, DOI 10.1016/0005-2728(82)90281-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASOVER GK, 1977, J BACTERIOL, V130, P297, DOI 10.1128/JB.130.1.297-302.1977; MEDVECZKY N, 1971, BIOCHIM BIOPHYS ACTA, V241, P494, DOI 10.1016/0005-2736(71)90048-4; MICHEL TA, 1990, J BACTERIOL, V172, P1430, DOI 10.1128/jb.172.3.1430-1435.1990; MICHELS PAM, 1979, FEMS MICROBIOL LETT, V5, P357, DOI 10.1111/j.1574-6968.1979.tb03339.x; MOLENAAR D, 1991, BIOCHIM BIOPHYS ACTA, V1115, P75, DOI 10.1016/0304-4165(91)90014-8; OTTO R, 1980, P NATL ACAD SCI-BIOL, V77, P5502, DOI 10.1073/pnas.77.9.5502; OTTO R, 1984, ARCH MICROBIOL, V139, P338, DOI 10.1007/BF00408376; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; POOLMAN B, 1987, J BACTERIOL, V169, P5373, DOI 10.1128/jb.169.12.5373-5378.1987; RAND MC, 1976, STANDARD METHODS EXA, P466; SHINBO T, 1978, ARCH BIOCHEM BIOPHYS, V187, P414, DOI 10.1016/0003-9861(78)90052-8; SIMPSON SJ, 1983, FEMS MICROBIOL LETT, V19, P111; SIMPSON SJ, 1983, EUR J BIOCHEM, V136, P63, DOI 10.1111/j.1432-1033.1983.tb07705.x; SMITH DGE, 1993, J BACTERIOL, V175, P3253, DOI 10.1128/jb.175.11.3253-3258.1993; TENBRINK B, 1980, EUR J BIOCHEM, V111, P59; van Groenestijn J.W., 1988, THESIS AGR U WAGENIN; VANGROENESTIJN JW, 1988, APPL ENVIRON MICROB, V54, P2894, DOI 10.1128/AEM.54.12.2894-2901.1988; VANGROENESTIJN JW, 1989, A VAN LEEUW J MICROB, V55, P67, DOI 10.1007/BF02309620; VANGROENESTIJN JW, 1989, APPL ENVIRON MICROB, V55, P219, DOI 10.1128/AEM.55.1.219-223.1989; VANGROENESTIJN JW, 1987, ARCH MICROBIOL, V148, P14, DOI 10.1007/BF00429640; VANGROENESTIJN JW, 1985, P INT C MANAGEMENT S, P405; VANVEEN HW, 1994, J BACTERIOL, V176, P2670, DOI 10.1128/JB.176.9.2670-2676.1994; VANVEEN HW, 1994, J BIOL CHEM, V269, P16212; VANVEEN HW, 1994, BIOCHEMISTRY-US, V33, P1766, DOI 10.1021/bi00173a020; VANVEEN HW, 1993, J BACTERIOL, V175, P200, DOI 10.1128/JB.175.1.200-206.1993; VANVEEN HW, 1993, J BIOL CHEM, V268, P19377; VANVEEN HW, 1994, PHOSPHATE IN MICROORGANISMS, P43; VANVEEN HW, 1994, THESIS AGR U WAGENIN	45	59	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29509	29514						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961934				2022-12-25	WOS:A1994PU28400033
J	IIDA, N; LOKESHWAR, VB; BOURGUIGNON, LYW				IIDA, N; LOKESHWAR, VB; BOURGUIGNON, LYW			MAPPING THE FODRIN BINDING DOMAIN IN CD45, A LEUKOCYTE MEMBRANE-ASSOCIATED TYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON ANTIGEN CD45; T-CELL RECEPTOR; SIGNAL TRANSDUCTION; HUMAN-PLACENTA; MESSENGER-RNA; BRAIN FODRIN; PROTEIN; KINASE; FAMILY; PHOSPHORYLATION	CD45 belongs to a family of high molecular mass leukocyte glycoproteins. It contains both an intrinsic protein tyrosine phosphatase (PTPase) activity and a cytoskeleton binding site in its cytoplasmic domain. Certain cytoskeletal proteins, such as fodrin (a spectrin like molecule), are known to play an important role in the regulation of CD45's PTPase activity. In this study we mapped the fodrin binding domain of CD45 by deleting various portions of the cytoplasmic region, followed by the expression of these truncated cDNAs using an in vitro transcription/translation system. The results of these experiments indicate that the CD45 fodrin binding domain resides between amino acids 825 and 939. Construction of a fusion protein encoding the region between amino acids 825 and 939 shows that this particular sequence itself is sufficient for fodrin binding. Further analyses indicate that the sequence ((930)EENKKKNRN(939)S) in CD45 has good sequence homology with the spectrin binding domain found in the MSP1 glycoprotein of the malarial parasite. Biochemical studies, using binding competition assays, and a synthetic peptide containing the sequence (930)EENKKKNRN(939)S, support the conclusion that the sequence between amino acids 930 and 939 is a critical part of CD45's fodrin binding domain. Further analyses indicate that this sequence is also involved in the fodrin-induced up-regulation of CD45 PTPase activity. Therefore, we suggest that fodrin binding to this domain is required for the onset of CD45-mediated signal transduction and leukocyte activation.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT R124,MIAMI,FL 33101	University of Miami					NCI NIH HHS [1F32CA06057] Funding Source: Medline; NIGMS NIH HHS [GM 36353] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKBAR AN, 1988, J IMMUNOL, V140, P2171; BARCLAY AN, 1987, EMBO J, V6, P1259, DOI 10.1002/j.1460-2075.1987.tb02362.x; BENNETT V, 1983, METHOD ENZYMOL, V96, P314; BEVERLEY PCL, 1992, BIOCHEM SOC T, V20, P184, DOI 10.1042/bst0200184; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; GLENNEY JR, 1982, J BIOL CHEM, V257, P9781; GLENNEY JR, 1982, P NATL ACAD SCI-BIOL, V79, P4002, DOI 10.1073/pnas.79.13.4002; GLENNY JR, 1980, CELL, V28, P843; HALL LR, 1988, J IMMUNOL, V141, P2781; HERRERA S, 1993, EMBO J, V12, P1607, DOI 10.1002/j.1460-2075.1993.tb05805.x; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; JOHNSON NA, 1989, J BIOL CHEM, V264, P6220; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KANNER SB, 1992, BIOCHEM SOC T, V20, P178, DOI 10.1042/bst0200178; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; MASEN D, 1992, BIOCHEM SOC T, V20, P188; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MORIMOTO C, 1985, J IMMUNOL, V134, P1508; MUSTELIN T, 1990, ONCOGENE, V5, P809; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; POT DA, 1992, J BIOL CHEM, V267, P140; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; RUDD CE, 1987, J EXP MED, V166, P1758, DOI 10.1084/jem.166.6.1758; SAGA Y, 1990, IMMUNOGENETICS, V31, P296, DOI 10.1007/BF02115003; SAITO H, 1992, BIOCHEM SOC T, V20, P165, DOI 10.1042/bst0200165; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; SUCHARD SJ, 1987, BIOCHIM BIOPHYS ACTA, V896, P35, DOI 10.1016/0005-2736(87)90353-1; TAN XH, 1993, J BIOL CHEM, V268, P6835; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; VALAREVIC S, 1993, SCIENCE, V260, P541	49	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28576	28583						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961804				2022-12-25	WOS:A1994PU16800013
J	WARRIAR, N; YU, CY; GOVINDAN, MV				WARRIAR, N; YU, CY; GOVINDAN, MV			HORMONE-BINDING DOMAIN OF HUMAN GLUCOCORTICOID RECEPTOR - ENHANCEMENT OF TRANSACTIVATION FUNCTION BY SUBSTITUTION MUTANTS M565R AND A573Q	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; HEAT-SHOCK PROTEIN; SINGLE AMINO-ACID; DNA-BINDING; PROGESTERONE RECEPTORS; STEROID-RECEPTORS; COMPLEX; ACTIVATION; REGION; LIGAND	To determine the importance of specific amino acids in the hormone-binding domain of the human glucocorticoid receptor (hGR), we have generated mutants M565R, G567A, and A573Q. In hormone binding assays using [H-3]cortisol, half-maximal saturation of dexamethasone competition was achieved at 10 pm with hGR M565R and hGR A573Q compared to 10 nM with wild type hGR. Similar results were obtained in competition assays with [H-3]dexamethasone and the glucocorticoid antagonist RU 486. The substitution mutants M565R and A573Q demonstrated a higher relative affinity for aldo-sterone compared to the wild type hGR. In CV-1 cells cotransfected with the mutant receptors, hGR M565R and A573Q showed a remarkable 6-fold elevated transcription activation of the chimeric reporter gene mouse mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT). The mutant hGR G567A failed to bind agonists and antagonists efficiently. Immunoblotting with hGR specific antibodies of the whole cell extract from transfected CV-1 cells revealed that these differences in hormone binding and transcription activation were not due to the decreased levels of expression. These data support the idea that Gly(567) in the hGR hormone-binding domain lies in a region crucial to ligand binding and transactivation function.	CHU LAVAL,RES CTR,MRC,MOLEC ENDOCRINOL GRP,QUEBEC CITY G1V 4G2,PQ,CANADA; UNIV LAVAL,QUEBEC CITY G1V 4G2,PQ,CANADA	Laval University; Laval University								ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DENIS M, 1988, J BIOL CHEM, V263, P18520; DENIS M, 1989, CANCER RES, V49, pS2275; ERIKSSON P, 1990, J BIOL CHEM, V265, P3535; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GOVINDAN MV, 1990, MOL ENDOCRINOL, V4, P417, DOI 10.1210/mend-4-3-417; GOVINDAN MV, 1982, P NATL ACAD SCI-BIOL, V79, P5157, DOI 10.1073/pnas.79.17.5157; GOVINDAN MV, 1984, J BIOL CHEM, V259, P2915; GOVINDAN MV, 1991, J STEROID BIOCHEM, V39, P91, DOI 10.1016/0960-0760(91)90017-Y; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1989, CANCER RES, V49, pS2292; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; HURLEY DM, 1991, J CLIN INVEST, V87, P680, DOI 10.1172/JCI115046; KROZOWSKI ZS, 1983, P NATL ACAD SCI-BIOL, V80, P6056, DOI 10.1073/pnas.80.19.6056; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Maniatis T., 1982, MOL CLONING; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PAGE N, 1994, IN PRESS AM J PHYSL; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; PRATT WB, 1988, J BIOL CHEM, V263, P267; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; Raynaud J.-P., 1983, STEROID HORMONE RECE, P141; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; TEUSCH G, 1990, J STEROID BIOCHEM, V31, P549; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WILSON JD, 1981, SCIENCE, V211, P1278, DOI 10.1126/science.7010602; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	45	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29010	29015						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961865				2022-12-25	WOS:A1994PU16800075
J	POLLEGIONI, L; FUKUI, K; MASSEY, V				POLLEGIONI, L; FUKUI, K; MASSEY, V			STUDIES ON THE KINETIC MECHANISM OF PIG-KIDNEY D-AMINO-ACID OXIDASE BY SITE-DIRECTED MUTAGENESIS OF TYROSINE-224 AND TYROSINE-228	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC FUNCTION; HALF-REACTION; ACTIVE-SITE; SUBSTRATE; PURIFICATION; EXPRESSION	Expression conditions in Escherichia coli of wild-type, Y224F, and Y228F mutants of pig kidney D-amino acid oxidase (DAAO) have been changed to yield more enzyme. The mutated proteins show spectral properties similar to those of the wild-type enzyme, in all oxidation-reduction states. Ah enzymes were studied by steady state and rapid reaction methods. Turnover numbers determined for Y224F DAAO with different substrates were similar to those of wild-type protein, while the Y228F DAAO always showed lower turnover numbers and higher K-m values for the D-amino acid. Analyses of reduction traces at 450 and 550 nm of stopped-flow experiments with wild-type DAAO showed the presence of a new phase, the conversion between two different charge-transfer complexes of the reduced enzyme and imino acid product. The substitution of Tyr-228 totally abolished the formation of the long wavelength bands while Y224F DAAO showed long wavelength absorbance only for the first intermediate. Reoxidation of the reduced flavin results from reaction of oxygen with the first charge-transfer complex. The rate of reduction with D-alanine as substrate was 1225,45 and 10 s(-1) for wild-type, Y224F, and Y228F DAAOs, respectively. Comparison of the properties of these two mutant enzyme forms with those of the wild-type DAAO indicate that both tyrosine residues have their main function in the reductive half-reaction of the; enzyme.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; NATL CARDIOVASC CTR,RES INST,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN	University of Michigan System; University of Michigan; National Cerebral & Cardiovascular Center - Japan				Fukui, Kiyoshi/0000-0002-7438-4938; POLLEGIONI, LOREDANO/0000-0003-1733-7243	NIGMS NIH HHS [GM11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATY NB, 1981, J BIOL CHEM, V256, P4619; BENESI HA, 1949, J AM CHEM SOC, V71, P2703, DOI 10.1021/ja01176a030; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; Curti B., 1991, CHEM BIOCH FLAVOENZY, V3, P69; DENU JM, 1992, BIOCHEMISTRY-US, V31, P8207, DOI 10.1021/bi00150a013; DUBOIS J, 1990, BIOCHEMISTRY-US, V29, P6393, DOI 10.1021/bi00479a008; FITZPATRICK PF, 1982, J BIOL CHEM, V257, P2916; FONDA ML, 1967, J BIOL CHEM, V242, P3957; FUKUI K, 1987, BIOCHEMISTRY-US, V26, P3612, DOI 10.1021/bi00386a054; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; HAFNER EW, 1971, P NATL ACAD SCI USA, V68, P987, DOI 10.1073/pnas.68.5.987; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACHEROUX P, 1993, EUR J BIOCHEM, V213, P1047, DOI 10.1111/j.1432-1033.1993.tb17852.x; MARCOTTE P, 1978, BIOCHEMISTRY-US, V17, P2864, DOI 10.1021/bi00607a026; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; MASSEY V, 1964, FED PROC, V23, P18; MASSEY V, 1965, BIOCHEMISTRY-US, V4, P1161, DOI 10.1021/bi00882a027; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MASSEY V, 1966, FLAVINS FLAVOPROTEIN, P133; MIURA R, 1988, BIOORG CHEM, V16, P97, DOI 10.1016/0045-2068(88)90039-9; MIYANO M, 1991, J BIOCHEM-TOKYO, V109, P171, DOI 10.1093/oxfordjournals.jbchem.a123340; MUH U, 1994, J BIOL CHEM, V269, P7994; PORTER DJT, 1977, J BIOL CHEM, V252, P4464; RONCHI S, 1980, J BIOL CHEM, V255, P6044; RONCHI S, 1982, FLAVINS FLAVOPROTEIN, P66; RUDIE MG, 1980, J BIOL CHEM, V255, P498; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; VANDENBERGHESNOREK S, 1985, J BIOL CHEM, V260, P3373; WALSH CT, 1973, J BIOL CHEM, V248, P1946; WATANABE F, 1989, BIOCHEM BIOPH RES CO, V165, P1422, DOI 10.1016/0006-291X(89)92762-9; WATANABE F, 1988, FEBS LETT, V238, P269, DOI 10.1016/0014-5793(88)80494-0; WATANABE F, 1989, J BIOCHEM-TOKYO, V105, P1024, DOI 10.1093/oxfordjournals.jbchem.a122760	34	57	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31666	31673						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989339				2022-12-25	WOS:A1994PX30300054
J	SADEK, CM; ALLENHOFFMANN, BL				SADEK, CM; ALLENHOFFMANN, BL			SUSPENSION-MEDIATED INDUCTION OF HEPA 1C1C7 CYP1A-1 EXPRESSION IS DEPENDENT ON THE AH RECEPTOR SIGNAL-TRANSDUCTION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; DIOXIN RECEPTOR; NUCLEAR RECEPTORS; BINDING; LIGAND; CDNA; GENE; CYTOCHROME-P1-450; SEQUENCES; CLONING	We have recently demonstrated that release of normal human epithelial cells from cell-substratum and/or cell-cell adhesion generates cellular signals that induce the expression of CYP1A1 in the absence of xenobiotic polycyclic aromatic hydrocarbons (Sadek, C. M,, and Allen-Hoffmann, B, L, (1994) J, Biol. Chem. 169, 16067-16074), To directly test the involvement of the Ah receptor signal transduction pathway in CYP1A1 induction following suspension of epithelial cells, we analyzed wild-type Hepa 1c1c7 cells, a subclone of the Hepa-1c1 mouse hepatoma Line, and two mutant Hepa 1c1c7 lines, Class I and Class II. Suspension of wild type Hepa 1c1c7 cells for 4 h led to an induction of steady state levels of CYP1A1 mRNA, similar to that obtained following treatment of adherent cells with 10(-9) M 2,3,7,8-tetrachlorodibenzo-p-dioxin, Mutants of the Hepa 1c1c7 cells defective in different aspects of the Ah receptor signal transduction pathway exhibited negligible (Class I) or no (Class II) suspension-mediated induction of CYP1A1 mRNA. Gel mobility shift analysis of nuclear extracts from suspended or 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated wild-type cells showed that both treatments produced identical shifts in the mobility of an XRE-containing probe, Antibody supershift experiments confirmed that the Ah receptor was a component of the DNA-protein complex from suspended wild-type Hepa 1c1c7 cells. These data directly demonstrate that suspension of wild-type Hepa 1c1c7 cells leads to nuclear localization and activation of the Ah receptor to a DNA-binding form.	UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53706; UNIV WISCONSIN,CTR ENVIRONM TOXICOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Sadek, Christine/A-7356-2010		NIAMS NIH HHS [AR40284] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040284, R01AR040284] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GONZALEZ FJ, 1984, GENE, V29, P281, DOI 10.1016/0378-1119(84)90057-X; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; KIMURA S, 1984, J BIOL CHEM, V259, P705; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OKEY AB, 1994, TOXICOL LETT, V70, P1, DOI 10.1016/0378-4274(94)90139-2; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SADEK CM, 1994, J BIOL CHEM, V269, P16067; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITLOCK JP, 1984, J BIOL CHEM, V259, P980	21	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31505	31509						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989317				2022-12-25	WOS:A1994PX30300030
J	TANIMOTO, K; SUGIYAMA, F; GOTO, Y; ISHIDA, J; TAKIMOTO, E; YAGAMI, K; FUKAMIZU, A; MURAKAMI, K				TANIMOTO, K; SUGIYAMA, F; GOTO, Y; ISHIDA, J; TAKIMOTO, E; YAGAMI, K; FUKAMIZU, A; MURAKAMI, K			ANGIOTENSINOGEN-DEFICIENT MICE WITH HYPOTENSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BLOOD-PRESSURE; MESSENGER-RNA; RENIN; SYSTEM; GENES; EXPRESSION; ENZYME; ACID	The renin-angiotensin system is an enzymatic cascade that produces a potent vasoconstrictor octapeptide angiotensin II, through its physiologically inactive intermediate decapeptide angiotensin I, from their precursor angiotensinogen, In the present study, we generated angiotensinogen-deficient mice by homologous recombination in mouse embryonic stem cells, These mice do not produce angiotensinogen in the liver, resulting in the complete loss of plasma immunoreactive angiotensin I, The systolic blood pressure of the homozygous mutant mice was 66.9 +/- 4.1 mm Hg, significantly lower than that of wild-type mice (100.4 +/- 4.4 mm Hg). This profound hypotension in angiotensinogen-deficient mice demonstrates an indispensable role for the renin-angiotensin system in maintaining blood pressure.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,LAB ANIM RES CTR,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; University of Tsukuba			fukamizu, akiyoshi/J-5350-2012; Tanimoto, Keiji/B-2600-2014	fukamizu, akiyoshi/0000-0002-8786-6020; Tanimoto, Keiji/0000-0003-1971-6546				BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; CATANZARO DF, 1985, ENDOCRINOLOGY, V117, P872, DOI 10.1210/endo-117-3-872; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; GOMEZ RA, 1988, AM J PHYSIOL, V254, pF900, DOI 10.1152/ajprenal.1988.254.6.F900; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hall JE, 1990, HYPERTENSION PATHOPH, P1105; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; MASUDA T, 1982, BIOMED RES-TOKYO, V3, P541, DOI 10.2220/biomedres.3.541; OGAWA Y, 1994, J CLIN INVEST, V93, P1911, DOI 10.1172/JCI117182; Okunishi H, 1984, J Hypertens, V2, P277; PAUL M, 1992, TRENDS CARDIOVAS MED, V2, P94, DOI 10.1016/1050-1738(92)90013-I; PRINTZ MP, 1977, J BIOL CHEM, V252, P1654; REID IA, 1978, ANNU REV PHYSIOL, V40, P377, DOI 10.1146/annurev.ph.40.030178.002113; SCHALEKAMP MADH, 1992, J HYPERTENS, V10, pS157; SMITHIES O, 1994, P NATL ACAD SCI USA, V91, P1612; STEINHELPER ME, 1990, HYPERTENSION, V16, P301, DOI 10.1161/01.HYP.16.3.301; TAMURA K, 1992, JPN HEART J, V33, P113; TANIMOTO K, 1994, EXP CELL RES, V211, P408, DOI 10.1006/excr.1994.1105; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; URATA H, 1990, J BIOL CHEM, V265, P22348; WANG J, 1994, HYPERTENSION, V23, P236, DOI 10.1161/01.HYP.23.2.236; WARD R, 1990, HYPERTENSION PATHOPH, P81; WOOD SA, 1993, P NATL ACAD SCI USA, V90, P4582, DOI 10.1073/pnas.90.10.4582; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458	28	325	330	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31334	31337						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989296				2022-12-25	WOS:A1994PX30300004
J	CHEN, HC; GUAN, JL				CHEN, HC; GUAN, JL			STIMULATION OF PHOSPHATIDYLINOSITOL 3'-KINASE ASSOCIATION WITH FOCAL ADHESION KINASE BY PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SWISS 3T3 CELLS; SIGNAL TRANSDUCTION; LYSOPHOSPHATIDIC ACID; ONCOGENIC TRANSFORMATION; INTACT-CELLS; PHOSPHORYLATION; ACTIVATION; RECEPTORS; BOMBESIN	We have previously described the stable association of the focal adhesion kinase (FAK) with phosphatidylinositol 3'-kinase (PI3K) in NIH 3T3 cells. This interaction was stimulated by cell adhesion in vivo and by autophosphorylation of recombinant FAK in vitro. In this report, we show that platelet-derived growth factor (PDGF) could also specifically stimulate this association in vivo. This stimulation is independent of cell adhesion or the integrity of the cytoskeleton, suggesting potentially different mechanisms by which the cell surface PDGF receptor and integrins regulate PI3K:FAK associations. We also found that this increased association in response to PDGF occurred in the membrane fractions, consistent with the recruitment of PI3K to the cell surface by the activated PDGF receptor. These results provide a novel mechanism of cross-talk between the signaling pathways initiated by PDGF and that initiated by integrins and raise the intriguing possibility that FAK might participate in some of the cellular effects of the growth factors in modulating cell morphology and migration.	CORNELL UNIV, COLL VET MED, DEPT PATHOL, CANC BIOL LABS, ITHACA, NY 14853 USA	Cornell University					NIGMS NIH HHS [R01GM48050] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048050] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FORCE T, 1991, J BIOL CHEM, V266, P6650; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GEIGER B, 1992, COLD SPRING HARB SYM, V57, P631, DOI 10.1101/SQB.1992.057.01.069; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MELLSTROM K, 1983, J MUSCLE RES CELL M, V4, P589, DOI 10.1007/BF00712117; MOOLENAAR WH, 1991, ADV CANCER RES, V57, P87; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	51	108	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31229	31233						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983066				2022-12-25	WOS:A1994PV51000075
J	HEYWORTH, PG; BOHL, BP; BOKOCH, GM; CURNUTTE, JT				HEYWORTH, PG; BOHL, BP; BOKOCH, GM; CURNUTTE, JT			RAC TRANSLOCATES INDEPENDENTLY OF THE NEUTROPHIL NADPH OXIDASE COMPONENTS P47(PHOX) AND P67(PHOX) - EVIDENCE FOR ITS INTERACTION WITH FLAVOCYTOCHROME B(558)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; GTP-BINDING PROTEIN; FULLY SOLUBLE SYSTEM; PLASMA-MEMBRANE; CYTOSOLIC COMPONENTS; ACTIVATION; SUPEROXIDE	When the neutrophil NADPH oxidase is activated to generate superoxide, the cytosolic components, p47(phox), p67(phox), and the GTP-binding protein Rac, become stably associated with the plasma membrane. The translocation of p47(phox) and p67(phox) is dependent on the presence in the membrane of the flavocytochrome b(558), itself composed of two subunits, gp91(phox) and p22(phox). In this study we have quantitated Rac1 and Rac2 in human neutrophils and show that >96% of the Rac protein is Rac2 and that chronic granulomatous disease (CGD) neutrophils contain normal levels of the protein. We used a cell-free translocation system as well as intact normal and CGD neutrophils to determine whether the translocation of Rac2 is dependent upon the presence of the other oxidase components. When cell-free reactions contained any combination of normal, p47(phox)-deficient or p67(phox)-deficient cytosol and normal or flavocytochrome b(558)-deficient membranes, the GTP gamma S (guanosine 5'-3-O-(thio)triphosphate) dependent association of Race with the re-isolated membranes was not significantly different from the control mixture of normal membranes and cytosol. In intact CGD neutrophils lacking p47(phox) or p67(phox) and stimulated with phorbol myristate acetate the translocation of Rac2 was also normal, and we conclude that Rac translocation can occur independently of the cytosolic NADPH oxidase components. In contrast, in the absence of flavocytochrome b(558) from intact X-chromosome linked CGD neutrophils, Rac2 translocation was reduced to only 25% of the control value. On the basis of these observations we propose that while Rac2 can bind to a site distinct from either gp91(phox) or p22(phox), it depends upon an interaction with the flavocytochrome b(558) for maximal stability in the membrane.	Scripps Res Inst, DEPT IMMUNOL & CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	HEYWORTH, PG (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, CAL 1,10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R23AI024834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48008] Funding Source: Medline; NIAID NIH HHS [AI24834] Funding Source: Medline; NIGMS NIH HHS [GM44428] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BADWEY JA, 1982, BIOCHEM BIOPH RES CO, V106, P170, DOI 10.1016/0006-291X(82)92073-3; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1994, J BIOL CHEM, V269, P10813; CURNUTTE JT, 1989, J CLIN INVEST, V83, P1236, DOI 10.1172/JCI114006; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; HEYWORTH PG, 1992, CELLULAR MOL MECHANI, V4, P43; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KRECK ML, 1994, J BIOL CHEM, V269, P4161; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; TSUNAWAKI S, 1994, BIOCHEM BIOPH RES CO, V199, P1378, DOI 10.1006/bbrc.1994.1383; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	32	210	213	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30749	30752						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7982999				2022-12-25	WOS:A1994PV51000003
J	LIM, HM				LIM, HM			ANALYSIS OF SUBUNIT INTERACTION BY INTRODUCING DISULFIDE BONDS AT THE DIMERIZATION DOMAIN OF HIN RECOMBINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; ESCHERICHIA-COLI; STRAND EXCHANGE; DNA INVERSION; GEL-ELECTROPHORESIS; CATALYTIC DOMAIN; PHASE VARIATION; CROSS-LINKING; PROTEIN; ENHANCER	The Rin recombinase exists as a homodimer in solution and binds to its recombination site (hix) as a dimer (Glasgow, A. C., Bruist, M. F., and Simon M. I. (1989) J. Biol. Chem. 264, 10072-10082). Previous mutational and structural studies of related proteins suggested the location of a putative dimerization domain. In order to probe the function of this region of the protein, cysteine residues were introduced at each of the seven positions comprising the domain. Proteins containing cysteine substitutions at positions 101 and 104 were able to form disulfide bonds spontaneously in crude extracts. M101C showed wild type inversion activity only if the cysteine residue was not engaged in a disulfide bond. This mutant, which is cross-linked by a disulfide bond at the dimeric interface, was found to be defective in the DNA cleavage step during inversion. H107C displayed the wild type DNA cleavage activity, even though its DNA binding activity was not detected by three different binding assays. This suggests that it maintains specificity for DNA binding but dissociates rapidly after binding. The remaining inversion-defective mutants fell into two groups. One group lost its capacity to specifically bind to DNA (G102C, F105C, and F106C), and the other group (R103C and F104C), while able to bind to DNA, was defective in subsequent steps of the inversion reaction. Characteristics of these mutants led me to postulate that movement of subunits at the dimerization interface is critical during DNA binding and during formation of the invertasome, which is the recombination structure. Furthermore, the relative position of subunits within the dimer may be important for maintaining stable DNA binding.			LIM, HM (corresponding author), CHUNGNAM NATL UNIV,COLL NAT SCI,DEPT BIOL,TAEJON 305764,SOUTH KOREA.			Lim, Heon/0000-0003-1711-2589				BENSON N, 1986, GENETICS, V114, P1; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUIST MF, 1987, SCIENCE, V235, P777, DOI 10.1126/science.3027895; BRUIST MF, 1987, GENE DEV, V1, P762, DOI 10.1101/gad.1.8.762; BRUIST MF, 1984, J BACTERIOL, V159, P71, DOI 10.1128/JB.159.1.71-79.1984; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5468, DOI 10.1021/bi00367a018; EILEN E, 1977, J MOL BIOL, V114, P47, DOI 10.1016/0022-2836(77)90282-0; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GLASGOW AC, 1989, J BIOL CHEM, V264, P10072; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; GRINDLEY NDF, 1985, GENOME REARRANGEMENT, V20, P77; HAFFTER P, 1988, EMBO J, V7, P3991, DOI 10.1002/j.1460-2075.1988.tb03287.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HIESTANDNAUER R, 1983, EMBO J, V2, P1733, DOI 10.1002/j.1460-2075.1983.tb01650.x; HUGHES KT, 1988, GENE DEV, V2, P937, DOI 10.1101/gad.2.8.937; HUGHES RE, 1993, EMBO J, V12, P1447, DOI 10.1002/j.1460-2075.1993.tb05788.x; JOHNSON RC, 1985, CELL, V41, P781, DOI 10.1016/S0092-8674(85)80059-3; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KLIPPEL A, 1988, EMBO J, V7, P3983, DOI 10.1002/j.1460-2075.1988.tb03286.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V84, P4767; LEDERBERG J, 1956, GENETICS, V41, P743; LIM HM, 1988, GENE ANAL TECH, V5, P32, DOI 10.1016/0735-0651(88)90024-6; LIM HM, 1992, J BIOL CHEM, V267, P11183; LIM HM, 1992, J BIOL CHEM, V267, P11176; MAZZARELLI JM, 1993, BIOCHEMISTRY-US, V32, P2979, DOI 10.1021/bi00063a008; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PLASTERK RHA, 1983, P NATL ACAD SCI-BIOL, V80, P5355, DOI 10.1073/pnas.80.17.5355; REED RR, 1982, NATURE, V300, P381, DOI 10.1038/300381a0; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; VIERA J, 1987, METHOD ENZYMOL, V153, P3; ZIEG J, 1977, SCIENCE, V196, P170, DOI 10.1126/science.322276; ZIEG J, 1980, P NATL ACAD SCI-BIOL, V77, P4196, DOI 10.1073/pnas.77.7.4196	41	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31134	31142						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983055				2022-12-25	WOS:A1994PV51000062
J	MCDONALD, WF; TRAKTMAN, P				MCDONALD, WF; TRAKTMAN, P			VACCINIA VIRUS-DNA POLYMERASE - IN-VITRO ANALYSIS OF PARAMETERS AFFECTING PROCESSIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-CHARACTERIZATION; REPLICATION; DELTA; YEAST; POXVIRUSES; RESISTANCE; HOMOLOGY; EPSILON; ALPHA; SITE	The polymerization and proofreading activities of the vaccinia virus DNA polymerase reside within a 118-kDa catalytic polypeptide. We report here an investigation of the intrinsic processivity of this enzyme on both natural and homopolymeric DNA templates. Inclusion of the Escherichia coli helix destabilizing protein allowed the viral enzyme, which lacks strand displacement activity, to utilize a singly primed M13 DNA template. In the presence of either 10 mM MgCl2 or 1 mM MgCl2 + 40 mM NaCl, synthesis was achieved in a highly distributive manner, RFII formation required a significant excess of enzyme, and less than or equal to 10 nucleotides (nt) were added per primer-template binding event. The apparent rate of primer elongation varied with the enzyme/template ratio and reached a maximum of 8 nt/s. A similar lack of processivity was observed on a poly(dA(390))-oligo(dT(12-18)) template. In contrast, highly processive synthesis was achieved on both templates in the presence of 1 mar MgCl2 and the absence of NaCl. A primer extension rate of 30 nt/s was observed, and greater than or equal to 2000 nt were added per binding event. These studies suggest that the catalytic polypeptide of the vaccinia virus DNA polymerase will require accessory protein(s) to form a stable enzyme-template interaction and direct processive DNA synthesis under isotonic conditions in vivo.	CORNELL UNIV, COLL MED, DEPT CELL BIOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT MICROBIOL, NEW YORK, NY 10021 USA	Cornell University; Cornell University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021758] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21758] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BURGERS PMJ, 1988, NUCLEIC ACIDS RES, V16, P6297, DOI 10.1093/nar/16.14.6297; BURGERS PMJ, 1989, PROG NUCLEIC ACID RE, V37, P235; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CAMPBELL JL, 1993, J BIOL CHEM, V268, P25261; CHALLBERG MD, 1979, J BIOL CHEM, V254, P7820; CHALLBERG MD, 1979, J BIOL CHEM, V254, P7812; CHALLBERG MD, 1991, SEMIN VIROL, V2, P247; DEFILIPPES FM, 1989, J VIROL, V63, P4060, DOI 10.1128/JVI.63.9.4060-4063.1989; EARL PL, 1986, P NATL ACAD SCI USA, V83, P3659, DOI 10.1073/pnas.83.11.3659; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; LEE SH, 1991, J BIOL CHEM, V266, P22707; MCDONALD WF, 1994, PROTEIN EXPRES PURIF, V5, P409, DOI 10.1006/prep.1994.1059; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ODONNELL ME, 1987, J BIOL CHEM, V262, P4252; SABATINO RD, 1988, BIOCHEMISTRY-US, V27, P2998, DOI 10.1021/bi00408a050; TADDIE JA, 1991, J VIROL, V65, P869, DOI 10.1128/JVI.65.2.869-879.1991; TADDIE JA, 1993, J VIROL, V67, P4323, DOI 10.1128/JVI.67.7.4323-4336.1993; TRAKTMAN P, 1990, CELL, V62, P621, DOI 10.1016/0092-8674(90)90106-O; TRAKTMAN P, 1990, CURR TOP MICROBIOL, V163, P93; TRAKTMAN P, 1984, J VIROL, V49, P125, DOI 10.1128/JVI.49.1.125-131.1984; TRAKTMAN P, 1989, J VIROL, V63, P841, DOI 10.1128/JVI.63.2.841-846.1989; TRAKTMAN P, 1991, SEMIN VIROL, V2, P291; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855	28	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31190	31197						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983061				2022-12-25	WOS:A1994PV51000070
J	PASTORINO, JG; SIMBULA, G; GILFOR, E; HOEK, JB; FARBER, JL				PASTORINO, JG; SIMBULA, G; GILFOR, E; HOEK, JB; FARBER, JL			PROTOPORPHYRIN-IX, AN ENDOGENOUS LIGAND OF THE PERIPHERAL BENZODIAZEPINE RECEPTOR, POTENTIATES INDUCTION OF THE MITOCHONDRIAL PERMEABILITY TRANSITION AND THE KILLING OF CULTURED-HEPATOCYTES BY ROTENONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; BINDING-SITES; CYCLOSPORINE; MEMBRANE; PORE; MODULATION; LOCALIZATION; ASSOCIATION; PORPHYRINS; MECHANISMS	The peripheral benzodiazepine receptor (PBzR) is associated with the outer mitochondrial membrane. Protoporphyrin IX (PPIX), an endogenous substance with high affinity for the PBzR, induced the inner membrane permeability transition (MPT) in respiring liver mitochondria de-energized by carbonyl cyanide p-trifluoromethoxyphenylhydrazone. Cyclosporin A (CyA), an inhibitor of the permeability transition, prevented this effect. In cultured hepatocytes, the MPT was measured as an increased [H-3]sucrose-accessible space sensitive to CyA. Nanomolar concentrations of PPIX potentiated the induction of the MPT and the extent of cell killing in hepatocyte cultures de-energized by rotenone. CyA prevented the enhanced cell killing by PPIX. PPIX did not increase the rate or extent of ATP depletion, the loss of the mitochondrial membrane potential, or the accumulation of long chain acyl-CoA thioesters. The association of the PBzR with the voltage-dependent anion channel of the outer mitochondrial membrane and with the adenine nucleotide carrier of the inner membrane suggests that this complex mediates the transport of PPIX across the mitochondrial membranes. In turn, this same complex participates in the MPT. Thus, the same structural complex (PBzR, voltage-dependent anion channel, and adenine nucleotide carrier) can interact with the endogenous substrate PPIX to result in different functional consequences depending on the state of mitochondrial energization.	THOMAS JEFFERSON UNIV,DEPT PATHOL,PHILADELPHIA,PA 19107	Jefferson University				SIMBULA, GABRIELLA/0000-0003-4946-532X; Hoek, Jan/0000-0001-7127-4218	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07186] Funding Source: Medline; NIDDK NIH HHS [DK38305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; BASILE AS, 1986, J NEUROCHEM, V46, P305, DOI 10.1111/j.1471-4159.1986.tb12965.x; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BIBIER LL, 1986, BIOCHEM SOC T, V14, P674; COLUCCI WJ, 1988, BIOORG CHEM, V16, P307, DOI 10.1016/0045-2068(88)90018-1; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; DOBLE A, 1987, MOL PHARMACOL, V31, P42; DOBLE A, 1987, J RECEPTOR RES, V7, P55, DOI 10.3109/10799898709054979; FARBER JL, 1981, ARCH BIOCHEM BIOPHYS, V211, P312, DOI 10.1016/0003-9861(81)90459-8; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; HOEK JB, 1980, J BIOL CHEM, V255, P1458; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; KANE AB, 1985, AM J PHYSIOL, V249, pC256, DOI 10.1152/ajpcell.1985.249.3.C256; MCENERY MW, 1992, J BIOENERG BIOMEMBR, V24, P63, DOI 10.1007/BF00769532; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; OBEIRNE GB, 1990, EUR J BIOCHEM, V188, P131, DOI 10.1111/j.1432-1033.1990.tb15380.x; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PASTORINO JG, 1994, IN PRESS AM J PHYSL; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P370; SNYDER SH, 1987, FASEB J, V1, P282, DOI 10.1096/fasebj.1.4.2820823; VERMA A, 1988, MOL PHARMACOL, V34, P800; VERMA A, 1989, ANNU REV PHARMACOL, V29, P307; VERMA A, 1987, P NATL ACAD SCI USA, V84, P2256, DOI 10.1073/pnas.84.8.2256; WALAJTYSRHODE E, 1992, J BIOL CHEM, V267, P370; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4	30	124	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31041	31046						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983042				2022-12-25	WOS:A1994PV51000049
J	BOULOUMIE, A; PLANAT, V; DEVEDJIAN, JC; VALET, P; SAULNIERBLACHE, JS; RECORD, M; LAFONTAN, M				BOULOUMIE, A; PLANAT, V; DEVEDJIAN, JC; VALET, P; SAULNIERBLACHE, JS; RECORD, M; LAFONTAN, M			ALPHA-(2)-ADRENERGIC STIMULATION PROMOTES PREADIPOCYTE PROLIFERATION - INVOLVEMENT OF MITOGEN-ACTIVATED PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; ALPHA-2-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; DIFFERENTIATION; EXPRESSION; FIBROBLASTS; CELLS; ADIPOCYTES; SUBTYPES; RATS	Primary cultures of rat preadipocytes were shown to express alpha(2)- and beta-adrenoreceptors when maintained in serum-deprived medium. alpha(2)-Adrenoreceptor stimulation led to an increase in cell number, whereas beta-adrenoreceptor stimulation was without effect. On 3T3-F442A clones stably transfected with the human alpha(2)-C10 gene and expressing a physiologically related number of alpha(2)-adrenoreceptors to overexpression, the proliferative effect of alpha(2)-adrenoreceptor agonist UK14304 was proportional to the level of alpha(2)-adrenoreceptor expressed in individual clones and required alpha(2)-adrenoreceptor stimulation. Analysis of the signaling pathway linked to alpha(2)-adrenoreceptor activation showed that the mitogenic effect was adenylyl cyclase- and protein kinase C-independent. It was pertussis toxin-sensitive, implying the involvement of pertussis toxin-sensitive G proteins. The activation of the mitogen-activated protein kinase pathway was increased after alpha(2)-adrenoreceptor stimulation in both 3T3-F442 clones and rat preadipocytes and inhibited by pertussis toxin treatment. So, catecholamines are involved in the control of white preadipocyte proliferation through the alpha(2)-adrenoreceptor activation, linked to the mitogen-activated protein kinase pathway.	UNIV TOULOUSE 3,CHU RANGUEIL,INST L BUGNARD,INSERM,U317,F-31054 TOULOUSE,FRANCE; CHU PURPAN,INSERM,U326,F-31052 TOULOUSE,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)			Valet, Philippe/N-7472-2017; Saulnier-Blache, Jean Sebastien/X-7729-2018; RECORD, Michel/G-3493-2017; Bouloumie-Diehl, Anne/M-4446-2017	Valet, Philippe/0000-0001-6520-7393; RECORD, Michel/0000-0003-1893-0022; Bouloumie-Diehl, Anne/0000-0001-5496-8891; Saulnier-Blache, Jean Sebastien/0000-0002-8971-7723; Planat-Benard, Valerie/0000-0002-0712-4220				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CARPENE C, 1990, J LIPID RES, V31, P811; COOK S, 1994, NATURE, V369, P361, DOI 10.1038/369361a0; COUSIN B, 1993, ENDOCRINOLOGY, V133, P2255, DOI 10.1210/en.133.5.2255; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DESLEX S, 1987, EXP CELL RES, V168, P15, DOI 10.1016/0014-4827(87)90412-5; DEVEDJIAN JC, 1991, J BIOL CHEM, V266, P14359; DEVEDJIAN JC, 1994, EUR J PHARMACOL, V252, P43, DOI 10.1016/0014-2999(94)90573-8; DJIAN P, 1983, J CLIN INVEST, V72, P1200, DOI 10.1172/JCI111075; GARCIASAINZ JA, 1989, BIOCHEM INT, V19, P899; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; HERMOUET S, 1993, CELL SIGNAL, V5, P215, DOI 10.1016/0898-6568(93)90072-T; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KILGOUR E, 1993, FEBS LETT, V328, P271, DOI 10.1016/0014-5793(93)80942-N; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOZAK UC, 1994, ENDOCRINOLOGY, V134, P906, DOI 10.1210/en.134.2.906; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LAFONTAN M, 1995, IN PRESS GENETICS MO; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; SAULNIERBLACHE JS, 1989, EUR J PHARMACOL, V171, P145, DOI 10.1016/0014-2999(89)90103-9; SAULNIERBLACHE JS, 1991, J LIPID RES, V32, P1489; SEUWEN K, 1990, CELL REGUL, V1, P445, DOI 10.1091/mbc.1.6.445; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; SU H, 1993, AM J PHYSIOL, V34, pC1729; TAOUIS M, 1989, J PHARMACOL EXP THER, V250, P1061; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UHLEN S, 1992, BRIT J PHARMACOL, V106, P986, DOI 10.1111/j.1476-5381.1992.tb14446.x	33	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30254	30259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982935				2022-12-25	WOS:A1994PU52500035
J	STAPLETON, D; GAO, GA; MICHELL, BJ; WIDMER, J; MITCHELHILL, K; TEH, T; HOUSE, CM; WITTERS, LA; KEMP, BE				STAPLETON, D; GAO, GA; MICHELL, BJ; WIDMER, J; MITCHELHILL, K; TEH, T; HOUSE, CM; WITTERS, LA; KEMP, BE			MAMMALIAN 5'-AMP-ACTIVATED PROTEIN-KINASE NONCATALYTIC SUBUNITS ARE HOMOLOGS OF PROTEINS THAT INTERACT WITH YEAST SNF1 PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHARACTERIZATION; GLUCOSE REPRESSION; FATTY-ACID; REDUCTASE; GENE; PHOSPHORYLATION	The 5'-AMP-activated protein kinase is responsible for the regulation of fatty acid synthesis by phosphorylation and inactivation of acetyl-CoA carboxylase. The porcine liver 5'-AMP-activated protein kinase 63-kDa catalytic subunit co-purifies 14,000-fold with a 38- and 4O-kDa protein (Mitchelhill, K. I. et al. (1994) J. Biol. Chem. 269, 2361-2364). The 63-kDa subunit is homologous to the Saccharomyces cerevisiae Snf1 protein kinase, which regulates gene expression during glucose derepression. Peptide amino acid and polymerase chain reaction-derived partial cDNA sequences of both the pig and rat fiver enzymes show that the 38-kDa protein is homologous to Snf4p (CAT3) and that the 40-kDa protein is homologous to the Sip1p/Spm/GAL83 family of Snf1p interacting proteins. Sucrose density gradient and cross-linking experiments with purified 5'-AMP-activated protein kinase suggest that both the 38- and 40-kDa proteins associate tightly with the 63-kDa catalytic polypeptide in either a heterotrimeric complex or in dimeric complexes. The 40-kDa subunit is autophosphorylated within the 63-kDa subunit complex. The sequence relationships between the mammalian 5'-AMP-activated protein kinase and yeast Snf1p extend to the subunit proteins consistent with conservation of the functional roles of these polypeptides in cellular regulation by this family of metabolite-sensing protein kinases.	ST VINCENTS INST MED RES, FITZROY, VIC 3065, AUSTRALIA; DARTMOUTH COLL, SCH MED, DIV ENDOCRINE METAB, HANOVER, NH 03755 USA	St. Vincent's Institute of Medical Research; Dartmouth College			Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082	NIDDK NIH HHS [DK35712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARLING D, 1994, J BIOL CHEM, V269, P11442; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CELENZA JL, 1991, METHOD ENZYMOL, V200, P423; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; DAVIES SP, 1994, EUR J BIOCHEM, V223, P351, DOI 10.1111/j.1432-1033.1994.tb19001.x; ERICKSON JR, 1993, GENETICS, V135, P655; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; KENNELLY PJ, 1991, ADV LIPID RES, V1, P19; LESAGE P, 1994, NUCLEIC ACIDS RES, V22, P597, DOI 10.1093/nar/22.4.597; LOUIS NA, 1992, J BIOL CHEM, V267, P2287; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; SCHULLER HJ, 1988, GENE, V67, P247; TIGANIS T, 1993, BIOCHIM BIOPHYS ACTA, V1203, P282, DOI 10.1016/0167-4838(93)90095-9; WITTERS LA, 1991, BIOCHEM BIOPH RES CO, V181, P1486, DOI 10.1016/0006-291X(91)92107-U; WOODS A, 1994, J BIOL CHEM, V269, P19509; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382	24	114	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29343	29346						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961907				2022-12-25	WOS:A1994PU28400003
J	ZHU, H; NAUJOKAS, MA; FIXMAN, ED; TOROSSIAN, K; PARK, M				ZHU, H; NAUJOKAS, MA; FIXMAN, ED; TOROSSIAN, K; PARK, M			TYROSINE-1356 IN THE CARBOXYL-TERMINAL TAIL OF THE HGF/SF RECEPTOR IS ESSENTIAL FOR THE TRANSDUCTION OF SIGNALS FOR CELL MOTILITY AND MORPHOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; C-MET PROTOONCOGENE; SCATTER FACTOR; EPITHELIAL-CELLS; SH3 DOMAINS; KINASE-ACTIVITY; PROTEIN; GRB2; RAS; ACTIVATION	The met proto-oncogene is a receptor tyrosine kinase for hepatocyte growth factor/scatter factor (HGF/SF). HGF/SF is a multifunctional cytokine that stimulates mitogenesis, motility, invasion, and tubulogenesis of a spectrum of epithelial and endothelial cells in culture. Using a chimeric receptor (CSF-MET), containing the extracellular domain of the colony stimulating factor-1 (CSF-1) receptor fused to the transmembrane and intracellular domain of the Met receptor, we have previously demonstrated that activation of the Met kinase domain is sufficient to mediate the motility, invasion and morphogenic signals of HGF/SF in Madin-Darby canine kidney epithelial cells (MDCK). In this study we have analyzed the role of tyrosine phosphorylation of the Met receptor in the transmission of these signals by site-directed mutagenesis of specific tyrosine residues. Mutation of two tyrosine residues (tyrosine 1234 and tyrosine 1235), involved in activation of the catalytic activity of the kinase, abrogates the biological activity of the chimera. In addition, we have identified a single noncatalytic tyrosine residue (tyrosine 1356) in the carboxyl terminus of the Met receptor, that is essential for the biological activity of the chimeric receptor. Mutation of tyrosine 1356 to a nonphosphorylatable phenylalanine residue does not affect the exogenous kinase activity of the receptor toward enolase, but it impairs the ability of the mutant protein to associate with the adaptor protein Grb2, and MDCK cells expressing this mutant fail to scatter, invade, and form branching tubules in response to CSF-1. These results support a crucial role for tyrosine 1356 in activation of signaling pathways involved in the biological activity of the Met receptor in response to HGF/SF.	MCGILL UNIV, ROYAL VICTORIA HOSP, MOLEC ONCOL LAB, MONTREAL H3A 1A1, PQ, CANADA; MCGILL UNIV, DEPT MED, MONTREAL H3A 1A1, PQ, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL H3A 1A1, PQ, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3A 1A1, PQ, CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University								BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FALETTO DL, 1993, HEPATOCYTE GROWTH FA, P108; FIXMAN ED, 1994, IN PRESS ONCOGENE; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HALABAN R, 1992, ONCOGENE, V7, P2195; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KOMADA M, 1993, ONCOGENE, V8, P2381; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU C, 1992, ONCOGENE, V7, P181; LONGATI P, 1994, ONCOGENE, V9, P49; MATSUMOTO K, 1993, HEPATOCYTE GROWTH FA, P226; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WHITE MF, 1988, J BIOL CHEM, V263, P2662; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359	44	121	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29943	29948						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961992				2022-12-25	WOS:A1994PU28400096
J	FINI, ME; BARTLETT, JD; MATSUBARA, M; RINEHART, WB; MODY, MK; GIRARD, MT; RAINVILLE, M				FINI, ME; BARTLETT, JD; MATSUBARA, M; RINEHART, WB; MODY, MK; GIRARD, MT; RAINVILLE, M			THE RABBIT GENE FOR 92-KDA MATRIX METALLOPROTEINASE - ROLE OF AP1 AND AP2 IN CELL-TYPE-SPECIFIC TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE GENE; FACTOR AP-2; GELATINOLYTIC ENZYMES; PHORBOL INDUCTION; HUMAN STROMELYSIN; MAMMALIAN-CELLS; BINDING-SITES; DNA-BINDING; HUMAN SKIN; EXPRESSION	We isolated the rabbit gene for the 92-kDa matrix metalloproteinase, gelatinase B, and sequenced 1802 contiguous bases covering the first three exons and 522 bases of DNA upstream of the start site for transcription. The DNA between bases -519 and +19 is sufficient to drive expression of a reporter gene in early passage cultures of corneal fibroblasts or primary cultures of corneal epithelial cells. Basal activity of the gelatinase B promotor in fibroblasts is lower than a collagenase promotor of 1800 base pairs, but activity of both promoters is similarly stimulated by treatment of transfected cells with phorbol 12-myristate 13-acetate, and stimulation is enhanced by co-treatment with transforming growth factor-beta. In contrast, basal activity of the gelatinase B promotor in epithelial cells is higher than the collagenase promotor. Deletion analysis demonstrated that sequences upstream of base -330 confer cell type-specific activity to the gelatinase B promotor. Site-directed mutagenesis revealed that an AP1-like element within this region is specifically utilized by fibroblasts. This region also contains elements that confer the capacity for activation by AP2, a transcription factor found to be expressed by corneal epithelial cells but not by corneal fibroblasts. In contrast, AP2 does not activate the collagenase promotor. These results provide a molecular basis for the unique cell type-specific expression pattern of gelatinase B as compared to other matrix metalloproteinases.	HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02114	Harvard University; Harvard Medical School	FINI, ME (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,CNY3,13TH ST,BOSTON,MA 02129, USA.		Bartlett, John/L-9832-2017	Bartlett, John/0000-0003-2052-6299	NATIONAL EYE INSTITUTE [R01EY008408] Funding Source: NIH RePORTER; NEI NIH HHS [R01-EY08408] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLEN RW, 1987, J BIOL CHEM, V262, P649; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1992, MATRIX METALLOPROTEI, P145; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINI ME, 1992, ACTA OPHTHALMOL, V70, P26; FINI ME, 1990, J CELL SCI, V97, P373; FINI ME, 1990, INVEST OPHTH VIS SCI, V31, P1779; FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032; FINI ME, 1989, J CELL BIOL, V108, P2045, DOI 10.1083/jcb.108.6.2045; FISHER SJ, 1989, J CELL BIOL, V109, P891, DOI 10.1083/jcb.109.2.891; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIRARD MT, 1993, J CELL SCI, V104, P1001; GIRARD MT, 1991, INVEST OPHTH VIS SCI, V32, P2441; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRABNER G, 1983, INVEST OPHTH VIS SCI, V24, P589; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MASURE S, 1993, EUR J BIOCHEM, V218, P129, DOI 10.1111/j.1432-1033.1993.tb18359.x; MATHIS DJ, 1981, NATURE, V290, P310, DOI 10.1038/290310a0; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATSUBARA M, 1991, INVEST OPHTH VIS SCI, V32, P3221; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURPHY G, 1989, J CELL SCI, V92, P487; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; OIKARINEN A, 1993, J INVEST DERMATOL, V101, P205, DOI 10.1111/1523-1747.ep12363823; PLUZNIK DH, 1992, EXP HEMATOL, V20, P57; PYKE C, 1992, CANCER RES, V52, P1336; SALO T, 1991, J BIOL CHEM, V266, P11436; Sambrook J, 1989, MOL CLONING LABORATO; SATO H, 1993, ONCOGENE, V8, P395; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709	55	103	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28620	28628						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961810				2022-12-25	WOS:A1994PU16800019
J	HAYES, KL; LEONG, L; HENRIKSEN, RA; BOUCHARD, BA; OUELLETTE, L; CHURCH, WR; TRACY, PB				HAYES, KL; LEONG, L; HENRIKSEN, RA; BOUCHARD, BA; OUELLETTE, L; CHURCH, WR; TRACY, PB			ALPHA-THROMBIN-INDUCED HUMAN PLATELET ACTIVATION RESULTS SOLELY FROM FORMATION OF A SPECIFIC ENZYME-SUBSTRATE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUICK-I; RECEPTOR ACTIVATION; AGONIST PEPTIDES; PHOSPHOLIPASE-C; FACTOR-XA; BINDING; DYSTHROMBIN; SITE; IDENTIFICATION; AGGREGATION	Prior studies using the mutant thrombin, thrombin Quick I, indicate that this protease induces maximum platelet aggregation and intraplatelet [Ca2+] fluxes at agonist concentrations where dissociable, equilibrium platelet binding is undetectable and led to the conclusion that thrombin interaction with its platelet ''receptor'' is best described kinetically by formation of an enzyme-substrate complex. This conclusion was substantiated further in the present studies by demonstrating that both thrombin Quick I and thrombin mimicked the thrombin receptor agonist peptide in the induction of the platelet activation-dependent events required for functional Prothrombinase assembly and that a rabbit antibody raised against KATNATLDPRSFLLR, a pentadecapeptide which represents amino acids 32-46 in the platelet thrombin receptor/substrate and spans the thrombin cleavage site, inhibited both thrombin- and thrombin Quick I-induced platelet activation responses equivalently. The antipeptide antibody had a more pronounced inhibitory effect on the rate of the thrombin-induced response rather than the magnitude of the response suggesting competition for the cleavage site, consistent with the observation that pretreatment of metabolically-inhibited platelets with thrombin, which was removed by washing, eliminated specific antibody binding due to removal and/or masking of antibody epitopes. Concentrations of the antipeptide antibody that inhibited thrombin- and thrombin Quick I-induced increases in intracellular [Ca2+] nux by as much as 97% did not alter the dissociable equilibrium binding of I-125-FPR-thrombin to platelets. These combined data indicate that the hydrolytic event initiated by thrombin or thrombin Quick I interaction with the platelet receptor/substrate for thrombin is unrelated to the dissociable equilibrium binding of thrombin to membrane sites described previously by classical receptor-ligand binding analyses.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405; UNIV VERMONT,CELL & MOLEC BIOL PROGRAM,BURLINGTON,VT 05405; E CAROLINA UNIV,SCH MED,DEPT MED,GREENVILLE,NC 27858	University of Vermont; University of Vermont; University of North Carolina; East Carolina University				Leong, Lilley/0000-0003-1041-0110	NHLBI NIH HHS [HL-45194, HL-46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045194, P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER RJ, 1983, ARCH BIOCHEM BIOPHYS, V222, P266, DOI 10.1016/0003-9861(83)90524-6; BAJAJ SP, 1981, PREP BIOCHEM, V11, P394; Bauminger S, 1980, Methods Enzymol, V70, P151; BERNDT MC, 1981, PLATELETS BIOL PATHO, P43; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; CHURCH WR, 1988, J BIOL CHEM, V263, P6259; DEGAN SJF, 1983, BIOCHEMISTRY-US, V22, P2087; DEMARCO L, 1990, J CLIN INVEST, V86, P25, DOI 10.1172/JCI114692; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; FENTON JW, 1977, CHEM BIOL THROMBIN, P43; GRECO NJ, 1991, P SOC EXP BIOL MED, V198, P792; HARMON JT, 1985, BIOCHEMISTRY-US, V24, P58, DOI 10.1021/bi00322a010; HENRIKSEN RA, 1980, J CLIN INVEST, V66, P934, DOI 10.1172/JCI109961; HENRIKSEN RA, 1983, J BIOL CHEM, V258, P3717; HENRIKSEN RA, 1988, BIOCHEMISTRY-US, V27, P9160, DOI 10.1021/bi00426a013; HENRIKSEN RA, 1987, J BIOL CHEM, V262, P4664; HOLMSEN H, 1974, BIOCHEM J, V144, P385, DOI 10.1042/bj1440385; HUANG RS, 1991, J BIOL CHEM, V266, P18435; HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; HUNG DT, 1992, J CLIN INVEST, V89, P444, DOI 10.1172/JCI115604; ISHII K, 1993, J BIOL CHEM, V268, P9780; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; KNUPP CL, 1985, BLOOD, V65, P578; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG L, 1992, BIOCHEMISTRY-US, V31, P2567, DOI 10.1021/bi00124a017; Mann K G, 1976, Methods Enzymol, V45, P123; MARTIN BM, 1976, BIOCHEMISTRY-US, V15, P4886, DOI 10.1021/bi00667a021; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; RITTENHOUSE SE, 1983, P NATL ACAD SCI-BIOL, V80, P5417, DOI 10.1073/pnas.80.17.5417; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SEILER SM, 1992, BIOCHEM BIOPH RES CO, V182, P1296, DOI 10.1016/0006-291X(92)91873-O; SHUMAN MA, 1976, BLOOD, V47, P43; STONE SR, 1991, BIOCHEMISTRY-US, V30, P6392, DOI 10.1021/bi00240a007; TAM SW, 1979, J BIOL CHEM, V254, P8723; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; TRACY PB, 1982, BLOOD, V60, P59; TRACY PB, 1992, METHOD ENZYMOL, V215, P329; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WORKMAN EF, 1977, J BIOL CHEM, V252, P7118	46	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28606	28612						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961808				2022-12-25	WOS:A1994PU16800017
J	KAPLIN, AI; FERRIS, CD; VOGLMAIER, SM; SNYDER, SH				KAPLIN, AI; FERRIS, CD; VOGLMAIER, SM; SNYDER, SH			PURIFIED RECONSTITUTED INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS - THIOL REAGENTS ACT DIRECTLY ON RECEPTOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM-RELEASE; CA2+ RELEASE; TRISPHOSPHATE RECEPTOR; LIPID VESICLES; HAMSTER EGGS; BINDING-SITE; THIMEROSAL; OSCILLATIONS; CELLS; HEPATOCYTES	Thimerosal, a sulfhydryl oxidizing reagent, has been shown to induce Ca2+ mobilization in several cell types and to increase the sensitivity of intracellular Ca2+ stores to inositol 1,4,5-trisphosphate (IP3). Using purified IP3 receptor (IP(3)R) protein reconstituted in vesicles, we demonstrate pronounced stimulation by thimerosal of its Ca2+ channel activity. Effects of thimerosal are dependent on the redox state of the receptor, implying an action of thimerosal on a critical sulfhydryl group(s) of IP(3)R. Thimerosal enhances the affinity of IP(3)R for IP3 binding. The manner in which thimerosal modulates IP(3)R responsiveness to IP3 provides evidence for receptor heterogeneity with implications for mechanisms of quantal Ca2+ release. These results clarify regulation of IP(3)R activity by redox modulation.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NIDA NIH HHS [DA00074] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN RG, 1991, P SOC EXP BIOL MED, V196, P117; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1993, J BIOL CHEM, V268, P17917; BOOTMAN MD, 1994, MOL CELL ENDOCRINOL, V98, P157, DOI 10.1016/0303-7207(94)90134-1; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BREDT DS, 1989, BIOCHEM BIOPH RES CO, V159, P976, DOI 10.1016/0006-291X(89)92204-3; BURDON RH, 1989, FREE RADICAL RES COM, V6, P345, DOI 10.3109/10715768909087918; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FISSORE RA, 1993, DEV BIOL, V159, P122, DOI 10.1006/dbio.1993.1226; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GRINNELL FL, 1969, BIOCHIM BIOPHYS ACTA, V185, P471, DOI 10.1016/0005-2744(69)90443-4; HATZELMANN A, 1990, BIOCHEM PHARMACOL, V39, P559, DOI 10.1016/0006-2952(90)90064-R; HECKER M, 1989, BIOCHEM BIOPH RES CO, V159, P961, DOI 10.1016/0006-291X(89)92202-X; HILLY M, 1993, J BIOL CHEM, V268, P16488; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASS GEN, 1992, CELLULAR MOL MECH IN, V4, P133; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MOUREY RJ, 1993, BIOCHEMISTRY-US, V32, P1719, DOI 10.1021/bi00058a004; MUALLEM S, 1989, J BIOL CHEM, V264, P205; PARYS JB, 1993, PFLUG ARCH EUR J PHY, V424, P516, DOI 10.1007/BF00374916; POITRAS M, 1993, J BIOL CHEM, V268, P24078; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; SAYERS LG, 1993, BIOCHEM J, V289, P883, DOI 10.1042/bj2890883; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1992, PFLUG ARCH EUR J PHY, V422, P173, DOI 10.1007/BF00370417; UHLIG S, 1992, LIFE SCI, V51, P1083, DOI 10.1016/0024-3205(92)90509-N; WATRAS J, 1991, J NEUROSCI, V11, P3239	46	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28972	28978						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961860				2022-12-25	WOS:A1994PU16800070
J	SAITO, T; KUMAZAKI, T; OCHIAI, H				SAITO, T; KUMAZAKI, T; OCHIAI, H			ASSIGNMENT OF DISULFIDE BONDS IN GP64, A PUTATIVE CELL-CELL ADHESION PROTEIN OF POLYSPHONDYLIUM-PALLIDUM - PRESENCE OF SUSHI DOMAINS IN THE CELLULAR SLIME-MOLD PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM; MONOCLONAL-ANTIBODIES; GLYCOPROTEIN; SITES; SEQUENCE; ANCHOR; GP24	The 64-kDa membrane-bound glycoprotein of the cellular slime mold Polysphondylium pallidum (referred to as gp64), seems to be implicated in cell-cell adhesion. Previously we have isolated a full-length gp64 cDNA, determined its nucleotide sequence, and found that all cysteine residues in the protein are involved in the formation of disulfide bonds. The disulfide arrangement of the 36 cysteines in gp64 was established by analysis of proteolytically cleaved protein and sequence analysis of cystine-containing fragments. Since gp64 has 36 Cys residues, 18 disulfide bonds must exist and the positions of 15 of them were determined. The 15 disulfide bonds in gp64 constitute five characteristic, so called Sushi do mains. In a Sushi domain, the first Cys in a sequence is connected to the third one and the second Cys to the fourth one. This is the first report describing the presence of Sushi domains in a cellular slime mold protein. From these data, gp64 appears to be distinct from all other previously described cell-adhesion proteins.	HOKKAIDO UNIV,FAC SCI,DEPT BIOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,FAC PHARMACEUT SCI,DEPT BIOCHEM,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; Hokkaido University								BEUG H, 1973, J CELL BIOL, V56, P647, DOI 10.1083/jcb.56.3.647; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BOZZARO S, 1978, J MOL BIOL, V120, P265, DOI 10.1016/0022-2836(78)90067-0; BRAR SK, 1993, J BIOL CHEM, V268, P24902; CHADWICK CM, 1984, NATURE, V307, P646, DOI 10.1038/307646a0; CHRISTENSEN U, 1985, J BIOCHEM-TOKYO, V98, P1263, DOI 10.1093/oxfordjournals.jbchem.a135393; DAVIE EW, 1986, COLD SPRING HARB SYM, V51, P509, DOI 10.1101/SQB.1986.051.01.062; GERISCH G, 1980, CELL ADHESION MOTILI, P293; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; KAMBOJ RK, 1989, CELL, V59, P615, DOI 10.1016/0092-8674(89)90007-X; KATO H, 1991, BIOCHEMISTRY-US, V30, P11687, DOI 10.1021/bi00114a012; KNECHT DA, 1987, DEV BIOL, V121, P277, DOI 10.1016/0012-1606(87)90160-6; MANABE R, 1990, J BIOCHEM-TOKYO, V108, P852, DOI 10.1093/oxfordjournals.jbchem.a123292; MANABE R, 1994, J BIOL CHEM, V269, P528; MUELLER K, 1979, European Journal of Biochemistry, V99, P419; MUELLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321; MUTA T, 1991, J BIOL CHEM, V266, P6554; NOEGEL A, 1986, EMBO J, V5, P1473, DOI 10.1002/j.1460-2075.1986.tb04384.x; SAITO T, 1993, EUR J BIOCHEM, V211, P147, DOI 10.1111/j.1432-1033.1993.tb19881.x; SAITO T, 1993, EUR J BIOCHEM, V218, P623, DOI 10.1111/j.1432-1033.1993.tb18415.x; STADLER J, 1989, EMBO J, V8, P371, DOI 10.1002/j.1460-2075.1989.tb03387.x; TODA K, 1984, EUR J BIOCHEM, V143, P477, DOI 10.1111/j.1432-1033.1984.tb08395.x	23	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28798	28802						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961835				2022-12-25	WOS:A1994PU16800045
J	ANDREU, JM; DIAZ, JF; GIL, R; DEPEREDA, JM; DELACOBA, MG; PEYROT, V; BRIAND, C; TOWNSANDREWS, E; BORDAS, J				ANDREU, JM; DIAZ, JF; GIL, R; DEPEREDA, JM; DELACOBA, MG; PEYROT, V; BRIAND, C; TOWNSANDREWS, E; BORDAS, J			SOLUTION STRUCTURE OF TAXOTERE-INDUCED MICROTUBULES TO 3-NM RESOLUTION - THE CHANGE IN PROTOFILAMENT NUMBER IS LINKED TO THE BINDING OF THE TAXOL SIDE-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; PURIFIED TUBULIN; SURFACE LATTICE; ANALOGS; MECHANISM; PROLIFERATION; COLCHICINE; CHEMISTRY; RP-56976; INVITRO	The synchrotron x-ray solution scattering profiles of microtubules assembled from purified GDP- or GTP-tubulin with the antitumor drug docetaxel (Taxotere(R)) are consistent with identical non-globular alpha and beta-tubulin monomers ordered within the known surface lattice of microtubules, with a center to center lateral spacing of 5.7 +/- 0.1 nm, The higher angle part of the scattering profile, and therefore the substructure of the microtubule wall is identical in Taxotere- and Taxol-induced microtubules, to the resolution of the measurements. However, Taxotere-induced microtubules have a mean diameter of 24.2 +/- 0.4 nm, which is 1.12 +/- 0.01 times larger than that of paclitaxel (Taxol(R)) induced microtubules, The population of Taxotere microtubules has on average 13.4 protofilaments, which is similar to control microtubules assembled with glycerol but is in marked contrast with Taxol-induced microtubules, which have on average 12 protofilaments under identical solution conditions, Model populations of Taxotere and Taxol microtubules with the distributions of protofilament numbers determined by electron microscopy reproduce the positions and approximate intensities of the experimental x-ray scattering data, Comparison of the structures and activities of both taxoids strongly suggests that the change of the more frequent lateral bond angle between tubulin molecules from 152.3 degrees (13-protofilament microtubules) to 150 degrees (12-protofilament microtubules) is linked to the binding of the side chain of Taxol. Optimal microtubule formation is obtained with unitary Taxotere to tubulin heterodimer ratio; however, ligand molecules in excess over tubulin dimers cause a loss of cylindrical scattering features, consistent with microtubule opening, The results are compatible with the observed biochemical and thermodynamic properties of this ligand-induced microtubule assembly system and also with the simple working hypothesis that taxoids would bind between adjacent microtubule protofilaments.	FAC PHARM MARSEILLE,GRIPP,F-13385 MARSEILLE 5,FRANCE; SERC,DARESBURY LAB,WARRINGTON WA4 4AD,CHESHIRE,ENGLAND	STFC Daresbury Laboratory	ANDREU, JM (corresponding author), CSIC,CTR INVEST BIOL,VELAZQUEZ 144,E-28006 MADRID,SPAIN.		de Pereda, Jose M/F-1733-2010; Díaz, J. Fernando/U-3532-2017; de Pereda, Jose M/AAE-5226-2022	de Pereda, Jose M/0000-0002-8912-6739; Díaz, J. Fernando/0000-0003-2743-3319; de Pereda, Jose M/0000-0002-8912-6739; Andreu, Jose M/0000-0001-8064-6933				AMOS LA, 1974, J CELL SCI, V14, P523; ANDREU JM, 1989, BIOCHEMISTRY-US, V28, P4036, DOI 10.1021/bi00435a060; ANDREU JM, 1982, BIOCHEMISTRY-US, V21, P534, DOI 10.1021/bi00532a019; ANDREU JM, 1992, J MOL BIOL, V226, P169, DOI 10.1016/0022-2836(92)90132-4; BARASOAIN I, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P329; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BISSERY MC, 1991, CANCER RES, V51, P4845; BORDAS J, 1983, J MOL BIOL, V164, P89, DOI 10.1016/0022-2836(83)90089-X; Briand C., 1993, Cellular Pharmacology, V1, pS1; CHALFIE M, 1982, J CELL BIOL, V93, P15, DOI 10.1083/jcb.93.1.15; CHRETIEN D, 1992, J CELL BIOL, V117, P1031, DOI 10.1083/jcb.117.5.1031; COMBEAU C, 1994, BIOCHEMISTRY-US, V33, P6676, DOI 10.1021/bi00187a038; DALLAI R, 1993, CELL MOTIL CYTOSKEL, V24, P49, DOI 10.1002/cm.970240106; DENIS JN, 1988, J AM CHEM SOC, V110, P5917, DOI 10.1021/ja00225a063; DIAZ JF, 1994, J MOL BIOL, V238, P214, DOI 10.1006/jmbi.1994.1282; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P10067, DOI 10.1021/bi00089a023; DONEHOWER RC, 1993, CANCER TREAT REV, V19, P63, DOI 10.1016/0305-7372(93)90049-W; DYE RB, 1993, J BIOL CHEM, V268, P6847; FETTNETO AG, 1992, BIO-TECHNOL, V10, P1572, DOI 10.1038/nbt1292-1572; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; GUENARD D, 1993, ACCOUNTS CHEM RES, V26, P160, DOI 10.1021/ar00028a005; GUERITTEVOEGELE.F, 1990, ACTA CRYSTALLOGR C, V46, P784; GUERITTEVOEGELEIN F, 1991, J MED CHEM, V34, P992, DOI 10.1021/jm00107a017; HOLTON RA, 1994, J AM CHEM SOC, V116, P1597, DOI 10.1021/ja00083a066; HOLTON RA, 1994, J AM CHEM SOC, V116, P1599, DOI 10.1021/ja00083a067; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; HOWARD WD, 1988, J BIOL CHEM, V263, P1342; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KINGSTON DGI, 1991, PHARMACOL THERAPEUT, V52, P1, DOI 10.1016/0163-7258(91)90085-Z; LATTMAN EE, 1994, CURR OPIN STRUC BIOL, V4, P87, DOI 10.1016/S0959-440X(94)90064-7; MANDELKOW E, 1977, P NATL ACAD SCI USA, V74, P3370, DOI 10.1073/pnas.74.8.3370; MANDELKOW EM, 1980, NATURE, V287, P595, DOI 10.1038/287595a0; MANGATAL L, 1989, TETRAHEDRON, V45, P4177, DOI 10.1016/S0040-4020(01)81313-2; MAURER HR, 1993, INT J ONCOL, V3, P161; NICOLAOU KC, 1994, NATURE, V367, P630, DOI 10.1038/367630a0; NICOLAOU KC, 1994, ANGEW CHEM INT EDIT, V33, P15, DOI 10.1002/anie.199400151; PANTOS E, 1994, J PURE APPL CHEM, V66, P77; PAZDUR R, 1992, J NATL CANCER I, V84, P1781, DOI 10.1093/jnci/84.23.1781; PRAKASH V, 1991, BIOCHEMISTRY-US, V30, P873, DOI 10.1021/bi00217a042; RAO S, 1994, J BIOL CHEM, V269, P3132; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; RINGEL I, 1991, J NATL CANCER I, V83, P288, DOI 10.1093/jnci/83.4.288; RIOU JF, 1992, BIOCHEM BIOPH RES CO, V187, P164, DOI 10.1016/S0006-291X(05)81474-3; ROTHWELL SW, 1986, J CELL BIOL, V102, P619, DOI 10.1083/jcb.102.2.619; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STIERLE A, 1993, SCIENCE, V260, P214, DOI 10.1126/science.8097061; SWINDELL CS, 1991, J MED CHEM, V34, P1176, DOI 10.1021/jm00107a042; TILNEY LG, 1973, J CELL BIOL, V59, P267, DOI 10.1083/jcb.59.2.267; Timasheff S., 1993, Cellular Pharmacology, V1, pS27; TOMIAK E, 1991, EJC SUPPL, V27, P1184; VENIER P, 1994, J BIOL CHEM, V269, P13353; WADE RH, 1990, J MOL BIOL, V212, P775, DOI 10.1016/0022-2836(90)90236-F; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WILLIAMS RC, 1989, J BIOL CHEM, V264, P1663; Wilson Leslie, 1994, V13, P59	59	75	75	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31785	31792						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989352				2022-12-25	WOS:A1994PX30300071
J	BEHAL, RH; DEBUYSERE, MS; DEMELER, B; HANSEN, JC; OLSON, MS				BEHAL, RH; DEBUYSERE, MS; DEMELER, B; HANSEN, JC; OLSON, MS			PYRUVATE-DEHYDROGENASE MULTIENZYME COMPLEX - CHARACTERIZATION OF ASSEMBLY INTERMEDIATES BY SEDIMENTATION-VELOCITY ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-X COMPONENT; SACCHAROMYCES-CEREVISIAE; BOVINE KIDNEY; TRANSACETYLASE; MUTAGENESIS; DOMAIN; HEART; GENE	The pyruvate dehydrogenase complex is a large, highly organized assembly of several different catalytic and regulatory component enzymes. The structural core of the complex is the E2-X subcomplex, consisting of 60 dihydrolipoamide transacetylase (E2) subunits arranged in a pentagonal dodecahedron; 6 protein X and 2 pyruvate dehydrogenase kinase molecules are tightly associated with this E2 60-mer. The native E2-X subcomplex exhibits a sedimentation coefficient of 32 S. The effects of several chaotropes (guanidinium chloride, potassium thiocyanide, and urea) on the E2-X subcomplex were assessed. Treatment of the E2-X subcomplex with 4 M guanidinium chloride caused a complete loss of enzymatic activity and the dissociation of the subcomplex into monomeric 1.5-3 S species. Removal of the chaotrope by dialysis for 18 h resulted in complete restoration of E2 enzymatic activity and reassembly of a 32 S subcomplex; this reassembled subcomplex contained less protein X than the native subcomplex. Sedimentation velocity analysis of reassembled E2-X subcomplex demonstrated the presence of an 8 S assembly intermediate; this sedimentation coefficient is characteristic of globular proteins of molecular weights similar to that expected for a trimer of E2. Shorter periods of dialysis also gave rise to the 8 S species; the amount of this intermediate decreased with increasing times of dialysis. The 8 S species associated non-cooperatively to yield additional assembly intermediates exhibiting sedimentation coefficients of 10-32 S.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio				Demeler, Borries/0000-0002-2414-9518	NCRR NIH HHS [RR-08352] Funding Source: Medline; NHLBI NIH HHS [HL-24654, HL-07305] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008352] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007305, R01HL024654] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEHAL RH, 1989, P NATL ACAD SCI USA, V86, P8732, DOI 10.1073/pnas.86.22.8732; BEHAL RH, 1993, ANNU REV NUTR, V13, P497, DOI 10.1146/annurev.nu.13.070193.002433; BUTTERWORTH PJ, 1975, J BIOL CHEM, V250, P1921; GOPALAKRISHNAN S, 1989, BIOCHEM BIOPH RES CO, V160, P715, DOI 10.1016/0006-291X(89)92492-3; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; JILKA JM, 1986, BIOCHEM BIOPH RES CO, V160, P715; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; NIU XD, 1990, BIOCHEMISTRY-US, V29, P8614, DOI 10.1021/bi00489a017; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; STANLEY CJ, 1980, BIOCHEM J, V191, P147, DOI 10.1042/bj1910147; VANHOLDE KE, PHYSICAL BIOCH, P117; VANHOLDE KE, 1978, BIOPOLYMERS, V25, P1981; WU TL, 1984, BIOCHEMISTRY-US, V23, P221, DOI 10.1021/bi00297a008	15	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31372	31377						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989301				2022-12-25	WOS:A1994PX30300010
J	BUJALOWSKI, W; KLONOWSKA, MM				BUJALOWSKI, W; KLONOWSKA, MM			CLOSE PROXIMITY OF TRYPTOPHAN RESIDUES AND ATP-BINDING SITE IN ESCHERICHIA-COLI PRIMARY REPLICATIVE HELICASE DNAB PROTEIN - MOLECULAR TOPOGRAPHY OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; AMINO-ACID-RESIDUES; SELECTIVE BINDING; TRANSFER RNAPHE; ENERGY-TRANSFER; GENE PRODUCT; MECHANISM; FLUORESCENCE; ASSOCIATION; TRIPHOSPHATASE	The binding of fluorescent nucleotide analogs to the Escherichia coli primary replicative helicase DnaB protein causes strong quenching of protein tryptophan fluorescence. It results from the efficient fluorescence energy transfer (E) from tryptophans to analogs bound in the nucleotide-binding site, indicating that protein tryptophans are ''clustered'' in close proximity to the binding site. This is in contrast to the lack of detectable energy transfer to the fluorescent single stranded DNA (ssDNA) derivative, suggesting a distant separation between two function-linked structural elements of the enzyme, the nucleotide- and ssDNA-binding sites. The dependence of E upon the average number of bound nucleotides/DnaB hexamer is nonlinear, implying a larger separation between tryptophans and the bound nucleotide in the low affinity sites. Spectroscopic studies reveal that tryptophan residues are located on the surface of the DnaB helicase in a hydrophobic cleft, whereas the environment of the tyrosines is heterogeneous, with 6 out of 10 tyrosine residues located on the surface of the helicase. The efficiency of the fluorescence energy transfer from the tyrosines to tryptophans suggests that the ''centers of mass'' of the residues are separated, possibly reflecting the separation of the nucleotide- and ssDNA-binding sites, with tyrosines constituting part of the ssDNA binding region.			BUJALOWSKI, W (corresponding author), UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,301 UNIV BLVD,GALVESTON,TX 77555, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046679] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM-46679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1991, J BIOL CHEM, V266, P22096; ANDO T, 1980, J BIOCHEM-TOKYO, V88, P255; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, J BIOL CHEM, V256, P5247; ARAI K, 1981, J BIOL CHEM, V256, P5267; ARAI K, 1981, J BIOL CHEM, V256, P5273; ARAI K, 1981, J BIOL CHEM, V256, P5253; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BERMAN HA, 1978, BIOCHEMISTRY-US, V17, P1704, DOI 10.1021/bi00602a019; BUJALOWSKI W, 1994, BIOCHEMISTRY-US, V33, P4682, DOI 10.1021/bi00181a028; BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; BUJALOWSKI W, 1991, J MOL BIOL, V217, P63, DOI 10.1016/0022-2836(91)90611-9; BUJALOWSKI W, 1991, J BIOL CHEM, V266, P1616; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; BUJALOWSKI W, 1988, BIOPHYS CHEM, V30, P151, DOI 10.1016/0301-4622(88)85012-9; BUJALOWSKI W, 1988, Z NATURFORSCH C, V43, P91; BUJALOWSKI W, 1984, NUCLEIC ACIDS RES, V12, P7549, DOI 10.1093/nar/12.19.7549; CHEUNG HC, 1984, J MUSCLE RES CELL M, V5, P65, DOI 10.1007/BF00713152; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; Eftink M. R., 1991, BIOPHYSICAL BIOCH AS, P1; EFTINK MR, 1977, BIOCHIM BIOPHYS ACTA, V491, P473, DOI 10.1016/0005-2795(77)90290-2; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EISINGER J, 1969, BIOCHEMISTRY-US, V8, P3902, DOI 10.1021/bi00838a004; Hill T. L., 1985, COOPERATIVITY THEORY; Kornberg A., 1992, DNA REPLICATION; LAKOWITZ JR, 1983, PRINCIPLES FLUORESCE, P319; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LONGWORTH JW, 1971, EXCITED STATES PROTE, pCH6; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MAYER R, 1979, J BIOL CHEM, V254, P75; MCMACKEN R, 1977, J BIOL CHEM, V253, P3313; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; NAKAYAMA N, 1984, J BIOL CHEM, V259, P97; Parker C.A, 1968, PHOTOLUMINESCENCE SO; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; SAITO Y, 1981, PHOTOCHEM PHOTOBIOL, V33, P289, DOI 10.1111/j.1751-1097.1981.tb05420.x; SCHEKMAN R, 1975, J BIOL CHEM, V250, P5859; SCHEKMAN R, 1974, SCIENCE, V186, P987, DOI 10.1126/science.186.4168.987; SCOTT TG, 1970, J AM CHEM SOC, V92, P687, DOI 10.1021/ja00706a043; Stern O, 1919, PHYS Z, V20, P183; UEDA K, 1978, J BIOL CHEM, V253, P261; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WEBER G, 1960, BIOCHEM J, V75, P335, DOI 10.1042/bj0750335; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WICKNER S, 1973, P NATL ACAD SCI USA, V71, P783; WICKNER SH, 1978, COLD SPRING HARB SYM, V43, P303	55	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31359	31371						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989300				2022-12-25	WOS:A1994PX30300009
J	ESTEBAN, JA; SOENGAS, MS; SALAS, M; BLANCO, L				ESTEBAN, JA; SOENGAS, MS; SALAS, M; BLANCO, L			3'-]5' EXONUCLEASE ACTIVE-SITE OF PHI-29 DNA-POLYMERASE - EVIDENCE FAVORING A METAL ION-ASSISTED REACTION-MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PRIMED INITIATION; I KLENOW FRAGMENT; AMINO-ACID; 3'-5' EXONUCLEASE; ESCHERICHIA-COLI; TERMINAL PROTEIN; NUCLEOPROTEIN COMPLEX; PHAGE PHI-29; REPLICATION; INVITRO	The residues forming the 3' --> 5' exonuclease active site of phi 29 DNA polymerase, located at the N-terminal conserved moths fro I, fro LI and fro III, have been defined by site-directed mutagenesis (Bernad, A., Blanco, L., Lazaro, J. M., Martin, G., and Salas, M. (1989) Cell 59, 219-228; Soengas, M. S., Esteban, J. A., Lazaro, J. M., Bernad, A., Blasco, M. A., Salas, M., and Blanco, L. (1992) EMBO J. 11, 4227-4237). To understand their catalytic role, the residual exonuclease activity of mutants at these active site residues has been kinetically studied. The critical function of residues Asp(12), Glu(14) ASp(66), and Asp(169) is supported by a 10(5)-fold reduction in the exonuclease catalytic rate upon single mutation. Residue Tyr(165) seems to play a secondary role in the exonuclease reaction based on the 10(2)-10(3)-fold reduced catalytic rate of mutants Y165F and Y165C. Most of the mutants were specially active in the presence of Mn2+ ions, which could be indicative of a direct involvement of these residues in a metal ion-assisted exonucleolytic reaction. The data obtained strongly suggest that the 3' --> 5' exonuclease active site of phi 29 DNA polymerase is structurally and functionally similar to that of the Escherichia coli DNA polymerase I. In addition, these residues were also very important for the strand displacement ability of phi 29 DNA polymerase, suggesting a structural overlapping of this activity with the 3' --> 5' exonuclease.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC SEVERO OCHOA, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Soengas, Maria S/H-6455-2015; Esteban, Jose/L-4944-2014; Salas, Margarita/J-9873-2014; Blanco, Luis/I-1848-2015	Soengas, Maria S/0000-0003-0612-6299; Esteban, Jose/0000-0002-3759-3300; Salas, Margarita/0000-0001-5939-3441; 	NIGMS NIH HHS [5R01 GM27242-15] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BLANCO L, 1985, NUCLEIC ACIDS RES, V13, P1239, DOI 10.1093/nar/13.4.1239; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BLANCO L, 1986, NUCLEIC ACIDS RES, V14, P4923, DOI 10.1093/nar/14.12.4923; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BLANCO L, 1994, IN PRESS METHODS ENZ; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1993, J BIOL CHEM, V268, P16763; BLASCO MA, 1993, J BIOL CHEM, V268, P24106; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; DAS SK, 1980, NUCLEIC ACIDS RES, V8, P657, DOI 10.1093/nar/8.3.657; DAS SK, 1979, J BIOL CHEM, V254, P1227; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; ESTEBAN JA, 1992, BIOCHEMISTRY-US, V31, P350, DOI 10.1021/bi00117a006; ESTEBAN JA, 1993, J BIOL CHEM, V268, P2719; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GARMENDIA C, 1992, J BIOL CHEM, V267, P2594; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kornberg A., 1992, DNA REPLICATION; LAZARO JM, 1994, IN PRESS METHODS ENZ; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PASTRANA R, 1985, NUCLEIC ACIDS RES, V13, P3083, DOI 10.1093/nar/13.9.3083; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; PRIETO I, 1988, P NATL ACAD SCI USA, V85, P314, DOI 10.1073/pnas.85.2.314; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SAVILAHTI H, 1991, J BIOL CHEM, V266, P18737; SERRANO M, 1993, J MOL BIOL, V230, P248, DOI 10.1006/jmbi.1993.1140; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SOENGAS MS, 1992, EMBO J, V11, P4227, DOI 10.1002/j.1460-2075.1992.tb05517.x; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WATABE K, 1984, BIOCHEM BIOPH RES CO, V123, P1019, DOI 10.1016/S0006-291X(84)80235-1; WATABE K, 1984, P NATL ACAD SCI-BIOL, V81, P5374, DOI 10.1073/pnas.81.17.5374; ZABALLOS A, 1989, GENE, V83, P187, DOI 10.1016/0378-1119(89)90104-2	54	46	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31946	31954						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989370				2022-12-25	WOS:A1994PX30300094
J	RODRIGUEZ, IR; MAZURUK, K; SCHOEN, TJ; CHADER, GJ				RODRIGUEZ, IR; MAZURUK, K; SCHOEN, TJ; CHADER, GJ			STRUCTURAL-ANALYSIS OF THE HUMAN HYDROXYINDOLE-O-METHYLTRANSFERASE GENE - PRESENCE OF 2 DISTINCT PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN PINEAL-GLAND; MELATONIN BIOSYNTHESIS; TRANSCRIPTION FACTORS; RETINA; BINDING; SITE; CREM; RAT; LOCALIZATION; ACTIVATION	Hydroxyindole-O-methyltransferase (HIOMT) catalyzes the last step in the metabolic pathway that synthesizes sizes the hormone melatonin. We have found HIOMT mRNA present in small amounts in human retina and in relatively high abundance in the pineal gland, Two dis tinct 5' ends were found in human retina using a solid-phase 5'-rapid amplification of cDNA ends technique, The two 5' regions appear to originate from two distinct putative promoters, Although many similarities exist between the two promoters, they contain distinctive elements. Putative promoter A, for example, contains a recently discovered photoreceptor-conserved element (PCE-1, CAATTAAG) at -27 not found in promoter B, while promoter B contains an Apl site (ATGAGTCAA at -166 and an octamer site (ATGCAAT) at -59 not found in promoter A. The HIOMT messages are also alternatively spliced in between exons 6 and 8, generating three dis tinct messages, One of the alternatively spliced messages contains a line-1 repetitive element that is spliced into the mRNA precisely as exon 6. Importantly, the downstream open reading frame is not altered by any of these splicing combinations, The gene is approximately 35 kilobases long containing either 9 or 10 exons (including the line-1 element) depending on which promoter is active. Ah of the splice sites follow the GT/AG rule. The dual promoters and opportunities for alternative splicing suggest a variety of mechanisms for control of HIOMT expression and biological activity in different tissues not previously recognized.			RODRIGUEZ, IR (corresponding author), NEI, RETINAL CELL & MOLEC BIOL LAB, BLDG 6, RM 304, BETHESDA, MD 20892 USA.							BERNARD M, 1993, BIOCHEM J, V290, P661, DOI 10.1042/bj2900661; Besharse J.C., 1988, PROGR RETINAL RES, V7, P21; CAHILL GM, 1993, NEURON, V10, P573, DOI 10.1016/0896-6273(93)90160-S; CARDINAL.DP, 1971, ENDOCRINOLOGY, V89, P301, DOI 10.1210/endo-89-1-301; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DONOHUE SJ, 1993, DNA CELL BIOL, V12, P715, DOI 10.1089/dna.1993.12.715; DUSING MR, 1994, NUCLEIC ACIDS RES, V22, P669, DOI 10.1093/nar/22.4.669; FINOCCHIARO LME, 1991, BIOCHEM J, V280, P727, DOI 10.1042/bj2800727; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; NERVLOV C, 1994, GENE DEV, V8, P350; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; REITER RJ, 1983, LIFE SCI, V32, P1229, DOI 10.1016/0024-3205(83)90192-3; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RODRIGUEZ IR, 1992, NUCLEIC ACIDS RES, V20, P3528, DOI 10.1093/nar/20.13.3528; ROONEY RJ, 1990, MOL CELL BIOL, V10, P5138, DOI 10.1128/MCB.10.10.5138; Sambrook J, 1989, MOL CLONING LABORATO; SLIM R, 1993, GENOMICS, V16, P691, DOI 10.1006/geno.1993.1249; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUGDEN D, 1987, METHOD ENZYMOL, V142, P590; TAMAI M, 1978, INVEST OPHTH VIS SCI, V17, P558; WIECHMANN AF, 1986, EXP EYE RES, V42, P507, DOI 10.1016/0014-4835(86)90042-4; WIECHMANN AF, 1993, NEUROSCI LETT, V150, P207, DOI 10.1016/0304-3940(93)90537-U; YI HF, 1993, HUM MOL GENET, V2, P127, DOI 10.1093/hmg/2.2.127; ZAWILSKA JB, 1992, NEUROCHEM INT, V20, P23, DOI 10.1016/0197-0186(92)90122-8; [No title captured]	34	90	93	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31969	31977						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989373				2022-12-25	WOS:A1994PX30300097
J	SEVERINOV, K; GOLDFARB, A				SEVERINOV, K; GOLDFARB, A			TOPOLOGY OF THE PRODUCT BINDING-SITE IN RNA-POLYMERASE REVEALED BY TRANSCRIPT SLIPPAGE AT THE PHAGE-LAMBDA P-L PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; ESCHERICHIA-COLI; TERNARY COMPLEXES; INITIATION; TERMINATION; CLEAVAGE; ENZYME	In the presence of transcription substrates ATP, CTP, and UTP a stable ternary complex containing tetranucleotide AUCA is formed on the phage lambda P-L promoter (starting sequence C(-3)A(-2)C(-1)A(+1)U(+2)C(+3)A(+4)G(+5)). We show that in the absence of GTP or at undersaturating GTP concentrations the AUCA transcript synthesized at the +1 to +4 segment slips back by 3 nucleotides and is stabilized in the ternary complex in such a way that only its 2 3'-proximal bases remain paired to the -1/+1 positions of the template DNA. The slipped transcript can be extended in a template-directed manner into longer chains that can be cleaved by the GreA or GreB proteins at the +1/+2 junction. The slipped stabilized tetranucleotide delineates the ''tight product binding site'' of RNA polymerase responsible for stable holding of the transcript in the ternary transcription complex. The results suggest that the tight product binding site encompasses the locality within the complex where the nascent transcript detaches from the template strand of DNA.	PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016				Severinov, Konstantin/C-8545-2016		NIGMS NIH HHS [GM49242] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN M, 1964, J MOL BIOL, V8, P708, DOI 10.1016/S0022-2836(64)80120-0; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; GRACHEV MA, 1980, FEBS LETT, V115, P23, DOI 10.1016/0014-5793(80)80718-6; HANSEN UM, 1980, J BIOL CHEM, V255, P564; JACQUES JP, 1990, GENE DEV, V4, P1801, DOI 10.1101/gad.4.10.1801; JOHNSTON DE, 1976, RNA POLYM, P101; KASHLEV M, 1993, CELL, V75, P147, DOI 10.1016/S0092-8674(05)80091-1; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KNAUS R, 1988, EMBO J, V7, P2919, DOI 10.1002/j.1460-2075.1988.tb03150.x; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; PARKER RC, 1986, BIOCHEMISTRY-US, V25, P6593, DOI 10.1021/bi00369a038; STRANEY SB, 1987, BIOCHEMISTRY-US, V26, P5063, DOI 10.1021/bi00390a027; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983	22	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31701	31705						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989343				2022-12-25	WOS:A1994PX30300059
J	YANG, CZ; SLEPNEV, VI; GOUD, B				YANG, CZ; SLEPNEV, VI; GOUD, B			RAB PROTEINS FORM IN-VIVO COMPLEXES WITH 2 ISOFORMS OF THE GDP-DISSOCIATION INHIBITOR PROTEIN (GDI)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ACTIVATING PROTEIN; SMG P25A; REGULATORY PROTEIN; SYNAPTIC VESICLES; EXCHANGE PROTEIN; SEC4 PROTEIN; ASSOCIATION; CYTOSOL; FAMILY	GTPases of the Rab family play a key role in the regulation of vesicular transport in eukaryotic cells. Several accessory proteins that regulate their GDP/GTP cycle as well as their subcellular localization have been identified within the past few years, The best known is Rab3A GDP dissociation inhibitor protein (GDI), originally identified as an inhibitor of GDP dissociation from Rdb3A, a Rab protein specifically expressed in neuronal and neuroendocrine cells. Recent studies have pointed out a role of Rab3A GDI as a chaperone of several Rab proteins during their cycling between cytosol and membranes and Rab3A GDI has been considered so far as a general regulator of Rab function. However, cDNAs encoding potential isoforms of this protein, called GDI beta and GDI-2, have been recently isolated. In this study,we have characterized cytosolic Rab protein complexes in various cell types and tissues using Mono and chromatography. We show that in rat brain and in insulin-secreting RINm5F cells, the majority of Rab proteins are complexed with Rab3A GDI, In contrast, in Chinese hamster ovary cells, they are mainly complexed to a protein that we have identified as GDI beta. In rat liver cytosol, Rab proteins form complexes with both isoforms. We also show that the proportion of Rab proteins complexed with either isoform depends on the relative abundance of Rab3A GrDI and GDI beta in the cytosol. These findings suggest that GDI isoforms are either redundant or could be involved in the fine control of Rab function.	INST PASTEUR, CNRS, URA 361, UNITE GENET SOMAT, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Goud, Bruno/GWC-4807-2022					ARAKI S, 1990, J BIOL CHEM, V265, P13007; BHULLAR RP, 1992, FEBS LETT, V298, P61, DOI 10.1016/0014-5793(92)80022-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; Goud B, 1992, Semin Cell Biol, V3, P301; HUBER LA, 1994, P NATL ACAD SCI USA, V91, P7874, DOI 10.1073/pnas.91.17.7874; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARIDONNEAUPARINI I, 1991, J CLIN INVEST, V87, P901, DOI 10.1172/JCI115096; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEELEMORTIMER O, 1993, FEBS LETT, V329, P313, DOI 10.1016/0014-5793(93)80244-O; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UEDA T, 1991, BIOCHEMISTRY-US, V30, P909, DOI 10.1021/bi00218a005; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; YANG CZ, 1992, BIOCHEM BIOPH RES CO, V182, P1499, DOI 10.1016/0006-291X(92)91903-4; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	39	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31891	31899						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989364				2022-12-25	WOS:A1994PX30300086
J	GIUFFRE, A; ANTONINI, G; BRUNORI, M; DITRI, E; MALATESTA, F; NICOLETTI, F; ANEMULLER, S; GLEISSNER, M; SCHAFER, G				GIUFFRE, A; ANTONINI, G; BRUNORI, M; DITRI, E; MALATESTA, F; NICOLETTI, F; ANEMULLER, S; GLEISSNER, M; SCHAFER, G			SULFOLOBUS-ACIDOCALDARIUS TERMINAL OXIDASE - KINETIC INVESTIGATION AND ITS STRUCTURAL INTERPRETATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOACIDOPHILIC ARCHAEBACTERIUM; PLASMA-MEMBRANE; PURIFICATION; CYTOCHROME-AA3; DEHYDROGENASE	The thermoacidophilic archaebacterium Sulfolobus acidocaldarius possesses a very unusual terminal oxidase. We report original kinetic experiments on membranes of this microorganism carried out by stopped flow using time-resolved optical spectroscopy combined with singular value decomposition analysis. The reduced-oxidized kinetic difference spectrum of the Sulfolobus membranes is characterized by three significant peaks in the visible region at 605, 586, and 560 nm. The 605-nm peak and part of the 586-nm peak (cytochrome aa(3)-type quinol oxidase) are reduced synchronously by both ascorbate plus N,N,N',N'-tetramethyl-p-phenylendiamine (TMPD) and dithionite, and they are very rapidly oxidized by molecular oxygen. A second pool of cytochromes seems to contribute to the 586-nm peak which is not reduced by ascorbate plus TMPD and reacts very slowly with dithionite. The b-type cytochromes (560 nm peak) are reduced by both reductants and are essentially ''non-autoxidizable'' at room temperature. Only one CO binding site with spectral features, kinetic properties, and ligand affinity not very dissimilar from those of mammalian cytochrome oxidase can be detected in the ascorbate-reduced membranes. On the contrary, a second CO binding site having unusual properties for aa(3) terminal oxidases can be detected in the dithionite-reduced membranes.	UNIV ROMA LA SAPIENZA, DEPT BIOCHEM SCI, I-00185 ROME, ITALY; UNIV ROMA TOR VERGATA, DEPT BIOCHEM SCI, ROME, ITALY; UNIV LUBECK, INST BIOCHEM, LUBECK, GERMANY; CNR, CTR MOLEC BIOL, ROME, ITALY	Sapienza University Rome; University of Rome Tor Vergata; University of Lubeck; Consiglio Nazionale delle Ricerche (CNR)			Malatesta, Francesco/AAT-4757-2020; Giuffrè, Alessandro/K-4341-2015	Giuffrè, Alessandro/0000-0001-5301-0681; Antonini, Giovanni/0000-0002-2115-8961; Brunori, Maurizio/0000-0002-7795-1635				ANEMULLER S, 1990, EUR J BIOCHEM, V191, P297, DOI 10.1111/j.1432-1033.1990.tb19123.x; ANEMULLER S, 1992, EUR J BIOCHEM, V210, P133, DOI 10.1111/j.1432-1033.1992.tb17400.x; ANEMULLER S, 1993, FEBS LETT, V318, P61, DOI 10.1016/0014-5793(93)81328-W; BECKER M, 1991, FEBS LETT, V291, P331, DOI 10.1016/0014-5793(91)81314-X; DEROSA M, 1977, J CHEM SOC PERK T 1, P653, DOI 10.1039/p19770000653; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; LUBBEN M, 1992, EMBO J, V11, P805, DOI 10.1002/j.1460-2075.1992.tb05117.x; LUBBEN M, 1994, EUR J BIOCHEM, V224, P151, DOI 10.1111/j.1432-1033.1994.tb20006.x; LUBBEN M, 1989, J BACTERIOL, V171, P6106; MOLL R, 1991, EUR J BIOCHEM, V201, P593, DOI 10.1111/j.1432-1033.1991.tb16319.x; WAKAO H, 1987, J BIOCHEM, V102, P255, DOI 10.1093/oxfordjournals.jbchem.a122049; YONETANI T, 1961, J BIOL CHEM, V236, P1680	13	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31006	31011						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983037				2022-12-25	WOS:A1994PV51000044
J	SCHLEMMER, SR; SIROTNAK, FM				SCHLEMMER, SR; SIROTNAK, FM			FUNCTIONAL-STUDIES OF P-GLYCOPROTEIN IN INSIDE-OUT PLASMA-MEMBRANE VESICLES DERIVED FROM MURINE ERYTHROLEUKEMIA-CELLS OVEREXPRESSING MDR-3 - PROPERTIES AND KINETICS OF THE INTERACTION OF VINBLASTINE WITH P-GLYCOPROTEIN AND EVIDENCE FOR ITS ACTIVE MEDIATED TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; EXPRESSING DIFFERENT LEVELS; GENE-PRODUCT; CANALICULAR MEMBRANE; DRUG-RESISTANCE; MAMMALIAN-CELLS; HAMSTER-CELLS; BINDING; DNA; SEQUENCES	Active [H-3]vinblastine (VBL) transport (efflux) was documented for inside-out plasma membrane vesicles from murine erythroleukemia cells (MEL/VCR-6) resistant to vinca alkaloids and overexpressing MDR 3 P-glycoprotein (P-gp) 80-fold. Uptake of [H-3]VBL at 37 degrees C by these inside-out vesicles, but not rightside-out vesicles or inside-out vesicles from wild-type cells, was obtained in the form of a rapid, initial phase (0-1 min) and a slower later phase (>1 min). The rapidity of each phase correlated with relative P-gp content among different MEL/VCR cell lines. The initial MDR-specific phase was temperature- and pH-dependent (optimum at pH 7), osmotically insensitive, and did not require ATP. The second MDR-specific phase was temperature-dependent, osmotically sensitive, and strictly dependent upon the presence of ATP (K-m = 0.37 +/- 0.04 mM). Although other triphosphate nucleotides were partially effective in replacing ATP, the nonhydrolyzable analogue ATP gamma S (adenosine 5'-O-(thiotriphosphate)) was ineffective. This time course appears to represent tandem binding of [H-3]VBL by P-gp and its mediated transport, with the latter process representing the rate-limiting step. In support of this conclusion, both binding and transport were inhibited by verapamil, quinidine, and reserpine, all known to be inhibitors of photoaffinity labeling of P-gp, but only transport was inhibited by C219 anti-P-gp antibody or orthovanadate. Although the rate of transport of [H-3]VBL was 7-7.5-fold lower than the rate of binding (V-max = 104 +/- 15 pmol/min/mg protein, K-m = 1.5 - 2 x 10(5) mol(-1) s(-1)) to P-gp, each phase exhibited saturation kinetics and values for apparent K-m and K-D for each process were approximately the same (215 +/- 35 and 195 +/- 30 nM). Intravesicular accumulation of [H-3]VBL was almost completely eliminated by high concentrations of nonradioactive VBL, suggesting that simple diffusion does not contribute appreciably to total accumulation of [H-3]VBL in this vesicle system. This could be at least partially explained by the fact that these inside-out vesicles under the conditions employed did not maintain a P-gp mediated pH gradient. However, ATP-dependent, intravesicular accumulation of osmotically sensitive [H-3]VBL occurred against a substantial permeant concentration gradient in both a time- and concentration-dependent manner consistent with an active, saturable process.	CORNELL UNIV,GRAD SCH MED SCI,MEM SLOAN KETTERING CANC CTR,PROGRAM PHARMACOL,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center			Schlemmer, Stephan/E-2903-2015	Schlemmer, Stephan/0000-0002-1421-7281	NCI NIH HHS [CA56517, CA18856, CA08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA056517, P01CA018856, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALTENBERG GA, 1993, P NATL ACAD SCI USA, V90, P9735, DOI 10.1073/pnas.90.20.9735; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; BIEDLER JL, 1970, CANCER RES, V30, P1174; BOSCOBOINIK D, 1990, BRIT J CANCER, V61, P568, DOI 10.1038/bjc.1990.127; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; DEPIERRE JW, 1973, J CELL BIOL, V56, P275, DOI 10.1083/jcb.56.2.275; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GAENSSLEN RE, 1971, ARCH BIOCHEM BIOPHYS, V147, P55, DOI 10.1016/0003-9861(71)90309-2; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; Gollapudi S., 1993, Cellular Pharmacology, V1, P3; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1986, P NATL ACAD SCI USA, V83, P337, DOI 10.1073/pnas.83.2.337; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HISSIN PJ, 1978, BIOCHIM BIOPHYS ACTA, V508, P401, DOI 10.1016/0005-2736(78)90342-5; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORIO M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P106, DOI 10.1016/0005-2736(91)90274-C; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; INABA M, 1978, BIOCHEM PHARMACOL, V27, P2123, DOI 10.1016/0006-2952(78)90284-8; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KESSEL D, 1985, CANCER LETT, V28, P187, DOI 10.1016/0304-3835(85)90074-6; KUNTEBOMMANAHAL.NT, 1985, CANCER RES, V45, P5382; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELONG IH, 1992, FEBS LETT, V304, P256, DOI 10.1016/0014-5793(92)80632-Q; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARIN R, 1986, BIOCHIM BIOPHYS ACTA, V858, P195, DOI 10.1016/0005-2736(86)90306-8; MILLER TP, 1991, J CLIN ONCOL, V9, P17, DOI 10.1200/JCO.1991.9.1.17; PEARCE HL, 1989, P NATL ACAD SCI USA, V86, P5128, DOI 10.1073/pnas.86.13.5128; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; ROEPE PD, 1993, BIOCHEMISTRY-US, V32, P11042, DOI 10.1021/bi00092a014; ROEPE PD, 1992, BIOCHEMISTRY-US, V31, P12555, DOI 10.1021/bi00165a003; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; ROTTENBERG H, 1972, EUR J BIOCHEM, V25, P54, DOI 10.1111/j.1432-1033.1972.tb01666.x; RUETZ S, 1993, P NATL ACAD SCI USA, V90, P11588, DOI 10.1073/pnas.90.24.11588; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; Schlemmer S. R., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P431; SCHLEMMER SR, 1992, J BIOL CHEM, V267, P14746; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SIMON S, 1994, P NATL ACAD SCI USA, V91, P1128, DOI 10.1073/pnas.91.3.1128; SORITNAK FM, 1986, J CELL PHYSL, V12, P266; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TAMAI I, 1990, J BIOL CHEM, V265, P16509; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALVERDE MA, 1992, NATURE, V355, P850; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671; VANDERBLIEK AM, 1988, GENE, V71, P407; ZAMORA JM, 1988, MOL PHARMACOL, V33, P454	62	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31059	31066						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983045				2022-12-25	WOS:A1994PV51000052
J	MATSUDA, T; TAKAO, T; SHIMONISHI, Y; MURATA, M; ASANO, T; YOSHIZAWA, T; FUKADA, Y				MATSUDA, T; TAKAO, T; SHIMONISHI, Y; MURATA, M; ASANO, T; YOSHIZAWA, T; FUKADA, Y			CHARACTERIZATION OF INTERACTIONS BETWEEN TRANSDUCIN ALPHA/BETA-GAMMA-SUBUNITS AND LIPID-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; BETA-GAMMA; RAS PROTEINS; PLASMA-MEMBRANE; BOVINE BRAIN; ASSOCIATION; MOTIF; CDNA; PALMITOYLATION; IDENTIFICATION	The gamma-subunits of heterotrimeric guanine nucleotide binding regulatory proteins (G-proteins) are isoprenylated and alpha-carboxyl methylated at their COOH-terminal cysteine residues. These modifications are necessary for membrane attachment of the beta gamma complex, but a requirement of an additional factor has been proposed for the stable binding. We explored a possible contribution of the blocked amino terminus of beta-subunits of bovine photoreceptor G-protein, transducin (T alpha/T beta gamma = G(t) alpha/beta(1) gamma(1)), and of three beta gamma complexes (beta(1) gamma(2), beta(1) gamma(3), and beta(1) gamma(7)) purified from bovine brains. Structural analyses revealed that every beta(1)-subunit has an N-acetylated serine, which is unlikely to contribute to the membrane association. Since neither protease nor heat treatment of photoreceptor membranes affected the membrane binding of T beta gamma, it seems unlikely that rhodopsin (or other membrane proteins) serves as an anchor protein for accepting T beta gamma. In fact, T beta gamma bound to phospholipid large unilamellar vesicles (LUVs), of which the polar head groups strongly influenced the binding: T beta gamma alone showed 2-fold higher binding for negatively charged phosphatidylserine-LUVs than for neutral phosphatidylcholine (PC)-LUVs, while the affinity of T alpha/T beta gamma complex for the phosphatidylserine-LUVs was lower than that for the PC-LUVs. These results indicate that 1) an ionic interaction between T beta gamma and membrane surface plays an important role in the stable membrane association, and 2) the domain(s) of T beta gamma responsible for the association would be different between trimeric and dissociated states. We also found that synthetic peptides corresponding to the COOH terminal region of T gamma inhibited T alpha-T beta gamma interaction only when the peptides were isoprenylated. This suggests that the isoprenyl moiety is located at the contact site between the subunits, not at the membrane-binding domain, when T beta gamma is complexed with T alpha.	UNIV TOKYO,COLL ARTS & SCI,DEPT PURE & APPL SCI,MEGURO KU,TOKYO 153,JAPAN; OSAKA UNIV,INST PROT RES,OSAKA 565,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN; AICHI PREFECTURAL COLONY,INST DEV RES,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN; OSAKA SANGYO UNIV,FAC ENGN,DEPT INFORMAT SYST ENGN,OSAKA 574,JAPAN	University of Tokyo; Osaka University; Kyoto University			吉孝, 深田/G-5090-2014					ASANO T, 1993, J BIOL CHEM, V268, P20512; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; BUTRYNSKI JE, 1992, BIOCHEMISTRY-US, V31, P8030, DOI 10.1021/bi00149a037; CALI JJ, 1992, J BIOL CHEM, V267, P24023; COHN EJ, 1943, PROTEINS AMINO ACIDS, P445; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUKADA Y, 1989, J BIOL CHEM, V264, P5937; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HARGRAVE P A, 1980, Neurochemistry International, V1, P231, DOI 10.1016/0197-0186(80)90063-7; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; Kuhn H., 1980, Neurochemistry International, V1, P269, DOI 10.1016/0197-0186(80)90066-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MORISHITA R, 1992, EUR J BIOCHEM, V210, P1061, DOI 10.1111/j.1432-1033.1992.tb17512.x; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; MURATA M, 1992, BIOCHEMISTRY-US, V31, P1986, DOI 10.1021/bi00122a013; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; OHGURO H, 1990, BIOCHEM BIOPH RES CO, V167, P1235, DOI 10.1016/0006-291X(90)90656-8; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; OKANO T, 1992, P NATL ACAD SCI USA, V89, P5932, DOI 10.1073/pnas.89.13.5932; OVCHINNIKOV YA, 1982, FEBS LETT, V148, P179, DOI 10.1016/0014-5793(82)80805-3; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAHMATULLAH M, 1994, J BIOL CHEM, V269, P3574; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; RUEGG R, 1959, HELV CHIM ACTA, V42, P2616, DOI 10.1002/hlca.19590420733; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; UEDA N, 1994, J BIOL CHEM, V269, P4388; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	51	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30358	30363						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982949				2022-12-25	WOS:A1994PU52500051
J	TALMAGE, DA; LISTERUD, M				TALMAGE, DA; LISTERUD, M			RETINOIC ACID SUPPRESSES POLYOMA-VIRUS TRANSFORMATION BY INHIBITING TRANSCRIPTION OF THE C-FOS PROTOONCOGENE	ONCOGENE			English	Article							SERUM RESPONSE ELEMENT; MIDDLE T-ANTIGEN; TUMOR-INDUCTION; CELL-LINE; EXPRESSION; GENE; PHOSPHORYLATION; GROWTH; JUN; REPLICATION	In a previous paper, we predicted that retinoic acid suppressed polyoma virus transformation of rat F111 fibroblasts by affecting the expression of one or more genes that are involved in signalling pathways normally activated by the viral mT oncogene (Talmage and Lackey, Oncogene 7, 1837-1845, 1992). We had identified the cellular c-fos proto-oncogene as a possible candidate target for both polyoma virus mT and retinoic acid regulated expression. In this report we present the results of experiments that demonstrate that retinoic acid does indeed inhibit transcriptional transactivation of the c-fos promoter by polyoma virus, as well as by calf serum and purified serum growth factors. Further experiments demonstrate that inhibition of c-fos expression with antisense fos RNA also prevents polyoma virus induced transformation. Restoration of c-fos expression, even in the presence of retinoic acid, restored transformation, indicating that retinoic acid inhibition of c-fos expression is sufficient to explain the retinoid suppression of transformation. These results identify the c-fos protooncogene as a key nuclear target for mT-dependent transformation and show that the anticarcinogenic properties of retinoic acid can be brought about by inhibiting c-fos expression.			TALMAGE, DA (corresponding author), COLUMBIA UNIV,INST HUMAN NUTR,NEW YORK,NY 10032, USA.			Talmage, David/0000-0003-4627-3007	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026854] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26854] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENJAMIN TL, 1982, BIOCHIM BIOPHYS ACTA, V695, P69, DOI 10.1016/0304-419X(82)90018-X; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DUBENSKY TW, 1991, J VIROL, V65, P342, DOI 10.1128/JVI.65.1.342-349.1991; FREUND R, 1991, J VIROL, V65, P335, DOI 10.1128/JVI.65.1.335-341.1991; FREUND R, 1992, VIROLOGY, V191, P716, DOI 10.1016/0042-6822(92)90247-M; GARCEA RL, 1989, VIROLOGY, V168, P312, DOI 10.1016/0042-6822(89)90271-7; GIESE NA, 1985, J NATL CANCER I, V74, P1135; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; JAFFEY P, 1992, CANCER RES, V52, P2384; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KOLCH W, 1993, ONCOGENE, V8, P361; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LOTAN R, 1977, J NATL CANCER I, V59, P1717, DOI 10.1093/jnci/59.6.1717; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MERCOLA D, 1987, BIOCHEM BIOPH RES CO, V147, P288, DOI 10.1016/S0006-291X(87)80119-5; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SCHNEIDTMAN KH, 1991, MOL CELL BIOL, V11, P1996; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TALMAGE DA, 1992, VIROLOGY, V187, P734, DOI 10.1016/0042-6822(92)90476-6; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1991, CELL GROWTH DIFFER, V2, P51; TALMAGE DA, 1992, ONCOGENE, V7, P1837; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; Treisman R, 1990, Semin Cancer Biol, V1, P47; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2721; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WICK M, 1992, ONCOGENE, V7, P859; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	46	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3557	3563						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970716				2022-12-25	WOS:A1994PT39200018
J	ZHAN, QM; FAN, SJ; BAE, I; GUILLOUF, C; LIEBERMANN, DA; OCONNOR, PM; FORNACE, AJ				ZHAN, QM; FAN, SJ; BAE, I; GUILLOUF, C; LIEBERMANN, DA; OCONNOR, PM; FORNACE, AJ			INDUCTION OF BAX BY GENOTOXIC STRESS IN HUMAN-CELLS CORRELATES WITH NORMAL P53 STATUS AND APOPTOSIS	ONCOGENE			English	Article							WILD-TYPE P53; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; NITROGEN-MUSTARD; BINDING-SITE; CYCLE ARREST; PROTEIN; BCL-2; DEATH; GENE	DNA-damaging agents such as ionizing radiation (IR) activate the tumor suppressor p53 and in some cases can cause apoptosis. M1 cells, which do not express the endogenous tumor suppressor gene p53, undergo apoptosis following activation of a temperature sensitive p53 transgene, where it has been shown that bax, an important mediator of apoptosis, is a p53 target gene (Selvakumaran et al, Oncogene 9, 1791-8, 1994). Since p53 can function as a transcription factor after activation by IR, the genetic response to this stress was examined in a panel of human cells with defined p53 status. Like the p53-regulated gene gadd45, bax was rapidly induced, as measured by increased mRNA levels,in the p53 wt (wild type) human myeloid line ML-1, and it was not induced in cells lacking functional p53. However, unlike other p53-regulated genes, bax was only induced in p53 wt cells in which IR also triggered apoptosis. In the case of bc12, which opposes bax function, mRNA levels were reduced in ML-1 cells after IR. Thus, bax appears to be an unique p53-regulated gene in that its induction by IR not only requires functional p53 but also requires that the cells be apoptosis ''proficient.''	NCI, DIV CANC TREATMENT, MOLEC PHARMACOL LAB, DEV THERAPEUT PROGRAM, BETHESDA, MD 20892 USA; TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	NCI NIH HHS [1RO1CA43618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1994, IN PRESS CANCER RES; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DOLE M, 1994, CANCER RES, V54, P3253; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN S, 1994, IN PRESS CANCER RES; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORNACE AJ, 1980, BIOCHIM BIOPHYS ACTA, V607, P432, DOI 10.1016/0005-2787(80)90153-7; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FORNACE AJ, 1980, MUTAT RES, V70, P323, DOI 10.1016/0027-5107(80)90022-6; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARPER JW, 1993, CELL, V75, P805; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1989, CANCER RES, V49, P1687; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KHANNA KK, 1993, ONCOGENE, V8, P3307; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIYASHITA T, 1994, NOCOGENE, V9, P1799; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OCONNOR PM, 1993, CANCER RES, V53, P4776; OCONNOR PM, 1991, CANCER RES, V51, P6550; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; STAMATO TD, 1982, SOMAT CELL GENET, V8, P643, DOI 10.1007/BF01542857; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALTON MI, 1993, CANCER RES, V53, P1853; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	45	413	423	1	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3743	3751						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970735				2022-12-25	WOS:A1994PT39200041
J	DAVEY, MJ; FUNNELL, BE				DAVEY, MJ; FUNNELL, BE			THE P1 PLASMID PARTITION PROTEIN PARA - A ROLE FOR ATP IN SITE-SPECIFIC DNA-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; INTEGRATION HOST FACTOR; UNIT-COPY MINIPLASMIDS; LARGE TUMOR-ANTIGEN; ESCHERICHIA-COLI; RECA-PROTEIN; F-PLASMID; AGROBACTERIUM-TUMEFACIENS; DAUGHTER CELLS; REPLICATION	ParA, a P1 protein required for partition of the prophage plasmid, regulates expression of its own gene and another partition gene, parB, from a promoter upstream of parA. The ATP-dependent ParA DNA binding activity to the par promoter is thought to mediate this regulation. An alternate purification for ParA is presented. This highly purified ParA was used to enamine ParA DNA binding activity using DNase I protection assays. At high concentration, ParA bound to the par promoter in the absence of ATP, demonstrating that although ATP stimulates, it is not required for DNA binding. Nonhydrolyzable ATP analogues as well as ADP stimulated binding more than ATP, suggesting that the act of hydrolysis is coupled to release of the DNA. Glycerol gradient sedimentation and chemical cross-linking experiments suggest that ParA exists in an monomer-dimer equilibrium that is shifted toward dimer formation by adding ATP or ADP. These observations lead to the proposal that the more active DNA binding form of ParA is a dimer and that the effects of ATP and ParA concentration on DNA binding are a direct result of their effects on oligomerization.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ON, CANADA	University of Toronto			Davey, Megan/B-4066-2012	Funnell, Barbara/0000-0002-1828-6567				ABELES AL, 1985, J MOL BIOL, V185, P261, DOI 10.1016/0022-2836(85)90402-4; ARAI K, 1981, J BIOL CHEM, V256, P5247; AUSTIN S, 1983, J MOL BIOL, V169, P373, DOI 10.1016/S0022-2836(83)80056-4; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DAVIS TL, 1992, MOL MICROBIOL, V6, P1981, DOI 10.1111/j.1365-2958.1992.tb01371.x; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; FRIEDMAN SA, 1988, PLASMID, V19, P103, DOI 10.1016/0147-619X(88)90049-2; FUNNELL BE, 1988, J BACTERIOL, V170, P954, DOI 10.1128/JB.170.2.954-960.1988; FUNNELL BE, 1993, J BIOL CHEM, V268, P3616; FUNNELL BE, 1991, J BIOL CHEM, V266, P14328; FUNNELL BE, 1988, P NATL ACAD SCI USA, V85, P6657, DOI 10.1073/pnas.85.18.6657; GALLIE DR, 1987, J MOL BIOL, V193, P465, DOI 10.1016/0022-2836(87)90260-9; GERDES K, 1986, J MOL BIOL, V190, P269, DOI 10.1016/0022-2836(86)90001-X; GIDONI D, 1982, J VIROL, V42, P456, DOI 10.1128/JVI.42.2.456-466.1982; HAYES F, 1994, MOL MICROBIOL, V11, P249, DOI 10.1111/j.1365-2958.1994.tb00305.x; KERRIGAN LA, 1992, NUCLEIC ACIDS RES, V20, P6673, DOI 10.1093/nar/20.24.6673; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KORANGY F, 1992, J BIOL CHEM, V267, P1727; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORIMER HE, 1991, J VIROL, V65, P687, DOI 10.1128/JVI.65.2.687-699.1991; MARTIN KA, 1991, J BACTERIOL, V173, P3630, DOI 10.1128/JB.173.12.3630-3634.1991; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MORI H, 1989, J BIOL CHEM, V264, P15535; MORI H, 1986, J MOL BIOL, V192, P1, DOI 10.1016/0022-2836(86)90459-6; NOLL M, 1974, NUCLEIC ACIDS RES, V1, P1573, DOI 10.1093/nar/1.11.1573; OGAWA T, 1979, COLD SPRING HARB SYM, V43, P909, DOI 10.1101/SQB.1979.043.01.099; OGURA T, 1983, CELL, V32, P351, DOI 10.1016/0092-8674(83)90454-3; ROBERTS JW, 1979, COLD SPRING HARB SYM, V43, P917, DOI 10.1101/SQB.1979.043.01.100; ROSNER JL, 1972, VIROLOGY, V48, P679, DOI 10.1016/0042-6822(72)90152-3; RUNZLER R, 1987, J VIROL, V61, P2076, DOI 10.1128/JVI.61.7.2076-2083.1987; Sambrook J, 1989, MOL CLONING LABORATO; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABUCHI A, 1992, J BACTERIOL, V174, P7629, DOI 10.1128/JB.174.23.7629-7634.1992	41	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29908	29913						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961987				2022-12-25	WOS:A1994PU28400091
J	DUTIL, EM; KERANEN, LM; DEPAOLIROACH, AA; NEWTON, AC				DUTIL, EM; KERANEN, LM; DEPAOLIROACH, AA; NEWTON, AC			IN-VIVO REGULATION OF PROTEIN-KINASE-C BY TRANS-PHOSPHORYLATION FOLLOWED BY AUTOPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; ACTIVATION; PHOSPHATIDYLSERINE; ALPHA; DIACYLGLYCEROL; IDENTIFICATION; PHOSPHATASE-1; INVITRO; BINDING	Dephosphorylation by the catalytic subunits of protein phosphatases 1 (CS1) and 2A (CS2) reveals that mature protein kinase C is phosphorylated at two distinct sites. Treatment of protein kinase C beta II with CS1 causes a significant increase in the protein's electrophoretic mobility (approximately 4 kDa) and a coincident loss in catalytic activity. The CS1-dephosphorylated enzyme cannot autophosphorylate or be phosphorylated by mature protein kinase C, indicating that a different kinase catalyzes the phosphorylation at this site. The loss of activity is consistent with dephosphorylation on protein kinase C's activation loop (Orr, J. W., and Newton, A. C., (1994) J. Biol. Chem. 269, 27715-27718). Treatment with CS2 results in a smaller shift in electrophoretic mobility (approximately 2 kDa) and no loss in catalytic activity. Furthermore, the CS2-dephosphorylated form can autophosphorylate and thus regain the electrophoretic mobility of mature enzyme, consistent with dephosphorylation at protein kinase C's carboxyl-terminal autophosphorylation site, which is modified in vivo (Flint, A. J., Paladini, R. D., and Koshland, D. E., Jr. (1990) Science 249, 408-411). In summary, two phosphorylations process protein kinase C to generate the mature form: a transphosphorylation that renders the kinase catalytically competent and an autophosphorylation that may be important for the subcellular localization of the enzyme.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043154, R37GM043154] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL06308] Funding Source: Medline; NIDDK NIH HHS [DK36569] Funding Source: Medline; NIGMS NIH HHS [GM 43154] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELL RM, 1991, J BIOL CHEM, V266, P4661; BORNER C, 1989, J BIOL CHEM, V264, P13902; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; FILIPUZZI I, 1993, J CELL BIOCHEM, V52, P78, DOI 10.1002/jcb.240520111; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1987, J BIOL CHEM, V262, P10185; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; POEHLING HM, 1981, ELECTROPHORESIS, V2, P141, DOI 10.1002/elps.1150020304; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TUNG HYL, 1984, EUR J BIOCHEM, V138, P635, DOI 10.1111/j.1432-1033.1984.tb07962.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG J, 1994, J BIOL CHEM, V269, P19578; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484	29	132	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29359	29362						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961910				2022-12-25	WOS:A1994PU28400007
J	SEKIGUCHI, J; SHUMAN, S				SEKIGUCHI, J; SHUMAN, S			STIMULATION OF VACCINIA TOPOISOMERASE-I BY NUCLEOSIDE TRIPHOSPHATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC INTERACTION; DNA TOPOISOMERASE; DUPLEX DNA; CLEAVAGE; PURIFICATION; BINDING	The rate of relaxation of supercoiled DNA by purified vaccinia topoisomerase I is stimulated 20-fold by 5 mM ATP. A similar effect is elicited by GTP, CTP, UTP, dATP, and adenosine 5'-(beta,gamma-imido)triphosphate. ATP-mediated rate enhancement requires salt as a coactivator. ADP and inorganic pyrophosphate also stimulate relaxation 10-20-fold, whereas AMP and inorganic phosphate have little effect. A model for allosteric activation of topoisomerase by nucleotides is suggested.			SEKIGUCHI, J (corresponding author), SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.			Sekiguchi, JoAnn/0000-0002-7178-4258	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CASTORA FJ, 1986, P NATL ACAD SCI USA, V83, P1680, DOI 10.1073/pnas.83.6.1680; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; FOGELSONG PD, 1984, J VIROL, V49, P1; GOTO T, 1984, J BIOL CHEM, V259, P422; LOW RL, 1985, NUCLEIC ACIDS RES, V13, P699; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; ROWE TC, 1981, J BIOL CHEM, V256, P354; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	17	23	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29760	29764						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961968				2022-12-25	WOS:A1994PU28400070
J	SINGH, SK; MAURIZI, MR				SINGH, SK; MAURIZI, MR			MUTATIONAL ANALYSIS DEMONSTRATES DIFFERENT FUNCTIONAL ROLES FOR THE 2 ATP-BINDING SITES IN CLPAP PROTEASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; DEPENDENT PROTEASE; DIRECTED MUTAGENESIS; UBIQUITIN; DEGRADATION; CELLS; PROTEOLYSIS; HYDROLYSIS; COMPONENT; BREAKDOWN	ClpA, the regulatory subunit of Clp protease from Escherichia coli, has two ATP-binding sites in nonhomologous regions of the protein, referred to as domain I and domain II. We have mutated the invariant lysine in the ATP-binding sites of domain I and domain II and studied the enzymatic properties of the purified mutant ClpA proteins. The domain I mutant, ClpA-K220Q, was unable to form a hexamer in the presence of nucleotide, but the comparable domain II mutant, ClpA-K501Q, associated into a hexamer in the presence of ATP, indicating that nucleotide binding to domain I favors a conformation required to stabilize the quaternary structure of ClpA ClpA-K220Q was defective in ATPase activity and in the ability to activate protein and peptide degradation by ClpP, but the defects could be partially overcome by formation of hybrid hexamers with wildtype ClpA Another domain I mutant, ClpA-K220R, readily formed hexamers in the presence of ATP and retained greater than or equal to 60% of the wild-type ATPase activity and ability to activate ClpP. These results indicate that hexamer formation is a prerequisite for expression of enzymatic activity. Domain II mutants ClpA-K501Q and ClpA-K501R had very low ATPase activity (<10% of wild-type) and a severe defect in activation of protein degradation, which requires ATP hydrolysis. Domain II mutants were able to activate ClpP to degrade a peptide whose degradation required nucleotide binding but not hydrolysis. Nucleotide binding to domain II of ClpA is important to form a productive complex with ClpP, and domain II appears to be primarily responsible for an energy-requiring step in the catalytic cycle unique to the degradation of large proteins.	NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GOLDBERG AL, 1985, J BIOL CHEM, V260, P2029; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HSIEH S, 1992, NUCLEIC ACIDS RES, V20, P5647, DOI 10.1093/nar/20.21.5647; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KAUR P, 1992, J BIOL CHEM, V267, P19272; KLOSE M, 1993, J BIOL CHEM, V268, P4504; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; MAURIZI MR, 1985, J BACTERIOL, V164, P1124, DOI 10.1128/JB.164.3.1124-1135.1985; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAURIZI MR, 1991, BIOCHEM SOC T, V19, P719, DOI 10.1042/bst0190719; Miller J.H., 1992, SHORT COURSE BACTERI, P150; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, IN PRESS NATURE; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; Sambrook J, 1989, MOL CLONING LABORATO; SEELIG A, 1991, BIOCHEM J, V280, P225, DOI 10.1042/bj2800225; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WAXMAN L, 1985, J BIOL CHEM, V260, P1994; WAXMAN L, 1982, P NATL ACAD SCI-BIOL, V79, P4883, DOI 10.1073/pnas.79.16.4883; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257; WICKNER S, 1994, IN PRESS P NATL ACAD; WOO KM, 1989, J BIOL CHEM, V264, P2088; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	47	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29537	29545						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961938				2022-12-25	WOS:A1994PU28400037
J	SONG, WX; APODACA, G; MOSTOV, K				SONG, WX; APODACA, G; MOSTOV, K			TRANSCYTOSIS OF THE POLYMERIC IMMUNOGLOBULIN RECEPTOR IS REGULATED IN MULTIPLE INTRACELLULAR COMPARTMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL SORTING SIGNAL; MDCK CELLS; CYTOPLASMIC DOMAIN; PROTEINS; PHOSPHORYLATION; TRANSPORT; VESICLES; SURFACES; RAT; IGA	Transcytosis of the polymeric immunoglobulin receptor (pIgR) can be experimentally divided into three steps: 1) internalization from the basolateral plasma membrane and delivery to basolateral early endosomes, 2) microtubule-dependent movement from basolateral early endosomes to apical recycling endosomes, and 3) delivery from apical recycling endosomes to the apical surface and cleavage of the pIgR to secretory component, which is released into the apical medium. Transcytosis of the pIgR is stimulated by two signals, phosphorylation of Ser-664 in the cytoplasmic domain of the pIgR and binding of the ligand, dimeric IgA, to the pIgR. These signals do not detectably alter step 1 of transcytosis. Here, we show that phosphorylation of Ser-664 stimulates both steps 2 and 3, whereas binding of dimeric IgA stimulates only step 3 of transcytosis.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Apodaca, Gerard/HCJ-0048-2022	mostov, keith/0000-0002-8123-6247	NIAID NIH HHS [1R01 AI 25144] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APODACA G, 1993, J BIOL CHEM, V268, P23712; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; BARR VA, 1993, GASTROENTEROLOGY, V105, P554, DOI 10.1016/0016-5085(93)90734-T; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HUGHSON EJ, 1990, J CELL BIOL, V110, P337, DOI 10.1083/jcb.110.2.337; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; QUINTART J, 1989, EUR J BIOCHEM, V184, P567, DOI 10.1111/j.1432-1033.1989.tb15051.x; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SONG WX, 1994, P NATL ACAD SCI USA, V91, P163, DOI 10.1073/pnas.91.1.163	27	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29474	29480						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961930				2022-12-25	WOS:A1994PU28400028
J	NESS, GC; ZHAO, ZH; WIGGINS, L				NESS, GC; ZHAO, ZH; WIGGINS, L			INSULIN AND GLUCAGON MODULATE HEPATIC 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE-ACTIVITY BY AFFECTING IMMUNOREACTIVE PROTEIN-LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; RAT-LIVER; CHOLESTEROL-SYNTHESIS; COA REDUCTASE; KINASE; PHOSPHORYLATION; PURIFICATION; DEGRADATION; MEVALONATE; FRACTIONS	The question of whether the effects of insulin and glucagon on hepatic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity are mediated largely by changes in the phosphorylation state of the enzyme or by changes in the quantity of enzyme protein was investigated by measuring enzyme protein and mRNA levels. If phosphorylation/dephosphorylation is responsible for the observed changes in HMG-CoA reductase activity, one would not expect to see changes in immunoreactive protein or mRNA levels in response to induction of diabetes, administration of insulin, or administration of insulin and glucagon. It was found that hepatic HMG-CoA reductase mRNA levels were decreased to 12% of control in diabetic rats. Immunoreactive protein was reduced to essentially undetectable levels. Administration of insulin restored both mRNA and immunoreactive protein levels. Glucagon blocked these effects. Enzyme activity changes were fully accounted for by changes in HMG-CoA reductase mRNA and immunoreactive protein. Fasting caused parallel falls in HMG-CoA reductase activity and immunoreactive protein levels with a lesser effect on mRNA levels. The insulin-mediated changes in HMG-CoA reductase gene expression correlated well with changes in blood glucose levels, indicating a physiological effect. Taken together, these results indicate that insulin and glucagon regulate HMG-CoA reductase gene expression largely at the level of enzyme protein through changes in mRNA concentrations.	UNIV S FLORIDA,INST BIOMOLEC SCI,TAMPA,FL 33612	State University System of Florida; University of South Florida	NESS, GC (corresponding author), UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,12901 BRUCE B DOWNS BLVD,TAMPA,FL 33612, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018094] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 18094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AREBALO RE, 1982, P NATL ACAD SCI-BIOL, V79, P51, DOI 10.1073/pnas.79.1.51; BEG ZH, 1982, FED PROC, V41, P2634; BEG ZH, 1973, BIOCHEM BIOPH RES CO, V54, P1362, DOI 10.1016/0006-291X(73)91137-6; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; DEVLIN TM, 1992, TXB BIOCH CLIN CORRE, P441; DUGAN RE, 1972, ARCH BIOCHEM BIOPHYS, V152, P21, DOI 10.1016/0003-9861(72)90188-9; EASOM RA, 1984, BIOCHEM J, V220, P739, DOI 10.1042/bj2200739; EDWARDS PA, 1986, J LIPID RES, V27, P398; FERRER A, 1985, BIOCHEM BIOPH RES CO, V132, P497, DOI 10.1016/0006-291X(85)91161-1; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HIGGINS M, 1973, NATURE-NEW BIOL, V246, P60, DOI 10.1038/newbio246060a0; HIGGINS MJP, 1974, ARCH BIOCHEM BIOPHYS, V163, P271, DOI 10.1016/0003-9861(74)90477-9; ILES RA, 1985, BIOCHEM J, V229, P141, DOI 10.1042/bj2290141; INGEBRITSEN TS, 1979, J BIOL CHEM, V254, P9986; KANDUTSCH AA, 1969, J BIOL CHEM, V244, P2299; LAKSHMANAN M R, 1973, Biochemical and Biophysical Research Communications, V50, P704, DOI 10.1016/0006-291X(73)91301-6; Lehninger A, 1993, PRINCIPLES BIOCH, P679; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MURRAY RK, 1993, HARPERS BIOCH, P270; NESS GC, 1982, ARCH BIOCHEM BIOPHYS, V214, P705, DOI 10.1016/0003-9861(82)90077-7; NESS GC, 1994, ARCH BIOCHEM BIOPHYS, V308, P420, DOI 10.1006/abbi.1994.1059; NESS GC, 1994, ARCH BIOCHEM BIOPHYS, V311, P277, DOI 10.1006/abbi.1994.1238; NESS GC, 1979, ARCH BIOCHEM BIOPHYS, V197, P493, DOI 10.1016/0003-9861(79)90272-8; NESS GC, 1986, BIOCHEM J, V233, P167, DOI 10.1042/bj2330167; NESS GC, 1994, ARCH BIOCHEM BIOPHYS, V309, P193, DOI 10.1006/abbi.1994.1102; NESS GC, 1985, J BIOL CHEM, V260, P6395; NESS GC, 1980, J BIOL CHEM, V255, P9013; NESS GC, 1983, MOL CELL BIOCHEM, V53-4, P299; OMKUMAR RV, 1994, J BIOL CHEM, V269, P6810; PARKER RA, 1989, J BIOL CHEM, V264, P4877; RAABO E, 1960, SCAND J CLIN LAB INV, V12, P402; RAWN JD, 1989, BIOCHEMISTRY-US, P559; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; SHAPIRO DJ, 1971, J BIOL CHEM, V246, P3210; START C, 1968, BIOCHEM J, V107, P411, DOI 10.1042/bj1070411; VOET D, 1990, BIOCHEMISTRY-US, P654; ZUBAY G, 1988, BIOCHEMISTRY-US, P728	40	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29168	29172						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961882				2022-12-25	WOS:A1994PU16800095
J	TSUMOTO, K; UEDA, Y; MAENAKA, K; WATANABE, K; OGASAHARA, K; YUTANI, K; KUMAGAI, I				TSUMOTO, K; UEDA, Y; MAENAKA, K; WATANABE, K; OGASAHARA, K; YUTANI, K; KUMAGAI, I			CONTRIBUTION TO ANTIBODY-ANTIGEN INTERACTION OF STRUCTURALLY PERTURBED ANTIGENIC RESIDUES UPON ANTIBODY-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-FOLDING THERMODYNAMICS; 3-DIMENSIONAL STRUCTURE; LYSOZYME; COMPLEX; SITE; FV; RECOGNITION; RESOLUTION; FRAGMENTS; HYDRATION	For elucidating the contribution of structurally perturbed antigenic residues upon antibody binding to antigen-antibody interaction, the interaction between hen egg white lysozyme (HEL) and HyHEL10 Fv fragment, which is one of several monoclonal antibodies against HEL and structurally well defined (Padlan, E.A., Silverton, E. W., Sheriff, S., Cohen, G. Il., Smith-Gill, S. J., and Davies, D. R. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 5938-5942), was investigated. Asp-101 and Trp-62 of HEL, whose conformations are perturbed by the binding of antibody HyHEL10 in this interaction, were replaced with Gly, and the resulting interactions were studied by assay of the inhibition of the lysozyme activity with the Fv fragment and by titration calorimetry. The results can be summarized as follows. 1) It was possible to prepare the fully functional Fv fragment of HyHEL10 using a secretory expression system in Escherichia coli. Its inhibition profile for HEL activity was almost indistinguishable from that of HyHEL10 IgG, and the contribution of enthalpy to driving the interaction was shown to be significant. 2) A thermodynamic study of the interaction between the D101G mutant HEL and the Fv fragment revealed that, although the negative enthalpy change was smaller than that for the wild type, the Gibbs energy was almost identical to that of the wild type, which resulted from the smaller entropy loss. 3) Study of the interaction between the W62G mutant HEL and this Fv fragment indicated that the rotation of the Trp-62 indole ring upon binding of the antibody made an enthalpic contribution to antibody-antigen interaction, although Trp-62 of HEL was proposed not to be the direct contact residue in the HyHEL10.HEL complex. 4) From these results, it was confirmed experimentally that structural perturbations of antigenic residues upon antibody binding of antigen would contribute 60 the gain of enthalpic energy, in spite of partial offset by entropic loss, and to driving the interaction.	UNIV TOKYO, FAC ENGN, DEPT CHEM & BIOTECHNOL, BUNKYO KU, TOKYO 113, JAPAN; OSAKA UNIV, INST PROT RES, SUITA, OSAKA 565, JAPAN	University of Tokyo; Osaka University								AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; Imoto T., 1972, ENZYMES, V7, P665; ITO W, 1993, J BIOL CHEM, V268, P16639; JANIN J, 1990, J BIOL CHEM, V265, P16027; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; KUMAGAI I, 1992, J BIOL CHEM, V267, P4608; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKHATADZE GI, 1993, J MOL BIOL, V232, P639, DOI 10.1006/jmbi.1993.1416; MARIUZZA RA, 1993, CURR OPIN IMMUNOL, V5, P50, DOI 10.1016/0952-7915(93)90080-C; MCMANUS S, 1991, BIOCHEMISTRY-US, V30, P5851, DOI 10.1021/bi00238a007; NOVOTNY J, 1991, MOL IMMUNOL, V28, P201, DOI 10.1016/0161-5890(91)90062-O; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; POST CB, 1986, J MOL BIOL, V190, P455, DOI 10.1016/0022-2836(86)90015-X; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SMITHGILL SJ, 1984, J IMMUNOL, V133, P384; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; UEDA Y, 1993, GENE, V129, P129; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	30	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28777	28782						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961832				2022-12-25	WOS:A1994PU16800042
J	FERRY, RC; UNSWORTH, CD; ARTYMYSHYN, RP; MOLINOFF, PB				FERRY, RC; UNSWORTH, CD; ARTYMYSHYN, RP; MOLINOFF, PB			REGULATION OF MESSENGER-RNA ENCODING 5-HT2A RECEPTORS IN P11 CELLS THROUGH A POSTTRANSCRIPTIONAL MECHANISM REQUIRING ACTIVATION OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; CEREBELLAR GRANULE CELLS; MESSENGER-RNA LEVELS; DOWN-REGULATION; BETA-2-ADRENERGIC RECEPTOR; SEROTONIN-2 RECEPTORS; RIBONUCLEIC-ACID; UP-REGULATION; EXPRESSION; ANTAGONISTS	Exposure of P11 cells to serotonin (5-HT) resulted in a transient increase in levels of 5-HT2A receptor mRNA. Exposure to 5-HT for as short a time as 1 min was sufficient to trigger a delayed increase in receptor mRNA. 5-HT-induced increases in receptor mRNA levels were not antagonized by the protein synthesis inhibitor cycloheximide. The increase in receptor mRNA levels was accompanied by a transient increase in the half-life of receptor mRNA; the rate of transcription of receptor mRNA was unchanged. Submaximal stimulation of phosphinositide hydrolysis by partial agonists or 6-fluoronorepinephrine, an alpha(1)-adrenergic receptor agonist, also increased receptor mRNA levels. Exposure to phorbol 12-myristate 13-acetate (FMA), an activator of protein kinase C, mimicked these effects, whereas the protein kinase C inhibitor bisindolyhmaleimide antagonized the effects of both 5-HT and PMA. When agonist-promoted increases in receptor mRNA were prevented, the rate of agonist-induced down-regulation was accelerated. These data suggest that levels of 5-HT2A receptor mRNA are regulated by phospholipase C-coupled receptors via a protein kinase C-dependent, post-transcriptional mechanism and indicate that agonist-promoted increases in levels of 5-HT2A receptor mRNA modulate receptor expression.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD026979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH048125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018591] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD-26979] Funding Source: Medline; NIMH NIH HHS [MH 48125] Funding Source: Medline; NINDS NIH HHS [NS 18591] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIYOSHI J, 1993, MOL PHARMACOL, V43, P349; BLACKSHEAR MA, 1983, N-S ARCH PHARMACOL, V324, P125, DOI 10.1007/BF00497017; BLACKSHEAR MA, 1986, NEUROPHARMACOLOGY, V25, P1267, DOI 10.1016/0028-3908(86)90146-2; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BUCKHOLTZ NS, 1988, LIFE SCI, V42, P2439, DOI 10.1016/0024-3205(88)90342-6; BUTLER MO, 1993, J NEUROCHEM, V61, P1270, DOI 10.1111/j.1471-4159.1993.tb13618.x; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; Chin Allison C., 1993, Society for Neuroscience Abstracts, V19, P632; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; COLLINS S, 1991, REGULATION GENE TRAN, P183; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; EISON AS, 1989, LIFE SCI, V44, P1419, DOI 10.1016/0024-3205(89)90400-1; FERRY RC, 1993, MOL PHARMACOL, V43, P729; FRAZER A, 1990, ANNU REV PHARMACOL, V30, P307; FUJIMOTO J, 1992, ENDOCRINOLOGY, V131, P1716, DOI 10.1210/en.131.4.1716; FUKAMAUCHI F, 1991, J NEUROCHEM, V56, P716, DOI 10.1111/j.1471-4159.1991.tb08210.x; GANDOLFI O, 1985, LIFE SCI, V36, P713, DOI 10.1016/0024-3205(85)90190-0; GREENBERG ME, 1990, CURRENT PROTOCOLS MO; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HADCOCK JR, 1991, TRENDS NEUROSCI, V14, P242, DOI 10.1016/0166-2236(91)90124-D; HU ZW, 1993, J BIOL CHEM, V268, P3610; HUMPHREY PPA, 1993, TRENDS PHARMACOL SCI, V14, P233, DOI 10.1016/0165-6147(93)90016-D; IVINS KJ, 1990, MOL PHARMACOL, V37, P622; IVINS KJ, 1991, J PHARMACOL EXP THER, V259, P423; KAGAYA A, 1990, J PHARMACOL EXP THER, V255, P305; NEVE KA, 1991, P NATL ACAD SCI USA, V88, P2802, DOI 10.1073/pnas.88.7.2802; PORT JD, 1992, J BIOL CHEM, V267, P24103; PRITCHETT DB, 1988, EMBO J, V7, P4135, DOI 10.1002/j.1460-2075.1988.tb03308.x; RINALDICARMONA M, 1994, J BIOL CHEM, V269, P396; ROTH BL, 1991, EUR J PHARM-MOLEC PH, V207, P169, DOI 10.1016/0922-4106(91)90093-W; RYDELEKFITZGERALD L, 1993, MOL CELL ENDOCRINOL, V92, P253, DOI 10.1016/0303-7207(93)90016-D; TOULLEC D, 1991, J BIOL CHEM, V266, P15771	33	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31850	31857						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989358				2022-12-25	WOS:A1994PX30300080
J	RYSSIKORA, KE; GHOSH, TK; GILL, DL				RYSSIKORA, KE; GHOSH, TK; GILL, DL			MODIFICATION OF GTP-ACTIVATED CALCIUM TRANSLOCATION BY FATTY ACYL-COA ESTERS - EVIDENCE FOR A GTP-INDUCED PREFUSION EVENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL VESICLES; ADP-RIBOSYLATION FACTOR; NEURONAL CELL-LINE; INTRACELLULAR CALCIUM; RAT-LIVER; COENZYME-A; INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; GUANINE-NUCLEOTIDES; BINDING PROTEINS	A sensitive and specific GTP-activated Ca2+ translocation process induces rapid Ca2+ movements within cells and appears to reflect G protein-induced membrane fusion or junctional communication between discrete sub populations of Ca2+-pumping organelles (Ghosh, T. H., Mullaney, J. M., Tarazi, F. I., and Gill, D. L. (1989) Nature 340, 236-239). Since fatty acylation can modify G;protein action, modification of GTP-induced Ca2+ translocation by fatty acyl-CoA was investigated to throw light on the mechanism underlying Ca2+ transfer. Using permeabilized DDT(1)MF-2 smooth muscle cells, 2 mu m palmitoyl-CoA completely blocked Ca2+ release activated by 20 mu M GTP, while having no effect on inositol 1,4,5-trisphosphate-induced Ca2+ release, The IC50 (50% inhibitory concentration) for palmitoyl-CoA was 0.5 mu M. Above 3 mu M, palmitoyl-CoA inhibited Ca2+ accumulation Fatty acyl chain length was important, C-13 to C-16 fatty acyl-CoA esters all fully blocking the action of GTP; the IC50 for myristoyl-CoA was also 0.5 mu M. C-18 or larger acyl groups had diminished effectiveness as did C-8 or smaller acyl groups. Acetyl-CoA had no blocking effect, In contrast, 10 mu M CoA itself blocked GTP-induced Ca2+ release, CoA required a free sulfhydryl group to block, desulfo-CoA having no effect. Removal of ATP by hexokinase and glucose prevented the action of CoA but not palmitoyl-CoA. The free sulfhydryl and ATP requirements indicated CoA was being acylated by endogenous fatty-acyl-CoA synthetase to be effective, The nonhydrolyzable myristoyl-CoA analog, S-(2-oxopentadecyl)-CoA, blocked the GTP effect identically to myristoyl- and palmitoyl-CoA (IC50 = 0.5 mu M); thus, fatty acyl transfer is not required, indicating that blockade is due to a direct allosteric modification of a component of the GTP activated process by acyl-CoA esters, Palmitoyl-CoA not only inhibited but completely reversed GTP-activated Ca2+ release, resulting in the released Ca2+ being taken back up into pools, In the presence of oxalate, GTP-activated Ca2+ transfer results in a substantial increase in Ca2+ accumulation; palmitoyl-CoA also completely reversed this effect resulting in rapid termination of Ca2+ uptake, This reversal provides strong evidence that GTP activated Ca2+ translocation does not reflect a membrane fusion event, Instead, it likely represents formation of a reversible junction or pore between organelles which may be a required prefusion event.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019304] Funding Source: NIH RePORTER; NINDS NIH HHS [NS19304] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHUEH SH, 1987, J BIOL CHEM, V262, P13857; CHUEH SH, 1986, J BIOL CHEM, V261, P13883; COMERFORD JG, 1988, BIOCHEM J, V249, P89, DOI 10.1042/bj2490089; COMERFORD JG, 1993, BIOCHEM J, V289, P561, DOI 10.1042/bj2890561; CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; DAWSON AP, 1987, BIOCHEM J, V244, P87, DOI 10.1042/bj2440087; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FULCERI R, 1994, CELL CALCIUM, V15, P109, DOI 10.1016/0143-4160(94)90049-3; FULCERI R, 1993, BIOCHEM J, V295, P663, DOI 10.1042/bj2950663; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GILL DL, 1985, J BIOL CHEM, V260, P9289; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; GILL DL, 1984, J BIOL CHEM, V259, P807; GILL DL, 1993, HDB EXPT PHARM GTPAS, V108, P625; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HUANG WH, 1989, J BIOL CHEM, V264, P2605; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MULLANEY JM, 1987, J BIOL CHEM, V262, P13865; MULLANEY JM, 1988, P NATL ACAD SCI USA, V85, P2499, DOI 10.1073/pnas.85.8.2499; NEDER KM, 1994, TETRAHEDRON, V50, P9847, DOI 10.1016/S0040-4020(01)89601-0; NEWMAN CMH, 1993, BIOCHIM BIOPHYS ACTA, V1155, P79, DOI 10.1016/0304-419X(93)90023-6; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PAIEMENT J, 1980, J CELL BIOL, V86, P29, DOI 10.1083/jcb.86.1.29; PAIGE LA, 1989, J MED CHEM, V32, P1665, DOI 10.1021/jm00128a001; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P311; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; Tanaka T, 1981, Methods Enzymol, V71 Pt C, P334; UEDA T, 1986, J BIOL CHEM, V261, P3184; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; VOGEL WK, 1989, MOL CELL BIOCHEM, V86, P171; WOLDEGIORGIS G, 1985, ANAL BIOCHEM, V150, P8, DOI 10.1016/0003-2697(85)90434-8; YAMANE HK, 1993, ANN REV PHARM TOXICO, V32, P201; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245	50	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31607	31613						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989331				2022-12-25	WOS:A1994PX30300044
J	LYLES, MM; GILBERT, HF				LYLES, MM; GILBERT, HF			MUTATIONS IN THE THIOREDOXIN SITES OF PROTEIN DISULFIDE-ISOMERASE REVEAL FUNCTIONAL NONEQUIVALENCE OF THE N-TERMINAL AND C-TERMINAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROLYL 4-HYDROXYLASE; HORMONE BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; BETA-SUBUNIT; SEQUENCE; BONDS; THIOL; POLYPEPTIDE; EXPRESSION	Protein disulfide isomerase (PDI), a foldase of the endoplasmic recticulum, is a multifunctional protein that catalyzes the formation and isomerization of disulfide bonds during protein folding. The wild-type protein contains two redox active thiol/disulfide sites near the N and C terminus that are homologous to the redox center of thioredoxin. Using site-directed mutagenesis, both cysteines of each of the thioredoxin-like centers, (C35S,C38S) and (C379S,C382S) were replaced by serines. In addition, a mutant PDI was constructed with all four of the active cysteines mutated to serine (C35S,C38S,C379S,C382S). The activity of the wild-type and mutant proteins in the oxidative renaturation of reduced, denatured RNase was analyzed over a wide range of RNase concentrations, PDI concentrations, and glutathione redox buffers compositions. All mutants, including the construct with no functional thioredoxin centers, have measurable disulfide isomerase activity. Both of the thioredoxin-like sites contribute some to apparent steady-state binding (K-m) and catalysis at saturating substrate concentrations (k(cat)); however their contributions are not equivalent. At saturating concentrations of RNase, the mutant with an inactivated C-terminal active site (k(cat) = 0.72 +/- 0.06 min(-1)) retains near wild-type activity (k(cat) = 0.76 +/- 0.02 min(-1)), while the N-terminal mutant exhibits a significantly lower k(cat) (0.24 +/- 0.01 min(-1)). The K-m for RNase is elevated for the C-terminal mutant (K-m = 29 +/- 4 mu M) while the N-terminal mutant (K-m = 7.1 +/- 1.1 mu M) exhibits a wild-type K-m (6.9 +/- 0.8 mu M). The larger K-m for the C-terminal mutant (4.2 times wild-type) and the lower k(cat) of N-terminal mutant (32% of wild-type) suggest that the C-terminal region contributes more to apparent steady-state substrate binding, and the N-terminal region contributes more to catalysis at saturating concentrations of substrate. Despite their complementary roles in catalysis, the thioredoxin-like centers exhibit the same dependence on the glutathione redox buffer composition as evidenced by the equivalent K-ox values for the wild-type (47 +/- 1 mu M), N-terminal mutant (43 +/- 3 mu M), and C-terminal mutant (44 +/- 1 mu M). The mutant with both thioredoxin sites mutated displays a low but detectable level of disulfide-isomerase activity (0.5% of wild-type) that can be observed at high PDI concentrations. At high RNase concentrations (greater than or equal to 26 mu M), wild-type PDI and all of the mutants catalyze intermolecular RNase aggregation in a nucleation growth reaction that is first order in PDI but fourth order with respect to RNase. Disulfide formation is required for RNase aggregation. This behavior is similar to the anti-chaperone activity previously observed for wild-type PDI (Puig, A., and Gilbert, H. F. (1994) J. Biol Chem. 269, 7764-7771; Puig, A., Lyles, M. M., Noiva, R., and Gilbert, H. F. (1994) J. Biol. Chem. 269, 19128-19135).	BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine								Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHENG SY, 1987, J BIOL CHEM, V262, P11221; DELLACOR.E, 1973, BIOCHEM J, V136, P597; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V28, P439, DOI 10.1101/SQB.1963.028.01.060; Fersht A, 1985, ENZYME STRUCTURE MEC, P104; FREEDMAN RB, 1984, BIOCHEM SOC T, V12, P929, DOI 10.1042/bst0120929; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; GUNTHER R, 1993, J BIOL CHEM, V268, P7728; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LU XJ, 1992, BIOCHEMISTRY-US, V31, P4205, DOI 10.1021/bi00132a008; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MORIN JE, 1985, METHOD ENZYMOL, V113, P541; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VAN PN, 1993, EUR J BIOCHEM, V213, P789, DOI 10.1111/j.1432-1033.1993.tb17821.x; VUORI K, 1992, J BIOL CHEM, V267, P7211; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; YAMAUCHI K, 1987, BIOCHEM BIOPH RES CO, V146, P1485, DOI 10.1016/0006-291X(87)90817-5; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	39	83	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30946	30952						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983029				2022-12-25	WOS:A1994PV51000035
J	MILES, AJ; SKUBITZ, APN; FURCHT, LT; FIELDS, GB				MILES, AJ; SKUBITZ, APN; FURCHT, LT; FIELDS, GB			PROMOTION OF CELL-ADHESION BY SINGLE-STRANDED AND TRIPLE-HELICAL PEPTIDE MODELS OF BASEMENT-MEMBRANE COLLAGEN ALPHA-1(IV)531-543 - EVIDENCE FOR CONFORMATIONALLY DEPENDENT AND CONFORMATIONALLY INDEPENDENT TYPE-IV COLLAGEN CELL-ADHESION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; HUMAN-MELANOMA CELLS; ALPHA-2-BETA-1 INTEGRINS; II COLLAGEN; IDENTIFICATION; MIGRATION; BINDING; MULTIPLE; LAMININ; VLA-2	Several regions within the triple-helical domain of type IV collagen function as cellular recognition sites. We have demonstrated previously that melanoma cell activities promoted by the alpha 1(IV)1263-1277 sequence are enhanced by triple helicity (Fields, C. G., Mickelson, D. J., Drake, S. L., McCarthy, J. B., and Fields, G. B. (1993) J. Biol. Chem. 268, 14153-14160), whereas Eble et al. reached similar conclusions for alpha 1 beta 1 integrin-mediated fibrosarcoma cell adhesion to [alpha 1(IV)](2) alpha(2)(IV)434-472 (Eble, J. A., Golbik, R., Mann, K., and Kuhn, K. (1993) EMBO J. 12, 4795-4802). In the present study, we have examined the cell adhesion activities of a third region in type IV collagen. A single-stranded peptide (SSP) incorporating the alpha 1(IV)531-543 sequence promoted the adhesion of melanoma, ovarian carcinoma, and Jurkat cells in a dose-dependent manner, with 40% cell adhesion observed at [SSP] = 1.8, 11.5, and 42.2 mu M, respectively. Nearly identical results were obtained for cell adhesion to an all-D-enantiomer of the SSP, suggesting that the cell surface receptor(s) for this site do not discriminate based on chirality. The alpha 1(IV)531-543 sequence maintained its cell adhesion promoting activity when incorporated into a homotrimeric triple-helical polypeptide, although relative levels of adhesion were either slightly enhanced or slightly diminished compared with the SSP. Triple-helical conformation was thus not critical for cellular recognition of the alpha 1(IV)531-543 sequence. Single-site substitution experiments of the SSP showed no overall correlation between the biological effects of substitutions and SSP conformation. The SSP, D-SSP, triple-helical polypeptide, and SSP substitution results suggest that cell recognition of the alpha 1(IV)531-543 sequence is generally independent of substrate conformation. The present and prior studies indicate that ''conformationally dependent'' and ''conformationally independent'' cellular recognition sites exist within the triple helical domain of type IV collagen.	UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,CTR BIOMED ENGN,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Skubitz, Amy/0000-0003-4672-3450	NCI NIH HHS [CA 21463] Funding Source: Medline; NIAMS NIH HHS [AR 01929] Funding Source: Medline; PHS HHS [KD 4494] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA021463, R01CA021463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUMAILLEY M, 1986, J CELL BIOL, V103, P1569, DOI 10.1083/jcb.103.4.1569; CAMERON JD, 1991, INVEST OPHTH VIS SCI, V32, P2766; CARDARELLI PM, 1992, J BIOL CHEM, V267, P23159; CARDARELLI PM, 1994, J BIOL CHEM, V269, P18668; CHELBERG MK, 1989, CANCER RES, V49, P4796; CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261; Cremer M A, 1988, Int Rev Immunol, V4, P65, DOI 10.3109/08830188809044771; DOLLING R, 1994, J CHEM SOC CHEM COMM, P853, DOI 10.1039/c39940000853; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ETOH T, 1993, J INVEST DERMATOL, V100, P640, DOI 10.1111/1523-1747.ep12472299; FIELDS CG, 1993, PEPTIDE RES, V6, P39; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107; Fields G B, 1994, Methods Mol Biol, V35, P17; GAUSEPOHL H, 1992, PEPTIDE RES, V5, P315; GLATTAUER V, 1991, INT J BIOL MACROMOL, V13, P140, DOI 10.1016/0141-8130(91)90038-V; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HERBST TJ, 1988, J CELL BIOL, V106, P1365, DOI 10.1083/jcb.106.4.1365; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; KU G, 1993, EUR J IMMUNOL, V23, P591, DOI 10.1002/eji.1830230302; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P8251, DOI 10.1021/bi00247a022; MCCARTHY JB, 1993, PEPTIDES 1992, P109; MYERS LK, 1993, J IMMUNOL, V150, P4652; OLIVERO DK, 1993, INVEST OPHTH VIS SCI, V34, P2825; PERRIS R, 1993, J CELL SCI, V106, P1357; RAO GHR, 1994, J BIOL CHEM, V269, P13899; RIDEOUT DC, 1985, J CELL PHYSIOL, V124, P365, DOI 10.1002/jcp.1041240302; RUBIN K, 1981, CELL, V24, P463, DOI 10.1016/0092-8674(81)90337-8; SANTALA P, 1994, J BIOL CHEM, V269, P1276; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TSILIBARY EC, 1986, J CELL BIOL, V103, P2467, DOI 10.1083/jcb.103.6.2467; TUCKWELL DS, 1994, J CELL SCI, V107, P993; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WILKE MS, 1990, J INVEST DERMATOL, V95, P264, DOI 10.1111/1523-1747.ep12484883	43	76	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30939	30945						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983028				2022-12-25	WOS:A1994PV51000034
J	NELSON, JE; KRAWETZ, SA				NELSON, JE; KRAWETZ, SA			CHARACTERIZATION OF A HUMAN LOCUS IN TRANSITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTAMINE GENES; DNA-SEQUENCES; HUMAN CHROMOSOME-16; ATTACHMENT REGIONS; SPERMATID NUCLEUS; REPETITIVE DNA; CLOSE LINKAGE; HUMAN GENOME; PROTEIN; PRM1	The spermatid-specific nucleoprotamine genes PRM1 and PRM2 and the transition protein gene TNP2 are clustered at a single site on human chromosome 16p13.2. To begin to understand the mechanism governing their genesis and coordinate regulation the primary sequence of this similar to 40.6 kilobase region was determined. This cluster of genes is embedded within a series of repetitive elements, including numerous Alu elements distributed at a frequency of >1 Alu element/kilobase. Multiple Alu elements have integrated into separate truncated L1 sequences within this region. Many of these Alu elements are tandemly inserted or clustered. The role of repetitive elements in the genomic organization and evolution of this gene cluster is discussed. Computer-assisted sequence analysis revealed the presence of structural sequence elements often associated with the boundary regions of active transcriptional domains. Further analysis identified a CpG island at the 3' end of this segment of chromosome 16 and other candidate coding segments within this region indicative of an additional linked gene. These sequence landmarks are commensurate with the complexity of the region.	WAYNE STATE UNIV,SCH MED,DEPT OBSTET & GYNECOL,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,CTR MOLEC MED & GENET,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,CTR HUMAN GROWTH & DEV,DETROIT,MI 48201	Wayne State University; Wayne State University; Wayne State University; Wayne State University			krawetz, stephen/GQQ-3308-2022		NICHD NIH HHS [1R01HD2850401A1] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028504] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADHAM IM, 1991, CYTOGENET CELL GENET, V57, P47, DOI 10.1159/000133113; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BONIFER C, 1991, J CELL BIOCHEM, V47, P99, DOI 10.1002/jcb.240470203; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DEJONCKHEERE J, 1994, HUM MOL GENET, V3, P1915; DENG ZM, 1993, GENOMICS, V18, P156, DOI 10.1006/geno.1993.1443; DEYEBRA L, 1993, J BIOL CHEM, V268, P10553; DOMENJOUD L, 1990, GENOMICS, V8, P127, DOI 10.1016/0888-7543(90)90234-L; EDWARDS A, 1990, GENOMICS, V6, P593, DOI 10.1016/0888-7543(90)90493-E; ENGEL W, 1992, CYTOGENET CELL GENET, V61, P158, DOI 10.1159/000133397; HATTORI M, 1985, NUCLEIC ACIDS RES, V13, P7813, DOI 10.1093/nar/13.21.7813; Hecht N.B., 1989, P396; HUANG XQ, 1992, GENOMICS, V14, P18, DOI 10.1016/S0888-7543(05)80277-0; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P11261; IRIS FJM, 1993, NAT GENET, V3, P137, DOI 10.1038/ng0293-137; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; JURKA J, 1992, J MOL EVOL, V35, P286, DOI 10.1007/BF00161166; JURKA J, 1993, NUCLEIC ACIDS RES, V21, P2252, DOI 10.1093/nar/21.9.2252; JURKA J, 1990, NUCLEIC ACIDS RES, V18, P137, DOI 10.1093/nar/18.1.137; KEIME S, 1992, BIOL CHEM H-S, V373, P261, DOI 10.1515/bchm3.1992.373.1.261; KRAWETZ SA, 1988, J BIOL CHEM, V263, P321; LABUDA D, 1989, NUCLEIC ACIDS RES, V17, P2477, DOI 10.1093/nar/17.7.2477; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; Meistrich M., 1989, HISTONES OTHER BASIC, P165; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; NELSON JE, 1992, ANAL BIOCHEM, V207, P197, DOI 10.1016/0003-2697(92)90523-A; NELSON JE, 1993, J BIOL CHEM, V268, P2932; NELSON JE, 1994, IN PRESS DNA SEQUENC; NELSON JE, 1994, BIOTECHNIQUES, V17, P5; Oliva R., 1991, PROGR NUCL ACID RES, P26; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; REEVES RH, 1989, J HERED, V80, P442, DOI 10.1093/oxfordjournals.jhered.a110895; REINHART N, 1991, BIOL CHEM H-S, V372, P431, DOI 10.1515/bchm3.1991.372.1.431; ROGERS JH, 1985, INT REV CYTOL, V93, P231; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SCHLUTER G, 1992, GENOMICS, V14, P377, DOI 10.1016/S0888-7543(05)80229-0; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P551, DOI 10.1093/nar/12.1Part2.551; STADEN R, 1985, GENETIC ENG PRINCIPL, P67; TOMLIN NV, 1990, FEBS LETT, V263, P69; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; UMEK RM, 1989, BIOCHIM BIOPHYS ACTA, V1007, P1, DOI 10.1016/0167-4781(89)90123-1; VIGUIE F, 1990, HUM GENET, V85, P171; WARD WS, 1989, CHROMOSOMA, V98, P153, DOI 10.1007/BF00329678; WARD WS, 1994, J CELL BIOCHEM, V55, P77, DOI 10.1002/jcb.240550109; WU J, 1990, MOL CELL BIOL, V10, P127; XU Y, 1994, GENETIC ENG PRINCIPL	52	39	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31067	31073						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983046				2022-12-25	WOS:A1994PV51000053
J	TUGORES, A; MAGNESS, ST; BRENNER, DA				TUGORES, A; MAGNESS, ST; BRENNER, DA			A SINGLE PROMOTER DIRECTS BOTH HOUSEKEEPING AND ERYTHROID PREFERENTIAL EXPRESSION OF THE HUMAN FERROCHELATASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; HUMAN ERYTHROPOIETIC PROTOPORPHYRIA; CULTURED SKIN FIBROBLASTS; BOX-BINDING-PROTEINS; TRANSCRIPTION FACTOR; DNA-BINDING; MOLECULAR DEFECT; CPG ISLANDS; ACTING ELEMENTS; MAMMALIAN-CELLS	We have isolated and characterized the 5'-flanking region of the gene for human ferrochelatase (HFC), the last enzyme of the heme biosynthetic pathway. The proximal promoter of the gene is contained within a region that structurally resembles a CpG island and is devoid of general cis elements such as TATA and CAAT boxes. Recognition sites for the ubiquitous Sp1 family of transcription factors, as well as for the erythroid-specific trans-acting factors NF-E2 and GATA-1 were found, and binding of regulatory proteins to these elements was analyzed by in vitro DNase I protection assays. The contribution of the various cis elements to both ubiquitous and erythroid preferential expression of the HFC gene was assessed by using transient transfection assays. These showed that a minimal Sp1-driven promoter devoid of the upstream erythroid-specific elements was sufficient for erythroid preferential expression of the HFC gene. However, elimination of a repressor sequence lying between the minimal promoter and the erythroid-specific elements resulted in high levels of expression in human erythroleukemic K562 cells only when the cis elements recognized by GATA-1 and NF-E2 were present, suggesting that the activity of these factors is regulated by a downstream repressor in erythroid cells.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Tugores, Antonio/AAE-7939-2021	Tugores, Antonio/0000-0002-1849-9239; Brenner, David/0000-0003-2573-525X; Magness, Scott/0000-0002-2746-1224	NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50528] Funding Source: Medline; NIDDK NIH HHS [DK 34987, DK46454] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BLOOMER JR, 1975, AM J MED, V58, P869, DOI 10.1016/0002-9343(75)90644-0; BLOOMER JR, 1980, J CLIN INVEST, V65, P321, DOI 10.1172/JCI109675; BONKOWSKY HL, 1975, J CLIN INVEST, V56, P1139, DOI 10.1172/JCI108189; BOTTOMLEY SS, 1975, J LAB CLIN MED, V86, P126; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; BRENNER DA, 1992, AM J HUM GENET, V50, P1203; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EMERSON BM, 1989, CELL, V57, P1189, DOI 10.1016/0092-8674(89)90056-1; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1988, J MOL BIOL, V199, P61, DOI 10.1016/0022-2836(88)90379-8; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LAMORIL J, 1991, BIOCHEM BIOPH RES CO, V181, P594, DOI 10.1016/0006-291X(91)91231-Z; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; MAGNESS ST, 1994, HUM MOL GENET, V3, P1695, DOI 10.1093/hmg/3.9.1695; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; Maxam A M, 1980, Methods Enzymol, V65, P499; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; NAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P281, DOI 10.1073/pnas.89.1.281; NAKAHASHI Y, 1993, HUM MOL GENET, V2, P1069, DOI 10.1093/hmg/2.7.1069; NAKAHASHI Y, 1993, HUM GENET, V91, P303; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; ORKIN SH, 1992, BLOOD, V80, P575; PORCHER C, 1991, J BIOL CHEM, V266, P10562; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAICH N, 1989, J BIOL CHEM, V264, P10186; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; RIDDLE RD, 1989, P NATL ACAD SCI USA, V86, P792, DOI 10.1073/pnas.86.3.792; RUBIO T, 1994, THESIS U AUTONOMA MA; SARKANY RPE, 1994, J INVEST DERMATOL, V102, P481, DOI 10.1111/1523-1747.ep12373073; SCHOENHAUT DS, 1986, GENE, V48, P55, DOI 10.1016/0378-1119(86)90351-3; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMITH DI, 1987, NUCLEIC ACIDS RES, V15, P1173, DOI 10.1093/nar/15.3.1173; TAKETANI S, 1992, EUR J BIOCHEM, V205, P217, DOI 10.1111/j.1432-1033.1992.tb16771.x; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TODD DJ, 1993, HUM MOL GENET, V2, P1495, DOI 10.1093/hmg/2.9.1495; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TUGORES A, 1994, BIOTECHNIQUES, V17, P410; TUGORES A, 1992, J IMMUNOL, V148, P2300; TUTOIS S, 1991, J CLIN INVEST, V88, P1730, DOI 10.1172/JCI115491; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WANG XH, 1994, BBA-MOL BASIS DIS, V1225, P187, DOI 10.1016/0925-4439(94)90077-9; WANG XH, 1993, BIOCHIM BIOPHYS ACTA, V1181, P198, DOI 10.1016/0925-4439(93)90112-E	64	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30789	30797						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983009				2022-12-25	WOS:A1994PV51000013
J	HUANG, LE; ZHANG, H; BAE, SW; LIU, AYC				HUANG, LE; ZHANG, H; BAE, SW; LIU, AYC			THIOL REDUCING REAGENTS INHIBIT THE HEAT-SHOCK RESPONSE - INVOLVEMENT OF A REDOX MECHANISM IN THE HEAT-SHOCK SIGNAL-TRANSDUCTION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC BINDING; DNA-BINDING; TRANSCRIPTION FACTOR; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; DIPLOID FIBROBLASTS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; ACTIVATION; PROTEIN	We evaluated the effects of thiol-reducing agents on the heat shock response in human and rodent cells in culture. Using HeLa cells as an example, we demonstrated that dithiothreitol (DTT, 2 mM) inhibited the heat (42 degrees C) induced increase in the synthesis of heat shock proteins (HSPs), abundance of mRNA of hsp 70, hsp 70 gene promoter activity, and the heat shock factor (HSF) DNA binding activity. This effect of DTT was specific and attributable to its reducing activity; oxidized DTT was ineffective, and other thiol reducing compounds had the same effect as DTT. Time course and dose-response stud ies showed that DTT significantly inhibited the heat shock induction of heat shock element binding activity with no preincubation and that 0.6 and 1-2 mM DTT gave half-maximal and maximal inhibition, respectively. The effect of DTT was reversible; removal of the DTT-containing medium prior to heat shock rendered the cells fully responsive. Analysis of the effects of DTT on the regulation and function of HSF suggests that DTT blocked an early and important step in the activation process without having a direct effect on the HSF protein. Thus, DTT inhibited the heat-induced trimerization, phosphorylation, and nuclear translocation of HSF and was also effective against a number of other reagents that are known to activate HSF. On the other hand, DTT did not block the response induced by heat shock at 45 degrees C, and in vitro addition of DTT failed to modulate the DNA binding activity of activated HSF present in cell extracts, suggesting that the HSF protein itself is unlikely to be a direct target of action of DTT. These results, together with the observation that activation of HSF DNA binding activity was attenuated under an anoxic condition and that hydrogen peroxide mimicked the effects of heat shock, suggest the involvement of a redox mechanism as an early and important step in the heat shock signal transduction pathway.	RUTGERS STATE UNIV,DEPT BIOL SCI,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick				Huang, Eric/0000-0002-6444-1708; Liu, Alice Y./0000-0002-6984-1671				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BECKER J, 1990, EUR J BIOCHEM, V189, P553, DOI 10.1111/j.1432-1033.1990.tb15522.x; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BURDON R H, 1990, P19; CHANG NT, 1993, J BIOL CHEM, V268, P1436; CHOI HS, 1990, J BIOL CHEM, V265, P18005; EDINGTON BV, 1989, J CELL PHYSL, V139, P221; FREEMAN ML, 1989, RADIAT RES, V117, P326, DOI 10.2307/3577333; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HOSOKAWA N, 1992, MOL CELL BIOL, V12, P3490, DOI 10.1128/MCB.12.8.3490; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KOGOMA T, 1992, J BACTERIOL, V174, P630, DOI 10.1128/jb.174.2.630-632.1992; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEE AS, 1983, J BIOL CHEM, V258, P597; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LIU AYC, 1994, J BIOL CHEM, V269, P14768; LIU AYC, 1989, J BIOL CHEM, V264, P12037; LOVEN DP, 1988, MED HYPOTHESES, V26, P39, DOI 10.1016/0306-9877(88)90111-9; MITCHELL JB, 1983, RADIAT RES, V95, P471, DOI 10.2307/3576094; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MORIMOTO RI, 1990, STRESS PROTEINS BIOL, P449; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; NOVER L, 1984, HEAT SHOCK RESPONSE, P82; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; POLONIS VR, 1991, J BIOL CHEM, V266, P11421; PRIVALLE CT, 1987, P NATL ACAD SCI USA, V84, P2723, DOI 10.1073/pnas.84.9.2723; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SPIRO S, 1991, TRENDS BIOCHEM SCI, V16, P310, DOI 10.1016/0968-0004(91)90125-F; SPITZ DR, 1987, J CELL PHYSIOL, V131, P364, DOI 10.1002/jcp.1041310308; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	50	97	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30718	30725						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982993				2022-12-25	WOS:A1994PU52500103
J	MUKHOPADHYAY, CK; CHATTERJEE, IB				MUKHOPADHYAY, CK; CHATTERJEE, IB			FREE METAL ION-INDEPENDENT OXIDATIVE DAMAGE OF COLLAGEN - PROTECTION BY ASCORBIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN RADICALS; SUPEROXIDE PRODUCTION; CATALYZED OXIDATION; PROTEIN DAMAGE; LIPID-PEROXIDATION; XANTHINE-OXIDASE; DEGRADATION; MECHANISMS; CYTOCHROME-P-450; FRAGMENTATION	In this paper we demonstrate that in the absence of free metal ions, active oxygen species, generated by activated macrophages or xanthine/xanthine oxidase (XOD), carry out oxidative degradation of collagen fibrils type I in conjunction with proteases. The collagen degradation is completely prevented by ascorbate (AH(2)) but not by catalase. The free metal ion-independent collagen degradation is a two step process: (i) oxidation of collagen and (ii) subsequent proteolytic cleavage of the oxidatively modified collagen. AH(2) completely prevents collagen oxidation and thereby protects the collagen from subsequent proteolytic degradation. This is in contrast to free metal ion-catalyzed spontaneous fragmentation of collagen, which is accelerated by AH(2) and inhibited by catalase (Kato, Y., Uchida, K., and Kawakishi, S. (1992) J. Biol. Chem. 267, 23646-23651). Studies using xanthine/XOD and model polypeptides, namely, poly-L-Pro, poly-L-hydroxyproline, poly-L-lys, and poly(Pro-Gly-Pro) indicate that although O-2(radical anion) is needed along with XOD, oxidation of model polypeptides appears to be a direct function of XOD iron, which is also stimulated by cytochrome P450.	UNIV COLL SCI CALCUTTA,DEPT BIOCHEM,CALCUTTA 700019,W BENGAL,INDIA	University of Calcutta								AMICI A, 1989, J BIOL CHEM, V264, P3341; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BIRD IN, 1990, BIOL CHEM H-S, V371, P265; BISKER A, 1982, ANAL BIOCHEM, V122, P52, DOI 10.1016/0003-2697(82)90250-0; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P8220; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; JOHNSTON RB, 1984, METHOD ENZYMOL, V105, P365; KATO Y, 1992, J BIOL CHEM, V267, P23646; KIM JH, 1993, J BIOL CHEM, V268, P44; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1990, METHOD ENZYMOL, V186, P164; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1974, SCIENCE, V185, P529, DOI 10.1126/science.185.4150.529; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; MILLER DM, 1992, ARCH BIOCHEM BIOPHYS, V295, P240, DOI 10.1016/0003-9861(92)90513-V; MINOTTI G, 1992, ARCH BIOCHEM BIOPHYS, V297, P189, DOI 10.1016/0003-9861(92)90661-F; MONBOISSE JC, 1983, BIOCHEM PHARMACOL, V32, P53, DOI 10.1016/0006-2952(83)90651-2; MONBOISSE JC, 1988, BIOCHIM BIOPHYS ACTA, V965, P29, DOI 10.1016/0304-4165(88)90147-X; NATHANS GR, 1975, BIOCHEM BIOPH RES CO, V66, P108, DOI 10.1016/S0006-291X(75)80301-9; OBRIEN PJ, 1984, METHOD ENZYMOL, V105, P370; OLSON JS, 1974, J BIOL CHEM, V249, P4363; OMURA T, 1964, J BIOL CHEM, V239, P2370; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; PORTER TD, 1991, J BIOL CHEM, V266, P13469; SCHILB LA, 1990, J LIQ CHROMATOGR, V13, P557, DOI 10.1080/01483919008051805; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; UCHIDA K, 1992, J AGR FOOD CHEM, V40, P9, DOI 10.1021/jf00013a002; VANDERHO.TA, 1974, J BIOL CHEM, V249, P6302; WERB Z, 1986, HDB EXPT IMMUNOLOGY, V2; WINTER ML, 1991, J BIOL CHEM, V266, P14446; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8; WOLFF SP, 1986, BIOCHEM J, V234, P399, DOI 10.1042/bj2340399	40	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30200	30205						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982927				2022-12-25	WOS:A1994PU52500027
J	YAMASAKI, R; KERWOOD, DE; SCHNEIDER, H; QUINN, KP; GRIFFISS, JM; MANDRELL, RE				YAMASAKI, R; KERWOOD, DE; SCHNEIDER, H; QUINN, KP; GRIFFISS, JM; MANDRELL, RE			THE STRUCTURE OF LIPOOLIGOSACCHARIDE PRODUCED BY NEISSERIA-GONORRHOEAE, STRAIN-15253, ISOLATED FROM A PATIENT WITH DISSEMINATED INFECTION - EVIDENCE FOR A NEW GLYCOSYLATION PATHWAY OF THE GONOCOCCAL LIPOOLIGOSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITOPE EXPRESSION; 2-DIMENSIONAL NMR; HUMAN-SERUM; NEURAMINIC ACID; BLOOD-CELLS; MENINGITIDIS; LIPOPOLYSACCHARIDE; RESISTANCE; OLIGOSACCHARIDES; HETEROGENEITY	We studied the structure of the lipooligosaccharide (EOS) that is produced by Neisseria gonorrhoeae, strain 15253. This strain, recovered from a patient with disseminated infection, produces predominately a single LOS component, and its oligosaccharide (OS) structure is different from those of previously studied LOSs. Definition of this OS structure provides additional information on the LOS biosynthesis. We determined that the 15253 OS has an unusual structure: 2 lactosyl residues at its nonreducing ends shown below, [GRAPHICS] where KDO is 2-keto-3-deoxy-mannooctulosonic acid and Hep is heptose. Comparison of this OS structure with those determined previously indicates the presence of a new glycosylation pathway for gonococcal OS biosynthesis: elongation of a GlcNAc-linked heptose, in contrast to elongation of the other heptose by sequential addition of glycoses which results in the antigenic similarity with human glycolipids. The current study provides not only additional structural information on LOS expressed during different clinical states of infection but also evidence for the diversity of gonococcal LOS biosynthesis. This evidence may be helpful in understanding the pathogenesis involving gonococcal LOS.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,CTR IMMUNOCHEM,SAN FRANCISCO,CA 94121; WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,WASHINGTON,DC 20307	University of California System; University of California San Francisco; University of California System; University of California San Francisco; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center			Mandrell, Robert E/O-9814-2018		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000212] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22998] Funding Source: Medline; NIA NIH HHS [T31AG00212] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APICELLA MA, 1986, J INFECT DIS, V153, P520, DOI 10.1093/infdis/153.3.520; APICELLA MA, 1987, INFECT IMMUN, V55, P1755, DOI 10.1128/IAI.55.8.1755-1761.1987; APICELLA MA, 1990, J INFECT DIS, V162, P506, DOI 10.1093/infdis/162.2.506; BASU M, 1987, METHOD ENZYMOL, V138, P575; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; DIFABIO JL, 1990, CAN J CHEM, V68, P1029, DOI 10.1139/v90-160; GIBSON BW, 1993, J BACTERIOL, V175, P2702, DOI 10.1128/JB.175.9.2702-2712.1993; GIBSON BW, 1989, P NATL ACAD SCI USA, V86, P17, DOI 10.1073/pnas.86.1.17; GREGG CR, 1981, J INFECT DIS, V143, P432, DOI 10.1093/infdis/143.3.432; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JENNINGS HJ, 1983, CARBOHYD RES, V121, P233, DOI 10.1016/0008-6215(83)84020-8; JOHN CM, 1991, J BIOL CHEM, V266, P19303; KERWOOD DE, 1992, BIOCHEMISTRY-US, V31, P12760, DOI 10.1021/bi00166a008; KIM JJ, 1994, INFECT IMMUN, V62, P1566, DOI 10.1128/IAI.62.5.1566-1575.1994; MANDELL RE, 1987, GONOCOCCI MENINGOCOC, P569; MANDRELL R, 1986, INFECT IMMUN, V54, P63, DOI 10.1128/IAI.54.1.63-69.1986; MANDRELL RE, 1992, INFECT IMMUN, V60, P3017, DOI 10.1128/IAI.60.7.3017-3020.1992; MANDRELL RE, 1993, MICROB PATHOGENESIS, V14, P315, DOI 10.1006/mpat.1993.1031; MANDRELL RE, 1991, J BACTERIOL, V173, P2823, DOI 10.1128/JB.173.9.2823-2832.1991; MANDRELL RE, 1990, J EXP MED, V171, P1649, DOI 10.1084/jem.171.5.1649; MANDRELL RE, 1994, METHOD ENZYMOL, V236, P231; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; MICHON F, 1990, J BIOL CHEM, V265, P7243; NAIRN CA, 1988, J GEN MICROBIOL, V134, P3295; NEUHAUS D, 1985, EUR J BIOCHEM, V151, P257, DOI 10.1111/j.1432-1033.1985.tb09096.x; OBRIEN JP, 1983, MEDICINE, V62, P395, DOI 10.1097/00005792-198311000-00005; PARSONS NJ, 1988, MICROB PATHOGENESIS, V5, P303, DOI 10.1016/0882-4010(88)90103-9; PAVLIAK V, 1993, J BIOL CHEM, V268, P14146; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RICE PA, 1977, J CLIN INVEST, V60, P1149, DOI 10.1172/JCI108867; SCHNEIDER H, 1982, J GEN MICROBIOL, V128, P13; SCHNEIDER H, 1984, INFECT IMMUN, V45, P544, DOI 10.1128/IAI.45.3.544-549.1984; SCHNEIDER H, 1991, J EXP MED, V174, P1601, DOI 10.1084/jem.174.6.1601; SCHOOLNIK GK, 1979, J IMMUNOL, V122, P1771; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; WARD ME, 1978, J GEN MICROBIOL, V108, P205, DOI 10.1099/00221287-108-2-205; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; YAMASAKI R, 1991, BIOCHEMISTRY-US, V30, P851, DOI 10.1021/bi00217a039; YAMASAKI R, 1988, MOL IMMUNOL, V25, P799, DOI 10.1016/0161-5890(88)90116-2; YAMASAKI R, 1993, J BACTERIOL, V175, P4565, DOI 10.1128/JB.175.14.4565-4568.1993; YAMASAKI R, 1991, BIOCHEMISTRY-US, V30, P10566, DOI 10.1021/bi00107a028; YAMASAKI R, 1991, MOL IMMUNOL, V28, P1232	42	62	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30345	30351						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982947				2022-12-25	WOS:A1994PU52500049
J	JANES, PW; DALY, RJ; DEFAZIO, A; SUTHERLAND, RL				JANES, PW; DALY, RJ; DEFAZIO, A; SUTHERLAND, RL			ACTIVATION OF THE RAS SIGNALING PATHWAY IN HUMAN BREAST-CANCER CELLS OVEREXPRESSING ERBB-2	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE-C-GAMMA; NIH 3T3 CELLS; EGF RECEPTOR; PROTO-ONCOGENE; SH2 DOMAIN; ADAPTER PROTEIN; OVARIAN-CANCER; TUMOR-CELLS	The c-erbB-2 proto-oncogene encodes a receptor tyrosine kinase (RTK) closely related to the epidermal growth factor receptor (EGFR). Overexpression of erbB-2 occurs in approximately 20% of human breast tumours, where increased expression correlates with poor patient prognosis. The EGFR is coupled to the Pas signalling pathway by interaction with the adaptor protein Grb2, and Sos, a Pas GDP-GTP exchange factor. In this study, activation of the erbB-2 receptor and its association with Grb2 and Sos was investigated in breast cancer cell lines which overexpress erbB-2. The receptor was found to be tyrosine phosphorylated in all cell lines in which it is overexpressed. Western blotting of Grb2 and Sos immuneprecipitates from such cells revealed co-precipitation of erbB-2, demonstrating association of the Grb2/Sos complex with erbB-2 in vivo. Furthermore, a fusion protein containing only the SH2 domain of Grb2 bound to erbB-2 immobilized on nitrocellulose, indicating that association with Grb2 is direct and mediated by the SH2 domain of Grb2. The degree of association between the erbB-2 receptor and Grb2 in vivo was related to erbB-2 overexpression, and MAP kinase, which functions downstream from Ras, displayed markedly increased activity in cell Lines overexpressing erbB-2. These results demonstrate that erbB-2 is coupled to Pas signalling via the Grb2/Sos complex, and that overexpression of this receptor in breast cancer cells leads to amplification of the Ras signalling pathway.	ST VINCENTS HOSP, GARVAN INST MED RES, DIV CANC BIOL, DARLINGHURST, NSW 2010, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			Sutherland, Robert L/A-8378-2008; DeFazio, Anna/O-2385-2019; Daly, Roger J/C-8179-2009; deFazio, Anna/D-3939-2013	DeFazio, Anna/0000-0003-0057-4744; deFazio, Anna/0000-0003-0057-4744; Daly, Roger/0000-0002-5739-8027				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BERCHUCK A, 1990, CANCER RES, V50, P4087; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DALY RJ, 1994, IN PRESS ONCOGENE; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GULLICK WJ, 1990, INT J CANCER, P55; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JALLAL B, 1992, J BIOL CHEM, V267, P4357; KAMEDA T, 1990, CANCER RES, V50, P8002; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SEGATTO O, 1993, ONCOGENE, V8, P2105; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WARE JL, 1991, HUM PATHOL, V22, P254, DOI 10.1016/0046-8177(91)90159-M; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	196	207	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3601	3608						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970720				2022-12-25	WOS:A1994PT39200023
J	POPOV, KM; KEDISHVILI, NY; ZHAO, Y; GUDI, R; HARRIS, RA				POPOV, KM; KEDISHVILI, NY; ZHAO, Y; GUDI, R; HARRIS, RA			MOLECULAR-CLONING OF THE P45 SUBUNIT OF PYRUVATE-DEHYDROGENASE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COENZYME-A; ACTIVATOR PROTEIN; BOVINE KIDNEY; RAT-HEART; PURIFICATION; MECHANISM; COMPLEX; INHIBITION; OXIDATION; ACID	Purified preparations of rat heart pyruvate dehydrogenase kinase have two polypeptides with molecular weights of 48,000 (p48) and 45,000 (p45). Recently, we reported the primary structure of p48 (Popov, K. M., Kedishvili, N. Y., Zhao, Y., Shimomura, Y., Crabb, D. W., and Harris, R. A. (1993) J. Biol. Chem. 268, 26602-26606) and presented evidence that (i) it exhibits kinase activity for pyruvate dehydrogenase and (ii) it belongs to a family of mitochondrial protein kinases unique from other eukaryotic protein kinases. Here, we report the molecular cloning and deduced amino acid sequence of p45. The protein sequence of p45 has 70% identity to the protein sequence of p48. Minor differences exist throughout the protein sequences with the greatest difference occurring at the amino termini. Recombinant p45 protein, expressed in Escherichia coli and purified to homogeneity, catalyzed the phosphorylation and inactivation of kinase-depleted pyruvate dehydrogenase complex, indicating that p45 and p48 correspond to different isoforms of pyruvate dehydrogenase kinase. Northern blot analysis revealed a single hybridizing species of 2.5 kilobases. The highest level of p45 message expression was found in heart and skeletal muscle and the lowest in spleen and lung. Liver, kidney, brain, and testis express intermediate amounts of p45 RNA. In contrast, p48 mRNA is predominantly expressed in heart, with other tissues expressing only a modest amount of this message. Tissue-specific expression of isoforms of pyruvate dehydrogenase kinase may indicate the existence of tissue-specific mechanisms for the regulation of pyruvate dehydrogenase activity.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis				Kedishvili, Natalia/0000-0001-6917-4891	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019259, R01DK047844] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 20542] Funding Source: Medline; NIDDK NIH HHS [DK 47844, DK 19259] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CATERSON ID, 1982, BIOCHEM J, V208, P53, DOI 10.1042/bj2080053; COOPER RH, 1974, BIOCHEM J, V143, P625, DOI 10.1042/bj1430625; DENYER GS, 1986, BIOCHEM J, V239, P347, DOI 10.1042/bj2390347; FATANIA H, 1981, FEBS LETT, V132, P285, DOI 10.1016/0014-5793(81)81180-5; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; JONES BS, 1991, BIOCHEM J, V275, P781, DOI 10.1042/bj2750781; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; KERBEY AL, 1977, BIOCHEM J, V164, P509, DOI 10.1042/bj1640509; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; LINN TC, 1969, P NATL ACAD SCI USA, V64, P227, DOI 10.1073/pnas.64.1.227; MISTRY SC, 1991, BIOCHEM J, V275, P775, DOI 10.1042/bj2750775; Popov K M, 1991, Protein Expr Purif, V2, P278, DOI 10.1016/1046-5928(91)90084-V; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1992, J BIOL CHEM, V267, P13129; PRATT ML, 1979, J BIOL CHEM, V254, P7191; PRIESTMAN DA, 1992, FEBS LETT, V308, P83, DOI 10.1016/0014-5793(92)81056-R; RAHMATULLAH M, 1985, J BIOL CHEM, V260, P146; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEPP LR, 1983, J BIOL CHEM, V258, P9454; TEAGUE WM, 1982, BIOCHEMISTRY-US, V21, P5585, DOI 10.1021/bi00265a031; WALSH DA, 1976, BIOCHEM J, V157, P41, DOI 10.1042/bj1570041; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625	24	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29720	29724						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961963				2022-12-25	WOS:A1994PU28400064
J	SAITO, S; WATABE, S; OZAKI, H; FUSETANI, N; KARAKI, H				SAITO, S; WATABE, S; OZAKI, H; FUSETANI, N; KARAKI, H			MYCALOLIDE-B, A NOVEL ACTIN DEPOLYMERIZING AGENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE MYOSIN; POLYMERIZATION; CYTOCHALASIN; PHALLOIDIN; SUBFRAGMENT-1; NUCLEATION; ELONGATION; FILAMENTS; PROFILIN; BINDING	We investigated the effects of a novel marine toxin, mycalolide B, on actin polymerization and actin-activated myosin Mg2+-ATPase activity using purified actin and myosin from rabbit skeletal muscle. The results were compared with cytochalasin D which inhibits actin polymerization by binding to the barbed end of F-actin. By monitoring fluorescent intensity of pyrenyl-actin, mycalolide B did not accelerate actin polymerization but quickly depolymerized F-actin, whereas cytochalasin D accelerated actin nucleation and depolymerized F-actin at slower rate. The kinetics of depolymerization suggest that mycalolide B severs F-actin. The relationship between the concentration of total actin and F-actin at different concentration of mycalolide B suggests that mycalolide B forms 1:1 complex with G-actin. Viscometry and electron microscopic observation further suggest that actin filament was depolymerized by mycalolide B. Unlike cytochalasin D, furthermore, mycalolide B suppressed actin-activated myosin Mg2+-ATPase activity. We concluded that mycalolide B severs F-actin and sequesters G-actin and may serve as a novel pharmacological tool for analyzing actin-mediated cell functions.	UNIV TOKYO,FAC AGR,DEPT MARINE BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	SAITO, S (corresponding author), UNIV TOKYO,FAC AGR,DEPT VET PHARMACOL,BUNKYO KU,YAYOI 1-1-1,TOKYO 113,JAPAN.							COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Fiske CH, 1925, J BIOL CHEM, V66, P375; FURUKAWA KI, 1993, J BIOL CHEM, V268, P26026; FUSETANI N, 1989, TETRAHEDRON LETT, V30, P2809, DOI 10.1016/S0040-4039(00)99131-7; FUSETANI N, 1987, BIOORGANIC MARINE CH, V1, P61; GODDETTE DW, 1985, BIOCHEM BIOPH RES CO, V128, P1087, DOI 10.1016/0006-291X(85)91051-4; HORI M, 1993, FEBS LETT, V322, P151, DOI 10.1016/0014-5793(93)81557-G; HOWARD TH, 1979, J SUPRAMOL STR CELL, V11, P283, DOI 10.1002/jss.400110303; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; ISHIBASHI M, 1986, J ORG CHEM, V51, P5300, DOI 10.1021/jo00376a047; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; LAL AA, 1985, J BIOL CHEM, V260, P132; MABUCHI I, 1983, J CELL BIOL, V97, P1612, DOI 10.1083/jcb.97.5.1612; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; NISHIDA E, 1984, J BIOCHEM-TOKYO, V95, P387, DOI 10.1093/oxfordjournals.jbchem.a134619; NISHIDA E, 1983, J BIOCHEM-TOKYO, V93, P1011, DOI 10.1093/oxfordjournals.jbchem.a134224; OFFER G, 1972, J MOL BIOL, V66, P435, DOI 10.1016/0022-2836(72)90425-1; PATTERSON GML, 1993, CELL MOTIL CYTOSKEL, V24, P39, DOI 10.1002/cm.970240105; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WENDEL H, 1986, BIOCHIM BIOPHYS ACTA, V873, P387, DOI 10.1016/0167-4838(86)90088-9	25	144	148	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29710	29714						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961961				2022-12-25	WOS:A1994PU28400062
J	YAN, BF; YANG, DF; BRADY, M; PARKINSON, A				YAN, BF; YANG, DF; BRADY, M; PARKINSON, A			RAT-KIDNEY CARBOXYLESTERASE - CLONING, SEQUENCING, CELLULAR-LOCALIZATION, AND RELATIONSHIP TO RAT-LIVER HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL-CHLOROFORM EXTRACTION; JUVENILE-HORMONE ESTERASE; SINGLE-STEP METHOD; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-SEQUENCE; MULTIGENE FAMILY; MICROSOMAL CARBOXYESTERASE-E1; CATALYTIC MECHANISM; RNA ISOLATION; MOUSE-LIVER	We recently purified from rat liver microsomes a carboxylesterase, designated hydrolase B, that catalyzes the hydrolysis of para-nitrophenylacetate with low affinity (K-m similar to 400 mu M) and is relatively insensitive to the inhibitory effects of phenylnethylsulfonyl fluoride. A carboxylesterase with identical properties is also present in rat kidney microsomes, at levels comparable to those in liver microsomes. The kidney enzyme is immunochemically indistinguishable from hydrolase B by Western immunoblotting and Ouchterlony double diffusion analysis. This study describes the cloning and sequencing of hydrolase B. A 1809-base pair (bp) cDNA was isolated from a rat kidney cDNA library screened with antibody against hydrolase B. Screening the same cDNA library by two-step polymerase chain reaction with external and internal primers based on the sequence of the 1809-bp cDNA and a primer based on the sequence of the adjoining lambda gt11 arm yielded a 279-bp cDNA that overlapped by 179 bp with the 1809-bp-sequence. Together these two cDNAs spanned a 1909-bp sequence with an opening reading frame encoding 561 amino acids, which includes all 543 amino acid residues in the mature protein plus an 18-amino acid signal peptide at the N terminus. The mature protein encoded by this kidney cDNA matches perfectly the N-terminal amino acid sequence of purified hydrolase B for 30 amino acid residues, as determined by automated Edman degradation. The mature protein contains 5 cysteine residues, two potential N-linked glycosylation sites, and a C-terminal tetrapeptide (His-Asn-Glu-Leu) that matches the HXEL consensus sequence for retaining proteins in the lumen of the endoplasmic reticulum. Based on alignment of conserved amino acid sequences in several mammalian carboxylesterases, and based on the mechanism of catalysis of serine proteases, the catalytic triad in hydrolase B is apparently composed of the nucleophile Ser(203), the basic amino acid His(418), and the acidic amino acid Asp(97) or Glu(228). Northern blots probed with the 1809-bp cDNA identified high levels of a similar to 2-kilobase mRNA for hydrolase B in liver and kidney. Little or no mRNA for hydrolase B was detected in testis, lung, prostate, brain, and heart, which confirms the tissue distribution of hydrolase B based on catalytic activity and Western immunoblotting. Immunocytochemical studies established that hydrolase B is localized in the centrilobular region of the liver and in the proximal tubules of the kidney, where it presumably plays a role in the metabolism of xenobiotics and possibly endogenous lipids, although a precise physiological role for hydrolase B remains to be determined.	UNIV KANSAS, MED CTR, CTR ENVIRONM & OCCUPAT HLTH, DEPT PHARMACOL TOXICOL & THERAPEUT, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center					NIEHS NIH HHS [ES04996] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004996] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AIDA K, 1993, BIOCHIM BIOPHYS ACTA, V1174, P72, DOI 10.1016/0167-4781(93)90093-S; ALEXSON SEH, 1993, EUR J BIOCHEM, V214, P719, DOI 10.1111/j.1432-1033.1993.tb17973.x; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BRAYER GD, 1979, J MOL BIOL, V131, P743, DOI 10.1016/0022-2836(79)90200-6; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIPERSIO LP, 1991, J BIOL CHEM, V266, P4033; FORKERT PG, 1988, MOL PHARMACOL, V34, P736; HANZLIK TN, 1989, J BIOL CHEM, V264, P12419; HARANO T, 1988, J BIOCHEM-TOKYO, V103, P149, DOI 10.1093/oxfordjournals.jbchem.a122221; HOSOKAWA M, 1990, ARCH BIOCHEM BIOPHYS, V277, P219, DOI 10.1016/0003-9861(90)90572-G; HUANG TL, 1993, PHARMACEUT RES, V10, P639, DOI 10.1023/A:1018987111362; KAWABATA TT, 1983, J BIOL CHEM, V258, P7767; KORZA G, 1988, J BIOL CHEM, V263, P3486; KROETZ DL, 1993, BIOCHEMISTRY-US, V32, P11606, DOI 10.1021/bi00094a018; LONG RM, 1988, BIOCHEM BIOPH RES CO, V156, P866, DOI 10.1016/S0006-291X(88)80924-0; MATSUSHIMA M, 1991, FEBS LETT, V293, P37, DOI 10.1016/0014-5793(91)81147-Z; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MENTLEIN R, 1980, ARCH BIOCHEM BIOPHYS, V200, P547, DOI 10.1016/0003-9861(80)90386-0; MUKHERJEE JJ, 1993, BIOCHEM J, V295, P81, DOI 10.1042/bj2950081; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MURAKAMI K, 1993, J BIOCHEM-TOKYO, V113, P61, DOI 10.1093/oxfordjournals.jbchem.a124004; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; OVNIC M, 1991, GENOMICS, V9, P344, DOI 10.1016/0888-7543(91)90263-E; OZOLS J, 1989, J BIOL CHEM, V264, P12533; PARKINSON A, 1991, METHOD ENZYMOL, V206, P233; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROBBI M, 1992, BIOCHEM BIOPH RES CO, V183, P836, DOI 10.1016/0006-291X(92)90559-4; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH H, 1989, P NATL ACAD SCI USA, V86, P322, DOI 10.1073/pnas.86.1.322; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; TSUJITA T, 1993, J LIPID RES, V34, P1773; TSUJITA T, 1992, J BIOL CHEM, V267, P23489; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WARD VK, 1992, INT J BIOCHEM, V24, P1933, DOI 10.1016/0020-711X(92)90289-D	38	66	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29688	29696						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961958				2022-12-25	WOS:A1994PU28400059
J	LOO, TW; CLARKE, DM				LOO, TW; CLARKE, DM			PROLONGED ASSOCIATION OF TEMPERATURE-SENSITIVE MUTANTS OF HUMAN P-GLYCOPROTEIN WITH CALNEXIN DURING BIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MULTIDRUG-RESISTANCE; ENDOPLASMIC-RETICULUM; CYSTIC-FIBROSIS; INTRACELLULAR-TRANSPORT; FUNCTIONAL CONSEQUENCES; SARCOPLASMIC-RETICULUM; PROTEIN MATURATION; BINDING-SITE; MEMBRANE	Mutation of amino acids located within or immediately NH2-terminal to transmembrane segment 7 of human P-glycoprotein abolished the ability of the protein to confer resistance to cytotoxic drugs. Each of these mutant P-glycoproteins had an apparent mass of 150 kDa, compared with 170 kDa for wild-type P-glycoprotein, and the apparent mass was altered by endoglycosidase H digestion. These observations suggest that these mutant proteins were processed improperly, so that they were located in the endoplasmic reticulum and were not targeted correctly to the plasma membrane. Processing of the 150-kDa P-glycoprotein to the 170-kDa mature form of the enzyme for all of the mutants, except Glu(707) --> Ala and Tyr(710) --> Ala, was dramatically increased when the cells were grown at 26 degrees C. At the lower growth temperature, the mature protein was targeted to the plasma membrane, and drug efflux activity was restored. We also analyzed the mutants for possible molecular interactions that may contribute to their intracellular retention. We found that core-glycosylated forms of the wild-type and mutant P-glycoproteins were associated with the molecular chaperone calnexin. Only wild-type enzyme, however, was able to escape association with calnexin and be targeted to the plasma membrane. Prolonged association of the mutants with calnexin may be due to misfolding of the protein as evidenced by their relative short half-life of about 3 h, compared with 50 h for the wild-type enzyme. These results suggest that calnexin contributes to a quality control mechanism to retain misfolded forms of P-glycoprotein in the endoplasmic reticulum.	UNIV TORONTO,DEPT MED,MRC,MEMBRANE BIOL GRP,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HENDRICK JP, 1993, ANN REV BIOCH, V62, P1099; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOO TW, 1994, IN PRESS BIOCH; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MARUYAMA K, 1989, CELL MOTIL CYTOSKEL, V14, P26, DOI 10.1002/cm.970140107; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PIND S, 1994, J BIOL CHEM, V269, P12784; PRINCE LS, 1993, AM J PHYSIOL, V264, pC491, DOI 10.1152/ajpcell.1993.264.2.C491; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7606; RIORDAN JR, 1989, SCIENCE, V245, P1066; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SKACH WR, 1993, J BIOL CHEM, V268, P6903; WADA I, 1991, J BIOL CHEM, V266, P19599; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; YANG Y, 1993, P NATL ACAD SCI USA, V90, P8480; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	57	127	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28683	28689						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961819				2022-12-25	WOS:A1994PU16800028
J	TAKAHASHI, S; REDDY, SV; CHIRGWIN, JM; DEVLIN, R; HAIPEK, C; ANDERSON, J; ROODMAN, GD				TAKAHASHI, S; REDDY, SV; CHIRGWIN, JM; DEVLIN, R; HAIPEK, C; ANDERSON, J; ROODMAN, GD			CLONING AND IDENTIFICATION OF ANNEXIN-II AS AN AUTOCRINE/PARACRINE FACTOR THAT INCREASES OSTEOCLAST FORMATION AND BONE-RESORPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MARROW CULTURES; MULTINUCLEATED CELLS; OSTEOTROPIC HORMONES; GROWTH-FACTOR; EXPRESSION; DEXAMETHASONE; STIMULATION; PRECURSORS; PHENOTYPE; ACID	Autocrine products of osteoclasts such as interleukin-6 may play an important role in normal osteoclast formation and activity, To identify novel stimulatory factors for osteoclasts, we have prepared a mammalian cDNA expression library generated from highly purified human osteoclast-like multinucleated cells (MNC) formed in long term bone marrow cultures and screened this library for autocrine factors that enhance MNC formation. A candidate clone which stimulated MNC formation was isolated. Sequence analysis showed that this cDNA encoded annexin II (AXII). Purified recombinant AXII significantly increased MNC formation in human bone marrow cultures in the absence of 1,25-(OH)(2) vitamin D-3 and enhanced MNC formation in mouse bone marrow cultures treated with 10(-9) M 1,25-(OH)(2) vitamin D-3. The enhanced MNC formation in murine marrow cultures resulted in increased bone resorption. Treatment of fetal rat long bones with AXII and 1,25 (OH)(2) vitamin D-3 significantly increased bone resorption compared to 1,25-(OH)(2) vitamin D-3 alone. Reverse transcriptase polymerase chain reaction analysis demonstrated that AXII mRNA was expressed at high levels in RNA isolated from highly purified giant cells from osteoclastomas, human osteoclast-like MNC, and pagetic bone. Western blot analysis of conditioned media collected from human marrow cultures showed that AXII was present in the media. Furthermore, approximately 50% of total AXII produced by cells transfected with AXII cDNA was present in the conditioned media. These data suggest that the AXII is an autocrine factor that enhances osteoclast formation and bone resorption and demonstrate a previous unknown function for AXII.	VET ADM MED CTR, DEPT MED HEMATOL & ENDOCRINOL, SAN ANTONIO, TX 78284 USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio					NIADDK NIH HHS [AM 35188] Funding Source: Medline; NIAMS NIH HHS [AR 41336, AR 39539] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041336] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; KRETSINGER RH, 1986, NATURE, V320, P573, DOI 10.1038/320573a0; KUKITA T, 1989, LAB INVEST, V60, P532; KURIHARA N, 1991, J BONE MINER RES, V6, P257; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; MACDONALD BR, 1987, ENDOCRINOLOGY, V120, P2326, DOI 10.1210/endo-120-6-2326; MACDONALD BR, 1986, J BONE MINER RES, V1, P227; Mundy G.R., 1987, BONE MINERAL RES ANN, P209; NESBITT SA, 1994, BONE MINER S1, V25, P548; OHSAKI Y, 1992, ENDOCRINOLOGY, V131, P2229, DOI 10.1210/en.131.5.2229; OREFFO ROC, 1988, J BONE MINER RES, V3, P203; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; RAISZ JG, 1969, ENDOCRINOLOGY, V85, P446, DOI 10.1210/endo-85-3-446; REDDY SV, 1994, J BONE MINER RES, V9, P753; ROODMAN GD, 1991, CRIT REV ORAL BIOL M, V2, P389, DOI 10.1177/10454411910020030601; SOLITO E, 1991, FEBS LETT, V291, P238, DOI 10.1016/0014-5793(91)81293-H; SUAREZ F, 1993, J BONE MINER RES, V8, P1201; TAKAHASHI N, 1986, J CLIN INVEST, V78, P894, DOI 10.1172/JCI112677; TAKAHASHI N, 1989, J CLIN INVEST, V83, P543, DOI 10.1172/JCI113916; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064	24	84	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28696	28701						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961821				2022-12-25	WOS:A1994PU16800030
J	MOR, A; HANI, K; NICOLAS, P				MOR, A; HANI, K; NICOLAS, P			THE VERTEBRATE PEPTIDE ANTIBIOTICS DERMASEPTINS HAVE OVERLAPPING STRUCTURAL FEATURES BUT TARGET SPECIFIC MICROORGANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDES; SECONDARY STRUCTURE; CDNA SEQUENCE; SKIN; MAGAININS; PRECURSOR; MEMBRANES; INSECTS; ANALOGS; TOAD	The physiological significance of the occurrence of sequence similar antimicrobial peptides in frog skin, as the bombinins in Bombina, the magainins in Xenopus, and the dermaseptins in Phyllomedusa, is a major unanswered question. Dermaseptins s1, s2, s3, s4, and s5, a family of cationic (lysine-rich), amphipathic antifungal peptides of 28-34 residues were thus synthesized, purified to homogeneity, and evaluated for their growth-inhibition activity in vitro against various pathogenic microorganisms, Although all five of these peptides shared a similar spectrum of lytic activity against the filamentous fungi that are responsible for opportunistic lethal infections that follow the immunodeficiency syndrome or the use of immunosuppressive agents, they exhibited marked differences in their potencies to arrest the growth of Gram-positive and Gram-negative pathogenic bacteria and yeasts, Likewise, whereas dermaseptins sl and s5 were devoid of hemolytic activity, dermaseptin s4 caused lysis of erythrocytes at micromolar concentrations. The dermaseptins exhibited dramatic synergy of action upon combination, resulting in some cases in a 100-fold increase in antibiotic activity of the mixture over the activity of the peptides separately. Shortening the peptide chain of dermaseptin s3 to dermaseptin s3-(1-16)-NH2 did not affect the antimicrobial potency of the peptide. Further reduction of the chain length yielded peptide derivatives gradually showing reduced activity. Surprisingly, however, analogs of dermaseptin s3 as shorter as 10-12 residues in length remained fully active against Enterococcus faecalis, Cryptococcus neoformans, and against Aeromonas caviae, the causal agent of red-leg disease in amphibians. Overall, these results suggest that, despite 40% sequence similarities, the dermaseptins have distinct spectra of antimicrobial activity and may act in concert to circumvent host invasion by providing frogs with a better shielding against a broad array of microorganisms, They also demonstrate the potential usefulness of short analogs of these peptides as potential candidates for biorational design of germicides.			MOR, A (corresponding author), UNIV PARIS 07,INST JACQUES MONOD,BIOACTIVAT PEPTIDES LAB,2 PL JUSSIEU,F-75251 PARIS 05,FRANCE.		Nicolas, Pierre/C-7908-2009					BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; CHUNG LA, 1992, BIOCHEMISTRY-US, V31, P6608, DOI 10.1021/bi00143a035; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P227; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBSON BW, 1991, J BIOL CHEM, V266, P23103; GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113; HERNANDEZ C, 1992, EUR J CELL BIOL, V59, P414; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOFFMANN JA, 1992, M S-MED SCI, V8, P432, DOI 10.4267/10608/3159; KATCHALSKI E, 1964, PROTEINS, V2, P406; KITE J, 1982, J MOL BIOL, V157, P105; LAZARUS LH, 1993, PROG NEUROBIOL, V41, P473, DOI 10.1016/0301-0082(93)90027-P; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; MCLEAN LR, 1991, BIOCHEMISTRY-US, V30, P31, DOI 10.1021/bi00215a005; MOR A, 1994, BIOCHEMISTRY-US, V33, P6642, DOI 10.1021/bi00187a034; MOR A, 1991, Journal de Mycologie Medicale, V1, P216; MOR A, 1994, J BIOL CHEM, V269, P1934; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; NICOLAS P, 1992, M S-MED SCI, V8, P423, DOI 10.4267/10608/3158; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; RANA FR, 1991, BIOCHEMISTRY-US, V30, P5858, DOI 10.1021/bi00238a008; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SIMMACO M, 1991, EUR J BIOCHEM, V199, P217, DOI 10.1111/j.1432-1033.1991.tb16112.x; TERRY AS, 1988, J BIOL CHEM, V263, P5745; WILLIAMS RW, 1990, BIOCHEMISTRY-US, V29, P4490, DOI 10.1021/bi00470a031; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910	32	251	260	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31635	31641						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989335				2022-12-25	WOS:A1994PX30300049
J	SONG, H; KOMUNIECKI, R				SONG, H; KOMUNIECKI, R			NOVEL REGULATION OF PYRUVATE-DEHYDROGENASE PHOSPHATASE PURIFIED FROM ANAEROBIC MUSCLE MITOCHONDRIA OF THE ADULT PARASITIC NEMATODE, ASCARIS-SUUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOYL TRANSACETYLASE COMPONENT; BOVINE KIDNEY; B PHOSPHATASE; COMPLEX; PURIFICATION; PHOSPHORYLATION; METABOLISM; SUBUNIT; HEART	Pyruvate dehydrogenase (PDHb) phosphatase has been purified to apparent homogeneity from mitochondria of the adult parasitic nematode, Ascaris suum, The enzyme is a heterodimer of 89 and 50 kDa, as judged by SDS-polyacrylamide gel electrophoresis, It appeared to copurify with its substrate, pyruvate dehydrogenase (E1) and could be separated by chromatography on Superose 12 in the presence of 0.5 M NaCl. Phosphatase activity was absolutely dependent on Mg2+, with an apparent K-m of about 4 mM. In contrast to PDHb phosphatases from other sources, the ascarid enzyme was not stimulated by Ca2+ or spermine, but it was stimulated by L-malate, the major mitochondrial substrate in A. suum, L-Malate had no effect on the dephosphorylation of isolated [P-32]E1, but it decreased the apparent K-m of the phosphatase for 32P-pyruvate dehydrogenase complex or [P-32]E1 in the reconstituted complex about 4-6-fold, suggesting that the dihydrolipoyl transacetylase (E2) core was necessary for malate activation. The activity of the pyruvate dehydrogenase complex (PDC) in isolated A. suum muscle mitochondria was significantly greater than that reported for other mitochondria, and the majority of the PDC appeared to be in the phosphorylated inactive state, Incubation of intact phosphorylating A, suum muscle mitochondria in the absence of substrate and the presence of an uncoupler did not lead to an activation of PDC activity, In contrast, incubation in malate plus Mg2+ markedly increased PDC activity, These results contrast markedly with those reported for aerobic mitochondria and suggest that the regulation of PDC activity in these anaerobic organelles differs significantly from that of their mammalian hosts.	UNIV TOLEDO,DEPT BIOL,TOLEDO,OH 43606	University of Toledo					NIAID NIH HHS [AI 18427] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018427] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRETT J, 1973, COMP BIOCHEM PHYSIOL, V44, P331, DOI 10.1016/0300-9629(73)90486-6; BEHAL RH, 1993, ANNU REV NUTR, V13, P497, DOI 10.1146/annurev.nu.13.070193.002433; CAMPOS L, 1989, FUZZY SET SYST, V32, P1, DOI 10.1016/0165-0114(89)90084-5; HANSFORD RG, 1985, REV PHYSIOL BIOCH P, V102, P1, DOI 10.1007/BFb0034084; JOHNSON KR, 1992, MOL BIOCHEM PARASIT, V51, P37, DOI 10.1016/0166-6851(92)90198-S; KITA K, 1992, PARASITOL TODAY, V8, P155, DOI 10.1016/0169-4758(92)90009-Q; KOMUNIECKI R, 1987, MOL BIOCHEM PARASIT, V24, P147, DOI 10.1016/0166-6851(87)90101-0; KOMUNIECKI R, 1983, MOL BIOCHEM PARASIT, V8, P165, DOI 10.1016/0166-6851(83)90007-5; KOMUNIECKI R, 1992, ARCH BIOCHEM BIOPHYS, V296, P115, DOI 10.1016/0003-9861(92)90552-8; KOMUNIECKI R, 1985, J BIOL CHEM, V260, P4770; KOMUNIECKI R, 1981, J PARASITOL, V67, P601, DOI 10.2307/3280432; KRESZE GB, 1981, EUR J BIOCHEM, V119, P581, DOI 10.1111/j.1432-1033.1981.tb05647.x; MA YC, 1993, J BIOL CHEM, V268, P20360; MATLIB MA, 1977, ARCH BIOCHEM BIOPHYS, V178, P396, DOI 10.1016/0003-9861(77)90209-0; Mattevi A., 1992, CURR OPIN STRUC BIOL, V2, P877, DOI [10.1016/0959-440X(92)90114-M, DOI 10.1016/0959-440X(92)90114-M]; MCCORMACK JG, 1981, BIOCHEM J, V196, P619, DOI 10.1042/bj1960619; MIERNYK JA, 1987, PLANT PHYSIOL, V83, P311, DOI 10.1104/pp.83.2.311; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; PRATT ML, 1982, EUR J BIOCHEM, V125, P349, DOI 10.1111/j.1432-1033.1982.tb06690.x; RAHMATULLAH M, 1988, J BIOL CHEM, V263, P8106; RIOUX A, 1984, J COMP PHYSIOL, V154, P349, DOI 10.1007/BF00684441; SALE GJ, 1981, EUR J BIOCHEM, V120, P535, DOI 10.1111/j.1432-1033.1981.tb05733.x; Saz H. J., 1981, The biochemistry of parasites. (Proc. Satellite Conf. of 13th Meet., Fed. Euro. Biochem. Soc. (FEBS), Jerusalem, Aug. 1980.), P177; SAZ HJ, 1971, COMP BIOCHEM PHYSIOL, V39, P627, DOI 10.1016/0305-0491(71)90207-0; STEPP LR, 1983, J BIOL CHEM, V258, P9454; TEAGUE WM, 1982, BIOCHEMISTRY-US, V21, P5585, DOI 10.1021/bi00265a031; THISSEN J, 1988, J BIOL CHEM, V263, P19092; THISSEN J, 1986, MOL BIOCHEM PARASIT, V24, P129; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114	30	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31573	31578						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989326				2022-12-25	WOS:A1994PX30300039
J	DEGTYAREV, MY; SPIEGEL, AM; JONES, TLZ				DEGTYAREV, MY; SPIEGEL, AM; JONES, TLZ			PALMITOYLATION OF A G-PROTEIN ALPHA(I) SUBUNIT REQUIRES MEMBRANE LOCALIZATION NOT MYRISTOYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; BETA-GAMMA-SUBUNITS; PHOSPHOLIPID-VESICLES; LIPID MODIFICATIONS; AMINO TERMINUS; COS CELLS; BRAIN; ATTACHMENT; ANTIBODIES; RECEPTOR	Palmitoylation is a dynamic, post-translational modification of the amino terminus of heterotrimeric G protein alpha subunits. Since myristoylation, beta gamma interactions, and membrane attachment also involve the amino terminus of the G protein alpha(i1) subunit, we studied the relationships between palmitoylation and these events. Using COS cell transfection, the turnover of palmitate was slower on alpha(i1) subunits co-expressed with beta and gamma subunits than on the alpha(i1) subunit expressed alone. Mutation of cysteine 3 of alpha(i1) prevented [H-3]palmitate but not [H-3]myristate incorporation and decreased the membrane localization of this protein. This nonpalmitoylated mutant could form a heterotrimer with co-expressed beta gamma subunits which restored its membrane localization. A nonmyristoylated alpha(i1) mutant (glycine 2 to alanine) could incorporate [H-3]palmitate when co-expressed with beta gamma subunits and localized to the membrane. The [H-3]palmitate turnover of this nonmyristoylated mutant was more rapid than seen with the wild-type alpha(i1) subunit. While myristoylation is not required for palmitoylation, both myristoylation and beta gamma association can slow the turnover of palmitate on alpha(i1). These results suggest that palmitoylation maintains the membrane attachment of the free alpha subunit and changes in beta gamma association could modulate palmitoylation during signaling.	NIDDK,METAB DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; BUTRYNSKI JE, 1992, BIOCHEMISTRY-US, V31, P8030, DOI 10.1021/bi00149a037; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; EIDE B, 1987, BIOCHEM BIOPH RES CO, V148, P1398, DOI 10.1016/S0006-291X(87)80287-5; GIERSCHIK P, 1986, P NATL ACAD SCI USA, V83, P2258, DOI 10.1073/pnas.83.7.2258; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; Grassie Morag A., 1993, Biochemical Society Transactions, V21, p499S; HALLAK H, 1994, J BIOL CHEM, V269, P4571; HUFF RM, 1986, J BIOL CHEM, V261, P1105; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JUHNN YS, 1992, J CELL BIOL, V119, P523, DOI 10.1083/jcb.119.3.523; KATADA T, 1986, J BIOL CHEM, V261, P8182; KINSELLA BT, 1994, TRENDS CARDIOVAS MED, V4, P27, DOI 10.1016/1050-1738(94)90022-1; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHINOZAWA T, 1980, P NATL ACAD SCI-BIOL, V77, P1408, DOI 10.1073/pnas.77.3.1408; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SIMONDS WF, 1989, BIOCHEM BIOPH RES CO, V164, P46, DOI 10.1016/0006-291X(89)91680-X; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VANDERNEUT R, 1993, J BIOL CHEM, V268, P436; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	42	94	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30898	30903						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983022				2022-12-25	WOS:A1994PV51000028
J	GOETHE, R; VAN, LP				GOETHE, R; VAN, LP			THE FAR UPSTREAM CHICKEN LYSOZYME ENHANCER AT -6.1-KILOBASE, BY INTERACTING WITH NF-M, MEDIATES LIPOPOLYSACCHARIDE-INDUCED EXPRESSION OF THE CHICKEN LYSOZYME GENE IN CHICKEN MYELOMONOCYTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; BINDING-PROTEIN; C/EBP-BETA; PHOSPHORYLATION; MACROPHAGES; CHROMATIN; PROMOTER; DISTINCT	Macrophages respond to lipopolysaccharide (LPS) with the activation of various genes, including the lysozyme gene. Here, we show that the level of lysozyme mRNA increases following treatment of chicken myelomonocytic HD11 cells with LPS. By transient and stable transfection of the chloramphenicol acetyltransferase (CAT) gene controlled by regulatory elements of the lysozyme gene, we identified a subfragment of the -6.1 kilobase (kb) lysozyme enhancer that mediates the LPS-induced lysozyme expression. This subfragment contains two elements (D and E), each of which matches the highly degenerate consensus sequence of binding sites for C/EBP-like transcription factors. Furthermore, we found protein complexes to interact with elements D and E whose binding activity to elements D and E is LPS-inducible in myelomonocytic HD11 cells. Immuno-mobility shift assays show that NF-M, a myeloid-specific C/EBP beta-related transcription factor is an essential component of these protein complexes. Mutations of the C/EBP binding sites within D and E cause a reduction of basal activity and abolish LPS responsiveness of the -6.1 kb lysozyme enhancer. These results show that the -6.1 kb lysozyme enhancer, in addition to its role in cell type-specific expression, can mediate, by interacting with NF-M, LPS-induced expression of the lysozyme gene in chicken myelomonocytic cells.	FED RES CTR AGR,INST SMALL ANIM RES,MOLEC GENET RES UNIT,D-29223 CELLE,GERMANY									AHNE B, 1994, J BIOL CHEM, V269, P17794; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BOULET I, 1992, ONCOGENE, V7, P703; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAVALLESE EM, 1989, MOL CELL BIOL, V9, P3184, DOI 10.1128/MCB.9.8.3184; GREWAL T, 1992, MOL CELL BIOL, V12, P2339, DOI 10.1128/MCB.12.5.2339; HAMILTON TA, 1987, IMMUNOL TODAY, V8, P151, DOI 10.1016/0167-5699(87)90145-9; Hauser H, 1981, Haematol Blood Transfus, V26, P175; HECHT A, 1988, EMBO J, V7, P2063, DOI 10.1002/j.1460-2075.1988.tb03046.x; JANTZEN K, 1986, NUCLEIC ACIDS RES, V14, P6085, DOI 10.1093/nar/14.15.6085; JUNG A, 1980, P NATL ACAD SCI-BIOL, V77, P5759, DOI 10.1073/pnas.77.10.5759; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANGLOIS AJ, 1974, CANCER RES, V34, P1457; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PALMITER RD, 1972, J BIOL CHEM, V247, P6450; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; RENKAWITZ R, 1984, CELL, V37, P503, DOI 10.1016/0092-8674(84)90380-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIPPEL AE, 1978, NUCLEIC ACIDS RES, V5, P3275, DOI 10.1093/nar/5.9.3275; STEINER C, 1987, NUCLEIC ACIDS RES, V15, P4136; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; STRATLING WH, 1986, BIOCHEMISTRY-US, V25, P495, DOI 10.1021/bi00350a033; THEISEN M, 1986, EMBO J, V5, P719, DOI 10.1002/j.1460-2075.1986.tb04273.x; VANPHI L, 1993, ENDOCRINOLOGY, V132, P30; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WILLIAMS M, 1991, GENE DEV, V5, P2353, DOI 10.1101/gad.5.12a.2353	44	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31302	31309						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983075				2022-12-25	WOS:A1994PV51000085
J	GRAHAMSIEGENTHALER, K; GAUTHIER, S; DAVIES, PL; ELCE, JS				GRAHAMSIEGENTHALER, K; GAUTHIER, S; DAVIES, PL; ELCE, JS			ACTIVE RECOMBINANT RAT CALPAIN-II - BACTERIALLY PRODUCED LARGE AND SMALL SUBUNITS ASSOCIATE BOTH IN-VIVO AND IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASE; SKELETAL-MUSCLE; MOLECULAR-CLONING; EXPRESSION; CALPASTATIN; SITE; INVOLUTION; PROTEINASE; AUTOLYSIS; PREGNANCY	cDNA for the C-terminal Ca2+-binding domain of rat calpain small subunit was cloned by means of the polymerase chain reaction. The encoded protein (21 kDa), which corresponds closely to the natural autolysis product of the small subunit, was produced in soluble form in Escherichia coli at a level of 20 mg/liter of cell culture. Rat calpain II large subunit (80 kDa) was produced from a cDNA clone in E. coli in soluble form at a level of approximately 1 mg/liter. The 80-kDa subunit alone had no proteinase activity, with or without Ca2+, but Ca2+ dependent proteinase activity was obtained following association of the two subunits, which was achieved either by co-expression of the two subunit cDNAs in E. coli, or by mixing the two partially purified subunits in the presence of 1 M NaSCN followed by dialysis. The heterodimeric (80 + 21 kDa) proteinase had a Ca2+ requirement for 50% activity of 0.35 mM and a specific activity at 2 mM Ca2+ of approximately 1 unit/mu g, values essentially identical to those of natural (80 + 30 kDa) calpain II. The results establish association and biological activity of the bacterially produced subunits and provide a system for studying structure-function relationships in calpain by means of mutagenesis.	QUEENS UNIV, DEPT BIOCHEM, KINGSTON K7L 3N6, ON, CANADA; QUEENS UNIV, DEPT BIOL, KINGSTON K7L 3N6, ON, CANADA	Queens University - Canada; Queens University - Canada								BROWN N, 1993, FEBS LETT, V322, P65, DOI 10.1016/0014-5793(93)81112-D; CRAWFORD C, 1993, BIOCHEM J, V296, P135, DOI 10.1042/bj2960135; CRAWFORD C, 1990, BIOCHEM J, V265, P575, DOI 10.1042/bj2650575; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DELUCA CI, 1993, BIOCHIM BIOPHYS ACTA, V1216, P81, DOI 10.1016/0167-4781(93)90040-K; EDMUNDS T, 1991, BIOCHIM BIOPHYS ACTA, V1077, P197, DOI 10.1016/0167-4838(91)90059-9; ELCE JS, 1984, BIOCHEM J, V220, P507, DOI 10.1042/bj2200507; EMORI Y, 1986, J BIOL CHEM, V261, P9472; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; IMAJOH S, 1986, J BIOCHEM-TOKYO, V100, P633, DOI 10.1093/oxfordjournals.jbchem.a121755; KIKUCHI T, 1984, ARCH BIOCHEM BIOPHYS, V234, P639, DOI 10.1016/0003-9861(84)90314-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOOMAN AC, 1987, EMBO J, V6, P2489, DOI 10.1002/j.1460-2075.1987.tb02530.x; MCCLELLAND P, 1989, J BIOL CHEM, V264, P17428; MELLOR GW, 1993, BIOCHEM J, V290, P75, DOI 10.1042/bj2900075; MINAMI Y, 1988, J BIOCHEM-TOKYO, V104, P927, DOI 10.1093/oxfordjournals.jbchem.a122585; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; PARKES C, 1985, BIOCHEM J, V230, P509, DOI 10.1042/bj2300509; SAMIS JA, 1991, BIOCHEM J, V276, P293, DOI 10.1042/bj2760293; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; TSUJI S, 1981, J BIOCHEM-TOKYO, V90, P233, DOI 10.1093/oxfordjournals.jbchem.a133455	23	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30457	30460						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982961				2022-12-25	WOS:A1994PU52500065
J	BJORNSTEDT, M; XUE, JY; HUANG, WH; AKESSON, B; HOLMGREN, A				BJORNSTEDT, M; XUE, JY; HUANG, WH; AKESSON, B; HOLMGREN, A			THE THIOREDOXIN AND GLUTAREDOXIN SYSTEMS ARE EFFICIENT ELECTRON-DONORS TO HUMAN PLASMA GLUTATHIONE-PEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							T-CELL LEUKEMIA; REDUCTASE; PURIFICATION; SELENODIGLUTATHIONE; SECRETION; SUBSTRATE; OXYGEN; ADF	Human plasma glutathione peroxidase (GSH-Px) is a distinct extracellular selenoenzyme that detoxifies hydroperoxides when used with GSH in high (mM) nonphysiological concentrations. We have discovered that NADPH and human thioredoxin reductase (TR) by itself or with thioredoxin (Trx) are efficient electron donors to this human plasma peroxidase. Incubation of 0.05 mu M TR with 0.25 mu M GSH-Px, in a system free from GSH, resulted in reduction of t-butyl hydroperoxide. Addition of Trx, 2.5 and 5 mu M, respectively, further increased the rate of the reaction. These data were obtained using an assay measuring the oxidation of NADPH. A direct assay demonstrated the formation of cumyl alcohol from cumene hydroperoxide in this GSH-independent peroxidase reaction. Incubation of 0.25 mu M GSH-Px with a low concentration of GSH (10 mu M), representing the upper level in plasma, plus excess glutathione reductase and NADPH did not result in any reduction of t-butyl hydroperoxide. However, after addition of 2.5 mu M human glutaredoxin, a Linear peroxidase reaction started. The results suggest that extracellular TR, Trx, or glutaredoxin are reductants for the selenium-dependent peroxidase rather than GSH.	KAROLINSKA INST, MED NOBEL INST BIOCHEM, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN; LUND UNIV, DEPT APPL NUTR & FOOD CHEM, S-22100 LUND, SWEDEN	Karolinska Institutet; Lund University			Akesson, Bjorn/Q-9163-2017					AKESSON B, 1994, BBA-PROTEIN STRUCT M, V1204, P243, DOI 10.1016/0167-4838(94)90014-0; [Anonymous], 1980, ENZYMATIC BASIS DETO; AVISSAR N, 1989, J BIOL CHEM, V264, P15850; Beutler E, 1984, RED CELL METABOLISM, P74; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; ERICSON ML, 1992, LYMPHOKINE CYTOK RES, V11, P201; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOLMGREN A, 1994, IN PRESS METHODS ENZ; Holmgren A., 1986, THIOREDOXIN GLUTARED; HUANG WH, 1993, CLIN CHIM ACTA, V219, P139, DOI 10.1016/0009-8981(93)90205-I; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MADDIPATI KR, 1987, J BIOL CHEM, V262, P17398; MARTIN H, 1991, BIOCHEM BIOPH RES CO, V175, P123, DOI 10.1016/S0006-291X(05)81209-4; MITSUI A, 1992, BIOCHEM BIOPH RES CO, V186, P1220, DOI 10.1016/S0006-291X(05)81536-0; PADILLA AC, 1994, IN PRESS EUR J BIOCH; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; SCHALLREUTER KU, 1991, INT J CANCER, V48, P15; SCHALLREUTER KU, 1988, BIOCHIM BIOPHYS ACTA, V967, P103, DOI 10.1016/0304-4165(88)90194-8; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; WENDEL A, 1980, FEBS LETT, V120, P209, DOI 10.1016/0014-5793(80)80299-7; YAMAUCHI A, 1992, MOL IMMUNOL, V29, P263; YODOI J, 1991, ADV CANCER RES, V57, P381	29	288	296	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29382	29384						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961915				2022-12-25	WOS:A1994PU28400013
J	JUNG, JE; KAROOR, V; SANDBAKEN, MG; LEE, BJ; OHAMA, T; GESTELAND, RF; ATKINS, JF; MULLENBACH, GT; HILL, KE; WAHBA, AJ; HATFIELD, DL				JUNG, JE; KAROOR, V; SANDBAKEN, MG; LEE, BJ; OHAMA, T; GESTELAND, RF; ATKINS, JF; MULLENBACH, GT; HILL, KE; WAHBA, AJ; HATFIELD, DL			UTILIZATION OF SELENOCYSTEYL-TRNA([SER]SEC) AND SERYL-TRNA([SER]SEC) IN PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE TRANSFER RNA<SER>SEC; GLUTATHIONE-PEROXIDASE GENE; I IODOTHYRONINE DEIODINASE; SERINE TRANSFER-RNA; MAMMALIAN-CELLS; UGA; CODON; SELENOPROTEIN; EXPRESSION; IDENTIFICATION	The UGA selenocysteine (Sec) codon in glutathione peroxidase mRNA and in selenoprotein P and the UGA stop codon in rabbit beta-globin mRNA were employed to study the utilization of Sec-tRNA([Ser]Sec) and Ser-tRNA([Ser]Sec) in protein synthesis. In vitro Ser-tRNA([Sec]Sec) served as a suppressor of the UGA Sec codon as well as the UGA stop codon, while Sec-tRNA([Ser]Sec) did not. However, in vivo Sec-tRNA([Ser]Sec) did donate Sec to glutathione peroxidase in Xenopus oocytes microinjected with glutathione peroxidase mRNA and Sec-tRNA A ribosome binding assay was devised to investigate the interaction of aminoacyl-tRNA, rabbit reticulocyte ribosomes, and eukaryotic elongation factor 1 (eEF-1) in response to the appropriate trinucleoside diphosphate template. Ser tRNA([Sec]Sec) bound weakly to ribosomes in the presence of eEF-1 and UGA as compared to Phe-tRNA, Ser-tRNA(IGA) and Met-tRNA(m) which bound more efficiently in the presence of eEF-1 and the appropriate template. No increase in the binding of Sec-tRNA([Ser]Sec) was observed under the same conditions as Ser-tRNA([Ser]Sec.) The ribosome binding studies substantiated the finding that Ser-tRNA([Ser]Sec) serves as a suppressor of UGA codons in protein synthesis, but SectRNA([Ser]Sec) does not. In addition, these studies provide strong evidence that a specific elongation factor is required in mammalian cells for insertion of Sec into protein from Sec-tRNA([Ser]Sec).	NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; UNIV UTAH,ECCLES INST HUMAN GENET,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; LYNX THERAPEUT INC,HAYWARD,CA 94545; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Mississippi; University of Mississippi Medical Center; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Vanderbilt University; Vanderbilt University				Atkins, John/0000-0001-7933-0165	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES002497, R01ES002497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025451] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES02497] Funding Source: Medline; NIGMS NIH HHS [GM25451] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BOCK A, 1994, SELENIUM BIOL HUMAN, P9; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; BUSTIN M, 1982, SCIENCE, V215, P1245, DOI 10.1126/science.6460317; CHOI IS, 1994, BIOCHEMISTRY-US, V33, P601, DOI 10.1021/bi00168a027; CHU FF, 1993, J BIOL CHEM, V268, P2571; DHOLAKIA JN, 1987, J BIOL CHEM, V262, P10164; DIAMOND A, 1981, CELL, V25, P497, DOI 10.1016/0092-8674(81)90068-4; DIAMOND AM, 1993, J BIOL CHEM, V268, P14215; GELPI C, 1992, P NATL ACAD SCI USA, V89, P9739, DOI 10.1073/pnas.89.20.9739; HATFIELD D, 1980, FEBS LETT, V113, P249, DOI 10.1016/0014-5793(80)80603-X; HATFIELD D, 1979, BIOCHIM BIOPHYS ACTA, V564, P414, DOI 10.1016/0005-2787(79)90032-7; HATFIELD D, 1982, P NATL ACAD SCI-BIOL, V79, P6215, DOI 10.1073/pnas.79.20.6215; HATFIELD D, 1991, NUCLEIC ACIDS RES, V19, P939, DOI 10.1093/nar/19.4.939; HATFIELD D, 1988, BIOCHEMISTRY-US, V27, P1179, DOI 10.1021/bi00404a017; HATFIELD D, 1992, BIOCHEM BIOPH RES CO, V184, P254, DOI 10.1016/0006-291X(92)91186-T; HATFIELD D, 1972, P NATL ACAD SCI USA, V67, P3014; Hatfield D.L., 1994, SELENOCYSTEINE TRNA; HILL KE, 1991, J BIOL CHEM, V266, P10050; KARIMPOUR I, 1992, DNA CELL BIOL, V11, P693, DOI 10.1089/dna.1992.11.693; Kemper W M, 1979, Methods Enzymol, V60, P638; KNUDSEN SM, 1993, EUR J BIOCHEM, V215, P549, DOI 10.1111/j.1432-1033.1993.tb18064.x; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LEE BJ, 1989, J BIOL CHEM, V264, P9724; LEE BJ, 1987, P NATL ACAD SCI USA, V84, P6384, DOI 10.1073/pnas.84.18.6384; LEE S, 1992, J BIOL CHEM, V267, P24064; MOSCOW JA, 1992, J BIOL CHEM, V267, P5949; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; SHEN QC, 1993, J BIOL CHEM, V268, P11463; STADTMAN TC, 1991, J BIOL CHEM, V266, P16257; VENDELAND SC, 1993, J BIOL CHEM, V268, P17103; ZASLOFF M, 1983, CELL, V46, P377	38	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29739	29745						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961966				2022-12-25	WOS:A1994PU28400067
J	WAKABAYASHIITO, N; NAGATA, S				WAKABAYASHIITO, N; NAGATA, S			CHARACTERIZATION OF THE REGULATORY ELEMENTS IN THE PROMOTER OF THE HUMAN ELONGATION FACTOR-1-ALPHA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN ELONGATION; FACTOR 1-ALPHA EF-1-ALPHA; STIMULATING FACTOR GENE; TRANSCRIPTION FACTORS; SACCHAROMYCES-CEREVISIAE; FACTOR-TU; 2 GENES; CHROMOSOMAL GENE; XENOPUS-LAEVIS; CULTURED-CELLS	Most eukaryotic cells abundantly express polypeptide chain elongation factor-1 alpha (EF-1 alpha), an enzyme which catalyzes the GTP-dependent binding of aminoacyl-tRNA to ribosomes. In this study, a series of deletion and scanning mutations was introduced in the promoter region of human EF-1 alpha chromosomal gene. Mutated promoters were fused to the bacterial chloramphenicol acetyltransferase gene, and their promoter activity was determined in human HeLa cells. These analyses indicated that both the 5'-flanking region and the first intron of the EF-1 alpha gene are essential for its promoter activity. The region responsible in the intron contains several Sp1 and Ap1 elements which seem to have additive effects on its promoter activity. In the 5'-flanking region, two cis-elements (EFP1 and EFP2) which work interdependently were identified. Gel shift assay with EFP1 and EFP2 elements indicated that several nuclear factors bind to EFP1 and EFP2, and one of the three retarded bands with EFP2 could be super-shifted with the anti-Sp1 antibody. These results indicate that Sp1 or its related factor cooperatively enhances the expression of the EF-1 alpha gene in the 5' flanking region.	OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN				Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ANN DK, 1992, J BIOL CHEM, V267, P699; ANN DK, 1991, J BIOL CHEM, V266, P10429; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DJE MK, 1990, NUCLEIC ACIDS RES, V18, P3489, DOI 10.1093/nar/18.12.3489; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOVEMANN B, 1988, NUCLEIC ACIDS RES, V16, P3175, DOI 10.1093/nar/16.8.3175; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JASKUNAS SR, 1975, NATURE, V257, P458, DOI 10.1038/257458a0; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; KAWAMOTO T, 1988, MOL CELL BIOL, V8, P267, DOI 10.1128/MCB.8.1.267; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KOCH I, 1990, ONCOGENE, V5, P839; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LEE S, 1992, J BIOL CHEM, V267, P24064; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LORENI F, 1993, NUCLEIC ACIDS RES, V21, P4721, DOI 10.1093/nar/21.20.4721; MADSEN HO, 1990, NUCLEIC ACIDS RES, V18, P1513, DOI 10.1093/nar/18.6.1513; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MIZUSHIMASUGANO J, 1985, EMBO J, V4, P1053, DOI 10.1002/j.1460-2075.1985.tb03738.x; NAGASHIMA K, 1986, GENE, V45, P265; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; NAGATA S, 1983, P NATL ACAD SCI-BIOL, V80, P6192, DOI 10.1073/pnas.80.20.6192; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; NISHIZAWA M, 1990, J BIOL CHEM, V265, P5897; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; ROTH WW, 1987, MOL CELL BIOL, V7, P3929, DOI 10.1128/MCB.7.11.3929; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SLOBIN LI, 1980, EUR J BIOCHEM, V110, P555, DOI 10.1111/j.1432-1033.1980.tb04898.x; TANIGUCHI S, 1991, NUCLEIC ACIDS RES, V19, P6949, DOI 10.1093/nar/19.24.6949; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; UETSUKI T, 1989, J BIOL CHEM, V264, P5791	39	66	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29831	29837						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961976				2022-12-25	WOS:A1994PU28400080
J	BALTENSPERGER, K; KOZMA, LM; JASPERS, SR; CZECH, MP				BALTENSPERGER, K; KOZMA, LM; JASPERS, SR; CZECH, MP			REGULATION BY INSULIN OF PHOSPHATIDYLINOSITOL 3'-KINASE BOUND TO ALPHA-ISOFORM AND BETA-ISOFORM OF P85 REGULATORY SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SUBSTRATE-1; PHOSPHOINOSITIDE 3-KINASE; PHOSPHOTYROSINE PROTEIN; SIGNALING COMPLEXES; 85-KDA SUBUNIT; INTACT-CELLS; SH2 DOMAINS; IRS-1; KINASE; PHOSPHORYLATION	The roles of the alpha- and beta-isoforms of phosphatidylinositol (PI) 3'-kinase p85 regulatory subunit were studied with isoform-specific antisera in three model systems in which the insulin receptor mediates rapid phosphorylation of insulin receptor substrate-1 (IRS-1). Insulin receptor signaling stimulated the association of IRS-1 with p85 alpha protein, and p85 alpha-associated PI 3-kinase activity in 3T3-L1 adipocytes, and in transfected Chinese hamster ovary cells (CHO-T) and COS-1 cells expressing high levels of human insulin receptors. While not detectable in 3T3-L1 adipocytes, the p85 beta isoform was also found to associate with IRS-1 in response to insulin receptor activation in COS-1 and CHO-T cells. However, selective immunoprecipitation of p85 beta from unstimulated COS-1 or CHO-T cell lysates was accompanied by higher levels of PI 3-kinase activity than that associated with p85 alpha. Remarkably, the large stimulation of PI 3-kinase activity associated with p85 alpha (7.8 +/- 2.0-fold, n = 6) in insulin-treated CHO-T cells was not observed in p85 beta immunoprecipitates (1.8 +/- 0.6-fold, n = 6), and in COS-1 cells p85 beta-associated PI 3-kinase activity was completely insensitive to stimulation by the insulin receptor. These data suggest the novel hypothesis that binding of p85 beta to IRS-1 complexes in COS-1 and CHO-T cells does not mediate marked activation of PI 3-kinase activity as does p85 alpha.	UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NIDDK NIH HHS [DK30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRY MJ, 1992, BIOCHEM J, V288, P383, DOI 10.1042/bj2880383; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; REIF K, 1993, J BIOL CHEM, V268, P10780; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; YANO H, 1993, J BIOL CHEM, V268, P25846; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	51	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28937	28946						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961856				2022-12-25	WOS:A1994PU16800066
J	GAO, JL; MURPHY, PM				GAO, JL; MURPHY, PM			HUMAN CYTOMEGALOVIRUS OPEN READING FRAME US28 ENCODES A FUNCTIONAL BETA-CHEMOKINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN INTERLEUKIN-8 RECEPTOR; HERPESVIRUS SAIMIRI; VIRUS; EXPRESSION; INFECTION; HOMOLOGS; CLONING	Human cytomegalovirus infects epithelial, smooth muscle, and white blood cells in vivo causing acute, latent, and chronic infections. A data base search that the amino acid sequence of the putative protein encoded by open reading frame US28 of human cytomegalovirus is similar to 30% identical to those of the mammalian leukocyte receptors for alpha and beta chemokines. This suggested that US28 was originally copied from a human chemokine receptor gene, perhaps to provide the virus with a selective advantage through molecular mimicry. Chemokines regulate the trafficking and activation of mammalian leukocytes and activate calcium-mobilizing, heptahelical, G protein-coupled receptors. We now show that US28 encodes a promiscuous calcium-mobilizing receptor for the beta chemokines RANTES (regulated upon activation, normal T expressed and secreted), macrophage inflammatory protein-1 alpha, and monocyte chemoattractant protein-1, but not for the alpha chemokines interleukin-8 or gamma IP10. The chemokine selectivity of the US28 product is distinct from that of known mammalian beta chemokine receptors. This finding suggests a role for beta chemokines in the pathogenesis of human cytomegalovirus infection by transmembrane signaling via the product of US28.	NIAID,HOST DEF LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Gao, Ji-Liang/Y-4397-2019					AHUJA SK, 1994, IMMUNOL TODAY, V15, P281, DOI 10.1016/0167-5699(94)90008-6; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; ALBRECHT T, 1990, INTERVIROLOGY, V31, P68, DOI 10.1159/000150140; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; ALFORD CA, 1990, VIROLOGY, P1981; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; DUNLOP DJ, 1992, BLOOD, V79, P2221; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GOODING LR, 1992, CELL, V71, P5; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1993, CELL, V72, P823, DOI 10.1016/0092-8674(93)90571-7; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SCHRIER RD, 1985, SCIENCE, V230, P1048, DOI 10.1126/science.2997930; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; VALYINAGY T, 1988, ARCH VIROL, V101, P199, DOI 10.1007/BF01311001; WELCH AR, 1991, J VIROL, V65, P3915, DOI 10.1128/JVI.65.7.3915-3918.1991	26	286	297	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28539	28542						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961796				2022-12-25	WOS:A1994PU16800005
J	OSTERYOUNG, KW; VIERLING, E				OSTERYOUNG, KW; VIERLING, E			DYNAMICS OF SMALL HEAT-SHOCK PROTEIN DISTRIBUTION WITHIN THE CHLOROPLASTS OF HIGHER-PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-LIKE STRUCTURES; CHICKEN-EMBRYO FIBROBLASTS; TOMATO CELL-CULTURES; ACTIN POLYMERIZATION; THYLAKOID MEMBRANES; ALPHA-CRYSTALLIN; RODENT CELLS; MOUSE CELLS; HSP27 GENE; LOCALIZATION	Accumulation of the small heat shock proteins (sHSPs) in response to high temperature stress is thought to contribute to the development of thermotolerance in eukaryotic organisms, but the mechanism of action is unknown. We are investigating the chloroplast-localized sHSP, HSP21, with the goal of defining its contribution to the acquisition of thermotolerance in plants. Following an initial heat stress and period of recovery, HSP21 is localized primarily in the soluble fraction of the chloroplast. During an additional stress, HSP21 undergoes a temperature-dependent redistribution from the soluble to the insoluble chloroplast fraction in both isolated organelles and intact plants. The change in HSP21 partitioning is accompanied by depletion of the 10-11 S HSP21-containing complexes from the soluble chloroplast fraction. HSP21 in the insoluble fraction cannot be solubilized by nonionic detergent under conditions that release essentially all the pigments and proteins from the thylakoid membranes, indicating that HSP21 in its insoluble state is not dependent for its insolubility on attachment to an intact membrane. The temperature-dependent redistribution of HSP21 is affected by light intensity but occurs in both leaf and root plastids, suggesting that the function of this activity is not strictly related to the presence of the photosynthetic apparatus. Our study indicates that the chloroplast sHSP has dynamic properties similar to those of cytoplasmic sHSPs from plants and other organisms and suggests that the ability to partition between a soluble and an insoluble state reflects a functionally important property of all sHSPs.			OSTERYOUNG, KW (corresponding author), UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721, USA.			Vierling, Elizabeth/0000-0002-0066-4881	NIGMS NIH HHS [R01 GM42762, F32 GM14953] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014953, R01GM042762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSKA I, 1991, EUR J BIOCHEM, V198, P375, DOI 10.1111/j.1432-1033.1991.tb16025.x; ANDERSSON LO, 1972, FEBS LETT, V20, P199, DOI 10.1016/0014-5793(72)80793-2; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1987, DEV BIOL, V122, P39, DOI 10.1016/0012-1606(87)90330-7; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARTUS NN, 1990, PHYSIOL PLANTARUM, V79, P641, DOI 10.1111/j.1399-3054.1990.tb00038.x; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BENTLEY NJ, 1992, YEAST, V8, P95, DOI 10.1002/yea.320080204; BERGER EM, 1983, EXP CELL RES, V147, P437, DOI 10.1016/0014-4827(83)90225-2; CHEN Q, 1994, J BIOL CHEM, V269, P13216; CHEN Q, 1990, J CELL BIOL, V110, P1873, DOI 10.1083/jcb.110.6.1873; CHEN Q, 1991, MOL GEN GENET, V226, P425, DOI 10.1007/BF00260655; CLARKE AK, 1992, PLANT PHYSIOL, V100, P2081, DOI 10.1104/pp.100.4.2081; COLLIER NC, 1988, J CELL BIOL, V106, P1131, DOI 10.1083/jcb.106.4.1131; COLLIER NC, 1986, J CELL BIOL, V103, P1495, DOI 10.1083/jcb.103.4.1495; DEROCHER AE, 1991, PLANT PHYSIOL, V96, P1038, DOI 10.1104/pp.96.4.1038; GLACZINSKI H, 1988, EUR J BIOCHEM, V173, P579, DOI 10.1111/j.1432-1033.1988.tb14038.x; HELM KW, 1993, MOL CELL BIOL, V13, P238, DOI 10.1128/MCB.13.1.238; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HUOT J, 1991, CANCER RES, V51, P5245; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1994, J BIOL CHEM, V269, P11274; KEY JL, 1983, CURRENT TOPICS PLANT, P107; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAWRENCE ME, 1984, BIOL CELL, V52, P77; LEE YJ, 1991, J CELL PHYSIOL, V149, P77, DOI 10.1002/jcp.1041490111; LEICHT BG, 1986, P NATL ACAD SCI USA, V83, P90, DOI 10.1073/pnas.83.1.90; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MANSFIELD MA, 1988, PLANT PHYSIOL, V86, P1240, DOI 10.1104/pp.86.4.1240; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MISHKIND ML, 1985, J CELL BIOL, V100, P226, DOI 10.1083/jcb.100.1.226; MORRISSEY PJ, 1986, EUR J BIOCHEM, V160, P389, DOI 10.1111/j.1432-1033.1986.tb09983.x; NGUYEN VT, 1989, J BIOL CHEM, V264, P10487; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; NOVER L, 1989, MOL CELL BIOL, V9, P1298, DOI 10.1128/MCB.9.3.1298; NOVER L, 1983, MOL CELL BIOL, V3, P1648, DOI 10.1128/MCB.3.9.1648; NOVER L, 1984, EUR J BIOCHEM, V139, P303, DOI 10.1111/j.1432-1033.1984.tb08008.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OROSS JW, 1991, CAN J BOT, V69, P136, DOI 10.1139/b91-019; OSTERYOUNG KW, 1993, MOL GEN GENET, V239, P323, DOI 10.1007/BF00276930; OSTERYOUNG KW, 1994, NATO ASI H, P97; ROLLET E, 1992, BIOCHEM BIOPH RES CO, V185, P116, DOI 10.1016/S0006-291X(05)80963-5; SAHRAWY M, 1990, PLANTA, V182, P319, DOI 10.1007/BF02411381; VIERLING E, 1991, ANNU REV PLANT PHYS, V42, P579, DOI 10.1146/annurev.pp.42.060191.003051; VIERLING E, 1989, MOL CELL BIOL, V9, P461, DOI 10.1128/MCB.9.2.461; VIERLING E, 1986, P NATL ACAD SCI USA, V83, P361, DOI 10.1073/pnas.83.2.361; VIERLING E, 1988, EMBO J, V7, P575, DOI 10.1002/j.1460-2075.1988.tb02849.x	53	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28676	28682						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961818				2022-12-25	WOS:A1994PU16800027
J	TODAKA, M; NISHIYAMA, T; MURAKAMI, T; SAITO, S; ITO, K; KANAI, F; KAN, M; ISHII, K; HAYASHI, H; SHICHIRI, M; EBINA, Y				TODAKA, M; NISHIYAMA, T; MURAKAMI, T; SAITO, S; ITO, K; KANAI, F; KAN, M; ISHII, K; HAYASHI, H; SHICHIRI, M; EBINA, Y			THE ROLE OF INSULIN IN ACTIVATION OF 2 ENHANCERS IN THE MOUSE GLUT1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE TRANSPORTER GENE; SERUM RESPONSE ELEMENT; MESSENGER-RNA; 3T3-L1 ADIPOCYTES; GROWTH-FACTORS; AMYLASE GENE; EXPRESSION; TRANSLOCATION; CELLS; CDNA	We identified two enhancer elements of the mouse GLUT1 gene responsive to serum, growth factor, and oncogenes; the first enhancer element (enhancer-1) is located 2.7 kilobases upstream of the cap site of the gene, and the second one (enhancer-2) is located in the second intron of the gene (Murakami, T., Nishiyama, T., Shirotani, T., Shinohara, Y., Kan, M., Ishii, K., Kanai, F., Nakazuru, S., and Ebina, Y. (1992) J. Biol. Chem. 267, 9300-9306). In the present work, we describe the role of insulin in activation of these two enhancers. NIH/3T3 HIR3.5 cells, which express a large number of insulin receptors, were stably transformed by hybrid genes containing the enhancer(s) and promoter of GLUT1 gene and the coding region of chloramphenicol acetyltransferase (CAT) gene as a reporter gene. In stable transformants of the reporter gene without the enhancers, the CAT mRNA was not induced by insulin; however, in clones containing the reporter gene with enhancer-1, the CAT mRNA was induced by insulin at 30 min and reached a maximum at 1 h. In clones transfected by the reporter gene with enhancer-2, the CAT mRNA was induced at 1 h and reached a maximum at 3 h. To determine the early response element to insulin in enhancer-1, transformants of hybrid reporter genes containing truncated or mutated enhancer-1 were examined. The homologous sequence with the serum response element in enhancer-1 is essential for an early response to insulin.	UNIV TOKUSHIMA,INST ENZYME RES,DEPT ENZYME GENET,TOKUSHIMA 770,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,DEPT OBSTET & GYNECOL,TOKUSHIMA 770,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,DEPT UROL,TOKUSHIMA 770,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT METAB MED,KUMAMOTO 860,JAPAN	Tokushima University; Tokushima University; Tokushima University; Kumamoto University			Ishii, Kazuo/N-9946-2019; Ishii, Kazuo/M-3099-2016; ishii, kazuo/K-7428-2014	Ishii, Kazuo/0000-0002-8363-8266; Hayashi, Hideki/0000-0003-4585-6542; ishii, kazuo/0000-0001-7801-1891				BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; GOULD GW, 1989, J BIOL CHEM, V264, P2180; HATANAKA M, 1974, BIOCHIM BIOPHYS ACTA, V355, P77, DOI 10.1016/0304-419X(74)90008-0; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; KANAI F, 1993, J BIOL CHEM, V268, P14523; KAUFMAN RJ, 1982, MOL CELL BIOL, V2, P1304, DOI 10.1128/MCB.2.11.1304; KELLER SA, 1990, GENE DEV, V4, P1316, DOI 10.1101/gad.4.8.1316; KITAGAWA T, 1989, BIOCHIM BIOPHYS ACTA, V980, P100, DOI 10.1016/0005-2736(89)90205-8; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; ROLLINS BJ, 1988, J BIOL CHEM, V263, P16523; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237	28	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29265	29270						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961896				2022-12-25	WOS:A1994PU16800109
J	LENG, XH; BLANCO, J; TSAI, SY; OZATO, K; OMALLEY, BW; TSAI, MJ				LENG, XH; BLANCO, J; TSAI, SY; OZATO, K; OMALLEY, BW; TSAI, MJ			MECHANISMS FOR SYNERGISTIC ACTIVATION OF THYROID-HORMONE RECEPTOR AND RETINOID-X RECEPTOR ON DIFFERENT RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; CLASS-I GENES; ACID RECEPTOR; DNA-BINDING; TRANSCRIPTION FACTOR; NUCLEAR RECEPTORS; SIGNALING PATHWAYS; DIRECT REPEATS; VITAMIN-D; RXR	The thyroid hormone receptors (TR) form heterodimers with the retinoid X receptors (RXR) and activate target genes through thyroid-responsive elements (TRE). Heterodimerization elevates the DNA binding efficiency and thus can result in functional synergism between TR and RXR. Here we demonstrate that DNA sequences dictate the cooperative activation between TR and RXR despite the high affinity binding of the heterodimer to those TREs. We provide evidence that the C-terminal activation domain of RXR can modulate the triiodothyronine (T-3) responsiveness of TR/RXR heterodimers on reporter genes without altering the DNA binding properties of the heterodimers. The modulation function of this relatively small region is under the control of specific TRE sequences and promoter context. These data indicate that this C-terminal region of RXR is likely involved in receptor-cellular factor(s) interactions. Finally, we propose that the synergistic activation by TR and RXR is achieved through elevated DNA binding and, dependent on the DNA sequence, the interaction of RXR with other transcription factors.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; NICHHD,MOLEC GROWTH REGULAT LAB,BETHESDA,MD 20892	Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Blanco, Jorge/AAW-3752-2020					BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORCE WR, 1994, J BIOL CHEM, V269, P8863; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; KATZ RW, 1994, J BIOL CHEM, V269, P9500; KING IN, 1993, J BIOL CHEM, V268, P495; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG X, 1995, IN PRESS MOL CELL BI; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; LU XP, 1993, MOL CELL BIOL, V13, P6509, DOI 10.1128/MCB.13.10.6509; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1993, J BIOL CHEM, V268, P591; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGATA T, 1992, P NATL ACAD SCI USA, V89, P937, DOI 10.1073/pnas.89.3.937; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	48	51	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31436	31442						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989311				2022-12-25	WOS:A1994PX30300020
J	MCCLEARY, WR; STOCK, JB				MCCLEARY, WR; STOCK, JB			ACETYL PHOSPHATE AND THE ACTIVATION OF 2-COMPONENT RESPONSE REGULATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; ENTERIC BACTERIA; ACETATE KINASE; CHEY PROTEIN; OMPC GENES; COENZYME-A; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION	Several bacterial response regulator proteins (CheY, NR(1), PhoB, and OmpR) become phosphorylated in vitro when incubated with acetyl phosphate. In the presence of high levels of acetyl phosphate and Mg2+, CheY reached steady state phosphorylation in less than 30 s; NR(I) and PhoB reached steady state more slowly (t1/2 to steady state of 1.5 and >15 min, respectively). A simple method was developed to measure acetyl phosphate levels in Escherichia coli grown in defined media, Levels of acetyl phosphate were elevated in cells grown in pyruvate, glucose, and glucuronic acid and were low in cells grown in fructose, glycerol, and fumarate. The effects of varying the intracellular amounts of acetyl phosphate on chemotaxis and the osmo-response were also investigated, Acetyl phosphate was not required but did influence each of these responses, These results suggest that acetyl phosphate may influence either the sensitivity or the magnitude of an adaptive response.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20980] Funding Source: Medline; NIGMS NIH HHS [GM14435] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1973, J GEN MICROBIOL, V74, P77, DOI 10.1099/00221287-74-1-77; BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BACKMAN KC, 1983, J BACTERIOL, V154, P516, DOI 10.1128/JB.154.1.516-519.1983; BOCHNER BR, 1982, ANAL BIOCHEM, V122, P100, DOI 10.1016/0003-2697(82)90257-3; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BROWN TDK, 1977, J GEN MICROBIOL, V102, P327, DOI 10.1099/00221287-102-2-327; DAILEY FE, 1993, J BACTERIOL, V175, P3236, DOI 10.1128/JB.175.10.3236-3239.1993; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; FORST S, 1990, J BACTERIOL, V172, P3473, DOI 10.1128/jb.172.6.3473-3477.1990; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; FORST S, 1988, ANNU REV CELL BIOL, V4, P21, DOI 10.1146/annurev.cb.04.110188.000321; HOLMS WH, 1986, CURR TOP CELL REGUL, V28, P69; HUNT AG, 1986, METHOD ENZYMOL, V122, P43; KOSHLAND DE, 1977, SCIENCE, V196, P1055, DOI 10.1126/science.870969; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; MAGASANIK B, 1993, J CELL BIOCHEM, V51, P34, DOI 10.1002/jcb.240510108; MAGASANIK B, 1987, ESCHERICHIA COLI SAL, P1318; MAKINO K, 1988, J MOL BIOL, V203, P85, DOI 10.1016/0022-2836(88)90093-9; MCCLEARY WR, 1993, J BACTERIOL, V175, P2793, DOI 10.1128/JB.175.10.2793-2798.1993; MCCLEARY WR, 1993, SIGNAL TRANSDUCTION, P17; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; SKARSTEDT MT, 1976, J BIOL CHEM, V251, P6775; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P228, DOI 10.1016/S0076-6879(57)03379-0; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1992, J BIOL CHEM, V267, P19753; STRYER L, 1988, BIOCHEMISTRY-US, P317; WANNER BL, 1993, J CELL BIOCHEM, V51, P47, DOI 10.1002/jcb.240510110; WANNER BL, 1992, J BACTERIOL, V174, P2124, DOI 10.1128/JB.174.7.2124-2130.1992; WANNER BL, 1992, J BACTERIOL, V174, P2053, DOI 10.1128/JB.174.7.2053-2058.1992; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N	36	275	277	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31567	31572						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989325				2022-12-25	WOS:A1994PX30300038
J	LEVYTOLEDANO, R; TAOUIS, M; BLAETTLER, DH; GORDEN, P; TAYLOR, SI				LEVYTOLEDANO, R; TAOUIS, M; BLAETTLER, DH; GORDEN, P; TAYLOR, SI			INSULIN-INDUCED ACTIVATION OF PHOSPHATIDYL-INOSITOL 3-KINASE - DEMONSTRATION THAT THE P85 SUBUNIT BINDS DIRECTLY TO THE COOH TERMINUS OF THE INSULIN-RECEPTOR IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; SIGNAL TRANSDUCTION; PROTEIN IRS-1; ASSOCIATION; PHOSPHORYLATION; SUBSTRATE; 3'-KINASE; ENDOCYTOSIS; TRUNCATION; AUTOPHOSPHORYLATION	Insulin activates the insulin receptor tyrosine kinase to phosphorylate signaling molecules such as insulin receptor substrate-1 (IRS-1). Phosphorylated IRS-1 binds to SH2 domains in the p85 regulatory subunit of phosphatidyl inositol (PI) 3-kinase, thereby stimulating the catalytic activity of PI 3-kinase. For most growth factor receptor tyrosine kinases (including receptors for epidermal growth factor and platelet-derived growth factor), the p85 regulatory subunit of PI 3-kinase binds directly to phosphorylated YXXM motifs contained in the cytoplasmic domain of the receptor itself. Previous studies in cell-free systems have shown that the phosphorylated YHTM sequence (amino acid residues 1322-1325) in the COOP terminus of the insulin receptor has the ability to bind to the p85 subunit of PI 3-kinase, thereby activating the enzyme. In this investigation, we demonstrate the occurrence of the same direct binding interaction in intact cells. Subsequent to insulin-stimulated phosphorylation of the insulin receptor, a complex is formed that contains the insulin receptor and PI 3-kinase. This complex can be immunoprecipitated by antibodies directed against either the insulin receptor or the p85 subunit of PI 3-kinase. The Delta 43 mutant insulin receptor that lacks 43 amino acids at the COOH terminus does not bind p85. In addition, the Delta 43 truncation impairs the ability of the receptor to mediate the activation of PI 3-kinase. Thus, by binding directly to p85, the phosphorylated YHTM motif in the COOH terminus of the insulin receptor contributes partially to mediating the effect of insulin to activate PI 3-kinase.	NIDDKD, DIABET BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Taouis, Mohammed/CAA-1797-2022	Taouis, Mohammed/0000-0002-4101-691X				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; CAMA A, 1992, J BIOL CHEM, V267, P8383; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOU CK, 1987, J BIOL CHEM, V262, P1842; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; HADARI YR, 1992, J BIOL CHEM, V267, P17483; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; KATO H, 1993, J BIOL CHEM, V268, P2655; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MYERS MG, 1991, J BIOL CHEM, V266, P10616; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YONEZAWA K, 1992, J BIOL CHEM, V267, P440; ZHANG WG, 1993, P NATL ACAD SCI USA, V90, P11317, DOI 10.1073/pnas.90.23.11317; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	75	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31178	31182						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983060				2022-12-25	WOS:A1994PV51000068
J	WELCH, JJ; RAUSCHER, FJ; BEERMAN, TA				WELCH, JJ; RAUSCHER, FJ; BEERMAN, TA			TARGETING DNA-BINDING DRUGS TO SEQUENCE-SPECIFIC TRANSCRIPTION FACTOR DNA COMPLEXES - DIFFERENTIAL-EFFECTS OF INTERCALATING AND MINOR-GROOVE BINDING-DRUGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; WILMS-TUMOR LOCUS; CRYSTAL-STRUCTURE; TATA-BOX; DEOXYRIBONUCLEIC-ACID; SELECTIVE BINDING; LEUCINE ZIPPER; NUCLEIC-ACIDS; DISTAMYCIN; NOGALAMYCIN	Intercalating, minor groove binding, and covalently bonding drugs were evaluated by mobility shift assays for their ability to interfere with transcription factors binding to their respective DNA recognition sequences. The Cys(2)His(2) zinc finger proteins EGR1, WT1, and NIL2A, the basic leucine-zipper protein wbJun/wbFos, and the minor groove binding protein hTBP were chosen as representative transcription factors. Their DNA recognition sites include G/C-rich, mixed, and AT-rich sequences. The intercalators nogalamycin and hedamycin, and the G/C-specific minor groove binding drug chromomycin A(3) were the most potent drugs, preventing transcription factor.DNA complex formation at concentrations less than 1 mu M. Similar concentrations of chromomycin A(3) disrupted preformed complexes while nogalamycin and hedamycin were 50-fold less potent if proteins were allowed to bind DNA prior to drug treatment. Echinomycin inhibited EGR1.DNA complex formation 50% at 5 mu M but had little effect on the formation of NIL2A.DNA complexes. Conversely, doxorubicin was found to inhibit NIL2A complex formation 50% at less than 1 mu M, but did not achieve this level of inhibition of EGR1/DNA complex formation even at 50 mu M. The A/T-directed minor groove binding drugs, while inhibiting hTBP at submicromolar concentrations, had no effect on either EGR1 or NIL2A.	ROSWELL PK CANC INST,DEPT EXPTL THERAPEUT,BUFFALO,NY 14263; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	Roswell Park Cancer Institute; The Wistar Institute					NATIONAL CANCER INSTITUTE [P01CA052009, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA52009, CA09072, CA16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BANVILLE DL, 1990, BIOCHEMISTRY-US, V29, P6521, DOI 10.1021/bi00479a026; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BROGGINI M, 1989, NUCLEIC ACIDS RES, V17, P1051, DOI 10.1093/nar/17.3.1051; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CHAIRES JB, 1987, BIOCHEMISTRY-US, V26, P8227, DOI 10.1021/bi00399a031; CHEN KX, 1985, J BIOMOL STRUCT DYN, V3, P445, DOI 10.1080/07391102.1985.10508434; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COLLIER DA, 1984, BIOCHEM PHARMACOL, V33, P2877, DOI 10.1016/0006-2952(84)90210-7; CONS BMG, 1990, BIOCHEM BIOPH RES CO, V171, P1064, DOI 10.1016/0006-291X(90)90792-L; DENNY WA, 1989, ANTI-CANCER DRUG DES, V4, P241; DORN A, 1992, EMBO J, V11, P279, DOI 10.1002/j.1460-2075.1992.tb05050.x; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; FOX KR, 1985, BIOCHIM BIOPHYS ACTA, V840, P383, DOI 10.1016/0304-4165(85)90219-3; FOX KR, 1985, NUCLEIC ACIDS RES, V13, P8695, DOI 10.1093/nar/13.24.8695; FOX KR, 1984, NUCLEIC ACIDS RES, V12, P9271, DOI 10.1093/nar/12.24.9271; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FREDERICK CA, 1990, BIOCHEMISTRY-US, V29, P2538, DOI 10.1021/bi00462a016; GAMBARI R, 1991, BIOCHEM PHARMACOL, V41, P497, DOI 10.1016/0006-2952(91)90620-K; GAO XL, 1990, BIOCHEMISTRY-US, V29, P10940, DOI 10.1021/bi00501a012; GAO XL, 1989, BIOCHEMISTRY-US, V28, P751, DOI 10.1021/bi00428a051; GAO YG, 1990, BIOCHEMISTRY-US, V29, P10307, DOI 10.1021/bi00497a004; ISLAM SA, 1985, J MED CHEM, V28, P857, DOI 10.1021/jm00145a003; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LIAW YC, 1989, BIOCHEMISTRY-US, V28, P9913, DOI 10.1021/bi00452a006; LIU CD, 1994, BIOCHEMISTRY-US, V33, P1419, DOI 10.1021/bi00172a019; LOW CML, 1986, NUCLEIC ACIDS RES, V14, P6785, DOI 10.1093/nar/14.17.6785; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maxam A M, 1980, Methods Enzymol, V65, P499; MORRIS JF, 1991, ONCOGENE, V6, P2339; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAYAK R, 1973, FEBS LETT, V30, P157, DOI 10.1016/0014-5793(73)80641-6; NEIDLE S, 1984, CRC CR REV BIOCH MOL, V17, P73, DOI 10.3109/10409238409110270; NIGHTINGALE KP, 1992, BIOCHEM J, V284, P929, DOI 10.1042/bj2840929; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; PETERSON M, 1993, TRENDS BIOTECHNOL, V111, P11; PETERSON MG, 1994, BIOCHEM PHARMACOL, V47, P127, DOI 10.1016/0006-2952(94)90445-6; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; REEVES R, 1990, J BIOL CHEM, V265, P8573; REYNOLDS VL, 1986, J ANTIBIOT, V39, P319, DOI 10.7164/antibiotics.39.319; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SEARLE MS, 1988, BIOCHEMISTRY-US, V27, P4340, DOI 10.1021/bi00412a022; SHEA RG, 1992, ANNU REP MED CHEM, V27, P311; SNYDER RC, 1991, BIOCHEMISTRY-US, V30, P4290, DOI 10.1021/bi00231a027; STANKUS A, 1992, BIOCHEMISTRY-US, V31, P9310, DOI 10.1021/bi00153a026; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRANEY D, 1987, BIOCHEMISTRY-US, V26, P1967; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUN DY, 1993, BIOCHEMISTRY-US, V32, P8068, DOI 10.1021/bi00083a003; TAKESHITA M, 1978, P NATL ACAD SCI USA, V75, P5983, DOI 10.1073/pnas.75.12.5983; THURSTON DE, 1993, MOL ASPECTS ANTICANC, P54; VANDYKE MM, 1984, SCIENCE, V225, P1122, DOI 10.1126/science.6089341; VANDYKE MW, 1982, P NATL ACAD SCI-BIOL, V79, P5470; VANDYKE MW, 1983, BIOCHEMISTRY-US, V22, P2373, DOI 10.1021/bi00279a011; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WARING M, 1970, Journal of Molecular Biology, V54, P247, DOI 10.1016/0022-2836(70)90429-8; WARING MJ, 1981, ANNU REV BIOCHEM, V50, P159, DOI 10.1146/annurev.bi.50.070181.001111; WARING MJ, 1974, NATURE, V252, P653, DOI 10.1038/252653a0; WHITE HL, 1969, BIOCHEMISTRY-US, V8, P1030, DOI 10.1021/bi00831a034; WILLIAMS LD, 1990, P NATL ACAD SCI USA, V87, P2225, DOI 10.1073/pnas.87.6.2225; WILLIAMS TM, 1991, SCIENCE, V254, P1791, DOI 10.1126/science.1840704; WILSON WD, 1990, BIOCHEMISTRY-US, V29, P8452, DOI 10.1021/bi00488a036; WILSON WR, 1981, MOL PHARMACOL, V20, P404; WOYNAROWSKI JM, 1989, MOL PHARMACOL, V35, P177; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZHANG XL, 1990, BIOCHEMISTRY-US, V29, P9451, DOI 10.1021/bi00492a020; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2	73	89	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31051	31058						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983044				2022-12-25	WOS:A1994PV51000051
J	BJELLAND, S; BIRKELAND, NK; BENNECHE, T; VOLDEN, G; SEEBERG, E				BJELLAND, S; BIRKELAND, NK; BENNECHE, T; VOLDEN, G; SEEBERG, E			DNA GLYCOSYLASE ACTIVITIES FOR THYMINE RESIDUES OXIDIZED IN THE METHYL-GROUP ARE FUNCTIONS OF THE ALKA ENZYME IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZING-RADIATION; ALKYLATING-AGENTS; ADAPTIVE RESPONSE; 3-METHYLADENINE-DNA GLYCOSYLASE; SACCHAROMYCES-CEREVISIAE; OXIDATIVE DAMAGE; ENDONUCLEASE-III; TREATED DNA; EXPRESSION; REPAIR	The alkA gene of Escherichia coli encodes a DNA glycosylase involved in base excision repair of DNA alkylation damage. In an attempt to define the reactions of the AIkA enzyme with methylated DNA we discovered that the enzyme released substantial amounts of radioactivity from [methyl-H-3]thymine-labeled DNA even without any exposure of the DNA to methylating agents. The excised material was identified by chromatography as two different oxidized derivatives of thymine, 5-hydroxymethyluracil and 5-formyluracil. These products are formed in such DNA by one and two consecutive decays, respectively, of the tritiums of the labeled methyl group. Kinetic analysis showed that both the apparent K-m and V-max values for 5-formyluracil removal are within the same range as found for 3-methyladenine removal, suggesting that this catalytic property of AlkA is also significant under in vivo conditions. Removal of 5-hydroxy- methyluracil proceeds at a rate that is 1-3 orders of magnitude slower. Since both 5-formyluracil and 5-hydroxymethyluracil are major products formed in DNA by exposure to ionizing radiation, these results implicate the alkA gene function also in the repair of oxidative DNA damage. Neither of the two other enzymes involved in the repair of oxidative DNA damage in E. coli, i.e. endonuclease III and formamidopyrimidine DNA glycosylase, has any affinity for oxidized unsaturated pyrimidines in DNA.	NORWEGIAN DEF RES ESTAB, DIV ENVIRONM TOXICOL, N-2007 KJELLER, NORWAY; UNIV OSLO, DEPT BIOL, N-0316 OSLO, NORWAY; UNIV OSLO, CTR BIOTECHNOL, N-0316 OSLO, NORWAY; LAB MICROBIAL GENE TECHNOL, N-1432 AS, NORWAY; UNIV OSLO, DEPT CHEM, N-0315 OSLO, NORWAY; UNIV TRONDHEIM, DEPT DERMATOL, N-7006 TRONDHEIM, NORWAY	Norwegian Defence Research Establishment; University of Oslo; University of Oslo; University of Oslo								BARSZCZ D, 1963, ACTA BIOCHIM POL, V10, P9; Battey, 1986, BASIC METHODS MOL BI; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; BERDAL KG, 1990, EMBO J, V9, P4563, DOI 10.1002/j.1460-2075.1990.tb07909.x; BERTANI LE, 1970, J GEN VIROL, V6, P201, DOI 10.1099/0022-1317-6-2-201; BJELLAND S, 1993, NUCLEIC ACIDS RES, V21, P2045, DOI 10.1093/nar/21.9.2045; BJELLAND S, 1987, NUCLEIC ACIDS RES, V15, P2787, DOI 10.1093/nar/15.7.2787; BOITEUX S, 1993, J PHOTOCH PHOTOBIO B, V19, P87, DOI 10.1016/1011-1344(93)87101-R; BOITEUX S, 1989, MOL GEN GENET, V215, P300, DOI 10.1007/BF00339732; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIMER LH, 1984, J BIOL CHEM, V259, P5543; BREIMER LH, 1985, BIOCHEMISTRY-US, V24, P4018, DOI 10.1021/bi00336a032; BROSSMER R, 1966, TETRAHEDRON LETT, P5253; CANNONCARLSON SV, 1989, J BIOL CHEM, V264, P13306; CARTER CA, 1988, BIOCHEM BIOPH RES CO, V155, P1261, DOI 10.1016/S0006-291X(88)81276-2; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; CHEN J, 1990, EMBO J, V9, P4569, DOI 10.1002/j.1460-2075.1990.tb07910.x; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; DECARROZ C, 1986, INT J RADIAT BIOL, V50, P491, DOI 10.1080/09553008614550901; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; EVENSEN G, 1982, NATURE, V296, P773, DOI 10.1038/296773a0; GANGULY T, 1990, BIOCHEMISTRY-US, V29, P7222, DOI 10.1021/bi00483a009; HOLLSTEIN MC, 1984, P NATL ACAD SCI-BIOL, V81, P4003, DOI 10.1073/pnas.81.13.4003; IIDA S, 1970, BIOCHIM BIOPHYS ACTA, V213, P1, DOI 10.1016/0005-2787(70)90002-X; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; KAASEN I, 1986, J BACTERIOL, V168, P642, DOI 10.1128/jb.168.2.642-647.1986; KALLEN RG, 1962, J MOL BIOL, V5, P248, DOI 10.1016/S0022-2836(62)80087-4; KARRAN P, 1982, NATURE, V296, P770, DOI 10.1038/296770a0; KASAI H, 1990, MUTAT RES, V243, P249, DOI 10.1016/0165-7992(90)90139-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY DD, 1991, NUCLEIC ACIDS RES, V19, P3337, DOI 10.1093/nar/19.12.3337; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LJUNGQUIST E, 1984, P NATL ACAD SCI-BIOL, V81, P3988, DOI 10.1073/pnas.81.13.3988; MATIJASEVIC Z, 1992, P NATL ACAD SCI USA, V89, P9331, DOI 10.1073/pnas.89.19.9331; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; MURAHASHI S, 1966, B CHEM SOC JPN, V39, P1559, DOI 10.1246/bcsj.39.1559; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3730; OKUBO S, 1964, VIROLOGY, V24, P552, DOI 10.1016/0042-6822(64)90207-7; RIAZUDDIN S, 1978, BIOCHEMISTRY-US, V17, P2110, DOI 10.1021/bi00604a014; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SHIRNAMEMORE L, 1987, MUTAT RES, V178, P177, DOI 10.1016/0027-5107(87)90267-3; TEEBOR GW, 1988, INT J RADIAT BIOL, V54, P131, DOI 10.1080/09553008814551591; TEEBOR GW, 1984, P NATL ACAD SCI-BIOL, V81, P318, DOI 10.1073/pnas.81.2.318; THOMAS L, 1982, BIOCHEMISTRY-US, V21, P1162, DOI 10.1021/bi00535a009; Tyrrel R.M., 1991, OXIDATIVE STRESS OXI, P57; VOIGT JM, 1989, J BIOL CHEM, V264, P5172; YAMAMOTO Y, 1978, J BACTERIOL, V135, P144, DOI 10.1128/JB.135.1.144-152.1978	50	124	125	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30489	30495						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982966				2022-12-25	WOS:A1994PU52500070
J	DUROVIC, S; MARZ, W; FRANK, S; SCHARNAGL, H; BAUMSTARK, MW; ZECHNER, R; KOSTNER, GM				DUROVIC, S; MARZ, W; FRANK, S; SCHARNAGL, H; BAUMSTARK, MW; ZECHNER, R; KOSTNER, GM			DECREASED BINDING OF APOLIPOPROTEIN (A) TO FAMILIAL DEFECTIVE APOLIPOPROTEIN B-100 (ARG(3500)-]GLN) - A STUDY OF THE ASSEMBLY OF RECOMBINANT APOLIPOPROTEIN (A) WITH MUTANT LOW-DENSITY LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTORS; PLASMA LIPOPROTEIN(A); LDL RECEPTOR; SERUM LIPOPROTEIN(A); MONOCLONAL-ANTIBODY; HOMOZYGOUS PATIENT; LP(A) LEVELS; HYPERCHOLESTEROLEMIA; GENE; PROTEIN	In familial defective apolipoprotein B-100 (FDB), glutamine is substituted for arginine at position 3500 of the amino acid sequence. This mutation alters the structure of low density lipoproteins (LDL) and reduces their binding to LDL receptors. We studied the assembly in vitro of FDB LDL with two recombinant apo(a) (r-apo(a)) isoforms containing 17 or 18 kringle IV-type repeats, respectively. R-apo(a) complexed to LDL in a concentration- and time dependent manner. When we mixed normal LDL at protein concentrations from 1 to 10 mg/liter with 200 mu g/liter r-apo(a) and incubated for 20 h, 15-44% of r-apo(a) were bound to LDL, forming an artificial Lp(a)-like particle. With LDL from a homozygous FDB patient, only 2-16% of r-apo(a) were complexed; heterozygous FDB-LDL bound 2-30% of r-apo(a). We also studied the effect of r-apo(a) on the interaction of the monoclonal antibody MB47 with normal and mutant apoB-100. FDB-LDL displayed enhanced binding of MB47. Adducts generated from normal LDL and r-apo(a) had an increased affinity for MB47, when compared to LDL alone. In contrast, r-apo(a) did not change MB47 reactivity when incubated with FDB-LDL. Altogether, our findings suggest that domains in apolipoprotein B which are important for the interaction with the LDL receptor play a role in the assembly of Lp(a) as well. They provide, in addition, an explanation for the observation that in Lp(a) of heterozygous FDB patients, the ratio of defective to normal apoB-100 is significantly smaller than in LDL from the same patients.	GRAZ UNIV, INST MED BIOCHEM, A-8010 GRAZ, AUSTRIA; UNIV FREIBURG, DEPT CLIN CHEM, MED CLIN, FREIBURG, GERMANY; UNIV FRANKFURT, GUSTAV EMBDEN CTR BIOL CHEM, FRANKFURT, GERMANY; UNIV FREIBURG, DEPT SPORTS MED, MED CLIN, FREIBURG, GERMANY	University of Graz; University of Freiburg; Goethe University Frankfurt; University of Freiburg			Baumstark, Manfred W/F-8432-2012	Baumstark, Manfred W/0000-0002-5442-1586; Zechner, Rudolf/0000-0001-5483-1182				ARMSTRONG VW, 1990, J LIPID RES, V31, P429; AUSTIN MA, 1992, AM J HUM GENET, V51, P829; BAUMSTARK MW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P48, DOI 10.1016/0167-4838(90)90100-T; BAUMSTARK MW, 1993, HORMONES LIPOPROTEIN, P165; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; CHIESA G, 1992, J BIOL CHEM, V267, P24369; EDELBERG JM, 1991, FIBRINOLYSIS, V5, P135, DOI 10.1016/0268-9499(91)90015-V; FRANK S, 1994, BIOCHEMISTRY-US, V33, P12329, DOI 10.1021/bi00206a041; FRIEDL W, 1991, ARTERIOSCLER THROMB, V11, P371, DOI 10.1161/01.ATV.11.2.371; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; GHISELLI G, 1992, METABOLISM, V41, P833, DOI 10.1016/0026-0495(92)90163-5; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HUNNINGHAKE DB, 1993, J CLIN PHARMACOL, V33, P574, DOI 10.1002/j.1552-4604.1993.tb04706.x; INNERARITY TL, 1990, J LIPID RES, V31, P1337; INNERARITY TL, 1987, P NATL ACAD SCI USA, V84, P6919, DOI 10.1073/pnas.84.19.6919; IRISH AB, 1992, AUST NZ J MED, V22, P243, DOI 10.1111/j.1445-5994.1992.tb02119.x; JENNER JL, 1993, CIRCULATION, V87, P1135, DOI 10.1161/01.CIR.87.4.1135; KAMBOH MI, 1991, AM J HUM GENET, V49, P1063; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; Kostner G. M., 1992, CURR OPIN LIPIDOL, V3, P279; KOSTNER GM, 1989, CIRCULATION, V80, P1313, DOI 10.1161/01.CIR.80.5.1313; KOSTNER GM, 1993, ARTERIOSCLER THROMB, V13, P1101, DOI 10.1161/01.ATV.13.7.1101; KRAFT HG, 1992, HUM GENET, V90, P220; KREMPLER F, 1983, J CLIN INVEST, V71, P1431, DOI 10.1172/JCI110896; KUHL H, 1993, CONTRACEPTION, V47, P69, DOI 10.1016/0010-7824(93)90110-S; Lindgren F. T., 1975, ANAL LIPIDS LIPOPROT, P204; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1991, J BIOL CHEM, V266, P2701; MAARTMANNMOE K, 1981, CLIN GENET, V20, P352; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MARZ W, 1993, J CLIN INVEST, V92, P2922, DOI 10.1172/JCI116915; MARZ W, 1993, EUR J CLIN CHEM CLIN, V31, P295; MARZ W, 1992, LANCET, V340, P1362, DOI 10.1016/0140-6736(92)92554-S; MARZ W, 1993, FEBS LETT, V325, P271, DOI 10.1016/0014-5793(93)81087-G; MARZ W, 1993, CLIN CHEM, V39, P2276; MARZ W, 1994, INT J CLIN PHARM TH, V32, P92; MARZ W, 1991, ELECTROPHORESIS, V12, P59, DOI 10.1002/elps.1150120111; MBEWU AD, 1991, ARTERIOSCLER THROMB, V11, P940, DOI 10.1161/01.ATV.11.4.940; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILNE R, 1989, J BIOL CHEM, V264, P19754; MYANT NB, 1993, ATHEROSCLEROSIS, V104, P1, DOI 10.1016/0021-9150(93)90171-P; PEROMBELON YFN, 1992, ATHEROSCLEROSIS, V92, P203, DOI 10.1016/0021-9150(92)90279-P; PEROMBELON YFN, 1994, J CLIN INVEST, V93, P1481, DOI 10.1172/JCI117126; PHILLIPS ML, 1993, BIOCHEMISTRY-US, V32, P3722, DOI 10.1021/bi00065a026; RADER DJ, 1993, J CLIN INVEST, V91, P443, DOI 10.1172/JCI116221; RAUH G, 1992, CLIN INVESTIGATOR, V70, P77, DOI 10.1007/BF00422946; Sambrook J, 1989, MOL CLONING LABORATO; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SIEKMEIER R, 1994, CLIN CHEM, V40, P1350; SORIA LF, 1989, P NATL ACAD SCI USA, V86, P587, DOI 10.1073/pnas.86.2.587; SOUTAR AK, 1991, J CLIN INVEST, V88, P483, DOI 10.1172/JCI115329; STEYRER E, 1990, J LIPID RES, V31, P1247; STEYRER E, 1994, IN PRESS J CLIN INVE; TJERK WA, 1993, J CLIN ENDOCR METAB, V76, P121; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1989, P NATL ACAD SCI USA, V86, P4171, DOI 10.1073/pnas.86.11.4171; UTERMANN G, 1988, HUM GENET, V78, P41, DOI 10.1007/BF00291232; VEGA GL, 1992, J INTERN MED, V232, P405, DOI 10.1111/j.1365-2796.1992.tb00606.x; VESSBY B, 1982, ATHEROSCLEROSIS, V44, P61, DOI 10.1016/0021-9150(82)90053-3; WANNER C, 1993, ANN INTERN MED, V119, P263, DOI 10.7326/0003-4819-119-4-199308150-00002; WEISGRABER KH, 1988, P NATL ACAD SCI USA, V85, P9758, DOI 10.1073/pnas.85.24.9758; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WHITE AL, 1993, J LIPID RES, V34, P509; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178; YOUNG SG, 1994, J LIPID RES, V35, P399; ZATLOUKAL K, 1992, ANN NY ACAD SCI, V660, P136, DOI 10.1111/j.1749-6632.1992.tb21066.x; ZECHNER R, 1984, BIOCHEM J, V224, P569, DOI 10.1042/bj2240569; ZECHNER R, 1986, METABOLISM, V35, P333, DOI 10.1016/0026-0495(86)90150-2	70	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30320	30325						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982944				2022-12-25	WOS:A1994PU52500045
J	GRAEFF, RM; WALSETH, TF; FRYXELL, K; BRANTON, WD; LEE, HC				GRAEFF, RM; WALSETH, TF; FRYXELL, K; BRANTON, WD; LEE, HC			ENZYMATIC-SYNTHESIS AND CHARACTERIZATIONS OF CYCLIC GDP-RIBOSE - A PROCEDURE FOR DISTINGUISHING ENZYMES WITH ADP-RIBOSYL CYCLASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; INOSITOL TRISPHOSPHATE; CALCIUM RELEASE; NAD+; METABOLITE; CA2+; CD38; HYDROLYSIS; TISSUES; PROTEIN	Cyclic nucleotides such as cAMP and cGMP are second messengers subserving various signaling pathways. Cyclic ADP-ribose (cADPR), a recently discovered member of the family, is derived from NAD(+) and is a mediator of Ca2+ mobilization in various cellular systems. The synthesis and degradation of cADPR are, respectively, catalyzed by ADP-ribosyl cyclase and cADPR hydrolase. CD38, a differentiation antigen of B lymphocytes, has recently been shown to be a bifunctional enzyme catalyzing both the formation and hydrolysis of cADPR. The overall reaction catalyzed by CD38 is the formation of ADP-ribose and nicotinamide from NAD(+), identical to that catalyzed by NADase. The difficulties in detecting the formation of cADPR have led to frequent identification of CD38 as a classical NADase. In this study, we show that both ADP-ribosyl cyclase and CD38, but not NADase, can cyclize nicotinamide guanine dinucleotide (NGD(+)) producing a new nucleotide. Analyses by high performance liquid chromatography and mass spectroscopy indicate the product is cyclic GDP-ribose (cGDPR) with a structure similar to cADPR except with guanine replacing adenine. Compared to cADPR, cGDPR is a more stable compound showing 2.8 times more resistance to heat-induced hydrolysis. These results are consistent with a catalytic scheme for CD38 where the cyclization of the substrate precedes the hydrolytic reaction. Spectroscopic analyses show that cGDPR is fluorescent and has an absorption spectrum different from both NGD(+) and GDPR, providing a very convenient way for monitoring its enzymatic formation. The use of NGD(+) as substrate for assaying the cyclization reaction was found to be applicable to pure enzymes as well as crude tissue extracts making it a useful diagnostic tool for distinguishing CD38-like enzymes from degradative NADases.	UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Lee, Hon Cheung/C-4329-2009; Graeff, Richard Milton/B-3425-2011; Walseth, Timothy F/F-9518-2010	Walseth, Timothy F/0000-0003-2558-7859	NICHD NIH HHS [HD 32040, HD17484] Funding Source: Medline; NIDA NIH HHS [DA08131] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484, R01HD032040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA008131] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1993, J BIOL CHEM, V268, P293; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; SUMIDA M, 1978, J BIOL CHEM, V253, P8772; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	22	235	240	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30260	30267						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982936				2022-12-25	WOS:A1994PU52500036
J	OBRIEN, RM; LUCAS, PC; YAMASAKI, T; NOISIN, EL; GRANNER, DK				OBRIEN, RM; LUCAS, PC; YAMASAKI, T; NOISIN, EL; GRANNER, DK			POTENTIAL CONVERGENCE OF INSULIN AND CAMP SIGNAL-TRANSDUCTION SYSTEMS AT THE PHOSPHOENOLPYRUVATE CARBOXYKINASE (PEPCK) GENE PROMOTER THROUGH CCAAT ENHANCER-BINDING PROTEIN (C/EBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ACID GLYCOPROTEIN GENE; RETINOIC ACID RECEPTORS; RESPONSE ELEMENT; GTP GENE; DNA-BINDING; THYROID-HORMONE; CYCLIC-AMP; GLUCOCORTICOID INDUCTION; TRANSCRIPTION FACTORS; REGULATORY ELEMENT	Adenosine 3',5'-monophosphate (cAMP) stimulates phosphoenolpyruvate carboxykinase (PEPCK) gene transcription, whereas insulin has the opposite effect. In H4IIE cells, the effect of insulin is dominant since it represses cAMP-stimulated transcription. Discrete cis-acting elements in the PEPCK promoter that serve as an insulin response sequence (IRS) and cAMP response element (CRE) have been identified. Here we show that common proteins can bind both elements, since: (i) an almost identical pattern of protein binding is seen when oligonucleotides representing either the IRS or the CRE are used as the labeled probe in a gel retardation assay and (ii) the unlabeled wild-type, but not mutated, CRE oligonucleotide competes for protein binding to the labeled IRS probe, and vice versa. Six homo- and het erodimer complexes interact with these DNA elements; the complexes are composed of three individual protein species: (a) 42-kDa C/EBP alpha, (b) 30-kDa C/EBP alpha, and (c) an unidentified 20-kDa factor termed p20- CRE/IRS Binding Protein (p20-C/IBP). These proteins have a 30-fold greater affinity for the CRE at room temperature, a difference explained by the rapid dissociation rate of protein bound to the IRS, since the association rate of protein binding to both the IRS and CRE is the same. Protease digestion experiments suggest that the proteins bind to the CRE and IRS in different conformations. The IRS and CRE both function in the context of a heterologous promoter to mediate effects of insulin and cAMP, respectively, but, although the PEPCK IRS and CRE bind common proteins, the PEPCK CRE is not a functional IRS and the PEPCK IRS is not a functional CRE.	VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University				Lucas, Peter/0000-0003-4880-7172	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035107, R01DK035107, P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07563, DK20593, DK35107] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM T, 1993, J BIOL CHEM, V268, P15681; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BEALE EG, 1986, DIABETES, V35, P546, DOI 10.2337/diabetes.35.5.546; BEEBE SJ, 1985, J BIOL CHEM, V260, P5781; BRASIER AR, 1990, MOL ENDOCRINOL, V4, P1921, DOI 10.1210/mend-4-12-1921; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHU DTW, 1986, J BIOL CHEM, V261, P6848; COLLINS S, 1990, J BIOL CHEM, V265, P19330; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE KL, 1985, J BIOL CHEM, V260, P6433; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIU J, 1991, MOL CELL BIOCHEM, V104, P89; LIU JS, 1991, J BIOL CHEM, V266, P19095; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MAURER RA, 1989, J BIOL CHEM, V264, P6870; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBRIEN RM, 1993, ADV SEC MESS PHOSPH, V28, P245; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; QUINN PG, 1994, J BIOL CHEM, V269, P14375; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMS PM, 1991, MOL CELL BIOL, V11, P4959, DOI 10.1128/MCB.11.10.4959	58	84	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30419	30428						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982956				2022-12-25	WOS:A1994PU52500060
J	LEE, JM; ABRAHAMSON, JLA; KANDEL, R; DONEHOWER, LA; BERNSTEIN, A				LEE, JM; ABRAHAMSON, JLA; KANDEL, R; DONEHOWER, LA; BERNSTEIN, A			SUSCEPTIBILITY TO RADIATION CARCINOGENESIS AND ACCUMULATION OF CHROMOSOMAL BREAKAGE IN P53 DEFICIENT MICE	ONCOGENE			English	Article							WILD-TYPE P53; CELL-CYCLE ARREST; IONIZING-RADIATION; TRANSCRIPTIONAL ACTIVATION; GENE AMPLIFICATION; DNA DAMAGE; APOPTOSIS; CANCER; INDUCTION; PROTEIN	The p53 tumour suppressor gene is an important participant in the cellular response to ionizing radiation and other DNA damaging agents. Cells which lack p53 are unable to arrest cell cycle or enter into apoptotic cell death following irradiation. Moreover, these p53 deficient cells exhibit an increased resistance to DNA damaging agents, including radiation. The significance of this radiation-resistance and its relationship to the role that p53 plays in tumour suppression and the cellular radiation response has not yet been determined. In this report we have analyzed p53 deficient mice, expressing either a mutant p53 transgene or having a targeted p53 null allele, in order to investigate the role that p53 plays in governing susceptibility to radiation-carcinogenesis and in controlling the in vivo accumulation of chromosomal abnormalities. We show that wild-type p53 plays a critical role in controlling susceptibility to gamma-radiation-induced tumorigenesis, and sarcomas and lymphomas rapidly appear in irradiated p53 transgenic mice. Moreover, this susceptibility to radiation-carcinogenesis is associated with a two-fold increase in the in vivo accumulation of radiation-induced double stranded chromosomal breaks relative to that observed in wild-type animals. Taken together, these observations suggest that p53 acts to suppress tumour formation in vivo by preventing the accumulation of cells that have sustained radiation-induced DNA damage.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ON,CANADA; MT SINAI HOSP,DEPT PATHOL,TORONTO M5G 1X5,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA; BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Baylor College of Medicine			Kandel, Rita/E-2149-2017; Kandel, Rita/AAU-9908-2021	Kandel, Rita/0000-0003-4047-3913; Kandel, Rita/0000-0003-4047-3913	NATIONAL CANCER INSTITUTE [R01CA054897] Funding Source: NIH RePORTER; NCI NIH HHS [CA54897] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDBERG EC, 1979, ADV RADIAT BIOL, V8, P85; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P5413; Haran-Ghera N, 1979, Adv Cancer Res, V30, P45, DOI 10.1016/S0065-230X(08)60894-5; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2456; HEDDLE JA, 1973, MUTAT RES, V18, P187, DOI 10.1016/0027-5107(73)90035-3; HUTCHINSON F, 1993, SEMIN CANCER BIOL, V4, P85; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERSEY JH, 1973, INT J CANCER, V12, P333, DOI 10.1002/ijc.2910120204; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEE JM, 1994, MUTAT RES, V307, P573, DOI 10.1016/0027-5107(94)90267-4; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKUMOTO M, 1990, CANCER RES, V50, P3848; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHMID W, 1975, MUTAT RES, V31, P9, DOI 10.1016/0165-1161(75)90058-8; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOMETSKO AM, 1992, MUTAT RES, V292, P145; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	45	115	117	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3731	3736						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970733				2022-12-25	WOS:A1994PT39200039
J	PAJUSOLA, K; APRELIKOVA, O; PELICCI, G; WEICH, H; CLAESSONWELSH, L; ALITALO, K				PAJUSOLA, K; APRELIKOVA, O; PELICCI, G; WEICH, H; CLAESSONWELSH, L; ALITALO, K			SIGNALING PROPERTIES OF FLT4, A PROTEOLYTICALLY PROCESSED RECEPTOR TYROSINE KINASE RELATED TO 2 VEGF RECEPTORS	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; HEPARIN-LIKE MOLECULES; PROTO-ONCOGENE; CELL-SURFACE; FACTOR GENE; SH2 DOMAIN; BINDING; EXPRESSION; ANGIOGENESIS	The FLT4, FLT1 and KDR/FLK1 genes encode, structurally similar endothelial cell receptor tyrosine kinases. Recently it has been shown that the FLT1 and KDR/FLK-1 proteins function as high-affinity receptors for vascular endothelial growth factor (VEGF). Here we show that FLT4 does not act as a receptor for VEGF, as VEGF did not show specific binding to the FLT4 tyrosine kinase or induce its autophosphorylation. Also, FLT4 did not interact with KDR in response to VEGF. However, when fused with the ligand binding domain of the colony stimulating factor-1 receptor (CSF-1R), the FLT4 tyrosine kinase was specifically activated by CSF-1. The activated FLT4 tyrosine kinase domain was found to interact with the Src homology 2 domains of the SHC and GRB2 adaptor proteins in vitro and with SHC in cells. CSF-1 stimulation of the CSF-1R/FLT4 receptor chimera induced thymidine incorporation in serum-starved NIH3T3 fibroblasts, but not in porcine aortic or murine lung capillary endothelial cells, although tyrosyl phosphorylation of the receptor and SHC occurred in these cells as well. These results suggest that the endothelial cell FLT4 receptor tyrosine kinase transmits signals for an as yet unidentified growth factor.	UNIV HELSINKI, DEPT PATHOL, MOLEC CANC BIOL LAB, SF-00014 HELSINKI, FINLAND; UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED, I-06100 PERUGIA, ITALY; GESELL BIOTECHNOL FORSCH MBH, DEPT GENE EXPRESS, W-3300 BRAUNSCHWEIG, GERMANY; LUDWIG INST CANC RES, UPPSALA BRANCH, S-75124 UPPSALA, SWEDEN	University of Helsinki; University of Perugia; Gesellschaft fur Biotechnologische Forschung mbH; Ludwig Institute for Cancer Research			Alitalo, Kari K/J-5013-2014; Pelicci, Giuliana/AAA-8921-2022	Alitalo, Kari K/0000-0002-7331-0902; Pelicci, Giuliana/0000-0003-0986-8255				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; APRELIKOVA O, 1992, CANCER RES, V52, P746; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BROWN LF, 1993, AM J PATHOL, V143, P1255; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FIEBICH BL, 1993, EUR J BIOCHEM, V211, P19, DOI 10.1111/j.1432-1033.1993.tb19865.x; GALLAND F, 1993, ONCOGENE, V8, P1233; GIORDANO S, 1989, ONCOGENE, V4, P1383; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; LAULAJAINEN T, 1993, LAB INVEST, V69, P183; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MARK MR, 1992, J BIOL CHEM, V267, P26166; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; ROBINSON DH, 1991, BLOOD, V77, P294; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WALTENBERGER J, 1994, IN PRESS J BIOL CHEM; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	121	136	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3545	3555						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970715				2022-12-25	WOS:A1994PT39200017
J	PATEL, U; GRUNDFESTBRONIATOWSKI, S; GUPTA, M; BANERJEE, S				PATEL, U; GRUNDFESTBRONIATOWSKI, S; GUPTA, M; BANERJEE, S			MICROSATELLITE INSTABILITIES AT 5 CHROMOSOMES IN PRIMARY BREAST-TUMORS	ONCOGENE			English	Note							DNA-POLYMERASE-BETA; DENYS-DRASH SYNDROME; COLORECTAL-CANCER; WILMS-TUMOR; LENGTH-POLYMORPHISMS; REPEAT POLYMORPHISM; SUPPRESSOR GENES; POINT MUTATIONS; LINKAGE MAP; WT1 GENE	The microsatellite instabilities at nine loci of chromosomes 2p, 8p, 10p and lip and the nm23-H1 locus on 17q21.3 were studied in primary breast tumors. Alterations in the short interspersed tandem repeats in tumor DNA in the form of either larger allele, smaller allele or LOH were observed. Significantly, a high occurrence of alterations in microsatellite polymorphisms at the ANK1, D8S135 and LPL loci of chromosome 8p (46-54%), the D2S119 locus of chromosome 2p (56%), the D10S197 locus at chromosome 10p (88%), and the nm23-H1 locus of chromosome 17q21.3 (46%) were observed in breast tumors. These results provide the first evidence for genomic instabilities at 2p, 8p and 10p in primary ductal and lobular breast carcinomas. No correlation has been found between the stage of the tumor and microsatellite instability, suggesting that microsatellite instability is an early genetic event in breast carcinogenesis.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT GEN SURG,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT CLIN PATHOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation								AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348; BACKER JM, 1993, ONCOGENE, V8, P497; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; EASTON DF, 1993, AM J HUM GENET, V52, P678; EMI M, 1992, CANCER RES, V52, P5368; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FERRELL RE, 1983, AM J HUM GENET, V35, P78; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUTREAL PA, 1992, CANCER RES, V52, P2624; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; HAN HJ, 1993, CANCER RES, V53, P5087; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KING MC, 1992, NAT GENET, V2, P125; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1991, CANCER RES, V51, P2490; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MCBRIDE OW, 1987, P NATL ACAD SCI USA, V84, P503, DOI 10.1073/pnas.84.2.503; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Patel U., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P184; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P969, DOI 10.1093/nar/19.4.969; RHYU MG, 1994, ONCOGENE, V9, P29; SADAKANE Y, 1994, BIOCHEM BIOPH RES CO, V200, P219, DOI 10.1006/bbrc.1994.1437; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SWEASY JB, 1993, P NATL ACAD SCI USA, V90, P4626, DOI 10.1073/pnas.90.10.4626; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; VARLEY JM, 1989, ONCOGENE, V4, P725; WADEY RB, 1990, ONCOGENE, V5, P901; WANG LM, 1992, CANCER RES, V52, P4824; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; YEE CJ, 1994, CANCER RES, V54, P1641; ZULIANI G, 1990, NUCLEIC ACIDS RES, V18, P4958, DOI 10.1093/nar/18.16.4958-a; 1993, LOCUS MAPS COMPLEX G; 1993, CELL, V72, P971	53	75	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3695	3700						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970728				2022-12-25	WOS:A1994PT39200034
J	WASYLYK, C; MAIRA, SM; SOBIESZCZUK, P; WASYLYK, B				WASYLYK, C; MAIRA, SM; SOBIESZCZUK, P; WASYLYK, B			REVERSION OF RAS TRANSFORMED-CELLS BY ETS TRANSDOMINANT MUTANTS	ONCOGENE			English	Article							MATRIX-DEGRADING METALLOPROTEINASES; TRANSCRIPTION FACTORS; PROTEIN-KINASE; SIGNAL TRANSDUCTION; ACTIVATION DOMAIN; GENE FAMILY; PHOSPHORYLATION; PHOTORECEPTOR; DROSOPHILA; CASCADE	Considerable progress has been made in elucidating the components of the Ras signalling pathway, from both biochemical and genetic investigations. However little is known about the nuclear targets of the pathway, and in particular those that mediate the long-term changes in gene expression resulting from Ras transformation. Ets family members may be involved in these processes since Ras stimulates transcription through ets-DNA binding sites. We show that a mutated Ets protein, Delta PU.1, inhibits Ras activation of transcription. Stable expression of Delta PU.1 in Ras transformed NIH3T3 fibroblasts reverts the transformed phenotype by many characteristics, including morphology, anchorage independent growth, saturation density, growth in low serum, tumour formation in nude mice and to some extent sensitivity to apoptotic cell death. Similar trans-dominant mutants of c-Ets-1 and c-Ets-2, the most divergent members of the Ets-family to PU.1, also revert Ras transformed cells, as indicated by morphology, anchorage-independent growth, saturation density and doubling time in low serum. Reversion may result from a shared property of the mutants, such as binding to ets motifs in promoters. These results provide evidence for an important role for Ets proteins in Ras transformation.	FAC MED STRASBOURG, INST CHIM BIOL, CNRS, LGME, INSERM, U184, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ADLER V, 1992, J BIOL CHEM, V267, P17001; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; HANCOCK JF, 1993, CURR BIOL, V3, P770, DOI 10.1016/0960-9822(93)90027-L; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK B, 1993, EUR J BIOCHEM, V21, P523; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WHARTON W, 1989, CELL GROWTH DIVISION, P139	37	85	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3665	3673						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970725				2022-12-25	WOS:A1994PT39200030
J	SHIBA, K; SCHIMMEL, P; MOTEGI, H; NODA, T				SHIBA, K; SCHIMMEL, P; MOTEGI, H; NODA, T			HUMAN GLYCYL-TRANSFER-RNA SYNTHETASE - WIDE DIVERGENCE OF PRIMARY STRUCTURE FROM BACTERIAL COUNTERPART AND SPECIES-SPECIFIC AMINOACYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; CHAIN RELEASE FACTOR; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; BOMBYX-MORI; GENE ENCODES; EXPRESSION; PROTEIN; MITOCHONDRIAL	Several class I and class II human tRNA synthetases are clearly related to their bacterial counterparts. We report here the cloning, cDNA sequence, deduced primary structure, and expression in bacteria of a class II human glycyl-tRNA synthetase. While the human sequence aligns well with a Bombyx mori and a Saccharomyces cerevisiae sequence for glycyl-tRNA synthetase, particularly in the region of the class II-defining sequence motifs, it diverges widely from that of the Escherichia coli enzyme. The divergence is so great that from the sequences alone we cannot conclude that the human and E. coli proteins are descended from homologous genes. Moreover, even though the human and E. coli class II alanyl-tRNA synthetases cross-acylate their respective tRNAs, aminoacylations by the recombinant human and E. coli glycyl-tRNA synthetases are restricted to their homologous tRNAs, The species-specific aminoacylations correlate with a nucleotide sequence difference at a location in the acceptor stem that is known to be critical for aminoacylations by the E. coli enzyme. Thus, glycyl-tRNA synthetase may have followed a path of historical development different in at least some respects from that of several other tRNA synthetases.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	SHIBA, K (corresponding author), JAPANESE FDN CANC RES, INST CANC, DEPT CELL BIOL, TOSHIMA KU, TOKYO 170, JAPAN.		Noda, Tetsuo/B-1667-2016; Shiba, Kiyotaka/I-9588-2014	Shiba, Kiyotaka/0000-0001-6459-0204	NIGMS NIH HHS [GM23562] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BUECHTER DD, 1993, BIOCHEMISTRY-US, V32, P5267, DOI 10.1021/bi00070a039; BULUWELA L, 1989, NUCLEIC ACIDS RES, V17, P452, DOI 10.1093/nar/17.1.452; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CHANG PK, 1990, J BIOL CHEM, V265, P20898; CHATTON B, 1988, J BIOL CHEM, V263, P52; CRUZEN ME, 1991, J BIOL CHEM, V266, P9919; CRUZEN ME, 1993, GENOMICS, V15, P692, DOI 10.1006/geno.1993.1128; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DIGNAM SS, 1984, J BIOL CHEM, V259, P4043; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1991, NUCLEIC ACIDS RES, V19, P265, DOI 10.1093/nar/19.2.265; FETT R, 1991, J BIOL CHEM, V266, P1448; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; GARRET M, 1991, BIOCHEMISTRY-US, V30, P7809, DOI 10.1021/bi00245a021; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HOU YM, 1989, BIOCHEMISTRY-US, V28, P6800, DOI 10.1021/bi00443a003; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; KENG T, 1982, J BIOL CHEM, V257, P12503; KENG T, 1983, J BIOMOL STRUCT DYN, V1, P225, DOI 10.1080/07391102.1983.10507436; KERN D, 1981, BIOCHEMISTRY-US, V20, P122, DOI 10.1021/bi00504a021; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE CC, 1990, P NATL ACAD SCI USA, V87, P3508, DOI 10.1073/pnas.87.9.3508; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; MAIZEL JV, 1981, P NATL ACAD SCI-BIOL, V78, P7665, DOI 10.1073/pnas.78.12.7665; MAYAUX JF, 1983, P NATL ACAD SCI-BIOL, V80, P6152, DOI 10.1073/pnas.80.20.6152; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P6147, DOI 10.1073/pnas.88.14.6147; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; NADA S, 1993, J BIOL CHEM, V268, P7660; NAGEL GM, 1991, P NATL ACAD SCI USA, V88, P8121, DOI 10.1073/pnas.88.18.8121; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; OHASHI M, 1980, EXP GERONTOL, V15, P121, DOI 10.1016/0531-5565(80)90083-2; OSTREM DL, 1970, P NATL ACAD SCI USA, V67, P1967, DOI 10.1073/pnas.67.4.1967; PIRTLE IL, 1986, GENE, V43, P155, DOI 10.1016/0378-1119(86)90019-3; PUTZER H, 1990, J BACTERIOL, V172, P4593, DOI 10.1128/jb.172.8.4593-4602.1990; RABEN N, 1992, NUCLEIC ACIDS RES, V20, P1075, DOI 10.1093/nar/20.5.1075; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Sambrook J, 1989, MOL CLONING LABORATO; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; SHIBA K, 1992, J BIOL CHEM, V267, P22703; SHIBA K, 1994, P NATL ACAD SCI USA, V91, P7435, DOI 10.1073/pnas.91.16.7435; SHORTRIDGE RD, 1985, GENE, V33, P269, DOI 10.1016/0378-1119(85)90234-3; STANBRIDGE EJ, 1981, SOMAT CELL GENET, V7, P699, DOI 10.1007/BF01538758; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SURGUCHOV AP, 1975, EUR J BIOCHEM, V54, P175, DOI 10.1111/j.1432-1033.1975.tb04127.x; TARGOFF IN, 1990, J IMMUNOL, V144, P1737; TOTH MJ, 1986, J BIOL CHEM, V261, P6643; TSUI FWL, 1987, NUCLEIC ACIDS RES, V15, P3349, DOI 10.1093/nar/15.8.3349; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	68	103	109	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					30049	30055						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7962006				2022-12-25	WOS:A1994PU28400110
J	YANG, SD; HUANG, TJ; SODERLING, TR				YANG, SD; HUANG, TJ; SODERLING, TR			IDENTIFICATION OF -R-X-(X)-S/T-X(3)-S/T- AS CONSENSUS SEQUENCE MOTIF FOR AUTOPHOSPHORYLATION-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; PHOSPHORYLATION SITE; RAT-BRAIN; PURIFICATION; MUSCLE; PHOSPHATASE-2A; ACTIVATION; CLEAVAGE	To identify consensus sequence motif for a new family of protein kinase termed autophosphorylation-dependent protein serine/threonine kinase (auto-kinase), we have tested several synthetic peptides. The well established protein serine/threonine kinases such as cAMP-dependent protein kinase, Ca2+/calmodulin-dependent protein kinase (CaM-kinase), and protein kinase C were found to be inactive toward phosphorylation of syntide-3 (RPRPASVPPSPSLSRHA), which turned out to be an excellent substrate only for auto-kinase, indicating that syntide-3 is a specific substrate for auto kinase. Modification of syntide-3 to become RPRPASVPPS/T did not affect the activity of auto-kinase. By contrast, autokinase became rather or almost inactive when the peptide was modified to become RPRPASVPPA/G/F/K/R/D/E/Y, indicating that amino acid number 10 in syntide-3 is crucial to the sequence motif recognized by auto-kinase. Phosphorylation of myelin basic protein (MBP) by autokinase revealed that auto-kinase predominantly phosphorylates MBP on one particular site with RTT(p)HYGS as the phosphorylation site sequence, which could not be phosphorylated by any other reported MBP kinases including cAMP-dependent protein kinase, CaM-kinase, protein kinase C, mitogen-activated protein kinase, and kinase FA/GSK-3. Taken together, the results provide initial evidence that -Arg-X-(X)-Ser/Thr-X(3)-Ser/Thr- may represent a unique consensus sequence motif specifically recognized by autophosphorylation-dependent protein kinase, a new family of multisubstrate/multifunctional protein serine/threonine kinase.	CHANG GUNG MED COLL, INST BASIC MED, TAYUAN, TAIWAN; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Chang Gung University; Vanderbilt University	YANG, SD (corresponding author), NATL TSING HUA UNIV, INST BIOMED SCI, HSINCHU 30043, TAIWAN.			Huang, Jeffrey/0000-0001-9982-2298				ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROSTOFF SW, 1974, J BIOL CHEM, V249, P559; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; EYLAR EH, 1969, ARCH BIOCHEM BIOPHYS, V132, P34, DOI 10.1016/0003-9861(69)90336-1; EYLAR EH, 1971, J BIOL CHEM, V246, P5770; GUO H, 1993, J BIOL CHEM, V268, P11193; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KINZEL V, 1976, BIOCHEM BIOPH RES CO, V71, P257, DOI 10.1016/0006-291X(76)90276-X; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laursen R A, 1980, Methods Biochem Anal, V26, P201, DOI 10.1002/9780470110461.ch6; LAURSEN RA, 1966, J AM CHEM SOC, V88, P5344, DOI 10.1021/ja00974a069; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; SHOJI S, 1987, J BIOCHEM-TOKYO, V102, P1113, DOI 10.1093/oxfordjournals.jbchem.a122149; YANG SD, 1993, J NEUROCHEM, V61, P1742, DOI 10.1111/j.1471-4159.1993.tb09811.x; YANG SD, 1986, J BIOL CHEM, V261, P1786; YANG SD, 1987, J BIOL CHEM, V262, P7034; YANG SD, 1987, J BIOL CHEM, V262, P9421; YU JS, 1994, J NEUROCHEM, V62, P1596; YU JS, 1993, J PROTEIN CHEM, V12, P667, DOI 10.1007/BF01024925	28	15	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29855	29859						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961979				2022-12-25	WOS:A1994PU28400083
J	FRITZ, TA; GABB, MM; WEI, G; ESKO, JD				FRITZ, TA; GABB, MM; WEI, G; ESKO, JD			2 N-ACETYLGLUCOSAMINYLTRANSFERASES CATALYZE THE BIOSYNTHESIS OF HEPARAN-SULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYLTRANSFERASE REACTIONS; GLUCURONOSYLTRANSFERASE; XYLOSIDE	We report that two N-acetylglucosaminyltransferases catalyze the biosynthesis of heparan sulfate in Chinese hamster ovary cells. The first enzyme initiates heparan sulfate biosynthesis and can be measured by the transfer of GlcNAc from UDP-GlcNAc to GlcUA beta 1-3Gal beta 1-O-naphthalenemethanol. The second enzyme catalyzes the polymerization of heparan sulfate and can be measured by the transfer of GlcNAc from UDP-GlcNAc to the nonreducing terminal GlcUA present in oligosaccharide fragments prepared from the Escherichia coli K5 capsular polysaccharide, N-acetylheparosan, Kinetic characterization of the initiating GlcNAc-transferase (alpha-GlcNAc-TI) indicates an apparent K-m for UDP-GlcNAc of 36 +/- 4 mu M. The apparent K-m for UDP-GlcNAc of the polymerizing GlcNAc-transferase (alpha-GlcNAc-TII) is 230 +/- 30 mu M. Both enzymes have broad pH optima and require a divalent cation for activity. alpha-GlcNAc-TI can use both Mn2+ and Ca2+, while alpha-GlcNAc-TII will use only Mn2+. Chinese hamster ovary cells deficient in the synthesis of heparan sulfate and lacking (alpha-GlcNAc-TII activity and S49 Thy 1(-)a lymphoma cells deficient in alpha-GlcNAc addition to phosphatidylinositol have wild-type (alpha-GlcNAc-TI activity. Thus, distinct alpha-GlcNAc-transferases catalyze the initiation and polymerization of heparan sulfate.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NCI NIH HHS [CA13148] Funding Source: Medline; NIGMS NIH HHS [GM33063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R37GM033063] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; DISCHE Z, 1950, J BIOL CHEM, V184, P517; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FRITZ TA, 1994, J BIOL CHEM, V269, P300; Goebel WF, 1934, J BIOL CHEM, V106, P63; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; Koenigs W, 1901, BER DTSCH CHEM GES, V34, P957, DOI 10.1002/cber.190103401162; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIND T, 1993, J BIOL CHEM, V268, P20705; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; Michaelis L, 1913, BIOCHEM Z, V49, P333; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; VANAKEN T, 1986, METHOD ENZYMOL, V125, P27; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WOLFROM ML, 1963, METHODS CARBOHYDRATE, V2, P341; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZSISKA M, 1991, CARBOHYD RES, V215, P279, DOI 10.1016/0008-6215(91)84027-C	29	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28809	28814						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961837				2022-12-25	WOS:A1994PU16800047
J	POURPLANCHE, C; LAMBERT, C; BERJOT, M; MARX, J; CHOPARD, C; ALIX, AJP; LARRETAGARDE, V				POURPLANCHE, C; LAMBERT, C; BERJOT, M; MARX, J; CHOPARD, C; ALIX, AJP; LARRETAGARDE, V			CONFORMATIONAL-CHANGES OF LIPOXYGENASE (LOX) IN MODIFIED ENVIRONMENTS - CONTRIBUTION TO THE VARIATION IN SPECIFICITY OF SOYBEAN LOX TYPE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINOLEIC-ACID; RAMAN-SPECTRA; OXYGEN-UPTAKE; PROTEINS; ENZYME; LYSOZYME; WATER; SPECTROSCOPY; HYDRATION; MICROENVIRONMENT	The addition of water-soluble cosolvents in the reaction medium of type 1 soybean lipoxygenase can modify the selectivity of the enzyme in the hydroperoxide synthesis reaction. This also results in changes in secondary reactions such as carbonyl compound formation. The possibility of a conformational change of the enzyme due to variations in its microenvironment was considered. Using enzyme immobilization and laser visible Raman spectroscopy, both indirect and direct observations of such a protein conformational rearrangement are described. Subtle modifications in the secondary and/or tertiary structures, for example in microenvironments of Tyr and Trp residues, in orientations of lateral side chains were evidenced, and their importance to enzyme specificity is discussed.	UNIV TECHNOL COMPIEGNE, TECHNOL ENZYMAT LAB, CNRS, URA 1442, F-60206 COMPIEGNE, FRANCE; UNIV REIMS, INSERM, U314, SPECT & STRUCT BIOMOLEC LAB, F-51062 REIMS, FRANCE; UNIV PARIS 05, CHIM & BIOCHIM PHARMACOL & TOXICOL LAB, CNRS, URA 400, F-75270 PARIS 06, FRANCE	Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite			larreta garde, veronique/E-9356-2013	larreta garde, veronique/0000-0003-3500-1364				AFFLECK R, 1992, P NATL ACAD SCI USA, V89, P1100, DOI 10.1073/pnas.89.3.1100; ALIX AJP, 1985, SPECTROSCOPY BIOL MO, P149; ALIX AJP, 1988, SPECTROSCOPY BIOL MO, P51; ANDERSSON E, 1987, BIOCHIM BIOPHYS ACTA, V912, P317, DOI 10.1016/0167-4838(87)90034-3; Axelrod B., 1981, METH ENZYMOL, V441, P451, DOI [10.1016/0076-6879(81)71055-3, DOI 10.1016/0076-6879(81)71055-3]; Bellamy L.J., 1975, INFRARED SPECTRA COM, P72, DOI [DOI 10.1007/978, 10.1007/978-94-011-6017-9]; BERJOT M, 1987, J RAMAN SPECTROSC, V18, P289, DOI 10.1002/jrs.1250180411; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BURKE PA, 1993, BIOTECHNOL BIOENG, V42, P87, DOI 10.1002/bit.260420112; BURKE PA, 1992, J BIOL CHEM, V267, P20057; Drapron R., 1977, Rivista Italiana delle Sostanze Grasse, V54, P218; Drapron R., 1985, PROPERTIES WATER FOO, P171, DOI DOI 10.1007/978-94-009-5103-7_11; DRAPRON R, 1968, ANN NUTR ALIMENT, V22, P393; EGMOND MR, 1976, EUR J BIOCHEM, V61, P93, DOI 10.1111/j.1432-1033.1976.tb10001.x; EGMOND MR, 1978, BIOCHIM BIOPHYS ACTA, V535, P418, DOI 10.1016/0005-2795(78)90107-1; FERSHT A, 1992, TRENDS BIOCHEM SCI, V17, P292, DOI 10.1016/0968-0004(92)90438-F; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P293; FITZPATRICK PA, 1994, BIOCHEM BIOPH RES CO, V198, P675, DOI 10.1006/bbrc.1994.1098; FITZPATRICK PA, 1993, P NATL ACAD SCI USA, V90, P8653, DOI 10.1073/pnas.90.18.8653; GALEY JB, 1988, BIOCHEMISTRY-US, V22, P1058; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GEKKO K, 1983, J BIOCHEM-TOKYO, V94, P199, DOI 10.1093/oxfordjournals.jbchem.a134330; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GEKKO K, 1983, STUD PHYS THEOR CHEM, V27, P339; GREGORY RB, 1993, BIOPOLYMERS, V33, P513, DOI 10.1002/bip.360330402; GREGORY RB, 1990, BIOPOLYMERS, V29, P1175, DOI 10.1002/bip.360290808; HARADA I, 1986, SPECTROCHIM ACTA A, V42, P307, DOI 10.1016/0584-8539(86)80193-3; HERTMANNI P, 1991, FEBS LETT, V279, P123, DOI 10.1016/0014-5793(91)80266-6; KACHALOVA GS, 1991, FEBS LETT, V284, P91, DOI 10.1016/0014-5793(91)80769-Y; KAHN PC, 1990, BIOCHEM BIOPH RES CO, V166, P1039, DOI 10.1016/0006-291X(90)90915-A; KLEIN BP, 1984, BIOCHIM BIOPHYS ACTA, V793, P72, DOI 10.1016/0005-2760(84)90054-7; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; KUHN H, 1986, BIOCHIM BIOPHYS ACTA, V876, P187, DOI 10.1016/0005-2760(86)90273-0; LARRETAGARDE V, 1988, BIOCHEM BIOPH RES CO, V155, P816, DOI 10.1016/S0006-291X(88)80568-0; LEGOY MD, 1980, BIOCHIMIE, V62, P341, DOI 10.1016/S0300-9084(80)80163-5; MIKAWA T, 1979, NATURE, V278, P473, DOI 10.1038/278473a0; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; MIURA T, 1988, BIOCHEMISTRY-US, V27, P88, DOI 10.1021/bi00401a015; NAVARATNAM S, 1988, BIOCHIM BIOPHYS ACTA, V956, P70, DOI 10.1016/0167-4838(88)90299-3; PARKER FS, 1983, APPLICATIONS INFRARE; POOLE PL, 1994, J FOOD ENG, V22, P349, DOI 10.1016/0260-8774(94)90039-6; POURPLANCHE C, 1991, ANAL BIOCHEM, V198, P160, DOI 10.1016/0003-2697(91)90522-U; POURPLANCHE C, 1992, PROGR BIOTECHNOL, V8, P275; REGDEL D, 1985, BIOMED BIOCHIM ACTA, V44, P1411; RUPLEY JA, 1983, TRENDS BIOCHEM SCI, V8, P18, DOI 10.1016/0968-0004(83)90063-4; SHIBATA D, 1987, J BIOL CHEM, V262, P10080; SIAMWIZA MN, 1975, BIOCHEMISTRY-US, V14, P4870, DOI 10.1021/bi00693a014; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SPAAPEN LJM, 1979, BIOCHIM BIOPHYS ACTA, V574, P301, DOI 10.1016/0005-2760(79)90011-0; START WG, 1986, PLANT MOL BIOL, V7, P11, DOI 10.1007/BF00020127; STECZKO J, 1992, BIOCHEMISTRY-US, V31, P4053, DOI 10.1021/bi00131a022; Tu A.T., 1982, RAMAN SPECTROSCOPY B; VERHAGEN J, 1979, ADV BIOCH PHYSL PLAN, P231; WESCOTT CR, 1994, BBA-PROTEIN STRUCT M, V1206, P1, DOI 10.1016/0167-4838(94)90065-5; XU ZF, 1989, BIOCHIM BIOPHYS ACTA, V998, P251, DOI 10.1016/0167-4838(89)90281-1; XU ZF, 1990, ANN NY ACAD SCI, V613, P506, DOI 10.1111/j.1749-6632.1990.tb18209.x; YU NT, 1974, PEPTIDES POLYPEPTIDE, P370; YU NT, 1973, BIOPOLYMERS, V12, P2161	59	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31585	31591						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989328				2022-12-25	WOS:A1994PX30300041
J	YAMAMOTO, Y; MIZUNO, R; NISHIMURA, T; OGAWA, Y; YOSHIKAWA, H; FUJIMURA, H; ADACHI, E; KISHIMOTO, T; YANAGIHARA, T; SAKODA, S				YAMAMOTO, Y; MIZUNO, R; NISHIMURA, T; OGAWA, Y; YOSHIKAWA, H; FUJIMURA, H; ADACHI, E; KISHIMOTO, T; YANAGIHARA, T; SAKODA, S			CLONING AND EXPRESSION OF MYELIN-ASSOCIATED OLIGODENDROCYTIC BASIC-PROTEIN - A NOVEL BASIC-PROTEIN CONSTITUTING THE CENTRAL-NERVOUS-SYSTEM MYELIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; EUKARYOTIC RIBOSOMES; SEQUENCES; GENES; GLYCOPROTEIN; BRAIN	We have screened genes predominantly expressed in the rat spinal cord, and we report here cloning of the most abundant unknown gene. It is a novel member of the central nervous system (CNS) myelin constituting proteins, myelin-associated oligodendrocytic basic protein (MOBP), MOBP is abundantly expressed specifically in oligodendrocytes at the mRNA level only next to myelin basic protein (MBP) and proteolipid protein. Two isoforms have been confirmed. One of them has proline-rich tandem repeats and has 84% homology with human counterpart in terms of predicted amino acid sequences. The cDNA-derived primary structure predicts a small, soluble, basic protein The immunoelectron tron microscopy has shown that MOBP is expressed throughout compact myelin. All these characteristics are similar to MBP. One definite difference between MBP and MOBP is that MOBP is expressed exclusively in the CNS myelin. These findings suggest that MOBP shares some important functions with MBP in the CNS myelin such as myelin compaction.	OSAKA UNIV, SCH MED, DEPT NEUROL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT ANAT 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MED 3, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University; Osaka University			Kishimoto, Tadamitsu/C-8470-2009					BROPHY PJ, 1993, TRENDS NEUROSCI, V16, P515, DOI 10.1016/0166-2236(93)90196-S; CAMPAGNONI AT, 1988, J NEUROCHEM, V51, P1, DOI 10.1111/j.1471-4159.1988.tb04827.x; CAPAGNONI AT, 1987, J NEUROSCI RES, V17, P102, DOI 10.1002/jnr.490170203; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DEMEL RA, 1973, BIOCHIM BIOPHYS ACTA, V311, P507, DOI 10.1016/0005-2736(73)90126-0; FANG H, 1993, DEV BIOL, V156, P201, DOI 10.1006/dbio.1993.1070; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; JACKSON DG, 1993, J BIOL CHEM, V268, P1894; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMKE G, 1988, NEURON, V1, P535, DOI 10.1016/0896-6273(88)90103-1; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MILNER RJ, 1985, CELL, V42, P931, DOI 10.1016/0092-8674(85)90289-2; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; ROACH A, 1983, CELL, V34, P799, DOI 10.1016/0092-8674(83)90536-6; SABATH DE, 1990, J BIOL CHEM, V265, P12671; Sambrook J, 1989, MOL CLONING LABORATO; SANKARAM MB, 1989, BIOCHEMISTRY-US, V28, P9692, DOI 10.1021/bi00451a023; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; VOGEL US, 1988, J NEUROCHEM, V50, P1667, DOI 10.1111/j.1471-4159.1988.tb02461.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	24	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31725	31730						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989345				2022-12-25	WOS:A1994PX30300063
J	YAO, M; KOW, YW				YAO, M; KOW, YW			STRAND-SPECIFIC CLEAVAGE OF MISMATCH-CONTAINING DNA BY DEOXYINOSINE 3'-ENDONUCLEASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXTRACTS; GENE-PRODUCT; REPAIR; RECOMBINATION; ENDONUCLEASE; HYPOXANTHINE; GLYCOSYLASE; SEQUENCE; INVITRO; SYSTEM	A deoxyinosine-specific endonuclease, deoxyinosine 3'-endonuclease (Yao, M., Hatahet, Z., Melamede, R. J., and Bow, Y. W. (1994) J. Biol. Chem. 269, 16260-16268), from Escherichia coli was found to recognize mismatches in DNA. Using DNA duplexes containing a unique mismatch, the enzyme was found to hydrolyze the second phosphodiester bond 3' to the mismatch, The cleavage efficiency of deoxyinosine S' endonuclease on mismatch-containing DNA was affected by the nature of the mismatches, The cleavage activity was also affected by the sequence context surrounding the mismatches, The presence of a G/C or C/G pair immediately 3' or 5' to the mismatch substantially reduced the ability of the enzyme to nick the mismatch-containing DNA. The presence of two G/C pairs, one 5' and the other 3' to the mismatch, abolishes the ability of the enzyme to recognize the mismatch, Interestingly, deoxyinosine 3'-endonuclease showed strong strand specificity on DNA containing mismatches, and only one strand of the mismatch-containing DNA was nicked by the enzyme, This strand specificity of mismatch cleveage was not affected by the nature of the mismatch, Preliminary data suggest that the strand specificity is terminus de pendent; the enzyme cleaves the strand with the mismatch closer to its 5' terminus, However, when DNA duplexes containing deoxyinosine were used as substrates, deoxyinosine 3'-endonuclease cleaved exclusively the strand containing deoxyinosine. Deoxyinosine 3'-endonuclease also cleaved single-stranded DNA containing deoxyinosine, but not DNA containing normal deoxynucleotides or deoxynebularine, suggesting the enzyme uses different mechanisms of recognition for deoxyinosine and mismatches in DNA.	UNIV VERMONT,MARKEY CTR MOLEC GENET,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405	University of Vermont					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; CHANG DY, 1991, NUCLEIC ACIDS RES, V19, P4761, DOI 10.1093/nar/19.17.4761; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; HAROSH I, 1988, J BIOL CHEM, V263, P3328; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; JONES M, 1987, J MOL BIOL, V194, P155, DOI 10.1016/0022-2836(87)90724-8; JONES M, 1987, CELL, V50, P621, DOI 10.1016/0092-8674(87)90035-3; KARRAN P, 1978, J BIOL CHEM, V253, P5877; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LANGLEROUAULT F, 1987, EMBO J, V6, P1121, DOI 10.1002/j.1460-2075.1987.tb04867.x; LIEB M, 1985, MOL GEN GENET, V199, P465; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LU AL, 1988, GENETICS, V118, P593; MESELSON M, 1988, RECOMBINATION GENETI, P91; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1989, J BIOL CHEM, V264, P6597; RADMAN M, 1986, ANNU REV GENET, V20, P523, DOI 10.1146/annurev.ge.20.120186.002515; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; YAO M, 1994, J BIOL CHEM, V269, P16260; YEH YC, 1991, J BIOL CHEM, V266, P6480; YEH YC, 1994, J BIOL CHEM, V269, P15498	27	57	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31390	31396						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989304				2022-12-25	WOS:A1994PX30300013
J	IMAMURA, T; TAKATA, Y; SASAOKA, T; TAKADA, Y; MORIOKA, H; HARUTA, T; SAWA, T; IWANISHI, M; HU, YG; SUZUKI, Y; HAMADA, J; KOBAYASHI, M				IMAMURA, T; TAKATA, Y; SASAOKA, T; TAKADA, Y; MORIOKA, H; HARUTA, T; SAWA, T; IWANISHI, M; HU, YG; SUZUKI, Y; HAMADA, J; KOBAYASHI, M			2 NATURALLY-OCCURRING MUTATIONS IN THE KINASE DOMAIN OF INSULIN-RECEPTOR ACCELERATE DEGRADATION OF THE INSULIN-RECEPTOR AND IMPAIR THE KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; GROWTH FACTOR-I; TYROSINE KINASE; POINT MUTATION; TRANSFECTED CELLS; PROTEIN-KINASE; ALPHA-SUBUNIT; CLEAVAGE SITE; CONSERVED FEATURES; PROLINE MUTATION	We identified two novel heterozygous missense mutations of the insulin receptor gene: the Asp(1179) mutation in one family and the Leu(1193) mutation in two unrelated families with extreme insulin resistance. In these patients, the number of insulin receptors on the cell surface was found to be markedly decreased by insulin binding and surface labeling studies in transformed lymphocytes. Insulin binding to the transfected COS 7 cells and Rat-1 cells with both mutant cDNAs was also decreased to 5-31% of normal, and the mutant insulin receptors showed a markedly decreased kinase activity. Although biosynthetic labeling studies revealed that both mutant receptors were synthesized as 190-kDa proreceptors, the degradation of the mutant proreceptors was 2-fold faster than that of the wild type proreceptors. However, the degradation rate of the mutant receptors on the cell surface was comparable to that of wild type insulin receptor. These results suggest that the Asp(1179) and Leu(1193) mutations in the kinase domain are unique in causing decreased insulin receptor number on the cell surface by accelerated intracellular degradation, and that insulin resistance in these patients is mainly due to the decreased receptor number rather than impaired kinase activity.	TOYAMA MED & PHARMACEUT UNIV, DEPT MED 1, SUGITANI, TOYAMA 93001, JAPAN; TOYOHASHI CITY HOSP, DEPT PEDIAT, TOYOHASHI, AICHI 440, JAPAN; NAGOYA KITAIRYOU SEIKYO HOSP, DEPT MED, NAGOYA, AICHI 462, JAPAN	University of Toyama								ACCILI D, 1992, J BIOL CHEM, V267, P586; ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; CAMA A, 1992, J BIOL CHEM, V267, P8383; CAMA A, 1993, J BIOL CHEM, V268, P8060; CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; CHIN JE, 1991, J BIOL CHEM, V266, P15587; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; GRONSKOV K, 1993, BIOCHEM BIOPH RES CO, V192, P905, DOI 10.1006/bbrc.1993.1501; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARUTA T, 1993, DIABETES, V42, P1837, DOI 10.2337/diabetes.42.12.1837; IWANISHI M, 1993, DIABETOLOGIA, V36, P414, DOI 10.1007/BF00402277; IWANISHI M, 1993, BIOCHEM BIOPH RES CO, V197, P353, DOI 10.1006/bbrc.1993.2486; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1990, J CLIN INVEST, V86, P254, DOI 10.1172/JCI114693; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KADOWAKI T, 1991, J BIOL CHEM, V266, P21224; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KLINKHAMER MP, 1989, EMBO J, V8, P2503, DOI 10.1002/j.1460-2075.1989.tb08387.x; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOBAYASHI M, 1988, BIOCHEM BIOPH RES CO, V153, P657, DOI 10.1016/S0006-291X(88)81145-8; KOBAYASHI M, 1990, BIOCHEM BIOPH RES CO, V167, P1073, DOI 10.1016/0006-291X(90)90632-W; KOBAYASHI M, 1988, DIABETES, V37, P653, DOI 10.2337/diabetes.37.5.653; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUSUKAWA N, 1990, BIOTECHNIQUES, V9, P66; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; LONGO N, 1993, P NATL ACAD SCI USA, V90, P60, DOI 10.1073/pnas.90.1.60; MAASSEN JA, 1991, BIOCHEMISTRY-US, V30, P10778, DOI 10.1021/bi00108a024; MOLLER DE, 1988, NEW ENGL J MED, V319, P1526, DOI 10.1056/NEJM198812083192306; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1990, MOL ENDOCRINOL, V4, P1183, DOI 10.1210/mend-4-8-1183; NAKANISHI O, 1985, GENE, V35, P289; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; SASAOKA T, 1988, DIABETES, V37, P1515, DOI 10.2337/diabetes.37.11.1515; SASAOKA T, 1989, DIABETOLOGIA, V32, P371, DOI 10.1007/BF00277261; SEINO S, 1990, DIABETES, V39, P123, DOI 10.2337/diabetes.39.1.123; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; SUGIBAYASHI M, 1992, METABOLISM, V41, P820, DOI 10.1016/0026-0495(92)90161-3; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1994, DIABETES METAB, V20, P31; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; TAKATA Y, 1986, METABOLISM, V35, P950, DOI 10.1016/0026-0495(86)90060-0; TAOUIS M, 1994, J BIOL CHEM, V269, P14912; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERVORM ER, 1992, J BIOL CHEM, V267, P66; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938	52	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31019	31027						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983039				2022-12-25	WOS:A1994PV51000046
J	BARKER, PA; BARBEE, G; MISKO, TP; SHOOTER, EM				BARKER, PA; BARBEE, G; MISKO, TP; SHOOTER, EM			THE LOW-AFFINITY NEUROTROPHIN RECEPTOR, P75(LNTR), IS PALMITOYLATED BY THIOESTER FORMATION THROUGH CYSTEINE-279	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MOLECULAR-CLONING; NGF RECEPTOR; GENE-TRANSFER; DEVELOPMENTAL EXPRESSION; SIGNAL-TRANSDUCTION; MEMBRANE ATTACHMENT; TYROSINE KINASE; PROTEIN; SYSTEM	The low affinity neurotrophin receptor, termed p75(LNTR), plays a role in increasing the amount of nerve growth factor that becomes bound to the tyrosine kinase receptor, trkA (Barker, P. A., and Shooter, E. M. (1994) Neuron 13:203-215), possibly by increasing the nerve growth factor concentration in the microenvironment surrounding the trkA receptor. Because protein acylation may be a means by which cell surface receptor distribution may be regulated, we have determined the acylation status of p75(LNTR). We find that p75(LNTR) expressed in PC12, PCNA, or transfected COS cells is metabolically labeled with [H-3]palmitic acid. This modification occurs post-translationally and the incorporated fatty acid is removed by hydroxylamine treatment at pH 7 or 11 and by sulfhydryl reducing agents, suggesting a thioester linkage to palmitic acid. Consistent with this, p75(LNTR) in which the juxtamembrane cysteine present at position 279 is substituted with alanine is expressed but cannot be metabolically labeled with [H-3]palmitic acid. Substitution of other cysteine residues present in the transmembrane or intracellular domain of the receptor has no effect on protein acylation, suggesting that only Cys(279) is esterified to palmitate.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University				Misko, Thomas/0000-0001-7917-422X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER; NINDS NIH HHS [NS04270] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALVEREZ E, 1990, J BIOL CHEM, V265, P16644; BARBACID M, 1993, ONCOGENE, V8, P2033; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BATTLEMAN DS, 1993, J NEUROSCI, V13, P941; BAZAN JF, 1993, CURR BIOL, V3, P603, DOI 10.1016/0960-9822(93)90009-D; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BONATTI S, 1989, J BIOL CHEM, V264, P12590; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GRASSIE MA, 1993, BIOCH SOC T S, V21, P499; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALLBOOK F, 1991, NEURON, V6, P848; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE KF, 1994, DEVELOPMENT, V120, P1027; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROSS AH, 1993, SOC NEUR ABSTR; ROVELLI G, 1993, P NATL ACAD SCI USA, V90, P8717, DOI 10.1073/pnas.90.18.8717; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; SCULLION BF, 1987, J CELL BIOL, V105, P69, DOI 10.1083/jcb.105.1.69; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WESKAMP G, 1991, NEURON, V6, P1; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978	60	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30645	30650						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982984				2022-12-25	WOS:A1994PU52500092
J	ELDER, PA; BELL, SM; KNOWLES, MA				ELDER, PA; BELL, SM; KNOWLES, MA			DELETION OF 2 REGIONS ON CHROMOSOME-4 IN BLADDER-CARCINOMA - DEFINITION OF A CRITICAL 750-KB REGION AT 4P16.3	ONCOGENE			English	Article							HUNTINGTON DISEASE REGION; HEPATOCELLULAR-CARCINOMA; INDEFINITE DIVISION; GENETIC-ANALYSIS; HUMAN-CELLS; HETEROZYGOSITY; CANCER; ALLELOTYPE	Loss of heterozygosity (LOH) of chromosome 4 has been identified in several human tumours including carcinomas of colorectum, ovary, liver and head and neck. LOH at loci on chromosome 4p has previously been identified in 22% of primary bladder tumours. We have assessed LOH in 178 bladder tumours using a panel of six microsatellite markers. Thirty-four tumours (19%) showed LOH at one or more loci. Twenty-three deletions involved restricted regions of 4p and could be used to define two common regions of deletion. A very small common region between D4S43 and D4S127 (estimated to be similar to 750 kB) was involved in 14/23 (61%) of 4p deletions. A second common region centromeric to D4S174 was deleted in 7/23 (30%) of tumours with deletions. Two tumours (9%) had deletions involving both regions independently. Previous functional studies have demonstrated both a senescence function and a suppressor of tumorigenicity on human chromosome 4. Localisation of the common regions of deletion in bladder tumours provides a starting point for positional cloning of the gene(s) concerned and for more precise comparative functional studies.	MARIE CURIE RES INST,GENET MOLEC LAB,OXTED RH8 0TL,SURREY,ENGLAND					Knowles, Margaret/0000-0002-9363-8657; Bell, Sandra/0000-0002-3022-9864				BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CAIRNS P, 1991, ONCOGENE, V6, P2305; CAIRNS P, 1993, CANCER RES, V53, P1230; FUJIMOTO Y, 1994, CANCER RES, V54, P281; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; KIRKNESS EF, 1991, GENOMICS, V10, P985, DOI 10.1016/0888-7543(91)90189-L; KLINGER HP, 1983, JNCI-J NATL CANCER I, V71, P559; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LOCKE PA, 1993, SOMAT CELL MOLEC GEN, V19, P95, DOI 10.1007/BF01233958; NAWROZ H, 1994, CANCER RES, V54, P1152; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OLUMI AF, 1990, CANCER RES, V50, P7081; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Pershouse M. A., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P539; PROCTOR AJ, 1991, ONCOGENE, V6, P789; SATO T, 1991, CANCER RES, V51, P5118; TSAI YC, 1990, CANCER RES, V50, P44; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WALKER GJ, 1991, CANCER RES, V51, P4367; ZUO J, 1992, HUM MOL GENET, V1, P149, DOI 10.1093/hmg/1.3.149; ZUO JA, 1993, HUM MOL GENET, V2, P889, DOI 10.1093/hmg/2.7.889; 1978, TNM CLASSIFICATION M, P113; 1973, WHO INT CLASSIFICATI, V10	24	42	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3433	3436						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970702				2022-12-25	WOS:A1994PT39200004
J	RIMESSI, P; GUALANDI, F; MORELLI, C; TRABANELLI, C; WU, Q; POSSATI, L; MONTESI, M; BARRETT, JC; BARBANTIBRODANO, G				RIMESSI, P; GUALANDI, F; MORELLI, C; TRABANELLI, C; WU, Q; POSSATI, L; MONTESI, M; BARRETT, JC; BARBANTIBRODANO, G			TRANSFER OF HUMAN-CHROMOSOME-3 TO AN OVARIAN-CARCINOMA CELL-LINE IDENTIFIES 3 REGIONS ON 3P INVOLVED IN OVARIAN-CANCER	ONCOGENE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; YEAST ARTIFICIAL CHROMOSOME; TUMOR-SUPPRESSOR GENE; FREQUENT LOSS; LUNG-CANCER; SHORT ARM; BREAST-CANCER; GROWTH-FACTOR; LOW-GRADE; HETEROZYGOSITY	The molecular pathogenesis of ovarian carcinoma involves altered expression of growth factors, activation of oncogenes and loss of tumor suppressor genes. Loss of heterozygosity on chromosomes 3p, 6q, 11p, 17 and 18q was reported as a significant alteration in ovarian cancer. However, no functional proof has been provided of tumor suppressor activity located in these chromosomal regions. We therefore introduced normal human chromosomes 3 and 11 into an ovarian carcinoma cell line by microcell mediated chromosome transfer. Transfer of chromosome 3 induced senescence acid growth arrest as well as suppression of tumorigenicity. Tumors induced by chromosome 3 monochromosomic hybrids consistently lost three small regions on 3p, two of which located in 3p23-24.2 and one located in 3p21.1-21.2, suggesting that these chromosomal regions are important for suppression of tumorigenicity of ovarian carcinoma cells. Transfer of chromosome 11 reduced the in vitro growth properties of ovarian cancer cells but did not significantly affect tumorigenicity. These results provide functional evidence for chromosome 3 tumor suppressor activity in ovarian cancer and define the chromosomal regions on 3p involved in the pathogenesis of this tumor. This experimental system, based on functional effects, may be useful for further delimitation and isolation of critical regions on 3p involved in tumor suppression.	UNIV FERRARA, SCH MED, INST MICROBIOL, I-44100 FERRARA, ITALY; UNIV FERRARA, SCH MED, INTERDEPT CTR BIOTECHNOL, I-44100 FERRARA, ITALY; UNIV ANCONA, INST BIOMED SCI, I-60131 ANCONA, ITALY; NIEHS, MOLEC CARCINOGENESIS LAB, RES TRIANGLE PK, NC 27709 USA	University of Ferrara; University of Ferrara; Marche Polytechnic University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Gualandi, Francesca/K-7513-2016	Gualandi, Francesca/0000-0001-9551-057X; Trabanelli, Cecilia/0000-0001-7107-0338				BARRETT JC, 1994, APOPTOSIS, V2, P253; BASSAM BJ, 1993, APPL BIOCHEM BIOTECH, V42, P181, DOI 10.1007/BF02788051; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; BAST RC, 1992, J NATL CANCER I, V84, P556, DOI 10.1093/jnci/84.8.556; BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P669, DOI 10.1016/S0002-9378(11)80044-X; BERCHUCK A, 1990, CANCER RES, V50, P4087; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUICK RN, 1985, CANCER RES, V45, P3668; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; DALY MC, 1993, ONCOGENE, V8, P1721; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DODSON MK, 1993, CANCER RES, V53, P4456; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; ELICEIRI B, 1991, P NATL ACAD SCI USA, V88, P2179, DOI 10.1073/pnas.88.6.2179; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HIBI K, 1992, ONCOGENE, V7, P445; JACOBS IJ, 1993, CANCER RES, V53, P1218; JAKOBOVITS A, 1993, NATURE, V362, P255, DOI 10.1038/362255a0; JENKINS RB, 1993, CANCER GENET CYTOGEN, V71, P76, DOI 10.1016/0165-4608(93)90205-Z; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KIECHLESCHWARZ M, 1993, CANCER, V72, P2423, DOI 10.1002/1097-0142(19931015)72:8<2423::AID-CNCR2820720821>3.0.CO;2-P; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOHLER MF, 1993, J NATL CANCER I, V85, P1513, DOI 10.1093/jnci/85.18.1513; KOHNO T, 1993, ONCOGENE, V8, P1825; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE JH, 1990, CANCER RES, V50, P2724; LEE JH, 1989, CANCER RES, V49, P1220; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; LYNCH HT, 1978, CANCER-AM CANCER SOC, V41, P1543, DOI 10.1002/1097-0142(197804)41:4<1543::AID-CNCR2820410444>3.0.CO;2-Y; LYNCH HT, 1991, CANCER GENET CYTOGEN, V53, P143, DOI 10.1016/0165-4608(91)90093-A; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; ROCHE J, 1994, HUM MOL GENET, V3, P215, DOI 10.1093/hmg/3.1.215; ROQUE L, 1993, GENE CHROMOSOME CANC, V8, P199, DOI 10.1002/gcc.2870080311; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; SATO T, 1991, CANCER RES, V51, P5794; SATO T, 1991, CANCER RES, V51, P5118; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; Saxon P J, 1987, Methods Enzymol, V151, P313, DOI 10.1016/S0076-6879(87)51026-6; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHIMIZU M, 1990, ONCOGENE, V5, P185; SIMARD J, 1993, HUM MOL GENET, V2, P1193, DOI 10.1093/hmg/2.8.1193; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STRAUSS WM, 1993, SCIENCE, V259, P1904, DOI 10.1126/science.8096090; STROMBERG K, 1992, CANCER RES, V52, P341; TANAKA K, 1992, CANCER GENET CYTOGEN, V61, P42, DOI 10.1016/0165-4608(92)90368-I; TAVASSOLI M, 1993, GENE CHROMOSOME CANC, V8, P195, DOI 10.1002/gcc.2870080310; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOSHIDA MA, 1994, MOL CARCINOGEN, V9, P114, DOI 10.1002/mc.2940090303; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZHENG JP, 1991, CANCER RES, V51, P4045	65	69	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3467	3474						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970706				2022-12-25	WOS:A1994PT39200008
J	BAROUCH, W; PRASAD, K; GREENE, LE; EISENBERG, E				BAROUCH, W; PRASAD, K; GREENE, LE; EISENBERG, E			ATPASE ACTIVITY ASSOCIATED WITH THE UNCOATING OF CLATHRIN BASKETS BY HSP70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; COATED VESICLES; BOVINE BRAIN; ASSEMBLY PROTEIN; STRESS PROTEINS; DISSOCIATION; BINDING; TRANSLOCATION; POLYPEPTIDES; HYDROLYSIS	In the presence of ATP, bovine brain hsp70 has been shown to remove clathrin from bovine brain clathrin-coated vesicles in a rapid stoichiometric initial burst followed by slow steady-state uncoating. In addition, it has been found recently that a 100-kDa cofactor is required for hsp70 to uncoat clathrin baskets prepared with the assembly protein AP-2. In this study the ATPase activity associated with uncoating was investigated, with baskets formed from clathrin and assembly proteins. Mixed assembly proteins or assembly protein AP-2 could not be used in ATPase studies because they activated the hsp70 ATPase activity even in the absence of clathrin. However, this was not the case with assembly protein AP(180). A stoichiometric initial burst of ATP hydrolysis was found to accompany the initial burst of uncoating of AP(180)-clathrin baskets by hsp70, with 1 mol of hydrolyzed ATP/mol of released clathrin heavy chain. Furthermore, the presence of a 100-kDa cofactor was needed for both processes. These results suggest that an initial burst of uncoating occurs with all clathrin baskets, that an initial burst of ATP hydrolysis accompanies this initial burst of uncoating, and that a 100-kDa cofactor is required for both.	NHLBI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; BAROUCH W, 1994, FASEB J, V8, pA1312; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHOCK SP, 1979, J BIOL CHEM, V254, P3229; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CYR DM, 1992, J BIOL CHEM, V267, P20927; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GAO BC, 1993, J BIOL CHEM, V268, P8507; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREENE LE, 1990, J BIOL CHEM, V265, P6682; GREENE LE, 1994, IN PRESS J BIOL CHEM; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; LINDNER R, 1992, J BIOL CHEM, V267, P16567; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PATZER EJ, 1982, J CELL BIOL, V93, P230, DOI 10.1083/jcb.93.1.230; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; PRASAD K, 1993, J BIOL CHEM, V268, P23758; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; PRASAD K, 1994, J BIOL CHEM, V269, P6931; Prasad K., 1993, Molecular Biology of the Cell, V4, p214A; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P44; SCHORUDER H, 1993, EMBO J, V12, P4137; SCHRODER S, 1991, J BIOL CHEM, V266, P7910	36	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28563	28568						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961802				2022-12-25	WOS:A1994PU16800011
J	DEFLORIN, J; RUDOLF, M; SEEBECK, T				DEFLORIN, J; RUDOLF, M; SEEBECK, T			THE MAJOR COMPONENTS OF THE PARAFLAGELLAR ROD OF TRYPANOSOMA-BRUCEI ARE 2 SIMILAR, BUT DISTINCT PROTEINS WHICH ARE ENCODED BY 2 DIFFERENT GENE LOCI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA	The flagellum of trypanosomatids contains two major structural elements, the microtubular axoneme, which is the mechanochemical motor of the cell, and the paraflagellar rod (PFR), a highly organized, three-dimensional fiber network of unknown function. Its occurrence is limited to a few groups of unicellular eukaryotes, the Euglenoids, Dinoflagellates, and Kinetoplastids. The PFR of trypanosomes consists of two similar proteins of approximate molecular masses of 69 and 73 kDa. This lab oratory and others have earlier characterized the genes coding for the 69-kDa PFR species in trypanosoma brucei and Trypanosoma cruzi. The present study reports the characterization of the genes coding for the 73-kDa PFR protein from T. brucei. Their gene product, PFR-C, is closely related to, but clearly distinct from, the 69 kDa species PFR-A. This finding indicates that the PFR fibers of the flagellum might represent heteropolymers formed by PFR-A and PFR-C, akin to the situation seen in microtubules or intermediate filaments. PFR A and PFR-C are each coded for by a similarly organized cluster of four closely spaced, tandemly arranged genes. The 5'-untranslated region of the first gene in each cluster is different from those of the following three genes, which are identical among each other. Conversely, the 3'-untranslated regions of the first three genes of each cluster are identical, while the corresponding region of the fourth gene is different. This unusual organization leads to the generation of mRNAs which contain identical coding sequences but different 5'- and 3'-noncoding regions.	UNIV BERN, INST GEN MICROBIOL, CH-3012 BERN, SWITZERLAND	University of Bern								BEARD CA, 1992, J BIOL CHEM, V267, P21656; BRUN R, 1979, ACTA TROP, V36, P289; CACHON J, 1988, BIOL CELL, V63, P169, DOI 10.1016/0248-4900(88)90056-1; FRIDOVICHKEIL JL, 1987, MOL CELL BIOL, V7, P3792, DOI 10.1128/MCB.7.10.3792; GALLO JM, 1985, EUR J CELL BIOL, V36, P163; GODART H, 1992, CELL MOTIL CYTOSKEL, V23, P310; HARDING JD, 1978, J BIOL CHEM, V253, P7531; HEMPHILL A, 1991, J PARASITOL, V77, P603, DOI 10.2307/3283167; HYAMS JS, 1982, J CELL SCI, V55, P199; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; RUDOLPH JE, 1987, MOL CELL BIOL, V7, P2231, DOI 10.1128/MCB.7.6.2231; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLAEPPI K, 1989, J CELL BIOL, V109, P1695, DOI 10.1083/jcb.109.4.1695; SCHNEIDER A, 1988, J CELL SCI, V90, P307; SCHURCH N, 1994, MOL CELL BIOL, V14, P3668, DOI 10.1128/MCB.14.6.3668; SEEBECK T, 1983, P NATL ACAD SCI-BIOL, V80, P4634, DOI 10.1073/pnas.80.15.4634; SMITH GE, 1980, ANAL BIOCHEM, V109, P123, DOI 10.1016/0003-2697(80)90019-6; VASSELLA E, 1994, NUCLEIC ACIDS RES, V22, P1359, DOI 10.1093/nar/22.8.1359	19	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28745	28751						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961827				2022-12-25	WOS:A1994PU16800037
J	SONAR, S; MARTI, T; RATH, P; FISCHER, W; COLEMAN, M; NILSSON, A; KHORANA, HG; ROTHSCHILD, KJ				SONAR, S; MARTI, T; RATH, P; FISCHER, W; COLEMAN, M; NILSSON, A; KHORANA, HG; ROTHSCHILD, KJ			A REDIRECTED PROTON PATHWAY IN THE BACTERIORHODOPSIN MUTANT TYR-57-]ASP EVIDENCE FOR PROTON TRANSLOCATION WITHOUT SCHIFF-BASE DEPROTONATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; DARK-ADAPTED BACTERIORHODOPSIN; TRANS-RETINAL CHROMOPHORE; VIBRATIONAL SPECTROSCOPY; PURPLE MEMBRANE; HALOBACTERIUM-HALOBIUM; N-INTERMEDIATE; ABSORPTION-SPECTROSCOPY; L550 INTERMEDIATE; INFRARED EVIDENCE	Light-driven proton pumping in bacteriorhodopsin involves deprotonation of the retinylidene Schiff base during M formation and reprotonation during N formation as key steps. This study reports on the spectroscopic characterization of the bacteriorhodopsin mutant Tyr-57 --> Asp (Y57D). The results reveal that although formation of the M intermediate and Schiff base deprotonation is blocked, the mutant still exhibits a significant level of light driven proton translocation. The photocycle of Y57D involves formation of K and L intermediates accompanied by the normal chromophore isomerization and changes in the hydrogen bonding of Asp-96 and Asp-115. However, an additional Asp residue deprotonates during formation of the L intermediate along with a transmembrane alpha-helical structural change that normally occurs upon N formation. We postulate that proton transport in Y57D occurs through a redirected pathway that does not involve the deprotonation of the Schiff base. Chromophore isomerization, which normally results in the transfer of a proton from the Schiff base to Asp-85, instead causes the deprotonation of Asp-57 in Y57D, most likely through an interaction involving Asp-212. This deprotonation of Asp-57 causes the release of a proton into the extracellular medium. Reprotonation of Asp-57 occurs through the Schiff base reprotonation pathway, which consists of a hydrogen-bonded network of residues spanning from Asp-96 to Asp-212. The results also indicate that the transmembrane a helical structural changes observed during N formation (Rothschild, K. J., Marti, T., Sonar, S., He, Y. W., Rath, P., Fischer, W., Bousche, O., and Khorana, H. G. (1993) J. Biol. Chem. 268, 27046-27052) do not require deprotonation of Asp-96 or of the Schiff base.	BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215; BOSTON UNIV,MOLEC BIOPHYS LAB,BOSTON,MA 02215; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Boston University; Boston University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			; Rothschild, Kenneth/P-6177-2018	Fischer, Wolfgang/0000-0001-7753-1828; Coleman, Matthew/0000-0003-1389-4018; Rothschild, Kenneth/0000-0002-2847-6671	NIAID NIH HHS [AI11479] Funding Source: Medline; NIGMS NIH HHS [GM28289] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028289, R37GM028289] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES JB, 1989, BIOCHEMISTRY-US, V28, P3681, DOI 10.1021/bi00435a009; AMES JB, 1990, BIOCHEMISTRY-US, V29, P7181, DOI 10.1021/bi00483a005; ARGADE PV, 1983, BIOCHEMISTRY-US, V22, P3460, DOI 10.1021/bi00283a024; ATON B, 1977, BIOCHEMISTRY-US, V16, P2995, DOI 10.1021/bi00632a029; BALASHOV SP, 1990, FEBS LETT, V271, P93, DOI 10.1016/0014-5793(90)80380-2; BALASHOV SP, 1991, BIOPHYS J, V60, P475, DOI 10.1016/S0006-3495(91)82074-4; BOGOMOLNI RA, 1984, P NATL ACAD SCI-BIOL, V81, P5408, DOI 10.1073/pnas.81.17.5408; BOUSCHE O, 1992, PHOTOCHEM PHOTOBIOL, V56, P1085, DOI 10.1111/j.1751-1097.1992.tb09732.x; BOUSCHE O, 1991, J BIOL CHEM, V266, P11063; BRAIMAN M, 1982, P NATL ACAD SCI-BIOL, V79, P403, DOI 10.1073/pnas.79.2.403; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1991, P NATL ACAD SCI USA, V88, P2388, DOI 10.1073/pnas.88.6.2388; CAO Y, 1993, BIOCHEMISTRY-US, V32, P1981, DOI 10.1021/bi00059a015; DOIG SJ, 1991, J PHYS CHEM-US, V95, P6372, DOI 10.1021/j100169a054; DUNACH M, 1990, J BIOL CHEM, V265, P16978; FISCHER U, 1979, BIOPHYS J, V28, P211, DOI 10.1016/S0006-3495(79)85172-3; FISCHER W, 1994, IN PRESS BIOCHEMISTR; FODOR SPA, 1988, P NATL ACAD SCI USA, V85, P2156, DOI 10.1073/pnas.85.7.2156; FODOR SPA, 1988, BIOCHEMISTRY-US, V27, P7097, DOI 10.1021/bi00418a064; HACKETT NR, 1987, J BIOL CHEM, V262, P9277; HARBISON GS, 1984, P NATL ACAD SCI-BIOL, V81, P1706, DOI 10.1073/pnas.81.6.1706; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KIMURA Y, 1984, PHOTOCHEM PHOTOBIOL, V40, P641, DOI 10.1111/j.1751-1097.1984.tb05353.x; KOUYAMA T, 1988, BIOCHEMISTRY-US, V27, P5855, DOI 10.1021/bi00416a006; KREBS MP, 1991, P NATL ACAD SCI USA, V88, P859, DOI 10.1073/pnas.88.3.859; KREBS MP, 1993, P NATL ACAD SCI USA, V90, P1987, DOI 10.1073/pnas.90.5.1987; LEWIS A, 1974, P NATL ACAD SCI USA, V71, P4462, DOI 10.1073/pnas.71.11.4462; LOHRMANN R, 1992, J RAMAN SPECTROSC, V23, P575, DOI 10.1002/jrs.1250231010; LOZIER RH, 1992, P NATL ACAD SCI USA, V89, P3610, DOI 10.1073/pnas.89.8.3610; LUGTENBURG J, 1988, TRENDS BIOCHEM SCI, V13, P388, DOI 10.1016/0968-0004(88)90181-8; MARCUS MA, 1978, BIOCHEMISTRY-US, V17, P4722, DOI 10.1021/bi00615a019; MARINETTI T, 1989, P NATL ACAD SCI USA, V86, P529, DOI 10.1073/pnas.86.2.529; MARTI T, 1991, J BIOL CHEM, V266, P6919; MATHIES R, 1977, J MOL BIOL, V109, P367, DOI 10.1016/S0022-2836(77)80040-5; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MILLER A, 1990, BIOCHIM BIOPHYS ACTA, V1020, P57, DOI 10.1016/0005-2728(90)90093-J; MOWERY PC, 1979, BIOCHEMISTRY-US, V18, P4100, DOI 10.1021/bi00586a007; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; PETRICH JW, 1987, CHEM PHYS LETT, V137, P369, DOI 10.1016/0009-2614(87)80902-8; PFEFFERLE JM, 1991, BIOCHEMISTRY-US, V30, P6548, DOI 10.1021/bi00240a027; POLLARD WT, 1989, J CHEM PHYS, V90, P199, DOI 10.1063/1.456658; RACKER E, 1979, ARCH BIOCHEM BIOPHYS, V198, P470, DOI 10.1016/0003-9861(79)90521-6; RATH P, 1993, J BIOL CHEM, V268, P17742; RATH P, 1993, BIOCHEMISTRY-US, V32, P2272, DOI 10.1021/bi00060a020; ROEPE P, 1987, BIOCHEMISTRY-US, V26, P6696, DOI 10.1021/bi00395a020; ROEPE PD, 1988, J BIOL CHEM, V263, P5110; ROTHSCHILD KJ, 1992, J BIOL CHEM, V267, P1615; ROTHSCHILD KJ, 1982, P NATL ACAD SCI-BIOL, V79, P4045, DOI 10.1073/pnas.79.13.4045; ROTHSCHILD KJ, 1984, BIOCHEMISTRY-US, V23, P6103, DOI 10.1021/bi00320a031; ROTHSCHILD KJ, 1993, J BIOL CHEM, V268, P27046; ROTHSCHILD KJ, 1989, FEBS LETT, V250, P448, DOI 10.1016/0014-5793(89)80774-4; ROTHSCHILD KJ, 1982, J BIOL CHEM, V257, P8592; ROTHSCHILD KJ, 1989, BIOCHEMISTRY-US, V28, P7052, DOI 10.1021/bi00443a041; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; ROTHSCHILD KJ, 1990, J BIOL CHEM, V265, P16985; ROTHSCHILD KJ, 1995, IN PRESS CRC HDB ORG; SASAKI J, 1992, J BIOL CHEM, V267, P20782; SMITH SO, 1987, J PHYS CHEM-US, V91, P804, DOI 10.1021/j100288a011; SMITH SO, 1984, P NATL ACAD SCI-BIOL, V81, P2055, DOI 10.1073/pnas.81.7.2055; SMITH SO, 1987, J AM CHEM SOC, V109, P3108, DOI 10.1021/ja00244a038; SMITH SO, 1983, BIOCHEMISTRY-US, V22, P6141, DOI 10.1021/bi00295a016; SONAR S, 1993, BIOCHEMISTRY-US, V32, P2263, DOI 10.1021/bi00060a019; SONAR S, 1994, IN PRESS NATURE; SONG L, 1993, SCIENCE, V261, P891, DOI 10.1126/science.261.5123.891; STOCKBURGER M, 1979, BIOCHEMISTRY-US, V18, P4886, DOI 10.1021/bi00589a017; VARO G, 1990, BIOCHEMISTRY-US, V29, P2241, DOI 10.1021/bi00461a006	68	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28851	28858						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961844				2022-12-25	WOS:A1994PU16800054
J	WU, ZG; CHACONAS, G				WU, ZG; CHACONAS, G			CHARACTERIZATION OF A REGION IN PHAGE MU TRANSPOSASE THAT IS INVOLVED IN INTERACTION WITH THE MU-B PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND-TRANSFER; INTEGRATION HOST FACTOR; BACTERIOPHAGE-MU; INVITRO TRANSPOSITION; TARGET IMMUNITY; CLEAVAGE; DOMAINS; MUTATIONS; SITE; TRANSPOSOSOMES	Mu A protein, the 75-kDa phage transposase, consists of three domains: a 30-kDa NH2 terminus, a 35-kDa central domain, and a 10-kDa COOH terminus (Nakayama, C., Teplow, D. B., and Harshey, R. M. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 1809-1813). Genetic and biochemical experiments have demonstrated that the COOH-terminal domain must be present for functional interaction with Mu B protein. To further investigate the COOH-terminal domain of Mu A, we fused this 89-amino acid region to the glutathione S-transferase gene to facilitate subsequent expression and purification. We show that either the glutathione S-transferase-peptide fusion protein or the COOH-terminal peptide severed from glutathione S-transferase is active in Mu B interaction. Addition of the COOH-terminal domain to the in vitro strand transfer reaction inhibits intermolecular strand transfer by a mechanism previously characterized for intact Mu A protein (Baker, T. A., Mizuuchi, M., and Mizuuchi, K. (1991) Cell 65, 1003-1013), although the COOH-terminal domain is 70 times less effective than intact Mu A. The transient interaction between the COOH terminal domain and Mu B does not inhibit Mu B stimulation of the strand cleavage and intramolecular strand transfer activity of Mu A. Deletion analysis has shown that the last 36 amino acids are sufficient for interaction with Mu B, but that removal of as few as 4 amino acids from the COOH terminus renders the peptide inactive. The recovery of an active COOH-terminal domain of Mu A will facilitate future structure/function studies of the Mu transposase.	UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ON,CANADA	Western University (University of Western Ontario)								ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1991, J BIOL CHEM, V266, P6159; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BETERMIER M, 1989, MOL MICROBIOL, V3, P1159, DOI 10.1111/j.1365-2958.1989.tb00266.x; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DESMET L, 1989, MOL MICROBIOL, V3, P1145, DOI 10.1111/j.1365-2958.1989.tb00265.x; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FAELEN M, 1978, NATURE, V271, P580, DOI 10.1038/271580a0; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Haniford DB, 1992, CURR OPIN GENET DEV, V2, P698, DOI 10.1016/S0959-437X(05)80129-7; HARSHEY RM, 1983, P NATL ACAD SCI-BIOL, V80, P2012, DOI 10.1073/pnas.80.7.2012; HARSHEY RM, 1986, J GENET, V65, P159, DOI 10.1007/BF02931149; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LAVOIE BD, 1994, IN PRESS CURR TOP MI; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; O'Day KJ, 1978, MICROBIOLOGY 1978, P48; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; WU ZG, 1992, J BIOL CHEM, V267, P9552	36	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28829	28833						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961840				2022-12-25	WOS:A1994PU16800050
J	ADACHI, K; REDDY, LR; SURREY, S				ADACHI, K; REDDY, LR; SURREY, S			POLE OF HYDROPHOBICITY OF PHENYLALANINE BETA-85 AND LEUCINE BETA-88 IN THE ACCEPTOR POCKET FOR VALINE BETA-6 DURING HEMOGLOBIN-S POLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYHEMOGLOBIN; SOLUBILITY; STABILITY; HB	Characterization of the hydrophobic EF acceptor pocket involving Phe-beta 85 and Leu-beta 88 as well as the Val-beta 6 donor site is critical for understanding the polymerization of deoxy Hb S, Glu substitutions at beta 85 or beta 88 in Hb S were made and expressed in yeast in an effort to evaluate the role of hydrophobicity in the acceptor pocket during polymerization of Hb S, Both substitutions result in decreased tetramer stability, increases in oxygen affinity, and inhibition in polymerization compared with Kb S, Critical concentrations for polymerization of Hb S-F beta 85E and Hb S-L beta 88E were 2.4- and 7-fold higher, respectively, than that of Hb S, while the value for Hb S-L beta 88E was intermediate between those previously reported for Hb S-L beta 88A and Hb S-L beta 88F (Adachi, K,, Konitzer, P., Paulraj, C, G,, and Surrey, S, (1994) J. Biol, Chem. 269, 17477-11480), Kinetics of polymerization of Glu-beta 85 and Glu-beta 88 deoxy Hb S tetramers were biphasic at lower hemoglobin concentrations like deoxy Hb S-L beta 88A: suggesting formation of two types of polymers during polymerization, The time required to form half the total amount of polymer (t(1/2)) for deoxy Hb S-F beta 85E was 10-fold shorter than that for deoxy Hb S-L beta 88E, In addition, t(1/2) for deoxy Hb S-F beta 85E was 2.5-fold shorter, while that for Hb S-L beta 88E was 4-fold longer than deoxy Hb S-L beta 88A,t equivalent concentrations, These results suggest that hydrophobicity of the amino acid at beta 88 appears more critical than that at beta 85 in the acceptor pocket for Val-beta 6, Furthermore, stereospecificity of the acceptor pocket in addition to hydrophobicity of beta 88 are critical for stable hydrophobic interactions with Val-beta 6 during deoxy Pb S polymerization.			ADACHI, K (corresponding author), UNIV PENN,CHILDRENS HOSP,SCH MED,DIV HEMATOL,34TH ST & CIVIC CTR BLVD,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [P60 HL-38632, HL-32908] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032908, P60HL038632] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1993, HEMOGLOBIN, V17, P329, DOI 10.3109/03630269308997486; ADACHI K, 1993, J BIOL CHEM, V268, P21650; ADACHI K, 1987, J BIOL CHEM, V262, P12920; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ADACHI K, 1993, FEBS LETT, V315, P47, DOI 10.1016/0014-5793(93)81130-R; ADACHI K, 1994, J BIOL CHEM, V269, P17477; ASAKURA T, 1975, BIOCHIM BIOPHYS ACTA, V412, P197, DOI 10.1016/0005-2795(75)90034-3; ASAKURA T, 1974, P NATL ACAD SCI USA, V71, P1594, DOI 10.1073/pnas.71.5.1594; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P125; HOLLENDER A, 1969, NATURE, V222, P953, DOI 10.1038/222953a0; PERUTZ MF, 1968, NATURE, V219, P131, DOI 10.1038/219131a0; RHODA MD, 1986, HEMOGLOBIN, V10, P21, DOI 10.3109/03630268609072468; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WEINSTRIN BI, 1973, ACTA HAEMATOL-BASEL, V50, P357; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2	15	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31563	31566						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989324				2022-12-25	WOS:A1994PX30300037
J	FOSKETT, JK; WONG, DCP				FOSKETT, JK; WONG, DCP			[CA2+](I) INHIBITION OF CA2+ RELEASE-ACTIVATED CA2+ INFLUX UNDERLIES AGONIST-INDUCED AND THAPSIGARGIN-INDUCED [CA2+](I) OSCILLATIONS IN SALIVARY SALIVARY ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INTRACELLULAR CALCIUM POOLS; TYROSINE KINASE INHIBITORS; INOSITOL TRISPHOSPHATE; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CA-2+ STORES; CYCLOPIAZONIC ACID; CYTOSOLIC CA-2+; TUMOR PROMOTER	Inhibition of sarcoplasmic/endoplasmic reticulum Ca2+-ATPases by thapsigargin elicits [Ca2+](i) oscillations in rat salivary gland (parotid) acinar cells which are similar to those activated by agonists but are neverthe less independent of inositol 1,4,5-trisphosphate (IP3) or IP3-sensitive Ca2+ stoves (Foskett, J,K., Roifman, C, M,, and Wong, D, (1991) J. Biol; Chem, 266, 2778-2782), Neither bafilomycin alone or together with monensin or chloroquine inhibited thapsigargin induced [Ca2+](i) oscillations, ruling out the involvement of vacuolar-type proton pumps or organellar acidity in the mechanisms underlying them, Acute inhibition of plasma membrane Ca2+-ATPase by 1 mM La3+ inhibited the decline of [Ca2+](i) during the falling phase of the oscillation, Acute inhibition of plasma membrane Ca2+ influx by removal of extracellular Ca2+, membrane depolarization, or inorganic channel blockers immediately abolished oscillations, even when applied during the [Ca2+](i) rising phase of the cycle, Ca2+ influx rate oscillated during [Ca2+](i) oscillations, varying 1.5-13-fold during a cycle, Modification of the rate of Ca2+ influx, by titrating the extent of depletion of IP3-sensitive stores or manipulating extracellular [Ca2+], indicated that oscillations depended on a high rate of Ca2+ influx. In thapsigargin- or carbachol-treated cells which did not exhibit a sustained [Ca2+](i) rise or [Ca2+](i) oscillations, inhibition of Ca2+ influx activated plasma membrane Ca2+ permeability, Thus, agonist- and thapsigargin-induced [Ca2+](i) oscillations in parotid acinar cells appear to be generated by plasma membrane-based mechanisms which involve periodic inactivation by [Ca2+](i) of the Ca2+ release-activated Ca2+ influx pathway,	UNIV TORONTO, DEPT PHYSIOL, TORONTO M5G 1X8, ON, CANADA	University of Toronto	FOSKETT, JK (corresponding author), HOSP SICK CHILDREN, DIV CELL BIOL, 555 UNIV AVE, TORONTO M5G 1X8, ON, CANADA.		Foskett, Kevin/R-2549-2019	Foskett, J. Kevin/0000-0002-8854-0268				ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERLIN RD, 1993, CELL CALCIUM, V14, P379, DOI 10.1016/0143-4160(93)90042-5; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHAD JE, 1986, J PHYSIOL-LONDON, V420, P207; DEMAUREX N, 1992, J CLIN INVEST, V90, P830, DOI 10.1172/JCI115958; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; DUNN T, 1994, J BIOL CHEM, V269, P7273; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FOSKETT JK, 1989, P NATL ACAD SCI USA, V86, P167, DOI 10.1073/pnas.86.1.167; FOSKETT JK, 1992, AM J PHYSIOL, V262, pC656, DOI 10.1152/ajpcell.1992.262.3.C656; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; HAWORTH RA, 1989, CELL CALCIUM, V10, P263, DOI 10.1016/0143-4160(89)90009-2; HEEMSKERK JWM, 1993, J BIOL CHEM, V268, P356; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUGHES AD, 1990, PFLUG ARCH EUR J PHY, V416, P462, DOI 10.1007/BF00370755; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LASKEY RE, 1992, P NATL ACAD SCI USA, V89, P1690, DOI 10.1073/pnas.89.5.1690; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MERRITT JE, 1987, J BIOL CHEM, V262, P4958; MERTZ LM, 1992, J MEMBRANE BIOL, V126, P183; MIKOSHIBA K, 1993, PHILOS T ROY SOC B, V340, P345, DOI 10.1098/rstb.1993.0077; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; MISSIAEN L, 1991, BIOCHEM BIOPH RES CO, V174, P1183, DOI 10.1016/0006-291X(91)91546-O; MONTERO M, 1993, J BIOL CHEM, V268, P26911; MONTERO M, 1994, J BIOL CHEM, V269, P3963; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERSEN O H, 1992, Cellular Physiology and Biochemistry, V2, P1, DOI 10.1159/000154621; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SARGEANT P, 1993, FEBS LETT, V315, P242, DOI 10.1016/0014-5793(93)81172-V; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TAKEMURA H, 1990, CELL CALCIUM, V11, P11, DOI 10.1016/0143-4160(90)90044-U; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TANAKA Y, 1993, BIOCHEMISTRY-US, V32, P12062, DOI 10.1021/bi00096a017; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; THEVENOD F, 1988, AM J PHYSIOL, V255, pG429, DOI 10.1152/ajpgi.1988.255.4.G429; THURINGER D, 1992, J MEMBRANE BIOL, V130, P139; VALDIVIA HH, 1989, FEBS LETT, V244, P333, DOI 10.1016/0014-5793(89)80557-5; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430; XU X, 1994, J BIOL CHEM, V269, P12645; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713; ZAHRADNIK I, 1993, PFLUG ARCH EUR J PHY, V424, P129, DOI 10.1007/BF00374603; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHAO H, 1990, J BIOL CHEM, V265, P21419; ZHOLOS AV, 1991, PFLUG ARCH EUR J PHY, V419, P267, DOI 10.1007/BF00371106; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	71	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31525	31532						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989320				2022-12-25	WOS:A1994PX30300033
J	VREESWIJK, MPG; VANHOFFEN, A; WESTLAND, BE; VRIELING, H; VANZEELAND, AA; MULLENDERS, LHF				VREESWIJK, MPG; VANHOFFEN, A; WESTLAND, BE; VRIELING, H; VANZEELAND, AA; MULLENDERS, LHF			ANALYSIS OF REPAIR OF CYCLOBUTANE PYRIMIDINE DIMERS AND PYRIMIDINE-6-4-PYRIMIDONE PHOTOPRODUCTS IN TRANSCRIPTIONALLY ACTIVE AND INACTIVE GENES IN CHINESE-HAMSTER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTATION GROUP-C; DIHYDROFOLATE-REDUCTASE GENE; ADENOSINE-DEAMINASE GENE; PREFERENTIAL DNA-REPAIR; MAMMALIAN-CELLS; OVARY CELLS; TRANSCRIBED STRAND; DHFR GENE; UV-LIGHT; ULTRAVIOLET-LIGHT	Irradiation of cells with short wave ultraviolet light (W-C) induces both cyclobutane pyrimidine dimers (CPD) as well as pyrimidine 6-4 pyrimidone photoproducts (6-4 PP). We have focused on the removal of both types of DNA photolesions from the transcriptionally active adenine phosphoribosyltransferase (APRT) and hypoxanthine-guanine phosphoribosyltransferase (HPRT) genes and the inactive c-mos gene, Induction levels of both CPD and 6-4 PP were similar for all three genes analyzed, with the induction of 6-4 PP being about 3-fold lower than of CPD, Repair of CPD was analyzed using the CPD-specific enzyme T4 endonuclease V; repair of 6-4 PP was examined employing Escherichia coli UVrABC excinuclease. Unlike the HPRT gene, in which CPD were removed selectively from the transcribed strand, both strands of the 16-kilobase fragment encompassing the 2.6-kilobase APRT gene were repaired efficiently. This suggests the existence of multiple transcription units in the APRT region including transcription units running in the opposite direction of the APRT gene. Only a marginal part of the CPD was removed from the inactive c-mos gene after 24 h. In all three genes investigated, 6-4 PP were repaired more rapidly than CPD and, as demonstrated for the HPRT and APRT genes, without strand specificity, The difference in the repair phenotype of CPD between the HPRT gene and the APRT gene coincides with differences between both genes with regard to the DNA strand distribution of previously published UV-induced mutations,	LEIDEN UNIV, CTR MED GENET, DEPT RADIAT GENET & CHEM MUTAGENESIS, 2333 AL LEIDEN, NETHERLANDS; JA COHEN INST, INTERUNIV RES INST RADIOPATHOL & RADIAT PROTECT, 2333 AL LEIDEN, NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Vrieling, Harry/ABC-8068-2020	Vrieling, Harry/0000-0002-3034-2664				ARMSTRONG JD, 1992, MUTAT RES, V268, P83, DOI 10.1016/0027-5107(92)90086-H; ARMSTRONG JD, 1992, MUTAT RES, V274, P123, DOI 10.1016/0921-8777(92)90059-C; BARSALOU LS, 1994, MUTAT RES, V315, P43, DOI 10.1016/0921-8777(94)90027-2; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1986, J BIOL CHEM, V261, P6666; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; BOURRE F, 1989, J VIROL, V63, P4520, DOI 10.1128/JVI.63.11.4520-4524.1989; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; BREIMER LH, 1986, J MOL BIOL, V192, P669, DOI 10.1016/0022-2836(86)90284-6; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; DECOCK JGR, 1992, NUCLEIC ACIDS RES, V20, P4789, DOI 10.1093/nar/20.18.4789; DROBETSKY EA, 1989, SOMAT CELL MOLEC GEN, V15, P401, DOI 10.1007/BF01534891; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; EKER APM, 1990, J BIOL CHEM, V265, P8009; EPE B, 1992, CHEM-BIOL INTERACT, V85, P265, DOI 10.1016/0009-2797(92)90067-U; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; HAQQ CM, 1987, RADIAT RES, V2, P418; HOLMQUIST GP, 1989, J MOL EVOL, V28, P469, DOI 10.1007/BF02602928; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LATTIER DL, 1989, NUCLEIC ACIDS RES, V17, P1061, DOI 10.1093/nar/17.3.1061; LAWRENCE CW, 1993, MUTAT RES, V299, P157, DOI 10.1016/0165-1218(93)90093-S; LEADON SA, 1988, MOL CELL BIOL, V8, P5331, DOI 10.1128/MCB.8.12.5331; LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L; LINK CJ, 1992, CARCINOGENESIS, V13, P1975, DOI 10.1093/carcin/13.11.1975; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MITCHELL DL, 1990, J BIOL CHEM, V265, P5353; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; NAIRN RS, 1985, INT J RADIAT BIOL, V47, P181, DOI 10.1080/09553008514550251; OKUMOTO DS, 1987, NUCLEIC ACIDS RES, V15, P10021, DOI 10.1093/nar/15.23.10021; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SETLOW RB, 1966, J MOL BIOL, V17, P237, DOI 10.1016/S0022-2836(66)80105-5; TASSERONDEJONG JG, 1993, MUTAGENESIS, V8, P399, DOI 10.1093/mutage/8.5.399; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; THOMPSON LH, 1989, MUTAGENESIS, V4, P140, DOI 10.1093/mutage/4.2.140; VANZEELAND AA, 1982, MUTAT RES, V92, P379, DOI 10.1016/0027-5107(82)90237-8; VANZEELAND AA, 1980, MOL GEN GENET, V180, P495, DOI 10.1007/BF00268052; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VENEMA J, 1992, J BIOL CHEM, V267, P8852; VISSE R, 1992, J BIOL CHEM, V267, P6736; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; WOOD RD, 1985, J MOL BIOL, V184, P577, DOI 10.1016/0022-2836(85)90304-3; WOOD RD, 1984, J MOL BIOL, V173, P273, DOI 10.1016/0022-2836(84)90121-9; ZDZIENICKA MZ, 1992, MUTAT RES, V273, P73, DOI 10.1016/0921-8777(92)90051-4	47	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31858	31863						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989359				2022-12-25	WOS:A1994PX30300081
J	XU, XX; ROCK, CO; QIU, ZH; LESLIE, CC; JACKOWSKI, S				XU, XX; ROCK, CO; QIU, ZH; LESLIE, CC; JACKOWSKI, S			REGULATION OF CYTOSOLIC PHOSPHOLIPASE A(2) PHOSPHORYLATION AND EICOSANOID PRODUCTION BY COLONY-STIMULATING FACTOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE CELL-LINE; PROTEIN-KINASE-C; FACTOR-I RECEPTOR; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; MARROW-DERIVED MACROPHAGES; GROWTH-FACTOR; PHOSPHATIDYLCHOLINE HYDROLYSIS; MYC EXPRESSION; MOBILIZING PHOSPHOLIPASE-A2; MITOGENIC RESPONSE	A colony-stimulating factor 1 (CSF-1)-dependent murine macrophage cell line (BAC1.2F5) and peritoneal macrophages were used to investigate the relationship between growth factor dependent phosphorylation/activation of the 85-kDa cytosolic phospholipase A, (cPLA(2)) and arachidonic acid metabolism, The addition of CSF-1 to quiescent BAC1.2F5 cells was followed by the rapid phosphorylation, electrophoretic gel retardation, and stable increase in the specific activity of cPLA(2) that correlated with the activation of ERK kinases. cPLA(2) phosphorylation depended on the presence of growth factor and persisted throughout the cell cycle, CSF-1 inhibited prostaglandin E(2) production and did not enhance arachidonic acid release or increase the levels of lysophosphatidylcholine or glycerophosphocholine. Treatment of BAC1.2F5 cells with the calcium ionophore A23187 plus CSF-I did not stimulate eicosanoid release. Instead, CSF-1 enhanced the rate of exogenous arachidonic acid incorporation into phosphatidylcholine and its subsequent transfer to phosphatidylethanolamine suggesting that big-her rates of arachidonic acid acylation may contribute to the supression of prostaglandin production. In peritoneal macrophage, ERK kinase activity was stimulated and cPLA(2) was phosphorylated and activated in response to CSF-1, However, CSF-I did not trigger eicosanoid release but did augment arachidonic acid mobilization and prostaglandin E(2) production elicited by zymosan and A23187. Thus, cPLA(2) phosphorylation/activation and calcium mobilization are not the only determinants for eicosanoid release, and additional components in differentiated tissue macrophages are also required,	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, DENVER, CO 80206 USA; UNIV COLORADO, SCH MED, DEPT PATHOL, DENVER, CO 80262 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NHLBI NIH HHS [HL 34303] Funding Source: Medline; NIGMS NIH HHS [GM 45737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BUSCHER D, 1993, ONCOGENE, V8, P3323; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHOUDHURY GG, 1991, FEBS LETT, V282, P351, DOI 10.1016/0014-5793(91)80511-Z; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DOMIN J, 1993, J BIOL CHEM, V268, P8927; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DUYSTER J, 1992, BIOCHEM BIOPH RES CO, V183, P1247, DOI 10.1016/S0006-291X(05)80324-9; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GOLDBERG H, 1994, BIOCHEM BIOPH RES CO, V198, P220, DOI 10.1006/bbrc.1994.1031; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; HAMILTON JA, 1989, J CELL PHYSIOL, V141, P618, DOI 10.1002/jcp.1041410321; HUWILER A, 1993, EUR J BIOCHEM, V217, P69, DOI 10.1111/j.1432-1033.1993.tb18219.x; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; JACKOWSKI S, 1990, J BIOL CHEM, V265, P6611; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRONER EE, 1981, J BIOL CHEM, V256, P3690; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1990, METHOD ENZYMOL, V187, P216; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LESLIE CC, 1994, ADV MOL CELL BIOL LI; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; POLLARD JW, 1991, P NATL ACAD SCI USA, V88, P1474, DOI 10.1073/pnas.88.4.1474; PURI J, 1991, PROSTAGLANDINS LEUKO, V45, P43; QUI ZH, 1993, J BIOL CHEM, V268, P24506; QUI ZH, 1994, J BIOL CHEM, V269, P19480; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAIRO G, 1991, IMMUNOL TODAY, V12, P362, DOI 10.1016/0167-5699(91)90067-4; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VIES N, 1991, J CELL PHYSL, V147, P298; WHETTON AD, 1986, EMBO J, V5, P3281, DOI 10.1002/j.1460-2075.1986.tb04640.x; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522	67	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31693	31700						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989342				2022-12-25	WOS:A1994PX30300058
J	KURABAYASHI, M; DUTTA, S; KEDES, L				KURABAYASHI, M; DUTTA, S; KEDES, L			SERUM-INDUCIBLE FACTORS BINDING TO AN ACTIVATING TRANSCRIPTION FACTOR MOTIF REGULATE TRANSCRIPTION OF THE ID2A PROMOTER DURING MYOGENIC DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FIBROBLAST GROWTH-FACTOR; AMP-RESPONSIVE ELEMENT; LOOP-HELIX PROTEINS; DNA-BINDING; RETINOBLASTOMA GENE; CELL-TYPE; SIGNAL TRANSDUCTION; 5'-FLANKING REGION; LEUCINE ZIPPER	Expression of Id, a dominant negative regulator of helix-loop-helix transcription factors, is tightly regulated during cellular differentiation. In this study, we have defined the sequences responsible for the transcriptional regulation of the human Id2A gene. 5' deletion and site-specific mutation analyses of the Id2A promoter showed that both an Sp-1 site and an activating transcription factor (ATF)-like site (referred to as IdATF sites) are required for expression in C2 cells, whereas these sites are not essential for the expression in nonmuscle cells, including HeLa and 10T1/2 cells. Gel shift assays revealed nuclear factors with specific binding to IdATF sites in both C2 and HeLa cells, which are efficiently competed by either legitimate ATF- or AP-1 binding sites. DNA binding activity to IdATF sites was clearly decreased during C2 cell differentiation and rapidly reactivated by treatment with either phorbol 12-myristate 13-acetate or serum, which correlated with the induction of endogenous Id2A mRNA expression. In addition, we show that overexpression of the catalytic domain of protein kinase C leads to the activation of the Id2A promoter through IdATF sites in C2 cells. These results suggest a model in which down-modulation of IdATF site binding activity by mitogen depletion contributes to the down-regulation of Id2A gene expression that is essential for myogenic differentiation.	UNIV SO CALIF,SCH MED,INST MED GENET,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033	University of Southern California								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GRAY JG, 1993, MOL CELL BIOL, V13, P6678, DOI 10.1128/MCB.13.11.6678; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; GUSTAFSON TA, 1988, MOL CELL BIOL, V7, P4100; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARDY S, 1993, MOL CELL BIOL, V13, P5943, DOI 10.1128/MCB.13.10.5943; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KANEIISHII C, 1989, NUCLEIC ACIDS RES, V17, P1521, DOI 10.1093/nar/17.4.1521; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KURABAYASHI M, 1993, J BIOL CHEM, V268, P5524; KURABAYASHI M, 1994, J BIOL CHEM, V269, P6031; KURABAYASHI M, 1993, GENE, V133, P305, DOI 10.1016/0378-1119(93)90658-P; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	57	24	24	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31162	31170						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983058				2022-12-25	WOS:A1994PV51000066
J	MURTHY, SS; ZILINSKAS, BA				MURTHY, SS; ZILINSKAS, BA			MOLECULAR-CLONING AND CHARACTERIZATION OF A CDNA-ENCODING PEA MONODEHYDROASCORBATE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBIC-ACID; SEQUENCE; PEROXIDASE; EXPRESSION; CUCUMBER; PROTEINS; BINDING; ENZYME; GENES; ION	Monodehydroascorbate radicals are generated in plant cells enzymatically by the hydrogen peroxide scavenging enzyme, ascorbate peroxidase, and nonenzymatically via the univalent oxidation of ascorbate by superoxide, hydroxyl, and various organic radicals. Regeneration of ascorbate is achieved by monodehydroascorbate reductase (EC 1.6.5.4) using NAD(P)H as an electron donor or, alternatively, by a set of two coupled reactions requiring dehydroascorbate reductase, glutathione reductase, glutathione, and NAD(P)H. As monodehydroascorbate reductase is a key enzyme in maintaining reduced pools of ascorbate, an important antioxidant, we undertook this study to learn more about its structure, function, and regulation. Herein we report the molecular cloning and characterization of a cDNA encoding monodehydroascorbate reductase of pea (Pisum sativum L.). The cDNA encodes a 433-amino acid polypeptide that shows, respectively, 73 and 87% identity with peptide fragments from soybean and cucumber monodehydroascorbate reductase. Monodehydroascorbate reductase contains the NAD(P)H and FAD binding domains of other flavin oxidoreductases. The cloned enzyme lacks a transit peptide, but the sequence of the carboxyl terminus is Ser-Lys-Ile, similar to the targeting motif found in peroxisomal proteins. When expressed in Escherichia coli fused to maltose-binding protein, monodehydroascorbate reductase has enzymatic properties comparable with purified soybean and cucumber monodehydroascorbate reductase. Northern blot analysis shows that the monodehydroascorbate reductase transcript is 1.6 kilobase in size and is expressed at relatively low levels in all plant tissues examined.	RUTGERS STATE UNIV, COOK COLL, DEPT PLANT SCI, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick								ABOAGYEKWARTENG T, 1992, MOL MICROBIOL, V6, P3089, DOI 10.1111/j.1365-2958.1992.tb01766.x; ARRIGONI O, 1981, FEBS LETT, V125, P242, DOI 10.1016/0014-5793(81)80729-6; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHHOUT TJ, 1991, OXIDATION PLASMA MEM, V2, P21; CABELLI DE, 1983, J PHYS CHEM-US, V87, P1809, DOI 10.1021/j100233a031; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALTON DA, 1992, ARCH BIOCHEM BIOPHYS, V292, P281, DOI 10.1016/0003-9861(92)90080-G; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; ERLMLER U, 1991, PROTEIN-STRUCT FUNCT, V9, P174; FOYER CH, 1976, PLANTA, V133, P21, DOI 10.1007/BF00386001; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; HOSSAIN MA, 1985, J BIOL CHEM, V260, P2920; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; KRAUTHSIEGEL RL, 1993, FEBS LETT, V317, P105, DOI 10.1016/0014-5793(93)81501-P; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MITTLER R, 1994, PLANT J, V5, P397, DOI 10.1111/j.1365-313X.1994.00397.x; MORRE DJ, 1986, PROTOPLASMA, V133, P195, DOI 10.1007/BF01304635; NAKANO Y, 1981, PLANT CELL PHYSIOL, V22, P867; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; PETERSON JA, 1992, J BIOL CHEM, V267, P14193; RIGGS P, 1990, CURRENT PROTOCOLS MO; ROSS RP, 1992, J MOL BIOL, V227, P658, DOI 10.1016/0022-2836(92)90215-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO S, 1992, RES PHOTOSYNTHESIS, V4, P533; SCARPA M, 1983, J BIOL CHEM, V258, P6695; SCHIERING N, 1991, NATURE, V352, P168, DOI 10.1038/352168a0; SCHULZE HU, 1972, H-S Z PHYSIOL CHEM, V353, P1931, DOI 10.1515/bchm2.1972.353.2.1931; TAN HM, 1993, GENE, V130, P33, DOI 10.1016/0378-1119(93)90343-2; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YAMAUCHI N, 1984, J JPN SOC HORTIC SCI, V53, P347, DOI 10.2503/jjshs.53.347; YAMAZAKI I, 1961, BIOCHIM BIOPHYS ACTA, V50, P62, DOI 10.1016/0006-3002(61)91060-5; ZYLSTRA GJ, 1989, J BIOL CHEM, V264, P14940	36	42	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31129	31133						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983054				2022-12-25	WOS:A1994PV51000061
J	CRESSMAN, DE; GREENBAUM, LE; HABER, BA; TAUB, R				CRESSMAN, DE; GREENBAUM, LE; HABER, BA; TAUB, R			RAPID ACTIVATION OF POST-HEPATECTOMY FACTOR NUCLEAR FACTOR KAPPA-B IN HEPATOCYTES, A PRIMARY RESPONSE IN THE REGENERATING LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SUBUNIT; STIMULATED H-35 CELLS; IMMEDIATE-EARLY GENES; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; 3T3 CELLS; PHORBOL ESTER; IN-VIVO; INDUCTION-PATTERNS; MOUSE FIBROBLASTS	The liver represents one of the few organs in the intact animal that has the capacity to regenerate following in jury or partial hepatectomy. One of the earliest responses that has been detected in the remnant liver is the activation of post-hepatectomy factor(s) (PHF), a kappa B site DNA binding activity. We reasoned that understanding the molecular nature of PHF might provide insight into what triggers liver regeneration. We found that PHF is rapidly activated and turned over in the regenerating liver, demonstrating peak activity at 30 min post-hepatectomy and virtual disappearance by 1 h. As determined by supershift, cross-linking, and crosslinking/immunoprecipitation analyses, PHF contains intact p50/p65 nuclear factor kappa B (NF-kappa B) subunits. To explore the basis for activation of PHF/NF-kappa B in the regenerating liver, we determined the level of individual Rel family subunits in the nuclei of normal and regenerating liver cells. We found evidence for nuclear translocation of p65/RelA, but other Rel family proteins including p50/NF-kappa B1 and p52/NF-kappa B2 are present at a low level in the nuclei of cells at a constitutive level pre- and post-hepatectomy and appear not to form DNA binding homodimers. The level of I kappa B-alpha falls slightly then increases at 3 h post-hepatectomy in concert with the induction of its mRNA. As demonstrated by the induction of I kappa B-alpha mRNA in hepatocytes in situ and identification of PHF/NF-kappa B in cultured hepatocytes, PHF/NF-kappa B is localized primarily in hepatocytes in the regenerating liver. This represents one of the few examples of NF-kappa B activation in the intact animal in a non-hematopoietic cell type. The activation of PHF/NF-kappa B suggests a mechanism by which hepatocytes regulate their mitogenic program during liver regeneration.	UNIV PENN,SCH MED,DEPT GENET & MED,DIV GASTROENTEROL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,DIV GASTROENTEROL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ARIAS IM, 1994, LIVER BIOL PATHOBIOL, P1059; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BALLARD D W, 1989, New Biologist, V1, P83; BANERJEE R, 1989, HEPATOLOGY, V10, P1008, DOI 10.1002/hep.1840100620; BEAUERLE PA, 1988, SCIENCE, V242, P540; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRAVO R, 1990, GROWTH FACTORS DIFFE, P134; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; CRESSMAN DE, 1994, IN PRESS J BIOL CHEM; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; FAUSTO N, 1989, LAB INVEST, V60, P4; FITZGERALD MJ, 1994, IN PRESS CELL GROWTH; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRILLI M, 1993, INT REV CYTOL, V143, P1; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUANG AA, 1993, MOL CELL BIOL, V13, P2536, DOI 10.1128/MCB.13.4.2536; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEE JY, 1994, HEPATOLOGY, V19, P656, DOI 10.1002/hep.1840190317; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIM RW, 1987, ONCOGENE, V1, P263; MENON SD, 1993, J BIOL CHEM, V268, P26805; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Seglen PO, 1976, METHOD CELL BIOL, P30; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zaret Kenneth S., 1994, P53; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	59	208	210	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30429	30435						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982957				2022-12-25	WOS:A1994PU52500061
J	FERBY, IM; WAGA, I; SAKANAKA, C; KUME, K; SHIMIZU, T				FERBY, IM; WAGA, I; SAKANAKA, C; KUME, K; SHIMIZU, T			WORTMANNIN INHIBITS MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION-INDUCED BY PLATELET-ACTIVATING-FACTOR IN GUINEA-PIG NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; TYROSINE PHOSPHORYLATION; FACTOR RECEPTOR; MAP KINASE; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-D; EXPRESSION; SEQUENCE; CLONING	Stimulation of guinea pig neutrophils with platelet-activating factor (PAF) caused a rapid and transient activation of mitogen-activated protein kinase (MAPK). Wortmannin, an inhibitor of phosphatidylinositol 3-kinase, partially (similar to 50%) inhibited PAF-induced MAPK activation. Half-maximal inhibition was observed with 200-300 nM wortmannin, while it did not inhibit phorbol ester-induced MAPK activation. Neutrophils preloaded with 1,2-bis-(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester (BAPTA/AM) failed to raise cytosolic Ca2+ concentrations toward PAF, while they still responded to PAF with a 40-50% activation of MAPK. However, when cells were treated with BAPTA/AM and wortmannin in combination, the MAPK activation was completely inhibited. These results suggest that PAF activates MAPK through two distinct pathways in guinea pig neutrophils, one Ca2+-dependent, and the other Ca2+-independent but wortmannin-sensitive.	UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Ferby, Ingvar/B-7895-2008	Ferby, Ingvar/0000-0002-3435-1728; Kume, Kazuhiko/0000-0003-4232-1657				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BARNES PJ, 1991, TRENDS BIOCHEM SCI, V16, P365, DOI 10.1016/0968-0004(91)90152-L; BITO H, 1994, J BIOL CHEM, V269, P12722; BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEWALD B, 1988, J BIOL CHEM, V263, P16179; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GOMEZCAMBRONERO J, 1993, BIOCHEM J, V291, P211, DOI 10.1042/bj2910211; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; KESSELS GCR, 1991, J BIOL CHEM, V266, P23152; KUIJPERS TW, 1992, J IMMUNOL, V148, P72; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OFLAHERTY JT, 1991, BIOCHEM J, V278, P705; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKUDA K, 1992, BLOOD, V79, P2880; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SAKANAKA C, 1994, IN PRESS BIOCH BIOPH; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TORRES M, 1993, J IMMUNOL, V150, P1563; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WAGA I, 1993, BIOCHEM BIOPH RES CO, V197, P465, DOI 10.1006/bbrc.1993.2502; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6	39	120	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30485	30488						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982965				2022-12-25	WOS:A1994PU52500069
J	GRANOT, I; DEKEL, N				GRANOT, I; DEKEL, N			PHOSPHORYLATION AND EXPRESSION OF CONNEXIN-43 OVARIAN GAP JUNCTION PROTEIN ARE REGULATED BY LUTEINIZING-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUMULUS-OOCYTE COMPLEX; GONADOTROPIN-RELEASING HORMONE; KINASE-C; TYROSINE PHOSPHORYLATION; GRANULOSA-CELLS; RAT; COMMUNICATION; MATURATION; ACID; PERMEABILITY	One important role of the junctional communication in the ovarian follicle is to mediate transmission of cAMP, the regulatory signal that maintains the oocyte in meiotic arrest. Luteinizing hormone (LH) interrupts cell to cell communication within the ovarian follicle, leading to a decrease in intraoocyte concentrations of cAMP followed by resumption of meiosis. Our experiments were directed at exploration of mechanisms involved in the LH-induced communication breakdown in the preovulatory ovarian follicle. Immunofluorescence and Western blot analysis, using highly specific antibodies, showed that connexin-43 (Cx43), the ovarian gap junction protein, is present in the cytoplasmic mem branes of the follicular cells in multiple phosphorylated forms. The relative amounts of the different forms of Cx43 vary in response to LH: short time exposure (10 min) stimulated phosphorylation of Cx43 followed by immediate dephosphorylation, while longer incubations (8 and 24 h) with this hormone resulted in elimination of the protein. Forskolin mimicked the LH-induced phosphorylation/dephosphorylation, as well as the decrease of Cx43 protein level. A gonadotropin-releasing hormone analog (GnRHa) also induced an immediate phosphorylation/dephosphorylation of Cx43 and a later reduction of the amount of Cx43. The direct PKC activator, 12-O-tetradecanoylphorbol-13-acetate (TPA), induced phosphorylation of Cx43 that was completely blocked by the protein kinase C inhibitor, staurosporine. This kinase inhibitor partially interfered with LH, but not forskolin-induced phosphorylation of Cx43. Analysis of the effect of LH on Cx43 gene expression revealed a significant decrease (45%) in Cx43 mRNA level at 24 h of incubation. A drop of Cx43 mRNA was also induced by GnRHa. Our results suggest that the LH-induced gating mechanism of the gap junctions in rat ovarian follicles is comprised of two steps: the immediate response is represented by a change in the phosphorylation state of the Cx43 protein, and the later response is manifested by a reduction of Cx43 protein level, due to attenuation of its gene expression. Phosphorylation of Cx43 may occur through PKA-, as well as PKC-dependent pathways.			GRANOT, I (corresponding author), WEIZMANN INST SCI, DEPT HORMONE RES, IL-76100 REHOVOT, ISRAEL.		DEKEL, NAVA/R-8817-2019					ABERDAM E, 1985, BIOCHEM BIOPH RES CO, V132, P570, DOI 10.1016/0006-291X(85)91171-4; BENNETT MVL, 1978, NEUROSCI RES PROG B, V16, P377; BERTHOUD VM, 1992, EUR J CELL BIOL, V57, P40; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE WC, 1986, AM J PHYSIOL, V251, pC411, DOI 10.1152/ajpcell.1986.251.3.C411; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; CROW DS, 1992, ONCOGENE, V7, P999; DAVIS JS, 1984, J BIOL CHEM, V259, P5028; Dekel N, 1989, J Reprod Fertil Suppl, V37, P319; DEKEL N, 1983, BIOL REPROD, V28, P161, DOI 10.1095/biolreprod28.1.161; DEKEL N, 1983, FEBS LETT, V151, P153, DOI 10.1016/0014-5793(83)80362-7; DEKEL N, 1987, ENDOCRINOLOGY PHYSL, P197; DEKEL N, 1988, CELL CELL COMMUNICAT, V49, P181; DEKEL N, 1988, MEIOTIC INHIBITION M, P87; DEMELLO WC, 1984, BIOCHEM BIOPH RES CO, V119, P1001, DOI 10.1016/0006-291X(84)90873-8; DIMINO MJ, 1987, BIOL REPROD, V37, P1129, DOI 10.1095/biolreprod37.5.1129; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; GILULA NB, 1972, NATURE, V235, P262, DOI 10.1038/235262a0; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; LARSEN WJ, 1981, BIOL REPROD, V25, P1119, DOI 10.1095/biolreprod25.5.1119; Lindner H R, 1974, Recent Prog Horm Res, V30, P79; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; LOEWENSTEIN WR, 1985, BIOCH SOC S, V50, P43; MELLONI E, 1986, J BIOL CHEM, V261, P4101; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MORENO AP, 1992, BIOPHYS J, V62, P51, DOI 10.1016/S0006-3495(92)81775-7; MORRIS JK, 1993, ENDOCRINOLOGY, V133, P770, DOI 10.1210/en.133.2.770; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; NAOR Z, 1985, P NATL ACAD SCI USA, V82, P8203, DOI 10.1073/pnas.82.23.8203; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PHILLIPS DM, 1991, MOL REPROD DEV, V28, P297, DOI 10.1002/mrd.1080280313; PITTS JD, 1977, EXP CELL RES, V104, P153, DOI 10.1016/0014-4827(77)90078-7; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; SAEZ JC, 1990, EUR J BIOCHEM, V192, P263, DOI 10.1111/j.1432-1033.1990.tb19223.x; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SHERIZLY I, 1988, HUM REPROD, V3, P761, DOI 10.1093/oxfordjournals.humrep.a136780; SUTOVSKY P, 1993, BIOL REPROD, V49, P1277, DOI 10.1095/biolreprod49.6.1277; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; VALDIMARSSON G, 1993, MOL REPROD DEV, V36, P7, DOI 10.1002/mrd.1080360103; VANDERHYDEN BC, 1992, BIOL REPROD, V46, P1196, DOI 10.1095/biolreprod46.6.1196; WERT SE, 1990, TISSUE CELL, V22, P827, DOI 10.1016/0040-8166(90)90047-D; WIESEN JF, 1993, ENDOCRINOLOGY, V133, P741, DOI 10.1210/en.133.2.741	49	130	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30502	30509						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982967				2022-12-25	WOS:A1994PU52500072
J	GUITON, M; GUNNMOORE, FJ; STITT, TN; YANCOPOULOS, GD; TAVARE, JM				GUITON, M; GUNNMOORE, FJ; STITT, TN; YANCOPOULOS, GD; TAVARE, JM			IDENTIFICATION OF IN-VIVO BRAIN-DERIVED NEUROTROPHIC FACTOR-STIMULATED AUTOPHOSPHORYLATION SITES ON THE TRKB RECEPTOR TYROSINE KINASE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN INSULIN-RECEPTOR; AFFINITY NGF RECEPTOR; PROTEIN-KINASE; BETA-SUBUNIT; DOMAIN AUTOPHOSPHORYLATION; THREONINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MUTATIONAL ANALYSIS; ACTIVATION	Brain-derived neurotrophic factor (BDNF) interacts with the TrkB receptor tyrosine kinase, the tyrosine kinase domain of which has homology with the insulin receptor subfamily of protein kinases. This includes the conservation of three regulatory tyrosines (residues 670, 674, and 675) known to play a crucial role in signal transmission by the insulin receptor (tyrosines 1158, 1162, and 1163). Wild-type TrkB and TrkB mutants with Y670F, Y674F/Y675F, Y751F (the tyrosine reported to be important in phosphatidylinositol 3-kinase binding (Obermeier, A., Lammers, R., Wiesmuller, K. H., June, G., Schlessinger, J., and Ullrich, A. (1993) J. Biol. Chem. 268, 22963-22966)), and K540R (consensus ATP binding lysine) substitutions were transiently expressed in COS cells for analysis of phosphorylation sites by two-dimensional phosphopeptide mapping. TrkB phosphorylation sites were also studied in MG86 cells stably expressing wild-type TrkB. In addition, the mutants were expressed in Chinese hamster ovary cells for analysis of the ability of the receptor to mediate BDNF-stimulated transcription from a 12-O-tetradecanoylphorbol-13-acetate response element (TRE). BDNF stimulated the phosphorylation of wild type TrkB on multiple tyrosine and serine residues. This phosphorylation occurred on tyrosines 670, 674, and 675 plus two other tyrosines and at least two serines that were not unequivocally identified. Wild-type TrkB mediated a pronounced stimulation of TRE-dependent transcription. A Y674F/Y675F, but not Y670F, substitution dramatically inhibited this response. Surprisingly, in COS cells, a Y751F substitution induced dramatically lower tyrosine and serine phosphorylation at all sites but mediated a normal BDNF-stimulated activation of a TRE. Our results demonstrate a critical role for the phosphorylation of tyrosines 674 and 675 in BDNF-dependent signaling by wild-type TrkB.	UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, AVON, ENGLAND; REGENERON PHARMACEUT INC, TARRYTOWN, NY 10591 USA	University of Bristol; Regeneron					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BARINAGA M, 1994, SCIENCE, V264, P772, DOI 10.1126/science.8171331; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; COCHET C, 1984, J BIOL CHEM, V259, P2553; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; MITRA G, 1991, ONCOGENE, V6, P2237; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1991, J BIOL CHEM, V266, P21804; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TAVARE JM, 1991, BIOCHEM J, V274, P173, DOI 10.1042/bj2740173; TAVARE JM, 1992, BIOCHEM BIOPH RES CO, V188, P86, DOI 10.1016/0006-291X(92)92353-Y; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	55	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30370	30377						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982951				2022-12-25	WOS:A1994PU52500053
J	LI, KW; HOEK, RM; SMITH, F; JIMENEZ, CR; VANDERSCHORS, RC; VANVEELEN, PA; CHEN, S; VANDERGREEF, J; PARISH, DC; BENJAMIN, P; GERAERTS, WPM				LI, KW; HOEK, RM; SMITH, F; JIMENEZ, CR; VANDERSCHORS, RC; VANVEELEN, PA; CHEN, S; VANDERGREEF, J; PARISH, DC; BENJAMIN, P; GERAERTS, WPM			DIRECT PEPTIDE PROFILING BY MASS-SPECTROMETRY OF SINGLE IDENTIFIED NEURONS REVEALS COMPLEX NEUROPEPTIDE-PROCESSING PATTERN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT YELLOW CELLS; LYMNAEA-STAGNALIS; CHEMICAL CHARACTERIZATION; GREEN CELLS; INSULIN; PROHORMONE; PURIFICATION; SNAIL	A novel strategy combining peptide fingerprinting of single neurons by matrix-assisted laser desorption ionization mass spectrometry, molecular cloning, peptide chemistry, and electrospray ionization mass spectrometry was used to study the intricate processing pattern of a preprohormone expressed in identified neurons, the neuroendocrine light yellow cells (LYCs) of the gastropod mollusc, Lymnaea stagnalis. The cDNA encoding the precursor, named prepro-LYCP (LYCPs, light yellow cell peptides), predicts a straightforward processing into three peptides, LYCP I, II, and III, at conventional dibasic processing sites flanking the peptide domains on the precursor. However, matrix-assisted laser desorption ionization mass spectrometry of single LYCs revealed trimmed variant peptides derived from LYCP I and II. The variants were much more abundant than the intact peptides, indicating that LYCP I and II serve as intermediates in a peptide-processing sequence. Using the molecular masses of the peptides as markers to guide their isolation by well established purification methods, the structural identities of the peptides could be confirmed by amino acid sequencing. Furthermore, matrix-assisted laser desorption ionization mass spectrometry could detect colocalization of a novel peptide with the LYCPs.	UNIV WARWICK,DEPT CHEM,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND; TNO,IBC,CTR STRUCT ELUCIDAT & INSTRUMENTAL ANAL,3700 AJ ZEIST,NETHERLANDS; UNIV SUSSEX,SUSSEX CTR NEUROSCI,SCH BIOL SCI,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND; ST MARYS HOSP,SCH MED,METAB MED UNIT,LONDON W2 1PG,ENGLAND	University of Warwick; Netherlands Organization Applied Science Research; University of Sussex; Imperial College London	LI, KW (corresponding author), VRIJE UNIV AMSTERDAM,FAC BIOL,GRAD SCH NEUROSCI,NEUROSCI RES INST,DE BOELELAAN 1087,1081 HV AMSTERDAM,NETHERLANDS.		Jimenez, Connie/AAI-3763-2020	van Veelen, Peter/0000-0002-7898-9408				BENJAMIN PR, 1989, CELLULAR NEURONAL OS, P173; BOER HH, 1994, CELL TISSUE RES, V275, P361, DOI 10.1007/BF00319435; BONGA WSE, 1970, Z ZELLFORSCH MIKROSK, V108, P190; CONLON JM, 1988, GEN COMP ENDOCR, V72, P154, DOI 10.1016/0016-6480(88)90191-8; DSOUZA NB, 1988, J BIOL CHEM, V263, P2548; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; FERGUSON GP, 1993, J EXP BIOL, V178, P251; FISHER JM, 1988, J BIOL CHEM, V263, P16515; GERAERTS WPM, 1991, CURRENT ASPECTS NEUR, V3, P255; HOEK RM, 1992, MOL BRAIN RES, V16, P71, DOI 10.1016/0169-328X(92)90195-H; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; LI KW, 1992, MOL CELL ENDOCRINOL, V85, P141, DOI 10.1016/0303-7207(92)90133-Q; LI KW, 1992, ENDOCRINOLOGY, V130, P3427, DOI 10.1210/en.130.6.3427; LI KW, 1992, EUR J BIOCHEM, V205, P675, DOI 10.1111/j.1432-1033.1992.tb16828.x; LI KW, 1993, BIOCHEM BIOPH RES CO, V197, P1056, DOI 10.1006/bbrc.1993.2585; LI KW, 1994, ENDOCRINOLOGY, V134, P1812, DOI 10.1210/en.134.4.1812; OBYRNE EM, 1989, ENDOCRINOLOGY, V124, P2920, DOI 10.1210/endo-124-6-2920; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SIGVARDT KA, 1986, J NEUROSCI, V6, P803; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMIT AB, 1993, CELL MOL NEUROBIOL, V13, P263, DOI 10.1007/BF00733754; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; TANG K, 1993, ANAL CHEM, V65, P2164, DOI 10.1021/ac00063a041; VANSWIGCHEM H, 1981, COMP BIOCHEM PHYS A, V68, P199, DOI 10.1016/0300-9629(81)90341-8; WATKINSON A, 1988, J BIOL CHEM, V263, P7147; WATKINSON A, 1989, REGUL PEPTIDES, V26, P313, DOI 10.1016/0167-0115(89)90199-7	27	72	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30288	30292						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982940				2022-12-25	WOS:A1994PU52500040
J	CODINA, J; BIRNBAUMER, L				CODINA, J; BIRNBAUMER, L			REQUIREMENT FOR INTRAMOLECULAR DOMAIN INTERACTION IN ACTIVATION OF G-PROTEIN ALPHA-SUBUNIT BY ALUMINUM FLUORIDE AND GDP BUT NOT BY GTP-GAMMA-S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADENYLYL CYCLASE; LUTEINIZING-HORMONE; BINDING PROTEINS; BETA-SUBUNIT; MEMBRANES; CHANNELS; RECEPTOR; ASSAY; CELLS	An ion-counterion interaction between the lysine of the NKXD motif in the GTPase domain and an aspartate in the inserted helical domain of cu subunits of heterotrimeric G proteins, Lys-278 and Asp-158, respectively, of G(s) alpha is shown to be essential for activation by AlF4- and partially so for interaction with beta gamma dimers and activation by GTP and receptor. However, this domain interaction is not required for activation by the non-hydrolyzable analog guanosine 5'-3-O-(thio)triphosphate. Proximity of the helical domain to the GTPase domain is thus involved in the fundamental inactive --> active transition of the protein in a way that further distinguishes alpha subunits of heterotrimeric G proteins from ras and ras-like GTPases that lack helical domains and are neither activated by AlF4- nor combine with beta gamma dimers.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine					NHLBI NIH HHS [HL-45198] Funding Source: Medline; NIDDK NIH HHS [DK-19318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019318, R37DK019318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONELLI M, 1994, FEBS LETT, V340, P249, DOI 10.1016/0014-5793(94)80148-7; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BIRNBAUMER L, 1976, ENDOCRINOLOGY, V99, P163, DOI 10.1210/endo-99-1-163; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHARDIN P, 1993, GTPASES BIOL, V1, P159; CLARK GJ, 1993, GTPASES BIOL, V1, P177; CODINA J, 1991, J RECEPTOR RES, V11, P587, DOI 10.3109/10799899109066429; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DER CJ, 1988, ONCOGENE, V3, P105; Dickey B.F., 1993, GTPASES BIOL; Dickey B.F., 1993, GTPASES BIOL, VII; GRAF R, 1992, EUR J BIOCHEM, V210, P609, DOI 10.1111/j.1432-1033.1992.tb17461.x; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HWANG YW, 1987, J BIOL CHEM, V262, P13081; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KIM SH, 1993, GTPASES BIOL, P177; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MATTERA R, 1986, FEBS LETT, V206, P36, DOI 10.1016/0014-5793(86)81336-9; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OLATE J, 1988, J BIOL CHEM, V263, P10394; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; ROSS EM, 1977, J BIOL CHEM, V252, P5761; ROSS EM, 1977, J BIOL CHEM, V252, P6966; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANFORD J, 1991, J BIOL CHEM, V266, P9570; WEI XY, 1991, J BIOL CHEM, V266, P21943	31	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29339	29342						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961906				2022-12-25	WOS:A1994PU28400002
J	EMMANUEL, F; STEINMETZ, A; ROSSENEU, M; BRASSEUR, R; GOSSELET, N; ATTENOT, F; CUINE, S; SEGURET, S; LATTA, M; FRUCHART, JC; DENEFLE, P				EMMANUEL, F; STEINMETZ, A; ROSSENEU, M; BRASSEUR, R; GOSSELET, N; ATTENOT, F; CUINE, S; SEGURET, S; LATTA, M; FRUCHART, JC; DENEFLE, P			IDENTIFICATION OF SPECIFIC AMPHIPATHIC ALPHA-HELICAL SEQUENCE OF HUMAN APOLIPOPROTEIN A-IV INVOLVED IN LECITHIN-CHOLESTEROL ACYLTRANSFERASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SYNTHETIC PEPTIDE ANALOGS; METAL CHELATE ADSORBENT; DISCOIDAL COMPLEXES; HUMAN-PLASMA; SECONDARY STRUCTURE; CNBR FRAGMENTS; APOA-I; C-III; PROTEINS	To investigate the structure-function relationship of human apolipoprotein A-IV (apoA-IV), several deletion mutants of this protein were constructed by sequentially removing pairs of ga-residue repeats, potentially having an amphipathic cu-helical conformation. The mutants, produced as recombinant poly-histidine tagged apolipoproteins (t-apo) in Escherichia coli, assembled with phosphatidylcholine (i.e. dimyristoylphosphatidylcholine, palmitoyloleoylphosphatidylcholine, or egg lecithin) as did native apoA-IV. Lecithin:cholesterol acyltransferase (LCAT) cofactor function, measured as cholesterol esterification occurring when t-apo-phosphatidylcholine-cholesterol complexes were incubated with purified enzyme, decreased significantly when pairs of repeats between residues 117 and 248 were deleted and most markedly when residues 117-160 were deleted. LCAT cofactor activity decreased by 90 and 75%, respectively, when egg lecithin or palmitoyloleoylphosphatidylcholine was used to form the particles with the Delta aa 117-160 mutant, Thus, on the basis of deletion scanning of t-apo, residues 117-160 seem to be involved in the LCAT cofactor function of apoA-IV.	RHONE POULENC RORER SA,DEPT BIOTECHNOL,VITRY,FRANCE; UNIV MARBURG,W-3550 MARBURG,GERMANY; ALGEMEEN ZIEKENHUIS ST JAN,DEPT CLIN CHEM,BRUGGE,BELGIUM; FREE UNIV BRUSSELS,MACROMOLEC INTERFACES LAB,BRUSSELS,BELGIUM; INST PASTEUR,F-59019 LILLE,FRANCE	Sanofi-Aventis; Philipps University Marburg; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille								ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P626; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BISGAIER CL, 1985, J LIPID RES, V26, P11; BONELLI FS, 1989, J BIOL CHEM, V264, P14723; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTRO GR, 1992, HUMAN APOLIPOPROTEIN, V73, P43; CHEN CH, 1985, BIOCHIM BIOPHYS ACTA, V836, P279, DOI 10.1016/0005-2760(85)90131-6; CHEN CH, 1982, J LIPID RES, V23, P680; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; DIEPLINGER H, 1992, EUR J CLIN INVEST, V22, P166, DOI 10.1111/j.1365-2362.1992.tb01822.x; DUVERGER N, 1991, EUR J BIOCHEM, V201, P373, DOI 10.1111/j.1432-1033.1991.tb16294.x; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; EPAND RM, 1987, J BIOL CHEM, V262, P9389; FUKUSHIMA D, 1980, J BIOL CHEM, V255, P651; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GORDON JI, 1984, J BIOL CHEM, V259, P468; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P486; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; JONAS A, 1991, J LIPID RES, V32, P97; JONAS A, 1978, J BIOL CHEM, V253, P5758; JONAS A, 1984, J BIOL CHEM, V259, P6369; JONAS A, 1982, BIOCHEMISTRY-US, V21, P6867, DOI 10.1021/bi00269a037; JUNG G, 1988, ANN INST PASTEUR MIC, V139, P129, DOI 10.1016/0769-2609(88)90100-7; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGROST L, 1989, J LIPID RES, V30, P1525; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; LINS L, 1993, BIOCHIM BIOPHYS ACTA, V1149, P267, DOI 10.1016/0005-2736(93)90210-Q; Lohse P., 1991, CURR OPIN LIPIDOL, V2, P90; MINNICH A, 1992, J BIOL CHEM, V267, P16553; ORDOVAS JM, 1989, J BIOL CHEM, V264, P16339; PONNUSWAMY PK, 1992, PROTEIN SEQUENCES DA, P47; RADER DJ, 1993, J CLIN INVEST, V92, P1009, DOI 10.1172/JCI116606; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SCHAMAUN O, 1984, HUM GENET, V68, P181, DOI 10.1007/BF00279311; SEGREST JP, 1992, J LIPID RES, V33, P141; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINMETZ A, 1989, BIOCHIM BIOPHYS ACTA, V1006, P173, DOI 10.1016/0005-2760(89)90192-6; STEINMETZ A, 1985, EUR J BIOCHEM, V152, P747, DOI 10.1111/j.1432-1033.1985.tb09256.x; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; SWANEY JB, 1974, BIOCHEM BIOPH RES CO, V59, P513, DOI 10.1016/S0006-291X(74)80010-0; TENKANEN H, 1991, ARTERIOSCLER THROMB, V11, P851, DOI 10.1161/01.ATV.11.4.851; Tenkanen Heli, 1993, Current Opinion in Lipidology, V4, P95, DOI 10.1097/00041433-199304000-00004; VANLOO B, 1992, BIOCHIM BIOPHYS ACTA, V1128, P258, DOI 10.1016/0005-2760(92)90316-N; VANLOO B, 1991, J LIPID RES, V32, P1253; WALD JH, 1990, J BIOL CHEM, V265, P20037; WEINBERG RB, 1990, J BIOL CHEM, V265, P18372; WEINBERG RB, 1985, J BIOL CHEM, V260, P4279	58	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29883	29890						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961983				2022-12-25	WOS:A1994PU28400087
J	LEPRETRE, N; MIRONNEAU, J; MOREL, JL				LEPRETRE, N; MIRONNEAU, J; MOREL, JL			BOTH ALPHA(1A)-ADRENOCEPTOR AND ALPHA(2A)-ADRENOCEPTOR SUBTYPES STIMULATE VOLTAGE-OPERATED L-TYPE CALCIUM CHANNELS IN RAT PORTAL-VEIN MYOCYTES - EVIDENCE FOR 2 DISTINCT TRANSDUCTION PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE; ADRENERGIC-RECEPTORS; ALPHA-1-ADRENOCEPTOR SUBTYPES; ALPHA-2-ADRENERGIC RECEPTORS; NORADRENALINE; ACTIVATION; CURRENTS; BINDING; CELLS	Previously, we have shown that myocytes hom rat portal vein express cu,alpha(1A)-adrenoreceptors that couple with a G(q)/G(11)-protein to stimulate phosphoinositide turnover and release of calcium from intracellular stores. The purpose of this study was to investigate the contribution of both alpha(1)- and alpha(2)-adrenoreceptor subtypes in inducing stimulation of voltage-operated calcium channels. Norepinephrine (a nonselective a-adrenoreceptor agonist), phenylephrine (an alpha(1)-adrenoreceptor agonist), clonidine, and oxymetazoline (alpha(2)-adrenoreceptor agonists) stimulated the calcium channel current by a similar extent. Using subtype-selective antagonists we showed that both alpha(1A)- and alpha(2A)-adrenoreceptors modulated voltage-operated calcium channels through two distinct transduction pathways. alpha(1A)-Adrenoreceptors coupled with a pertussis toxin-insensitive G-protein whereas alpha(2A)-adrenoreceptors coupled with a pertussis toxin-sensitive G-protein. Portal vein myocytes expressed G-proteins that were recognized by anti-alpha(q)/alpha(11), -alpha(i(1-2)), and -alpha(i(3)) antibodies. As internal applications of anti-phosphatidylinositol and anti-alpha(q)/alpha(11) antibodies had no effect on the alpha(2A)-adrenoreceptor-induced enhancement of calcium channel current, these findings suggest that phosphatidylinositol hydrolysis and G(q)/G(11)-protein are not involved in the alpha(2A)-adrenoreceptor-induced coupling process. A protein kinase C inhibitor, GF 109203X, and a long term (24 h) treatment with phorbol dibutyrate to decrease the activity of protein kinase C blocked the alpha(1A)- and alpha(2A)-adrenoreceptor-induced stimulation of calcium channels as well as that stimulation induced by phorbol dibutyrate. Moreover, activation of alpha(2A)-adrenoreceptors did not induce a significant calcium release from intracellular stores. These data suggest that two distinct G-proteins, probably G(q)/G(11) and G(i), coupled to alpha(1A)- and alpha(2A)-adrenoreceptors regulate calcium influx through voltage-operated calcium channels by two different transduction pathways leading to activation of protein kinase C.	UNIV BORDEAUX 2,PHYSIOL CELLULAIRE & PHARMACOL MOLEC LAB,CNRS,URA 1489,F-33076 BORDEAUX,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux			Morel, Jean-Luc/AAY-9235-2020	MACREZ, Nathalie/0000-0002-3844-4403; morel, jean-luc/0000-0001-8079-6851				AHMAD S, 1991, CAN J PHYSIOL PHARM, V69, P837, DOI 10.1139/y91-126; ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; BARON A, 1994, EUR J PHARM-MOLEC PH, V269, P105, DOI 10.1016/0922-4106(94)90032-9; BYLUND DB, 1992, FASEB J, V6, P832, DOI 10.1096/fasebj.6.3.1346768; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DEVEDJIAN JC, 1994, EUR J PHARMACOL, V252, P43, DOI 10.1016/0014-2999(94)90573-8; EXTON JH, 1990, J BIOL CHEM, V265, P1; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAN C, 1987, NATURE, V329, P333, DOI 10.1038/329333a0; HEIKKILA J, 1993, BIOCHEM BIOPH RES CO, V197, P1185, DOI 10.1006/bbrc.1993.2602; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LEPRETRE N, 1994, J PHARMACOL EXP THER, V268, P167; LOIRAND G, 1990, J PHYSIOL-LONDON, V428, P517, DOI 10.1113/jphysiol.1990.sp018225; LOIRAND G, 1992, J BIOL CHEM, V267, P4312; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; MIRONNEAU C, 1991, EUR J PHARM-MOLEC PH, V208, P223, DOI 10.1016/0922-4106(91)90099-4; NEBIGIL C, 1992, J PHARMACOL EXP THER, V260, P849; PACAUD P, 1991, BRIT J PHARMACOL, V104, P1000, DOI 10.1111/j.1476-5381.1991.tb12540.x; RUFFOLO RR, 1994, MED RES REV, V14, P229, DOI 10.1002/med.2610140204; RUFFOLO RR, 1993, ANN REV PHARM TOXICO, V32, P243; SAYET I, 1993, BRIT J PHARMACOL, V110, P207, DOI 10.1111/j.1476-5381.1993.tb13793.x; SCHWINN DA, 1992, EUR J PHARM-MOLEC PH, V227, P433, DOI 10.1016/0922-4106(92)90162-O; STROSBERG AD, 1993, PROTEIN SCI, V2, P1198, DOI 10.1002/pro.5560020802; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSAI H, 1993, EUR J PHARMACOL, V237, P311, DOI 10.1016/0014-2999(93)90283-N; UHLEN S, 1992, BRIT J PHARMACOL, V106, P986, DOI 10.1111/j.1476-5381.1992.tb14446.x; XIAO XH, 1989, BRIT J PHARMACOL, V98, P1032, DOI 10.1111/j.1476-5381.1989.tb14635.x	29	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29546	29552						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961939				2022-12-25	WOS:A1994PU28400038
J	TORCHIA, J; YI, Q; SEN, AK				TORCHIA, J; YI, Q; SEN, AK			CARBACHOL-STIMULATED PHOSPHORYLATION OF THE NA-K-CL COTRANSPORTER OF AVIAN SALT-GLAND - REQUIREMENT FOR CA2+ AND PKC ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SHARK RECTAL GLAND; H-3 BUMETANIDE BINDING; NA+/K+/CL COTRANSPORT; PHORBOL ESTERS; CYCLIC-AMP; CALCIUM MOBILIZATION; NA/K/2CL COTRANSPORT; INTRACELLULAR CA-2+; CELLS	The Na-K-CI cotransporter of avian salt gland is a membrane-bound 170-kDa protein that is phosphorylated in response to cAMP- and Ca2+-dependent secretegogues and is homologous to the Na-L-Cl cotransporter in another Cl-secreting epithelia; the shark rectal gland (Torchia, J., Lytle, C., Pen, D. J., Forbush, B., and Sen, A a (1992) J. Biol. Chem. 267, 25444-25450). In the present study we assess the role of Ca2+ and protein kinase C (PKC) activation on the phosphorylation of the Na-II-CI cotransporter. Although the addition of ionomycin alone did not significantly stimulate cotransporter phosphorylation, concurrent addition of ionomycin plus the tumor promoter phorbol 12-myristate 13-acetate (PMA) resulted in a concentration-dependent increase in phosphorylation. Immunoprecipitation experiments, using a monoclonal antibody which specifically recognizes the cotransporter, suggested that the response to CCh or ionomycin plus PMA was quantitatively similar (5-fold) and was localized exclusively on serine residues. In contrast, when 4 alpha-phorbol was added in the presence of ionomycin, no stimulation was observed. To further assess the involvement of PKC on cotransporter phosphorylation the effects of protein kinase inhibitors were tested. Both staurosporine and calphostin C inhibited phosphorylation of the cotransporter at concentrations known to inhibit PHC, whereas the calmodulin antagonist W-7 had no significant effect. The requirement for Ca2+ was tested further by removing Ca2+ from the incubation medium and stimulating with CCh. Under these conditions, the CCh-stimulated phosphorylation was transient and, furthermore, could be completely inhibited by preloading the cells with the Ca2+ chelator BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid) prior to stimulation. The involvement of protein phosphatases on the phosphorylation of the Na-L-Cl cotransporter was also tested. The addition of okadaic acid stimulated phosphorylation by approximately 3-fold Taken together these results suggest that the phosphorylation state of the cotransporter involves a dynamic interplay between changes in intracellular Ca2+, PKC, and protein phosphatase activities.	UNIV TORONTO, DEPT PHARMACOL, TORONTO M5S 1A8, ON, CANADA	University of Toronto								ALTAMIRANO AA, 1987, J GEN PHYSIOL, V89, P669, DOI 10.1085/jgp.89.5.669; BLACKSHEAR PJ, 1988, AM J MED SCI, V296, P231, DOI 10.1016/S0002-9629(15)40866-3; BONEH A, 1989, BIOCHIM BIOPHYS ACTA, V1012, P308, DOI 10.1016/0167-4889(89)90113-4; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COHEN P, 1989, J BIOL CHEM, V264, P21435; DUHM J, 1984, J MEMBRANE BIOL, V77, P243, DOI 10.1007/BF01870572; FEARON CW, 1985, J BIOL CHEM, V260, P8366; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; FRANKLIN CC, 1989, J BIOL CHEM, V264, P6667; GARAY RP, 1982, BIOCHIM BIOPHYS ACTA, V688, P786, DOI 10.1016/0005-2736(82)90292-9; GECK P, 1980, BIOCHIM BIOPHYS ACTA, V600, P432, DOI 10.1016/0005-2736(80)90446-0; HAAS M, 1988, BIOCHIM BIOPHYS ACTA, V939, P131, DOI 10.1016/0005-2736(88)90054-5; HAAS M, 1987, AM J PHYSIOL, V253, pC243, DOI 10.1152/ajpcell.1987.253.2.C243; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HOKIN MR, 1967, J GEN PHYSIOL, V50, P793, DOI 10.1085/jgp.50.4.793; HOMMA T, 1990, J BIOL CHEM, V265, P17613; IWATSUKI N, 1985, JPN J PHYSIOL, V35, P933, DOI 10.2170/jjphysiol.35.933; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KIM HD, 1988, BIOCHIM BIOPHYS ACTA, V946, P397, DOI 10.1016/0005-2736(88)90415-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU S, 1987, AM J PHYSIOL, V253, pC721, DOI 10.1152/ajpcell.1987.253.5.C721; LOWY JR, 1985, J CELL BIOL, V101, P478; LOWY RJ, 1987, AM J PHYSIOL, V253, pR801, DOI 10.1152/ajpregu.1987.253.6.R801; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, J BIOL CHEM, V267, P25438; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MARSHALL AT, 1985, J COMP PHYSIOL B, V156, P213, DOI 10.1007/BF00695776; MAY WS, 1985, NATURE, V317, P549, DOI 10.1038/317549a0; ODONNELL ME, 1991, J BIOL CHEM, V266, P11559; ODONNELL ME, 1989, AM J PHYSIOL, V257, pC36, DOI 10.1152/ajpcell.1989.257.1.C36; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P9146; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; Peaker M., 1975, SALT GLANDS BIRDS RE; PEWITT EB, 1990, J BIOL CHEM, V265, P14364; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RICHARDS NW, 1989, J GEN PHYSIOL, V93, P1171, DOI 10.1085/jgp.93.6.1171; SHUTTLEWORTH TJ, 1987, AM J PHYSIOL, V252, pR428, DOI 10.1152/ajpregu.1987.252.2.R428; SHUTTLEWORTH TJ, 1989, AM J PHYSIOL 1, V257, pC1020; SIESS W, 1988, BIOCHEM J, V255, P309; SMITH JB, 1987, J MEMBRANE BIOL, V99, P51, DOI 10.1007/BF01870621; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; STEWART DJ, 1979, AM J PHYSIOL, V237, pC200, DOI 10.1152/ajpcell.1979.237.5.C200; STUENKEL EL, 1990, AM J PHYSIOL, V258, pC289, DOI 10.1152/ajpcell.1990.258.2.C289; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TORCHIA J, 1992, J BIOL CHEM, V267, P25444; TORCHIA J, 1991, AM J PHYSIOL, V261, pC543, DOI 10.1152/ajpcell.1991.261.3.C543; TOSKULKAO C, 1990, AM J PHYSIOL, V258, pC879, DOI 10.1152/ajpcell.1990.258.5.C879; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	52	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29778	29784						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961970				2022-12-25	WOS:A1994PU28400073
J	HICKMAN, AB; PALMER, I; ENGELMAN, A; CRAIGIE, R; WINGFIELD, P				HICKMAN, AB; PALMER, I; ENGELMAN, A; CRAIGIE, R; WINGFIELD, P			BIOPHYSICAL AND ENZYMATIC-PROPERTIES OF THE CATALYTIC DOMAIN OF HIV-1 INTEGRASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CIRCULAR DICHROIC ANALYSIS; DNA-BINDING; VIRAL-DNA; POLYNUCLEOTIDYL TRANSFER; SEQUENCE REQUIREMENTS; RETROVIRUS INTEGRASE; PROTEIN CONFORMATION; ANGSTROM RESOLUTION; MUTATIONAL ANALYSIS	A deletion derivative of the integrase protein from human immunodeficiency virus type-1 (HIV-1) consisting of the central core domain (amino acids 50-212) has been characterized biophysically and biochemically. This deletion mutant is of particular interest for structural studies as it can carry out the disintegration reaction suggesting the presence of an active site and, under certain conditions, is more soluble than full-length integrase. The circular dichroism and fluorescence of the deletion mutant and the 288-residue full-length integrase were similar, indicating that the core residues maintain similar overall conformations in both proteins. The deletion mutant is approximately 10% more alpha-helical than the full-length protein. Analytical centrifugation demonstrated that both proteins undergo monomer-dimer association although the truncated protein showed slightly less tendency to dimerize; the dissociation constants were 2.5 x 10(-5) M for the full-length protein and 8.0 x 10(-5) M for the truncated protein. The disintegration activity of both proteins was also compared. Although a higher concentration of the truncation mutant was required for optimal activity, the mutant did not have altered pH or Mn2+ requirements relative to the full-length protein. The combined biophysical and enzymatic studies suggest that this truncated form of HIV-1 integrase is likely to be useful for structural studies.	NIDDK, MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NIH, PROT EXPRESS LAB, OFF DIRECTOR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA				Wingfield, Paul/0000-0002-9515-4752				ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; BUSHMAN FD, 1990, J VIROL, V64, P5645, DOI 10.1128/JVI.64.11.5645-5648.1990; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; Coffin J. M., 1990, VIROLOGY, P1437; Cohn E. J., 1943, PROTEINS AMINO ACIDS; CRAIGIE R, 1994, IN PRESS HIV, V2; DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; ERICKSON JW, 1992, ANNU REP MED CHEM, V27, P271; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; GRANDGENETT DP, 1978, VIROLOGY, V89, P119, DOI 10.1016/0042-6822(78)90046-6; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JONES KS, 1992, J BIOL CHEM, V267, P16037; KALPANA GV, 1993, P NATL ACAD SCI USA, V90, P10593, DOI 10.1073/pnas.90.22.10593; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; KUNTZ ID, 1971, J AM CHEM SOC, V93, P514, DOI 10.1021/ja00731a036; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; LIN TH, 1989, PROTEINS, V5, P156, DOI 10.1002/prot.340050210; MAZUMDER A, 1994, NUCLEIC ACIDS RES, V22, P1037, DOI 10.1093/nar/22.6.1037; McRorie D. K., 1993, SELF ASS SYSTEMS ANA; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MULLER B, 1993, P NATL ACAD SCI USA, V90, P11633, DOI 10.1073/pnas.90.24.11633; MUMM SR, 1991, J VIROL, V65, P1160, DOI 10.1128/JVI.65.3.1160-1167.1991; PEPINSKY RB, 1991, ANAL BIOCHEM, V195, P177, DOI 10.1016/0003-2697(91)90315-K; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROTH MJ, 1991, J VIROL, V65, P2141, DOI 10.1128/JVI.65.4.2141-2145.1991; ROTH MJ, 1988, J MOL BIOL, V203, P131, DOI 10.1016/0022-2836(88)90097-6; SCHAUER M, 1992, BIOCHEM BIOPH RES CO, V185, P874, DOI 10.1016/0006-291X(92)91708-X; SCHERAGA HA, 1961, PROTEIN STRUCTURE; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VANHOLDE KE, 1975, PROTEINS, V1, P225; VENYAMINOV SY, 1993, ANAL BIOCHEM, V214, P17, DOI 10.1006/abio.1993.1450; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VINK C, 1994, J VIROL, V68, P1468, DOI 10.1128/JVI.68.3.1468-1474.1994; Washburn EW., 1929, INT CRITICAL TABLES; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WINGFIELD P, 1988, EUR J BIOCHEM, V173, P65, DOI 10.1111/j.1432-1033.1988.tb13967.x; WINGFIELD PT, 1987, PROTEIN ENG, V1, P413, DOI 10.1093/protein/1.5.413; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WOERNER AM, 1992, AIDS RES HUM RETROV, V8, P297, DOI 10.1089/aid.1992.8.297; YANG JT, 1986, METHOD ENZYMOL, V130, P208	66	70	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29279	29287						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961898				2022-12-25	WOS:A1994PU16800111
J	HUANG, SA; CHAKRABARTY, S				HUANG, SA; CHAKRABARTY, S			EXPRESSION OF ANTISENSE FIBRONECTIN RNA IN HUMAN COLON-CARCINOMA CELLS DISRUPTS THE REGULATION OF CARCINOEMBRYONIC ANTIGEN BY TRANSFORMING GROWTH-FACTOR-BETA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; GENE-EXPRESSION; MESSENGER-RNAS; DIFFERENTIATION; PROLIFERATION; FACTOR-BETA-1; MODULATION; INHIBITION; ADHESION; COLLAGEN	Transforming growth factor beta 1 regulates the expression of extracellular matrix adhesion molecules and the carcinoembryonic antigen gene family of glycoproteins in the Moser colon carcinoma cell line. Expression of fibronectin antisense RNA in the Moser cells down-regulated fibronectin mRNA expression and blocked the ability of transforming growth factor beta 1 to stimulate fibronectin secretion. Cells expressing antisense fibronectin RNA exhibited a higher rate of proliferation, changed their morphology, and produced more laminin in response to treatment with transforming growth factor beta 1. The stimulation of carcinoembryonic antigen secretion by transforming growth factor beta 1 (which normally lagged 10-16 h behind that of fibronectin secretion stimulated by transforming growth factor beta 1) was blocked by the expression of antisense fibronectin RNA. Thus, the stimulation of fibronectin secretion by transforming growth factor beta 1 was a prerequisite for subsequent stimulation of carcinoembryonic antigen secretion. In addition, the stimulation of the cellular expression of carcinoembryonic antigen and three carcinoembryonic antigen cross-reactive species of glyco proteins by transforming growth factor beta 1 was downmodulated in cells expressing antisense fibronectin RNA. We therefore conclude that fibronectin may play an important role in the mechanisms of transforming growth factor beta 1 regulation of the expression of carcinoembryonic antigen gene family of glycoproteins.	UNIV TEXAS,MD ANDERSON CANC CTR,DIV LAB MED,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R29CA047775, R01CA047775] Funding Source: NIH RePORTER; NCI NIH HHS [CA47775] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHAKRABARTY S, 1992, J CELL PHYSIOL, V152, P494, DOI 10.1002/jcp.1041520308; CHAKRABARTY S, 1992, INT J CANCER, V50, P968, DOI 10.1002/ijc.2910500624; CHAKRABARTY S, 1990, INT J CANCER, V46, P493, DOI 10.1002/ijc.2910460328; CHAKRABARTY S, 1989, CANCER RES, V49, P212; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DEAN DC, 1991, AM REV RESPIR DIS, V144, pS25, DOI 10.1164/ajrccm/144.3_pt_2.S25; HUANG S, 1992, INT J CANCER, V52, P978, DOI 10.1002/ijc.2910520625; HUANG S, 1991, J CELL PHYSIOL, V148, P220, DOI 10.1002/jcp.1041480206; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LEVINE AE, 1992, INT J CANCER, V50, P653, DOI 10.1002/ijc.2910500429; LIN CQ, 1993, FASEB J, V7, P735; MARKS ME, 1986, CANCER RES, V46, P5248; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PIGNATELLI M, 1988, P NATL ACAD SCI USA, V85, P5561, DOI 10.1073/pnas.85.15.5561; RUOSLAHTI E, 1984, CANCER METAST REV, V3, P43, DOI 10.1007/BF00047692; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; Sambrook J, 1989, MOL CLONING LABORATO; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; THOMPSON J, 1988, TUMOR BIOL, V9, P63, DOI 10.1159/000217547; VARANI J, 1990, J CELL PHYSIOL, V143, P445, DOI 10.1002/jcp.1041430307; VARANI J, 1991, MICROCIRCULATION CAN; WICHA MS, 1982, P NATL ACAD SCI-BIOL, V79, P3213, DOI 10.1073/pnas.79.10.3213; WIRTH PJ, 1992, ELECTROPHORESIS, V13, P305, DOI 10.1002/elps.1150130163; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; YUEHWA E, 1985, P NATL ACAD SCI USA, V82, P1419	37	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28764	28768						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961830				2022-12-25	WOS:A1994PU16800040
J	LU, D; BOVILL, EG; LONG, GL				LU, D; BOVILL, EG; LONG, GL			MOLECULAR MECHANISM FOR FAMILIAL PROTEIN-C DEFICIENCY AND THROMBOSIS IN PROTEIN C-VERMONT (GLU(20)-]ALA AND VAL(34)-]MET)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; K-DEPENDENT PROTEINS; PHOSPHOLIPID-VESICLES; POLYACRYLAMIDE GELS; NUCLEIC-ACIDS; FORCE-FIELD; GLA DOMAIN; FACTOR-IX; FACTOR-V; PROTHROMBIN	The role of two protein C gamma-carboxyglutamic acid domain mutations in familial thrombosis, protein C-Vermont (Bovill, E. G., Tomczak, J. A., Grant, B., Bhushan, F., Pillemer, E., Rainville, I. R., and Long, G. L. (1992) Blood 79, 1456-1465), was investigated. Two single mutations (Glu(20) --> Ala and Val(34) --> Met) and the naturally occurring double mutation mere created by site directed mutagenesis and were expressed in human kidney 293 cells. Purified recombinant protein C with the mutation glutamate to alanine at position 20 is defective in the assays of activated partial thromboplastin time, factor Va inactivation, and fibrinolysis. Mutation from valine to methionine at position 34 has only a minor effect. Activation of Glu(20) mutants by thrombin-thrombomodulin was not enhanced by phospholipid vesicles and showed a different calcium dependence compared with the wild type, suggesting that Gla(20) is important in the interaction of the protein C Gla domain with a phospholipid-mediated site on the thrombomodulin molecule. Glu(20)-substituted protein C is not inhibited by calcium ion in its interaction with the calcium-dependent monoclonal antibody H-11, suggesting that this mutation has lost the calcium-induced, lipid-independent conformational transition of the protein C Gla domain. These data indicate that the loss of Gla(20) causes the major familial dysfunction of protein C to associate with phospholipid as well as to undergo Ca2+-dependent, lipid-independent conformational changes and are consistent with the importance of Gla(20) in both external and internal Ca2+ binding based upon the x-ray-derived structure of the homologous Gla domain in bovine prothrombin.	UNIV VERMONT, COLL MED, DEPT BIOCHEM, BURLINGTON, VT 05405 USA; UNIV VERMONT, COLL MED, DEPT PATHOL, BURLINGTON, VT 05405 USA	University of Vermont; University of Vermont					NHLBI NIH HHS [C06-HL39475] Funding Source: Medline; PHS HHS [P01-46703] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAJAJ SP, 1983, PREP BIOCHEM, V13, P191, DOI 10.1080/00327488308064248; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; BOVILL EG, 1989, BLOOD, V73, P712; BOVILL EG, 1992, BLOOD, V79, P1456, DOI 10.1182/blood.V79.6.1456.bloodjournal7961456; BROEKMANS AW, 1983, NEW ENGL J MED, V309, P340, DOI 10.1056/NEJM198308113090604; CHURCH WR, 1989, BLOOD, V74, P2418; CHURCH WR, 1989, J BIOL CHEM, V264, P17882; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; Freshney R. I., 1987, CULTURE ANIMAL CELLS, P137; FREYSSINET JM, 1986, BIOCHEM J, V238, P151, DOI 10.1042/bj2380151; FULCHER C, 1983, FED PROC, V42, P1176; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HORELLOU MH, 1984, BRIT MED J, V289, P1285, DOI 10.1136/bmj.289.6454.1285; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KUSTER H, 1992, J BIOL CHEM, V267, P12782; KUWADA M, 1981, ANAL BIOCHEM, V117, P259, DOI 10.1016/0003-2697(81)90720-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONG GL, 1987, J CELL BIOCHEM, V33, P185, DOI 10.1002/jcb.240330305; LU DS, 1994, BLOOD, V84, P687; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1990, ADV AP BIOT, V11, P119; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SUTTIE JW, 1987, P NATL ACAD SCI USA, V84, P634, DOI 10.1073/pnas.84.3.634; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHANG L, 1993, J BIOL CHEM, V268, P12040; ZHANG L, 1992, BLOOD, V80, P942	47	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29032	29038						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961868				2022-12-25	WOS:A1994PU16800078
J	SAHU, A; PANGBURN, MK				SAHU, A; PANGBURN, MK			COVALENT ATTACHMENT OF HUMAN-COMPLEMENT C3 TO IGG - IDENTIFICATION OF THE AMINO-ACID RESIDUE INVOLVED IN ESTER LINKAGE FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE PRECIPITATION; ALTERNATIVE PATHWAY; BINDING-SITE; HEAVY-CHAIN; MEDIATED INHIBITION; 3RD COMPONENT; ANTIBODY; C-3; ACTIVATION; SYSTEM	C3 (native complement component 3) plays a central role in the activation of complement and in the transport and processing of immune complexes. Proteolytic activation of C3 exposes a highly reactive thioester bond which preferentially reacts with the hydroxyl groups of acceptor molecules on activators such as immune complexes or carbohydrates on microorganisms. Recently, a C3 attachment site has been localized on the CH1 domain of IgG(1) between Val(134) and Lys(156). We have synthesized a series of peptide analogs of this region to identify the preferred residue for C3b (the proteolytically activated form of C3) attachment. The parent peptide included all 6 hydroxyl-containing amino acids present in the proposed binding site and was highly reactive with activated C3. The C3b-peptide complex was sensitive to hydroxylamine as was C3b-IgG indicating that both were ester linked. The kinetic profile of hydrolysis of the C3b-peptide complex under physiologic conditions was found to be nearly identical to the profiles of C3b-IgG, C3b-IgG(1), and C3b-glycerol complexes. Site-specific amino acid substitution of threonine and serine residues in the peptide indicated that, in contrast to the attachment site in C4b, little or no attachment occurred at serine residues. The threonine corresponding to Thr(144) in the CH1 domain of IgG was found to be the major acceptor site for C3b. Thr(148) was the second most reactive site on the peptide, but this residue is buried in native IgG.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,TYLER,TX 75710	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)			Sahu, Arvind/C-2178-2012		NIDDK NIH HHS [DK-35081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035081, R01DK035081] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anton L. C., 1993, Molecular Immunology, V30, P1; ANTON LC, 1989, BIOCHEM J, V257, P831, DOI 10.1042/bj2570831; BALLOW M, 1969, J IMMUNOL, V103, P944; CAPEL PJA, 1978, J IMMUNOL, V121, P2566; DODDS AW, 1988, COMPLEMENT INFLAMMAT, V5, P89, DOI 10.1159/000463039; FEARON DT, 1984, IMMUNOL TODAY, V5, P105, DOI 10.1016/0167-5699(84)90044-6; GADD KJ, 1981, IMMUNOLOGY, V42, P75; GADD KJ, 1981, BIOCHEM J, V195, P471, DOI 10.1042/bj1950471; GOTZE O, 1970, J EXP MED, V132, P898, DOI 10.1084/jem.132.5.898; GOTZE O, 1971, J EXP MED, V134, pS90; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; HONG K, 1984, J IMMUNOL, V133, P1464; KIM YU, 1992, J BIOL CHEM, V267, P4171; LAW SK, 1979, J IMMUNOL, V123, P1388; LAW SKA, 1981, BIOCHEMISTRY-US, V20, P7457, DOI 10.1021/bi00529a020; LAW SKA, 1990, BIOCHEM SOC T, V18, P1155; LESAVRE PH, 1979, J IMMUNOL, V123, P529; LEVINE RP, 1989, CURR TOP MICROBIOL I, V153, P73; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MILLER GW, 1975, P NATL ACAD SCI USA, V72, P418, DOI 10.1073/pnas.72.2.418; ONEIL KM, 1988, J IMMUNOL, V140, P1939; PANGBURN MK, 1987, J IMMUNOL METHODS, V102, P7, DOI 10.1016/S0022-1759(87)80003-0; REID R, 1994, FASEB J, V8, pA768; SAHU A, 1994, BIOCHEM J, V302, P429, DOI 10.1042/bj3020429; SCHIFFERLI JA, 1982, CLIN EXP IMMUNOL, V47, P555; SCHIFFERLI JA, 1982, CLIN EXP IMMUNOL, V47, P563; SCHIFFERLI JA, 1980, CLIN EXP IMMUNOL, V42, P387; SHOHET JM, 1991, J BIOL CHEM, V266, P18520; SHOHET JM, 1993, J BIOL CHEM, V268, P5866; SIM RB, 1981, BIOCHEM J, V193, P115, DOI 10.1042/bj1930115; TACK BF, 1980, J BIOL CHEM, V255, P8842; TAKATA Y, 1984, J IMMUNOL, V132, P2531; VENKATESH YP, 1984, J IMMUNOL, V132, P1435	33	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28997	29002						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961863				2022-12-25	WOS:A1994PU16800073
J	SINGH, Y; KLIMPEL, KR; ARORA, N; SHARMA, M; LEPPLA, SH				SINGH, Y; KLIMPEL, KR; ARORA, N; SHARMA, M; LEPPLA, SH			THE CHYMOTRYPSIN-SENSITIVE SITE, FFD315, IN ANTHRAX TOXIN PROTECTIVE ANTIGEN IS REQUIRED FOR TRANSLOCATION OF LETHAL FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; BACILLUS-ANTHRACIS; PSEUDOMONAS EXOTOXIN; ADENYLATE-CYCLASE; LOW-PH; CELLS; SEQUENCE; CYTOSOL; ENTRY; MACROPHAGES	The protective antigen (PA) component of anthrax toxin contains two sites that are uniquely sensitive to proteolytic cleavage. Cleavage at the sequence RKKR(167) by the cellular protease furin is absolutely required for toxicity, whereas cleavage by chymotrypsin or thermolysin at the sequence FFD315 inactivates the protein, apparently by blocking the ability of PA to translocate the catalytic moieties of the toxins, lethal factor (LF) and edema factor (EF), to the cytosol of eukaryotic cells. To specify the role of the chymotrypsin-sensitive site of PA in the translocation of LF, we altered residues 313-315. None of the mutations in this region interfered with the ability of PA to bind to its cellular receptor, be cleaved by cell surface furin, and bind LF. Substitution of Ala for Asp(315) Or for both Phe(313) and Phe(314) reduced the ability of PA to intoxicate cells in the presence of LF by 3- and 7-fold, respectively. Substitution of Phe(313) by Cys greatly reduced the rate of LF translocation and delayed toxicity. The rate at which the Cys-substituted PA killed cells was increased significantly by blocking the sulfhydryl group with iodoacetamide, suggesting that this added Cys interacts with cellular proteins and slows translocation of LF. Deletion of the 2 Phe rendered PA completely non-toxic. This deleted PA protein lacked the ability shown by native PA to form oligomers on cells and in solution and to induce release of Rb-86 from Chinese hamster ovary cells. These results suggest that the chymotrypsin-sensitive site in PA is required for membrane channel formation and translocation of LF into the cytosol. PA double mutants were constructed that cannot be cleaved at either the furin or chymotrypsin sites. These PA proteins were more stable in Bacillus anthracis culture supernatants and may therefore be useful as a replacement for PA in anthrax vaccines.	NIDR,MICROBIAL ECOL LAB,BETHESDA,MD 20892; CTR BIOCHEM TECHNOL,DELHI 110007,INDIA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB)								ARORA N, 1993, J BIOL CHEM, V268, P3334; ARORA N, 1992, J BIOL CHEM, V267, P15542; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; ESCUYER V, 1991, INFECT IMMUN, V59, P3381, DOI 10.1128/IAI.59.10.3381-3386.1991; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; HANNA PC, 1992, MOL BIOL CELL, V3, P1269, DOI 10.1091/mbc.3.11.1269; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1980, J BIOL CHEM, V255, P2247; Leppla SH, 1988, BACTERIAL PROTEIN TO, P111; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MILNE JC, 1994, J BIOL CHEM, V269, P20607; MILNE JC, 1991, J CELL BIOL, V115, P2720; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709; NOVAK JM, 1992, J BIOL CHEM, V267, P17186; PAPINI E, 1993, J BIOL CHEM, V268, P1567; QUINN CP, 1991, J BIOL CHEM, V266, P20124; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SINGH Y, 1989, J BIOL CHEM, V264, P11099; SINGH Y, 1989, J BIOL CHEM, V264, P19103; SMITH H, 1962, J GEN MICROBIOL, V29, P517, DOI 10.1099/00221287-29-3-517; STANLEY JL, 1961, J GEN MICROBIOL, V26, P49, DOI 10.1099/00221287-26-1-49; TURNBULL PCB, 1991, VACCINE, V9, P533, DOI 10.1016/0264-410X(91)90237-Z; WELKOS SL, 1988, GENE, V69, P287, DOI 10.1016/0378-1119(88)90439-8	35	78	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29039	29046						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961869				2022-12-25	WOS:A1994PU16800079
J	SHIRAZI, A; IIZUKA, K; FADDEN, P; MOSSE, C; SOMLYO, AP; SOMLYO, AV; HAYSTEAD, TAJ				SHIRAZI, A; IIZUKA, K; FADDEN, P; MOSSE, C; SOMLYO, AP; SOMLYO, AV; HAYSTEAD, TAJ			PURIFICATION AND CHARACTERIZATION OF THE MAMMALIAN MYOSIN LIGHT-CHAIN PHOSPHATASE HOLOENZYME - THE DIFFERENTIAL-EFFECTS OF THE HOLOENZYME AND ITS SUBUNITS ON SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; GLYCOGEN-BOUND FORM; PROTEIN-KINASE; CYCLIC-GMP; CA2+ SENSITIZATION; PHOSPHORYLATION; CA-2+; MECHANISM; GIZZARDS; RELEASE	We have purified to homogeneity from the myofibrillar fraction of pig bladder a mammalian heterotrimeric form of PP-1, SMPP-1M. Purified pig bladder SMPP-1M is similar in composition and substrate specificity to avian gizzard PP-1M reported by Alessi et al. (Alessi, D., Macdougall, L. K., Sola, M. M., Ikebe, M., and Cohen. P. (1992) Eur. J. Biochem. 210, 1023-1035) and consists of the catalytic subunit of PP-1 (37 kDa) and two other equimolar subunits of 130 and 20 kDa. The properties of SMPP-1M and the role of its regulatory subunits in the dephosphorylation of myosin and in the initiation of relaxation were characterized both in vitro and in smooth muscle, We show that the relaxant effect of the catalytic subunit in smooth muscle is markedly potentiated by the addition of the regulatory subunits of SMPP-1M, Our findings demonstrate that SMPP-1M is the major phosphatase dephosphorylating myosin in mammalian smooth muscle and that myosin dephosphorylation is regulated in. vivo via targeting subunits that specifically alter the substrate specificity of PP-1C toward myosin.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT MOLEC PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NHLBI NIH HHS [P01-HL-19272-18] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CUATRECASAS P, 1971, ANNU REV BIOCHEM, V40, P259, DOI 10.1146/annurev.bi.40.070171.001355; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; GEISTLICH A, 1992, EUR J BIOCHEM, V207, P147, DOI 10.1111/j.1432-1033.1992.tb17031.x; GONG MC, 1992, J BIOL CHEM, V267, P21492; GONG MC, 1992, J BIOL CHEM, V267, P14662; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HASHIMOTO Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P41, DOI 10.1016/0003-9861(90)90228-Q; HIRAGA A, 1987, EUR J BIOCHEM, V163, P253, DOI 10.1111/j.1432-1033.1987.tb10795.x; HORIUTI K, 1988, J PHYSIOL-LONDON, V398, P131, DOI 10.1113/jphysiol.1988.sp017034; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; IKEBE M, 1990, J BIOL CHEM, V265, P8975; IKEBE M, 1985, J BIOL CHEM, V260, P3146; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1991, AM J PHYSIOL, V260, pC364, DOI 10.1152/ajpcell.1991.260.2.C364; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KREBS EG, 1955, J BIOL CHEM, V216, P113; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LINCOLN TM, 1991, BLOOD VESSELS, V28, P129; MITSUI T, 1992, J BIOL CHEM, V267, P16727; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8429; NISHIMURA J, 1990, AM J PHYSIOL, V259, pH2, DOI 10.1152/ajpheart.1990.259.1.H2; NOMURA M, 1992, BIOCHEMISTRY-US, V31, P11915, DOI 10.1021/bi00162a034; OKUBO S, 1994, BIOCHEM BIOPH RES CO, V200, P429, DOI 10.1006/bbrc.1994.1467; OKUBO S, 1993, ADV PROTEIN PHOSPHAT, V7, P295; PATO MD, 1985, J BIOL CHEM, V260, P2359; PFITZER G, 1984, PFLUG ARCH EUR J PHY, V401, P277, DOI 10.1007/BF00582596; RAPOPORT RM, 1982, P NATL ACAD SCI-BIOL, V79, P6470, DOI 10.1073/pnas.79.21.6470; SOMLYO AP, 1991, HEART CARDIOVASCULAR, P1; SOMLYO AP, 1994, MIE INT S REGULATION; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; STULL JT, 1988, MOL ASPECTS CELLULAR, V5, P91; SUMLYO AP, 1989, ADV PROTEIN PHOSPHAT, V5, P181; TANSEY MG, 1994, J BIOL CHEM, V259, P9912; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168	41	180	184	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31598	31606						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989330				2022-12-25	WOS:A1994PX30300043
J	FRA, AM; WILLIAMSON, E; SIMONS, K; PARTON, RG				FRA, AM; WILLIAMSON, E; SIMONS, K; PARTON, RG			DETERGENT-INSOLUBLE GLYCOLIPID MICRODOMAINS IN LYMPHOCYTES IN THE ABSENCE OF CAVEOLAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; GPI-ANCHORED PROTEINS; TRANS-GOLGI-NETWORK; EPITHELIAL-CELLS; T-CELLS; SIGNAL TRANSDUCTION; MOLECULES; COMPLEXES; SURFACE	Antibody binding to glycolipids and glycophosphatidylinositol (GPI)-anchored proteins of lymphocytes can trigger activation of specific signal transduction pathways. The finding that GPI-anchored proteins are present in detergent-insoluble complexes with several tyrosine kinases of the Src family suggested that these complexes may represent membrane microdomains involved in the transduction of signals to the cell interior. Recent work has suggested a link between detergent-insoluble microdomains and plasma membrane in vaginations termed caveolae. Here we show that lymphocytes lack plasma membrane domains with the characteristic features of caveolae. Furthermore, VIP21-caveolin was not detectable in four different lymphocyte cell lines at the protein or mRNA level. In addition to the lack of caveolar domains, capping experiments suggested that the bulk of the GPI-anchored protein Thy1 and the glycosphingolipid G(M1) were not stably associated in the lymphocyte plasma membrane. Despite this, Thy1 and G(M1) were present in detergent-insoluble complexes. We conclude that detergent insolubility does not correlate with the presence of caveolae or of VIP21-caveolin and that caveolae, as defined by a number of different markers, are not involved in signal transduction in lymphocytes.	EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Fra, Annamaria/I-5532-2012; Parton, Robert G/C-5673-2009	Fra, Annamaria/0000-0002-4327-3004; Parton, Robert G/0000-0002-7494-5248; Simons, Kai/0000-0002-9231-9996				Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BLACKMAN MA, 1992, J EXP MED, V176, P275, DOI 10.1084/jem.176.1.275; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown Deborah A., 1992, Trends in Cell Biology, V2, P338; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CINEK T, 1992, J IMMUNOL, V149, P2262; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Griffiths G, 1993, FINE STRUCTURE IMMUN, P371, DOI [10.1007/978-3-642-77095-1_11, DOI 10.1007/978-3-642-77095-1_11]; HSI ED, 1989, J BIOL CHEM, V264, P10836; KIM KJ, 1979, J IMMUNOL, V122, P549; KROCZEK RA, 1986, NATURE, V322, P181, DOI 10.1038/322181a0; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PARTON RG, 1992, J CELL BIOL, V119, P123, DOI 10.1083/jcb.119.1.123; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Sambrook J, 1989, MOL CLONING LABORATO; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STREULI CH, 1981, EXP CELL RES, V136, P247, DOI 10.1016/0014-4827(81)90002-1; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	29	430	431	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30745	30748						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7982998				2022-12-25	WOS:A1994PV51000002
J	NAKAMURA, J				NAKAMURA, J			2 TYPES OF PROTON-MODULATED CALCIUM-BINDING IN THE SARCOPLASMIC-RETICULUM CA2+-ATPASE .2. CHARACTERISTICS OF THEIR CALCIUM BINDINGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-ATPASE; CONFORMATIONAL TRANSITION; CA-2+-ATPASE; PUMP; TEMPERATURE; TRANSPORT; VESICLES; CA-2+; PH; PHOSPHORYLATION	The first part of this study reported the existence of two different conformations of chemically equivalent Ca2+-ATPase molecules from the sarcoplasmic reticulum, which were in pH-dependent equilibrium between E(1) (high affinity state for calcium) and E(2) (low affinity state for calcium) and predominantly in E, independent of pH, respectively, before calcium binding (Nakamura, J., and Furokohri, T. (1994) J. Biol. Chem, 269, 30818- 30821). Here, calcium bindings at the ATPase molecules were further studied by varying [Ca2+] and pH at 0 degrees C. The molecule, which pre-existed in equilibrium between E(1) and E(2), noncooperatively (the Hill value (n(H)) similar to 1) bound calcium with an apparent calcium affinity (K-0.5) of 2-6 mu M independent of pH. n(H) of the pH profile of the pre-existing equilibrium was about 2, suggesting participation of two protons in the equilibrium. On the other hand, the molecule, which predominantly pre existed in E(2), cooperatively (n(H) similar to 2) bound calcium with K-0.5, which was increased from about 7 mu M to about 0.2 mu M by increasing pH from 6.23 to 7.40. Analysis of pH dependency of the K-0.5 showed participation of 1 proton/calcium in competition for the binding sites. Calcium bindings at the two ATPase molecules seem to be differently modulated by the proton(s).			NAKAMURA, J (corresponding author), TOHOKU UNIV,FAC SCI,INST BIOL,AOBA KU,SENDAI,MIYAGI 980,JAPAN.							CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; De Meis L., 1982, MEMBRANE TRANSPORT C, P141; DIXON M, 1979, ENZYMES, P399; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; FORGE V, 1993, J BIOL CHEM, V268, P10961; Gronall A., 1949, J BIOL CHEM, V177, P751; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; INESI G, 1980, J BIOL CHEM, V255, P3025; KODAMA T, 1980, J BIOCHEM-TOKYO, V88, P1259, DOI 10.1093/oxfordjournals.jbchem.a133094; LEVY D, 1990, J BIOL CHEM, V265, P19524; MADEIRA VMC, 1978, ARCH BIOCHEM BIOPHYS, V185, P316, DOI 10.1016/0003-9861(78)90173-X; MEISSNER G, 1981, J BIOL CHEM, V256, P636; NAKAMURA J, 1987, J BIOL CHEM, V262, P14492; NAKAMURA J, 1986, BIOCHIM BIOPHYS ACTA, V870, P495, DOI 10.1016/0167-4838(86)90258-X; NAKAMURA J, 1994, J BIOL CHEM, V269, P30818; NAKAMURA J, 1983, BIOCHIM BIOPHYS ACTA, V723, P182, DOI 10.1016/0005-2728(83)90118-4; NAKAMURA J, 1989, J BIOL CHEM, V264, P17029; PICK U, 1982, J BIOL CHEM, V257, P6120; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; TADA M, 1978, PHYSIOL REV, V56, P1; TAKAKUWA Y, 1979, BIOCHEM BIOPH RES CO, V88, P1209, DOI 10.1016/0006-291X(79)91108-2; TAKISAWA H, 1981, NATURE, V290, P271, DOI 10.1038/290271a0; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; UENO T, 1981, J BIOCHEM-TOKYO, V89, P1239; VERZOVSKIALMEID.S, 1981, J BIOL CHEM, V256, P2940; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P10613, DOI 10.1021/bi00499a006; WATANABE T, 1981, BIOCHEMISTRY-US, V20, P6617, DOI 10.1021/bi00526a015; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; YAMAGUCHI M, 1984, J BIOL CHEM, V259, P9526	32	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30822	30827						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983013				2022-12-25	WOS:A1994PV51000017
J	SUBBARAYA, I; RUIZ, CC; HELEKAR, BS; ZHAO, XY; GORCZYCA, WA; PETTENATI, MJ; RAO, PN; PALCZEWSKI, K; BAEHR, W				SUBBARAYA, I; RUIZ, CC; HELEKAR, BS; ZHAO, XY; GORCZYCA, WA; PETTENATI, MJ; RAO, PN; PALCZEWSKI, K; BAEHR, W			MOLECULAR CHARACTERIZATION OF HUMAN AND MOUSE PHOTORECEPTOR GUANYLATE CYCLASE-ACTIVATING PROTEIN (GCAP) AND CHROMOSOMAL LOCALIZATION OF THE HUMAN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGENERATION SLOW RDS; BETA-SUBUNIT GENE; PHOSPHODIESTERASE ALPHA-SUBUNIT; CALCIUM-BINDING PROTEINS; AMINO-ACID-SEQUENCE; RETINITIS-PIGMENTOSA; MESSENGER-RNA; NONSENSE MUTATION; RECOVERIN; IDENTIFICATION	Guanylate cyclase-activating protein (GCAP) is a novel Ca2+-binding protein that stimulates synthesis of cGMP in photoreceptors. Molecular cloning of human and mouse GCAP cDNA revealed that the known mammalian GCAPs are more than 90% similar, consist of 201-205 amino acids, and contain three identically conserved EF hand Ca2+-binding sites. The sequence homology with recoverin, a related photoreceptor Ca2+-binding protein, is less than 35%. In situ hybridization in primate retinas shows that the GCAP gene is expressed exclusively in photoreceptor inner segments. To investigate the GCAP gene structure, we probed 10 eucaryotic genomic DNAs with a bovine GCAP cDNA under stringent conditions. The results demonstrate that the GCAP gene has been well conserved during evolution of vertebrate species and that each gene is most Likely present as a single copy. By genomic cloning, polymerase chain reaction, mapping, and direct sequencing, we show that the human GCAP gene spans approximately 6 kilobases of genomic DNA, and consists of four exons (>250, 146, 94, and 800 base pairs) separated by three introns (4.5 kilobases, 370 base pairs, and 347 base pairs). Using human/hamster hybrid panels and fluorescent in situ hybridization, the GCAP gene was localized to the short arm of chromosome 6 (p21.1).	BAYLOR COLL MED,DEPT OPHTHALMOL,HOUSTON,TX 77030; UNIV WASHINGTON,DEPT OPHTHALMOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PEDIAT,MED GENET SECT,WINSTON SALEM,NC 27157	Baylor College of Medicine; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University; Wake Forest Baptist Medical Center				Ruiz, Claudia/0000-0002-3613-1809	NEI NIH HHS [EY08061, EY 08123, EY01730] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY008061, P30EY001730, R01EY008061, R01EY008123] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON RA, 1993, GENOMICS, V15, P245, DOI 10.1006/geno.1993.1052; BAEHR W, 1991, FEBS LETT, V278, P107, DOI 10.1016/0014-5793(91)80095-K; BAGBY S, 1994, BIOCHEMISTRY-US, V33, P2409, DOI 10.1021/bi00175a009; BAYLOR DA, 1987, INVEST OPHTH VIS SCI, V28, P34; BENN PA, 1992, HUMAN CYTOGENETICS P; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; COLLINS JH, 1973, FEBS LETT, V36, P268, DOI 10.1016/0014-5793(73)80388-6; COTE RH, 1993, J BIOL CHEM, V268, P17190; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1994, NEURON, V12, P1; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; FISCHER R, 1988, J BIOL CHEM, V263, P17055; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GAL A, 1994, NAT GENET, V7, P64, DOI 10.1038/ng0594-64; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1994, BIOCHEMISTRY-US, V33, P3217, DOI 10.1021/bi00177a011; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; KAJIWARA K, 1993, NAT GENET, V3, P208, DOI 10.1038/ng0393-208; KNOWLES JA, 1994, HUM MOL GENET, V3, P1401, DOI 10.1093/hmg/3.8.1401; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; MARTIN RL, 1986, SCIENCE, V232, P1266, DOI 10.1126/science.3010467; MILLER JL, 1993, J GEN PHYSIOL, V101, P933, DOI 10.1085/jgp.101.6.933; MURAKAMI A, 1992, BIOCHEM BIOPH RES CO, V187, P234, DOI 10.1016/S0006-291X(05)81483-4; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; PITTLER SJ, 1990, GENOMICS, V6, P272, DOI 10.1016/0888-7543(90)90567-E; PITTLER SJ, 1992, J BIOL CHEM, V267, P6257; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RAO PN, 1992, GENOMICS, V14, P532, DOI 10.1016/S0888-7543(05)80262-9; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Sambrook J, 1989, MOL CLONING LABORATO; SENGUPTA B, 1987, J BIOL CHEM, V262, P16663; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968; TRAVIS GH, 1991, GENOMICS, V10, P733, DOI 10.1016/0888-7543(91)90457-P; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; WEITZ CJ, 1992, AM J HUM GENET, V50, P498; WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; YANG ZH, 1992, J BIOL CHEM, V267, P23197; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	56	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31080	31089						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983048				2022-12-25	WOS:A1994PV51000055
J	TONE, Y; COLLINGWOOD, TN; ADAMS, M; CHATTERJEE, VK				TONE, Y; COLLINGWOOD, TN; ADAMS, M; CHATTERJEE, VK			FUNCTIONAL-ANALYSIS OF A TRANSACTIVATION DOMAIN IN THE THYROID-HORMONE BETA-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE INHIBITION; MOUSE ESTROGEN-RECEPTOR; RETINOIC ACID RECEPTOR; V-ERBA; C-ERBA; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTOR; EXPRESSION; BINDING; GENE	Hormone-dependent transcriptional activation (AF-2) by the thyroid hormone beta receptor (TR beta) localizes to its carboxyl-terminal domain. A putative transactivation sequence within this domain was analyzed by mutating individual residues to alanine. Mutant receptor carboxyl terminal domains were tested coupled to the heterologous DNA binding domain of Ga14. A single mutant receptor (E460A) showed normal hormone binding and activation, whereas several others (P453A, F455A, L456A, F459A) exhibited impaired transactivation which correlated with their reduced ligand binding. Two mutations (L454A, E457A) were able to dissociate these properties, generating transcriptionally defective mutant proteins with preserved hormone binding. A further conservative substitution (E457D) was also non functional, and these three mutations were equally deleterious when tested in the context of full-length TR beta with a natural thyroid hormone response element containing promoter. This loss of activity was not due to altered DNA binding or expression of mutant receptors in cultured cells. They also retained the ability to recruit VP16-tagged retinoid X receptor in vivo as well as bind the basal transcription factors TFIIB and TBP in vitro. Our observations indicate that conserved hydrophobic (Leu(454)) and charged (GlU(457)) residues mediate AF-2 activity of TR beta, possibly via a co-activator that has yet to be identified.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT MED, CAMBRIDGE CB2 2QQ, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge				Chatterjee, Vengalil Krishna/0000-0002-2654-8854	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHIN WW, 1991, NUCLEAR HORMONE RECE; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRISHNA V, 1991, J CLIN INVEST, V87, P1977, DOI 10.1172/JCI115225; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; YEN PM, 1992, J BIOL CHEM, V267, P3565; ZAVACKI AM, 1993, MOL ENDOCRINOL, V7, P1319, DOI 10.1210/me.7.10.1319; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	39	116	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31157	31161						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983057				2022-12-25	WOS:A1994PV51000065
J	DYPBUKT, JM; ANKARCRONA, M; BURKITT, M; SJOHOLM, A; STROM, K; ORRENIUS, S; NICOTERA, P				DYPBUKT, JM; ANKARCRONA, M; BURKITT, M; SJOHOLM, A; STROM, K; ORRENIUS, S; NICOTERA, P			DIFFERENT PROOXIDANT LEVELS STIMULATE GROWTH, TRIGGER APOPTOSIS, OR PRODUCE NECROSIS OF INSULIN-SECRETING RINM5F CELLS - THE ROLE OF INTRACELLULAR POLYAMINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE ACTIVITY; SKIN TUMOR PROMOTION; PROTEIN KINASE-C; FREE-RADICALS; DNA; PROLIFERATION; ACTIVATION; DEATH; ENDONUCLEASE; MODULATION	Increasing concentrations (1-100 mu M) of the redox cycling quinone, 2,3-dimethoxy-1,4-naphthoquinone (DMNQ), stimulated growth, triggered apoptosis, or caused necrosis of pancreatic RINm5F cells, depending on the dose and duration of the exposure. Following the exposure of RINm5F cells to 10 mu M DMNQ, ornithine decarboxylase activity and polyamine biosynthesis increased. This was accompanied by enhanced cell proliferation. Conversely, exposure to 30 mu M DMNQ for 3 h resulted in the inhibition of ornithine decarboxylase, intracellular polyamine depletion, and apoptotic cell killing. Pretreatment of the cultures with the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate, restored polyamine levels and prevented apoptosis. Exposure to the same DMNQ concentration for only 1 h, with subsequent re-incubation in growth medium, neither caused polyamine depletion nor resulted in apoptosis. Finally, exposure to an even higher DMNQ concentration (100 mu M) for either 1 or 3 h caused rapid intracellular Ca2+ overload, ATP, NAD(+), and glutathione depletion, and extensive DNA single strand breakage, which resulted in necrotic cell death. Our results show that a disturbance of polyamine biosynthesis occurred prior to cell growth or apoptosis elicited by oxidative stress. In addition, we show that effects as opposite as cell proliferation and deletion, by either apoptosis or necrosis, can be induced, in the same system, by varying the exposure to a prooxidant.	KAROLINSKA INST, INST ENVIRONM MED, DIV TOXICOL, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet								ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BELLOMO G, 1992, CANCER RES, V52, P1342; BIRNBOIM HC, 1982, SCIENCE, V215, P1247, DOI 10.1126/science.6276978; BRUNE B, 1991, EXP CELL RES, V195, P323, DOI 10.1016/0014-4827(91)90380-D; BURDON RH, 1989, FREE RADICAL RES COM, V6, P345, DOI 10.3109/10715768909087918; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHAUDHRI G, 1986, J IMMUNOL, V137, P2646; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CRAWFORD D, 1988, ONCOGENE, V3, P27; DYPBUKT JM, 1990, FREE RADICAL RES COM, V8, P347, DOI 10.3109/10715769009053368; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FLAMIGNI F, 1989, BIOCHEM J, V259, P111, DOI 10.1042/bj2590111; GANT TW, 1988, CHEM-BIOL INTERACT, V65, P157, DOI 10.1016/0009-2797(88)90052-X; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GRASSILLI E, 1991, BIOCHEM BIOPH RES CO, V180, P59, DOI 10.1016/S0006-291X(05)81254-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARRIS CC, 1991, CANCER RES, V51, pS5023; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JONES DP, 1981, J CHROMATOGR, V225, P446, DOI 10.1016/S0378-4347(00)80293-5; KANA DJ, 1993, SCIENCE, V262, P1274; KASS GEN, 1989, BIOCHEM J, V260, P499, DOI 10.1042/bj2600499; KEY JE, 1971, FEBS LETT, V16, P9; KHAN AU, 1992, P NATL ACAD SCI USA, V89, P11428, DOI 10.1073/pnas.89.23.11428; KOHN KW, 1981, DNA REPAIR LABORATOR, P379; KUNG AL, 1990, CANCER RES, V50, P7307; LARSSON R, 1988, J BIOL CHEM, V263, P17452; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALORNI W, 1993, FEBS LETT, V336, P335, DOI 10.1016/0014-5793(93)80832-F; MATES JM, 1991, BIOCHEM PHARMACOL, V42, P1045, DOI 10.1016/0006-2952(91)90287-F; MATES JM, 1989, FEBS LETT, V250, P257, DOI 10.1016/0014-5793(89)80733-1; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NICOTERA P, 1994, PEZ FDN SYM, V5, P97; ORRENIUS S, 1987, B EUR PHYSIOPATH RES, V23, P291; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1982, AM J PHYSIOL, V243, P212; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; Sies H., 1985, OXIDATIVE STRESS, V501, P1, DOI DOI 10.1016/B978-0-12-642760-8.50005-3; SNYDER RD, 1989, BIOCHEM J, V260, P697, DOI 10.1042/bj2600697; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VERMA AK, 1986, CARCINOGENESIS, V7, P1019, DOI 10.1093/carcin/7.6.1019; VERMA AK, 1979, CANCER RES, V39, P419; WARING P, 1988, J BIOL CHEM, V263, P18493; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WICKSTROM K, 1991, J LIQ CHROMATOGR, V14, P675, DOI 10.1080/01483919108049280; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	53	351	364	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30553	30560						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982974				2022-12-25	WOS:A1994PU52500079
J	KELLOKUMPU, S; SORMUNEN, R; HEIKKINEN, J; MYLLYLA, R				KELLOKUMPU, S; SORMUNEN, R; HEIKKINEN, J; MYLLYLA, R			LYSYL HYDROXYLASE, A COLLAGEN PROCESSING ENZYME, EXEMPLIFIES A NOVEL CLASS OF LUMINALLY-ORIENTED PERIPHERAL MEMBRANE-PROTEINS IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROLYL 4-HYDROXYLASE; TRANS-GOLGI NETWORK; TRANSMEMBRANE PROTEINS; MONOCLONAL-ANTIBODIES; SECRETORY PROTEINS; MOLECULAR-CLONING; ER PROTEINS; RETENTION; LOCALIZATION; SEQUENCE	Lysyl hydroxylase (LH), an enzyme required early during collagen biosynthesis, appears to be exceptional among proteins that are thought to be residents of the endoplasmic reticulum (ER). It is a homodimer and does not contain either of the two previously characterized ER-specific retention motifs (KDEL or the double lysine motif) in its primary structure. We now show that LH, nevertheless, resides in the lumen of the ER. In immunofluorescence experiments, LH co-localizes with a KDEL-containing protein, protein disulfide isomerase (PDI), and also co-sediments with it after fractionation of subcellular organelles by sucrose density gradient centrifugation. In addition, LH seems to be stress-inducible. In one respect, however, LH differs from PDI and other known luminal proteins in the organelle. It is found in situ only in association with the ER membranes. Our cell fractionation and Triton X-114 phase separation experiments suggest that it binds to the membranes via weak electrostatic interactions. LH can thus be regarded as a first luminally-oriented ''peripheral membrane'' protein which has been characterized in the ER. The results suggest a novel possibility by which ER lumen can acquire its specific protein components from the bulk flow.	UNIV OULU,DEPT BIOCHEM & MED BIOCHEM,SF-90220 OULU,FINLAND; UNIV OULU,BIOCTR,SF-90220 OULU,FINLAND; UNIV OULU,DEPT PATHOL,SF-90220 OULU,FINLAND	University of Oulu; University of Oulu; University of Oulu	KELLOKUMPU, S (corresponding author), UNIV OULU,DEPT ANAT,KAJAANINTIE 52A,SF-90220 OULU,FINLAND.							ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BAUMAN O, 1991, P NATL ACAD SCI USA, V84, P741; BISHOFF J, 1990, J BIOL CHEM, V265, P17110; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GUZMAN NA, 1976, ARCH BIOCHEM BIOPHYS, V172, P449, DOI 10.1016/0003-9861(76)90097-7; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; HAUTALA T, 1992, BIOCHEM J, V283, P51, DOI 10.1042/bj2830051; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HOYHTYA M, 1984, EUR J BIOCHEM, V141, P477, DOI 10.1111/j.1432-1033.1984.tb08217.x; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KELLOKUMPU S, 1988, SCIENCE, V242, P1308, DOI 10.1126/science.2461589; KIVIRIKKO K, 1989, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1992, FOCUS POST TRANSLATI, P1; KOCH GLE, 1987, J CELL SCI, V87, P491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MYLLYLA R, 1988, BIOCHEM J, V253, P489, DOI 10.1042/bj2530489; MYLLYLA R, 1991, J BIOL CHEM, V266, P2805; OLSEN BR, 1973, SCIENCE, V182, P825, DOI 10.1126/science.182.4114.825; ORCI L, 1984, CELL, V38, P535; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PETERKOFSKY B, 1979, J BIOL CHEM, V254, P4714; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TURPEENNIEMIHUJANEN TM, 1980, BIOCHEM J, V189, P247, DOI 10.1042/bj1890247; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WARREN G, 1990, CELL, V62, P1, DOI 10.1016/0092-8674(90)90229-8; WILSON DW, 1993, J BIOL CHEM, V268, P7465	43	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 2	1994	269	48					30524	30529						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU525	7982970				2022-12-25	WOS:A1994PU52500075
J	TAMAGNONE, L; LAHTINEN, I; MUSTONEN, T; VIRTANEVA, K; FRANCIS, F; MUSCATELLI, F; ALITALO, R; SMITH, CIE; LARSSON, C; ALITALO, K				TAMAGNONE, L; LAHTINEN, I; MUSTONEN, T; VIRTANEVA, K; FRANCIS, F; MUSCATELLI, F; ALITALO, R; SMITH, CIE; LARSSON, C; ALITALO, K			BMX, A NOVEL NONRECEPTOR TYROSINE KINASE GENE OF THE BTK/ITK/TEC/TXK FAMILY LOCATED IN CHROMOSOME XP22.2	ONCOGENE			English	Note							X-LINKED AGAMMAGLOBULINEMIA; SRC FAMILY; SIGNAL TRANSDUCTION; HEMATOPOIETIC-CELLS; MESSENGER-RNAS; EXPRESSION; RECEPTOR; IDENTIFICATION; PP60C-SRC; SEQUENCE	The Bmx sequence was identified and cloned during our search for novel tyrosine kinase genes expressed in human bone marrow cells. Bmx cDNA comprises a long open reading frame of 675 amino acids, containing one SH3, one SH2 and one tyrosine kinase domain, which are about 70% identical with Btk, Itk and Tec and somewhat less with Txk tyrosine kinase sequences. The amino terminal sequences of these four tyrosine kinases are about 40% identical and each contains a so-called pleckstrin homology domain. The 2.7 kb Bmx mRNA was expressed in endothelial cells and several human tissues by Northern blotting and an 80 kD Bmx polypeptide was detected in human endothelial cells. Immunoprecipitates of COS cells transfected with a Bmx expression vector and NIH3T3 cells expressing a Bmx retrovirus contained a tyrosyl phosphorylated Bmx polypeptide of similar molecular weight. The BMX gene was located in chromosomal band Xp22.2 between the DXS197 and DXS207 loci. Interestingly, chromosome X also contains the closest relative of BMX, the BTK gene, implicated in X-linked agammaglobulinemia. The BMX gene thus encodes a novel nonreceptor tyrosine kinase, which may play a role;in the growth and differentiation of hematopoietic cells.	UNIV HELSINKI,TRANSPLANTAT LAB,SF-00014 HELSINKI,FINLAND; UNIV HELSINKI,DEPT GENET,MOLEC CANC BIOL LAB,SF-00014 HELSINKI,FINLAND; IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,OXFORD OX3 9DU,ENGLAND; KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN; KAROLINSKA HOSP,DEPT CLIN GENET,S-17176 STOCKHOLM,SWEDEN	University of Helsinki; University of Helsinki; Cancer Research UK; University of Oxford; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital			Muscatelli, Françoise/P-4650-2016; Francis, Fiona/B-5854-2016; Alitalo, Kari K/J-5013-2014; Tamagnone, Luca/J-8948-2018	Muscatelli, Françoise/0000-0003-4001-6528; Alitalo, Kari K/0000-0002-7331-0902; Tamagnone, Luca/0000-0002-2884-7946; SMITH, C. I. Edvard/0000-0003-1907-3392; Francis, Fiona/0000-0001-8542-7537; Mustonen, Tuija/0000-0002-2429-5064				BOLEN JB, 1993, ONCOGENE, V8, P2025; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GIBSON S, 1993, BLOOD, V82, P1561; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MANO H, 1993, ONCOGENE, V8, P417; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MORGENSTERN JP, 1990, NUC ACIDS RES, V12, P6460; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; MUSTELIN T, 1994, SRC FAMILY TYROSINE; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; SICILIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194; SMITH CIE, 1994, IMMUNOL REV, V138, P159, DOI 10.1111/j.1600-065X.1994.tb00851.x; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; ZHU QL, 1994, J EXP MED, V180, P461, DOI 10.1084/jem.180.2.461	39	167	178	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3683	3688						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970727				2022-12-25	WOS:A1994PT39200032
J	FLUGEL, A; SCHULZEKOOPS, H; HEESEMANN, J; KUHN, K; SOROKIN, L; BURKHARDT, H; VONDERMARK, K; EMMRICH, F				FLUGEL, A; SCHULZEKOOPS, H; HEESEMANN, J; KUHN, K; SOROKIN, L; BURKHARDT, H; VONDERMARK, K; EMMRICH, F			INTERACTION OF ENTEROPATHOGENIC YERSINIA-ENTEROCOLITICA WITH COMPLEX BASEMENT-MEMBRANES AND THE EXTRACELLULAR-MATRIX PROTEINS COLLAGEN TYPE-IV, LAMININ-1 AND LAMININ-2, AND NIDOGEN/ENTACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATES SPECIFIC BINDING; VIRULENCE PLASMID; SERUM RESISTANCE; NIDOGEN COMPLEX; YADA; PHAGOCYTOSIS; ABILITY; PSEUDOTUBERCULOSIS; DIFFERENTIATION; IDENTIFICATION	The plasmid-encoded virulence factor yersinia adhesin A (YadA) contributes to pathogenicity of Yersinia enterocolitica which might be related to its adhesive potential. Therefore, we have investigated the interaction of Y. enterocolitica with basement membrane (BM) and with the major BM proteins collagen type IV laminin, and nidogen/entactin. Recombinant YadA-positive but not YadA-negative yersiniae bound specifically to lens capsule BM tissue, as well as purified collagen type IV and the laminin-1 and -2 (formally known as merosin) isoforms. Binding sites are located on the alpha 1 chain of the 58-nm amino-terminal 7sL fragment of collagen type IV and on the elastase-fragment E1 of laminin-1. YadA-mediated binding of yersiniae to collagen type IV was rapid and saturable, it was independent of divalent cations, stable over a wide pH range, and not influenced by higher salt concentrations. D-Glucose and D-galactose did not interfere with binding, indicating a protein-protein interaction. In contrast, adhesion of yersiniae to the laminin-2 isoform occurred also independent of YadA expression and no binding was observed to nidogen/ entactin. The results support the hypothesis that adhesion of Y. enterocolitica could contribute to pathogenicity of enteropathogenic yersiniae. Further definition of binding sites for YadA on BM proteins might allow determination of the relevance of Yersinia-BM interactions to infection.	UNIV HOSP WURZBURG, INST HYG & MICROBIOL, D-97080 WURZBURG, GERMANY; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	University of Wurzburg; Max Planck Society	FLUGEL, A (corresponding author), UNIV ERLANGEN NURNBERG, INST CLIN IMMUNOL, MAX PLANCK SOC, CLIN RES UNIT RHEUMATOL IMMUNOL, D-91054 ERLANGEN, GERMANY.			Sorokin, Lydia/0000-0001-7704-7921				ADAMS JC, 1993, DEVELOPMENT, V117, P1183; BOLIN I, 1988, INFECT IMMUN, V56, P343; BOTTONE EJ, 1977, CRC CR REV MICROBIOL, V5, P211, DOI 10.3109/10408417709102312; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHINA B, 1993, INFECT IMMUN, V61, P3129, DOI 10.1128/IAI.61.8.3129-3136.1993; CORNELIS GR, 1989, MOL MICROBIOL, V3, P1455, DOI 10.1111/j.1365-2958.1989.tb00129.x; COVER TL, 1989, NEW ENGL J MED, V321, P16, DOI 10.1056/NEJM198907063210104; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EMODY L, 1989, J BACTERIOL, V171, P6674; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GLANVILLE RW, 1985, EUR J BIOCHEM, V152, P213, DOI 10.1111/j.1432-1033.1985.tb09186.x; GRANT DS, 1988, J HISTOCHEM CYTOCHEM, V36, P271, DOI 10.1177/36.3.2963856; HANSKI C, 1989, INFECT IMMUN, V57, P673, DOI 10.1128/IAI.57.3.673-678.1989; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; HEATHCOTE JG, 1981, INT REV CONNECT TISS, V9, P191; HEESEMANN J, 1987, FEMS MICROBIOL LETT, V40, P37, DOI 10.1016/0378-1097(87)90512-X; HEESEMANN J, 1984, INFECT IMMUN, V46, P105, DOI 10.1128/IAI.46.1.105-110.1984; HEESEMANN J, 1983, J INFECT DIS, V147, P107, DOI 10.1093/infdis/147.1.107; HEESEMANN J, 1985, J CLIN MICROBIOL, V22, P168, DOI 10.1128/JCM.22.2.168-175.1985; Kapperud G, 1987, Contrib Microbiol Immunol, V9, P165; KEFALIDE.NA, 1972, BIOCHEM BIOPH RES CO, V47, P1151, DOI 10.1016/0006-291X(72)90955-2; KUHN K, 1981, FEBS LETT, V125, P123, DOI 10.1016/0014-5793(81)81012-5; LACHICA RV, 1984, INFECT IMMUN, V46, P272, DOI 10.1128/IAI.46.1.272-275.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLOND CP, 1989, AM J ANAT, V185, P367, DOI 10.1002/aja.1001850403; LIAN CJ, 1987, J MED MICROBIOL, V24, P219, DOI 10.1099/00222615-24-3-219; MANN K, 1988, EUR J BIOCHEM, V178, P71, DOI 10.1111/j.1432-1033.1988.tb14430.x; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MARTINEZ RJ, 1989, J BACTERIOL, V171, P3732, DOI 10.1128/jb.171.7.3732-3739.1989; MOHAN PS, 1986, J BIOL CHEM, V261, P4328; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAERREGAARD A, 1991, INFECT IMMUN, V59, P253, DOI 10.1128/IAI.59.1.253-260.1991; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PILZ D, 1992, INFECT IMMUN, V60, P189, DOI 10.1128/IAI.60.1.189-195.1992; PORTNOY DA, 1985, CURR TOP MICROBIOL, V118, P29; RISTELI J, 1980, EUR J BIOCHEM, V108, P239, DOI 10.1111/j.1432-1033.1980.tb04717.x; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; SCHULZEKOOPS H, 1992, INFECT IMMUN, V60, P2153, DOI 10.1128/IAI.60.6.2153-2159.1992; SCHULZEKOOPS H, 1993, INFECT IMMUN, V61, P2513, DOI 10.1128/IAI.61.6.2513-2519.1993; SIMONASSMANN P, 1994, IN PRESS DEV DYNAMIC; TABRIZI SN, 1992, MICROB PATHOGENESIS, V13, P171, DOI 10.1016/0882-4010(92)90018-J; TAMM A, 1993, MOL MICROBIOL, V10, P995, DOI 10.1111/j.1365-2958.1993.tb00971.x; TERTTI R, 1992, INFECT IMMUN, V60, P3021, DOI 10.1128/IAI.60.7.3021-3024.1992; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; VANTRAPPEN G, 1977, GASTROENTEROLOGY, V72, P220; VESIKARI T, 1983, ACTA PATH MICRO IM B, V91, P121; VONDERMARK K, 1993, ADHESIVE GLYCOPROTEI, P211; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; ZINK DL, 1980, NATURE, V283, P224, DOI 10.1038/283224a0	53	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29732	29738						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961965				2022-12-25	WOS:A1994PU28400066
J	GABIG, TG; MANTEL, PL; ROSLI, R; CREAN, CD				GABIG, TG; MANTEL, PL; ROSLI, R; CREAN, CD			REQUIEM - A NOVEL ZINC-FINGER GENE ESSENTIAL FOR APOPTOSIS IN MYELOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEGANS; DEATH; SURVIVAL; PROTEIN; ENZYME; BCL-2; CED-3	To identify genes mediating programmed cell death triggered by interleukin 3 (IL-3)-deprivation of myeloid cells, the IL-3-dependent murine myeloid cell line FDCP-1 was used to screen a mammalian cell expression library for cDNAs that would promote survival following withdrawal of IL-3. A unique 892-base pair cDNA was cloned that prevented the programmed cell death response following IL-3 deprivation by causing antisense suppression of an endogenous 2.4-kilobase (kb) mRNA. A 2.3-kb cDNA containing the identical 892-base pair overlapping sequence was cloned that encoded a deduced 371-amino acid protein containing a single Kruppel-type zinc finger and a cluster of 4 cysteine/histidine-rich repeats resembling atypical zinc fingers. The 2.4-kb mRNA was found to be ubiquitously expressed in murine tissues and its abundance in FDCP-1 cells was not altered in response to IL-3 deprivation. Since expression of this 2.4-kb mRNA was a prerequisite for the apoptosis response following IL-3 deprivation, the gene encoding it was named requiem. Requiem is likely to encode a transcription factor required for the apoptosis response following survival factor withdrawal from myeloid cells.			GABIG, TG (corresponding author), INDIANA UNIV,SCH MED,DEPT MED,442 IB BLDG,975 W WALNUT ST,INDIANAPOLIS,IN 46202, USA.				NATIONAL CANCER INSTITUTE [R01CA054432] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54432] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUCHMAN VL, 1992, NUCLEIC ACIDS RES, V20, P5579, DOI 10.1093/nar/20.21.5579; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYAJIMA A, 1993, BLOOD, V82, P1960; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	17	72	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29515	29519						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961935				2022-12-25	WOS:A1994PU28400034
J	PROSHLYAKOV, DA; OGURA, T; SHINZAWAITOH, K; YOSHIKAWA, S; APPELMAN, EH; KITAGAWA, T				PROSHLYAKOV, DA; OGURA, T; SHINZAWAITOH, K; YOSHIKAWA, S; APPELMAN, EH; KITAGAWA, T			SELECTIVE RESONANCE RAMAN OBSERVATION OF THE 607 NM FORM GENERATED IN THE REACTION OF OXIDIZED CYTOCHROME-C-OXIDASE WITH HYDROGEN-PEROXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ELECTRON-PARAMAGNETIC-RESONANCE; HORSERADISH-PEROXIDASE; DIOXYGEN REDUCTION; ROOM-TEMPERATURE; COMPOUND-II; OXYGEN; FERRYL; SPECTROSCOPY; INTERMEDIATE; ACETONITRILE	Resonance Raman spectra were measured selectively for the ''607 nm'' form, which had been assigned to a peroxy intermediate formed in the reaction of oxidized cytochrome c oxidase with hydrogen peroxide at ambient temperature. A single oxygen isotope-sensitive band was found at 803 cm(-1) for the reaction with (H2O2)-O-16 (at 769 cm(-1) with (H2O2)-O-18) upon excitation at 607 nm, the wave-length of the difference absorption maximum characteristic of the ''peroxy'' intermediate. Upon excitation at shorter wavelengths (down to 580 nm), the Raman spectrum simply became weaker without yielding any new features. When (H2OO)-O-16-O-18 was used, two bands were observed at 803 and 769 cm(-1) (within an accuracy of 0.5 cm(-1)), but with only half the intensity of those observed with (H2O2)-O-16 or (H2O2)-O-18, which ruled out the possibility that the 803 cm(-1) band arose from the O-O or Fe-O-2 stretching of the Fe-II(O-O-) heme. Conversely the 34-cm(-1) downshift with O-18 is in good agreement with the calculated O-16/O-18 Shift (35 cm(-1)) expected for the diatomic Fe=O-16 oscillator at 803 cm(-1). This band exhibited an upshift by 1.3 cm(-1) in (H2O)-H-2, similar to the case of compound II of horseradish peroxidase at neutral pH, and indicative of the presence of a hydrogen bond to the Fe-IV=O oxygen. The 803/769 cm(-1) pair of resonance Raman bands were also observed upon blue excitation, as is the case for the bands found in the dioxygen cycle of this enzyme (Ogura, T., Takahashi, S., Hirota, S., Shinzawa-Itoh, K., Yoshikawa, S., Appelman, E. H., and Kitagawa, T. (1993) J. Am. Chem. Sec. 115, 8527-8536). This observation provides the first direct characterization of the 607 nm form of this enzyme in its reaction with H2O2.	OKAZAKI NATL RES INST, GRAD UNIV ADV STUDIES, OKAZAKI, AICHI 444, JAPAN; OKAZAKI NATL RES INST, INST MOLEC SCI, OKAZAKI, AICHI 444, JAPAN; HIMEJI INST TECHNOL, FAC SCI, DEPT LIFE SCI, KAMIGORI, HYOGO 67812, JAPAN; ARGONNE NATL LAB, DIV CHEM, ARGONNE, IL 60439 USA	Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Okazaki Institute for Integrative Bioscience (OIIB); University of Hyogo; United States Department of Energy (DOE); Argonne National Laboratory								APPELMAN EH, 1979, INORG CHEM, V18, P909, DOI 10.1021/ic50194a001; APPELMAN EH, 1992, J FLUORINE CHEM, V56, P199, DOI 10.1016/S0022-1139(00)81103-3; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BLAIR DF, 1985, J AM CHEM SOC, V107, P7389, DOI 10.1021/ja00311a029; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; CHANCE B, 1975, J BIOL CHEM, V250, P9226; CHANCE B, 1975, P NATL ACAD SCI USA, V72, P1635, DOI 10.1073/pnas.72.4.1635; CLORE GM, 1980, BIOCHEM J, V185, P155, DOI 10.1042/bj1850155; CLORE GM, 1980, BIOCHEM J, V185, P139, DOI 10.1042/bj1850139; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HANSSON O, 1982, EMBO J, V1, P1295, DOI 10.1002/j.1460-2075.1982.tb01313.x; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HASHIMOTO S, 1984, P JPN ACAD B-PHYS, V60, P345, DOI 10.2183/pjab.60.345; HILL BC, 1983, BIOCHEM J, V215, P659, DOI 10.1042/bj2150659; HILL BC, 1984, BIOCHEM J, V218, P913, DOI 10.1042/bj2180913; KITAGAWA T, 1986, ADV SPECTROSC, V13, P443; KSENZENKO MY, 1992, FEBS LETT, V297, P63, DOI 10.1016/0014-5793(92)80328-E; KUMAR C, 1984, J BIOL CHEM, V259, P1668; MIKI T, 1986, J BIOCHEM-TOKYO, V100, P735, DOI 10.1093/oxfordjournals.jbchem.a121766; OGURA T, 1991, B CHEM SOC JPN, V64, P2901, DOI 10.1246/bcsj.64.2901; OGURA T, 1988, REV SCI INSTRUM, V59, P1316, DOI 10.1063/1.1139716; OGURA T, 1993, J AM CHEM SOC, V115, P8527, DOI 10.1021/ja00072a002; OLIVEBERG M, 1989, BIOCHIM BIOPHYS ACTA, V977, P322, DOI 10.1016/S0005-2728(89)80087-8; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; ROZEN S, 1986, ANGEW CHEM INT EDIT, V25, P554, DOI 10.1002/anie.198605541; SPIRO TG, 1988, BIOL APPLICATIONS RA, V3; TERNER J, 1985, BIOCHIM BIOPHYS ACTA, V828, P73, DOI 10.1016/0167-4838(85)90011-1; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; VYGODINA TV, 1988, ANN NY ACAD SCI, V550, P124, DOI 10.1111/j.1749-6632.1988.tb35329.x; VYGODINA TV, 1993, BIOL MEMBR, V6, P883; WIKSTROM M, 1992, J BIOL CHEM, V267, P10266; Wikstrom M., 1981, CYTOCHROME OXIDASE S; WITT SN, 1987, J BIOL CHEM, V262, P1446; WRIGGLESWORTH JM, 1984, BIOCHEM J, V217, P715, DOI 10.1042/bj2170715; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498	35	110	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29385	29388						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961916				2022-12-25	WOS:A1994PU28400014
J	BERMUDES, D; PECK, KR; AFIFI, MA; BECKERS, CJM; JOINER, KA				BERMUDES, D; PECK, KR; AFIFI, MA; BECKERS, CJM; JOINER, KA			TANDEMLY REPEATED GENES ENCODE NUCLEOSIDE TRIPHOSPHATE HYDROLASE ISOFORMS SECRETED INTO THE PARASITOPHOROUS VACUOLE OF TOXOPLASMA-GONDII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; ATP-SYNTHASE; 5'-NUCLEOTIDASE; CLONING; ENZYMES; CELLS; EXPRESSION; PARASITES; FRAGMENT	The obligate intracellular parasite Toxoplasma gondii produces a nucleoside triphosphate hydrolase (NTPase) (nucleoside-triphosphatase, EC 3.6.1.15) activable by dithiol-containing compounds. We have isolated the genomic DNA for the NTPase from the RH strain of Toxoplasma and determined the nucleotide sequence of three tandemly arranged open reading frames termed NTP1, NTP2, and NTP3. We have also isolated and sequenced cDNAs for NTP1 and NTP3; no cDNA for NTP2 was obtained. The two cDNA clones encode proteins that are more than 97% identical at the amino acid level but significantly differ within two small domains, indicating the presence of NTPase isoforms. Both possess N-terminal signal sequences and two regions with partial homology to certain known ATP binding motifs: the glycine-rich loop common to many ATP binding proteins and the beta-phosphate binding domain found in the hexokinase-actin-hsp70 family. Antiserum against a NTP1-fusion protein immunoprecipitated NTPase activity from extracellular parasites that was increased in activity by treatment with dithiothreitol, confirming the identity of the cloned genes. By immunofluorescence, the NTPase is located in vesicular structures within the parasite, and in infected cells it is secreted into the vacuolar space and becomes partially associated with the parasitophorous vacuolar membrane. Since the vacuolar membrane is freely permeable to small molecules of <1300 Da, host cell ATP may serve as a substrate for the NTPase and supply the energy for parasite-directed processes in the vacuolar space.	YALE UNIV, SCH MED, DEPT INTERNAL MED, INFECT DIS SECT, NEW HAVEN, CT 06520 USA; SAMSUNG MED CTR, SEOUL 135230, SOUTH KOREA	Yale University; Sungkyunkwan University (SKKU); Samsung Medical Center			Afifi, Mohammed/K-7851-2014; Peck, Kyong Ran/AGV-5205-2022; Joiner, Keith/AAH-1059-2021; Bermudes, David/W-1626-2019	Bermudes, David/0000-0003-1910-3192; Joiner, Keith/0000-0003-3062-823X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031808] Funding Source: NIH RePORTER; NIAID NIH HHS [UOI AI 31808] Funding Source: Medline; PHS HHS [R01 A1 30060] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASAI T, 1986, COMP BIOCHEM PHYS B, V85, P365, DOI 10.1016/0305-0491(86)90013-1; ASAI T, 1983, J BIOL CHEM, V258, P6816; ASAI T, 1987, ZBL BAKT-INT J MED M, V264, P464; ASAI T, 1990, FEMS MICROBIOL LETT, V72, P89, DOI 10.1111/j.1574-6968.1990.tb03867.x; BENZ R, 1985, CRC CR REV BIOCH MOL, V19, P145, DOI 10.3109/10409238509082542; BERMUDES D, IN PRESS MOL BIOCH P; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BURNSTOCK G, 1991, NUCLEOS NUCLEOT NUCL, V10, P917, DOI 10.1080/07328319108047230; CESBRONDELAUW MF, 1989, P NATL ACAD SCI USA, V86, P7537, DOI 10.1073/pnas.86.19.7537; DOVER G, 1982, NATURE, V299, P111, DOI 10.1038/299111a0; DOVER GA, 1993, METHOD ENZYMOL, V224, P525, DOI 10.1016/0076-6879(93)24039-W; DOVER GA, 1984, CELL, V38, P622, DOI 10.1016/0092-8674(84)90255-1; DUBREMETZ JF, 1993, PARASITOL RES, V79, P402, DOI 10.1007/BF00931830; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; Gottlieb M., 1988, MBL (Marine Biology Laboratory) Lectures in Biology, V9, P449; JOHNSON AM, 1989, GENE, V85, P215, DOI 10.1016/0378-1119(89)90484-8; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; JONES TC, 1972, J EXP MED, V136, P1173, DOI 10.1084/jem.136.5.1173; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; KRUG EC, 1989, J BIOL CHEM, V264, P10601; LECORDIER L, 1993, MOL BIOCHEM PARASIT, V59, P143, DOI 10.1016/0166-6851(93)90015-P; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; MERCIER C, 1993, MOL BIOCHEM PARASIT, V58, P71, DOI 10.1016/0166-6851(93)90092-C; MEVELEC MN, 1992, MOL BIOCHEM PARASIT, V56, P227, DOI 10.1016/0166-6851(92)90172-G; NAGEL SD, 1988, MOL BIOCHEM PARASIT, V29, P261, DOI 10.1016/0166-6851(88)90081-3; NISHI S, 1988, BIOCHEM BIOPH RES CO, V157, P937, DOI 10.1016/S0006-291X(88)80964-1; OSSORIO PN, 1994, J BIOL CHEM, V269, P15350; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; Pfefferkorn E.R., 1988, MBL (Marine Biology Laboratory) Lectures in Biology, V9, P479; PFEFFERKORN ER, 1978, J PARASITOL, V64, P486, DOI 10.2307/3279789; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; RICHARDSON PJ, 1987, NATURE, V327, P232, DOI 10.1038/327232a0; RODRIGUEZ JF, 1986, P NATL ACAD SCI USA, V83, P9566, DOI 10.1073/pnas.83.24.9566; ROOS DS, 1993, J BIOL CHEM, V268, P6269; Sambrook J, 1989, MOL CLONING LABORATO; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SCHWARTZMAN JD, 1982, EXP PARASITOL, V53, P77, DOI 10.1016/0014-4894(82)90094-7; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SIBLEY LD, 1985, NATURE, V315, P416, DOI 10.1038/315416a0; SIBLEY LD, 1993, 1993 MOL PAR C WOODS; SUNDERMAN FW, 1990, ANN CLIN LAB SCI, V20, P123; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOLKNANDT W, 1991, EUR J BIOCHEM, V202, P855, DOI 10.1111/j.1432-1033.1991.tb16443.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Weber K., 1975, PROTEINS, VI, P179; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345; 1991, PROGRAM MANUAL GCG P	50	132	146	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29252	29260						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961894				2022-12-25	WOS:A1994PU16800107
J	CASTEELSJOSSON, K; ZHANG, W; CAPACI, T; CASTEELS, P; TEMPST, P				CASTEELSJOSSON, K; ZHANG, W; CAPACI, T; CASTEELS, P; TEMPST, P			ACUTE TRANSCRIPTIONAL RESPONSE OF THE HONEYBEE PEPTIDE-ANTIBIOTICS GENE REPERTOIRE AND REQUIRED POSTTRANSLATIONAL CONVERSION OF THE PRECURSOR STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCIBLE ANTIBACTERIAL PEPTIDES; INSECT IMMUNITY; SARCOPHAGA-PEREGRINA; PHORMIA-TERRANOVAE; SIGNAL SEQUENCE; APIS-MELLIFERA; ALPHA-FACTOR; DNA-BINDING; FLESH FLY	The cell free immune repertoire of honeybees (Apis mellifera) consists of four polypeptides that are induced by bacterial infection and, through complementarity, provide broad-spectrum antibacterial defense. apidaecin is overproduced by a combination of low threshold transcriptional activation and a unique, genetically encoded amplification mechanism. In contrast, sizable experimental infections are required for induction of the normally silent hymenoptaecin, abaecin, and bee defensin genes; even so, bee defensin transcription is minimal and delayed, and only minute quantities of corresponding peptide are produced. The specific, temporal organization of the multi component immune response in bees has therefore likely been selected to cope with infection of prevalent, plant-associated Gram-negative bacteria. Post-translational processing and modifications are substantially different for each of the four antibacterial peptides. While no similarities were observed among precursor structures of the various bee peptides, surprisingly, the signal sequences of abaecin (bee) and drosocin (Drosophila) shared unmistakable homology, possibly indicating common ancestral secretion/processing mechanisms. Finally, we report that bee defensin contains a typical disulfide-rich structure (40 amino acids) but also a unique, amphipathic, putatively amidated carboxyl-terminal tail (10 amino acids). We speculate that this structure is a ''co-drug'' assembled by fusing ''disulfide-rich'' and ''alpha-helical'' class peptide antibiotics, a novel concept in naturally occurring antibacterials.	CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Cornell University	CASTEELSJOSSON, K (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA08748-29] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BLOMBACK B, 1967, METHOD ENZYMOL, V11, P398; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BULET P, 1993, J BIOL CHEM, V268, P14893; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASTEELS P, 1994, BIOCHEM BIOPH RES CO, V199, P339, DOI 10.1006/bbrc.1994.1234; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1990, EUR J BIOCHEM, V187, P381, DOI 10.1111/j.1432-1033.1990.tb15315.x; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; CASTEELS P, 1988, EUROPEAN RES VARROAT, P105; CASTEELSJOSSON K, 1993, EMBO J, V12, P1569, DOI 10.1002/j.1460-2075.1993.tb05801.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DIMARCQ JL, 1990, EMBO J, V9, P2507, DOI 10.1002/j.1460-2075.1990.tb07430.x; DORSETT D, 1989, GENE DEV, V3, P454, DOI 10.1101/gad.3.4.454; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; ENGSTROM P, 1984, EMBO J, V3, P3347, DOI 10.1002/j.1460-2075.1984.tb02302.x; ENGSTROM Y, 1993, J MOL BIOL, V232, P327, DOI 10.1006/jmbi.1993.1392; FINNEY M, 1992, CURRENT PROTOCOLS MO; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FUJIWARA S, 1990, J BIOL CHEM, V265, P11333; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRILLI M, 1993, INT REV CYTOL, V143, P1; GUNNE H, 1993, EUR J BIOCHEM, V214, P287, DOI 10.1111/j.1432-1033.1993.tb17923.x; HOFFMANN JA, 1993, FEBS LETT, V325, P63, DOI 10.1016/0014-5793(93)81414-U; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; KANAI A, 1990, MOL CELL BIOL, V10, P6114, DOI 10.1128/MCB.10.12.6114; KANOST MR, 1988, ARCH INSECT BIOCHEM, V8, P147, DOI 10.1002/arch.940080302; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; KATOPODIS AG, 1991, BIOCHEMISTRY-US, V30, P6189, DOI 10.1021/bi00239a016; KOBAYASHI A, 1993, MOL CELL BIOL, V13, P4049, DOI 10.1128/MCB.13.7.4049; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; MAHBUBANI MH, 1991, BIOTECHNIQUES, V10, P48; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17112; NANBU R, 1993, J BIOCHEM-TOKYO, V114, P432, DOI 10.1093/oxfordjournals.jbchem.a124193; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; REICHHART JM, 1989, EUR J BIOCHEM, V182, P423, DOI 10.1111/j.1432-1033.1989.tb14848.x; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SINGH A, 1983, NUCLEIC ACIDS RES, V11, P4049, DOI 10.1093/nar/11.12.4049; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1058, DOI 10.1006/bbrc.1993.2358; SUN SC, 1992, EUR J BIOCHEM, V204, P885, DOI 10.1111/j.1432-1033.1992.tb16708.x; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATERS MG, 1988, J BIOL CHEM, V263, P6209; WICKER C, 1990, J BIOL CHEM, V265, P22493	52	111	120	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28569	28575						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961803				2022-12-25	WOS:A1994PU16800012
J	FRUETEL, JA; MACKMAN, RL; PETERSON, JA; DEMONTELLANO, PRO				FRUETEL, JA; MACKMAN, RL; PETERSON, JA; DEMONTELLANO, PRO			RELATIONSHIP OF ACTIVE-SITE TOPOLOGY TO SUBSTRATE-SPECIFICITY FOR CYTOCHROME P450(TERP) (CYP108)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYL-IRON COMPLEXES; INSITU REARRANGEMENT; CRYSTAL-STRUCTURE; ABSOLUTE STEREOCHEMISTRY; OXIDATION REACTIONS; FATTY-ACIDS; REGIOSPECIFICITY; MONOOXYGENASES; HYDROXYLATION; P450BM-3	Earlier studies have shown that the reactions of cytochrome P450 with arylhydrazines yield aryl-iron complexes, and that oxidative migration of the aryl groups to the pyrrole nitrogens of the heme provides information on the active site topology. Comparison of cytochromes P450(terp) (CYP108), P450(cam) (CYP101), and P450(BM-3) (CYP102) by this method suggests that the active site of P450(terp) is effectively more sterically restricted than those of the other two enzymes and is primarily open above pyrrole ring D of the heme group. This experimental model of the P450(terp) active site differs from that deduced by x-ray crystallography, which shows that pyrrole ring C is also relatively open. The results suggest that aryl shifts can be used to probe conformations of the active site other than that trapped in the crystal state. Identification of the product formed from a terpineol by P450(terp) shows that the enzyme exclusively hydroxylates the most sterically accessible, allylically activated position. The enzyme also oxidizes substituted thioanisoles and styrenes unrelated to alpha-terpineol to the corresponding sulfoxides and epoxides. In the case of 4-methylthioanisole and 4-methylstyrene, methyl hydroxylation competes effectively with sulfoxidation and epoxidation in the reaction catalyzed by P450(terp) but not those catalyzed by P450(BM-3) or P450(cam). Comparison of the stereoselectivity of thioanisole sulfoxidation and styrene epoxidation by P450(terp), P450(cam) and P450(BM-3) shows that P450(terp) is the most, and P450(BM-3) the least, stereospecific. The stereospecificity of thioanisole sulfoxidation by P450(terp) depends on the electronic nature of the para-substituent and rises from an (R):(S) ratio of 20:80 for p-MeO to a value of < 01:99 for p-CN. The (R):(S) ratio for the epoxides produced by P450(terp) is approximately 90:10 for the two substituents investigated. Cytochromes P450(cam) and P450(BM-3) are much less stereoselective. A model is suggested by the stereochemical and topological data for the binding of substrates in P450(terp).	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515, R01GM043479] Funding Source: NIH RePORTER; NIDDK NIH HHS [P-30 DK26743] Funding Source: Medline; NIGMS NIH HHS [GM25515, GM43479] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMAN A, 1987, SYNTHESIS-STUTTGART, P696; BACKES WL, 1993, ARCH BIOCHEM BIOPHYS, V304, P27, DOI 10.1006/abbi.1993.1317; BLUTHE N, 1980, J CHEM SOC PERK T 1, P1747, DOI 10.1039/p19800001747; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; COLONNA S, 1992, TETRAHEDRON-ASYMMETR, V3, P95, DOI 10.1016/S0957-4166(00)82316-2; DESJARLAIS RL, 1988, J MED CHEM, V31, P722, DOI 10.1021/jm00399a006; FILIPOVIC D, 1992, BIOCHEM BIOPH RES CO, V189, P488, DOI 10.1016/0006-291X(92)91584-D; FRUETEL JA, 1992, J AM CHEM SOC, V114, P6987, DOI 10.1021/ja00044a006; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; HARADA N, 1984, J BIOL CHEM, V259, P3005; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; HUNSBERGER IM, 1956, J ORG CHEM, V21, P394, DOI 10.1021/jo01110a004; JONES JP, 1993, J AM CHEM SOC, V115, P381, DOI 10.1021/ja00055a002; KOYMANS L, 1992, CHEM RES TOXICOL, V5, P211, DOI 10.1021/tx00026a010; MANSUY D, 1989, EUR J BIOCHEM, V184, P267, DOI 10.1111/j.1432-1033.1989.tb15017.x; MEUNIER B, 1992, CHEM REV, V92, P1411, DOI 10.1021/cr00014a008; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; PETERSON JA, 1992, J BIOL CHEM, V267, P14193; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RETTIE AE, 1990, MOL PHARMACOL, V37, P643; SHIRANE N, 1993, BIOCHEMISTRY-US, V32, P13732, DOI 10.1021/bi00212a044; SLIGAR SG, 1986, CYTOCHROME P450 STRU, P429; STROBL GR, 1993, J MED CHEM, V36, P1136, DOI 10.1021/jm00061a004; SWANSON BA, 1991, J AM CHEM SOC, V113, P8146, DOI 10.1021/ja00021a046; SWANSON BA, 1992, ARCH BIOCHEM BIOPHYS, V292, P42, DOI 10.1016/0003-9861(92)90048-2; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; THAKKER DR, 1982, BIOL REACTIVE INTE A, V2, P525; TUCK SF, 1992, J BIOL CHEM, V267, P5614; TUCK SF, 1992, BIOCHEMISTRY-US, V31, P6911, DOI 10.1021/bi00145a007; TUCK SF, 1992, J BIOL CHEM, V267, P13175; TUCK SF, 1993, BIOCHEMISTRY-US, V32, P2548, DOI 10.1021/bi00061a012; TUCK SF, 1993, J BIOL CHEM, V268, P269	35	48	58	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28815	28821						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961838				2022-12-25	WOS:A1994PU16800048
J	GE, Q; TRIEU, EP; TARGOFF, IN				GE, Q; TRIEU, EP; TARGOFF, IN			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF HUMAN GLYCYL-TRANSFER-RNA SYNTHETASE, AN AUTOANTIGEN IN MYOSITIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; INTERSTITIAL LUNG-DISEASE; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; BOMBYX-MORI; EVOLUTIONARY RELATIONSHIPS; NUCLEOTIDE-SEQUENCE; YEAST ENZYMES; AUTOANTIBODIES; VIRUS	Two identical cDNAs encoding human glycyl-tRNA synthetase were isolated from K562 and HEL cell lambda gt11 libraries by screening with ''anti-EJ'' autoantibodies from a patient with dermatomyositis, previously shown to specifically inhibit this enzyme. The sequenced cDNA had 2,385 base pairs, with a predicted protein of 685 amino acids and M(r) 77,500. The antigen reactive with anti-EJ was immunoaffinity-purified from HeLa cells, and two proteolytic peptides matched areas of the predicted amino acid sequence. The sequence was 61.6% identical with that of silk moth glycyl-tRNA synthetase. Several very highly conserved regions were identified, including the single class II synthetase motif region and an N-terminal region similar to one found in at least three other synthetases. Near identity in other regions suggested that they also had important functions. Expression of the cDNA in Escherichia coli yielded a protein of expected size that reacted with the autoantibodies and was active as glycyl-tRNA synthetase.	OKLAHOMA MED RES FDN, ARTHRITIS IMMUNOL PROGRAM, ARTHRITIS IMMUNOL SECT, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, OKLAHOMA CITY, OK 73104 USA; VET AFFAIRS MED CTR, OKLAHOMA CITY, OK 73104 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI021568, R29AI027181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032214] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-21568, AI-27181] Funding Source: Medline; NIAMS NIH HHS [AR-32214] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARNETT FC, 1981, J RHEUMATOL, V8, P925; BUNN CC, 1986, J EXP MED, V163, P1281, DOI 10.1084/jem.163.5.1281; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CHANG PK, 1990, J BIOL CHEM, V265, P20898; CHOW CM, 1989, MOL CELL BIOL, V9, P4645, DOI 10.1128/MCB.9.11.4645; CRUZEN ME, 1991, J BIOL CHEM, V266, P9919; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM SS, 1984, J BIOL CHEM, V259, P4043; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FETT R, 1991, J BIOL CHEM, V266, P1448; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; GARRET M, 1991, BIOCHEMISTRY-US, V30, P7809, DOI 10.1021/bi00245a021; GE Q, 1992, J CLIN INVEST, V90, P559, DOI 10.1172/JCI115895; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; JOHNSON KR, 1993, GENE, V123, P283, DOI 10.1016/0378-1119(93)90139-T; KHAN AS, 1991, J VIROL, V65, P7061, DOI 10.1128/JVI.65.12.7061-7065.1991; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUHNEL H, 1990, NUCLEIC ACIDS RES, V18, P6142, DOI 10.1093/nar/18.20.6142; MARGUERIE C, 1990, Q J MED, V77, P1019, DOI 10.1093/qjmed/77.1.1019; MATHEWS MB, 1984, J EXP MED, V160, P420, DOI 10.1084/jem.160.2.420; MATHEWS MB, 1983, NATURE, V304, P177, DOI 10.1038/304177a0; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P9272, DOI 10.1073/pnas.88.20.9272; MILLER FW, 1990, P NATL ACAD SCI USA, V87, P9933, DOI 10.1073/pnas.87.24.9933; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1989, J BIOL CHEM, V264, P842; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; NADA S, 1993, J BIOL CHEM, V268, P7660; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; RABEN N, 1992, NUCLEIC ACIDS RES, V20, P1075, DOI 10.1093/nar/20.5.1075; RABEN N, 1992, ARTHRITIS RHEUM, V35, pS170; RAMSDEN DA, 1989, J IMMUNOL, V143, P2267; ROBERTS M M, 1989, Arthritis and Rheumatism, V32, pS22; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMMEL P, 1991, TRENDS BIOCHEM SCI, V16, P1, DOI 10.1016/0968-0004(91)90002-D; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHMALJOHN CS, 1988, J GEN VIROL, V69, P1949, DOI 10.1099/0022-1317-69-8-1949; SCOFIELD RH, 1991, P NATL ACAD SCI USA, V88, P3343, DOI 10.1073/pnas.88.8.3343; TARGOFF IN, 1992, ARTHRITIS RHEUM, V35, P821, DOI 10.1002/art.1780350718; TARGOFF IN, 1993, J CLIN INVEST, V91, P2556, DOI 10.1172/JCI116493; TARGOFF IN, 1989, J CLIN INVEST, V84, P162, DOI 10.1172/JCI114136; TARGOFF IN, 1987, J IMMUNOL, V138, P2874; TARGOFF IN, 1990, J IMMUNOL, V144, P1737; TARGOFF IN, 1992, RHEUM DIS CLIN N AM, V18, P455; THOMMES P, 1988, NUCLEIC ACIDS RES, V16, P5391, DOI 10.1093/nar/16.12.5391; TREANOR J, 1989, VIRUS RES, V14, P257, DOI 10.1016/0168-1702(89)90006-3; TSUI FWL, 1985, MOL CELL BIOL, V5, P2381, DOI 10.1128/MCB.5.9.2381; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	54	38	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28790	28797						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961834				2022-12-25	WOS:A1994PU16800044
J	LETEURTRE, F; FUJIMORI, A; TANIZAWA, A; CHHABRA, A; MAZUMDER, A; KOHLHAGEN, G; NAKANO, H; POMMIER, Y				LETEURTRE, F; FUJIMORI, A; TANIZAWA, A; CHHABRA, A; MAZUMDER, A; KOHLHAGEN, G; NAKANO, H; POMMIER, Y			SAINTOPIN, A DUAL INHIBITOR OF DNA TOPOISOMERASE-I AND TOPOISOMERASE-II, AS A PROBE FOR DRUG-ENZYME INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-ASSOCIATED REGION; C-MYC; EUKARYOTIC TOPOISOMERASE; SEQUENCE REQUIREMENTS; INTOPLICINE RP-60475; INTERACTION DOMAINS; CLEAVAGE ACTIVITY; ANTITUMOR AGENT; CAMPTOTHECIN; PROTEIN	Stabilization of the topoisomerase-cleavable complexes is the common initial event leading to the cytotoxicity of topoisomerase I and II (top1 and top2) inhibitors. Using saintopin (STP), a poison of both topoisomerases, we studied top1- and top2-cleavable complexes (Yamashita, Y., Kawada, S.-Z., Fujii, N., and Nakano, H. (1991) Biochemistry 30, 5838-5845). top1 and top2 sites induced in the presence of STP showed the same preferences for the base located 3' to the topoisomerase-induced DNA break (position +1): preference for G and not C. A camptothecin-resistant top1 with a mutation (Asn(722) --> Ser) next to the catalytic tyrosine (Tyr(723)) was cross-resistant to STP, suggesting that both STP and camptothecin interact with the protein near the catalytic tyrosine. These results are consistent with a dual interaction of the drug with the enzyme and the DNA and provide further evidence for the ''drug-stacking'' model. This model proposes that topoisomerase inhibitors bind, possibly through hydrogen bonding and/or stacking, with one of the bases flanking the DNA termini (guanine at position +1 in the case of STP) and within the enzyme catalytic pocket, most likely by stacking with the catalytic tyrosine.	NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MOLEC PHARMACOL LAB,BETHESDA,MD 20892; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,MACHIDA,TOKYO 194,JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyowa Kirin Ltd				Francois, Leteurtre/0000-0001-7373-6180				ALSNER J, 1992, J BIOL CHEM, V267, P12408; [Anonymous], DEV CANC CHEMOTHERAP; BECK WT, 1993, ADV ENZYME REGUL, V33, P113; CAPRANICO G, 1993, BIOCHEMISTRY-US, V32, P3038, DOI 10.1021/bi00063a015; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CAPRANICO G, 1994, J MOL BIOL, V235, P1218, DOI 10.1006/jmbi.1994.1075; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHOU RH, 1991, AM J ANAT, V191, P312, DOI 10.1002/aja.1001910311; CHOU RH, 1990, CANCER RES, V50, P3199; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; FOSSE P, 1991, NUCLEIC ACIDS RES, V19, P2861, DOI 10.1093/nar/19.11.2861; FREUDENREICH CH, 1993, EMBO J, V12, P2085, DOI 10.1002/j.1460-2075.1993.tb05857.x; FROELICHAMMON SJ, 1994, J BIOL CHEM, V269, P7719; FUJII N, 1993, J BIOL CHEM, V268, P13160; FUJII N, 1993, J ANTIBIOT, V46, P1173, DOI 10.7164/antibiotics.46.1173; Fujimori A., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P363; HARKER G, 1994, P AM ASSOC CANC RES, V35, P456; JANIN YL, 1993, J MED CHEM, V36, P3686, DOI 10.1021/jm00075a025; JAXEL C, 1991, J BIOL CHEM, V266, P20418; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; LARSEN AK, 1993, BIOCHEM PHARMACOL, V46, P1403, DOI 10.1016/0006-2952(93)90105-6; LETEURTRE F, 1993, BIOCHEMISTRY-US, V32, P8955, DOI 10.1021/bi00085a029; LETEURTRE F, 1994, J BIOL CHEM, V269, P7863; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MINFORD J, 1986, BIOCHEMISTRY-US, V25, P9, DOI 10.1021/bi00349a002; PODDEVIN B, 1993, MOL PHARMACOL, V44, P767; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; POMMIER Y, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P215; POMMIER Y, 1991, J MOL BIOL, V222, P909, DOI 10.1016/0022-2836(91)90585-T; Pommier Y, 1993, CANCER CHEMOTHERAPY, P214; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; RIOU JF, 1993, CANCER RES, V53, P5987; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROSE D, 1993, MOL CELL BIOL, V13, P3445, DOI 10.1128/MCB.13.6.3445; SORENSEN BS, 1992, J MOL BIOL, V228, P778, DOI 10.1016/0022-2836(92)90863-F; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5157, DOI 10.1093/nar/21.22.5157; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WASSERMANN K, 1990, MOL PHARMACOL, V38, P38; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; YAMASHITA Y, 1991, BIOCHEMISTRY-US, V30, P5838, DOI 10.1021/bi00238a005; YU BW, 1993, J BIOL CHEM, V268, P19586	49	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28702	28707						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961822				2022-12-25	WOS:A1994PU16800031
J	WANG, N; MAURIZI, MR; EMMERTBUCK, L; GOTTESMAN, MM				WANG, N; MAURIZI, MR; EMMERTBUCK, L; GOTTESMAN, MM			SYNTHESIS, PROCESSING, AND LOCALIZATION OF HUMAN LON PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; MITOCHONDRIAL MATRIX; LIVER-MITOCHONDRIA; TARGETING PEPTIDES; ESCHERICHIA-COLI; IMPORT MACHINERY; RAT-LIVER; PRECURSOR; PROTEINS; AMINOTRANSFERASE	The synthesis, maturation, and localization of the human homolog of the bacterial ATP-dependent Lon protease have been studied in cultured cells and in a cell-free system. Immunofluorescence microscopy of cells transfected with a recombinant human Lon protease FLAG epitope chimeric protein confirmed the mitochondrial location of human Lon protease. The primary product of transcription and translation directed by a human LON cDNA in vitro had an apparent mass of similar to 107 kDa, and incubation of the translation product with isolated rat liver mitochondria converted the precursor into the similar to 100-kDa mature form. The latter pelleted with mitochondria and was resistant to trypsin digestion. Maturation of human Lon protease in vitro was dependent on mitochondrial inner membrane potential, as the uncoupling agent 2,4-dinitrophenol (DNP) completely blocked this process. In intact cultured cells treated with DNP, newly synthesized Lon protease also accumulated as the precursor form, and subsequent removal of DNP allowed the precursor to be translocated into mitochondria and cleaved to its mature form. A pulse-chase experiment in the absence of DNP showed that the Lon protease precursor is converted to the mature form with a half-time of <2 min and that the mature human Lon protease is indefinitely stable in intact cells. Submitochondrial fractionation and immunoblot analysis of rat liver mitochondrial proteins using the polyclonal antihuman Lon protease antiserum indicated that the protease is located exclusively in the matrix. These data demonstrate that the maturation of human Lon protease is characterized by steps similar to those reported for other mitochondrial matrix proteins.	NCI,CELL BIOL LAB,BETHESDA,MD 20892; UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore								ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; DESAUTELS M, 1982, J BIOL CHEM, V257, P1673; DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008; Englard S., 1969, METHOD ENZYMOL, V13, P99; FENTON WA, 1984, J BIOL CHEM, V259, P6616; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GLOVER LA, 1992, BIOCHEM J, V284, P609, DOI 10.1042/bj2840609; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; JAUSSI R, 1982, J BIOL CHEM, V257, P13334; KALNOV SL, 1979, BIOCHEM J, V182, P195, DOI 10.1042/bj1820195; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; MACARA IG, 1980, TRENDS BIOCHEM SCI, V5, P92, DOI 10.1016/0968-0004(80)90256-X; MORAES CT, 1991, AM J HUM GENET, V48, P492; ODA T, 1990, J BIOL CHEM, V265, P7513; OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379; PAPADIMITRIOU A, 1984, PEDIATR RES, V18, P1023, DOI 10.1203/00006450-198418100-00023; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; ROSE AM, 1992, MOL CELL BIOL, V12, P5652, DOI 10.1128/MCB.12.12.5652; SAMBOROK J, 1989, MOL CLONING LABORATO; SCHATZ G, 1993, PROTEIN SCI, V2, P141; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TAYLOR R, 1992, J NIH RES, V4, P62; VANDYCK L, 1994, J BIOL CHEM, V269, P238; VEEGER C, 1969, METHOD ENZYMOL, V13, P81, DOI DOI 10.1016/0076-6879(69)13020-7; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WATABE S, 1985, J BIOL CHEM, V260, P5511; WATABE S, 1985, J BIOL CHEM, V260, P4498; WHEELDON LW, 1974, EUR J BIOCHEM, V46, P189, DOI 10.1111/j.1432-1033.1974.tb03611.x; YASUNOBU KT, 1971, METHOD ENZYMOL, V17, P698; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0	41	49	52	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29308	29313						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961901				2022-12-25	WOS:A1994PU16800114
J	WILSON, K; BERENS, RL; SIFRI, CD; ULLMAN, B				WILSON, K; BERENS, RL; SIFRI, CD; ULLMAN, B			AMPLIFICATION OF THE INOSINATE DEHYDROGENASE GENE IN TRYPANOSOMA-BRUCEI-GAMBIENSE DUE TO AN INCREASE IN CHROMOSOME COPY NUMBER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHOTREXATE-RESISTANT LEISHMANIA; ORNITHINE DECARBOXYLASE GENE; ALPHA-DIFLUOROMETHYLORNITHINE; EXTRACHROMOSOMAL CIRCLES; MULTIDRUG RESISTANCE; MOLECULAR-CLONING; DRUG-RESISTANCE; MESSENGER-RNAS; TUBULIN GENES; DONOVANI	Drug resistance is a significant impediment to the therapy of African sleeping sickness in humans. To evaluate molecular mechanisms that contribute to drug resistance in African trypanosomes, a clonal strain of Trypanosoma brucei gambiense, MPA10, was selected in medium containing mycophenolic acid (MPA), an inhibitor of IMP dehydrogenase (IMPDH) activity. IMPDH activity in MPA10 cells was similar to 6-fold higher than that of wild type parental cells, although the enzymes in both strains were equally sensitive to inhibition by MPA. To evaluate the mechanism of IMPDH overexpression in MPA10 cells, the gene encoding IMPDH (impdh) was isolated from a T. b. brucei library by cross-hybridization to the Leishmania donovani impdh. Sequence analysis indicated that the T. brucei IMPDH was 76% identical with the L. donovani IMPDH. The T. brucei impdh hybridized to a 2.7-kb transcript that was expressed at similar to 10-fold greater levels in the MPA10 cells, and this impdh over-expression could be ascribed to an similar to 10-fold amplification of the impdh copy number. Pulsed field gel electrophoresis revealed that the extra impdh copies in MPA10 cells were localized to an similar to 6.0-Mb chromosome that comigrated with the wild type chromosome encompassing impdh. The amplification of impdh could be ascribed to an increased copy number of this 6.0-Mb chromosome, and a predicted augmented DNA content in MPA10 cells was confirmed by flow cytometry. This is the first demonstration that DNA amplification can serve as a molecular mechanism by which T. brucei become resistant to cytotoxic drugs, and the amplification of the 6.0-Mb chromosome represents a novel mechanism of drug resistance in parasitic protozoa.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; UNIV COLORADO, HLTH SCI CTR, DEPT INFECT DIS, DENVER, CO 80262 USA	Oregon Health & Science University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Sifri, Costi/0000-0001-6033-2515	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032036, R01AI021909, R37AI023682, R01AI023682] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32036, AI21909, AI23682] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Battey, 1986, BASIC METHODS MOL BI; BELLOFATTO V, 1987, MOL BIOCHEM PARASIT, V25, P227, DOI 10.1016/0166-6851(87)90086-7; BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; BEVERLEY SM, 1989, ANAL BIOCHEM, V177, P110, DOI 10.1016/0003-2697(89)90023-7; BISHOP RP, 1987, MOL BIOCHEM PARASIT, V24, P263, DOI 10.1016/0166-6851(87)90158-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUN R, 1979, ACTA TROP, V36, P289; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; Campbell W.C., 1986, CHEMOTHERAPY PARASIT; CRUZ AK, 1993, P NATL ACAD SCI USA, V90, P1599, DOI 10.1073/pnas.90.4.1599; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DOBERSTYN EB, 1984, EXPERIENTIA, V40, P1311, DOI 10.1007/BF01951884; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15094; FERNANDES AP, 1993, P NATL ACAD SCI USA, V90, P11608, DOI 10.1073/pnas.90.24.11608; FISH WR, 1982, BIOCHIM BIOPHYS ACTA, V714, P422, DOI 10.1016/0304-4165(82)90149-0; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GARVEY EP, 1985, MOL BIOCHEM PARASIT, V17, P79, DOI 10.1016/0166-6851(85)90129-X; GIBSON W, 1992, MOL BIOCHEM PARASIT, V51, P189, DOI 10.1016/0166-6851(92)90069-V; GOTTESDIENER K, 1990, MOL CELL BIOL, V10, P6079, DOI 10.1128/MCB.10.11.6079; GRAHAM ML, 1989, CANCER RES, V49, P3934; GRONDIN K, 1993, NUCLEIC ACIDS RES, V21, P1895, DOI 10.1093/nar/21.8.1895; HAHN PJ, 1992, MOL CELL BIOL, V12, P2911, DOI 10.1128/MCB.12.7.2911; HANSON S, 1992, J BIOL CHEM, V267, P2350; HANSON S, 1992, MOL CELL BIOL, V12, P5499, DOI 10.1128/MCB.12.12.5499; HENDERSON DM, 1992, MOL CELL BIOL, V12, P2855, DOI 10.1128/MCB.12.6.2855; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; IOVANNISCI DM, 1989, MOL BIOCHEM PARASIT, V34, P177, DOI 10.1016/0166-6851(89)90009-1; KATAKURA K, 1991, MOL BIOCHEM PARASIT, V44, P233, DOI 10.1016/0166-6851(91)90009-U; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; LOOKER D, 1988, NUCLEIC ACIDS RES, V16, P7198, DOI 10.1093/nar/16.14.7198; PAPADOPOULOU B, 1993, NUCLEIC ACIDS RES, V21, P4305, DOI 10.1093/nar/21.18.4305; PETERS W, 1985, PARASITOLOGY, V90, P705, DOI 10.1017/S003118200005232X; PHILLIPS MA, 1987, MOL BIOCHEM PARASIT, V22, P9, DOI 10.1016/0166-6851(87)90064-8; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; ROVAI L, 1992, MOL BIOCHEM PARASIT, V50, P115, DOI 10.1016/0166-6851(92)90249-J; Sambrook J, 1989, MOL CLONING LABORATO; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TEIDEMAN AA, 1991, GENE, V97, P289; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; VANDERPLOEG LHT, 1984, CELL, V39, P213, DOI 10.1016/0092-8674(84)90207-1; WANG CC, 1982, TRENDS BIOCHEM SCI, V7, P354, DOI 10.1016/0968-0004(82)90108-6; WILSON K, 1991, J BIOL CHEM, V266, P1665; WILSON K, 1992, MOL BIOCHEM PARASIT, V55, P197, DOI 10.1016/0166-6851(92)90140-F; WONG S, 1992, MOL BIOCHEM PARASIT, V55, P187, DOI 10.1016/0166-6851(92)90139-B; 1982, B WORLD HEALTH ORGAN, V60, P821	53	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28979	28987						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961861				2022-12-25	WOS:A1994PU16800071
J	WONG, K; CANTLEY, LC				WONG, K; CANTLEY, LC			CLONING AND CHARACTERIZATION OF A HUMAN PHOSPHATIDYLINOSITOL 4-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR KINASE; RAT-LIVER; PHOSPHOINOSITIDE KINASES; PHOSPHOLIPASE-C; G-PROTEINS; PHOSPHORYLATION; PURIFICATION; 3-KINASE; BINDING	Phosphatidylinositol (PtdIns) 4-kinase catalyzes the first committed step in the biosynthesis of phosphatidylinositol 4,5-bisphosphate. Here we report the first mammalian cDNA clone of a PtdIns 4-kinase (named PI4K alpha). The 2.6-kb cDNA encodes a protein of 854 amino acids that is highly homologous to the recently cloned yeast PtdIns 4-kinase STT4 and is also homologous to a second yeast PtdIns 4-kinase, PIK1. PI4K alpha has more distant sequence homology to the catalytic domains of mammalian and yeast PtdIns 3-kinases and to the yeast Tor family of proteins. It also has a region of similarity to pleckstrin homology domains and a potential ankyrin repeat. Cross-hybridizing messages were detected in all human tissues investigated. The enzymatic properties of the protein expressed in insect cells are characteristic of type II PtdIns 4-kinases (activated by detergent and inhibited by adenosine), and PI4K alpha is recognized by an antibody specific for type II PtdIns 4-kinases.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02115; TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Tufts University			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036624] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36624] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1990, METHODS INOSITIDE RE, P155; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COCHET C, 1991, J BIOL CHEM, V266, P637; COCKCROFT S, 1985, BIOCHIM BIOPHYS ACTA, V845, P163, DOI 10.1016/0167-4889(85)90173-9; COLLINS CA, 1983, J BIOL CHEM, V258, P2130; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; HAGA K, 1992, J BIOL CHEM, V267, P2222; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HUSEBYE ES, 1988, BIOCHIM BIOPHYS ACTA, V968, P261, DOI 10.1016/0167-4889(88)90015-8; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JERGIL B, 1983, J BIOL CHEM, V258, P7968; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUROSAWA M, 1986, J IMMUNOL, V136, P616; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PORTER FD, 1988, J BIOL CHEM, V263, P8989; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; Sambrook J, 1989, MOL CLONING LABORATO; SMITH CD, 1983, J BIOL CHEM, V258, P9368; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	35	91	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28878	28884						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961848				2022-12-25	WOS:A1994PU16800058
J	HUNYADY, L; BOR, M; BALLA, T; CATT, KJ				HUNYADY, L; BOR, M; BALLA, T; CATT, KJ			IDENTIFICATION OF A CYTOPLASMIC SER-THR-LEU MOTIF THAT DETERMINES AGONIST-INDUCED INTERNALIZATION OF THE AT(1) ANGIOTENSIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; II TYPE-1 RECEPTOR; MEDIATED ENDOCYTOSIS; POTENTIAL MECHANISM; PHEROMONE RECEPTOR; CARBOXYL-TERMINUS; MOLECULAR-CLONING; EXPRESSION; SEQUESTRATION; SUBTYPE	The type 1 angiotensin II (AT(1)) receptor undergoes rapid endocytosis and down-regulation after agonist binding. In studies on the structural determinants of agonist-induced endocytosis, serial deletions in the cytoplasmic tail of the rat AT(1a) receptor showed that the carboxyl-terminal 22 amino acids are not necessary for its internalization. However, internalization was markedly impaired by the removal of one additional amino acid (Leu(337)) and was reduced by 95% after removal of Ser(335) and Thr(336). Single alanine replacements of amino acids in this region showed that individual substitutions of Thr(332), Ser(335), Thr(336), Leu(337), and Ser(338) caused moderate but significant impairment of the internalization rate, Replacement of both Ser(335) and Thr(336) with alanine residues further impaired the internalization rate, and triple alanine replacement of the Ser-Thr-Leu motif reduced internalization to almost the same extent as the corresponding tail deletion mutant. The Ser-Thr-Leu motif is highly conserved in mammalian AT(1) receptors but is mot present in the noninternalizing type 2 angiotensin II receptor. These data demonstrate that a serine/threonine-rich region including Leu(337) in the cytoplasmic tail of the AT(1) receptor is a major requirement for endocytosis of the hormone-receptor complex and support the concept that similar motifs in other G protein-coupled receptors are determinants of their agonist-induced internalization.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892; SEMMELWEIS UNIV MED,SCH MED,DEPT PHYSIOL,H-1444 BUDAPEST,HUNGARY	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Semmelweis University				Balla, Tamas/0000-0002-9077-3335				BALLA T, 1991, J BIOL CHEM, V266, P24719; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BROWN VI, 1991, DNA CELL BIOL, V10, P399, DOI 10.1089/dna.1991.10.399; BURNS KD, 1993, AM J PHYSIOL, V264, pF645, DOI 10.1152/ajprenal.1993.264.4.F645; BURNS L, 1994, FEBS LETT, V343, P146, DOI 10.1016/0014-5793(94)80307-2; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHAKI S, 1993, FASEB J, V7, pA462; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; HUNYADY L, 1991, J BIOL CHEM, V266, P2783; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ITAZAKI K, 1993, EUR J PHARM-MOLEC PH, V245, P147, DOI 10.1016/0922-4106(93)90122-P; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KOCSIS JF, 1994, GEN COMP ENDOCR, V96, P92, DOI 10.1006/gcen.1994.1162; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; MORO O, 1994, J BIOL CHEM, V269, P6651; MORO O, 1993, J BIOL CHEM, V268, P6862; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; SANDBERG K, 1992, J BIOL CHEM, V267, P9455; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; YU SS, 1993, J BIOL CHEM, V268, P337; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N; Zar JH., 1999, BIOSTAT ANAL	39	163	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31378	31382						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989302				2022-12-25	WOS:A1994PX30300011
J	NANOFF, C; BOEHM, S; HOHENEGGER, M; SCHUTZ, W; FREISSMUTH, M				NANOFF, C; BOEHM, S; HOHENEGGER, M; SCHUTZ, W; FREISSMUTH, M			2',3'-DIALDEHYDE GTP AS AN IRREVERSIBLE G-PROTEIN ANTAGONIST - DISRUPTION AND RECONSTITUTION OF G-PROTEIN-MEDIATED SIGNAL-TRANSDUCTION IN CELLS AND CELL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK SYMPATHETIC NEURONS; BETA-GAMMA-SUBUNITS; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; BOVINE BRAIN; ESCHERICHIA-COLI; SYNTHETIC PEPTIDES; PLATELET MEMBRANES; ADENOSINE RECEPTOR; CALCIUM CURRENTS	The 2',3'-dialdehyde analogue of GTP, oGTP, was devised as an irreversible antagonist of regulatory GTP-binding proteins (G proteins), Here, we show that oGTP uncouples transmembrane signaling mediated by a set of distinct G proteins both in isolated membranes and in whole cells, In human platelet membranes, pretreatment with oGTP suppressed receptor- and G protein-controlled regulation of adenylyl cyclase activity, In chick neuronal cells, inhibition of the voltage-sensitive Ca2+-current by various membrane receptors (alpha(2)-adrenergic, somatostatin, GABA(B)) was eliminated when oGTP was applied intracellularly in the whole cell patch-clamp configuration, Disruption of endogenous signaling pathways by oGTP occurred through specific blockage of the GTP-binding site of G protein alpha-subunits by the following criteria: (i) pretreatment of membranes with oGTP blocked direct G protein activation by guanine nucleotides as well as labeling of G(s alpha) and G(i alpha), with the photoaffinity probe [(alpha-P-32]GTP azidoanilide, (ii) The effect of oGTP was antagonized by the simultaneous introduction of guanosine 5'-(3-O-thio)triphosphate into the patch-clamped cell, (iii) The time to onset of action was similar for oGTP and guanosine 5'-O-thio)diphosphate, (iv) Inactivation of G protein-dependent signaling was overcome by substituting G protein alpha-subunits. Addition of both the short and long form of recombinant G(s alpha)(rG(s alpha-s) and rG(s alpha-L)) restored guanine nucleotide-dependent adenylyl cyclase activity to oGTP-treated platelet membranes with rG(s alpha-L) being similar to 3-10-fold more potent than rG(s alpha-s). This apparent preference was due to the intrinsically different activation rates of rG(s alpha-L) and rG(s alpha-s). When reconstituted with exogenous rG(s alpha), the A(2) adenosine receptor did not discriminate among the two forms of rG(s alpha).Thus, G(s alpha-L) is the primary determinant of basal cARIP formation in platelets, In contrast, neither the addition of various recombinant subtypes of G(i/o) nor purified bovine brain py-dimers reconstituted adenylyl cyclase inhibition in oGTP-treated membranes, All subtypes of G(i alpha) stimulated adenylyl cyclase, In the presence of rG(s alpha), a conditional. stimulation by beta gamma-dimers was observed, This pattern of stimulation shows that platelet adenylyl cyclase is a type II-Iike isoform, Either a differently modified G protein or an ancillary GTP-binding component is required for adenylyl cyclase inhibition in platelets, oGTP can be considered a useful tool for disruption and reconstitution of transmembrane signaling mediated by presumably all classes of heterotrimeric G proteins.	UNIV VIENNA, INST PHARMACOL, A-1090 VIENNA, AUSTRIA; UNIV VIENNA, INST NEUROPHARMACOL, A-1090 VIENNA, AUSTRIA	University of Vienna; University of Vienna			Hohenegger, Martin/AAF-6479-2020	Freissmuth, Michael/0000-0001-9398-1765; Boehm, Stefan/0000-0002-0205-2459; nanoff, christian/0000-0002-8857-2470; Hohenegger, Martin/0000-0001-6537-9574				BERTIN B, 1992, J BIOL CHEM, V267, P8200; BOEHM S, 1992, N-S ARCH PHARMACOL, V345, P606; BOEHM S, 1994, J NEUROCHEM, V63, P146; BOEHM S, 1991, N-S ARCH PHARMACOL, V344, P382; Boehm S., 1993, Society for Neuroscience Abstracts, V19, P1263; BRAUN S, 1979, BIOCHEMISTRY-US, V18, P2134, DOI 10.1021/bi00577a045; CARBONE E, 1989, PROG BIOPHYS MOL BIO, V54, P31, DOI 10.1016/0079-6107(89)90008-4; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; DIVERSEPIERLUISSI M, 1993, NEURON, V10, P753, DOI 10.1016/0896-6273(93)90175-Q; ELMSLIE KS, 1993, PFLUG ARCH EUR J PHY, V423, P472, DOI 10.1007/BF00374943; FREISSMUTH M, 1991, BIOCHEM J, V275, P651, DOI 10.1042/bj2750651; FREISSMUTH M, 1991, P NATL ACAD SCI USA, V88, P8548, DOI 10.1073/pnas.88.19.8548; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLARD A, 1993, J NEUROSCI, V13, P3884; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HOHENEGGER M, 1994, J BIOL CHEM, V269, P32008; HUTTEMANN E, 1984, N-S ARCH PHARMACOL, V325, P226, DOI 10.1007/BF00495948; JAKOBS KH, 1989, EUR J BIOCHEM, V183, P115, DOI 10.1111/j.1432-1033.1989.tb14903.x; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P32; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MCCLUE SJ, 1992, BIOCHEM J, V284, P565, DOI 10.1042/bj2840565; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P239, DOI 10.1016/0165-6147(93)90019-G; MILLIGAN G, 1989, BIOCHEM J, V262, P643, DOI 10.1042/bj2620643; MORRIS D, 1990, BIOCHEMISTRY-US, V29, P9079, DOI 10.1021/bi00490a027; MUKAI H, 1992, J BIOL CHEM, V267, P16237; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NANOFF C, 1993, J RECEPTOR RES, V13, P961, DOI 10.3109/10799899309073703; NANOFF C, 1991, MOL PHARMACOL, V39, P130; OFFERMANNS S, 1991, J BIOL CHEM, V266, P3365; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; OPPI C, 1992, P NATL ACAD SCI USA, V89, P8268, DOI 10.1073/pnas.89.17.8268; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PFEUFFER E, 1985, P NATL ACAD SCI USA, V82, P3086, DOI 10.1073/pnas.82.10.3086; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; PIERCE KD, 1992, BIOCHEM BIOPH RES CO, V187, P86, DOI 10.1016/S0006-291X(05)81462-7; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOSS T, 1993, J BIOL CHEM, V268, P4637; WIELAND T, 1992, J BIOL CHEM, V267, P20791	54	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31999	32007						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989376				2022-12-25	WOS:A1994PX30300101
J	YOU, JC; MCHENRY, CS				YOU, JC; MCHENRY, CS			HUMAN-IMMUNODEFICIENCY-VIRUS NUCLEOCAPSID PROTEIN ACCELERATES STRAND TRANSFER OF THE TERMINALLY REDUNDANT SEQUENCES INVOLVED IN REVERSE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY-DNA STRANDS; ESCHERICHIA-COLI; DIMER FORMATION; RNA; REPLICATION; EXPRESSION; CATALYSIS; RECOMBINATION; REQUIREMENTS; MECHANISM	During the initial stages of human immunodeficiency virus (HIV) replication, 5'-terminally redundant (R') DNA, the minus strand synthesized as the complement of the 5'-long terminal repeat (LTR) terminal redundancy, must anneal to the 3'-LTR RNA to enable template transfer. The (R')DNA sequences contain the site involved in the tot-TAR interaction and extensive secondary structures that strongly interfere with annealing. The novel annealing reaction between (R')DNA and 3'-LTR RNA follows first-order kinetics, consistent with an unusually slow unfolding of the secondary structure as the rate-limiting step followed by a more rapid nucleation step. The HIV nucleocapsid protein accelerates the annealing reaction 3000-fold under optimal conditions. This acceleration may be necessary for strand transfer to efficiently occur in vivo and may provide a target for anti-HIV chemotherapeutic agents.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,PROGRAM MOLEC BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIAID NIH HHS [R01AI26600] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026600] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; BARAT C, 1993, J MOL BIOL, V231, P185, DOI 10.1006/jmbi.1993.1273; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; BOONE LR, 1981, J VIROL, V37, P109, DOI 10.1128/JVI.37.1.109-116.1981; BUISER RG, 1991, J BIOL CHEM, V266, P13103; CHRISTIANSEN C, 1977, J MOL BIOL, V115, P441, DOI 10.1016/0022-2836(77)90164-4; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7032; HAMY F, 1993, J MOL BIOL, V230, P111, DOI 10.1006/jmbi.1993.1129; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; KHAN R, 1992, J BIOL CHEM, V267, P6689; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; MANIATIS T, 1983, MOL CLONING; MCHENRY C, 1989, MOL BIOL CHROMOSOME, pCH5; MERIC C, 1986, J VIROL, V60, P450; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; PONTIUS BW, 1992, J BIOL CHEM, V267, P13815; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; STUDIER FW, 1969, J MOL BIOL, V41, P199, DOI 10.1016/0022-2836(69)90385-4; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; VARMUS H, 1984, RNA TUMOR VIRUSES, V2; VARMUS Z, 1984, RNA TUMOR VIRUSES, V1; WETMUR JG, 1968, J MOL BIOL, V31, P349, DOI 10.1016/0022-2836(68)90414-2; YOU JC, 1993, J BIOL CHEM, V268, P16519	32	192	193	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31491	31495						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989315				2022-12-25	WOS:A1994PX30300028
J	FUKAMIZU, A; SAGARA, M; SUGIYAMA, F; HORIGUCHI, H; KAMMA, H; HATAE, T; OGATA, T; YAGAMI, K; MURAKAMI, K				FUKAMIZU, A; SAGARA, M; SUGIYAMA, F; HORIGUCHI, H; KAMMA, H; HATAE, T; OGATA, T; YAGAMI, K; MURAKAMI, K			NEUROECTODERMAL TUMORS EXPRESSING C-MYC, L-MYC, AND N-MYC IN TRANSGENIC MICE THAT CARRY THE E1A/E1B GENE OF HUMAN ADENOVIRUS-TYPE-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANGIOTENSINOGEN GENE; CELL-ADHESION MOLECULE; HUMAN NEURO-BLASTOMA; E1A PROTEINS; DIFFERENTIAL EXPRESSION; HUMAN RENIN; RAT-CELLS; MOUSE; NEUROBLASTOMA; TRANSCRIPTION	Adenovirus early 1 (E1) region gene products, including E1A and E1B, are required for transformation of primary cultured rodent cells. In order to investigate in vivo action of the E1 region, we established a line of transgenic mice carrying the oncogenic E1A and E1B genes of human adenovirus type 12 under control of the human angiotensinogen promoter. Histopathological analyses indicated that transgenic mice heritably develop neuroectodermal tumors arising from the pelvic region with varying degrees of incidence. The transgene was expressed in the neuroectodermal tumors as well as in TNT-1 cells, a cell line established from the tumors, where the human angiotensinogen promoter was constitutively active. The high level expression of c-, L-, and N-myc without gene amplification was notable in the original tumors and TNT-1 cells, but not in another tissue examined. The co-expression of the three sets of myc family genes in both the original tumors and the established cell line provided the possibility that the target cells for transformation may belong to a specific cell type that expresses all these oncogenes during development.	UNIV TSUKUBA, LAB ANIM RES CTR, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, INST BASIC MED SCI, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba; University of Tsukuba	FUKAMIZU, A (corresponding author), UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN.		fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				AGUZZI A, 1990, New Biologist, V2, P533; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; BEHRINGER RR, 1988, P NATL ACAD SCI USA, V85, P2648, DOI 10.1073/pnas.85.8.2648; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLUM RG, 1990, CANCER CELL-MON REV, V2, P69; COMPERE SJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P129, DOI 10.1016/0304-419X(88)90008-X; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; FUKAMIZU A, 1991, BIOMED BIOCHIM ACTA, V50, P659; GALLIMORE PH, 1979, COLD SPRING HARB SYM, V44, P703, DOI 10.1101/SQB.1980.044.01.075; GARINCHESA P, 1991, AM J PATHOL, V139, P275; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HOGAN B, 1986, MANIPULATING MOUSE E; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; IWAMOTO T, 1993, BRIT J CANCER, V67, P504, DOI 10.1038/bjc.1993.94; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KLEBE RJ, 1969, J CELL BIOL, V43, pA69; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOIKE K, 1989, P NATL ACAD SCI USA, V86, P5615, DOI 10.1073/pnas.86.14.5615; KOIKE K, 1990, J VIROL, V64, P3988, DOI 10.1128/JVI.64.8.3988-3991.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NISEN P, 1986, CANCER RES, V46, P6127; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; ORMONDT HV, 1984, CURR TOP MICROBIOL I, V110, P73; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PATEL K, 1991, BRIT J CANCER, V63, P20; PEEPER DS, 1992, VIROLOGY, V190, P733, DOI 10.1016/0042-6822(92)90911-8; PHIMISTER E, 1991, J CLIN PATHOL, V44, P580, DOI 10.1136/jcp.44.7.580; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1992, BIOCHIM BIOPHYS ACTA, V1114, P43, DOI 10.1016/0304-419X(92)90005-J; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SHENK T, 1991, ADV CANCER RES, V57, P47; SHIROKI K, 1992, J VIROL, V66, P1449, DOI 10.1128/JVI.66.3.1449-1457.1992; SKALNIK DG, 1991, MOL CELL BIOL, V11, P4518, DOI 10.1128/MCB.11.9.4518; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; SWANSON LW, 1985, NATURE, V317, P363, DOI 10.1038/317363a0; TAKAHASHI S, 1991, BIOCHEM BIOPH RES CO, V180, P1103, DOI 10.1016/S0006-291X(05)81180-5; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; Wada R K, 1988, Prog Clin Biol Res, V271, P57; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	74	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31252	31258						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983069				2022-12-25	WOS:A1994PV51000078
J	HAWKINS, C; XU, A; NARAYANAN, N				HAWKINS, C; XU, A; NARAYANAN, N			SARCOPLASMIC-RETICULUM CALCIUM-PUMP IN CARDIAC AND SLOW-TWITCH SKELETAL-MUSCLE BUT NOT FAST-TWITCH SKELETAL-MUSCLE UNDERGOES PHOSPHORYLATION BY ENDOGENOUS AND EXOGENOUS CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE - CHARACTERIZATION OF OPTIMAL CONDITIONS FOR CALCIUM-PUMP PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RYANODINE RECEPTOR; PHOSPHOLAMBAN PHOSPHORYLATION; MONOCLONAL-ANTIBODY; CA-2+ ATPASE; CALMODULIN; TRANSPORT; CA2+-ATPASE; EXPRESSION; SITE; RAT	We have demonstrated recently that in cardiac sarcoplasmic reticulum (SR), a membrane-associated Ca2+/calmodulin-dependent protein kinase (CaM kinase) phosphorylates and activates the Ca2+-pumping ATPase (Ca2+ ATPase) in addition to phosphorylating the previously characterized substrates, phospholamban, and Ca2+ release channel (ryanodine receptor) (Xu, A., Hawkins, C., and Narayanan, N. (1993) J. Biol. Chem. 268, 8394-8397). The present study shows that a CaM kinase regulatory system capable of modulating SR Ca2+ pump activity through direct phosphorylation of the Ca2+-ATPase is functional in slow twitch but not fast twitch skeletal muscle. Incubation of SR vesicles isolated from rabbit slow twitch (soleus) and fast twitch (adductor magnus) skeletal muscles in the presence of Ca2+ and calmodulin resulted in phosphorylation of the Ca2+-ATPase in slow twitch muscle SR but not in fast twitch muscle SR. Exogenous CaM kinase II, which stimulated phosphorylation of the cardiac and slow twitch muscle SR Ca2+-ATPase, failed to phosphorylate fast twitch muscle SR Ca2+-ATPase. These observations demonstrate that CaM kinase catalyzed phosphorylation of the Ca2+ pump is isoform-specific since heart and slow twitch muscle express the same Ca2+-ATPase isoform (SERCA2a), which is distinct from that of fast twitch muscle (SERCA1). As in the case of cardiac SR Ca2+-ATPase, phosphorylation of the slow twitch muscle SR Ca2+-ATPase (occurring at a serine residue) resulted in a 2-fold increase in catalytic activity of the enzyme without alteration in its Ca2+ sensitivity. In addition, Ca2+/calmodulin-dependent pre-phosphorylation of slow twitch muscle SR resulted in a greater than a-fold increase in its Ca2+ transport activity. In both cardiac and slow twitch muscle SR, phosphorylation of the Ca2+-ATPase by the endogenous CaM kinase occurred rapidly (maximum within 2 min at 37 degrees C), had similar pH optimum (8.5-9.0), temperature optimum (30 degrees C), and calmodulin concentration-dependence (k(0.5) 50-60 nM). cAMP-dependent protein kinase did not phosphorylate the Ca2+-ATPase appreciably in either cardiac or slow twitch muscle SR These findings suggest a muscle-specific role for the membrane-associated CaM	UNIV WESTERN ONTARIO, DEPT PHYSIOL, LONDON N6A 5C1, ON, CANADA	Western University (University of Western Ontario)								ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; COLL RJ, 1984, J BIOL CHEM, V259, P4249; CORVERA S, 1988, J BIOL CHEM, V263, P3116; DAVIS BA, 1990, MOL CELL BIOCHEM, V99, P83; FABIATO A, 1985, CELL CALCIUM, V6, P95, DOI 10.1016/0143-4160(85)90037-5; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FEHER JJ, 1990, CALCIUM HEART, P199; FUJII J, 1988, FEBS LETT, V227, P51, DOI 10.1016/0014-5793(88)81412-1; FUJII J, 1986, BIOCHEM BIOPH RES CO, V138, P1044, DOI 10.1016/S0006-291X(86)80387-4; GRAND RJA, 1979, BIOCHEM J, V183, P285, DOI 10.1042/bj1830285; HAWKINS C, 1994, BBA-BIOMEMBRANES, V1191, P231, DOI 10.1016/0005-2736(94)90174-0; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JIANG MT, 1993, CIRC RES, V72, P102, DOI 10.1161/01.RES.72.1.102; JIANG MT, 1990, MECH AGEING DEV, V54, P87, DOI 10.1016/0047-6374(90)90018-B; KHAN I, 1993, CELL CALCIUM, V14, P111, DOI 10.1016/0143-4160(93)90081-G; KIM HW, 1990, J BIOL CHEM, V265, P1702; KIRCHBERGER MA, 1986, BIOCHEMISTRY-US, V25, P5484, DOI 10.1021/bi00367a021; KIRCHBERGER MA, 1976, J BIOL CHEM, V251, P725; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; LU YZ, 1993, BIOCHEMISTRY-US, V32, P3105, DOI 10.1021/bi00063a023; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MACLENNAN DH, 1992, ION MOTIVE ATPASES S, V167, P1; MANDEL F, 1982, CIRC RES, V50, P310, DOI 10.1161/01.RES.50.2.310; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MOLNAR E, 1990, BIOCHIM BIOPHYS ACTA, V1023, P147, DOI 10.1016/0005-2736(90)90410-P; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; NAKAMARU Y, 1970, BIOCHEM BIOPH RES CO, V41, P830, DOI 10.1016/0006-291X(70)90157-9; NAKAMURA J, 1983, J BIOL CHEM, V258, P5079; NARAYANAN N, 1981, BIOCHIM BIOPHYS ACTA, V678, P442, DOI 10.1016/0304-4165(81)90126-4; NARAYANAN N, 1991, BIOCHIM BIOPHYS ACTA, V1070, P83, DOI 10.1016/0005-2736(91)90149-3; ORCHARD CH, 1990, AM J PHYSIOL, V258, pC967, DOI 10.1152/ajpcell.1990.258.6.C967; OTSU K, 1990, J BIOL CHEM, V265, P13472; PANNIER JL, 1968, ARCH INT PHYS BIOCH, V76, P624, DOI 10.3109/13813456809058730; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; POOLEWILSON PA, 1975, AM J PHYSIOL, V229, P570, DOI 10.1152/ajplegacy.1975.229.3.570; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; SULAKHE PV, 1978, BIOCHEM J, V175, P171, DOI 10.1042/bj1750171; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TADA M, 1988, METHOD ENZYMOL, V157, P107; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; THOMPSON RB, 1990, CALCIUM HEART; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1994, IN PRESS J BIOL CHEM; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; TYBERG JV, 1970, AM J PHYSIOL, V218, P1780, DOI 10.1152/ajplegacy.1970.218.6.1780; VANWINKLE WB, 1978, J BIOL CHEM, V253, P8671; VANWINKLE WB, 1981, J BIOL CHEM, V256, P2268; WANG JX, 1992, NATURE, V359, P739, DOI 10.1038/359739a0; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; WEISFELDT ML, 1974, J CLIN INVEST, V53, P1626, DOI 10.1172/JCI107713; WITCHER DR, 1992, J BIOL CHEM, V267, P4963; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; XU A, 1993, J BIOL CHEM, V268, P8394; XU A, 1994, FASEB J, V8, pA612; XU A, 1992, FASEB J, V6, pA1188; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	74	101	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31198	31206						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983062				2022-12-25	WOS:A1994PV51000071
J	MAYORGA, LS; BERON, W; SARROUF, MN; COLOMBO, MI; CREUTZ, C; STAHL, PD				MAYORGA, LS; BERON, W; SARROUF, MN; COLOMBO, MI; CREUTZ, C; STAHL, PD			CALCIUM-DEPENDENT FUSION AMONG ENDOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSYLATION FACTOR ARF; CELL-FREE SYSTEM; PROTEIN-TRANSPORT; SECRETORY PATHWAY; CHROMAFFIN CELLS; EXOCYTOSIS; INVITRO; PHAGOSOMES; RECEPTOR; INHIBITION	Fusion among endosomes is an important step for transport and sorting of internalized macromolecules. Working in a cell-free system, we have previously reported that, in the absence of externally added calcium, endosome fusion requires cytosol, ATP, and is sensitive to N-ethylmaleimide (NEM) and to anti-NEM-sensitive factor (NSF) antibody. This cytosol-dependent fusion is regulated by monomeric and heterotrimeric GTP-binding proteins. Further studies have revealed, however, that in the presence of micromolar concentrations of free calcium, fusion is observed even in the absence of cytosol and ATP. At the electron microscope level, Ca2+-dependent endosome aggregation and fusion were similar to that observed for cytosol-dependent fusion. Calcium-dependent fusion was not affected by nonhydrolyzable analogs of GTP or GDP nor by NEM or anti-NSF antibody. However, Ca2+-dependent fusion was abrogated by trypsin treatment of the vesicles or by a membrane wash with 60 mM EDTA indicating that peripheral proteins are required. An anti-annexin II antibody and an annexin II peptide blocked Ca2+-dependent fusion by 50%. After the EDTA wash, Ca2+-dependent fusion was reconstituted by addition of purified annexin II and arachidonic acid. We conclude that endosomes can fuse by two mechanisms, one that has an absolute requirement for calcium and is probably mediated by annexins, and another that does not require calcium.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; UNIV NACL CUYO, CONICET, FAC CIENCIAS MED, INST HISTOL & EMBRIOL, MENDOZA, ARGENTINA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; UNIV VIRGINIA, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA	Washington University (WUSTL); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza; Washington University (WUSTL); University of Virginia			Stahl, Philip/D-6315-2012	Mayorga, Luis S/0000-0002-5995-0671	NCI NIH HHS [CA 12858] Funding Source: Medline; NIAID NIH HHS [AI 20015] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA012858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020015, R01AI020015] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; BALCH W, 1990, TRENDS BIOCHEM SCI, V15, P437; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURGOYNE RD, 1987, NATURE, V328, P112, DOI 10.1038/328112a0; CARPENTIER JL, 1992, EXP CELL RES, V198, P144, DOI 10.1016/0014-4827(92)90160-A; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; COLOMBO MI, 1994, J BIOL CHEM, V269, P14919; COLOMBO MI, 1991, J BIOL CHEM, V266, P23438; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DAMER CK, 1992, MOL BIOL CELL, V3, P61; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DIAZ R, 1989, J BIOL CHEM, V264, P13171; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; JACONI MEE, 1990, J CELL BIOL, V110, P1555, DOI 10.1083/jcb.110.5.1555; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; JOINER KA, 1989, J CELL BIOL, V109, P2771, DOI 10.1083/jcb.109.6.2771; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KNIGHT DE, 1989, TRENDS NEUROSCI, V12, P451, DOI 10.1016/0166-2236(89)90095-7; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; PITT A, 1992, J CLIN INVEST, V90, P1978, DOI 10.1172/JCI116077; POPOV SV, 1993, CELL, V73, P1247, DOI 10.1016/0092-8674(93)90352-Q; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; TAGAYA M, 1993, FEBS LETT, V324, P201, DOI 10.1016/0014-5793(93)81393-E; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; THOMAS L, 1992, J BIOL CHEM, V267, P6183; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P16751	44	100	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30927	30934						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983026				2022-12-25	WOS:A1994PV51000032
J	SELL, SM; REESE, D; OSSOWSKI, VM				SELL, SM; REESE, D; OSSOWSKI, VM			INSULIN-INDUCIBLE CHANGES IN INSULIN-RECEPTOR MESSENGER-RNA SPLICE VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEPENDENT DIABETES-MELLITUS; MESSENGER-RNA; ALTERED EXPRESSION; PREMESSENGER RNA; SKELETAL-MUSCLE; HEPATOMA-CELLS; 2 ISOFORMS; GENE; DEXAMETHASONE; TISSUES	Alternative splicing of insulin receptor pre-mRNA has been shown to be regulated in a tissue specific and developmental manner. We investigated whether the receptor ligand might regulate the relative distribution of alternatively spliced mRNA in insulin-sensitive cells and found that changes in the relative expression of the two alternatively spliced insulin receptor RNA isotypes expressed in hepatocytes are regulated by insulin. In addition, we observed significant differences (p less than or equal to 0.001) in insulin receptor isotype expression in subjects who were hyperinsulinemic and insulin-resistant versus subjects who were insulin sensitive. These results support a role for insulin in the regulation of the relative expression of alternatively spliced mRNA expressed in insulin-responsive cells and tissues.			SELL, SM (corresponding author), NIDDKD, CLIN DIABET & NUTR SECT, 4212 N 16TH ST, PHOENIX, AZ 85016 USA.				DRS NIH HHS [ISRSA0005-01 ISR73] Funding Source: Medline	DRS NIH HHS		ABOTT AM, 1992, J BIOL CHEM, V267, P10759; ALEXANDERBRIDGES M, 1992, ADV ENZYME REGUL, V32, P149; ANDERSON CM, 1993, J CLIN ENDOCR METAB, V76, P1380, DOI 10.1210/jc.76.5.1380; BENECKE H, 1993, DIABETES, V42, P206, DOI 10.2337/diabetes.42.1.206; BENECKE H, 1992, J CLIN INVEST, V89, P2066, DOI 10.1172/JCI115819; BERGSTROM J, 1962, SCAND J CLIN LAB I S, V68, P1; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BOGARDUS C, 1984, J CLIN INVEST, V73, P1185, DOI 10.1172/JCI111304; BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER DR, 1993, EXP CLIN ENDOCR S, V101, P153; DEFRONZO RA, 1992, DIABETOLOGIA, V35, P389, DOI 10.1007/BF00401208; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; GOLDSTEIN BJ, 1987, MOL ENDOCRINOL, V1, P759, DOI 10.1210/mend-1-11-759; HANSEN T, 1993, J CLIN ENDOCR METAB, V77, P1500, DOI 10.1210/jc.77.6.1500; ITOH N, 1993, J BIOL CHEM, V268, P17983; KELLERER M, 1993, DIABETOLOGIA, V36, P628, DOI 10.1007/BF00404072; KELLERER M, 1992, BIOCHEMISTRY-US, V31, P4588, DOI 10.1021/bi00134a008; KOSAKI A, 1993, J BIOL CHEM, V268, P21990; LEVY JR, 1992, J BIOL CHEM, V267, P25289; LEVY JR, 1991, DIABETES, V40, P58, DOI 10.2337/diabetes.40.1.58; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOSTHAF L, 1993, P NATL ACAD SCI USA, V90, P2633, DOI 10.1073/pnas.90.7.2633; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; MOSTHAF L, 1991, P NATL ACAD SCI USA, V88, P4728, DOI 10.1073/pnas.88.11.4728; NORGREN S, 1994, P NATL ACAD SCI USA, V91, P1465, DOI 10.1073/pnas.91.4.1465; NORGREN S, 1993, DIABETES, V42, P675, DOI 10.2337/diabetes.42.5.675; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; SESTI G, 1991, BIOCHEM BIOPH RES CO, V181, P1419, DOI 10.1016/0006-291X(91)92097-4; SHAY NF, 1990, J BIOL CHEM, V265, P17844; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; TEWARI M, 1991, MOL ENDOCRINOL, V5, P653, DOI 10.1210/mend-5-5-653; WERTHEIMER E, 1993, NAT GENET, V5, P71, DOI 10.1038/ng0993-71; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058; YAMAGUCHI Y, 1993, ENDOCRINOLOGY, V132, P1132, DOI 10.1210/en.132.3.1132	35	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30769	30772						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983004				2022-12-25	WOS:A1994PV51000008
J	LARSON, RC; FISCH, P; LARSON, TA; LAVENIR, I; LANGFORD, T; KING, G; RABBITTS, TH				LARSON, RC; FISCH, P; LARSON, TA; LAVENIR, I; LANGFORD, T; KING, G; RABBITTS, TH			T-CELL TUMORS OF DISPARATE PHENOTYPE IN MICE TRANSGENIC FOR RBTN-2	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOMAL TRANSLOCATION; ANTIGEN RECEPTOR; HOMEOBOX GENE; PROTEIN; LYMPHOMA; FUSION; FAMILY; HOX11; ONCOGENES	RBTN2 is a LIM domain protein which can be activated by the translocation t(11;14)(p13;q11) in childhood T cell acute leukaemia. Transgenic mice were examined in which rbtn2 protein is expressed in the T cell lineage. An average of 72% of these mice developed T cell tumours before 18 months of age, compared with 9% in transgenic mice expressing the related gene Rbtn-1. Rbtn2-induced tumours first appeared at 5 months of age and were clonal. They displayed a range of phenotypes, the most notable being CD3/CD45R double-positive cells. Tumours expressing either T cell receptor alpha/beta or gamma/delta heterodimers were found. Thus rbtn2 can promote tumours within a range of T cell types and maturities. The latency period before tumour development indicates that secondary events must occur before the onset of overt malignancy.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology			Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				ASENSI V, 1990, CLIN EXP IMMUNOL, V80, P268; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLARK SS, 1993, J VIROL, V67, P6033, DOI 10.1128/JVI.67.10.6033-6046.1993; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUBE ID, 1991, BLOOD, V78, P2996; FISCH P, 1992, ONCOGENE, V7, P2389; FIZZOTTI M, 1994, LEUKEMIA, V8, P1124; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; KAPFF CT, 1991, ACUTE LYMPHATIC LEUK; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RIBEIRO RC, 1991, BLOOD, V78, P466; RIBEIRO RC, 1992, LEUKEMIA LYMPHOMA, V7, P351, DOI 10.3109/10428199209049790; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Sperling A I, 1989, Int Immunol, V1, P434, DOI 10.1093/intimm/1.4.434; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, IN PRESS EMBO J, V13; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; Yagita H, 1989, INT IMMUNOL, V1, P94, DOI 10.1093/intimm/1.1.94	34	89	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3675	3681						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970726				2022-12-25	WOS:A1994PT39200031
J	MARTELLI, F; CENCIARELLI, C; SANTARELLI, G; POLIKAR, B; FELSANI, A; CARUSO, M				MARTELLI, F; CENCIARELLI, C; SANTARELLI, G; POLIKAR, B; FELSANI, A; CARUSO, M			MYOD INDUCES RETINOBLASTOMA GENE-EXPRESSION DURING MYOGENIC DIFFERENTIATION	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; LOOP-HELIX PROTEINS; DNA-BINDING; CELL-CYCLE; SUSCEPTIBILITY GENE; MOUSE MUSCLE; RB1 GENE; PRODUCT; DOMAIN; PHOSPHORYLATION	In skeletal muscle cells permanent withdrawal from the cell cycle is a prerequisite for terminal differentiation. The muscle-specific transcription factor MyoD can activate downstream muscle structural genes and myogenic conversion in many different cell types. It has been demonstrated that the product of the retinoblastoma susceptibility gene, with its growth-suppressive activity, is involved in the myogenic function of MyoD (Caruso et al., 1993; Gu et al., 1993). The present study characterises the modulation of retinoblastoma (Rb1) mRNA levels during myogenic differentiation of the murine C2 cell line and provides evidence that the muscle-specific regulatory factor MyoD enhances Rb1 gene transcription. We demonstrate that MyoD mediates the transactivation of a CAT construct whose expression is driven by the human Rbl gene promoter, and that this is not a consequence of direct binding of MyoD to an E-box DNA sequence motif present in the Rb1 promoter sequences. In addition we have tested the capability of several MyoD mutant proteins of inducing the Rb1 promoter CAT construct. Our results indicate that the MyoD function required for induction of Rb1 promoter activity is distinct from its myogenic function.	CNR,IST TECNOL BIOMED,I-00161 ROME,ITALY; IST REGINA ELENA STUDIO & CURA TUMORI,I-00158 ROME,ITALY; CNR,IST BIOL CELLULARE,I-00137 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR)			Felsani, Armando/D-1784-2010; Martelli, Fabio/AAL-3788-2020; Caruso, Maurizia/G-8895-2013	Felsani, Armando/0000-0001-8851-6295; Martelli, Fabio/0000-0002-8624-7738; Caruso, Maurizia/0000-0001-5445-6343; Cenciarelli, Carlo/0000-0001-7480-4608	Telethon [298] Funding Source: Medline	Telethon(Fondazione Telethon)		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; CARUSO M, 1993, ONCOGENE, V8, P267; CARUSO M, 1990, EMBO J, V9, P947, DOI 10.1002/j.1460-2075.1990.tb08193.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COPPOLA JA, 1990, ONCOGENE, V5, P1731; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAUBAS P, 1985, NUCLEIC ACIDS RES, V13, P4623, DOI 10.1093/nar/13.13.4623; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LARSON DE, 1989, BIOCHIM BIOPHYS ACTA, V1009, P177, DOI 10.1016/0167-4781(89)90098-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PAGANO M, 1992, ONCOGENE, V7, P1681; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SLACK RS, 1993, ONCOGENE, V8, P1585; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STAPPERT J, 1992, NUCLEIC ACIDS RES, V20, P624, DOI 10.1093/nar/20.3.624; STEIN G S, 1992, Current Opinion in Cell Biology, V4, P166, DOI 10.1016/0955-0674(92)90028-B; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TANG A, 1989, ONCOGENE, V4, P401; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343	69	104	104	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3579	3590						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970718				2022-12-25	WOS:A1994PT39200021
J	WADMAN, IA; HSU, HL; COBB, MH; BAER, R				WADMAN, IA; HSU, HL; COBB, MH; BAER, R			THE MAP KINASE PHOSPHORYLATION SITE OF TAL1 OCCURS WITHIN A TRANSCRIPTIONAL ACTIVATION DOMAIN	ONCOGENE			English	Note							LOOP-HELIX PROTEINS; T-CELL LEUKEMIA; DNA-BINDING; ENHANCER-BINDING; MAMMALIAN-CELLS; GENE; TRANSLOCATION; MOTIF; EXPRESSION; YEAST	Alteration of the TAL1 gene is the most common genetic lesion found in patients with T cell acute lymphoblastic leukemia. TAL1 encodes a basic helix-loop-helix transcription factor that is phosphorylated on serine residue 122 by the mitogen-activated protein (MAP) kinase ERK1. Here we show that the amino-terminal sequences of TAL1 (residues 1-166) function in vivo as a transcriptional activation domain. Mutation of serine residue 122 reduces the potency of the transactivation domain by more than half. The data suggest that the amino-terminal transactivation domain of TAL1 is positively regulated by S122 phosphorylation and that the functional properties of TAL1 can be influenced by signal transduction pathways that involve the MAP kinases.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Cobb, Melanie/0000-0003-0833-5473	NATIONAL CANCER INSTITUTE [R01CA063191] Funding Source: NIH RePORTER; NCI NIH HHS [CA63191] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BERNARD O, 1991, ONCOGENE, V6, P1477; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODWIN G, 1991, NUCLEIC ACIDS RES, V20, P368; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOUTHON MA, 1993, BLOOD, V81, P647; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SADOWSKI I, 1988, NATURE, V335, P559; SETH A, 1991, J BIOL CHEM, V266, P23521; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	36	36	37	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3713	3716						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970731				2022-12-25	WOS:A1994PT39200037
J	ZHOU, XL; TARMIN, L; YIN, J; JIANG, HY; SUZUKI, H; RHYU, MG; ABRAHAM, JM; MELTZER, SJ				ZHOU, XL; TARMIN, L; YIN, J; JIANG, HY; SUZUKI, H; RHYU, MG; ABRAHAM, JM; MELTZER, SJ			THE MTS1 GENE IS FREQUENTLY MUTATED IN PRIMARY HUMAN ESOPHAGEAL TUMORS	ONCOGENE			English	Article							P53; CANCERS; HETEROZYGOSITY; MUTATIONS	Homozygous and heterozygous deletions involving chromosome 9p21 have been reported in a variety of primary human tumors in vivo, and point mutations have been reported in melanoma cell lines in vitro within a probable tumor suppressor gene, MTS1, located at chromosome 9p21. We describe six sequence alterations occurring among twenty-four primary esophageal squamous carcinomas and nineteen primary esophageal adenocarcinomas analyzed by DNA sequencing of MTS1 exon 2. Nucleotide substitutions were observed in five squamous cell carcinomas and in one adenocarcinoma. Two occurred in the germline, while four were somatic alterations. All six nucleotide changes resulted in marked alterations in amino acid sequence. Four were nonsense mutations leading to premature termination codons; nucleotide substitutions identical to two of these stop codons were previously reported in other tumor types. Loss of heterozygosity occurred in all five informative (constitutionally heterozygous) cases in which a sequence alteration was present. Esophageal cancer is one primary human tumor in which MTS1 constitutes an apparent target of heterozygous or homozygous deletions occurring at chromosome 9p21.	UNIV MARYLAND,SCH MED,DEPT MED,DIV GI,BALTIMORE,MD 21201; VET AFFAIRS HOSP,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NIDDK NIH HHS [R01 DK47717] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT WP, 1991, ONCOGENE, V6, P1779; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; BRISEBOIS JJ, 1993, MUTAT RES, V287, P191, DOI 10.1016/0027-5107(93)90012-5; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1994, CANCER RES, V54, P1422; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; HARRIS CC, 1991, ONCOGENE, V6, P1779; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HUANG Y, 1993, CANCER RES, V53, P1889; HUANG Y, 1992, CANCER RES, V52, P6525; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MARX J, 1994, SCIENCE, V264, P344, DOI 10.1126/science.8153613; MEAD LJ, 1994, CANCER RES, V54, P2307; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2322; MERLO A, 1994, CANCER RES, V54, P640; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; ORLOW I, 1994, CANCER RES, V54, P2848; POWELL SM, 1994, IN PRESS GASTROENTER; RHYU MG, 1994, ONCOGENE, V9, P29; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; ZHANG LH, 1992, J MOL BIOL, V223, P627, DOI 10.1016/0022-2836(92)90979-T	29	143	151	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3737	3741						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970734				2022-12-25	WOS:A1994PT39200040
J	BHANOT, OS; SINGH, US; SOLOMON, JJ				BHANOT, OS; SINGH, US; SOLOMON, JJ			THE ROLE OF 3-HYDROXYETHYLDEOXYURIDINE IN MUTAGENESIS BY ETHYLENE-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALF THYMUS DNA; ESCHERICHIA-COLI; N-NITROSOUREA; HPRT LOCUS; MOLECULAR ANALYSIS; ETHYLATING AGENTS; NEU ONCOGENE; RATS; MUTATION; INVITRO	Ethylene oxide, a direct-acting mutagen and carcinogen, produces 3-hydroxyethyldeoxyuridine (3-HE-dU) after initial alkylation at N3 of de, followed by rapid hydrolytic deamination. The significance of formation of 3-HE-dU in DNA was investigated by in vitro DNA replication of 3-HE-dU. A 55-nucleotide DNA template, containing 3-HE-dU at a single site, was constructed. DNA products, synthesized on the site-modified template, were analyzed and mutagenic bypass at 3-HE-dU estimated. The 3-HE-dU lesion blocked DNA replication by the Klenow fragment of Escherichia coli polymerase I (Rf Pol I) and bacteriophage T7 polymerase (T7 Pol) 3' to 3-HE-dU and after incorporating a nucleotide opposite 3-HE-dU. DNA synthesis past 3-HE-dU was negligible (<3%). Substitution of Kf Pol I (exo(-)) and T7 Pol (exo(-)), polymerases lacking 3' --> 5' exonuclease proofreading activity, for Hf Pol I and T7 Pol, respectively, facilitated DNA synthesis past 3-HE-dU. The bypass synthesis by Kf Poll (exo(-)) was 60% and 90% by T7 Pol (exo(-)). These results suggest that the 3-HE-dU lesion could be bypassed, but that the extension at 3-HE-dU is rate-limiting. In the absence of proofreading, the nucleotide incorporated opposite 3-HE-dU is not excised and remains in position long enough for extension to occur. During post-lesion synthesis, both dA and dT were incorporated opposite 3-HE-dU. Since 3-HE-dU is derived from dC alkylation by ethylene oxide, incorporation of dA and dT opposite 3-HE-dU implicates this lesion in G.C --> A.T and G.C --> T.A mutagenesis.			BHANOT, OS (corresponding author), NYU, MED CTR, DEPT ENVIRONM MED, NEW YORK, NY 10016 USA.				NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005694, P30ES000260] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16087] Funding Source: Medline; NIEHS NIH HHS [ES 05694, ES 00260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASTLOVA T, 1993, MUTAT RES, V287, P283, DOI 10.1016/0027-5107(93)90021-7; BASU AK, 1988, CHEM RES TOXICOL, V1, P1, DOI 10.1021/tx00001a001; BHANOT OS, 1986, P NATL ACAD SCI USA, V83, P7348, DOI 10.1073/pnas.83.19.7348; BHANOT OS, 1990, BIOCHEMISTRY-US, V29, P10357, DOI 10.1021/bi00497a010; BHANOT OS, 1992, NUCLEIC ACIDS RES, V20, P587, DOI 10.1093/nar/20.3.587; BHANOT OS, 1994, ENVIRON HEALTH PERSP, V102, P81, DOI 10.2307/3431767; Bolt H M, 1984, Toxicol Pathol, V12, P101; CARUTHERS MH, 1985, SCIENCE, V230, P281, DOI 10.1126/science.3863253; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; DELLARCO VL, 1990, ENVIRON MOL MUTAGEN, V16, P85, DOI 10.1002/em.2850160207; DORPER T, 1983, NUCLEIC ACIDS RES, V11, P2575, DOI 10.1093/nar/11.9.2575; DUNKELBERG H, 1982, BRIT J CANCER, V46, P924, DOI 10.1038/bjc.1982.303; ECKERT KA, 1988, MOL CARCINOGEN, V1, P50, DOI 10.1002/mc.2940010111; EHRENBERG L, 1981, MUTAT RES, V86, P1, DOI 10.1016/0165-1110(81)90034-8; EHRENBERG L, 1974, MUTAT RES, V24, P83, DOI 10.1016/0027-5107(74)90123-7; EINISTO P, 1993, ENVIRON MOL MUTAGEN, V21, P253, DOI 10.1002/em.2850210308; EMBREE JW, 1977, TOXICOL APPL PHARM, V40, P261, DOI 10.1016/0041-008X(77)90096-5; FAHMY OG, 1970, CANCER RES, V30, P195; FAROOQI Z, 1993, MUTAT RES, V288, P223, DOI 10.1016/0027-5107(93)90088-W; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; FILSER JG, 1983, MUTAT RES, V120, P57, DOI 10.1016/0165-7992(83)90074-X; GENEROSO WM, 1980, MUTAT RES, V73, P133, DOI 10.1016/0027-5107(80)90142-6; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GOTH R, 1974, P NATL ACAD SCI USA, V71, P639, DOI 10.1073/pnas.71.3.639; GREVATT PC, 1991, J BIOL CHEM, V266, P1269; GREVATT PC, 1992, BIOCHEMISTRY-US, V31, P4181, DOI 10.1021/bi00132a005; HARBACH PR, 1992, ENVIRON MOL MUTAGEN, V20, P96, DOI 10.1002/em.2850200205; HOGSTEDT C, 1986, JAMA-J AM MED ASSOC, V255, P1575, DOI 10.1001/jama.255.12.1575; HUH NH, 1988, INT J CANCER, V41, P762, DOI 10.1002/ijc.2910410521; KELSEY KT, 1988, CANCER RES, V48, P5045; KOEPKE SR, 1988, CANCER RES, V48, P1537; KOLMAN A, 1983, MOL GEN GENET, V189, P222, DOI 10.1007/BF00337808; KOLMAN A, 1986, CARCINOGENESIS, V7, P1245, DOI 10.1093/carcin/7.8.1245; LANDRIGAN PJ, 1984, AM J IND MED, V6, P103, DOI 10.1002/ajim.4700060205; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; LEWIS JG, 1980, NATURE, V288, P185, DOI 10.1038/288185a0; LEWIS SE, 1985, P NATL ACAD SCI USA, V82, P5829, DOI 10.1073/pnas.82.17.5829; LI FJ, 1992, CHEM-BIOL INTERACT, V83, P35, DOI 10.1016/0009-2797(92)90090-8; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; LOECHLER EL, 1984, P NATL ACAD SCI-BIOL, V81, P6271, DOI 10.1073/pnas.81.20.6271; LUDEKE BI, 1988, CARCINOGENESIS, V9, P147, DOI 10.1093/carcin/9.1.147; LYNCH DW, 1982, TOXICOLOGIST, V2, P11; MAXAM AM, 1980, METHOD ENZYMOL, V65, P497; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; POPP RA, 1983, GENETICS, V105, P157; PRESTON BD, 1986, P NATL ACAD SCI USA, V83, P8501, DOI 10.1073/pnas.83.22.8501; RANNUG U, 1976, CHEM-BIOL INTERACT, V12, P251, DOI 10.1016/0009-2797(76)90041-7; SAHM J, 1989, BIOCHEMISTRY-US, V28, P2836, DOI 10.1021/bi00433a014; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGA GA, 1991, MUTAT RES, V249, P339, DOI 10.1016/0027-5107(91)90009-D; SEGAL A, 1990, CANCER BIOCHEM BIOPH, V11, P59; SEGERBACK D, 1983, CHEM-BIOL INTERACT, V45, P139, DOI 10.1016/0009-2797(83)90064-9; SEGERBACK D, 1990, CARCINOGENESIS, V11, P307, DOI 10.1093/carcin/11.2.307; SINGER B, 1986, CANCER RES, V46, P4879; SKOPEK TR, 1992, P NATL ACAD SCI USA, V89, P7866, DOI 10.1073/pnas.89.17.7866; SOLOMON JJ, 1993, CHEM-BIOL INTERACT, V88, P115, DOI 10.1016/0009-2797(93)90087-F; SOLOMON JJ, 1988, CHEM-BIOL INTERACT, V67, P275, DOI 10.1016/0009-2797(88)90064-6; SOLOMON JJ, 1994, IARC SCI PUBL, V125, P179; SOLOMON JJ, 1991, ENVIRON MOL MUTAGEN, V17, P69; STAYNER L, 1993, AM J EPIDEMIOL, V138, P787, DOI 10.1093/oxfordjournals.aje.a116782; STOWERS SJ, 1988, CARCINOGENESIS, V9, P271, DOI 10.1093/carcin/9.2.271; SWENBERG JA, 1984, P NATL ACAD SCI-BIOL, V81, P1692, DOI 10.1073/pnas.81.6.1692; TABOR S, 1987, J BIOL CHEM, V262, P16212; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TATES AD, 1991, MUTAT RES, V250, P483, DOI 10.1016/0027-5107(91)90205-3; WALKER VE, 1993, MUTAT RES, V288, P151, DOI 10.1016/0027-5107(93)90216-3; WALKER VE, 1990, MUTAT RES, V233, P151, DOI 10.1016/0027-5107(90)90159-2; WALKER VE, 1992, CANCER RES, V52, P4328; 1985, INT AGENCY RES CANCE, V36, P189	71	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					30056	30064						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7962007				2022-12-25	WOS:A1994PU28400111
J	EISENSTEIN, E				EISENSTEIN, E			ENERGETICS OF COOPERATIVE LIGAND-BINDING TO THE ACTIVE-SITES OF BIOSYNTHETIC THREONINE DEAMINASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; TRYPTOPHAN SYNTHASE; SUBUNIT INTERACTIONS; SERINE; PURIFICATION; SYNTHETASE; MUTATIONS; ASPARTATE; SUBSTRATE; ENZYMES	The sigmoidal kinetics of alpha-ketobutyrate production catalyzed by threonine deaminase are shifted in the presence of the feedback inhibitor isoleucine and the activator valine to control carbon now through branched-chain amino acid biosynthesis in Escherichia coli. As an initial effort toward developing a molecular mechanism for cooperativity and feedback inhibition in this enzyme, the binding of the substrate analogs 2-aminobutyrate and alanine were measured. Binding isotherms were determined in potassium phosphate at pH 7.5 by detection of an 8-10-fold increase in intrinsic fluorescence of the external aldimine Schiff base of these analogs with the essential pyridoxal phosphate cofactor of the enzyme. Both 2-aminobutyrate and alanine bind cooperatively to four sites on threonine deaminase, with an average dissociation constant of 12.7 and 43.8 mM, respectively. The feedback inhibitor isoleucine decreases the average affinity for the ligands and increases the degree of cooperativity. The activator valine decreases the degree of cooperativity, but gives rise to a slight increase in the average dissociation constant for 2-aminobutyrate and alanine, possibly due to a competitive effect with active site ligands. The temperature dependence of the average affinity of ligands for the active sites indicates that binding is entropically controlled, with average values for Delta H-0 of +6.0 kcal/mol for alanine and +4.87 kcal/mol for 2-aminobutyrate. Since none of the Ligands under investigation had any effect on the tetrameric quaternary structure of the enzyme as judged by sedimentation equilibrium, an initial attempt to describe cooperative ligand association with threonine deaminase was undertaken by analysis of the binding isotherms in terms of a two-state model in which the enzyme equilibrates between two conformations, T and R, that differ in their affinity for ligands. This analysis suggests that cooperative binding to the enzyme is largely the result of the high preferential affinity of ligands for the R state. In addition, estimates for the allosteric equilibrium constant L range from 2 to 5, in the absence of modifiers, to 35 in the presence of isoleucine, and 0.9 in the presence of valine. To a first approximation, the data are consistent with isoleucine and valine regulating threonine deaminase by shifting the allosteric equilibrium between the different affinity forms,	UNIV MARYLAND,INST BIOTECHNOL,CTR ADV RES BIOTECHNOL,BALTIMORE,MD 21228; UNIV MARYLAND,DEPT CHEM & BIOCHEM,BALTIMORE,MD 21228	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore								Adair GS, 1925, J BIOL CHEM, V63, P529; BURNS RO, 1979, J BIOL CHEM, V254, P1074; CALHOUN DH, 1973, J BIOL CHEM, V248, P3511; CHANGEUX JEAN-PIERRE, 1962, JOUR MOLECULAR BIOL, V4, P220; CHANGEUX JP, 1963, COLD SPRING HARB SYM, V28, P497, DOI 10.1101/SQB.1963.028.01.066; CHANGEUX JP, 1993, BIOESSAYS, V15, P625, DOI 10.1002/bies.950150909; CHANGEUX JP, 1961, COLD SPRING HARB SYM, V26, P313, DOI 10.1101/SQB.1961.026.01.037; COX JL, 1987, GENE, V56, P185, DOI 10.1016/0378-1119(87)90136-3; Dahlquist F W, 1978, Methods Enzymol, V48, P270; DECEDUE CJ, 1975, J BIOL CHEM, V250, P1563; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; EISENSTEIN E, 1991, J BIOL CHEM, V266, P5801; EISENSTEIN E, 1994, J BIOL CHEM, V269, P29423; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FEDERIUK CS, 1983, J BIOL CHEM, V258, P5379; FISHER KE, 1993, J BACTERIOL, V175, P6605, DOI 10.1128/jb.175.20.6605-6613.1993; FREUNDLICH M, 1963, COLD SPRING HARB SYM, V28, P505, DOI 10.1101/SQB.1963.028.01.067; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; HAMMES GG, 1967, BIOCHIM BIOPHYS ACTA, V146, P312, DOI 10.1016/0005-2744(67)90104-0; HARDING WM, 1970, CAN J BIOCHEM CELL B, V48, P812, DOI 10.1139/o70-126; HATFIELD GW, 1970, J BIOL CHEM, V245, P787; HATFIELD GW, 1971, BIOCHEM BIOPH RES CO, V44, P464, DOI 10.1016/0006-291X(71)90624-3; HENSLEY P, 1981, J MOL BIOL, V152, P131, DOI 10.1016/0022-2836(81)90098-X; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HOFLER JG, 1978, J BIOL CHEM, V253, P1245; JANSONIUS JN, 1987, ACTIVE SITES ENZYMES, P187; JENKINS WT, 1961, J BIOL CHEM, V234, P1121; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; JULIN DA, 1989, BIOCHEMISTRY-US, V28, P3825, DOI 10.1021/bi00435a031; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2137, DOI 10.1093/nar/15.5.2137; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; METZLER CM, 1988, BIOCHEMISTRY-US, V27, P4923, DOI 10.1021/bi00413a050; METZLER CM, 1991, J BIOL CHEM, V266, P9374; MILES EW, 1974, J BIOL CHEM, V249, P2852; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MORINO Y, 1967, J BIOL CHEM, V242, P2800; NOBLE RW, 1969, J MOL BIOL, V39, P479, DOI 10.1016/0022-2836(69)90139-9; ROARK DE, 1976, BIOPHYS CHEM, V5, P185, DOI 10.1016/0301-4622(76)80034-8; TAILLON BE, 1988, GENE, V63, P245, DOI 10.1016/0378-1119(88)90528-8; UMBARGER H E, 1990, P1; UMBARGER HE, 1973, ADV ENZYMOL RAMB, V37, P349; UMBARGER HE, 1992, PROTEIN SCI, V1, P1392, DOI 10.1002/pro.5560011019; UMBARGER HE, 1956, SCIENCE, V123, P848, DOI 10.1126/science.123.3202.848; UMBARGER HE, 1957, J BACTERIOL, V73, P105, DOI 10.1128/JB.73.1.105-112.1957; UMBARGER HE, 1956, J BACTERIOL, V71, P443, DOI 10.1128/JB.71.4.443-449.1956; UMBARGER HE, 1957, J BIOL CHEM, V233, P415; WIESINGER H, 1984, BIOCHEMISTRY-US, V23, P4928, DOI 10.1021/bi00316a016; WIESINGER H, 1984, BIOCHEMISTRY-US, V23, P4921, DOI 10.1021/bi00316a015; WYMAN J, 1963, COLD SPRING HARB SYM, V28, P483, DOI 10.1101/SQB.1963.028.01.064; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Wyman J, 1990, BINDING LINKAGE FUNC; YORK SS, 1972, BIOCHEMISTRY-US, V11, P2733, DOI 10.1021/bi00764a029	52	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29416	29422						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961921				2022-12-25	WOS:A1994PU28400019
J	JOYAL, JL; SACKS, DB				JOYAL, JL; SACKS, DB			INSULIN-DEPENDENT PHOSPHORYLATION OF CALMODULIN IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; RECEPTOR TYROSINE KINASE; STIMULATED PHOSPHORYLATION; GROWTH-FACTOR; BOVINE BRAIN; PROTEIN; ACTIVATION; EXPRESSION; ADIPOCYTES; SUBSTRATE	Insulin-stimulated phosphorylation of calmodulin in vivo was examined using a highly specific anti-calmodulin monoclonal antibody combined with high resolution two-dimensional gel electrophoresis. The two major isoforms of calmodulin immunoprecipitated from insulin-treated hepatocytes migrated on two-dimensional gel electrophoresis to the same position as nonphosphorylated calmodulin and calmodulin phosphorylated in vitro. Immunoblotting verified the identity of calmodulin. Insulin enhanced the phosphorylation of calmodulin 3.1 +/- 0.4-fold (mean +/- S.E., n = 10), with a stoichiometry in insulin-treated hepatocytes of 0.47 +/- 0.06 (mean +/- S.E., n = 3) mel of phosphate/mol of calmodulin. Two-dimensional phosphopeptide mapping of calmodulin immunoprecipitated from rat hepatocytes and calmodulin phosphorylated in vitro by the insulin receptor kinase or casein kinase II revealed several common phosphopeptides. The common phosphopeptides that appeared insulin-sensitive in intact cells comprised 61 and 40% of casein kinase II- and insulin receptor-catalyzed P-32 incorporation into calmodulin in vitro, respectively. This suggests that casein kinase II and the insulin receptor kinase are, at least in part, responsible for insulin-stimulated phosphorylation of calmodulin in rat hepatocytes. These data indicate that phosphorylation of calmodulin in intact hepatocytes is significantly enhanced by insulin, supporting a critical role for calmodulin in insulin signal transduction.	BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Sacks, David/0000-0003-3100-0735	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043682, F32DK009062] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09062, DK43682] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BACHS O, 1987, J BIOL CHEM, V262, P10786; BLACKSHEAR PJ, 1989, J BIOL CHEM, V264, P3854; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohen P, 1988, CALMODULIN; COHEN P, 1991, METHOD ENZYMOL, V201, P153; COLCA JR, 1987, J BIOL CHEM, V262, P11399; COOPER JA, 1991, METHOD ENZYMOL, V201, P251; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DENTON RM, 1986, ADV CYCLIC NUCL PROT, V20, P293; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FUKAMI Y, 1986, P NATL ACAD SCI USA, V83, P4190, DOI 10.1073/pnas.83.12.4190; GORG A, 1991, NATURE, V349, P545, DOI 10.1038/349545a0; GRAND RJA, 1979, BIOCHEM J, V183, P285, DOI 10.1042/bj1830285; GRAVES CB, 1986, J BIOL CHEM, V261, P429; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; HINRICHSEN RD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P277, DOI 10.1016/0304-419X(93)90010-A; HRESKO RC, 1990, J BIOL CHEM, V265, P21075; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KALLEN RG, 1990, BIOCHEM BIOPH RES CO, V168, P616, DOI 10.1016/0006-291X(90)92365-7; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KIM SJ, 1994, J BIOL CHEM, V269, P11887; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LAURINO JP, 1988, ARCH BIOCHEM BIOPHYS, V265, P8, DOI 10.1016/0003-9861(88)90365-7; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; NAKAJO S, 1988, J BIOCHEM-TOKYO, V104, P946, DOI 10.1093/oxfordjournals.jbchem.a122588; PLANCKE YD, 1983, MOL CELL BIOL, V3, P1412, DOI 10.1128/MCB.3.8.1412; QUADRONI M, 1994, J BIOL CHEM, V269, P16116; RASMUSSEN CD, 1989, TRENDS NEUROSCI, V12, P433, DOI 10.1016/0166-2236(89)90092-1; REDDY GPV, 1992, BIOCHEMISTRY-US, V31, P10426, DOI 10.1021/bi00158a002; SACKS DB, 1988, J BIOL CHEM, V263, P2377; SACKS DB, 1989, BIOCHEM J, V263, P803, DOI 10.1042/bj2630803; SACKS DB, 1992, BIOCHEM J, V283, P21, DOI 10.1042/bj2830021; SACKS DB, 1994, BBA-PROTEIN STRUCT M, V1206, P120, DOI 10.1016/0167-4838(94)90080-9; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; SAITOH T, 1983, P NATL ACAD SCI-BIOL, V80, P6708, DOI 10.1073/pnas.80.21.6708; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WALL CM, 1981, BIOCHEM J, V195, P307, DOI 10.1042/bj1950307; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMS JP, 1994, ARCH BIOCHEM BIOPHYS, V315, P119, DOI 10.1006/abbi.1994.1479; WITTERS LA, 1983, J BIOL CHEM, V258, P5643; WOLFF DJ, 1977, J BIOL CHEM, V252, P4108	52	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					30039	30048						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7962005				2022-12-25	WOS:A1994PU28400109
J	LAMAR, GN; DALICHOW, F; ZHAO, XF; DOU, Y; IKEDASAITO, M; CHIU, ML; SLIGAR, SG				LAMAR, GN; DALICHOW, F; ZHAO, XF; DOU, Y; IKEDASAITO, M; CHIU, ML; SLIGAR, SG			H-1-NMR INVESTIGATION OF DISTAL MUTANT DEOXY MYOGLOBINS - INTERPRETATION OF PROXIMAL HIS CONTACT SHIFTS IN TERMS OF A LOCALIZED DISTAL WATER MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SPERM WHALE MYOGLOBIN; CYANO-MET MYOGLOBIN; QUATERNARY STRUCTURE; HEME POCKET; ELECTRONIC-STRUCTURE; HYBRID HEMOGLOBINS; HISTIDINE MUTANTS; ESCHERICHIA-COLI; RAMAN-SCATTERING	H-1 NMR spectra of a series of distal point mutants of human and sperm whale deoxy myoglobin have been recorded and their spectral parameters compared with those of wild type. The substitutions investigated include His(64)(E7) --> Gly, Ala, Val, Leu, Ile, and Gln and Val(68)(E11) --> Ala, Ile. The three resonances from the proximal His F8 imidazole ring, as well as two heme methyl signals, are identified in each of the proteins. Significant perturbations of the NMR spectra of mutant deoxy myoglobins (Mbs) occurred only upon substitution of His(64)(E7) by any non-polar residue, with only minor variation in parameters throughout the range of side chains. These spectral changes are attributed to the elimination of a non coordinated ordered water molecule in the distal pocket found hydrogen bonded to His(64)(E7) in crystals of wild-type deoxy Mb, but abolished in the His(64)(E7) --> Leu mutant deoxy Mb crystal (Quillin, M. L., Arduini, R. M., Olson, J. S., and Philips, G. N., Jr. (1993) J. Mol. Biol. 234, 140-155). The observed spectral changes, increased His F8 ring spin delocalization, and decreased heme in-plane asymmetry, can be directly attributed to the weakening of the effective axial field and a decrease in the asymmetry in the rhombic ligand field resulting from removal of the water molecule. The hyperfine shift patterns for the mutants His(64)(E7) --> Gln and Val(68)(E11) --> Ile deoxy Mbs are minimally perturbed from that of wild type and are interpreted to reflect a conserved distal water-binding site. In the point mutant Val(68)(E11) --> Ala, the decreased covalency to the axial His F8 is interpreted as reflecting a conserved distal water molecule that can interact more strongly with the iron due to the reduced steric bulk of the E11 side chain. The differential H-1 NMR spectral parameters for the His F8 resonances in the two subunits of T state deoxy Hb A are shown to be similarly consistent with the known occupation of the distal water binding site in the alpha-, but not beta-subunit.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; UNIV ILLINOIS,BECKMAN INST ADV SCI & TECHNOL,DEPT CHEM,URBANA,IL 61801; UNIV ILLINOIS,BECKMAN INST ADV SCI & TECHNOL,DEPT BIOCHEM,URBANA,IL 61801; UNIV ILLINOIS,BECKMAN INST ADV SCI & TECHNOL,DEPT PHYSIOL,URBANA,IL 61801; UNIV ILLINOIS,BECKMAN INST ADV SCI & TECHNOL,DEPT BIOPHYS,URBANA,IL 61801	Case Western Reserve University; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	LAMAR, GN (corresponding author), UNIV CALIF DAVIS,DEPT CHEM,DAVIS,CA 95616, USA.		Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015	Chiu, Mark/0000-0001-6300-404X	NHLBI NIH HHS [HL16087] Funding Source: Medline; NIGMS NIH HHS [GM31786, GM33775] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016087, R37HL016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033775] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BANCI L, 1993, EUR J BIOCHEM, V215, P431, DOI 10.1111/j.1432-1033.1993.tb18050.x; BUCHLER JW, 1982, STRUCT BOND, V24, P79; CARVER TE, 1990, J BIOL CHEM, V26, P20007; DENE H, 1980, PROC R SOC SER B-BIO, V207, P111, DOI 10.1098/rspb.1980.0016; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1546; FERMI G, 1975, J MOL BIOL, V97, P237, DOI 10.1016/S0022-2836(75)80037-4; FUNG LWM, 1975, BIOCHEMISTRY-US, V14, P2526, DOI 10.1021/bi00682a036; GOFF H, 1977, J AM CHEM SOC, V99, P6599, DOI 10.1021/ja00462a022; GUPTA RK, 1976, J MAGN RESON, V24, P461, DOI 10.1016/0022-2364(76)90124-4; HO C, 1992, ADV PROTEIN CHEM, V43, P153, DOI 10.1016/S0065-3233(08)60555-0; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; INUBUSHI T, 1986, J AM CHEM SOC, V108, P3799, DOI 10.1021/ja00273a040; JOHNSON ME, 1977, J AM CHEM SOC, V99, P1245, DOI 10.1021/ja00446a041; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; La Mar G.N, 1979, BIOL APPLICATIONS MA, P305; LAMAR GN, 1980, BIOCHEM BIOPH RES CO, V96, P1172, DOI 10.1016/0006-291X(80)90075-3; LAMAR GN, 1977, BIOCHEM BIOPH RES CO, V77, P104, DOI 10.1016/S0006-291X(77)80170-8; LAMAR GN, 1993, J AM CHEM SOC, V115, P3869, DOI 10.1021/ja00063a003; LAMAR GN, 1978, BIOCHIM BIOPHYS ACTA, V537, P270, DOI 10.1016/0005-2795(78)90510-X; LECOMTE JTJ, 1987, J AM CHEM SOC, V109, P7219, DOI 10.1021/ja00257a068; NAGAI K, 1980, J MOL BIOL, V136, P271, DOI 10.1016/0022-2836(80)90374-5; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P2033, DOI 10.1073/pnas.77.4.2033; NAGAI K, 1982, BIOCHEMISTRY-US, V21, P842, DOI 10.1021/bi00534a005; ONDRIAS MR, 1982, J BIOL CHEM, V257, P8766; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; QIN J, 1993, J BIOL CHEM, V268, P24012; QIN J, 1993, BIOPHYS J, V65, P2178, DOI 10.1016/S0006-3495(93)81270-0; QIN J, 1992, J MOL BIOL, V224, P891, DOI 10.1016/0022-2836(92)90456-T; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAJARATHNAM K, 1991, J AM CHEM SOC, V113, P7886, DOI 10.1021/ja00021a010; RAJARATHNAM K, 1992, J AM CHEM SOC, V114, P9048, DOI 10.1021/ja00049a042; RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V33, P5493, DOI 10.1021/bi00184a018; RAJARATHNAM K, 1993, BIOCHEMISTRY-US, V32, P5670, DOI 10.1021/bi00072a024; SAKAN Y, 1993, BIOCHEMISTRY-US, V32, P5815, DOI 10.1021/bi00073a014; SANKAR SS, 1987, BIOCHIM BIOPHYS ACTA, V912, P220, DOI 10.1016/0167-4838(87)90092-6; SHARMA VS, 1982, J BIOL CHEM, V257, P1887; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; TAKAHASHI S, 1980, BIOCHEMISTRY-US, V19, P5196, DOI 10.1021/bi00564a007; TAKANO T, 1977, J MOL BIOL, V110, P569, DOI 10.1016/S0022-2836(77)80112-5; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681; VIGGIANO G, 1978, BIOCHEMISTRY-US, V17, P795, DOI 10.1021/bi00598a007; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; WUTHRICH K, 1985, J MAGN RESON, V19, P111; YAMAMOTO Y, 1992, J BIOCHEM, V112, P414, DOI 10.1093/oxfordjournals.jbchem.a123914; [No title captured]; [No title captured]	50	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29629	29635						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961951				2022-12-25	WOS:A1994PU28400051
J	MORGAN, A; DIMALINE, R; BURGOYNE, RD				MORGAN, A; DIMALINE, R; BURGOYNE, RD			THE ATPASE ACTIVITY OF N-ETHYLMALEIMIDE-SENSITIVE FUSION PROTEIN (NSF) IS REGULATED BY SOLUBLE NSF ATTACHMENT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VESICULAR TRANSPORT; MEMBRANE-FUSION; CELLS; YEAST; PURIFICATION; REQUIRES; FAMILY; SNAPS	N-Ethylmaleimide-sensitive fusion protein (NSF) is an ATPase required in multiple stages of the secretory and endocytic pathways. NSF requires other proteins for its action in vesicular transport including the soluble NSF attachment proteins (SNAPs), which act to bind NSF to integral membrane proteins. We have investigated the ATPase activity of NSF and its modulation by alpha- and gamma-SNAPs using His(6)-tagged recombinant proteins. His(6)-NSF possessed ATPase activity, which was enhanced in a dose-dependent manner by immobilized (i.e. plastic-adsorbed) but not soluble His(6)-tagged SNAPs. NSF displayed complex enzyme kinetics consistent with the possession of two ATPase domains with different affinities for ATP. SNAPs apparently enhanced NSF ATPase activity primarily by decreasing the K-m of its low affinity site 100-fold. In vivo this effect would be predicted to sensitize the low affinity site to physiological ATP concentrations. Thus SNAPs could act as a molecular switch by ''turning on'' the normally dormant low affinity ATPase site of NSF.			MORGAN, A (corresponding author), UNIV LIVERPOOL,PHYSIOL LAB,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.		Morgan, Alan/AAI-8875-2020; Burgoyne, Robert/C-6706-2008; Burgoyne, Robert D/P-6641-2019	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387; Morgan, Alan/0000-0002-0346-1289	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; KAKEI M, 1986, FEBS LETT, V208, P63, DOI 10.1016/0014-5793(86)81533-2; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; PAINTER GR, 1989, P NATL ACAD SCI USA, V86, P2239, DOI 10.1073/pnas.86.7.2239; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	17	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29347	29350						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961908				2022-12-25	WOS:A1994PU28400004
J	SAHA, SK; MANISCALCO, SJ; SINGH, N; FISHER, HF				SAHA, SK; MANISCALCO, SJ; SINGH, N; FISHER, HF			THE DEMONSTRATION OF A GLUTAMATE DEHYDROGENASE-NADP-L-GLUTAMATE CHARGE-TRANSFER COMPLEX AND ITS LOCATION ON THE REACTION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								In previous transient state kinetic work from this laboratory, we proposed a new mechanism for the glutamate dehydrogenase-catalyzed oxidative deamination reaction involving an initial replacement of a proton from lysine 126 by a single bound water molecule, followed by closure of the active site cleft and expulsion of bulk water, providing a hydrophobic environment for the ensuing hydride transfer step. Here, we report the results of further transient state fluorescence, absorbance, and kinetic isotope effect studies, which demonstrate the occurrence of an unusual intermediate in the early steps of that reaction. This phenomenon is revealed by an initial fluorescence burst that occurs in the time period where the absorbance signal is still in its lag phase. Using an extension of the proton/product ratio approach we have described earlier, we show that this intermediate is a strongly fluorescent but weakly absorbing species whose absorption maximum is redshifted beyond that of other known complexes of this enzyme. The transient state kinetic isotope effects of the fluorescence and absorbance signals are compatible only with a reaction scheme in which the formation of the fluorescent complex precedes the hydride transfer step. The optical properties of this enzyme-oxidized coenzyme-substrate intermediate strongly suggest that it is a charge-transfer complex, similar in nature to the complex responsible for the well known ''Racker band'' reported in 1952 for glyceraldehyde-3-phosphate dehydrogenase (Racker, E., and Krimsky, I. (1952) Nature 169, 1043-1044). The crystal structure studies of the enzyme-coenzyme and enzyme-L-glutamate complexes of the closely analogous Clostridium symbosium glutamate dehydrogenase, reported by the Sheffield group (Stillman, T. J., Baker, P. J., Britton, K. L., and Rice, D. W. (1993) J. Mel. Biol. 234, 1131-1139), provide a basis for a physical explanation of the phenomenon. We conclude that the charge transfer phenomenon is caused by the near apposition of the unprotonated alpha-amino group of the substrate in a form of the enzyme in which a conformational change has caused the complete closing of the active site cleft.	UNIV KANSAS,MED CTR,DEPT BIOCHEM,MOLEC BIOCHEM LAB,KANSAS CITY,MO 64128	University of Kansas	SAHA, SK (corresponding author), VET ADM MED CTR,RES SERV,4801 LINWOOD BLVD,KANSAS CITY,MO 64128, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005373] Funding Source: NIH RePORTER; NCRR NIH HHS [S07 RR05373] Funding Source: Medline; NIGMS NIH HHS [GM-15188] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BUCHNER M, 1974, J MOL BIOL, V82, P563; COLEN AH, 1975, J BIOL CHEM, V250, P5243; FISHER HF, 1988, J BIOL CHEM, V263, P11704; FISHER HF, 1984, P NATL ACAD SCI-BIOL, V81, P2747, DOI 10.1073/pnas.81.9.2747; FISHER HF, 1992, BIOCHIM BIOPHYS ACTA, V1119, P52, DOI 10.1016/0167-4838(92)90233-4; HARRIS JL, 1976, ENZMES, V13, P29; KOSOWER EM, 1956, J AM CHEM SOC, V78, P3497, DOI 10.1021/ja01595a062; RACKER E, 1952, NATURE, V169, P1043, DOI 10.1038/1691043a0; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2328, DOI 10.1021/bi00552a008; RIZZO V, 1987, PYRIDINE NUCLEOTIDE, P122; SINGH N, 1993, J BIOL CHEM, V268, P21; STILLMAN TJ, 1993, J MOL BIOL, V234, P1131, DOI 10.1006/jmbi.1993.1665	13	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29592	29597						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961946				2022-12-25	WOS:A1994PU28400045
J	SWOPE, SL; HUGANIR, RL				SWOPE, SL; HUGANIR, RL			BINDING OF THE NICOTINIC ACETYLCHOLINE-RECEPTOR TO SH2 DOMAINS OF FYN AND FYK PROTEIN-TYROSINE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; EXTRACELLULAR-MATRIX; FIBROBLAST GROWTH; ELECTRIC ORGAN; GENE-PRODUCT; MUSCLE-CELLS; PHOSPHORYLATION; DIFFERENTIATION; MOLECULES; NERVE	The nicotinic acetylcholine receptor (AChR) is phosphorylated on tyrosine both in vitro and in vivo. To identify the protein tyrosine kinase that phosphorylates the receptor, we have previously cloned and characterized two protein tyrosine kinases, Fyn and Fyk, that are highly expressed in Torpedo electric organ, a tissue enriched in the AChR. Both kinases were shown by coimmunoprecipitation to be specifically associated with the AChR. In this study, we examined the molecular basis for the interaction of Fyn and Fyk with the AChR using fusion proteins containing the SH2 domains of the two kinases as affinity reagents. The AChR bound specifically and in a protein concentration-dependent manner to the SH2 domain fusion proteins of Fyn and Fyk. Quantitation of the association revealed that the binding of the AChR to Fyn and Fyk SH2 domain fusion proteins was to a single class of saturable high affinity sites. In addition, the association of the AChR with the SH2 domain fusion proteins was dependent on tyrosine phosphorylation of the AChR and was mediated by the delta subunit of the receptor. Furthermore, upon dissociation of the AChR into subunits, the delta subunit coimmunoprecipitated with both Fyn and Fyk. These data suggest that the association of the AChR with Fyn and Fyk is mediated by an interaction of the tyrosine-phosphorylated delta subunit of the receptor with the SH2 domains of the protein tyrosine kinases.			SWOPE, SL (corresponding author), JOHNS HOPKINS UNIV, SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI, 725 N WOLFE ST, 900 PCTB, BALTIMORE, MD 21205 USA.				NINDS NIH HHS [NS24418] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024418] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BAKER LP, 1992, J CELL SCI, V102, P543; BAKER LP, 1993, J CELL BIOL, V120, P185, DOI 10.1083/jcb.120.1.185; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; Burridge K., 1992, Current Biology, V2, P537, DOI 10.1016/0960-9822(92)90020-B; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BYLUND DB, 1980, RECEPTOR BINDING TEC, P70; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COBB RJ, 1992, ANAL CHEM, V64, P1027; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COOKE M P, 1989, New Biologist, V1, P66; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KITAS EA, 1989, TETRAHEDRON LETT, V30, P6229, DOI 10.1016/S0040-4039(01)93351-9; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGILLSOLC C, 1990, J EXP BIOL, V153, P1; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENG HB, 1991, NEURON, V6, P237; PENG HB, 1993, J CELL BIOL, V120, P197, DOI 10.1083/jcb.120.1.197; QU ZC, 1990, NEURON, V4, P367, DOI 10.1016/0896-6273(90)90049-L; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUDOL M, 1993, MOL BASIS HUMAN CANC, P203; SWOPE SL, 1993, J BIOL CHEM, V268, P25152; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER K, 1991, J BIOL CHEM, V266, P23784; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29817	29824						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961974				2022-12-25	WOS:A1994PU28400078
J	DELLANGELICA, EC; SCHLEICHER, CH; SANTOME, JA				DELLANGELICA, EC; SCHLEICHER, CH; SANTOME, JA			PRIMARY STRUCTURE AND BINDING-PROPERTIES OF CALGRANULIN-C, A NOVEL S100-LIKE CALCIUM-BINDING PROTEIN FROM PIG GRANULOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM; HUMAN-NEUTROPHILS; CONFORMATIONAL-CHANGES; SECONDARY STRUCTURE; MOLECULAR-CLONING; S100 PROTEINS; MYELOID CELLS; IONS BINDING; BOVINE BRAIN; EXPRESSION	In this paper we report the biochemical characterization of calgranulin C, a new member of the S100 protein family. The protein is highly abundant in the cytosol of pig granulocytes, with relatively small amounts in lymphocytes. A simple protocol for the rapid purification of calgranulin C is described. The purified protein mi grates as a single entity on SDS-polyacrylamide gel electrophoresis while it has two isoforms focusing at pH 5.8 and 5.5. Gel filtration and cross-linking experiments indicate that calgranulin C is capable of dimerization. The complete amino acid sequence was determined by Edman degradation of peptides generated by trypsin and V8 protease digestion. Calgranulin C consists of 91 residues and has a calculated molecular mass of 10,614 daltons. This value is virtually identical to that obtained by electrospray mass spectrometry. Sequence analysis predicts two EF-hand calcium-binding motifs, the first having an extended loop that is distinctive of the S100 protein family. The metal-binding properties were studied by means of a direct Ca-45(2+)-binding assay and by tyrosine fluorescence titration. Calgranulin C binds not only calcium but also zinc ions. A single high affinity Zn2+-binding site per monomer was evidenced by fluorimetric titration. Zinc binding to calgranulin C induces a remarkable increase in the protein affinity for calcium; in the absence of zinc, the protein binds 1 Ca2+/monomer with a binding constant of about 2 x 10(4) M(-1), whereas the Zn2+-loaded form binds 2 Ca2+/monomer with K-a values of approximately 3 x 10(7) and 6 x 10(4) M(-1). Circular dichroism analysis showed that the binding of calcium to calgranulin C induces a 15% decrease in the apparent alpha-helix content. This result and the calcium dependent binding of the protein to a phenyl-Superose column strongly suggest that calgranulin C undergoes a gross conformational change upon calcium binding, thus supporting the idea that this protein may be involved in Ca(2+)dependent signal transduction events.			DELLANGELICA, EC (corresponding author), UNIV BUENOS AIRES,FAC FARM & BIOQUIM,INST QUIM & FISICOQUIM BIOL,JUNIN 956,RA-1113 BUENOS AIRES,DF,ARGENTINA.							ADMON A, 1992, TECHNIQUES PROTEIN C, V3, P45; BAUDIER J, 1986, J BIOL CHEM, V261, P8204; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BECKER T, 1992, EUR J BIOCHEM, V207, P541, DOI 10.1111/j.1432-1033.1992.tb17080.x; BOYHAN A, 1992, J BIOL CHEM, V267, P2928; BRANDTS JF, 1973, BIOCHEMISTRY-US, V12, P2011, DOI 10.1021/bi00734a027; BRUNS GAP, 1989, CYTOGENET CELL GENET, V51, P67, DOI 10.1159/000132781; BURGOYNE RD, 1992, BIOCHEM SOC T, V20, P834, DOI 10.1042/bst0200834; CALABRETTA B, 1986, P NATL ACAD SCI USA, V83, P1495, DOI 10.1073/pnas.83.5.1495; CALABRETTA B, 1985, P NATL ACAD SCI USA, V82, P4463, DOI 10.1073/pnas.82.13.4463; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; DAVIES BR, 1993, ONCOGENE, V8, P999; DIANOUX AC, 1992, BIOCHEMISTRY-US, V31, P5898, DOI 10.1021/bi00140a028; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; EDGEWORTH J, 1989, NATURE, V342, P189, DOI 10.1038/342189a0; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; ERNST JD, 1990, J CLIN INVEST, V85, P1065, DOI 10.1172/JCI114537; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; HINRICHSEN RD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P277, DOI 10.1016/0304-419X(93)90010-A; JONES HP, 1982, BIOCHIM BIOPHYS ACTA, V714, P152, DOI 10.1016/0304-4165(82)90137-4; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAGASSE E, 1992, BLOOD, V79, P1907; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LEW PD, 1984, J CELL BIOL, V99, P1212, DOI 10.1083/jcb.99.4.1212; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANI RS, 1987, METHOD ENZYMOL, V139, P168; MANI RS, 1990, BIOCHEMISTRY-US, V29, P1398, DOI 10.1021/bi00458a009; MURAO S, 1989, J BIOL CHEM, V264, P8356; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; OHTA H, 1991, FEBS LETT, V295, P93, DOI 10.1016/0014-5793(91)81393-M; PEDROCCHI M, 1994, BIOCHEMISTRY-US, V33, P6732, DOI 10.1021/bi00187a045; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROTH J, 1993, BLOOD, V82, P1875; SAWYER DW, 1985, SCIENCE, V230, P663, DOI 10.1126/science.4048951; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLEICHER CH, 1993, INT J BIOCHEM, V25, P1251, DOI 10.1016/0020-711X(93)90075-P; SCHLEICHER CH, 1994, FASEB J, V8, pA1351; SKELTON NJ, 1994, NAT STRUCT BIOL, V1, P239, DOI 10.1038/nsb0494-239; SMOLEN JE, 1981, BIOCHIM BIOPHYS ACTA, V677, P512, DOI 10.1016/0304-4165(81)90267-1; SNYDERMAN R, 1981, SCIENCE, V213, P830, DOI 10.1126/science.6266014; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TANAKA T, 1980, J BIOL CHEM, V255, P1078; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; Thorton J, 1989, PROTEIN SEQUENCING P, P147; WILKINSON MM, 1988, J CELL SCI, V91, P221; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462; [No title captured]	54	118	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28929	28936						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961855				2022-12-25	WOS:A1994PU16800065
J	LOBIE, PE; WOOD, TJJ; CHEN, CM; WATERS, MJ; NORSTEDT, G				LOBIE, PE; WOOD, TJJ; CHEN, CM; WATERS, MJ; NORSTEDT, G			NUCLEAR TRANSLOCATION AND ANCHORAGE OF THE GROWTH-HORMONE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM BINDING-PROTEIN; INSULIN-RECEPTOR; NUCLEOCYTOPLASMIC TRANSPORT; EXTRACELLULAR DOMAIN; MEMBRANE-RECEPTOR; GENE-REGULATION; EGF RECEPTOR; RAT; CELLS; PURIFICATION	The extracellular domain of the rabbit growth hormone (GH) receptor has previously been shown to be associated with the nucleus, However, in this species the GH binding protein (BP) is derived by proteolytic cleavage of the full-length receptor, and thus distinction between the receptor and EP is difficult, The intracellular domain of the GH receptor is required for GH-stimulated function, Thus a direct nuclear function of GH would presumably require the receptor intracellular domain in the nucleus, We have therefore characterized the rat nuclear GH receptor and BP based on their distinct antigenic identity, We show, in vivo, that the full-length receptor is associated with the nucleus, including the respective subnuclear fractions (nucleoplasm, outer nuclear membranes, inner nuclear membranes, and chromatin). In vivo, the receptor is also subject to ligand-dependent nuclear translocation, Cellular transfection of rat GH receptor cDNA resulted in the appearance of nuclear binding sites for I-125-labeled human GH not present in the untransfected parental cell line (Chinese hamster ovary (CHO), buffalo rat liver), To determine which portion of the receptor was responsible for nuclear anchorage, we examined the binding of I-125-labeled human GH to whole nuclei isolated from CHO cells expressing the full-length receptor, a receptor in which 184 amino acids had been deleted from the carkoxyl-terminal intracellular domain (CHO-454) and a receptor containing only 5 of 349 amino acids in the intracellular domain (CHO-294), Nuclear binding above the level of the untransfected parental cell line was detected only in CHO 638 and CHO-454 cells, suggesting that amino acids 294-454 of the receptor are necessary for nuclear anchorage, This observation was not due to membrane contamination, as the CHO-294 cells express a membrane-bound receptor that was not anchored in the nucleus. The full-length GH receptor in receptor cDNA-transfected cells is nucleocytoplasmic in the absence of ligand but is also subject to rapid ligand-dependent nuclear translocation. The presence of the intracellular domain of the GH receptor in the nucleus allows the possibility of a direct nuclear response to GH,	NOVUM, INST MED NARINGSLARA, S-14186 HUDDINGE, SWEDEN; UNIV QUEENSLAND, DEPT PHYSIOL & PHARMACOL, BRISBANE, QLD 4072, AUSTRALIA; UNIV QUEENSLAND, CTR CELLULAR & MOLEC BIOL, BRISBANE, QLD 4072, AUSTRALIA	Karolinska Institutet; University of Queensland; University of Queensland	LOBIE, PE (corresponding author), KAROLINSKA INST, CTR BIOTEKN, S-14186 HUDDINGE, SWEDEN.		waters, michael j/C-9582-2014					ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BARNARD R, 1985, BIOCHEM J, V231, P459, DOI 10.1042/bj2310459; BARNARD R, 1986, BIOCHEM J, V237, P885, DOI 10.1042/bj2370885; BARNARD R, 1984, ENDOCRINOLOGY, V115, P1805, DOI 10.1210/endo-115-5-1805; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLEY AR, 1992, ARCH BIOCHEM BIOPHYS, V296, P198, DOI 10.1016/0003-9861(92)90563-C; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; BURWEN SJ, 1987, TRENDS BIOCHEM SCI, V12, P159, DOI 10.1016/0968-0004(87)90074-0; CARLSSON B, 1990, MOL CELL ENDOCRINOL, V73, pR1, DOI 10.1016/0303-7207(90)90048-D; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOMCZYNSKI P, 1974, BIOCHEM BIOPH RES CO, V60, P56, DOI 10.1016/0006-291X(74)90171-5; CLEVENGER CV, 1990, P NATL ACAD SCI USA, V87, P6460, DOI 10.1073/pnas.87.16.6460; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FRANCIS SM, 1993, MOL ENDOCRINOL, V7, P972, DOI 10.1210/me.7.8.972; FRASER RA, 1992, ENDOCRINOLOGY, V130, P3593, DOI 10.1210/en.130.6.3593; FRICK GP, 1992, ENDOCRINOLOGY, V131, P3083, DOI 10.1210/en.131.6.3083; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HAPP B, 1993, J STEROID BIOCHEM, V47, P21, DOI 10.1016/0960-0760(93)90053-Y; JIANG LW, 1990, J CELL BIOL, V110, P559, DOI 10.1083/jcb.110.3.559; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LIM L, 1990, ENDOCRINOLOGY, V127, P1287, DOI 10.1210/endo-127-3-1287; LOBIE PE, 1990, ENDOCRINOLOGY, V126, P299, DOI 10.1210/endo-126-1-299; LOBIE PE, 1994, J BIOL CHEM, V269, P21330; LOBIE PE, 1991, J BIOL CHEM, V266, P22645; LOBIE PE, 1992, ENDOCRINOLOGY, V130, P3057, DOI 10.1210/en.130.5.3057; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MOLLER C, 1992, J BIOL CHEM, V267, P23403; PAPA V, 1993, ENDOCRINOLOGY, V133, P1369, DOI 10.1210/en.133.3.1369; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PODLECKI DA, 1987, J BIOL CHEM, V262, P3362; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; RE RN, 1984, BIOCHEM BIOPH RES CO, V119, P220, DOI 10.1016/0006-291X(84)91641-3; SADAGHI H, 1990, MOL ENDOCRINOL, P1799; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SLIVA D, 1994, J BIOL CHEM, V269, P26208; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH RM, 1987, P NATL ACAD SCI USA, V84, P459, DOI 10.1073/pnas.84.2.459; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SOTIROPOULOS A, 1993, ENDOCRINOLOGY, V132, P1863, DOI 10.1210/en.132.4.1863; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; VANDERKUUR J, 1994, IN PRESS J BIOL CHEM; VIGNERI R, 1978, J BIOL CHEM, V253, P2098; VOLONTE C, 1993, J BIOL CHEM, V268, P21410; Wang T.Y., 1967, METHOD ENZYMOL, V12, P417; WATERS MJ, 1979, J BIOL CHEM, V254, P6815; YANKNER BA, 1979, P NATL ACAD SCI USA, V76, P1269, DOI 10.1073/pnas.76.3.1269; YOON JB, 1990, J BIOL CHEM, V265, P19947	70	117	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	1994	269	50					31735	31746						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX303	7989347				2022-12-25	WOS:A1994PX30300065
J	KOWALCZYK, AP; PALKA, HL; LUU, HH; NILLES, LA; ANDERSON, JE; WHEELOCK, MJ; GREEN, KJ				KOWALCZYK, AP; PALKA, HL; LUU, HH; NILLES, LA; ANDERSON, JE; WHEELOCK, MJ; GREEN, KJ			POSTTRANSLATIONAL REGULATION OF PLAKOGLOBIN EXPRESSION - INFLUENCE OF THE DESMOSOMAL CADHERINS ON PLAKOGLOBIN METABOLIC STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; INTERMEDIATE FILAMENT NETWORKS; UVOMORULIN-CATENIN COMPLEX; KIDNEY EPITHELIAL-CELLS; BETA-CATENIN; GLYCOPROTEIN-3 DESMOCOLLINS; CYTOPLASMIC DOMAINS; PROTEIN; JUNCTIONS; FAMILY	Desmosomes are adhesive intercellular junctions that act as cell surface attachment sites for intermediate filaments. The desmosomal glycoproteins, desmogleins and desmocollins, are members of the cadherin family of adhesion molecules. In addition, desmoglein has been shown to coimmunoprecipitate with the junctional protein plakoglobin. To characterize further the interaction between plakoglobin and the desmosomal cadherins, stable mouse fibroblast (L-cells) cell lines were generated that express plakoglobin, desmoglein and plakoglobin, or desmocollin and plakoglobin. L-cell lines transfected with a plasmid encoding human plakoglobin expressed plakoglobin mRNA but very little plakoglobin protein. However plakoglobin protein was expressed at high levels in L-cells coexpressing either desmoglein or desmocollin. In addition, both desmocollin and desmoglein were found to coimmunoprecipitate with plakoglobin. The transient expression of desmoglein in L-cell Lines expressing plakoglobin mRNA resulted in the formation of a complex between plakoglobin and desmoglein and in the accumulation of plakoglobin protein. Furthermore, the rate of plakoglobin protein degradation was decreased by 15-20-fold in cell Lines expressing either desmoglein or desmocollin. These results demonstrate that the desmosomal cadherins posttranslationally regulate plakoglobin expression by decreasing the rate of plakoglobin degradation.	NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT DERMATOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,ROBERT H LURIE CANC CTR,CHICAGO,IL 60611; UNIV TOLEDO,DEPT BIOL,TOLEDO,OH 43606	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University System of Ohio; University of Toledo					NIAMS NIH HHS [AR41836] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041836] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMAGAI M, 1994, J INVEST DERMATOL, V102, P402, DOI 10.1111/1523-1747.ep12372164; ARNEMANN J, 1993, J CELL SCI, V104, P741; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Green Kathleen J., 1994, P157; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOLTON JL, 1990, J CELL SCI, V97, P239; JOHSON KR, 1993, EXP CELL RES, V207, P252; Jones JCR, 1991, CURR OPIN CELL BIOL, V3, P127, DOI 10.1016/0955-0674(91)90175-X; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KOCH PJ, 1992, P NATL ACAD SCI USA, V89, P353, DOI 10.1073/pnas.89.1.353; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; KULESH DA, 1989, MOL CELL BIOL, V9, P1553, DOI 10.1128/MCB.9.4.1553; LEGAN PK, 1994, J CELL BIOL, V126, P507, DOI 10.1083/jcb.126.2.507; MATHUR M, 1994, J BIOL CHEM, V269, P14075; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; NILLES LA, 1991, J CELL SCI, V99, P809; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; OKA H, 1993, CANCER RES, V53, P1696; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PARKER AE, 1991, J BIOL CHEM, V266, P10438; PASDAR M, 1989, J CELL BIOL, V109, P163, DOI 10.1083/jcb.109.1.163; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PENN EJ, 1987, J CELL BIOL, V105, P2327, DOI 10.1083/jcb.105.5.2327; PIEPENHAGEN PA, 1993, J CELL SCI, V104, P751; PLOTT RT, 1994, J INVEST DERMATOL, V103, P168, DOI 10.1111/1523-1747.ep12392642; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SCHWARZ MA, 1990, ANNU REV CELL BIOL, V6, P461, DOI 10.1146/annurev.cb.06.110190.002333; SHORE EM, 1991, J BIOL CHEM, V266, P19672; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TANIHARA H, 1994, J CELL SCI, V107, P1694; Thiery Jean Paul, 1992, Current Opinion in Cell Biology, V4, P782, DOI 10.1016/0955-0674(92)90101-H; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796; WIESE RJ, 1992, J BIOL CHEM, V267, P20082	61	95	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31214	31223						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983064				2022-12-25	WOS:A1994PV51000073
J	NATSUME, T; KOIDE, T; YOKOTA, S; HIRAYOSHI, K; NAGATA, K				NATSUME, T; KOIDE, T; YOKOTA, S; HIRAYOSHI, K; NAGATA, K			INTERACTIONS BETWEEN COLLAGEN-BINDING STRESS PROTEIN HSP47 AND COLLAGEN - ANALYSIS OF KINETIC-PARAMETERS BY SURFACE-PLASMON RESONANCE BIOSENSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; BIOSPECIFIC INTERACTION ANALYSIS; ENDOPLASMIC-RETICULUM; GROWTH-FACTOR; EMBRYO FIBROBLASTS; SECRETORY PROTEINS; BASEMENT-MEMBRANE; TRANSFORMATION; TRANSLOCATION; RECEPTOR	A 47-kDa heat shock protein (HSP47) is a collagen-binding stress protein which is localized in the endoplasmic reticulum (ER) of collagen secreting cells. Recent studies have shown that HSP47 transiently binds to newly synthesized procollagens and that conformationally abnormal procollagen is also bound by HSP47 for a much longer time in the ER (Nakai, A, Satoh, M., Hirayoshi, K., and Nagata, K. (1992) J. Cell Biol. 117, 903-914). HSP47 is thus suggested to have a collagen-specific molecular chaperone-like function. In this report, we analyzed the interaction of HSP47 and types I to V collagen using BIAcore(TM) system, an optical biosensor based on the principles of surface plasmon resonance. Types I-V collagen were purified from porcine skin, porcine articular cartilage, bovine lens capsule, and porcine placenta and immobilized on sensorchips of the BIAcore(TM) system at a surface concentration of 10-15 ng/mm(2). Purified recombinant mouse HSP47 (rmHSP47) expressed in Escherichia coli was passed over the sensorchips at a now rate of 2 mu l/min and binding curves of rmHSP47 to collagens were monitored. Using this approach, accurate association and dissociation rate constants were determined in addition to dissociation constants. rmHSP47 was found to bind to types I-V collagen with similar dissociation constants of the order of 10(-7) M. This relatively low dissociation constant resulted from the rapid dissociation rate constant (k(diss) > 10(-2) s(-1)) and considerably high (k(ass) approximate to 2 x 10(4) m(-1) s(-1)) association rate constant. These kinetic parameters may reflect a transient interaction between HSP47 and procollagen in vivo.	KYOTO UNIV,CHEST DIS RES INST,DEPT CELL BIOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	NATSUME, T (corresponding author), NIPPON MEAT PACKERS INC,CTR RES & DEV,3-3 MIDORIGAHARA,TSUKUBA,IBARAKI 30026,JAPAN.							ANDRES DA, 1990, J BIOL CHEM, V265, P5952; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BORREBAECK CAK, 1992, BIO-TECHNOL, V10, P697, DOI 10.1038/nbt0692-697; CLARKE EP, 1992, BIOCHIM BIOPHYS ACTA, V1129, P246, DOI 10.1016/0167-4781(92)90498-O; CLARKE EP, 1991, J BIOL CHEM, V266, P17230; DEHM P, 1978, J BIOL CHEM, V253, P6680; Dixit S. V, 1982, IMMUNOCHEMISTRY EXTR, V1, P61; DIXIT SN, 1979, BIOCHEMISTRY-US, V18, P5686, DOI 10.1021/bi00592a026; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P327; FAGERSTAM L, 1991, TECHNIQUES PROTEIN P, V2; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; GAY S, 1979, ARCH BIOCHEM BIOPHYS, V198, P370, DOI 10.1016/0003-9861(79)90509-5; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREGORY CF, 1991, NATURE, V353, P726; HATAKEYAMA M, 1985, NATURE, V318, P467, DOI 10.1038/318467a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIRAYOSHI K, 1991, MOL CELL BIOL, V11, P4036, DOI 10.1128/MCB.11.8.4036; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P520; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; LAEMMLI UK, 1970, NATURE, V283, P249; LILLIE JH, 1987, METHOD ENZYMOL, V145, P171; LOFAS S, 1990, J CHEM SOC CHEM COMM, V21, P1526; MARK MR, 1992, J BIOL CHEM, V267, P26166; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASUDA H, 1994, IN PRESS J CLIN INVE; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MILLER EJ, 1984, EXTRACELLULAR MATRIX, P63; NAGATA K, 1986, J BIOL CHEM, V261, P7531; NAGATA K, 1986, J CELL BIOL, V103, P223, DOI 10.1083/jcb.103.1.223; NAKAI A, 1990, J BIOL CHEM, V265, P992; NAKAI A, 1989, BIOCHEM BIOPH RES CO, V164, P259, DOI 10.1016/0006-291X(89)91711-7; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; RAJAN JC, 1978, BIOCHEM BIOPH RES CO, V83, P180; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; VADGAMA P, 1992, ANALYST, V117, P1657, DOI 10.1039/an9921701657; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; VOGT PK, 1969, FUNDAMENTAL TECHNIQU	45	137	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					31224	31228						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983065				2022-12-25	WOS:A1994PV51000074
J	QWARNSTROM, EE; OSTBERG, CO; TURK, GL; RICHARDSON, CA; BOMSZTYK, K				QWARNSTROM, EE; OSTBERG, CO; TURK, GL; RICHARDSON, CA; BOMSZTYK, K			FIBRONECTIN ATTACHMENT ACTIVATES THE NF-KAPPA-B P50/P65 HETERODIMER IN FIBROBLASTS AND SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; GENE-EXPRESSION; PROTEINS; BINDING; INTERLEUKIN-1; INTEGRINS	The nuclear factor kappa B, NF-kappa B, is activated by numerous inflammatory mediators, regulating biological responses that in part are dependent on the extracellular matrix. Analyses of the influence of cell-matrix interaction on NF-kappa B activation revealed that attachment to fibronectin caused an increase in NF-kappa B activity corresponding to 3-fold the level in cells plated on bare plastic. This effect was dependent on the degree of attachment and appeared to involve both the RGD motif of the cell-binding domain, and the heparin-binding domain of fibronectin. Fibronectin attachment specifically caused activation of the p50/p65 heterodimeric form of NF-kappa B, resulting in an increase of this complex to a level similar to that induced by cytokine stimulation. These data show that cell attachment has a pronounced influence on the level of NF-kappa B activity, affecting specific dimeric complexes, and suggest this to be a pathway through which effects depending on cell-matrix interaction can regulate cell behavior and cytokine responses.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	QWARNSTROM, EE (corresponding author), UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA.			Qwarnstrom, Eva/0000-0003-4417-8663	NIDCR NIH HHS [DE-10363, DE-08172] Funding Source: Medline; NIGMS NIH HHS [GM-45134] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE008172, R01DE010363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045134] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRD TA, 1991, J BIOL CHEM, V266, P22661; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794; LENARDO M, 1994, IMMUNOL TODAY, V15, P145, DOI 10.1016/0167-5699(94)90308-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ruoslahti E., 1991, CELL BIOL EXTRACELLU, P343; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SYMINGTON BE, 1990, CELL REGUL, V1, P637, DOI 10.1091/mbc.1.9.637; TREMBLE P, 1994, MOL BIOL CELL, V5, P439, DOI 10.1091/mbc.5.4.439; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YAMADA KM, 1985, J CELL BIOCHEM, V28, P79, DOI 10.1002/jcb.240280202	33	78	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	1994	269	49					30765	30768						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV510	7983003				2022-12-25	WOS:A1994PV51000007
J	LI, NX; SCHLESSINGER, J; MARGOLIS, B				LI, NX; SCHLESSINGER, J; MARGOLIS, B			AUTOPHOSPHORYLATION MUTANTS OF THE EGF-RECEPTOR SIGNAL THROUGH AUXILIARY MECHANISMS INVOLVING SH2 DOMAIN PROTEINS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE-C-GAMMA; MOTH-EATEN MICE; POINT MUTATION; BINDING-SITE; HEMATOPOIETIC-CELLS; MITOGENIC SIGNAL; PHOSPHORYLATION	Many growth factors bind and activate receptors with intrinsic protein tyrosine kinase activity. Once activated these receptors undergo autophosphorylation allowing them to bind src homology 2 (SH2) domain proteins. We mutated or deleted all known autophosphorylation sites of the Epidermal Growth Factor-Receptor (EGF-receptor) and examined the effects of these mutations on gene expression, MAP kinase activation and mitogenesis. We find that the mutant receptors, although unable to bind SH2 domain proteins, are fully competent to activate all these signaling pathways. Our data indicates that these mutant receptors utilize several different compensatory mechanisms to overcome the lack of autophosphorylation sites. One mechanism is the use of tyrosine phosphorylated cellular proteins as surrogates for binding SH2 domain proteins. We find that all these mutant receptors can induce tyrosine phosphorylation of She which then acts as a binding site for the Grb2/Sos signaling complex. This data indicates that even though autophosphorylation mutants of the EGF-receptor cannot directly bind SH2 domain proteins, they are able to use auxiliary signals that result in activation of SH2 domain proteins crucial for mitogenesis.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University								BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HSIAO WLW, 1992, MOL CARCINOGEN, V5, P140, DOI 10.1002/mc.2940050210; JIANG W, 1992, CANCER RES, V52, P2980; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, J BIOL CHEM, V267, P9678; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SOLER C, 1993, J BIOL CHEM, V268, P22010; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SURMACZ E, 1992, CANCER RES, V52, P4522; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WHITE MF, 1994, J BIOL CHEM, V269, P1; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	52	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3457	3465						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970705				2022-12-25	WOS:A1994PT39200007
J	MCCRACKEN, S; LEUNG, S; BOSSELUT, R; GHYSDAEL, J; MIYAMOTO, NG				MCCRACKEN, S; LEUNG, S; BOSSELUT, R; GHYSDAEL, J; MIYAMOTO, NG			MYB AND ETS RELATED TRANSCRIPTION FACTORS ARE REQUIRED FOR ACTIVITY OF THE HUMAN LCK TYPE-I PROMOTER	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; T-CELL DEVELOPMENT; LONG TERMINAL REPEAT; DIFFERENTIAL EXPRESSION; THYMOCYTE DEVELOPMENT; GENE; PROTEIN; ACTIVATION; PRODUCT; P56LCK	The lck gene, which encodes a lymphoid-specific Src family tyrosine kinase, is transcribed from two promoters that are differentially utilized during T cell development. We have shown previously that the human lck type I promoter, which is preferentially expressed in immature thymocytes, requires a binding site (-97 to -90) for the Ets family of transcription factors for its activity in Jurkat T leukemia cells. Three putative Myb binding sites (-86 to -82, -77 to -72 and -59 to -54) were analysed for their ability to activate the lck type I promoter. In vitro assays demonstrated specific binding of purified, bacterially expressed c-Myb DNA binding domain to the Myb (-59 to -54) site. Transient transfection assays using the site-directed mutants of the lck type I promoter in Jurkat cells revealed that mutation of the Myb (-59 to -54) site abolished transcriptional activity. In transiently transfected HeLa cells, the lck type I promoter was activated by cotransfection with a vector that expresses c-Myb. This c-Myb dependent activation required the presence of intact Myb and Ets binding sites, indicating that the expressed c-Myb functions with endogenous Ets related transcription factors to activate the lck type I promoter. This effect was further enhanced by co-transfection with vectors that express either Ets1 or Ets2. These results demonstrate that Myb and Ets related transcription factors synergistically activate the human lck type I promoter.	INST CURIE,BIOL SECT,CNRS,U1443,F-91405 ORSAY,FRANCE; PRINCESS MARGARET HOSP,ONTARIO CANC INST,DIV CELLULAR & MOLEC BIOL,TORONTO M4X 1K9,ON,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ON,CANADA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto			GHYSDAEL, Jacques/F-3377-2013					ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; ASCIONE R, 1992, INT J ONCOL, V1, P631; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOSSELUT R, 1992, VIROLOGY, V186, P764, DOI 10.1016/0042-6822(92)90044-P; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; CASSEL DL, 1983, CANCER RES, V43, P4582; CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LEUNG S, 1993, ONCOGENE, V8, P989; LEUNG S, 1991, J CELL PHYSIOL, V148, P344, DOI 10.1002/jcp.1041480304; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	37	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3609	3615						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970721				2022-12-25	WOS:A1994PT39200024
J	COMBATES, NJ; RZEPKA, RW; CHEN, YNP; COHEN, D				COMBATES, NJ; RZEPKA, RW; CHEN, YNP; COHEN, D			NF-IL6, A MEMBER OF THE C/EBP FAMILY OF TRANSCRIPTION FACTORS, BINDS AND TRANS-ACTIVATES THE HUMAN MDR1 GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; FUNCTIONAL-ANALYSIS; MAMMALIAN-CELLS; EXPRESSION; PROTEIN; DNA; SEQUENCE; RAS; AMPLIFICATION; MUTAGENESIS	Revealing the regulatory mechanisms involved in P-glycoprotein expression is important to our understanding of multidrug resistance (MDR) in tumor cells. The MDR1 gene encoding P-glycoprotein contained a promoter sequence (-157 to -125) that was found to be hemologous with other mdr gene promoters and that specifically interacted with a nuclear protein. The nuclear protein was identified, using a HeLa lambda gt11 cDNA expression library, to be the transcriptional regulator nuclear factor for interleukin-6 (NF-IL6), a member of the C/EBP family of transcription factors that bound an NF-IL-6-like concensus element 5'-TTTCGCAGT-3'. Furthermore, a glutathione S-transferase fusion protein (10.1-glutathione S-transferase) containing the partial NF-ILG cDNA was also found to specifically interact with the MDR1 promoter sequence. Co-transfection of an NF-ILG expression vector with a chloramphenicol acetyltransferase reporter gene driven by 1018 base pairs of MDR1 5'-flanking sequences demonstrated that NF-ILG transactivated the MDR1 promoter. This trans-activation was significantly reduced when the NF-IL6 element in the reporter gene construct was deleted or mutated. Identification of NF-ILG as an important transcriptional regulator and the implications of its potential role in MDR1 gene induction in response to a variety of stimuli are discussed.	SANDOZ PHARMACEUT CORP,SANDOZ RES INST,SANDOZ PHARMACEUT GRP,PRECLIN RES,ONCOL RES GRP,E HANOVER,NJ 07936	Novartis; Sandoz								ABO J, 1993, BLOOD, V82, P2829; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COHEN D, 1994, DNA CELL BIOL, V13, P641, DOI 10.1089/dna.1994.13.641; CORNWELL MM, 1993, J BIOL CHEM, V268, P15347; CORNWELL MM, 1993, J BIOL CHEM, V268, P19505; DIEHL AM, 1994, HEPATOLOGY, V19, P447; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GOTTESMAN MM, 1991, MOL CELLULAR BIOL MU, P291; GOTTESMAN MM, 1991, MOL CELLULAR BIOL MU, P279; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADDEN MJ, 1993, J BIOL CHEM, V268, P8290; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NAKATSUKASA H, 1994, HEPATOLOGY, V18, P1202; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; RONINSON IB, 1992, MUTAT RES, V276, P151, DOI 10.1016/0165-1110(92)90005-T; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTTO KW, 1986, SCIENCE, V232, P751, DOI 10.1126/science.2421411; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; UEDA K, 1987, J BIOL CHEM, V262, P17432; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YU LJ, 1993, J BIOL CHEM, V268, P7520; ZASTAWNY RL, 1993, BIOCHIM BIOPHYS ACTA, V1173, P303, DOI 10.1016/0167-4781(93)90128-Z	35	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29715	29719						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961962				2022-12-25	WOS:A1994PU28400063
J	ISHIBASHI, T; BOTTARO, DP; MICHIELI, P; KELLEY, CA; AARONSON, SA				ISHIBASHI, T; BOTTARO, DP; MICHIELI, P; KELLEY, CA; AARONSON, SA			A NOVEL DUAL-SPECIFICITY PHOSPHATASE INDUCED BY SERUM STIMULATION AND HEAT-SHOCK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; IMMEDIATE-EARLY GENE; VACCINIA VIRUS VH1; MAP KINASE; ACTIVATES P34CDC2; CLONING SYSTEM; HUMAN-PLACENTA; EXPRESSION; FAMILY; YEAST	To identify new members of a family of protein-tyrosine phosphatases (PTPs), of which VH1 is prototype, we screened a B5/589 human mammary epithelial cell cDNA library by low stringency hybridization with probes for the catalytic domains of the human VHR and mouse 3CH134 phosphatases. Two overlapping clones of 1.8 and 2.5 kilobase pairs were detected by 3CH134 but not VHR probes. Sequence analysis of the largest clone, B23, revealed a 2470-nucleotide open reading frame encoding a novel protein. Within the 397 amino acid sequence, the HCXAGXXR signature sequence for PTPs was located at positions 261-268. The closest similarities were to 3CH134, its human homolog CL100, and PAC-1, PTPs induced as early response genes to mitogen stimulation. Less relatedness was observed with VHR and VH1 dual specificity phosphatases of human and vaccinia virus, respectively. A bacterially expressed recombinant protein containing the catalytic domain of B23 showed significant but consistently lower activity than VHR in vitro. Among the substrates tested, B23 displayed the highest relative activity toward phosphorylated extracellular signal regulated kinase-1, suggesting that it may be a target for B23 activity in vivo. The B23 transcript was detected in a wide variety of normal human tissues, with relatively high expression in pancreas and brain. B23 was induced by serum stimulation of human fibroblasts as well as by heat shock with similar kinetics to those observed with CL100. Thus, B23 is a new human protein phosphatase which appears to be regulated in response to mitogenic signaling and at least some forms of stress.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NHLBI, MOLEC CARDIOL LAB, BETHESDA, MD 20892 USA; MT SINAI MED CTR, RUTTENBERG CANC CTR, NEW YORK, NY 10029 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Icahn School of Medicine at Mount Sinai			Bottaro, Donald P/F-8550-2010; Michieli, Paolo/A-2588-2011; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Michieli, Paolo/0000-0002-3093-8871; Bottaro, Donald P/0000-0002-5057-5334				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVEREAUX J, 1992, GCG PROCEDURE LIBRAR; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GUAN K, 1993, TRENDS BIOCHEM SCI, V18, P6, DOI 10.1016/0968-0004(93)90079-3; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAKES DJ, 1993, P NATL ACAD SCI USA, V90, P4017, DOI 10.1073/pnas.90.9.4017; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOLT JC, 1975, BIOCHEMISTRY-US, V14, P4600, DOI 10.1021/bi00692a007; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELLERS JR, 1988, BIOCHEMISTRY-US, V27, P6977, DOI 10.1021/bi00418a046; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TONKS NK, 1988, J BIOL CHEM, V263, P6731; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0	40	132	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29897	29902						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961985				2022-12-25	WOS:A1994PU28400089
J	TENG, BB; BLUMENTHAL, S; FORTE, T; NAVARATNAM, N; SCOTT, J; GOTTO, AM; CHAN, L				TENG, BB; BLUMENTHAL, S; FORTE, T; NAVARATNAM, N; SCOTT, J; GOTTO, AM; CHAN, L			ADENOVIRUS-MEDIATED GENE-TRANSFER OF RAT APOLIPOPROTEIN-B MESSENGER-RNA-EDITING PROTEIN IN MICE VIRTUALLY ELIMINATES APOLIPOPROTEIN B-100 AND NORMAL LOW-DENSITY-LIPOPROTEIN PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; METABOLIC HETEROGENEITY; TRIGLYCERIDE-RICH; PLASMA-LEVELS; APOPROTEIN-B; EXPRESSION; HYPERCHOLESTEROLEMIA; RECEPTOR; VECTORS; THERAPY	Apolipoprotein (apo) B-100 is the major protein component in low density lipoprotein (LDL); it contains the binding domain for the LDL receptor and the attachment site for apolipoprotein(a) in lipoprotein(a). ApoB-48 is colinear with the amino-terminal half of apoB-100 and misses the part of the molecule required for LDL receptor interaction and lipoprotein(a) formation. ApoB-48 mRNA is produced by the editing of apoB-100 mRNA, a process by which the codon CAA for Gln-2153 is changed to UAA, an in-frame stop codon. We used the cloned catalytic component of the rat apoB mRNA-editing enzyme (REPR) to construct a replication-defective recombinant adenoviral vector containing REPR cDNA (AvREPR) and a control vector (Av1LacZ4) containing a beta-galactosidase cDNA to investigate the effect of REPR gene delivery in C57BL/6 mice. Intravenous injection of AvREPR in mice resulted in efficient transduction of liver cells, where REPR mRNA and protein were overexpressed, reaching a peak at 7 and 12 days, returning toward control levels at 39 days after AvREPR administration. ApoB mRNA editing activity in liver extracts showed changes parallel to those of REPR mRNA expression; the proportion of edited apoB mRNA in the total hepatic apoB mRNA increased from similar to 60% to more than 90% at the peak of REPR expression. The proportion of plasma apoB-100 in AvREPR-transduced animals decreased from similar to 50% to <10% of total plasma apoB concentration. Plasma very low density lipoproteins were polydisperse in control animals with an average diameter of 54.9 +/- 20.6 mo (uninjected control) and 54.7 +/- 16.8 nn (Av1LacZ4-treated), respectively. They became much smaller (average diameter 39.3 +/- 12.7 nm) and more uniform in size at day 12 following AvREPR administration. On the same day, the normal plasma LDL (26.2-25.5 nm) was almost completely eliminated in treated animals. Adenovirus-mediated transfer of the REPR cDNA is an efficient method to reduce plasma apoB-100 and normal LDL production.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; METHODIST HOSP, HOUSTON, TX 77030 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, MRC, MOLEC MED GRP, LONDON W12 0NN, ENGLAND	Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Imperial College London	TENG, BB (corresponding author), BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL027341, P01HL018574, P50HL027341] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-18574, HL-27341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUM CL, 1990, J BIOL CHEM, V265, P19263; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BERKNER KL, 1992, CURR TOP MICROBIOL, V158, P39; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNZELL JD, 1984, ARTERIOSCLEROSIS, V4, P79, DOI 10.1161/01.ATV.4.2.79; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; ELOVSON J, 1981, P NATL ACAD SCI-BIOL, V78, P157, DOI 10.1073/pnas.78.1.157; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; FARESE RV, 1992, J INTERN MED, V231, P643, DOI 10.1111/j.1365-2796.1992.tb01253.x; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; GREEVE J, 1993, J LIPID RES, V34, P1367; GRUNDY SM, 1976, METABOLISM, V25, P1225, DOI 10.1016/S0026-0495(76)80006-6; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JACKSON TK, 1990, J CLIN INVEST, V86, P1746, DOI 10.1172/JCI114900; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; KAY MA, 1994, P NATL ACAD SCI USA, V91, P2353, DOI 10.1073/pnas.91.6.2353; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MORGAN RA, 1993, ANNU REV BIOCHEM, V62, P191; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; PACKARD CJ, 1976, METABOLISM, V25, P995, DOI 10.1016/0026-0495(76)90129-3; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SALMONS B, 1993, HUM GENE THER, V4, P129, DOI 10.1089/hum.1993.4.2-129; Scanu A. M., 1990, LIPOPROTEIN A; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; SNIDERMAN AD, 1990, ARTERIOSCLEROSIS, V10, P665, DOI 10.1161/01.ATV.10.5.665; SPARKS CE, 1981, J LIPID RES, V22, P519; STALENHOEF AFH, 1984, P NATL ACAD SCI-BIOL, V81, P1839, DOI 10.1073/pnas.81.6.1839; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; SWIFT LL, 1987, J LIPID RES, V28, P207; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; VANTHOOFT FM, 1982, P NATL ACAD SCI-BIOL, V79, P179; WILSON JM, 1992, J BIOL CHEM, V267, P11483; WU AL, 1981, J BIOL CHEM, V256, P3615; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	53	84	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1994	269	47					29395	29404						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU284	7961918				2022-12-25	WOS:A1994PU28400016
J	HUNZIKER, W				HUNZIKER, W			THE CALMODULIN ANTAGONIST W-7 AFFECTS TRANSCYTOSIS, LYSOSOMAL TRANSPORT, AND RECYCLING BUT NOT ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; DEPENDENT PROTEIN-KINASE; CANINE KIDNEY-CELLS; MDCK CELLS; SYNAPSIN-I; MEMBRANE; PHOSPHORYLATION; IDENTIFICATION; BINDING; FUSION	Cahmodulin is a ubiquitous calcium-binding protein involved in the regulation of a variety of calcium dependent cell functions. The present study provides evidence for a role of calmodulin in several steps of membrane transport along the endocytic pathway. Treatment of Madin-Darby canine kidney cells expressing the polymeric immunoglobulin receptor or a macrophage IgG Fc receptor with the calmodulin antagonist N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide (W-7) inhibited their ability to mediate transcytosis of dimeric IgA or lysosomal degradation of immune complexes, respectively. Since both pathways rely on intact microtubules, the inhibitory effect of W-7 may reflect an effect on calmodulin-regulated microtubule function. However, although W-7 did not affect endocytosis, the drug also inhibited recycling of receptors from apical or basolateral endosomes back to the respective surfaces. Thus, calmodulin may regulate microtubule-dependent and independent endocytic membrane transport pathways.			HUNZIKER, W (corresponding author), UNIV LAUSANNE,INST BIOCHEM,CHEM BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND.		Hunziker, Walter/B-3140-2010; Hunziker, Walter/GSM-8190-2022	Hunziker, Walter/0000-0002-5265-4933; 				APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BRANDLI AW, 1990, J CELL BIOL, V111, P2909, DOI 10.1083/jcb.111.6.2909; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CARDONE M, 1993, J CELL BIOCHEM     S, V17, P1; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; ENRICH C, 1988, BIOCHEM J, V255, P999, DOI 10.1042/bj2550999; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GRASSO JA, 1990, BIOCHEM J, V266, P261, DOI 10.1042/bj2660261; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; Gruenberg Jean, 1993, Trends in Cell Biology, V3, P224, DOI 10.1016/0962-8924(93)90116-I; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDAKA H, 1988, METHOD ENZYMOL, V159, P652; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JOB D, 1981, P NATL ACAD SCI-BIOL, V78, P4679, DOI 10.1073/pnas.78.8.4679; KAKIUCHI S, 1983, TRENDS BIOCHEM SCI, V8, P59, DOI 10.1016/0968-0004(83)90391-2; KANAHO Y, 1992, J IMMUNOL, V149, P622; KEITH C, 1983, J CELL BIOL, V97, P1918, DOI 10.1083/jcb.97.6.1918; Lee G, 1993, CURR OPIN CELL BIOL, V5, P88, DOI 10.1016/S0955-0674(05)80013-4; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MARGOLIS RL, 1986, P NATL ACAD SCI USA, V83, P639, DOI 10.1073/pnas.83.3.639; MCGRAW TE, 1988, J CELL BIOL, V106, P1061, DOI 10.1083/jcb.106.4.1061; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; OHMORI Y, 1992, J IMMUNOL, V148, P538; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; OHYA Y, 1992, CELL CALCIUM, V13, P445, DOI 10.1016/0143-4160(92)90057-Y; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; PIRROLET F, 1992, BIOCHEMISTRY-US, V31, P8849; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SCHWARTZ AL, 1990, ANNU REV IMMUNOL, V8, P195, DOI 10.1146/annurev.immunol.8.1.195; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; TANAKA T, 1985, CALMODULIN ANTAGONIS, P524; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; VEIGL ML, 1989, PHARMACOL THERAPEUT, V44, P181, DOI 10.1016/0163-7258(89)90066-1	53	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					29003	29009						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961864				2022-12-25	WOS:A1994PU16800074
J	MYERS, MG; GRAMMER, TC; WANG, LM; SUN, XJ; PIERCE, JH; BLENIS, J; WHITE, MF				MYERS, MG; GRAMMER, TC; WANG, LM; SUN, XJ; PIERCE, JH; BLENIS, J; WHITE, MF			INSULIN-RECEPTOR SUBSTRATE-1 MEDIATES PHOSPHATIDYLINOSITOL 3'-KINASE AND P70(S6K) SIGNALING DURING INSULIN, INSULIN-LIKE GROWTH-FACTOR-I, AND INTERLEUKIN-4 STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; HEMATOPOIETIC-CELLS; IRS-1; PHOSPHORYLATION; TRANSDUCTION; ASSOCIATION; EXPRESSION; ACTIVATION; 3-KINASE; PDGF	Insulin Receptor Substrate-1 (IRS-1) is an endogenous cellular protein that is tyrosine phosphorylated during stimulation of cells with insulin, IGF-1, and interleukin 4 (IL-4). Phosphorylated IRS-1 regulates multiple regulatory pathways by recruiting signaling molecules containing Src homology 2 domains (SH2 proteins). The 32D myeloid progenitor cell line contains few insulin receptors and no detectable IRS-1. Expression of the insulin receptor alone partially mediates insulin-stimulated microtubule-associated protein (MAP) kinase activation, and the addition of IRS-1 enhances this effect (Myers, M. G., Jr., Wang, L.-M., Sun, X. J., Zhang, Y., Yenush, L. P., Schlessinger, J., Pierce, J. H., and White, M. F. (1994) Mol. Cell. Biol. 14, 3577-3587). Alone, insulin receptors mediate phosphatidylinositol (PI) 3'-kinase and p70(S6k) activation poorly if at all during insulin stimulation. Expression of IRS-1 alone in 32D cells mediates the stimulation of p70(S6k) by insulin, IGF-1, or IL 4; addition of insulin receptor to these cells increases the sensitivity of the insulin response. In contrast, full insulin stimulation of PI 3'-kinase requires both the insulin receptor and IRS-1, suggesting that a high level of IRS-1 phosphorylation is required for insulin-stimulated PI 3'-kinase activation, whereas a low level of IRS-1 tyrosine phosphorylation transmits an essential signal to p70(S6k). Both insulin receptors and IRS-1 are required for mitogenic signaling in 32D cells suggesting that MAP kinase or p70(S6k) alone are not sufficient, and that both or additional unknown IRS-1-mediated signals are necessary.	JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, PROGRAM CELL & DEV BIOL, BOSTON, MA 02215 USA; NIH, CELL & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; Harvard University; Harvard Medical School					NCI NIH HHS [CA 46595] Funding Source: Medline; NIDDK NIH HHS [DK 38712, DK 43808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046595, R37CA046595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK038712, R01DK043808, R01DK038712, R29DK038712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OKADA T, 1994, J BIOL CHEM, V269, P3568; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	243	244	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28783	28789						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961833				2022-12-25	WOS:A1994PU16800043
J	STEINMAN, HM; WEINSTEIN, L; BRENOWITZ, M				STEINMAN, HM; WEINSTEIN, L; BRENOWITZ, M			THE MANGANESE SUPEROXIDE-DISMUTASE OF ESCHERICHIA-COLI K-12 ASSOCIATES WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; BINDING; SITE; IRON; LOCALIZATION; OXIDATION; RADICALS; DAMAGE; ASSAY	Superoxide dismutases (SODs) are vital components in the resistance of aerobic organisms to the toxicity of oxygen. Escherichia coli contains two highly homologous cytoplasmic SODs, a manganese- and an iron-containing enzyme (MnSOD, FeSOD). We previously demonstrated that MnSOD and FeSOD have different physiological functions and that MnSOD is more effective in preventing oxidative damage to DNA. In this report, purified E. coli MnSOD was shown to bind nonspecifically to DNA by electrophoretic mobility shift assay and nitrocellulose-filter binding methodologies. From electrophoretic mobility shift assay, the equilibrium dissociation constants for interaction with a variety of double-stranded and single-stranded oligonucleotides ranged from 1.5 +/- 0.2 to 8.4 +/- 1.3 mu M at 20 degrees C. This range of concentrations corresponds to MnSOD concentrations in aerobically grown E. coli. In vivo binding of MnSOD to DNA was supported by colocalization of MnSOD and the E. coli nucleoid in immunoelectron microscopy. Both MnSOD and DNA were inhomogeneously distributed in the cytosol, the concentration of each being higher in the center of the cell and relatively low near the inner membrane. In contrast, there was no evidence for physiologically relevant interaction of FeSOD with DNA. finding to DNA in vitro was weak, K-d > 40-220 mu M, concentrations 7-40 times higher than found in vivo. In addition, the cytoplasmic distribution of FeSOD did not correlate with DNA. FeSOD concentration was higher near the inner membrane and lower in the center of the cytosol. These results demonstrate that E. coli MnSOD associates with DNA in vitro and in vivo. Combined with prior data demonstrating that MnSOD preferentially protects DNA in vivo while an equal enzymatic activity of FeSOD does not (Hopkin, K. A., Papazian, M. A., and Steinman, H. M. (1992) J. Biol. Chem. 267, 24253-24258), our data suggest that E. coli MnSOD acts as a ''tethered antioxidant''; association of MnSOD with DNA localizes dismutase activity near a target of oxidative stress and increases protection of DNA from oxidative damage. This model has implications for the therapeutic use of SODs as antioxidants.			STEINMAN, HM (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA.				NIGMS NIH HHS [GM 40468, GM 39929] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039929, R01GM039929] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDRICH HC, 1992, J BACTERIOL, V174, P4504, DOI 10.1128/JB.174.13.4504-4508.1992; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; BJORNSTI MA, 1986, BACTERIAL CHROMATIN, P64; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; BRENOWITZ M, 1989, MOL BIOL; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CARLIOZ A, 1988, J BIOL CHEM, V263, P1555; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; CHEVION M, 1988, FREE RADICAL BIO MED, V5, P27, DOI 10.1016/0891-5849(88)90059-7; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DRLICA K, 1987, ESCHERICHIA COLI SAL, P91; FARR SB, 1988, J BACTERIOL, V170, P1837, DOI 10.1128/jb.170.4.1837-1842.1988; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GOLDBLUM P, 1986, FOCUS, V2, P2; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GREGORY EM, 1973, J BACTERIOL, V115, P987, DOI 10.1128/JB.115.3.987-991.1973; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; HASSAN HM, 1989, ADV GENET, V26, P65; HOPKIN KA, 1992, J BIOL CHEM, V267, P24253; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; IMLAY JA, 1992, J BACTERIOL, V174, P953, DOI 10.1128/jb.174.3.953-961.1992; KOWALCZYKOWSKI SC, 1980, BIOPHYS J, V32, P403, DOI 10.1016/S0006-3495(80)84964-2; MARX G, 1986, BIOCHEM J, V236, P397, DOI 10.1042/bj2360397; MILLER JH, 1992, HDB ESCHERICHIA COLI; OLIVER DB, 1987, ESCHERICHIA COLI SAL, P56; Omar B A, 1992, Adv Pharmacol, V23, P109, DOI 10.1016/S1054-3589(08)60964-3; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; PRIVALLE CT, 1990, J BIOL CHEM, V265, P21966; PUGH SYR, 1984, J BACTERIOL, V160, P137, DOI 10.1128/JB.160.1.137-142.1984; SENEAR DF, 1986, BIOCHEMISTRY-US, V25, P7344, DOI 10.1021/bi00371a016; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STEINMAN HM, 1985, J BACTERIOL, V162, P1255, DOI 10.1128/JB.162.3.1255-1260.1985	37	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28629	28634						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961811				2022-12-25	WOS:A1994PU16800020
J	WATSON, PA; KRUPINSKI, J; KEMPINSKI, AM; FRANKENFIELD, CD				WATSON, PA; KRUPINSKI, J; KEMPINSKI, AM; FRANKENFIELD, CD			MOLECULAR-CLONING AND CHARACTERIZATION OF THE TYPE-VII ISOFORM OF MAMMALIAN ADENYLYL-CYCLASE EXPRESSED WIDELY IN MOUSE-TISSUES AND IN S49 MOUSE LYMPHOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTERS; PROTEIN; STIMULATION; SEQUENCE; FAMILY	We have isolated a 5199-nucleotide cDNA from a mouse library containing an open reading frame encoding the 1099 amino acid type VII adenylyl cyclase protein. The type VII protein is most closely related in primary structure to an unpublished human adenylyl cyclase clone (GenBank(TM) accession no. D25538) and type II adenylyl cyclase. Northern blot analysis demonstrates that the type VII mRNA is most abundant in mouse heart, spleen, and lung. cAMP content rises rapidly in HEK 293 cells overexpressing type VII adenylyl cyclase following treatment with phorbol ester, peaking by 4 min, while cells expressing the type II adenylyl cyclase reach peak accumulation only after 20 min. Increases in intracellular calcium through treatment of type VII-293 cells with either ATP or A23187 alone failed to increase intracellular cAMP content. Phorbol ester treatment acted synergistically with beta-adrenergic stimulation to increase cAMP content in type VII-transformed cells. Pretreatment of type VII-transformed cells with pertussis toxin fails to prevent phorbol ester potentiation of isoproterenol stimulation. Thus the ability of phorbol ester to increase basal and isoproterenol-stimulated type VII activity appears to be a direct effect on this adenylyl cyclase isoform and not the result of modification of the inhibitory G protein, G(i).			WATSON, PA (corresponding author), WEIS CTR RES,GEISINGER CLIN,100 N ACAD AVE,DANVILLE,PA 17822, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046395] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46395] Funding Source: Medline; PHITPO CDC HHS [HK42365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHITPO CDC HHS		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BELL JD, 1987, AM J PHYSIOL, V252, pE783, DOI 10.1152/ajpendo.1987.252.6.E783; BELL JD, 1986, J BIOL CHEM, V261, P2036; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HELLEVUO K, 1993, BIOCHEM BIOPH RES CO, V192, P311, DOI 10.1006/bbrc.1993.1415; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KATADA T, 1984, J BIOL CHEM, V259, P3568; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Sambrook J, 1989, MOL CLONING LABORATO; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; WATSON PA, 1990, J BIOL CHEM, V265, P6569; WATSON PA, 1989, J BIOL CHEM, V264, P14735; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	27	147	155	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28893	28898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961850				2022-12-25	WOS:A1994PU16800060
